6794356	Tricuspid valve regurgitation and lithium carbonate toxicity in a newborn infant .|A newborn with massive tricuspid regurgitation , atrial flutter , congestive heart failure , and a high serum lithium level is described .|This is the first patient to initially manifest tricuspid regurgitation and atrial flutter , and the 11th described patient with cardiac disease among infants exposed to lithium compounds in the first trimester of pregnancy .|Sixty - three percent of these infants had tricuspid valve involvement .|Lithium carbonate may be a factor in the increasing incidence of congenital heart disease when taken during early pregnancy .|It also causes neurologic depression , cyanosis , and cardiac arrhythmia when consumed prior to delivery .	1:NR:2	R2L	NON-CROSS	4-6	0-3	D016651	lithium carbonate|Lithium carbonate	Chemical	4:82	6:84	0:4	D014262	Tricuspid valve regurgitation|tricuspid regurgitation|tricuspid regurgitation	Disease	0:16:43	3:18:45	0:1:2	1:NR:2	R2L	NON-CROSS	30-31	16-18	D008094	lithium|lithium	Chemical	30:61	31:62	1:2	D014262	Tricuspid valve regurgitation|tricuspid regurgitation|tricuspid regurgitation	Disease	0:16:43	3:18:45	0:1:2	1:NR:2	L2R	NON-CROSS	4-6	6-7	D016651	lithium carbonate|Lithium carbonate	Chemical	4:82	6:84	0:4	D064420	toxicity	Disease	6	7	0	1:NR:2	L2R	CROSS	4-6	19-21	D016651	lithium carbonate|Lithium carbonate	Chemical	4:82	6:84	0:4	D001282	atrial flutter|atrial flutter	Disease	19:46	21:48	1:2	1:NR:2	L2R	CROSS	4-6	22-25	D016651	lithium carbonate|Lithium carbonate	Chemical	4:82	6:84	0:4	D006333	congestive heart failure	Disease	22	25	1	1:NR:2	L2R	NON-CROSS	82-84	93-96	D016651	lithium carbonate|Lithium carbonate	Chemical	4:82	6:84	0:4	D006331	cardiac disease|congenital heart disease	Disease	55:93	57:96	2:4	1:CID:2	L2R	CROSS	82-84	105-107	D016651	lithium carbonate|Lithium carbonate	Chemical	4:82	6:84	0:4	D003866	neurologic depression	Disease	105	107	5	1:CID:2	L2R	CROSS	82-84	108-109	D016651	lithium carbonate|Lithium carbonate	Chemical	4:82	6:84	0:4	D003490	cyanosis	Disease	108	109	5	1:CID:2	L2R	CROSS	82-84	111-113	D016651	lithium carbonate|Lithium carbonate	Chemical	4:82	6:84	0:4	D001145	cardiac arrhythmia	Disease	111	113	5	1:NR:2	R2L	CROSS	30-31	6-7	D008094	lithium|lithium	Chemical	30:61	31:62	1:2	D064420	toxicity	Disease	6	7	0	1:NR:2	R2L	NON-CROSS	30-31	19-21	D008094	lithium|lithium	Chemical	30:61	31:62	1:2	D001282	atrial flutter|atrial flutter	Disease	19:46	21:48	1:2	1:NR:2	R2L	NON-CROSS	30-31	22-25	D008094	lithium|lithium	Chemical	30:61	31:62	1:2	D006333	congestive heart failure	Disease	22	25	1	1:NR:2	L2R	NON-CROSS	55-57	61-62	D008094	lithium|lithium	Chemical	30:61	31:62	1:2	D006331	cardiac disease|congenital heart disease	Disease	55:93	57:96	2:4	1:NR:2	L2R	CROSS	61-62	105-107	D008094	lithium|lithium	Chemical	30:61	31:62	1:2	D003866	neurologic depression	Disease	105	107	5	1:NR:2	L2R	CROSS	61-62	108-109	D008094	lithium|lithium	Chemical	30:61	31:62	1:2	D003490	cyanosis	Disease	108	109	5	1:NR:2	L2R	CROSS	61-62	111-113	D008094	lithium|lithium	Chemical	30:61	31:62	1:2	D001145	cardiac arrhythmia	Disease	111	113	5
6504332	Phenobarbital - induced dyskinesia in a neurologically - impaired child .|A 2 - year - old child with known neurologic impairment developed a dyskinesia soon after starting phenobarbital therapy for seizures .|Known causes of movement disorders were eliminated after evaluation .|On repeat challenge with phenobarbital , the dyskinesia recurred .|Phenobarbital should be added to the list of anticonvulsant drugs that can cause movement disorders .	1:CID:2	L2R	NON-CROSS	0-1	3-4	D010634	Phenobarbital|phenobarbital|phenobarbital|Phenobarbital	Chemical	0:28:47:53	1:29:48:54	0:1:3:4	D004409	dyskinesia|dyskinesia|dyskinesia	Disease	3:24:50	4:25:51	0:1:3	1:NR:2	L2R	NON-CROSS	0-1	6-9	D010634	Phenobarbital|phenobarbital|phenobarbital|Phenobarbital	Chemical	0:28:47:53	1:29:48:54	0:1:3:4	D009422	neurologically - impaired|neurologic impairment	Disease	6:20	9:22	0:1	1:NR:2	L2R	NON-CROSS	28-29	31-32	D010634	Phenobarbital|phenobarbital|phenobarbital|Phenobarbital	Chemical	0:28:47:53	1:29:48:54	0:1:3:4	D012640	seizures	Disease	31	32	1	1:NR:2	L2R	NON-CROSS	28-29	36-38	D010634	Phenobarbital|phenobarbital|phenobarbital|Phenobarbital	Chemical	0:28:47:53	1:29:48:54	0:1:3:4	D009069	movement disorders|movement disorders	Disease	36:66	38:68	2:4
6436733	Acute changes of blood ammonia may predict short - term adverse effects of valproic acid .|Valproic acid ( VPA ) was given to 24 epileptic patients who were already being treated with other antiepileptic drugs .|A standardized loading dose of VPA was administered , and venous blood was sampled at 0 , 1 , 2 , 3 , and 4 hours .|Ammonia ( NH3 ) was higher in patients who , during continuous therapy , complained of drowsiness ( 7 patients ) than in those who were symptom - free ( 17 patients ) , although VPA plasma levels were similar in both groups .|By measuring VPA - induced changes of blood NH3 content , it may be possible to identify patients at higher risk of obtundation when VPA is given chronically .	1:NR:2	L2R	CROSS	4-5	25-26	D000641	ammonia|Ammonia|NH3|NH3	Chemical	4:64:66:116	5:65:67:117	0:3:3:4	D004827	epileptic	Disease	25	26	1	1:CID:2	L2R	NON-CROSS	66-67	80-81	D000641	ammonia|Ammonia|NH3|NH3	Chemical	4:64:66:116	5:65:67:117	0:3:3:4	D006970	drowsiness	Disease	80	81	3	1:NR:2	L2R	NON-CROSS	19-20	25-26	D014635	valproic acid|Valproic acid|VPA|VPA|VPA|VPA|VPA	Chemical	13:16:19:42:99:110:132	15:18:20:43:100:111:133	0:1:1:2:3:4:4	D004827	epileptic	Disease	25	26	1	1:CID:2	L2R	NON-CROSS	80-81	99-100	D014635	valproic acid|Valproic acid|VPA|VPA|VPA|VPA|VPA	Chemical	13:16:19:42:99:110:132	15:18:20:43:100:111:133	0:1:1:2:3:4:4	D006970	drowsiness	Disease	80	81	3
6293644	Effects of calcitonin on rat extrapyramidal motor system : behavioral and biochemical data .|The effects of i . v . c .|injection of human and salmon calcitonin on biochemical and behavioral parameters related to the extrapyramidal motor system , were investigated in male rats .|Calcitonin injection resulted in a potentiation of haloperidol - induced catalepsy and a partial prevention of apomorphine - induced hyperactivity .|Moreover calcitonin induced a significant decrease in nigral GAD activity but no change in striatal DA and DOPAC concentration or GAD activity .|The results are discussed in view of a primary action of calcitonin on the striatonigral GABAergic pathway mediating the DA - related behavioral messages of striatal origin .	1:CID:2	L2R	NON-CROSS	54-55	57-58	D006220	haloperidol	Chemical	54	55	3	D002375	catalepsy	Disease	57	58	3	1:NR:2	L2R	NON-CROSS	54-55	66-67	D006220	haloperidol	Chemical	54	55	3	D006948	hyperactivity	Disease	66	67	3	1:NR:2	R2L	NON-CROSS	63-64	57-58	D001058	apomorphine	Chemical	63	64	3	D002375	catalepsy	Disease	57	58	3	1:NR:2	R2L	CROSS	83-84	57-58	D004298	DA|DA	Chemical	83:110	84:111	4:5	D002375	catalepsy	Disease	57	58	3	1:NR:2	R2L	CROSS	85-86	57-58	D015102	DOPAC	Chemical	85	86	4	D002375	catalepsy	Disease	57	58	3	1:CID:2	L2R	NON-CROSS	63-64	66-67	D001058	apomorphine	Chemical	63	64	3	D006948	hyperactivity	Disease	66	67	3	1:NR:2	R2L	CROSS	83-84	66-67	D004298	DA|DA	Chemical	83:110	84:111	4:5	D006948	hyperactivity	Disease	66	67	3	1:NR:2	R2L	CROSS	85-86	66-67	D015102	DOPAC	Chemical	85	86	4	D006948	hyperactivity	Disease	66	67	3
6203632	Development of isoproterenol - induced cardiac hypertrophy .|The development of cardiac hypertrophy was studied in adult female Wistar rats following daily subcutaneous injections of isoproterenol ( ISO ) ( 0 . 3 mg / kg body weight ) .|A time course was established for the change in tissue mass , RNA and DNA content , as well as hydroxyproline content .|Heart weight increased 44 % after 8 days of treatment with a half time of 3 . 4 days .|Ventricular RNA content was elevated 26 % after 24 h of a single injection and reached a maximal level following 8 days of therapy .|The half time for RNA accumulation was 2 . 0 days .|The total content of hydroxyproline remained stable during the first 2 days of treatment but increased 46 % after 4 days of therapy .|Ventricular DNA content was unchanged during the early stage ( 1 - 4 days ) of hypertrophic growth but increased to a new steady - state level 19 % above the controls after 8 days of treatment .|Intraventricular pressures and coronary flow measures were similar for control and experimental animals following 4 days of developed hypertrophy .|However , dP / dt in the ISO - treated hearts was slightly but significantly ( P less than 0 . 05 ) elevated .|These data indicate that the adaptive response to ISO shows an early hypertrophic phase ( 1 - 4 days ) characterized by a substantial increase in RNA content and cardiac mass in the absence of changes in DNA .|However , prolonged stimulation ( 8 - 12 days ) appears to represent a complex integration of both cellular hypertrophy and hyperplasia within the heart .	1:CID:2	L2R	NON-CROSS	2-3	5-7	D007545	isoproterenol|isoproterenol|ISO|ISO|ISO	Chemical	2:25:27:209:235	3:26:28:210:236	0:1:1:9:10	D006332	cardiac hypertrophy|cardiac hypertrophy	Disease	5:11	7:13	0:1	1:NR:2	L2R	NON-CROSS	235-236	239-240	D007545	isoproterenol|isoproterenol|ISO|ISO|ISO	Chemical	2:25:27:209:235	3:26:28:210:236	0:1:1:9:10	D006984	hypertrophic|hypertrophy|hypertrophic|hypertrophy	Disease	160:200:239:285	161:201:240:286	7:8:10:11	1:CID:2	L2R	CROSS	235-236	287-288	D007545	isoproterenol|isoproterenol|ISO|ISO|ISO	Chemical	2:25:27:209:235	3:26:28:210:236	0:1:1:9:10	D006965	hyperplasia	Disease	287	288	11	1:NR:2	R2L	CROSS	60-61	11-13	D006909	hydroxyproline|hydroxyproline	Chemical	60:124	61:125	2:6	D006332	cardiac hypertrophy|cardiac hypertrophy	Disease	5:11	7:13	0:1	1:NR:2	L2R	CROSS	124-125	160-161	D006909	hydroxyproline|hydroxyproline	Chemical	60:124	61:125	2:6	D006984	hypertrophic|hypertrophy|hypertrophic|hypertrophy	Disease	160:200:239:285	161:201:240:286	7:8:10:11	1:NR:2	L2R	CROSS	124-125	287-288	D006909	hydroxyproline|hydroxyproline	Chemical	60:124	61:125	2:6	D006965	hyperplasia	Disease	287	288	11
3131282	Co - carcinogenic effect of retinyl acetate on forestomach carcinogenesis of male F344 rats induced with butylated hydroxyanisole .|The potential modifying effect of retinyl acetate ( RA ) on butylated hydroxyanisole ( BHA ) - induced rat forestomach tumorigenesis was examined .|Male F344 rats , 5 weeks of age , were maintained on diet containing 1 % or 2 % BHA by weight and simultaneously on drinking water supplemented with RA at various concentrations ( w / v ) for 52 weeks .|In groups given 2 % BHA , although marked hyperplastic changes of the forestomach epithelium were observed in all animals , co - administration of 0 . 25 % RA significantly ( P less than 0 . 05 ) increased the incidence of forestomach tumors ( squamous cell papilloma and carcinoma ) to 60 % ( 9 / 15 , 2 rats with carcinoma ) from 15 % ( 3 / 20 , one rat with carcinoma ) in the group given RA - free water .|In rats given 1 % BHA , RA co - administered at a dose of 0 . 05 , 0 . 1 , 0 . 2 or 0 . 25 % showed a dose - dependent enhancing effect on the development of the BHA - induced epithelial hyperplasia .|Tumors , all papillomas , were induced in 3 rats ( 17 % ) with 0 . 25 % RA and in one rat ( 10 % ) with 0 . 05 % RA co - administration .|RA alone did not induce hyperplastic changes in the forestomach .|These findings indicate that RA acted as a co - carcinogen in the BHA forestomach carcinogenesis of the rat .	1:NR:2	R2L	NON-CROSS	5-7	2-3	C009166	retinyl acetate|retinyl acetate|RA|RA|RA|RA|RA|RA|RA|RA|RA	Chemical	5:24:27:72:114:167:179:240:254:259:274	7:26:28:73:115:168:180:241:255:260:275	0:1:1:2:3:3:4:5:5:6:7	D063646	carcinogenic	Disease	2	3	0	1:NR:2	R2L	NON-CROSS	16-18	2-3	D002083	butylated hydroxyanisole|butylated hydroxyanisole|BHA|BHA|BHA|BHA|BHA|BHA	Chemical	16:30:33:62:90:177:215:283	18:32:34:63:91:178:216:284	0:1:1:2:3:4:4:7	D063646	carcinogenic	Disease	2	3	0	1:NR:2	L2R	NON-CROSS	5-7	8-10	C009166	retinyl acetate|retinyl acetate|RA|RA|RA|RA|RA|RA|RA|RA|RA	Chemical	5:24:27:72:114:167:179:240:254:259:274	7:26:28:73:115:168:180:241:255:260:275	0:1:1:2:3:3:4:5:5:6:7	D013274	forestomach carcinogenesis|forestomach tumorigenesis|forestomach tumors|forestomach carcinogenesis	Disease	8:38:128:284	10:40:130:286	0:1:3:7	1:NR:2	L2R	NON-CROSS	224-225	240-241	C009166	retinyl acetate|retinyl acetate|RA|RA|RA|RA|RA|RA|RA|RA|RA	Chemical	5:24:27:72:114:167:179:240:254:259:274	7:26:28:73:115:168:180:241:255:260:275	0:1:1:2:3:3:4:5:5:6:7	D010212	squamous cell papilloma|papillomas	Disease	131:224	134:225	3:5	1:NR:2	L2R	NON-CROSS	161-162	167-168	C009166	retinyl acetate|retinyl acetate|RA|RA|RA|RA|RA|RA|RA|RA|RA	Chemical	5:24:27:72:114:167:179:240:254:259:274	7:26:28:73:115:168:180:241:255:260:275	0:1:1:2:3:3:4:5:5:6:7	D002277	carcinoma|carcinoma|carcinoma	Disease	135:148:161	136:149:162	3:3:3	1:NR:2	L2R	NON-CROSS	218-220	240-241	C009166	retinyl acetate|retinyl acetate|RA|RA|RA|RA|RA|RA|RA|RA|RA	Chemical	5:24:27:72:114:167:179:240:254:259:274	7:26:28:73:115:168:180:241:255:260:275	0:1:1:2:3:3:4:5:5:6:7	D017573	epithelial hyperplasia	Disease	218	220	4	1:NR:2	L2R	NON-CROSS	221-222	240-241	C009166	retinyl acetate|retinyl acetate|RA|RA|RA|RA|RA|RA|RA|RA|RA	Chemical	5:24:27:72:114:167:179:240:254:259:274	7:26:28:73:115:168:180:241:255:260:275	0:1:1:2:3:3:4:5:5:6:7	D009369	Tumors	Disease	221	222	5	1:CID:2	R2L	NON-CROSS	284-286	283-284	D002083	butylated hydroxyanisole|butylated hydroxyanisole|BHA|BHA|BHA|BHA|BHA|BHA	Chemical	16:30:33:62:90:177:215:283	18:32:34:63:91:178:216:284	0:1:1:2:3:4:4:7	D013274	forestomach carcinogenesis|forestomach tumorigenesis|forestomach tumors|forestomach carcinogenesis	Disease	8:38:128:284	10:40:130:286	0:1:3:7	1:NR:2	L2R	NON-CROSS	215-216	224-225	D002083	butylated hydroxyanisole|butylated hydroxyanisole|BHA|BHA|BHA|BHA|BHA|BHA	Chemical	16:30:33:62:90:177:215:283	18:32:34:63:91:178:216:284	0:1:1:2:3:4:4:7	D010212	squamous cell papilloma|papillomas	Disease	131:224	134:225	3:5	1:NR:2	L2R	NON-CROSS	161-162	177-178	D002083	butylated hydroxyanisole|butylated hydroxyanisole|BHA|BHA|BHA|BHA|BHA|BHA	Chemical	16:30:33:62:90:177:215:283	18:32:34:63:91:178:216:284	0:1:1:2:3:4:4:7	D002277	carcinoma|carcinoma|carcinoma	Disease	135:148:161	136:149:162	3:3:3	1:NR:2	L2R	NON-CROSS	215-216	218-220	D002083	butylated hydroxyanisole|butylated hydroxyanisole|BHA|BHA|BHA|BHA|BHA|BHA	Chemical	16:30:33:62:90:177:215:283	18:32:34:63:91:178:216:284	0:1:1:2:3:4:4:7	D017573	epithelial hyperplasia	Disease	218	220	4	1:NR:2	L2R	CROSS	215-216	221-222	D002083	butylated hydroxyanisole|butylated hydroxyanisole|BHA|BHA|BHA|BHA|BHA|BHA	Chemical	16:30:33:62:90:177:215:283	18:32:34:63:91:178:216:284	0:1:1:2:3:4:4:7	D009369	Tumors	Disease	221	222	5
3115150	Ketanserin pretreatment reverses alfentanil - induced muscle rigidity .|Systemic pretreatment with ketanserin , a relatively specific type - 2 serotonin receptor antagonist , significantly attenuated the muscle rigidity produced in rats by the potent short - acting opiate agonist alfentanil .|Following placement of subcutaneous electrodes in each animal 's left gastrocnemius muscle , rigidity was assessed by analyzing root - mean - square electromyographic activity .|Intraperitoneal ketanserin administration at doses of 0 . 63 and 2 . 5 mg / kg prevented the alfentanil - induced increase in electromyographic activity compared with animals pretreated with saline .|Chlordiazepoxide at doses up to 10 mg / kg failed to significantly influence the rigidity produced by alfentanil .|Despite the absence of rigidity , animals that received ketanserin ( greater than 0 . 31 mg / kg i . p . ) followed by alfentanil were motionless , flaccid , and less responsive to external stimuli than were animals receiving alfentanil alone .|Rats that received ketanserin and alfentanil exhibited less rearing and exploratory behavior at the end of the 60 - min recording period than did animals that received ketanserin alone .|These results , in combination with previous work , suggest that muscle rigidity , a clinically relevant side - effect of parenteral narcotic administration , may be partly mediated via serotonergic pathways .|Pretreatment with type - 2 serotonin antagonists may be clinically useful in attenuating opiate - induced rigidity , although further studies will be necessary to assess the interaction of possibly enhanced CNS , cardiovascular , and respiratory depression .	1:NR:2	L2R	NON-CROSS	123-124	128-129	D007650	Ketanserin|ketanserin|ketanserin|ketanserin|ketanserin|ketanserin	Chemical	0:12:69:128:167:191	1:13:70:129:168:192	0:1:3:5:6:6	D009127	muscle rigidity|muscle rigidity|rigidity|rigidity|rigidity|muscle rigidity|rigidity	Disease	6:27:55:114:123:205:243	8:29:56:115:124:207:244	0:1:2:4:5:7:8	1:NR:2	L2R	CROSS	191-192	260-265	D007650	Ketanserin|ketanserin|ketanserin|ketanserin|ketanserin|ketanserin	Chemical	0:12:69:128:167:191	1:13:70:129:168:192	0:1:3:5:6:6	D002318	cardiovascular , and respiratory depression	Disease	260	265	8	1:NR:2	L2R	CROSS	191-192	260-265	D007650	Ketanserin|ketanserin|ketanserin|ketanserin|ketanserin|ketanserin	Chemical	0:12:69:128:167:191	1:13:70:129:168:192	0:1:3:5:6:6	D012131	cardiovascular , and respiratory depression	Disease	260	265	8	1:CID:2	L2R	NON-CROSS	3-4	6-8	D015760	alfentanil|alfentanil|alfentanil|alfentanil|alfentanil|alfentanil|alfentanil	Chemical	3:40:86:117:145:161:169	4:41:87:118:146:162:170	0:1:3:4:5:5:6	D009127	muscle rigidity|muscle rigidity|rigidity|rigidity|rigidity|muscle rigidity|rigidity	Disease	6:27:55:114:123:205:243	8:29:56:115:124:207:244	0:1:2:4:5:7:8	1:NR:2	L2R	CROSS	169-170	260-265	D015760	alfentanil|alfentanil|alfentanil|alfentanil|alfentanil|alfentanil|alfentanil	Chemical	3:40:86:117:145:161:169	4:41:87:118:146:162:170	0:1:3:4:5:5:6	D002318	cardiovascular , and respiratory depression	Disease	260	265	8	1:NR:2	L2R	CROSS	169-170	260-265	D015760	alfentanil|alfentanil|alfentanil|alfentanil|alfentanil|alfentanil|alfentanil	Chemical	3:40:86:117:145:161:169	4:41:87:118:146:162:170	0:1:3:4:5:5:6	D012131	cardiovascular , and respiratory depression	Disease	260	265	8	1:NR:2	R2L	NON-CROSS	27-29	20-21	D012701	serotonin|serotonin	Chemical	20:232	21:233	1:8	D009127	muscle rigidity|muscle rigidity|rigidity|rigidity|rigidity|muscle rigidity|rigidity	Disease	6:27:55:114:123:205:243	8:29:56:115:124:207:244	0:1:2:4:5:7:8	1:NR:2	R2L	NON-CROSS	114-115	100-101	D002707	Chlordiazepoxide	Chemical	100	101	4	D009127	muscle rigidity|muscle rigidity|rigidity|rigidity|rigidity|muscle rigidity|rigidity	Disease	6:27:55:114:123:205:243	8:29:56:115:124:207:244	0:1:2:4:5:7:8	1:NR:2	L2R	NON-CROSS	232-233	260-265	D012701	serotonin|serotonin	Chemical	20:232	21:233	1:8	D002318	cardiovascular , and respiratory depression	Disease	260	265	8	1:NR:2	L2R	NON-CROSS	232-233	260-265	D012701	serotonin|serotonin	Chemical	20:232	21:233	1:8	D012131	cardiovascular , and respiratory depression	Disease	260	265	8	1:NR:2	L2R	CROSS	100-101	260-265	D002707	Chlordiazepoxide	Chemical	100	101	4	D002318	cardiovascular , and respiratory depression	Disease	260	265	8	1:NR:2	L2R	CROSS	100-101	260-265	D002707	Chlordiazepoxide	Chemical	100	101	4	D012131	cardiovascular , and respiratory depression	Disease	260	265	8
2917114	Glycopyrronium requirements for antagonism of the muscarinic side effects of edrophonium .|We have compared , in 60 adult patients , the cardiovascular effects of glycopyrronium 5 micrograms kg - 1 and 10 micrograms kg - 1 given either simultaneously or 1 min before edrophonium 1 mg kg - 1 .|Significant differences between the four groups were detected ( P less than 0 . 001 ) .|Both groups receiving 10 micrograms kg - 1 showed increases in heart rate of up to 30 beat min - 1 ( 95 % confidence limits 28 - 32 beat min - 1 ) .|Use of glycopyrronium 5 micrograms kg - 1 provided greater cardiovascular stability and , given 1 min before the edrophonium , was sufficient to minimize early , edrophonium - induced bradycardias .|This low dose of glycopyrronium provided good control of oropharyngeal secretions .	1:NR:2	L2R	NON-CROSS	133-134	139-140	D006024	Glycopyrronium|glycopyrronium|glycopyrronium|glycopyrronium	Chemical	0:25:105:139	1:26:106:140	0:1:4:5	D001919	bradycardias	Disease	133	134	4	1:CID:2	L2R	NON-CROSS	130-131	133-134	D004491	edrophonium|edrophonium|edrophonium|edrophonium	Chemical	10:44:122:130	11:45:123:131	0:1:4:4	D001919	bradycardias	Disease	133	134	4
2564649	Involvement of locus coeruleus and noradrenergic neurotransmission in fentanyl - induced muscular rigidity in the rat .|Whereas muscular rigidity is a well - known side effect that is associated with high - dose fentanyl anesthesia , a paucity of information exists with regard to its underlying mechanism ( s ) .|We investigated in this study the possible engagement of locus coeruleus of the pons in this phenomenon , using male Sprague - Dawley rats anesthetized with ketamine .|Under proper control of respiration , body temperature and end - tidal CO2 , intravenous administration of fentanyl ( 50 or 100 micrograms / kg ) consistently promoted an increase in electromyographic activity recorded from the gastrocnemius and abdominal rectus muscles .|Such an induced muscular rigidity by the narcotic agent was significantly antagonized or even reduced by prior electrolytic lesions of the locus coeruleus or pretreatment with the alpha - adrenoceptor blocker , prazosin .|Microinjection of fentanyl ( 2 . 5 micrograms / 50 nl ) directly into this pontine nucleus , on the other hand , elicited discernible electromyographic excitation .|It is speculated that the induction of muscular rigidity by fentanyl may involve the coerulospinal noradrenergic fibers to the spinal motoneurons .	1:CID:2	L2R	NON-CROSS	191-193	194-195	D005283	fentanyl|fentanyl|fentanyl|fentanyl|fentanyl	Chemical	8:34:97:158:194	9:35:98:159:195	0:1:3:5:6	D009127	muscular rigidity|muscular rigidity|muscular rigidity|muscular rigidity	Disease	11:18:125:191	13:20:127:193	0:1:4:6	1:NR:2	R2L	CROSS	125-127	78-79	D007649	ketamine	Chemical	78	79	2	D009127	muscular rigidity|muscular rigidity|muscular rigidity|muscular rigidity	Disease	11:18:125:191	13:20:127:193	0:1:4:6	1:NR:2	R2L	CROSS	125-127	92-93	D002245	CO2	Chemical	92	93	3	D009127	muscular rigidity|muscular rigidity|muscular rigidity|muscular rigidity	Disease	11:18:125:191	13:20:127:193	0:1:4:6	1:NR:2	R2L	NON-CROSS	154-155	125-127	D011224	prazosin	Chemical	154	155	4	D009127	muscular rigidity|muscular rigidity|muscular rigidity|muscular rigidity	Disease	11:18:125:191	13:20:127:193	0:1:4:6
2339463	Cerebral sinus thrombosis as a potential hazard of antifibrinolytic treatment in menorrhagia .|We describe a 42 - year - old woman who developed superior sagittal and left transverse sinus thrombosis associated with prolonged epsilon - aminocaproic acid therapy for menorrhagia .|This antifibrinolytic agent has been used in women with menorrhagia to promote clotting and reduce blood loss .|Although increased risk of thromboembolic disease has been reported during treatment with epsilon - aminocaproic acid , cerebral sinus thrombosis has not been previously described .|Careful use of epsilon - aminocaproic acid therapy is recommended .	1:NR:2	R2L	NON-CROSS	77-80	72-76	D015119	epsilon - aminocaproic acid|epsilon - aminocaproic acid|epsilon - aminocaproic acid	Chemical	34:72:89	38:76:93	1:3:4	D012851	Cerebral sinus thrombosis|cerebral sinus thrombosis	Disease	0:77	3:80	0:3	1:NR:2	R2L	NON-CROSS	40-41	34-38	D015119	epsilon - aminocaproic acid|epsilon - aminocaproic acid|epsilon - aminocaproic acid	Chemical	34:72:89	38:76:93	1:3:4	D008595	menorrhagia|menorrhagia|menorrhagia	Disease	11:40:51	12:41:52	0:1:2	1:CID:2	R2L	NON-CROSS	34-38	25-31	D015119	epsilon - aminocaproic acid|epsilon - aminocaproic acid|epsilon - aminocaproic acid	Chemical	34:72:89	38:76:93	1:3:4	D020225	sagittal and left transverse sinus thrombosis	Disease	25	31	1	1:NR:2	R2L	NON-CROSS	34-38	25-31	D015119	epsilon - aminocaproic acid|epsilon - aminocaproic acid|epsilon - aminocaproic acid	Chemical	34:72:89	38:76:93	1:3:4	D020227	sagittal and left transverse sinus thrombosis	Disease	25	31	1	1:NR:2	L2R	CROSS	57-59	72-76	D015119	epsilon - aminocaproic acid|epsilon - aminocaproic acid|epsilon - aminocaproic acid	Chemical	34:72:89	38:76:93	1:3:4	D006473	blood loss	Disease	57	59	2	1:NR:2	L2R	NON-CROSS	64-66	72-76	D015119	epsilon - aminocaproic acid|epsilon - aminocaproic acid|epsilon - aminocaproic acid	Chemical	34:72:89	38:76:93	1:3:4	D013923	thromboembolic disease	Disease	64	66	3
1545575	Hemorrhagic cystitis complicating bone marrow transplantation .|Hemorrhagic cystitis is a potentially serious complication of high - dose cyclophosphamide therapy administered before bone marrow transplantation .|As standard practice at our institution , patients who are scheduled to receive a bone marrow transplant are treated prophylactically with forced hydration and bladder irrigation .|In an attempt to obviate the inconvenience of bladder irrigation , we conducted a feasibility trial of uroprophylaxis with mesna , which neutralizes the hepatic metabolite of cyclophosphamide that causes hemorrhagic cystitis .|Of 97 patients who received standard prophylaxis , 4 had symptomatic hemorrhagic cystitis .|In contrast , two of four consecutive patients who received mesna uroprophylaxis before allogeneic bone marrow transplantation had severe hemorrhagic cystitis for at least 2 weeks .|Because of this suboptimal result , we resumed the use of bladder irrigation and forced hydration to minimize the risk of hemorrhagic cystitis .	1:CID:2	R2L	NON-CROSS	83-85	80-81	D003520	cyclophosphamide|cyclophosphamide	Chemical	18:80	19:81	1:3	D006470	Hemorrhagic cystitis|Hemorrhagic cystitis|hemorrhagic cystitis|hemorrhagic cystitis|hemorrhagic cystitis|hemorrhagic cystitis	Disease	0:7:83:97:119:148	2:9:85:99:121:150	0:1:3:4:5:6	1:NR:2	R2L	NON-CROSS	119-121	110-111	D015080	mesna|mesna	Chemical	72:110	73:111	3:5	D006470	Hemorrhagic cystitis|Hemorrhagic cystitis|hemorrhagic cystitis|hemorrhagic cystitis|hemorrhagic cystitis|hemorrhagic cystitis	Disease	0:7:83:97:119:148	2:9:85:99:121:150	0:1:3:4:5:6	1:CID:2	R2L	NON-CROSS	83-85	80-81	D003520	cyclophosphamide|cyclophosphamide	Chemical	18:80	19:81	1:3	D003556	Hemorrhagic cystitis|Hemorrhagic cystitis|hemorrhagic cystitis|hemorrhagic cystitis|hemorrhagic cystitis|hemorrhagic cystitis	Disease	0:7:83:97:119:148	2:9:85:99:121:150	0:1:3:4:5:6	1:NR:2	R2L	NON-CROSS	119-121	110-111	D015080	mesna|mesna	Chemical	72:110	73:111	3:5	D003556	Hemorrhagic cystitis|Hemorrhagic cystitis|hemorrhagic cystitis|hemorrhagic cystitis|hemorrhagic cystitis|hemorrhagic cystitis	Disease	0:7:83:97:119:148	2:9:85:99:121:150	0:1:3:4:5:6
1286498	Reversal of central benzodiazepine effects by flumazenil after intravenous conscious sedation with diazepam and opioids : report of a double - blind multicenter study .|The Flumazenil in Intravenous Conscious Sedation with Diazepam Multicenter Study Group II .|The efficacy and safety of a new benzodiazepine antagonist , flumazenil , were assessed in a double - blind multicenter study .|Flumazenil ( mean dose , 0 . 76 mg ) or placebo ( mean dose , 8 . 9 ml ) was administered intravenously to 130 and 67 patients , respectively , who had been given diazepam in conjunction with an opioid ( fentanyl , meperidine , or morphine ) for the induction and maintenance of intravenous conscious sedation for diagnostic or therapeutic surgical procedures .|The group assessable for efficacy comprised 122 patients treated with flumazenil and 64 patients given placebo .|After 5 minutes , 80 / 115 ( 70 % ) flumazenil - treated patients , compared with 21 / 63 ( 33 % ) placebo - treated patients , were completely awake and alert , as indicated by a score of 5 on the Observer 's Assessment of Alertness / Sedation Scale .|Ninety - five percent of patients in each group who attained a score of 5 at the 5 - minute assessment showed no loss of alertness throughout the 180 - minute assessment period .|Flumazenil - treated patients also performed significantly better on the Finger - to - Nose Test and the recall of pictures shown at the 5 - minute assessment .|Flumazenil was well tolerated , with no serious adverse effects reported .|Thirty - nine ( 30 % ) of flumazenil - treated patients , compared with 17 ( 25 % ) of placebo - treated patients had one or more drug - related adverse experiences .|The most common adverse effects were nausea and vomiting in the flumazenil group and nausea and injection - site pain in the placebo group .|Flumazenil was found to promptly reverse sedation induced by diazepam in the presence of opioids .	1:NR:2	L2R	CROSS	45-46	313-314	D001569	benzodiazepine|benzodiazepine	Chemical	3:45	4:46	0:2	D009325	nausea|nausea	Disease	313:321	314:322	10:10	1:NR:2	L2R	CROSS	45-46	315-316	D001569	benzodiazepine|benzodiazepine	Chemical	3:45	4:46	0:2	D014839	vomiting	Disease	315	316	10	1:NR:2	L2R	CROSS	45-46	326-327	D001569	benzodiazepine|benzodiazepine	Chemical	3:45	4:46	0:2	D010146	pain	Disease	326	327	10	1:CID:2	L2R	NON-CROSS	318-319	321-322	D005442	flumazenil|Flumazenil|flumazenil|Flumazenil|flumazenil|flumazenil|Flumazenil|Flumazenil|flumazenil|flumazenil|Flumazenil	Chemical	6:26:48:60:136:154:231:260:280:318:332	7:27:49:61:137:155:232:261:281:319:333	0:1:2:3:4:5:7:8:9:10:11	D009325	nausea|nausea	Disease	313:321	314:322	10:10	1:CID:2	L2R	NON-CROSS	315-316	318-319	D005442	flumazenil|Flumazenil|flumazenil|Flumazenil|flumazenil|flumazenil|Flumazenil|Flumazenil|flumazenil|flumazenil|Flumazenil	Chemical	6:26:48:60:136:154:231:260:280:318:332	7:27:49:61:137:155:232:261:281:319:333	0:1:2:3:4:5:7:8:9:10:11	D014839	vomiting	Disease	315	316	10	1:NR:2	L2R	NON-CROSS	326-327	332-333	D005442	flumazenil|Flumazenil|flumazenil|Flumazenil|flumazenil|flumazenil|Flumazenil|Flumazenil|flumazenil|flumazenil|Flumazenil	Chemical	6:26:48:60:136:154:231:260:280:318:332	7:27:49:61:137:155:232:261:281:319:333	0:1:2:3:4:5:7:8:9:10:11	D010146	pain	Disease	326	327	10	1:NR:2	L2R	CROSS	321-322	341-342	D003975	diazepam|Diazepam|diazepam|diazepam	Chemical	12:32:96:341	13:33:97:342	0:1:3:11	D009325	nausea|nausea	Disease	313:321	314:322	10:10	1:NR:2	L2R	CROSS	315-316	341-342	D003975	diazepam|Diazepam|diazepam|diazepam	Chemical	12:32:96:341	13:33:97:342	0:1:3:11	D014839	vomiting	Disease	315	316	10	1:NR:2	L2R	CROSS	326-327	341-342	D003975	diazepam|Diazepam|diazepam|diazepam	Chemical	12:32:96:341	13:33:97:342	0:1:3:11	D010146	pain	Disease	326	327	10	1:NR:2	L2R	CROSS	103-104	313-314	D005283	fentanyl	Chemical	103	104	3	D009325	nausea|nausea	Disease	313:321	314:322	10:10	1:NR:2	L2R	CROSS	103-104	315-316	D005283	fentanyl	Chemical	103	104	3	D014839	vomiting	Disease	315	316	10	1:NR:2	L2R	CROSS	103-104	326-327	D005283	fentanyl	Chemical	103	104	3	D010146	pain	Disease	326	327	10	1:NR:2	L2R	CROSS	105-106	313-314	D008614	meperidine	Chemical	105	106	3	D009325	nausea|nausea	Disease	313:321	314:322	10:10	1:NR:2	L2R	CROSS	105-106	315-316	D008614	meperidine	Chemical	105	106	3	D014839	vomiting	Disease	315	316	10	1:NR:2	L2R	CROSS	105-106	326-327	D008614	meperidine	Chemical	105	106	3	D010146	pain	Disease	326	327	10	1:NR:2	L2R	CROSS	108-109	313-314	D009020	morphine	Chemical	108	109	3	D009325	nausea|nausea	Disease	313:321	314:322	10:10	1:NR:2	L2R	CROSS	108-109	315-316	D009020	morphine	Chemical	108	109	3	D014839	vomiting	Disease	315	316	10	1:NR:2	L2R	CROSS	108-109	326-327	D009020	morphine	Chemical	108	109	3	D010146	pain	Disease	326	327	10
839274	Hepatic adenomas and focal nodular hyperplasia of the liver in young women on oral contraceptives : case reports .|Two cases of hepatic adenoma and one of focal nodular hyperplasia presumably associated with the use of oral contraceptives , are reported .|Special reference is made to their clinical presentation , which may be totally asymptomatic .|Liver - function tests are of little diagnostic value , but valuable information may be obtained from both liver scanning and hepatic angiography .|Histologic differences and clinical similarities between hepatic adenoma and focal nodular hyperplasia of the liver are discussed .	1:CID:2	R2L	NON-CROSS	23-24	13-15	D003276	oral contraceptives|oral contraceptives	Chemical	13:36	15:38	0:1	D000236	adenomas|adenoma|adenoma	Disease	1:23:88	2:24:89	0:1:4	1:CID:2	R2L	NON-CROSS	36-38	27-30	D003276	oral contraceptives|oral contraceptives	Chemical	13:36	15:38	0:1	D020518	focal nodular hyperplasia|focal nodular hyperplasia|focal nodular hyperplasia	Disease	3:27:90	6:30:93	0:1:4
591536	Arterial thromboembolism in patients receiving systemic heparin therapy : a complication associated with heparin - induced thrombocytopenia .|Arterial thromboembolism is a recognized complication of systemic heparin therapy .|Characteristic of the entity is arterial occlusion by platelet - fibrin thrombi with distal ischemia occurring four to twenty days after the initiation of heparin therapy , preceded by profound thrombocytopenia with platelet counts in the range of 30 , 000 to 40 , 000 per cubic millimeter .|The clinically apparent occlusion may be preceded by gastrointestinal and musculoskeletal symptoms that appear to be ischemic in origin , and might serve to warn the clinician of these complications .|Previous reports of these phenomena as well as recent studies of the effect of heparin are reviewed .|The common factor relating thromboembolism and thrombocytopenia is heparin - induced platelet aggregation .|Appropriate treatment consists of discontinuation of heparin , and anticoagulation with sodium warfarin if necessary .|Vascular procedures are performed as indicated .	1:NR:2	R2L	NON-CROSS	135-136	131-132	D006493	heparin|heparin|heparin|heparin|heparin|heparin|heparin	Chemical	6:13:26:53:123:135:147	7:14:27:54:124:136:148	0:0:1:2:4:5:6	D013923	thromboembolism|thromboembolism|thromboembolism	Disease	1:19:131	2:20:132	0:1:5	1:NR:2	R2L	CROSS	152-154	131-132	D014859	sodium warfarin	Chemical	152	154	6	D013923	thromboembolism|thromboembolism|thromboembolism	Disease	1:19:131	2:20:132	0:1:5	1:CID:2	L2R	NON-CROSS	133-134	135-136	D006493	heparin|heparin|heparin|heparin|heparin|heparin|heparin	Chemical	6:13:26:53:123:135:147	7:14:27:54:124:136:148	0:0:1:2:4:5:6	D013921	thrombocytopenia|thrombocytopenia|thrombocytopenia	Disease	16:59:133	17:60:134	0:2:5	1:CID:2	L2R	NON-CROSS	26-27	34-36	D006493	heparin|heparin|heparin|heparin|heparin|heparin|heparin	Chemical	6:13:26:53:123:135:147	7:14:27:54:124:136:148	0:0:1:2:4:5:6	D001157	arterial occlusion	Disease	34	36	2	1:NR:2	L2R	NON-CROSS	40-41	53-54	D006493	heparin|heparin|heparin|heparin|heparin|heparin|heparin	Chemical	6:13:26:53:123:135:147	7:14:27:54:124:136:148	0:0:1:2:4:5:6	D013927	thrombi	Disease	40	41	2	1:NR:2	L2R	NON-CROSS	43-44	53-54	D006493	heparin|heparin|heparin|heparin|heparin|heparin|heparin	Chemical	6:13:26:53:123:135:147	7:14:27:54:124:136:148	0:0:1:2:4:5:6	D007511	ischemia|ischemic	Disease	43:94	44:95	2:3	1:NR:2	L2R	CROSS	53-54	86-90	D006493	heparin|heparin|heparin|heparin|heparin|heparin|heparin	Chemical	6:13:26:53:123:135:147	7:14:27:54:124:136:148	0:0:1:2:4:5:6	D005767	gastrointestinal and musculoskeletal symptoms	Disease	86	90	3	1:NR:2	L2R	CROSS	53-54	86-90	D006493	heparin|heparin|heparin|heparin|heparin|heparin|heparin	Chemical	6:13:26:53:123:135:147	7:14:27:54:124:136:148	0:0:1:2:4:5:6	D009140	gastrointestinal and musculoskeletal symptoms	Disease	86	90	3	1:NR:2	L2R	NON-CROSS	135-136	138-140	D006493	heparin|heparin|heparin|heparin|heparin|heparin|heparin	Chemical	6:13:26:53:123:135:147	7:14:27:54:124:136:148	0:0:1:2:4:5:6	D001791	platelet aggregation	Disease	138	140	5	1:NR:2	R2L	CROSS	152-154	133-134	D014859	sodium warfarin	Chemical	152	154	6	D013921	thrombocytopenia|thrombocytopenia|thrombocytopenia	Disease	16:59:133	17:60:134	0:2:5	1:NR:2	R2L	CROSS	152-154	34-36	D014859	sodium warfarin	Chemical	152	154	6	D001157	arterial occlusion	Disease	34	36	2	1:NR:2	R2L	CROSS	152-154	40-41	D014859	sodium warfarin	Chemical	152	154	6	D013927	thrombi	Disease	40	41	2	1:NR:2	R2L	CROSS	152-154	94-95	D014859	sodium warfarin	Chemical	152	154	6	D007511	ischemia|ischemic	Disease	43:94	44:95	2:3	1:NR:2	R2L	CROSS	152-154	86-90	D014859	sodium warfarin	Chemical	152	154	6	D005767	gastrointestinal and musculoskeletal symptoms	Disease	86	90	3	1:NR:2	R2L	CROSS	152-154	86-90	D014859	sodium warfarin	Chemical	152	154	6	D009140	gastrointestinal and musculoskeletal symptoms	Disease	86	90	3	1:NR:2	R2L	CROSS	152-154	138-140	D014859	sodium warfarin	Chemical	152	154	6	D001791	platelet aggregation	Disease	138	140	5
20735774	Long - term prognosis for transplant - free survivors of paracetamol - induced acute liver failure .|BACKGROUND : The prognosis for transplant - free survivors of paracetamol - induced acute liver failure remains unknown .|AIM : To examine whether paracetamol - induced acute liver failure increases long - term mortality .|METHODS : We followed up all transplant - free survivors of paracetamol - induced acute liver injury , hospitalized in a Danish national referral centre during 1984 - 2004 .|We compared age - specific mortality rates from 1 year post - discharge through 2008 between those in whom the liver injury led to an acute liver failure and those in whom it did not .|RESULTS : We included 641 patients .|On average , age - specific mortality rates were slightly higher for the 101 patients whose paracetamol - induced liver injury had caused an acute liver failure ( adjusted mortality rate ratio = 1 . 70 , 95 % CI 1 . 02 - 2 . 85 ) , but the association was age - dependent , and no survivors of acute liver failure died of liver disease , whereas suicides were frequent in both groups .|These observations speak against long - term effects of acute liver failure .|More likely , the elevated mortality rate ratio resulted from incomplete adjustment for the greater prevalence of substance abuse among survivors of acute liver failure .|CONCLUSIONS : Paracetamol - induced acute liver failure did not affect long - term mortality .|Clinical follow - up may be justified by the cause of the liver failure , but not by the liver failure itself .	1:CID:2	L2R	NON-CROSS	10-11	13-16	D000082	paracetamol|paracetamol|paracetamol|paracetamol|paracetamol|Paracetamol	Chemical	10:27:41:64:142:244	11:28:42:65:143:245	0:1:2:3:6:9	D017114	acute liver failure|acute liver failure|acute liver failure|acute liver failure|acute liver failure|acute liver failure|acute liver failure|acute liver failure|acute liver failure	Disease	13:30:44:108:150:187:212:238:247	16:33:47:111:153:190:215:241:250	0:1:2:4:6:6:7:8:9	1:NR:2	L2R	NON-CROSS	64-65	67-70	D000082	paracetamol|paracetamol|paracetamol|paracetamol|paracetamol|Paracetamol	Chemical	10:27:41:64:142:244	11:28:42:65:143:245	0:1:2:3:6:9	D056486	acute liver injury|liver injury|liver injury	Disease	67:103:145	70:105:147	3:4:6	1:NR:2	L2R	NON-CROSS	142-143	192-194	D000082	paracetamol|paracetamol|paracetamol|paracetamol|paracetamol|Paracetamol	Chemical	10:27:41:64:142:244	11:28:42:65:143:245	0:1:2:3:6:9	D008107	liver disease	Disease	192	194	6	1:NR:2	L2R	CROSS	233-235	244-245	D000082	paracetamol|paracetamol|paracetamol|paracetamol|paracetamol|Paracetamol	Chemical	10:27:41:64:142:244	11:28:42:65:143:245	0:1:2:3:6:9	D019966	substance abuse	Disease	233	235	8	1:NR:2	L2R	CROSS	244-245	270-272	D000082	paracetamol|paracetamol|paracetamol|paracetamol|paracetamol|Paracetamol	Chemical	10:27:41:64:142:244	11:28:42:65:143:245	0:1:2:3:6:9	D017093	liver failure|liver failure	Disease	270:277	272:279	10:10
20705401	Serotonin 6 receptor gene is associated with methamphetamine - induced psychosis in a Japanese population .|BACKGROUND : Altered serotonergic neural transmission is hypothesized to be a susceptibility factor for psychotic disorders such as schizophrenia .|The serotonin 6 ( 5 - HT6 ) receptor is therapeutically targeted by several second generation antipsychotics , such as clozapine and olanzapine , and d - amphetamine - induced hyperactivity in rats is corrected with the use of a selective 5 - HT6 receptor antagonist .|In addition , the disrupted prepulse inhibition induced by d - amphetamine or phencyclidine was restored by 5 - HT6 receptor antagonist in an animal study using rats .|These animal models were considered to reflect the positive symptoms of schizophrenia , and the above evidence suggests that altered 5 - HT6 receptors are involved in the pathophysiology of psychotic disorders .|The symptoms of methamphetamine ( METH ) - induced psychosis are similar to those of paranoid type schizophrenia .|Therefore , we conducted an analysis of the association of the 5 - HT6 gene ( HTR6 ) with METH - induced psychosis .|METHOD : Using five tagging SNPs ( rs6693503 , rs1805054 , rs4912138 , rs3790757 and rs9659997 ) , we conducted a genetic association analysis of case - control samples ( 197 METH - induced psychosis patients and 337 controls ) in the Japanese population .|The age and sex of the control subjects did not differ from those of the methamphetamine dependence patients .|RESULTS : rs6693503 was associated with METH - induced psychosis patients in the allele / genotype - wise analysis .|Moreover , this association remained significant after Bonferroni correction .|In the haplotype - wise analysis , we detected an association between two markers ( rs6693503 and rs1805054 ) and three markers ( rs6693503 , rs1805054 and rs4912138 ) in HTR6 and METH - induced psychosis patients , respectively .|CONCLUSION : HTR6 may play an important role in the pathophysiology of METH - induced psychosis in the Japanese population .	1:NR:2	L2R	NON-CROSS	30-32	37-38	D012701	Serotonin|serotonin|5 - HT|5 - HT|5 - HT|5 - HT|5 - HT	Chemical	0:37:40:77:100:132:175	1:38:43:80:103:135:178	0:2:2:2:3:4:6	D011605	psychosis|psychotic disorders|psychotic disorders|psychosis|psychosis|psychosis|psychosis|psychosis|psychosis	Disease	10:30:142:154:186:222:261:317:337	11:32:144:155:187:223:262:318:338	0:1:4:5:6:7:9:11:12	1:NR:2	L2R	NON-CROSS	34-35	37-38	D012701	Serotonin|serotonin|5 - HT|5 - HT|5 - HT|5 - HT|5 - HT	Chemical	0:37:40:77:100:132:175	1:38:43:80:103:135:178	0:2:2:2:3:4:6	D012559	schizophrenia|schizophrenia	Disease	34:123	35:124	1:4	1:NR:2	L2R	NON-CROSS	66-67	77-80	D012701	Serotonin|serotonin|5 - HT|5 - HT|5 - HT|5 - HT|5 - HT	Chemical	0:37:40:77:100:132:175	1:38:43:80:103:135:178	0:2:2:2:3:4:6	D006948	hyperactivity	Disease	66	67	2	1:NR:2	L2R	CROSS	160-163	175-178	D012701	Serotonin|serotonin|5 - HT|5 - HT|5 - HT|5 - HT|5 - HT	Chemical	0:37:40:77:100:132:175	1:38:43:80:103:135:178	0:2:2:2:3:4:6	D012563	paranoid type schizophrenia	Disease	160	163	5	1:CID:2	L2R	NON-CROSS	7-8	10-11	D008694	methamphetamine|methamphetamine|METH|METH|METH|methamphetamine|METH|METH|METH	Chemical	7:148:150:183:219:248:258:314:334	8:149:151:184:220:249:259:315:335	0:5:5:6:7:8:9:11:12	D011605	psychosis|psychotic disorders|psychotic disorders|psychosis|psychosis|psychosis|psychosis|psychosis|psychosis	Disease	10:30:142:154:186:222:261:317:337	11:32:144:155:187:223:262:318:338	0:1:4:5:6:7:9:11:12	1:NR:2	L2R	CROSS	123-124	148-149	D008694	methamphetamine|methamphetamine|METH|METH|METH|methamphetamine|METH|METH|METH	Chemical	7:148:150:183:219:248:258:314:334	8:149:151:184:220:249:259:315:335	0:5:5:6:7:8:9:11:12	D012559	schizophrenia|schizophrenia	Disease	34:123	35:124	1:4	1:NR:2	L2R	CROSS	7-8	66-67	D008694	methamphetamine|methamphetamine|METH|METH|METH|methamphetamine|METH|METH|METH	Chemical	7:148:150:183:219:248:258:314:334	8:149:151:184:220:249:259:315:335	0:5:5:6:7:8:9:11:12	D006948	hyperactivity	Disease	66	67	2	1:NR:2	L2R	NON-CROSS	150-151	160-163	D008694	methamphetamine|methamphetamine|METH|METH|METH|methamphetamine|METH|METH|METH	Chemical	7:148:150:183:219:248:258:314:334	8:149:151:184:220:249:259:315:335	0:5:5:6:7:8:9:11:12	D012563	paranoid type schizophrenia	Disease	160	163	5	1:NR:2	R2L	CROSS	56-57	30-32	D003024	clozapine	Chemical	56	57	2	D011605	psychosis|psychotic disorders|psychotic disorders|psychosis|psychosis|psychosis|psychosis|psychosis|psychosis	Disease	10:30:142:154:186:222:261:317:337	11:32:144:155:187:223:262:318:338	0:1:4:5:6:7:9:11:12	1:NR:2	R2L	CROSS	58-59	30-32	C076029	olanzapine	Chemical	58	59	2	D011605	psychosis|psychotic disorders|psychotic disorders|psychosis|psychosis|psychosis|psychosis|psychosis|psychosis	Disease	10:30:142:154:186:222:261:317:337	11:32:144:155:187:223:262:318:338	0:1:4:5:6:7:9:11:12	1:NR:2	R2L	CROSS	61-64	30-32	D003913	d - amphetamine|d - amphetamine	Chemical	61:92	64:95	2:3	D011605	psychosis|psychotic disorders|psychotic disorders|psychosis|psychosis|psychosis|psychosis|psychosis|psychosis	Disease	10:30:142:154:186:222:261:317:337	11:32:144:155:187:223:262:318:338	0:1:4:5:6:7:9:11:12	1:NR:2	R2L	CROSS	142-144	96-97	D010622	phencyclidine	Chemical	96	97	3	D011605	psychosis|psychotic disorders|psychotic disorders|psychosis|psychosis|psychosis|psychosis|psychosis|psychosis	Disease	10:30:142:154:186:222:261:317:337	11:32:144:155:187:223:262:318:338	0:1:4:5:6:7:9:11:12	1:NR:2	R2L	CROSS	56-57	34-35	D003024	clozapine	Chemical	56	57	2	D012559	schizophrenia|schizophrenia	Disease	34:123	35:124	1:4	1:NR:2	R2L	CROSS	58-59	34-35	C076029	olanzapine	Chemical	58	59	2	D012559	schizophrenia|schizophrenia	Disease	34:123	35:124	1:4	1:NR:2	R2L	CROSS	61-64	34-35	D003913	d - amphetamine|d - amphetamine	Chemical	61:92	64:95	2:3	D012559	schizophrenia|schizophrenia	Disease	34:123	35:124	1:4	1:NR:2	R2L	CROSS	123-124	96-97	D010622	phencyclidine	Chemical	96	97	3	D012559	schizophrenia|schizophrenia	Disease	34:123	35:124	1:4	1:NR:2	L2R	NON-CROSS	56-57	66-67	D003024	clozapine	Chemical	56	57	2	D006948	hyperactivity	Disease	66	67	2	1:NR:2	L2R	CROSS	56-57	160-163	D003024	clozapine	Chemical	56	57	2	D012563	paranoid type schizophrenia	Disease	160	163	5	1:NR:2	L2R	NON-CROSS	58-59	66-67	C076029	olanzapine	Chemical	58	59	2	D006948	hyperactivity	Disease	66	67	2	1:NR:2	L2R	CROSS	58-59	160-163	C076029	olanzapine	Chemical	58	59	2	D012563	paranoid type schizophrenia	Disease	160	163	5	1:NR:2	L2R	NON-CROSS	61-64	66-67	D003913	d - amphetamine|d - amphetamine	Chemical	61:92	64:95	2:3	D006948	hyperactivity	Disease	66	67	2	1:NR:2	L2R	CROSS	92-95	160-163	D003913	d - amphetamine|d - amphetamine	Chemical	61:92	64:95	2:3	D012563	paranoid type schizophrenia	Disease	160	163	5	1:NR:2	R2L	CROSS	96-97	66-67	D010622	phencyclidine	Chemical	96	97	3	D006948	hyperactivity	Disease	66	67	2	1:NR:2	L2R	CROSS	96-97	160-163	D010622	phencyclidine	Chemical	96	97	3	D012563	paranoid type schizophrenia	Disease	160	163	5
19105845	Effect of increasing intraperitoneal infusion rates on bupropion hydrochloride - induced seizures in mice .|BACKGROUND : It is not known if there is a relationship between input rate and incidence of bupropion - induced seizures .|This is important , since different controlled release formulations of bupropion release the active drug at different rates .|METHODS : We investigated the effect of varying the intraperitoneal infusion rates of bupropion HCl 120 mg / kg , a known convulsive dose 50 ( CD50 ) , on the incidence and severity of bupropion - induced convulsions in the Swiss albino mice .|A total of 69 mice , approximately 7 weeks of age , and weighing 21 . 0 to 29 . 1 g were randomly assigned to bupropion HCl 120 mg / kg treatment by intraperitoneal ( IP ) administration in 7 groups ( 9 to 10 animals per group ) .|Bupropion HCl was infused through a surgically implanted IP dosing catheter with infusions in each group of 0 min , 15 min , 30 min , 60 min , 90 min , 120 min , and 240 min .|The number , time of onset , duration and the intensity of the convulsions or absence of convulsions were recorded .|RESULTS : The results showed that IP administration of bupropion HCl 120 mg / kg by bolus injection induced convulsions in 6 out of 10 mice ( 60 % of convulsing mice ) in group 1 .|Logistic regression analysis revealed that infusion time was significant ( p = 0 . 0004 ; odds ratio = 0 . 974 ) and increasing the IP infusion time of bupropion HCl 120 mg / kg was associated with a 91 % reduced odds of convulsions at infusion times of 15 to 90 min compared to bolus injection .|Further increase in infusion time resulted in further reduction in the odds of convulsions to 99 . 8 % reduction at 240 min .|CONCLUSION : In conclusion , the demonstration of an inverse relationship between infusion time of a fixed and convulsive dose of bupropion and the risk of convulsions in a prospective study is novel .	1:CID:2	L2R	NON-CROSS	7-9	11-12	D016642	bupropion hydrochloride|bupropion|bupropion|bupropion HCl|bupropion|bupropion HCl|Bupropion HCl|bupropion HCl|bupropion HCl|bupropion	Chemical	7:32:47:69:91:127:152:221:279:353	9:33:48:71:92:129:154:223:281:354	0:1:2:3:3:4:5:7:8:10	D012640	seizures|seizures|convulsive|convulsions|convulsions|convulsions|convulsions|convulsions|convulsions|convulsive|convulsions	Disease	11:35:78:94:204:208:231:294:321:350:358	12:36:79:95:205:209:232:295:322:351:359	0:1:3:3:6:6:7:8:9:10:10
18657397	Detailed spectral profile analysis of penicillin - induced epileptiform activity in anesthetized rats .|Penicillin model is a widely used experimental model for epilepsy research .|In the present study we aimed to portray a detailed spectral analysis of penicillin - induced epileptiform activity in comparison with basal brain activity in anesthetized Wistar rats .|Male Wistar rats were anesthetized with i . p .|urethane and connected to an electrocorticogram setup .|After a short period of basal activity recording , epileptic focus was induced by injecting 400IU / 2 microl penicillin - G potassium into the left lateral ventricle while the cortical activity was continuously recorded .|Basal activity , latent period and the penicillin - induced epileptiform activity periods were then analyzed using both conventional methods and spectral analysis .|Spectral analyses were conducted by dividing the whole spectrum into different frequency bands including delta , theta ( slow and fast ) , alpha - sigma , beta ( 1 and 2 ) and gamma ( 1 and 2 ) bands .|Our results show that the most affected frequency bands were delta , theta , beta - 2 and gamma - 2 bands during the epileptiform activity and there were marked differences in terms of spectral densities between three investigated episodes ( basal activity , latent period and epileptiform activity ) .|Our results may help to analyze novel data obtained using similar experimental models and the simple analysis method described here can be used in similar studies to investigate the basic neuronal mechanism of this or other types of experimental epilepsies .	1:NR:2	L2R	NON-CROSS	5-6	8-10	D010406	penicillin|Penicillin|penicillin|penicillin	Chemical	5:14:39:116	6:15:40:117	0:1:2:6	D004827	epileptiform activity|epilepsy|epileptiform activity|epileptic|epileptiform activity|epileptiform activity|epileptiform activity|epilepsies	Disease	8:23:42:82:119:199:222:265	10:24:44:83:121:201:224:266	0:1:2:5:6:8:8:9	1:NR:2	R2L	CROSS	82-83	65-66	D014520	urethane	Chemical	65	66	4	D004827	epileptiform activity|epilepsy|epileptiform activity|epileptic|epileptiform activity|epileptiform activity|epileptiform activity|epilepsies	Disease	8:23:42:82:119:199:222:265	10:24:44:83:121:201:224:266	0:1:2:5:6:8:8:9	1:CID:2	R2L	NON-CROSS	92-96	82-83	D010400	penicillin - G potassium	Chemical	92	96	5	D004827	epileptiform activity|epilepsy|epileptiform activity|epileptic|epileptiform activity|epileptiform activity|epileptiform activity|epilepsies	Disease	8:23:42:82:119:199:222:265	10:24:44:83:121:201:224:266	0:1:2:5:6:8:8:9
18363626	High dose dexmedetomidine as the sole sedative for pediatric MRI .|OBJECTIVE : This large - scale retrospective review evaluates the sedation profile of dexmedetomidine .|AIM : To determine the hemodynamic responses , efficacy and adverse events associated with the use of high dose dexmedetomidine as the sole sedative for magnetic resonance imaging ( MRI ) studies .|BACKGROUND : Dexmedetomidine has been used at our institution since 2005 to provide sedation for pediatric radiological imaging studies .|Over time , an effective protocol utilizing high dose dexmedetomidine as the sole sedative agent has evolved .|METHODS / MATERIALS : As part of the ongoing Quality Assurance process , data on all sedations are reviewed monthly and protocols modified as needed .|Data were analyzed from all 747 consecutive patients who received dexmedetomidine for MRI sedation from April 2005 to April 2007 .|RESULTS : Since 2005 , the 10 - min loading dose of our dexmedetomidine protocol increased from 2 to 3 microg . kg ( - 1 ) , and the infusion rate increased from 1 to 1 . 5 to 2 microg . kg ( - 1 ) . h ( - 1 ) .|The current sedation protocol progressively increased the rate of successful sedation ( able to complete the imaging study ) when using dexmedetomidine alone from 91 . 8 % to 97 . 6 % ( P = 0 . 009 ) , reducing the requirement for adjuvant pentobarbital in the event of sedation failure with dexmedetomidine alone and decreased the mean recovery time by 10 min ( P < 0 . 001 ) .|Although dexmedetomidine sedation was associated with a 16 % incidence of bradycardia , all concomitant mean arterial blood pressures were within 20 % of age - adjusted normal range and oxygen saturations were 95 % or higher .|CONCLUSION : Dexmedetomidine in high doses provides adequate sedation for pediatric MRI studies .|While use of high dose dexmedetomidine is associated with decreases in heart rate and blood pressure outside the established ' awake ' norms , this deviation is generally within 20 % of norms , and is not associated with adverse sequelae .|Dexmedetomidine is useful as the sole sedative for pediatric MRI .	1:CID:2	L2R	NON-CROSS	273-274	283-284	D020927	dexmedetomidine|dexmedetomidine|dexmedetomidine|Dexmedetomidine|dexmedetomidine|dexmedetomidine|dexmedetomidine|dexmedetomidine|dexmedetomidine|dexmedetomidine|Dexmedetomidine|dexmedetomidine|Dexmedetomidine	Chemical	2:24:45:61:88:133:157:220:253:273:312:329:366	3:25:46:62:89:134:158:221:254:274:313:330:367	0:1:2:3:4:6:7:8:8:9:10:11:12	D001919	bradycardia	Disease	283	284	9	1:NR:2	L2R	CROSS	245-246	283-284	D010424	pentobarbital	Chemical	245	246	8	D001919	bradycardia	Disease	283	284	9	1:NR:2	R2L	NON-CROSS	302-303	283-284	D010100	oxygen	Chemical	302	303	9	D001919	bradycardia	Disease	283	284	9
16192988	Methamphetamine causes alterations in the MAP kinase - related pathways in the brains of mice that display increased aggressiveness .|Aggressive behaviors have been reported in patients who suffer from some psychiatric disorders , and are common in methamphetamine ( METH ) abusers .|Herein , we report that multiple ( but not single ) injections of METH significantly increased aggressiveness in male CD - 1 mice .|This increase in aggressiveness was not secondary to METH - induced hyperactivity .|Analysis of protein expression using antibody microarrays and Western blotting revealed differential changes in MAP kinase - related pathways after multiple and single METH injections .|There were statistically significant ( p < 0 . 05 ) decreases in MEK1 , Erk2p , GSK3alpha , 14 - 3 - 3e , and MEK7 in the striata of mice after multiple injections of METH .|MEK1 was significantly decreased also after a single injection of METH , but to a much lesser degree than after multiple injections of METH .|In the frontal cortex , there was a statistically significant decrease in GSK3alpha after multiple ( but not single ) injections of METH .|These findings suggest that alterations in MAP kinase - related pathways in the prefronto - striatal circuitries might be involved in the manifestation of aggressive behaviors in mice .	1:CID:2	L2R	NON-CROSS	57-58	60-61	D008694	Methamphetamine|methamphetamine|METH|METH|METH|METH|METH|METH|METH|METH	Chemical	0:38:40:57:76:104:143:155:168:192	1:39:41:58:77:105:144:156:169:193	0:1:1:2:3:4:5:6:6:7	D001523	aggressiveness|Aggressive behaviors|psychiatric disorders|aggressiveness|aggressiveness|aggressive behaviors	Disease	18:20:31:60:71:218	19:22:33:61:72:220	0:1:1:2:3:8	1:NR:2	L2R	NON-CROSS	76-77	79-80	D008694	Methamphetamine|methamphetamine|METH|METH|METH|METH|METH|METH|METH|METH	Chemical	0:38:40:57:76:104:143:155:168:192	1:39:41:58:77:105:144:156:169:193	0:1:1:2:3:4:5:6:6:7	D006948	hyperactivity	Disease	79	80	3
16157917	Lamotrigine associated with exacerbation or de novo myoclonus in idiopathic generalized epilepsies .|Five patients with idiopathic generalized epilepsies ( IGE ) treated with lamotrigine ( LTG ) experienced exacerbation or de novo appearance of myoclonic jerks ( MJ ) .|In three patients , LTG exacerbated MJ in a dose - dependent manner with early aggravation during titration .|MJ disappeared when LTG dose was decreased by 25 to 50 % .|In two patients , LTG exacerbated MJ in a delayed but more severe manner , with myoclonic status that only ceased after LTG withdrawal .	1:CID:2	L2R	NON-CROSS	45-46	47-48	C047781	Lamotrigine|lamotrigine|LTG|LTG|LTG|LTG|LTG	Chemical	0:24:26:45:63:77:95	1:25:27:46:64:78:96	0:1:1:2:3:4:4	D009207	myoclonus|myoclonic jerks|MJ|MJ|MJ|MJ|myoclonic status	Disease	7:35:38:47:60:79:89	8:37:39:48:61:80:91	0:1:1:2:3:4:4	1:NR:2	L2R	NON-CROSS	20-21	24-25	C047781	Lamotrigine|lamotrigine|LTG|LTG|LTG|LTG|LTG	Chemical	0:24:26:45:63:77:95	1:25:27:46:64:78:96	0:1:1:2:3:4:4	C562694	idiopathic generalized epilepsies|idiopathic generalized epilepsies|IGE	Disease	9:16:20	12:19:21	0:1:1
16116131	rTMS of supplementary motor area modulates therapy - induced dyskinesias in Parkinson disease .|The neural mechanisms and circuitry involved in levodopa - induced dyskinesia are unclear .|Using repetitive transcranial magnetic stimulation ( rTMS ) over the supplementary motor area ( SMA ) in a group of patients with advanced Parkinson disease , the authors investigated whether modulation of SMA excitability may result in a modification of a dyskinetic state induced by continuous apomorphine infusion .|rTMS at 1 Hz was observed to markedly reduce drug - induced dyskinesias , whereas 5 - Hz rTMS induced a slight but not significant increase .	1:CID:2	R2L	NON-CROSS	24-25	21-22	D007980	levodopa	Chemical	21	22	1	D004409	dyskinesias|dyskinesia|dyskinetic|drug - induced dyskinesias	Disease	9:24:69:86	10:25:70:90	0:1:2:3	1:NR:2	R2L	NON-CROSS	74-75	69-70	D001058	apomorphine	Chemical	74	75	2	D004409	dyskinesias|dyskinesia|dyskinetic|drug - induced dyskinesias	Disease	9:24:69:86	10:25:70:90	0:1:2:3	1:NR:2	R2L	CROSS	21-22	11-13	D007980	levodopa	Chemical	21	22	1	D010300	Parkinson disease|Parkinson disease	Disease	11:51	13:53	0:2	1:NR:2	R2L	NON-CROSS	74-75	51-53	D001058	apomorphine	Chemical	74	75	2	D010300	Parkinson disease|Parkinson disease	Disease	11:51	13:53	0:2
15930398	Assessment of the onset and persistence of amnesia during procedural sedation with propofol .|OBJECTIVES : To assess patients ' ability to repeat and recall words presented to them while undergoing procedural sedation with propofol , and correlate their recall with their level of awareness as measured by bispectral index ( BIS ) monitoring .|METHODS : This was a prospective , single - intervention study of consenting adult patients undergoing procedural sedation with propofol between December 28 , 2002 , and October 31 , 2003 .|BIS monitoring was initiated starting 3 minutes before the procedure and continuing until the patient had regained baseline mental status .|At 1 - minute intervals during the procedural sedation , until the patient regained baseline mental status at the end of the procedure , a word from a standardized list was read aloud , and the patient was asked to immediately repeat the word to the investigator .|The BIS score at the time the word was read and the patient 's ability to repeat the word were recorded .|After the procedure , the patient was asked to state all of the words from the list that he or she could recall , and to identify the last word recalled from prior to the start of the procedure and the first word recalled from after the procedure was completed .|RESULTS : Seventy - five consenting patients were enrolled ; one patient was excluded from data analysis for a protocol violation .|No serious adverse events were noted during the procedural sedations .|The mean ( + / - standard deviation ) time of data collection was 16 . 4 minutes ( + / - 7 . 1 ; range 5 to 34 minutes ) .|The mean initial ( preprocedure ) BIS score was 97 . 1 ( + / - 2 . 3 ; range 92 to 99 ) .|The mean lowest BIS score occurring during these procedural sedations was 66 . 9 ( + / - 14 . 4 ; range 33 to 91 ) .|The mean lowest BIS score corresponding to the ability of the patient to immediately repeat words read from the list was 77 . 1 ( 95 % CI = 74 . 3 to 80 . 0 ) .|The mean highest BIS score corresponding to the inability to repeat words was 81 . 5 ( 95 % CI = 78 . 1 to 84 . 8 ) .|The mean BIS score corresponding to the last word recalled from prior to the initiation of the sedation was 96 . 7 ( + / - 2 . 4 ; range 84 to 98 ) .|The mean BIS score corresponding to the first word recalled after the procedure was completed was 91 . 2 ( 95 % CI = 88 . 1 to 94 . 3 ) .|All patients recalled at least one word that had been read to them during the protocol .|The mean lowest BIS score for any recalled word was 91 . 5 ( + / - 11 . 1 ; range 79 to 98 ) , and no words were recalled when the corresponding BIS score was less than 90 .|CONCLUSIONS : There is a range of BIS scores during which sedated patients are able to repeat words read to them but are not able to subsequently recall these words .|Furthermore , patients had no recall of words repeated prior to procedural sedation in BIS ranges associated with recall after procedural sedation , suggestive of retrograde amnesia .	1:CID:2	R2L	NON-CROSS	12-13	7-8	D015742	propofol|propofol|propofol	Chemical	12:34:74	13:35:75	0:1:2	D000647	amnesia|inability to repeat words	Disease	7:395	8:399	0:13	1:NR:2	L2R	CROSS	74-75	601-603	D015742	propofol|propofol|propofol	Chemical	12:34:74	13:35:75	0:1:2	D000648	retrograde amnesia	Disease	601	603	19
15867025	Assessment of perinatal hepatitis B and rubella prevention in New Hampshire delivery hospitals .|OBJECTIVE : To evaluate current performance on recommended perinatal hepatitis B and rubella prevention practices in New Hampshire .|METHODS : Data were extracted from 2021 paired mother - infant records for the year 2000 birth cohort in New Hampshire 's 25 delivery hospitals .|Assessment was done on the following : prenatal screening for hepatitis B and rubella , administration of the hepatitis B vaccine birth dose to all infants , administration of hepatitis B immune globulin to infants who were born to hepatitis B surface antigen - positive mothers , rubella immunity , and administration of in - hospital postpartum rubella vaccine to rubella nonimmune women .|RESULTS : Prenatal screening rates for hepatitis B ( 98 . 8 % ) and rubella ( 99 . 4 % ) were high .|Hepatitis B vaccine birth dose was administered to 76 . 2 % of all infants .|All infants who were born to hepatitis B surface antigen - positive mothers also received hepatitis B immune globulin .|Multivariate logistic regression showed that the month of delivery and infant birth weight were independent predictors of hepatitis B vaccination .|The proportion of infants who were vaccinated in January and February 2000 ( 48 . 5 % and 67 . 5 % , respectively ) was less than any other months , whereas the proportion who were vaccinated in December 2000 ( 88 . 2 % ) was the highest .|Women who were born between 1971 and 1975 had the highest rate of rubella nonimmunity ( 9 . 5 % ) .|In - hospital postpartum rubella vaccine administration was documented for 75 . 6 % of nonimmune women .|CONCLUSION : This study documents good compliance in New Hampshire 's birthing hospitals with national guidelines for perinatal hepatitis B and rubella prevention and highlights potential areas for improvement .	1:CID:2	R2L	NON-CROSS	179-181	170-174	D006514	hepatitis B surface antigen|hepatitis B surface antigen	Chemical	98:170	102:174	3:6	D006509	hepatitis B|hepatitis B|hepatitis B|hepatitis B|hepatitis B|hepatitis B|Hepatitis B|hepatitis B|hepatitis B|hepatitis B	Disease	3:23:69:77:88:129:148:179:201:314	5:25:71:79:90:131:150:181:203:316	0:1:3:3:3:4:5:6:7:11	1:NR:2	R2L	NON-CROSS	106-107	98-102	D006514	hepatitis B surface antigen|hepatitis B surface antigen	Chemical	98:170	102:174	3:6	D012409	rubella|rubella|rubella|rubella|rubella|rubella|rubella|rubella|rubella|rubella	Disease	6:26:72:106:116:119:138:269:282:317	7:27:73:107:117:120:139:270:283:318	0:1:3:3:3:3:4:9:10:11
14975762	Expression of p300 protects cardiac myocytes from apoptosis in vivo .|Doxorubicin is an anti - tumor agent that represses cardiac - specific gene expression and induces myocardial cell apoptosis .|Doxorubicin depletes cardiac p300 , a transcriptional coactivator that is required for the maintenance of the differentiated phenotype of cardiac myocytes .|However , the role of p300 in protection against doxorubicin - induced apoptosis is unknown .|Transgenic mice overexpressing p300 in the heart and wild - type mice were subjected to doxorubicin treatment .|Compared with wild - type mice , transgenic mice exhibited higher survival rate as well as more preserved left ventricular function and cardiac expression of alpha - sarcomeric actin .|Doxorubicin induced myocardial cell apoptosis in wild - type mice but not in transgenic mice .|Expression of p300 increased the cardiac level of bcl - 2 and mdm - 2 , but not that of p53 or other members of the bcl - 2 family .|These findings demonstrate that overexpression of p300 protects cardiac myocytes from doxorubicin - induced apoptosis and reduces the extent of acute heart failure in adult mice in vivo .	1:NR:2	L2R	NON-CROSS	11-12	16-17	D004317	Doxorubicin|Doxorubicin|doxorubicin|doxorubicin|Doxorubicin|doxorubicin	Chemical	11:31:62:84:117:175	12:32:63:85:118:176	1:2:3:4:6:8	D009369	tumor	Disease	16	17	1	1:CID:2	L2R	NON-CROSS	175-176	185-187	D004317	Doxorubicin|Doxorubicin|doxorubicin|doxorubicin|Doxorubicin|doxorubicin	Chemical	11:31:62:84:117:175	12:32:63:85:118:176	1:2:3:4:6:8	D006333	heart failure	Disease	185	187	8
14736955	Mitochondrial DNA and its respiratory chain products are defective in doxorubicin nephrosis .|BACKGROUND : Doxorubicin induces a self - perpetuating nephropathy characterized by early glomerular and late - onset tubular lesions in rats .|We investigated the potential role of mitochondrial injury in the onset of these lesions .|METHODS : Rats were treated with intravenous doxorubicin ( 1 mg kg ( - 1 ) week ( - 1 ) ) for 7 weeks and were sacrificed either 1 week ( ' short - term ' ) or 30 weeks ( ' long - term ' ) following the last dose .|Additional rats received a single dose either 6 days or 2 h prior to euthanasia .|All rats were killed at 48 weeks of age .|Glomerular and tubular injury was monitored and correlated to the activity or expression of respiratory chain components .|Finally , we quantified both nuclear and mitochondrial DNA ( mtDNA ) as well as superoxide production and the 4834 base pair ' common ' mtDNA deletion .|RESULTS : The ' long - term ' group had significant glomerular and tubular lesions , depressed activities of mtDNA - encoded NADH dehydrogenase and cytochrome - c oxidase ( COX ) and increased citrate synthase activity .|In addition , expression of the mtDNA - encoded COX subunit I was reduced and mtDNA levels were decreased .|In ' short - term ' rats , there were fewer tubular lesions , but similar numbers of glomerular lesions activity .|Among all animals , glomerular and tubular injury were inversely correlated with mtDNA levels , mtDNA - encoded respiratory chain activities and with the expression of the mtDNA - encoded respiratory chain subunit COX - I .|Injury was positively correlated with superoxide production and the activities of nucleus - encoded mitochondrial or cytoplasmic enzymes .|Kidneys from the ' long - term ' group showed more mtDNA deletions than in ' short - term ' animals and these were not observed in the other groups .|CONCLUSIONS : These results suggest an important role for quantitative and qualitative mtDNA alterations through the reduction of mtDNA - encoded respiratory chain function and induction of superoxide in doxorubicin - induced renal lesions .	1:CID:2	L2R	NON-CROSS	10-11	11-12	D004317	doxorubicin|Doxorubicin|doxorubicin|doxorubicin	Chemical	10:15:57:371	11:16:58:372	0:1:3:14	D009401	nephrosis	Disease	11	12	0	1:NR:2	L2R	NON-CROSS	371-372	374-376	D004317	doxorubicin|Doxorubicin|doxorubicin|doxorubicin	Chemical	10:15:57:371	11:16:58:372	0:1:3:14	D007674	nephropathy|glomerular and late - onset tubular lesions|Glomerular and tubular injury|glomerular and tubular lesions|tubular lesions|glomerular lesions|glomerular and tubular injury|renal lesions	Disease	21:25:129:186:244:251:259:374	22:32:133:190:246:253:263:376	1:1:6:8:10:10:11:14	1:NR:2	L2R	CROSS	41-43	57-58	D004317	doxorubicin|Doxorubicin|doxorubicin|doxorubicin	Chemical	10:15:57:371	11:16:58:372	0:1:3:14	D028361	mitochondrial injury	Disease	41	43	2	1:NR:2	R2L	CROSS	162-163	11-12	D013481	superoxide|superoxide|superoxide	Chemical	162:297:369	163:298:370	7:12:14	D009401	nephrosis	Disease	11	12	0	1:NR:2	R2L	CROSS	209-210	11-12	C102006	citrate	Chemical	209	210	8	D009401	nephrosis	Disease	11	12	0	1:NR:2	R2L	NON-CROSS	374-376	369-370	D013481	superoxide|superoxide|superoxide	Chemical	162:297:369	163:298:370	7:12:14	D007674	nephropathy|glomerular and late - onset tubular lesions|Glomerular and tubular injury|glomerular and tubular lesions|tubular lesions|glomerular lesions|glomerular and tubular injury|renal lesions	Disease	21:25:129:186:244:251:259:374	22:32:133:190:246:253:263:376	1:1:6:8:10:10:11:14	1:NR:2	R2L	NON-CROSS	209-210	186-190	C102006	citrate	Chemical	209	210	8	D007674	nephropathy|glomerular and late - onset tubular lesions|Glomerular and tubular injury|glomerular and tubular lesions|tubular lesions|glomerular lesions|glomerular and tubular injury|renal lesions	Disease	21:25:129:186:244:251:259:374	22:32:133:190:246:253:263:376	1:1:6:8:10:10:11:14	1:NR:2	R2L	CROSS	162-163	41-43	D013481	superoxide|superoxide|superoxide	Chemical	162:297:369	163:298:370	7:12:14	D028361	mitochondrial injury	Disease	41	43	2	1:NR:2	R2L	CROSS	209-210	41-43	C102006	citrate	Chemical	209	210	8	D028361	mitochondrial injury	Disease	41	43	2
11573852	Amphotericin B - induced seizures in a patient with AIDS .|OBJECTIVE : To report a case of multiple episodes of seizure activity in an AIDS patent following amphotericin B infusion .|CASE SUMMARY : A 46 - year - old African - American man experienced recurrent grand mal seizures during intravenous infusion of amphotericin B , then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time .|The patients concurrent medications included didanosine , hydroxyzine , promethazine , hydrocortisone , and prochlorperazine .|Despite administration of phenytoin and lorazepam , the seizures persisted and occurred only during amphotercin B administration .|DISCUSSION : AIDS and cryptococcal meningitis , both of which the patient had , can potentially cause seizures .|The patient had a history of alcohol abuse ; alcohol intake as well as withdrawal can also cause seizures .|Didanosine also has a potential for inducing seizures .|However , these other potential causes of seizure were ruled out .|The time course of events suggested that amphotericin B was the cause of the seizures in this AIDS patient .|CONCLUSIONS : Amphotericin B seems to be the probable cause of the seizures .|To date , only three cases of seizures associated with amphotericin B have been reported in the literature , but healthcare providers should be aware of the potential for this rare adverse effect .	1:CID:2	L2R	NON-CROSS	0-2	4-5	D000666	Amphotericin B|amphotericin B|amphotericin B|amphotercin B|amphotericin B|Amphotericin B|amphotericin B	Chemical	0:28:54:104:175:190:212	2:30:56:106:177:192:214	0:1:2:4:9:10:11	D012640	seizures|seizure|seizures|seizures|seizures|seizures|seizures|seizure|seizures|seizures|seizures	Disease	4:21:60:98:125:145:154:163:182:200:209	5:22:61:99:126:146:155:164:183:201:210	0:1:2:4:5:6:7:8:9:10:11	1:NR:2	L2R	NON-CROSS	25-26	28-30	D000666	Amphotericin B|amphotericin B|amphotericin B|amphotercin B|amphotericin B|Amphotericin B|amphotericin B	Chemical	0:28:54:104:175:190:212	2:30:56:106:177:192:214	0:1:2:4:9:10:11	D000163	AIDS|AIDS|AIDS|AIDS	Disease	9:25:110:185	10:26:111:186	0:1:5:9	1:NR:2	L2R	NON-CROSS	47-50	54-56	D000666	Amphotericin B|amphotericin B|amphotericin B|amphotercin B|amphotericin B|Amphotericin B|amphotericin B	Chemical	0:28:54:104:175:190:212	2:30:56:106:177:192:214	0:1:2:4:9:10:11	D004830	grand mal seizures	Disease	47	50	2	1:NR:2	L2R	CROSS	104-106	112-114	D000666	Amphotericin B|amphotericin B|amphotericin B|amphotercin B|amphotericin B|Amphotericin B|amphotericin B	Chemical	0:28:54:104:175:190:212	2:30:56:106:177:192:214	0:1:2:4:9:10:11	D016919	cryptococcal meningitis	Disease	112	114	5	1:NR:2	L2R	CROSS	104-106	133-135	D000666	Amphotericin B|amphotericin B|amphotericin B|amphotercin B|amphotericin B|Amphotericin B|amphotericin B	Chemical	0:28:54:104:175:190:212	2:30:56:106:177:192:214	0:1:2:4:9:10:11	D000437	alcohol abuse	Disease	133	135	6	1:NR:2	R2L	NON-CROSS	147-148	145-146	D016049	didanosine|Didanosine	Chemical	79:147	80:148	3:7	D012640	seizures|seizure|seizures|seizures|seizures|seizures|seizures|seizure|seizures|seizures|seizures	Disease	4:21:60:98:125:145:154:163:182:200:209	5:22:61:99:126:146:155:164:183:201:210	0:1:2:4:5:6:7:8:9:10:11	1:NR:2	R2L	CROSS	98-99	81-82	D006919	hydroxyzine	Chemical	81	82	3	D012640	seizures|seizure|seizures|seizures|seizures|seizures|seizures|seizure|seizures|seizures|seizures	Disease	4:21:60:98:125:145:154:163:182:200:209	5:22:61:99:126:146:155:164:183:201:210	0:1:2:4:5:6:7:8:9:10:11	1:NR:2	R2L	CROSS	98-99	83-84	D011398	promethazine	Chemical	83	84	3	D012640	seizures|seizure|seizures|seizures|seizures|seizures|seizures|seizure|seizures|seizures|seizures	Disease	4:21:60:98:125:145:154:163:182:200:209	5:22:61:99:126:146:155:164:183:201:210	0:1:2:4:5:6:7:8:9:10:11	1:NR:2	R2L	CROSS	98-99	85-86	D006854	hydrocortisone	Chemical	85	86	3	D012640	seizures|seizure|seizures|seizures|seizures|seizures|seizures|seizure|seizures|seizures|seizures	Disease	4:21:60:98:125:145:154:163:182:200:209	5:22:61:99:126:146:155:164:183:201:210	0:1:2:4:5:6:7:8:9:10:11	1:NR:2	R2L	CROSS	98-99	88-89	D011346	prochlorperazine	Chemical	88	89	3	D012640	seizures|seizure|seizures|seizures|seizures|seizures|seizures|seizure|seizures|seizures|seizures	Disease	4:21:60:98:125:145:154:163:182:200:209	5:22:61:99:126:146:155:164:183:201:210	0:1:2:4:5:6:7:8:9:10:11	1:NR:2	R2L	NON-CROSS	98-99	93-94	D010672	phenytoin	Chemical	93	94	4	D012640	seizures|seizure|seizures|seizures|seizures|seizures|seizures|seizure|seizures|seizures|seizures	Disease	4:21:60:98:125:145:154:163:182:200:209	5:22:61:99:126:146:155:164:183:201:210	0:1:2:4:5:6:7:8:9:10:11	1:NR:2	R2L	NON-CROSS	98-99	95-96	D008140	lorazepam	Chemical	95	96	4	D012640	seizures|seizure|seizures|seizures|seizures|seizures|seizures|seizure|seizures|seizures|seizures	Disease	4:21:60:98:125:145:154:163:182:200:209	5:22:61:99:126:146:155:164:183:201:210	0:1:2:4:5:6:7:8:9:10:11	1:NR:2	R2L	NON-CROSS	145-146	136-137	D000431	alcohol	Chemical	136	137	6	D012640	seizures|seizure|seizures|seizures|seizures|seizures|seizures|seizure|seizures|seizures|seizures	Disease	4:21:60:98:125:145:154:163:182:200:209	5:22:61:99:126:146:155:164:183:201:210	0:1:2:4:5:6:7:8:9:10:11	1:NR:2	R2L	CROSS	110-111	79-80	D016049	didanosine|Didanosine	Chemical	79:147	80:148	3:7	D000163	AIDS|AIDS|AIDS|AIDS	Disease	9:25:110:185	10:26:111:186	0:1:5:9	1:NR:2	R2L	CROSS	110-111	81-82	D006919	hydroxyzine	Chemical	81	82	3	D000163	AIDS|AIDS|AIDS|AIDS	Disease	9:25:110:185	10:26:111:186	0:1:5:9	1:NR:2	R2L	CROSS	110-111	83-84	D011398	promethazine	Chemical	83	84	3	D000163	AIDS|AIDS|AIDS|AIDS	Disease	9:25:110:185	10:26:111:186	0:1:5:9	1:NR:2	R2L	CROSS	110-111	85-86	D006854	hydrocortisone	Chemical	85	86	3	D000163	AIDS|AIDS|AIDS|AIDS	Disease	9:25:110:185	10:26:111:186	0:1:5:9	1:NR:2	R2L	CROSS	110-111	88-89	D011346	prochlorperazine	Chemical	88	89	3	D000163	AIDS|AIDS|AIDS|AIDS	Disease	9:25:110:185	10:26:111:186	0:1:5:9	1:NR:2	R2L	CROSS	110-111	93-94	D010672	phenytoin	Chemical	93	94	4	D000163	AIDS|AIDS|AIDS|AIDS	Disease	9:25:110:185	10:26:111:186	0:1:5:9	1:NR:2	R2L	CROSS	110-111	95-96	D008140	lorazepam	Chemical	95	96	4	D000163	AIDS|AIDS|AIDS|AIDS	Disease	9:25:110:185	10:26:111:186	0:1:5:9	1:NR:2	R2L	CROSS	136-137	110-111	D000431	alcohol	Chemical	136	137	6	D000163	AIDS|AIDS|AIDS|AIDS	Disease	9:25:110:185	10:26:111:186	0:1:5:9	1:NR:2	R2L	CROSS	79-80	47-50	D016049	didanosine|Didanosine	Chemical	79:147	80:148	3:7	D004830	grand mal seizures	Disease	47	50	2	1:NR:2	R2L	CROSS	81-82	47-50	D006919	hydroxyzine	Chemical	81	82	3	D004830	grand mal seizures	Disease	47	50	2	1:NR:2	R2L	CROSS	83-84	47-50	D011398	promethazine	Chemical	83	84	3	D004830	grand mal seizures	Disease	47	50	2	1:NR:2	R2L	CROSS	85-86	47-50	D006854	hydrocortisone	Chemical	85	86	3	D004830	grand mal seizures	Disease	47	50	2	1:NR:2	R2L	CROSS	88-89	47-50	D011346	prochlorperazine	Chemical	88	89	3	D004830	grand mal seizures	Disease	47	50	2	1:NR:2	R2L	CROSS	93-94	47-50	D010672	phenytoin	Chemical	93	94	4	D004830	grand mal seizures	Disease	47	50	2	1:NR:2	R2L	CROSS	95-96	47-50	D008140	lorazepam	Chemical	95	96	4	D004830	grand mal seizures	Disease	47	50	2	1:NR:2	R2L	CROSS	136-137	47-50	D000431	alcohol	Chemical	136	137	6	D004830	grand mal seizures	Disease	47	50	2	1:NR:2	L2R	CROSS	79-80	112-114	D016049	didanosine|Didanosine	Chemical	79:147	80:148	3:7	D016919	cryptococcal meningitis	Disease	112	114	5	1:NR:2	L2R	CROSS	133-135	147-148	D016049	didanosine|Didanosine	Chemical	79:147	80:148	3:7	D000437	alcohol abuse	Disease	133	135	6	1:NR:2	L2R	CROSS	81-82	112-114	D006919	hydroxyzine	Chemical	81	82	3	D016919	cryptococcal meningitis	Disease	112	114	5	1:NR:2	L2R	CROSS	81-82	133-135	D006919	hydroxyzine	Chemical	81	82	3	D000437	alcohol abuse	Disease	133	135	6	1:NR:2	L2R	CROSS	83-84	112-114	D011398	promethazine	Chemical	83	84	3	D016919	cryptococcal meningitis	Disease	112	114	5	1:NR:2	L2R	CROSS	83-84	133-135	D011398	promethazine	Chemical	83	84	3	D000437	alcohol abuse	Disease	133	135	6	1:NR:2	L2R	CROSS	85-86	112-114	D006854	hydrocortisone	Chemical	85	86	3	D016919	cryptococcal meningitis	Disease	112	114	5	1:NR:2	L2R	CROSS	85-86	133-135	D006854	hydrocortisone	Chemical	85	86	3	D000437	alcohol abuse	Disease	133	135	6	1:NR:2	L2R	CROSS	88-89	112-114	D011346	prochlorperazine	Chemical	88	89	3	D016919	cryptococcal meningitis	Disease	112	114	5	1:NR:2	L2R	CROSS	88-89	133-135	D011346	prochlorperazine	Chemical	88	89	3	D000437	alcohol abuse	Disease	133	135	6	1:NR:2	L2R	CROSS	93-94	112-114	D010672	phenytoin	Chemical	93	94	4	D016919	cryptococcal meningitis	Disease	112	114	5	1:NR:2	L2R	CROSS	93-94	133-135	D010672	phenytoin	Chemical	93	94	4	D000437	alcohol abuse	Disease	133	135	6	1:NR:2	L2R	CROSS	95-96	112-114	D008140	lorazepam	Chemical	95	96	4	D016919	cryptococcal meningitis	Disease	112	114	5	1:NR:2	L2R	CROSS	95-96	133-135	D008140	lorazepam	Chemical	95	96	4	D000437	alcohol abuse	Disease	133	135	6	1:NR:2	R2L	CROSS	136-137	112-114	D000431	alcohol	Chemical	136	137	6	D016919	cryptococcal meningitis	Disease	112	114	5	1:NR:2	R2L	NON-CROSS	136-137	133-135	D000431	alcohol	Chemical	136	137	6	D000437	alcohol abuse	Disease	133	135	6
9875685	Therapeutic drug monitoring of tobramycin : once - daily versus twice - daily dosage schedules .|OBJECTIVE : To evaluate the effect of dosage regimen ( once - daily vs . twice - daily ) of tobramicyn on steady - state serum concentrations and toxicity .|MATERIALS AND METHODS : Patients undergoing treatment with i . v .|tobramycin ( 4 mg / kg / day ) were randomised to two groups .|Group OD ( n = 22 ) received a once - daily dose of tobramycin and group TD ( n = 21 ) received the same dose divided into two doses daily .|Tobramycin serum concentrations ( peak and trough ) were measured by enzyme multiplied immunoassay .|The renal and auditory functions of the patients were monitored before , during and immediately after treatment .|RESULTS : The two groups were comparable with respect to sex , age , body weight and renal function .|No statistically significant differences were found in mean daily dose , duration of treatment , or cumulative dose .|Trough concentrations were < 2 g / ml in the two groups ( 100 % ) .|Peak concentrations were > 6 microg / ml in 100 % of the OD group and in 67 % of the TD group ( P < 0 . 01 ) .|Mean peak concentrations were markedly different : 11 . 00 + / - 2 . 89 microg / ml in OD vs . 6 . 53 + / - 1 . 45 microg / ml in TD ( P < 0 . 01 ) .|The pharmacokinetics parameters were : Ke , ( 0 . 15 + / - 0 . 03 / h in OD vs . 0 . 24 + / - 0 . 06 / h in TD ) , t1 / 2 , ( 4 . 95 + / - 1 . 41 h in OD vs . 3 . 07 + / - 0 . 71 h in TD ) , Vd ( 0 . 35 + / - 0 . 11 l / kg in OD vs . 0 . 33 + / - 0 . 09 l / kg in TD ) , Cl ( 0 . 86 + / - 0 . 29 ml / min / kg in OD vs . 1 . 28 + / - 0 . 33 ml / min / kg in TD ) .|Increased serum creatinine was observed in 73 % of patients in OD versus 57 % of patients in TD , without evidence of nephrotoxicity .|In TD group , three patients developed decreased auditory function , of which one presented with an auditory loss of - 30 dB , whereas in the OD group only one patient presented decreased auditory function .|CONCLUSION : This small study suggests that a once - daily dosing regimen of tobramycin is at least as effective as and is no more and possibly less toxic than the twice - daily regimen .|Using a single - dose therapy , peak concentration determination is not necessary , only trough samples should be monitored to ensure levels below 2 microg / ml .	1:NR:2	L2R	NON-CROSS	36-37	44-45	D014031	tobramycin|tobramicyn|tobramycin|tobramycin|Tobramycin|tobramycin	Chemical	4:36:58:87:106:490	5:37:59:88:107:491	0:1:3:4:5:15	D064420	toxicity	Disease	44	45	1	1:NR:2	L2R	CROSS	437-438	490-491	D014031	tobramycin|tobramicyn|tobramycin|tobramycin|Tobramycin|tobramycin	Chemical	4:36:58:87:106:490	5:37:59:88:107:491	0:1:3:4:5:15	D007674	nephrotoxicity	Disease	437	438	13	1:CID:2	L2R	CROSS	472-475	490-491	D014031	tobramycin|tobramicyn|tobramycin|tobramycin|Tobramycin|tobramycin	Chemical	4:36:58:87:106:490	5:37:59:88:107:491	0:1:3:4:5:15	D034381	decreased auditory function|auditory loss|decreased auditory function	Disease	446:456:472	449:458:475	14:14:14	1:NR:2	R2L	CROSS	416-417	44-45	D003404	creatinine	Chemical	416	417	13	D064420	toxicity	Disease	44	45	1	1:NR:2	L2R	NON-CROSS	416-417	437-438	D003404	creatinine	Chemical	416	417	13	D007674	nephrotoxicity	Disease	437	438	13	1:NR:2	L2R	CROSS	416-417	446-449	D003404	creatinine	Chemical	416	417	13	D034381	decreased auditory function|auditory loss|decreased auditory function	Disease	446:456:472	449:458:475	14:14:14
9848575	Chronic effects of a novel synthetic anthracycline derivative ( SM - 5887 ) on normal heart and doxorubicin - induced cardiomyopathy in beagle dogs .|This study was designed to investigate the chronic cardiotoxic potential of SM - 5887 and a possible deteriorating effect of SM - 5887 on low - grade cardiotoxicity pre - induced by doxorubicin in beagle dogs .|In the chronic treatment , beagle dogs of each sex were given intravenously once every 3 weeks , either a sublethal dose of doxorubicin ( 1 . 5 mg / kg ) or SM - 5887 ( 2 . 5 mg / kg ) .|The experiment was terminated 3 weeks after the ninth dosing .|Animals which received over six courses of doxorubicin demonstrated the electrocardiogram ( ECG ) changes , decrease of blood pressure and high - grade histopathological cardiomyopathy , while animals which were terminally sacrificed after the SM - 5887 administration did not show any changes in ECG , blood pressure and histopathological examinations .|To examine a possibly deteriorating cardiotoxic effect of SM - 5887 , low - grade cardiomyopathy was induced in dogs by four courses of doxorubicin ( 1 . 5 mg / kg ) .|Nine weeks after pre - treatment , dogs were given four courses of either doxorubicin ( 1 . 5 mg / kg ) or SM - 5887 ( 2 . 5 mg / kg ) once every 3 weeks .|The low - grade cardiotoxic changes were enhanced by the additional doxorubicin treatment .|On the contrary , the SM - 5887 treatment did not progress the grade of cardiomyopathy .|In conclusion , SM - 5887 does not have any potential of chronic cardiotoxicity and deteriorating effect on doxorubicin - induced cardiotoxicity in dogs .	1:NR:2	L2R	NON-CROSS	6-7	20-21	D018943	anthracycline	Chemical	6	7	0	D009202	cardiomyopathy|cardiomyopathy|cardiomyopathy|cardiomyopathy	Disease	20:143:186:274	21:144:187:275	0:4:5:8	1:NR:2	L2R	CROSS	6-7	33-34	D018943	anthracycline	Chemical	6	7	0	D066126	cardiotoxic|cardiotoxicity|cardiotoxic|cardiotoxic|cardiotoxicity|cardiotoxicity	Disease	33:52:176:249:289:297	34:53:177:250:290:298	1:1:5:7:9:9	1:NR:2	L2R	NON-CROSS	179-182	186-187	C055866	SM - 5887|SM - 5887|SM - 5887|SM - 5887|SM - 5887|SM - 5887|SM - 5887|SM - 5887|SM - 5887	Chemical	9:36:45:95:153:179:229:264:279	12:39:48:98:156:182:232:267:282	0:1:1:2:4:5:6:8:9	D009202	cardiomyopathy|cardiomyopathy|cardiomyopathy|cardiomyopathy	Disease	20:143:186:274	21:144:187:275	0:4:5:8	1:NR:2	L2R	NON-CROSS	176-177	179-182	C055866	SM - 5887|SM - 5887|SM - 5887|SM - 5887|SM - 5887|SM - 5887|SM - 5887|SM - 5887|SM - 5887	Chemical	9:36:45:95:153:179:229:264:279	12:39:48:98:156:182:232:267:282	0:1:1:2:4:5:6:8:9	D066126	cardiotoxic|cardiotoxicity|cardiotoxic|cardiotoxic|cardiotoxicity|cardiotoxicity	Disease	33:52:176:249:289:297	34:53:177:250:290:298	1:1:5:7:9:9	1:CID:2	L2R	NON-CROSS	17-18	20-21	D004317	doxorubicin|doxorubicin|doxorubicin|doxorubicin|doxorubicin|doxorubicin|doxorubicin|doxorubicin	Chemical	17:57:85:125:195:219:256:294	18:58:86:126:196:220:257:295	0:1:2:4:5:6:7:9	D009202	cardiomyopathy|cardiomyopathy|cardiomyopathy|cardiomyopathy	Disease	20:143:186:274	21:144:187:275	0:4:5:8	1:NR:2	L2R	NON-CROSS	294-295	297-298	D004317	doxorubicin|doxorubicin|doxorubicin|doxorubicin|doxorubicin|doxorubicin|doxorubicin|doxorubicin	Chemical	17:57:85:125:195:219:256:294	18:58:86:126:196:220:257:295	0:1:2:4:5:6:7:9	D066126	cardiotoxic|cardiotoxicity|cardiotoxic|cardiotoxic|cardiotoxicity|cardiotoxicity	Disease	33:52:176:249:289:297	34:53:177:250:290:298	1:1:5:7:9:9
9321531	Posteroventral medial pallidotomy in advanced Parkinson 's disease .|BACKGROUND : Posteroventral medial pallidotomy sometimes produces striking improvement in patients with advanced Parkinson 's disease , but the studies to date have involved small numbers of patients and short - term follow - up .|METHODS : Forty patients with Parkinson 's disease underwent serial , detailed assessments both after drug withdrawal ( " off " period ) and while taking their optimal medical regimens ( " on " period ) .|All patients were examined preoperatively and 39 were examined at six months ; 27 of the patients were also examined at one year , and 11 at two years .|RESULTS : The percent improvements at six months were as follows : off - period score for overall motor function , 28 percent ( 95 percent confidence interval , 19 to 38 percent ) , with most of the improvement in the contralateral limbs ; off - period score for activities of daily living , 29 percent ( 95 percent confidence interval , 19 to 39 percent ) ; on - period score for contralateral dyskinesias , 82 percent ( 95 percent confidence interval , 72 to 91 percent ) ; and on - period score for ipsilateral dyskinesias , 44 percent ( 95 percent confidence interval , 29 to 59 percent ) .|The improvements in dyskinesias and the total scores for off - period parkinsonism , contralateral bradykinesia , and rigidity were sustained in the 11 patients examined at two years .|The improvement in ipsilateral dyskinesias was lost after one year , and the improvements in postural stability and gait lasted only three to six months .|Approximately half the patients who had been dependent on assistance in activities of daily living in the off period before surgery became independent after surgery .|The complications of surgery were generally well tolerated , and there were no significant changes in the use of medication .|CONCLUSIONS : In late - stage Parkinson 's disease , pallidotomy significantly reduces levodopa - induced dyskinesias and off - period disability .|Much of the benefit is sustained at two years , although some improvements , such as those on the ipsilateral side and in axial symptoms , wane within the first year .|The on - period symptoms that are resistant to dopaminergic therapy do not respond to pallidotomy .	1:NR:2	R2L	NON-CROSS	342-343	335-338	D007980	levodopa	Chemical	342	343	9	D010300	Parkinson 's disease|Parkinson 's disease|Parkinson 's disease|parkinsonism|Parkinson 's disease	Disease	5:22:50:238:335	8:25:53:239:338	0:1:2:5:9	1:CID:2	R2L	NON-CROSS	345-346	342-343	D007980	levodopa	Chemical	342	343	9	D004409	dyskinesias|dyskinesias|dyskinesias|dyskinesias|dyskinesias	Disease	187:210:229:260:345	188:211:230:261:346	4:4:5:6:9	1:NR:2	R2L	CROSS	342-343	241-242	D007980	levodopa	Chemical	342	343	9	D018476	bradykinesia	Disease	241	242	5	1:NR:2	R2L	CROSS	342-343	244-245	D007980	levodopa	Chemical	342	343	9	D009127	rigidity	Disease	244	245	5
9305828	Neuropeptide - Y immunoreactivity in the pilocarpine model of temporal lobe epilepsy .|Neuropeptide - Y ( NPY ) is expressed by granule cells and mossy fibres of the hippocampal dentate gyrus during experimental temporal lobe epilepsy ( TLE ) .|This expression may represent an endogenous damping mechanism since NPY has been shown to block seizure - like events following high - frequency stimulation in hippocampal slices .|The pilocarpine ( PILO ) model of epilepsy is characterized by an acute period of status epilepticus followed by spontaneous recurrent seizures and related brain damage .|We report peroxidase - antiperoxidase immunostaining for NPY in several brain regions in this model .|PILO - injected animals exhibited NPY immunoreactivity in the region of the mossy fibre terminals , in the dentate gyrus inner molecular layer and , in a few cases , within presumed granule cells .|NPY immunoreactivity was also dramatically changed in the entorhinal cortex , amygdala and sensorimotor areas .|In addition , PILO injected animals exhibited a reduction in the number of NPY - immunoreactive interneurons compared with controls .|The results demonstrate that changes in NPY expression , including expression in the granule cells and mossy fibres and the loss of vulnerable NPY neurons , are present in the PILO model of TLE .|However , the significance of this changed synthesis of NPY remains to be determined .	1:CID:2	L2R	NON-CROSS	6-7	9-12	D010862	pilocarpine|pilocarpine|PILO|PILO|PILO|PILO	Chemical	6:70:72:112:166:214	7:71:73:113:167:215	0:3:3:5:7:8	D004833	temporal lobe epilepsy|temporal lobe epilepsy|TLE|TLE	Disease	9:34:38:217	12:37:39:218	0:1:1:8	1:NR:2	L2R	NON-CROSS	56-57	70-71	D010862	pilocarpine|pilocarpine|PILO|PILO|PILO|PILO	Chemical	6:70:72:112:166:214	7:71:73:113:167:215	0:3:3:5:7:8	D012640	seizure|seizures	Disease	56:90	57:91	2:3	1:NR:2	L2R	NON-CROSS	72-73	76-77	D010862	pilocarpine|pilocarpine|PILO|PILO|PILO|PILO	Chemical	6:70:72:112:166:214	7:71:73:113:167:215	0:3:3:5:7:8	D004827	epilepsy	Disease	76	77	3	1:NR:2	L2R	NON-CROSS	72-73	84-86	D010862	pilocarpine|pilocarpine|PILO|PILO|PILO|PILO	Chemical	6:70:72:112:166:214	7:71:73:113:167:215	0:3:3:5:7:8	D013226	status epilepticus	Disease	84	86	3	1:NR:2	L2R	NON-CROSS	93-95	112-113	D010862	pilocarpine|pilocarpine|PILO|PILO|PILO|PILO	Chemical	6:70:72:112:166:214	7:71:73:113:167:215	0:3:3:5:7:8	D001930	brain damage	Disease	93	95	3
9041081	Effect of myopic excimer laser photorefractive keratectomy on the electrophysiologic function of the retina and optic nerve .|PURPOSE : To assess by electrophysiologic testing the effect of photorefractive keratectomy ( PRK ) on the retina and optic nerve .|SETTING : Eye Clinic , S . Salvatore Hospital , L ' Aquila University , Italy .|METHODS : Standard pattern electroretinograms ( P - ERGs ) and standard pattern visual evoked potentials ( P - VEPs ) were done in 25 eyes of 25 patients who had myopic PRK for an attempted correction between 5 . 00 and 15 . 00 diopters ( D ) ( mean 8 . 00 D ) .|Testing was done preoperatively and 3 , 6 , 12 , and 18 months postoperatively .|The contralateral eyes served as controls .|During the follow - up , 3 patients ( 12 % ) developed steroid - induced elevated intraocular pressure ( IOP ) that resolved after corticosteroid therapy was discontinued .|RESULTS : No statistically significant differences were seen between treated and control eyes nor between treated eyes preoperatively and postoperatively .|CONCLUSION : Myopic excimer laser PRK did not seem to affect the posterior segment .|The transient steroid - induced IOP rise did not seem to cause functional impairment .	1:NR:2	L2R	NON-CROSS	150-151	153-156	D013256	steroid|steroid	Chemical	150:205	151:206	6:9	D009798	elevated intraocular pressure|IOP rise	Disease	153:208	156:210	6:9	1:CID:2	R2L	NON-CROSS	162-163	153-156	D000305	corticosteroid	Chemical	162	163	6	D009798	elevated intraocular pressure|IOP rise	Disease	153:208	156:210	6:9
8305357	Liposomal daunorubicin in advanced Kaposi 's sarcoma : a phase II study .|We report a non - randomized Phase II clinical trial to assess the efficacy and safety of liposomal daunorubicin ( DaunoXome ) in the treatment of AIDS related Kaposi 's sarcoma .|Eleven homosexual men with advanced Kaposi 's sarcoma were entered in the trial .|Changes in size , colour and associated oedema of selected ' target ' lesions were measured .|Clinical , biochemical and haematological toxicities were assessed .|Ten subjects were evaluated .|A partial response was achieved in four , of whom two subsequently relapsed .|Stabilization of Kaposi 's sarcoma occurred in the remaining six , maintained until the end of the trial period in four .|The drug was generally well tolerated , with few mild symptoms of toxicity .|The main problem encountered was haematological toxicity , with three subjects experiencing severe neutropenia ( neutrophil count < 0 . 5 x 10 ( 9 ) / l ) .|There was no evidence of cardiotoxicity .|In this small patient sample , liposomal daunorubicin was an effective and well tolerated agent in the treatment of Kaposi 's sarcoma .	1:NR:2	L2R	NON-CROSS	1-2	4-7	D003630	daunorubicin|daunorubicin|daunorubicin	Chemical	1:31:184	2:32:185	0:1:11	D012514	Kaposi 's sarcoma|Kaposi 's sarcoma|Kaposi 's sarcoma|Kaposi 's sarcoma|Kaposi 's sarcoma	Disease	4:41:50:106:196	7:44:53:109:199	0:1:2:7:11	1:NR:2	L2R	NON-CROSS	31-32	39-40	D003630	daunorubicin|daunorubicin|daunorubicin	Chemical	1:31:184	2:32:185	0:1:11	D000163	AIDS	Disease	39	40	1	1:NR:2	L2R	CROSS	31-32	66-67	D003630	daunorubicin|daunorubicin|daunorubicin	Chemical	1:31:184	2:32:185	0:1:11	D004487	oedema	Disease	66	67	3	1:NR:2	L2R	CROSS	146-147	184-185	D003630	daunorubicin|daunorubicin|daunorubicin	Chemical	1:31:184	2:32:185	0:1:11	D064420	toxicities|toxicity|toxicity	Disease	81:138:146	82:139:147	4:8:9	1:CID:2	L2R	CROSS	153-154	184-185	D003630	daunorubicin|daunorubicin|daunorubicin	Chemical	1:31:184	2:32:185	0:1:11	D009503	neutropenia	Disease	153	154	9	1:NR:2	L2R	CROSS	175-176	184-185	D003630	daunorubicin|daunorubicin|daunorubicin	Chemical	1:31:184	2:32:185	0:1:11	D066126	cardiotoxicity	Disease	175	176	10
8012887	Failure of ancrod in the treatment of heparin - induced arterial thrombosis .|The morbidity and mortality associated with heparin - induced thrombosis remain high despite numerous empirical therapies .|Ancrod has been used successfully for prophylaxis against development of thrombosis in patients with heparin induced platelet aggregation who require brief reexposure to heparin , but its success in patients who have developed the thrombosis syndrome is not well defined .|The authors present a case of failure of ancrod treatment in a patient with heparin - induced thrombosis .	1:CID:2	L2R	NON-CROSS	19-20	22-23	D006493	heparin|heparin|heparin|heparin|heparin	Chemical	7:19:44:53:85	8:20:45:54:86	0:1:2:2:3	D013927	thrombosis|thrombosis|thrombosis|thrombosis|thrombosis	Disease	11:22:40:64:88	12:23:41:65:89	0:1:2:2:3	1:NR:2	L2R	NON-CROSS	44-45	46-48	D006493	heparin|heparin|heparin|heparin|heparin	Chemical	7:19:44:53:85	8:20:45:54:86	0:1:2:2:3	D001791	platelet aggregation	Disease	46	48	2
7651879	Seizure after flumazenil administration in a pediatric patient .|Flumazenil is a benzodiazepine receptor antagonist used to reverse sedation and respiratory depression induced by benzodiazepines .|Seizures and cardiac arrhythmias have complicated its use in adult patients .|Overdose patients who have coingested tricyclic antidepressants have a higher risk of these complications .|Little information exists concerning adverse effects of flumazenil in children .|We report the occurrence of a generalized tonic - clonic seizure in a pediatric patient following the administration of flumazenil .	1:CID:2	R2L	NON-CROSS	2-3	0-1	D005442	flumazenil|Flumazenil|flumazenil|flumazenil	Chemical	2:9:60:83	3:10:61:84	0:1:4:5	D012640	Seizure|Seizures|tonic - clonic seizure	Disease	0:26:71	1:27:75	0:2:5	1:NR:2	R2L	CROSS	26-27	24-25	D001569	benzodiazepine|benzodiazepines	Chemical	12:24	13:25	1:1	D012640	Seizure|Seizures|tonic - clonic seizure	Disease	0:26:71	1:27:75	0:2:5	1:NR:2	L2R	NON-CROSS	9-10	20-22	D005442	flumazenil|Flumazenil|flumazenil|flumazenil	Chemical	2:9:60:83	3:10:61:84	0:1:4:5	D012131	respiratory depression	Disease	20	22	1	1:NR:2	L2R	CROSS	9-10	28-30	D005442	flumazenil|Flumazenil|flumazenil|flumazenil	Chemical	2:9:60:83	3:10:61:84	0:1:4:5	D001145	cardiac arrhythmias	Disease	28	30	2	1:NR:2	L2R	CROSS	38-39	60-61	D005442	flumazenil|Flumazenil|flumazenil|flumazenil	Chemical	2:9:60:83	3:10:61:84	0:1:4:5	D062787	Overdose	Disease	38	39	3	1:NR:2	L2R	NON-CROSS	20-22	24-25	D001569	benzodiazepine|benzodiazepines	Chemical	12:24	13:25	1:1	D012131	respiratory depression	Disease	20	22	1	1:NR:2	L2R	CROSS	24-25	28-30	D001569	benzodiazepine|benzodiazepines	Chemical	12:24	13:25	1:1	D001145	cardiac arrhythmias	Disease	28	30	2	1:NR:2	L2R	CROSS	24-25	38-39	D001569	benzodiazepine|benzodiazepines	Chemical	12:24	13:25	1:1	D062787	Overdose	Disease	38	39	3
3015327	Remodelling of nerve structure in experimental isoniazid neuropathy in the rat .|The neuropathy caused by a single dose of isoniazid in rats was studied with a computer - assisted morphometric method .|Scatter diagrams of the g ratio ( quotient fibre diameter / axon diameter ) define regenerating fibres as a distinct population , distinguishable from the surviving fibres by reduced sheath thickness and reduced axon calibre .|There was also evidence of a subtle direct toxic effect on the entire fibre population , causing axon shrinkage masked by readjustment of the myelin sheath .	1:CID:2	L2R	NON-CROSS	6-7	7-8	D007538	isoniazid|isoniazid	Chemical	6:20	7:21	0:1	D009422	neuropathy|neuropathy	Disease	7:13	8:14	0:1
2980315	Selective injection of iopentol , iohexol and metrizoate into the left coronary artery of the dog .|Induction of ventricular fibrillation and decrease of aortic pressure .|In twenty beagle dogs selective injections were made into the left coronary artery with iopentol , iohexol and metrizoate in doses of 4 ml , 8 ml and 16 ml .|Thirty - six iopentol injections , 35 iohexol injections and 37 metrizoate injections were made .|Frequencies of ventricular fibrillation were significantly lower ( p less than 0 . 05 ) after iopentol ( 0 % ) and iohexol ( 3 % ) than after metrizoate ( 22 % ) .|Iopentol and iohexol also produced significantly less decrease in aortic blood pressure than metrizoate at the different doses .	1:NR:2	L2R	NON-CROSS	76-78	90-91	C053571	iopentol|iopentol|iopentol|iopentol|Iopentol	Chemical	3:41:61:90:109	4:42:62:91:110	0:2:3:4:5	D014693	ventricular fibrillation|ventricular fibrillation	Disease	19:76	21:78	1:4	1:NR:2	L2R	NON-CROSS	65-66	76-78	D007472	iohexol|iohexol|iohexol|iohexol|iohexol	Chemical	5:43:65:96:111	6:44:66:97:112	0:2:3:4:5	D014693	ventricular fibrillation|ventricular fibrillation	Disease	19:76	21:78	1:4	1:CID:2	L2R	NON-CROSS	69-70	76-78	D008794	metrizoate|metrizoate|metrizoate|metrizoate|metrizoate	Chemical	7:45:69:103:122	8:46:70:104:123	0:2:3:4:5	D014693	ventricular fibrillation|ventricular fibrillation	Disease	19:76	21:78	1:4
2819587	Magnetic resonance imaging of cerebral venous thrombosis secondary to " low - dose " birth control pills .|The clinical and radiographic features of cerebral deep venous thrombosis in a 21 - year - old white woman are presented .|This nulliparous patient presented with relatively mild clinical symptoms and progressing mental status changes .|The only known risk factor was " low - dose " oral contraceptive pills .|The magnetic resonance image ( MRI ) showed increased signal intensity from the internal cerebral veins , vein of Galen , and straight sinus .|The diagnosis was confirmed by arterial angiography .	1:CID:2	R2L	CROSS	66-68	25-28	D003276	oral contraceptive	Chemical	66	68	3	D020246	venous thrombosis|deep venous thrombosis	Disease	5:25	7:28	0:1
1564236	Relation of perfusion defects observed with myocardial contrast echocardiography to the severity of coronary stenosis : correlation with thallium - 201 single - photon emission tomography .|It has been previously shown that myocardial contrast echocardiography is a valuable technique for delineating regions of myocardial underperfusion secondary to coronary occlusion and to critical coronary stenoses in the presence of hyperemic stimulation .|The aim of this study was to determine whether myocardial contrast echocardiography performed with a stable solution of sonicated albumin could detect regions of myocardial underperfusion resulting from various degrees of coronary stenosis .|The perfusion defect produced in 16 open chest dogs was compared with the anatomic area at risk measured by the postmortem dual - perfusion technique and with thallium - 201 single - photon emission tomography ( SPECT ) .|During a transient ( 20 - s ) coronary occlusion , a perfusion defect was observed with contrast echocardiography in 14 of the 15 dogs in which the occlusion was produced .|The perfusion defect correlated significantly with the anatomic area at risk ( r = 0 . 74 ; p less than 0 . 002 ) .|During dipyridamole - induced hyperemia , 12 of the 16 dogs with a partial coronary stenosis had a visible area of hypoperfusion by contrast echocardiography .|The four dogs without a perfusion defect had a stenosis that resulted in a mild ( 0 % to 50 % ) reduction in dipyridamole - induced hyperemia .|The size of the perfusion defect during stenosis correlated significantly with the anatomic area at risk ( r = 0 . 61 ; p = 0 . 02 ) .|Thallium - 201 SPECT demonstrated a perfusion defect in all 14 dogs analyzed during dipyridamole - induced hyperemia ; the size of the perfusion defect correlated with the anatomic area at risk ( r = 0 . 58 ; p less than 0 . 03 ) and with the perfusion defect by contrast echocardiography ( r = 0 . 58 ; p less than 0 . 03 ) .|Thus , myocardial contrast echocardiography can be used to visualize and quantitate the amount of jeopardized myocardium during moderate to severe degrees of coronary stenosis .|The results obtained show a correlation with the anatomic area at risk similar to that obtained with thallium - 201 SPECT .	1:NR:2	R2L	NON-CROSS	18-19	13-15	D013793	thallium|thallium|Thallium|thallium	Chemical	18:123:278:390	19:124:279:391	0:3:9:11	D023921	coronary stenosis|coronary stenoses|coronary stenosis|coronary stenosis|coronary stenosis	Disease	13:53:93:207:370	15:55:95:209:372	0:1:2:6:10	1:NR:2	R2L	NON-CROSS	207-209	194-195	D004176	dipyridamole|dipyridamole|dipyridamole	Chemical	194:243:292	195:244:293	6:7:9	D023921	coronary stenosis|coronary stenoses|coronary stenosis|coronary stenosis|coronary stenosis	Disease	13:53:93:207:370	15:55:95:209:372	0:1:2:6:10	1:NR:2	L2R	CROSS	123-124	143-145	D013793	thallium|thallium|Thallium|thallium	Chemical	18:123:278:390	19:124:279:391	0:3:9:11	D054059	coronary occlusion|coronary occlusion	Disease	48:143	50:145	1:4	1:NR:2	L2R	NON-CROSS	278-279	295-296	D013793	thallium|thallium|Thallium|thallium	Chemical	18:123:278:390	19:124:279:391	0:3:9:11	D006940	hyperemic|hyperemia|hyperemia|hyperemia	Disease	59:197:246:295	60:198:247:296	1:6:7:9	1:NR:2	R2L	CROSS	194-195	143-145	D004176	dipyridamole|dipyridamole|dipyridamole	Chemical	194:243:292	195:244:293	6:7:9	D054059	coronary occlusion|coronary occlusion	Disease	48:143	50:145	1:4	1:CID:2	R2L	NON-CROSS	197-198	194-195	D004176	dipyridamole|dipyridamole|dipyridamole	Chemical	194:243:292	195:244:293	6:7:9	D006940	hyperemic|hyperemia|hyperemia|hyperemia	Disease	59:197:246:295	60:198:247:296	1:6:7:9
1300436	Potential deleterious effect of furosemide in radiocontrast nephropathy .|The purpose of the study was to determine the efficacy of furosemide in addition to intravenous fluids in the prevention of radiocontrast nephropathy .|18 patients , referred to a radiocontrast study , considered at risk because of preexisting renal insufficiency , were enrolled in a prospective , randomized , controlled trial , performed at the secondary care center of a 1 , 100 - bed private university hospital .|In addition to fluids , the treatment group received furosemide ( mean dose 110 mg ) intravenously 30 min prior to the injection of contrast material .|The control group received fluids ( mean 3 liters ) .|Radiological studies were mostly angiographies performed with both ionic and non - ionic contrast material , at an average dose of 245 ml .|Renal function significantly deteriorated in the group pretreated with furosemide ( p < 0 . 005 by ANOVA ) , with a rise in serum creatinine from 145 + / - 13 to 182 + / - 16 mumol / l at 24 h , while no change occurred in the control group ( from 141 + / - 6 to 142 + / - 7 mumol / l ) .|Renal failure was associated with weight loss in the furosemide - treated group .|Furosemide may be deleterious in the prevention of radiocontrast nephropathy .	1:NR:2	L2R	NON-CROSS	4-5	7-8	D005665	furosemide|furosemide|furosemide|furosemide|furosemide|Furosemide	Chemical	4:20:88:150:221:226	5:21:89:151:222:227	0:1:3:6:7:8	D007674	nephropathy|nephropathy|nephropathy	Disease	7:31:235	8:32:236	0:1:8	1:NR:2	L2R	NON-CROSS	212-214	221-222	D005665	furosemide|furosemide|furosemide|furosemide|furosemide|Furosemide	Chemical	4:20:88:150:221:226	5:21:89:151:222:227	0:1:3:6:7:8	D051437	renal insufficiency|Renal failure	Disease	48:212	50:214	2:7	1:CID:2	L2R	NON-CROSS	141-145	150-151	D005665	furosemide|furosemide|furosemide|furosemide|furosemide|Furosemide	Chemical	4:20:88:150:221:226	5:21:89:151:222:227	0:1:3:6:7:8	D058186	Renal function significantly deteriorated	Disease	141	145	6	1:NR:2	L2R	NON-CROSS	217-219	221-222	D005665	furosemide|furosemide|furosemide|furosemide|furosemide|Furosemide	Chemical	4:20:88:150:221:226	5:21:89:151:222:227	0:1:3:6:7:8	D015431	weight loss	Disease	217	219	7	1:NR:2	R2L	CROSS	235-236	166-167	D003404	creatinine	Chemical	166	167	6	D007674	nephropathy|nephropathy|nephropathy	Disease	7:31:235	8:32:236	0:1:8	1:NR:2	R2L	CROSS	212-214	166-167	D003404	creatinine	Chemical	166	167	6	D051437	renal insufficiency|Renal failure	Disease	48:212	50:214	2:7	1:NR:2	R2L	NON-CROSS	166-167	141-145	D003404	creatinine	Chemical	166	167	6	D058186	Renal function significantly deteriorated	Disease	141	145	6	1:NR:2	L2R	CROSS	166-167	217-219	D003404	creatinine	Chemical	166	167	6	D015431	weight loss	Disease	217	219	7
1141447	The renal pathology in a case of lithium - induced diabetes insipidus .|A case of lithium - induced diabetes insipidus is reported .|At necropsy microscopy shoed unique and extensive damage to cells lining the distal nephron .|It is suggested that these changes represent a specific toxic effect of lithium , reported here for the first time in man .	1:CID:2	L2R	NON-CROSS	7-8	10-12	D008094	lithium|lithium|lithium	Chemical	7:16:51	8:17:52	0:1:3	D003919	diabetes insipidus|diabetes insipidus	Disease	10:19	12:21	0:1
188339	Etiologic factors in the pathogenesis of liver tumors associated with oral contraceptives .|Within the last several years , previously rare liver tumors have been seen in young women using oral contraceptive steroids .|The Registry for Liver Tumors Associated with Oral Contraceptives at the University of California , Irvine , has clearly identified 27 cases .|The recent literature contains 44 case reports .|Common to these 71 cases has been a histopathologic diagnosis of focal nodular hyperplasia , adenoma , hamartoma , and hepatoma .|Significant statistical etiologic factors include prolonged uninterrupted usage of oral contraceptive steroids .|Eight deaths and liver rupture in 18 patients attest to the seriousness of this new potentially lethal adverse phenomenon .	1:CID:2	R2L	NON-CROSS	10-12	6-8	D003276	oral contraceptives|oral contraceptive|Oral Contraceptives|oral contraceptive	Chemical	10:30:41:96	12:32:43:98	0:1:2:5	D008113	liver tumors|liver tumors|Liver Tumors	Disease	6:21:37	8:23:39	0:1:2	1:NR:2	R2L	NON-CROSS	37-39	32-33	D013256	steroids|steroids	Chemical	32:98	33:99	1:5	D008113	liver tumors|liver tumors|Liver Tumors	Disease	6:21:37	8:23:39	0:1:2	1:NR:2	L2R	CROSS	76-79	96-98	D003276	oral contraceptives|oral contraceptive|Oral Contraceptives|oral contraceptive	Chemical	10:30:41:96	12:32:43:98	0:1:2:5	D020518	focal nodular hyperplasia	Disease	76	79	4	1:NR:2	L2R	CROSS	80-81	96-98	D003276	oral contraceptives|oral contraceptive|Oral Contraceptives|oral contraceptive	Chemical	10:30:41:96	12:32:43:98	0:1:2:5	D000236	adenoma	Disease	80	81	4	1:NR:2	L2R	CROSS	82-83	96-98	D003276	oral contraceptives|oral contraceptive|Oral Contraceptives|oral contraceptive	Chemical	10:30:41:96	12:32:43:98	0:1:2:5	D006222	hamartoma	Disease	82	83	4	1:NR:2	L2R	CROSS	85-86	96-98	D003276	oral contraceptives|oral contraceptive|Oral Contraceptives|oral contraceptive	Chemical	10:30:41:96	12:32:43:98	0:1:2:5	D006528	hepatoma	Disease	85	86	4	1:NR:2	L2R	CROSS	96-98	104-105	D003276	oral contraceptives|oral contraceptive|Oral Contraceptives|oral contraceptive	Chemical	10:30:41:96	12:32:43:98	0:1:2:5	D012421	rupture	Disease	104	105	6	1:NR:2	L2R	CROSS	76-79	98-99	D013256	steroids|steroids	Chemical	32:98	33:99	1:5	D020518	focal nodular hyperplasia	Disease	76	79	4	1:NR:2	L2R	CROSS	80-81	98-99	D013256	steroids|steroids	Chemical	32:98	33:99	1:5	D000236	adenoma	Disease	80	81	4	1:NR:2	L2R	CROSS	82-83	98-99	D013256	steroids|steroids	Chemical	32:98	33:99	1:5	D006222	hamartoma	Disease	82	83	4	1:NR:2	L2R	CROSS	85-86	98-99	D013256	steroids|steroids	Chemical	32:98	33:99	1:5	D006528	hepatoma	Disease	85	86	4	1:NR:2	L2R	CROSS	98-99	104-105	D013256	steroids|steroids	Chemical	32:98	33:99	1:5	D012421	rupture	Disease	104	105	6
19135948	Graft - versus - host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy : results of the EVTAC trial .|A calcineurin inhibitor combined with methotrexate is the standard prophylaxis for graft - versus - host disease ( GVHD ) after allogeneic hematopoietic stem cell transplantation ( HSCT ) .|Everolimus , a derivative of sirolimus , seems to mediate antileukemia effects .|We report on a combination of everolimus and tacrolimus in 24 patients ( median age , 62 years ) with either myelodysplastic syndrome ( MDS ; n = 17 ) or acute myeloid leukemia ( AML ; n = 7 ) undergoing intensive conditioning followed by HSCT from related ( n = 4 ) or unrelated ( n = 20 ) donors .|All patients engrafted , and only 1 patient experienced grade IV mucositis .|Nine patients ( 37 % ) developed acute grade II - IV GVHD , and 11 of 17 evaluable patients ( 64 % ) developed chronic extensive GVHD .|Transplantation - associated microangiopathy ( TMA ) occurred in 7 patients ( 29 % ) , with 2 cases of acute renal failure .|The study was terminated prematurely because an additional 6 patients ( 25 % ) developed sinusoidal obstruction syndrome ( SOS ) , which was fatal in 2 cases .|With a median follow - up of 26 months , the 2 - year overall survival rate was 47 % .|Although this new combination appears to be effective as a prophylactic regimen for acute GVHD , the incidence of TMA and SOS is considerably higher than seen with other regimens .	1:NR:2	R2L	NON-CROSS	8-9	0-6	C107135	everolimus|Everolimus|everolimus	Chemical	8:60:79	9:61:80	0:2:3	D006086	Graft - versus - host disease|graft - versus - host disease|GVHD|GVHD|GVHD|GVHD	Disease	0:41:48:161:176:266	6:47:49:162:177:267	0:1:1:5:5:9	1:NR:2	R2L	NON-CROSS	10-11	0-6	D016559	tacrolimus|tacrolimus	Chemical	10:81	11:82	0:3	D006086	Graft - versus - host disease|graft - versus - host disease|GVHD|GVHD|GVHD|GVHD	Disease	0:41:48:161:176:266	6:47:49:162:177:267	0:1:1:5:5:9	1:NR:2	R2L	NON-CROSS	41-47	35-36	D008727	methotrexate	Chemical	35	36	1	D006086	Graft - versus - host disease|graft - versus - host disease|GVHD|GVHD|GVHD|GVHD	Disease	0:41:48:161:176:266	6:47:49:162:177:267	0:1:1:5:5:9	1:NR:2	R2L	CROSS	65-66	48-49	D020123	sirolimus	Chemical	65	66	2	D006086	Graft - versus - host disease|graft - versus - host disease|GVHD|GVHD|GVHD|GVHD	Disease	0:41:48:161:176:266	6:47:49:162:177:267	0:1:1:5:5:9	1:CID:2	L2R	NON-CROSS	8-9	18-21	C107135	everolimus|Everolimus|everolimus	Chemical	8:60:79	9:61:80	0:2:3	D006504	sinusoidal obstruction syndrome|sinusoidal obstruction syndrome|SOS|SOS	Disease	18:217:221:273	21:220:222:274	0:7:7:9	1:CID:2	L2R	NON-CROSS	8-9	22-23	C107135	everolimus|Everolimus|everolimus	Chemical	8:60:79	9:61:80	0:2:3	D014652	microangiopathy|Transplantation - associated microangiopathy|TMA|TMA	Disease	22:178:183:271	23:182:184:272	0:6:6:9	1:NR:2	L2R	NON-CROSS	79-80	94-96	C107135	everolimus|Everolimus|everolimus	Chemical	8:60:79	9:61:80	0:2:3	D009190	myelodysplastic syndrome|MDS	Disease	94:97	96:98	3:3	1:NR:2	L2R	NON-CROSS	79-80	104-107	C107135	everolimus|Everolimus|everolimus	Chemical	8:60:79	9:61:80	0:2:3	D015470	acute myeloid leukemia|AML	Disease	104:108	107:109	3:3	1:NR:2	L2R	CROSS	79-80	147-148	C107135	everolimus|Everolimus|everolimus	Chemical	8:60:79	9:61:80	0:2:3	D052016	mucositis	Disease	147	148	4	1:CID:2	L2R	CROSS	79-80	198-201	C107135	everolimus|Everolimus|everolimus	Chemical	8:60:79	9:61:80	0:2:3	D058186	acute renal failure	Disease	198	201	6	1:CID:2	L2R	NON-CROSS	10-11	18-21	D016559	tacrolimus|tacrolimus	Chemical	10:81	11:82	0:3	D006504	sinusoidal obstruction syndrome|sinusoidal obstruction syndrome|SOS|SOS	Disease	18:217:221:273	21:220:222:274	0:7:7:9	1:CID:2	L2R	NON-CROSS	10-11	22-23	D016559	tacrolimus|tacrolimus	Chemical	10:81	11:82	0:3	D014652	microangiopathy|Transplantation - associated microangiopathy|TMA|TMA	Disease	22:178:183:271	23:182:184:272	0:6:6:9	1:NR:2	L2R	NON-CROSS	81-82	94-96	D016559	tacrolimus|tacrolimus	Chemical	10:81	11:82	0:3	D009190	myelodysplastic syndrome|MDS	Disease	94:97	96:98	3:3	1:NR:2	L2R	NON-CROSS	81-82	104-107	D016559	tacrolimus|tacrolimus	Chemical	10:81	11:82	0:3	D015470	acute myeloid leukemia|AML	Disease	104:108	107:109	3:3	1:NR:2	L2R	CROSS	81-82	147-148	D016559	tacrolimus|tacrolimus	Chemical	10:81	11:82	0:3	D052016	mucositis	Disease	147	148	4	1:CID:2	L2R	CROSS	81-82	198-201	D016559	tacrolimus|tacrolimus	Chemical	10:81	11:82	0:3	D058186	acute renal failure	Disease	198	201	6	1:NR:2	R2L	CROSS	35-36	18-21	D008727	methotrexate	Chemical	35	36	1	D006504	sinusoidal obstruction syndrome|sinusoidal obstruction syndrome|SOS|SOS	Disease	18:217:221:273	21:220:222:274	0:7:7:9	1:NR:2	R2L	CROSS	65-66	18-21	D020123	sirolimus	Chemical	65	66	2	D006504	sinusoidal obstruction syndrome|sinusoidal obstruction syndrome|SOS|SOS	Disease	18:217:221:273	21:220:222:274	0:7:7:9	1:NR:2	R2L	CROSS	35-36	22-23	D008727	methotrexate	Chemical	35	36	1	D014652	microangiopathy|Transplantation - associated microangiopathy|TMA|TMA	Disease	22:178:183:271	23:182:184:272	0:6:6:9	1:NR:2	R2L	CROSS	65-66	22-23	D020123	sirolimus	Chemical	65	66	2	D014652	microangiopathy|Transplantation - associated microangiopathy|TMA|TMA	Disease	22:178:183:271	23:182:184:272	0:6:6:9	1:NR:2	L2R	CROSS	35-36	94-96	D008727	methotrexate	Chemical	35	36	1	D009190	myelodysplastic syndrome|MDS	Disease	94:97	96:98	3:3	1:NR:2	L2R	CROSS	35-36	104-107	D008727	methotrexate	Chemical	35	36	1	D015470	acute myeloid leukemia|AML	Disease	104:108	107:109	3:3	1:NR:2	L2R	CROSS	35-36	147-148	D008727	methotrexate	Chemical	35	36	1	D052016	mucositis	Disease	147	148	4	1:NR:2	L2R	CROSS	35-36	198-201	D008727	methotrexate	Chemical	35	36	1	D058186	acute renal failure	Disease	198	201	6	1:NR:2	L2R	CROSS	65-66	94-96	D020123	sirolimus	Chemical	65	66	2	D009190	myelodysplastic syndrome|MDS	Disease	94:97	96:98	3:3	1:NR:2	L2R	CROSS	65-66	104-107	D020123	sirolimus	Chemical	65	66	2	D015470	acute myeloid leukemia|AML	Disease	104:108	107:109	3:3	1:NR:2	L2R	CROSS	65-66	147-148	D020123	sirolimus	Chemical	65	66	2	D052016	mucositis	Disease	147	148	4	1:NR:2	L2R	CROSS	65-66	198-201	D020123	sirolimus	Chemical	65	66	2	D058186	acute renal failure	Disease	198	201	6
14704468	Effect of some convulsants on the protective activity of loreclezole and its combinations with valproate or clonazepam in amygdala - kindled rats .|Loreclezole ( 5 mg / kg ) exerted a significant protective action in amygdala - kindled rats , reducing both seizure and afterdischarge durations .|The combinations of loreclezole ( 2 . 5 mg / kg ) with valproate , clonazepam , or carbamazepine ( applied at their subprotective doses ) also exhibited antiseizure effect in this test .|However , only two first combinations occurred to be of pharmacodynamic nature .|Among several chemoconvulsants , bicuculline , N - methyl - D - aspartic acid and BAY k - 8644 ( the opener of L - type calcium channels ) reversed the protective activity of loreclezole alone and its combination with valproate .|On the other hand , bicuculline , aminophylline and BAY k - 8644 inhibited the anticonvulsive action of loreclezole combined with clonazepam .|The results support the hypothesis that the protective activity of loreclezole and its combinations with other antiepileptics may involve potentiation of GABAergic neurotransmission and blockade of L - type of calcium channels .	1:NR:2	L2R	NON-CROSS	43-44	51-52	C066440	loreclezole|Loreclezole|loreclezole|loreclezole|loreclezole|loreclezole	Chemical	9:23:51:129:155:170	10:24:52:130:156:171	0:1:2:4:5:6	D012640	seizure	Disease	43	44	1	1:NR:2	L2R	CROSS	43-44	61-62	D014635	valproate|valproate|valproate	Chemical	14:61:135	15:62:136	0:2:4	D012640	seizure	Disease	43	44	1	1:NR:2	L2R	CROSS	43-44	63-64	D002998	clonazepam|clonazepam|clonazepam	Chemical	16:63:158	17:64:159	0:2:5	D012640	seizure	Disease	43	44	1	1:NR:2	R2L	CROSS	66-67	43-44	D002220	carbamazepine	Chemical	66	67	2	D012640	seizure	Disease	43	44	1	1:CID:2	R2L	CROSS	99-100	43-44	D001640	bicuculline|bicuculline	Chemical	99:142	100:143	4:5	D012640	seizure	Disease	43	44	1	1:NR:2	R2L	CROSS	101-109	43-44	D016202	N - methyl - D - aspartic acid	Chemical	101	109	4	D012640	seizure	Disease	43	44	1	1:CID:2	R2L	CROSS	110-114	43-44	D001498	BAY k - 8644|BAY k - 8644	Chemical	110:146	114:150	4:5	D012640	seizure	Disease	43	44	1	1:NR:2	R2L	CROSS	121-122	43-44	D002118	calcium|calcium	Chemical	121:190	122:191	4:6	D012640	seizure	Disease	43	44	1	1:CID:2	R2L	CROSS	144-145	43-44	D000628	aminophylline	Chemical	144	145	5	D012640	seizure	Disease	43	44	1
12549952	Acute liver failure with concurrent bupropion and carbimazole therapy .|OBJECTIVE : To report a case of fatal liver failure possibly associated with concurrent use of bupropion and carbimazole .|CASE SUMMARY : A 41 - year - old Chinese man with a history of hyperthyroidism had been treated with carbimazole and propranolol for the past 5 years .|He received a 10 - day course of bupropion as an aid for smoking cessation 10 weeks prior to presentation .|He developed acute liver failure with rapid deterioration of renal function .|Liver biopsy showed evidence of nonspecific drug - induced acute liver injury .|His condition was further complicated by sepsis and coagulopathy .|Death resulted 19 days after the onset of symptoms .|The likelihood that bupropion induced hepatotoxicity in our patient was possible , based on the Naranjo probability scale .|DISCUSSION : Although there is increasing evidence of hepatotoxicity induced by bupropion , this is the first case of fatality that could have resulted from acute liver failure in a patient receiving bupropion while on concomitant treatment with carbimazole .|CONCLUSIONS : Clinicians should be aware of the possibility of acute liver insult induced by bupropion given concurrently with other hepatotoxic drugs .	1:CID:2	R2L	NON-CROSS	5-6	0-3	D016642	bupropion|bupropion|bupropion|bupropion|bupropion|bupropion|bupropion	Chemical	5:26:67:128:155:176:199	6:27:68:129:156:177:200	0:1:3:8:9:9:10	D017114	Acute liver failure|acute liver failure|acute liver failure|acute liver insult	Disease	0:82:169:194	3:85:172:197	0:4:9:10	1:CID:2	R2L	NON-CROSS	7-8	0-3	D002231	carbimazole|carbimazole|carbimazole|carbimazole	Chemical	7:28:50:182	8:29:51:183	0:1:2:9	D017114	Acute liver failure|acute liver failure|acute liver failure|acute liver insult	Disease	0:82:169:194	3:85:172:197	0:4:9:10	1:NR:2	R2L	CROSS	82-85	52-53	D011433	propranolol	Chemical	52	53	2	D017114	Acute liver failure|acute liver failure|acute liver failure|acute liver insult	Disease	0:82:169:194	3:85:172:197	0:4:9:10	1:NR:2	L2R	NON-CROSS	18-20	26-27	D016642	bupropion|bupropion|bupropion|bupropion|bupropion|bupropion|bupropion	Chemical	5:26:67:128:155:176:199	6:27:68:129:156:177:200	0:1:3:8:9:9:10	D017093	liver failure	Disease	18	20	1	1:NR:2	L2R	CROSS	26-27	45-46	D016642	bupropion|bupropion|bupropion|bupropion|bupropion|bupropion|bupropion	Chemical	5:26:67:128:155:176:199	6:27:68:129:156:177:200	0:1:3:8:9:9:10	D006980	hyperthyroidism	Disease	45	46	2	1:CID:2	L2R	NON-CROSS	128-129	130-131	D016642	bupropion|bupropion|bupropion|bupropion|bupropion|bupropion|bupropion	Chemical	5:26:67:128:155:176:199	6:27:68:129:156:177:200	0:1:3:8:9:9:10	D056486	drug - induced acute liver injury|hepatotoxicity|hepatotoxicity|hepatotoxic	Disease	98:130:152:204	104:131:153:205	5:8:9:10	1:NR:2	L2R	CROSS	111-112	128-129	D016642	bupropion|bupropion|bupropion|bupropion|bupropion|bupropion|bupropion	Chemical	5:26:67:128:155:176:199	6:27:68:129:156:177:200	0:1:3:8:9:9:10	D018805	sepsis	Disease	111	112	6	1:NR:2	L2R	CROSS	113-114	128-129	D016642	bupropion|bupropion|bupropion|bupropion|bupropion|bupropion|bupropion	Chemical	5:26:67:128:155:176:199	6:27:68:129:156:177:200	0:1:3:8:9:9:10	D001778	coagulopathy	Disease	113	114	6	1:NR:2	L2R	NON-CROSS	18-20	28-29	D002231	carbimazole|carbimazole|carbimazole|carbimazole	Chemical	7:28:50:182	8:29:51:183	0:1:2:9	D017093	liver failure	Disease	18	20	1	1:NR:2	L2R	NON-CROSS	45-46	50-51	D002231	carbimazole|carbimazole|carbimazole|carbimazole	Chemical	7:28:50:182	8:29:51:183	0:1:2:9	D006980	hyperthyroidism	Disease	45	46	2	1:CID:2	L2R	NON-CROSS	182-183	204-205	D002231	carbimazole|carbimazole|carbimazole|carbimazole	Chemical	7:28:50:182	8:29:51:183	0:1:2:9	D056486	drug - induced acute liver injury|hepatotoxicity|hepatotoxicity|hepatotoxic	Disease	98:130:152:204	104:131:153:205	5:8:9:10	1:NR:2	L2R	CROSS	50-51	111-112	D002231	carbimazole|carbimazole|carbimazole|carbimazole	Chemical	7:28:50:182	8:29:51:183	0:1:2:9	D018805	sepsis	Disease	111	112	6	1:NR:2	L2R	CROSS	50-51	113-114	D002231	carbimazole|carbimazole|carbimazole|carbimazole	Chemical	7:28:50:182	8:29:51:183	0:1:2:9	D001778	coagulopathy	Disease	113	114	6	1:NR:2	R2L	CROSS	52-53	18-20	D011433	propranolol	Chemical	52	53	2	D017093	liver failure	Disease	18	20	1	1:NR:2	R2L	NON-CROSS	52-53	45-46	D011433	propranolol	Chemical	52	53	2	D006980	hyperthyroidism	Disease	45	46	2	1:NR:2	L2R	CROSS	52-53	98-104	D011433	propranolol	Chemical	52	53	2	D056486	drug - induced acute liver injury|hepatotoxicity|hepatotoxicity|hepatotoxic	Disease	98:130:152:204	104:131:153:205	5:8:9:10	1:NR:2	L2R	CROSS	52-53	111-112	D011433	propranolol	Chemical	52	53	2	D018805	sepsis	Disease	111	112	6	1:NR:2	L2R	CROSS	52-53	113-114	D011433	propranolol	Chemical	52	53	2	D001778	coagulopathy	Disease	113	114	6
19370593	Long term hormone therapy for perimenopausal and postmenopausal women .|BACKGROUND : Hormone therapy ( HT ) is widely used for controlling menopausal symptoms and has also been used for the management and prevention of cardiovascular disease , osteoporosis and dementia in older women .|This is an updated version of the original Cochrane review first published in 2005 .|OBJECTIVES : To assess the effect of long - term HT on mortality , cardiovascular outcomes , cancer , gallbladder disease , cognition , fractures and quality of life .|SEARCH STRATEGY : We searched the following databases to November 2007 : Trials Register of the Cochrane Menstrual Disorders and Subfertility Group , Cochrane Central Register of Controlled Trials , MEDLINE , EMBASE , Biological Abstracts .|Also relevant non - indexed journals and conference abstracts .|SELECTION CRITERIA : Randomised double - blind trials of HT versus placebo , taken for at least one year by perimenopausal or postmenopausal women .|HT included oestrogens , with or without progestogens , via oral , transdermal , subcutaneous or transnasal routes .|DATA COLLECTION AND ANALYSIS : Two authors independently assessed trial quality and extracted data .|MAIN RESULTS : Nineteen trials involving 41 , 904 women were included .|In relatively healthy women , combined continuous HT significantly increased the risk of venous thrombo - embolism or coronary event ( after one year 's use ) , stroke ( after three years ) , breast cancer and gallbladder disease .|Long - term oestrogen - only HT significantly increased the risk of venous thrombo - embolism , stroke and gallbladder disease ( after one to two years , three years and seven years ' use respectively ) , but did not significantly increase the risk of breast cancer .|The only statistically significant benefits of HT were a decreased incidence of fractures and ( for combined HT ) colon cancer , with long - term use .|Among women aged over 65 who were relatively healthy ( i . e . generally fit , without overt disease ) and taking continuous combined HT , there was a statistically significant increase in the incidence of dementia .|Among women with cardiovascular disease , long - term use of combined continuous HT significantly increased the risk of venous thrombo - embolism . One trial analysed subgroups of 2839 relatively healthy 50 to 59 year old women taking combined continuous HT and 1637 taking oestrogen - only HT , versus similar - sized placebo groups .|The only significantly increased risk reported was for venous thrombo - embolism in women taking combined continuous HT : their absolute risk remained low , at less than 1 / 500 .|However , this study was not powered to detect differences between groups of younger women .|AUTHORS ' CONCLUSIONS : HT is not indicated for the routine management of chronic disease .|We need more evidence on the safety of HT for menopausal symptom control , though short - term use appears to be relatively safe for healthy younger women .	1:NR:2	R2L	NON-CROSS	411-412	369-371	D004967	oestrogens|oestrogen|oestrogen	Chemical	164:253:411	165:254:412	7:11:14	D002318	cardiovascular disease|cardiovascular disease	Disease	35:369	37:371	1:14	1:NR:2	R2L	CROSS	169-170	35-37	D011374	progestogens	Chemical	169	170	7	D002318	cardiovascular disease|cardiovascular disease	Disease	35:369	37:371	1:14	1:NR:2	R2L	CROSS	164-165	38-39	D004967	oestrogens|oestrogen|oestrogen	Chemical	164:253:411	165:254:412	7:11:14	D010024	osteoporosis	Disease	38	39	1	1:NR:2	R2L	CROSS	169-170	38-39	D011374	progestogens	Chemical	169	170	7	D010024	osteoporosis	Disease	38	39	1	1:CID:2	R2L	CROSS	411-412	364-365	D004967	oestrogens|oestrogen|oestrogen	Chemical	164:253:411	165:254:412	7:11:14	D003704	dementia|dementia	Disease	40:364	41:365	1:13	1:CID:2	R2L	CROSS	169-170	40-41	D011374	progestogens	Chemical	169	170	7	D003704	dementia|dementia	Disease	40:364	41:365	1:13	1:NR:2	R2L	CROSS	164-165	77-78	D004967	oestrogens|oestrogen|oestrogen	Chemical	164:253:411	165:254:412	7:11:14	D009369	cancer	Disease	77	78	3	1:NR:2	R2L	CROSS	169-170	77-78	D011374	progestogens	Chemical	169	170	7	D009369	cancer	Disease	77	78	3	1:CID:2	R2L	NON-CROSS	253-254	247-249	D004967	oestrogens|oestrogen|oestrogen	Chemical	164:253:411	165:254:412	7:11:14	D005705	gallbladder disease|gallbladder disease|gallbladder disease	Disease	79:247:269	81:249:271	3:10:11	1:NR:2	R2L	CROSS	247-249	169-170	D011374	progestogens	Chemical	169	170	7	D005705	gallbladder disease|gallbladder disease|gallbladder disease	Disease	79:247:269	81:249:271	3:10:11	1:NR:2	R2L	CROSS	311-312	253-254	D004967	oestrogens|oestrogen|oestrogen	Chemical	164:253:411	165:254:412	7:11:14	D050723	fractures|fractures	Disease	84:311	85:312	3:12	1:NR:2	R2L	CROSS	169-170	84-85	D011374	progestogens	Chemical	169	170	7	D050723	fractures|fractures	Disease	84:311	85:312	3:12	1:NR:2	R2L	CROSS	164-165	107-109	D004967	oestrogens|oestrogen|oestrogen	Chemical	164:253:411	165:254:412	7:11:14	D008599	Menstrual Disorders	Disease	107	109	4	1:NR:2	R2L	CROSS	169-170	107-109	D011374	progestogens	Chemical	169	170	7	D008599	Menstrual Disorders	Disease	107	109	4	1:CID:2	L2R	NON-CROSS	253-254	262-266	D004967	oestrogens|oestrogen|oestrogen	Chemical	164:253:411	165:254:412	7:11:14	D054556	venous thrombo - embolism|venous thrombo - embolism|venous thrombo - embolism|venous thrombo - embolism	Disease	222:262:385:431	226:266:389:435	10:11:14:15	1:CID:2	L2R	NON-CROSS	253-254	267-268	D004967	oestrogens|oestrogen|oestrogen	Chemical	164:253:411	165:254:412	7:11:14	D020521	stroke|stroke	Disease	237:267	238:268	10:11	1:NR:2	L2R	NON-CROSS	244-246	253-254	D004967	oestrogens|oestrogen|oestrogen	Chemical	164:253:411	165:254:412	7:11:14	D001943	breast cancer|breast cancer	Disease	244:296	246:298	10:11	1:NR:2	L2R	CROSS	253-254	318-320	D004967	oestrogens|oestrogen|oestrogen	Chemical	164:253:411	165:254:412	7:11:14	D003110	colon cancer	Disease	318	320	12	1:CID:2	L2R	CROSS	169-170	222-226	D011374	progestogens	Chemical	169	170	7	D054556	venous thrombo - embolism|venous thrombo - embolism|venous thrombo - embolism|venous thrombo - embolism	Disease	222:262:385:431	226:266:389:435	10:11:14:15	1:NR:2	L2R	CROSS	169-170	237-238	D011374	progestogens	Chemical	169	170	7	D020521	stroke|stroke	Disease	237:267	238:268	10:11	1:NR:2	L2R	CROSS	169-170	244-246	D011374	progestogens	Chemical	169	170	7	D001943	breast cancer|breast cancer	Disease	244:296	246:298	10:11	1:NR:2	L2R	CROSS	169-170	318-320	D011374	progestogens	Chemical	169	170	7	D003110	colon cancer	Disease	318	320	12
17019386	Passage of mannitol into the brain around gliomas : a potential cause of rebound phenomenon .|A study on 21 patients .|AIM : Widespread use of mannitol to reduce brain edema and lower elevated ICP in brain tumor patients continues to be afflicted by the so - called rebound phenomenon .|Leakage of mannitol into the brain parenchyma through an altered BBB and secondary reversal of osmotic gradient is considered the major cause of rebound . This has only been demonstrated experimentally in animals .|As a contribution to this issue we decided to research the possible passage of mannitol into the brain after administration to 21 brain tumor patients .|METHODS : Mannitol ( 18 % solution ; 1 g / kg ) was administered as a bolus to patients ( ten had malignant glioma , seven brain metastases and four meningioma ) about 30 minutes before craniotomy .|During resection , a sample of the surrounding edematous white matter was taken at the same time as a 10 ml venous blood sample .|Mannitol concentrations were measured in plasma and white matter by a modified version of the enzyme assay of Blonquist et al .|RESULTS : In most glioma patients , mannitol concentrations in white matter were 2 to 6 times higher than in plasma ( mean 3 . 5 times ) .|In meningioma and metastases patients plasma concentrations of mannitol were higher than white matter concentrations except in three cases with infiltration by neoplastic cells .|CONCLUSIONS : The results of our study show that even after a single bolus , mannitol may leak through the altered BBB near gliomas , reversing the initial plasma - to - blood osmotic gradient , aggravating peritumoral edema and promoting rebound of ICP .	1:NR:2	L2R	NON-CROSS	202-203	205-206	D008353	mannitol|mannitol|mannitol|mannitol|Mannitol|Mannitol|mannitol|mannitol|mannitol	Chemical	2:27:54:100:114:176:205:235:267	3:28:55:101:115:177:206:236:268	0:2:3:4:5:7:8:9:10	D005910	gliomas|malignant glioma|glioma|gliomas	Disease	7:135:202:275	8:137:203:276	0:5:8:10	1:NR:2	L2R	NON-CROSS	27-28	30-32	D008353	mannitol|mannitol|mannitol|mannitol|Mannitol|Mannitol|mannitol|mannitol|mannitol	Chemical	2:27:54:100:114:176:205:235:267	3:28:55:101:115:177:206:236:268	0:2:3:4:5:7:8:9:10	D001929	brain edema	Disease	30	32	2	1:CID:2	L2R	NON-CROSS	27-28	34-36	D008353	mannitol|mannitol|mannitol|mannitol|Mannitol|Mannitol|mannitol|mannitol|mannitol	Chemical	2:27:54:100:114:176:205:235:267	3:28:55:101:115:177:206:236:268	0:2:3:4:5:7:8:9:10	D019586	elevated ICP	Disease	34	36	2	1:NR:2	L2R	NON-CROSS	108-110	114-115	D008353	mannitol|mannitol|mannitol|mannitol|Mannitol|Mannitol|mannitol|mannitol|mannitol	Chemical	2:27:54:100:114:176:205:235:267	3:28:55:101:115:177:206:236:268	0:2:3:4:5:7:8:9:10	D001932	brain tumor|brain tumor	Disease	37:108	39:110	2:4	1:NR:2	L2R	NON-CROSS	230-231	235-236	D008353	mannitol|mannitol|mannitol|mannitol|Mannitol|Mannitol|mannitol|mannitol|mannitol	Chemical	2:27:54:100:114:176:205:235:267	3:28:55:101:115:177:206:236:268	0:2:3:4:5:7:8:9:10	D009362	metastases|metastases	Disease	140:230	141:231	5:9	1:NR:2	L2R	NON-CROSS	228-229	235-236	D008353	mannitol|mannitol|mannitol|mannitol|Mannitol|Mannitol|mannitol|mannitol|mannitol	Chemical	2:27:54:100:114:176:205:235:267	3:28:55:101:115:177:206:236:268	0:2:3:4:5:7:8:9:10	D008579	meningioma|meningioma	Disease	143:228	144:229	5:9	1:NR:2	L2R	NON-CROSS	159-160	176-177	D008353	mannitol|mannitol|mannitol|mannitol|Mannitol|Mannitol|mannitol|mannitol|mannitol	Chemical	2:27:54:100:114:176:205:235:267	3:28:55:101:115:177:206:236:268	0:2:3:4:5:7:8:9:10	D004487	edematous|edema	Disease	159:290	160:291	6:10
12452237	Can lidocaine reduce succinylcholine induced postoperative myalgia ?|This study was undertaken to determine the effect of lidocaine pretreatment on reduction of succinylcholine - induced myalgia in patients undergoing general anesthesia for gynecological surgery .|One hundred and thirty - five patients were assigned to one of three groups in a prospective , double blind , randomized manner .|Group PS , the control group , received normal saline and succinylcholine 1 . 5 mg x kg ( - 1 ) ; Group LS , lidocaine 1 . 5 mg x kg ( - 1 ) and succinylcholine 1 . 5 mg x kg ( - 1 ) ; Group PR , normal saline and rocuronium 0 . 6 mg x kg ( - 1 ) .|Morphine 0 . 1 mg x kg ( - 1 ) iv was given for premedication and all patients were monitored with a noninvasive blood pressure monitor , ECG and pulse oximetry .|Anesthesia was induced with 5 mg . kg ( - 1 ) thiopental iv .|followed by succinylcholine ( Group PS , LS ) or rocuronium ( Group PR ) for tracheal intubation .|Following administration of these agents , the presence , and degree of fasciculation were assessed visually on a four point scale by one investigator who was blinded to the drug administered .|The blood pressure and heart rate of each patient were monitored on nine occasions .|Twenty - four hours later , any myalgia experienced was assessed according to a structured questionaire and graded by a four point scale by one investigator blinded to the intraoperative management .|The results indicate that muscle fasciculation was not found in Group PR while the patients in Group LS had a lower incidence of muscle fasciculation than those in Group PS ( p < 0 . 001 ) .|At 24 h , the incidence of myalgia was higher in Group PS than in Group LS and PR ( p < 0 . 05 ) .|A correlation was not found between the incidence of myalgia and the occurrence of muscle fasciculation .|The changes in systolic and diastolic blood pressure and heart rate were not significant among the three groups .|In conclusion , where succinylcholine is used , lidocaine is proven to be the useful pretreatment agent for the reduction of postoperative myalgia .	1:NR:2	L2R	NON-CROSS	1-2	5-7	D008012	lidocaine|lidocaine|lidocaine|lidocaine	Chemical	1:17:85:382	2:18:86:383	0:1:3:14	D010149	postoperative myalgia|postoperative myalgia	Disease	5:395	7:397	0:14	1:NR:2	L2R	NON-CROSS	17-18	25-26	D008012	lidocaine|lidocaine|lidocaine|lidocaine	Chemical	1:17:85:382	2:18:86:383	0:1:3:14	D063806	myalgia|myalgia|myalgia|myalgia	Disease	25:248:318:347	26:249:319:348	1:9:11:12	1:NR:2	L2R	CROSS	352-354	382-383	D008012	lidocaine|lidocaine|lidocaine|lidocaine	Chemical	1:17:85:382	2:18:86:383	0:1:3:14	D005207	fasciculation|muscle fasciculation|muscle fasciculation|muscle fasciculation	Disease	206:277:296:352	207:279:298:354	7:10:10:12	1:CID:2	L2R	NON-CROSS	3-4	5-7	D013390	succinylcholine|succinylcholine|succinylcholine|succinylcholine|succinylcholine|succinylcholine	Chemical	3:22:70:97:177:378	4:23:71:98:178:379	0:1:3:3:6:14	D010149	postoperative myalgia|postoperative myalgia	Disease	5:395	7:397	0:14	1:NR:2	L2R	NON-CROSS	22-23	25-26	D013390	succinylcholine|succinylcholine|succinylcholine|succinylcholine|succinylcholine|succinylcholine	Chemical	3:22:70:97:177:378	4:23:71:98:178:379	0:1:3:3:6:14	D063806	myalgia|myalgia|myalgia|myalgia	Disease	25:248:318:347	26:249:319:348	1:9:11:12	1:CID:2	L2R	CROSS	352-354	378-379	D013390	succinylcholine|succinylcholine|succinylcholine|succinylcholine|succinylcholine|succinylcholine	Chemical	3:22:70:97:177:378	4:23:71:98:178:379	0:1:3:3:6:14	D005207	fasciculation|muscle fasciculation|muscle fasciculation|muscle fasciculation	Disease	206:277:296:352	207:279:298:354	7:10:10:12	1:NR:2	R2L	CROSS	115-116	5-7	C061870	rocuronium|rocuronium	Chemical	115:185	116:186	3:6	D010149	postoperative myalgia|postoperative myalgia	Disease	5:395	7:397	0:14	1:NR:2	R2L	CROSS	127-128	5-7	D009020	Morphine	Chemical	127	128	4	D010149	postoperative myalgia|postoperative myalgia	Disease	5:395	7:397	0:14	1:NR:2	R2L	CROSS	172-173	5-7	D013874	thiopental	Chemical	172	173	5	D010149	postoperative myalgia|postoperative myalgia	Disease	5:395	7:397	0:14	1:NR:2	R2L	CROSS	248-249	185-186	C061870	rocuronium|rocuronium	Chemical	115:185	116:186	3:6	D063806	myalgia|myalgia|myalgia|myalgia	Disease	25:248:318:347	26:249:319:348	1:9:11:12	1:NR:2	R2L	CROSS	127-128	25-26	D009020	Morphine	Chemical	127	128	4	D063806	myalgia|myalgia|myalgia|myalgia	Disease	25:248:318:347	26:249:319:348	1:9:11:12	1:NR:2	R2L	CROSS	248-249	172-173	D013874	thiopental	Chemical	172	173	5	D063806	myalgia|myalgia|myalgia|myalgia	Disease	25:248:318:347	26:249:319:348	1:9:11:12	1:NR:2	L2R	CROSS	185-186	206-207	C061870	rocuronium|rocuronium	Chemical	115:185	116:186	3:6	D005207	fasciculation|muscle fasciculation|muscle fasciculation|muscle fasciculation	Disease	206:277:296:352	207:279:298:354	7:10:10:12	1:NR:2	L2R	CROSS	127-128	206-207	D009020	Morphine	Chemical	127	128	4	D005207	fasciculation|muscle fasciculation|muscle fasciculation|muscle fasciculation	Disease	206:277:296:352	207:279:298:354	7:10:10:12	1:NR:2	L2R	CROSS	172-173	206-207	D013874	thiopental	Chemical	172	173	5	D005207	fasciculation|muscle fasciculation|muscle fasciculation|muscle fasciculation	Disease	206:277:296:352	207:279:298:354	7:10:10:12
9564988	Open - label assessment of levofloxacin for the treatment of acute bacterial sinusitis in adults .|PURPOSE : To evaluate the efficacy and safety of levofloxacin ( 500 mg orally once daily for 10 to 14 days ) in treating adult outpatients with acute bacterial sinusitis .|PATIENTS AND METHODS : A total of 329 patients enrolled in the study at 24 centers .|All patients had a pre - therapy Gram 's stain and culture of sinus exudate obtained by antral puncture or nasal endoscopy .|Clinical response was assessed on the basis of signs and symptoms and sinus radiograph or computed tomography results .|Microbiologic cure rates were determined on the basis of presumed plus documented eradication of the pre - therapy pathogen ( s ) .|RESULTS : The most common pathogens were Haemophilus influenzae , Streptococcus pneumoniae , Staphylococcus aureus , and Moraxella catarrhalis .|Of 300 clinically evaluable patients , 175 ( 58 % ) were cured and 90 ( 30 % ) were improved at the post - therapy evaluation , resulting in a clinical success rate of 88 % .|Thirty - five patients ( 12 % ) clinically failed treatment .|The microbiologic eradication rate ( presumed plus documented ) among 138 microbiologically evaluable patients was 92 % .|Microbiologic eradication rates ( presumed plus documented ) of the most common pathogens ranged from 93 % ( M . catarrhalis ) to 100 % ( S . pneumoniae ) at the post - therapy visit .|All but one of the 265 patients who were cured or improved at post - therapy returned for a long - term follow - up visit ; 243 ( 92 % ) remained well 4 to 6 weeks after therapy ; and 21 ( 8 % ) had a relapse of symptoms .|Adverse events considered to be related to levofloxacin administration were reported by 29 patients ( 9 % ) .|The most common drug - related adverse events were diarrhea , flatulence , and nausea ; most adverse events were mild to moderate in severity .|CONCLUSION : The results of this study indicate that levofloxacin 500 mg once daily is an effective and safe treatment for acute bacterial sinusitis .	1:NR:2	L2R	NON-CROSS	5-6	12-13	D064704	levofloxacin|levofloxacin|levofloxacin|levofloxacin	Chemical	5:25:314:361	6:26:315:362	0:1:12:14	D012852	sinusitis|sinusitis|sinusitis	Disease	12:45:375	13:46:376	0:1:14	1:CID:2	L2R	CROSS	314-315	335-336	D064704	levofloxacin|levofloxacin|levofloxacin|levofloxacin	Chemical	5:25:314:361	6:26:315:362	0:1:12:14	D003967	diarrhea	Disease	335	336	13	1:CID:2	L2R	CROSS	314-315	337-338	D064704	levofloxacin|levofloxacin|levofloxacin|levofloxacin	Chemical	5:25:314:361	6:26:315:362	0:1:12:14	D005414	flatulence	Disease	337	338	13	1:CID:2	L2R	CROSS	340-341	361-362	D064704	levofloxacin|levofloxacin|levofloxacin|levofloxacin	Chemical	5:25:314:361	6:26:315:362	0:1:12:14	D009325	nausea	Disease	340	341	13
7596955	Clinical evaluation on combined administration of oral prostacyclin analogue beraprost and phosphodiesterase inhibitor cilostazol .|Among various oral antiplatelets , a combination of a novel prostacyclin analogue beraprost ( BPT ) and a potent phosphodiesterase inhibitor cilostazol ( CLZ ) may result in untoward clinical effects due to possible synergistic elevation of intracellular cAMP ( cyclic adenosine 3 ' , 5 ' - monophosphate ) .|Thereby , a clinical study of the combined administration of the two agents was attempted .|Twelve healthy volunteers were assigned to take BPT / CLZ in the following schedule ; BPT : 40 micrograms at day 1 and 120 micrograms t . i . d .|from day 7 to 14 , CLZ : 200 mg t . i . d .|from day 3 to 14 .|At various time intervals , physical examination and blood collection for ex vivo platelet aggregation and determination of intraplatelet cAMP were performed .|Throughout the observation period , no significant alteration in vital signs was observed .|Seven out of 12 subjects experienced headache of a short duration accompanying facial flush in one and nausea in one , especially after ingestion of CLZ .|All of these symptoms , probably caused by the vasodilating effect of the two agents , were of mild degree and no special treatment was required .|Intraplatelet cAMP content was gradually but significantly increased to 9 . 84 + / - 4 . 59 pmol per 10 ( 9 ) platelets at day 14 in comparison with the initial value ( 6 . 87 + / - 2 . 25 pmol ) .|The platelet aggregability was significantly suppressed at various time intervals but no additive or synergistic inhibitory effect by the combined administration was noted .|In conclusion , the combined administration of BPT / CLZ is safe at doses used in the study , though the beneficial clinical effect of the combined administration has yet to be elucidated .	1:NR:2	L2R	CROSS	25-26	148-150	D011464	prostacyclin|prostacyclin	Chemical	7:25	8:26	0:1	D001791	platelet aggregation	Disease	148	150	6	1:NR:2	L2R	CROSS	25-26	178-179	D011464	prostacyclin|prostacyclin	Chemical	7:25	8:26	0:1	D006261	headache	Disease	178	179	8	1:NR:2	L2R	CROSS	25-26	184-186	D011464	prostacyclin|prostacyclin	Chemical	7:25	8:26	0:1	D005483	facial flush	Disease	184	186	8	1:NR:2	L2R	CROSS	25-26	189-190	D011464	prostacyclin|prostacyclin	Chemical	7:25	8:26	0:1	D009325	nausea	Disease	189	190	8	1:NR:2	L2R	CROSS	97-98	148-150	C048081	beraprost|beraprost|BPT|BPT|BPT|BPT	Chemical	9:27:29:89:97:304	10:28:30:90:98:305	0:1:1:3:3:12	D001791	platelet aggregation	Disease	148	150	6	1:CID:2	L2R	CROSS	97-98	178-179	C048081	beraprost|beraprost|BPT|BPT|BPT|BPT	Chemical	9:27:29:89:97:304	10:28:30:90:98:305	0:1:1:3:3:12	D006261	headache	Disease	178	179	8	1:CID:2	L2R	CROSS	97-98	184-186	C048081	beraprost|beraprost|BPT|BPT|BPT|BPT	Chemical	9:27:29:89:97:304	10:28:30:90:98:305	0:1:1:3:3:12	D005483	facial flush	Disease	184	186	8	1:CID:2	L2R	CROSS	97-98	189-190	C048081	beraprost|beraprost|BPT|BPT|BPT|BPT	Chemical	9:27:29:89:97:304	10:28:30:90:98:305	0:1:1:3:3:12	D009325	nausea	Disease	189	190	8	1:NR:2	L2R	CROSS	119-120	148-150	C045645	cilostazol|cilostazol|CLZ|CLZ|CLZ|CLZ|CLZ	Chemical	13:36:38:91:119:197:306	14:37:39:92:120:198:307	0:1:1:3:4:8:12	D001791	platelet aggregation	Disease	148	150	6	1:CID:2	L2R	NON-CROSS	178-179	197-198	C045645	cilostazol|cilostazol|CLZ|CLZ|CLZ|CLZ|CLZ	Chemical	13:36:38:91:119:197:306	14:37:39:92:120:198:307	0:1:1:3:4:8:12	D006261	headache	Disease	178	179	8	1:CID:2	L2R	NON-CROSS	184-186	197-198	C045645	cilostazol|cilostazol|CLZ|CLZ|CLZ|CLZ|CLZ	Chemical	13:36:38:91:119:197:306	14:37:39:92:120:198:307	0:1:1:3:4:8:12	D005483	facial flush	Disease	184	186	8	1:CID:2	L2R	NON-CROSS	189-190	197-198	C045645	cilostazol|cilostazol|CLZ|CLZ|CLZ|CLZ|CLZ	Chemical	13:36:38:91:119:197:306	14:37:39:92:120:198:307	0:1:1:3:4:8:12	D009325	nausea	Disease	189	190	8	1:NR:2	L2R	NON-CROSS	148-150	154-155	D000242	cAMP|cyclic adenosine 3 ' , 5 ' - monophosphate|cAMP|cAMP	Chemical	53:55:154:227	54:64:155:228	1:1:6:10	D001791	platelet aggregation	Disease	148	150	6	1:NR:2	L2R	CROSS	154-155	178-179	D000242	cAMP|cyclic adenosine 3 ' , 5 ' - monophosphate|cAMP|cAMP	Chemical	53:55:154:227	54:64:155:228	1:1:6:10	D006261	headache	Disease	178	179	8	1:NR:2	L2R	CROSS	154-155	184-186	D000242	cAMP|cyclic adenosine 3 ' , 5 ' - monophosphate|cAMP|cAMP	Chemical	53:55:154:227	54:64:155:228	1:1:6:10	D005483	facial flush	Disease	184	186	8	1:NR:2	L2R	CROSS	154-155	189-190	D000242	cAMP|cyclic adenosine 3 ' , 5 ' - monophosphate|cAMP|cAMP	Chemical	53:55:154:227	54:64:155:228	1:1:6:10	D009325	nausea	Disease	189	190	8
17965424	Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients : results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial ( EDGE - II ) .|OBJECTIVE : A randomised , double - blind study to compare the gastrointestinal ( GI ) tolerability , safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis ( RA ) .|PATIENTS AND METHODS : A total of 4086 patients ( mean age 60 . 8 years ) diagnosed with RA were enrolled and received etoricoxib 90 mg daily ( n = 2032 ) or diclofenac 75 mg twice daily ( n = 2054 ) .|Use of gastroprotective agents and low - dose aspirin was allowed .|The prespecified primary end point consisted of the cumulative rate of patient discontinuations due to clinical and laboratory GI adverse experiences ( AEs ) .|General safety was also assessed , including adjudicated thrombotic cardiovascular event data .|Efficacy was evaluated using the Patient Global Assessment of Disease Status ( PGADS ; 0 - 4 point scale ) .|RESULTS : Mean ( SD ; maximum ) duration of treatment was 19 . 3 ( 10 . 3 ; 32 . 9 ) and 19 . 1 ( 10 . 4 ; 33 . 1 ) months in the etoricoxib and diclofenac groups , respectively .|The cumulative discontinuation rate due to GI AEs was significantly lower with etoricoxib than diclofenac ( 5 . 2 vs 8 . 5 events per 100 patient - years , respectively ; hazard ratio 0 . 62 ( 95 % CI : 0 . 47 , 0 . 81 ; p < or = 0 . 001 ) ) .|The incidence of discontinuations for hypertension - related and oedema - related AEs were significantly higher with etoricoxib ( 2 . 5 % and 1 . 1 % respectively ) compared with diclofenac ( 1 . 5 % and 0 . 4 % respectively ; p < 0 . 001 for hypertension and p < 0 . 01 for oedema ) .|Etoricoxib and diclofenac treatment resulted in similar efficacy ( PGADS mean changes from baseline - 0 . 62 vs - 0 . 58 , respectively ) .|CONCLUSIONS : Etoricoxib 90 mg demonstrated a significantly lower risk for discontinuing treatment due to GI AEs compared with diclofenac 150 mg .|Discontinuations from renovascular AEs , although less common than discontinuations from GI AEs , were significantly higher with etoricoxib .	1:NR:2	L2R	NON-CROSS	3-4	5-7	C422649	etoricoxib|etoricoxib|etoricoxib|etoricoxib|etoricoxib|etoricoxib|etoricoxib|Etoricoxib|Etoricoxib|etoricoxib	Chemical	3:12:49:85:217:236:301:346:375:414	4:13:50:86:218:237:302:347:376:415	0:0:1:2:7:8:9:10:11:12	D001172	rheumatoid arthritis|rheumatoid arthritis|RA|RA	Disease	5:55:58:80	7:57:59:81	0:1:1:2	1:NR:2	L2R	CROSS	151-153	217-218	C422649	etoricoxib|etoricoxib|etoricoxib|etoricoxib|etoricoxib|etoricoxib|etoricoxib|Etoricoxib|Etoricoxib|etoricoxib	Chemical	3:12:49:85:217:236:301:346:375:414	4:13:50:86:218:237:302:347:376:415	0:0:1:2:7:8:9:10:11:12	D002318	thrombotic cardiovascular	Disease	151	153	5	1:NR:2	L2R	NON-CROSS	230-232	236-237	C422649	etoricoxib|etoricoxib|etoricoxib|etoricoxib|etoricoxib|etoricoxib|etoricoxib|Etoricoxib|Etoricoxib|etoricoxib	Chemical	3:12:49:85:217:236:301:346:375:414	4:13:50:86:218:237:302:347:376:415	0:0:1:2:7:8:9:10:11:12	D005767	GI AEs|GI AEs|GI AEs	Disease	230:388:407	232:390:409	8:11:12	1:CID:2	L2R	NON-CROSS	335-336	346-347	C422649	etoricoxib|etoricoxib|etoricoxib|etoricoxib|etoricoxib|etoricoxib|etoricoxib|Etoricoxib|Etoricoxib|etoricoxib	Chemical	3:12:49:85:217:236:301:346:375:414	4:13:50:86:218:237:302:347:376:415	0:0:1:2:7:8:9:10:11:12	D006973	hypertension|hypertension	Disease	289:335	290:336	9:9	1:CID:2	L2R	NON-CROSS	343-344	346-347	C422649	etoricoxib|etoricoxib|etoricoxib|etoricoxib|etoricoxib|etoricoxib|etoricoxib|Etoricoxib|Etoricoxib|etoricoxib	Chemical	3:12:49:85:217:236:301:346:375:414	4:13:50:86:218:237:302:347:376:415	0:0:1:2:7:8:9:10:11:12	D004487	oedema|oedema	Disease	293:343	294:344	9:9	1:NR:2	R2L	NON-CROSS	55-57	51-52	D004008	diclofenac sodium|diclofenac|diclofenac|diclofenac|diclofenac|diclofenac|diclofenac|diclofenac	Chemical	14:51:95:219:238:316:348:392	16:52:96:220:239:317:349:393	0:1:2:7:8:9:10:11	D001172	rheumatoid arthritis|rheumatoid arthritis|RA|RA	Disease	5:55:58:80	7:57:59:81	0:1:1:2	1:NR:2	R2L	CROSS	114-115	80-81	D001241	aspirin	Chemical	114	115	3	D001172	rheumatoid arthritis|rheumatoid arthritis|RA|RA	Disease	5:55:58:80	7:57:59:81	0:1:1:2	1:NR:2	L2R	CROSS	95-96	151-153	D004008	diclofenac sodium|diclofenac|diclofenac|diclofenac|diclofenac|diclofenac|diclofenac|diclofenac	Chemical	14:51:95:219:238:316:348:392	16:52:96:220:239:317:349:393	0:1:2:7:8:9:10:11	D002318	thrombotic cardiovascular	Disease	151	153	5	1:CID:2	L2R	NON-CROSS	388-390	392-393	D004008	diclofenac sodium|diclofenac|diclofenac|diclofenac|diclofenac|diclofenac|diclofenac|diclofenac	Chemical	14:51:95:219:238:316:348:392	16:52:96:220:239:317:349:393	0:1:2:7:8:9:10:11	D005767	GI AEs|GI AEs|GI AEs	Disease	230:388:407	232:390:409	8:11:12	1:NR:2	L2R	NON-CROSS	335-336	348-349	D004008	diclofenac sodium|diclofenac|diclofenac|diclofenac|diclofenac|diclofenac|diclofenac|diclofenac	Chemical	14:51:95:219:238:316:348:392	16:52:96:220:239:317:349:393	0:1:2:7:8:9:10:11	D006973	hypertension|hypertension	Disease	289:335	290:336	9:9	1:NR:2	L2R	NON-CROSS	343-344	348-349	D004008	diclofenac sodium|diclofenac|diclofenac|diclofenac|diclofenac|diclofenac|diclofenac|diclofenac	Chemical	14:51:95:219:238:316:348:392	16:52:96:220:239:317:349:393	0:1:2:7:8:9:10:11	D004487	oedema|oedema	Disease	293:343	294:344	9:9	1:NR:2	L2R	CROSS	114-115	151-153	D001241	aspirin	Chemical	114	115	3	D002318	thrombotic cardiovascular	Disease	151	153	5	1:NR:2	L2R	CROSS	114-115	230-232	D001241	aspirin	Chemical	114	115	3	D005767	GI AEs|GI AEs|GI AEs	Disease	230:388:407	232:390:409	8:11:12	1:NR:2	L2R	CROSS	114-115	289-290	D001241	aspirin	Chemical	114	115	3	D006973	hypertension|hypertension	Disease	289:335	290:336	9:9	1:NR:2	L2R	CROSS	114-115	293-294	D001241	aspirin	Chemical	114	115	3	D004487	oedema|oedema	Disease	293:343	294:344	9:9
17042884	Placebo - level incidence of extrapyramidal symptoms ( EPS ) with quetiapine in controlled studies of patients with bipolar mania .|OBJECTIVES : To evaluate extrapyramidal symptoms ( EPS ) , including akathisia , with quetiapine in patients with bipolar mania .|METHODS : Data were analyzed from four similarly designed , randomized , double - blind , 3 - to 12 - week studies .|Two studies evaluated quetiapine monotherapy ( up to 800 mg / day ) ( n = 209 ) versus placebo ( n = 198 ) , with lithium or haloperidol monotherapy as respective active controls .|Two studies evaluated quetiapine ( up to 800 mg / day ) in combination with a mood stabilizer ( lithium or divalproex , QTP + Li / DVP ) ( n = 196 ) compared to placebo and mood stabilizer ( PBO + Li / DVP ) ( n = 203 ) .|Extrapyramidal symptoms were evaluated using the Simpson - Angus Scale ( SAS ) , the Barnes Akathisia Rating Scale ( BARS ) , adverse event reports and anticholinergic drug usage .|RESULTS : The incidence of EPS - related adverse events , including akathisia , was no different with quetiapine monotherapy ( 12 . 9 % ) than with placebo ( 13 . 1 % ) .|Similarly , EPS - related adverse events with QTP + Li / DVP ( 21 . 4 % ) were no different than with PBO + Li / DVP ( 19 . 2 % ) .|Adverse events related to EPS occurred in 59 . 6 % of patients treated with haloperidol ( n = 99 ) monotherapy , whereas 26 . 5 % of patients treated with lithium ( n = 98 ) monotherapy experienced adverse events related to EPS .|The incidence of akathisia was low and similar with quetiapine monotherapy ( 3 . 3 % ) and placebo ( 6 . 1 % ) , and with QTP + Li / DVP ( 3 . 6 % ) and PBO + Li / DVP ( 4 . 9 % ) .|Lithium was associated with a significantly higher incidence ( p < 0 . 05 ) of tremor ( 18 . 4 % ) than quetiapine ( 5 . 6 % ) ; cerebellar tremor , which is a known adverse effect of lithium , may have contributed to the elevated rate of tremor in patients receiving lithium therapy .|Haloperidol induced a significantly higher incidence ( p < 0 . 001 ) of akathisia ( 33 . 3 % versus 5 . 9 % ) , tremor ( 30 . 3 % versus 7 . 8 % ) , and extrapyramidal syndrome ( 35 . 4 % versus 5 . 9 % ) than quetiapine .|No significant differences were observed between quetiapine and placebo on SAS and BARS scores .|Anticholinergic use was low and similar with quetiapine or placebo .|CONCLUSIONS : In bipolar mania , the incidence of EPS , including akathisia , with quetiapine therapy is similar to that with placebo .	1:NR:2	R2L	NON-CROSS	11-12	8-9	C069541	quetiapine|quetiapine|quetiapine|quetiapine|QTP|quetiapine|QTP|quetiapine|QTP|quetiapine|quetiapine|quetiapine|quetiapine|quetiapine	Chemical	11:35:69:105:125:204:230:313:332:380:470:478:494:513	12:36:70:106:126:205:231:314:333:381:471:479:495:514	0:1:3:4:4:6:7:9:9:10:11:12:13:14	D001480	extrapyramidal symptoms|EPS|extrapyramidal symptoms|EPS|Extrapyramidal symptoms|EPS|EPS|EPS|EPS|extrapyramidal syndrome|EPS	Disease	5:8:25:28:155:191:224:262:302:456:507	7:9:27:29:157:192:225:263:303:458:508	0:0:1:1:5:6:7:8:8:11:14	1:CID:2	R2L	NON-CROSS	232-233	224-225	D008094	lithium|lithium|Li|Li|Li|Li|lithium|Li|Li|Lithium|lithium|lithium	Chemical	93:121:127:145:232:248:290:334:346:356:398:412	94:122:128:146:233:249:291:335:347:357:399:413	3:4:4:4:7:7:8:9:9:10:10:10	D001480	extrapyramidal symptoms|EPS|extrapyramidal symptoms|EPS|Extrapyramidal symptoms|EPS|EPS|EPS|EPS|extrapyramidal syndrome|EPS	Disease	5:8:25:28:155:191:224:262:302:456:507	7:9:27:29:157:192:225:263:303:458:508	0:0:1:1:5:6:7:8:8:11:14	1:CID:2	R2L	NON-CROSS	273-274	262-263	D006220	haloperidol|haloperidol|Haloperidol	Chemical	95:273:415	96:274:416	3:8:11	D001480	extrapyramidal symptoms|EPS|extrapyramidal symptoms|EPS|Extrapyramidal symptoms|EPS|EPS|EPS|EPS|extrapyramidal syndrome|EPS	Disease	5:8:25:28:155:191:224:262:302:456:507	7:9:27:29:157:192:225:263:303:458:508	0:0:1:1:5:6:7:8:8:11:14	1:NR:2	R2L	NON-CROSS	155-157	147-148	D014635	divalproex|DVP|DVP|DVP|DVP|DVP|DVP	Chemical	123:129:147:234:250:336:348	124:130:148:235:251:337:349	4:4:4:7:7:9:9	D001480	extrapyramidal symptoms|EPS|extrapyramidal symptoms|EPS|Extrapyramidal symptoms|EPS|EPS|EPS|EPS|extrapyramidal syndrome|EPS	Disease	5:8:25:28:155:191:224:262:302:456:507	7:9:27:29:157:192:225:263:303:458:508	0:0:1:1:5:6:7:8:8:11:14	1:NR:2	L2R	NON-CROSS	35-36	39-41	C069541	quetiapine|quetiapine|quetiapine|quetiapine|QTP|quetiapine|QTP|quetiapine|QTP|quetiapine|quetiapine|quetiapine|quetiapine|quetiapine	Chemical	11:35:69:105:125:204:230:313:332:380:470:478:494:513	12:36:70:106:126:205:231:314:333:381:471:479:495:514	0:1:3:4:4:6:7:9:9:10:11:12:13:14	D001714	bipolar mania|bipolar mania|bipolar mania	Disease	18:39:501	20:41:503	0:1:14	1:NR:2	L2R	NON-CROSS	32-33	35-36	C069541	quetiapine|quetiapine|quetiapine|quetiapine|QTP|quetiapine|QTP|quetiapine|QTP|quetiapine|quetiapine|quetiapine|quetiapine|quetiapine	Chemical	11:35:69:105:125:204:230:313:332:380:470:478:494:513	12:36:70:106:126:205:231:314:333:381:471:479:495:514	0:1:3:4:4:6:7:9:9:10:11:12:13:14	D017109	akathisia|akathisia|akathisia|akathisia|akathisia	Disease	32:198:307:429:510	33:199:308:430:511	1:6:9:11:14	1:NR:2	L2R	NON-CROSS	372-373	380-381	C069541	quetiapine|quetiapine|quetiapine|quetiapine|QTP|quetiapine|QTP|quetiapine|QTP|quetiapine|quetiapine|quetiapine|quetiapine|quetiapine	Chemical	11:35:69:105:125:204:230:313:332:380:470:478:494:513	12:36:70:106:126:205:231:314:333:381:471:479:495:514	0:1:3:4:4:6:7:9:9:10:11:12:13:14	D014202	tremor|tremor|tremor|tremor	Disease	372:389:408:442	373:390:409:443	10:10:10:11	1:NR:2	R2L	CROSS	93-94	39-41	D008094	lithium|lithium|Li|Li|Li|Li|lithium|Li|Li|Lithium|lithium|lithium	Chemical	93:121:127:145:232:248:290:334:346:356:398:412	94:122:128:146:233:249:291:335:347:357:399:413	3:4:4:4:7:7:8:9:9:10:10:10	D001714	bipolar mania|bipolar mania|bipolar mania	Disease	18:39:501	20:41:503	0:1:14	1:NR:2	R2L	CROSS	95-96	39-41	D006220	haloperidol|haloperidol|Haloperidol	Chemical	95:273:415	96:274:416	3:8:11	D001714	bipolar mania|bipolar mania|bipolar mania	Disease	18:39:501	20:41:503	0:1:14	1:NR:2	R2L	CROSS	123-124	39-41	D014635	divalproex|DVP|DVP|DVP|DVP|DVP|DVP	Chemical	123:129:147:234:250:336:348	124:130:148:235:251:337:349	4:4:4:7:7:9:9	D001714	bipolar mania|bipolar mania|bipolar mania	Disease	18:39:501	20:41:503	0:1:14	1:NR:2	R2L	NON-CROSS	307-308	290-291	D008094	lithium|lithium|Li|Li|Li|Li|lithium|Li|Li|Lithium|lithium|lithium	Chemical	93:121:127:145:232:248:290:334:346:356:398:412	94:122:128:146:233:249:291:335:347:357:399:413	3:4:4:4:7:7:8:9:9:10:10:10	D017109	akathisia|akathisia|akathisia|akathisia|akathisia	Disease	32:198:307:429:510	33:199:308:430:511	1:6:9:11:14	1:CID:2	R2L	NON-CROSS	429-430	415-416	D006220	haloperidol|haloperidol|Haloperidol	Chemical	95:273:415	96:274:416	3:8:11	D017109	akathisia|akathisia|akathisia|akathisia|akathisia	Disease	32:198:307:429:510	33:199:308:430:511	1:6:9:11:14	1:NR:2	R2L	NON-CROSS	336-337	307-308	D014635	divalproex|DVP|DVP|DVP|DVP|DVP|DVP	Chemical	123:129:147:234:250:336:348	124:130:148:235:251:337:349	4:4:4:7:7:9:9	D017109	akathisia|akathisia|akathisia|akathisia|akathisia	Disease	32:198:307:429:510	33:199:308:430:511	1:6:9:11:14	1:CID:2	L2R	NON-CROSS	408-409	412-413	D008094	lithium|lithium|Li|Li|Li|Li|lithium|Li|Li|Lithium|lithium|lithium	Chemical	93:121:127:145:232:248:290:334:346:356:398:412	94:122:128:146:233:249:291:335:347:357:399:413	3:4:4:4:7:7:8:9:9:10:10:10	D014202	tremor|tremor|tremor|tremor	Disease	372:389:408:442	373:390:409:443	10:10:10:11	1:CID:2	L2R	NON-CROSS	408-409	415-416	D006220	haloperidol|haloperidol|Haloperidol	Chemical	95:273:415	96:274:416	3:8:11	D014202	tremor|tremor|tremor|tremor	Disease	372:389:408:442	373:390:409:443	10:10:10:11	1:NR:2	L2R	CROSS	348-349	372-373	D014635	divalproex|DVP|DVP|DVP|DVP|DVP|DVP	Chemical	123:129:147:234:250:336:348	124:130:148:235:251:337:349	4:4:4:7:7:9:9	D014202	tremor|tremor|tremor|tremor	Disease	372:389:408:442	373:390:409:443	10:10:10:11
8586822	Contribution of the sympathetic nervous system to salt - sensitivity in lifetime captopril - treated spontaneously hypertensive rats .|OBJECTIVE : To test the hypothesis that , in lifetime captopril - treated spontaneously hypertensive rats ( SHR ) , the sympathetic nervous system contributes importantly to the hypertensive effect of dietary sodium chloride supplementation .|METHODS : Male SHR ( aged 6 weeks ) that had been treated from conception onward with either captopril or vehicle remained on a basal sodium chloride diet or were fed a high sodium chloride diet .|After 2 weeks , the rats were subjected to ganglionic blockade and 2 days later , an infusion of clonidine .|RESULTS : Lifetime captopril treatment significantly lowered mean arterial pressure in both groups .|Intravenous infusion of the ganglionic blocker hexamethonium resulted in a rapid decline in MAP that eliminated the dietary sodium chloride - induced increase in MAP in both groups .|Infusion of the central nervous system alpha2 - adrenergic receptor agonist clonidine also resulted in a greater reduction in MAP in both groups of SHR that were fed the high ( compared with the basal ) sodium chloride diet .|CONCLUSIONS : In both lifetime captopril - treated and control SHR , the sympathetic nervous system contributes to the pressor effects of a high sodium chloride diet .	1:NR:2	L2R	NON-CROSS	12-13	16-17	D002216	captopril|captopril|captopril|captopril|captopril	Chemical	12:29:73:116:201	13:30:74:117:202	0:1:2:4:7	D006973	hypertensive|hypertensive|hypertensive|increase in MAP	Disease	16:33:47:149	17:34:48:152	0:1:1:5	1:CID:2	R2L	NON-CROSS	50-53	47-48	D017673	dietary sodium chloride|dietary sodium chloride	Chemical	50:144	53:147	1:5	D006973	hypertensive|hypertensive|hypertensive|increase in MAP	Disease	16:33:47:149	17:34:48:152	0:1:1:5	1:NR:2	R2L	CROSS	80-82	47-48	D012965	sodium chloride|sodium chloride|sodium chloride|sodium chloride	Chemical	80:88:192:220	82:90:194:222	2:2:6:7	D006973	hypertensive|hypertensive|hypertensive|increase in MAP	Disease	16:33:47:149	17:34:48:152	0:1:1:5	1:NR:2	R2L	CROSS	167-168	149-152	D003000	clonidine|clonidine	Chemical	111:167	112:168	3:6	D006973	hypertensive|hypertensive|hypertensive|increase in MAP	Disease	16:33:47:149	17:34:48:152	0:1:1:5	1:NR:2	R2L	NON-CROSS	149-152	133-134	D018738	hexamethonium	Chemical	133	134	5	D006973	hypertensive|hypertensive|hypertensive|increase in MAP	Disease	16:33:47:149	17:34:48:152	0:1:1:5	1:NR:2	R2L	CROSS	162-167	149-152	D058647	alpha2 - adrenergic receptor agonist	Chemical	162	167	6	D006973	hypertensive|hypertensive|hypertensive|increase in MAP	Disease	16:33:47:149	17:34:48:152	0:1:1:5
3961813	Dose - related beneficial and adverse effects of dietary corticosterone on organophosphorus - induced delayed neuropathy in chickens .|Tri - ortho - tolyl phosphate ( TOTP ) , 360 mg / kg , po , and 0 , 0 ' - diisopropyl phosphorofluoridate ( DFP ) , 1 mg / kg sc , were administered to adult White Leghorn chickens 24 hr after they were placed on diets containing 0 to 300 ppm corticosterone .|Supplemented diets were continued until clinical signs and lesions of delayed neuropathy appeared .|Although low concentrations ( less than or equal to 50 ppm ) of corticosterone had beneficial effects on TOTP - induced neuropathy , greater than or equal to 200 ppm exacerbated clinical signs in chickens given either TOTP or DFP .|Neurotoxic esterase activities 24 hr after TOTP or DFP were less than 20 % of values measured in chickens not given organophosphorous compounds .|Chickens given 200 ppm corticosterone without TOTP or DFP had significantly elevated activity of plasma cholinesterase and significantly inhibited activity of liver carboxylesterase .|Degenerating myelinated fibers were also evident in distal levels of the peripheral nerves of chickens given TOTP or DFP .	1:NR:2	L2R	NON-CROSS	9-10	15-16	D003345	corticosterone|corticosterone|corticosterone|corticosterone	Chemical	9:74:103:159	10:75:104:160	0:1:3:5	D009422	neuropathy|neuropathy|neuropathy	Disease	15:87:111	16:88:112	0:2:3	1:NR:2	L2R	CROSS	103-104	131-132	D003345	corticosterone|corticosterone|corticosterone|corticosterone	Chemical	9:74:103:159	10:75:104:160	0:1:3:5	D020258	Neurotoxic	Disease	131	132	4	1:NR:2	L2R	CROSS	159-160	179-182	D003345	corticosterone|corticosterone|corticosterone|corticosterone	Chemical	9:74:103:159	10:75:104:160	0:1:3:5	D009410	Degenerating myelinated fibers	Disease	179	182	6	1:NR:2	L2R	NON-CROSS	11-12	15-16	D010755	organophosphorus|organophosphorous	Chemical	11:152	12:153	0:4	D009422	neuropathy|neuropathy|neuropathy	Disease	15:87:111	16:88:112	0:2:3	1:NR:2	L2R	NON-CROSS	131-132	152-153	D010755	organophosphorus|organophosphorous	Chemical	11:152	12:153	0:4	D020258	Neurotoxic	Disease	131	132	4	1:NR:2	L2R	CROSS	152-153	179-182	D010755	organophosphorus|organophosphorous	Chemical	11:152	12:153	0:4	D009410	Degenerating myelinated fibers	Disease	179	182	6	1:CID:2	R2L	NON-CROSS	111-112	108-109	C025541	Tri - ortho - tolyl phosphate|TOTP|TOTP|TOTP|TOTP|TOTP|TOTP	Chemical	19:26:108:127:137:161:195	25:27:109:128:138:162:196	1:1:3:3:4:5:6	D009422	neuropathy|neuropathy|neuropathy	Disease	15:87:111	16:88:112	0:2:3	1:CID:2	R2L	NON-CROSS	129-130	111-112	D007531	0 , 0 ' - diisopropyl phosphorofluoridate|DFP|DFP|DFP|DFP|DFP	Chemical	37:45:129:139:163:197	44:46:130:140:164:198	1:1:3:4:5:6	D009422	neuropathy|neuropathy|neuropathy	Disease	15:87:111	16:88:112	0:2:3	1:NR:2	L2R	NON-CROSS	127-128	131-132	C025541	Tri - ortho - tolyl phosphate|TOTP|TOTP|TOTP|TOTP|TOTP|TOTP	Chemical	19:26:108:127:137:161:195	25:27:109:128:138:162:196	1:1:3:3:4:5:6	D020258	Neurotoxic	Disease	131	132	4	1:CID:2	L2R	NON-CROSS	179-182	195-196	C025541	Tri - ortho - tolyl phosphate|TOTP|TOTP|TOTP|TOTP|TOTP|TOTP	Chemical	19:26:108:127:137:161:195	25:27:109:128:138:162:196	1:1:3:3:4:5:6	D009410	Degenerating myelinated fibers	Disease	179	182	6	1:NR:2	L2R	NON-CROSS	129-130	131-132	D007531	0 , 0 ' - diisopropyl phosphorofluoridate|DFP|DFP|DFP|DFP|DFP	Chemical	37:45:129:139:163:197	44:46:130:140:164:198	1:1:3:4:5:6	D020258	Neurotoxic	Disease	131	132	4	1:CID:2	L2R	NON-CROSS	163-164	179-182	D007531	0 , 0 ' - diisopropyl phosphorofluoridate|DFP|DFP|DFP|DFP|DFP	Chemical	37:45:129:139:163:197	44:46:130:140:164:198	1:1:3:4:5:6	D009410	Degenerating myelinated fibers	Disease	179	182	6
20973483	In vivo characterization of a dual adenosine A2A / A1 receptor antagonist in animal models of Parkinson 's disease .|The in vivo characterization of a dual adenosine A ( 2A ) / A ( 1 ) receptor antagonist in several animal models of Parkinson 's disease is described .|Discovery and scale - up syntheses of compound 1 are described in detail , highlighting optimization steps that increased the overall yield of 1 from 10 . 0 % to 30 . 5 % .|Compound 1 is a potent A ( 2A ) / A ( 1 ) receptor antagonist in vitro ( A ( 2A ) K ( i ) = 4 . 1 nM ; A ( 1 ) K ( i ) = 17 . 0 nM ) that has excellent activity , after oral administration , across a number of animal models of Parkinson 's disease including mouse and rat models of haloperidol - induced catalepsy , mouse model of reserpine - induced akinesia , rat 6 - hydroxydopamine ( 6 - OHDA ) lesion model of drug - induced rotation , and MPTP - treated non - human primate model .	1:NR:2	L2R	NON-CROSS	6-12	16-19	D058915	adenosine A2A / A1 receptor antagonist|adenosine A ( 2A ) / A ( 1 ) receptor antagonist	Chemical	6:27	12:39	0:1	D010300	Parkinson 's disease|Parkinson 's disease|Parkinson 's disease	Disease	16:44:148	19:47:151	0:1:3	1:NR:2	L2R	CROSS	27-39	160-161	D058915	adenosine A2A / A1 receptor antagonist|adenosine A ( 2A ) / A ( 1 ) receptor antagonist	Chemical	6:27	12:39	0:1	D002375	catalepsy	Disease	160	161	3	1:NR:2	L2R	CROSS	27-39	168-169	D058915	adenosine A2A / A1 receptor antagonist|adenosine A ( 2A ) / A ( 1 ) receptor antagonist	Chemical	6:27	12:39	0:1	D004409	akinesia	Disease	168	169	3	1:NR:2	R2L	NON-CROSS	157-158	148-151	D006220	haloperidol	Chemical	157	158	3	D010300	Parkinson 's disease|Parkinson 's disease|Parkinson 's disease	Disease	16:44:148	19:47:151	0:1:3	1:NR:2	R2L	NON-CROSS	165-166	148-151	D012110	reserpine	Chemical	165	166	3	D010300	Parkinson 's disease|Parkinson 's disease|Parkinson 's disease	Disease	16:44:148	19:47:151	0:1:3	1:NR:2	R2L	NON-CROSS	171-174	148-151	D016627	6 - hydroxydopamine|6 - OHDA	Chemical	171:175	174:178	3:3	D010300	Parkinson 's disease|Parkinson 's disease|Parkinson 's disease	Disease	16:44:148	19:47:151	0:1:3	1:NR:2	R2L	NON-CROSS	188-189	148-151	D015632	MPTP	Chemical	188	189	3	D010300	Parkinson 's disease|Parkinson 's disease|Parkinson 's disease	Disease	16:44:148	19:47:151	0:1:3	1:CID:2	L2R	NON-CROSS	157-158	160-161	D006220	haloperidol	Chemical	157	158	3	D002375	catalepsy	Disease	160	161	3	1:NR:2	L2R	NON-CROSS	157-158	168-169	D006220	haloperidol	Chemical	157	158	3	D004409	akinesia	Disease	168	169	3	1:NR:2	R2L	NON-CROSS	165-166	160-161	D012110	reserpine	Chemical	165	166	3	D002375	catalepsy	Disease	160	161	3	1:NR:2	R2L	NON-CROSS	171-174	160-161	D016627	6 - hydroxydopamine|6 - OHDA	Chemical	171:175	174:178	3:3	D002375	catalepsy	Disease	160	161	3	1:NR:2	R2L	NON-CROSS	188-189	160-161	D015632	MPTP	Chemical	188	189	3	D002375	catalepsy	Disease	160	161	3	1:CID:2	L2R	NON-CROSS	165-166	168-169	D012110	reserpine	Chemical	165	166	3	D004409	akinesia	Disease	168	169	3	1:NR:2	R2L	NON-CROSS	171-174	168-169	D016627	6 - hydroxydopamine|6 - OHDA	Chemical	171:175	174:178	3:3	D004409	akinesia	Disease	168	169	3	1:NR:2	R2L	NON-CROSS	188-189	168-169	D015632	MPTP	Chemical	188	189	3	D004409	akinesia	Disease	168	169	3
17511042	An extremely rare case of delusional parasitosis in a chronic hepatitis C patient during pegylated interferon alpha - 2b and ribavirin treatment .|During treatment of chronic hepatitis C patients with interferon and ribavirin , a lot of side effects are described .|Twenty - three percent to 44 % of patients develop depression .|A minority of patients evolve to psychosis .|To the best of our knowledge , no cases of psychogenic parasitosis occurring during interferon therapy have been described in the literature .|We present a 49 - year - old woman who developed a delusional parasitosis during treatment with pegylated interferon alpha - 2b weekly and ribavirin .|She complained of seeing parasites and the larvae of fleas in her stools .|This could not be confirmed by any technical examination .|All the complaints disappeared after stopping pegylated interferon alpha - 2b and reappeared after restarting it .|She had a complete sustained viral response .	1:CID:2	R2L	NON-CROSS	103-108	98-100	C417083	pegylated interferon alpha - 2b|pegylated interferon alpha - 2b|pegylated interferon alpha - 2b	Chemical	14:103:142	19:108:147	0:5:8	D063726	delusional parasitosis|psychogenic parasitosis|delusional parasitosis	Disease	5:73:98	7:75:100	0:4:5	1:CID:2	R2L	NON-CROSS	110-111	98-100	D012254	ribavirin|ribavirin|ribavirin	Chemical	20:33:110	21:34:111	0:1:5	D063726	delusional parasitosis|psychogenic parasitosis|delusional parasitosis	Disease	5:73:98	7:75:100	0:4:5	1:NR:2	R2L	NON-CROSS	14-19	9-12	C417083	pegylated interferon alpha - 2b|pegylated interferon alpha - 2b|pegylated interferon alpha - 2b	Chemical	14:103:142	19:108:147	0:5:8	D019698	chronic hepatitis C|chronic hepatitis C	Disease	9:26	12:29	0:1	1:NR:2	R2L	NON-CROSS	33-34	26-29	D012254	ribavirin|ribavirin|ribavirin	Chemical	20:33:110	21:34:111	0:1:5	D019698	chronic hepatitis C|chronic hepatitis C	Disease	9:26	12:29	0:1	1:NR:2	L2R	CROSS	14-19	53-54	C417083	pegylated interferon alpha - 2b|pegylated interferon alpha - 2b|pegylated interferon alpha - 2b	Chemical	14:103:142	19:108:147	0:5:8	D003866	depression	Disease	53	54	2	1:NR:2	L2R	CROSS	61-62	103-108	C417083	pegylated interferon alpha - 2b|pegylated interferon alpha - 2b|pegylated interferon alpha - 2b	Chemical	14:103:142	19:108:147	0:5:8	D011605	psychosis	Disease	61	62	3	1:NR:2	L2R	CROSS	33-34	53-54	D012254	ribavirin|ribavirin|ribavirin	Chemical	20:33:110	21:34:111	0:1:5	D003866	depression	Disease	53	54	2	1:NR:2	L2R	CROSS	33-34	61-62	D012254	ribavirin|ribavirin|ribavirin	Chemical	20:33:110	21:34:111	0:1:5	D011605	psychosis	Disease	61	62	3
16720068	Possible neuroleptic malignant syndrome related to concomitant treatment with paroxetine and alprazolam .|A 74 - year - old man with depressive symptoms was admitted to a psychiatric hospital due to insomnia , loss of appetite , exhaustion , and agitation .|Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1 . 2 mg alprazolam .|On the 10th day of paroxetine and alprazolam treatment , the patient exhibited marked psychomotor retardation , disorientation , and severe muscle rigidity with tremors .|The patient had a fever ( 38 . 2 degrees C ) , fluctuating blood pressure ( between 165 / 90 and 130 / 70 mg mm Hg ) , and severe extrapyramidal symptoms .|Laboratory tests showed an elevation of creatine phosphokinase ( 2218 IU / L ) , aspartate aminotransferase ( 134 IU / L ) , alanine aminotransferase ( 78 IU / L ) , and BUN ( 27 . 9 mg / ml ) levels .|The patient received bromocriptine and diazepam to treat his symptoms .|7 days later , the fever disappeared and the patient 's serum CPK levels were normalized ( 175 IU / L ) .|This patient presented with symptoms of neuroleptic malignant syndrome ( NMS ) , thus demonstrating that NMS - like symptoms can occur after combined paroxetine and alprazolam treatment .|The adverse drug reaction score obtained by the Naranjo algorithm was 6 in our case , indicating a probable relationship between the patient 's NMS - like adverse symptoms and the combined treatment used in this case .|The involvement of physiologic and environmental aspects specific to this patient was suspected .|Several risk factors for NMS should be noted in elderly depressive patients whose symptoms often include dehydration , agitation , malnutrition , and exhaustion .|Careful therapeutic intervention is necessary in cases involving elderly patients who suffer from depression .	1:CID:2	R2L	NON-CROSS	9-10	1-4	D017374	paroxetine|paroxetine|paroxetine|paroxetine	Chemical	9:53:66:225	10:54:67:226	0:2:3:8	D009459	neuroleptic malignant syndrome|neuroleptic malignant syndrome|NMS|NMS|NMS|NMS	Disease	1:207:211:217:254:286	4:210:212:218:255:287	0:8:8:8:9:11	1:CID:2	R2L	NON-CROSS	11-12	1-4	D000525	alprazolam|alprazolam|alprazolam|alprazolam	Chemical	11:59:68:227	12:60:69:228	0:2:3:8	D009459	neuroleptic malignant syndrome|neuroleptic malignant syndrome|NMS|NMS|NMS|NMS	Disease	1:207:211:217:254:286	4:210:212:218:255:287	0:8:8:8:9:11	1:NR:2	R2L	CROSS	207-210	128-129	D003401	creatine	Chemical	128	129	5	D009459	neuroleptic malignant syndrome|neuroleptic malignant syndrome|NMS|NMS|NMS|NMS	Disease	1:207:211:217:254:286	4:210:212:218:255:287	0:8:8:8:9:11	1:NR:2	R2L	CROSS	207-210	137-138	D001224	aspartate	Chemical	137	138	5	D009459	neuroleptic malignant syndrome|neuroleptic malignant syndrome|NMS|NMS|NMS|NMS	Disease	1:207:211:217:254:286	4:210:212:218:255:287	0:8:8:8:9:11	1:NR:2	R2L	CROSS	207-210	146-147	D000409	alanine	Chemical	146	147	5	D009459	neuroleptic malignant syndrome|neuroleptic malignant syndrome|NMS|NMS|NMS|NMS	Disease	1:207:211:217:254:286	4:210:212:218:255:287	0:8:8:8:9:11	1:NR:2	R2L	CROSS	207-210	170-171	D001971	bromocriptine	Chemical	170	171	6	D009459	neuroleptic malignant syndrome|neuroleptic malignant syndrome|NMS|NMS|NMS|NMS	Disease	1:207:211:217:254:286	4:210:212:218:255:287	0:8:8:8:9:11	1:NR:2	R2L	CROSS	207-210	172-173	D003975	diazepam	Chemical	172	173	6	D009459	neuroleptic malignant syndrome|neuroleptic malignant syndrome|NMS|NMS|NMS|NMS	Disease	1:207:211:217:254:286	4:210:212:218:255:287	0:8:8:8:9:11	1:NR:2	L2R	CROSS	9-10	21-23	D017374	paroxetine|paroxetine|paroxetine|paroxetine	Chemical	9:53:66:225	10:54:67:226	0:2:3:8	D003866	depressive symptoms|depressive|depression	Disease	21:292:320	23:293:321	1:11:12	1:NR:2	L2R	CROSS	9-10	27-28	D017374	paroxetine|paroxetine|paroxetine|paroxetine	Chemical	9:53:66:225	10:54:67:226	0:2:3:8	D001523	psychiatric	Disease	27	28	1	1:NR:2	L2R	CROSS	9-10	31-32	D017374	paroxetine|paroxetine|paroxetine|paroxetine	Chemical	9:53:66:225	10:54:67:226	0:2:3:8	D007319	insomnia	Disease	31	32	1	1:NR:2	L2R	CROSS	33-36	53-54	D017374	paroxetine|paroxetine|paroxetine|paroxetine	Chemical	9:53:66:225	10:54:67:226	0:2:3:8	D001068	loss of appetite	Disease	33	36	1	1:NR:2	L2R	CROSS	40-41	53-54	D017374	paroxetine|paroxetine|paroxetine|paroxetine	Chemical	9:53:66:225	10:54:67:226	0:2:3:8	D011595	agitation|agitation	Disease	40:300	41:301	1:11	1:NR:2	L2R	NON-CROSS	66-67	75-77	D017374	paroxetine|paroxetine|paroxetine|paroxetine	Chemical	9:53:66:225	10:54:67:226	0:2:3:8	D011596	psychomotor retardation	Disease	75	77	3	1:NR:2	L2R	NON-CROSS	66-67	82-84	D017374	paroxetine|paroxetine|paroxetine|paroxetine	Chemical	9:53:66:225	10:54:67:226	0:2:3:8	D009127	muscle rigidity	Disease	82	84	3	1:NR:2	L2R	NON-CROSS	66-67	85-86	D017374	paroxetine|paroxetine|paroxetine|paroxetine	Chemical	9:53:66:225	10:54:67:226	0:2:3:8	D014202	tremors	Disease	85	86	3	1:NR:2	L2R	CROSS	66-67	91-92	D017374	paroxetine|paroxetine|paroxetine|paroxetine	Chemical	9:53:66:225	10:54:67:226	0:2:3:8	D005334	fever|fever	Disease	91:183	92:184	4:7	1:NR:2	L2R	CROSS	66-67	119-121	D017374	paroxetine|paroxetine|paroxetine|paroxetine	Chemical	9:53:66:225	10:54:67:226	0:2:3:8	D001480	extrapyramidal symptoms	Disease	119	121	4	1:NR:2	L2R	CROSS	225-226	298-299	D017374	paroxetine|paroxetine|paroxetine|paroxetine	Chemical	9:53:66:225	10:54:67:226	0:2:3:8	D003681	dehydration	Disease	298	299	11	1:NR:2	L2R	CROSS	225-226	302-303	D017374	paroxetine|paroxetine|paroxetine|paroxetine	Chemical	9:53:66:225	10:54:67:226	0:2:3:8	D044342	malnutrition	Disease	302	303	11	1:NR:2	L2R	CROSS	11-12	21-23	D000525	alprazolam|alprazolam|alprazolam|alprazolam	Chemical	11:59:68:227	12:60:69:228	0:2:3:8	D003866	depressive symptoms|depressive|depression	Disease	21:292:320	23:293:321	1:11:12	1:NR:2	L2R	CROSS	11-12	27-28	D000525	alprazolam|alprazolam|alprazolam|alprazolam	Chemical	11:59:68:227	12:60:69:228	0:2:3:8	D001523	psychiatric	Disease	27	28	1	1:NR:2	L2R	CROSS	11-12	31-32	D000525	alprazolam|alprazolam|alprazolam|alprazolam	Chemical	11:59:68:227	12:60:69:228	0:2:3:8	D007319	insomnia	Disease	31	32	1	1:NR:2	L2R	CROSS	11-12	33-36	D000525	alprazolam|alprazolam|alprazolam|alprazolam	Chemical	11:59:68:227	12:60:69:228	0:2:3:8	D001068	loss of appetite	Disease	33	36	1	1:NR:2	L2R	CROSS	40-41	59-60	D000525	alprazolam|alprazolam|alprazolam|alprazolam	Chemical	11:59:68:227	12:60:69:228	0:2:3:8	D011595	agitation|agitation	Disease	40:300	41:301	1:11	1:NR:2	L2R	NON-CROSS	68-69	75-77	D000525	alprazolam|alprazolam|alprazolam|alprazolam	Chemical	11:59:68:227	12:60:69:228	0:2:3:8	D011596	psychomotor retardation	Disease	75	77	3	1:NR:2	L2R	NON-CROSS	68-69	82-84	D000525	alprazolam|alprazolam|alprazolam|alprazolam	Chemical	11:59:68:227	12:60:69:228	0:2:3:8	D009127	muscle rigidity	Disease	82	84	3	1:NR:2	L2R	NON-CROSS	68-69	85-86	D000525	alprazolam|alprazolam|alprazolam|alprazolam	Chemical	11:59:68:227	12:60:69:228	0:2:3:8	D014202	tremors	Disease	85	86	3	1:NR:2	L2R	CROSS	68-69	91-92	D000525	alprazolam|alprazolam|alprazolam|alprazolam	Chemical	11:59:68:227	12:60:69:228	0:2:3:8	D005334	fever|fever	Disease	91:183	92:184	4:7	1:NR:2	L2R	CROSS	68-69	119-121	D000525	alprazolam|alprazolam|alprazolam|alprazolam	Chemical	11:59:68:227	12:60:69:228	0:2:3:8	D001480	extrapyramidal symptoms	Disease	119	121	4	1:NR:2	L2R	CROSS	227-228	298-299	D000525	alprazolam|alprazolam|alprazolam|alprazolam	Chemical	11:59:68:227	12:60:69:228	0:2:3:8	D003681	dehydration	Disease	298	299	11	1:NR:2	L2R	CROSS	227-228	302-303	D000525	alprazolam|alprazolam|alprazolam|alprazolam	Chemical	11:59:68:227	12:60:69:228	0:2:3:8	D044342	malnutrition	Disease	302	303	11	1:NR:2	R2L	CROSS	128-129	21-23	D003401	creatine	Chemical	128	129	5	D003866	depressive symptoms|depressive|depression	Disease	21:292:320	23:293:321	1:11:12	1:NR:2	R2L	CROSS	137-138	21-23	D001224	aspartate	Chemical	137	138	5	D003866	depressive symptoms|depressive|depression	Disease	21:292:320	23:293:321	1:11:12	1:NR:2	R2L	CROSS	146-147	21-23	D000409	alanine	Chemical	146	147	5	D003866	depressive symptoms|depressive|depression	Disease	21:292:320	23:293:321	1:11:12	1:NR:2	R2L	CROSS	292-293	170-171	D001971	bromocriptine	Chemical	170	171	6	D003866	depressive symptoms|depressive|depression	Disease	21:292:320	23:293:321	1:11:12	1:NR:2	R2L	CROSS	292-293	172-173	D003975	diazepam	Chemical	172	173	6	D003866	depressive symptoms|depressive|depression	Disease	21:292:320	23:293:321	1:11:12	1:NR:2	R2L	CROSS	128-129	27-28	D003401	creatine	Chemical	128	129	5	D001523	psychiatric	Disease	27	28	1	1:NR:2	R2L	CROSS	137-138	27-28	D001224	aspartate	Chemical	137	138	5	D001523	psychiatric	Disease	27	28	1	1:NR:2	R2L	CROSS	146-147	27-28	D000409	alanine	Chemical	146	147	5	D001523	psychiatric	Disease	27	28	1	1:NR:2	R2L	CROSS	170-171	27-28	D001971	bromocriptine	Chemical	170	171	6	D001523	psychiatric	Disease	27	28	1	1:NR:2	R2L	CROSS	172-173	27-28	D003975	diazepam	Chemical	172	173	6	D001523	psychiatric	Disease	27	28	1	1:NR:2	R2L	CROSS	128-129	31-32	D003401	creatine	Chemical	128	129	5	D007319	insomnia	Disease	31	32	1	1:NR:2	R2L	CROSS	137-138	31-32	D001224	aspartate	Chemical	137	138	5	D007319	insomnia	Disease	31	32	1	1:NR:2	R2L	CROSS	146-147	31-32	D000409	alanine	Chemical	146	147	5	D007319	insomnia	Disease	31	32	1	1:NR:2	R2L	CROSS	170-171	31-32	D001971	bromocriptine	Chemical	170	171	6	D007319	insomnia	Disease	31	32	1	1:NR:2	R2L	CROSS	172-173	31-32	D003975	diazepam	Chemical	172	173	6	D007319	insomnia	Disease	31	32	1	1:NR:2	R2L	CROSS	128-129	33-36	D003401	creatine	Chemical	128	129	5	D001068	loss of appetite	Disease	33	36	1	1:NR:2	R2L	CROSS	137-138	33-36	D001224	aspartate	Chemical	137	138	5	D001068	loss of appetite	Disease	33	36	1	1:NR:2	R2L	CROSS	146-147	33-36	D000409	alanine	Chemical	146	147	5	D001068	loss of appetite	Disease	33	36	1	1:NR:2	R2L	CROSS	170-171	33-36	D001971	bromocriptine	Chemical	170	171	6	D001068	loss of appetite	Disease	33	36	1	1:NR:2	R2L	CROSS	172-173	33-36	D003975	diazepam	Chemical	172	173	6	D001068	loss of appetite	Disease	33	36	1	1:NR:2	R2L	CROSS	128-129	40-41	D003401	creatine	Chemical	128	129	5	D011595	agitation|agitation	Disease	40:300	41:301	1:11	1:NR:2	R2L	CROSS	137-138	40-41	D001224	aspartate	Chemical	137	138	5	D011595	agitation|agitation	Disease	40:300	41:301	1:11	1:NR:2	R2L	CROSS	146-147	40-41	D000409	alanine	Chemical	146	147	5	D011595	agitation|agitation	Disease	40:300	41:301	1:11	1:NR:2	R2L	CROSS	170-171	40-41	D001971	bromocriptine	Chemical	170	171	6	D011595	agitation|agitation	Disease	40:300	41:301	1:11	1:NR:2	R2L	CROSS	300-301	172-173	D003975	diazepam	Chemical	172	173	6	D011595	agitation|agitation	Disease	40:300	41:301	1:11	1:NR:2	R2L	CROSS	128-129	75-77	D003401	creatine	Chemical	128	129	5	D011596	psychomotor retardation	Disease	75	77	3	1:NR:2	R2L	CROSS	137-138	75-77	D001224	aspartate	Chemical	137	138	5	D011596	psychomotor retardation	Disease	75	77	3	1:NR:2	R2L	CROSS	146-147	75-77	D000409	alanine	Chemical	146	147	5	D011596	psychomotor retardation	Disease	75	77	3	1:NR:2	R2L	CROSS	170-171	75-77	D001971	bromocriptine	Chemical	170	171	6	D011596	psychomotor retardation	Disease	75	77	3	1:NR:2	R2L	CROSS	172-173	75-77	D003975	diazepam	Chemical	172	173	6	D011596	psychomotor retardation	Disease	75	77	3	1:NR:2	R2L	CROSS	128-129	82-84	D003401	creatine	Chemical	128	129	5	D009127	muscle rigidity	Disease	82	84	3	1:NR:2	R2L	CROSS	137-138	82-84	D001224	aspartate	Chemical	137	138	5	D009127	muscle rigidity	Disease	82	84	3	1:NR:2	R2L	CROSS	146-147	82-84	D000409	alanine	Chemical	146	147	5	D009127	muscle rigidity	Disease	82	84	3	1:NR:2	R2L	CROSS	170-171	82-84	D001971	bromocriptine	Chemical	170	171	6	D009127	muscle rigidity	Disease	82	84	3	1:NR:2	R2L	CROSS	172-173	82-84	D003975	diazepam	Chemical	172	173	6	D009127	muscle rigidity	Disease	82	84	3	1:NR:2	R2L	CROSS	128-129	85-86	D003401	creatine	Chemical	128	129	5	D014202	tremors	Disease	85	86	3	1:NR:2	R2L	CROSS	137-138	85-86	D001224	aspartate	Chemical	137	138	5	D014202	tremors	Disease	85	86	3	1:NR:2	R2L	CROSS	146-147	85-86	D000409	alanine	Chemical	146	147	5	D014202	tremors	Disease	85	86	3	1:NR:2	R2L	CROSS	170-171	85-86	D001971	bromocriptine	Chemical	170	171	6	D014202	tremors	Disease	85	86	3	1:NR:2	R2L	CROSS	172-173	85-86	D003975	diazepam	Chemical	172	173	6	D014202	tremors	Disease	85	86	3	1:NR:2	R2L	CROSS	128-129	91-92	D003401	creatine	Chemical	128	129	5	D005334	fever|fever	Disease	91:183	92:184	4:7	1:NR:2	R2L	CROSS	137-138	91-92	D001224	aspartate	Chemical	137	138	5	D005334	fever|fever	Disease	91:183	92:184	4:7	1:NR:2	R2L	CROSS	183-184	146-147	D000409	alanine	Chemical	146	147	5	D005334	fever|fever	Disease	91:183	92:184	4:7	1:NR:2	R2L	CROSS	183-184	170-171	D001971	bromocriptine	Chemical	170	171	6	D005334	fever|fever	Disease	91:183	92:184	4:7	1:NR:2	R2L	CROSS	183-184	172-173	D003975	diazepam	Chemical	172	173	6	D005334	fever|fever	Disease	91:183	92:184	4:7	1:NR:2	R2L	CROSS	128-129	119-121	D003401	creatine	Chemical	128	129	5	D001480	extrapyramidal symptoms	Disease	119	121	4	1:NR:2	R2L	CROSS	137-138	119-121	D001224	aspartate	Chemical	137	138	5	D001480	extrapyramidal symptoms	Disease	119	121	4	1:NR:2	R2L	CROSS	146-147	119-121	D000409	alanine	Chemical	146	147	5	D001480	extrapyramidal symptoms	Disease	119	121	4	1:NR:2	R2L	CROSS	170-171	119-121	D001971	bromocriptine	Chemical	170	171	6	D001480	extrapyramidal symptoms	Disease	119	121	4	1:NR:2	R2L	CROSS	172-173	119-121	D003975	diazepam	Chemical	172	173	6	D001480	extrapyramidal symptoms	Disease	119	121	4	1:NR:2	L2R	CROSS	128-129	298-299	D003401	creatine	Chemical	128	129	5	D003681	dehydration	Disease	298	299	11	1:NR:2	L2R	CROSS	128-129	302-303	D003401	creatine	Chemical	128	129	5	D044342	malnutrition	Disease	302	303	11	1:NR:2	L2R	CROSS	137-138	298-299	D001224	aspartate	Chemical	137	138	5	D003681	dehydration	Disease	298	299	11	1:NR:2	L2R	CROSS	137-138	302-303	D001224	aspartate	Chemical	137	138	5	D044342	malnutrition	Disease	302	303	11	1:NR:2	L2R	CROSS	146-147	298-299	D000409	alanine	Chemical	146	147	5	D003681	dehydration	Disease	298	299	11	1:NR:2	L2R	CROSS	146-147	302-303	D000409	alanine	Chemical	146	147	5	D044342	malnutrition	Disease	302	303	11	1:NR:2	L2R	CROSS	170-171	298-299	D001971	bromocriptine	Chemical	170	171	6	D003681	dehydration	Disease	298	299	11	1:NR:2	L2R	CROSS	170-171	302-303	D001971	bromocriptine	Chemical	170	171	6	D044342	malnutrition	Disease	302	303	11	1:NR:2	L2R	CROSS	172-173	298-299	D003975	diazepam	Chemical	172	173	6	D003681	dehydration	Disease	298	299	11	1:NR:2	L2R	CROSS	172-173	302-303	D003975	diazepam	Chemical	172	173	6	D044342	malnutrition	Disease	302	303	11
16596970	Pilocarpine seizures cause age - dependent impairment in auditory location discrimination .|Children who have status epilepticus have continuous or rapidly repeating seizures that may be life - threatening and may cause life - long changes in brain and behavior .|The extent to which status epilepticus causes deficits in auditory discrimination is unknown .|A naturalistic auditory location discrimination method was used to evaluate this question using an animal model of status epilepticus .|Male Sprague - Dawley rats were injected with saline on postnatal day ( P ) 20 , or a convulsant dose of pilocarpine on P20 or P45 .|Pilocarpine on either day induced status epilepticus ; status epilepticus at P45 resulted in CA3 cell loss and spontaneous seizures , whereas P20 rats had no cell loss or spontaneous seizures .|Mature rats were trained with sound - source location and sound - silence discriminations .|Control ( saline P20 ) rats acquired both discriminations immediately .|In status epilepticus ( P20 ) rats , acquisition of the sound - source location discrimination was moderately impaired .|Status epilepticus ( P45 ) rats failed to acquire either sound - source location or sound - silence discriminations .|Status epilepticus in rat causes an age - dependent , long - term impairment in auditory discrimination .|This impairment may explain one cause of impaired auditory location discrimination in humans .	1:NR:2	L2R	NON-CROSS	0-1	1-2	D010862	Pilocarpine|pilocarpine|Pilocarpine	Chemical	0:97:103	1:98:104	0:4:5	D012640	seizures|seizures|seizures|seizures	Disease	1:22:122:133	2:23:123:134	0:1:5:5	1:CID:2	L2R	NON-CROSS	0-1	6-11	D010862	Pilocarpine|pilocarpine|Pilocarpine	Chemical	0:97:103	1:98:104	0:4:5	D001308	impairment in auditory location discrimination|deficits in auditory discrimination|impairment in auditory discrimination|impaired auditory location discrimination	Disease	6:48:214:226	11:52:218:230	0:2:10:11	1:CID:2	L2R	NON-CROSS	103-104	108-110	D010862	Pilocarpine|pilocarpine|Pilocarpine	Chemical	0:97:103	1:98:104	0:4:5	D013226	status epilepticus|status epilepticus|status epilepticus|status epilepticus|status epilepticus|status epilepticus|Status epilepticus|Status epilepticus	Disease	15:45:72:108:111:162:181:201	17:47:74:110:113:164:183:203	1:2:3:5:5:8:9:10
16586083	Cardiovascular risk with cyclooxygenase inhibitors : general problem with substance specific differences ?|Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction , stroke , hypertension and heart failure during treatment with cyclooxygenase inhibitors .|Adverse cardiovascular effects occurred mainly , but not exclusively , in patients with concomitant risk factors .|Cyclooxygenase inhibitors cause complex changes in renal , vascular and cardiac prostanoid profiles thereby increasing vascular resistance and fluid retention .|The incidence of cardiovascular adverse events tends to increase with the daily dose and total exposure time .|A comparison of individual selective and unselective cyclooxygenase inhibitors suggests substance - specific differences , which may depend on differences in pharmacokinetic parameters or inhibitory potency and may be contributed by prostaglandin - independent effects .|Diagnostic markers such as N - terminal pro brain natriuretic peptide ( NT - proBNP ) or high - sensitive C - reactive protein might help in the early identification of patients at risk , thus avoiding the occurrence of serious cardiovascular toxicity .	1:CID:2	L2R	NON-CROSS	25-27	37-39	D016861	cyclooxygenase inhibitors|cyclooxygenase inhibitors|Cyclooxygenase inhibitors|cyclooxygenase inhibitors	Chemical	3:37:57:103	5:39:59:105	0:1:3:5	D009203	myocardial infarction	Disease	25	27	1	1:CID:2	L2R	NON-CROSS	28-29	37-39	D016861	cyclooxygenase inhibitors|cyclooxygenase inhibitors|Cyclooxygenase inhibitors|cyclooxygenase inhibitors	Chemical	3:37:57:103	5:39:59:105	0:1:3:5	D020521	stroke	Disease	28	29	1	1:CID:2	L2R	NON-CROSS	30-31	37-39	D016861	cyclooxygenase inhibitors|cyclooxygenase inhibitors|Cyclooxygenase inhibitors|cyclooxygenase inhibitors	Chemical	3:37:57:103	5:39:59:105	0:1:3:5	D006973	hypertension	Disease	30	31	1	1:CID:2	L2R	NON-CROSS	32-34	37-39	D016861	cyclooxygenase inhibitors|cyclooxygenase inhibitors|Cyclooxygenase inhibitors|cyclooxygenase inhibitors	Chemical	3:37:57:103	5:39:59:105	0:1:3:5	D006333	heart failure	Disease	32	34	1	1:NR:2	L2R	CROSS	103-105	173-175	D016861	cyclooxygenase inhibitors|cyclooxygenase inhibitors|Cyclooxygenase inhibitors|cyclooxygenase inhibitors	Chemical	3:37:57:103	5:39:59:105	0:1:3:5	D002318	cardiovascular toxicity	Disease	173	175	6	1:NR:2	R2L	CROSS	127-128	25-27	D011453	prostaglandin	Chemical	127	128	5	D009203	myocardial infarction	Disease	25	27	1	1:NR:2	R2L	CROSS	136-143	25-27	C109794	N - terminal pro brain natriuretic peptide|NT - proBNP	Chemical	136:144	143:147	6:6	D009203	myocardial infarction	Disease	25	27	1	1:NR:2	R2L	CROSS	127-128	28-29	D011453	prostaglandin	Chemical	127	128	5	D020521	stroke	Disease	28	29	1	1:NR:2	R2L	CROSS	136-143	28-29	C109794	N - terminal pro brain natriuretic peptide|NT - proBNP	Chemical	136:144	143:147	6:6	D020521	stroke	Disease	28	29	1	1:NR:2	R2L	CROSS	127-128	30-31	D011453	prostaglandin	Chemical	127	128	5	D006973	hypertension	Disease	30	31	1	1:NR:2	R2L	CROSS	136-143	30-31	C109794	N - terminal pro brain natriuretic peptide|NT - proBNP	Chemical	136:144	143:147	6:6	D006973	hypertension	Disease	30	31	1	1:NR:2	R2L	CROSS	127-128	32-34	D011453	prostaglandin	Chemical	127	128	5	D006333	heart failure	Disease	32	34	1	1:NR:2	R2L	CROSS	136-143	32-34	C109794	N - terminal pro brain natriuretic peptide|NT - proBNP	Chemical	136:144	143:147	6:6	D006333	heart failure	Disease	32	34	1	1:NR:2	L2R	CROSS	127-128	173-175	D011453	prostaglandin	Chemical	127	128	5	D002318	cardiovascular toxicity	Disease	173	175	6	1:NR:2	L2R	NON-CROSS	144-147	173-175	C109794	N - terminal pro brain natriuretic peptide|NT - proBNP	Chemical	136:144	143:147	6:6	D002318	cardiovascular toxicity	Disease	173	175	6
10539815	Predictors of decreased renal function in patients with heart failure during angiotensin - converting enzyme inhibitor therapy : results from the studies of left ventricular dysfunction ( SOLVD )|BACKGROUND : Although angiotensin - converting enzyme inhibitor therapy reduces mortality rates in patients with congestive heart failure ( CHF ) , it may also cause decreased renal function .|Little information is available to predict which patients are at highest risk for this complication .|OBJECTIVE : To quantify specific clinical predictors of reduction in renal function in patients with CHF who are prescribed angiotensin - converting enzyme inhibitor therapy .|METHOD : We analyzed data from the Studies of Left Ventricular Dysfunction ( SOLVD ) , a randomized , double - blind , placebo - controlled trial of enalapril for the treatment of CHF .|There were 3379 patients randomly assigned to enalapril with a median follow - up of 974 days and 3379 patients randomly assigned to placebo with a mean follow - up of 967 days .|Decreased renal function was defined as a rise in serum creatinine > / = 0 . 5 mg / dL ( 44 micromol / L ) from baseline .|We used time - to - event analysis to identify potential predictors of decrease in renal function including age , baseline ejection fraction , baseline creatinine , low systolic blood pressure ( < 100 mm Hg ) , history of hypertension , diabetes , and use of antiplatelet , diuretic , and beta - blocker therapy .|RESULTS : Patients randomly assigned to enalapril had a 33 % greater likelihood of decreased renal function than controls ( P = . 003 ) .|By multivariate analysis , in both the placebo and enalapril groups older age , diuretic therapy , and diabetes were associated with decreased renal function , whereas beta - blocker therapy and higher ejection fraction were renoprotective .|Older age was associated with a greater risk of developing decreased renal function in both groups , but significantly more so in the enalapril group ( enalapril : risk ratio [ RR ] 1 . 42 per 10 years , 95 % confidence interval [ CI ] 1 . 32 - 1 . 52 with enalapril ; placebo : RR 1 . 18 , 95 % CI 1 . 12 - 1 . 25 ) .|Diuretic therapy was likewise associated with a greater risk of decreased renal function in the enalapril group ( RR 1 . 89 , 95 % CI 1 . 70 - 2 . 08 ) than in the placebo group ( RR 1 . 35 , 95 % CI 1 . 09 - 1 . 66 ) .|Conversely , enalapril had a relative renoprotective effect ( RR 1 . 33 , 95 % CI 1 . 13 - 1 . 53 ) compared with placebo ( RR 1 . 96 , 95 % CI 1 . 57 - 2 . 44 ) in patients with diabetes .|A lower risk of renal impairment was seen in both groups with beta - blocker therapy ( RR 0 . 70 , 95 % CI 0 . 57 - 0 . 85 ) and higher baseline ejection fraction ( RR 0 . 93 per 5 % increment , 95 % CI 0 . 91 - 0 .|96 ) .|CONCLUSIONS : Enalapril use caused a 33 % increase in the risk of decreased renal function in patients with CHF .|Diuretic use and advanced age increased this risk .|Diabetes was associated with an increased risk of renal impairment in all patients with CHF , but this risk was reduced in the enalapril group compared with the placebo group .|beta - Blocker therapy and higher ejection fraction were renoprotective in all patients regardless of therapy .	1:NR:2	R2L	NON-CROSS	11-12	2-5	D000809	angiotensin|angiotensin|angiotensin	Chemical	11:32:94	12:33:95	0:1:3	D051437	decreased renal function|decreased renal function|reduction in renal function|Decreased renal function|decreased renal function|decreased renal function|decreased renal function|decreased renal function|renal impairment|decreased renal function|renal impairment	Disease	2:55:83:170:270:304:330:406:507:576:601	5:58:87:173:273:307:333:409:509:579:603	0:1:3:6:8:9:10:11:13:15:17	1:CID:2	R2L	NON-CROSS	411-412	406-409	D004656	enalapril|enalapril|enalapril|enalapril|enalapril|enalapril|enalapril|enalapril|enalapril|Enalapril|enalapril	Chemical	129:143:262:291:343:346:375:411:455:565:616	130:144:263:292:344:347:376:412:456:566:617	4:5:8:9:10:10:10:11:12:15:17	D051437	decreased renal function|decreased renal function|reduction in renal function|Decreased renal function|decreased renal function|decreased renal function|decreased renal function|decreased renal function|renal impairment|decreased renal function|renal impairment	Disease	2:55:83:170:270:304:330:406:507:576:601	5:58:87:173:273:307:333:409:509:579:603	0:1:3:6:8:9:10:11:13:15:17	1:NR:2	R2L	NON-CROSS	180-181	170-173	D003404	creatinine|creatinine	Chemical	180:224	181:225	6:7	D051437	decreased renal function|decreased renal function|reduction in renal function|Decreased renal function|decreased renal function|decreased renal function|decreased renal function|decreased renal function|renal impairment|decreased renal function|renal impairment	Disease	2:55:83:170:270:304:330:406:507:576:601	5:58:87:173:273:307:333:409:509:579:603	0:1:3:6:8:9:10:11:13:15:17	1:CID:2	R2L	NON-CROSS	584-585	576-579	D004232	diuretic|diuretic|Diuretic|Diuretic	Chemical	248:296:396:584	249:297:397:585	7:9:11:16	D051437	decreased renal function|decreased renal function|reduction in renal function|Decreased renal function|decreased renal function|decreased renal function|decreased renal function|decreased renal function|renal impairment|decreased renal function|renal impairment	Disease	2:55:83:170:270:304:330:406:507:576:601	5:58:87:173:273:307:333:409:509:579:603	0:1:3:6:8:9:10:11:13:15:17	1:NR:2	R2L	NON-CROSS	11-12	8-10	D000809	angiotensin|angiotensin|angiotensin	Chemical	11:32:94	12:33:95	0:1:3	D006333	heart failure|congestive heart failure|CHF|CHF|CHF|CHF|CHF	Disease	8:44:48:90:134:582:607	10:47:49:91:135:583:608	0:1:1:3:4:15:17	1:NR:2	R2L	NON-CROSS	134-135	129-130	D004656	enalapril|enalapril|enalapril|enalapril|enalapril|enalapril|enalapril|enalapril|enalapril|Enalapril|enalapril	Chemical	129:143:262:291:343:346:375:411:455:565:616	130:144:263:292:344:347:376:412:456:566:617	4:5:8:9:10:10:10:11:12:15:17	D006333	heart failure|congestive heart failure|CHF|CHF|CHF|CHF|CHF	Disease	8:44:48:90:134:582:607	10:47:49:91:135:583:608	0:1:1:3:4:15:17	1:NR:2	R2L	CROSS	180-181	134-135	D003404	creatinine|creatinine	Chemical	180:224	181:225	6:7	D006333	heart failure|congestive heart failure|CHF|CHF|CHF|CHF|CHF	Disease	8:44:48:90:134:582:607	10:47:49:91:135:583:608	0:1:1:3:4:15:17	1:NR:2	R2L	CROSS	584-585	582-583	D004232	diuretic|diuretic|Diuretic|Diuretic	Chemical	248:296:396:584	249:297:397:585	7:9:11:16	D006333	heart failure|congestive heart failure|CHF|CHF|CHF|CHF|CHF	Disease	8:44:48:90:134:582:607	10:47:49:91:135:583:608	0:1:1:3:4:15:17	1:NR:2	L2R	NON-CROSS	23-26	32-33	D000809	angiotensin|angiotensin|angiotensin	Chemical	11:32:94	12:33:95	0:1:3	D018487	left ventricular dysfunction|Left Ventricular Dysfunction	Disease	23:110	26:113	0:4	1:NR:2	L2R	CROSS	94-95	239-240	D000809	angiotensin|angiotensin|angiotensin	Chemical	11:32:94	12:33:95	0:1:3	D006973	hypertension	Disease	239	240	7	1:NR:2	L2R	CROSS	94-95	241-242	D000809	angiotensin|angiotensin|angiotensin	Chemical	11:32:94	12:33:95	0:1:3	D003920	diabetes|diabetes|diabetes|Diabetes	Disease	241:300:501:593	242:301:502:594	7:9:12:17	1:NR:2	R2L	NON-CROSS	129-130	110-113	D004656	enalapril|enalapril|enalapril|enalapril|enalapril|enalapril|enalapril|enalapril|enalapril|Enalapril|enalapril	Chemical	129:143:262:291:343:346:375:411:455:565:616	130:144:263:292:344:347:376:412:456:566:617	4:5:8:9:10:10:10:11:12:15:17	D018487	left ventricular dysfunction|Left Ventricular Dysfunction	Disease	23:110	26:113	0:4	1:NR:2	R2L	CROSS	180-181	110-113	D003404	creatinine|creatinine	Chemical	180:224	181:225	6:7	D018487	left ventricular dysfunction|Left Ventricular Dysfunction	Disease	23:110	26:113	0:4	1:NR:2	R2L	CROSS	248-249	110-113	D004232	diuretic|diuretic|Diuretic|Diuretic	Chemical	248:296:396:584	249:297:397:585	7:9:11:16	D018487	left ventricular dysfunction|Left Ventricular Dysfunction	Disease	23:110	26:113	0:4	1:NR:2	L2R	CROSS	239-240	262-263	D004656	enalapril|enalapril|enalapril|enalapril|enalapril|enalapril|enalapril|enalapril|enalapril|Enalapril|enalapril	Chemical	129:143:262:291:343:346:375:411:455:565:616	130:144:263:292:344:347:376:412:456:566:617	4:5:8:9:10:10:10:11:12:15:17	D006973	hypertension	Disease	239	240	7	1:NR:2	L2R	NON-CROSS	291-292	300-301	D004656	enalapril|enalapril|enalapril|enalapril|enalapril|enalapril|enalapril|enalapril|enalapril|Enalapril|enalapril	Chemical	129:143:262:291:343:346:375:411:455:565:616	130:144:263:292:344:347:376:412:456:566:617	4:5:8:9:10:10:10:11:12:15:17	D003920	diabetes|diabetes|diabetes|Diabetes	Disease	241:300:501:593	242:301:502:594	7:9:12:17	1:NR:2	L2R	NON-CROSS	224-225	239-240	D003404	creatinine|creatinine	Chemical	180:224	181:225	6:7	D006973	hypertension	Disease	239	240	7	1:NR:2	L2R	NON-CROSS	224-225	241-242	D003404	creatinine|creatinine	Chemical	180:224	181:225	6:7	D003920	diabetes|diabetes|diabetes|Diabetes	Disease	241:300:501:593	242:301:502:594	7:9:12:17	1:NR:2	R2L	NON-CROSS	248-249	239-240	D004232	diuretic|diuretic|Diuretic|Diuretic	Chemical	248:296:396:584	249:297:397:585	7:9:11:16	D006973	hypertension	Disease	239	240	7	1:NR:2	R2L	NON-CROSS	300-301	296-297	D004232	diuretic|diuretic|Diuretic|Diuretic	Chemical	248:296:396:584	249:297:397:585	7:9:11:16	D003920	diabetes|diabetes|diabetes|Diabetes	Disease	241:300:501:593	242:301:502:594	7:9:12:17
9022662	Pemoline induced acute choreoathetosis : case report and review of the literature .|BACKGROUND : Pemoline is an oxazolidine derivative that is structurally different from amphetamines and used in the treatment of attention deficit disorder .|Pemoline has not been commonly associated in the literature as a cause of acute movement disorders .|The following case describes two children acutely poisoned with pemoline who experienced profound choreoathetosis .|CASE REPORT : Two , 3 - year - old male , identical twin siblings presented to the emergency department after found playing with a an empty bottle of pemoline originally containing 59 tablets .|The children had a medical history significant for attention deficit disorder previously treated with methylphenidate without success .|This was their first day of pemoline therapy .|The choreoathetoid movements began 45 min to 1 h after ingestion .|The children gave no history of prior movement disorders and there was no family history of movement disorders .|The children received gastrointestinal decontamination and high doses of intravenous benzodiazepines in an attempt to control the choreoathetoid movements .|Despite treatment , the children continued to have choreoathetosis for approximately 24 hours .|Forty - eight hours after admission , the children appeared to be at their baseline and were discharged home .|CONCLUSION : Pemoline associated movement disorder has been rarely reported in the acute toxicology literature .|The possibility of choreoathetoid movements should be considered in patients presenting after pemoline overdose .	1:CID:2	L2R	NON-CROSS	0-1	3-4	D010389	Pemoline|Pemoline|Pemoline|pemoline|pemoline|pemoline|Pemoline|pemoline	Chemical	0:15:36:62:97:127:217:243	1:16:37:63:98:128:218:244	0:1:2:3:4:6:12:13	D002819	choreoathetosis|choreoathetosis|choreoathetoid|choreoathetoid|choreoathetosis|choreoathetoid	Disease	3:66:131:178:189:234	4:67:132:179:190:235	0:3:7:9:10:13	1:CID:2	L2R	NON-CROSS	0-1	3-4	D010389	Pemoline|Pemoline|Pemoline|pemoline|pemoline|pemoline|Pemoline|pemoline	Chemical	0:15:36:62:97:127:217:243	1:16:37:63:98:128:218:244	0:1:2:3:4:6:12:13	D001264	choreoathetosis|choreoathetosis|choreoathetoid|choreoathetoid|choreoathetosis|choreoathetoid	Disease	3:66:131:178:189:234	4:67:132:179:190:235	0:3:7:9:10:13	1:NR:2	L2R	NON-CROSS	32-35	36-37	D010389	Pemoline|Pemoline|Pemoline|pemoline|pemoline|pemoline|Pemoline|pemoline	Chemical	0:15:36:62:97:127:217:243	1:16:37:63:98:128:218:244	0:1:2:3:4:6:12:13	D001289	attention deficit disorder|attention deficit disorder	Disease	32:111	35:114	1:5	1:NR:2	L2R	NON-CROSS	217-218	219-221	D010389	Pemoline|Pemoline|Pemoline|pemoline|pemoline|pemoline|Pemoline|pemoline	Chemical	0:15:36:62:97:127:217:243	1:16:37:63:98:128:218:244	0:1:2:3:4:6:12:13	D009069	movement disorders|movement disorders|movement disorders|movement disorder	Disease	50:149:158:219	52:151:160:221	2:8:8:12	1:CID:2	L2R	NON-CROSS	243-244	244-245	D010389	Pemoline|Pemoline|Pemoline|pemoline|pemoline|pemoline|Pemoline|pemoline	Chemical	0:15:36:62:97:127:217:243	1:16:37:63:98:128:218:244	0:1:2:3:4:6:12:13	D062787	overdose	Disease	244	245	13	1:NR:2	R2L	CROSS	18-19	3-4	C064210	oxazolidine	Chemical	18	19	1	D002819	choreoathetosis|choreoathetosis|choreoathetoid|choreoathetoid|choreoathetosis|choreoathetoid	Disease	3:66:131:178:189:234	4:67:132:179:190:235	0:3:7:9:10:13	1:NR:2	R2L	CROSS	25-26	3-4	D000662	amphetamines	Chemical	25	26	1	D002819	choreoathetosis|choreoathetosis|choreoathetoid|choreoathetoid|choreoathetosis|choreoathetoid	Disease	3:66:131:178:189:234	4:67:132:179:190:235	0:3:7:9:10:13	1:NR:2	R2L	CROSS	131-132	117-118	D008774	methylphenidate	Chemical	117	118	5	D002819	choreoathetosis|choreoathetosis|choreoathetoid|choreoathetoid|choreoathetosis|choreoathetoid	Disease	3:66:131:178:189:234	4:67:132:179:190:235	0:3:7:9:10:13	1:NR:2	R2L	NON-CROSS	178-179	171-172	D001569	benzodiazepines	Chemical	171	172	9	D002819	choreoathetosis|choreoathetosis|choreoathetoid|choreoathetoid|choreoathetosis|choreoathetoid	Disease	3:66:131:178:189:234	4:67:132:179:190:235	0:3:7:9:10:13	1:NR:2	R2L	CROSS	18-19	3-4	C064210	oxazolidine	Chemical	18	19	1	D001264	choreoathetosis|choreoathetosis|choreoathetoid|choreoathetoid|choreoathetosis|choreoathetoid	Disease	3:66:131:178:189:234	4:67:132:179:190:235	0:3:7:9:10:13	1:NR:2	R2L	CROSS	25-26	3-4	D000662	amphetamines	Chemical	25	26	1	D001264	choreoathetosis|choreoathetosis|choreoathetoid|choreoathetoid|choreoathetosis|choreoathetoid	Disease	3:66:131:178:189:234	4:67:132:179:190:235	0:3:7:9:10:13	1:NR:2	R2L	CROSS	131-132	117-118	D008774	methylphenidate	Chemical	117	118	5	D001264	choreoathetosis|choreoathetosis|choreoathetoid|choreoathetoid|choreoathetosis|choreoathetoid	Disease	3:66:131:178:189:234	4:67:132:179:190:235	0:3:7:9:10:13	1:NR:2	R2L	NON-CROSS	178-179	171-172	D001569	benzodiazepines	Chemical	171	172	9	D001264	choreoathetosis|choreoathetosis|choreoathetoid|choreoathetoid|choreoathetosis|choreoathetoid	Disease	3:66:131:178:189:234	4:67:132:179:190:235	0:3:7:9:10:13	1:NR:2	L2R	NON-CROSS	18-19	32-35	C064210	oxazolidine	Chemical	18	19	1	D001289	attention deficit disorder|attention deficit disorder	Disease	32:111	35:114	1:5	1:NR:2	L2R	CROSS	18-19	50-52	C064210	oxazolidine	Chemical	18	19	1	D009069	movement disorders|movement disorders|movement disorders|movement disorder	Disease	50:149:158:219	52:151:160:221	2:8:8:12	1:NR:2	L2R	CROSS	18-19	244-245	C064210	oxazolidine	Chemical	18	19	1	D062787	overdose	Disease	244	245	13	1:NR:2	L2R	NON-CROSS	25-26	32-35	D000662	amphetamines	Chemical	25	26	1	D001289	attention deficit disorder|attention deficit disorder	Disease	32:111	35:114	1:5	1:NR:2	L2R	CROSS	25-26	50-52	D000662	amphetamines	Chemical	25	26	1	D009069	movement disorders|movement disorders|movement disorders|movement disorder	Disease	50:149:158:219	52:151:160:221	2:8:8:12	1:NR:2	L2R	CROSS	25-26	244-245	D000662	amphetamines	Chemical	25	26	1	D062787	overdose	Disease	244	245	13	1:NR:2	R2L	NON-CROSS	117-118	111-114	D008774	methylphenidate	Chemical	117	118	5	D001289	attention deficit disorder|attention deficit disorder	Disease	32:111	35:114	1:5	1:NR:2	R2L	CROSS	171-172	111-114	D001569	benzodiazepines	Chemical	171	172	9	D001289	attention deficit disorder|attention deficit disorder	Disease	32:111	35:114	1:5	1:NR:2	R2L	CROSS	149-151	117-118	D008774	methylphenidate	Chemical	117	118	5	D009069	movement disorders|movement disorders|movement disorders|movement disorder	Disease	50:149:158:219	52:151:160:221	2:8:8:12	1:NR:2	R2L	CROSS	171-172	158-160	D001569	benzodiazepines	Chemical	171	172	9	D009069	movement disorders|movement disorders|movement disorders|movement disorder	Disease	50:149:158:219	52:151:160:221	2:8:8:12	1:NR:2	L2R	CROSS	117-118	244-245	D008774	methylphenidate	Chemical	117	118	5	D062787	overdose	Disease	244	245	13	1:NR:2	L2R	CROSS	171-172	244-245	D001569	benzodiazepines	Chemical	171	172	9	D062787	overdose	Disease	244	245	13
8677458	Continuous subcutaneous administration of mesna to prevent ifosfamide - induced hemorrhagic cystitis .|Hemorrhagic cystitis is a major potential toxicity of ifosfamide that can be prevented by administering mesna along with the cytotoxic agent .|Mesna is generally administered by the intravenous route , although experience with oral delivery of the drug has increased .|The continuous subcutaneous administration of mesna has the advantage of not requiring intravenous access .|In addition , subcutaneous delivery of the neutralizing agent will not be associated with the risk of inadequate urinary mesna concentrations , such as in a patient taking oral mesna who experiences severe ifosfamide - induced emesis and is unable to absorb the drug .|Limited clinical experience with continuous subcutaneous mesna administration suggests it is a safe , practical , and economic method of drug delivery that permits ifosfamide to be administered successfully in the outpatient setting .	1:CID:2	L2R	NON-CROSS	4-5	10-12	D015080	mesna|mesna|Mesna|mesna|mesna|mesna|mesna	Chemical	4:28:35:60:89:99:121	5:29:36:61:90:100:122	0:1:2:3:4:4:5	D006470	hemorrhagic cystitis|Hemorrhagic cystitis	Disease	10:13	12:15	0:1	1:CID:2	L2R	NON-CROSS	4-5	10-12	D015080	mesna|mesna|Mesna|mesna|mesna|mesna|mesna	Chemical	4:28:35:60:89:99:121	5:29:36:61:90:100:122	0:1:2:3:4:4:5	D003556	hemorrhagic cystitis|Hemorrhagic cystitis	Disease	10:13	12:15	0:1	1:NR:2	L2R	NON-CROSS	19-20	28-29	D015080	mesna|mesna|Mesna|mesna|mesna|mesna|mesna	Chemical	4:28:35:60:89:99:121	5:29:36:61:90:100:122	0:1:2:3:4:4:5	D064420	toxicity	Disease	19	20	1	1:NR:2	L2R	NON-CROSS	99-100	106-107	D015080	mesna|mesna|Mesna|mesna|mesna|mesna|mesna	Chemical	4:28:35:60:89:99:121	5:29:36:61:90:100:122	0:1:2:3:4:4:5	D014839	emesis	Disease	106	107	4	1:CID:2	L2R	NON-CROSS	7-8	10-12	D007069	ifosfamide|ifosfamide|ifosfamide|ifosfamide	Chemical	7:21:103:139	8:22:104:140	0:1:4:5	D006470	hemorrhagic cystitis|Hemorrhagic cystitis	Disease	10:13	12:15	0:1	1:CID:2	L2R	NON-CROSS	7-8	10-12	D007069	ifosfamide|ifosfamide|ifosfamide|ifosfamide	Chemical	7:21:103:139	8:22:104:140	0:1:4:5	D003556	hemorrhagic cystitis|Hemorrhagic cystitis	Disease	10:13	12:15	0:1	1:NR:2	L2R	NON-CROSS	19-20	21-22	D007069	ifosfamide|ifosfamide|ifosfamide|ifosfamide	Chemical	7:21:103:139	8:22:104:140	0:1:4:5	D064420	toxicity	Disease	19	20	1	1:NR:2	L2R	NON-CROSS	103-104	106-107	D007069	ifosfamide|ifosfamide|ifosfamide|ifosfamide	Chemical	7:21:103:139	8:22:104:140	0:1:4:5	D014839	emesis	Disease	106	107	4
6323692	Modification of drug action by hyperammonemia .|Pretreatment with ammonium acetate ( NH4Ac ) ( 6 mmol / kg s . c . ) approximately doubled the time morphine - treated mice remained on a hot surface and similarly increased muscular incoordination by diazepam , but NH4Ac treatment alone had no effect .|Thus , hyperammonemia is capable of altering drug action and must be considered along with impaired drug metabolism in enhanced drug responses associated with liver disease .|Experiments in vitro showed that acetylcholine - induced catecholamine release from bovine adrenal medulla is depressed as much as 50 % by 0 . 3 mM NH4Ac and KCl - induced contractions of guinea - pig ileum were inhibited 20 % by 5 mM NH4Ac .|Addition of excess calcium reversed the depression in both tissues , but calcium - independent catecholamine release by acetaldehyde was not blocked by NH4Ac .|These results suggested that ammonia blocks calcium channels .|Parallels in the actions of NH4Ac and the calcium channel blocker verapamil support this concept .|Both verapamil ( 10 mg / kg i . p . ) and NH4Ac pretreatment enhanced morphine analgesia - and diazepam - induced muscular incoordination and antagonized amphetamine - induced motor activity , and neither verapamil nor NH4Ac affected the convulsant action of metrazol .|The data suggest that hyperammonemia exerts a calcium channel blocking action which enhances the effects of central nervous system depressants and certain opioid analgesics .	1:NR:2	R2L	CROSS	9-11	5-6	C018824	ammonium acetate|NH4Ac|NH4Ac|NH4Ac|NH4Ac|NH4Ac|NH4Ac|NH4Ac|NH4Ac	Chemical	9:12:46:106:124:149:165:189:213	11:13:47:107:125:150:166:190:214	1:1:1:3:3:4:6:7:7	D022124	hyperammonemia|hyperammonemia|hyperammonemia	Disease	5:55:225	6:56:226	0:2:8	1:NR:2	R2L	CROSS	28-29	5-6	D009020	morphine|morphine	Chemical	28:192	29:193	1:7	D022124	hyperammonemia|hyperammonemia|hyperammonemia	Disease	5:55:225	6:56:226	0:2:8	1:NR:2	R2L	CROSS	55-56	43-44	D003975	diazepam|diazepam	Chemical	43:196	44:197	1:7	D022124	hyperammonemia|hyperammonemia|hyperammonemia	Disease	5:55:225	6:56:226	0:2:8	1:NR:2	R2L	CROSS	85-86	55-56	D000109	acetylcholine	Chemical	85	86	3	D022124	hyperammonemia|hyperammonemia|hyperammonemia	Disease	5:55:225	6:56:226	0:2:8	1:NR:2	R2L	CROSS	88-89	55-56	D002395	catecholamine|catecholamine	Chemical	88:141	89:142	3:4	D022124	hyperammonemia|hyperammonemia|hyperammonemia	Disease	5:55:225	6:56:226	0:2:8	1:NR:2	R2L	CROSS	108-109	55-56	D011189	KCl	Chemical	108	109	3	D022124	hyperammonemia|hyperammonemia|hyperammonemia	Disease	5:55:225	6:56:226	0:2:8	1:NR:2	R2L	NON-CROSS	228-229	225-226	D002118	calcium|calcium|calcium|calcium|calcium	Chemical	129:138:157:168:228	130:139:158:169:229	4:4:5:6:8	D022124	hyperammonemia|hyperammonemia|hyperammonemia	Disease	5:55:225	6:56:226	0:2:8	1:NR:2	R2L	CROSS	225-226	144-145	D000079	acetaldehyde	Chemical	144	145	4	D022124	hyperammonemia|hyperammonemia|hyperammonemia	Disease	5:55:225	6:56:226	0:2:8	1:NR:2	R2L	CROSS	225-226	155-156	D000641	ammonia	Chemical	155	156	5	D022124	hyperammonemia|hyperammonemia|hyperammonemia	Disease	5:55:225	6:56:226	0:2:8	1:NR:2	R2L	CROSS	225-226	211-212	D014700	verapamil|verapamil|verapamil	Chemical	171:177:211	172:178:212	6:7:7	D022124	hyperammonemia|hyperammonemia|hyperammonemia	Disease	5:55:225	6:56:226	0:2:8	1:NR:2	R2L	CROSS	225-226	203-204	D000661	amphetamine	Chemical	203	204	7	D022124	hyperammonemia|hyperammonemia|hyperammonemia	Disease	5:55:225	6:56:226	0:2:8	1:NR:2	R2L	CROSS	225-226	219-220	D010433	metrazol	Chemical	219	220	7	D022124	hyperammonemia|hyperammonemia|hyperammonemia	Disease	5:55:225	6:56:226	0:2:8	1:CID:2	L2R	NON-CROSS	41-42	46-47	C018824	ammonium acetate|NH4Ac|NH4Ac|NH4Ac|NH4Ac|NH4Ac|NH4Ac|NH4Ac|NH4Ac	Chemical	9:12:46:106:124:149:165:189:213	11:13:47:107:125:150:166:190:214	1:1:1:3:3:4:6:7:7	D001259	incoordination|incoordination	Disease	41:200	42:201	1:7	1:NR:2	L2R	CROSS	77-79	106-107	C018824	ammonium acetate|NH4Ac|NH4Ac|NH4Ac|NH4Ac|NH4Ac|NH4Ac|NH4Ac|NH4Ac	Chemical	9:12:46:106:124:149:165:189:213	11:13:47:107:125:150:166:190:214	1:1:1:3:3:4:6:7:7	D008107	liver disease	Disease	77	79	2	1:NR:2	L2R	NON-CROSS	124-125	132-133	C018824	ammonium acetate|NH4Ac|NH4Ac|NH4Ac|NH4Ac|NH4Ac|NH4Ac|NH4Ac|NH4Ac	Chemical	9:12:46:106:124:149:165:189:213	11:13:47:107:125:150:166:190:214	1:1:1:3:3:4:6:7:7	D003866	depression	Disease	132	133	4	1:NR:2	L2R	NON-CROSS	189-190	193-194	C018824	ammonium acetate|NH4Ac|NH4Ac|NH4Ac|NH4Ac|NH4Ac|NH4Ac|NH4Ac|NH4Ac	Chemical	9:12:46:106:124:149:165:189:213	11:13:47:107:125:150:166:190:214	1:1:1:3:3:4:6:7:7	D000699	analgesia	Disease	193	194	7	1:NR:2	L2R	NON-CROSS	192-193	200-201	D009020	morphine|morphine	Chemical	28:192	29:193	1:7	D001259	incoordination|incoordination	Disease	41:200	42:201	1:7	1:NR:2	L2R	CROSS	28-29	77-79	D009020	morphine|morphine	Chemical	28:192	29:193	1:7	D008107	liver disease	Disease	77	79	2	1:NR:2	L2R	CROSS	132-133	192-193	D009020	morphine|morphine	Chemical	28:192	29:193	1:7	D003866	depression	Disease	132	133	4	1:NR:2	L2R	NON-CROSS	192-193	193-194	D009020	morphine|morphine	Chemical	28:192	29:193	1:7	D000699	analgesia	Disease	193	194	7	1:CID:2	R2L	NON-CROSS	43-44	41-42	D003975	diazepam|diazepam	Chemical	43:196	44:197	1:7	D001259	incoordination|incoordination	Disease	41:200	42:201	1:7	1:NR:2	R2L	CROSS	85-86	41-42	D000109	acetylcholine	Chemical	85	86	3	D001259	incoordination|incoordination	Disease	41:200	42:201	1:7	1:NR:2	R2L	CROSS	88-89	41-42	D002395	catecholamine|catecholamine	Chemical	88:141	89:142	3:4	D001259	incoordination|incoordination	Disease	41:200	42:201	1:7	1:NR:2	R2L	CROSS	108-109	41-42	D011189	KCl	Chemical	108	109	3	D001259	incoordination|incoordination	Disease	41:200	42:201	1:7	1:NR:2	R2L	CROSS	228-229	200-201	D002118	calcium|calcium|calcium|calcium|calcium	Chemical	129:138:157:168:228	130:139:158:169:229	4:4:5:6:8	D001259	incoordination|incoordination	Disease	41:200	42:201	1:7	1:NR:2	R2L	CROSS	200-201	144-145	D000079	acetaldehyde	Chemical	144	145	4	D001259	incoordination|incoordination	Disease	41:200	42:201	1:7	1:NR:2	R2L	CROSS	200-201	155-156	D000641	ammonia	Chemical	155	156	5	D001259	incoordination|incoordination	Disease	41:200	42:201	1:7	1:NR:2	R2L	NON-CROSS	211-212	200-201	D014700	verapamil|verapamil|verapamil	Chemical	171:177:211	172:178:212	6:7:7	D001259	incoordination|incoordination	Disease	41:200	42:201	1:7	1:NR:2	R2L	NON-CROSS	203-204	200-201	D000661	amphetamine	Chemical	203	204	7	D001259	incoordination|incoordination	Disease	41:200	42:201	1:7	1:NR:2	R2L	NON-CROSS	219-220	200-201	D010433	metrazol	Chemical	219	220	7	D001259	incoordination|incoordination	Disease	41:200	42:201	1:7	1:NR:2	L2R	CROSS	43-44	77-79	D003975	diazepam|diazepam	Chemical	43:196	44:197	1:7	D008107	liver disease	Disease	77	79	2	1:NR:2	L2R	CROSS	132-133	196-197	D003975	diazepam|diazepam	Chemical	43:196	44:197	1:7	D003866	depression	Disease	132	133	4	1:NR:2	L2R	NON-CROSS	193-194	196-197	D003975	diazepam|diazepam	Chemical	43:196	44:197	1:7	D000699	analgesia	Disease	193	194	7	1:NR:2	R2L	CROSS	85-86	77-79	D000109	acetylcholine	Chemical	85	86	3	D008107	liver disease	Disease	77	79	2	1:NR:2	R2L	CROSS	88-89	77-79	D002395	catecholamine|catecholamine	Chemical	88:141	89:142	3:4	D008107	liver disease	Disease	77	79	2	1:NR:2	R2L	CROSS	108-109	77-79	D011189	KCl	Chemical	108	109	3	D008107	liver disease	Disease	77	79	2	1:NR:2	R2L	CROSS	129-130	77-79	D002118	calcium|calcium|calcium|calcium|calcium	Chemical	129:138:157:168:228	130:139:158:169:229	4:4:5:6:8	D008107	liver disease	Disease	77	79	2	1:NR:2	R2L	CROSS	144-145	77-79	D000079	acetaldehyde	Chemical	144	145	4	D008107	liver disease	Disease	77	79	2	1:NR:2	R2L	CROSS	155-156	77-79	D000641	ammonia	Chemical	155	156	5	D008107	liver disease	Disease	77	79	2	1:NR:2	R2L	CROSS	171-172	77-79	D014700	verapamil|verapamil|verapamil	Chemical	171:177:211	172:178:212	6:7:7	D008107	liver disease	Disease	77	79	2	1:NR:2	R2L	CROSS	203-204	77-79	D000661	amphetamine	Chemical	203	204	7	D008107	liver disease	Disease	77	79	2	1:NR:2	R2L	CROSS	219-220	77-79	D010433	metrazol	Chemical	219	220	7	D008107	liver disease	Disease	77	79	2	1:NR:2	L2R	CROSS	85-86	132-133	D000109	acetylcholine	Chemical	85	86	3	D003866	depression	Disease	132	133	4	1:NR:2	L2R	CROSS	85-86	193-194	D000109	acetylcholine	Chemical	85	86	3	D000699	analgesia	Disease	193	194	7	1:NR:2	L2R	NON-CROSS	132-133	141-142	D002395	catecholamine|catecholamine	Chemical	88:141	89:142	3:4	D003866	depression	Disease	132	133	4	1:NR:2	L2R	CROSS	141-142	193-194	D002395	catecholamine|catecholamine	Chemical	88:141	89:142	3:4	D000699	analgesia	Disease	193	194	7	1:NR:2	L2R	CROSS	108-109	132-133	D011189	KCl	Chemical	108	109	3	D003866	depression	Disease	132	133	4	1:NR:2	L2R	CROSS	108-109	193-194	D011189	KCl	Chemical	108	109	3	D000699	analgesia	Disease	193	194	7	1:NR:2	L2R	NON-CROSS	129-130	132-133	D002118	calcium|calcium|calcium|calcium|calcium	Chemical	129:138:157:168:228	130:139:158:169:229	4:4:5:6:8	D003866	depression	Disease	132	133	4	1:NR:2	L2R	CROSS	168-169	193-194	D002118	calcium|calcium|calcium|calcium|calcium	Chemical	129:138:157:168:228	130:139:158:169:229	4:4:5:6:8	D000699	analgesia	Disease	193	194	7	1:NR:2	R2L	NON-CROSS	144-145	132-133	D000079	acetaldehyde	Chemical	144	145	4	D003866	depression	Disease	132	133	4	1:NR:2	R2L	CROSS	155-156	132-133	D000641	ammonia	Chemical	155	156	5	D003866	depression	Disease	132	133	4	1:NR:2	R2L	CROSS	171-172	132-133	D014700	verapamil|verapamil|verapamil	Chemical	171:177:211	172:178:212	6:7:7	D003866	depression	Disease	132	133	4	1:NR:2	R2L	CROSS	203-204	132-133	D000661	amphetamine	Chemical	203	204	7	D003866	depression	Disease	132	133	4	1:NR:2	R2L	CROSS	219-220	132-133	D010433	metrazol	Chemical	219	220	7	D003866	depression	Disease	132	133	4	1:NR:2	L2R	CROSS	144-145	193-194	D000079	acetaldehyde	Chemical	144	145	4	D000699	analgesia	Disease	193	194	7	1:NR:2	L2R	CROSS	155-156	193-194	D000641	ammonia	Chemical	155	156	5	D000699	analgesia	Disease	193	194	7	1:NR:2	L2R	NON-CROSS	177-178	193-194	D014700	verapamil|verapamil|verapamil	Chemical	171:177:211	172:178:212	6:7:7	D000699	analgesia	Disease	193	194	7	1:NR:2	R2L	NON-CROSS	203-204	193-194	D000661	amphetamine	Chemical	203	204	7	D000699	analgesia	Disease	193	194	7	1:NR:2	R2L	NON-CROSS	219-220	193-194	D010433	metrazol	Chemical	219	220	7	D000699	analgesia	Disease	193	194	7
20195852	Risk of nephropathy after consumption of nonionic contrast media by children undergoing cardiac angiography : a prospective study .|Despite increasing reports on nonionic contrast media - induced nephropathy ( CIN ) in hospitalized adult patients during cardiac procedures , the studies in pediatrics are limited , with even less focus on possible predisposing factors and preventive measures for patients undergoing cardiac angiography .|This prospective study determined the incidence of CIN for two nonionic contrast media ( CM ) , iopromide and iohexol , among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis .|The 80 patients in the study consecutively received either iopromide ( group A , n = 40 ) or iohexol ( group B , n = 40 ) .|Serum sodium ( Na ) , potassium ( K ) , and creatinine ( Cr ) were measured 24 h before angiography as baseline values , then measured again at 12 - , 24 - , and 48 - h intervals after CM use .|Urine samples for Na and Cr also were checked at the same intervals .|Risk of renal failure , Injury to the kidney , Failure of kidney function , Loss of kidney function , and End - stage renal damage ( RIFLE criteria ) were used to define CIN and its incidence in the study population .|Accordingly , among the 15 CIN patients ( 18 . 75 % ) , 7 . 5 % of the patients in group A had increased risk and 3 . 75 % had renal injury , whereas 5 % of group B had increased risk and 2 . 5 % had renal injury .|Whereas 33 . 3 % of the patients with CIN were among those who received the proper dosage of CM , the percentage increased to 66 . 6 % among those who received larger doses , with a significant difference in the incidence of CIN related to the different dosages of CM ( p = 0 . 014 ) .|Among the 15 patients with CIN , 6 had cyanotic congenital heart diseases , but the incidence did not differ significantly from that for the noncyanotic patients ( p = 0 . 243 ) .|Although clinically silent , CIN is not rare in pediatrics .|The incidence depends on dosage but not on the type of consumed nonionic CM , nor on the presence of cyanosis , and although CIN usually is reversible , more concern is needed for the prevention of such a complication in children .	1:CID:2	R2L	NON-CROSS	28-29	24-26	D003287	contrast media|contrast media|contrast media|CM|CM|CM|CM|CM|CM	Chemical	7:24:75:78:107:185:318:350:418	9:26:77:79:108:186:319:351:419	0:1:2:2:2:4:8:8:11	D007674	nephropathy|nephropathy|CIN|CIN|renal damage|CIN|CIN|CIN|CIN|CIN|CIN|CIN	Disease	2:28:30:71:226:236:250:308:343:364:398:429	3:29:31:72:228:237:251:309:344:365:399:430	0:1:1:2:6:6:7:8:8:9:10:11	1:CID:2	R2L	NON-CROSS	81-82	71-72	C038192	iopromide|iopromide	Chemical	81:123	82:124	2:3	D007674	nephropathy|nephropathy|CIN|CIN|renal damage|CIN|CIN|CIN|CIN|CIN|CIN|CIN	Disease	2:28:30:71:226:236:250:308:343:364:398:429	3:29:31:72:228:237:251:309:344:365:399:430	0:1:1:2:6:6:7:8:8:9:10:11	1:CID:2	R2L	NON-CROSS	83-84	71-72	D007472	iohexol|iohexol	Chemical	83:133	84:134	2:3	D007674	nephropathy|nephropathy|CIN|CIN|renal damage|CIN|CIN|CIN|CIN|CIN|CIN|CIN	Disease	2:28:30:71:226:236:250:308:343:364:398:429	3:29:31:72:228:237:251:309:344:365:399:430	0:1:1:2:6:6:7:8:8:9:10:11	1:NR:2	R2L	CROSS	226-228	191-192	D012964	sodium|Na|Na	Chemical	144:146:191	145:147:192	4:4:5	D007674	nephropathy|nephropathy|CIN|CIN|renal damage|CIN|CIN|CIN|CIN|CIN|CIN|CIN	Disease	2:28:30:71:226:236:250:308:343:364:398:429	3:29:31:72:228:237:251:309:344:365:399:430	0:1:1:2:6:6:7:8:8:9:10:11	1:NR:2	R2L	CROSS	226-228	151-152	D011188	potassium|K	Chemical	149:151	150:152	4:4	D007674	nephropathy|nephropathy|CIN|CIN|renal damage|CIN|CIN|CIN|CIN|CIN|CIN|CIN	Disease	2:28:30:71:226:236:250:308:343:364:398:429	3:29:31:72:228:237:251:309:344:365:399:430	0:1:1:2:6:6:7:8:8:9:10:11	1:NR:2	R2L	CROSS	226-228	193-194	D003404	creatinine|Cr|Cr	Chemical	155:157:193	156:158:194	4:4:5	D007674	nephropathy|nephropathy|CIN|CIN|renal damage|CIN|CIN|CIN|CIN|CIN|CIN|CIN	Disease	2:28:30:71:226:236:250:308:343:364:398:429	3:29:31:72:228:237:251:309:344:365:399:430	0:1:1:2:6:6:7:8:8:9:10:11	1:NR:2	L2R	NON-CROSS	107-108	112-113	D003287	contrast media|contrast media|contrast media|CM|CM|CM|CM|CM|CM	Chemical	7:24:75:78:107:185:318:350:418	9:26:77:79:108:186:319:351:419	0:1:2:2:2:4:8:8:11	D003490	cyanosis|cyanosis	Disease	112:425	113:426	2:11	1:NR:2	L2R	CROSS	185-186	204-206	D003287	contrast media|contrast media|contrast media|CM|CM|CM|CM|CM|CM	Chemical	7:24:75:78:107:185:318:350:418	9:26:77:79:108:186:319:351:419	0:1:2:2:2:4:8:8:11	D051437	renal failure|Failure of kidney function|Loss of kidney function	Disease	204:212:217	206:216:221	6:6:6	1:NR:2	L2R	CROSS	296-298	318-319	D003287	contrast media|contrast media|contrast media|CM|CM|CM|CM|CM|CM	Chemical	7:24:75:78:107:185:318:350:418	9:26:77:79:108:186:319:351:419	0:1:2:2:2:4:8:8:11	D058186	Injury to the kidney|renal injury|renal injury	Disease	207:278:296	211:280:298	6:7:7	1:NR:2	L2R	CROSS	350-351	369-372	D003287	contrast media|contrast media|contrast media|CM|CM|CM|CM|CM|CM	Chemical	7:24:75:78:107:185:318:350:418	9:26:77:79:108:186:319:351:419	0:1:2:2:2:4:8:8:11	D006331	congenital heart diseases	Disease	369	372	9	1:NR:2	L2R	NON-CROSS	112-113	123-124	C038192	iopromide|iopromide	Chemical	81:123	82:124	2:3	D003490	cyanosis|cyanosis	Disease	112:425	113:426	2:11	1:NR:2	L2R	CROSS	123-124	204-206	C038192	iopromide|iopromide	Chemical	81:123	82:124	2:3	D051437	renal failure|Failure of kidney function|Loss of kidney function	Disease	204:212:217	206:216:221	6:6:6	1:NR:2	L2R	CROSS	123-124	207-211	C038192	iopromide|iopromide	Chemical	81:123	82:124	2:3	D058186	Injury to the kidney|renal injury|renal injury	Disease	207:278:296	211:280:298	6:7:7	1:NR:2	L2R	CROSS	123-124	369-372	C038192	iopromide|iopromide	Chemical	81:123	82:124	2:3	D006331	congenital heart diseases	Disease	369	372	9	1:NR:2	L2R	NON-CROSS	112-113	133-134	D007472	iohexol|iohexol	Chemical	83:133	84:134	2:3	D003490	cyanosis|cyanosis	Disease	112:425	113:426	2:11	1:NR:2	L2R	CROSS	133-134	204-206	D007472	iohexol|iohexol	Chemical	83:133	84:134	2:3	D051437	renal failure|Failure of kidney function|Loss of kidney function	Disease	204:212:217	206:216:221	6:6:6	1:NR:2	L2R	CROSS	133-134	207-211	D007472	iohexol|iohexol	Chemical	83:133	84:134	2:3	D058186	Injury to the kidney|renal injury|renal injury	Disease	207:278:296	211:280:298	6:7:7	1:NR:2	L2R	CROSS	133-134	369-372	D007472	iohexol|iohexol	Chemical	83:133	84:134	2:3	D006331	congenital heart diseases	Disease	369	372	9	1:NR:2	R2L	CROSS	144-145	112-113	D012964	sodium|Na|Na	Chemical	144:146:191	145:147:192	4:4:5	D003490	cyanosis|cyanosis	Disease	112:425	113:426	2:11	1:NR:2	R2L	CROSS	149-150	112-113	D011188	potassium|K	Chemical	149:151	150:152	4:4	D003490	cyanosis|cyanosis	Disease	112:425	113:426	2:11	1:NR:2	R2L	CROSS	155-156	112-113	D003404	creatinine|Cr|Cr	Chemical	155:157:193	156:158:194	4:4:5	D003490	cyanosis|cyanosis	Disease	112:425	113:426	2:11	1:NR:2	L2R	CROSS	191-192	204-206	D012964	sodium|Na|Na	Chemical	144:146:191	145:147:192	4:4:5	D051437	renal failure|Failure of kidney function|Loss of kidney function	Disease	204:212:217	206:216:221	6:6:6	1:NR:2	L2R	CROSS	191-192	207-211	D012964	sodium|Na|Na	Chemical	144:146:191	145:147:192	4:4:5	D058186	Injury to the kidney|renal injury|renal injury	Disease	207:278:296	211:280:298	6:7:7	1:NR:2	L2R	CROSS	191-192	369-372	D012964	sodium|Na|Na	Chemical	144:146:191	145:147:192	4:4:5	D006331	congenital heart diseases	Disease	369	372	9	1:NR:2	L2R	CROSS	151-152	204-206	D011188	potassium|K	Chemical	149:151	150:152	4:4	D051437	renal failure|Failure of kidney function|Loss of kidney function	Disease	204:212:217	206:216:221	6:6:6	1:NR:2	L2R	CROSS	151-152	207-211	D011188	potassium|K	Chemical	149:151	150:152	4:4	D058186	Injury to the kidney|renal injury|renal injury	Disease	207:278:296	211:280:298	6:7:7	1:NR:2	L2R	CROSS	151-152	369-372	D011188	potassium|K	Chemical	149:151	150:152	4:4	D006331	congenital heart diseases	Disease	369	372	9	1:NR:2	L2R	CROSS	193-194	204-206	D003404	creatinine|Cr|Cr	Chemical	155:157:193	156:158:194	4:4:5	D051437	renal failure|Failure of kidney function|Loss of kidney function	Disease	204:212:217	206:216:221	6:6:6	1:NR:2	L2R	CROSS	193-194	207-211	D003404	creatinine|Cr|Cr	Chemical	155:157:193	156:158:194	4:4:5	D058186	Injury to the kidney|renal injury|renal injury	Disease	207:278:296	211:280:298	6:7:7	1:NR:2	L2R	CROSS	193-194	369-372	D003404	creatinine|Cr|Cr	Chemical	155:157:193	156:158:194	4:4:5	D006331	congenital heart diseases	Disease	369	372	9
18997632	A case of ventricular tachycardia related to caffeine pretreatment .|Suboptimal seizure duration is commonly encountered in electroconvulsive therapy practice , especially in older patients with higher seizure thresholds .|Intravenous caffeine is commonly used to improve seizure duration and quality in such patients and is generally well tolerated aside from occasional reports of relatively benign ventricular ectopy .|We describe a patient with no previous history of cardiac disease or arrhythmia who developed sustained bigeminy and 2 brief runs of ventricular tachycardia after caffeine administration .|Although intravenous caffeine is generally well tolerated , the clinician should be aware of the potential for unpredictable and serious ventricular arrhythmias .	1:CID:2	R2L	NON-CROSS	84-85	81-83	D002110	caffeine|caffeine|caffeine|caffeine	Chemical	7:31:84:89	8:32:85:90	0:2:3:4	D017180	ventricular tachycardia|ventricular tachycardia	Disease	3:81	5:83	0:3	1:CID:2	L2R	NON-CROSS	7-8	11-12	D002110	caffeine|caffeine|caffeine|caffeine	Chemical	7:31:84:89	8:32:85:90	0:2:3:4	D012640	seizure|seizure|seizure	Disease	11:27:37	12:28:38	1:1:2	1:CID:2	L2R	NON-CROSS	31-32	56-58	D002110	caffeine|caffeine|caffeine|caffeine	Chemical	7:31:84:89	8:32:85:90	0:2:3:4	D018879	ventricular ectopy	Disease	56	58	2	1:NR:2	L2R	NON-CROSS	68-70	84-85	D002110	caffeine|caffeine|caffeine|caffeine	Chemical	7:31:84:89	8:32:85:90	0:2:3:4	D006331	cardiac disease	Disease	68	70	3	1:NR:2	L2R	NON-CROSS	71-72	84-85	D002110	caffeine|caffeine|caffeine|caffeine	Chemical	7:31:84:89	8:32:85:90	0:2:3:4	D001145	arrhythmia|ventricular arrhythmias	Disease	71:107	72:109	3:4
15565293	Optical coherence tomography can measure axonal loss in patients with ethambutol - induced optic neuropathy .|PURPOSE : To map and identify the pattern , in vivo , of axonal degeneration in ethambutol - induced optic neuropathy using optical coherence tomography ( OCT ) .|Ethambutol is an antimycobacterial agent often used to treat tuberculosis .|A serious complication of ethambutol is an optic neuropathy that impairs visual acuity , contrast sensitivity , and color vision .|However , early on , when the toxic optic neuropathy is mild and partly reversible , the funduscopic findings are often subtle and easy to miss .|METHODS : Three subjects with a history of ethambutol ( EMB ) - induced optic neuropathy of short - , intermediate - , and long - term visual deficits were administered a full neuro - ophthalmologic examination including visual acuity , color vision , contrast sensitivity , and fundus examination .|In addition , OCT ( OCT 3000 , Humphrey - Zeiss , Dublin , CA ) was performed on both eyes of each subject using the retinal nerve fiber layer ( RNFL ) analysis protocol .|OCT interpolates data from 100 points around the optic nerve to effectively map out the RNFL .|RESULTS : The results were compared to the calculated average RNFL of normal eyes accumulated from four prior studies using OCT , n = 661 .|In all subjects with history of EMB - induced optic neuropathy , there was a mean loss of 72 % nerve fiber layer thickness in the temporal quadrant ( patient A , with eventual recovery of visual acuity and fields , 58 % loss ; patient B , with intermediate visual deficits , 68 % loss ; patient C , with chronic visual deficits , 90 % loss ) , with an average mean optic nerve thickness of 26 + / - 16 microm .|There was a combined mean loss of 46 % of fibers from the superior , inferior , and nasal quadrants in the ( six ) eyes of all three subjects ( mean average thickness of 55 + / - 29 microm ) .|In both sets ( four ) of eyes of the subjects with persistent visual deficits ( patients B and C ) , there was an average loss of 79 % of nerve fiber thickness in the temporal quadrant .|CONCLUSIONS : The OCT results in these patients with EMB - induced optic neuropathy show considerable loss especially of the temporal fibers .|This is consistent with prior histopathological studies that show predominant loss of parvo - cellular axons ( or small - caliber axons ) within the papillo - macular bundle in toxic or hereditary optic neuropathies .|OCT can be a valuable tool in the quantitative analysis of optic neuropathies .|Additionally , in terms of management of EMB - induced optic neuropathy , it is important to properly manage ethambutol dosing in patients with renal impairment and to achieve proper transition to a maintenance dose once an appropriate loading dose has been reached .	1:CID:2	L2R	NON-CROSS	10-11	13-15	D004977	ethambutol|ethambutol|Ethambutol|ethambutol|ethambutol|EMB|EMB|EMB|EMB|ethambutol	Chemical	10:32:45:60:112:114:240:410:481:493	11:33:46:61:113:115:241:411:482:494	0:1:2:3:5:5:9:12:15:15	D009901	optic neuropathy|optic neuropathy|optic neuropathy|optic neuropathy|optic neuropathy|optic neuropathy|optic neuropathy|optic neuropathies|optic neuropathies|optic neuropathy	Disease	13:35:63:85:118:243:413:457:471:484	15:37:65:87:120:245:415:459:473:486	0:1:3:4:5:9:12:13:14:15	1:NR:2	L2R	NON-CROSS	29-31	32-33	D004977	ethambutol|ethambutol|Ethambutol|ethambutol|ethambutol|EMB|EMB|EMB|EMB|ethambutol	Chemical	10:32:45:60:112:114:240:410:481:493	11:33:46:61:113:115:241:411:482:494	0:1:2:3:5:5:9:12:15:15	D009410	axonal degeneration	Disease	29	31	1	1:NR:2	L2R	NON-CROSS	54-55	60-61	D004977	ethambutol|ethambutol|Ethambutol|ethambutol|ethambutol|EMB|EMB|EMB|EMB|ethambutol	Chemical	10:32:45:60:112:114:240:410:481:493	11:33:46:61:113:115:241:411:482:494	0:1:2:3:5:5:9:12:15:15	D014376	tuberculosis	Disease	54	55	2	1:CID:2	L2R	NON-CROSS	114-115	131-133	D004977	ethambutol|ethambutol|Ethambutol|ethambutol|ethambutol|EMB|EMB|EMB|EMB|ethambutol	Chemical	10:32:45:60:112:114:240:410:481:493	11:33:46:61:113:115:241:411:482:494	0:1:2:3:5:5:9:12:15:15	D014786	visual deficits|visual deficits|visual deficits|visual deficits	Disease	131:284:296:375	133:286:298:377	5:9:9:11	1:NR:2	L2R	NON-CROSS	493-494	498-500	D004977	ethambutol|ethambutol|Ethambutol|ethambutol|ethambutol|EMB|EMB|EMB|EMB|ethambutol	Chemical	10:32:45:60:112:114:240:410:481:493	11:33:46:61:113:115:241:411:482:494	0:1:2:3:5:5:9:12:15:15	D051437	renal impairment	Disease	498	500	15
15266215	Effects of the cyclooxygenase - 2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis .|There have been concerns that the risk of cardiovascular thrombotic events may be higher with cyclooxygenase ( COX ) - 2 - specific inhibitors than nonselective nonsteroidal antiinflammatory drugs ( NSAIDs ) .|We evaluated cardiovascular event data for valdecoxib , a new COX - 2 - specific inhibitor in approximately 8000 patients with osteoarthritis and rheumatoid arthritis treated with this agent in randomized clinical trials .|The incidence of cardiovascular thrombotic events ( cardiac , cerebrovascular and peripheral vascular , or arterial thrombotic ) was determined by analyzing pooled valdecoxib ( 10 - 80 mg daily ) , nonselective NSAID ( diclofenac 75 mg bid , ibuprofen 800 mg tid , or naproxen 500 mg bid ) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6 - 52 weeks in duration .|The incidence rates of events were determined in all patients ( n = 7934 ) and in users of low - dose ( < or = 325 mg daily ) aspirin ( n = 1051 ) and nonusers of aspirin ( n = 6883 ) .|Crude and exposure - adjusted incidences of thrombotic events were similar for valdecoxib , NSAIDs , and placebo .|The risk of serious thrombotic events was also similar for each valdecoxib dose .|Thrombotic risk was consistently higher for users of aspirin users than nonusers of aspirin ( placebo , 1 . 4 % vs . 0 % ; valdecoxib , 1 . 7 % vs . 0 . 2 % ; NSAIDs , 1 . 9 % vs . 0 . 5 % ) .|The rates of events in users of aspirin were similar for all 3 treatment groups and across valdecoxib doses .|Short - and intermediate - term treatment with therapeutic ( 10 or 20 mg daily ) and supratherapeutic ( 40 or 80 mg daily ) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials .	1:NR:2	L2R	NON-CROSS	238-239	241-242	C406224	valdecoxib|valdecoxib|valdecoxib|valdecoxib|valdecoxib|valdecoxib|valdecoxib|valdecoxib	Chemical	8:63:114:220:238:267:311:339	9:64:115:221:239:268:312:340	0:2:3:5:6:7:8:9	D013927	thrombotic|thrombotic|thrombotic|thrombotic|thrombotic|thrombotic|Thrombotic|thrombotic	Disease	17:33:95:107:215:231:241:349	18:34:96:108:216:232:242:350	0:1:3:3:5:6:7:9	1:NR:2	L2R	NON-CROSS	8-9	22-23	C406224	valdecoxib|valdecoxib|valdecoxib|valdecoxib|valdecoxib|valdecoxib|valdecoxib|valdecoxib	Chemical	8:63:114:220:238:267:311:339	9:64:115:221:239:268:312:340	0:2:3:5:6:7:8:9	D001168	arthritis	Disease	22	23	0	1:NR:2	L2R	NON-CROSS	63-64	78-79	C406224	valdecoxib|valdecoxib|valdecoxib|valdecoxib|valdecoxib|valdecoxib|valdecoxib|valdecoxib	Chemical	8:63:114:220:238:267:311:339	9:64:115:221:239:268:312:340	0:2:3:5:6:7:8:9	D010003	osteoarthritis|osteoarthritis|osteoarthritis	Disease	78:148:358	79:149:359	2:3:9	1:NR:2	L2R	NON-CROSS	63-64	80-82	C406224	valdecoxib|valdecoxib|valdecoxib|valdecoxib|valdecoxib|valdecoxib|valdecoxib|valdecoxib	Chemical	8:63:114:220:238:267:311:339	9:64:115:221:239:268:312:340	0:2:3:5:6:7:8:9	D001172	rheumatoid arthritis|rheumatoid arthritis|rheumatoid arthritis	Disease	80:150:360	82:152:362	2:3:9	1:NR:2	R2L	NON-CROSS	126-127	107-108	D004008	diclofenac	Chemical	126	127	3	D013927	thrombotic|thrombotic|thrombotic|thrombotic|thrombotic|thrombotic|Thrombotic|thrombotic	Disease	17:33:95:107:215:231:241:349	18:34:96:108:216:232:242:350	0:1:3:3:5:6:7:9	1:NR:2	R2L	NON-CROSS	131-132	107-108	D007052	ibuprofen	Chemical	131	132	3	D013927	thrombotic|thrombotic|thrombotic|thrombotic|thrombotic|thrombotic|Thrombotic|thrombotic	Disease	17:33:95:107:215:231:241:349	18:34:96:108:216:232:242:350	0:1:3:3:5:6:7:9	1:NR:2	R2L	NON-CROSS	137-138	107-108	D009288	naproxen	Chemical	137	138	3	D013927	thrombotic|thrombotic|thrombotic|thrombotic|thrombotic|thrombotic|Thrombotic|thrombotic	Disease	17:33:95:107:215:231:241:349	18:34:96:108:216:232:242:350	0:1:3:3:5:6:7:9	1:CID:2	R2L	NON-CROSS	249-250	241-242	D001241	aspirin|aspirin|aspirin|aspirin|aspirin	Chemical	192:201:249:254:301	193:202:250:255:302	4:4:7:7:8	D013927	thrombotic|thrombotic|thrombotic|thrombotic|thrombotic|thrombotic|Thrombotic|thrombotic	Disease	17:33:95:107:215:231:241:349	18:34:96:108:216:232:242:350	0:1:3:3:5:6:7:9	1:NR:2	R2L	CROSS	126-127	22-23	D004008	diclofenac	Chemical	126	127	3	D001168	arthritis	Disease	22	23	0	1:NR:2	R2L	CROSS	131-132	22-23	D007052	ibuprofen	Chemical	131	132	3	D001168	arthritis	Disease	22	23	0	1:NR:2	R2L	CROSS	137-138	22-23	D009288	naproxen	Chemical	137	138	3	D001168	arthritis	Disease	22	23	0	1:NR:2	R2L	CROSS	192-193	22-23	D001241	aspirin|aspirin|aspirin|aspirin|aspirin	Chemical	192:201:249:254:301	193:202:250:255:302	4:4:7:7:8	D001168	arthritis	Disease	22	23	0	1:NR:2	R2L	NON-CROSS	148-149	126-127	D004008	diclofenac	Chemical	126	127	3	D010003	osteoarthritis|osteoarthritis|osteoarthritis	Disease	78:148:358	79:149:359	2:3:9	1:NR:2	R2L	NON-CROSS	148-149	131-132	D007052	ibuprofen	Chemical	131	132	3	D010003	osteoarthritis|osteoarthritis|osteoarthritis	Disease	78:148:358	79:149:359	2:3:9	1:NR:2	R2L	NON-CROSS	148-149	137-138	D009288	naproxen	Chemical	137	138	3	D010003	osteoarthritis|osteoarthritis|osteoarthritis	Disease	78:148:358	79:149:359	2:3:9	1:NR:2	R2L	CROSS	192-193	148-149	D001241	aspirin|aspirin|aspirin|aspirin|aspirin	Chemical	192:201:249:254:301	193:202:250:255:302	4:4:7:7:8	D010003	osteoarthritis|osteoarthritis|osteoarthritis	Disease	78:148:358	79:149:359	2:3:9	1:NR:2	R2L	NON-CROSS	150-152	126-127	D004008	diclofenac	Chemical	126	127	3	D001172	rheumatoid arthritis|rheumatoid arthritis|rheumatoid arthritis	Disease	80:150:360	82:152:362	2:3:9	1:NR:2	R2L	NON-CROSS	150-152	131-132	D007052	ibuprofen	Chemical	131	132	3	D001172	rheumatoid arthritis|rheumatoid arthritis|rheumatoid arthritis	Disease	80:150:360	82:152:362	2:3:9	1:NR:2	R2L	NON-CROSS	150-152	137-138	D009288	naproxen	Chemical	137	138	3	D001172	rheumatoid arthritis|rheumatoid arthritis|rheumatoid arthritis	Disease	80:150:360	82:152:362	2:3:9	1:NR:2	R2L	CROSS	192-193	150-152	D001241	aspirin|aspirin|aspirin|aspirin|aspirin	Chemical	192:201:249:254:301	193:202:250:255:302	4:4:7:7:8	D001172	rheumatoid arthritis|rheumatoid arthritis|rheumatoid arthritis	Disease	80:150:360	82:152:362	2:3:9
14742097	A randomized , placebo - controlled , crossover study of ephedrine for SSRI - induced female sexual dysfunction .|The objective of this study was to determine whether ephedrine , an alpha - and beta - adrenergic agonist previously shown to enhance genital blood flow in women , has beneficial effects in reversing antidepressant - induced sexual dysfunction .|Nineteen sexually dysfunctional women receiving either fluoxetine , sertraline , or paroxetine participated in an eight - week , double - blind , placebo - controlled , cross - over study of the effects of ephedrine ( 50 mg ) on self - report measures of sexual desire , arousal , orgasm , and sexual satisfaction .|Although there were significant improvements relative to baseline in sexual desire and orgasm intensity / pleasure on 50 mg ephedrine 1 - hr prior to sexual activity , significant improvements in these measures , as well as in sexual arousal and orgasmic ability also were noted with placebo .|These findings highlight the importance of conducting placebo - controlled trials for this condition .	1:NR:2	L2R	NON-CROSS	10-11	16-18	D004809	ephedrine|ephedrine|ephedrine|ephedrine	Chemical	10:28:94:135	11:29:95:136	0:1:2:3	D020018	sexual dysfunction|sexual dysfunction|sexually dysfunctional	Disease	16:56:60	18:58:62	0:1:2	1:CID:2	R2L	NON-CROSS	65-66	60-62	D005473	fluoxetine	Chemical	65	66	2	D020018	sexual dysfunction|sexual dysfunction|sexually dysfunctional	Disease	16:56:60	18:58:62	0:1:2	1:CID:2	R2L	NON-CROSS	67-68	60-62	D020280	sertraline	Chemical	67	68	2	D020018	sexual dysfunction|sexual dysfunction|sexually dysfunctional	Disease	16:56:60	18:58:62	0:1:2	1:CID:2	R2L	NON-CROSS	70-71	60-62	D017374	paroxetine	Chemical	70	71	2	D020018	sexual dysfunction|sexual dysfunction|sexually dysfunctional	Disease	16:56:60	18:58:62	0:1:2
11890511	Erectile dysfunction occurs following substantia nigra lesions in the rat .|Erectile function was assessed 6 weeks following uni - and bilateral injections of 6 - hydroxydopamine in the substantia nigra nucleus of the brain .|Behavioral apomorphine - induced penile erections were reduced ( 5 / 8 ) and increased ( 3 / 8 ) in uni - and bilateral lesioned animals .|Intracavernous pressures , following electrical stimulation of the cavernous nerve , decreased in lesioned animals .|Lesions of the substantia nigra were confirmed by histology .|Concentration of dopamine and its metabolites were decreased in the striatum of substantia nigra lesioned rats .|Lesions of the substantia nigra are therefore associated with erectile dysfunction in rats and may serve as a model to study erectile dysfunction in Parkinson 's disease .	1:CID:2	R2L	CROSS	24-27	0-2	D016627	6 - hydroxydopamine	Chemical	24	27	1	D007172	Erectile dysfunction|erectile dysfunction|erectile dysfunction	Disease	0:116:128	2:118:130	0:6:6	1:NR:2	R2L	CROSS	37-38	0-2	D001058	apomorphine	Chemical	37	38	2	D007172	Erectile dysfunction|erectile dysfunction|erectile dysfunction	Disease	0:116:128	2:118:130	0:6:6	1:NR:2	R2L	CROSS	116-118	92-93	D004298	dopamine	Chemical	92	93	5	D007172	Erectile dysfunction|erectile dysfunction|erectile dysfunction	Disease	0:116:128	2:118:130	0:6:6	1:NR:2	L2R	CROSS	24-27	131-134	D016627	6 - hydroxydopamine	Chemical	24	27	1	D010300	Parkinson 's disease	Disease	131	134	6	1:NR:2	L2R	CROSS	37-38	131-134	D001058	apomorphine	Chemical	37	38	2	D010300	Parkinson 's disease	Disease	131	134	6	1:NR:2	L2R	CROSS	92-93	131-134	D004298	dopamine	Chemical	92	93	5	D010300	Parkinson 's disease	Disease	131	134	6
9270571	Potential therapeutic use of the selective dopamine D1 receptor agonist , A - 86929 : an acute study in parkinsonian levodopa - primed monkeys .|The clinical utility of dopamine ( DA ) D1 receptor agonists in the treatment of Parkinson 's disease ( PD ) is still unclear .|The therapeutic use of selective DA D1 receptor agonists such as SKF - 82958 ( 6 - chloro - 7 , 8 - dihydroxy - 3 - allyl - 1 - phenyl - 2 , 3 , 4 , 5 - tetrahydro - 1H - 3 - benzaze pine hydrobromide ) and A - 77636 ( [ 1R , 3S ] 3 - [ 1 ' - admantyl ] - 1 - aminomethyl - 3 , 4 - dihydro - 5 , 6 - dihydroxy - 1H - 2 - benzo pyran hydrochloride ) seems limited because of their duration of action , which is too short for SKF - 82958 ( < 1 hr ) and too long for A - 77636 ( > 20 hr , leading to behavioral tolerance ) .|We therefore conducted the present acute dose - response study in four 1 - methyl - 4 - phenyl - 1 , 2 , 3 , 6 - tetrahydropyridine ( MPTP ) - exposed cynomolgus monkeys primed to exhibit levodopa - induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses ( from 0 . 03 to 1 . 0 mg / kg ) of A - 86929 ( [ - ] - [ 5aR , 11bS ] - 4 , 5 , 5a , 6 , 7 , 11b - hexahydro - 2 - propyl - 3 - thia - 5 - + + + azacyclopent - 1 - ena [ c ] phenathrene - 9 - 10 - diol ) , a selective and full DA D1 - like receptor agonist with an intermediate duration of action .|Levodopa and the DA D2 - like receptor agonist , LY - 171555 ( [ 4aR - trans ] - 4 , 4a , 5 , 6 , 7 , 8 , 8a , 9 - o - dihydro - 5n - propyl - 2H - pyrazo lo - 3 - 4 - quinoline hydrochloride ) were also used for comparison .|Acute administration of A - 86929 was as efficacious in alleviating MPTP - induced parkinsonism as levodopa and LY - 171555 , but was less likely to reproduce the levodopa - induced dyskinesias in these animals than with either LY - 171555 or subsequent challenge of levodopa .|Selective stimulation of the DA D1 receptor may provide better integration of neural inputs transmitted to the internal segment of the globus pallidus ( referred to as the basal ganglia output ) compared with levodopa and selective DA D2 receptor agonist .|Potent DA D1 receptor agents with an intermediate duration of efficacy such as A - 86929 ( approximately 4 hr at higher doses tested ) are potential therapeutic tools in PD and merit further attention .	1:NR:2	L2R	NON-CROSS	19-20	29-30	D004298	dopamine|dopamine|DA|DA|DA|DA|DA|DA|DA	Chemical	6:29:31:55:315:331:442:475:481	7:30:32:56:316:332:443:476:482	0:1:1:2:3:4:6:6:7	D020734	parkinsonian|parkinsonism	Disease	19:404	20:405	0:5	1:NR:2	L2R	NON-CROSS	31-32	40-43	D004298	dopamine|dopamine|DA|DA|DA|DA|DA|DA|DA	Chemical	6:29:31:55:315:331:442:475:481	7:30:32:56:316:332:443:476:482	0:1:1:2:3:4:6:6:7	D010300	Parkinson 's disease|PD|PD	Disease	40:44:510	43:45:511	1:1:7	1:NR:2	L2R	NON-CROSS	422-423	442-443	D004298	dopamine|dopamine|DA|DA|DA|DA|DA|DA|DA	Chemical	6:29:31:55:315:331:442:475:481	7:30:32:56:316:332:443:476:482	0:1:1:2:3:4:6:6:7	D004409	dyskinesias|dyskinetic|dyskinesias	Disease	226:232:422	227:233:423	3:3:5	1:NR:2	L2R	NON-CROSS	11-14	19-20	C095427	A - 86929|A - 86929|[ - ] - [ 5aR , 11bS ] - 4 , 5 , 5a , 6 , 7 , 11b - hexahydro - 2 - propyl - 3 - thia - 5 - + + + azacyclopent - 1 - ena [ c ] phenathrene - 9 - 10 - diol|A - 86929|A - 86929	Chemical	11:253:257:393:493	14:256:309:396:496	0:3:3:5:7	D020734	parkinsonian|parkinsonism	Disease	19:404	20:405	0:5	1:NR:2	L2R	NON-CROSS	493-496	510-511	C095427	A - 86929|A - 86929|[ - ] - [ 5aR , 11bS ] - 4 , 5 , 5a , 6 , 7 , 11b - hexahydro - 2 - propyl - 3 - thia - 5 - + + + azacyclopent - 1 - ena [ c ] phenathrene - 9 - 10 - diol|A - 86929|A - 86929	Chemical	11:253:257:393:493	14:256:309:396:496	0:3:3:5:7	D010300	Parkinson 's disease|PD|PD	Disease	40:44:510	43:45:511	1:1:7	1:NR:2	L2R	NON-CROSS	232-233	253-256	C095427	A - 86929|A - 86929|[ - ] - [ 5aR , 11bS ] - 4 , 5 , 5a , 6 , 7 , 11b - hexahydro - 2 - propyl - 3 - thia - 5 - + + + azacyclopent - 1 - ena [ c ] phenathrene - 9 - 10 - diol|A - 86929|A - 86929	Chemical	11:253:257:393:493	14:256:309:396:496	0:3:3:5:7	D004409	dyskinesias|dyskinetic|dyskinesias	Disease	226:232:422	227:233:423	3:3:5	1:NR:2	R2L	NON-CROSS	20-21	19-20	D007980	levodopa|levodopa|Levodopa|levodopa|levodopa|levodopa|levodopa	Chemical	20:223:328:406:419:436:472	21:224:329:407:420:437:473	0:3:4:5:5:5:6	D020734	parkinsonian|parkinsonism	Disease	19:404	20:405	0:5	1:NR:2	R2L	CROSS	61-64	19-20	C071262	SKF - 82958|6 - chloro - 7 , 8 - dihydroxy - 3 - allyl - 1 - phenyl - 2 , 3 , 4 , 5 - tetrahydro - 1H - 3 - benzaze pine hydrobromide|SKF - 82958	Chemical	61:65:158	64:100:161	2:2:2	D020734	parkinsonian|parkinsonism	Disease	19:404	20:405	0:5	1:NR:2	R2L	CROSS	102-105	19-20	C079415	A - 77636|[ 1R , 3S ] 3 - [ 1 ' - admantyl ] - 1 - aminomethyl - 3 , 4 - dihydro - 5 , 6 - dihydroxy - 1H - 2 - benzo pyran hydrochloride|A - 77636	Chemical	102:106:170	105:143:173	2:2:2	D020734	parkinsonian|parkinsonism	Disease	19:404	20:405	0:5	1:CID:2	R2L	NON-CROSS	404-405	401-402	D015632	1 - methyl - 4 - phenyl - 1 , 2 , 3 , 6 - tetrahydropyridine|MPTP|MPTP	Chemical	196:214:401	213:215:402	3:3:5	D020734	parkinsonian|parkinsonism	Disease	19:404	20:405	0:5	1:NR:2	R2L	NON-CROSS	408-411	404-405	C416545	LY - 171555|[ 4aR - trans ] - 4 , 4a , 5 , 6 , 7 , 8 , 8a , 9 - o - dihydro - 5n - propyl - 2H - pyrazo lo - 3 - 4 - quinoline hydrochloride|LY - 171555|LY - 171555	Chemical	338:342:408:429	341:383:411:432	4:4:5:5	D020734	parkinsonian|parkinsonism	Disease	19:404	20:405	0:5	1:NR:2	L2R	CROSS	20-21	40-43	D007980	levodopa|levodopa|Levodopa|levodopa|levodopa|levodopa|levodopa	Chemical	20:223:328:406:419:436:472	21:224:329:407:420:437:473	0:3:4:5:5:5:6	D010300	Parkinson 's disease|PD|PD	Disease	40:44:510	43:45:511	1:1:7	1:CID:2	L2R	NON-CROSS	223-224	226-227	D007980	levodopa|levodopa|Levodopa|levodopa|levodopa|levodopa|levodopa	Chemical	20:223:328:406:419:436:472	21:224:329:407:420:437:473	0:3:4:5:5:5:6	D004409	dyskinesias|dyskinetic|dyskinesias	Disease	226:232:422	227:233:423	3:3:5	1:NR:2	R2L	CROSS	61-64	44-45	C071262	SKF - 82958|6 - chloro - 7 , 8 - dihydroxy - 3 - allyl - 1 - phenyl - 2 , 3 , 4 , 5 - tetrahydro - 1H - 3 - benzaze pine hydrobromide|SKF - 82958	Chemical	61:65:158	64:100:161	2:2:2	D010300	Parkinson 's disease|PD|PD	Disease	40:44:510	43:45:511	1:1:7	1:NR:2	R2L	CROSS	102-105	44-45	C079415	A - 77636|[ 1R , 3S ] 3 - [ 1 ' - admantyl ] - 1 - aminomethyl - 3 , 4 - dihydro - 5 , 6 - dihydroxy - 1H - 2 - benzo pyran hydrochloride|A - 77636	Chemical	102:106:170	105:143:173	2:2:2	D010300	Parkinson 's disease|PD|PD	Disease	40:44:510	43:45:511	1:1:7	1:NR:2	R2L	CROSS	510-511	401-402	D015632	1 - methyl - 4 - phenyl - 1 , 2 , 3 , 6 - tetrahydropyridine|MPTP|MPTP	Chemical	196:214:401	213:215:402	3:3:5	D010300	Parkinson 's disease|PD|PD	Disease	40:44:510	43:45:511	1:1:7	1:NR:2	R2L	CROSS	510-511	429-432	C416545	LY - 171555|[ 4aR - trans ] - 4 , 4a , 5 , 6 , 7 , 8 , 8a , 9 - o - dihydro - 5n - propyl - 2H - pyrazo lo - 3 - 4 - quinoline hydrochloride|LY - 171555|LY - 171555	Chemical	338:342:408:429	341:383:411:432	4:4:5:5	D010300	Parkinson 's disease|PD|PD	Disease	40:44:510	43:45:511	1:1:7	1:NR:2	L2R	CROSS	158-161	226-227	C071262	SKF - 82958|6 - chloro - 7 , 8 - dihydroxy - 3 - allyl - 1 - phenyl - 2 , 3 , 4 , 5 - tetrahydro - 1H - 3 - benzaze pine hydrobromide|SKF - 82958	Chemical	61:65:158	64:100:161	2:2:2	D004409	dyskinesias|dyskinetic|dyskinesias	Disease	226:232:422	227:233:423	3:3:5	1:NR:2	L2R	CROSS	170-173	226-227	C079415	A - 77636|[ 1R , 3S ] 3 - [ 1 ' - admantyl ] - 1 - aminomethyl - 3 , 4 - dihydro - 5 , 6 - dihydroxy - 1H - 2 - benzo pyran hydrochloride|A - 77636	Chemical	102:106:170	105:143:173	2:2:2	D004409	dyskinesias|dyskinetic|dyskinesias	Disease	226:232:422	227:233:423	3:3:5	1:NR:2	L2R	NON-CROSS	214-215	226-227	D015632	1 - methyl - 4 - phenyl - 1 , 2 , 3 , 6 - tetrahydropyridine|MPTP|MPTP	Chemical	196:214:401	213:215:402	3:3:5	D004409	dyskinesias|dyskinetic|dyskinesias	Disease	226:232:422	227:233:423	3:3:5	1:NR:2	R2L	NON-CROSS	429-432	422-423	C416545	LY - 171555|[ 4aR - trans ] - 4 , 4a , 5 , 6 , 7 , 8 , 8a , 9 - o - dihydro - 5n - propyl - 2H - pyrazo lo - 3 - 4 - quinoline hydrochloride|LY - 171555|LY - 171555	Chemical	338:342:408:429	341:383:411:432	4:4:5:5	D004409	dyskinesias|dyskinetic|dyskinesias	Disease	226:232:422	227:233:423	3:3:5
7189975	Deaths from local anesthetic - induced convulsions in mice .|Median convulsant ( CD50 ) and median lethal ( LD50 ) doses of three representative local anesthetics were determined in adult mice to evaluate the threat to life of local anesthetic - induced convulsions .|The CD50 and LD50 , respectively , were 57 . 7 and 58 . 7 mg / kg for bupivacaine , 111 . 0 and 133 . 1 mg / kg for lidocaine , and 243 . 4 and 266 . 5 mg / kg for chloroprocaine .|When given intraperitoneally , bupivacaine thus was only about twice as toxic as lidocaine and four times as toxic as chloroprocaine .|Convulsions always preceded death , except after precipitous cardiopulmonary arrest from extreme doses .|A CD50 dose of local anesthetic ( causing convulsions in 50 % of mice ) was fatal in 90 % of bupivacaine - induced seizures , in 57 % of the chloroprocaine group , and in 6 % of the lidocaine group .|The narrow gap between convulsant and lethal doses of local anesthetics indicates that untreated convulsions present much more of a threat to life than heretofore appreciated .	1:CID:2	R2L	NON-CROSS	153-154	150-151	D002045	bupivacaine|bupivacaine|bupivacaine	Chemical	64:97:150	65:98:151	2:3:5	D012640	convulsions|convulsions|Convulsions|convulsions|seizures|convulsions	Disease	6:43:115:137:153:186	7:44:116:138:154:187	0:1:4:5:5:6	1:CID:2	R2L	NON-CROSS	115-116	106-107	D008012	lidocaine|lidocaine|lidocaine	Chemical	77:106:169	78:107:170	2:3:5	D012640	convulsions|convulsions|Convulsions|convulsions|seizures|convulsions	Disease	6:43:115:137:153:186	7:44:116:138:154:187	0:1:4:5:5:6	1:CID:2	R2L	NON-CROSS	115-116	113-114	C004616	chloroprocaine|chloroprocaine|chloroprocaine	Chemical	91:113:160	92:114:161	2:3:5	D012640	convulsions|convulsions|Convulsions|convulsions|seizures|convulsions	Disease	6:43:115:137:153:186	7:44:116:138:154:187	0:1:4:5:5:6	1:NR:2	L2R	CROSS	97-98	123-125	D002045	bupivacaine|bupivacaine|bupivacaine	Chemical	64:97:150	65:98:151	2:3:5	D006323	cardiopulmonary arrest	Disease	123	125	4	1:NR:2	L2R	CROSS	106-107	123-125	D008012	lidocaine|lidocaine|lidocaine	Chemical	77:106:169	78:107:170	2:3:5	D006323	cardiopulmonary arrest	Disease	123	125	4	1:NR:2	L2R	CROSS	113-114	123-125	C004616	chloroprocaine|chloroprocaine|chloroprocaine	Chemical	91:113:160	92:114:161	2:3:5	D006323	cardiopulmonary arrest	Disease	123	125	4
6415512	Myoclonic , atonic , and absence seizures following institution of carbamazepine therapy in children .|Five children , aged 3 to 11 years , treated with carbamazepine for epilepsy , had an acute aberrant reaction characterized by the onset of myoclonic , atypical absence and / or atonic ( minor motor ) seizures within a few days .|When the carbamazepine was discontinued , two of the children returned to their former state very quickly , two had the minor motor seizures resolve in 3 and 6 months , and one had the seizures persist .|The child in whom the seizures persisted was later found to have ceroid lipofuscinosis .|The other children are doing well on other anticonvulsants .	1:CID:2	R2L	NON-CROSS	10-11	0-7	D002220	carbamazepine|carbamazepine|carbamazepine	Chemical	10:26:60	11:27:61	0:1:2	D004831	Myoclonic , atonic , and absence seizures|myoclonic , atypical absence and / or atonic ( minor motor ) seizures	Disease	0:40	7:53	0:1	1:CID:2	R2L	NON-CROSS	10-11	0-7	D002220	carbamazepine|carbamazepine|carbamazepine	Chemical	10:26:60	11:27:61	0:1:2	D004832	Myoclonic , atonic , and absence seizures|myoclonic , atypical absence and / or atonic ( minor motor ) seizures	Disease	0:40	7:53	0:1	1:NR:2	L2R	NON-CROSS	26-27	28-29	D002220	carbamazepine|carbamazepine|carbamazepine	Chemical	10:26:60	11:27:61	0:1:2	D004827	epilepsy	Disease	28	29	1	1:NR:2	L2R	NON-CROSS	60-61	81-82	D002220	carbamazepine|carbamazepine|carbamazepine	Chemical	10:26:60	11:27:61	0:1:2	D012640	seizures|seizures|seizures	Disease	81:93:101	82:94:102	2:2:3	1:NR:2	L2R	CROSS	60-61	108-110	D002220	carbamazepine|carbamazepine|carbamazepine	Chemical	10:26:60	11:27:61	0:1:2	D009472	ceroid lipofuscinosis	Disease	108	110	3
1928887	Naloxone reversal of hypotension due to captopril overdose .|The hemodynamic effects of captopril and other angiotensin - converting enzyme inhibitors may be mediated by the endogenous opioid system .|The opioid antagonist naloxone has been shown to block or reverse the hypotensive actions of captopril .|We report a case of an intentional captopril overdose , manifested by marked hypotension , that resolved promptly with the administration of naloxone .|To our knowledge , this is the first reported case of captopril - induced hypotension treated with naloxone .|Our experience demonstrates a possible role of naloxone in the reversal of hypotension resulting from captopril .	1:NR:2	L2R	NON-CROSS	0-1	3-4	D009270	Naloxone|naloxone|naloxone|naloxone|naloxone	Chemical	0:33:69:88:97	1:34:70:89:98	0:2:3:4:5	D007022	hypotension|hypotensive|hypotension|hypotension|hypotension	Disease	3:42:60:85:102	4:43:61:86:103	0:2:3:4:5	1:NR:2	L2R	NON-CROSS	0-1	7-8	D009270	Naloxone|naloxone|naloxone|naloxone|naloxone	Chemical	0:33:69:88:97	1:34:70:89:98	0:2:3:4:5	D062787	overdose|overdose	Disease	7:55	8:56	0:3	1:NR:2	R2L	NON-CROSS	6-7	3-4	D002216	captopril|captopril|captopril|captopril|captopril|captopril	Chemical	6:13:45:54:82:105	7:14:46:55:83:106	0:1:2:3:4:5	D007022	hypotension|hypotensive|hypotension|hypotension|hypotension	Disease	3:42:60:85:102	4:43:61:86:103	0:2:3:4:5	1:CID:2	R2L	CROSS	16-21	3-4	D000806	angiotensin - converting enzyme inhibitors	Chemical	16	21	1	D007022	hypotension|hypotensive|hypotension|hypotension|hypotension	Disease	3:42:60:85:102	4:43:61:86:103	0:2:3:4:5	1:NR:2	L2R	NON-CROSS	6-7	7-8	D002216	captopril|captopril|captopril|captopril|captopril|captopril	Chemical	6:13:45:54:82:105	7:14:46:55:83:106	0:1:2:3:4:5	D062787	overdose|overdose	Disease	7:55	8:56	0:3	1:CID:2	R2L	CROSS	16-21	7-8	D000806	angiotensin - converting enzyme inhibitors	Chemical	16	21	1	D062787	overdose|overdose	Disease	7:55	8:56	0:3
1728915	Carbamazepine - induced cardiac dysfunction .|Characterization of two distinct clinical syndromes .|A patient with sinus bradycardia and atrioventricular block , induced by carbamazepine , prompted an extensive literature review of all previously reported cases .|From the analysis of these cases , two distinct forms of carbamazepine - associated cardiac dysfunction emerged .|One patient group developed sinus tachycardias in the setting of a massive carbamazepine overdose .|The second group consisted almost exclusively of elderly women who developed potentially life - threatening bradyarrhythmias or atrioventricular conduction delay , associated with either therapeutic or modestly elevated carbamazepine serum levels .|Because carbamazepine is widely used in the treatment of many neurologic and psychiatric conditions , the recognition of the latter syndrome has important implications for the use of this drug in elderly patients .	1:NR:2	L2R	NON-CROSS	0-1	3-5	D002220	Carbamazepine|carbamazepine|carbamazepine|carbamazepine|carbamazepine|carbamazepine	Chemical	0:24:48:67:98:103	1:25:49:68:99:104	0:2:3:4:5:6	D006331	cardiac dysfunction|cardiac dysfunction	Disease	3:51	5:53	0:3	1:CID:2	L2R	NON-CROSS	17-18	24-25	D002220	Carbamazepine|carbamazepine|carbamazepine|carbamazepine|carbamazepine|carbamazepine	Chemical	0:24:48:67:98:103	1:25:49:68:99:104	0:2:3:4:5:6	D001919	bradycardia|bradyarrhythmias	Disease	17:85	18:86	2:5	1:CID:2	L2R	NON-CROSS	19-21	24-25	D002220	Carbamazepine|carbamazepine|carbamazepine|carbamazepine|carbamazepine|carbamazepine	Chemical	0:24:48:67:98:103	1:25:49:68:99:104	0:2:3:4:5:6	D054537	atrioventricular block|atrioventricular conduction delay	Disease	19:87	21:90	2:5	1:CID:2	L2R	NON-CROSS	59-61	67-68	D002220	Carbamazepine|carbamazepine|carbamazepine|carbamazepine|carbamazepine|carbamazepine	Chemical	0:24:48:67:98:103	1:25:49:68:99:104	0:2:3:4:5:6	D013616	sinus tachycardias	Disease	59	61	4	1:NR:2	L2R	NON-CROSS	67-68	68-69	D002220	Carbamazepine|carbamazepine|carbamazepine|carbamazepine|carbamazepine|carbamazepine	Chemical	0:24:48:67:98:103	1:25:49:68:99:104	0:2:3:4:5:6	D062787	overdose	Disease	68	69	4	1:NR:2	L2R	NON-CROSS	103-104	114-115	D002220	Carbamazepine|carbamazepine|carbamazepine|carbamazepine|carbamazepine|carbamazepine	Chemical	0:24:48:67:98:103	1:25:49:68:99:104	0:2:3:4:5:6	D001523	psychiatric	Disease	114	115	6
20558148	Glutamatergic neurotransmission mediated by NMDA receptors in the inferior colliculus can modulate haloperidol - induced catalepsy .|The inferior colliculus ( IC ) is primarily involved in the processing of auditory information , but it is distinguished from other auditory nuclei in the brainstem by its connections with structures of the motor system .|Functional evidence relating the IC to motor behavior derives from experiments showing that activation of the IC by electrical stimulation or excitatory amino acid microinjection causes freezing , escape - like behavior , and immobility .|However , the nature of this immobility is still unclear .|The present study examined the influence of excitatory amino acid - mediated mechanisms in the IC on the catalepsy induced by the dopamine receptor blocker haloperidol administered systemically ( 1 or 0 . 5 mg / kg ) in rats .|Haloperidol - induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists , MK - 801 ( 15 or 30 mmol / 0 . 5 microl ) and AP7 ( 10 or 20 nmol / 0 . 5 microl ) , or of the NMDA receptor agonist N - methyl - d - aspartate ( NMDA , 20 or 30 nmol / 0 . 5 microl ) .|The results showed that intracollicular microinjection of MK - 801 and AP7 previous to systemic injections of haloperidol significantly attenuated the catalepsy , as indicated by a reduced latency to step down from a horizontal bar .|Accordingly , intracollicular microinjection of NMDA increased the latency to step down the bar .|These findings suggest that glutamate - mediated mechanisms in the neural circuits at the IC level influence haloperidol - induced catalepsy and participate in the regulation of motor activity .	1:NR:2	L2R	NON-CROSS	145-146	154-155	D016202	NMDA|NMDA|NMDA|N - methyl - d - aspartate|NMDA|NMDA	Chemical	4:154:189:192:200:255	5:155:190:199:201:256	0:5:5:5:5:7	D002375	catalepsy|catalepsy|catalepsy|catalepsy|catalepsy	Disease	15:119:145:234:285	16:120:146:235:286	0:4:5:6:8	1:CID:2	L2R	NON-CROSS	12-13	15-16	D006220	haloperidol|haloperidol|Haloperidol|haloperidol|haloperidol	Chemical	12:126:142:230:282	13:127:143:231:283	0:4:5:6:8	D002375	catalepsy|catalepsy|catalepsy|catalepsy|catalepsy	Disease	15:119:145:234:285	16:120:146:235:286	0:4:5:6:8	1:NR:2	R2L	NON-CROSS	119-120	109-111	D000596	amino acid|amino acid	Chemical	76:109	78:111	2:4	D002375	catalepsy|catalepsy|catalepsy|catalepsy|catalepsy	Disease	15:119:145:234:285	16:120:146:235:286	0:4:5:6:8	1:NR:2	R2L	NON-CROSS	123-124	119-120	D004298	dopamine	Chemical	123	124	4	D002375	catalepsy|catalepsy|catalepsy|catalepsy|catalepsy	Disease	15:119:145:234:285	16:120:146:235:286	0:4:5:6:8	1:NR:2	R2L	NON-CROSS	153-154	145-146	D018698	glutamate|glutamate	Chemical	153:269	154:270	5:8	D002375	catalepsy|catalepsy|catalepsy|catalepsy|catalepsy	Disease	15:119:145:234:285	16:120:146:235:286	0:4:5:6:8	1:NR:2	R2L	NON-CROSS	234-235	220-223	D016291	MK - 801|MK - 801	Chemical	158:220	161:223	5:6	D002375	catalepsy|catalepsy|catalepsy|catalepsy|catalepsy	Disease	15:119:145:234:285	16:120:146:235:286	0:4:5:6:8	1:NR:2	R2L	NON-CROSS	234-235	224-225	C031231	AP7|AP7	Chemical	173:224	174:225	5:6	D002375	catalepsy|catalepsy|catalepsy|catalepsy|catalepsy	Disease	15:119:145:234:285	16:120:146:235:286	0:4:5:6:8
19940105	Metabotropic glutamate 7 receptor subtype modulates motor symptoms in rodent models of Parkinson 's disease .|Metabotropic glutamate ( mGlu ) receptors modulate synaptic transmission in the central nervous system and represent promising therapeutic targets for symptomatic treatment of Parkinson 's disease ( PD ) .|Among the eight mGlu receptor subtypes , mGlu7 receptor is prominently expressed in the basal ganglia , but its role in restoring motor function in animal models of PD is not known .|The effects of N , N ' - dibenzhydrylethane - 1 , 2 - diamine dihydrochloride ( AMN082 ) , the first selective allosteric activator of mGlu7 receptors , were thus tested in different rodent models of PD .|Here , we show that oral ( 5 mg / kg ) or intrastriatal administration ( 0 . 1 and 0 . 5 nmol ) of AMN082 reverses haloperidol - induced catalepsy in rats .|AMN082 ( 2 . 5 and 5 mg / kg ) reduces apomorphine - induced rotations in unilateral 6 - hydroxydopamine ( 6 - OHDA ) - lesioned rats .|In a more complex task commonly used to evaluate major akinetic symptoms of PD patients , 5 mg / kg AMN082 reverses the increased reaction time to respond to a cue of bilateral 6 - OHDA - lesioned rats .|In addition , AMN082 reduces the duration of haloperidol - induced catalepsy in a mGlu7 receptor - dependent manner in wild - type but not mGlu7 receptor knockout mice .|Higher doses of AMN082 ( 10 and 20 mg / kg p . o . ) have no effect on the same models of PD .|Overall these findings suggest that mGlu7 receptor activation can reverse motor dysfunction associated with reduced dopamine activity .|Selective ligands of mGlu7 receptor subtypes may thus be considered as promising compounds for the development of antiparkinsonian therapeutic strategies .	1:NR:2	L2R	NON-CROSS	12-15	17-18	D018698	glutamate|glutamate	Chemical	1:17	2:18	0:1	D010300	Parkinson 's disease|Parkinson 's disease|PD|PD|PD|PD|PD	Disease	12:39:43:74:116:196:277	15:42:44:75:117:197:278	0:1:1:2:3:6:8	1:NR:2	L2R	CROSS	17-18	149-150	D018698	glutamate|glutamate	Chemical	1:17	2:18	0:1	D002375	catalepsy|catalepsy	Disease	149:234	150:235	4:7	1:NR:2	L2R	CROSS	17-18	193-194	D018698	glutamate|glutamate	Chemical	1:17	2:18	0:1	D018476	akinetic	Disease	193	194	6	1:NR:2	R2L	NON-CROSS	203-204	196-197	C507346	N , N ' - dibenzhydrylethane - 1 , 2 - diamine dihydrochloride|AMN082|AMN082|AMN082|AMN082|AMN082|AMN082	Chemical	82:96:144:153:203:226:256	95:97:145:154:204:227:257	3:3:4:5:6:7:8	D010300	Parkinson 's disease|Parkinson 's disease|PD|PD|PD|PD|PD	Disease	12:39:43:74:116:196:277	15:42:44:75:117:197:278	0:1:1:2:3:6:8	1:NR:2	R2L	CROSS	146-147	116-117	D006220	haloperidol|haloperidol	Chemical	146:231	147:232	4:7	D010300	Parkinson 's disease|Parkinson 's disease|PD|PD|PD|PD|PD	Disease	12:39:43:74:116:196:277	15:42:44:75:117:197:278	0:1:1:2:3:6:8	1:NR:2	R2L	CROSS	196-197	165-166	D001058	apomorphine	Chemical	165	166	5	D010300	Parkinson 's disease|Parkinson 's disease|PD|PD|PD|PD|PD	Disease	12:39:43:74:116:196:277	15:42:44:75:117:197:278	0:1:1:2:3:6:8	1:NR:2	R2L	NON-CROSS	216-219	196-197	D016627	6 - hydroxydopamine|6 - OHDA|6 - OHDA	Chemical	171:175:216	174:178:219	5:5:6	D010300	Parkinson 's disease|Parkinson 's disease|PD|PD|PD|PD|PD	Disease	12:39:43:74:116:196:277	15:42:44:75:117:197:278	0:1:1:2:3:6:8	1:NR:2	R2L	CROSS	294-295	277-278	D004298	dopamine	Chemical	294	295	9	D010300	Parkinson 's disease|Parkinson 's disease|PD|PD|PD|PD|PD	Disease	12:39:43:74:116:196:277	15:42:44:75:117:197:278	0:1:1:2:3:6:8	1:NR:2	L2R	NON-CROSS	149-150	153-154	C507346	N , N ' - dibenzhydrylethane - 1 , 2 - diamine dihydrochloride|AMN082|AMN082|AMN082|AMN082|AMN082|AMN082	Chemical	82:96:144:153:203:226:256	95:97:145:154:204:227:257	3:3:4:5:6:7:8	D002375	catalepsy|catalepsy	Disease	149:234	150:235	4:7	1:NR:2	L2R	NON-CROSS	193-194	203-204	C507346	N , N ' - dibenzhydrylethane - 1 , 2 - diamine dihydrochloride|AMN082|AMN082|AMN082|AMN082|AMN082|AMN082	Chemical	82:96:144:153:203:226:256	95:97:145:154:204:227:257	3:3:4:5:6:7:8	D018476	akinetic	Disease	193	194	6	1:CID:2	L2R	NON-CROSS	146-147	149-150	D006220	haloperidol|haloperidol	Chemical	146:231	147:232	4:7	D002375	catalepsy|catalepsy	Disease	149:234	150:235	4:7	1:NR:2	L2R	CROSS	193-194	231-232	D006220	haloperidol|haloperidol	Chemical	146:231	147:232	4:7	D018476	akinetic	Disease	193	194	6	1:NR:2	R2L	CROSS	165-166	149-150	D001058	apomorphine	Chemical	165	166	5	D002375	catalepsy|catalepsy	Disease	149:234	150:235	4:7	1:NR:2	R2L	CROSS	234-235	216-219	D016627	6 - hydroxydopamine|6 - OHDA|6 - OHDA	Chemical	171:175:216	174:178:219	5:5:6	D002375	catalepsy|catalepsy	Disease	149:234	150:235	4:7	1:NR:2	R2L	CROSS	294-295	234-235	D004298	dopamine	Chemical	294	295	9	D002375	catalepsy|catalepsy	Disease	149:234	150:235	4:7	1:NR:2	L2R	CROSS	165-166	193-194	D001058	apomorphine	Chemical	165	166	5	D018476	akinetic	Disease	193	194	6	1:NR:2	L2R	NON-CROSS	175-178	193-194	D016627	6 - hydroxydopamine|6 - OHDA|6 - OHDA	Chemical	171:175:216	174:178:219	5:5:6	D018476	akinetic	Disease	193	194	6	1:NR:2	R2L	CROSS	294-295	193-194	D004298	dopamine	Chemical	294	295	9	D018476	akinetic	Disease	193	194	6
19923525	Nimodipine prevents memory impairment caused by nitroglycerin - induced hypotension in adult mice .|BACKGROUND : Hypotension and a resultant decrease in cerebral blood flow have been implicated in the development of cognitive dysfunction .|We tested the hypothesis that nimodipine ( NIMO ) administered at the onset of nitroglycerin ( NTG ) - induced hypotension would preserve long - term associative memory .|METHODS : The passive avoidance ( PA ) paradigm was used to assess memory retention .|For PA training , latencies ( seconds ) were recorded for entry from a suspended platform into a Plexiglas tube where a shock was automatically delivered .|Latencies were recorded 48 h later for a testing trial .|Ninety - six Swiss - Webster mice ( 30 - 35 g , 6 - 8 wk ) , were randomized into 6 groups 1 ) saline ( control ) , 2 ) NTG immediately after learning , 3 ) NTG 3 h after learning , 4 ) NTG and NIMO , 5 ) vehicle , and 6 ) NIMO alone .|The extent of hypotension and changes in brain tissue oxygenation ( PbtO ( 2 ) ) and in cerebral blood flow were studied in a separate group of animals .|RESULTS : All groups exhibited similar training latencies ( 17 . 0 + / - 4 . 6 s ) .|Mice subjected to hypotensive episodes showed a significant decrease in latency time ( 178 + / - 156 s ) compared with those injected with saline , NTG + NIMO , or delayed NTG ( 580 + / - 81 s , 557 + / - 67 s , and 493 + / - 146 s , respectively ) .|A Kruskal - Wallis 1 - way analysis of variance indicated a significant difference among the 4 treatment groups ( H = 15 . 34 ; P < 0 . 001 ) .|In a separate group of mice not subjected to behavioral studies , the same dose of NTG ( n = 3 ) and NTG + NIMO ( n = 3 ) caused mean arterial blood pressure to decrease from 85 . 9 + / - 3 . 8 mm Hg sem to 31 . 6 + / - 0 . 8 mm Hg sem and from 86 . 2 + / - 3 . 7 mm Hg sem to 32 . 6 + / - 0 . 2 mm Hg sem , respectively .|Mean arterial blood pressure in mice treated with NIMO alone decreased from 88 . 1 + / - 3 . 8 mm Hg to 80 . 0 + / - 2 . 9 mm Hg .|The intergroup difference was statistically significant ( P < 0 . 05 ) .|PbtO ( 2 ) decreased from 51 . 7 + / - 4 . 5 mm Hg sem to 33 . 8 + / - 5 . 2 mm Hg sem in the NTG group and from 38 . 6 + / - 6 . 1 mm Hg sem to 25 . 4 + / - 2 . 0 mm Hg sem in the NTG + NIMO groups , respectively .|There were no significant differences among groups .|CONCLUSION : In a PA retention paradigm , the injection of NTG immediately after learning produced a significant impairment of long - term associative memory in mice , whereas delayed induced hypotension had no effect .|NIMO attenuated the disruption in consolidation of long - term memory caused by NTG but did not improve latency in the absence of hypotension .|The observed effect of NIMO may have been attributable to the preservation of calcium homeostasis during hypotension , because there were no differences in the PbtO ( 2 ) indices among groups .	1:NR:2	L2R	NON-CROSS	0-1	2-4	D009553	Nimodipine|nimodipine|NIMO|NIMO|NIMO|NIMO|NIMO|NIMO|NIMO|NIMO|NIMO	Chemical	0:40:42:168:177:260:349:426:534:583:612	1:41:43:169:178:261:350:427:535:584:613	0:2:2:6:6:9:11:12:14:17:18	D008569	memory impairment	Disease	2	4	0	1:NR:2	L2R	NON-CROSS	578-579	583-584	D009553	Nimodipine|nimodipine|NIMO|NIMO|NIMO|NIMO|NIMO|NIMO|NIMO|NIMO|NIMO	Chemical	0:40:42:168:177:260:349:426:534:583:612	1:41:43:169:178:261:350:427:535:584:613	0:2:2:6:6:9:11:12:14:17:18	D007022	hypotension|Hypotension|hypotension|hypotension|hypotensive|hypotension|hypotension|hypotension	Disease	9:16:55:183:234:578:606:624	10:17:56:184:235:579:607:625	0:1:2:7:9:16:17:18	1:NR:2	L2R	CROSS	32-34	40-41	D009553	Nimodipine|nimodipine|NIMO|NIMO|NIMO|NIMO|NIMO|NIMO|NIMO|NIMO|NIMO	Chemical	0:40:42:168:177:260:349:426:534:583:612	1:41:43:169:178:261:350:427:535:584:613	0:2:2:6:6:9:11:12:14:17:18	D003072	cognitive dysfunction	Disease	32	34	1	1:CID:2	R2L	NON-CROSS	6-7	2-4	D005996	nitroglycerin|nitroglycerin|NTG|NTG|NTG|NTG|NTG|NTG|NTG|NTG|NTG|NTG|NTG|NTG	Chemical	6:49:51:151:158:166:258:264:340:347:501:532:558:596	7:50:52:152:159:167:259:265:341:348:502:533:559:597	0:2:2:6:6:6:9:9:11:11:14:14:16:17	D008569	memory impairment	Disease	2	4	0	1:NR:2	R2L	CROSS	621-622	2-4	D002118	calcium	Chemical	621	622	18	D008569	memory impairment	Disease	2	4	0	1:CID:2	L2R	NON-CROSS	6-7	9-10	D005996	nitroglycerin|nitroglycerin|NTG|NTG|NTG|NTG|NTG|NTG|NTG|NTG|NTG|NTG|NTG|NTG	Chemical	6:49:51:151:158:166:258:264:340:347:501:532:558:596	7:50:52:152:159:167:259:265:341:348:502:533:559:597	0:2:2:6:6:6:9:9:11:11:14:14:16:17	D007022	hypotension|Hypotension|hypotension|hypotension|hypotensive|hypotension|hypotension|hypotension	Disease	9:16:55:183:234:578:606:624	10:17:56:184:235:579:607:625	0:1:2:7:9:16:17:18	1:NR:2	L2R	CROSS	32-34	49-50	D005996	nitroglycerin|nitroglycerin|NTG|NTG|NTG|NTG|NTG|NTG|NTG|NTG|NTG|NTG|NTG|NTG	Chemical	6:49:51:151:158:166:258:264:340:347:501:532:558:596	7:50:52:152:159:167:259:265:341:348:502:533:559:597	0:2:2:6:6:6:9:9:11:11:14:14:16:17	D003072	cognitive dysfunction	Disease	32	34	1	1:NR:2	R2L	NON-CROSS	624-625	621-622	D002118	calcium	Chemical	621	622	18	D007022	hypotension|Hypotension|hypotension|hypotension|hypotensive|hypotension|hypotension|hypotension	Disease	9:16:55:183:234:578:606:624	10:17:56:184:235:579:607:625	0:1:2:7:9:16:17:18	1:NR:2	R2L	CROSS	621-622	32-34	D002118	calcium	Chemical	621	622	18	D003072	cognitive dysfunction	Disease	32	34	1
19058474	Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin .|We report a case of fatal internal haemorrhage in an elderly man who consumed only cranberry juice for two weeks while maintaining his usual dosage of warfarin .|We propose that naturally occurring compounds such as flavonoids , which are present in fruit juices , may increase the potency of warfarin by competing for the enzymes that normally inactivate warfarin .|While traditionally regarded as foodstuffs , consumption of fruit juices should be considered when patients develop adverse drug reactions .	1:NR:2	R2L	NON-CROSS	13-14	1-2	D014859	warfarin|warfarin|warfarin|warfarin	Chemical	13:41:65:74	14:42:66:75	0:1:2:2	D010490	haemopericardium	Disease	1	2	0	1:NR:2	R2L	CROSS	51-52	1-2	D005419	flavonoids	Chemical	51	52	2	D010490	haemopericardium	Disease	1	2	0	1:CID:2	R2L	NON-CROSS	13-14	3-5	D014859	warfarin|warfarin|warfarin|warfarin	Chemical	13:41:65:74	14:42:66:75	0:1:2:2	D006471	gastrointestinal haemorrhage	Disease	3	5	0	1:CID:2	R2L	CROSS	51-52	3-5	D005419	flavonoids	Chemical	51	52	2	D006471	gastrointestinal haemorrhage	Disease	3	5	0	1:NR:2	L2R	NON-CROSS	13-14	22-23	D014859	warfarin|warfarin|warfarin|warfarin	Chemical	13:41:65:74	14:42:66:75	0:1:2:2	D006470	haemorrhage	Disease	22	23	1	1:NR:2	R2L	CROSS	51-52	22-23	D005419	flavonoids	Chemical	51	52	2	D006470	haemorrhage	Disease	22	23	1
18808529	Isoproterenol induces primary loss of dystrophin in rat hearts : correlation with myocardial injury .|The mechanism of isoproterenol - induced myocardial damage is unknown , but a mismatch of oxygen supply vs . demand following coronary hypotension and myocardial hyperactivity is the best explanation for the complex morphological alterations observed .|Severe alterations in the structural integrity of the sarcolemma of cardiomyocytes have been demonstrated to be caused by isoproterenol .|Taking into account that the sarcolemmal integrity is stabilized by the dystrophin - glycoprotein complex ( DGC ) that connects actin and laminin in contractile machinery and extracellular matrix and by integrins , this study tests the hypothesis that isoproterenol affects sarcolemmal stability through changes in the DGC and integrins .|We found different sensitivity of the DGC and integrin to isoproterenol subcutaneous administration .|Immunofluorescent staining revealed that dystrophin is the most sensitive among the structures connecting the actin in the cardiomyocyte cytoskeleton and the extracellular matrix .|The sarcomeric actin dissolution occurred after the reduction or loss of dystrophin .|Subsequently , after lysis of myofilaments , gamma - sarcoglycan , beta - dystroglycan , beta1 - integrin , and laminin alpha - 2 expressions were reduced followed by their breakdown , as epiphenomena of the myocytolytic process .|In conclusion , administration of isoproterenol to rats results in primary loss of dystrophin , the most sensitive among the structural proteins that form the DGC that connects the extracellular matrix and the cytoskeleton in cardiomyocyte .|These changes , related to ischaemic injury , explain the severe alterations in the structural integrity of the sarcolemma of cardiomyocytes and hence severe and irreversible injury induced by isoproterenol .	1:CID:2	L2R	NON-CROSS	18-19	21-23	D007545	Isoproterenol|isoproterenol|isoproterenol|isoproterenol|isoproterenol|isoproterenol|isoproterenol	Chemical	0:18:70:111:133:218:279	1:19:71:112:134:219:280	0:1:2:3:4:8:9	D009202	myocardial injury|myocardial damage|myocardial hyperactivity	Disease	12:21:39	14:23:41	0:1:1	1:NR:2	L2R	NON-CROSS	18-19	37-38	D007545	Isoproterenol|isoproterenol|isoproterenol|isoproterenol|isoproterenol|isoproterenol|isoproterenol	Chemical	0:18:70:111:133:218:279	1:19:71:112:134:219:280	0:1:2:3:4:8:9	D007022	hypotension	Disease	37	38	1	1:CID:2	L2R	NON-CROSS	255-257	279-280	D007545	Isoproterenol|isoproterenol|isoproterenol|isoproterenol|isoproterenol|isoproterenol|isoproterenol	Chemical	0:18:70:111:133:218:279	1:19:71:112:134:219:280	0:1:2:3:4:8:9	D007511	ischaemic injury	Disease	255	257	9	1:NR:2	R2L	NON-CROSS	30-31	21-23	D010100	oxygen	Chemical	30	31	1	D009202	myocardial injury|myocardial damage|myocardial hyperactivity	Disease	12:21:39	14:23:41	0:1:1	1:NR:2	L2R	NON-CROSS	30-31	37-38	D010100	oxygen	Chemical	30	31	1	D007022	hypotension	Disease	37	38	1	1:NR:2	L2R	CROSS	30-31	255-257	D010100	oxygen	Chemical	30	31	1	D007511	ischaemic injury	Disease	255	257	9
18674790	High fat diet - fed obese rats are highly sensitive to doxorubicin - induced cardiotoxicity .|Often , chemotherapy by doxorubicin ( Adriamycin ) is limited due to life threatening cardiotoxicity in patients during and posttherapy .|Recently , we have shown that moderate diet restriction remarkably protects against doxorubicin - induced cardiotoxicity .|This cardioprotection is accompanied by decreased cardiac oxidative stress and triglycerides and increased cardiac fatty - acid oxidation , ATP synthesis , and upregulated JAK / STAT3 pathway .|In the current study , we investigated whether a physiological intervention by feeding 40 % high fat diet ( HFD ) , which induces obesity in male Sprague - Dawley rats ( 250 - 275 g ) , sensitizes to doxorubicin - induced cardiotoxicity .|A LD ( 10 ) dose ( 8 mg doxorubicin / kg , ip ) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity , cardiac dysfunction , lipid peroxidation , and 80 % mortality in the obese ( OB ) rats in the absence of any significant renal or hepatic toxicity .|Doxorubicin toxicokinetics studies revealed no change in accumulation of doxorubicin and doxorubicinol ( toxic metabolite ) in the normal diet - fed ( ND ) and OB hearts .|Mechanistic studies revealed that OB rats are sensitized due to : ( 1 ) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3 , ( 2 ) downregulation of cardiac peroxisome proliferators activated receptor - alpha , ( 3 ) decreased plasma adiponectin levels , ( 4 ) decreased cardiac fatty - acid oxidation ( 666 . 9 + / - 14 . 0 nmol / min / g heart in ND versus 400 . 2 + / - 11 . 8 nmol / min / g heart in OB ) , ( 5 ) decreased mitochondrial AMP - alpha2 protein kinase , and ( 6 ) 86 % drop in cardiac ATP levels accompanied by decreased ATP / ADP ratio after doxorubicin administration .|Decreased cardiac erythropoietin and increased SOCS3 further downregulated the cardioprotective JAK / STAT3 pathway .|In conclusion , HFD - induced obese rats are highly sensitized to doxorubicin - induced cardiotoxicity by substantially downregulating cardiac mitochondrial ATP generation , increasing oxidative stress and downregulating the JAK / STAT3 pathway .	1:CID:2	L2R	NON-CROSS	1-2	5-6	D004041	fat|fat	Chemical	1:99	2:100	0:4	D009765	obese|obesity|obese|OB|OB|OB|OB|obese	Disease	5:107:169:171:211:218:306:363	6:108:170:172:212:219:307:364	0:4:5:5:6:7:7:9	1:NR:2	L2R	NON-CROSS	1-2	14-15	D004041	fat|fat	Chemical	1:99	2:100	0:4	D066126	cardiotoxicity|cardiotoxicity|cardiotoxicity|cardiotoxicity|cardiotoxicity|cardiotoxicity	Disease	14:30:52:126:155:372	15:31:53:127:156:373	0:1:2:4:5:9	1:NR:2	L2R	CROSS	99-100	157-159	D004041	fat|fat	Chemical	1:99	2:100	0:4	D006331	cardiac dysfunction	Disease	157	159	5	1:NR:2	L2R	CROSS	99-100	180-184	D004041	fat|fat	Chemical	1:99	2:100	0:4	D007674	renal or hepatic toxicity	Disease	180	184	5	1:NR:2	L2R	CROSS	99-100	180-184	D004041	fat|fat	Chemical	1:99	2:100	0:4	D056486	renal or hepatic toxicity	Disease	180	184	5	1:NR:2	R2L	NON-CROSS	11-12	5-6	D004317	doxorubicin|doxorubicin|Adriamycin|doxorubicin|doxorubicin|doxorubicin|Doxorubicin|doxorubicin|doxorubicin|doxorubicin	Chemical	11:20:22:49:123:137:185:194:339:369	12:21:23:50:124:138:186:195:340:370	0:1:1:2:4:5:6:6:7:9	D009765	obese|obesity|obese|OB|OB|OB|OB|obese	Disease	5:107:169:171:211:218:306:363	6:108:170:172:212:219:307:364	0:4:5:5:6:7:7:9	1:NR:2	R2L	CROSS	107-108	64-65	D014280	triglycerides	Chemical	64	65	3	D009765	obese|obesity|obese|OB|OB|OB|OB|obese	Disease	5:107:169:171:211:218:306:363	6:108:170:172:212:219:307:364	0:4:5:5:6:7:7:9	1:NR:2	R2L	NON-CROSS	378-379	363-364	D000255	ATP|ATP|ATP|ATP	Chemical	73:329:334:378	74:330:335:379	3:7:7:9	D009765	obese|obesity|obese|OB|OB|OB|OB|obese	Disease	5:107:169:171:211:218:306:363	6:108:170:172:212:219:307:364	0:4:5:5:6:7:7:9	1:NR:2	R2L	NON-CROSS	211-212	196-197	C010013	doxorubicinol	Chemical	196	197	6	D009765	obese|obesity|obese|OB|OB|OB|OB|obese	Disease	5:107:169:171:211:218:306:363	6:108:170:172:212:219:307:364	0:4:5:5:6:7:7:9	1:NR:2	R2L	NON-CROSS	314-315	306-307	D000249	AMP	Chemical	314	315	7	D009765	obese|obesity|obese|OB|OB|OB|OB|obese	Disease	5:107:169:171:211:218:306:363	6:108:170:172:212:219:307:364	0:4:5:5:6:7:7:9	1:NR:2	R2L	NON-CROSS	363-364	336-337	D000244	ADP	Chemical	336	337	7	D009765	obese|obesity|obese|OB|OB|OB|OB|obese	Disease	5:107:169:171:211:218:306:363	6:108:170:172:212:219:307:364	0:4:5:5:6:7:7:9	1:NR:2	L2R	NON-CROSS	11-12	14-15	D004317	doxorubicin|doxorubicin|Adriamycin|doxorubicin|doxorubicin|doxorubicin|Doxorubicin|doxorubicin|doxorubicin|doxorubicin	Chemical	11:20:22:49:123:137:185:194:339:369	12:21:23:50:124:138:186:195:340:370	0:1:1:2:4:5:6:6:7:9	D066126	cardiotoxicity|cardiotoxicity|cardiotoxicity|cardiotoxicity|cardiotoxicity|cardiotoxicity	Disease	14:30:52:126:155:372	15:31:53:127:156:373	0:1:2:4:5:9	1:CID:2	L2R	NON-CROSS	137-138	157-159	D004317	doxorubicin|doxorubicin|Adriamycin|doxorubicin|doxorubicin|doxorubicin|Doxorubicin|doxorubicin|doxorubicin|doxorubicin	Chemical	11:20:22:49:123:137:185:194:339:369	12:21:23:50:124:138:186:195:340:370	0:1:1:2:4:5:6:6:7:9	D006331	cardiac dysfunction	Disease	157	159	5	1:NR:2	L2R	NON-CROSS	180-184	185-186	D004317	doxorubicin|doxorubicin|Adriamycin|doxorubicin|doxorubicin|doxorubicin|Doxorubicin|doxorubicin|doxorubicin|doxorubicin	Chemical	11:20:22:49:123:137:185:194:339:369	12:21:23:50:124:138:186:195:340:370	0:1:1:2:4:5:6:6:7:9	D007674	renal or hepatic toxicity	Disease	180	184	5	1:NR:2	L2R	NON-CROSS	180-184	185-186	D004317	doxorubicin|doxorubicin|Adriamycin|doxorubicin|doxorubicin|doxorubicin|Doxorubicin|doxorubicin|doxorubicin|doxorubicin	Chemical	11:20:22:49:123:137:185:194:339:369	12:21:23:50:124:138:186:195:340:370	0:1:1:2:4:5:6:6:7:9	D056486	renal or hepatic toxicity	Disease	180	184	5	1:NR:2	R2L	CROSS	64-65	52-53	D014280	triglycerides	Chemical	64	65	3	D066126	cardiotoxicity|cardiotoxicity|cardiotoxicity|cardiotoxicity|cardiotoxicity|cardiotoxicity	Disease	14:30:52:126:155:372	15:31:53:127:156:373	0:1:2:4:5:9	1:NR:2	R2L	NON-CROSS	378-379	372-373	D000255	ATP|ATP|ATP|ATP	Chemical	73:329:334:378	74:330:335:379	3:7:7:9	D066126	cardiotoxicity|cardiotoxicity|cardiotoxicity|cardiotoxicity|cardiotoxicity|cardiotoxicity	Disease	14:30:52:126:155:372	15:31:53:127:156:373	0:1:2:4:5:9	1:NR:2	R2L	CROSS	196-197	155-156	C010013	doxorubicinol	Chemical	196	197	6	D066126	cardiotoxicity|cardiotoxicity|cardiotoxicity|cardiotoxicity|cardiotoxicity|cardiotoxicity	Disease	14:30:52:126:155:372	15:31:53:127:156:373	0:1:2:4:5:9	1:NR:2	R2L	CROSS	372-373	314-315	D000249	AMP	Chemical	314	315	7	D066126	cardiotoxicity|cardiotoxicity|cardiotoxicity|cardiotoxicity|cardiotoxicity|cardiotoxicity	Disease	14:30:52:126:155:372	15:31:53:127:156:373	0:1:2:4:5:9	1:NR:2	R2L	CROSS	372-373	336-337	D000244	ADP	Chemical	336	337	7	D066126	cardiotoxicity|cardiotoxicity|cardiotoxicity|cardiotoxicity|cardiotoxicity|cardiotoxicity	Disease	14:30:52:126:155:372	15:31:53:127:156:373	0:1:2:4:5:9	1:NR:2	L2R	CROSS	64-65	157-159	D014280	triglycerides	Chemical	64	65	3	D006331	cardiac dysfunction	Disease	157	159	5	1:NR:2	L2R	CROSS	64-65	180-184	D014280	triglycerides	Chemical	64	65	3	D007674	renal or hepatic toxicity	Disease	180	184	5	1:NR:2	L2R	CROSS	64-65	180-184	D014280	triglycerides	Chemical	64	65	3	D056486	renal or hepatic toxicity	Disease	180	184	5	1:NR:2	L2R	CROSS	73-74	157-159	D000255	ATP|ATP|ATP|ATP	Chemical	73:329:334:378	74:330:335:379	3:7:7:9	D006331	cardiac dysfunction	Disease	157	159	5	1:NR:2	L2R	CROSS	73-74	180-184	D000255	ATP|ATP|ATP|ATP	Chemical	73:329:334:378	74:330:335:379	3:7:7:9	D007674	renal or hepatic toxicity	Disease	180	184	5	1:NR:2	L2R	CROSS	73-74	180-184	D000255	ATP|ATP|ATP|ATP	Chemical	73:329:334:378	74:330:335:379	3:7:7:9	D056486	renal or hepatic toxicity	Disease	180	184	5	1:NR:2	R2L	CROSS	196-197	157-159	C010013	doxorubicinol	Chemical	196	197	6	D006331	cardiac dysfunction	Disease	157	159	5	1:NR:2	R2L	CROSS	314-315	157-159	D000249	AMP	Chemical	314	315	7	D006331	cardiac dysfunction	Disease	157	159	5	1:NR:2	R2L	CROSS	336-337	157-159	D000244	ADP	Chemical	336	337	7	D006331	cardiac dysfunction	Disease	157	159	5	1:NR:2	R2L	CROSS	196-197	180-184	C010013	doxorubicinol	Chemical	196	197	6	D007674	renal or hepatic toxicity	Disease	180	184	5	1:NR:2	R2L	CROSS	314-315	180-184	D000249	AMP	Chemical	314	315	7	D007674	renal or hepatic toxicity	Disease	180	184	5	1:NR:2	R2L	CROSS	336-337	180-184	D000244	ADP	Chemical	336	337	7	D007674	renal or hepatic toxicity	Disease	180	184	5	1:NR:2	R2L	CROSS	196-197	180-184	C010013	doxorubicinol	Chemical	196	197	6	D056486	renal or hepatic toxicity	Disease	180	184	5	1:NR:2	R2L	CROSS	314-315	180-184	D000249	AMP	Chemical	314	315	7	D056486	renal or hepatic toxicity	Disease	180	184	5	1:NR:2	R2L	CROSS	336-337	180-184	D000244	ADP	Chemical	336	337	7	D056486	renal or hepatic toxicity	Disease	180	184	5
18441470	Complete atrioventricular block secondary to lithium therapy .|Sinus node dysfunction has been reported most frequently among the adverse cardiovascular effects of lithium .|In the present case , complete atrioventricular ( AV ) block with syncopal attacks developed secondary to lithium therapy , necessitating permanent pacemaker implantation .|Serum lithium levels remained under or within the therapeutic range during the syncopal attacks .|Lithium should be used with extreme caution , especially in patients with mild disturbance of AV conduction .	1:CID:2	R2L	NON-CROSS	5-6	1-3	D008094	lithium|lithium|lithium|lithium|Lithium	Chemical	5:22:41:50:64	6:23:42:51:65	0:1:2:3:4	D054537	atrioventricular block|atrioventricular ( AV ) block	Disease	1:30	3:35	0:2	1:CID:2	L2R	NON-CROSS	5-6	8-11	D008094	lithium|lithium|lithium|lithium|Lithium	Chemical	5:22:41:50:64	6:23:42:51:65	0:1:2:3:4	D012804	Sinus node dysfunction	Disease	8	11	1	1:NR:2	L2R	NON-CROSS	61-63	64-65	D008094	lithium|lithium|lithium|lithium|Lithium	Chemical	5:22:41:50:64	6:23:42:51:65	0:1:2:3:4	D013575	syncopal attacks|syncopal attacks	Disease	36:61	38:63	2:3
17366349	Neuroleptic malignant syndrome induced by ziprasidone on the second day of treatment .|Neuroleptic malignant syndrome ( NMS ) is the rarest and most serious of the neuroleptic - induced movement disorders .|We describe a case of neuroleptic malignant syndrome ( NMS ) associated with the use of ziprasidone .|Although conventional neuroleptics are more frequently associated with NMS , atypical antipsychotic drugs like ziprasidone may also be a cause .|The patient is a 24 - year - old male with a history of schizophrenia who developed signs and symptoms of NMS after 2 days of treatment with an 80 - mg / day dose of orally administrated ziprasidone .|This case is the earliest ( second day of treatment ) NMS due to ziprasidone reported in the literature .	1:CID:2	R2L	NON-CROSS	5-6	0-3	C092292	ziprasidone|ziprasidone|ziprasidone|ziprasidone|ziprasidone	Chemical	5:49:65:110:126	6:50:66:111:127	0:2:3:4:5	D009459	Neuroleptic malignant syndrome|Neuroleptic malignant syndrome|NMS|neuroleptic malignant syndrome|NMS|NMS|NMS|NMS	Disease	0:13:17:38:42:59:93:123	3:16:18:41:43:60:94:124	0:1:1:2:2:3:4:5	1:NR:2	L2R	CROSS	30-32	49-50	C092292	ziprasidone|ziprasidone|ziprasidone|ziprasidone|ziprasidone	Chemical	5:49:65:110:126	6:50:66:111:127	0:2:3:4:5	D009069	movement disorders	Disease	30	32	1	1:NR:2	L2R	NON-CROSS	65-66	86-87	C092292	ziprasidone|ziprasidone|ziprasidone|ziprasidone|ziprasidone	Chemical	5:49:65:110:126	6:50:66:111:127	0:2:3:4:5	D012559	schizophrenia	Disease	86	87	4
16584858	Role of mangiferin on biochemical alterations and antioxidant status in isoproterenol - induced myocardial infarction in rats .|The current study dealt with the protective role of mangiferin , a polyphenol from Mangifera indica Linn .|( Anacardiaceae ) , on isoproterenol ( ISPH ) - induced myocardial infarction ( MI ) in rats through its antioxidative mechanism .|Subcutaneous injection of ISPH ( 200 mg / kg body weight in 1 ml saline ) to rats for 2 consecutive days caused myocardial damage in rat heart , which was determined by the increased activity of serum lactate dehydrogenase ( LDH ) and creatine phosphokinase isoenzymes ( CK - MB ) , increased uric acid level and reduced plasma iron binding capacity .|The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride ( TTC ) test used for macroscopic enzyme mapping assay of the ischemic myocardium .|The heart tissue antioxidant enzymes such as superoxide dismutase , catalase , glutathione peroxidase , glutathione transferase and glutathione reductase activities , non - enzymic antioxidants such as cerruloplasmin , Vitamin C , Vitamin E and glutathione levels were altered in MI rats .|Upon pretreatment with mangiferin ( 100 mg / kg body weight suspended in 2 ml of dimethyl sulphoxide ) given intraperitoneally for 28 days to MI rats protected the above - mentioned parameters to fall from the normal levels .|Activities of heart tissue enzymic antioxidants and serum non - enzymic antioxidants levels rose significantly upon mangiferin administration as compared to ISPH - induced MI rats .|From the present study it is concluded that mangiferin exerts a beneficial effect against ISPH - induced MI due to its antioxidant potential , which regulated the tissues defense system against cardiac damage .	1:NR:2	L2R	NON-CROSS	190-191	196-197	C013592	mangiferin|mangiferin|mangiferin|mangiferin|mangiferin|mangiferin	Chemical	2:27:127:196:249:268	3:28:128:197:250:269	0:1:4:6:7:8	D009203	myocardial infarction|myocardial infarction|MI|MI|MI|MI|MI	Disease	13:47:50:190:218:257:277	15:49:51:191:219:258:278	0:2:2:5:6:7:8	1:NR:2	L2R	CROSS	82-84	127-128	C013592	mangiferin|mangiferin|mangiferin|mangiferin|mangiferin|mangiferin	Chemical	2:27:127:196:249:268	3:28:128:197:250:269	0:1:4:6:7:8	D009202	myocardial damage	Disease	82	84	3	1:NR:2	L2R	NON-CROSS	127-128	146-148	C013592	mangiferin|mangiferin|mangiferin|mangiferin|mangiferin|mangiferin	Chemical	2:27:127:196:249:268	3:28:128:197:250:269	0:1:4:6:7:8	D017202	ischemic myocardium	Disease	146	148	4	1:NR:2	L2R	NON-CROSS	268-269	291-293	C013592	mangiferin|mangiferin|mangiferin|mangiferin|mangiferin|mangiferin	Chemical	2:27:127:196:249:268	3:28:128:197:250:269	0:1:4:6:7:8	D006331	cardiac damage	Disease	291	293	8	1:CID:2	L2R	NON-CROSS	10-11	13-15	D007545	isoproterenol|isoproterenol|ISPH|ISPH|ISPH|ISPH	Chemical	10:41:43:62:254:274	11:42:44:63:255:275	0:2:2:3:7:8	D009203	myocardial infarction|myocardial infarction|MI|MI|MI|MI|MI	Disease	13:47:50:190:218:257:277	15:49:51:191:219:258:278	0:2:2:5:6:7:8	1:NR:2	L2R	NON-CROSS	62-63	82-84	D007545	isoproterenol|isoproterenol|ISPH|ISPH|ISPH|ISPH	Chemical	10:41:43:62:254:274	11:42:44:63:255:275	0:2:2:3:7:8	D009202	myocardial damage	Disease	82	84	3	1:NR:2	L2R	CROSS	62-63	146-148	D007545	isoproterenol|isoproterenol|ISPH|ISPH|ISPH|ISPH	Chemical	10:41:43:62:254:274	11:42:44:63:255:275	0:2:2:3:7:8	D017202	ischemic myocardium	Disease	146	148	4	1:NR:2	L2R	NON-CROSS	274-275	291-293	D007545	isoproterenol|isoproterenol|ISPH|ISPH|ISPH|ISPH	Chemical	10:41:43:62:254:274	11:42:44:63:255:275	0:2:2:3:7:8	D006331	cardiac damage	Disease	291	293	8	1:NR:2	R2L	CROSS	30-31	13-15	D059808	polyphenol	Chemical	30	31	1	D009203	myocardial infarction|myocardial infarction|MI|MI|MI|MI|MI	Disease	13:47:50:190:218:257:277	15:49:51:191:219:258:278	0:2:2:5:6:7:8	1:NR:2	R2L	CROSS	97-98	50-51	D019344	lactate	Chemical	97	98	3	D009203	myocardial infarction|myocardial infarction|MI|MI|MI|MI|MI	Disease	13:47:50:190:218:257:277	15:49:51:191:219:258:278	0:2:2:5:6:7:8	1:NR:2	R2L	CROSS	103-104	50-51	D003401	creatine	Chemical	103	104	3	D009203	myocardial infarction|myocardial infarction|MI|MI|MI|MI|MI	Disease	13:47:50:190:218:257:277	15:49:51:191:219:258:278	0:2:2:5:6:7:8	1:NR:2	R2L	CROSS	113-115	50-51	D014527	uric acid	Chemical	113	115	3	D009203	myocardial infarction|myocardial infarction|MI|MI|MI|MI|MI	Disease	13:47:50:190:218:257:277	15:49:51:191:219:258:278	0:2:2:5:6:7:8	1:NR:2	R2L	CROSS	119-120	50-51	D007501	iron	Chemical	119	120	3	D009203	myocardial infarction|myocardial infarction|MI|MI|MI|MI|MI	Disease	13:47:50:190:218:257:277	15:49:51:191:219:258:278	0:2:2:5:6:7:8	1:NR:2	R2L	CROSS	190-191	135-136	C009591	triphenyl tetrazolium chloride|TTC	Chemical	131:135	134:136	4:4	D009203	myocardial infarction|myocardial infarction|MI|MI|MI|MI|MI	Disease	13:47:50:190:218:257:277	15:49:51:191:219:258:278	0:2:2:5:6:7:8	1:NR:2	R2L	NON-CROSS	190-191	156-157	D013481	superoxide	Chemical	156	157	5	D009203	myocardial infarction|myocardial infarction|MI|MI|MI|MI|MI	Disease	13:47:50:190:218:257:277	15:49:51:191:219:258:278	0:2:2:5:6:7:8	1:NR:2	R2L	NON-CROSS	190-191	185-186	D005978	glutathione|glutathione|glutathione|glutathione	Chemical	161:164:167:185	162:165:168:186	5:5:5:5	D009203	myocardial infarction|myocardial infarction|MI|MI|MI|MI|MI	Disease	13:47:50:190:218:257:277	15:49:51:191:219:258:278	0:2:2:5:6:7:8	1:NR:2	R2L	NON-CROSS	190-191	179-181	D001205	Vitamin C	Chemical	179	181	5	D009203	myocardial infarction|myocardial infarction|MI|MI|MI|MI|MI	Disease	13:47:50:190:218:257:277	15:49:51:191:219:258:278	0:2:2:5:6:7:8	1:NR:2	R2L	NON-CROSS	190-191	182-184	D014810	Vitamin E	Chemical	182	184	5	D009203	myocardial infarction|myocardial infarction|MI|MI|MI|MI|MI	Disease	13:47:50:190:218:257:277	15:49:51:191:219:258:278	0:2:2:5:6:7:8	1:NR:2	R2L	NON-CROSS	218-219	209-211	D004121	dimethyl sulphoxide	Chemical	209	211	6	D009203	myocardial infarction|myocardial infarction|MI|MI|MI|MI|MI	Disease	13:47:50:190:218:257:277	15:49:51:191:219:258:278	0:2:2:5:6:7:8	1:NR:2	L2R	CROSS	30-31	82-84	D059808	polyphenol	Chemical	30	31	1	D009202	myocardial damage	Disease	82	84	3	1:NR:2	L2R	CROSS	30-31	146-148	D059808	polyphenol	Chemical	30	31	1	D017202	ischemic myocardium	Disease	146	148	4	1:NR:2	L2R	CROSS	30-31	291-293	D059808	polyphenol	Chemical	30	31	1	D006331	cardiac damage	Disease	291	293	8	1:NR:2	R2L	NON-CROSS	97-98	82-84	D019344	lactate	Chemical	97	98	3	D009202	myocardial damage	Disease	82	84	3	1:NR:2	R2L	NON-CROSS	103-104	82-84	D003401	creatine	Chemical	103	104	3	D009202	myocardial damage	Disease	82	84	3	1:NR:2	R2L	NON-CROSS	113-115	82-84	D014527	uric acid	Chemical	113	115	3	D009202	myocardial damage	Disease	82	84	3	1:NR:2	R2L	NON-CROSS	119-120	82-84	D007501	iron	Chemical	119	120	3	D009202	myocardial damage	Disease	82	84	3	1:NR:2	R2L	CROSS	131-134	82-84	C009591	triphenyl tetrazolium chloride|TTC	Chemical	131:135	134:136	4:4	D009202	myocardial damage	Disease	82	84	3	1:NR:2	R2L	CROSS	156-157	82-84	D013481	superoxide	Chemical	156	157	5	D009202	myocardial damage	Disease	82	84	3	1:NR:2	R2L	CROSS	161-162	82-84	D005978	glutathione|glutathione|glutathione|glutathione	Chemical	161:164:167:185	162:165:168:186	5:5:5:5	D009202	myocardial damage	Disease	82	84	3	1:NR:2	R2L	CROSS	179-181	82-84	D001205	Vitamin C	Chemical	179	181	5	D009202	myocardial damage	Disease	82	84	3	1:NR:2	R2L	CROSS	182-184	82-84	D014810	Vitamin E	Chemical	182	184	5	D009202	myocardial damage	Disease	82	84	3	1:NR:2	R2L	CROSS	209-211	82-84	D004121	dimethyl sulphoxide	Chemical	209	211	6	D009202	myocardial damage	Disease	82	84	3	1:NR:2	L2R	CROSS	97-98	146-148	D019344	lactate	Chemical	97	98	3	D017202	ischemic myocardium	Disease	146	148	4	1:NR:2	L2R	CROSS	97-98	291-293	D019344	lactate	Chemical	97	98	3	D006331	cardiac damage	Disease	291	293	8	1:NR:2	L2R	CROSS	103-104	146-148	D003401	creatine	Chemical	103	104	3	D017202	ischemic myocardium	Disease	146	148	4	1:NR:2	L2R	CROSS	103-104	291-293	D003401	creatine	Chemical	103	104	3	D006331	cardiac damage	Disease	291	293	8	1:NR:2	L2R	CROSS	113-115	146-148	D014527	uric acid	Chemical	113	115	3	D017202	ischemic myocardium	Disease	146	148	4	1:NR:2	L2R	CROSS	113-115	291-293	D014527	uric acid	Chemical	113	115	3	D006331	cardiac damage	Disease	291	293	8	1:NR:2	L2R	CROSS	119-120	146-148	D007501	iron	Chemical	119	120	3	D017202	ischemic myocardium	Disease	146	148	4	1:NR:2	L2R	CROSS	119-120	291-293	D007501	iron	Chemical	119	120	3	D006331	cardiac damage	Disease	291	293	8	1:NR:2	L2R	NON-CROSS	135-136	146-148	C009591	triphenyl tetrazolium chloride|TTC	Chemical	131:135	134:136	4:4	D017202	ischemic myocardium	Disease	146	148	4	1:NR:2	L2R	CROSS	135-136	291-293	C009591	triphenyl tetrazolium chloride|TTC	Chemical	131:135	134:136	4:4	D006331	cardiac damage	Disease	291	293	8	1:NR:2	R2L	CROSS	156-157	146-148	D013481	superoxide	Chemical	156	157	5	D017202	ischemic myocardium	Disease	146	148	4	1:NR:2	R2L	CROSS	161-162	146-148	D005978	glutathione|glutathione|glutathione|glutathione	Chemical	161:164:167:185	162:165:168:186	5:5:5:5	D017202	ischemic myocardium	Disease	146	148	4	1:NR:2	R2L	CROSS	179-181	146-148	D001205	Vitamin C	Chemical	179	181	5	D017202	ischemic myocardium	Disease	146	148	4	1:NR:2	R2L	CROSS	182-184	146-148	D014810	Vitamin E	Chemical	182	184	5	D017202	ischemic myocardium	Disease	146	148	4	1:NR:2	R2L	CROSS	209-211	146-148	D004121	dimethyl sulphoxide	Chemical	209	211	6	D017202	ischemic myocardium	Disease	146	148	4	1:NR:2	L2R	CROSS	156-157	291-293	D013481	superoxide	Chemical	156	157	5	D006331	cardiac damage	Disease	291	293	8	1:NR:2	L2R	CROSS	185-186	291-293	D005978	glutathione|glutathione|glutathione|glutathione	Chemical	161:164:167:185	162:165:168:186	5:5:5:5	D006331	cardiac damage	Disease	291	293	8	1:NR:2	L2R	CROSS	179-181	291-293	D001205	Vitamin C	Chemical	179	181	5	D006331	cardiac damage	Disease	291	293	8	1:NR:2	L2R	CROSS	182-184	291-293	D014810	Vitamin E	Chemical	182	184	5	D006331	cardiac damage	Disease	291	293	8	1:NR:2	L2R	CROSS	209-211	291-293	D004121	dimethyl sulphoxide	Chemical	209	211	6	D006331	cardiac damage	Disease	291	293	8
16563323	Remifentanil pretreatment reduces myoclonus after etomidate .|STUDY OBJECTIVE : The aim of the study was to compare the effect of pretreatment with remifentanil 1 microg / kg and the effect of gender on the incidence of myoclonus after anesthesia induction with etomidate .|DESIGN : This was a randomized , double - blind study .|SETTING : The study was conducted at a university hospital .|PATIENTS : Sixty patients were pretreated in a randomized double - blinded fashion with remifentanil 1 microg / kg or placebo .|Two minutes after remifentanil or placebo injection , etomidate 0 . 3 mg / kg was given .|MEASUREMENTS : Myoclonus was recorded with a scale of 0 to 3 .|The grade of sedation ( none , mild , moderate , severe ) , nausea , pruritus , and apnea were recorded after injection of both drugs .|MAIN RESULTS : The incidence of myoclonus was significantly lower in the remifentanil group ( 6 . 7 % ) than in the placebo group ( 70 % ) ( P < 0 . 001 ) .|None of the patients experienced sedation , apnea , nausea , or pruritus after injection of both drugs .|In the placebo group , male patients were associated with significantly increased incidence of myoclonus after etomidate administration .|CONCLUSION : Pretreatment with remifentanil 1 microg / kg reduced myoclonus after etomidate induction without side effects such as sedation , apnea , nausea , or pruritus .|Men experience increased incidence of myoclonus than women after etomidate administration .	1:NR:2	L2R	NON-CROSS	0-1	3-4	C071741	Remifentanil|remifentanil|remifentanil|remifentanil|remifentanil|remifentanil	Chemical	0:23:81:92:160:227	1:24:82:93:161:228	0:1:4:5:8:11	D009207	myoclonus|myoclonus|Myoclonus|myoclonus|myoclonus|myoclonus|myoclonus	Disease	3:37:109:154:218:233:256	4:38:110:155:219:234:257	0:1:6:8:10:11:12	1:NR:2	L2R	NON-CROSS	227-228	246-247	C071741	Remifentanil|remifentanil|remifentanil|remifentanil|remifentanil|remifentanil	Chemical	0:23:81:92:160:227	1:24:82:93:161:228	0:1:4:5:8:11	D009325	nausea|nausea|nausea	Disease	134:194:246	135:195:247	7:9:11	1:NR:2	L2R	NON-CROSS	227-228	249-250	C071741	Remifentanil|remifentanil|remifentanil|remifentanil|remifentanil|remifentanil	Chemical	0:23:81:92:160:227	1:24:82:93:161:228	0:1:4:5:8:11	D011537	pruritus|pruritus|pruritus	Disease	136:197:249	137:198:250	7:9:11	1:NR:2	L2R	NON-CROSS	227-228	244-245	C071741	Remifentanil|remifentanil|remifentanil|remifentanil|remifentanil|remifentanil	Chemical	0:23:81:92:160:227	1:24:82:93:161:228	0:1:4:5:8:11	D001049	apnea|apnea|apnea	Disease	139:192:244	140:193:245	7:9:11	1:CID:2	R2L	NON-CROSS	5-6	3-4	D005045	etomidate|etomidate|etomidate|etomidate|etomidate|etomidate	Chemical	5:42:97:220:235:260	6:43:98:221:236:261	0:1:5:10:11:12	D009207	myoclonus|myoclonus|Myoclonus|myoclonus|myoclonus|myoclonus|myoclonus	Disease	3:37:109:154:218:233:256	4:38:110:155:219:234:257	0:1:6:8:10:11:12	1:NR:2	L2R	NON-CROSS	235-236	246-247	D005045	etomidate|etomidate|etomidate|etomidate|etomidate|etomidate	Chemical	5:42:97:220:235:260	6:43:98:221:236:261	0:1:5:10:11:12	D009325	nausea|nausea|nausea	Disease	134:194:246	135:195:247	7:9:11	1:NR:2	L2R	NON-CROSS	249-250	260-261	D005045	etomidate|etomidate|etomidate|etomidate|etomidate|etomidate	Chemical	5:42:97:220:235:260	6:43:98:221:236:261	0:1:5:10:11:12	D011537	pruritus|pruritus|pruritus	Disease	136:197:249	137:198:250	7:9:11	1:NR:2	L2R	NON-CROSS	235-236	244-245	D005045	etomidate|etomidate|etomidate|etomidate|etomidate|etomidate	Chemical	5:42:97:220:235:260	6:43:98:221:236:261	0:1:5:10:11:12	D001049	apnea|apnea|apnea	Disease	139:192:244	140:193:245	7:9:11
16428827	Daidzein activates choline acetyltransferase from MC - IXC cells and improves drug - induced amnesia .|The choline acetyltransferase ( ChAT ) activator , which enhances cholinergic transmission via an augmentation of the enzymatic production of acetylcholine ( ACh ) , is an important factor in the treatment of Alzheimer 's disease ( AD ) .|Methanolic extracts from Pueraria thunbergiana exhibited an activation effect ( 46 % ) on ChAT in vitro .|Via the sequential isolation of Pueraria thunbergiana , the active component was ultimately identified as daidzein ( 4 ' , 7 - dihydroxy - isoflavone ) .|In order to investigate the effects of daidzein from Pueraria thunbergiana on scopolamine - induced impairments of learning and memory , we conducted a series of in vivo tests .|Administration of daidzein ( 4 . 5 mg / kg body weight ) to mice was shown significantly to reverse scopolamine - induced amnesia , according to the results of a Y - maze test .|Injections of scopolamine into mice resulted in impaired performance on Y - maze tests ( a 37 % decreases in alternation behavior ) .|By way of contrast , mice treated with daidzein prior to the scopolamine injections were noticeably protected from this performance impairment ( an approximately 12 % - 21 % decrease in alternation behavior ) .|These results indicate that daidzein might play a role in acetylcholine biosynthesis as a ChAT activator , and that it also ameliorates scopolamine - induced amnesia .	1:NR:2	L2R	NON-CROSS	0-1	14-15	C004742	Daidzein|daidzein|4 ' , 7 - dihydroxy - isoflavone|daidzein|daidzein|daidzein|daidzein	Chemical	0:89:91:108:133:199:230	1:90:99:109:134:200:231	0:3:3:4:5:7:8	D000647	amnesia|amnesia|amnesia	Disease	14:154:251	15:155:252	0:5:8	1:NR:2	L2R	CROSS	53-54	89-90	C004742	Daidzein|daidzein|4 ' , 7 - dihydroxy - isoflavone|daidzein|daidzein|daidzein|daidzein	Chemical	0:89:91:108:133:199:230	1:90:99:109:134:200:231	0:3:3:4:5:7:8	D000544	Alzheimer 's disease|AD	Disease	49:53	52:54	1:1	1:NR:2	L2R	NON-CROSS	108-109	116-121	C004742	Daidzein|daidzein|4 ' , 7 - dihydroxy - isoflavone|daidzein|daidzein|daidzein|daidzein	Chemical	0:89:91:108:133:199:230	1:90:99:109:134:200:231	0:3:3:4:5:7:8	D007859	impairments of learning and memory	Disease	116	121	4	1:NR:2	L2R	NON-CROSS	108-109	116-121	C004742	Daidzein|daidzein|4 ' , 7 - dihydroxy - isoflavone|daidzein|daidzein|daidzein|daidzein	Chemical	0:89:91:108:133:199:230	1:90:99:109:134:200:231	0:3:3:4:5:7:8	D008569	impairments of learning and memory	Disease	116	121	4	1:NR:2	L2R	NON-CROSS	14-15	17-18	D002794	choline|choline	Chemical	2:17	3:18	0:1	D000647	amnesia|amnesia|amnesia	Disease	14:154:251	15:155:252	0:5:8	1:NR:2	L2R	NON-CROSS	17-18	49-52	D002794	choline|choline	Chemical	2:17	3:18	0:1	D000544	Alzheimer 's disease|AD	Disease	49:53	52:54	1:1	1:NR:2	L2R	CROSS	17-18	116-121	D002794	choline|choline	Chemical	2:17	3:18	0:1	D007859	impairments of learning and memory	Disease	116	121	4	1:NR:2	L2R	CROSS	17-18	116-121	D002794	choline|choline	Chemical	2:17	3:18	0:1	D008569	impairments of learning and memory	Disease	116	121	4	1:NR:2	R2L	NON-CROSS	251-252	236-237	D000109	acetylcholine|ACh|acetylcholine	Chemical	36:38:236	37:39:237	1:1:8	D000647	amnesia|amnesia|amnesia	Disease	14:154:251	15:155:252	0:5:8	1:CID:2	R2L	NON-CROSS	154-155	151-152	D012601	scopolamine|scopolamine|scopolamine|scopolamine|scopolamine	Chemical	113:151:169:203:248	114:152:170:204:249	4:5:6:7:8	D000647	amnesia|amnesia|amnesia	Disease	14:154:251	15:155:252	0:5:8	1:NR:2	L2R	NON-CROSS	38-39	49-52	D000109	acetylcholine|ACh|acetylcholine	Chemical	36:38:236	37:39:237	1:1:8	D000544	Alzheimer 's disease|AD	Disease	49:53	52:54	1:1	1:NR:2	L2R	CROSS	38-39	116-121	D000109	acetylcholine|ACh|acetylcholine	Chemical	36:38:236	37:39:237	1:1:8	D007859	impairments of learning and memory	Disease	116	121	4	1:NR:2	L2R	CROSS	38-39	116-121	D000109	acetylcholine|ACh|acetylcholine	Chemical	36:38:236	37:39:237	1:1:8	D008569	impairments of learning and memory	Disease	116	121	4	1:NR:2	R2L	CROSS	113-114	53-54	D012601	scopolamine|scopolamine|scopolamine|scopolamine|scopolamine	Chemical	113:151:169:203:248	114:152:170:204:249	4:5:6:7:8	D000544	Alzheimer 's disease|AD	Disease	49:53	52:54	1:1	1:NR:2	L2R	NON-CROSS	113-114	116-121	D012601	scopolamine|scopolamine|scopolamine|scopolamine|scopolamine	Chemical	113:151:169:203:248	114:152:170:204:249	4:5:6:7:8	D007859	impairments of learning and memory	Disease	116	121	4	1:NR:2	L2R	NON-CROSS	113-114	116-121	D012601	scopolamine|scopolamine|scopolamine|scopolamine|scopolamine	Chemical	113:151:169:203:248	114:152:170:204:249	4:5:6:7:8	D008569	impairments of learning and memory	Disease	116	121	4
15985056	Possible azithromycin - associated hiccups .|OBJECTIVE : To report a case of persistent hiccups associated by azithromycin therapy .|CASE SUMMARY : A 76 - year - old man presented with persistent hiccups after beginning azithromycin for the treatment of pharyngitis .|Hiccups were persistent and exhausting .|Discontinuation of azithromycin and therapy with baclofen finally resolved hiccups .|No organic cause of hiccups was identified despite extensive investigation .|DISCUSSION : Pharmacotherapeutic agents have been uncommonly associated with hiccups .|Corticosteroids ( dexamethasone and methylprednisolone ) , benzodiazepines ( midazolam ) and general anaesthesia have been the specific agents mentioned most frequently in the literature as being associated with the development of hiccups .|Few cases of drug - induced hiccups have been reported related to macrolide antimicrobials .|Using the Naranjo adverse effect reaction probability scale this event could be classified as possible ( score 5 points ) , mostly because of the close temporal sequence , previous reports on this reaction with other macrolides and the absence of any alternative explanation for hiccups .|Our hypothesis is that a vagal mechanism mediated by azithromycin could be the pathogenesis of hiccups in our patient .|CONCLUSIONS : Diagnosis of drug - induced hiccups is difficult and often achieved only by a process of elimination .|However , macrolide antimicrobials have been reported to be associated with hiccups and vagal mechanism could explain the development of this side - effect .	1:CID:2	L2R	NON-CROSS	1-2	4-5	D017963	azithromycin|azithromycin|azithromycin|azithromycin|azithromycin	Chemical	1:17:36:51:187	2:18:37:52:188	0:1:2:4:10	D006606	hiccups|hiccups|hiccups|Hiccups|hiccups|hiccups|hiccups|hiccups|hiccups|hiccups|hiccups|hiccups|hiccups	Disease	4:14:33:43:58:64:80:114:122:176:193:205:229	5:15:34:44:59:65:81:115:123:177:194:206:230	0:1:2:3:4:5:6:7:8:9:10:11:12	1:NR:2	L2R	NON-CROSS	36-37	41-42	D017963	azithromycin|azithromycin|azithromycin|azithromycin|azithromycin	Chemical	1:17:36:51:187	2:18:37:52:188	0:1:2:4:10	D010612	pharyngitis	Disease	41	42	2	1:CID:2	R2L	NON-CROSS	58-59	55-56	D001418	baclofen	Chemical	55	56	4	D006606	hiccups|hiccups|hiccups|Hiccups|hiccups|hiccups|hiccups|hiccups|hiccups|hiccups|hiccups|hiccups|hiccups	Disease	4:14:33:43:58:64:80:114:122:176:193:205:229	5:15:34:44:59:65:81:115:123:177:194:206:230	0:1:2:3:4:5:6:7:8:9:10:11:12	1:NR:2	R2L	NON-CROSS	84-85	80-81	D003907	dexamethasone	Chemical	84	85	7	D006606	hiccups|hiccups|hiccups|Hiccups|hiccups|hiccups|hiccups|hiccups|hiccups|hiccups|hiccups|hiccups|hiccups	Disease	4:14:33:43:58:64:80:114:122:176:193:205:229	5:15:34:44:59:65:81:115:123:177:194:206:230	0:1:2:3:4:5:6:7:8:9:10:11:12	1:NR:2	R2L	NON-CROSS	86-87	80-81	D008775	methylprednisolone	Chemical	86	87	7	D006606	hiccups|hiccups|hiccups|Hiccups|hiccups|hiccups|hiccups|hiccups|hiccups|hiccups|hiccups|hiccups|hiccups	Disease	4:14:33:43:58:64:80:114:122:176:193:205:229	5:15:34:44:59:65:81:115:123:177:194:206:230	0:1:2:3:4:5:6:7:8:9:10:11:12	1:NR:2	R2L	NON-CROSS	89-90	80-81	D001569	benzodiazepines	Chemical	89	90	7	D006606	hiccups|hiccups|hiccups|Hiccups|hiccups|hiccups|hiccups|hiccups|hiccups|hiccups|hiccups|hiccups|hiccups	Disease	4:14:33:43:58:64:80:114:122:176:193:205:229	5:15:34:44:59:65:81:115:123:177:194:206:230	0:1:2:3:4:5:6:7:8:9:10:11:12	1:NR:2	R2L	NON-CROSS	91-92	80-81	D008874	midazolam	Chemical	91	92	7	D006606	hiccups|hiccups|hiccups|Hiccups|hiccups|hiccups|hiccups|hiccups|hiccups|hiccups|hiccups|hiccups|hiccups	Disease	4:14:33:43:58:64:80:114:122:176:193:205:229	5:15:34:44:59:65:81:115:123:177:194:206:230	0:1:2:3:4:5:6:7:8:9:10:11:12	1:NR:2	R2L	NON-CROSS	128-129	122-123	D018942	macrolide|macrolides|macrolide	Chemical	128:167:220	129:168:221	8:9:12	D006606	hiccups|hiccups|hiccups|Hiccups|hiccups|hiccups|hiccups|hiccups|hiccups|hiccups|hiccups|hiccups|hiccups	Disease	4:14:33:43:58:64:80:114:122:176:193:205:229	5:15:34:44:59:65:81:115:123:177:194:206:230	0:1:2:3:4:5:6:7:8:9:10:11:12	1:NR:2	R2L	CROSS	55-56	41-42	D001418	baclofen	Chemical	55	56	4	D010612	pharyngitis	Disease	41	42	2	1:NR:2	R2L	CROSS	84-85	41-42	D003907	dexamethasone	Chemical	84	85	7	D010612	pharyngitis	Disease	41	42	2	1:NR:2	R2L	CROSS	86-87	41-42	D008775	methylprednisolone	Chemical	86	87	7	D010612	pharyngitis	Disease	41	42	2	1:NR:2	R2L	CROSS	89-90	41-42	D001569	benzodiazepines	Chemical	89	90	7	D010612	pharyngitis	Disease	41	42	2	1:NR:2	R2L	CROSS	91-92	41-42	D008874	midazolam	Chemical	91	92	7	D010612	pharyngitis	Disease	41	42	2	1:NR:2	R2L	CROSS	128-129	41-42	D018942	macrolide|macrolides|macrolide	Chemical	128:167:220	129:168:221	8:9:12	D010612	pharyngitis	Disease	41	42	2
15276120	Time trends in warfarin - associated hemorrhage .|The annual incidence of warfarin - related bleeding at Brigham and Women 's Hospital increased from 0 . 97 / 1 , 000 patient admissions in the first time period ( January 1995 to October 1998 ) to 1 . 19 / 1 , 000 patient admissions in the second time period ( November 1998 to August 2002 ) of this study .|The proportion of patients with major and intracranial bleeding increased from 20 . 2 % and 1 . 9 % , respectively , in the first time period , to 33 . 3 % and 7 . 8 % , respectively , in the second .	1:CID:2	L2R	NON-CROSS	3-4	6-7	D014859	warfarin|warfarin	Chemical	3:12	4:13	0:1	D006470	hemorrhage|bleeding	Disease	6:15	7:16	0:1	1:CID:2	L2R	CROSS	12-13	78-80	D014859	warfarin|warfarin	Chemical	3:12	4:13	0:1	D020300	intracranial bleeding	Disease	78	80	2
11271907	Fatal haemorrhagic myocarditis secondary to cyclophosphamide therapy .|Haemorrhagic myocarditis is a rare but important complication of cyclophosphamide therapy .|Echocardiographic identification of the disorder can be made .|We believe that the ultrasound features of this disorder have not been previously reported .	1:CID:2	R2L	NON-CROSS	5-6	1-3	D003520	cyclophosphamide|cyclophosphamide	Chemical	5:17	6:18	0:1	D006470	haemorrhagic myocarditis|Haemorrhagic myocarditis	Disease	1:8	3:10	0:1	1:CID:2	R2L	NON-CROSS	5-6	1-3	D003520	cyclophosphamide|cyclophosphamide	Chemical	5:17	6:18	0:1	D009205	haemorrhagic myocarditis|Haemorrhagic myocarditis	Disease	1:8	3:10	0:1
10524660	Glyceryl trinitrate induces attacks of migraine without aura in sufferers of migraine with aura .|Migraine with aura and migraine without aura have the same pain phase , thus indicating that migraine with aura and migraine without aura share a common pathway of nociception .|In recent years , increasing evidence has suggested that the messenger molecule nitric oxide ( NO ) is involved in pain mechanisms of migraine without aura .|In order to clarify whether the same is true for migraine with aura , in the present study we examined the headache response to intravenous infusion of glyceryl trinitrate ( GTN ) ( 0 . 5 microg / kg / min for 20 min ) in 12 sufferers of migraine with aura .|The specific aim was to elucidate whether an aura and / or an attack of migraine without aura could be induced .|Fourteen healthy subjects served as controls .|Aura symptoms were not elicited in any subject .|Headache was more severe in migraineurs than in the controls during and immediately after GTN infusion ( p = 0 . 037 ) as well as during the following 11 h ( p = 0 . 008 ) .|In the controls , the GTN - induced headache gradually disappeared , whereas in migraineurs peak headache intensity occurred at a mean time of 240 min post - infusion .|At this time the induced headache in 6 of 12 migraineurs fulfilled the diagnostic criteria for migraine without aura of the International Headache Society .|The results therefore suggest that NO is involved in the pain mechanisms of migraine with aura .|Since cortical spreading depression has been shown to liberate NO in animals , this finding may help our understanding of the coupling between cortical spreading depression and headache in migraine with aura .	1:CID:2	L2R	NON-CROSS	0-2	5-8	D005996	Glyceryl trinitrate|glyceryl trinitrate|GTN|GTN|GTN	Chemical	0:99:102:177:207	2:101:103:178:208	0:3:3:7:8	D020326	migraine without aura|migraine without aura|migraine without aura|migraine without aura|migraine without aura|migraine without aura	Disease	5:19:35:68:140:248	8:22:38:71:143:251	0:1:1:2:4:9	1:NR:2	L2R	NON-CROSS	0-2	11-14	D005996	Glyceryl trinitrate|glyceryl trinitrate|GTN|GTN|GTN	Chemical	0:99:102:177:207	2:101:103:178:208	0:3:3:7:8	D020325	migraine with aura|Migraine with aura|migraine with aura|migraine with aura|migraine with aura|migraine with aura|migraine with aura	Disease	11:15:31:82:121:270:303	14:18:34:85:124:273:306	0:1:1:3:3:10:11	1:NR:2	L2R	CROSS	0-2	25-26	D005996	Glyceryl trinitrate|glyceryl trinitrate|GTN|GTN|GTN	Chemical	0:99:102:177:207	2:101:103:178:208	0:3:3:7:8	D010146	pain|pain|pain	Disease	25:65:267	26:66:268	1:2:10	1:NR:2	L2R	NON-CROSS	207-208	210-211	D005996	Glyceryl trinitrate|glyceryl trinitrate|GTN|GTN|GTN	Chemical	0:99:102:177:207	2:101:103:178:208	0:3:3:7:8	D006261	headache|Headache|headache|headache|headache|Headache|headache	Disease	93:163:210:218:237:254:301	94:164:211:219:238:255:302	3:7:8:8:9:9:11	1:NR:2	L2R	NON-CROSS	168-169	177-178	D005996	Glyceryl trinitrate|glyceryl trinitrate|GTN|GTN|GTN	Chemical	0:99:102:177:207	2:101:103:178:208	0:3:3:7:8	D008881	migraineurs|migraineurs|migraineurs	Disease	168:216:242	169:217:243	7:8:9	1:NR:2	L2R	CROSS	207-208	277-278	D005996	Glyceryl trinitrate|glyceryl trinitrate|GTN|GTN|GTN	Chemical	0:99:102:177:207	2:101:103:178:208	0:3:3:7:8	D003866	depression|depression	Disease	277:299	278:300	11:11	1:CID:2	R2L	NON-CROSS	68-71	60-61	D009569	nitric oxide|NO|NO|NO	Chemical	57:60:262:283	59:61:263:284	2:2:10:11	D020326	migraine without aura|migraine without aura|migraine without aura|migraine without aura|migraine without aura|migraine without aura	Disease	5:19:35:68:140:248	8:22:38:71:143:251	0:1:1:2:4:9	1:NR:2	R2L	NON-CROSS	270-273	262-263	D009569	nitric oxide|NO|NO|NO	Chemical	57:60:262:283	59:61:263:284	2:2:10:11	D020325	migraine with aura|Migraine with aura|migraine with aura|migraine with aura|migraine with aura|migraine with aura|migraine with aura	Disease	11:15:31:82:121:270:303	14:18:34:85:124:273:306	0:1:1:3:3:10:11	1:NR:2	R2L	NON-CROSS	65-66	60-61	D009569	nitric oxide|NO|NO|NO	Chemical	57:60:262:283	59:61:263:284	2:2:10:11	D010146	pain|pain|pain	Disease	25:65:267	26:66:268	1:2:10	1:NR:2	L2R	NON-CROSS	254-255	262-263	D009569	nitric oxide|NO|NO|NO	Chemical	57:60:262:283	59:61:263:284	2:2:10:11	D006261	headache|Headache|headache|headache|headache|Headache|headache	Disease	93:163:210:218:237:254:301	94:164:211:219:238:255:302	3:7:8:8:9:9:11	1:NR:2	L2R	CROSS	242-243	262-263	D009569	nitric oxide|NO|NO|NO	Chemical	57:60:262:283	59:61:263:284	2:2:10:11	D008881	migraineurs|migraineurs|migraineurs	Disease	168:216:242	169:217:243	7:8:9	1:NR:2	L2R	NON-CROSS	277-278	283-284	D009569	nitric oxide|NO|NO|NO	Chemical	57:60:262:283	59:61:263:284	2:2:10:11	D003866	depression|depression	Disease	277:299	278:300	11:11
9799166	Stroke and cocaine or amphetamine use .|The association of cocaine and amphetamine use with hemorrhagic and ischemic stroke is based almost solely on data from case series .|The limited number of epidemiologic studies of stroke and use of cocaine and / or amphetamine have been done in settings that serve mostly the poor and / or minorities .|This case - control study was conducted in the defined population comprising members of Kaiser Permanente of Northern and Southern California .|We attempted to identify all incident strokes in women ages 15 - 44 years during a 3 - year period using hospital admission and discharge records , emergency department logs , and payment requests for out - of - plan hospitalizations .|We selected controls , matched on age and facility of usual care , at random from healthy members of the health plan .|We obtained information in face - to - face interviews .|There were 347 confirmed stroke cases and 1 , 021 controls .|The univariate matched odds ratio for stroke in women who admitted to using cocaine and / or amphetamine was 8 . 5 ( 95 % confidence interval = 3 . 6 - 20 . 0 ) .|After further adjustment for potential confounders , the odds ratio in women who reported using cocaine and / or amphetamine was 7 . 0 ( 95 % confidence interval = 2 . 8 - 17 . 9 ) .|The use of cocaine and / or amphetamine is a strong risk factor for stroke in this socioeconomically heterogeneous , insured urban population .	1:CID:2	R2L	NON-CROSS	2-3	0-1	D003042	cocaine|cocaine|cocaine|cocaine|cocaine|cocaine	Chemical	2:10:40:183:222:249	3:11:41:184:223:250	0:1:2:8:9:10	D020521	Stroke|stroke|stroke|strokes|stroke|stroke|stroke	Disease	0:18:36:88:162:176:260	1:19:37:89:163:177:261	0:1:2:4:7:8:10	1:CID:2	R2L	NON-CROSS	4-5	0-1	D000661	amphetamine|amphetamine|amphetamine|amphetamine|amphetamine|amphetamine	Chemical	4:12:44:187:226:253	5:13:45:188:227:254	0:1:2:8:9:10	D020521	Stroke|stroke|stroke|strokes|stroke|stroke|stroke	Disease	0:18:36:88:162:176:260	1:19:37:89:163:177:261	0:1:2:4:7:8:10	1:NR:2	L2R	NON-CROSS	10-11	17-18	D003042	cocaine|cocaine|cocaine|cocaine|cocaine|cocaine	Chemical	2:10:40:183:222:249	3:11:41:184:223:250	0:1:2:8:9:10	D007511	ischemic	Disease	17	18	1	1:NR:2	L2R	NON-CROSS	12-13	17-18	D000661	amphetamine|amphetamine|amphetamine|amphetamine|amphetamine|amphetamine	Chemical	4:12:44:187:226:253	5:13:45:188:227:254	0:1:2:8:9:10	D007511	ischemic	Disease	17	18	1
9672273	Prevention of breast cancer with tamoxifen : preliminary findings from the Italian randomised trial among hysterectomised women .|Italian Tamoxifen Prevention Study .|BACKGROUND : Tamoxifen is a candidate chemopreventive agent in breast cancer , although the drug may be associated with the development of endometrial cancer .|Therefore we did a trial in hysterectomised women of tamoxifen as a chemopreventive .|METHODS : In October , 1992 , we started a double - blind placebo - controlled , randomised trial of tamoxifen in women ( mainly in Italy ) who did not have breast cancer and who had had a hysterectomy .|Women were randomised to receive tamoxifen 20 mg per day or placebo , both orally for 5 years .|The original plan was to follow the intervention phase by 5 years ' follow - up .|In June , 1997 , the trialists and the data - monitoring committee decided to end recruitment primarily because of the number of women dropping out of the study .|Recruitment ended on July 11 , 1997 , and the study will continue as planned .|The primary endpoints are the occurrence of and deaths from breast cancer .|This preliminary interim analysis is based on intention - to - treat .|FINDINGS : 5408 women were randomised ; participating women have a median follow - up of 46 months for major endpoints .|41 cases of breast cancer occurred so far ; there have been no deaths from breast cancer .|There is no difference in breast - cancer frequency between the placebo ( 22 cases ) and tamoxifen ( 19 ) arms .|There is a statistically significant reduction of breast cancer among women receiving tamoxifen who also used hormone - replacement therapy during the trial : among 390 women on such therapy and allocated to placebo , we found eight cases of breast cancer compared with one case among 362 women allocated to tamoxifen .|Compared with the placebo group , there was a significantly increased risk of vascular events and hypertriglyceridaemia among women on tamoxifen .|INTERPRETATION : Although this preliminary analysis has low power , in this cohort of women at low - to - normal risk of breast cancer , the postulated protective effects of tamoxifen are not yet apparent .|Women using hormone - replacement therapy appear to have benefited from use of tamoxifen .|There were no deaths from breast cancer recorded in women in the study .|It is essential to continue follow - up to quantify the long - term risks and benefits of tamoxifen therapy .	1:NR:2	R2L	NON-CROSS	5-6	2-4	D013629	tamoxifen|Tamoxifen|Tamoxifen|tamoxifen|tamoxifen|tamoxifen|tamoxifen|tamoxifen|tamoxifen|tamoxifen|tamoxifen|tamoxifen|tamoxifen	Chemical	5:19:25:57:82:108:268:286:325:347:380:399:433	6:20:26:58:83:109:269:287:326:348:381:400:434	0:1:2:3:4:5:13:14:14:15:16:17:19	D001943	breast cancer|breast cancer|breast cancer|breast cancer|breast cancer|breast cancer|breast - cancer|breast cancer|breast cancer|breast cancer|breast cancer	Disease	2:32:94:195:236:248:256:281:314:372:406	4:34:96:197:238:250:259:283:316:374:408	0:2:4:9:12:12:13:14:14:16:18	1:NR:2	L2R	NON-CROSS	45-47	57-58	D013629	tamoxifen|Tamoxifen|Tamoxifen|tamoxifen|tamoxifen|tamoxifen|tamoxifen|tamoxifen|tamoxifen|tamoxifen|tamoxifen|tamoxifen|tamoxifen	Chemical	5:19:25:57:82:108:268:286:325:347:380:399:433	6:20:26:58:83:109:269:287:326:348:381:400:434	0:1:2:3:4:5:13:14:14:15:16:17:19	D016889	endometrial cancer	Disease	45	47	2	1:CID:2	L2R	NON-CROSS	340-342	347-348	D013629	tamoxifen|Tamoxifen|Tamoxifen|tamoxifen|tamoxifen|tamoxifen|tamoxifen|tamoxifen|tamoxifen|tamoxifen|tamoxifen|tamoxifen|tamoxifen	Chemical	5:19:25:57:82:108:268:286:325:347:380:399:433	6:20:26:58:83:109:269:287:326:348:381:400:434	0:1:2:3:4:5:13:14:14:15:16:17:19	D014652	vascular events	Disease	340	342	15	1:CID:2	L2R	NON-CROSS	343-344	347-348	D013629	tamoxifen|Tamoxifen|Tamoxifen|tamoxifen|tamoxifen|tamoxifen|tamoxifen|tamoxifen|tamoxifen|tamoxifen|tamoxifen|tamoxifen|tamoxifen	Chemical	5:19:25:57:82:108:268:286:325:347:380:399:433	6:20:26:58:83:109:269:287:326:348:381:400:434	0:1:2:3:4:5:13:14:14:15:16:17:19	D015228	hypertriglyceridaemia	Disease	343	344	15
8854309	A measure of pupillary oscillation as a marker of cocaine - induced paranoia .|Cocaine - induced paranoia ( CIP ) remains an important drug - induced model of idiopathic paranoia for which no psychophysiologic marker has yet emerged .|Measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past CIP ( n = 32 ) from another group of crack addicts who denied past CIP ( n = 29 ) .	1:CID:2	R2L	NON-CROSS	9-10	3-5	D003042	cocaine|Cocaine	Chemical	9:14	10:15	0:1	D011681	pupillary oscillation|pupillary oscillation	Disease	3:42	5:44	0:2	1:NR:2	R2L	NON-CROSS	53-55	42-44	D016578	crack cocaine|crack	Chemical	53:68	55:69	2:2	D011681	pupillary oscillation|pupillary oscillation	Disease	3:42	5:44	0:2	1:CID:2	L2R	NON-CROSS	12-13	14-15	D003042	cocaine|Cocaine	Chemical	9:14	10:15	0:1	D010259	paranoia|paranoia|CIP|paranoia|CIP|CIP	Disease	12:17:19:30:58:73	13:18:20:31:59:74	0:1:1:1:2:2	1:NR:2	R2L	NON-CROSS	58-59	53-55	D016578	crack cocaine|crack	Chemical	53:68	55:69	2:2	D010259	paranoia|paranoia|CIP|paranoia|CIP|CIP	Disease	12:17:19:30:58:73	13:18:20:31:59:74	0:1:1:1:2:2
8473723	Seizures induced by combined levomepromazine - fluvoxamine treatment .|We report a case of combined levomepromazine - fluvoxamine treatment - induced seizures .|It seems that combined treatment of fluvoxamine with phenothiazines may possess proconvulsive activity .	1:CID:2	R2L	NON-CROSS	4-5	0-1	D008728	levomepromazine|levomepromazine	Chemical	4:15	5:16	0:1	D012640	Seizures|seizures	Disease	0:21	1:22	0:1	1:CID:2	R2L	NON-CROSS	21-22	17-18	D016666	fluvoxamine|fluvoxamine|fluvoxamine	Chemical	6:17:29	7:18:30	0:1:2	D012640	Seizures|seizures	Disease	0:21	1:22	0:1	1:NR:2	R2L	CROSS	31-32	21-22	D010640	phenothiazines	Chemical	31	32	2	D012640	Seizures|seizures	Disease	0:21	1:22	0:1
6674249	Why may epsilon - aminocaproic acid ( EACA ) induce myopathy in man ? Report of a case and literature review .|A case of necrotizing myopathy due to a short epsilon - aminocaproic acid ( EACA ) treatment in a 72 year - old patient with subarachnoid haemorrhage ( SAH ) is described .|Pathogenetic hypotheses are discussed .	1:CID:2	L2R	NON-CROSS	7-8	10-11	D015119	epsilon - aminocaproic acid|EACA|epsilon - aminocaproic acid|EACA	Chemical	2:7:31:36	6:8:35:37	0:0:1:1	D009135	myopathy|necrotizing myopathy	Disease	10:25	11:27	0:1	1:CID:2	L2R	NON-CROSS	25-27	31-35	D015119	epsilon - aminocaproic acid|EACA|epsilon - aminocaproic acid|EACA	Chemical	2:7:31:36	6:8:35:37	0:0:1:1	D009336	necrotizing myopathy	Disease	25	27	1	1:NR:2	L2R	NON-CROSS	36-37	47-49	D015119	epsilon - aminocaproic acid|EACA|epsilon - aminocaproic acid|EACA	Chemical	2:7:31:36	6:8:35:37	0:0:1:1	D013345	subarachnoid haemorrhage|SAH	Disease	47:50	49:51	1:1
6150641	Comparison of the effectiveness of ranitidine and cimetidine in inhibiting acid secretion in patients with gastric hypersecretory states .|The H2 - histamine receptor antagonists ranitidine and cimetidine were compared for their abilities to control gastric acid hypersecretion on a short - and long - term basis in 22 patients with gastric acid hypersecretory states .|Nineteen patients had Zollinger - Ellison syndrome , one patient had systemic mastocytosis , and two patients had idiopathic hypersecretion .|The rates of onset of the action of cimetidine and ranitidine were the same .|The actions of both drugs were increased by anticholinergic agents , and there was a close correlation between the daily maintenance dose of each drug needed to control acid secretion .|However , ranitidine was threefold more potent than cimetidine both in acute inhibition studies and in the median maintenance dose needed ( 1 . 2 g per day for ranitidine and 3 . 6 g per day for cimetidine ) .|Sixty percent of the males developed breast changes or impotence while taking cimetidine and in all cases these changes disappeared when cimetidine was replaced by ranitidine .|Treatment with high doses of cimetidine ( one to 60 months ; median , 11 months ) or ranitidine ( two to 31 months ; median , 14 months ) was not associated with hepatic or hematologic toxicity or alterations of serum gastrin concentrations , but ranitidine therapy was associated with a significantly lower serum creatinine level than seen with cimetidine therapy .|The results show that both drugs can adequately inhibit acid secretion in patients with gastric hypersecretory states .|Both are safe at high doses , but ranitidine is threefold more potent and does not cause the antiandrogen side effects frequently seen with high doses of cimetidine .	1:NR:2	L2R	CROSS	59-63	87-88	D011899	ranitidine|ranitidine|ranitidine|ranitidine|ranitidine|ranitidine|ranitidine|ranitidine|ranitidine	Chemical	5:25:87:125:152:189:209:237:280	6:26:88:126:153:190:210:238:281	0:1:3:5:5:6:7:7:9	D015043	Zollinger - Ellison syndrome	Disease	59	63	2	1:NR:2	L2R	CROSS	67-69	87-88	D011899	ranitidine|ranitidine|ranitidine|ranitidine|ranitidine|ranitidine|ranitidine|ranitidine|ranitidine	Chemical	5:25:87:125:152:189:209:237:280	6:26:88:126:153:190:210:238:281	0:1:3:5:5:6:7:7:9	D034721	systemic mastocytosis	Disease	67	69	2	1:NR:2	L2R	NON-CROSS	173-174	189-190	D011899	ranitidine|ranitidine|ranitidine|ranitidine|ranitidine|ranitidine|ranitidine|ranitidine|ranitidine	Chemical	5:25:87:125:152:189:209:237:280	6:26:88:126:153:190:210:238:281	0:1:3:5:5:6:7:7:9	D007172	impotence	Disease	173	174	6	1:NR:2	L2R	NON-CROSS	225-229	237-238	D011899	ranitidine|ranitidine|ranitidine|ranitidine|ranitidine|ranitidine|ranitidine|ranitidine|ranitidine	Chemical	5:25:87:125:152:189:209:237:280	6:26:88:126:153:190:210:238:281	0:1:3:5:5:6:7:7:9	D056486	hepatic or hematologic toxicity	Disease	225	229	7	1:NR:2	L2R	NON-CROSS	225-229	237-238	D011899	ranitidine|ranitidine|ranitidine|ranitidine|ranitidine|ranitidine|ranitidine|ranitidine|ranitidine	Chemical	5:25:87:125:152:189:209:237:280	6:26:88:126:153:190:210:238:281	0:1:3:5:5:6:7:7:9	D006402	hepatic or hematologic toxicity	Disease	225	229	7	1:NR:2	L2R	CROSS	59-63	85-86	D002927	cimetidine|cimetidine|cimetidine|cimetidine|cimetidine|cimetidine|cimetidine|cimetidine|cimetidine|cimetidine	Chemical	7:27:85:131:161:176:185:196:251:299	8:28:86:132:162:177:186:197:252:300	0:1:3:5:5:6:6:7:7:9	D015043	Zollinger - Ellison syndrome	Disease	59	63	2	1:NR:2	L2R	CROSS	67-69	85-86	D002927	cimetidine|cimetidine|cimetidine|cimetidine|cimetidine|cimetidine|cimetidine|cimetidine|cimetidine|cimetidine	Chemical	7:27:85:131:161:176:185:196:251:299	8:28:86:132:162:177:186:197:252:300	0:1:3:5:5:6:6:7:7:9	D034721	systemic mastocytosis	Disease	67	69	2	1:CID:2	L2R	NON-CROSS	173-174	176-177	D002927	cimetidine|cimetidine|cimetidine|cimetidine|cimetidine|cimetidine|cimetidine|cimetidine|cimetidine|cimetidine	Chemical	7:27:85:131:161:176:185:196:251:299	8:28:86:132:162:177:186:197:252:300	0:1:3:5:5:6:6:7:7:9	D007172	impotence	Disease	173	174	6	1:NR:2	L2R	NON-CROSS	225-229	251-252	D002927	cimetidine|cimetidine|cimetidine|cimetidine|cimetidine|cimetidine|cimetidine|cimetidine|cimetidine|cimetidine	Chemical	7:27:85:131:161:176:185:196:251:299	8:28:86:132:162:177:186:197:252:300	0:1:3:5:5:6:6:7:7:9	D056486	hepatic or hematologic toxicity	Disease	225	229	7	1:NR:2	L2R	NON-CROSS	225-229	251-252	D002927	cimetidine|cimetidine|cimetidine|cimetidine|cimetidine|cimetidine|cimetidine|cimetidine|cimetidine|cimetidine	Chemical	7:27:85:131:161:176:185:196:251:299	8:28:86:132:162:177:186:197:252:300	0:1:3:5:5:6:6:7:7:9	D006402	hepatic or hematologic toxicity	Disease	225	229	7	1:NR:2	L2R	CROSS	22-23	59-63	D006632	histamine	Chemical	22	23	1	D015043	Zollinger - Ellison syndrome	Disease	59	63	2	1:NR:2	L2R	CROSS	22-23	67-69	D006632	histamine	Chemical	22	23	1	D034721	systemic mastocytosis	Disease	67	69	2	1:NR:2	L2R	CROSS	22-23	173-174	D006632	histamine	Chemical	22	23	1	D007172	impotence	Disease	173	174	6	1:NR:2	L2R	CROSS	22-23	225-229	D006632	histamine	Chemical	22	23	1	D056486	hepatic or hematologic toxicity	Disease	225	229	7	1:NR:2	L2R	CROSS	22-23	225-229	D006632	histamine	Chemical	22	23	1	D006402	hepatic or hematologic toxicity	Disease	225	229	7	1:NR:2	R2L	CROSS	246-247	59-63	D003404	creatinine	Chemical	246	247	7	D015043	Zollinger - Ellison syndrome	Disease	59	63	2	1:NR:2	R2L	CROSS	246-247	67-69	D003404	creatinine	Chemical	246	247	7	D034721	systemic mastocytosis	Disease	67	69	2	1:NR:2	R2L	CROSS	246-247	173-174	D003404	creatinine	Chemical	246	247	7	D007172	impotence	Disease	173	174	6	1:NR:2	R2L	NON-CROSS	246-247	225-229	D003404	creatinine	Chemical	246	247	7	D056486	hepatic or hematologic toxicity	Disease	225	229	7	1:NR:2	R2L	NON-CROSS	246-247	225-229	D003404	creatinine	Chemical	246	247	7	D006402	hepatic or hematologic toxicity	Disease	225	229	7
3670965	A catch in the Reye .|Twenty - six cases of Reye syndrome from The Children 's Hospital , Camperdown , Australia , occurring between 1973 and 1982 were reviewed .|Of these , 20 cases met the US Public Health Service Centers for Disease Control criteria for the diagnosis of Reye syndrome .|Aspirin or salicylate ingestion had occurred in only one of the 20 cases ( 5 % ) , and paracetamol ( acetaminophen ) had been administered in only six of the cases ( 30 % ) .|Pathologic confirmation of the diagnosis of Reye syndrome was accomplished in 90 % of the cases .|The incidence of Reye syndrome in New South Wales , Australia , is estimated from this study to be approximately nine cases per 1 million children compared with recent US data of ten to 20 cases per 1 million children and three to seven cases per 1 million children in Great Britain .|The mortality for these Reye syndrome cases in Australia was 45 % as compared with a 32 % case - fatality rate in the United States .|In Australia , the pediatric usage of aspirin has been extremely low for the past 25 years ( less than 1 % of total dosage units sold ) , with paracetamol ( acetaminophen ) dominating the pediatric analgesic and antipyretic market .|Reye syndrome may be disappearing from Australia despite a total lack of association with salicylates or aspirin ingestion , since there were no cases found at The Children 's Hospital in 1983 , 1984 , or 1985 .	1:CID:2	R2L	NON-CROSS	54-55	51-53	D001241	Aspirin|aspirin|aspirin	Chemical	54:195:246	55:196:247	3:7:8	D012202	Reye|Reye syndrome|Reye syndrome|Reye syndrome|Reye syndrome|Reye syndrome|Reye syndrome	Disease	4:11:51:97:111:165:230	5:13:53:99:113:167:232	0:1:2:4:5:6:8	1:NR:2	R2L	NON-CROSS	56-57	51-53	D012459	salicylate|salicylates	Chemical	56:244	57:245	3:8	D012202	Reye|Reye syndrome|Reye syndrome|Reye syndrome|Reye syndrome|Reye syndrome|Reye syndrome	Disease	4:11:51:97:111:165:230	5:13:53:99:113:167:232	0:1:2:4:5:6:8	1:NR:2	R2L	CROSS	230-232	220-221	D000082	paracetamol|acetaminophen|paracetamol|acetaminophen	Chemical	73:75:218:220	74:76:219:221	3:3:7:7	D012202	Reye|Reye syndrome|Reye syndrome|Reye syndrome|Reye syndrome|Reye syndrome|Reye syndrome	Disease	4:11:51:97:111:165:230	5:13:53:99:113:167:232	0:1:2:4:5:6:8
3300918	St . Anthony 's fire , then and now : a case report and historical review .|A rare case of morbid vasospasm , together with striking angiographic findings , is described secondary to the ingestion of methysergide by a 48 - year - old woman .|A brief review of the literature on similar cases is presented .|A discussion of the history of ergot includes its original discovery , the epidemics of gangrene that it has caused through the ages and its past and present role in the management of migraine headache .|Despite the advent of calcium channel blockers and beta - adrenergic antagonists , ergot preparations continue to play a major role in migraine therapy , so that the danger of St . Anthony 's fire persists .	1:NR:2	R2L	CROSS	37-38	0-5	D008784	methysergide	Chemical	37	38	1	D004881	St . Anthony 's fire|St . Anthony 's fire	Disease	0:125	5:130	0:4	1:NR:2	R2L	NON-CROSS	125-130	108-109	D004876	ergot|ergot	Chemical	65:108	66:109	3:4	D004881	St . Anthony 's fire|St . Anthony 's fire	Disease	0:125	5:130	0:4	1:NR:2	R2L	NON-CROSS	125-130	99-100	D002118	calcium	Chemical	99	100	4	D004881	St . Anthony 's fire|St . Anthony 's fire	Disease	0:125	5:130	0:4	1:CID:2	R2L	NON-CROSS	37-38	22-23	D008784	methysergide	Chemical	37	38	1	D014652	vasospasm	Disease	22	23	1	1:NR:2	R2L	CROSS	65-66	22-23	D004876	ergot|ergot	Chemical	65:108	66:109	3:4	D014652	vasospasm	Disease	22	23	1	1:NR:2	R2L	CROSS	99-100	22-23	D002118	calcium	Chemical	99	100	4	D014652	vasospasm	Disease	22	23	1	1:NR:2	L2R	CROSS	37-38	74-75	D008784	methysergide	Chemical	37	38	1	D005734	gangrene	Disease	74	75	3	1:NR:2	L2R	CROSS	37-38	92-94	D008784	methysergide	Chemical	37	38	1	D008881	migraine headache|migraine	Disease	92:117	94:118	3:4	1:NR:2	L2R	NON-CROSS	65-66	74-75	D004876	ergot|ergot	Chemical	65:108	66:109	3:4	D005734	gangrene	Disease	74	75	3	1:CID:2	L2R	NON-CROSS	108-109	117-118	D004876	ergot|ergot	Chemical	65:108	66:109	3:4	D008881	migraine headache|migraine	Disease	92:117	94:118	3:4	1:NR:2	R2L	CROSS	99-100	74-75	D002118	calcium	Chemical	99	100	4	D005734	gangrene	Disease	74	75	3	1:NR:2	R2L	NON-CROSS	99-100	92-94	D002118	calcium	Chemical	99	100	4	D008881	migraine headache|migraine	Disease	92:117	94:118	3:4
2826064	Beta - 2 - adrenoceptor - mediated hypokalemia and its abolishment by oxprenolol .|The time course and concentration - effect relationship of terbutaline - induced hypokalemia was studied , using computer - aided pharmacokinetic - dynamic modeling .|Subsequently we investigated the efficacy of oxprenolol in antagonizing such hypokalemia , together with the pharmacokinetic interaction between both drugs .|Six healthy subjects were given a 0 . 5 mg subcutaneous dose of terbutaline on two occasions : 1 hour after oral administration of a placebo and 1 hour after 80 mg oxprenolol orally .|In the 7 - hour period after terbutaline administration , plasma samples were taken for determination of plasma potassium levels and drug concentrations .|The sigmoid Emax model offered a good description of the relation between terbutaline concentrations and potassium effects .|Oxprenolol caused decreases of 65 % and 56 % of terbutaline volume of distribution and clearance , respectively , and an increase of 130 % of its AUC .|In spite of higher terbutaline concentrations after oxprenolol pretreatment , the hypokalemia was almost completely antagonized by the beta 2 - blocking action .	1:NR:2	R2L	NON-CROSS	49-50	45-46	D010096	oxprenolol|oxprenolol|oxprenolol|Oxprenolol|oxprenolol	Chemical	12:45:92:137:173	13:46:93:138:174	0:2:3:6:7	D007008	hypokalemia|hypokalemia|hypokalemia|hypokalemia	Disease	7:26:49:177	8:27:50:178	0:1:2:7	1:CID:2	R2L	NON-CROSS	26-27	23-24	D013726	terbutaline|terbutaline|terbutaline|terbutaline|terbutaline|terbutaline	Chemical	23:73:102:131:147:170	24:74:103:132:148:171	1:3:4:5:6:7	D007008	hypokalemia|hypokalemia|hypokalemia|hypokalemia	Disease	7:26:49:177	8:27:50:178	0:1:2:7	1:NR:2	R2L	CROSS	177-178	134-135	D011188	potassium|potassium	Chemical	113:134	114:135	4:5	D007008	hypokalemia|hypokalemia|hypokalemia|hypokalemia	Disease	7:26:49:177	8:27:50:178	0:1:2:7
2422478	Midline B3 serotonin nerves in rat medulla are involved in hypotensive effect of methyldopa .|Previous experiments in this laboratory have shown that microinjection of methyldopa onto the ventrolateral cells of the B3 serotonin neurons in the medulla elicits a hypotensive response mediated by a projection descending into the spinal cord .|The present experiments were designed to investigate the role of the midline cells of the B3 serotonin neurons in the medulla , coinciding with the raphe magnus .|In spontaneously hypertensive , stroke - prone rats , microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30 - 40 mm Hg , which was maximal 2 - 3 h after administration and was abolished by the serotonin neurotoxin 5 , 7 - dihydroxytryptamine ( 5 , 7 - DHT ) injected intracerebroventricularly .|However , intraspinal injection of 5 , 7 - DHT to produce a more selective lesion of only descending serotonin projections in the spinal cord did not affect this hypotension .|Further , 5 , 7 - DHT lesion of serotonin nerves travelling in the median forebrain bundle , one of the main ascending pathways from the B3 serotonin cells , did not affect the fall in blood pressure associated with a midline B3 serotonin methyldopa injection .|It is concluded therefore that , unlike the ventrolateral B3 cells which mediate a methyldopa - induced hypotension via descending projections , the midline serotonin B3 cells in the medulla contribute to the hypotensive action of methyldopa , either by way of an ascending projection which does not pass through the median forebrain bundle , or through a projection restricted to the caudal brainstem .	1:NR:2	L2R	NON-CROSS	33-34	40-41	D012701	serotonin|serotonin|serotonin|serotonin|serotonin|serotonin|serotonin|serotonin|serotonin|serotonin	Chemical	2:33:68:99:131:167:188:206:222:250	3:34:69:100:132:168:189:207:223:251	0:1:2:3:3:4:5:5:5:6	D007022	hypotensive|hypotensive|hypotension|hypotension|hypotension|hypotensive	Disease	10:40:109:177:243:259	11:41:110:178:244:260	0:1:3:4:6:6	1:NR:2	L2R	NON-CROSS	68-69	82-83	D012701	serotonin|serotonin|serotonin|serotonin|serotonin|serotonin|serotonin|serotonin|serotonin|serotonin	Chemical	2:33:68:99:131:167:188:206:222:250	3:34:69:100:132:168:189:207:223:251	0:1:2:3:3:4:5:5:5:6	D006973	hypertensive	Disease	82	83	3	1:NR:2	L2R	NON-CROSS	84-85	99-100	D012701	serotonin|serotonin|serotonin|serotonin|serotonin|serotonin|serotonin|serotonin|serotonin|serotonin	Chemical	2:33:68:99:131:167:188:206:222:250	3:34:69:100:132:168:189:207:223:251	0:1:2:3:3:4:5:5:5:6	D020521	stroke	Disease	84	85	3	1:CID:2	R2L	NON-CROSS	13-14	10-11	D008750	methyldopa|methyldopa|methyldopa|methyldopa|methyldopa|methyldopa	Chemical	13:25:91:223:240:262	14:26:92:224:241:263	0:1:3:5:6:6	D007022	hypotensive|hypotensive|hypotension|hypotension|hypotension|hypotensive	Disease	10:40:109:177:243:259	11:41:110:178:244:260	0:1:3:4:6:6	1:NR:2	R2L	NON-CROSS	181-186	177-178	D015116	5 , 7 - dihydroxytryptamine|5 , 7 - DHT|5 , 7 - DHT|5 , 7 - DHT	Chemical	133:139:153:181	138:144:158:186	3:3:4:5	D007022	hypotensive|hypotensive|hypotension|hypotension|hypotension|hypotensive	Disease	10:40:109:177:243:259	11:41:110:178:244:260	0:1:3:4:6:6	1:NR:2	L2R	NON-CROSS	82-83	91-92	D008750	methyldopa|methyldopa|methyldopa|methyldopa|methyldopa|methyldopa	Chemical	13:25:91:223:240:262	14:26:92:224:241:263	0:1:3:5:6:6	D006973	hypertensive	Disease	82	83	3	1:NR:2	L2R	NON-CROSS	84-85	91-92	D008750	methyldopa|methyldopa|methyldopa|methyldopa|methyldopa|methyldopa	Chemical	13:25:91:223:240:262	14:26:92:224:241:263	0:1:3:5:6:6	D020521	stroke	Disease	84	85	3	1:NR:2	R2L	NON-CROSS	133-138	82-83	D015116	5 , 7 - dihydroxytryptamine|5 , 7 - DHT|5 , 7 - DHT|5 , 7 - DHT	Chemical	133:139:153:181	138:144:158:186	3:3:4:5	D006973	hypertensive	Disease	82	83	3	1:NR:2	R2L	NON-CROSS	133-138	84-85	D015116	5 , 7 - dihydroxytryptamine|5 , 7 - DHT|5 , 7 - DHT|5 , 7 - DHT	Chemical	133:139:153:181	138:144:158:186	3:3:4:5	D020521	stroke	Disease	84	85	3
1535072	Yohimbine treatment of sexual side effects induced by serotonin reuptake blockers .|BACKGROUND : Preclinical and clinical studies suggest that yohimbine facilitates sexual behavior and may be helpful in the treatment of male impotence .|A single case report suggests that yohimbine may be used to treat the sexual side effects of clomipramine .|This study evaluated yohimbine as a treatment for the sexual side effects caused by serotonin reuptake blockers .|METHOD : Six patients with either obsessive compulsive disorder , trichotillomania , anxiety , or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p . r . n .|basis in an open clinical trial .|Various doses of yohimbine were used to determine the ideal dose for each patient .|RESULTS : Five of the six patients experienced improved sexual functioning after taking yohimbine .|One patient who failed to comply with yohimbine treatment had no therapeutic effects .|Side effects of yohimbine included excessive sweating , increased anxiety , and a wound - up feeling in some patients .|CONCLUSION : The results of this study indicate that yohimbine may be an effective treatment for the sexual side effects caused by serotonin reuptake blockers .|Future controlled studies are needed to further investigate the effectiveness and safety of yohimbine for this indication .	1:NR:2	L2R	NON-CROSS	0-1	3-6	D015016	Yohimbine|yohimbine|yohimbine|yohimbine|yohimbine|yohimbine|yohimbine|yohimbine|yohimbine|yohimbine|yohimbine	Chemical	0:20:41:57:102:121:146:155:165:192:222	1:21:42:58:103:122:147:156:166:193:223	0:1:2:3:4:6:7:8:9:10:11	D020018	sexual side effects|sexual side effects|sexual side effects|sexual side effects|sexual side effects	Disease	3:48:63:91:200	6:51:66:94:203	0:2:3:4:10	1:NR:2	L2R	NON-CROSS	32-34	41-42	D015016	Yohimbine|yohimbine|yohimbine|yohimbine|yohimbine|yohimbine|yohimbine|yohimbine|yohimbine|yohimbine|yohimbine	Chemical	0:20:41:57:102:121:146:155:165:192:222	1:21:42:58:103:122:147:156:166:193:223	0:1:2:3:4:6:7:8:9:10:11	D007172	male impotence	Disease	32	34	1	1:NR:2	L2R	NON-CROSS	57-58	78-81	D015016	Yohimbine|yohimbine|yohimbine|yohimbine|yohimbine|yohimbine|yohimbine|yohimbine|yohimbine|yohimbine|yohimbine	Chemical	0:20:41:57:102:121:146:155:165:192:222	1:21:42:58:103:122:147:156:166:193:223	0:1:2:3:4:6:7:8:9:10:11	D009771	obsessive compulsive disorder	Disease	78	81	4	1:NR:2	L2R	NON-CROSS	82-83	102-103	D015016	Yohimbine|yohimbine|yohimbine|yohimbine|yohimbine|yohimbine|yohimbine|yohimbine|yohimbine|yohimbine|yohimbine	Chemical	0:20:41:57:102:121:146:155:165:192:222	1:21:42:58:103:122:147:156:166:193:223	0:1:2:3:4:6:7:8:9:10:11	D014256	trichotillomania	Disease	82	83	4	1:NR:2	L2R	NON-CROSS	165-166	171-172	D015016	Yohimbine|yohimbine|yohimbine|yohimbine|yohimbine|yohimbine|yohimbine|yohimbine|yohimbine|yohimbine|yohimbine	Chemical	0:20:41:57:102:121:146:155:165:192:222	1:21:42:58:103:122:147:156:166:193:223	0:1:2:3:4:6:7:8:9:10:11	D001008	anxiety|anxiety	Disease	84:171	85:172	4:9	1:NR:2	L2R	NON-CROSS	87-89	102-103	D015016	Yohimbine|yohimbine|yohimbine|yohimbine|yohimbine|yohimbine|yohimbine|yohimbine|yohimbine|yohimbine|yohimbine	Chemical	0:20:41:57:102:121:146:155:165:192:222	1:21:42:58:103:122:147:156:166:193:223	0:1:2:3:4:6:7:8:9:10:11	D019964	affective disorders	Disease	87	89	4	1:NR:2	R2L	NON-CROSS	8-9	3-6	D012701	serotonin|serotonin|serotonin|serotonin	Chemical	8:68:97:205	9:69:98:206	0:3:4:10	D020018	sexual side effects|sexual side effects|sexual side effects|sexual side effects|sexual side effects	Disease	3:48:63:91:200	6:51:66:94:203	0:2:3:4:10	1:CID:2	R2L	NON-CROSS	52-53	48-51	D002997	clomipramine	Chemical	52	53	2	D020018	sexual side effects|sexual side effects|sexual side effects|sexual side effects|sexual side effects	Disease	3:48:63:91:200	6:51:66:94:203	0:2:3:4:10	1:NR:2	L2R	CROSS	8-9	32-34	D012701	serotonin|serotonin|serotonin|serotonin	Chemical	8:68:97:205	9:69:98:206	0:3:4:10	D007172	male impotence	Disease	32	34	1	1:NR:2	L2R	NON-CROSS	68-69	78-81	D012701	serotonin|serotonin|serotonin|serotonin	Chemical	8:68:97:205	9:69:98:206	0:3:4:10	D009771	obsessive compulsive disorder	Disease	78	81	4	1:NR:2	L2R	NON-CROSS	68-69	82-83	D012701	serotonin|serotonin|serotonin|serotonin	Chemical	8:68:97:205	9:69:98:206	0:3:4:10	D014256	trichotillomania	Disease	82	83	4	1:NR:2	L2R	NON-CROSS	84-85	97-98	D012701	serotonin|serotonin|serotonin|serotonin	Chemical	8:68:97:205	9:69:98:206	0:3:4:10	D001008	anxiety|anxiety	Disease	84:171	85:172	4:9	1:NR:2	L2R	NON-CROSS	87-89	97-98	D012701	serotonin|serotonin|serotonin|serotonin	Chemical	8:68:97:205	9:69:98:206	0:3:4:10	D019964	affective disorders	Disease	87	89	4	1:NR:2	R2L	CROSS	52-53	32-34	D002997	clomipramine	Chemical	52	53	2	D007172	male impotence	Disease	32	34	1	1:NR:2	L2R	CROSS	52-53	78-81	D002997	clomipramine	Chemical	52	53	2	D009771	obsessive compulsive disorder	Disease	78	81	4	1:NR:2	L2R	CROSS	52-53	82-83	D002997	clomipramine	Chemical	52	53	2	D014256	trichotillomania	Disease	82	83	4	1:NR:2	L2R	CROSS	52-53	84-85	D002997	clomipramine	Chemical	52	53	2	D001008	anxiety|anxiety	Disease	84:171	85:172	4:9	1:NR:2	L2R	CROSS	52-53	87-89	D002997	clomipramine	Chemical	52	53	2	D019964	affective disorders	Disease	87	89	4
1504402	Hypersensitivity immune reaction as a mechanism for dilevalol - associated hepatitis .|OBJECTIVE : To assess lymphocyte reactivity to dilevalol and to serum containing putative ex vivo dilevalol antigens or metabolites in a case of dilevalol - induced liver injury .|PATIENT : A 58 - year - old woman with a clinical diagnosis of dilevalol - induced liver injury .|METHODS : Peripheral blood mononuclear cells collected from the patient were cultured in the presence of a solution of dilevalol and also with sera collected from a volunteer before and after dilevalol intake .|A similar protocol was performed with lymphocytes from a healthy subject .|RESULTS : No lymphocyte proliferation was observed either in the patient or in the healthy volunteer in the presence of dilevalol solutions .|A significant proliferative response to serum collected after dilevalol intake was observed in the case of the patient compared with the proliferative response to the serum collected before the drug intake .|No reactivity was found when lymphocytes from the healthy subject were tested under similar conditions .|CONCLUSIONS : The methodology used allowed the detection of lymphocyte sensitization to sera containing ex vivo - prepared dilevalol antigens , suggesting the involvement of an immunologic mechanism in dilevalol - induced liver injury .	1:CID:2	R2L	NON-CROSS	7-8	0-1	D007741	dilevalol|dilevalol|dilevalol|dilevalol|dilevalol|dilevalol|dilevalol|dilevalol|dilevalol|dilevalol|dilevalol	Chemical	7:19:27:35:55:80:92:127:138:196:207	8:20:28:36:56:81:93:128:139:197:208	0:1:1:1:2:3:3:5:6:8:8	D004342	Hypersensitivity	Disease	0	1	0	1:CID:2	L2R	NON-CROSS	7-8	10-11	D007741	dilevalol|dilevalol|dilevalol|dilevalol|dilevalol|dilevalol|dilevalol|dilevalol|dilevalol|dilevalol|dilevalol	Chemical	7:19:27:35:55:80:92:127:138:196:207	8:20:28:36:56:81:93:128:139:197:208	0:1:1:1:2:3:3:5:6:8:8	D056486	hepatitis|liver injury|liver injury|liver injury	Disease	10:38:58:210	11:40:60:212	0:1:2:8
19917396	Reversible myocardial hypertrophy induced by tacrolimus in a pediatric heart transplant recipient : case report .|Tacrolimus is a potent immunosuppressant that is frequently used in organ transplantation .|However , adverse effects include cardiac toxicity .|Herein we describe transient myocardial hypertrophy induced by tacrolimus after heart transplantation .|The hypertrophy caused no clinical symptoms but was noted because of elevation of plasma brain natriuretic peptide concentration and confirmed at echocardiography .|Initially , allograft rejection was feared ; however , myocardial biopsy samples revealed only interstitial edema and mild myocardial hypertrophy ; neither cellular nor humoral rejection was detected .|The blood tacrolimus concentration was higher than usual at that time ; thus , tacrolimus dosage was reduced .|Myocardial hypertrophy completely resolved upon reducing the target concentration of tacrolimus and did not recur , as confirmed at echocardiography and myocardial biopsy .|Thus , we conclude that tacrolimus induces reversible myocardial hypertrophy .|In patients receiving tacrolimus therapy , blood concentration should be carefully controlled and extreme attention paid to cardiac involvement .	1:CID:2	R2L	NON-CROSS	5-6	1-3	D016559	tacrolimus|Tacrolimus|tacrolimus|tacrolimus|tacrolimus|tacrolimus|tacrolimus|tacrolimus	Chemical	5:16:45:104:116:131:150:159	6:17:46:105:117:132:151:160	0:1:3:6:6:7:8:9	D006332	myocardial hypertrophy|myocardial hypertrophy|myocardial hypertrophy|Myocardial hypertrophy|myocardial hypertrophy	Disease	1:41:91:121:153	3:43:93:123:155	0:3:5:7:8	1:NR:2	L2R	CROSS	34-36	45-46	D016559	tacrolimus|Tacrolimus|tacrolimus|tacrolimus|tacrolimus|tacrolimus|tacrolimus|tacrolimus	Chemical	5:16:45:104:116:131:150:159	6:17:46:105:117:132:151:160	0:1:3:6:6:7:8:9	D066126	cardiac toxicity	Disease	34	36	2	1:NR:2	L2R	CROSS	45-46	51-52	D016559	tacrolimus|Tacrolimus|tacrolimus|tacrolimus|tacrolimus|tacrolimus|tacrolimus|tacrolimus	Chemical	5:16:45:104:116:131:150:159	6:17:46:105:117:132:151:160	0:1:3:6:6:7:8:9	D006984	hypertrophy	Disease	51	52	4	1:NR:2	L2R	CROSS	88-89	104-105	D016559	tacrolimus|Tacrolimus|tacrolimus|tacrolimus|tacrolimus|tacrolimus|tacrolimus|tacrolimus	Chemical	5:16:45:104:116:131:150:159	6:17:46:105:117:132:151:160	0:1:3:6:6:7:8:9	D004487	edema	Disease	88	89	5
19234905	Comparison of unilateral pallidotomy and subthalamotomy findings in advanced idiopathic Parkinson 's disease .|A prospective , randomized , double - blind pilot study to compare the results of stereotactic unilateral pallidotomy and subthalamotomy in advanced idiopathic Parkinson 's disease ( PD ) refractory to medical treatment was designed .|Ten consecutive patients ( mean age , 58 . 4 + / - 6 . 8 years ; 7 men , 3 women ) with similar characteristics at the duration of disease ( mean disease time , 8 . 4 + / - 3 . 5 years ) , disabling motor fluctuations ( Hoehn _ Yahr stage 3 - 5 in off - drug phases ) and levodopa - induced dyskinesias were selected .|All patients had bilateral symptoms and their levodopa equivalent dosing were analysed .|Six patients were operated on in the globus pallidus interna ( GPi ) and four in the subthalamic nucleus ( STN ) .|Clinical evaluation included the use of the Unified Parkinson 's Disease Rating Scale ( UPDRS ) , Hoehn_Yahr score and Schwab England activities of daily living ( ADL ) score in ' on ' - and ' off ' - drug conditions before surgery and 6 months after surgery .|There was statistically significant improvement in all contralateral major parkinsonian motor signs in all patients followed for 6 months .|Levodopa equivalent daily intake was significantly reduced in the STN group .|Changes in UPDRS , Hoehn _ Yahr and Schwab England ADL scores were similar in both groups .|Cognitive functions were unchanged in both groups .|Complications were observed in two patients : one had a left homonymous hemianopsia after pallidotomy and another one developed left hemiballistic movements 3 days after subthalamotomy which partly improved within 1 month with Valproate 1000 mg / day .|The findings of this study suggest that lesions of the unilateral STN and GPi are equally effective treatment for patients with advanced PD refractory to medical treatment .	1:NR:2	R2L	CROSS	230-231	219-220	D007980	levodopa|levodopa|Levodopa	Chemical	117:131:230	118:132:231	2:3:7	D010300	idiopathic Parkinson 's disease|idiopathic Parkinson 's disease|PD|Parkinson 's Disease|parkinsonian|PD	Disease	9:36:41:168:219:329	13:40:42:171:220:330	0:1:1:5:6:11	1:NR:2	R2L	CROSS	329-330	301-302	D014635	Valproate	Chemical	301	302	10	D010300	idiopathic Parkinson 's disease|idiopathic Parkinson 's disease|PD|Parkinson 's Disease|parkinsonian|PD	Disease	9:36:41:168:219:329	13:40:42:171:220:330	0:1:1:5:6:11	1:CID:2	L2R	NON-CROSS	117-118	120-121	D007980	levodopa|levodopa|Levodopa	Chemical	117:131:230	118:132:231	2:3:7	D004409	dyskinesias	Disease	120	121	2	1:NR:2	L2R	CROSS	230-231	279-281	D007980	levodopa|levodopa|Levodopa	Chemical	117:131:230	118:132:231	2:3:7	D006423	homonymous hemianopsia	Disease	279	281	10	1:NR:2	R2L	CROSS	301-302	120-121	D014635	Valproate	Chemical	301	302	10	D004409	dyskinesias	Disease	120	121	2	1:NR:2	R2L	NON-CROSS	301-302	279-281	D014635	Valproate	Chemical	301	302	10	D006423	homonymous hemianopsia	Disease	279	281	10
18541230	Protective effects of antithrombin on puromycin aminonucleoside nephrosis in rats .|We investigated the effects of antithrombin , a plasma inhibitor of coagulation factors , in rats with puromycin aminonucleoside - induced nephrosis , which is an experimental model of human nephrotic syndrome .|Antithrombin ( 50 or 500 IU / kg / i . v . ) was administered to rats once a day for 10 days immediately after the injection of puromycin aminonucleoside ( 50 mg / kg / i . v . ) .|Treatment with antithrombin attenuated the puromycin aminonucleoside - induced hematological abnormalities .|Puromycin aminonucleoside - induced renal dysfunction and hyperlipidemia were also suppressed .|Histopathological examination revealed severe renal damage such as proteinaceous casts in tubuli and tubular expansion in the kidney of control rats , while an improvement of the damage was seen in antithrombin - treated rats .|In addition , antithrombin treatment markedly suppressed puromycin aminonucleoside - induced apoptosis of renal tubular epithelial cells .|Furthermore , puromycin aminonucleoside - induced increases in renal cytokine content were also decreased .|These findings suggest that thrombin plays an important role in the pathogenesis of puromycin aminonucleoside - induced nephrotic syndrome .|Treatment with antithrombin may be clinically effective in patients with nephrotic syndrome .	1:CID:2	L2R	NON-CROSS	5-7	7-8	D011692	puromycin aminonucleoside|puromycin aminonucleoside|puromycin aminonucleoside|puromycin aminonucleoside|Puromycin aminonucleoside|puromycin aminonucleoside|puromycin aminonucleoside|puromycin aminonucleoside	Chemical	5:28:73:92:99:154:167:193	7:30:75:94:101:156:169:195	0:1:2:3:4:6:7:8	D009401	nephrosis|nephrosis	Disease	7:32	8:33	0:1	1:NR:2	L2R	NON-CROSS	193-195	197-199	D011692	puromycin aminonucleoside|puromycin aminonucleoside|puromycin aminonucleoside|puromycin aminonucleoside|Puromycin aminonucleoside|puromycin aminonucleoside|puromycin aminonucleoside|puromycin aminonucleoside	Chemical	5:28:73:92:99:154:167:193	7:30:75:94:101:156:169:195	0:1:2:3:4:6:7:8	D009404	nephrotic syndrome|nephrotic syndrome|nephrotic syndrome	Disease	41:197:210	43:199:212	1:8:9	1:NR:2	L2R	NON-CROSS	96-98	99-101	D011692	puromycin aminonucleoside|puromycin aminonucleoside|puromycin aminonucleoside|puromycin aminonucleoside|Puromycin aminonucleoside|puromycin aminonucleoside|puromycin aminonucleoside|puromycin aminonucleoside	Chemical	5:28:73:92:99:154:167:193	7:30:75:94:101:156:169:195	0:1:2:3:4:6:7:8	D006402	hematological abnormalities	Disease	96	98	3	1:NR:2	L2R	NON-CROSS	99-101	103-105	D011692	puromycin aminonucleoside|puromycin aminonucleoside|puromycin aminonucleoside|puromycin aminonucleoside|Puromycin aminonucleoside|puromycin aminonucleoside|puromycin aminonucleoside|puromycin aminonucleoside	Chemical	5:28:73:92:99:154:167:193	7:30:75:94:101:156:169:195	0:1:2:3:4:6:7:8	D007674	renal dysfunction|renal damage	Disease	103:115	105:117	4:5	1:NR:2	L2R	NON-CROSS	99-101	106-107	D011692	puromycin aminonucleoside|puromycin aminonucleoside|puromycin aminonucleoside|puromycin aminonucleoside|Puromycin aminonucleoside|puromycin aminonucleoside|puromycin aminonucleoside|puromycin aminonucleoside	Chemical	5:28:73:92:99:154:167:193	7:30:75:94:101:156:169:195	0:1:2:3:4:6:7:8	D006949	hyperlipidemia	Disease	106	107	4
18177388	Reverse or inverted left ventricular apical ballooning syndrome ( reverse Takotsubo cardiomyopathy ) in a young woman in the setting of amphetamine use .|Transient left ventricular apical ballooning syndrome was first described in Japan as " Takotsubo cardiomyopathy . " This syndrome has been identified in many other countries .|Many variations of this syndrome have been recently described in the literature .|One of the rarest is the reverse type of this syndrome , with hyperdynamic apex and complete akinesia of the base ( as opposed to the classic apical ballooning ) .|In this article , we report an interesting case of a young woman who presented with this rare type of reverse apical ballooning syndrome occurring after amphetamine use .|This report is followed by review of the literature .	1:CID:2	R2L	NON-CROSS	121-122	116-119	D000661	amphetamine|amphetamine	Chemical	21:121	22:122	0:4	D054549	left ventricular apical ballooning syndrome|Takotsubo cardiomyopathy|left ventricular apical ballooning syndrome|Takotsubo cardiomyopathy|apical ballooning|apical ballooning syndrome	Disease	3:10:25:37:91:116	8:12:30:39:93:119	0:0:1:1:3:4	1:NR:2	L2R	CROSS	81-82	121-122	D000661	amphetamine|amphetamine	Chemical	21:121	22:122	0:4	D004409	akinesia	Disease	81	82	3
17490864	Attenuated disruption of prepulse inhibition by dopaminergic stimulation after maternal deprivation and adolescent corticosterone treatment in rats .|The development of schizophrenia may include an early neurodevelopmental stress component which increases vulnerability to later stressful life events , in combination leading to overt disease .|We investigated the effect of an early stress , in the form of maternal deprivation , combined with a later stress , simulated by chronic periadolescent corticosterone treatment , on behaviour in rats .|Acute treatment with apomorphine caused disruption of prepulse inhibition ( PPI ) in controls and in rats that had undergone either maternal deprivation or corticosterone treatment , but was surprisingly absent in rats that had undergone the combined early and late stress .|Amphetamine treatment significantly disrupted PPI in both non - deprived groups , but was absent in both maternally deprived groups .|The serotonin - 1A receptor agonist , 8 - OH - DPAT , induced a significant disruption of PPI in all groups .|Amphetamine - induced locomotor hyperactivity was similar in all groups .|These results show an inhibitory interaction of early stress , caused by maternal deprivation , combined with ' adolescent ' stress , simulated by corticosterone treatment , on dopaminergic regulation of PPI .|The altered effects of apomorphine and amphetamine could indicate differential changes in dopamine receptor signalling leading to functional desensitisation , or altered modulation of sensory gating in the nucleus accumbens by limbic structures such as the hippocampus .	1:NR:2	L2R	CROSS	13-14	21-22	D003345	corticosterone|corticosterone|corticosterone|corticosterone	Chemical	13:71:103:201	14:72:104:202	0:2:3:7	D012559	schizophrenia	Disease	21	22	1	1:NR:2	L2R	CROSS	169-171	201-202	D003345	corticosterone|corticosterone|corticosterone|corticosterone	Chemical	13:71:103:201	14:72:104:202	0:2:3:7	D006948	locomotor hyperactivity	Disease	169	171	6	1:NR:2	R2L	CROSS	82-83	21-22	D001058	apomorphine|apomorphine	Chemical	82:214	83:215	3:8	D012559	schizophrenia	Disease	21	22	1	1:NR:2	R2L	CROSS	122-123	21-22	D000661	Amphetamine|Amphetamine|amphetamine	Chemical	122:166:216	123:167:217	4:6:8	D012559	schizophrenia	Disease	21	22	1	1:NR:2	R2L	CROSS	144-145	21-22	D012701	serotonin	Chemical	144	145	5	D012559	schizophrenia	Disease	21	22	1	1:NR:2	R2L	CROSS	150-155	21-22	D017371	8 - OH - DPAT	Chemical	150	155	5	D012559	schizophrenia	Disease	21	22	1	1:NR:2	R2L	CROSS	222-223	21-22	D004298	dopamine	Chemical	222	223	8	D012559	schizophrenia	Disease	21	22	1	1:NR:2	L2R	CROSS	169-171	214-215	D001058	apomorphine|apomorphine	Chemical	82:214	83:215	3:8	D006948	locomotor hyperactivity	Disease	169	171	6	1:CID:2	L2R	NON-CROSS	166-167	169-171	D000661	Amphetamine|Amphetamine|amphetamine	Chemical	122:166:216	123:167:217	4:6:8	D006948	locomotor hyperactivity	Disease	169	171	6	1:NR:2	L2R	CROSS	144-145	169-171	D012701	serotonin	Chemical	144	145	5	D006948	locomotor hyperactivity	Disease	169	171	6	1:NR:2	L2R	CROSS	150-155	169-171	D017371	8 - OH - DPAT	Chemical	150	155	5	D006948	locomotor hyperactivity	Disease	169	171	6	1:NR:2	R2L	CROSS	222-223	169-171	D004298	dopamine	Chemical	222	223	8	D006948	locomotor hyperactivity	Disease	169	171	6
17490790	Peripheral iron dextran induced degeneration of dopaminergic neurons in rat substantia nigra .|Iron accumulation is considered to be involved in the pathogenesis of Parkinson 's disease .|To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra ( SN ) , in the present study we used fast cyclic voltammetry , tyrosine hydroxylase ( TH ) immunohistochemistry , Perls ' iron staining , and high performance liquid chromatography - electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals .|The findings showed that peripheral iron dextran overload increased the iron staining positive cells and reduced the number of TH - immunoreactive neurons in the SN .|As a result , dopamine release and content , as well as its metabolites contents were decreased in caudate putamen .|Even more dramatic changes were found in chronic overload group .|These results suggest that peripheral iron dextran can increase the iron level in the SN , where excessive iron causes the degeneration of dopaminergic neurons .|The chronic iron overload may be more destructive to dopaminergic neurons than the acute iron overload .	1:CID:2	L2R	NON-CROSS	1-3	4-8	D007505	iron dextran|iron dextran|iron dextran|iron dextran	Chemical	1:93:103:162	3:95:105:164	0:2:3:6	D009410	degeneration of dopaminergic neurons|degeneration of dopaminergic neurons|degeneration of dopaminergic neurons	Disease	4:81:178	8:85:182	0:2:6	1:NR:2	L2R	CROSS	1-3	24-27	D007505	iron dextran|iron dextran|iron dextran|iron dextran	Chemical	1:93:103:162	3:95:105:164	0:2:3:6	D010300	Parkinson 's disease	Disease	24	27	1	1:NR:2	R2L	NON-CROSS	87-88	81-85	D007501	Iron|iron|iron|iron|iron|iron|iron|iron|iron	Chemical	13:34:67:87:108:167:175:185:197	14:35:68:88:109:168:176:186:198	1:2:2:2:3:6:6:7:7	D009410	degeneration of dopaminergic neurons|degeneration of dopaminergic neurons|degeneration of dopaminergic neurons	Disease	4:81:178	8:85:182	0:2:6	1:NR:2	R2L	NON-CROSS	81-85	58-59	D014443	tyrosine	Chemical	58	59	2	D009410	degeneration of dopaminergic neurons|degeneration of dopaminergic neurons|degeneration of dopaminergic neurons	Disease	4:81:178	8:85:182	0:2:6	1:NR:2	R2L	CROSS	129-130	81-85	D004298	dopamine	Chemical	129	130	4	D009410	degeneration of dopaminergic neurons|degeneration of dopaminergic neurons|degeneration of dopaminergic neurons	Disease	4:81:178	8:85:182	0:2:6	1:NR:2	L2R	NON-CROSS	24-27	34-35	D007501	Iron|iron|iron|iron|iron|iron|iron|iron|iron	Chemical	13:34:67:87:108:167:175:185:197	14:35:68:88:109:168:176:186:198	1:2:2:2:3:6:6:7:7	D010300	Parkinson 's disease	Disease	24	27	1	1:NR:2	R2L	CROSS	58-59	24-27	D014443	tyrosine	Chemical	58	59	2	D010300	Parkinson 's disease	Disease	24	27	1	1:NR:2	R2L	CROSS	129-130	24-27	D004298	dopamine	Chemical	129	130	4	D010300	Parkinson 's disease	Disease	24	27	1
16047871	Warfarin - induced leukocytoclastic vasculitis .|Skin reactions associated with oral coumarin - derived anticoagulants are an uncommon occurrence .|Leukocytoclastic vasculitis ( LV ) is primarily a cutaneous small vessel vasculitis , though systemic involvement may be encountered .|We report 4 patients with late - onset LV probably due to warfarin .|All 4 patients presented with skin eruptions that developed after receiving warfarin for several years .|The results of skin lesion biopsies were available in 3 patients , confirming LV Cutaneous lesions resolved in all patients after warfarin was discontinued .|In 2 of the 4 patients , rechallenge with warfarin led to recurrence of the lesions .|LV may be a late - onset adverse reaction associated with warfarin therapy .	1:NR:2	L2R	NON-CROSS	0-1	3-5	D014859	Warfarin|warfarin|warfarin|warfarin|warfarin|warfarin	Chemical	0:52:65:91:104:123	1:53:66:92:105:124	0:3:4:5:6:7	C535509	leukocytoclastic vasculitis|Leukocytoclastic vasculitis|LV|LV|LV	Disease	3:20:23:48:112	5:22:24:49:113	0:2:2:3:7	1:NR:2	L2R	CROSS	28-32	52-53	D014859	Warfarin|warfarin|warfarin|warfarin|warfarin|warfarin	Chemical	0:52:65:91:104:123	1:53:66:92:105:124	0:3:4:5:6:7	C565222	cutaneous small vessel vasculitis	Disease	28	32	2	1:NR:2	L2R	NON-CROSS	59-61	65-66	D014859	Warfarin|warfarin|warfarin|warfarin|warfarin|warfarin	Chemical	0:52:65:91:104:123	1:53:66:92:105:124	0:3:4:5:6:7	D012871	skin eruptions|skin lesion	Disease	59:73	61:75	4:5	1:CID:2	L2R	NON-CROSS	83-86	91-92	D014859	Warfarin|warfarin|warfarin|warfarin|warfarin|warfarin	Chemical	0:52:65:91:104:123	1:53:66:92:105:124	0:3:4:5:6:7	D018366	LV Cutaneous lesions	Disease	83	86	5	1:NR:2	R2L	CROSS	11-12	3-5	C030123	coumarin	Chemical	11	12	1	C535509	leukocytoclastic vasculitis|Leukocytoclastic vasculitis|LV|LV|LV	Disease	3:20:23:48:112	5:22:24:49:113	0:2:2:3:7	1:NR:2	L2R	CROSS	11-12	28-32	C030123	coumarin	Chemical	11	12	1	C565222	cutaneous small vessel vasculitis	Disease	28	32	2	1:NR:2	L2R	CROSS	11-12	59-61	C030123	coumarin	Chemical	11	12	1	D012871	skin eruptions|skin lesion	Disease	59:73	61:75	4:5	1:NR:2	L2R	CROSS	11-12	83-86	C030123	coumarin	Chemical	11	12	1	D018366	LV Cutaneous lesions	Disease	83	86	5
15673851	The activation of spinal N - methyl - D - aspartate receptors may contribute to degeneration of spinal motor neurons induced by neuraxial morphine after a noninjurious interval of spinal cord ischemia .|We investigated the relationship between the degeneration of spinal motor neurons and activation of N - methyl - d - aspartate ( NMDA ) receptors after neuraxial morphine following a noninjurious interval of aortic occlusion in rats .|Spinal cord ischemia was induced by aortic occlusion for 6 min with a balloon catheter .|In a microdialysis study , 10 muL of saline ( group C ; n = 8 ) or 30 mug of morphine ( group M ; n = 8 ) was injected intrathecally ( IT ) 0 . 5 h after reflow , and 30 mug of morphine ( group SM ; n = 8 ) or 10 muL of saline ( group SC ; n = 8 ) was injected IT 0 . 5 h after sham operation .|Microdialysis samples were collected preischemia , before IT injection , and at 2 , 4 , 8 , 24 , and 48 h of reperfusion ( after IT injection ) .|Second , we investigated the effect of IT MK - 801 ( 30 mug ) on the histopathologic changes in the spinal cord after morphine - induced spastic paraparesis .|After IT morphine , the cerebrospinal fluid ( CSF ) glutamate concentration was increased in group M relative to both baseline and group C ( P < 0 . 05 ) .|This increase persisted for 8 hrs .|IT MK - 801 significantly reduced the number of dark - stained alpha - motoneurons after morphine - induced spastic paraparesis compared with the saline group .|These data indicate that IT morphine induces spastic paraparesis with a concomitant increase in CSF glutamate , which is involved in NMDA receptor activation .|We suggest that opioids may be neurotoxic in the setting of spinal cord ischemia via NMDA receptor activation .	1:NR:2	L2R	NON-CROSS	330-333	334-335	D016202	N - methyl - D - aspartate|N - methyl - d - aspartate|NMDA|NMDA|NMDA	Chemical	4:47:55:315:334	11:54:56:316:335	0:1:1:9:10	D020760	spinal cord ischemia|Spinal cord ischemia|spinal cord ischemia	Disease	29:71:330	32:74:333	0:2:10	1:NR:2	L2R	NON-CROSS	55-56	66-68	D016202	N - methyl - D - aspartate|N - methyl - d - aspartate|NMDA|NMDA|NMDA	Chemical	4:47:55:315:334	11:54:56:316:335	0:1:1:9:10	D001157	aortic occlusion|aortic occlusion	Disease	66:77	68:79	1:2	1:NR:2	L2R	NON-CROSS	301-303	315-316	D016202	N - methyl - D - aspartate|N - methyl - d - aspartate|NMDA|NMDA|NMDA	Chemical	4:47:55:315:334	11:54:56:316:335	0:1:1:9:10	D020336	spastic paraparesis|spastic paraparesis|spastic paraparesis	Disease	225:286:301	227:288:303	5:8:9	1:NR:2	L2R	NON-CROSS	325-326	334-335	D016202	N - methyl - D - aspartate|N - methyl - d - aspartate|NMDA|NMDA|NMDA	Chemical	4:47:55:315:334	11:54:56:316:335	0:1:1:9:10	D020258	neurotoxic	Disease	325	326	10	1:NR:2	L2R	NON-CROSS	23-24	29-32	D009020	morphine|morphine|morphine|morphine|morphine|morphine|morphine|morphine	Chemical	23:60:108:134:222:230:283:299	24:61:109:135:223:231:284:300	0:1:3:3:5:6:8:9	D020760	spinal cord ischemia|Spinal cord ischemia|spinal cord ischemia	Disease	29:71:330	32:74:333	0:2:10	1:NR:2	L2R	NON-CROSS	60-61	66-68	D009020	morphine|morphine|morphine|morphine|morphine|morphine|morphine|morphine	Chemical	23:60:108:134:222:230:283:299	24:61:109:135:223:231:284:300	0:1:3:3:5:6:8:9	D001157	aortic occlusion|aortic occlusion	Disease	66:77	68:79	1:2	1:CID:2	L2R	NON-CROSS	299-300	301-303	D009020	morphine|morphine|morphine|morphine|morphine|morphine|morphine|morphine	Chemical	23:60:108:134:222:230:283:299	24:61:109:135:223:231:284:300	0:1:3:3:5:6:8:9	D020336	spastic paraparesis|spastic paraparesis|spastic paraparesis	Disease	225:286:301	227:288:303	5:8:9	1:NR:2	L2R	CROSS	299-300	325-326	D009020	morphine|morphine|morphine|morphine|morphine|morphine|morphine|morphine	Chemical	23:60:108:134:222:230:283:299	24:61:109:135:223:231:284:300	0:1:3:3:5:6:8:9	D020258	neurotoxic	Disease	325	326	10	1:NR:2	R2L	CROSS	330-333	268-271	D016291	MK - 801|MK - 801	Chemical	206:268	209:271	5:8	D020760	spinal cord ischemia|Spinal cord ischemia|spinal cord ischemia	Disease	29:71:330	32:74:333	0:2:10	1:NR:2	R2L	CROSS	330-333	309-310	D018698	glutamate|glutamate	Chemical	238:309	239:310	6:9	D020760	spinal cord ischemia|Spinal cord ischemia|spinal cord ischemia	Disease	29:71:330	32:74:333	0:2:10	1:NR:2	R2L	CROSS	206-209	77-79	D016291	MK - 801|MK - 801	Chemical	206:268	209:271	5:8	D001157	aortic occlusion|aortic occlusion	Disease	66:77	68:79	1:2	1:NR:2	R2L	CROSS	238-239	77-79	D018698	glutamate|glutamate	Chemical	238:309	239:310	6:9	D001157	aortic occlusion|aortic occlusion	Disease	66:77	68:79	1:2	1:NR:2	L2R	NON-CROSS	268-271	286-288	D016291	MK - 801|MK - 801	Chemical	206:268	209:271	5:8	D020336	spastic paraparesis|spastic paraparesis|spastic paraparesis	Disease	225:286:301	227:288:303	5:8:9	1:NR:2	L2R	CROSS	268-271	325-326	D016291	MK - 801|MK - 801	Chemical	206:268	209:271	5:8	D020258	neurotoxic	Disease	325	326	10	1:NR:2	R2L	NON-CROSS	309-310	301-303	D018698	glutamate|glutamate	Chemical	238:309	239:310	6:9	D020336	spastic paraparesis|spastic paraparesis|spastic paraparesis	Disease	225:286:301	227:288:303	5:8:9	1:NR:2	L2R	CROSS	309-310	325-326	D018698	glutamate|glutamate	Chemical	238:309	239:310	6:9	D020258	neurotoxic	Disease	325	326	10
12481039	Reduced sodium channel density , altered voltage dependence of inactivation , and increased susceptibility to seizures in mice lacking sodium channel beta 2 - subunits .|Sodium channel beta - subunits modulate channel gating , assembly , and cell surface expression in heterologous cell systems .|We generated beta2 ( - / - ) mice to investigate the role of beta2 in control of sodium channel density , localization , and function in neurons in vivo .|Measurements of [ ( 3 ) H ] saxitoxin ( STX ) binding showed a significant reduction in the level of plasma membrane sodium channels in beta2 ( - / - ) neurons .|The loss of beta2 resulted in negative shifts in the voltage dependence of inactivation as well as significant decreases in sodium current density in acutely dissociated hippocampal neurons .|The integral of the compound action potential in optic nerve was significantly reduced , and the threshold for action potential generation was increased , indicating a reduction in the level of functional plasma membrane sodium channels .|In contrast , the conduction velocity , the number and size of axons in the optic nerve , and the specific localization of Na ( v ) 1 . 6 channels in the nodes of Ranvier were unchanged .|beta2 ( - / - ) mice displayed increased susceptibility to seizures , as indicated by reduced latency and threshold for pilocarpine - induced seizures , but seemed normal in other neurological tests .|Our observations show that beta2 - subunits play an important role in the regulation of sodium channel density and function in neurons in vivo and are required for normal action potential generation and control of excitability .	1:NR:2	L2R	NON-CROSS	15-16	19-20	D012964	sodium|sodium|Sodium|sodium|sodium|sodium|sodium|Na|sodium	Chemical	1:19:26:64:100:131:174:200:265	2:20:27:65:101:132:175:201:266	0:0:1:2:3:4:5:6:8	D012640	seizures|seizures|seizures	Disease	15:227:240	16:228:241	0:7:7	1:NR:2	R2L	CROSS	85-86	15-16	D012530	saxitoxin|STX	Chemical	85:87	86:88	3:3	D012640	seizures|seizures|seizures	Disease	15:227:240	16:228:241	0:7:7	1:CID:2	R2L	NON-CROSS	240-241	237-238	D010862	pilocarpine	Chemical	237	238	7	D012640	seizures|seizures|seizures	Disease	15:227:240	16:228:241	0:7:7
11185967	Screening for stimulant use in adult emergency department seizure patients .|OBJECTIVE : The objective of this study was to determine the prevalence of positive plasma drug screening for cocaine or amphetamine in adult emergency department seizure patients .|METHODS : This prospective study evaluated consecutive eligible seizure patients who had a plasma sample collected as part of their clinical evaluation .|Plasma was tested for amphetamine and the cocaine metabolite benzoylecgonine using enzyme - mediated immunoassay methodology .|Plasma samples with benzoylecgonine greater than 150 ng / mL or an amphetamine greater than 500 ng / mL were defined as positive .|Patient demographics , history of underlying drug or alcohol - related seizure disorder , estimated time from seizure to sample collection , history or suspicion of cocaine or amphetamine abuse , results of clinical urine testing for drugs of abuse , and assay results were recorded without patient identifiers .|RESULTS : Fourteen of 248 ( 5 . 6 % , 95 % CI 2 . 7 % - 8 . 5 % ) plasma samples were positive by immunoassay testing for benzoylecgonine and no samples ( 0 % , 95 % CI 0 - 1 . 2 % ) were positive for amphetamine .|Positive test results were more common in patient visits where there was a history or suspicion of cocaine or amphetamine abuse ( p < 0 . 0005 ) .|CONCLUSIONS : During this study period , routine plasma screening for cocaine and amphetamines in adult seizure patients had a low yield .|As a result , routine plasma screening would yield few cases of stimulant drug in which there was neither a history nor suspicion of drug abuse in this population .	1:NR:2	R2L	NON-CROSS	253-254	248-249	D003042	cocaine|cocaine|cocaine	Chemical	29:69:248	30:70:249	1:3:8	D012640	seizure|seizure|seizure|seizure|seizure|seizure	Disease	8:36:47:114:120:253	9:37:48:115:121:254	0:1:2:5:5:8	1:NR:2	R2L	NON-CROSS	36-37	31-32	D000661	amphetamine|amphetamine|amphetamine|amphetamine	Chemical	31:66:91:206	32:67:92:207	1:3:4:6	D012640	seizure|seizure|seizure|seizure|seizure|seizure	Disease	8:36:47:114:120:253	9:37:48:115:121:254	0:1:2:5:5:8	1:CID:2	R2L	CROSS	71-72	47-48	C005618	benzoylecgonine|benzoylecgonine|benzoylecgonine	Chemical	71:82:185	72:83:186	3:4:6	D012640	seizure|seizure|seizure|seizure|seizure|seizure	Disease	8:36:47:114:120:253	9:37:48:115:121:254	0:1:2:5:5:8	1:NR:2	R2L	NON-CROSS	114-115	111-112	D000431	alcohol	Chemical	111	112	5	D012640	seizure|seizure|seizure|seizure|seizure|seizure	Disease	8:36:47:114:120:253	9:37:48:115:121:254	0:1:2:5:5:8	1:NR:2	R2L	NON-CROSS	253-254	250-251	D000662	amphetamines	Chemical	250	251	8	D012640	seizure|seizure|seizure|seizure|seizure|seizure	Disease	8:36:47:114:120:253	9:37:48:115:121:254	0:1:2:5:5:8	1:NR:2	L2R	CROSS	225-229	248-249	D003042	cocaine|cocaine|cocaine	Chemical	29:69:248	30:70:249	1:3:8	D019970	cocaine or amphetamine abuse|cocaine or amphetamine abuse	Disease	129:225	133:229	5:7	1:NR:2	L2R	CROSS	225-229	248-249	D003042	cocaine|cocaine|cocaine	Chemical	29:69:248	30:70:249	1:3:8	D019969	cocaine or amphetamine abuse|cocaine or amphetamine abuse	Disease	129:225	133:229	5:7	1:NR:2	L2R	CROSS	248-249	284-286	D003042	cocaine|cocaine|cocaine	Chemical	29:69:248	30:70:249	1:3:8	D019966	drug abuse	Disease	284	286	9	1:NR:2	L2R	CROSS	206-207	225-229	D000661	amphetamine|amphetamine|amphetamine|amphetamine	Chemical	31:66:91:206	32:67:92:207	1:3:4:6	D019970	cocaine or amphetamine abuse|cocaine or amphetamine abuse	Disease	129:225	133:229	5:7	1:NR:2	L2R	CROSS	206-207	225-229	D000661	amphetamine|amphetamine|amphetamine|amphetamine	Chemical	31:66:91:206	32:67:92:207	1:3:4:6	D019969	cocaine or amphetamine abuse|cocaine or amphetamine abuse	Disease	129:225	133:229	5:7	1:NR:2	L2R	CROSS	206-207	284-286	D000661	amphetamine|amphetamine|amphetamine|amphetamine	Chemical	31:66:91:206	32:67:92:207	1:3:4:6	D019966	drug abuse	Disease	284	286	9	1:NR:2	L2R	CROSS	185-186	225-229	C005618	benzoylecgonine|benzoylecgonine|benzoylecgonine	Chemical	71:82:185	72:83:186	3:4:6	D019970	cocaine or amphetamine abuse|cocaine or amphetamine abuse	Disease	129:225	133:229	5:7	1:NR:2	L2R	CROSS	185-186	225-229	C005618	benzoylecgonine|benzoylecgonine|benzoylecgonine	Chemical	71:82:185	72:83:186	3:4:6	D019969	cocaine or amphetamine abuse|cocaine or amphetamine abuse	Disease	129:225	133:229	5:7	1:NR:2	L2R	CROSS	185-186	284-286	C005618	benzoylecgonine|benzoylecgonine|benzoylecgonine	Chemical	71:82:185	72:83:186	3:4:6	D019966	drug abuse	Disease	284	286	9	1:NR:2	L2R	NON-CROSS	111-112	129-133	D000431	alcohol	Chemical	111	112	5	D019970	cocaine or amphetamine abuse|cocaine or amphetamine abuse	Disease	129:225	133:229	5:7	1:NR:2	L2R	NON-CROSS	111-112	129-133	D000431	alcohol	Chemical	111	112	5	D019969	cocaine or amphetamine abuse|cocaine or amphetamine abuse	Disease	129:225	133:229	5:7	1:NR:2	L2R	CROSS	111-112	284-286	D000431	alcohol	Chemical	111	112	5	D019966	drug abuse	Disease	284	286	9	1:NR:2	R2L	CROSS	250-251	225-229	D000662	amphetamines	Chemical	250	251	8	D019970	cocaine or amphetamine abuse|cocaine or amphetamine abuse	Disease	129:225	133:229	5:7	1:NR:2	R2L	CROSS	250-251	225-229	D000662	amphetamines	Chemical	250	251	8	D019969	cocaine or amphetamine abuse|cocaine or amphetamine abuse	Disease	129:225	133:229	5:7	1:NR:2	L2R	CROSS	250-251	284-286	D000662	amphetamines	Chemical	250	251	8	D019966	drug abuse	Disease	284	286	9
11099450	Evidence of functional somatotopy in GPi from results of pallidotomy .|The objective of this study was to explore the functional anatomy of the globus pallidus internus ( GPi ) by studying the effects of unilateral pallidotomy on parkinsonian ' off ' signs and levodopa - induced dyskinesias ( LID ) .|We found significant positive correlations between the preoperative levodopa responsiveness of motor signs and the levodopa responsiveness of scores in timed tests ( Core Assessment Program for Intracerebral Transplantations ) in the contralateral limbs and the improvement in these scores after surgery , whereas there was no correlation with the improvement in LID .|We also found a highly significant correlation ( P : < 0 . 0001 , r = 0 . 8 ) between the volume of the ventral lesion in the GPi and the improvement in LID in the contralateral limbs , whereas there was no correlation between the ventral volume and the improvement in parkinsonian ' off ' signs .|The volumes of the total lesion cylinder and the dorsal lesion did not correlate with the outcome of either dyskinesias or parkinsonian ' off ' signs .|The differential predictive value of levodopa responsiveness for the outcome of parkinsonian ' off ' signs and LID and the different correlations of ventral lesion volume with dyskinesias and parkinsonian ' off ' signs indicate that different anatomical or pathophysiological substrates may be responsible for the generation of parkinsonian ' off ' signs and dyskinesias .|Whereas cells in a wider area of the GPi may be implicated in parkinsonism , the ventral GPi seems to be crucial for the manifestation of LID .|We suggest that our observations are additional proof of the functional somatotopy of the systems within the GPi that mediate parkinsonism and dyskinesias , especially along the dorsoventral trajectory used in pallidotomy .|The outcome of pallidotomy in which the lesion involves the ventral and dorsal GPi could be the net effect of alteration in the activity of pathways which mediate different symptoms , and hence could be variable .	1:NR:2	R2L	NON-CROSS	44-45	38-39	D007980	levodopa|levodopa|levodopa|levodopa	Chemical	44:60:67:198	45:61:68:199	1:2:2:5	D010300	parkinsonian|parkinsonian|parkinsonian|parkinsonian|parkinsonian|parkinsonian|parkinsonism|parkinsonism	Disease	38:160:187:204:222:241:262:297	39:161:188:205:223:242:263:298	1:3:4:5:5:5:6:7	1:CID:2	L2R	NON-CROSS	44-45	47-48	D007980	levodopa|levodopa|levodopa|levodopa	Chemical	44:60:67:198	45:61:68:199	1:2:2:5	D004409	dyskinesias|LID|LID|LID|dyskinesias|LID|dyskinesias|dyskinesias|LID|dyskinesias	Disease	47:49:104:141:185:210:220:247:275:299	48:50:105:142:186:211:221:248:276:300	1:1:2:3:4:5:5:5:6:7
11027904	Pain responses in methadone - maintained opioid abusers .|Providing pain management for known opioid abusers is a challenging clinical task , in part because little is known about their pain experience and analgesic requirements .|This study was designed to describe pain tolerance and analgesic response in a sample of opioid addicts stabilized in methadone - maintenance ( MM ) treatment ( n = 60 ) in comparison to matched nondependent control subjects ( n = 60 ) .|By using a placebo - controlled , two - way factorial design , tolerance to cold - pressor ( CP ) pain was examined , both before and after oral administration of therapeutic doses of common opioid ( hydromorphone 2 mg ) and nonsteroidal anti - inflammatory ( ketorolac 10 mg ) analgesic agents .|Results showed that MM individuals were significantly less tolerant of CP pain than control subjects , replicating previous work .|Analgesic effects were significant neither for medication nor group .|These data indicate that MM opioid abusers represent a pain - intolerant subset of clinical patients .|Their complaints of pain should be evaluated seriously and managed aggressively .	1:NR:2	R2L	NON-CROSS	3-4	0-1	D008691	methadone|methadone	Chemical	3:55	4:56	0:2	D010146	Pain|pain|pain|pain|pain|pain|pain	Disease	0:10:30:42:101:146:185	1:11:31:43:102:147:186	0:1:1:2:3:4:7	1:NR:2	R2L	NON-CROSS	118-119	101-102	D004091	hydromorphone	Chemical	118	119	3	D010146	Pain|pain|pain|pain|pain|pain|pain	Disease	0:10:30:42:101:146:185	1:11:31:43:102:147:186	0:1:1:2:3:4:7	1:NR:2	R2L	NON-CROSS	146-147	128-129	D020910	ketorolac	Chemical	128	129	3	D010146	Pain|pain|pain|pain|pain|pain|pain	Disease	0:10:30:42:101:146:185	1:11:31:43:102:147:186	0:1:1:2:3:4:7	1:NR:2	L2R	NON-CROSS	51-53	55-56	D008691	methadone|methadone	Chemical	3:55	4:56	0:2	D009293	opioid addicts	Disease	51	53	2	1:CID:2	L2R	CROSS	55-56	174-177	D008691	methadone|methadone	Chemical	3:55	4:56	0:2	D006930	pain - intolerant	Disease	174	177	6	1:NR:2	R2L	CROSS	118-119	51-53	D004091	hydromorphone	Chemical	118	119	3	D009293	opioid addicts	Disease	51	53	2	1:NR:2	R2L	CROSS	128-129	51-53	D020910	ketorolac	Chemical	128	129	3	D009293	opioid addicts	Disease	51	53	2	1:NR:2	L2R	CROSS	118-119	174-177	D004091	hydromorphone	Chemical	118	119	3	D006930	pain - intolerant	Disease	174	177	6	1:NR:2	L2R	CROSS	128-129	174-177	D020910	ketorolac	Chemical	128	129	3	D006930	pain - intolerant	Disease	174	177	6
10193809	Urine N - acetyl - beta - D - glucosaminidase - - a marker of tubular damage ?|BACKGROUND : Although an indicator of renal tubular dysfunction , an increased urinary N - acetyl - beta - D - glucosaminidase ( NAG ) activity might reflect increased lysosomal activity in renal tubular cells .|METHODS : Puromycin aminonucleoside ( PAN ) was administered to Sprague Dawley rats to induce proteinuria .|Total protein , albumin , NAG activity and protein electrophoretic pattern were assessed in daily urine samples for 33 days .|The morphological appearance of the kidneys was examined on days three , four , six , eight and thirty three and the NAG isoenzyme patterns on days zero , four , eight and thirty three .|RESULTS : Following intravenous PAN urine volume and urine NAG activity increased significantly by day two , but returned to normal by day four .|After day four all treated animals exhibited a marked rise in urine albumin , total protein excretion and NAG activity .|Electrophoresis showed a generalised increase in middle and high molecular weight urine proteins from day four onwards .|Protein droplets first appeared prominent in tubular cells on day four .|Peak urine NAG activity and a change in NAG isoenzyme pattern coincided with both the peak proteinuria and the reduction in intracellular protein and NAG droplets ( day six onwards ) .|CONCLUSIONS : This animal model demonstrates that an increase in lysosomal turnover and hence urine NAG activity , occurs when increased protein is presented to the tubular cells .|Urine NAG activity is thus a measure of altered function in the renal tubules and not simply an indicator of damage .	1:NR:2	R2L	CROSS	56-58	24-27	D011692	Puromycin aminonucleoside|PAN|PAN	Chemical	56:59:132	58:60:133	2:2:5	D005198	renal tubular dysfunction	Disease	24	27	1	1:CID:2	L2R	NON-CROSS	59-60	69-70	D011692	Puromycin aminonucleoside|PAN|PAN	Chemical	56:59:132	58:60:133	2:2:5	D011507	proteinuria|proteinuria	Disease	69:220	70:221	2:9
9214597	Over expression of vascular endothelial growth factor and its receptor during the development of estrogen - induced rat pituitary tumors may mediate estrogen - initiated tumor angiogenesis .|Estrogens , which have been associated with several types of human and animal cancers , can induce tumor angiogenesis in the pituitary of Fischer 344 rats .|The mechanistic details of tumor angiogenesis induction , during estrogen carcinogenesis , are still unknown .|To elucidate the role of estrogen in the regulation of tumor angiogenesis in the pituitary of female rats , the density of blood vessels was analysed using factor VIII related antigen ( FVIIIRAg ) immunohistochemistry and the expression of vascular endothelial growth factor / vascular permeability factor ( VEGF / VPF ) was examined by Western blot and immunohistochemical analysis .|The expression of VEGF receptor ( VEGFR - 2 / Flk - 1 / KDR ) was also examined by immunohistochemistry .|The results demonstrated that 17beta - estradiol ( E2 ) induces neovascularization , as well as the growth and enlargement of blood vessels after 7 days of exposure .|The high tumor angiogenic potential was associated with an elevated VEGF / VPF protein expression in the E2 exposed pituitary of ovariectomized ( OVEX ) rats .|VEGF / VPF and FVIIIRAg immunohistochemistry and endothelial specific lectin ( UEA1 ) binding studies , indicate that the elevation of VEGF protein expression initially occurred in both blood vessels and non - endothelial cells .|After 15 days of E2 exposure , VEGF / VPF protein expression , in the non - endothelial cell population , sharply declined and was restricted to the blood vessels .|The function of non - endothelial - derived VEGF is not clear .|Furthermore , immunohistochemical studies demonstrated that VEGFR - 2 ( flk - 1 / KDR ) , expression was elevated significantly in the endothelial cells of microblood vessels after 7 days of E2 exposure .|These findings suggest that over expression of VEGF and its receptor ( VEGFR - 2 ) may play an important role in the initial step of the regulation of estrogen induced tumor angiogenesis in the rat pituitary .	1:NR:2	L2R	NON-CROSS	18-20	22-23	D004967	estrogen|estrogen|Estrogens|estrogen|estrogen|estrogen	Chemical	14:22:28:64:76:354	15:23:29:65:77:355	0:0:1:2:3:11	D010911	pituitary tumors	Disease	18	20	0	1:NR:2	L2R	NON-CROSS	354-355	356-357	D004967	estrogen|estrogen|Estrogens|estrogen|estrogen|estrogen	Chemical	14:22:28:64:76:354	15:23:29:65:77:355	0:0:1:2:3:11	D009369	tumor|cancers|tumor|tumor|tumor|tumor|tumor	Disease	25:41:45:59:81:185:356	26:42:46:60:82:186:357	0:1:1:2:3:6:11	1:NR:2	L2R	NON-CROSS	64-65	65-66	D004967	estrogen|estrogen|Estrogens|estrogen|estrogen|estrogen	Chemical	14:22:28:64:76:354	15:23:29:65:77:355	0:0:1:2:3:11	D063646	carcinogenesis	Disease	65	66	2	1:CID:2	R2L	CROSS	158-161	18-20	D004958	17beta - estradiol|E2|E2|E2|E2	Chemical	158:162:200:250:322	161:163:201:251:323	5:5:6:8:10	D010911	pituitary tumors	Disease	18	20	0	1:NR:2	R2L	NON-CROSS	200-201	185-186	D004958	17beta - estradiol|E2|E2|E2|E2	Chemical	158:162:200:250:322	161:163:201:251:323	5:5:6:8:10	D009369	tumor|cancers|tumor|tumor|tumor|tumor|tumor	Disease	25:41:45:59:81:185:356	26:42:46:60:82:186:357	0:1:1:2:3:6:11	1:NR:2	R2L	CROSS	158-161	65-66	D004958	17beta - estradiol|E2|E2|E2|E2	Chemical	158:162:200:250:322	161:163:201:251:323	5:5:6:8:10	D063646	carcinogenesis	Disease	65	66	2
7604176	Pravastatin - associated myopathy .|Report of a case .|A case of acute inflammatory myopathy associated with the use of pravastatin , a new hydrophilic 3 - hydroxy - 3 methylglutaril coenzyme A reductase inhibitor , is reported .|The patient , a 69 - year - old man was affected by non - insulin - dependent diabetes mellitus and hypertension .|He assumed pravastatin ( 20 mg / day ) because of hypercholesterolemia .|He was admitted with acute myopathy of the lower limbs which resolved in a few days after pravastatin discontinuation .|A previously unknown hypothyroidism , probably due to chronic autoimmune thyroiditis , was evidenced .|Muscle biopsy ( left gastrocnemius ) revealed a perimysial and endomysial inflammatory infiltrate with a prevalence of CD4 + lymphocytes .|While lovastatin and simvastatin have been associated with toxic myopathy , pravastatin - associated myopathy could represent a distinct , inflammatory entity .	1:NR:2	L2R	NON-CROSS	141-142	143-144	D017035	Pravastatin|pravastatin|pravastatin|pravastatin|pravastatin	Chemical	0:21:65:93:143	1:22:66:94:144	0:2:4:5:8	D009135	myopathy|myopathy|myopathy|myopathy	Disease	3:81:141:146	4:82:142:147	0:5:8:8	1:CID:2	L2R	NON-CROSS	14-16	21-22	D017035	Pravastatin|pravastatin|pravastatin|pravastatin|pravastatin	Chemical	0:21:65:93:143	1:22:66:94:144	0:2:4:5:8	D009220	inflammatory myopathy	Disease	14	16	2	1:NR:2	L2R	CROSS	53-60	65-66	D017035	Pravastatin|pravastatin|pravastatin|pravastatin|pravastatin	Chemical	0:21:65:93:143	1:22:66:94:144	0:2:4:5:8	D003924	non - insulin - dependent diabetes mellitus	Disease	53	60	3	1:NR:2	L2R	CROSS	61-62	65-66	D017035	Pravastatin|pravastatin|pravastatin|pravastatin|pravastatin	Chemical	0:21:65:93:143	1:22:66:94:144	0:2:4:5:8	D006973	hypertension	Disease	61	62	3	1:NR:2	L2R	NON-CROSS	65-66	74-75	D017035	Pravastatin|pravastatin|pravastatin|pravastatin|pravastatin	Chemical	0:21:65:93:143	1:22:66:94:144	0:2:4:5:8	D006937	hypercholesterolemia	Disease	74	75	4	1:NR:2	L2R	CROSS	93-94	99-100	D017035	Pravastatin|pravastatin|pravastatin|pravastatin|pravastatin	Chemical	0:21:65:93:143	1:22:66:94:144	0:2:4:5:8	D007037	hypothyroidism	Disease	99	100	6	1:NR:2	L2R	CROSS	93-94	105-107	D017035	Pravastatin|pravastatin|pravastatin|pravastatin|pravastatin	Chemical	0:21:65:93:143	1:22:66:94:144	0:2:4:5:8	D013967	autoimmune thyroiditis	Disease	105	107	6	1:NR:2	R2L	NON-CROSS	141-142	133-134	D008148	lovastatin	Chemical	133	134	8	D009135	myopathy|myopathy|myopathy|myopathy	Disease	3:81:141:146	4:82:142:147	0:5:8:8	1:NR:2	R2L	NON-CROSS	141-142	135-136	D019821	simvastatin	Chemical	135	136	8	D009135	myopathy|myopathy|myopathy|myopathy	Disease	3:81:141:146	4:82:142:147	0:5:8:8	1:NR:2	R2L	CROSS	133-134	14-16	D008148	lovastatin	Chemical	133	134	8	D009220	inflammatory myopathy	Disease	14	16	2	1:NR:2	R2L	CROSS	135-136	14-16	D019821	simvastatin	Chemical	135	136	8	D009220	inflammatory myopathy	Disease	14	16	2	1:NR:2	R2L	CROSS	133-134	53-60	D008148	lovastatin	Chemical	133	134	8	D003924	non - insulin - dependent diabetes mellitus	Disease	53	60	3	1:NR:2	R2L	CROSS	135-136	53-60	D019821	simvastatin	Chemical	135	136	8	D003924	non - insulin - dependent diabetes mellitus	Disease	53	60	3	1:NR:2	R2L	CROSS	133-134	61-62	D008148	lovastatin	Chemical	133	134	8	D006973	hypertension	Disease	61	62	3	1:NR:2	R2L	CROSS	135-136	61-62	D019821	simvastatin	Chemical	135	136	8	D006973	hypertension	Disease	61	62	3	1:NR:2	R2L	CROSS	133-134	74-75	D008148	lovastatin	Chemical	133	134	8	D006937	hypercholesterolemia	Disease	74	75	4	1:NR:2	R2L	CROSS	135-136	74-75	D019821	simvastatin	Chemical	135	136	8	D006937	hypercholesterolemia	Disease	74	75	4	1:NR:2	R2L	CROSS	133-134	99-100	D008148	lovastatin	Chemical	133	134	8	D007037	hypothyroidism	Disease	99	100	6	1:NR:2	R2L	CROSS	135-136	99-100	D019821	simvastatin	Chemical	135	136	8	D007037	hypothyroidism	Disease	99	100	6	1:NR:2	R2L	CROSS	133-134	105-107	D008148	lovastatin	Chemical	133	134	8	D013967	autoimmune thyroiditis	Disease	105	107	6	1:NR:2	R2L	CROSS	135-136	105-107	D019821	simvastatin	Chemical	135	136	8	D013967	autoimmune thyroiditis	Disease	105	107	6
7282516	Dose - effect and structure - function relationships in doxorubicin cardiomyopathy .|The cardiomyopathy ( CM ) produced by the anticancer drug doxorubicin ( DXR ) ( Adriamycin ) provides a unique opportunity to analyze dose - effect and structure - function relationships during development of myocardial disease .|We measured the degree of morphologic damage by ultrastructural examination of endomyocardial biopsy and the degree of performance abnormally by right heart catheterization in patients receiving DXR .|Morphologic damage was variable but was proportional to the total cumulative DXR dose between 100 and 600 mg / m2 .|Performance abnormalities correlated weakly with dose , exhibited a curvilinear relationship , and had a " threshold " for expression .|Catheterization abnormalities correlated well with morphologic damage ( r = 0 . 57 to 0 . 78 ) in a subgroup of patients in whom exercise hemodynamics were measured , and this relationship also exhibited a curvilinear , threshold configuration .|In DXR - CM myocardial damage is proportional to the degree of cytotoxic insult ( DXR dose ) while myocardial function is preserved until a critical dose or degree of damage is reached , after which myocardial performance deteriorates rapidly .	1:CID:2	L2R	NON-CROSS	9-10	10-11	D004317	doxorubicin|doxorubicin|DXR|Adriamycin|DXR|DXR|DXR|DXR	Chemical	9:22:24:27:75:88:161:175	10:23:25:28:76:89:162:176	0:1:1:1:2:3:6:6	D009202	cardiomyopathy|cardiomyopathy|CM|myocardial disease|CM|myocardial damage	Disease	10:13:15:46:163:164	11:14:16:48:164:166	0:1:1:1:6:6
7072798	Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol .|A 73 - year - old woman died of aplastic anemia less than two months after undergoing cataract extraction and beginning topical therapy with chloramphenicol .|The first signs of pancytopenia began within one month of the surgery .|The pattern of the aplastic anemia was associated with an idiosyncratic response to chloramphenicol .|This was the second report of fatal aplastic anemia after topical treatment with chloramphenicol for ocular conditions , although two cases of reversible bone marrow hypoplasia have also been reported .|Any other suspected cases of ocular toxicity associated with topically applied chloramphenicol should be reported to the National Registry of Drug - Induced Ocular Side Effects , Oregon Health Sciences University , Portland , OR 97201 .	1:CID:2	R2L	NON-CROSS	77-78	71-73	D002701	chloramphenicol|chloramphenicol|chloramphenicol|chloramphenicol|chloramphenicol	Chemical	8:34:62:77:106	9:35:63:78:107	0:1:3:4:5	D000741	aplastic anemia|aplastic anemia|aplastic anemia|aplastic anemia	Disease	1:19:53:71	3:21:55:73	0:1:3:4	1:NR:2	L2R	NON-CROSS	27-28	34-35	D002701	chloramphenicol|chloramphenicol|chloramphenicol|chloramphenicol|chloramphenicol	Chemical	8:34:62:77:106	9:35:63:78:107	0:1:3:4:5	D002386	cataract	Disease	27	28	1	1:NR:2	L2R	CROSS	34-35	40-41	D002701	chloramphenicol|chloramphenicol|chloramphenicol|chloramphenicol|chloramphenicol	Chemical	8:34:62:77:106	9:35:63:78:107	0:1:3:4:5	D010198	pancytopenia	Disease	40	41	2	1:NR:2	L2R	NON-CROSS	77-78	87-90	D002701	chloramphenicol|chloramphenicol|chloramphenicol|chloramphenicol|chloramphenicol	Chemical	8:34:62:77:106	9:35:63:78:107	0:1:3:4:5	D001855	bone marrow hypoplasia	Disease	87	90	4	1:NR:2	L2R	NON-CROSS	100-102	106-107	D002701	chloramphenicol|chloramphenicol|chloramphenicol|chloramphenicol|chloramphenicol	Chemical	8:34:62:77:106	9:35:63:78:107	0:1:3:4:5	D005128	ocular toxicity	Disease	100	102	5
3769769	Bradycardia due to trihexyphenidyl hydrochloride .|A chronic schizophrenic patient was treated with an anticholinergic drug , trihexyphenidyl hydrochloride .|The patient developed , paradoxically , sinus bradycardia .|The reaction was specific to trihexyphenidyl and not to other anticholinergic drugs .|This antidyskinetic drug is widely used in clinical psychiatric practice and physicians should be aware of this side effect .	1:CID:2	R2L	NON-CROSS	3-5	0-1	D014282	trihexyphenidyl hydrochloride|trihexyphenidyl hydrochloride|trihexyphenidyl	Chemical	3:17:34	5:19:35	0:1:3	D001919	Bradycardia|bradycardia	Disease	0:27	1:28	0:2	1:NR:2	L2R	NON-CROSS	3-5	8-9	D014282	trihexyphenidyl hydrochloride|trihexyphenidyl hydrochloride|trihexyphenidyl	Chemical	3:17:34	5:19:35	0:1:3	D012559	schizophrenic	Disease	8	9	1	1:NR:2	L2R	CROSS	34-35	50-51	D014282	trihexyphenidyl hydrochloride|trihexyphenidyl hydrochloride|trihexyphenidyl	Chemical	3:17:34	5:19:35	0:1:3	D001523	psychiatric	Disease	50	51	4
3708922	Experimental cyclosporine nephrotoxicity : risk of concomitant chemotherapy .|The role of cyclosporine ( CSA ) alone or in combination with various chemotherapeutics in the development of renal toxicity was evaluated in rats .|Administration of 20 mg / kg / day CSA for 4 weeks caused renal functional and structural changes similar to those reported in man .|The combined administration of CSA and various chemotherapeutic drugs with a nephrotoxic potential , such as gentamicin ( at therapeutic doses ) , amphothericin B and ketoconazole , which are frequently used in immunosuppressed patients , did not aggravate the CSA induced toxicity in the rat model .|Gentamicin at toxic doses , however , increased CSA nephrotoxicity .|Thus , the nephrotoxicity induced by CSA has a different pathogenetic mechanism .	1:CID:2	L2R	NON-CROSS	1-2	2-3	D016572	cyclosporine|cyclosporine|CSA|CSA|CSA|CSA|CSA|CSA	Chemical	1:12:14:42:63:99:115:124	2:13:15:43:64:100:116:125	0:1:1:2:3:3:4:5	D007674	nephrotoxicity|renal toxicity|nephrotoxic|nephrotoxicity|nephrotoxicity	Disease	2:27:70:116:121	3:29:71:117:122	0:1:3:4:5	1:NR:2	L2R	NON-CROSS	99-100	101-102	D016572	cyclosporine|cyclosporine|CSA|CSA|CSA|CSA|CSA|CSA	Chemical	1:12:14:42:63:99:115:124	2:13:15:43:64:100:116:125	0:1:1:2:3:3:4:5	D064420	toxicity	Disease	101	102	3	1:NR:2	R2L	NON-CROSS	75-76	70-71	D005839	gentamicin|Gentamicin	Chemical	75:107	76:108	3:4	D007674	nephrotoxicity|renal toxicity|nephrotoxic|nephrotoxicity|nephrotoxicity	Disease	2:27:70:116:121	3:29:71:117:122	0:1:3:4:5	1:NR:2	R2L	NON-CROSS	82-84	70-71	D000666	amphothericin B	Chemical	82	84	3	D007674	nephrotoxicity|renal toxicity|nephrotoxic|nephrotoxicity|nephrotoxicity	Disease	2:27:70:116:121	3:29:71:117:122	0:1:3:4:5	1:NR:2	R2L	NON-CROSS	85-86	70-71	D007654	ketoconazole	Chemical	85	86	3	D007674	nephrotoxicity|renal toxicity|nephrotoxic|nephrotoxicity|nephrotoxicity	Disease	2:27:70:116:121	3:29:71:117:122	0:1:3:4:5	1:NR:2	L2R	NON-CROSS	101-102	107-108	D005839	gentamicin|Gentamicin	Chemical	75:107	76:108	3:4	D064420	toxicity	Disease	101	102	3	1:NR:2	L2R	NON-CROSS	82-84	101-102	D000666	amphothericin B	Chemical	82	84	3	D064420	toxicity	Disease	101	102	3	1:NR:2	L2R	NON-CROSS	85-86	101-102	D007654	ketoconazole	Chemical	85	86	3	D064420	toxicity	Disease	101	102	3
3220106	Receptor mechanisms of nicotine - induced locomotor hyperactivity in chronic nicotine - treated rats .|Rats were pretreated with saline or nicotine ( 1 . 5 mg / kg per day ) by subcutaneously implanting each animal with an Alzet osmotic mini - pump which continuously released saline or nicotine for 1 , 5 and 14 days .|At the end of each pretreatment period , animals were used for ( i ) determining their locomotor response to acutely injected nicotine ( 0 . 2 mg / kg , s . c . ) and ( ii ) measuring the density of L - [ 3H ] nicotine and [ 3H ] spiperone binding sites in the striatum .|We observed no changes in nicotine - induced locomotor response , striatal L - [ 3H ] nicotine and [ 3H ] spiperone binding in the animals pretreated with nicotine for 1 day .|In rats which were pretreated with nicotine for 5 days , there was a significant increase in the nicotine - stimulated locomotor response which was associated with an increase in the number of L - [ 3H ] nicotine binding sites and also with an elevated dopamine ( DA ) level in the striatum .|The number of striatal [ 3H ] spiperone binding sites was not affected .|In animals pretreated with nicotine for 14 days , the nicotine - induced locomotor response remained to be potentiated .|However , this response was correlated with an elevated number of striatal [ 3H ] spiperone binding sites , whereas the number of striatal L - [ 3H ] nicotine binding sites and the striatal DA level were normal .|These results suggest that chronic nicotine - treated rats develop locomotor hyperactivity in response to nicotine initially due to increases of both the density of nicotinic receptors and DA concentration , followed by inducing DA receptor supersensitivity in the striatum .	1:CID:2	L2R	NON-CROSS	3-4	6-8	D009538	nicotine|nicotine|nicotine|nicotine|nicotine|nicotine|nicotine|nicotine|nicotine|nicotine|nicotine|nicotine|nicotine|nicotine|nicotine|nicotine|nicotine	Chemical	3:10:21:49:80:107:124:136:148:159:171:191:226:232:271:287:297	4:11:22:50:81:108:125:137:149:160:172:192:227:233:272:288:298	0:0:1:1:2:2:3:3:3:4:4:4:6:6:7:8:8	D006948	locomotor hyperactivity|locomotor hyperactivity	Disease	6:292	8:294	0:8	1:NR:2	R2L	CROSS	292-294	257-258	D013134	spiperone|spiperone|spiperone|spiperone	Chemical	112:141:215:257	113:142:216:258	2:3:5:7	D006948	locomotor hyperactivity|locomotor hyperactivity	Disease	6:292	8:294	0:8	1:NR:2	R2L	NON-CROSS	292-294	277-278	D004298	dopamine|DA|DA|DA|DA	Chemical	199:201:277:310:316	200:202:278:311:317	4:4:7:8:8	D006948	locomotor hyperactivity|locomotor hyperactivity	Disease	6:292	8:294	0:8
2722224	Hydrocortisone - induced hypertension in humans : pressor responsiveness and sympathetic function .|Oral hydrocortisone increases blood pressure and enhances pressor responsiveness in normal human subjects .|We studied the effects of 1 week of oral hydrocortisone ( 200 mg / day ) on blood pressure , cardiac output , total peripheral resistance , forearm vascular resistance , and norepinephrine spillover to plasma in eight healthy male volunteers .|Although diastolic blood pressure remained unchanged , systolic blood pressure increased from 119 to 135 mm Hg ( SED + / - 3 . 4 , p less than 0 . 01 ) , associated with an increased cardiac output ( 5 . 85 - 7 . 73 l / min , SED + / - 0 . 46 , p less than 0 . 01 ) .|Total peripheral vascular resistance fell from 15 . 1 to 12 . 2 mm Hg / l / min ( SED + / - 1 . 03 , p less than 0 . 05 ) .|Resting forearm vascular resistance remained unchanged , but the reflex response to the cold pressor test was accentuated , the rise in resistance increasing from 10 . 5 mm Hg / ml / 100 ml / min ( R units ) before treatment to 32 . 6 R units after treatment ( SED + / - 6 . 4 , p less than 0 . 025 ) .|The rise in forearm vascular resistance accompanying intra - arterial norepinephrine ( 25 , 50 , and 100 ng / min ) was also significantly greater after hydrocortisone , increasing from an average of 14 . 9 + / - 2 . 4 R units before treatment to 35 . 1 + / - 5 . 5 R units after hydrocortisone ( SED + / - 6 . 0 , p less than 0 . 05 ) .|A shift to the left in the dose - response relation and fall in threshold suggested increased sensitivity to norepinephrine after treatment .|Measurement of resting norepinephrine spillover rate to plasma and norepinephrine uptake indicated that overall resting sympathetic nervous system activity was not increased .|The rise in resting blood pressure with hydrocortisone is associated with an increased cardiac output ( presumably due to increased blood volume ) . ( ABSTRACT TRUNCATED AT 250 WORDS )	1:CID:2	L2R	NON-CROSS	366-371	372-373	D006854	Hydrocortisone|hydrocortisone|hydrocortisone|hydrocortisone|hydrocortisone|hydrocortisone	Chemical	0:14:36:268:301:372	1:15:37:269:302:373	0:1:2:6:6:9	D006973	hypertension|rise in resting blood pressure	Disease	3:366	4:371	0:9	1:NR:2	L2R	NON-CROSS	372-373	377-380	D006854	Hydrocortisone|hydrocortisone|hydrocortisone|hydrocortisone|hydrocortisone|hydrocortisone	Chemical	0:14:36:268:301:372	1:15:37:269:302:373	0:1:2:6:6:9	D016534	increased cardiac output|increased cardiac output	Disease	106:377	109:380	3:9	1:NR:2	R2L	CROSS	366-371	351-352	D009638	norepinephrine|norepinephrine|norepinephrine|norepinephrine|norepinephrine	Chemical	59:251:338:345:351	60:252:339:346:352	2:6:7:8:8	D006973	hypertension|rise in resting blood pressure	Disease	3:366	4:371	0:9	1:NR:2	L2R	CROSS	351-352	377-380	D009638	norepinephrine|norepinephrine|norepinephrine|norepinephrine|norepinephrine	Chemical	59:251:338:345:351	60:252:339:346:352	2:6:7:8:8	D016534	increased cardiac output|increased cardiac output	Disease	106:377	109:380	3:9
1636026	Effects of suprofen on the isolated perfused rat kidney .|Although suprofen has been associated with the development of acute renal failure in greater than 100 subjects , the mechanism of damage remains unclear .|The direct nephrotoxic effects of a single dose of 15 mg of suprofen were compared in the recirculating isolated rat kidney perfused with cell - free buffer with or without the addition of 5 mg / dL of uric acid .|There were no significant differences in renal sodium excretion , oxygen consumption , or urinary flow rates in kidneys perfused with suprofen compared with the drug - free control groups .|In contrast , a significant decline in glomerular filtration rate was found after the introduction of suprofen to the kidney perfused with uric acid ; no changes were found with suprofen in the absence of uric acid .|A significant decrease in the baseline excretion rate of uric acid was found in rats given suprofen , compared with drug - free controls .|However , the fractional excretion of uric acid was unchanged between the groups over the experimental period .|In summary , suprofen causes acute declines in renal function , most likely by directly altering the intrarenal distribution of uric acid .	1:CID:2	L2R	NON-CROSS	191-192	193-198	D013496	suprofen|suprofen|suprofen|suprofen|suprofen|suprofen|suprofen|suprofen	Chemical	2:11:47:97:123:137:161:191	3:12:48:98:124:138:162:192	0:1:2:3:4:4:5:7	D058186	acute renal failure|acute declines in renal function	Disease	19:193	22:198	1:7	1:NR:2	L2R	NON-CROSS	37-38	47-48	D013496	suprofen|suprofen|suprofen|suprofen|suprofen|suprofen|suprofen|suprofen	Chemical	2:11:47:97:123:137:161:191	3:12:48:98:124:138:162:192	0:1:2:3:4:4:5:7	D007674	nephrotoxic	Disease	37	38	2	1:NR:2	R2L	NON-CROSS	208-210	193-198	D014527	uric acid|uric acid|uric acid|uric acid|uric acid|uric acid	Chemical	73:129:142:154:176:208	75:131:144:156:178:210	2:4:4:5:6:7	D058186	acute renal failure|acute declines in renal function	Disease	19:193	22:198	1:7	1:NR:2	R2L	CROSS	83-84	19-22	D012964	sodium	Chemical	83	84	3	D058186	acute renal failure|acute declines in renal function	Disease	19:193	22:198	1:7	1:NR:2	R2L	CROSS	86-87	19-22	D010100	oxygen	Chemical	86	87	3	D058186	acute renal failure|acute declines in renal function	Disease	19:193	22:198	1:7	1:NR:2	R2L	NON-CROSS	73-75	37-38	D014527	uric acid|uric acid|uric acid|uric acid|uric acid|uric acid	Chemical	73:129:142:154:176:208	75:131:144:156:178:210	2:4:4:5:6:7	D007674	nephrotoxic	Disease	37	38	2	1:NR:2	R2L	CROSS	83-84	37-38	D012964	sodium	Chemical	83	84	3	D007674	nephrotoxic	Disease	37	38	2	1:NR:2	R2L	CROSS	86-87	37-38	D010100	oxygen	Chemical	86	87	3	D007674	nephrotoxic	Disease	37	38	2
1610717	Cocaine - induced brainstem seizures and behavior .|A variety of abnormal sensory / motor behaviors associated with electrical discharges recorded from the bilateral brainstem were induced in adult WKY rats by mechanical ( electrode implants ) and DC electrical current stimulations and by acute and chronic administration of cocaine .|The electrode implant implicated one side or the other of the reticular system of the brainstem but subjects were not incapacitated by the stimulations .|Cocaine ( 40 mg / kg ) was injected subcutaneously for an acute experiment and subsequent 20 mg / kg doses twice daily for 3 days in a chronic study .|Cocaine generated more abnormal behaviors in the brainstem perturbation group , especially the electrically perturbated subjects .|The abnormal behaviors were yawning , retrocollis , hyperactivity , hypersensitivity , " beating drum " behavior , squealing , head bobbing , circling , sniffing , abnormal posturing , and facial twitching .|Shifts in the power frequency spectra of the discharge patterns were noted between quiet and pacing behavioral states .|Hypersensitivity to various auditory , tactile , and visual stimulation was present and shifts in the brainstem ambient power spectral frequency occurred in response to tactile stimulation .|These findings suggest that the brainstem generates and propagates pathological discharges that can be elicited by mechanical and DC electrical perturbation .|Cocaine was found to activate the discharge system and thus induce abnormal behaviors that are generated at the discharge site and at distant sites to which the discharge propagates .|Cognitive functions may also be involved since dopaminergic and serotonergic cellular elements at the brainstem level are also implicated .	1:CID:2	L2R	NON-CROSS	0-1	4-5	D003042	Cocaine|cocaine|Cocaine|Cocaine|Cocaine	Chemical	0:49:76:107:227	1:50:77:108:228	0:1:3:4:9	D012640	seizures	Disease	4	5	0	1:NR:2	L2R	CROSS	107-108	132-133	D003042	Cocaine|cocaine|Cocaine|Cocaine|Cocaine	Chemical	0:49:76:107:227	1:50:77:108:228	0:1:3:4:9	D006948	hyperactivity	Disease	132	133	5	1:NR:2	L2R	CROSS	107-108	134-135	D003042	Cocaine|cocaine|Cocaine|Cocaine|Cocaine	Chemical	0:49:76:107:227	1:50:77:108:228	0:1:3:4:9	D004342	hypersensitivity|Hypersensitivity	Disease	134:177	135:178	5:7
873132	Increased sulfation and decreased 7alpha - hydroxylation of deoxycholic acid in ethinyl estradiol - induced cholestasis in rats .|Deoxycholic acid conjugation , transport capacity , and metabolism were compared in control and ethinyl estradiol - treated rats .|Control rats were found to have a lower capacity to transport deoxycholic acid than taurodeoxycholic acid , and both were decreased by ethinyl estradiol treatment .|During [ 24 - 14C ] sodium deoxycholate infusion , [ 14C ] biliary bile acid secretion increased , but bile flow did not change significantly in either control or ethinyl estradiol - treated rats .|Ethinyl estradiol - treated animals excreted significantly less 14C as taurocholic acid than did control animals , consistent with an impairment of 7alpha - hydroxylation of taurodeoxycholic acid .|Ethinyl estradiol treatment did not impair conjugation of deoxycholic acid , but did result in an increase in sulfation of taurodeoxycholic acid from 1 . 5 % in controls to nearly 4 . 0 % ( P less than 0 . 01 ) .|These results are consistent with the hypothesis that the rat has a poorer tolerance for deoxycholic acid than do certain other species .|Furthermore , the rat converts deoxycholic acid , a poor choleretic , to taurocholic acid , a good choleretic .|When this conversion is impaired with ethinyl estradiol treatment , sulfation may be an important alternate pathway for excretion of this potentially harmful bile acid .	1:NR:2	L2R	NON-CROSS	15-16	19-21	D003840	deoxycholic acid|Deoxycholic acid|deoxycholic acid|sodium deoxycholate|deoxycholic acid|deoxycholic acid|deoxycholic acid	Chemical	8:19:50:71:138:189:202	10:21:52:73:140:191:204	0:1:2:3:5:6:7	D002779	cholestasis	Disease	15	16	0	1:CID:2	L2R	NON-CROSS	11-13	15-16	D004997	ethinyl estradiol|ethinyl estradiol|ethinyl estradiol|ethinyl estradiol|Ethinyl estradiol|Ethinyl estradiol|ethinyl estradiol	Chemical	11:33:61:95:101:130:223	13:35:63:97:103:132:225	0:1:2:3:4:5:8	D002779	cholestasis	Disease	15	16	0	1:NR:2	R2L	CROSS	53-55	15-16	D013657	taurodeoxycholic acid|taurodeoxycholic acid|taurodeoxycholic acid	Chemical	53:127:150	55:129:152	2:4:5	D002779	cholestasis	Disease	15	16	0	1:NR:2	R2L	CROSS	79-81	15-16	D001647	bile acid|bile acid	Chemical	79:240	81:242	3:8	D002779	cholestasis	Disease	15	16	0	1:NR:2	R2L	CROSS	111-113	15-16	D013656	taurocholic acid|taurocholic acid	Chemical	111:210	113:212	4:7	D002779	cholestasis	Disease	15	16	0
783197	Effects of ouabain on myocardial oxygen supply and demand in patients with chronic coronary artery disease .|A hemodynamic , volumetric , and metabolic study in patients without heart failure .|The effects of digitalis glycosides on myocardial oxygen supply and demand are of particular interest in the presence of obstructive coronary artery disease , but have not been measured previously in man .|We assessed the effects of ouabain ( 0 . 015 mg / kg body weight ) on hemodynamic , volumetric , and metabolic parameters in 11 patients with severe chronic coronary artery disease without clinical congestive heart failure .|Because the protocol was long and involved interventions which might affect the determinations , we also studied in nine patients using an identical protocol except that ouabain administration was omitted .|Left ventricular end - diastolic pressure and left ventricular end - diastolic volume fell in each patient given ouabain , even though they were initially elevated in only two patients .|Left ventricular end - diastolic pressure fell from 11 . 5 + / - 1 . 4 ( mean + / - SE ) to 5 . 6 + / - 0 . 9 mm Hg ( P less than 0 . 001 ) and left ventricular end - diastolic volume fell from 100 + / - 17 to 82 + / - 12 ml / m2 ( P less than 0 . 01 ) 1 h after ouabain infusion was completed .|The maximum velocity of contractile element shortening increased from 1 . 68 + / - 0 . 11 ml / s to 2 . 18 + / - 0 . 21 muscle - lengths / s ( P less than 0 . 05 ) and is consistent with an increase in contractility .|No significant change in these parameters occurred in the control patients .|No significant change in myocardial oxygen consumption occurred after ouabain administration but this may be related to a greater decrease in mean arterial pressure in the ouabain patients than in the control patients .|We conclude that in patients with chronic coronary artery disease who are not in clinical congestive heart failure left ventricular end - diastolic volume falls after ouabain administration even when it is initially normal .|Though this fall would be associated with a decrease in wall tension , and , therefore , of myocardial oxygen consumption , it may not be of sufficient magnitude to prevent a net increase in myocardial oxygen consumption .|Nevertheless , compensatory mechanisms prevent a deterioration of resting myocardial metabolism .	1:NR:2	L2R	NON-CROSS	2-3	13-16	D010042	ouabain|ouabain|ouabain|ouabain|ouabain|ouabain|ouabain|ouabain	Chemical	2:69:129:152:243:322:339:373	3:70:130:153:244:323:340:374	0:3:4:5:6:9:9:10	D003324	coronary artery disease|coronary artery disease|coronary artery disease|coronary artery disease	Disease	13:51:94:354	16:54:97:357	0:2:3:10	1:NR:2	L2R	NON-CROSS	362-365	373-374	D010042	ouabain|ouabain|ouabain|ouabain|ouabain|ouabain|ouabain|ouabain	Chemical	2:69:129:152:243:322:339:373	3:70:130:153:244:323:340:374	0:3:4:5:6:9:9:10	D006333	heart failure|congestive heart failure|congestive heart failure	Disease	28:99:362	30:102:365	1:3:10	1:CID:2	L2R	NON-CROSS	365-372	373-374	D010042	ouabain|ouabain|ouabain|ouabain|ouabain|ouabain|ouabain|ouabain	Chemical	2:69:129:152:243:322:339:373	3:70:130:153:244:323:340:374	0:3:4:5:6:9:9:10	D002303	left ventricular end - diastolic volume falls	Disease	365	372	10	1:NR:2	L2R	NON-CROSS	5-6	13-16	D010100	oxygen|oxygen|oxygen|oxygen|oxygen	Chemical	5:38:318:401:418	6:39:319:402:419	0:2:9:11:11	D003324	coronary artery disease|coronary artery disease|coronary artery disease|coronary artery disease	Disease	13:51:94:354	16:54:97:357	0:2:3:10	1:NR:2	L2R	CROSS	28-30	38-39	D010100	oxygen|oxygen|oxygen|oxygen|oxygen	Chemical	5:38:318:401:418	6:39:319:402:419	0:2:9:11:11	D006333	heart failure|congestive heart failure|congestive heart failure	Disease	28:99:362	30:102:365	1:3:10	1:NR:2	L2R	CROSS	365-372	401-402	D010100	oxygen|oxygen|oxygen|oxygen|oxygen	Chemical	5:38:318:401:418	6:39:319:402:419	0:2:9:11:11	D002303	left ventricular end - diastolic volume falls	Disease	365	372	10	1:NR:2	R2L	NON-CROSS	51-54	34-36	D004071	digitalis glycosides	Chemical	34	36	2	D003324	coronary artery disease|coronary artery disease|coronary artery disease|coronary artery disease	Disease	13:51:94:354	16:54:97:357	0:2:3:10	1:NR:2	R2L	CROSS	34-36	28-30	D004071	digitalis glycosides	Chemical	34	36	2	D006333	heart failure|congestive heart failure|congestive heart failure	Disease	28:99:362	30:102:365	1:3:10	1:NR:2	L2R	CROSS	34-36	365-372	D004071	digitalis glycosides	Chemical	34	36	2	D002303	left ventricular end - diastolic volume falls	Disease	365	372	10
9545159	Prolongation of the QT interval related to cisapride - diltiazem interaction .|Cisapride , a cytochrome P450 3A4 ( CYP3A4 ) substrate , is widely prescribed for the treatment of gastrointestinal motility disorders .|Prolongation of QT interval , torsades de pointes , and sudden cardiac death have been reported after concomitant administration with erythromycin or azole antifungal agents , but not with other CYP3A4 inhibitors .|A possible drug interaction occurred in a 45 - year - old woman who was taking cisapride for gastroesophageal reflux disorder and diltiazem , an agent that has inhibitory effect on CYP3A4 , for hypertension .|The patient was in near syncope and had QT - interval prolongation .|After discontinuing cisapride , the QT interval returned to normal and symptoms did not recur .|We suggest that caution be taken when cisapride is prescribed with any potent inhibitor of CYP3A4 , including diltiazem .	1:CID:2	R2L	NON-CROSS	7-8	0-5	D020117	cisapride|Cisapride|cisapride|cisapride|cisapride	Chemical	7:12:83:118:139	8:13:84:119:140	0:1:3:5:6	D008133	Prolongation of the QT interval|Prolongation of QT interval|QT - interval prolongation	Disease	0:34:111	5:38:115	0:2:4	1:CID:2	R2L	NON-CROSS	9-10	0-5	D004110	diltiazem|diltiazem|diltiazem	Chemical	9:89:150	10:90:151	0:3:6	D008133	Prolongation of the QT interval|Prolongation of QT interval|QT - interval prolongation	Disease	0:34:111	5:38:115	0:2:4	1:CID:2	R2L	NON-CROSS	54-55	34-38	D004917	erythromycin	Chemical	54	55	2	D008133	Prolongation of the QT interval|Prolongation of QT interval|QT - interval prolongation	Disease	0:34:111	5:38:115	0:2:4	1:CID:2	R2L	NON-CROSS	56-57	34-38	D001393	azole	Chemical	56	57	2	D008133	Prolongation of the QT interval|Prolongation of QT interval|QT - interval prolongation	Disease	0:34:111	5:38:115	0:2:4	1:NR:2	L2R	NON-CROSS	12-13	30-33	D020117	cisapride|Cisapride|cisapride|cisapride|cisapride	Chemical	7:12:83:118:139	8:13:84:119:140	0:1:3:5:6	D015835	gastrointestinal motility disorders	Disease	30	33	1	1:CID:2	L2R	CROSS	12-13	39-42	D020117	cisapride|Cisapride|cisapride|cisapride|cisapride	Chemical	7:12:83:118:139	8:13:84:119:140	0:1:3:5:6	D016171	torsades de pointes	Disease	39	42	2	1:CID:2	L2R	CROSS	12-13	44-47	D020117	cisapride|Cisapride|cisapride|cisapride|cisapride	Chemical	7:12:83:118:139	8:13:84:119:140	0:1:3:5:6	D016757	sudden cardiac death	Disease	44	47	2	1:NR:2	L2R	NON-CROSS	83-84	85-88	D020117	cisapride|Cisapride|cisapride|cisapride|cisapride	Chemical	7:12:83:118:139	8:13:84:119:140	0:1:3:5:6	D005764	gastroesophageal reflux disorder	Disease	85	88	3	1:NR:2	L2R	NON-CROSS	101-102	118-119	D020117	cisapride|Cisapride|cisapride|cisapride|cisapride	Chemical	7:12:83:118:139	8:13:84:119:140	0:1:3:5:6	D006973	hypertension	Disease	101	102	3	1:NR:2	L2R	CROSS	108-109	118-119	D020117	cisapride|Cisapride|cisapride|cisapride|cisapride	Chemical	7:12:83:118:139	8:13:84:119:140	0:1:3:5:6	D013575	syncope	Disease	108	109	4	1:NR:2	L2R	CROSS	9-10	30-33	D004110	diltiazem|diltiazem|diltiazem	Chemical	9:89:150	10:90:151	0:3:6	D015835	gastrointestinal motility disorders	Disease	30	33	1	1:NR:2	L2R	CROSS	9-10	39-42	D004110	diltiazem|diltiazem|diltiazem	Chemical	9:89:150	10:90:151	0:3:6	D016171	torsades de pointes	Disease	39	42	2	1:NR:2	L2R	CROSS	9-10	44-47	D004110	diltiazem|diltiazem|diltiazem	Chemical	9:89:150	10:90:151	0:3:6	D016757	sudden cardiac death	Disease	44	47	2	1:NR:2	L2R	NON-CROSS	85-88	89-90	D004110	diltiazem|diltiazem|diltiazem	Chemical	9:89:150	10:90:151	0:3:6	D005764	gastroesophageal reflux disorder	Disease	85	88	3	1:NR:2	L2R	NON-CROSS	89-90	101-102	D004110	diltiazem|diltiazem|diltiazem	Chemical	9:89:150	10:90:151	0:3:6	D006973	hypertension	Disease	101	102	3	1:NR:2	L2R	CROSS	89-90	108-109	D004110	diltiazem|diltiazem|diltiazem	Chemical	9:89:150	10:90:151	0:3:6	D013575	syncope	Disease	108	109	4	1:NR:2	R2L	CROSS	54-55	30-33	D004917	erythromycin	Chemical	54	55	2	D015835	gastrointestinal motility disorders	Disease	30	33	1	1:NR:2	R2L	CROSS	56-57	30-33	D001393	azole	Chemical	56	57	2	D015835	gastrointestinal motility disorders	Disease	30	33	1	1:CID:2	R2L	NON-CROSS	54-55	39-42	D004917	erythromycin	Chemical	54	55	2	D016171	torsades de pointes	Disease	39	42	2	1:CID:2	R2L	NON-CROSS	56-57	39-42	D001393	azole	Chemical	56	57	2	D016171	torsades de pointes	Disease	39	42	2	1:CID:2	R2L	NON-CROSS	54-55	44-47	D004917	erythromycin	Chemical	54	55	2	D016757	sudden cardiac death	Disease	44	47	2	1:CID:2	R2L	NON-CROSS	56-57	44-47	D001393	azole	Chemical	56	57	2	D016757	sudden cardiac death	Disease	44	47	2	1:NR:2	L2R	CROSS	54-55	85-88	D004917	erythromycin	Chemical	54	55	2	D005764	gastroesophageal reflux disorder	Disease	85	88	3	1:NR:2	L2R	CROSS	54-55	101-102	D004917	erythromycin	Chemical	54	55	2	D006973	hypertension	Disease	101	102	3	1:NR:2	L2R	CROSS	54-55	108-109	D004917	erythromycin	Chemical	54	55	2	D013575	syncope	Disease	108	109	4	1:NR:2	L2R	CROSS	56-57	85-88	D001393	azole	Chemical	56	57	2	D005764	gastroesophageal reflux disorder	Disease	85	88	3	1:NR:2	L2R	CROSS	56-57	101-102	D001393	azole	Chemical	56	57	2	D006973	hypertension	Disease	101	102	3	1:NR:2	L2R	CROSS	56-57	108-109	D001393	azole	Chemical	56	57	2	D013575	syncope	Disease	108	109	4
8643973	Paclitaxel combined with carboplatin in the first - line treatment of advanced ovarian cancer .|In a phase I study to determine the maximum tolerated dose of paclitaxel ( Taxol ; Bristol - Myers Squibb Company , Princeton , NJ ) given as a 3 - hour infusion in combination with carboplatin administered every 21 days to women with advanced ovarian cancer , paclitaxel doses were escalated as follows : level 1 , 135 mg / m2 ; level 2 , 160 mg / m2 ; level 3 , 185 mg / m2 ; and level 4 , 210 mg / m2 .|The fixed dose of carboplatin at levels 1 through 4 was given to achieve an area under the concentration - time curve ( AUC ) of 5 using the Calvert formula .|In levels 5 and 6 the carboplatin dose was targeted at AUCs of 6 and 7 . 5 , respectively , combined with a fixed paclitaxel dose of 185 mg / m2 .|To date , 30 previously untreated patients , all with a good performance status ( Eastern Cooperative Oncology Group 0 to 2 ) have been entered into this ongoing study .|The dose - limiting toxicity of the combination was myelosuppression ( leukopenia , granulocytopenia , and thrombocytopenia ) .|Neurotoxicity was largely moderate .|So far , 14 patients are evaluable for response ; of these , eight ( 57 % ) showed objective ( complete or partial ) response and disease stabilized in six patients .|No patient had disease progression .|We conclude that the combination of paclitaxel 185 mg / m2 administered as a 3 - hour infusion followed immediately by a 1 - hour infusion of carboplatin at an AUC of 6 can be administered safely in a 21 - day schedule in the outpatient setting .|The recommended dose for phase III studies is paclitaxel 185 mg / m2 and carboplatin AUC 6 .	1:NR:2	L2R	NON-CROSS	60-62	63-64	D017239	Paclitaxel|paclitaxel|Taxol|paclitaxel|paclitaxel|paclitaxel|paclitaxel	Chemical	0:27:29:63:160:268:318	1:28:30:64:161:269:319	0:1:1:1:3:9:10	D010051	ovarian cancer|ovarian cancer	Disease	12:60	14:62	0:1	1:NR:2	L2R	CROSS	160-161	203-204	D017239	Paclitaxel|paclitaxel|Taxol|paclitaxel|paclitaxel|paclitaxel|paclitaxel	Chemical	0:27:29:63:160:268:318	1:28:30:64:161:269:319	0:1:1:1:3:9:10	D064420	toxicity	Disease	203	204	5	1:NR:2	L2R	CROSS	160-161	208-209	D017239	Paclitaxel|paclitaxel|Taxol|paclitaxel|paclitaxel|paclitaxel|paclitaxel	Chemical	0:27:29:63:160:268:318	1:28:30:64:161:269:319	0:1:1:1:3:9:10	D001855	myelosuppression	Disease	208	209	5	1:CID:2	L2R	CROSS	160-161	210-211	D017239	Paclitaxel|paclitaxel|Taxol|paclitaxel|paclitaxel|paclitaxel|paclitaxel	Chemical	0:27:29:63:160:268:318	1:28:30:64:161:269:319	0:1:1:1:3:9:10	D007970	leukopenia	Disease	210	211	5	1:CID:2	L2R	CROSS	160-161	212-213	D017239	Paclitaxel|paclitaxel|Taxol|paclitaxel|paclitaxel|paclitaxel|paclitaxel	Chemical	0:27:29:63:160:268:318	1:28:30:64:161:269:319	0:1:1:1:3:9:10	D000380	granulocytopenia	Disease	212	213	5	1:CID:2	L2R	CROSS	215-216	268-269	D017239	Paclitaxel|paclitaxel|Taxol|paclitaxel|paclitaxel|paclitaxel|paclitaxel	Chemical	0:27:29:63:160:268:318	1:28:30:64:161:269:319	0:1:1:1:3:9:10	D013921	thrombocytopenia	Disease	215	216	5	1:CID:2	L2R	CROSS	218-219	268-269	D017239	Paclitaxel|paclitaxel|Taxol|paclitaxel|paclitaxel|paclitaxel|paclitaxel	Chemical	0:27:29:63:160:268:318	1:28:30:64:161:269:319	0:1:1:1:3:9:10	D020258	Neurotoxicity	Disease	218	219	6	1:NR:2	L2R	NON-CROSS	3-4	12-14	D016190	carboplatin|carboplatin|carboplatin|carboplatin|carboplatin|carboplatin	Chemical	3:51:107:141:289:324	4:52:108:142:290:325	0:1:2:3:9:10	D010051	ovarian cancer|ovarian cancer	Disease	12:60	14:62	0:1	1:NR:2	L2R	CROSS	141-142	203-204	D016190	carboplatin|carboplatin|carboplatin|carboplatin|carboplatin|carboplatin	Chemical	3:51:107:141:289:324	4:52:108:142:290:325	0:1:2:3:9:10	D064420	toxicity	Disease	203	204	5	1:NR:2	L2R	CROSS	141-142	208-209	D016190	carboplatin|carboplatin|carboplatin|carboplatin|carboplatin|carboplatin	Chemical	3:51:107:141:289:324	4:52:108:142:290:325	0:1:2:3:9:10	D001855	myelosuppression	Disease	208	209	5	1:CID:2	L2R	CROSS	141-142	210-211	D016190	carboplatin|carboplatin|carboplatin|carboplatin|carboplatin|carboplatin	Chemical	3:51:107:141:289:324	4:52:108:142:290:325	0:1:2:3:9:10	D007970	leukopenia	Disease	210	211	5	1:CID:2	L2R	CROSS	141-142	212-213	D016190	carboplatin|carboplatin|carboplatin|carboplatin|carboplatin|carboplatin	Chemical	3:51:107:141:289:324	4:52:108:142:290:325	0:1:2:3:9:10	D000380	granulocytopenia	Disease	212	213	5	1:CID:2	L2R	CROSS	141-142	215-216	D016190	carboplatin|carboplatin|carboplatin|carboplatin|carboplatin|carboplatin	Chemical	3:51:107:141:289:324	4:52:108:142:290:325	0:1:2:3:9:10	D013921	thrombocytopenia	Disease	215	216	5	1:CID:2	L2R	CROSS	218-219	289-290	D016190	carboplatin|carboplatin|carboplatin|carboplatin|carboplatin|carboplatin	Chemical	3:51:107:141:289:324	4:52:108:142:290:325	0:1:2:3:9:10	D020258	Neurotoxicity	Disease	218	219	6
10743694	Treatment of tacrolimus - related adverse effects by conversion to cyclosporine in liver transplant recipients .|When tacrolimus side effects persist despite dose reduction , conversion to cyclosporine - based immunosuppression ( CyA ) is necessary .|We characterized tacrolimus side effects that warranted discontinuation of the drug , and outcomes after conversion .|Of 388 liver recipients who received tacrolimus as primary immunosuppression , 70 required conversion to CyA .|We recorded indication for conversion , whether conversion was early or late after transplantation , tacrolimus dose and trough blood level at conversion , and incidence of rejection after conversion .|Conversion was early in 29 patients ( 41 . 4 % ) and late in 41 ( 58 . 6 % ) .|Indications for early conversion were neurotoxicity ( 20 ) , ( insulin - dependent ) diabetes mellitus ( IDDM ) ( 5 ) , nephrotoxicity ( 3 ) , gastrointestinal ( GI ) toxicity ( 6 ) , and cardiomyopathy ( 1 ) , and for late conversion were neurotoxicity ( 15 ) , IDDM ( 12 ) , nephrotoxicity ( 3 ) , GI toxicity ( 5 ) , hepatotoxicity ( 6 ) , post - transplant lmphoproliferate disease ( PTLD ) ( 2 ) , cardiomyopathy ( 1 ) , hemolytic anemia ( 1 ) , and pruritus ( 1 ) .|All early - conversion patients showed improvement / resolution of symptoms .|Among late - conversion patients , 37 ( 90 . 2 % ) had improvement / resolution ; in 4 ( 9 . 8 % ) , adverse effects persisted .|The overall rejection rate was 30 % .|Sixty - two patients ( 88 . 6 % ) are alive with functioning grafts 686 + / - 362 days ( range , 154 - 1433 days ) after conversion .|When tacrolimus side effects are unresponsive to dose reduction , conversion to CyA can be accomplished safely , with no increased risk of rejection and excellent long - term outcome .	1:CID:2	L2R	CROSS	86-87	130-131	D016559	tacrolimus|tacrolimus|tacrolimus|tacrolimus|tacrolimus|tacrolimus	Chemical	2:17:39:60:86:313	3:18:40:61:87:314	0:1:2:3:4:11	D020258	neurotoxicity|neurotoxicity	Disease	130:174	131:175	6:6	1:CID:2	L2R	CROSS	86-87	135-142	D016559	tacrolimus|tacrolimus|tacrolimus|tacrolimus|tacrolimus|tacrolimus	Chemical	2:17:39:60:86:313	3:18:40:61:87:314	0:1:2:3:4:11	D003922	( insulin - dependent ) diabetes mellitus|IDDM|IDDM	Disease	135:143:179	142:144:180	6:6:6	1:CID:2	L2R	CROSS	86-87	149-150	D016559	tacrolimus|tacrolimus|tacrolimus|tacrolimus|tacrolimus|tacrolimus	Chemical	2:17:39:60:86:313	3:18:40:61:87:314	0:1:2:3:4:11	D007674	nephrotoxicity|nephrotoxicity	Disease	149:184	150:185	6:6	1:CID:2	L2R	CROSS	86-87	154-159	D016559	tacrolimus|tacrolimus|tacrolimus|tacrolimus|tacrolimus|tacrolimus	Chemical	2:17:39:60:86:313	3:18:40:61:87:314	0:1:2:3:4:11	D005767	gastrointestinal ( GI ) toxicity|GI toxicity	Disease	154:189	159:191	6:6	1:CID:2	L2R	CROSS	86-87	164-165	D016559	tacrolimus|tacrolimus|tacrolimus|tacrolimus|tacrolimus|tacrolimus	Chemical	2:17:39:60:86:313	3:18:40:61:87:314	0:1:2:3:4:11	D009202	cardiomyopathy|cardiomyopathy	Disease	164:212	165:213	6:6	1:CID:2	L2R	CROSS	86-87	195-196	D016559	tacrolimus|tacrolimus|tacrolimus|tacrolimus|tacrolimus|tacrolimus	Chemical	2:17:39:60:86:313	3:18:40:61:87:314	0:1:2:3:4:11	D056486	hepatotoxicity	Disease	195	196	6	1:CID:2	L2R	CROSS	206-207	313-314	D016559	tacrolimus|tacrolimus|tacrolimus|tacrolimus|tacrolimus|tacrolimus	Chemical	2:17:39:60:86:313	3:18:40:61:87:314	0:1:2:3:4:11	D008232	post - transplant lmphoproliferate disease|PTLD	Disease	200:206	205:207	6:6	1:CID:2	L2R	CROSS	217-219	313-314	D016559	tacrolimus|tacrolimus|tacrolimus|tacrolimus|tacrolimus|tacrolimus	Chemical	2:17:39:60:86:313	3:18:40:61:87:314	0:1:2:3:4:11	D000743	hemolytic anemia	Disease	217	219	6	1:CID:2	L2R	CROSS	224-225	313-314	D016559	tacrolimus|tacrolimus|tacrolimus|tacrolimus|tacrolimus|tacrolimus	Chemical	2:17:39:60:86:313	3:18:40:61:87:314	0:1:2:3:4:11	D011537	pruritus	Disease	224	225	6	1:NR:2	L2R	CROSS	27-28	130-131	D016572	cyclosporine|cyclosporine	Chemical	10:27	11:28	0:1	D020258	neurotoxicity|neurotoxicity	Disease	130:174	131:175	6:6	1:NR:2	L2R	CROSS	27-28	135-142	D016572	cyclosporine|cyclosporine	Chemical	10:27	11:28	0:1	D003922	( insulin - dependent ) diabetes mellitus|IDDM|IDDM	Disease	135:143:179	142:144:180	6:6:6	1:NR:2	L2R	CROSS	27-28	149-150	D016572	cyclosporine|cyclosporine	Chemical	10:27	11:28	0:1	D007674	nephrotoxicity|nephrotoxicity	Disease	149:184	150:185	6:6	1:NR:2	L2R	CROSS	27-28	154-159	D016572	cyclosporine|cyclosporine	Chemical	10:27	11:28	0:1	D005767	gastrointestinal ( GI ) toxicity|GI toxicity	Disease	154:189	159:191	6:6	1:NR:2	L2R	CROSS	27-28	164-165	D016572	cyclosporine|cyclosporine	Chemical	10:27	11:28	0:1	D009202	cardiomyopathy|cardiomyopathy	Disease	164:212	165:213	6:6	1:NR:2	L2R	CROSS	27-28	195-196	D016572	cyclosporine|cyclosporine	Chemical	10:27	11:28	0:1	D056486	hepatotoxicity	Disease	195	196	6	1:NR:2	L2R	CROSS	27-28	200-205	D016572	cyclosporine|cyclosporine	Chemical	10:27	11:28	0:1	D008232	post - transplant lmphoproliferate disease|PTLD	Disease	200:206	205:207	6:6	1:NR:2	L2R	CROSS	27-28	217-219	D016572	cyclosporine|cyclosporine	Chemical	10:27	11:28	0:1	D000743	hemolytic anemia	Disease	217	219	6	1:NR:2	L2R	CROSS	27-28	224-225	D016572	cyclosporine|cyclosporine	Chemical	10:27	11:28	0:1	D011537	pruritus	Disease	224	225	6
3535719	Relative efficacy and toxicity of netilmicin and tobramycin in oncology patients .|We prospectively compared the efficacy and safety of netilmicin sulfate or tobramycin sulfate in conjunction with piperacillin sodium in 118 immunocompromised patients with presumed severe infections .|The two treatment regimens were equally efficacious .|Nephrotoxicity occurred in a similar proportion in patients treated with netilmicin and tobramycin ( 17 % vs 11 % ) .|Ototoxicity occurred in four ( 9 . 5 % ) of 42 netilmicin and piperacillin and in 12 ( 22 % ) of 54 tobramycin and piperacillin - treated patients .|Of those evaluated with posttherapy audiograms , three of four netilmicin and piperacillin - treated patients had auditory thresholds return to baseline compared with one of nine tobramycin and piperacillin - treated patients .|The number of greater than or equal to 15 - dB increases in auditory threshold as a proportion of total greater than or equal to 15 - dB changes ( increases and decreases ) was significantly lower in netilmicin and piperacillin - vs tobramycin and piperacillin - treated patients ( 18 of 78 vs 67 of 115 ) .|We conclude that aminoglycoside - associated ototoxicity was less severe and more often reversible with netilmicin than with tobramycin .	1:NR:2	R2L	NON-CROSS	5-6	3-4	D009428	netilmicin|netilmicin sulfate|netilmicin|netilmicin|netilmicin|netilmicin|netilmicin	Chemical	5:20:57:80:109:171:207	6:22:58:81:110:172:208	0:1:3:4:5:6:7	D064420	toxicity	Disease	3	4	0	1:NR:2	R2L	NON-CROSS	7-8	3-4	D014031	tobramycin|tobramycin sulfate|tobramycin|tobramycin|tobramycin|tobramycin|tobramycin	Chemical	7:23:59:92:126:176:210	8:25:60:93:127:177:211	0:1:3:4:5:6:7	D064420	toxicity	Disease	3	4	0	1:NR:2	R2L	CROSS	28-30	3-4	D010878	piperacillin sodium|piperacillin|piperacillin|piperacillin|piperacillin|piperacillin|piperacillin	Chemical	28:82:94:111:128:173:178	30:83:95:112:129:174:179	1:4:4:5:5:6:6	D064420	toxicity	Disease	3	4	0	1:NR:2	R2L	CROSS	195-196	3-4	D000617	aminoglycoside	Chemical	195	196	7	D064420	toxicity	Disease	3	4	0	1:NR:2	L2R	NON-CROSS	20-22	37-38	D009428	netilmicin|netilmicin sulfate|netilmicin|netilmicin|netilmicin|netilmicin|netilmicin	Chemical	5:20:57:80:109:171:207	6:22:58:81:110:172:208	0:1:3:4:5:6:7	D007239	infections	Disease	37	38	1	1:CID:2	L2R	NON-CROSS	47-48	57-58	D009428	netilmicin|netilmicin sulfate|netilmicin|netilmicin|netilmicin|netilmicin|netilmicin	Chemical	5:20:57:80:109:171:207	6:22:58:81:110:172:208	0:1:3:4:5:6:7	D007674	Nephrotoxicity	Disease	47	48	3	1:CID:2	L2R	NON-CROSS	198-199	207-208	D009428	netilmicin|netilmicin sulfate|netilmicin|netilmicin|netilmicin|netilmicin|netilmicin	Chemical	5:20:57:80:109:171:207	6:22:58:81:110:172:208	0:1:3:4:5:6:7	D006311	Ototoxicity|ototoxicity	Disease	68:198	69:199	4:7	1:NR:2	L2R	NON-CROSS	23-25	37-38	D014031	tobramycin|tobramycin sulfate|tobramycin|tobramycin|tobramycin|tobramycin|tobramycin	Chemical	7:23:59:92:126:176:210	8:25:60:93:127:177:211	0:1:3:4:5:6:7	D007239	infections	Disease	37	38	1	1:CID:2	L2R	NON-CROSS	47-48	59-60	D014031	tobramycin|tobramycin sulfate|tobramycin|tobramycin|tobramycin|tobramycin|tobramycin	Chemical	7:23:59:92:126:176:210	8:25:60:93:127:177:211	0:1:3:4:5:6:7	D007674	Nephrotoxicity	Disease	47	48	3	1:CID:2	L2R	NON-CROSS	59-60	68-69	D014031	tobramycin|tobramycin sulfate|tobramycin|tobramycin|tobramycin|tobramycin|tobramycin	Chemical	7:23:59:92:126:176:210	8:25:60:93:127:177:211	0:1:3:4:5:6:7	D006311	Ototoxicity|ototoxicity	Disease	68:198	69:199	4:7	1:NR:2	L2R	NON-CROSS	28-30	37-38	D010878	piperacillin sodium|piperacillin|piperacillin|piperacillin|piperacillin|piperacillin|piperacillin	Chemical	28:82:94:111:128:173:178	30:83:95:112:129:174:179	1:4:4:5:5:6:6	D007239	infections	Disease	37	38	1	1:CID:2	L2R	CROSS	28-30	47-48	D010878	piperacillin sodium|piperacillin|piperacillin|piperacillin|piperacillin|piperacillin|piperacillin	Chemical	28:82:94:111:128:173:178	30:83:95:112:129:174:179	1:4:4:5:5:6:6	D007674	Nephrotoxicity	Disease	47	48	3	1:CID:2	L2R	NON-CROSS	68-69	82-83	D010878	piperacillin sodium|piperacillin|piperacillin|piperacillin|piperacillin|piperacillin|piperacillin	Chemical	28:82:94:111:128:173:178	30:83:95:112:129:174:179	1:4:4:5:5:6:6	D006311	Ototoxicity|ototoxicity	Disease	68:198	69:199	4:7	1:NR:2	R2L	CROSS	195-196	37-38	D000617	aminoglycoside	Chemical	195	196	7	D007239	infections	Disease	37	38	1	1:NR:2	R2L	CROSS	195-196	47-48	D000617	aminoglycoside	Chemical	195	196	7	D007674	Nephrotoxicity	Disease	47	48	3	1:NR:2	R2L	NON-CROSS	198-199	195-196	D000617	aminoglycoside	Chemical	195	196	7	D006311	Ototoxicity|ototoxicity	Disease	68:198	69:199	4:7
6433367	Effect of prostaglandin synthetase inhibitors on experimentally induced convulsions in rats .|To investigate the relationship of prostaglandins ( PGs ) to seizure induction , the effects of six PG synthetase inhibitors on convulsions induced by flurothyl , picrotoxin , pentetrazol ( PTZ ) , electroshock or bicuculline were evaluated .|Ibuprofen , sulindac , mefenamic acid , and low dose meclofenamic acid increased the latency - to - onset in the flurothyl and / or PTZ models ; the electroshock , picrotoxin and bicuculline models were not significantly affected by any of the pretreatment agents .|These results suggest that PGs are involved in the mechanism ( s ) underlying fluorthyl - and PTZ - induced convulsions , but not picrotoxin - , electroshock - , or bicuculline - induced convulsions .	1:NR:2	L2R	NON-CROSS	19-20	22-23	D011453	prostaglandin|prostaglandins|PGs|PGs	Chemical	2:17:19:101	3:18:20:102	0:1:1:3	D012640	convulsions|seizure|convulsions|convulsions|convulsions	Disease	8:22:33:117:131	9:23:34:118:132	0:1:1:3:3	1:CID:2	R2L	NON-CROSS	36-37	33-34	D005481	flurothyl|flurothyl|fluorthyl	Chemical	36:72:111	37:73:112	1:2:3	D012640	convulsions|seizure|convulsions|convulsions|convulsions	Disease	8:22:33:117:131	9:23:34:118:132	0:1:1:3:3	1:CID:2	R2L	NON-CROSS	121-122	117-118	D010852	picrotoxin|picrotoxin|picrotoxin	Chemical	38:82:121	39:83:122	1:2:3	D012640	convulsions|seizure|convulsions|convulsions|convulsions	Disease	8:22:33:117:131	9:23:34:118:132	0:1:1:3:3	1:CID:2	R2L	NON-CROSS	117-118	114-115	D010433	pentetrazol|PTZ|PTZ|PTZ	Chemical	40:42:76:114	41:43:77:115	1:1:2:3	D012640	convulsions|seizure|convulsions|convulsions|convulsions	Disease	8:22:33:117:131	9:23:34:118:132	0:1:1:3:3	1:CID:2	R2L	NON-CROSS	131-132	128-129	D001640	bicuculline|bicuculline|bicuculline	Chemical	47:84:128	48:85:129	1:2:3	D012640	convulsions|seizure|convulsions|convulsions|convulsions	Disease	8:22:33:117:131	9:23:34:118:132	0:1:1:3:3	1:NR:2	R2L	CROSS	51-52	33-34	D007052	Ibuprofen	Chemical	51	52	2	D012640	convulsions|seizure|convulsions|convulsions|convulsions	Disease	8:22:33:117:131	9:23:34:118:132	0:1:1:3:3	1:NR:2	R2L	CROSS	53-54	33-34	D013467	sulindac	Chemical	53	54	2	D012640	convulsions|seizure|convulsions|convulsions|convulsions	Disease	8:22:33:117:131	9:23:34:118:132	0:1:1:3:3	1:NR:2	R2L	CROSS	55-57	33-34	D008528	mefenamic acid	Chemical	55	57	2	D012640	convulsions|seizure|convulsions|convulsions|convulsions	Disease	8:22:33:117:131	9:23:34:118:132	0:1:1:3:3	1:NR:2	R2L	CROSS	61-63	33-34	D008469	meclofenamic acid	Chemical	61	63	2	D012640	convulsions|seizure|convulsions|convulsions|convulsions	Disease	8:22:33:117:131	9:23:34:118:132	0:1:1:3:3
17285209	Angiotensin - converting enzyme ( ACE ) inhibitor - associated angioedema of the stomach and small intestine : a case report .|This is a case report on a 45 - year old African - American female with newly diagnosed hypertension , who was started on a combination pill of amlodipine / benazapril 10 / 5 mg .|The very next day , she presented at the emergency room ( ER ) with abdominal pain , nausea and vomiting .|Physical exam , complete metabolic panel , and hemogram were in the normal range .|She was discharged from the ER after a few hours of treatment with fluid and analgesics .|However , she returned to the ER the next day with the same complaints .|This time the physical exam was significant for a distended abdomen with dullness to percussion .|CT scan of the abdomen revealed markedly thickened antrum of the stomach , duodenum and jejunum , along with fluid in the abdominal and pelvic cavity .|Angiotensin - converting enzyme inhibitor ( ACEI ) - induced angioedema was suspected , and anti - hypertensive medications were discontinued .|Her symptoms improved within the next 24 hours , and repeat CT after 72 hours revealed marked improvement in stomach and small bowel thickening and resolution of ascites .|The recognition of angiotensin - converting enzyme ( ACE ) and angiotensin receptor blocker ( ARB ) intestinal angioedema constitutes a challenge to primary care physicians , internists , emergency room personal and surgeons .	1:CID:2	R2L	CROSS	50-51	10-11	D017311	amlodipine	Chemical	50	51	1	D000799	angioedema|angioedema|intestinal angioedema	Disease	10:180:238	11:181:240	0:8:10	1:CID:2	R2L	CROSS	52-53	10-11	C044946	benazapril	Chemical	52	53	1	D000799	angioedema|angioedema|intestinal angioedema	Disease	10:180:238	11:181:240	0:8:10	1:NR:2	R2L	NON-CROSS	238-240	232-233	D000809	angiotensin|angiotensin	Chemical	224:232	225:233	10:10	D000799	angioedema|angioedema|intestinal angioedema	Disease	10:180:238	11:181:240	0:8:10	1:NR:2	R2L	NON-CROSS	50-51	40-41	D017311	amlodipine	Chemical	50	51	1	D006973	hypertension|hypertensive	Disease	40:187	41:188	1:8	1:NR:2	R2L	NON-CROSS	52-53	40-41	C044946	benazapril	Chemical	52	53	1	D006973	hypertension|hypertensive	Disease	40:187	41:188	1:8	1:NR:2	R2L	CROSS	224-225	187-188	D000809	angiotensin|angiotensin	Chemical	224:232	225:233	10:10	D006973	hypertension|hypertensive	Disease	40:187	41:188	1:8	1:NR:2	L2R	CROSS	50-51	73-75	D017311	amlodipine	Chemical	50	51	1	D015746	abdominal pain	Disease	73	75	2	1:NR:2	L2R	CROSS	50-51	76-77	D017311	amlodipine	Chemical	50	51	1	D009325	nausea	Disease	76	77	2	1:NR:2	L2R	CROSS	50-51	78-79	D017311	amlodipine	Chemical	50	51	1	D014839	vomiting	Disease	78	79	2	1:NR:2	L2R	CROSS	50-51	219-220	D017311	amlodipine	Chemical	50	51	1	D001201	ascites	Disease	219	220	9	1:CID:2	L2R	CROSS	50-51	238-240	D017311	amlodipine	Chemical	50	51	1	D007410	intestinal angioedema	Disease	238	240	10	1:NR:2	L2R	CROSS	52-53	73-75	C044946	benazapril	Chemical	52	53	1	D015746	abdominal pain	Disease	73	75	2	1:NR:2	L2R	CROSS	52-53	76-77	C044946	benazapril	Chemical	52	53	1	D009325	nausea	Disease	76	77	2	1:NR:2	L2R	CROSS	52-53	78-79	C044946	benazapril	Chemical	52	53	1	D014839	vomiting	Disease	78	79	2	1:NR:2	L2R	CROSS	52-53	219-220	C044946	benazapril	Chemical	52	53	1	D001201	ascites	Disease	219	220	9	1:CID:2	L2R	CROSS	52-53	238-240	C044946	benazapril	Chemical	52	53	1	D007410	intestinal angioedema	Disease	238	240	10	1:NR:2	R2L	CROSS	224-225	73-75	D000809	angiotensin|angiotensin	Chemical	224:232	225:233	10:10	D015746	abdominal pain	Disease	73	75	2	1:NR:2	R2L	CROSS	224-225	76-77	D000809	angiotensin|angiotensin	Chemical	224:232	225:233	10:10	D009325	nausea	Disease	76	77	2	1:NR:2	R2L	CROSS	224-225	78-79	D000809	angiotensin|angiotensin	Chemical	224:232	225:233	10:10	D014839	vomiting	Disease	78	79	2	1:NR:2	R2L	CROSS	224-225	219-220	D000809	angiotensin|angiotensin	Chemical	224:232	225:233	10:10	D001201	ascites	Disease	219	220	9	1:NR:2	L2R	NON-CROSS	232-233	238-240	D000809	angiotensin|angiotensin	Chemical	224:232	225:233	10:10	D007410	intestinal angioedema	Disease	238	240	10
15858223	Valproic acid I : time course of lipid peroxidation biomarkers , liver toxicity , and valproic acid metabolite levels in rats .|A single dose of valproic acid ( VPA ) , which is a widely used antiepileptic drug , is associated with oxidative stress in rats , as recently demonstrated by elevated levels of 15 - F ( 2t ) - isoprostane ( 15 - F ( 2t ) - IsoP ) .|To determine whether there was a temporal relationship between VPA - associated oxidative stress and hepatotoxicity , adult male Sprague - Dawley rats were treated ip with VPA ( 500 mg / kg ) or 0 . 9 % saline ( vehicle ) once daily for 2 , 4 , 7 , 10 , or 14 days .|Oxidative stress was assessed by determining plasma and liver levels of 15 - F ( 2t ) - IsoP , lipid hydroperoxides ( LPO ) , and thiobarbituric acid reactive substances ( TBARs ) .|Plasma and liver 15 - F ( 2t ) - IsoP were elevated and reached a plateau after day 2 of VPA treatment compared to control .|Liver LPO levels were not elevated until day 7 of treatment ( 1 . 8 - fold versus control , p < 0 . 05 ) .|Liver and plasma TBARs were not increased until 14 days ( 2 - fold vs . control , p < 0 . 05 ) .|Liver toxicity was evaluated based on serum levels of alpha - glutathione S - transferase ( alpha - GST ) and by histology .|Serum alpha - GST levels were significantly elevated by day 4 , which corresponded to hepatotoxicity as shown by the increasing incidence of inflammation of the liver capsule , necrosis , and steatosis throughout the study .|The liver levels of beta - oxidation metabolites of VPA were decreased by day 14 , while the levels of 4 - ene - VPA and ( E ) - 2 , 4 - diene - VPA were not elevated throughout the study .|Overall , these findings indicate that VPA treatment results in oxidative stress , as measured by levels of 15 - F ( 2t ) - IsoP , which precedes the onset of necrosis , steatosis , and elevated levels of serum alpha - GST .	1:CID:2	L2R	NON-CROSS	11-13	15-17	D014635	Valproic acid|valproic acid|valproic acid|VPA|VPA|VPA|VPA|VPA|VPA	Chemical	0:15:26:29:83:101:188:316:357	2:17:28:30:84:102:189:317:358	0:0:1:1:2:2:4:9:10	D056486	liver toxicity|hepatotoxicity|Liver toxicity|hepatotoxicity	Disease	11:89:246:285	13:90:248:286	0:2:7:8	1:NR:2	L2R	CROSS	293-294	316-317	D014635	Valproic acid|valproic acid|valproic acid|VPA|VPA|VPA|VPA|VPA|VPA	Chemical	0:15:26:29:83:101:188:316:357	2:17:28:30:84:102:189:317:358	0:0:1:1:2:2:4:9:10	D007249	inflammation	Disease	293	294	8	1:CID:2	L2R	NON-CROSS	299-300	316-317	D014635	Valproic acid|valproic acid|valproic acid|VPA|VPA|VPA|VPA|VPA|VPA	Chemical	0:15:26:29:83:101:188:316:357	2:17:28:30:84:102:189:317:358	0:0:1:1:2:2:4:9:10	D009336	necrosis|necrosis	Disease	299:383	300:384	8:10	1:CID:2	L2R	NON-CROSS	302-303	316-317	D014635	Valproic acid|valproic acid|valproic acid|VPA|VPA|VPA|VPA|VPA|VPA	Chemical	0:15:26:29:83:101:188:316:357	2:17:28:30:84:102:189:317:358	0:0:1:1:2:2:4:9:10	D005234	steatosis|steatosis	Disease	302:385	303:386	8:10	1:CID:2	R2L	CROSS	89-90	64-72	C075750	15 - F ( 2t ) - isoprostane|15 - F ( 2t ) - IsoP|15 - F ( 2t ) - IsoP|15 - F ( 2t ) - IsoP|15 - F ( 2t ) - IsoP	Chemical	55:64:143:170:369	63:72:151:178:377	1:1:3:4:10	D056486	liver toxicity|hepatotoxicity|Liver toxicity|hepatotoxicity	Disease	11:89:246:285	13:90:248:286	0:2:7:8	1:CID:2	R2L	CROSS	246-248	195-196	D008054	lipid hydroperoxides|LPO|LPO	Chemical	152:155:195	154:156:196	3:3:5	D056486	liver toxicity|hepatotoxicity|Liver toxicity|hepatotoxicity	Disease	11:89:246:285	13:90:248:286	0:2:7:8	1:CID:2	R2L	CROSS	246-248	224-225	D017392	thiobarbituric acid reactive substances|TBARs|TBARs	Chemical	159:164:224	163:165:225	3:3:6	D056486	liver toxicity|hepatotoxicity|Liver toxicity|hepatotoxicity	Disease	11:89:246:285	13:90:248:286	0:2:7:8	1:NR:2	R2L	NON-CROSS	257-258	246-248	D005978	glutathione	Chemical	257	258	7	D056486	liver toxicity|hepatotoxicity|Liver toxicity|hepatotoxicity	Disease	11:89:246:285	13:90:248:286	0:2:7:8	1:NR:2	R2L	CROSS	327-332	285-286	C045022	4 - ene - VPA	Chemical	327	332	9	D056486	liver toxicity|hepatotoxicity|Liver toxicity|hepatotoxicity	Disease	11:89:246:285	13:90:248:286	0:2:7:8	1:NR:2	R2L	CROSS	337-344	285-286	C556631	2 , 4 - diene - VPA	Chemical	337	344	9	D056486	liver toxicity|hepatotoxicity|Liver toxicity|hepatotoxicity	Disease	11:89:246:285	13:90:248:286	0:2:7:8	1:NR:2	L2R	CROSS	293-294	369-377	C075750	15 - F ( 2t ) - isoprostane|15 - F ( 2t ) - IsoP|15 - F ( 2t ) - IsoP|15 - F ( 2t ) - IsoP|15 - F ( 2t ) - IsoP	Chemical	55:64:143:170:369	63:72:151:178:377	1:1:3:4:10	D007249	inflammation	Disease	293	294	8	1:NR:2	L2R	NON-CROSS	369-377	383-384	C075750	15 - F ( 2t ) - isoprostane|15 - F ( 2t ) - IsoP|15 - F ( 2t ) - IsoP|15 - F ( 2t ) - IsoP|15 - F ( 2t ) - IsoP	Chemical	55:64:143:170:369	63:72:151:178:377	1:1:3:4:10	D009336	necrosis|necrosis	Disease	299:383	300:384	8:10	1:NR:2	L2R	NON-CROSS	369-377	385-386	C075750	15 - F ( 2t ) - isoprostane|15 - F ( 2t ) - IsoP|15 - F ( 2t ) - IsoP|15 - F ( 2t ) - IsoP|15 - F ( 2t ) - IsoP	Chemical	55:64:143:170:369	63:72:151:178:377	1:1:3:4:10	D005234	steatosis|steatosis	Disease	302:385	303:386	8:10	1:NR:2	L2R	CROSS	195-196	293-294	D008054	lipid hydroperoxides|LPO|LPO	Chemical	152:155:195	154:156:196	3:3:5	D007249	inflammation	Disease	293	294	8	1:NR:2	L2R	CROSS	195-196	299-300	D008054	lipid hydroperoxides|LPO|LPO	Chemical	152:155:195	154:156:196	3:3:5	D009336	necrosis|necrosis	Disease	299:383	300:384	8:10	1:NR:2	L2R	CROSS	195-196	302-303	D008054	lipid hydroperoxides|LPO|LPO	Chemical	152:155:195	154:156:196	3:3:5	D005234	steatosis|steatosis	Disease	302:385	303:386	8:10	1:NR:2	L2R	CROSS	224-225	293-294	D017392	thiobarbituric acid reactive substances|TBARs|TBARs	Chemical	159:164:224	163:165:225	3:3:6	D007249	inflammation	Disease	293	294	8	1:NR:2	L2R	CROSS	224-225	299-300	D017392	thiobarbituric acid reactive substances|TBARs|TBARs	Chemical	159:164:224	163:165:225	3:3:6	D009336	necrosis|necrosis	Disease	299:383	300:384	8:10	1:NR:2	L2R	CROSS	224-225	302-303	D017392	thiobarbituric acid reactive substances|TBARs|TBARs	Chemical	159:164:224	163:165:225	3:3:6	D005234	steatosis|steatosis	Disease	302:385	303:386	8:10	1:NR:2	L2R	CROSS	257-258	293-294	D005978	glutathione	Chemical	257	258	7	D007249	inflammation	Disease	293	294	8	1:NR:2	L2R	CROSS	257-258	299-300	D005978	glutathione	Chemical	257	258	7	D009336	necrosis|necrosis	Disease	299:383	300:384	8:10	1:NR:2	L2R	CROSS	257-258	302-303	D005978	glutathione	Chemical	257	258	7	D005234	steatosis|steatosis	Disease	302:385	303:386	8:10	1:NR:2	R2L	CROSS	327-332	293-294	C045022	4 - ene - VPA	Chemical	327	332	9	D007249	inflammation	Disease	293	294	8	1:NR:2	R2L	CROSS	337-344	293-294	C556631	2 , 4 - diene - VPA	Chemical	337	344	9	D007249	inflammation	Disease	293	294	8	1:NR:2	R2L	CROSS	327-332	299-300	C045022	4 - ene - VPA	Chemical	327	332	9	D009336	necrosis|necrosis	Disease	299:383	300:384	8:10	1:NR:2	R2L	CROSS	337-344	299-300	C556631	2 , 4 - diene - VPA	Chemical	337	344	9	D009336	necrosis|necrosis	Disease	299:383	300:384	8:10	1:NR:2	R2L	CROSS	327-332	302-303	C045022	4 - ene - VPA	Chemical	327	332	9	D005234	steatosis|steatosis	Disease	302:385	303:386	8:10	1:NR:2	R2L	CROSS	337-344	302-303	C556631	2 , 4 - diene - VPA	Chemical	337	344	9	D005234	steatosis|steatosis	Disease	302:385	303:386	8:10
15811908	Pheochromocytoma unmasked by amisulpride and tiapride .|OBJECTIVE : To describe the unmasking of pheochromocytoma in a patient treated with amisulpride and tiapride .|CASE SUMMARY : A 42 - year - old white man developed acute hypertension with severe headache and vomiting 2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg .|Both drugs were immediately discontinued , and the patient recovered after subsequent nicardipine and verapamil treatment .|Abdominal ultrasound showed an adrenal mass , and postoperative histologic examination confirmed the diagnosis of pheochromocytoma .|DISCUSSION : Drug - induced symptoms of pheochromocytoma are often associated with the use of substituted benzamide drugs , but the underlying mechanism is unknown .|In our case , use of the Naranjo probability scale indicated a possible relationship between the hypertensive crisis and amisulpride and tiapride therapy .|CONCLUSIONS : As of March 24 , 2005 , this is the first reported case of amisulpride - and tiapride - induced hypertensive crisis in a patient with pheochromocytoma .|Physicians and other healthcare professionals should be aware of this potential adverse effect of tiapride and amisulpride .	1:NR:2	R2L	NON-CROSS	3-4	0-1	C012052	amisulpride|amisulpride|amisulpride|amisulpride|amisulpride|amisulpride	Chemical	3:20:50:137:158:188	4:21:51:138:159:189	0:1:2:6:7:8	D010673	Pheochromocytoma|pheochromocytoma|pheochromocytoma|pheochromocytoma|pheochromocytoma	Disease	0:14:90:99:170	1:15:91:100:171	0:1:4:5:7	1:NR:2	R2L	NON-CROSS	5-6	0-1	D063325	tiapride|tiapride|tiapride|tiapride|tiapride|tiapride	Chemical	5:22:54:139:161:186	6:23:55:140:162:187	0:1:2:6:7:8	D010673	Pheochromocytoma|pheochromocytoma|pheochromocytoma|pheochromocytoma|pheochromocytoma	Disease	0:14:90:99:170	1:15:91:100:171	0:1:4:5:7	1:NR:2	R2L	CROSS	90-91	70-71	D009529	nicardipine	Chemical	70	71	3	D010673	Pheochromocytoma|pheochromocytoma|pheochromocytoma|pheochromocytoma|pheochromocytoma	Disease	0:14:90:99:170	1:15:91:100:171	0:1:4:5:7	1:NR:2	R2L	CROSS	90-91	72-73	D014700	verapamil	Chemical	72	73	3	D010673	Pheochromocytoma|pheochromocytoma|pheochromocytoma|pheochromocytoma|pheochromocytoma	Disease	0:14:90:99:170	1:15:91:100:171	0:1:4:5:7	1:NR:2	R2L	NON-CROSS	108-109	99-100	C037689	benzamide	Chemical	108	109	5	D010673	Pheochromocytoma|pheochromocytoma|pheochromocytoma|pheochromocytoma|pheochromocytoma	Disease	0:14:90:99:170	1:15:91:100:171	0:1:4:5:7	1:CID:2	L2R	NON-CROSS	134-135	137-138	C012052	amisulpride|amisulpride|amisulpride|amisulpride|amisulpride|amisulpride	Chemical	3:20:50:137:158:188	4:21:51:138:159:189	0:1:2:6:7:8	D006973	hypertension|hypertensive|hypertensive	Disease	37:134:164	38:135:165	2:6:7	1:CID:2	L2R	NON-CROSS	40-41	50-51	C012052	amisulpride|amisulpride|amisulpride|amisulpride|amisulpride|amisulpride	Chemical	3:20:50:137:158:188	4:21:51:138:159:189	0:1:2:6:7:8	D006261	headache	Disease	40	41	2	1:CID:2	L2R	NON-CROSS	42-43	50-51	C012052	amisulpride|amisulpride|amisulpride|amisulpride|amisulpride|amisulpride	Chemical	3:20:50:137:158:188	4:21:51:138:159:189	0:1:2:6:7:8	D014839	vomiting	Disease	42	43	2	1:CID:2	L2R	NON-CROSS	161-162	164-165	D063325	tiapride|tiapride|tiapride|tiapride|tiapride|tiapride	Chemical	5:22:54:139:161:186	6:23:55:140:162:187	0:1:2:6:7:8	D006973	hypertension|hypertensive|hypertensive	Disease	37:134:164	38:135:165	2:6:7	1:CID:2	L2R	NON-CROSS	40-41	54-55	D063325	tiapride|tiapride|tiapride|tiapride|tiapride|tiapride	Chemical	5:22:54:139:161:186	6:23:55:140:162:187	0:1:2:6:7:8	D006261	headache	Disease	40	41	2	1:CID:2	L2R	NON-CROSS	42-43	54-55	D063325	tiapride|tiapride|tiapride|tiapride|tiapride|tiapride	Chemical	5:22:54:139:161:186	6:23:55:140:162:187	0:1:2:6:7:8	D014839	vomiting	Disease	42	43	2	1:NR:2	R2L	CROSS	70-71	37-38	D009529	nicardipine	Chemical	70	71	3	D006973	hypertension|hypertensive|hypertensive	Disease	37:134:164	38:135:165	2:6:7	1:NR:2	R2L	CROSS	72-73	37-38	D014700	verapamil	Chemical	72	73	3	D006973	hypertension|hypertensive|hypertensive	Disease	37:134:164	38:135:165	2:6:7	1:NR:2	R2L	CROSS	134-135	108-109	C037689	benzamide	Chemical	108	109	5	D006973	hypertension|hypertensive|hypertensive	Disease	37:134:164	38:135:165	2:6:7	1:NR:2	R2L	CROSS	70-71	40-41	D009529	nicardipine	Chemical	70	71	3	D006261	headache	Disease	40	41	2	1:NR:2	R2L	CROSS	72-73	40-41	D014700	verapamil	Chemical	72	73	3	D006261	headache	Disease	40	41	2	1:NR:2	R2L	CROSS	108-109	40-41	C037689	benzamide	Chemical	108	109	5	D006261	headache	Disease	40	41	2	1:NR:2	R2L	CROSS	70-71	42-43	D009529	nicardipine	Chemical	70	71	3	D014839	vomiting	Disease	42	43	2	1:NR:2	R2L	CROSS	72-73	42-43	D014700	verapamil	Chemical	72	73	3	D014839	vomiting	Disease	42	43	2	1:NR:2	R2L	CROSS	108-109	42-43	C037689	benzamide	Chemical	108	109	5	D014839	vomiting	Disease	42	43	2
15764424	Quantitative drug levels in stimulant psychosis : relationship to symptom severity , catecholamines and hyperkinesia .|To examine the relationship between quantitative stimulant drug levels , catecholamines , and psychotic symptoms , nineteen patients in a psychiatric emergency service with a diagnosis of amphetamine - or cocaine - induced psychosis were interviewed , and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels .|Methamphetamine or amphetamine levels were related to several psychopathology scores and the global hyperkinesia rating .|HVA levels were related to global hyperkinesia but not to psychopathology ratings .|Although many other factors such as sensitization may play a role , intensity of stimulant - induced psychotic symptoms and stereotypies appears to be at least in part dose - related .	1:NR:2	R2L	NON-CROSS	29-31	26-27	D002395	catecholamines|catecholamines|catecholamine	Chemical	12:26:66	13:27:67	0:1:1	D011605	psychosis|psychotic symptoms|psychosis|psychotic symptoms	Disease	5:29:49:116	6:31:50:118	0:1:1:4	1:CID:2	R2L	NON-CROSS	49-50	43-44	D000661	amphetamine|amphetamine	Chemical	43:72	44:73	1:2	D011605	psychosis|psychotic symptoms|psychosis|psychotic symptoms	Disease	5:29:49:116	6:31:50:118	0:1:1:4	1:CID:2	R2L	NON-CROSS	49-50	46-47	D003042	cocaine	Chemical	46	47	1	D011605	psychosis|psychotic symptoms|psychosis|psychotic symptoms	Disease	5:29:49:116	6:31:50:118	0:1:1:4	1:CID:2	R2L	CROSS	70-71	49-50	D008694	Methamphetamine	Chemical	70	71	2	D011605	psychosis|psychotic symptoms|psychosis|psychotic symptoms	Disease	5:29:49:116	6:31:50:118	0:1:1:4	1:NR:2	L2R	NON-CROSS	12-13	14-15	D002395	catecholamines|catecholamines|catecholamine	Chemical	12:26:66	13:27:67	0:1:1	D006948	hyperkinesia|hyperkinesia|hyperkinesia	Disease	14:83:92	15:84:93	0:2:3	1:NR:2	L2R	NON-CROSS	26-27	36-37	D002395	catecholamines|catecholamines|catecholamine	Chemical	12:26:66	13:27:67	0:1:1	D001523	psychiatric	Disease	36	37	1	1:NR:2	L2R	CROSS	66-67	119-120	D002395	catecholamines|catecholamines|catecholamine	Chemical	12:26:66	13:27:67	0:1:1	D019956	stereotypies	Disease	119	120	4	1:CID:2	R2L	NON-CROSS	83-84	72-73	D000661	amphetamine|amphetamine	Chemical	43:72	44:73	1:2	D006948	hyperkinesia|hyperkinesia|hyperkinesia	Disease	14:83:92	15:84:93	0:2:3	1:CID:2	R2L	CROSS	46-47	14-15	D003042	cocaine	Chemical	46	47	1	D006948	hyperkinesia|hyperkinesia|hyperkinesia	Disease	14:83:92	15:84:93	0:2:3	1:CID:2	R2L	NON-CROSS	83-84	70-71	D008694	Methamphetamine	Chemical	70	71	2	D006948	hyperkinesia|hyperkinesia|hyperkinesia	Disease	14:83:92	15:84:93	0:2:3	1:NR:2	R2L	NON-CROSS	43-44	36-37	D000661	amphetamine|amphetamine	Chemical	43:72	44:73	1:2	D001523	psychiatric	Disease	36	37	1	1:NR:2	R2L	NON-CROSS	46-47	36-37	D003042	cocaine	Chemical	46	47	1	D001523	psychiatric	Disease	36	37	1	1:NR:2	R2L	CROSS	70-71	36-37	D008694	Methamphetamine	Chemical	70	71	2	D001523	psychiatric	Disease	36	37	1	1:NR:2	L2R	CROSS	72-73	119-120	D000661	amphetamine|amphetamine	Chemical	43:72	44:73	1:2	D019956	stereotypies	Disease	119	120	4	1:NR:2	L2R	CROSS	46-47	119-120	D003042	cocaine	Chemical	46	47	1	D019956	stereotypies	Disease	119	120	4	1:NR:2	L2R	CROSS	70-71	119-120	D008694	Methamphetamine	Chemical	70	71	2	D019956	stereotypies	Disease	119	120	4
12101159	Delayed asystolic cardiac arrest after diltiazem overdose ; resuscitation with high dose intravenous calcium .|A 51 year old man took a mixed overdose including 1 . 8 - 3 . 6 g of diltiazem , paracetamol , aspirin , isosorbide nitrate , and alcohol .|He initially presented to hospital after six hours with mild hypotension and was treated with activated charcoal and intravenous fluids .|Eighteen hours after the overdose he had two generalised tonic - clonic seizures .|The patient remained unresponsive with junctional bradycardia , unrecordable blood pressure , and then became asystolic .|He was resuscitated with high dose ( 13 . 5 g ) intravenous calcium and adrenaline ( epinephrine ) .|He required inotropic support and temporary pacing over the next 48 hours .|This case suggests there is a role for aggressive high dose intravenous calcium therapy in severe diltiazem overdose , particularly with the onset of asystole .|It should be considered early in cases of cardiac arrest after diltiazem overdose .|The case also highlights the problems with delayed toxicity when whole bowel irrigation is not administered .	1:CID:2	R2L	NON-CROSS	5-6	2-4	D004110	diltiazem|diltiazem|diltiazem|diltiazem	Chemical	5:34:147:168	6:35:148:169	0:1:7:8	D006323	asystolic|cardiac arrest|asystolic|asystole|cardiac arrest	Disease	1:2:96:155:165	2:4:97:156:167	0:0:4:7:8	1:NR:2	R2L	NON-CROSS	13-14	2-4	D002118	calcium|calcium|calcium	Chemical	13:111:143	14:112:144	0:5:7	D006323	asystolic|cardiac arrest|asystolic|asystole|cardiac arrest	Disease	1:2:96:155:165	2:4:97:156:167	0:0:4:7:8	1:NR:2	R2L	CROSS	36-37	2-4	D000082	paracetamol	Chemical	36	37	1	D006323	asystolic|cardiac arrest|asystolic|asystole|cardiac arrest	Disease	1:2:96:155:165	2:4:97:156:167	0:0:4:7:8	1:NR:2	R2L	CROSS	38-39	2-4	D001241	aspirin	Chemical	38	39	1	D006323	asystolic|cardiac arrest|asystolic|asystole|cardiac arrest	Disease	1:2:96:155:165	2:4:97:156:167	0:0:4:7:8	1:NR:2	R2L	CROSS	40-41	2-4	D007547	isosorbide	Chemical	40	41	1	D006323	asystolic|cardiac arrest|asystolic|asystole|cardiac arrest	Disease	1:2:96:155:165	2:4:97:156:167	0:0:4:7:8	1:NR:2	R2L	CROSS	41-42	2-4	D009566	nitrate	Chemical	41	42	1	D006323	asystolic|cardiac arrest|asystolic|asystole|cardiac arrest	Disease	1:2:96:155:165	2:4:97:156:167	0:0:4:7:8	1:NR:2	R2L	CROSS	44-45	2-4	D000431	alcohol	Chemical	44	45	1	D006323	asystolic|cardiac arrest|asystolic|asystole|cardiac arrest	Disease	1:2:96:155:165	2:4:97:156:167	0:0:4:7:8	1:NR:2	R2L	CROSS	113-114	96-97	D004837	adrenaline|epinephrine	Chemical	113:115	114:116	5:5	D006323	asystolic|cardiac arrest|asystolic|asystole|cardiac arrest	Disease	1:2:96:155:165	2:4:97:156:167	0:0:4:7:8	1:CID:2	L2R	NON-CROSS	5-6	6-7	D004110	diltiazem|diltiazem|diltiazem|diltiazem	Chemical	5:34:147:168	6:35:148:169	0:1:7:8	D062787	overdose|overdose|overdose|overdose|overdose	Disease	6:23:71:148:169	7:24:72:149:170	0:1:3:7:8	1:CID:2	L2R	CROSS	34-35	56-57	D004110	diltiazem|diltiazem|diltiazem|diltiazem	Chemical	5:34:147:168	6:35:148:169	0:1:7:8	D007022	hypotension	Disease	56	57	2	1:NR:2	L2R	CROSS	34-35	76-80	D004110	diltiazem|diltiazem|diltiazem|diltiazem	Chemical	5:34:147:168	6:35:148:169	0:1:7:8	D004830	tonic - clonic seizures	Disease	76	80	3	1:CID:2	L2R	CROSS	34-35	87-88	D004110	diltiazem|diltiazem|diltiazem|diltiazem	Chemical	5:34:147:168	6:35:148:169	0:1:7:8	D001919	bradycardia	Disease	87	88	4	1:NR:2	L2R	CROSS	168-169	179-180	D004110	diltiazem|diltiazem|diltiazem|diltiazem	Chemical	5:34:147:168	6:35:148:169	0:1:7:8	D064420	toxicity	Disease	179	180	9	1:NR:2	R2L	NON-CROSS	148-149	143-144	D002118	calcium|calcium|calcium	Chemical	13:111:143	14:112:144	0:5:7	D062787	overdose|overdose|overdose|overdose|overdose	Disease	6:23:71:148:169	7:24:72:149:170	0:1:3:7:8	1:NR:2	R2L	NON-CROSS	36-37	23-24	D000082	paracetamol	Chemical	36	37	1	D062787	overdose|overdose|overdose|overdose|overdose	Disease	6:23:71:148:169	7:24:72:149:170	0:1:3:7:8	1:NR:2	R2L	NON-CROSS	38-39	23-24	D001241	aspirin	Chemical	38	39	1	D062787	overdose|overdose|overdose|overdose|overdose	Disease	6:23:71:148:169	7:24:72:149:170	0:1:3:7:8	1:NR:2	R2L	NON-CROSS	40-41	23-24	D007547	isosorbide	Chemical	40	41	1	D062787	overdose|overdose|overdose|overdose|overdose	Disease	6:23:71:148:169	7:24:72:149:170	0:1:3:7:8	1:NR:2	R2L	NON-CROSS	41-42	23-24	D009566	nitrate	Chemical	41	42	1	D062787	overdose|overdose|overdose|overdose|overdose	Disease	6:23:71:148:169	7:24:72:149:170	0:1:3:7:8	1:NR:2	R2L	NON-CROSS	44-45	23-24	D000431	alcohol	Chemical	44	45	1	D062787	overdose|overdose|overdose|overdose|overdose	Disease	6:23:71:148:169	7:24:72:149:170	0:1:3:7:8	1:NR:2	R2L	CROSS	148-149	115-116	D004837	adrenaline|epinephrine	Chemical	113:115	114:116	5:5	D062787	overdose|overdose|overdose|overdose|overdose	Disease	6:23:71:148:169	7:24:72:149:170	0:1:3:7:8	1:NR:2	L2R	CROSS	13-14	56-57	D002118	calcium|calcium|calcium	Chemical	13:111:143	14:112:144	0:5:7	D007022	hypotension	Disease	56	57	2	1:NR:2	L2R	CROSS	76-80	111-112	D002118	calcium|calcium|calcium	Chemical	13:111:143	14:112:144	0:5:7	D004830	tonic - clonic seizures	Disease	76	80	3	1:NR:2	L2R	CROSS	87-88	111-112	D002118	calcium|calcium|calcium	Chemical	13:111:143	14:112:144	0:5:7	D001919	bradycardia	Disease	87	88	4	1:NR:2	L2R	CROSS	143-144	179-180	D002118	calcium|calcium|calcium	Chemical	13:111:143	14:112:144	0:5:7	D064420	toxicity	Disease	179	180	9	1:NR:2	L2R	CROSS	36-37	56-57	D000082	paracetamol	Chemical	36	37	1	D007022	hypotension	Disease	56	57	2	1:NR:2	L2R	CROSS	36-37	76-80	D000082	paracetamol	Chemical	36	37	1	D004830	tonic - clonic seizures	Disease	76	80	3	1:NR:2	L2R	CROSS	36-37	87-88	D000082	paracetamol	Chemical	36	37	1	D001919	bradycardia	Disease	87	88	4	1:NR:2	L2R	CROSS	36-37	179-180	D000082	paracetamol	Chemical	36	37	1	D064420	toxicity	Disease	179	180	9	1:NR:2	L2R	CROSS	38-39	56-57	D001241	aspirin	Chemical	38	39	1	D007022	hypotension	Disease	56	57	2	1:NR:2	L2R	CROSS	38-39	76-80	D001241	aspirin	Chemical	38	39	1	D004830	tonic - clonic seizures	Disease	76	80	3	1:NR:2	L2R	CROSS	38-39	87-88	D001241	aspirin	Chemical	38	39	1	D001919	bradycardia	Disease	87	88	4	1:NR:2	L2R	CROSS	38-39	179-180	D001241	aspirin	Chemical	38	39	1	D064420	toxicity	Disease	179	180	9	1:NR:2	L2R	CROSS	40-41	56-57	D007547	isosorbide	Chemical	40	41	1	D007022	hypotension	Disease	56	57	2	1:NR:2	L2R	CROSS	40-41	76-80	D007547	isosorbide	Chemical	40	41	1	D004830	tonic - clonic seizures	Disease	76	80	3	1:NR:2	L2R	CROSS	40-41	87-88	D007547	isosorbide	Chemical	40	41	1	D001919	bradycardia	Disease	87	88	4	1:NR:2	L2R	CROSS	40-41	179-180	D007547	isosorbide	Chemical	40	41	1	D064420	toxicity	Disease	179	180	9	1:NR:2	L2R	CROSS	41-42	56-57	D009566	nitrate	Chemical	41	42	1	D007022	hypotension	Disease	56	57	2	1:NR:2	L2R	CROSS	41-42	76-80	D009566	nitrate	Chemical	41	42	1	D004830	tonic - clonic seizures	Disease	76	80	3	1:NR:2	L2R	CROSS	41-42	87-88	D009566	nitrate	Chemical	41	42	1	D001919	bradycardia	Disease	87	88	4	1:NR:2	L2R	CROSS	41-42	179-180	D009566	nitrate	Chemical	41	42	1	D064420	toxicity	Disease	179	180	9	1:NR:2	L2R	CROSS	44-45	56-57	D000431	alcohol	Chemical	44	45	1	D007022	hypotension	Disease	56	57	2	1:NR:2	L2R	CROSS	44-45	76-80	D000431	alcohol	Chemical	44	45	1	D004830	tonic - clonic seizures	Disease	76	80	3	1:NR:2	L2R	CROSS	44-45	87-88	D000431	alcohol	Chemical	44	45	1	D001919	bradycardia	Disease	87	88	4	1:NR:2	L2R	CROSS	44-45	179-180	D000431	alcohol	Chemical	44	45	1	D064420	toxicity	Disease	179	180	9	1:NR:2	R2L	CROSS	113-114	56-57	D004837	adrenaline|epinephrine	Chemical	113:115	114:116	5:5	D007022	hypotension	Disease	56	57	2	1:NR:2	R2L	CROSS	113-114	76-80	D004837	adrenaline|epinephrine	Chemical	113:115	114:116	5:5	D004830	tonic - clonic seizures	Disease	76	80	3	1:NR:2	R2L	CROSS	113-114	87-88	D004837	adrenaline|epinephrine	Chemical	113:115	114:116	5:5	D001919	bradycardia	Disease	87	88	4	1:NR:2	L2R	CROSS	115-116	179-180	D004837	adrenaline|epinephrine	Chemical	113:115	114:116	5:5	D064420	toxicity	Disease	179	180	9
6699841	Renal papillary necrosis due to naproxen .|A 31 - year - old man with rheumatoid arthritis , who had previously been treated with sulindac , fenoprofen calcium , high dose salicylates and gold salts , developed renal papillary necrosis ( RPN ) 4 months after institution of naproxen therapy .|No other factor predisposing to RPN could be discovered .|Sulindac was substituted for naproxen and no further adverse renal effects occurred over the next 12 months .|We review previous reports linking RPN to antiinflammatory drug use and discuss possible advantages of sulindac in patients who have experienced renal toxicity from other antiinflammatory agents .	1:CID:2	R2L	NON-CROSS	5-6	0-3	D009288	naproxen|naproxen|naproxen	Chemical	5:48:65	6:49:66	0:1:3	D007681	Renal papillary necrosis|renal papillary necrosis|RPN|RPN|RPN	Disease	0:37:41:56:84	3:40:42:57:85	0:1:1:2:4	1:NR:2	R2L	NON-CROSS	61-62	56-57	D013467	sulindac|Sulindac|sulindac	Chemical	24:61:94	25:62:95	1:3:4	D007681	Renal papillary necrosis|renal papillary necrosis|RPN|RPN|RPN	Disease	0:37:41:56:84	3:40:42:57:85	0:1:1:2:4	1:NR:2	R2L	NON-CROSS	37-40	26-28	D005279	fenoprofen calcium	Chemical	26	28	1	D007681	Renal papillary necrosis|renal papillary necrosis|RPN|RPN|RPN	Disease	0:37:41:56:84	3:40:42:57:85	0:1:1:2:4	1:NR:2	R2L	NON-CROSS	37-40	31-32	D012459	salicylates	Chemical	31	32	1	D007681	Renal papillary necrosis|renal papillary necrosis|RPN|RPN|RPN	Disease	0:37:41:56:84	3:40:42:57:85	0:1:1:2:4	1:NR:2	R2L	NON-CROSS	37-40	33-34	D006046	gold	Chemical	33	34	1	D007681	Renal papillary necrosis|renal papillary necrosis|RPN|RPN|RPN	Disease	0:37:41:56:84	3:40:42:57:85	0:1:1:2:4	1:NR:2	L2R	NON-CROSS	5-6	15-17	D009288	naproxen|naproxen|naproxen	Chemical	5:48:65	6:49:66	0:1:3	D001172	rheumatoid arthritis	Disease	15	17	1	1:NR:2	L2R	CROSS	65-66	100-102	D009288	naproxen|naproxen|naproxen	Chemical	5:48:65	6:49:66	0:1:3	D007674	renal toxicity	Disease	100	102	4	1:NR:2	R2L	NON-CROSS	24-25	15-17	D013467	sulindac|Sulindac|sulindac	Chemical	24:61:94	25:62:95	1:3:4	D001172	rheumatoid arthritis	Disease	15	17	1	1:NR:2	R2L	NON-CROSS	26-28	15-17	D005279	fenoprofen calcium	Chemical	26	28	1	D001172	rheumatoid arthritis	Disease	15	17	1	1:NR:2	R2L	NON-CROSS	31-32	15-17	D012459	salicylates	Chemical	31	32	1	D001172	rheumatoid arthritis	Disease	15	17	1	1:NR:2	R2L	NON-CROSS	33-34	15-17	D006046	gold	Chemical	33	34	1	D001172	rheumatoid arthritis	Disease	15	17	1	1:NR:2	L2R	NON-CROSS	94-95	100-102	D013467	sulindac|Sulindac|sulindac	Chemical	24:61:94	25:62:95	1:3:4	D007674	renal toxicity	Disease	100	102	4	1:NR:2	L2R	CROSS	26-28	100-102	D005279	fenoprofen calcium	Chemical	26	28	1	D007674	renal toxicity	Disease	100	102	4	1:NR:2	L2R	CROSS	31-32	100-102	D012459	salicylates	Chemical	31	32	1	D007674	renal toxicity	Disease	100	102	4	1:NR:2	L2R	CROSS	33-34	100-102	D006046	gold	Chemical	33	34	1	D007674	renal toxicity	Disease	100	102	4
6127992	Adverse interaction between beta - adrenergic blocking drugs and verapamil - - report of three cases .|Three patients with ischaemic heart disease developed profound cardiac failure , hypotension and bradycardia during combined therapy with verapamil and beta - adrenergic blocking drugs .|This clinical picture resolved completely with cessation of the combined therapy .|Baseline left ventricular function , assessed by cardiac catheterisation or nuclear angiography , was normal in two patients and only mildly reduced in the other .|Simultaneously administration of beta - adrenergic blocking drugs and verapamil may result in profound adverse interactions and should only be administered with great caution .	1:NR:2	L2R	NON-CROSS	3-8	20-23	D000319	beta - adrenergic blocking drugs|beta - adrenergic blocking drugs|beta - adrenergic blocking drugs	Chemical	3:37:84	8:42:89	0:1:4	D017202	ischaemic heart disease	Disease	20	23	1	1:CID:2	L2R	NON-CROSS	25-27	37-42	D000319	beta - adrenergic blocking drugs|beta - adrenergic blocking drugs|beta - adrenergic blocking drugs	Chemical	3:37:84	8:42:89	0:1:4	D006333	cardiac failure	Disease	25	27	1	1:CID:2	L2R	NON-CROSS	28-29	37-42	D000319	beta - adrenergic blocking drugs|beta - adrenergic blocking drugs|beta - adrenergic blocking drugs	Chemical	3:37:84	8:42:89	0:1:4	D007022	hypotension	Disease	28	29	1	1:CID:2	L2R	NON-CROSS	30-31	37-42	D000319	beta - adrenergic blocking drugs|beta - adrenergic blocking drugs|beta - adrenergic blocking drugs	Chemical	3:37:84	8:42:89	0:1:4	D001919	bradycardia	Disease	30	31	1	1:NR:2	L2R	NON-CROSS	9-10	20-23	D014700	verapamil|verapamil|verapamil	Chemical	9:35:90	10:36:91	0:1:4	D017202	ischaemic heart disease	Disease	20	23	1	1:CID:2	L2R	NON-CROSS	25-27	35-36	D014700	verapamil|verapamil|verapamil	Chemical	9:35:90	10:36:91	0:1:4	D006333	cardiac failure	Disease	25	27	1	1:CID:2	L2R	NON-CROSS	28-29	35-36	D014700	verapamil|verapamil|verapamil	Chemical	9:35:90	10:36:91	0:1:4	D007022	hypotension	Disease	28	29	1	1:CID:2	L2R	NON-CROSS	30-31	35-36	D014700	verapamil|verapamil|verapamil	Chemical	9:35:90	10:36:91	0:1:4	D001919	bradycardia	Disease	30	31	1
6115999	Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension .|Report of Medical Research Council Working Party on Mild to Moderate Hypertension .|Participants in the Medical Research Council treatment trial for mild hypertension are randomly allocated to one of four treatment groups : bendrofluazide , propranolol , or a placebo for either of these drugs .|The trial is single - blind .|23 582 patient - years of observation have been completed so far , 10 684 on active drugs and 12 898 on placebos .|The results show an association between bendrofluazide treatment and impotence , and impotence also occurred more frequently in patients taking propranolol than in those taking placebos .|Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men , associated with bendrofluazide treatment , and Raynaud 's phenomenon and dyspnoea in men and women taking propranolol .|No corneal disease is known to have occurred in the propranolol group .|Mean serum potassium level fell , and urea and uric acid levels rose , in men and women taking bendrofluazide .|In the propranolol group , serum potassium and uric acid levels rose in both sexes , but the urea level rose significantly in women only .	1:NR:2	L2R	NON-CROSS	3-4	11-12	D001539	bendrofluazide|bendrofluazide|bendrofluazide|bendrofluazide|bendrofluazide	Chemical	3:47:97:141:189	4:48:98:142:190	0:2:5:6:8	D006973	hypertension|Hypertension|hypertension	Disease	11:24:36	12:25:37	0:1:2	1:CID:2	L2R	NON-CROSS	97-98	100-101	D001539	bendrofluazide|bendrofluazide|bendrofluazide|bendrofluazide|bendrofluazide	Chemical	3:47:97:141:189	4:48:98:142:190	0:2:5:6:8	D007172	impotence|impotence	Disease	100:103	101:104	5:5	1:CID:2	L2R	NON-CROSS	127-130	141-142	D001539	bendrofluazide|bendrofluazide|bendrofluazide|bendrofluazide|bendrofluazide	Chemical	3:47:97:141:189	4:48:98:142:190	0:2:5:6:8	D018149	impaired glucose tolerance	Disease	127	130	6	1:CID:2	L2R	NON-CROSS	135-136	141-142	D001539	bendrofluazide|bendrofluazide|bendrofluazide|bendrofluazide|bendrofluazide	Chemical	3:47:97:141:189	4:48:98:142:190	0:2:5:6:8	D006073	gout	Disease	135	136	6	1:NR:2	L2R	NON-CROSS	141-142	145-148	D001539	bendrofluazide|bendrofluazide|bendrofluazide|bendrofluazide|bendrofluazide	Chemical	3:47:97:141:189	4:48:98:142:190	0:2:5:6:8	D011928	Raynaud 's phenomenon	Disease	145	148	6	1:NR:2	L2R	NON-CROSS	141-142	149-150	D001539	bendrofluazide|bendrofluazide|bendrofluazide|bendrofluazide|bendrofluazide	Chemical	3:47:97:141:189	4:48:98:142:190	0:2:5:6:8	D004417	dyspnoea	Disease	149	150	6	1:NR:2	L2R	CROSS	141-142	158-160	D001539	bendrofluazide|bendrofluazide|bendrofluazide|bendrofluazide|bendrofluazide	Chemical	3:47:97:141:189	4:48:98:142:190	0:2:5:6:8	D003316	corneal disease	Disease	158	160	7	1:NR:2	L2R	NON-CROSS	5-6	11-12	D011433	propranolol|propranolol|propranolol|propranolol|propranolol|propranolol	Chemical	5:49:111:155:167:193	6:50:112:156:168:194	0:2:5:6:7:9	D006973	hypertension|Hypertension|hypertension	Disease	11:24:36	12:25:37	0:1:2	1:CID:2	L2R	NON-CROSS	103-104	111-112	D011433	propranolol|propranolol|propranolol|propranolol|propranolol|propranolol	Chemical	5:49:111:155:167:193	6:50:112:156:168:194	0:2:5:6:7:9	D007172	impotence|impotence	Disease	100:103	101:104	5:5	1:NR:2	L2R	NON-CROSS	111-112	127-130	D011433	propranolol|propranolol|propranolol|propranolol|propranolol|propranolol	Chemical	5:49:111:155:167:193	6:50:112:156:168:194	0:2:5:6:7:9	D018149	impaired glucose tolerance	Disease	127	130	6	1:NR:2	L2R	NON-CROSS	135-136	155-156	D011433	propranolol|propranolol|propranolol|propranolol|propranolol|propranolol	Chemical	5:49:111:155:167:193	6:50:112:156:168:194	0:2:5:6:7:9	D006073	gout	Disease	135	136	6	1:CID:2	L2R	NON-CROSS	145-148	155-156	D011433	propranolol|propranolol|propranolol|propranolol|propranolol|propranolol	Chemical	5:49:111:155:167:193	6:50:112:156:168:194	0:2:5:6:7:9	D011928	Raynaud 's phenomenon	Disease	145	148	6	1:CID:2	L2R	NON-CROSS	149-150	155-156	D011433	propranolol|propranolol|propranolol|propranolol|propranolol|propranolol	Chemical	5:49:111:155:167:193	6:50:112:156:168:194	0:2:5:6:7:9	D004417	dyspnoea	Disease	149	150	6	1:NR:2	L2R	NON-CROSS	155-156	158-160	D011433	propranolol|propranolol|propranolol|propranolol|propranolol|propranolol	Chemical	5:49:111:155:167:193	6:50:112:156:168:194	0:2:5:6:7:9	D003316	corneal disease	Disease	158	160	7	1:NR:2	R2L	CROSS	172-173	36-37	D011188	potassium|potassium	Chemical	172:197	173:198	8:9	D006973	hypertension|Hypertension|hypertension	Disease	11:24:36	12:25:37	0:1:2	1:NR:2	R2L	CROSS	177-178	36-37	D014508	urea|urea	Chemical	177:209	178:210	8:9	D006973	hypertension|Hypertension|hypertension	Disease	11:24:36	12:25:37	0:1:2	1:NR:2	R2L	CROSS	179-181	36-37	D014527	uric acid|uric acid	Chemical	179:199	181:201	8:9	D006973	hypertension|Hypertension|hypertension	Disease	11:24:36	12:25:37	0:1:2	1:NR:2	R2L	CROSS	172-173	103-104	D011188	potassium|potassium	Chemical	172:197	173:198	8:9	D007172	impotence|impotence	Disease	100:103	101:104	5:5	1:NR:2	R2L	CROSS	177-178	103-104	D014508	urea|urea	Chemical	177:209	178:210	8:9	D007172	impotence|impotence	Disease	100:103	101:104	5:5	1:NR:2	R2L	CROSS	179-181	103-104	D014527	uric acid|uric acid	Chemical	179:199	181:201	8:9	D007172	impotence|impotence	Disease	100:103	101:104	5:5	1:NR:2	R2L	CROSS	172-173	127-130	D011188	potassium|potassium	Chemical	172:197	173:198	8:9	D018149	impaired glucose tolerance	Disease	127	130	6	1:NR:2	R2L	CROSS	177-178	127-130	D014508	urea|urea	Chemical	177:209	178:210	8:9	D018149	impaired glucose tolerance	Disease	127	130	6	1:NR:2	R2L	CROSS	179-181	127-130	D014527	uric acid|uric acid	Chemical	179:199	181:201	8:9	D018149	impaired glucose tolerance	Disease	127	130	6	1:NR:2	R2L	CROSS	172-173	135-136	D011188	potassium|potassium	Chemical	172:197	173:198	8:9	D006073	gout	Disease	135	136	6	1:NR:2	R2L	CROSS	177-178	135-136	D014508	urea|urea	Chemical	177:209	178:210	8:9	D006073	gout	Disease	135	136	6	1:NR:2	R2L	CROSS	179-181	135-136	D014527	uric acid|uric acid	Chemical	179:199	181:201	8:9	D006073	gout	Disease	135	136	6	1:NR:2	R2L	CROSS	172-173	145-148	D011188	potassium|potassium	Chemical	172:197	173:198	8:9	D011928	Raynaud 's phenomenon	Disease	145	148	6	1:NR:2	R2L	CROSS	177-178	145-148	D014508	urea|urea	Chemical	177:209	178:210	8:9	D011928	Raynaud 's phenomenon	Disease	145	148	6	1:NR:2	R2L	CROSS	179-181	145-148	D014527	uric acid|uric acid	Chemical	179:199	181:201	8:9	D011928	Raynaud 's phenomenon	Disease	145	148	6	1:NR:2	R2L	CROSS	172-173	149-150	D011188	potassium|potassium	Chemical	172:197	173:198	8:9	D004417	dyspnoea	Disease	149	150	6	1:NR:2	R2L	CROSS	177-178	149-150	D014508	urea|urea	Chemical	177:209	178:210	8:9	D004417	dyspnoea	Disease	149	150	6	1:NR:2	R2L	CROSS	179-181	149-150	D014527	uric acid|uric acid	Chemical	179:199	181:201	8:9	D004417	dyspnoea	Disease	149	150	6	1:NR:2	R2L	CROSS	172-173	158-160	D011188	potassium|potassium	Chemical	172:197	173:198	8:9	D003316	corneal disease	Disease	158	160	7	1:NR:2	R2L	CROSS	177-178	158-160	D014508	urea|urea	Chemical	177:209	178:210	8:9	D003316	corneal disease	Disease	158	160	7	1:NR:2	R2L	CROSS	179-181	158-160	D014527	uric acid|uric acid	Chemical	179:199	181:201	8:9	D003316	corneal disease	Disease	158	160	7
18086064	Dexmedetomidine and cardiac protection for non - cardiac surgery : a meta - analysis of randomised controlled trials .|We conducted a systematic review of the effects of dexmedetomidine on cardiac outcomes following non - cardiac surgery .|We included prospective , randomised peri - operative studies of dexmedetomidine that reported mortality , cardiac morbidity or adverse drug events .|A PubMed Central and EMBASE search was conducted up to July 2007 .|The reference lists of identified papers were examined for further trials .|Of 425 studies identified , 20 were included in the meta - analysis ( 840 patients ) .|Dexmedetomidine was associated with a trend towards improved cardiac outcomes ; all - cause mortality ( OR 0 . 27 , 95 % CI 0 . 01 - 7 . 13 , p = 0 . 44 ) , non - fatal myocardial infarction ( OR 0 . 26 , 95 % CI 0 . 04 - 1 . 60 , p = 0 . 14 ) , and myocardial ischaemia ( OR 0 . 65 , 95 % CI 0 . 26 - 1 . 63 , p = 0 . 36 ) .|Peri - operative hypotension ( 26 % , OR 3 . 80 , 95 % CI 1 . 91 - 7 . 54 , p = 0 . 0001 ) and bradycardia ( 17 % , OR 5 . 45 , 95 % CI 2 . 98 - 9 . 95 , p < 0 . 00001 ) were significantly increased .|An anticholinergic did not reduce the incidence of bradycardia ( p = 0 . 43 ) .|A randomised placebo - controlled trial of dexmedetomidine is warranted .	1:NR:2	L2R	NON-CROSS	103-104	145-147	D020927	Dexmedetomidine|dexmedetomidine|dexmedetomidine|Dexmedetomidine|dexmedetomidine	Chemical	0:28:48:103:284	1:29:49:104:285	0:1:2:6:9	D009203	myocardial infarction	Disease	145	147	6	1:NR:2	L2R	NON-CROSS	103-104	172-174	D020927	Dexmedetomidine|dexmedetomidine|dexmedetomidine|Dexmedetomidine|dexmedetomidine	Chemical	0:28:48:103:284	1:29:49:104:285	0:1:2:6:9	D017202	myocardial ischaemia	Disease	172	174	6	1:CID:2	L2R	CROSS	201-202	284-285	D020927	Dexmedetomidine|dexmedetomidine|dexmedetomidine|Dexmedetomidine|dexmedetomidine	Chemical	0:28:48:103:284	1:29:49:104:285	0:1:2:6:9	D007022	hypotension	Disease	201	202	7	1:CID:2	L2R	CROSS	268-269	284-285	D020927	Dexmedetomidine|dexmedetomidine|dexmedetomidine|Dexmedetomidine|dexmedetomidine	Chemical	0:28:48:103:284	1:29:49:104:285	0:1:2:6:9	D001919	bradycardia|bradycardia	Disease	229:268	230:269	7:8
12739036	Differential diagnosis of high serum creatine kinase levels in systemic lupus erythematosus .|We report the clinical and bioptic findings for a 57 - year - old woman with severe chloroquine - induced myopathy .|Since 1989 , she had been suffering from systemic lupus erythematosus ( SLE ) with renal involvement and undergone periods of treatment with azathioprine and cyclophosphamide .|Additional therapy with chloroquine ( CQ ) was started because of arthralgia .|At the same time , slightly increased creatine kinase ( CK ) levels were noted .|Myositis was suspected , and the patient was treated with steroids .|The CK increase persisted , however , and she developed progressive muscular weakness and muscular atrophy .|Routine controls revealed markedly elevated CK levels of 1 , 700 U / l .|The neurological and electrophysiological findings were not typical of myositis .|Thus , muscle biopsy of the deltoid muscle was performed in order to exclude polymyositis or toxic myopathy .|As it revealed chloroquine - induced myopathy , medication was stopped .|Discriminating between primary SLE - induced affection of the musculoskeletal system and drug - induced side effects is important for appropriate treatment of SLE patients .	1:NR:2	L2R	NON-CROSS	5-6	9-12	D003401	creatine|creatine	Chemical	5:82	6:83	0:4	D008180	systemic lupus erythematosus|systemic lupus erythematosus|SLE|SLE|SLE	Disease	9:43:47:180:200	12:46:48:181:201	0:2:2:11:11	1:NR:2	L2R	CROSS	5-6	33-34	D003401	creatine|creatine	Chemical	5:82	6:83	0:4	D009135	myopathy|myopathy|myopathy	Disease	33:163:171	34:164:172	1:9:10	1:NR:2	L2R	CROSS	50-52	82-83	D003401	creatine|creatine	Chemical	5:82	6:83	0:4	D007674	renal involvement	Disease	50	52	2	1:NR:2	L2R	CROSS	73-74	82-83	D003401	creatine|creatine	Chemical	5:82	6:83	0:4	D018771	arthralgia	Disease	73	74	3	1:NR:2	L2R	CROSS	82-83	91-92	D003401	creatine|creatine	Chemical	5:82	6:83	0:4	D009220	Myositis|myositis	Disease	91:144	92:145	5:8	1:NR:2	L2R	CROSS	82-83	114-116	D003401	creatine|creatine	Chemical	5:82	6:83	0:4	D018908	muscular weakness	Disease	114	116	6	1:NR:2	L2R	CROSS	82-83	117-119	D003401	creatine|creatine	Chemical	5:82	6:83	0:4	D009133	muscular atrophy	Disease	117	119	6	1:NR:2	L2R	CROSS	82-83	160-161	D003401	creatine|creatine	Chemical	5:82	6:83	0:4	D017285	polymyositis	Disease	160	161	9	1:NR:2	L2R	CROSS	82-83	183-188	D003401	creatine|creatine	Chemical	5:82	6:83	0:4	D009140	affection of the musculoskeletal system	Disease	183	188	11	1:NR:2	R2L	CROSS	180-181	168-169	D002738	chloroquine|chloroquine|CQ|chloroquine	Chemical	30:65:67:168	31:66:68:169	1:3:3:10	D008180	systemic lupus erythematosus|systemic lupus erythematosus|SLE|SLE|SLE	Disease	9:43:47:180:200	12:46:48:181:201	0:2:2:11:11	1:NR:2	R2L	NON-CROSS	58-59	47-48	D001379	azathioprine	Chemical	58	59	2	D008180	systemic lupus erythematosus|systemic lupus erythematosus|SLE|SLE|SLE	Disease	9:43:47:180:200	12:46:48:181:201	0:2:2:11:11	1:NR:2	R2L	NON-CROSS	60-61	47-48	D003520	cyclophosphamide	Chemical	60	61	2	D008180	systemic lupus erythematosus|systemic lupus erythematosus|SLE|SLE|SLE	Disease	9:43:47:180:200	12:46:48:181:201	0:2:2:11:11	1:NR:2	R2L	CROSS	101-102	47-48	D013256	steroids	Chemical	101	102	5	D008180	systemic lupus erythematosus|systemic lupus erythematosus|SLE|SLE|SLE	Disease	9:43:47:180:200	12:46:48:181:201	0:2:2:11:11	1:NR:2	L2R	NON-CROSS	30-31	33-34	D002738	chloroquine|chloroquine|CQ|chloroquine	Chemical	30:65:67:168	31:66:68:169	1:3:3:10	D009135	myopathy|myopathy|myopathy	Disease	33:163:171	34:164:172	1:9:10	1:NR:2	L2R	CROSS	50-52	65-66	D002738	chloroquine|chloroquine|CQ|chloroquine	Chemical	30:65:67:168	31:66:68:169	1:3:3:10	D007674	renal involvement	Disease	50	52	2	1:NR:2	L2R	NON-CROSS	67-68	73-74	D002738	chloroquine|chloroquine|CQ|chloroquine	Chemical	30:65:67:168	31:66:68:169	1:3:3:10	D018771	arthralgia	Disease	73	74	3	1:NR:2	L2R	CROSS	67-68	91-92	D002738	chloroquine|chloroquine|CQ|chloroquine	Chemical	30:65:67:168	31:66:68:169	1:3:3:10	D009220	Myositis|myositis	Disease	91:144	92:145	5:8	1:CID:2	L2R	CROSS	67-68	114-116	D002738	chloroquine|chloroquine|CQ|chloroquine	Chemical	30:65:67:168	31:66:68:169	1:3:3:10	D018908	muscular weakness	Disease	114	116	6	1:CID:2	L2R	CROSS	67-68	117-119	D002738	chloroquine|chloroquine|CQ|chloroquine	Chemical	30:65:67:168	31:66:68:169	1:3:3:10	D009133	muscular atrophy	Disease	117	119	6	1:NR:2	L2R	CROSS	160-161	168-169	D002738	chloroquine|chloroquine|CQ|chloroquine	Chemical	30:65:67:168	31:66:68:169	1:3:3:10	D017285	polymyositis	Disease	160	161	9	1:NR:2	L2R	CROSS	168-169	183-188	D002738	chloroquine|chloroquine|CQ|chloroquine	Chemical	30:65:67:168	31:66:68:169	1:3:3:10	D009140	affection of the musculoskeletal system	Disease	183	188	11	1:NR:2	R2L	CROSS	58-59	33-34	D001379	azathioprine	Chemical	58	59	2	D009135	myopathy|myopathy|myopathy	Disease	33:163:171	34:164:172	1:9:10	1:NR:2	R2L	CROSS	60-61	33-34	D003520	cyclophosphamide	Chemical	60	61	2	D009135	myopathy|myopathy|myopathy	Disease	33:163:171	34:164:172	1:9:10	1:NR:2	R2L	CROSS	163-164	101-102	D013256	steroids	Chemical	101	102	5	D009135	myopathy|myopathy|myopathy	Disease	33:163:171	34:164:172	1:9:10	1:NR:2	R2L	NON-CROSS	58-59	50-52	D001379	azathioprine	Chemical	58	59	2	D007674	renal involvement	Disease	50	52	2	1:NR:2	R2L	NON-CROSS	60-61	50-52	D003520	cyclophosphamide	Chemical	60	61	2	D007674	renal involvement	Disease	50	52	2	1:NR:2	R2L	CROSS	101-102	50-52	D013256	steroids	Chemical	101	102	5	D007674	renal involvement	Disease	50	52	2	1:NR:2	L2R	CROSS	58-59	73-74	D001379	azathioprine	Chemical	58	59	2	D018771	arthralgia	Disease	73	74	3	1:NR:2	L2R	CROSS	58-59	91-92	D001379	azathioprine	Chemical	58	59	2	D009220	Myositis|myositis	Disease	91:144	92:145	5:8	1:NR:2	L2R	CROSS	58-59	114-116	D001379	azathioprine	Chemical	58	59	2	D018908	muscular weakness	Disease	114	116	6	1:NR:2	L2R	CROSS	58-59	117-119	D001379	azathioprine	Chemical	58	59	2	D009133	muscular atrophy	Disease	117	119	6	1:NR:2	L2R	CROSS	58-59	160-161	D001379	azathioprine	Chemical	58	59	2	D017285	polymyositis	Disease	160	161	9	1:NR:2	L2R	CROSS	58-59	183-188	D001379	azathioprine	Chemical	58	59	2	D009140	affection of the musculoskeletal system	Disease	183	188	11	1:NR:2	L2R	CROSS	60-61	73-74	D003520	cyclophosphamide	Chemical	60	61	2	D018771	arthralgia	Disease	73	74	3	1:NR:2	L2R	CROSS	60-61	91-92	D003520	cyclophosphamide	Chemical	60	61	2	D009220	Myositis|myositis	Disease	91:144	92:145	5:8	1:NR:2	L2R	CROSS	60-61	114-116	D003520	cyclophosphamide	Chemical	60	61	2	D018908	muscular weakness	Disease	114	116	6	1:NR:2	L2R	CROSS	60-61	117-119	D003520	cyclophosphamide	Chemical	60	61	2	D009133	muscular atrophy	Disease	117	119	6	1:NR:2	L2R	CROSS	60-61	160-161	D003520	cyclophosphamide	Chemical	60	61	2	D017285	polymyositis	Disease	160	161	9	1:NR:2	L2R	CROSS	60-61	183-188	D003520	cyclophosphamide	Chemical	60	61	2	D009140	affection of the musculoskeletal system	Disease	183	188	11	1:NR:2	R2L	CROSS	101-102	73-74	D013256	steroids	Chemical	101	102	5	D018771	arthralgia	Disease	73	74	3	1:NR:2	R2L	NON-CROSS	101-102	91-92	D013256	steroids	Chemical	101	102	5	D009220	Myositis|myositis	Disease	91:144	92:145	5:8	1:NR:2	L2R	CROSS	101-102	114-116	D013256	steroids	Chemical	101	102	5	D018908	muscular weakness	Disease	114	116	6	1:NR:2	L2R	CROSS	101-102	117-119	D013256	steroids	Chemical	101	102	5	D009133	muscular atrophy	Disease	117	119	6	1:NR:2	L2R	CROSS	101-102	160-161	D013256	steroids	Chemical	101	102	5	D017285	polymyositis	Disease	160	161	9	1:NR:2	L2R	CROSS	101-102	183-188	D013256	steroids	Chemical	101	102	5	D009140	affection of the musculoskeletal system	Disease	183	188	11
12093990	Intravenous ribavirin treatment for severe adenovirus disease in immunocompromised children .|BACKGROUND : Adenovirus is an important cause of morbidity and mortality in the immunocompromised host .|The incidence of severe adenovirus disease in pediatrics is increasing in association with growing numbers of immunocompromised children , where case fatality rates as high as 50 % to 80 % have been reported .|There are no approved antiviral agents with proven efficacy for the treatment of severe adenovirus disease , nor are there any prospective randomized , controlled trials of potentially useful anti - adenovirus therapies .|Apparent clinical success in the treatment of severe adenovirus disease is limited to a few case reports and small series .|Experience is greatest with intravenous ribavirin and cidofovir .|Ribavirin , a guanosine analogue , has broad antiviral activity against both RNA and DNA viruses , including documented activity against adenovirus in vitro .|Ribavirin is licensed in aerosol form for the treatment of respiratory syncytial virus infection , and orally in combination with interferon to treat hepatitis C .|Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses .|The most common adverse effect of intravenous ribavirin is reversible mild anemia .|The use of cidofovir in severe adenovirus infection has been limited by adverse effects , the most significant of which is nephrotoxicity .|OBJECTIVE : We report our experience with intravenous ribavirin therapy for severe adenovirus disease in a series of immunocompromised children and review the literature .|DESIGN / METHODS : We retrospectively reviewed the medical records of 5 children treated with intravenous ribavirin for documented severe adenovirus disease .|Two patients developed adenovirus hemorrhagic cystitis after cardiac and bone marrow transplants , respectively .|The bone marrow transplant patient also received intravenous cidofovir for progressive disseminated disease .|An additional 3 children developed adenovirus pneumonia ; 2 were neonates , 1 of whom had partial DiGeorge syndrome .|The remaining infant had recently undergone a cardiac transplant .|Intravenous ribavirin was administered on a compassionate - use protocol .|RESULTS : Complete clinical recovery followed later by viral clearance was observed in 2 children : the cardiac transplant recipient with adenovirus hemorrhagic cystitis and the immunocompetent neonate with adenovirus pneumonia .|The remaining 3 children died of adenovirus disease .|Intravenous ribavirin therapy was well tolerated .|Use of cidofovir in 1 child was associated with progressive renal failure and neutropenia .|DISCUSSION : Our series of patients is representative of the spectrum of immunocompromised children at greatest risk for severe adenovirus disease , namely solid - organ and bone marrow transplant recipients , neonates , and children with immunodeficiency .|Although intravenous ribavirin was not effective for all children with severe adenovirus disease in this series or in the literature , therapy is unlikely to be of benefit if begun late in the course of the infection .|Early identification , eg by polymerase chain reaction of those patients at risk of disseminated adenovirus disease may permit earlier antiviral treatment and better evaluation of therapeutic response .|CONCLUSIONS : Two of 5 children with severe adenovirus disease treated with intravenous ribavirin recovered .|The availability of newer rapid diagnostic techniques , such as polymerase chain reaction , may make earlier , more effective treatment of adenovirus infection possible .|Given the seriousness and increasing prevalence of adenovirus disease in certain hosts , especially children , a large , multicenter clinical trial of potentially useful anti - adenoviral therapies , such as intravenous ribavirin , is clearly required to demonstrate the most effective and least toxic therapy .	1:NR:2	L2R	NON-CROSS	383-385	387-388	D012254	ribavirin|ribavirin|Ribavirin|Ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin	Chemical	1:122:126:151:178:198:235:268:335:387:449:527:589	2:123:127:152:179:199:236:269:336:388:450:528:590	0:5:6:7:8:9:11:12:17:20:23:25:27	D000257	adenovirus disease|adenovirus disease|adenovirus disease|adenovirus disease|adenovirus infection|adenovirus disease|adenovirus disease|adenovirus pneumonia|adenovirus pneumonia|adenovirus disease|adenovirus disease|adenovirus disease|adenovirus disease|adenovirus disease|adenovirus infection|adenovirus disease	Disease	5:31:76:104:210:239:272:309:374:383:427:458:500:522:552:563	7:33:78:106:212:241:274:311:376:385:429:460:502:524:554:565	0:2:3:4:10:11:12:15:18:19:22:23:24:25:26:27	1:NR:2	L2R	NON-CROSS	151-152	161-165	D012254	ribavirin|ribavirin|Ribavirin|Ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin	Chemical	1:122:126:151:178:198:235:268:335:387:449:527:589	2:123:127:152:179:199:236:269:336:388:450:528:590	0:5:6:7:8:9:11:12:17:20:23:25:27	D018357	respiratory syncytial virus infection	Disease	161	165	7	1:NR:2	L2R	NON-CROSS	174-176	178-179	D012254	ribavirin|ribavirin|Ribavirin|Ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin	Chemical	1:122:126:151:178:198:235:268:335:387:449:527:589	2:123:127:152:179:199:236:269:336:388:450:528:590	0:5:6:7:8:9:11:12:17:20:23:25:27	D006526	hepatitis C	Disease	174	176	7	1:NR:2	L2R	NON-CROSS	178-179	185-190	D012254	ribavirin|ribavirin|Ribavirin|Ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin	Chemical	1:122:126:151:178:198:235:268:335:387:449:527:589	2:123:127:152:179:199:236:269:336:388:450:528:590	0:5:6:7:8:9:11:12:17:20:23:25:27	D006482	infection with hemorrhagic fever viruses	Disease	185	190	8	1:NR:2	L2R	NON-CROSS	198-199	202-203	D012254	ribavirin|ribavirin|Ribavirin|Ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin	Chemical	1:122:126:151:178:198:235:268:335:387:449:527:589	2:123:127:152:179:199:236:269:336:388:450:528:590	0:5:6:7:8:9:11:12:17:20:23:25:27	D000740	anemia	Disease	202	203	9	1:NR:2	L2R	CROSS	225-226	235-236	D012254	ribavirin|ribavirin|Ribavirin|Ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin	Chemical	1:122:126:151:178:198:235:268:335:387:449:527:589	2:123:127:152:179:199:236:269:336:388:450:528:590	0:5:6:7:8:9:11:12:17:20:23:25:27	D007674	nephrotoxicity	Disease	225	226	10	1:NR:2	L2R	CROSS	268-269	279-281	D012254	ribavirin|ribavirin|Ribavirin|Ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin	Chemical	1:122:126:151:178:198:235:268:335:387:449:527:589	2:123:127:152:179:199:236:269:336:388:450:528:590	0:5:6:7:8:9:11:12:17:20:23:25:27	D006470	hemorrhagic cystitis|hemorrhagic cystitis	Disease	279:367	281:369	13:18	1:NR:2	L2R	CROSS	268-269	279-281	D012254	ribavirin|ribavirin|Ribavirin|Ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin	Chemical	1:122:126:151:178:198:235:268:335:387:449:527:589	2:123:127:152:179:199:236:269:336:388:450:528:590	0:5:6:7:8:9:11:12:17:20:23:25:27	D003556	hemorrhagic cystitis|hemorrhagic cystitis	Disease	279:367	281:369	13:18	1:NR:2	L2R	CROSS	374-376	387-388	D012254	ribavirin|ribavirin|Ribavirin|Ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin	Chemical	1:122:126:151:178:198:235:268:335:387:449:527:589	2:123:127:152:179:199:236:269:336:388:450:528:590	0:5:6:7:8:9:11:12:17:20:23:25:27	D011024	adenovirus pneumonia|adenovirus pneumonia	Disease	309:374	311:376	15:18	1:NR:2	L2R	CROSS	321-323	335-336	D012254	ribavirin|ribavirin|Ribavirin|Ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin	Chemical	1:122:126:151:178:198:235:268:335:387:449:527:589	2:123:127:152:179:199:236:269:336:388:450:528:590	0:5:6:7:8:9:11:12:17:20:23:25:27	D004062	DiGeorge syndrome	Disease	321	323	15	1:NR:2	L2R	CROSS	387-388	402-405	D012254	ribavirin|ribavirin|Ribavirin|Ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin	Chemical	1:122:126:151:178:198:235:268:335:387:449:527:589	2:123:127:152:179:199:236:269:336:388:450:528:590	0:5:6:7:8:9:11:12:17:20:23:25:27	D058186	progressive renal failure	Disease	402	405	21	1:NR:2	L2R	CROSS	387-388	406-407	D012254	ribavirin|ribavirin|Ribavirin|Ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin	Chemical	1:122:126:151:178:198:235:268:335:387:449:527:589	2:123:127:152:179:199:236:269:336:388:450:528:590	0:5:6:7:8:9:11:12:17:20:23:25:27	D009503	neutropenia	Disease	406	407	21	1:NR:2	L2R	CROSS	445-446	449-450	D012254	ribavirin|ribavirin|Ribavirin|Ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin	Chemical	1:122:126:151:178:198:235:268:335:387:449:527:589	2:123:127:152:179:199:236:269:336:388:450:528:590	0:5:6:7:8:9:11:12:17:20:23:25:27	D007153	immunodeficiency	Disease	445	446	22	1:NR:2	L2R	NON-CROSS	449-450	483-484	D012254	ribavirin|ribavirin|Ribavirin|Ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin	Chemical	1:122:126:151:178:198:235:268:335:387:449:527:589	2:123:127:152:179:199:236:269:336:388:450:528:590	0:5:6:7:8:9:11:12:17:20:23:25:27	D007239	infection	Disease	483	484	23	1:NR:2	R2L	NON-CROSS	210-212	207-208	C059262	cidofovir|cidofovir|cidofovir|cidofovir	Chemical	124:207:298:395	125:208:299:396	5:10:14:21	D000257	adenovirus disease|adenovirus disease|adenovirus disease|adenovirus disease|adenovirus infection|adenovirus disease|adenovirus disease|adenovirus pneumonia|adenovirus pneumonia|adenovirus disease|adenovirus disease|adenovirus disease|adenovirus disease|adenovirus disease|adenovirus infection|adenovirus disease	Disease	5:31:76:104:210:239:272:309:374:383:427:458:500:522:552:563	7:33:78:106:212:241:274:311:376:385:429:460:502:524:554:565	0:2:3:4:10:11:12:15:18:19:22:23:24:25:26:27	1:NR:2	R2L	CROSS	129-130	104-106	D006151	guanosine	Chemical	129	130	6	D000257	adenovirus disease|adenovirus disease|adenovirus disease|adenovirus disease|adenovirus infection|adenovirus disease|adenovirus disease|adenovirus pneumonia|adenovirus pneumonia|adenovirus disease|adenovirus disease|adenovirus disease|adenovirus disease|adenovirus disease|adenovirus infection|adenovirus disease	Disease	5:31:76:104:210:239:272:309:374:383:427:458:500:522:552:563	7:33:78:106:212:241:274:311:376:385:429:460:502:524:554:565	0:2:3:4:10:11:12:15:18:19:22:23:24:25:26:27	1:NR:2	L2R	CROSS	124-125	161-165	C059262	cidofovir|cidofovir|cidofovir|cidofovir	Chemical	124:207:298:395	125:208:299:396	5:10:14:21	D018357	respiratory syncytial virus infection	Disease	161	165	7	1:NR:2	L2R	CROSS	174-176	207-208	C059262	cidofovir|cidofovir|cidofovir|cidofovir	Chemical	124:207:298:395	125:208:299:396	5:10:14:21	D006526	hepatitis C	Disease	174	176	7	1:NR:2	L2R	CROSS	185-190	207-208	C059262	cidofovir|cidofovir|cidofovir|cidofovir	Chemical	124:207:298:395	125:208:299:396	5:10:14:21	D006482	infection with hemorrhagic fever viruses	Disease	185	190	8	1:NR:2	L2R	CROSS	202-203	207-208	C059262	cidofovir|cidofovir|cidofovir|cidofovir	Chemical	124:207:298:395	125:208:299:396	5:10:14:21	D000740	anemia	Disease	202	203	9	1:NR:2	L2R	NON-CROSS	207-208	225-226	C059262	cidofovir|cidofovir|cidofovir|cidofovir	Chemical	124:207:298:395	125:208:299:396	5:10:14:21	D007674	nephrotoxicity	Disease	225	226	10	1:NR:2	L2R	CROSS	279-281	298-299	C059262	cidofovir|cidofovir|cidofovir|cidofovir	Chemical	124:207:298:395	125:208:299:396	5:10:14:21	D006470	hemorrhagic cystitis|hemorrhagic cystitis	Disease	279:367	281:369	13:18	1:NR:2	L2R	CROSS	279-281	298-299	C059262	cidofovir|cidofovir|cidofovir|cidofovir	Chemical	124:207:298:395	125:208:299:396	5:10:14:21	D003556	hemorrhagic cystitis|hemorrhagic cystitis	Disease	279:367	281:369	13:18	1:NR:2	L2R	CROSS	298-299	309-311	C059262	cidofovir|cidofovir|cidofovir|cidofovir	Chemical	124:207:298:395	125:208:299:396	5:10:14:21	D011024	adenovirus pneumonia|adenovirus pneumonia	Disease	309:374	311:376	15:18	1:NR:2	L2R	CROSS	298-299	321-323	C059262	cidofovir|cidofovir|cidofovir|cidofovir	Chemical	124:207:298:395	125:208:299:396	5:10:14:21	D004062	DiGeorge syndrome	Disease	321	323	15	1:CID:2	L2R	NON-CROSS	395-396	402-405	C059262	cidofovir|cidofovir|cidofovir|cidofovir	Chemical	124:207:298:395	125:208:299:396	5:10:14:21	D058186	progressive renal failure	Disease	402	405	21	1:CID:2	L2R	NON-CROSS	395-396	406-407	C059262	cidofovir|cidofovir|cidofovir|cidofovir	Chemical	124:207:298:395	125:208:299:396	5:10:14:21	D009503	neutropenia	Disease	406	407	21	1:NR:2	L2R	CROSS	395-396	445-446	C059262	cidofovir|cidofovir|cidofovir|cidofovir	Chemical	124:207:298:395	125:208:299:396	5:10:14:21	D007153	immunodeficiency	Disease	445	446	22	1:NR:2	L2R	CROSS	395-396	483-484	C059262	cidofovir|cidofovir|cidofovir|cidofovir	Chemical	124:207:298:395	125:208:299:396	5:10:14:21	D007239	infection	Disease	483	484	23	1:NR:2	L2R	CROSS	129-130	161-165	D006151	guanosine	Chemical	129	130	6	D018357	respiratory syncytial virus infection	Disease	161	165	7	1:NR:2	L2R	CROSS	129-130	174-176	D006151	guanosine	Chemical	129	130	6	D006526	hepatitis C	Disease	174	176	7	1:NR:2	L2R	CROSS	129-130	185-190	D006151	guanosine	Chemical	129	130	6	D006482	infection with hemorrhagic fever viruses	Disease	185	190	8	1:NR:2	L2R	CROSS	129-130	202-203	D006151	guanosine	Chemical	129	130	6	D000740	anemia	Disease	202	203	9	1:NR:2	L2R	CROSS	129-130	225-226	D006151	guanosine	Chemical	129	130	6	D007674	nephrotoxicity	Disease	225	226	10	1:NR:2	L2R	CROSS	129-130	279-281	D006151	guanosine	Chemical	129	130	6	D006470	hemorrhagic cystitis|hemorrhagic cystitis	Disease	279:367	281:369	13:18	1:NR:2	L2R	CROSS	129-130	279-281	D006151	guanosine	Chemical	129	130	6	D003556	hemorrhagic cystitis|hemorrhagic cystitis	Disease	279:367	281:369	13:18	1:NR:2	L2R	CROSS	129-130	309-311	D006151	guanosine	Chemical	129	130	6	D011024	adenovirus pneumonia|adenovirus pneumonia	Disease	309:374	311:376	15:18	1:NR:2	L2R	CROSS	129-130	321-323	D006151	guanosine	Chemical	129	130	6	D004062	DiGeorge syndrome	Disease	321	323	15	1:NR:2	L2R	CROSS	129-130	402-405	D006151	guanosine	Chemical	129	130	6	D058186	progressive renal failure	Disease	402	405	21	1:NR:2	L2R	CROSS	129-130	406-407	D006151	guanosine	Chemical	129	130	6	D009503	neutropenia	Disease	406	407	21	1:NR:2	L2R	CROSS	129-130	445-446	D006151	guanosine	Chemical	129	130	6	D007153	immunodeficiency	Disease	445	446	22	1:NR:2	L2R	CROSS	129-130	483-484	D006151	guanosine	Chemical	129	130	6	D007239	infection	Disease	483	484	23
3962737	Hepatotoxicity of amiodarone .|Amiodarone has proved very effective in the treatment of otherwise resistant cardiac tachyarrhythmias .|The use of amiodarone has , however , been limited due to its serious side - effects .|A patient with cholestatic hepatitis due to amiodarone treatment is presented below and a review of the hepatotoxicity of amiodarone is given .|It is concluded that solid evidence exists of hepatic injury due to amiodarone treatment , including steatosis , alterations resembling alcoholic hepatitis , cholestatic hepatitis and micronodular cirrhosis of the liver .|Patients receiving amiodarone should be regularly screened with respect to hepatic enzyme levels .|Therapy should be discontinued on the suspicion of cholestatic injury or hepatomegaly .	1:CID:2	R2L	NON-CROSS	2-3	0-1	D000638	amiodarone|Amiodarone|amiodarone|amiodarone|amiodarone|amiodarone|amiodarone	Chemical	2:4:21:43:55:71:93	3:5:22:44:56:72:94	0:1:2:3:3:4:5	D056486	Hepatotoxicity|cholestatic hepatitis|hepatotoxicity|hepatic injury|cholestatic hepatitis	Disease	0:39:53:67:82	1:41:54:69:84	0:3:3:4:4	1:NR:2	L2R	NON-CROSS	16-17	21-22	D000638	amiodarone|Amiodarone|amiodarone|amiodarone|amiodarone|amiodarone|amiodarone	Chemical	2:4:21:43:55:71:93	3:5:22:44:56:72:94	0:1:2:3:3:4:5	D013610	tachyarrhythmias	Disease	16	17	1	1:CID:2	L2R	NON-CROSS	39-41	43-44	D000638	amiodarone|Amiodarone|amiodarone|amiodarone|amiodarone|amiodarone|amiodarone	Chemical	2:4:21:43:55:71:93	3:5:22:44:56:72:94	0:1:2:3:3:4:5	D002779	cholestatic hepatitis|cholestatic hepatitis|cholestatic injury	Disease	39:82:113	41:84:115	3:4:6	1:CID:2	L2R	NON-CROSS	71-72	75-76	D000638	amiodarone|Amiodarone|amiodarone|amiodarone|amiodarone|amiodarone|amiodarone	Chemical	2:4:21:43:55:71:93	3:5:22:44:56:72:94	0:1:2:3:3:4:5	D005234	steatosis	Disease	75	76	4	1:NR:2	L2R	NON-CROSS	71-72	79-81	D000638	amiodarone|Amiodarone|amiodarone|amiodarone|amiodarone|amiodarone|amiodarone	Chemical	2:4:21:43:55:71:93	3:5:22:44:56:72:94	0:1:2:3:3:4:5	D006519	alcoholic hepatitis	Disease	79	81	4	1:CID:2	L2R	NON-CROSS	86-90	93-94	D000638	amiodarone|Amiodarone|amiodarone|amiodarone|amiodarone|amiodarone|amiodarone	Chemical	2:4:21:43:55:71:93	3:5:22:44:56:72:94	0:1:2:3:3:4:5	D008103	cirrhosis of the liver	Disease	86	90	4	1:NR:2	L2R	CROSS	93-94	116-117	D000638	amiodarone|Amiodarone|amiodarone|amiodarone|amiodarone|amiodarone|amiodarone	Chemical	2:4:21:43:55:71:93	3:5:22:44:56:72:94	0:1:2:3:3:4:5	D006529	hepatomegaly	Disease	116	117	6
2716967	Catalepsy induced by combinations of ketamine and morphine : potentiation , antagonism , tolerance and cross - tolerance in the rat .|Previous studies demonstrated that both ketamine and morphine induced analgesia and catalepsy in the rat .|Pre - treatment with ketamine produced cross - tolerance to morphine , whereas pretreatment with morphine did not induce cross - tolerance to ketamine but rather augmented the cataleptic response ; this augmentation was attributed to residual morphine in the brain .|The present studies explored the duration of the loss of righting reflex induced by sub - effective doses of ketamine and morphine , administered simultaneously .|There was mutual potentiation between sub - effective doses of ketamine and morphine , but sub - effective doses of ketamine partly antagonized fully - effective doses of morphine .|Latency to the loss of righting reflex , rigidity and behavior on recovery , reflected the relative predominance of ketamine or morphine in each combination .|Naloxone inhibited the induced cataleptic effects .|The degree and time course of development of tolerance to daily administration of sub - effective dose combinations of ketamine and morphine were similar .|Rats , tolerant to ketamine - dominant combinations , were cross - tolerant to both drugs , while those tolerant to morphine - dominant combinations were cross - tolerant to morphine but showed either no cross - tolerance or an augmented response to ketamine .|While the mutual potentiation , antagonism and tolerance suggest common mechanisms for the induced catalepsy , differences in latency , rigidity and behavior , asymmetry of cross - tolerance and a widely - different ID50 for naloxone would argue against an action at a single opioid site .	1:CID:2	R2L	NON-CROSS	5-6	0-1	D007649	ketamine|ketamine|ketamine|ketamine|ketamine|ketamine|ketamine|ketamine|ketamine|ketamine|ketamine	Chemical	5:27:42:61:99:116:126:155:188:198:237	6:28:43:62:100:117:127:156:189:199:238	0:1:2:2:3:4:4:5:7:8:8	D002375	Catalepsy|catalepsy|cataleptic|cataleptic|catalepsy	Disease	0:33:66:166:253	1:34:67:167:254	0:1:2:6:9	1:CID:2	R2L	NON-CROSS	33-34	29-30	D009020	morphine|morphine|morphine|morphine|morphine|morphine|morphine|morphine|morphine|morphine|morphine|morphine	Chemical	7:29:48:53:75:101:118:134:157:190:215:224	8:30:49:54:76:102:119:135:158:191:216:225	0:1:2:2:2:3:4:4:5:7:8:8	D002375	Catalepsy|catalepsy|cataleptic|cataleptic|catalepsy	Disease	0:33:66:166:253	1:34:67:167:254	0:1:2:6:9	1:NR:2	R2L	NON-CROSS	166-167	162-163	D009270	Naloxone|naloxone	Chemical	162:275	163:276	6:9	D002375	Catalepsy|catalepsy|cataleptic|cataleptic|catalepsy	Disease	0:33:66:166:253	1:34:67:167:254	0:1:2:6:9	1:NR:2	L2R	NON-CROSS	27-28	31-32	D007649	ketamine|ketamine|ketamine|ketamine|ketamine|ketamine|ketamine|ketamine|ketamine|ketamine|ketamine	Chemical	5:27:42:61:99:116:126:155:188:198:237	6:28:43:62:100:117:127:156:189:199:238	0:1:2:2:3:4:4:5:7:8:8	D000699	analgesia	Disease	31	32	1	1:NR:2	L2R	NON-CROSS	144-145	155-156	D007649	ketamine|ketamine|ketamine|ketamine|ketamine|ketamine|ketamine|ketamine|ketamine|ketamine|ketamine	Chemical	5:27:42:61:99:116:126:155:188:198:237	6:28:43:62:100:117:127:156:189:199:238	0:1:2:2:3:4:4:5:7:8:8	D009127	rigidity|rigidity	Disease	144:259	145:260	5:9	1:NR:2	L2R	NON-CROSS	29-30	31-32	D009020	morphine|morphine|morphine|morphine|morphine|morphine|morphine|morphine|morphine|morphine|morphine|morphine	Chemical	7:29:48:53:75:101:118:134:157:190:215:224	8:30:49:54:76:102:119:135:158:191:216:225	0:1:2:2:2:3:4:4:5:7:8:8	D000699	analgesia	Disease	31	32	1	1:NR:2	L2R	NON-CROSS	134-135	144-145	D009020	morphine|morphine|morphine|morphine|morphine|morphine|morphine|morphine|morphine|morphine|morphine|morphine	Chemical	7:29:48:53:75:101:118:134:157:190:215:224	8:30:49:54:76:102:119:135:158:191:216:225	0:1:2:2:2:3:4:4:5:7:8:8	D009127	rigidity|rigidity	Disease	144:259	145:260	5:9	1:NR:2	R2L	CROSS	162-163	31-32	D009270	Naloxone|naloxone	Chemical	162:275	163:276	6:9	D000699	analgesia	Disease	31	32	1	1:NR:2	R2L	NON-CROSS	275-276	259-260	D009270	Naloxone|naloxone	Chemical	162:275	163:276	6:9	D009127	rigidity|rigidity	Disease	144:259	145:260	5:9
19642243	Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis .|Renal failure developed after a prolonged course of vancomycin therapy in 2 patients who were receiving tenofovir disoproxil fumarate as part of an antiretroviral regimen .|Tenofovir has been implicated in the development of Fanconi syndrome and renal insufficiency because of its effects on the proximal renal tubule .|Vancomycin nephrotoxicity is infrequent but may result from coadministration with a nephrotoxic agent .|Clinicians should be aware that tenofovir may raise the risk of renal failure during prolonged administration of vancomycin .	1:NR:2	R2L	NON-CROSS	8-9	0-3	C096918	tenofovir|Tenofovir|tenofovir	Chemical	8:43:85	9:44:86	0:2:4	D058186	Acute renal failure	Disease	0	3	0	1:CID:2	R2L	NON-CROSS	12-13	0-3	D014640	vancomycin|vancomycin|Vancomycin|vancomycin	Chemical	12:25:66:97	13:26:67:98	0:1:3:4	D058186	Acute renal failure	Disease	0	3	0	1:CID:2	R2L	CROSS	33-36	0-3	C418563	tenofovir disoproxil fumarate	Chemical	33	36	1	D058186	Acute renal failure	Disease	0	3	0	1:NR:2	R2L	NON-CROSS	8-9	6-7	C096918	tenofovir|Tenofovir|tenofovir	Chemical	8:43:85	9:44:86	0:2:4	D000163	AIDS	Disease	6	7	0	1:NR:2	R2L	NON-CROSS	12-13	6-7	D014640	vancomycin|vancomycin|Vancomycin|vancomycin	Chemical	12:25:66:97	13:26:67:98	0:1:3:4	D000163	AIDS	Disease	6	7	0	1:NR:2	R2L	CROSS	33-36	6-7	C418563	tenofovir disoproxil fumarate	Chemical	33	36	1	D000163	AIDS	Disease	6	7	0	1:NR:2	L2R	NON-CROSS	8-9	15-16	C096918	tenofovir|Tenofovir|tenofovir	Chemical	8:43:85	9:44:86	0:2:4	D010019	osteomyelitis	Disease	15	16	0	1:NR:2	L2R	NON-CROSS	85-86	91-93	C096918	tenofovir|Tenofovir|tenofovir	Chemical	8:43:85	9:44:86	0:2:4	D051437	Renal failure|renal insufficiency|renal failure	Disease	17:54:91	19:56:93	1:2:4	1:NR:2	L2R	NON-CROSS	43-44	51-53	C096918	tenofovir|Tenofovir|tenofovir	Chemical	8:43:85	9:44:86	0:2:4	D005198	Fanconi syndrome	Disease	51	53	2	1:NR:2	L2R	CROSS	77-78	85-86	C096918	tenofovir|Tenofovir|tenofovir	Chemical	8:43:85	9:44:86	0:2:4	D007674	nephrotoxicity|nephrotoxic	Disease	67:77	68:78	3:3	1:NR:2	L2R	NON-CROSS	12-13	15-16	D014640	vancomycin|vancomycin|Vancomycin|vancomycin	Chemical	12:25:66:97	13:26:67:98	0:1:3:4	D010019	osteomyelitis	Disease	15	16	0	1:NR:2	L2R	NON-CROSS	12-13	17-19	D014640	vancomycin|vancomycin|Vancomycin|vancomycin	Chemical	12:25:66:97	13:26:67:98	0:1:3:4	D051437	Renal failure|renal insufficiency|renal failure	Disease	17:54:91	19:56:93	1:2:4	1:NR:2	L2R	CROSS	51-53	66-67	D014640	vancomycin|vancomycin|Vancomycin|vancomycin	Chemical	12:25:66:97	13:26:67:98	0:1:3:4	D005198	Fanconi syndrome	Disease	51	53	2	1:NR:2	L2R	NON-CROSS	66-67	67-68	D014640	vancomycin|vancomycin|Vancomycin|vancomycin	Chemical	12:25:66:97	13:26:67:98	0:1:3:4	D007674	nephrotoxicity|nephrotoxic	Disease	67:77	68:78	3:3	1:NR:2	R2L	CROSS	33-36	15-16	C418563	tenofovir disoproxil fumarate	Chemical	33	36	1	D010019	osteomyelitis	Disease	15	16	0	1:NR:2	R2L	NON-CROSS	33-36	17-19	C418563	tenofovir disoproxil fumarate	Chemical	33	36	1	D051437	Renal failure|renal insufficiency|renal failure	Disease	17:54:91	19:56:93	1:2:4	1:NR:2	L2R	CROSS	33-36	51-53	C418563	tenofovir disoproxil fumarate	Chemical	33	36	1	D005198	Fanconi syndrome	Disease	51	53	2	1:NR:2	L2R	CROSS	33-36	67-68	C418563	tenofovir disoproxil fumarate	Chemical	33	36	1	D007674	nephrotoxicity|nephrotoxic	Disease	67:77	68:78	3:3
17682013	Delayed leukoencephalopathy with stroke - like presentation in chemotherapy recipients .|BACKGROUND : A transient leukoencephalopathy mimicking cerebrovascular accident has been described as a complication of chemotherapy , most commonly in recipients of intrathecal methotrexate for childhood leukaemia .|Recently published neuroimaging data suggest a common pathophysiology associated with a variety of chemotherapy agents and modes of administration .|METHODS : We reviewed the medical literature for single reports and case series of patients presenting with stroke - like episodes while receiving systemic or intrathecal chemotherapy .|We only included studies providing detailed neuroimaging data .|Patients with cerebrovascular accidents were excluded .|RESULTS : We identified 27 reports of toxic leukoencephalopathy in patients treated with methotrexate ( intrathecal , systemic ) , 5 - fluorouracil and its derivative carmofur , and capecitabine .|Diffusion weighted imaging ( DWI ) of all patients revealed well demarcated hyperintense lesions within the subcortical white matter of the cerebral hemispheres and the corpus callosum , corresponding to areas of decreased proton diffusion on apparent diffusion coefficient ( ADC ) maps ( available in 21 / 27 patients ) .|Lesions exceeded the confines of adjacent vascular territories .|Complete resolution of symptoms within 1 - 4 days was accompanied by normalisation of ADC abnormalities .|However , fluid attenuated inversion recovery ( FLAIR ) sequences frequently revealed persistent white matter abnormalities .|CONCLUSIONS : Several pathophysiological models of delayed leukoencephalopathy after exposure to intrathecal or systemic chemotherapy have been proposed .|DWI findings in this cohort are indicative of cytotoxic oedema within cerebral white matter and lend support to an at least partially reversible metabolic derangement as the basis for this syndrome .	1:CID:2	R2L	NON-CROSS	116-117	111-112	D008727	methotrexate|methotrexate	Chemical	34:116	35:117	1:6	D056784	leukoencephalopathy|leukoencephalopathy|leukoencephalopathy|lesions within the subcortical white matter|white matter abnormalities|leukoencephalopathy	Disease	1:15:111:147:225:236	2:16:112:153:228:237	0:1:6:7:10:11	1:CID:2	R2L	NON-CROSS	123-126	111-112	D005472	5 - fluorouracil	Chemical	123	126	6	D056784	leukoencephalopathy|leukoencephalopathy|leukoencephalopathy|lesions within the subcortical white matter|white matter abnormalities|leukoencephalopathy	Disease	1:15:111:147:225:236	2:16:112:153:228:237	0:1:6:7:10:11	1:CID:2	R2L	NON-CROSS	129-130	111-112	C017367	carmofur	Chemical	129	130	6	D056784	leukoencephalopathy|leukoencephalopathy|leukoencephalopathy|lesions within the subcortical white matter|white matter abnormalities|leukoencephalopathy	Disease	1:15:111:147:225:236	2:16:112:153:228:237	0:1:6:7:10:11	1:CID:2	R2L	NON-CROSS	147-153	132-133	C110904	capecitabine	Chemical	132	133	6	D056784	leukoencephalopathy|leukoencephalopathy|leukoencephalopathy|lesions within the subcortical white matter|white matter abnormalities|leukoencephalopathy	Disease	1:15:111:147:225:236	2:16:112:153:228:237	0:1:6:7:10:11	1:NR:2	R2L	CROSS	34-35	3-4	D008727	methotrexate|methotrexate	Chemical	34:116	35:117	1:6	D020521	stroke|stroke	Disease	3:76	4:77	0:3	1:NR:2	R2L	CROSS	123-126	76-77	D005472	5 - fluorouracil	Chemical	123	126	6	D020521	stroke|stroke	Disease	3:76	4:77	0:3	1:NR:2	R2L	CROSS	129-130	76-77	C017367	carmofur	Chemical	129	130	6	D020521	stroke|stroke	Disease	3:76	4:77	0:3	1:NR:2	R2L	CROSS	132-133	76-77	C110904	capecitabine	Chemical	132	133	6	D020521	stroke|stroke	Disease	3:76	4:77	0:3	1:NR:2	R2L	NON-CROSS	34-35	17-19	D008727	methotrexate|methotrexate	Chemical	34:116	35:117	1:6	D002544	cerebrovascular accident|cerebrovascular accidents	Disease	17:98	19:100	1:5	1:NR:2	R2L	CROSS	123-126	98-100	D005472	5 - fluorouracil	Chemical	123	126	6	D002544	cerebrovascular accident|cerebrovascular accidents	Disease	17:98	19:100	1:5	1:NR:2	R2L	CROSS	129-130	98-100	C017367	carmofur	Chemical	129	130	6	D002544	cerebrovascular accident|cerebrovascular accidents	Disease	17:98	19:100	1:5	1:NR:2	R2L	CROSS	132-133	98-100	C110904	capecitabine	Chemical	132	133	6	D002544	cerebrovascular accident|cerebrovascular accidents	Disease	17:98	19:100	1:5	1:NR:2	L2R	NON-CROSS	34-35	37-38	D008727	methotrexate|methotrexate	Chemical	34:116	35:117	1:6	D007938	leukaemia	Disease	37	38	1	1:NR:2	L2R	CROSS	116-117	256-262	D008727	methotrexate|methotrexate	Chemical	34:116	35:117	1:6	D001929	cytotoxic oedema within cerebral white matter	Disease	256	262	12	1:NR:2	R2L	CROSS	123-126	37-38	D005472	5 - fluorouracil	Chemical	123	126	6	D007938	leukaemia	Disease	37	38	1	1:NR:2	R2L	CROSS	129-130	37-38	C017367	carmofur	Chemical	129	130	6	D007938	leukaemia	Disease	37	38	1	1:NR:2	R2L	CROSS	132-133	37-38	C110904	capecitabine	Chemical	132	133	6	D007938	leukaemia	Disease	37	38	1	1:NR:2	L2R	CROSS	123-126	256-262	D005472	5 - fluorouracil	Chemical	123	126	6	D001929	cytotoxic oedema within cerebral white matter	Disease	256	262	12	1:NR:2	L2R	CROSS	129-130	256-262	C017367	carmofur	Chemical	129	130	6	D001929	cytotoxic oedema within cerebral white matter	Disease	256	262	12	1:NR:2	L2R	CROSS	132-133	256-262	C110904	capecitabine	Chemical	132	133	6	D001929	cytotoxic oedema within cerebral white matter	Disease	256	262	12
16725121	Down - regulation of norepinephrine transporter function induced by chronic administration of desipramine linking to the alteration of sensitivity of local - anesthetics - induced convulsions and the counteraction by co - administration with local anesthetics .|Alterations of norepinephrine transporter ( NET ) function by chronic inhibition of NET in relation to sensitization to seizures induce by cocaine and local anesthetics were studied in mice .|Daily administration of desipramine , an inhibitor of the NET , for 5 days decreased [ ( 3 ) H ] norepinephrine uptake in the P2 fractions of hippocampus but not cortex , striatum or amygdalae .|Co - administration of lidocaine , bupivacaine or tricaine with desipramine reversed this effect .|Daily treatment of cocaine increased [ ( 3 ) H ] norepinephrine uptake into the hippocampus .|Daily administration of desipramine increased the incidence of appearance of lidocaine - induced convulsions and decreased that of cocaine - induced convulsions .|Co - administration of lidocaine with desipramine reversed the changes of convulsive activity of lidocaine and cocaine induced by repeated administration of desipramine .|These results suggest that down - regulation of hippocampal NET induced by chronic administration of desipramine may be relevant to desipramine - induced sensitization of lidocaine convulsions .|Inhibition of Na ( + ) channels by local anesthetics may regulate desipramine - induced down - regulation of NET function .|Repeated administration of cocaine induces up - regulation of hippocampal NET function .|Desipramine - induced sensitization of lidocaine seizures may have a mechanism distinct from kindling resulting from repeated administration of cocaine .	1:NR:2	L2R	NON-CROSS	25-26	39-40	D009638	norepinephrine|norepinephrine|norepinephrine|norepinephrine	Chemical	4:39:88:130	5:40:89:131	0:1:2:4	D012640	convulsions|seizures|convulsions|convulsions|convulsive|convulsions|seizures	Disease	25:55:149:157:170:209:252	26:56:150:158:171:210:253	0:1:5:5:6:7:10	1:NR:2	L2R	NON-CROSS	165-166	170-171	D003891	desipramine|desipramine|desipramine|desipramine|desipramine|desipramine|desipramine|desipramine|desipramine|Desipramine	Chemical	12:70:114:139:165:181:198:203:223:246	13:71:115:140:166:182:199:204:224:247	0:2:3:5:6:6:7:7:8:10	D012640	convulsions|seizures|convulsions|convulsions|convulsive|convulsions|seizures	Disease	25:55:149:157:170:209:252	26:56:150:158:171:210:253	0:1:5:5:6:7:10	1:CID:2	R2L	NON-CROSS	58-59	55-56	D003042	cocaine|cocaine|cocaine|cocaine|cocaine|cocaine	Chemical	58:122:154:175:236:265	59:123:155:176:237:266	1:4:5:6:9:10	D012640	convulsions|seizures|convulsions|convulsions|convulsive|convulsions|seizures	Disease	25:55:149:157:170:209:252	26:56:150:158:171:210:253	0:1:5:5:6:7:10	1:CID:2	R2L	NON-CROSS	209-210	208-209	D008012	lidocaine|lidocaine|lidocaine|lidocaine|lidocaine|lidocaine	Chemical	108:146:163:173:208:251	109:147:164:174:209:252	3:5:6:6:7:10	D012640	convulsions|seizures|convulsions|convulsions|convulsive|convulsions|seizures	Disease	25:55:149:157:170:209:252	26:56:150:158:171:210:253	0:1:5:5:6:7:10	1:NR:2	R2L	CROSS	149-150	110-111	D002045	bupivacaine	Chemical	110	111	3	D012640	convulsions|seizures|convulsions|convulsions|convulsive|convulsions|seizures	Disease	25:55:149:157:170:209:252	26:56:150:158:171:210:253	0:1:5:5:6:7:10	1:NR:2	R2L	CROSS	149-150	112-113	C003636	tricaine	Chemical	112	113	3	D012640	convulsions|seizures|convulsions|convulsions|convulsive|convulsions|seizures	Disease	25:55:149:157:170:209:252	26:56:150:158:171:210:253	0:1:5:5:6:7:10	1:NR:2	R2L	CROSS	213-214	209-210	D012964	Na	Chemical	213	214	8	D012640	convulsions|seizures|convulsions|convulsions|convulsive|convulsions|seizures	Disease	25:55:149:157:170:209:252	26:56:150:158:171:210:253	0:1:5:5:6:7:10
16629641	Definition and management of anemia in patients infected with hepatitis C virus .|Chronic infection with hepatitis C virus ( HCV ) can progress to cirrhosis , hepatocellular carcinoma , and end - stage liver disease .|The current best treatment for HCV infection is combination therapy with pegylated interferon and ribavirin .|Although this regimen produces sustained virologic responses ( SVRs ) in approximately 50 % of patients , it can be associated with a potentially dose - limiting hemolytic anemia .|Hemoglobin concentrations decrease mainly as a result of ribavirin - induced hemolysis , and this anemia can be problematic in patients with HCV infection , especially those who have comorbid renal or cardiovascular disorders .|In general , anemia can increase the risk of morbidity and mortality , and may have negative effects on cerebral function and quality of life .|Although ribavirin - associated anemia can be reversed by dose reduction or discontinuation , this approach compromises outcomes by significantly decreasing SVR rates .|Recombinant human erythropoietin has been used to manage ribavirin - associated anemia but has other potential disadvantages .|Viramidine , a liver - targeting prodrug of ribavirin , has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with chronic hepatitis C .	1:NR:2	R2L	CROSS	49-50	4-5	D007372	interferon	Chemical	49	50	2	D000740	anemia|anemia|anemia|anemia|anemia	Disease	4:98:121:148:179	5:99:122:149:180	0:4:5:6:7	1:NR:2	R2L	NON-CROSS	148-149	145-146	D012254	ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin	Chemical	51:91:145:176:194:205	52:92:146:177:195:206	2:4:6:7:8:8	D000740	anemia|anemia|anemia|anemia|anemia	Disease	4:98:121:148:179	5:99:122:149:180	0:4:5:6:7	1:NR:2	R2L	CROSS	186-187	179-180	C026956	Viramidine	Chemical	186	187	8	D000740	anemia|anemia|anemia|anemia|anemia	Disease	4:98:121:148:179	5:99:122:149:180	0:4:5:6:7	1:NR:2	R2L	NON-CROSS	49-50	42-44	D007372	interferon	Chemical	49	50	2	D006526	infected with hepatitis C virus|HCV infection|HCV infection	Disease	7:42:105	12:44:107	0:2:4	1:NR:2	R2L	NON-CROSS	51-52	42-44	D012254	ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin	Chemical	51:91:145:176:194:205	52:92:146:177:195:206	2:4:6:7:8:8	D006526	infected with hepatitis C virus|HCV infection|HCV infection	Disease	7:42:105	12:44:107	0:2:4	1:NR:2	R2L	CROSS	186-187	105-107	C026956	Viramidine	Chemical	186	187	8	D006526	infected with hepatitis C virus|HCV infection|HCV infection	Disease	7:42:105	12:44:107	0:2:4	1:NR:2	R2L	CROSS	49-50	13-19	D007372	interferon	Chemical	49	50	2	D019698	Chronic infection with hepatitis C virus|chronic hepatitis C	Disease	13:216	19:219	1:8	1:NR:2	R2L	NON-CROSS	216-219	205-206	D012254	ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin	Chemical	51:91:145:176:194:205	52:92:146:177:195:206	2:4:6:7:8:8	D019698	Chronic infection with hepatitis C virus|chronic hepatitis C	Disease	13:216	19:219	1:8	1:NR:2	R2L	NON-CROSS	216-219	186-187	C026956	Viramidine	Chemical	186	187	8	D019698	Chronic infection with hepatitis C virus|chronic hepatitis C	Disease	13:216	19:219	1:8	1:NR:2	R2L	CROSS	49-50	25-26	D007372	interferon	Chemical	49	50	2	D005355	cirrhosis	Disease	25	26	1	1:NR:2	R2L	CROSS	51-52	25-26	D012254	ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin	Chemical	51:91:145:176:194:205	52:92:146:177:195:206	2:4:6:7:8:8	D005355	cirrhosis	Disease	25	26	1	1:NR:2	R2L	CROSS	186-187	25-26	C026956	Viramidine	Chemical	186	187	8	D005355	cirrhosis	Disease	25	26	1	1:NR:2	R2L	CROSS	49-50	27-29	D007372	interferon	Chemical	49	50	2	D006528	hepatocellular carcinoma	Disease	27	29	1	1:NR:2	R2L	CROSS	51-52	27-29	D012254	ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin	Chemical	51:91:145:176:194:205	52:92:146:177:195:206	2:4:6:7:8:8	D006528	hepatocellular carcinoma	Disease	27	29	1	1:NR:2	R2L	CROSS	186-187	27-29	C026956	Viramidine	Chemical	186	187	8	D006528	hepatocellular carcinoma	Disease	27	29	1	1:NR:2	R2L	CROSS	49-50	31-36	D007372	interferon	Chemical	49	50	2	D058625	end - stage liver disease	Disease	31	36	1	1:NR:2	R2L	CROSS	51-52	31-36	D012254	ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin	Chemical	51:91:145:176:194:205	52:92:146:177:195:206	2:4:6:7:8:8	D058625	end - stage liver disease	Disease	31	36	1	1:NR:2	R2L	CROSS	186-187	31-36	C026956	Viramidine	Chemical	186	187	8	D058625	end - stage liver disease	Disease	31	36	1	1:CID:2	L2R	CROSS	49-50	80-82	D007372	interferon	Chemical	49	50	2	D000743	hemolytic anemia|hemolytic anemia	Disease	80:211	82:213	3:8	1:NR:2	L2R	CROSS	49-50	94-95	D007372	interferon	Chemical	49	50	2	D006461	hemolysis	Disease	94	95	4	1:NR:2	L2R	CROSS	49-50	113-117	D007372	interferon	Chemical	49	50	2	D007674	renal or cardiovascular disorders	Disease	113	117	4	1:NR:2	L2R	CROSS	49-50	113-117	D007372	interferon	Chemical	49	50	2	D002318	renal or cardiovascular disorders	Disease	113	117	4	1:CID:2	L2R	NON-CROSS	205-206	211-213	D012254	ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin	Chemical	51:91:145:176:194:205	52:92:146:177:195:206	2:4:6:7:8:8	D000743	hemolytic anemia|hemolytic anemia	Disease	80:211	82:213	3:8	1:NR:2	L2R	NON-CROSS	91-92	94-95	D012254	ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin	Chemical	51:91:145:176:194:205	52:92:146:177:195:206	2:4:6:7:8:8	D006461	hemolysis	Disease	94	95	4	1:NR:2	L2R	NON-CROSS	91-92	113-117	D012254	ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin	Chemical	51:91:145:176:194:205	52:92:146:177:195:206	2:4:6:7:8:8	D007674	renal or cardiovascular disorders	Disease	113	117	4	1:NR:2	L2R	NON-CROSS	91-92	113-117	D012254	ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin	Chemical	51:91:145:176:194:205	52:92:146:177:195:206	2:4:6:7:8:8	D002318	renal or cardiovascular disorders	Disease	113	117	4	1:NR:2	R2L	NON-CROSS	211-213	186-187	C026956	Viramidine	Chemical	186	187	8	D000743	hemolytic anemia|hemolytic anemia	Disease	80:211	82:213	3:8	1:NR:2	R2L	CROSS	186-187	94-95	C026956	Viramidine	Chemical	186	187	8	D006461	hemolysis	Disease	94	95	4	1:NR:2	R2L	CROSS	186-187	113-117	C026956	Viramidine	Chemical	186	187	8	D007674	renal or cardiovascular disorders	Disease	113	117	4	1:NR:2	R2L	CROSS	186-187	113-117	C026956	Viramidine	Chemical	186	187	8	D002318	renal or cardiovascular disorders	Disease	113	117	4
16006300	Calcium carbonate toxicity : the updated milk - alkali syndrome ; report of 3 cases and review of the literature .|OBJECTIVE : To describe 3 patients with calcium carbonate - induced hypercalcemia and gain insights into the cause and management of the milk - alkali syndrome .|METHODS : We report the clinical and laboratory data in 3 patients who presented with severe hypercalcemia ( corrected serum calcium > or = 14 mg / dL ) and review the pertinent literature on milk - alkali syndrome .|RESULTS : The 3 patients had acute renal insufficiency , relative metabolic alkalosis , and low parathyroid hormone ( PTH ) , PTH - related peptide , and 1 , 25 - dihydroxyvitamin D concentrations .|No malignant lesion was found .|Treatment included aggressive hydration and varied amounts of furosemide .|The 2 patients with the higher serum calcium concentrations received pamidronate intravenously ( 60 and 30 mg , respectively ) , which caused severe hypocalcemia .|Of the 3 patients , 2 were ingesting acceptable doses of elemental calcium ( 1 g and 2 g daily , respectively ) in the form of calcium carbonate .|In addition to our highlighted cases , we review the history , classification , pathophysiologic features , and treatment of milk - alkali syndrome and summarize the cases reported from early 1995 to November 2003 .|CONCLUSION : Milk - alkali syndrome may be a common cause of unexplained hypercalcemia and can be precipitated by small amounts of orally ingested calcium carbonate in susceptible persons .|Treatment with hydration , furosemide , and discontinuation of the calcium and vitamin D source is adequate .|Pamidronate treatment is associated with considerable risk for hypocalcemia , even in cases of initially severe hypercalcemia .	1:NR:2	L2R	NON-CROSS	0-2	2-3	D002119	Calcium carbonate|calcium carbonate|calcium carbonate|calcium carbonate	Chemical	0:28:193:256	2:30:195:258	0:1:7:9	D064420	toxicity	Disease	2	3	0	1:CID:2	L2R	NON-CROSS	28-30	32-33	D002119	Calcium carbonate|calcium carbonate|calcium carbonate|calcium carbonate	Chemical	0:28:193:256	2:30:195:258	0:1:7:9	D006934	milk - alkali syndrome|hypercalcemia|milk - alkali syndrome|hypercalcemia|milk - alkali syndrome|milk - alkali syndrome|Milk - alkali syndrome|hypercalcemia|hypercalcemia	Disease	6:32:43:64:83:216:234:245:296	10:33:47:65:87:220:238:246:297	0:1:1:2:2:8:9:9:11	1:NR:2	L2R	CROSS	28-30	94-97	D002119	Calcium carbonate|calcium carbonate|calcium carbonate|calcium carbonate	Chemical	0:28:193:256	2:30:195:258	0:1:7:9	D058186	acute renal insufficiency	Disease	94	97	3	1:NR:2	L2R	CROSS	28-30	99-101	D002119	Calcium carbonate|calcium carbonate|calcium carbonate|calcium carbonate	Chemical	0:28:193:256	2:30:195:258	0:1:7:9	D000471	metabolic alkalosis	Disease	99	101	3	1:NR:2	L2R	CROSS	164-165	193-195	D002119	Calcium carbonate|calcium carbonate|calcium carbonate|calcium carbonate	Chemical	0:28:193:256	2:30:195:258	0:1:7:9	D006996	hypocalcemia|hypocalcemia	Disease	164:288	165:289	6:11	1:NR:2	R2L	CROSS	68-69	2-3	D002118	calcium|calcium|calcium|calcium	Chemical	68:147:178:272	69:148:179:273	2:6:7:10	D064420	toxicity	Disease	2	3	0	1:NR:2	R2L	CROSS	116-122	2-3	C097949	1 , 25 - dihydroxyvitamin D	Chemical	116	122	3	D064420	toxicity	Disease	2	3	0	1:NR:2	R2L	CROSS	138-139	2-3	D005665	furosemide|furosemide	Chemical	138:266	139:267	5:10	D064420	toxicity	Disease	2	3	0	1:NR:2	R2L	CROSS	150-151	2-3	C019248	pamidronate|Pamidronate	Chemical	150:280	151:281	6:11	D064420	toxicity	Disease	2	3	0	1:NR:2	R2L	CROSS	274-276	2-3	D014807	vitamin D	Chemical	274	276	10	D064420	toxicity	Disease	2	3	0	1:NR:2	R2L	NON-CROSS	68-69	64-65	D002118	calcium|calcium|calcium|calcium	Chemical	68:147:178:272	69:148:179:273	2:6:7:10	D006934	milk - alkali syndrome|hypercalcemia|milk - alkali syndrome|hypercalcemia|milk - alkali syndrome|milk - alkali syndrome|Milk - alkali syndrome|hypercalcemia|hypercalcemia	Disease	6:32:43:64:83:216:234:245:296	10:33:47:65:87:220:238:246:297	0:1:1:2:2:8:9:9:11	1:NR:2	R2L	CROSS	116-122	83-87	C097949	1 , 25 - dihydroxyvitamin D	Chemical	116	122	3	D006934	milk - alkali syndrome|hypercalcemia|milk - alkali syndrome|hypercalcemia|milk - alkali syndrome|milk - alkali syndrome|Milk - alkali syndrome|hypercalcemia|hypercalcemia	Disease	6:32:43:64:83:216:234:245:296	10:33:47:65:87:220:238:246:297	0:1:1:2:2:8:9:9:11	1:NR:2	R2L	CROSS	266-267	245-246	D005665	furosemide|furosemide	Chemical	138:266	139:267	5:10	D006934	milk - alkali syndrome|hypercalcemia|milk - alkali syndrome|hypercalcemia|milk - alkali syndrome|milk - alkali syndrome|Milk - alkali syndrome|hypercalcemia|hypercalcemia	Disease	6:32:43:64:83:216:234:245:296	10:33:47:65:87:220:238:246:297	0:1:1:2:2:8:9:9:11	1:NR:2	R2L	NON-CROSS	296-297	280-281	C019248	pamidronate|Pamidronate	Chemical	150:280	151:281	6:11	D006934	milk - alkali syndrome|hypercalcemia|milk - alkali syndrome|hypercalcemia|milk - alkali syndrome|milk - alkali syndrome|Milk - alkali syndrome|hypercalcemia|hypercalcemia	Disease	6:32:43:64:83:216:234:245:296	10:33:47:65:87:220:238:246:297	0:1:1:2:2:8:9:9:11	1:NR:2	R2L	CROSS	296-297	274-276	D014807	vitamin D	Chemical	274	276	10	D006934	milk - alkali syndrome|hypercalcemia|milk - alkali syndrome|hypercalcemia|milk - alkali syndrome|milk - alkali syndrome|Milk - alkali syndrome|hypercalcemia|hypercalcemia	Disease	6:32:43:64:83:216:234:245:296	10:33:47:65:87:220:238:246:297	0:1:1:2:2:8:9:9:11	1:NR:2	L2R	CROSS	68-69	94-97	D002118	calcium|calcium|calcium|calcium	Chemical	68:147:178:272	69:148:179:273	2:6:7:10	D058186	acute renal insufficiency	Disease	94	97	3	1:NR:2	L2R	CROSS	68-69	99-101	D002118	calcium|calcium|calcium|calcium	Chemical	68:147:178:272	69:148:179:273	2:6:7:10	D000471	metabolic alkalosis	Disease	99	101	3	1:NR:2	L2R	NON-CROSS	164-165	178-179	D002118	calcium|calcium|calcium|calcium	Chemical	68:147:178:272	69:148:179:273	2:6:7:10	D006996	hypocalcemia|hypocalcemia	Disease	164:288	165:289	6:11	1:NR:2	R2L	NON-CROSS	116-122	94-97	C097949	1 , 25 - dihydroxyvitamin D	Chemical	116	122	3	D058186	acute renal insufficiency	Disease	94	97	3	1:NR:2	R2L	CROSS	138-139	94-97	D005665	furosemide|furosemide	Chemical	138:266	139:267	5:10	D058186	acute renal insufficiency	Disease	94	97	3	1:NR:2	R2L	CROSS	150-151	94-97	C019248	pamidronate|Pamidronate	Chemical	150:280	151:281	6:11	D058186	acute renal insufficiency	Disease	94	97	3	1:NR:2	R2L	CROSS	274-276	94-97	D014807	vitamin D	Chemical	274	276	10	D058186	acute renal insufficiency	Disease	94	97	3	1:NR:2	R2L	NON-CROSS	116-122	99-101	C097949	1 , 25 - dihydroxyvitamin D	Chemical	116	122	3	D000471	metabolic alkalosis	Disease	99	101	3	1:NR:2	R2L	CROSS	138-139	99-101	D005665	furosemide|furosemide	Chemical	138:266	139:267	5:10	D000471	metabolic alkalosis	Disease	99	101	3	1:NR:2	R2L	CROSS	150-151	99-101	C019248	pamidronate|Pamidronate	Chemical	150:280	151:281	6:11	D000471	metabolic alkalosis	Disease	99	101	3	1:NR:2	R2L	CROSS	274-276	99-101	D014807	vitamin D	Chemical	274	276	10	D000471	metabolic alkalosis	Disease	99	101	3	1:NR:2	L2R	CROSS	116-122	164-165	C097949	1 , 25 - dihydroxyvitamin D	Chemical	116	122	3	D006996	hypocalcemia|hypocalcemia	Disease	164:288	165:289	6:11	1:NR:2	L2R	CROSS	266-267	288-289	D005665	furosemide|furosemide	Chemical	138:266	139:267	5:10	D006996	hypocalcemia|hypocalcemia	Disease	164:288	165:289	6:11	1:CID:2	L2R	NON-CROSS	280-281	288-289	C019248	pamidronate|Pamidronate	Chemical	150:280	151:281	6:11	D006996	hypocalcemia|hypocalcemia	Disease	164:288	165:289	6:11	1:NR:2	R2L	CROSS	288-289	274-276	D014807	vitamin D	Chemical	274	276	10	D006996	hypocalcemia|hypocalcemia	Disease	164:288	165:289	6:11
11705128	Management strategies for ribavirin - induced hemolytic anemia in the treatment of hepatitis C : clinical and economic implications .|OBJECTIVES : Recently published studies have demonstrated increased efficacy and cost - effectiveness of combination therapy with interferon and alpha - 2b / ribavirin compared with interferon - alpha monotherapy in the treatment of chronic hepatitis C ( CHC ) .|Combination therapy is associated with a clinically important adverse effect : ribavirin - induced hemolytic anemia ( RIHA ) .|The objective of this study was to evaluate the direct health - care costs and management of RIHA during treatment of CHC in a clinical trial setting .|METHODS : A systematic literature review was conducted to synthesize information on the incidence and management of RIHA .|Decision - analytic techniques were used to estimate the cost of treating RIHA .|Uncertainty was evaluated using sensitivity analyses .|RESULTS : RIHA , defined as a reduction in hemoglobin to less than 100 g / L , occurs in approximately 7 % to 9 % of patients treated with combination therapy .|The standard of care for management of RIHA is reduction or discontinuation of the ribavirin dosage .|We estimated the direct cost of treating clinically significant RIHA to be 170 per patient receiving combination therapy per 48 - week treatment course ( range 68 - 692 ) .|The results of the one - way sensitivity analyses ranged from 57 to 317 .|In comparison , the cost of 48 weeks of combination therapy is 16 , 459 .|CONCLUSIONS : The direct cost of treating clinically significant RIHA is 1 % ( 170 / 16 , 459 ) of drug treatment costs .|Questions remain about the optimal dose of ribavirin and the incidence of RIHA in a real - world population .|Despite these uncertainties , this initial evaluation of the direct cost of treating RIHA provides an estimate of the cost and management implications of this clinically important adverse effect .	1:CID:2	L2R	NON-CROSS	3-4	6-8	D012254	ribavirin|ribavirin|ribavirin|ribavirin|ribavirin	Chemical	3:43:72:196:293	4:44:73:197:294	0:1:2:8:13	D000743	hemolytic anemia|hemolytic anemia|RIHA|RIHA|RIHA|RIHA|RIHA|RIHA|RIHA|RIHA|RIHA|RIHA	Disease	6:75:78:98:126:140:151:189:208:270:298:319	8:77:79:99:127:141:152:190:209:271:299:320	0:2:2:3:4:5:7:8:9:12:13:14	1:NR:2	L2R	NON-CROSS	3-4	12-14	D012254	ribavirin|ribavirin|ribavirin|ribavirin|ribavirin	Chemical	3:43:72:196:293	4:44:73:197:294	0:1:2:8:13	D006526	hepatitis C	Disease	12	14	0	1:NR:2	L2R	NON-CROSS	43-44	54-57	D012254	ribavirin|ribavirin|ribavirin|ribavirin|ribavirin	Chemical	3:43:72:196:293	4:44:73:197:294	0:1:2:8:13	D019698	chronic hepatitis C|CHC|CHC	Disease	54:58:102	57:59:103	1:1:3	1:CID:2	R2L	CROSS	75-77	46-49	D016898	interferon - alpha	Chemical	46	49	1	D000743	hemolytic anemia|hemolytic anemia|RIHA|RIHA|RIHA|RIHA|RIHA|RIHA|RIHA|RIHA|RIHA|RIHA	Disease	6:75:78:98:126:140:151:189:208:270:298:319	8:77:79:99:127:141:152:190:209:271:299:320	0:2:2:3:4:5:7:8:9:12:13:14	1:NR:2	R2L	CROSS	46-49	12-14	D016898	interferon - alpha	Chemical	46	49	1	D006526	hepatitis C	Disease	12	14	0	1:NR:2	L2R	NON-CROSS	46-49	54-57	D016898	interferon - alpha	Chemical	46	49	1	D019698	chronic hepatitis C|CHC|CHC	Disease	54:58:102	57:59:103	1:1:3
6540303	Effects of amine pretreatment on ketamine catatonia in pinealectomized or hypophysectomized animals .|The present studies were designed to clarify the role of catecholamines and pineal idolamines on ketamine - induced catatonia in the intact , pinealectomized or hypophysectomized chick and rat .|In the pinealectomized chick , pretreatment with dopamine increased the duration of catatonia ( DOC ) after ketamine , but pretreatment with norepinephrine did not .|The pineal indolamines exhibited mixed actions .|Serotonin and N - acetyl serotonin which augmented ketamine DOC , did not do so in the absence of the pineal gland , whereas melatonin potentiated the ketamine DOC in both the intact and pinealectomized chick .|Ketamine was more potent in the hypophysectomized chick and the circadian rhythm noted in the intact chick was absent ; furthermore , melatonin did not augment the ketamine DOC whereas dopamine continued to do so .|This study did not demonstrate a species difference regarding the role of the amines on the pineal in spite of the immature blood - brain barrier in the young chick and the intact barrier in the rat .|In addition , these data indicate a direct role of the pituitary in the augmentation of ketamine DOC induced by melatonin .|Furthermore , dopamine appeared to act on systems more closely involved with the induction of ketamine catatonia rather than directly on the pituitary .	1:NR:2	L2R	NON-CROSS	2-3	6-7	D000588	amine|amines	Chemical	2:162	3:163	0:6	D002389	catatonia|catatonia|catatonia|catatonia	Disease	6:31:55:225	7:32:56:226	0:1:2:8	1:CID:2	L2R	NON-CROSS	5-6	6-7	D007649	ketamine|ketamine|ketamine|ketamine|ketamine|Ketamine|ketamine|ketamine|ketamine	Chemical	5:28:60:84:103:113:140:203:224	6:29:61:85:104:114:141:204:225	0:1:2:4:4:5:5:7:8	D002389	catatonia|catatonia|catatonia|catatonia	Disease	6:31:55:225	7:32:56:226	0:1:2:8	1:NR:2	R2L	NON-CROSS	31-32	23-24	D002395	catecholamines	Chemical	23	24	1	D002389	catatonia|catatonia|catatonia|catatonia	Disease	6:31:55:225	7:32:56:226	0:1:2:8	1:CID:2	R2L	NON-CROSS	55-56	50-51	D004298	dopamine|dopamine|dopamine	Chemical	50:143:211	51:144:212	2:5:8	D002389	catatonia|catatonia|catatonia|catatonia	Disease	6:31:55:225	7:32:56:226	0:1:2:8	1:NR:2	R2L	NON-CROSS	65-66	55-56	D009638	norepinephrine	Chemical	65	66	2	D002389	catatonia|catatonia|catatonia|catatonia	Disease	6:31:55:225	7:32:56:226	0:1:2:8	1:CID:2	R2L	CROSS	76-77	55-56	D012701	Serotonin	Chemical	76	77	4	D002389	catatonia|catatonia|catatonia|catatonia	Disease	6:31:55:225	7:32:56:226	0:1:2:8	1:NR:2	R2L	CROSS	78-82	55-56	C006389	N - acetyl serotonin	Chemical	78	82	4	D002389	catatonia|catatonia|catatonia|catatonia	Disease	6:31:55:225	7:32:56:226	0:1:2:8	1:CID:2	R2L	CROSS	225-226	207-208	D008550	melatonin|melatonin|melatonin	Chemical	100:135:207	101:136:208	4:5:7	D002389	catatonia|catatonia|catatonia|catatonia	Disease	6:31:55:225	7:32:56:226	0:1:2:8
3057041	Multicenter , double - blind , multiple - dose , parallel - groups efficacy and safety trial of azelastine , chlorpheniramine , and placebo in the treatment of spring allergic rhinitis .|Azelastine , a novel antiallergic medication , was compared with chlorpheniramine maleate and placebo for efficacy and safety in the treatment of spring allergic rhinitis in a multicenter , double - blind , multiple - dose , parallel - groups study .|One hundred fifty - five subjects participated .|Subjects ranged in age from 18 to 60 years of age and had at least a 2 - year history of spring allergic rhinitis , confirmed by positive skin test to spring aeroallergens .|Medications were given four times daily ; the azelastine groups received 0 . 5 , 1 . 0 , or 2 . 0 mg in the morning and evening with placebo in the early and late afternoon ; the chlorpheniramine group received 4 . 0 mg four times daily .|Daily subject symptom cards were completed during a screening period to assess pretreatment symptoms and during a 4 - week treatment period while subjects received study medications .|Individual symptoms , total symptoms , and major symptoms were compared to determine efficacy of medication .|Elicited , volunteered , and observed adverse experiences were recorded for each subject and compared among groups .|Vital signs , body weights , serum chemistry values , complete blood cell counts , urine studies , and electrocardiograms were obtained for each subject and compared among groups .|Symptoms relief in the group receiving the highest concentration of azelastine ( 2 . 0 mg twice daily ) was statistically greater than in the placebo group during all weeks of the study .|Lower doses of azelastine were statistically more effective than placebo only during portions of the first 3 weeks of the study .|In contrast , although the chlorpheniramine group did have fewer symptoms than the placebo group during the study , the difference never reached statistical significance during any week of the study .|There were no serious side effects in any of the treatment groups .|Drowsiness and altered taste perception were increased significantly over placebo only in the high - dose azelastine group .|Azelastine appears to be a safe , efficacious medication for seasonal allergic rhinitis .	1:NR:2	L2R	NON-CROSS	28-31	32-33	C020976	azelastine|Azelastine|azelastine|azelastine|azelastine|azelastine|Azelastine	Chemical	18:32:124:269:296:376:379	19:33:125:270:297:377:380	0:1:4:9:10:13:14	D006255	spring allergic rhinitis|spring allergic rhinitis|spring allergic rhinitis|seasonal allergic rhinitis	Disease	28:54:103:389	31:57:106:392	0:1:3:14	1:CID:2	L2R	NON-CROSS	360-361	376-377	C020976	azelastine|Azelastine|azelastine|azelastine|azelastine|azelastine|Azelastine	Chemical	18:32:124:269:296:376:379	19:33:125:270:297:377:380	0:1:4:9:10:13:14	D006970	Drowsiness	Disease	360	361	13	1:CID:2	L2R	NON-CROSS	362-365	376-377	C020976	azelastine|Azelastine|azelastine|azelastine|azelastine|azelastine|Azelastine	Chemical	18:32:124:269:296:376:379	19:33:125:270:297:377:380	0:1:4:9:10:13:14	D013651	altered taste perception	Disease	362	365	13	1:NR:2	L2R	NON-CROSS	20-21	28-31	D002744	chlorpheniramine|chlorpheniramine maleate|chlorpheniramine|chlorpheniramine	Chemical	20:42:155:320	21:44:156:321	0:1:4:11	D006255	spring allergic rhinitis|spring allergic rhinitis|spring allergic rhinitis|seasonal allergic rhinitis	Disease	28:54:103:389	31:57:106:392	0:1:3:14	1:NR:2	L2R	CROSS	320-321	360-361	D002744	chlorpheniramine|chlorpheniramine maleate|chlorpheniramine|chlorpheniramine	Chemical	20:42:155:320	21:44:156:321	0:1:4:11	D006970	Drowsiness	Disease	360	361	13	1:NR:2	L2R	CROSS	320-321	362-365	D002744	chlorpheniramine|chlorpheniramine maleate|chlorpheniramine|chlorpheniramine	Chemical	20:42:155:320	21:44:156:321	0:1:4:11	D013651	altered taste perception	Disease	362	365	13
625456	Obsolete but dangerous antacid preparations .|One case of acute hypercalcaemia and two of recurrent nephrolithiasis are reported in patients who had regularly consumed large amounts of calcium carbon - ate - sodium bicarbonate powders for more than 20 years .|The powders had been obtained from pharmacists unknown to the patients ' medical practitioners .|It is suggested that these preparations were responsible for the patient 's problems , and that such powders should no longer be freely obtainable .	1:CID:2	R2L	NON-CROSS	27-31	10-11	D002119	calcium carbon - ate	Chemical	27	31	1	D006934	hypercalcaemia	Disease	10	11	1	1:CID:2	R2L	NON-CROSS	32-34	10-11	D017693	sodium bicarbonate	Chemical	32	34	1	D006934	hypercalcaemia	Disease	10	11	1	1:CID:2	R2L	NON-CROSS	27-31	15-16	D002119	calcium carbon - ate	Chemical	27	31	1	D053040	nephrolithiasis	Disease	15	16	1	1:CID:2	R2L	NON-CROSS	32-34	15-16	D017693	sodium bicarbonate	Chemical	32	34	1	D053040	nephrolithiasis	Disease	15	16	1
7910951	Prolonged paralysis due to nondepolarizing neuromuscular blocking agents and corticosteroids .|The long - term use of nondepolarizing neuromuscular blocking agents ( ND - NMBA ) has recently been implicated as a cause of prolonged muscle weakness , although the site of the lesion and the predisposing factors have been unclear .|We report 3 patients ( age 37 - 52 years ) with acute respiratory insufficiency who developed prolonged weakness following the discontinuation of ND - NMBAs .|Two patients also received intravenous corticosteroids .|Renal function was normal but hepatic function was impaired in all patients , and all had acidosis .|Electrophysiologic studies revealed low amplitude compound motor action potentials , normal sensory studies , and fibrillations .|Repetitive stimulation at 2 Hz showed a decremental response in 2 patients .|The serum vecuronium level measured in 1 patient 14 days after the drug had been discontinued was 172 ng / mL .|A muscle biopsy in this patient showed loss of thick , myosin filaments .|The weakness in these patients is due to pathology at both the neuromuscular junction ( most likely due to ND - NMBA ) and muscle ( most likely due to corticosteroids ) .|Hepatic dysfunction and acidosis are contributing risk factors .	1:NR:2	R2L	NON-CROSS	4-8	1-2	D003473	nondepolarizing neuromuscular blocking agents|nondepolarizing neuromuscular blocking agents|ND - NMBA|ND - NMBAs|ND - NMBA	Chemical	4:17:22:75:189	8:21:25:78:192	0:1:1:2:9	D010243	paralysis	Disease	1	2	0	1:NR:2	R2L	NON-CROSS	9-10	1-2	D000305	corticosteroids|corticosteroids|corticosteroids	Chemical	9:84:200	10:85:201	0:3:9	D010243	paralysis	Disease	1	2	0	1:NR:2	R2L	CROSS	136-137	1-2	D014673	vecuronium	Chemical	136	137	7	D010243	paralysis	Disease	1	2	0	1:CID:2	L2R	NON-CROSS	70-71	75-78	D003473	nondepolarizing neuromuscular blocking agents|nondepolarizing neuromuscular blocking agents|ND - NMBA|ND - NMBAs|ND - NMBA	Chemical	4:17:22:75:189	8:21:25:78:192	0:1:1:2:9	D018908	muscle weakness|weakness|weakness	Disease	35:70:171	37:71:172	1:2:9	1:NR:2	L2R	NON-CROSS	65-67	75-78	D003473	nondepolarizing neuromuscular blocking agents|nondepolarizing neuromuscular blocking agents|ND - NMBA|ND - NMBAs|ND - NMBA	Chemical	4:17:22:75:189	8:21:25:78:192	0:1:1:2:9	D012131	respiratory insufficiency	Disease	65	67	2	1:NR:2	L2R	CROSS	189-192	206-207	D003473	nondepolarizing neuromuscular blocking agents|nondepolarizing neuromuscular blocking agents|ND - NMBA|ND - NMBAs|ND - NMBA	Chemical	4:17:22:75:189	8:21:25:78:192	0:1:1:2:9	D000138	acidosis|acidosis	Disease	102:206	103:207	4:10	1:NR:2	L2R	CROSS	163-169	189-192	D003473	nondepolarizing neuromuscular blocking agents|nondepolarizing neuromuscular blocking agents|ND - NMBA|ND - NMBAs|ND - NMBA	Chemical	4:17:22:75:189	8:21:25:78:192	0:1:1:2:9	D009135	loss of thick , myosin filaments	Disease	163	169	8	1:CID:2	L2R	NON-CROSS	178-184	189-192	D003473	nondepolarizing neuromuscular blocking agents|nondepolarizing neuromuscular blocking agents|ND - NMBA|ND - NMBAs|ND - NMBA	Chemical	4:17:22:75:189	8:21:25:78:192	0:1:1:2:9	D009468	pathology at both the neuromuscular junction	Disease	178	184	9	1:NR:2	L2R	CROSS	189-192	203-205	D003473	nondepolarizing neuromuscular blocking agents|nondepolarizing neuromuscular blocking agents|ND - NMBA|ND - NMBAs|ND - NMBA	Chemical	4:17:22:75:189	8:21:25:78:192	0:1:1:2:9	D008107	Hepatic dysfunction	Disease	203	205	10	1:NR:2	L2R	NON-CROSS	70-71	84-85	D000305	corticosteroids|corticosteroids|corticosteroids	Chemical	9:84:200	10:85:201	0:3:9	D018908	muscle weakness|weakness|weakness	Disease	35:70:171	37:71:172	1:2:9	1:NR:2	L2R	CROSS	65-67	84-85	D000305	corticosteroids|corticosteroids|corticosteroids	Chemical	9:84:200	10:85:201	0:3:9	D012131	respiratory insufficiency	Disease	65	67	2	1:NR:2	L2R	CROSS	200-201	206-207	D000305	corticosteroids|corticosteroids|corticosteroids	Chemical	9:84:200	10:85:201	0:3:9	D000138	acidosis|acidosis	Disease	102:206	103:207	4:10	1:CID:2	L2R	CROSS	163-169	200-201	D000305	corticosteroids|corticosteroids|corticosteroids	Chemical	9:84:200	10:85:201	0:3:9	D009135	loss of thick , myosin filaments	Disease	163	169	8	1:NR:2	L2R	NON-CROSS	178-184	200-201	D000305	corticosteroids|corticosteroids|corticosteroids	Chemical	9:84:200	10:85:201	0:3:9	D009468	pathology at both the neuromuscular junction	Disease	178	184	9	1:NR:2	L2R	CROSS	200-201	203-205	D000305	corticosteroids|corticosteroids|corticosteroids	Chemical	9:84:200	10:85:201	0:3:9	D008107	Hepatic dysfunction	Disease	203	205	10	1:NR:2	R2L	CROSS	171-172	136-137	D014673	vecuronium	Chemical	136	137	7	D018908	muscle weakness|weakness|weakness	Disease	35:70:171	37:71:172	1:2:9	1:NR:2	R2L	CROSS	136-137	65-67	D014673	vecuronium	Chemical	136	137	7	D012131	respiratory insufficiency	Disease	65	67	2	1:NR:2	R2L	CROSS	136-137	102-103	D014673	vecuronium	Chemical	136	137	7	D000138	acidosis|acidosis	Disease	102:206	103:207	4:10	1:NR:2	L2R	CROSS	136-137	163-169	D014673	vecuronium	Chemical	136	137	7	D009135	loss of thick , myosin filaments	Disease	163	169	8	1:NR:2	L2R	CROSS	136-137	178-184	D014673	vecuronium	Chemical	136	137	7	D009468	pathology at both the neuromuscular junction	Disease	178	184	9	1:NR:2	L2R	CROSS	136-137	203-205	D014673	vecuronium	Chemical	136	137	7	D008107	Hepatic dysfunction	Disease	203	205	10
7752389	Prostaglandin E2 - induced bladder hyperactivity in normal , conscious rats : involvement of tachykinins ?|In normal conscious rats investigated by continuous cystometry , intravesically instilled prostaglandin ( PG ) E2 facilitated micturition and increased basal intravesical pressure .|The effect was attenuated by both the NK1 receptor selective antagonist RP 67 , 580 and the NK2 receptor selective antagonist SR 48 , 968 , given intra - arterially , suggesting that it was mediated by stimulation of both NK1 and NK2 receptors .|Intra - arterially given PGE2 produced a distinct increase in bladder pressure before initiating a micturition reflex , indicating that the PG had a direct contractant effect on the detrusor smooth muscle .|The effect of intra - arterial PGE2 could not be blocked by intra - arterial RP 67 , 580 or SR 48 , 968 , which opens the possibility that the micturition reflex elicited by intra - arterial PGE2 was mediated by pathways other than the reflex initiated when the PG was given intravesically .|The present results thus suggest that intra - arterial PGE2 , given near the bladder , may initiate micturition in the normal rat chiefly by directly contracting the smooth muscle of the detrusor .|However , when given intravesically , PGE2 may stimulate micturition by releasing tachykinins from nerves in and / or immediately below the urothelium .|These tachykinins , in turn , initiate a micturition reflex by stimulating NK1 and NK2 receptors .|Prostanoids may , via release of tachykinins , contribute to both urge and bladder hyperactivity seen in inflammatory conditions of the lower urinary tract .	1:CID:2	L2R	NON-CROSS	0-2	4-6	D015232	Prostaglandin E2|prostaglandin ( PG ) E2|PGE2|PGE2|PGE2|PGE2|PGE2	Chemical	0:27:89:124:156:182:213	2:32:90:125:157:183:214	0:1:3:4:4:5:6	D053201	bladder hyperactivity|bladder hyperactivity	Disease	4:261	6:263	0:8	1:NR:2	R2L	NON-CROSS	261-263	254-255	D015320	tachykinins|tachykinins|tachykinins|tachykinins	Chemical	14:219:232:254	15:220:233:255	0:6:7:8	D053201	bladder hyperactivity|bladder hyperactivity	Disease	4:261	6:263	0:8	1:NR:2	R2L	CROSS	51-55	4-6	C071693	RP 67 , 580|RP 67 , 580	Chemical	51:133	55:137	2:4	D053201	bladder hyperactivity|bladder hyperactivity	Disease	4:261	6:263	0:8	1:NR:2	R2L	CROSS	61-65	4-6	C073839	SR 48 , 968|SR 48 , 968	Chemical	61:138	65:142	2:4	D053201	bladder hyperactivity|bladder hyperactivity	Disease	4:261	6:263	0:8	1:NR:2	R2L	NON-CROSS	261-263	248-249	D011453	PG|PG|Prostanoids	Chemical	106:168:248	107:169:249	3:4:8	D053201	bladder hyperactivity|bladder hyperactivity	Disease	4:261	6:263	0:8
6942642	Thiazide diuretics , hypokalemia and cardiac arrhythmias .|Thiazide diuretics are widely accepted as the cornerstone of antihypertensive treatment programs .|Hypokalemia is a commonly encountered metabolic consequence of chronic thiazide therapy .|We treated 38 patients ( 22 low renin , 16 normal renin ) with moderate diastolic hypertension with hydrochlorothiazide ( HCTC ) administered on a twice daily schedule .|Initial dose was 50 mg and the dose was increased at monthly intervals to 100 mg , 150 mg and 200 mg daily until blood pressure normalized .|The serum K during the control period was 4 . 5 + / - 0 . 2 mEq / l an on 50 , 100 , 150 and 200 mg HCTZ daily 3 . 9 + / - 0 . 3 , 3 . 4 + / - 0 . 2 , 2 . 9 + / - 0 . 2 , and 2 . 4 + / - 0 . 3 mEq / l , respectively .|Corresponding figures for whole body K were 4107 + / - 208 , 3722 + / - 319 , 3628 + / - 257 , 3551 + / - 336 , and 3269 + / - 380 mEq , respectively .|In 13 patients we observed the effects of HCTZ therapy ( 100 mg daily ) on the occurrence of PVC 's during rest as well as during static and dynamic exercise .|During rest we observed 0 . 6 + / - 0 . 08 PVC beats / min + / - SEM and during static and dynamic exercise 0 . 6 + / - 0 . 06 and 0 . 8 + / - 0 . 15 , respectively .|Corresponding figures during HCTZ therapy 100 mg daily were 1 . 4 + / - 0 . 1 , 3 . 6 + / - 0 . 7 and 5 . 7 4 / - 0 . 8 , respectively .|The occurrence of PVC 's correlated significantly with the fall in serum K + observed r = 0 . 72 , p less than 0 . 001 .|In conclusion we found that thiazide diuretics cause hypokalemia and depletion of body potassium .|The more profound hypokalemia , the greater the propensity for the occurrence of PVC 's .	1:NR:2	L2R	NON-CROSS	0-1	3-4	D049971	Thiazide|Thiazide|thiazide|thiazide	Chemical	0:8:30:364	1:9:31:365	0:1:2:11	D007008	hypokalemia|Hypokalemia|hypokalemia|hypokalemia	Disease	3:21:367:377	4:22:368:378	0:2:11:12	1:NR:2	L2R	NON-CROSS	5-7	8-9	D049971	Thiazide|Thiazide|thiazide|thiazide	Chemical	0:8:30:364	1:9:31:365	0:1:2:11	D001145	cardiac arrhythmias	Disease	5	7	0	1:NR:2	L2R	CROSS	30-31	48-50	D049971	Thiazide|Thiazide|thiazide|thiazide	Chemical	0:8:30:364	1:9:31:365	0:1:2:11	C563897	diastolic hypertension	Disease	48	50	3	1:CID:2	R2L	CROSS	51-52	21-22	D006852	hydrochlorothiazide|HCTC|HCTZ|HCTZ|HCTZ	Chemical	51:53:120:217:293	52:54:121:218:294	3:3:5:7:9	D007008	hypokalemia|Hypokalemia|hypokalemia|hypokalemia	Disease	3:21:367:377	4:22:368:378	0:2:11:12	1:NR:2	R2L	NON-CROSS	372-373	367-368	D011188	K|K|K|potassium	Chemical	92:173:343:372	93:174:344:373	5:6:10:11	D007008	hypokalemia|Hypokalemia|hypokalemia|hypokalemia	Disease	3:21:367:377	4:22:368:378	0:2:11:12	1:CID:2	R2L	CROSS	51-52	5-7	D006852	hydrochlorothiazide|HCTC|HCTZ|HCTZ|HCTZ	Chemical	51:53:120:217:293	52:54:121:218:294	3:3:5:7:9	D001145	cardiac arrhythmias	Disease	5	7	0	1:NR:2	R2L	CROSS	92-93	5-7	D011188	K|K|K|potassium	Chemical	92:173:343:372	93:174:344:373	5:6:10:11	D001145	cardiac arrhythmias	Disease	5	7	0	1:NR:2	R2L	NON-CROSS	51-52	48-50	D006852	hydrochlorothiazide|HCTC|HCTZ|HCTZ|HCTZ	Chemical	51:53:120:217:293	52:54:121:218:294	3:3:5:7:9	C563897	diastolic hypertension	Disease	48	50	3	1:NR:2	R2L	CROSS	92-93	48-50	D011188	K|K|K|potassium	Chemical	92:173:343:372	93:174:344:373	5:6:10:11	C563897	diastolic hypertension	Disease	48	50	3
3732088	Diuretics , potassium and arrhythmias in hypertensive coronary disease .|It has been proposed that modest changes in plasma potassium can alter the tendency towards cardiac arrhythmias .|If this were so , patients with coronary artery disease might be especially susceptible .|Thus , myocardial electrical excitability was measured in patients with mild essential hypertension and known coronary artery disease after 8 weeks of treatment with a potassium - conserving diuretic ( amiloride ) and a similar period on a potassium - losing diuretic ( chlorthalidone ) in a randomised study .|Plasma potassium concentrations were on average 1 mmol / L lower during the chlorthalidone phase compared to amiloride therapy .|Blood pressure and volume states as assessed by bodyweight , plasma renin and noradrenaline ( norepinephrine ) concentrations were similar on the 2 regimens .|Compared to amiloride treatment , the chlorthalidone phase was associated with an increased frequency of ventricular ectopic beats ( 24 - hour Holter monitoring ) and a higher Lown grading , increased upslope and duration of the monophasic action potential , prolonged ventricular effective refractory period , and increased electrical instability during programmed ventricular stimulation .|The above results indicate that because potassium - losing diuretic therapy can increase myocardial electrical excitability in patients with ischaemic heart disease , even minor falls in plasma potassium concentrations are probably best avoided in such patients .	1:NR:2	L2R	NON-CROSS	2-3	4-5	D011188	potassium|potassium|potassium|potassium|potassium|potassium|potassium	Chemical	2:19:68:81:94:200:222	3:20:69:82:95:201:223	0:1:3:3:4:7:7	D001145	arrhythmias|cardiac arrhythmias	Disease	4:25	5:27	0:1	1:NR:2	L2R	NON-CROSS	2-3	6-7	D011188	potassium|potassium|potassium|potassium|potassium|potassium|potassium	Chemical	2:19:68:81:94:200:222	3:20:69:82:95:201:223	0:1:3:3:4:7:7	D006973	hypertensive|hypertension	Disease	6:55	7:56	0:3	1:NR:2	L2R	NON-CROSS	2-3	7-9	D011188	potassium|potassium|potassium|potassium|potassium|potassium|potassium	Chemical	2:19:68:81:94:200:222	3:20:69:82:95:201:223	0:1:3:3:4:7:7	D003327	coronary disease	Disease	7	9	0	1:NR:2	L2R	NON-CROSS	58-61	68-69	D011188	potassium|potassium|potassium|potassium|potassium|potassium|potassium	Chemical	2:19:68:81:94:200:222	3:20:69:82:95:201:223	0:1:3:3:4:7:7	D003324	coronary artery disease|coronary artery disease	Disease	35:58	38:61	2:3	1:NR:2	L2R	CROSS	153-156	200-201	D011188	potassium|potassium|potassium|potassium|potassium|potassium|potassium	Chemical	2:19:68:81:94:200:222	3:20:69:82:95:201:223	0:1:3:3:4:7:7	D018879	ventricular ectopic beats	Disease	153	156	6	1:NR:2	L2R	NON-CROSS	213-216	222-223	D011188	potassium|potassium|potassium|potassium|potassium|potassium|potassium	Chemical	2:19:68:81:94:200:222	3:20:69:82:95:201:223	0:1:3:3:4:7:7	D017202	ischaemic heart disease	Disease	213	216	7	1:NR:2	R2L	CROSS	73-74	25-27	D000584	amiloride|amiloride|amiloride	Chemical	73:110:140	74:111:141	3:4:6	D001145	arrhythmias|cardiac arrhythmias	Disease	4:25	5:27	0:1	1:NR:2	R2L	CROSS	86-87	25-27	D002752	chlorthalidone|chlorthalidone|chlorthalidone	Chemical	86:106:144	87:107:145	3:4:6	D001145	arrhythmias|cardiac arrhythmias	Disease	4:25	5:27	0:1	1:NR:2	R2L	CROSS	126-127	25-27	D009638	noradrenaline|norepinephrine	Chemical	126:128	127:129	5:5	D001145	arrhythmias|cardiac arrhythmias	Disease	4:25	5:27	0:1	1:NR:2	R2L	NON-CROSS	73-74	55-56	D000584	amiloride|amiloride|amiloride	Chemical	73:110:140	74:111:141	3:4:6	D006973	hypertensive|hypertension	Disease	6:55	7:56	0:3	1:NR:2	R2L	NON-CROSS	86-87	55-56	D002752	chlorthalidone|chlorthalidone|chlorthalidone	Chemical	86:106:144	87:107:145	3:4:6	D006973	hypertensive|hypertension	Disease	6:55	7:56	0:3	1:NR:2	R2L	CROSS	126-127	55-56	D009638	noradrenaline|norepinephrine	Chemical	126:128	127:129	5:5	D006973	hypertensive|hypertension	Disease	6:55	7:56	0:3	1:NR:2	R2L	CROSS	73-74	7-9	D000584	amiloride|amiloride|amiloride	Chemical	73:110:140	74:111:141	3:4:6	D003327	coronary disease	Disease	7	9	0	1:NR:2	R2L	CROSS	86-87	7-9	D002752	chlorthalidone|chlorthalidone|chlorthalidone	Chemical	86:106:144	87:107:145	3:4:6	D003327	coronary disease	Disease	7	9	0	1:NR:2	R2L	CROSS	126-127	7-9	D009638	noradrenaline|norepinephrine	Chemical	126:128	127:129	5:5	D003327	coronary disease	Disease	7	9	0	1:NR:2	R2L	NON-CROSS	73-74	58-61	D000584	amiloride|amiloride|amiloride	Chemical	73:110:140	74:111:141	3:4:6	D003324	coronary artery disease|coronary artery disease	Disease	35:58	38:61	2:3	1:NR:2	R2L	NON-CROSS	86-87	58-61	D002752	chlorthalidone|chlorthalidone|chlorthalidone	Chemical	86:106:144	87:107:145	3:4:6	D003324	coronary artery disease|coronary artery disease	Disease	35:58	38:61	2:3	1:NR:2	R2L	CROSS	126-127	58-61	D009638	noradrenaline|norepinephrine	Chemical	126:128	127:129	5:5	D003324	coronary artery disease|coronary artery disease	Disease	35:58	38:61	2:3	1:NR:2	L2R	NON-CROSS	140-141	153-156	D000584	amiloride|amiloride|amiloride	Chemical	73:110:140	74:111:141	3:4:6	D018879	ventricular ectopic beats	Disease	153	156	6	1:NR:2	L2R	CROSS	140-141	213-216	D000584	amiloride|amiloride|amiloride	Chemical	73:110:140	74:111:141	3:4:6	D017202	ischaemic heart disease	Disease	213	216	7	1:CID:2	L2R	NON-CROSS	144-145	153-156	D002752	chlorthalidone|chlorthalidone|chlorthalidone	Chemical	86:106:144	87:107:145	3:4:6	D018879	ventricular ectopic beats	Disease	153	156	6	1:NR:2	L2R	CROSS	144-145	213-216	D002752	chlorthalidone|chlorthalidone|chlorthalidone	Chemical	86:106:144	87:107:145	3:4:6	D017202	ischaemic heart disease	Disease	213	216	7	1:NR:2	L2R	CROSS	128-129	153-156	D009638	noradrenaline|norepinephrine	Chemical	126:128	127:129	5:5	D018879	ventricular ectopic beats	Disease	153	156	6	1:NR:2	L2R	CROSS	128-129	213-216	D009638	noradrenaline|norepinephrine	Chemical	126:128	127:129	5:5	D017202	ischaemic heart disease	Disease	213	216	7
2893236	GABA involvement in naloxone induced reversal of respiratory paralysis produced by thiopental .|No agent is yet available to reverse respiratory paralysis produced by CNS depressants , such as general anesthetics .|In this study naloxone reversed respiratory paralysis induced by thiopental in rats .|25 mg / kg , i . v .|thiopental produced anesthesia without altering respiratory rate , increased GABA , decreased glutamate , and had no effect on aspartate or glycine levels compared to controls in rat cortex and brain stem .|Pretreatment of rats with thiosemicarbazide for 30 minutes abolished the anesthetic action as well as the respiratory depressant action of thiopental .|50 mg / kg , i . v .|thiopental produced respiratory arrest with further increase in GABA and decrease in glutamate again in cortex and brain stem without affecting any of the amino acids studied in four regions of rat brain .|Naloxone ( 2 . 5 mg / kg , i . v . ) reversed respiratory paralysis , glutamate and GABA levels to control values in brain stem and cortex with no changes in caudate or cerebellum .|These data suggest naloxone reverses respiratory paralysis produced by thiopental and involves GABA in its action .	1:NR:2	L2R	NON-CROSS	167-169	172-173	D005680	GABA|GABA|GABA|GABA|GABA	Chemical	0:63:126:172:202	1:64:127:173:203	0:4:7:8:9	D012133	respiratory paralysis|respiratory paralysis|respiratory paralysis|respiratory paralysis|respiratory paralysis	Disease	7:20:37:167:195	9:22:39:169:197	0:1:2:8:9	1:NR:2	L2R	NON-CROSS	120-122	126-127	D005680	GABA|GABA|GABA|GABA|GABA	Chemical	0:63:126:172:202	1:64:127:173:203	0:4:7:8:9	D012131	respiratory arrest	Disease	120	122	7	1:NR:2	L2R	NON-CROSS	35-36	37-39	D009270	naloxone|naloxone|Naloxone|naloxone	Chemical	3:35:152:193	4:36:153:194	0:2:8:9	D012133	respiratory paralysis|respiratory paralysis|respiratory paralysis|respiratory paralysis|respiratory paralysis	Disease	7:20:37:167:195	9:22:39:169:197	0:1:2:8:9	1:NR:2	L2R	CROSS	120-122	152-153	D009270	naloxone|naloxone|Naloxone|naloxone	Chemical	3:35:152:193	4:36:153:194	0:2:8:9	D012131	respiratory arrest	Disease	120	122	7	1:CID:2	R2L	NON-CROSS	11-12	7-9	D013874	thiopental|thiopental|thiopental|thiopental|thiopental|thiopental	Chemical	11:41:54:107:118:199	12:42:55:108:119:200	0:2:4:5:7:9	D012133	respiratory paralysis|respiratory paralysis|respiratory paralysis|respiratory paralysis|respiratory paralysis	Disease	7:20:37:167:195	9:22:39:169:197	0:1:2:8:9	1:NR:2	R2L	NON-CROSS	170-171	167-169	D018698	glutamate|glutamate|glutamate	Chemical	66:130:170	67:131:171	4:7:8	D012133	respiratory paralysis|respiratory paralysis|respiratory paralysis|respiratory paralysis|respiratory paralysis	Disease	7:20:37:167:195	9:22:39:169:197	0:1:2:8:9	1:NR:2	R2L	CROSS	73-74	37-39	D001224	aspartate	Chemical	73	74	4	D012133	respiratory paralysis|respiratory paralysis|respiratory paralysis|respiratory paralysis|respiratory paralysis	Disease	7:20:37:167:195	9:22:39:169:197	0:1:2:8:9	1:NR:2	R2L	CROSS	75-76	37-39	D005998	glycine	Chemical	75	76	4	D012133	respiratory paralysis|respiratory paralysis|respiratory paralysis|respiratory paralysis|respiratory paralysis	Disease	7:20:37:167:195	9:22:39:169:197	0:1:2:8:9	1:NR:2	R2L	CROSS	91-92	37-39	C005151	thiosemicarbazide	Chemical	91	92	5	D012133	respiratory paralysis|respiratory paralysis|respiratory paralysis|respiratory paralysis|respiratory paralysis	Disease	7:20:37:167:195	9:22:39:169:197	0:1:2:8:9	1:NR:2	R2L	CROSS	167-169	142-144	D000596	amino acids	Chemical	142	144	7	D012133	respiratory paralysis|respiratory paralysis|respiratory paralysis|respiratory paralysis|respiratory paralysis	Disease	7:20:37:167:195	9:22:39:169:197	0:1:2:8:9	1:NR:2	L2R	NON-CROSS	118-119	120-122	D013874	thiopental|thiopental|thiopental|thiopental|thiopental|thiopental	Chemical	11:41:54:107:118:199	12:42:55:108:119:200	0:2:4:5:7:9	D012131	respiratory arrest	Disease	120	122	7	1:NR:2	L2R	NON-CROSS	120-122	130-131	D018698	glutamate|glutamate|glutamate	Chemical	66:130:170	67:131:171	4:7:8	D012131	respiratory arrest	Disease	120	122	7	1:NR:2	L2R	CROSS	73-74	120-122	D001224	aspartate	Chemical	73	74	4	D012131	respiratory arrest	Disease	120	122	7	1:NR:2	L2R	CROSS	75-76	120-122	D005998	glycine	Chemical	75	76	4	D012131	respiratory arrest	Disease	120	122	7	1:NR:2	L2R	CROSS	91-92	120-122	C005151	thiosemicarbazide	Chemical	91	92	5	D012131	respiratory arrest	Disease	120	122	7	1:NR:2	R2L	NON-CROSS	142-144	120-122	D000596	amino acids	Chemical	142	144	7	D012131	respiratory arrest	Disease	120	122	7
2533791	National project on the prevention of mother - to - infant infection by hepatitis B virus in Japan .|In Japan , a nationwide prevention program against mother - to - infant infection by hepatitis B virus ( HBV ) started in 1985 .|This program consists of double screenings of pregnant women and prophylactic treatment to the infants born to both hepatitis B surface antigen ( HBsAg ) and hepatitis B e antigen ( HBeAg ) positive mothers .|These infants are treated with two injections of hepatitis B immune globulin ( HBIG ) and at least three injections of plasma derived hepatitis B vaccine .|We sent questionnaires about the numbers of each procedure or examination during nine months of investigation period to each local government in 1986 and 1987 .|93 . 4 % pregnant women had the chance to be examined for HBsAg , and the positive rate was 1 . 4 to 1 . 5 % .|The HBeAg positive rate in HBsAg positive was 23 to 26 % .|The HBsAg positive rate in neonates and in infants before two months were 3 % and 2 % respectively .|Some problems may arise , because 27 to 30 % of infants need the fourth vaccination in some restricted areas .	1:CID:2	R2L	CROSS	88-90	67-68	D006514	hepatitis B surface antigen|HBsAg|HBsAg|HBsAg|HBsAg	Chemical	62:67:146:167:176	66:68:147:168:177	2:2:5:6:7	D006509	infection by hepatitis B virus|infection by hepatitis B virus|hepatitis B	Disease	11:32:88	16:37:90	0:1:3	1:CID:2	R2L	CROSS	88-90	75-76	D006513	hepatitis B e antigen|HBeAg|HBeAg	Chemical	70:75:163	74:76:164	2:2:6	D006509	infection by hepatitis B virus|infection by hepatitis B virus|hepatitis B	Disease	11:32:88	16:37:90	0:1:3	1:NR:2	R2L	NON-CROSS	103-106	88-90	D017325	hepatitis B vaccine	Chemical	103	106	3	D006509	infection by hepatitis B virus|infection by hepatitis B virus|hepatitis B	Disease	11:32:88	16:37:90	0:1:3
2322844	Nociceptive effects induced by intrathecal administration of prostaglandin D2 , E2 , or F2 alpha to conscious mice .|The effects of intrathecal administration of prostaglandins on pain responses in conscious mice were evaluated by using hot plate and acetic acid writhing tests .|Prostaglandin D2 ( 0 . 5 - 3 ng / mouse ) had a hyperalgesic action on the response to a hot plate during a 3 - 60 min period after injection .|Prostaglandin E2 showed a hyperalgesic effect at doses of 1 pg to 10 ng / mouse , but the effect lasted shorter ( 3 - 30 min ) than that of prostaglandin D2 .|Similar results were obtained by acetic acid writhing tests .|The hyperalgesic effect of prostaglandin D2 was blocked by simultaneous injection of a substance P antagonist ( greater than or equal to 100 ng ) but not by AH6809 , a prostanoid EP1 - receptor antagonist .|Conversely , prostaglandin E2 - induced hyperalgesia was blocked by AH6809 ( greater than or equal to 500 ng ) but not by the substance P antagonist .|Prostaglandin F2 alpha had little effect on pain responses .|These results demonstrate that both prostaglandin D2 and prostaglandin E2 exert hyperalgesia in the spinal cord , but in different ways .	1:NR:2	L2R	CROSS	193-194	201-203	D015230	prostaglandin D2 , E2 , or F2 alpha|Prostaglandin D2|prostaglandin D2|prostaglandin D2|prostaglandin D2	Chemical	7:44:108:125:201	15:46:110:127:203	0:2:3:5:8	D010146	pain|pain	Disease	27:193	28:194	1:7	1:CID:2	L2R	NON-CROSS	122-123	125-127	D015230	prostaglandin D2 , E2 , or F2 alpha|Prostaglandin D2|prostaglandin D2|prostaglandin D2|prostaglandin D2	Chemical	7:44:108:125:201	15:46:110:127:203	0:2:3:5:8	D006930	hyperalgesic|hyperalgesic|hyperalgesic|hyperalgesia|hyperalgesia	Disease	58:81:122:164:207	59:82:123:165:208	2:3:5:6:8	1:NR:2	L2R	CROSS	193-194	204-206	D015232	prostaglandin D2 , E2 , or F2 alpha|Prostaglandin E2|prostaglandin E2|prostaglandin E2	Chemical	7:77:160:204	15:79:162:206	0:3:6:8	D010146	pain|pain	Disease	27:193	28:194	1:7	1:CID:2	L2R	NON-CROSS	204-206	207-208	D015232	prostaglandin D2 , E2 , or F2 alpha|Prostaglandin E2|prostaglandin E2|prostaglandin E2	Chemical	7:77:160:204	15:79:162:206	0:3:6:8	D006930	hyperalgesic|hyperalgesic|hyperalgesic|hyperalgesia|hyperalgesia	Disease	58:81:122:164:207	59:82:123:165:208	2:3:5:6:8	1:NR:2	L2R	NON-CROSS	186-189	193-194	D015237	prostaglandin D2 , E2 , or F2 alpha|Prostaglandin F2 alpha	Chemical	7:186	15:189	0:7	D010146	pain|pain	Disease	27:193	28:194	1:7	1:NR:2	L2R	CROSS	186-189	207-208	D015237	prostaglandin D2 , E2 , or F2 alpha|Prostaglandin F2 alpha	Chemical	7:186	15:189	0:7	D006930	hyperalgesic|hyperalgesic|hyperalgesic|hyperalgesia|hyperalgesia	Disease	58:81:122:164:207	59:82:123:165:208	2:3:5:6:8	1:NR:2	L2R	NON-CROSS	25-26	27-28	D011453	prostaglandins|pg	Chemical	25:87	26:88	1:3	D010146	pain|pain	Disease	27:193	28:194	1:7	1:NR:2	L2R	NON-CROSS	81-82	87-88	D011453	prostaglandins|pg	Chemical	25:87	26:88	1:3	D006930	hyperalgesic|hyperalgesic|hyperalgesic|hyperalgesia|hyperalgesia	Disease	58:81:122:164:207	59:82:123:165:208	2:3:5:6:8	1:NR:2	R2L	NON-CROSS	39-41	27-28	D019342	acetic acid|acetic acid	Chemical	39:116	41:118	1:4	D010146	pain|pain	Disease	27:193	28:194	1:7	1:NR:2	R2L	CROSS	193-194	168-169	C053876	AH6809|AH6809	Chemical	149:168	150:169	5:6	D010146	pain|pain	Disease	27:193	28:194	1:7	1:NR:2	L2R	CROSS	116-118	122-123	D019342	acetic acid|acetic acid	Chemical	39:116	41:118	1:4	D006930	hyperalgesic|hyperalgesic|hyperalgesic|hyperalgesia|hyperalgesia	Disease	58:81:122:164:207	59:82:123:165:208	2:3:5:6:8	1:NR:2	R2L	NON-CROSS	168-169	164-165	C053876	AH6809|AH6809	Chemical	149:168	150:169	5:6	D006930	hyperalgesic|hyperalgesic|hyperalgesic|hyperalgesia|hyperalgesia	Disease	58:81:122:164:207	59:82:123:165:208	2:3:5:6:8
20552622	Swallowing - induced atrial tachyarrhythmia triggered by salbutamol : case report and review of the literature .|CASE : A 49 - year - old patient experienced chest discomfort while swallowing .|On electrocardiogram , episodes of atrial tachyarrhythmia were recorded immediately after swallowing ; 24 - hour Holter monitoring recorded several events .|The arrhythmia resolved after therapy with atenolol , but recurred a year later .|The patient noticed that before these episodes he had been using an inhalator of salbutamol .|After stopping the beta - agonist , and after a week with the atenolol , the arrhythmia disappeared .|DISCUSSION : Swallowing - induced atrial tachyarrhythmia ( SIAT ) is a rare phenomenon .|Fewer than 50 cases of SIAT have been described in the literature .|This article summarizes all the cases published , creating a comprehensive review of the current knowledge and approach to SIAT .|It discusses demographics , clinical characteristics and types of arrhythmia , postulated mechanisms of SIAT , and different treatment possibilities such as medications , surgery , and radiofrequency catheter ablation ( RFCA ) .|CONCLUSION : Salbutamol is presented here as a possible trigger for SIAT .|Although it is difficult to define causality in a case report , it is logical to think that a beta - agonist like salbutamol ( known to induce tachycardia ) may be the trigger of adrenergic reflexes originating in the esophagus while swallowing and that a beta - blocker such as atenolol ( that blocks the adrenergic activity ) may relieve it .	1:CID:2	R2L	NON-CROSS	7-8	3-5	D000420	salbutamol|salbutamol|Salbutamol|salbutamol	Chemical	7:82:188:222	8:83:189:223	0:4:10:11	D013617	atrial tachyarrhythmia|atrial tachyarrhythmia|atrial tachyarrhythmia|SIAT|SIAT|SIAT|SIAT|SIAT	Disease	3:37:108:111:123:150:166:197	5:39:110:112:124:151:167:198	0:2:6:6:7:8:9:10	1:NR:2	R2L	CROSS	108-110	97-98	D001262	atenolol|atenolol|atenolol	Chemical	60:97:250	61:98:251	3:5:11	D013617	atrial tachyarrhythmia|atrial tachyarrhythmia|atrial tachyarrhythmia|SIAT|SIAT|SIAT|SIAT|SIAT	Disease	3:37:108:111:123:150:166:197	5:39:110:112:124:151:167:198	0:2:6:6:7:8:9:10	1:NR:2	L2R	CROSS	82-83	100-101	D000420	salbutamol|salbutamol|Salbutamol|salbutamol	Chemical	7:82:188:222	8:83:189:223	0:4:10:11	D001145	arrhythmia|arrhythmia|arrhythmia	Disease	55:100:161	56:101:162	3:5:9	1:NR:2	L2R	NON-CROSS	222-223	227-228	D000420	salbutamol|salbutamol|Salbutamol|salbutamol	Chemical	7:82:188:222	8:83:189:223	0:4:10:11	D013610	tachycardia	Disease	227	228	11	1:NR:2	R2L	NON-CROSS	100-101	97-98	D001262	atenolol|atenolol|atenolol	Chemical	60:97:250	61:98:251	3:5:11	D001145	arrhythmia|arrhythmia|arrhythmia	Disease	55:100:161	56:101:162	3:5:9	1:NR:2	L2R	NON-CROSS	227-228	250-251	D001262	atenolol|atenolol|atenolol	Chemical	60:97:250	61:98:251	3:5:11	D013610	tachycardia	Disease	227	228	11
20510337	Coenzyme Q10 treatment ameliorates acute cisplatin nephrotoxicity in mice .|The nephroprotective effect of coenzyme Q10 was investigated in mice with acute renal injury induced by a single i . p .|injection of cisplatin ( 5 mg / kg ) .|Coenzyme Q10 treatment ( 10 mg / kg / day , i . p . ) was applied for 6 consecutive days , starting 1 day before cisplatin administration .|Coenzyme Q10 significantly reduced blood urea nitrogen and serum creatinine levels which were increased by cisplatin .|Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms ( reduced glutathione level and superoxide dismutase activity ) , suppressed lipid peroxidation , decreased the elevations of tumor necrosis factor - alpha , nitric oxide and platinum ion concentration , and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration .|Also , histopathological renal tissue damage mediated by cisplatin was ameliorated by coenzyme Q10 treatment .|Immunohistochemical analysis revealed that coenzyme Q10 significantly decreased the cisplatin - induced overexpression of inducible nitric oxide synthase , nuclear factor - kappaB , caspase - 3 and p53 in renal tissue .|It was concluded that coenzyme Q10 represents a potential therapeutic option to protect against acute cisplatin nephrotoxicity commonly encountered in clinical practice .	1:NR:2	L2R	NON-CROSS	0-2	6-7	C024989	Coenzyme Q10|coenzyme Q10|Coenzyme Q10|Coenzyme Q10|Coenzyme Q10|coenzyme Q10|coenzyme Q10|coenzyme Q10	Chemical	0:14:42:72:89:159:167:200	2:16:44:74:91:161:169:202	0:1:3:4:5:6:7:8	D007674	nephrotoxicity|renal tissue damage|nephrotoxicity	Disease	6:150:212	7:153:213	0:6:8	1:NR:2	L2R	NON-CROSS	14-16	21-24	C024989	Coenzyme Q10|coenzyme Q10|Coenzyme Q10|Coenzyme Q10|Coenzyme Q10|coenzyme Q10|coenzyme Q10|coenzyme Q10	Chemical	0:14:42:72:89:159:167:200	2:16:44:74:91:161:169:202	0:1:3:4:5:6:7:8	D058186	acute renal injury	Disease	21	24	1	1:NR:2	L2R	NON-CROSS	89-91	117-118	C024989	Coenzyme Q10|coenzyme Q10|Coenzyme Q10|Coenzyme Q10|Coenzyme Q10|coenzyme Q10|coenzyme Q10|coenzyme Q10	Chemical	0:14:42:72:89:159:167:200	2:16:44:74:91:161:169:202	0:1:3:4:5:6:7:8	D009369	tumor	Disease	117	118	5	1:NR:2	L2R	NON-CROSS	89-91	118-119	C024989	Coenzyme Q10|coenzyme Q10|Coenzyme Q10|Coenzyme Q10|Coenzyme Q10|coenzyme Q10|coenzyme Q10|coenzyme Q10	Chemical	0:14:42:72:89:159:167:200	2:16:44:74:91:161:169:202	0:1:3:4:5:6:7:8	D009336	necrosis	Disease	118	119	5	1:NR:2	L2R	NON-CROSS	5-6	6-7	D002945	cisplatin|cisplatin|cisplatin|cisplatin|cisplatin|cisplatin|cisplatin|cisplatin	Chemical	5:34:69:87:144:155:172:211	6:35:70:88:145:156:173:212	0:2:3:4:5:6:7:8	D007674	nephrotoxicity|renal tissue damage|nephrotoxicity	Disease	6:150:212	7:153:213	0:6:8	1:CID:2	L2R	CROSS	21-24	34-35	D002945	cisplatin|cisplatin|cisplatin|cisplatin|cisplatin|cisplatin|cisplatin|cisplatin	Chemical	5:34:69:87:144:155:172:211	6:35:70:88:145:156:173:212	0:2:3:4:5:6:7:8	D058186	acute renal injury	Disease	21	24	1	1:NR:2	L2R	NON-CROSS	117-118	144-145	D002945	cisplatin|cisplatin|cisplatin|cisplatin|cisplatin|cisplatin|cisplatin|cisplatin	Chemical	5:34:69:87:144:155:172:211	6:35:70:88:145:156:173:212	0:2:3:4:5:6:7:8	D009369	tumor	Disease	117	118	5	1:NR:2	L2R	NON-CROSS	118-119	144-145	D002945	cisplatin|cisplatin|cisplatin|cisplatin|cisplatin|cisplatin|cisplatin|cisplatin	Chemical	5:34:69:87:144:155:172:211	6:35:70:88:145:156:173:212	0:2:3:4:5:6:7:8	D009336	necrosis	Disease	118	119	5	1:NR:2	R2L	CROSS	76-79	6-7	D001806	blood urea nitrogen	Chemical	76	79	4	D007674	nephrotoxicity|renal tissue damage|nephrotoxicity	Disease	6:150:212	7:153:213	0:6:8	1:NR:2	R2L	CROSS	150-153	81-82	D003404	creatinine	Chemical	81	82	4	D007674	nephrotoxicity|renal tissue damage|nephrotoxicity	Disease	6:150:212	7:153:213	0:6:8	1:NR:2	R2L	CROSS	150-153	100-102	D005978	reduced glutathione	Chemical	100	102	5	D007674	nephrotoxicity|renal tissue damage|nephrotoxicity	Disease	6:150:212	7:153:213	0:6:8	1:NR:2	R2L	CROSS	150-153	104-105	D013481	superoxide	Chemical	104	105	5	D007674	nephrotoxicity|renal tissue damage|nephrotoxicity	Disease	6:150:212	7:153:213	0:6:8	1:NR:2	R2L	CROSS	178-180	150-153	D009569	nitric oxide|nitric oxide	Chemical	123:178	125:180	5:7	D007674	nephrotoxicity|renal tissue damage|nephrotoxicity	Disease	6:150:212	7:153:213	0:6:8	1:NR:2	R2L	CROSS	150-153	126-127	D010984	platinum	Chemical	126	127	5	D007674	nephrotoxicity|renal tissue damage|nephrotoxicity	Disease	6:150:212	7:153:213	0:6:8	1:NR:2	R2L	CROSS	150-153	135-136	D012643	selenium	Chemical	135	136	5	D007674	nephrotoxicity|renal tissue damage|nephrotoxicity	Disease	6:150:212	7:153:213	0:6:8	1:NR:2	R2L	CROSS	150-153	137-138	D015032	zinc	Chemical	137	138	5	D007674	nephrotoxicity|renal tissue damage|nephrotoxicity	Disease	6:150:212	7:153:213	0:6:8	1:NR:2	R2L	CROSS	76-79	21-24	D001806	blood urea nitrogen	Chemical	76	79	4	D058186	acute renal injury	Disease	21	24	1	1:NR:2	R2L	CROSS	81-82	21-24	D003404	creatinine	Chemical	81	82	4	D058186	acute renal injury	Disease	21	24	1	1:NR:2	R2L	CROSS	100-102	21-24	D005978	reduced glutathione	Chemical	100	102	5	D058186	acute renal injury	Disease	21	24	1	1:NR:2	R2L	CROSS	104-105	21-24	D013481	superoxide	Chemical	104	105	5	D058186	acute renal injury	Disease	21	24	1	1:NR:2	R2L	CROSS	123-125	21-24	D009569	nitric oxide|nitric oxide	Chemical	123:178	125:180	5:7	D058186	acute renal injury	Disease	21	24	1	1:NR:2	R2L	CROSS	126-127	21-24	D010984	platinum	Chemical	126	127	5	D058186	acute renal injury	Disease	21	24	1	1:NR:2	R2L	CROSS	135-136	21-24	D012643	selenium	Chemical	135	136	5	D058186	acute renal injury	Disease	21	24	1	1:NR:2	R2L	CROSS	137-138	21-24	D015032	zinc	Chemical	137	138	5	D058186	acute renal injury	Disease	21	24	1	1:NR:2	L2R	CROSS	76-79	117-118	D001806	blood urea nitrogen	Chemical	76	79	4	D009369	tumor	Disease	117	118	5	1:NR:2	L2R	CROSS	76-79	118-119	D001806	blood urea nitrogen	Chemical	76	79	4	D009336	necrosis	Disease	118	119	5	1:NR:2	L2R	CROSS	81-82	117-118	D003404	creatinine	Chemical	81	82	4	D009369	tumor	Disease	117	118	5	1:NR:2	L2R	CROSS	81-82	118-119	D003404	creatinine	Chemical	81	82	4	D009336	necrosis	Disease	118	119	5	1:NR:2	L2R	NON-CROSS	100-102	117-118	D005978	reduced glutathione	Chemical	100	102	5	D009369	tumor	Disease	117	118	5	1:NR:2	L2R	NON-CROSS	100-102	118-119	D005978	reduced glutathione	Chemical	100	102	5	D009336	necrosis	Disease	118	119	5	1:NR:2	L2R	NON-CROSS	104-105	117-118	D013481	superoxide	Chemical	104	105	5	D009369	tumor	Disease	117	118	5	1:NR:2	L2R	NON-CROSS	104-105	118-119	D013481	superoxide	Chemical	104	105	5	D009336	necrosis	Disease	118	119	5	1:NR:2	R2L	NON-CROSS	123-125	117-118	D009569	nitric oxide|nitric oxide	Chemical	123:178	125:180	5:7	D009369	tumor	Disease	117	118	5	1:NR:2	R2L	NON-CROSS	126-127	117-118	D010984	platinum	Chemical	126	127	5	D009369	tumor	Disease	117	118	5	1:NR:2	R2L	NON-CROSS	135-136	117-118	D012643	selenium	Chemical	135	136	5	D009369	tumor	Disease	117	118	5	1:NR:2	R2L	NON-CROSS	137-138	117-118	D015032	zinc	Chemical	137	138	5	D009369	tumor	Disease	117	118	5	1:NR:2	R2L	NON-CROSS	123-125	118-119	D009569	nitric oxide|nitric oxide	Chemical	123:178	125:180	5:7	D009336	necrosis	Disease	118	119	5	1:NR:2	R2L	NON-CROSS	126-127	118-119	D010984	platinum	Chemical	126	127	5	D009336	necrosis	Disease	118	119	5	1:NR:2	R2L	NON-CROSS	135-136	118-119	D012643	selenium	Chemical	135	136	5	D009336	necrosis	Disease	118	119	5	1:NR:2	R2L	NON-CROSS	137-138	118-119	D015032	zinc	Chemical	137	138	5	D009336	necrosis	Disease	118	119	5
20164825	Metformin prevents experimental gentamicin - induced nephropathy by a mitochondria - dependent pathway .|The antidiabetic drug metformin can diminish apoptosis induced by oxidative stress in endothelial cells and prevent vascular dysfunction even in nondiabetic patients .|Here we tested whether it has a beneficial effect in a rat model of gentamicin toxicity .|Mitochondrial analysis , respiration intensity , levels of reactive oxygen species , permeability transition , and cytochrome c release were assessed 3 and 6 days after gentamicin administration .|Metformin treatment fully blocked gentamicin - mediated acute renal failure .|This was accompanied by a lower activity of N - acetyl - beta - D - glucosaminidase , together with a decrease of lipid peroxidation and increase of antioxidant systems .|Metformin also protected the kidney from histological damage 6 days after gentamicin administration .|These in vivo markers of kidney dysfunction and their correction by metformin were complemented by in vitro studies of mitochondrial function .|We found that gentamicin treatment depleted respiratory components ( cytochrome c , NADH ) , probably due to the opening of mitochondrial transition pores .|These injuries , partly mediated by a rise in reactive oxygen species from the electron transfer chain , were significantly decreased by metformin .|Thus , our study suggests that pleiotropic effects of metformin can lessen gentamicin nephrotoxicity and improve mitochondrial homeostasis .	1:NR:2	L2R	NON-CROSS	219-220	223-224	D008687	Metformin|metformin|Metformin|Metformin|metformin|metformin|metformin	Chemical	0:17:83:125:150:208:219	1:18:84:126:151:209:220	0:1:4:6:7:9:10	D007674	nephropathy|kidney dysfunction|nephrotoxicity	Disease	6:144:223	7:146:224	0:7:10	1:NR:2	L2R	NON-CROSS	17-18	30-32	D008687	Metformin|metformin|Metformin|Metformin|metformin|metformin|metformin	Chemical	0:17:83:125:150:208:219	1:18:84:126:151:209:220	0:1:4:6:7:9:10	D014652	vascular dysfunction	Disease	30	32	1	1:NR:2	L2R	CROSS	52-53	83-84	D008687	Metformin|metformin|Metformin|Metformin|metformin|metformin|metformin	Chemical	0:17:83:125:150:208:219	1:18:84:126:151:209:220	0:1:4:6:7:9:10	D064420	toxicity	Disease	52	53	2	1:NR:2	L2R	NON-CROSS	83-84	90-93	D008687	Metformin|metformin|Metformin|Metformin|metformin|metformin|metformin	Chemical	0:17:83:125:150:208:219	1:18:84:126:151:209:220	0:1:4:6:7:9:10	D058186	acute renal failure	Disease	90	93	4	1:NR:2	L2R	NON-CROSS	222-223	223-224	D005839	gentamicin|gentamicin|gentamicin|gentamicin|gentamicin|gentamicin|gentamicin	Chemical	3:51:80:87:136:164:222	4:52:81:88:137:165:223	0:2:3:4:6:8:10	D007674	nephropathy|kidney dysfunction|nephrotoxicity	Disease	6:144:223	7:146:224	0:7:10	1:NR:2	L2R	CROSS	30-32	51-52	D005839	gentamicin|gentamicin|gentamicin|gentamicin|gentamicin|gentamicin|gentamicin	Chemical	3:51:80:87:136:164:222	4:52:81:88:137:165:223	0:2:3:4:6:8:10	D014652	vascular dysfunction	Disease	30	32	1	1:NR:2	L2R	NON-CROSS	51-52	52-53	D005839	gentamicin|gentamicin|gentamicin|gentamicin|gentamicin|gentamicin|gentamicin	Chemical	3:51:80:87:136:164:222	4:52:81:88:137:165:223	0:2:3:4:6:8:10	D064420	toxicity	Disease	52	53	2	1:CID:2	L2R	NON-CROSS	87-88	90-93	D005839	gentamicin|gentamicin|gentamicin|gentamicin|gentamicin|gentamicin|gentamicin	Chemical	3:51:80:87:136:164:222	4:52:81:88:137:165:223	0:2:3:4:6:8:10	D058186	acute renal failure	Disease	90	93	4	1:NR:2	R2L	CROSS	223-224	196-197	D010100	oxygen|oxygen	Chemical	63:196	64:197	3:9	D007674	nephropathy|kidney dysfunction|nephrotoxicity	Disease	6:144:223	7:146:224	0:7:10	1:NR:2	R2L	CROSS	63-64	30-32	D010100	oxygen|oxygen	Chemical	63:196	64:197	3:9	D014652	vascular dysfunction	Disease	30	32	1	1:NR:2	R2L	CROSS	63-64	52-53	D010100	oxygen|oxygen	Chemical	63:196	64:197	3:9	D064420	toxicity	Disease	52	53	2	1:NR:2	L2R	CROSS	63-64	90-93	D010100	oxygen|oxygen	Chemical	63:196	64:197	3:9	D058186	acute renal failure	Disease	90	93	4
20042557	Sedation depth during spinal anesthesia and the development of postoperative delirium in elderly patients undergoing hip fracture repair .|OBJECTIVE : To determine whether limiting intraoperative sedation depth during spinal anesthesia for hip fracture repair in elderly patients can decrease the prevalence of postoperative delirium .|PATIENTS AND METHODS : We performed a double - blind , randomized controlled trial at an academic medical center of elderly patients ( > or = 65 years ) without preoperative delirium or severe dementia who underwent hip fracture repair under spinal anesthesia with propofol sedation .|Sedation depth was titrated using processed electroencephalography with the bispectral index ( BIS ) , and patients were randomized to receive either deep ( BIS , approximately 50 ) or light ( BIS , > or = 80 ) sedation .|Postoperative delirium was assessed as defined by Diagnostic and Statistical Manual of Mental Disorders ( Third Edition Revised ) criteria using the Confusion Assessment Method beginning at any time from the second day after surgery .|RESULTS : From April 2 , 2005 , through October 30 , 2008 , a total of 114 patients were randomized .|The prevalence of postoperative delirium was significantly lower in the light sedation group ( 11 / 57 [ 19 % ] vs 23 / 57 [ 40 % ] in the deep sedation group ; P = . 02 ) , indicating that 1 incident of delirium will be prevented for every 4 . 7 patients treated with light sedation .|The mean + / - SD number of days of delirium during hospitalization was lower in the light sedation group than in the deep sedation group ( 0 . 5 + / - 1 . 5 days vs 1 . 4 + / - 4 . 0 days ; P = . 01 ) .|CONCLUSION : The use of light propofol sedation decreased the prevalence of postoperative delirium by 50 % compared with deep sedation .|Limiting depth of sedation during spinal anesthesia is a simple , safe , and cost - effective intervention for preventing postoperative delirium in elderly patients that could be widely and readily adopted .	1:CID:2	R2L	NON-CROSS	320-322	314-315	D015742	propofol|propofol	Chemical	90:314	91:315	2:8	D011183	postoperative delirium|postoperative delirium|Postoperative delirium|postoperative delirium|postoperative delirium|postoperative delirium	Disease	9:43:134:195:320:350	11:45:136:197:322:352	0:1:4:6:8:9	1:CID:2	R2L	NON-CROSS	320-322	314-315	D015742	propofol|propofol	Chemical	90:314	91:315	2:8	D003693	postoperative delirium|postoperative delirium|delirium|Postoperative delirium|postoperative delirium|delirium|delirium|postoperative delirium|postoperative delirium	Disease	9:43:77:134:195:238:263:320:350	11:45:78:136:197:239:264:322:352	0:1:2:4:6:6:7:8:9	1:NR:2	R2L	NON-CROSS	90-91	83-85	D015742	propofol|propofol	Chemical	90:314	91:315	2:8	D006620	hip fracture|hip fracture|hip fracture	Disease	15:32:83	17:34:85	0:1:2	1:NR:2	R2L	NON-CROSS	90-91	80-81	D015742	propofol|propofol	Chemical	90:314	91:315	2:8	D003704	dementia	Disease	80	81	2	1:NR:2	L2R	CROSS	90-91	146-148	D015742	propofol|propofol	Chemical	90:314	91:315	2:8	D001523	Mental Disorders	Disease	146	148	4
19944333	Sorafenib - induced acute myocardial infarction due to coronary artery spasm .|A 65 - year - old man with advanced renal cell carcinoma was admitted due to continuing chest pain at rest .|Two weeks before his admission , sorafenib had been started .|He was diagnosed with non - ST - elevation myocardial infarction by laboratory data and electrocardiogram .|Enhanced heart magnetic resonance imaging also showed subendocardial infarction .|However , there was no stenosis in coronary arteries on angiography .|Coronary artery spasm was induced by a provocative test .|Cessation of sorafenib and administration of Ca - channel blocker and nitrates ameliorated his symptoms , but relapse occurred after resumption of sorafenib .|Addition of oral nicorandil reduced his symptoms and maintained stable angina status .|We report the first case of sorafenib - induced coronary artery spasm .|Sorafenib is a multikinase inhibitor that targets signaling pathways necessary for cellular proliferation and survival .|On the other hand , the Rho / ROCK pathway has an important role in the pathogenesis of coronary artery spasm .|Our report may show an adverse effect on the Rho / ROCK pathway by sorafenib use .	1:NR:2	L2R	NON-CROSS	0-1	4-6	C471405	Sorafenib|sorafenib|sorafenib|sorafenib|sorafenib|Sorafenib|sorafenib	Chemical	0:40:96:116:137:144:196	1:41:97:117:138:145:197	0:2:7:7:9:10:12	D009203	myocardial infarction|myocardial infarction|subendocardial infarction	Disease	4:54:69	6:56:71	0:3:4	1:CID:2	L2R	NON-CROSS	140-143	144-145	C471405	Sorafenib|sorafenib|sorafenib|sorafenib|sorafenib|Sorafenib|sorafenib	Chemical	0:40:96:116:137:144:196	1:41:97:117:138:145:197	0:2:7:7:9:10:12	D003329	coronary artery spasm|Coronary artery spasm|coronary artery spasm|coronary artery spasm	Disease	8:84:140:178	11:87:143:181	0:6:9:11	1:NR:2	L2R	CROSS	21-24	40-41	C471405	Sorafenib|sorafenib|sorafenib|sorafenib|sorafenib|Sorafenib|sorafenib	Chemical	0:40:96:116:137:144:196	1:41:97:117:138:145:197	0:2:7:7:9:10:12	D002292	renal cell carcinoma	Disease	21	24	1	1:NR:2	L2R	CROSS	29-31	40-41	C471405	Sorafenib|sorafenib|sorafenib|sorafenib|sorafenib|Sorafenib|sorafenib	Chemical	0:40:96:116:137:144:196	1:41:97:117:138:145:197	0:2:7:7:9:10:12	D002637	chest pain	Disease	29	31	1	1:NR:2	L2R	CROSS	127-129	137-138	C471405	Sorafenib|sorafenib|sorafenib|sorafenib|sorafenib|Sorafenib|sorafenib	Chemical	0:40:96:116:137:144:196	1:41:97:117:138:145:197	0:2:7:7:9:10:12	D060050	stable angina	Disease	127	129	8	1:NR:2	R2L	CROSS	100-101	69-71	D002118	Ca	Chemical	100	101	7	D009203	myocardial infarction|myocardial infarction|subendocardial infarction	Disease	4:54:69	6:56:71	0:3:4	1:NR:2	R2L	CROSS	105-106	69-71	D009566	nitrates	Chemical	105	106	7	D009203	myocardial infarction|myocardial infarction|subendocardial infarction	Disease	4:54:69	6:56:71	0:3:4	1:NR:2	R2L	CROSS	121-122	69-71	D020108	nicorandil	Chemical	121	122	8	D009203	myocardial infarction|myocardial infarction|subendocardial infarction	Disease	4:54:69	6:56:71	0:3:4	1:NR:2	R2L	CROSS	100-101	84-87	D002118	Ca	Chemical	100	101	7	D003329	coronary artery spasm|Coronary artery spasm|coronary artery spasm|coronary artery spasm	Disease	8:84:140:178	11:87:143:181	0:6:9:11	1:NR:2	R2L	CROSS	105-106	84-87	D009566	nitrates	Chemical	105	106	7	D003329	coronary artery spasm|Coronary artery spasm|coronary artery spasm|coronary artery spasm	Disease	8:84:140:178	11:87:143:181	0:6:9:11	1:NR:2	R2L	CROSS	140-143	121-122	D020108	nicorandil	Chemical	121	122	8	D003329	coronary artery spasm|Coronary artery spasm|coronary artery spasm|coronary artery spasm	Disease	8:84:140:178	11:87:143:181	0:6:9:11	1:NR:2	R2L	CROSS	100-101	21-24	D002118	Ca	Chemical	100	101	7	D002292	renal cell carcinoma	Disease	21	24	1	1:NR:2	R2L	CROSS	105-106	21-24	D009566	nitrates	Chemical	105	106	7	D002292	renal cell carcinoma	Disease	21	24	1	1:NR:2	R2L	CROSS	121-122	21-24	D020108	nicorandil	Chemical	121	122	8	D002292	renal cell carcinoma	Disease	21	24	1	1:NR:2	R2L	CROSS	100-101	29-31	D002118	Ca	Chemical	100	101	7	D002637	chest pain	Disease	29	31	1	1:NR:2	R2L	CROSS	105-106	29-31	D009566	nitrates	Chemical	105	106	7	D002637	chest pain	Disease	29	31	1	1:NR:2	R2L	CROSS	121-122	29-31	D020108	nicorandil	Chemical	121	122	8	D002637	chest pain	Disease	29	31	1	1:NR:2	L2R	CROSS	100-101	127-129	D002118	Ca	Chemical	100	101	7	D060050	stable angina	Disease	127	129	8	1:NR:2	L2R	CROSS	105-106	127-129	D009566	nitrates	Chemical	105	106	7	D060050	stable angina	Disease	127	129	8	1:NR:2	L2R	NON-CROSS	121-122	127-129	D020108	nicorandil	Chemical	121	122	8	D060050	stable angina	Disease	127	129	8
17975693	Anxiogenic potential of ciprofloxacin and norfloxacin in rats .|INTRODUCTION : The possible anxiogenic effects of fluoroquinolones , namely ciprofloxacin and norfloxacin , were investigated in adult Charles Foster albino rats of either sex , weighing 150 - 200 g .|METHODS : The drugs were given orally , in doses of 50 mg / kg for five consecutive days and the experiments were performed on the fifth day .|The tests included open - field exploratory behaviour , elevated plus maze and elevated zero maze , social interaction and novelty - suppressed feeding latency behaviour .|RESULTS : The results indicate that ciprofloxacin - and norfloxacin - treated rats showed anxious behaviour in comparison to control rats in all the parameters studied .|However , ciprofloxacin - and norfloxacin - treated rats did not differ significantly from each other in various behavioural parameters .|CONCLUSION : The present experimental findings substantiate the clinically observed anxiogenic potential of ciprofloxacin and norfloxacin .	1:CID:2	L2R	NON-CROSS	103-104	111-113	D002939	ciprofloxacin|ciprofloxacin|ciprofloxacin|ciprofloxacin|ciprofloxacin	Chemical	3:19:103:126:158	4:20:104:127:159	0:1:4:5:6	D001008	anxious behaviour	Disease	111	113	4	1:CID:2	L2R	NON-CROSS	106-107	111-113	D009643	norfloxacin|norfloxacin|norfloxacin|norfloxacin|norfloxacin	Chemical	5:21:106:129:160	6:22:107:130:161	0:1:4:5:6	D001008	anxious behaviour	Disease	111	113	4	1:NR:2	L2R	CROSS	16-17	111-113	D024841	fluoroquinolones	Chemical	16	17	1	D001008	anxious behaviour	Disease	111	113	4
17943461	Myocardial Fas ligand expression increases susceptibility to AZT - induced cardiomyopathy .|BACKGROUND : Dilated cardiomyopathy ( DCM ) and myocarditis occur in many HIV - infected individuals , resulting in symptomatic heart failure in up to 5 % of patients .|Highly active antiretroviral therapy ( HAART ) has significantly reduced morbidity and mortality of acquired immunodeficiency syndrome ( AIDS ) , but has resulted in an increase in cardiac and skeletal myopathies .|METHODS AND RESULTS : In order to investigate whether the HAART component zidovudine ( 3 ' - azido - 2 ' , 3 ' - deoxythymidine ; AZT ) triggers the Fas - dependent cell - death pathway and cause cytoskeletal disruption in a murine model of DCM , 8 - week - old transgenic ( expressing Fas ligand in the myocardium : FasL Tg ) and non - transgenic ( NTg ) mice received water ad libitum containing different concentrations of AZT ( 0 , 0 . 07 , 0 . 2 , and 0 . 7 mg / ml ) .|After 6 weeks , cardiac function was assessed by echocardiography and morphology was assessed by histopathologic and immunohistochemical methods .|NTg and untreated FasL Tg mice showed little or no change in cardiac structure or function .|In contrast , AZT - treated FasL Tg mice developed cardiac dilation and depressed cardiac function in a dose - dependent manner , with concomitant inflammatory infiltration of both ventricles .|These changes were associated with an increased sarcolemmal expression of Fas and FasL , as well as increased activation of caspase 3 , translocation of calpain 1 to the sarcolemma and sarcomere , and increased numbers of cells undergoing apoptosis .|These were associated with changes in dystrophin and cardiac troponin I localization , as well as loss of sarcolemmal integrity .|CONCLUSIONS : The expression of Fas ligand in the myocardium , as identified in HIV - positive patients , might increase the susceptibility to HAART - induced cardiomyopathy due to activation of apoptotic pathways , resulting in cardiac dilation and dysfunction .	1:CID:2	L2R	NON-CROSS	7-8	10-11	D015215	AZT|zidovudine|3 ' - azido - 2 ' , 3 ' - deoxythymidine|AZT|AZT|AZT	Chemical	7:87:89:102:157:218	8:88:101:103:158:219	0:3:3:3:3:6	D009202	cardiomyopathy|cardiomyopathy	Disease	10:335	11:336	0:9	1:CID:2	L2R	NON-CROSS	7-8	14-16	D015215	AZT|zidovudine|3 ' - azido - 2 ' , 3 ' - deoxythymidine|AZT|AZT|AZT	Chemical	7:87:89:102:157:218	8:88:101:103:158:219	0:3:3:3:3:6	D002311	Dilated cardiomyopathy|DCM|DCM|cardiac dilation|cardiac dilation and dysfunction	Disease	14:17:122:225:345	16:18:123:227:349	1:1:3:6:9	1:NR:2	L2R	CROSS	7-8	20-21	D015215	AZT|zidovudine|3 ' - azido - 2 ' , 3 ' - deoxythymidine|AZT|AZT|AZT	Chemical	7:87:89:102:157:218	8:88:101:103:158:219	0:3:3:3:3:6	D009205	myocarditis	Disease	20	21	1	1:NR:2	L2R	CROSS	7-8	24-27	D015215	AZT|zidovudine|3 ' - azido - 2 ' , 3 ' - deoxythymidine|AZT|AZT|AZT	Chemical	7:87:89:102:157:218	8:88:101:103:158:219	0:3:3:3:3:6	D015658	HIV - infected	Disease	24	27	1	1:NR:2	L2R	CROSS	7-8	32-34	D015215	AZT|zidovudine|3 ' - azido - 2 ' , 3 ' - deoxythymidine|AZT|AZT|AZT	Chemical	7:87:89:102:157:218	8:88:101:103:158:219	0:3:3:3:3:6	D006333	heart failure	Disease	32	34	1	1:NR:2	L2R	CROSS	60-61	87-88	D015215	AZT|zidovudine|3 ' - azido - 2 ' , 3 ' - deoxythymidine|AZT|AZT|AZT	Chemical	7:87:89:102:157:218	8:88:101:103:158:219	0:3:3:3:3:6	D000163	acquired immunodeficiency syndrome|AIDS	Disease	56:60	59:61	2:2	1:NR:2	L2R	CROSS	70-74	102-103	D015215	AZT|zidovudine|3 ' - azido - 2 ' , 3 ' - deoxythymidine|AZT|AZT|AZT	Chemical	7:87:89:102:157:218	8:88:101:103:158:219	0:3:3:3:3:6	C538496	cardiac and skeletal myopathies	Disease	70	74	2	1:NR:2	L2R	CROSS	218-219	345-349	D015215	AZT|zidovudine|3 ' - azido - 2 ' , 3 ' - deoxythymidine|AZT|AZT|AZT	Chemical	7:87:89:102:157:218	8:88:101:103:158:219	0:3:3:3:3:6	D006331	cardiac dilation and dysfunction	Disease	345	349	9
17074608	Valproate - induced chorea and encephalopathy in atypical nonketotic hyperglycinemia .|Nonketotic hyperglycinemia is a disorder of amino acid metabolism in which a defect in the glycine cleavage system leads to an accumulation of glycine in the brain and other body compartments .|In the classical form it presents as neonatal apnea , intractable seizures , and hypotonia , followed by significant psychomotor retardation .|An important subset of children with nonketotic hyperglycinemia are atypical variants who present in a heterogeneous manner .|This report describes a patient with mild language delay and mental retardation , who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of valproate therapy .	1:CID:2	L2R	NON-CROSS	0-1	3-4	D014635	Valproate|valproate	Chemical	0:115	1:116	0:4	D002819	chorea|chorea	Disease	3:110	4:111	0:4	1:CID:2	L2R	NON-CROSS	0-1	5-6	D014635	Valproate|valproate	Chemical	0:115	1:116	0:4	D001927	encephalopathy|encephalopathy	Disease	5:108	6:109	0:4	1:NR:2	L2R	NON-CROSS	0-1	8-10	D014635	Valproate|valproate	Chemical	0:115	1:116	0:4	D020158	nonketotic hyperglycinemia|Nonketotic hyperglycinemia|nonketotic hyperglycinemia|nonketotic hyperglycinemia	Disease	8:11:71:101	10:13:73:103	0:1:3:4	1:NR:2	L2R	CROSS	0-1	15-20	D014635	Valproate|valproate	Chemical	0:115	1:116	0:4	D000592	disorder of amino acid metabolism	Disease	15	20	1	1:NR:2	L2R	CROSS	0-1	51-52	D014635	Valproate|valproate	Chemical	0:115	1:116	0:4	D001049	apnea	Disease	51	52	2	1:NR:2	L2R	CROSS	0-1	54-55	D014635	Valproate|valproate	Chemical	0:115	1:116	0:4	D012640	seizures	Disease	54	55	2	1:NR:2	L2R	CROSS	0-1	57-58	D014635	Valproate|valproate	Chemical	0:115	1:116	0:4	D009123	hypotonia	Disease	57	58	2	1:NR:2	L2R	CROSS	62-64	115-116	D014635	Valproate|valproate	Chemical	0:115	1:116	0:4	D011596	psychomotor retardation	Disease	62	64	2	1:NR:2	L2R	NON-CROSS	90-92	115-116	D014635	Valproate|valproate	Chemical	0:115	1:116	0:4	D007805	language delay	Disease	90	92	4	1:NR:2	L2R	NON-CROSS	93-95	115-116	D014635	Valproate|valproate	Chemical	0:115	1:116	0:4	D008607	mental retardation	Disease	93	95	4	1:NR:2	R2L	CROSS	26-27	3-4	D005998	glycine|glycine	Chemical	26:34	27:35	1:1	D002819	chorea|chorea	Disease	3:110	4:111	0:4	1:NR:2	R2L	CROSS	26-27	5-6	D005998	glycine|glycine	Chemical	26:34	27:35	1:1	D001927	encephalopathy|encephalopathy	Disease	5:108	6:109	0:4	1:NR:2	R2L	NON-CROSS	26-27	11-13	D005998	glycine|glycine	Chemical	26:34	27:35	1:1	D020158	nonketotic hyperglycinemia|Nonketotic hyperglycinemia|nonketotic hyperglycinemia|nonketotic hyperglycinemia	Disease	8:11:71:101	10:13:73:103	0:1:3:4	1:NR:2	R2L	NON-CROSS	26-27	15-20	D005998	glycine|glycine	Chemical	26:34	27:35	1:1	D000592	disorder of amino acid metabolism	Disease	15	20	1	1:NR:2	L2R	CROSS	34-35	51-52	D005998	glycine|glycine	Chemical	26:34	27:35	1:1	D001049	apnea	Disease	51	52	2	1:NR:2	L2R	CROSS	34-35	54-55	D005998	glycine|glycine	Chemical	26:34	27:35	1:1	D012640	seizures	Disease	54	55	2	1:NR:2	L2R	CROSS	34-35	57-58	D005998	glycine|glycine	Chemical	26:34	27:35	1:1	D009123	hypotonia	Disease	57	58	2	1:NR:2	L2R	CROSS	34-35	62-64	D005998	glycine|glycine	Chemical	26:34	27:35	1:1	D011596	psychomotor retardation	Disease	62	64	2	1:NR:2	L2R	CROSS	34-35	90-92	D005998	glycine|glycine	Chemical	26:34	27:35	1:1	D007805	language delay	Disease	90	92	4	1:NR:2	L2R	CROSS	34-35	93-95	D005998	glycine|glycine	Chemical	26:34	27:35	1:1	D008607	mental retardation	Disease	93	95	4
16364460	Microinjection of ritanserin into the CA1 region of hippocampus improves scopolamine - induced amnesia in adult male rats .|The effect of ritanserin ( 5 - HT2 antagonist ) on scopolamine ( muscarinic cholinergic antagonist ) - induced amnesia in Morris water maze ( MWM ) was investigated .|Rats were divided into eight groups and bilaterally cannulated into CA1 region of the hippocampus .|One week later , they received repeatedly vehicles ( saline , DMSO , saline + DMSO ) , scopolamine ( 2 microg / 0 . 5 microl saline / side ; 30 min before training ) , ritanserin ( 2 , 4 and 8 microg / 0 . 5 microl DMSO / side ; 20 min before training ) and scopolamine ( 2 microg / 0 . 5 microl ; 30 min before ritanserin injection ) + ritanserin ( 4 microg / 0 . 5 microl DMSO ) through cannulae each day .|Animals were tested for four consecutive days ( 4 trial / day ) in MWM during which the position of hidden platform was unchanged .|In the fifth day , the platform was elevated above the water surface in another position to evaluate the function of motor , motivational and visual systems .|The results showed a significant increase in escape latencies and traveled distances to find platform in scopolamine - treated group as compared to saline group .|Ritanserin - treated rats ( 4 microg / 0 . 5 microl / side ) showed a significant decrease in the mentioned parameters as compared to DMSO - treated group .|However , scopolamine and ritanserin co - administration resulted in a significant decrease in escape latencies and traveled distances as compared to the scopolamine - treated rats .|Our findings show that microinjection of ritanserin into the CA1 region of the hippocampus improves the scopolamine - induced amnesia .	1:NR:2	L2R	NON-CROSS	13-14	22-23	D016713	ritanserin|ritanserin|ritanserin|ritanserin|ritanserin|Ritanserin|ritanserin|ritanserin	Chemical	2:22:102:138:142:237:272:302	3:23:103:139:143:238:273:303	0:1:3:3:3:7:8:9	D000647	amnesia|amnesia|amnesia	Disease	13:38:315	14:39:316	0:1:9	1:CID:2	L2R	NON-CROSS	10-11	13-14	D012601	scopolamine|scopolamine|scopolamine|scopolamine|scopolamine|scopolamine|scopolamine|scopolamine	Chemical	10:30:83:125:227:270:291:312	11:31:84:126:228:271:292:313	0:1:3:3:6:8:8:9	D000647	amnesia|amnesia|amnesia	Disease	13:38:315	14:39:316	0:1:9	1:NR:2	R2L	CROSS	76-77	38-39	D004121	DMSO|DMSO|DMSO|DMSO|DMSO	Chemical	76:80:115:151:263	77:81:116:152:264	3:3:3:3:7	D000647	amnesia|amnesia|amnesia	Disease	13:38:315	14:39:316	0:1:9
15579441	Hypoxia in renal disease with proteinuria and / or glomerular hypertension .|Despite the increasing need to identify and quantify tissue oxygenation at the cellular level , relatively few methods have been available .|In this study , we developed a new hypoxia - responsive reporter vector using a hypoxia - responsive element of the 5 ' vascular endothelial growth factor untranslated region and generated a novel hypoxia - sensing transgenic rat .|We then applied this animal model to the detection of tubulointerstitial hypoxia in the diseased kidney .|With this model , we were able to identify diffuse cortical hypoxia in the puromycin aminonucleoside - induced nephrotic syndrome and focal and segmental hypoxia in the remnant kidney model .|Expression of the hypoxia - responsive transgene increased throughout the observation period , reaching 2 . 2 - fold at 2 weeks in the puromycin aminonucleoside model and 2 . 6 - fold at 4 weeks in the remnant kidney model , whereas that of vascular endothelial growth factor showed a mild decrease , reflecting distinct behaviors of the two genes .|The degree of hypoxia showed a positive correlation with microscopic tubulointerstitial injury in both models .|Finally , we identified the localization of proliferating cell nuclear antigen - positive , ED - 1 - positive , and terminal dUTP nick - end labeled - positive cells in the hypoxic cortical area in the remnant kidney model .|We propose here a possible pathological tie between chronic tubulointerstitial hypoxia and progressive glomerular diseases .	1:CID:2	R2L	NON-CROSS	104-106	101-102	D011692	puromycin aminonucleoside|puromycin aminonucleoside	Chemical	104:145	106:147	4:5	D000860	Hypoxia|hypoxia|hypoxia|hypoxia|hypoxia|hypoxia|hypoxia|hypoxia|hypoxia|hypoxic|hypoxia	Disease	0:42:49:67:84:101:114:124:186:231:250	1:43:50:68:85:102:115:125:187:232:251	0:2:2:2:3:4:4:5:6:7:8	1:NR:2	R2L	CROSS	104-106	87-89	D011692	puromycin aminonucleoside|puromycin aminonucleoside	Chemical	104:145	106:147	4:5	D007674	renal disease|diseased kidney|glomerular diseases	Disease	2:87:253	4:89:255	0:3:8	1:NR:2	R2L	CROSS	104-106	5-6	D011692	puromycin aminonucleoside|puromycin aminonucleoside	Chemical	104:145	106:147	4:5	D011507	proteinuria	Disease	5	6	0	1:NR:2	R2L	CROSS	104-106	10-11	D011692	puromycin aminonucleoside|puromycin aminonucleoside	Chemical	104:145	106:147	4:5	D006973	hypertension	Disease	10	11	0	1:CID:2	L2R	NON-CROSS	104-106	108-110	D011692	puromycin aminonucleoside|puromycin aminonucleoside	Chemical	104:145	106:147	4:5	D009404	nephrotic syndrome	Disease	108	110	4
15517007	Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases , with special reference to systemic sclerosis and multiple sclerosis .|Autologous haematopoietic stem cell transplantation is now a feasible and effective treatment for selected patients with severe autoimmune diseases .|Worldwide , over 650 patients have been transplanted in the context of phase I and II clinical trials .|The results are encouraging enough to begin randomised phase III trials .|However , as predicted , significant transplant - related morbidity and mortality have been observed .|This is primarily due to complications related to either the stage of the disease at transplant or due to infections .|The number of deaths related to cardiac toxicity is low .|However , caution is required when cyclophosphamide or anthracyclines such as mitoxantrone are used in patients with a possible underlying heart damage , for example , systemic sclerosis patients .|In November 2002 , a meeting was held in Florence , bringing together a number of experts in various fields , including rheumatology , cardiology , neurology , pharmacology and transplantation medicine .|The object of the meeting was to analyse existing data , both published or available , in the European Group for Blood and Marrow Transplantation autoimmune disease database , and to propose a safe approach to such patients .|A full cardiological assessment before and during the transplant emerged as the major recommendation .	1:NR:2	R2L	CROSS	132-133	121-123	D003520	cyclophosphamide	Chemical	132	133	7	D066126	cardiotoxicity|cardiac toxicity	Disease	3:121	4:123	0:6	1:NR:2	R2L	CROSS	134-135	121-123	D018943	anthracyclines	Chemical	134	135	7	D066126	cardiotoxicity|cardiac toxicity	Disease	3:121	4:123	0:6	1:NR:2	R2L	CROSS	137-138	121-123	D008942	mitoxantrone	Chemical	137	138	7	D066126	cardiotoxicity|cardiac toxicity	Disease	3:121	4:123	0:6	1:NR:2	R2L	CROSS	214-216	132-133	D003520	cyclophosphamide	Chemical	132	133	7	D001327	autoimmune diseases|autoimmune diseases|autoimmune disease	Disease	14:44:214	16:46:216	0:1:9	1:NR:2	R2L	CROSS	214-216	134-135	D018943	anthracyclines	Chemical	134	135	7	D001327	autoimmune diseases|autoimmune diseases|autoimmune disease	Disease	14:44:214	16:46:216	0:1:9	1:NR:2	R2L	CROSS	214-216	137-138	D008942	mitoxantrone	Chemical	137	138	7	D001327	autoimmune diseases|autoimmune diseases|autoimmune disease	Disease	14:44:214	16:46:216	0:1:9	1:NR:2	R2L	NON-CROSS	152-154	132-133	D003520	cyclophosphamide	Chemical	132	133	7	D012595	systemic sclerosis|systemic sclerosis	Disease	21:152	23:154	0:7	1:NR:2	R2L	NON-CROSS	152-154	134-135	D018943	anthracyclines	Chemical	134	135	7	D012595	systemic sclerosis|systemic sclerosis	Disease	21:152	23:154	0:7	1:NR:2	R2L	NON-CROSS	152-154	137-138	D008942	mitoxantrone	Chemical	137	138	7	D012595	systemic sclerosis|systemic sclerosis	Disease	21:152	23:154	0:7	1:NR:2	R2L	CROSS	132-133	24-26	D003520	cyclophosphamide	Chemical	132	133	7	D009103	multiple sclerosis	Disease	24	26	0	1:NR:2	R2L	CROSS	134-135	24-26	D018943	anthracyclines	Chemical	134	135	7	D009103	multiple sclerosis	Disease	24	26	0	1:NR:2	R2L	CROSS	137-138	24-26	D008942	mitoxantrone	Chemical	137	138	7	D009103	multiple sclerosis	Disease	24	26	0	1:NR:2	R2L	CROSS	132-133	113-114	D003520	cyclophosphamide	Chemical	132	133	7	D007239	infections	Disease	113	114	5	1:NR:2	R2L	CROSS	134-135	113-114	D018943	anthracyclines	Chemical	134	135	7	D007239	infections	Disease	113	114	5	1:NR:2	R2L	CROSS	137-138	113-114	D008942	mitoxantrone	Chemical	137	138	7	D007239	infections	Disease	113	114	5	1:CID:2	L2R	NON-CROSS	132-133	146-148	D003520	cyclophosphamide	Chemical	132	133	7	D006331	heart damage	Disease	146	148	7	1:NR:2	L2R	NON-CROSS	134-135	146-148	D018943	anthracyclines	Chemical	134	135	7	D006331	heart damage	Disease	146	148	7	1:CID:2	L2R	NON-CROSS	137-138	146-148	D008942	mitoxantrone	Chemical	137	138	7	D006331	heart damage	Disease	146	148	7
12180796	Immunohistochemical study on inducible type of nitric oxide ( iNOS ) , basic fibroblast growth factor ( bFGF ) and tumor growth factor - beta1 ( TGF - beta1 ) in arteritis induced in rats by fenoldopam and theophylline , vasodilators .|Arteritis induced in rats by vasodilators , fenoldopam and theophylline , was examined immunohistochemically for expressions of inducible type of nitric oxide synthase ( iNOS ) , basic fibroblast growth factor ( bFGF ) and tumor growth factor - beta1 ( TGF - beta1 ) .|Rats were administered fenoldopam for 24 hours by intravenous infusion with or without following repeated daily oral administrations of theophylline .|Irrespective of theophylline administration , iNOS antigens were remarkably abundant in ED - 1 - positive cells on day 5 and 8 post - fenoldopam - infusion ( DPI ) ; bFGF antigens were remarkably abundant in ED - 1 - positive cells on 1 and 3 DPI ; TGF - beta1 antigens were observed in ED - 1 - positive cells on and after 5 DPI .|These results suggest that the peak expression of iNOS antigen was followed by that of bFGF antigen , and bFGF may have a suppressive effect on iNOS expression in these rat arteritis models .|On the other hand , TGF - beta1 was not considered to have a suppressive effect on iNOS expression in these models .	1:NR:2	L2R	NON-CROSS	6-8	20-21	D009569	nitric oxide|nitric oxide	Chemical	6:62	8:64	0:1	D009369	tumor|tumor	Disease	20:77	21:78	0:1	1:NR:2	L2R	NON-CROSS	42-43	62-64	D009569	nitric oxide|nitric oxide	Chemical	6:62	8:64	0:1	D001167	arteritis|Arteritis|arteritis	Disease	31:42:208	32:43:209	0:1:4	1:NR:2	R2L	NON-CROSS	91-92	77-78	D018818	fenoldopam|fenoldopam|fenoldopam|fenoldopam	Chemical	36:49:91:133	37:50:92:134	0:1:2:3	D009369	tumor|tumor	Disease	20:77	21:78	0:1	1:NR:2	R2L	NON-CROSS	38-39	20-21	D013806	theophylline|theophylline|theophylline|theophylline	Chemical	38:51:107:111	39:52:108:112	0:1:2:3	D009369	tumor|tumor	Disease	20:77	21:78	0:1	1:CID:2	R2L	NON-CROSS	36-37	31-32	D018818	fenoldopam|fenoldopam|fenoldopam|fenoldopam	Chemical	36:49:91:133	37:50:92:134	0:1:2:3	D001167	arteritis|Arteritis|arteritis	Disease	31:42:208	32:43:209	0:1:4	1:CID:2	R2L	NON-CROSS	42-43	38-39	D013806	theophylline|theophylline|theophylline|theophylline	Chemical	38:51:107:111	39:52:108:112	0:1:2:3	D001167	arteritis|Arteritis|arteritis	Disease	31:42:208	32:43:209	0:1:4
12109865	Low - molecular - weight heparin for the treatment of patients with mechanical heart valves .|BACKGROUND : The interruption of oral anticoagulant ( OAC ) administration is sometimes indicated in patients with mechanical heart valves , mainly before noncardiac surgery , non - surgical interventions , and pregnancy .|Unfractionated heparin ( UH ) is currently the substitute for selected patients .|Low - molecular - weight heparin ( LMWH ) offers theoretical advantages over UH , but is not currently considered in clinical guidelines as an alternative to UH in patients with prosthetic valves .|HYPOTHESIS : The aim of the present study was to review the data accumulated so far on the use of LMWH in this patient population and to discuss its applicability in common practice .|METHODS : For this paper , the current medical literature on LMWH in patients with mechanical heart valves was extensively reviewed .|RESULTS : There were eight series and six case reports .|None of the studies was randomized , and only one was prospective .|Data to establish the thromboembolic risk were incomplete .|After excluding case reports , the following groups were constructed : ( a ) short - term administration , after valve insertion ( n = 212 ) ; ( b ) short - term , perioperative ( noncardiac ) / periprocedural ( n = 114 ) ; ( c ) long - term , due to intolerance to OAC ( n = 16 ) ; ( d ) long - term , in pregnancy ( n = 10 ) .|The incidence rate of thromboembolism was 0 . 9 % for all the studies and 0 . 5 , 0 , 20 , and 0 % in groups a , b , c , and d , respectively ; for hemorrhage , the overall rate was 3 . 4 % ( 3 . 8 , 2 . 6 , 10 , and 0 % for the respective groups ) .|CONCLUSIONS : In patients with mechanical heart valves , short - term LMWH therapy compares favorably with UH .|Data on mid - and long - term LMWH administration in these patients are sparse .|Further randomized studies are needed to confirm the safety and precise indications for the use of LMWH in patients with mechanical heart valves .	1:CID:2	L2R	CROSS	142-143	181-182	D006495	Low - molecular - weight heparin|Low - molecular - weight heparin|LMWH|LMWH|LMWH|LMWH|LMWH|LMWH	Chemical	0:63:70:117:142:348:363:387	6:69:71:118:143:349:364:388	0:3:3:4:5:11:12:13	D013923	thromboembolic|thromboembolism	Disease	181:270	182:271	8:10	1:CID:2	L2R	CROSS	306-307	348-349	D006495	Low - molecular - weight heparin|Low - molecular - weight heparin|LMWH|LMWH|LMWH|LMWH|LMWH|LMWH	Chemical	0:63:70:117:142:348:363:387	6:69:71:118:143:349:364:388	0:3:3:4:5:11:12:13	D006470	hemorrhage	Disease	306	307	10	1:NR:2	L2R	CROSS	270-271	353-354	D006493	Unfractionated heparin|UH|UH|UH|UH	Chemical	50:53:76:90:353	52:54:77:91:354	2:2:3:3:11	D013923	thromboembolic|thromboembolism	Disease	181:270	182:271	8:10	1:NR:2	L2R	CROSS	306-307	353-354	D006493	Unfractionated heparin|UH|UH|UH|UH	Chemical	50:53:76:90:353	52:54:77:91:354	2:2:3:3:11	D006470	hemorrhage	Disease	306	307	10
12042105	Topiramate - induced nephrolithiasis .|Topiramate is a recently developed antiepileptic medication that is becoming more widely prescribed because of its efficacy in treating refractory seizures .|Urologists should be aware that this medication can cause metabolic acidosis in patients secondary to inhibition of carbonic anhydrase .|In addition , a distal tubular acidification defect may result , thus impairing the normal compensatory drop in urine pH .|These factors can lead to the development of calcium phosphate nephrolithiasis .|We report the first two cases of topiramate - induced nephrolithiasis in the urologic literature .	1:CID:2	L2R	NON-CROSS	3-4	5-6	C052342	Topiramate|Topiramate|topiramate	Chemical	0:5:87	1:6:88	0:1:5	D053040	nephrolithiasis|nephrolithiasis|nephrolithiasis	Disease	3:78:90	4:79:91	0:4:5	1:NR:2	L2R	NON-CROSS	5-6	24-26	C052342	Topiramate|Topiramate|topiramate	Chemical	0:5:87	1:6:88	0:1:5	D004827	refractory seizures	Disease	24	26	1	1:NR:2	L2R	CROSS	5-6	36-38	C052342	Topiramate|Topiramate|topiramate	Chemical	0:5:87	1:6:88	0:1:5	D000138	metabolic acidosis	Disease	36	38	2	1:NR:2	R2L	NON-CROSS	78-79	76-78	C020243	calcium phosphate	Chemical	76	78	4	D053040	nephrolithiasis|nephrolithiasis|nephrolithiasis	Disease	3:78:90	4:79:91	0:4:5	1:NR:2	R2L	CROSS	76-78	24-26	C020243	calcium phosphate	Chemical	76	78	4	D004827	refractory seizures	Disease	24	26	1	1:NR:2	R2L	CROSS	76-78	36-38	C020243	calcium phosphate	Chemical	76	78	4	D000138	metabolic acidosis	Disease	36	38	2
11868798	Spironolactone : is it a novel drug for the prevention of amphotericin B - related hypokalemia in cancer patients ?|OBJECTIVE : Nephrotoxicity is the major adverse effect of amphotericin B ( AmB ) , often limiting administration of full dosage .|Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB .|Potassium depletion also potentiates the tubular toxicity of AmB .|This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment .|METHODS : In this study 26 patients with various hematological disorders were randomized to receive either intravenous AmB alone or AmB and oral spironolactone 100 mg twice daily when developing a proven or suspected fungal infection .|RESULTS : Patients receiving concomitant AmB and spironolactone had significantly higher plasma potassium levels than those receiving AmB alone ( P = 0 . 0027 ) .|Those patients receiving AmB and spironolactone required significantly less potassium supplementation to maintain their plasma potassium within the normal range ( P = 0 . 022 ) .|Moreover , urinary potassium losses were significantly less in patients receiving AmB and spironolactone than those receiving AmB alone ( P = 0 . 040 ) .|CONCLUSION : This study showed that spironolactone can reduce potassium requirements and prevent hypokalemia by reducing urinary potassium loss in neutropenic patients on AmB treatment .	1:NR:2	L2R	NON-CROSS	228-229	235-236	D013148	Spironolactone|spironolactone|spironolactone|spironolactone|spironolactone|spironolactone|spironolactone	Chemical	0:87:126:147:172:208:228	1:88:127:148:173:209:229	0:4:5:6:7:8:9	D007008	hypokalemia|hypokalemia|hypokalemia	Disease	15:95:235	16:96:236	0:4:9	1:NR:2	L2R	NON-CROSS	0-1	17-18	D013148	Spironolactone|spironolactone|spironolactone|spironolactone|spironolactone|spironolactone|spironolactone	Chemical	0:87:126:147:172:208:228	1:88:127:148:173:209:229	0:4:5:6:7:8:9	D009369	cancer	Disease	17	18	0	1:NR:2	L2R	CROSS	0-1	22-23	D013148	Spironolactone|spironolactone|spironolactone|spironolactone|spironolactone|spironolactone|spironolactone	Chemical	0:87:126:147:172:208:228	1:88:127:148:173:209:229	0:4:5:6:7:8:9	D007674	Nephrotoxicity	Disease	22	23	1	1:NR:2	L2R	CROSS	74-75	87-88	D013148	Spironolactone|spironolactone|spironolactone|spironolactone|spironolactone|spironolactone|spironolactone	Chemical	0:87:126:147:172:208:228	1:88:127:148:173:209:229	0:4:5:6:7:8:9	D064420	toxicity|toxicity	Disease	46:74	47:75	2:3	1:NR:2	L2R	NON-CROSS	87-88	97-98	D013148	Spironolactone|spironolactone|spironolactone|spironolactone|spironolactone|spironolactone|spironolactone	Chemical	0:87:126:147:172:208:228	1:88:127:148:173:209:229	0:4:5:6:7:8:9	D009503	neutropenic|neutropenic	Disease	97:242	98:243	4:9	1:NR:2	L2R	NON-CROSS	112-114	126-127	D013148	Spironolactone|spironolactone|spironolactone|spironolactone|spironolactone|spironolactone|spironolactone	Chemical	0:87:126:147:172:208:228	1:88:127:148:173:209:229	0:4:5:6:7:8:9	D006402	hematological disorders	Disease	112	114	5	1:NR:2	L2R	NON-CROSS	137-139	147-148	D013148	Spironolactone|spironolactone|spironolactone|spironolactone|spironolactone|spironolactone|spironolactone	Chemical	0:87:126:147:172:208:228	1:88:127:148:173:209:229	0:4:5:6:7:8:9	D009181	fungal infection	Disease	137	139	5	1:CID:2	L2R	NON-CROSS	11-13	15-16	D000666	amphotericin B|amphotericin B|AmB|AmB|AmB|AmB|AmB|AmB|AmB|AmB|AmB|AmB|AmB|AmB	Chemical	11:29:32:66:76:100:120:123:145:157:170:206:212:245	13:31:33:67:77:101:121:124:146:158:171:207:213:246	0:1:1:2:3:4:5:5:6:6:7:8:8:9	D007008	hypokalemia|hypokalemia|hypokalemia	Disease	15:95:235	16:96:236	0:4:9	1:NR:2	L2R	NON-CROSS	11-13	17-18	D000666	amphotericin B|amphotericin B|AmB|AmB|AmB|AmB|AmB|AmB|AmB|AmB|AmB|AmB|AmB|AmB	Chemical	11:29:32:66:76:100:120:123:145:157:170:206:212:245	13:31:33:67:77:101:121:124:146:158:171:207:213:246	0:1:1:2:3:4:5:5:6:6:7:8:8:9	D009369	cancer	Disease	17	18	0	1:NR:2	L2R	NON-CROSS	22-23	29-31	D000666	amphotericin B|amphotericin B|AmB|AmB|AmB|AmB|AmB|AmB|AmB|AmB|AmB|AmB|AmB|AmB	Chemical	11:29:32:66:76:100:120:123:145:157:170:206:212:245	13:31:33:67:77:101:121:124:146:158:171:207:213:246	0:1:1:2:3:4:5:5:6:6:7:8:8:9	D007674	Nephrotoxicity	Disease	22	23	1	1:NR:2	L2R	NON-CROSS	74-75	76-77	D000666	amphotericin B|amphotericin B|AmB|AmB|AmB|AmB|AmB|AmB|AmB|AmB|AmB|AmB|AmB|AmB	Chemical	11:29:32:66:76:100:120:123:145:157:170:206:212:245	13:31:33:67:77:101:121:124:146:158:171:207:213:246	0:1:1:2:3:4:5:5:6:6:7:8:8:9	D064420	toxicity|toxicity	Disease	46:74	47:75	2:3	1:NR:2	L2R	NON-CROSS	97-98	100-101	D000666	amphotericin B|amphotericin B|AmB|AmB|AmB|AmB|AmB|AmB|AmB|AmB|AmB|AmB|AmB|AmB	Chemical	11:29:32:66:76:100:120:123:145:157:170:206:212:245	13:31:33:67:77:101:121:124:146:158:171:207:213:246	0:1:1:2:3:4:5:5:6:6:7:8:8:9	D009503	neutropenic|neutropenic	Disease	97:242	98:243	4:9	1:NR:2	L2R	NON-CROSS	112-114	120-121	D000666	amphotericin B|amphotericin B|AmB|AmB|AmB|AmB|AmB|AmB|AmB|AmB|AmB|AmB|AmB|AmB	Chemical	11:29:32:66:76:100:120:123:145:157:170:206:212:245	13:31:33:67:77:101:121:124:146:158:171:207:213:246	0:1:1:2:3:4:5:5:6:6:7:8:8:9	D006402	hematological disorders	Disease	112	114	5	1:NR:2	L2R	NON-CROSS	137-139	145-146	D000666	amphotericin B|amphotericin B|AmB|AmB|AmB|AmB|AmB|AmB|AmB|AmB|AmB|AmB|AmB|AmB	Chemical	11:29:32:66:76:100:120:123:145:157:170:206:212:245	13:31:33:67:77:101:121:124:146:158:171:207:213:246	0:1:1:2:3:4:5:5:6:6:7:8:8:9	D009181	fungal infection	Disease	137	139	5	1:NR:2	R2L	NON-CROSS	235-236	231-232	D011188	potassium|Potassium|potassium|potassium|potassium|potassium|potassium|potassium|potassium	Chemical	54:68:90:152:176:182:198:231:239	55:69:91:153:177:183:199:232:240	2:3:4:6:7:7:8:9:9	D007008	hypokalemia|hypokalemia|hypokalemia	Disease	15:95:235	16:96:236	0:4:9	1:NR:2	R2L	CROSS	54-55	17-18	D011188	potassium|Potassium|potassium|potassium|potassium|potassium|potassium|potassium|potassium	Chemical	54:68:90:152:176:182:198:231:239	55:69:91:153:177:183:199:232:240	2:3:4:6:7:7:8:9:9	D009369	cancer	Disease	17	18	0	1:NR:2	R2L	CROSS	54-55	22-23	D011188	potassium|Potassium|potassium|potassium|potassium|potassium|potassium|potassium|potassium	Chemical	54:68:90:152:176:182:198:231:239	55:69:91:153:177:183:199:232:240	2:3:4:6:7:7:8:9:9	D007674	Nephrotoxicity	Disease	22	23	1	1:NR:2	R2L	NON-CROSS	74-75	68-69	D011188	potassium|Potassium|potassium|potassium|potassium|potassium|potassium|potassium|potassium	Chemical	54:68:90:152:176:182:198:231:239	55:69:91:153:177:183:199:232:240	2:3:4:6:7:7:8:9:9	D064420	toxicity|toxicity	Disease	46:74	47:75	2:3	1:NR:2	L2R	NON-CROSS	239-240	242-243	D011188	potassium|Potassium|potassium|potassium|potassium|potassium|potassium|potassium|potassium	Chemical	54:68:90:152:176:182:198:231:239	55:69:91:153:177:183:199:232:240	2:3:4:6:7:7:8:9:9	D009503	neutropenic|neutropenic	Disease	97:242	98:243	4:9	1:NR:2	L2R	CROSS	90-91	112-114	D011188	potassium|Potassium|potassium|potassium|potassium|potassium|potassium|potassium|potassium	Chemical	54:68:90:152:176:182:198:231:239	55:69:91:153:177:183:199:232:240	2:3:4:6:7:7:8:9:9	D006402	hematological disorders	Disease	112	114	5	1:NR:2	L2R	CROSS	137-139	152-153	D011188	potassium|Potassium|potassium|potassium|potassium|potassium|potassium|potassium|potassium	Chemical	54:68:90:152:176:182:198:231:239	55:69:91:153:177:183:199:232:240	2:3:4:6:7:7:8:9:9	D009181	fungal infection	Disease	137	139	5
11860278	Dopamine D2 receptor signaling controls neuronal cell death induced by muscarinic and glutamatergic drugs .|Dopamine ( DA ) , through D1 / D2 receptor - mediated signaling , plays a major role in the control of epileptic seizures arising in the limbic system .|Excitotoxicity leading to neuronal cell death in the affected areas is a major consequence of seizures at the cellular level .|In this respect , little is known about the role of DA receptors in the occurrence of epilepsy - induced neuronal cell death .|Here we analyze the occurrence of seizures and neurotoxicity in D2R - / - mice treated with the cholinergic agonist pilocarpine .|We compared these results with those previously obtained with kainic acid ( KA ) , a potent glutamate agonist .|Importantly , D2R - / - mice develop seizures at doses of both drugs that are not epileptogenic for WT littermates and show greater neurotoxicity .|However , pilocarpine - induced seizures result in a more widespread neuronal death in both WT and D2R - / - brains in comparison to KA .|Thus , the absence of D2R lowers the threshold for seizures induced by both glutamate and acetylcholine .|Moreover , the dopaminergic control of epilepsy - induced neurodegeneration seems to be mediated by distinct interactions of D2R signaling with these two neurotransmitters .	1:NR:2	L2R	NON-CROSS	77-78	83-84	D004298	Dopamine|Dopamine|DA|DA	Chemical	0:15:17:77	1:16:18:78	0:1:1:3	D004827	epileptic seizures|epilepsy|epilepsy	Disease	37:83:209	39:84:210	1:3:9	1:NR:2	L2R	CROSS	60-61	77-78	D004298	Dopamine|Dopamine|DA|DA	Chemical	0:15:17:77	1:16:18:78	0:1:1:3	D012640	seizures|seizures|seizures|seizures|seizures	Disease	60:96:140:163:195	61:97:141:164:196	2:4:6:7:8	1:NR:2	L2R	CROSS	77-78	98-99	D004298	Dopamine|Dopamine|DA|DA	Chemical	0:15:17:77	1:16:18:78	0:1:1:3	D020258	neurotoxicity|neurotoxicity	Disease	98:156	99:157	4:6	1:NR:2	L2R	CROSS	77-78	212-213	D004298	Dopamine|Dopamine|DA|DA	Chemical	0:15:17:77	1:16:18:78	0:1:1:3	D019636	neurodegeneration	Disease	212	213	9	1:NR:2	R2L	CROSS	110-111	83-84	D010862	pilocarpine|pilocarpine	Chemical	110:160	111:161	4:7	D004827	epileptic seizures|epilepsy|epilepsy	Disease	37:83:209	39:84:210	1:3:9	1:NR:2	R2L	CROSS	209-210	183-184	D007608	kainic acid|KA|KA	Chemical	121:124:183	123:125:184	5:5:7	D004827	epileptic seizures|epilepsy|epilepsy	Disease	37:83:209	39:84:210	1:3:9	1:NR:2	R2L	CROSS	209-210	199-200	D018698	glutamate|glutamate	Chemical	129:199	130:200	5:8	D004827	epileptic seizures|epilepsy|epilepsy	Disease	37:83:209	39:84:210	1:3:9	1:NR:2	R2L	CROSS	209-210	201-202	D000109	acetylcholine	Chemical	201	202	8	D004827	epileptic seizures|epilepsy|epilepsy	Disease	37:83:209	39:84:210	1:3:9	1:CID:2	R2L	NON-CROSS	163-164	160-161	D010862	pilocarpine|pilocarpine	Chemical	110:160	111:161	4:7	D012640	seizures|seizures|seizures|seizures|seizures	Disease	60:96:140:163:195	61:97:141:164:196	2:4:6:7:8	1:CID:2	R2L	NON-CROSS	195-196	183-184	D007608	kainic acid|KA|KA	Chemical	121:124:183	123:125:184	5:5:7	D012640	seizures|seizures|seizures|seizures|seizures	Disease	60:96:140:163:195	61:97:141:164:196	2:4:6:7:8	1:NR:2	R2L	NON-CROSS	199-200	195-196	D018698	glutamate|glutamate	Chemical	129:199	130:200	5:8	D012640	seizures|seizures|seizures|seizures|seizures	Disease	60:96:140:163:195	61:97:141:164:196	2:4:6:7:8	1:NR:2	R2L	NON-CROSS	201-202	195-196	D000109	acetylcholine	Chemical	201	202	8	D012640	seizures|seizures|seizures|seizures|seizures	Disease	60:96:140:163:195	61:97:141:164:196	2:4:6:7:8	1:NR:2	R2L	NON-CROSS	160-161	156-157	D010862	pilocarpine|pilocarpine	Chemical	110:160	111:161	4:7	D020258	neurotoxicity|neurotoxicity	Disease	98:156	99:157	4:6	1:NR:2	R2L	CROSS	121-123	98-99	D007608	kainic acid|KA|KA	Chemical	121:124:183	123:125:184	5:5:7	D020258	neurotoxicity|neurotoxicity	Disease	98:156	99:157	4:6	1:NR:2	R2L	CROSS	156-157	129-130	D018698	glutamate|glutamate	Chemical	129:199	130:200	5:8	D020258	neurotoxicity|neurotoxicity	Disease	98:156	99:157	4:6	1:NR:2	R2L	CROSS	201-202	156-157	D000109	acetylcholine	Chemical	201	202	8	D020258	neurotoxicity|neurotoxicity	Disease	98:156	99:157	4:6	1:NR:2	L2R	CROSS	160-161	212-213	D010862	pilocarpine|pilocarpine	Chemical	110:160	111:161	4:7	D019636	neurodegeneration	Disease	212	213	9	1:NR:2	L2R	CROSS	183-184	212-213	D007608	kainic acid|KA|KA	Chemical	121:124:183	123:125:184	5:5:7	D019636	neurodegeneration	Disease	212	213	9	1:NR:2	L2R	CROSS	199-200	212-213	D018698	glutamate|glutamate	Chemical	129:199	130:200	5:8	D019636	neurodegeneration	Disease	212	213	9	1:NR:2	L2R	CROSS	201-202	212-213	D000109	acetylcholine	Chemical	201	202	8	D019636	neurodegeneration	Disease	212	213	9
11838826	Treatment of risperidone - induced hyperprolactinemia with a dopamine agonist in children .|BACKGROUND : Risperidone , a potent antagonist of both serotonergic ( 5HT2A ) and dopaminergic D2 receptors is associated with hyperprolactinemia in adults and children .|Chronically elevated prolactin levels in children with prolactinomas may be associated with arrested growth and development resulting in either delayed puberty or short stature .|These possibilities stress the importance of developing a safe and effective approach to drug - induced hyperprolactinemia in youth .|We report the successful treatment of risperidone - induced hyperprolactinemia with cabergoline in youth .|METHODS : We undertook a retrospective case review of four children with risperidone - induced hyperprolactinemia treated with cabergoline .|RESULTS : Four males ( age 6 - 11 years ) with Diagnostic and Statistical Manual of Mental Disorders ( fourth edition ) bipolar disorder or psychoses , with risperidone - induced elevations in serum prolactin levels ( 57 . 5 - 129 ng / mL , normal 5 - 15 ng / mL ) , were treated with cabergoline ( mean dose 2 . 13 + / - 0 . 09 mg / week ) .|When serum prolactin levels normalized in all four subjects ( mean 11 . 2 + / - 10 . 9 ng / mL ) , the cabergoline dose was reduced to 1 mg / week in three of four subjects .|The mean duration of therapy with cabergoline was 523 . 5 + / - 129 . 7 days , and the mean duration of therapy with risperidone was 788 . 5 + / - 162 . 5 days .|Cabergoline was well tolerated without adverse effects .|CONCLUSIONS : Cabergoline may be useful for the treatment of risperidone - induced hyperprolactinemia in youth ; however , further research is needed .	1:CID:2	L2R	NON-CROSS	2-3	5-6	D018967	risperidone|Risperidone|risperidone|risperidone|risperidone|risperidone|risperidone	Chemical	2:15:90:111:148:263:294	3:16:91:112:149:264:295	0:1:4:5:6:8:10	D006966	hyperprolactinemia|hyperprolactinemia|hyperprolactinemia|hyperprolactinemia|hyperprolactinemia|hyperprolactinemia	Disease	5:33:80:93:114:297	6:34:81:94:115:298	0:1:3:4:5:10	1:NR:2	L2R	CROSS	15-16	46-47	D018967	risperidone|Risperidone|risperidone|risperidone|risperidone|risperidone|risperidone	Chemical	2:15:90:111:148:263:294	3:16:91:112:149:264:295	0:1:4:5:6:8:10	D015175	prolactinomas	Disease	46	47	2	1:NR:2	L2R	CROSS	58-60	90-91	D018967	risperidone|Risperidone|risperidone|risperidone|risperidone|risperidone|risperidone	Chemical	2:15:90:111:148:263:294	3:16:91:112:149:264:295	0:1:4:5:6:8:10	D011628	delayed puberty	Disease	58	60	2	1:NR:2	L2R	NON-CROSS	136-138	148-149	D018967	risperidone|Risperidone|risperidone|risperidone|risperidone|risperidone|risperidone	Chemical	2:15:90:111:148:263:294	3:16:91:112:149:264:295	0:1:4:5:6:8:10	D001523	Mental Disorders	Disease	136	138	6	1:NR:2	L2R	NON-CROSS	142-144	148-149	D018967	risperidone|Risperidone|risperidone|risperidone|risperidone|risperidone|risperidone	Chemical	2:15:90:111:148:263:294	3:16:91:112:149:264:295	0:1:4:5:6:8:10	D001714	bipolar disorder	Disease	142	144	6	1:NR:2	L2R	NON-CROSS	145-146	148-149	D018967	risperidone|Risperidone|risperidone|risperidone|risperidone|risperidone|risperidone	Chemical	2:15:90:111:148:263:294	3:16:91:112:149:264:295	0:1:4:5:6:8:10	D011605	psychoses	Disease	145	146	6	1:NR:2	R2L	NON-CROSS	8-9	5-6	D004298	dopamine	Chemical	8	9	0	D006966	hyperprolactinemia|hyperprolactinemia|hyperprolactinemia|hyperprolactinemia|hyperprolactinemia|hyperprolactinemia	Disease	5:33:80:93:114:297	6:34:81:94:115:298	0:1:3:4:5:10	1:NR:2	R2L	NON-CROSS	95-96	93-94	C047047	cabergoline|cabergoline|cabergoline|cabergoline|cabergoline|Cabergoline|Cabergoline	Chemical	95:117:178:222:243:276:286	96:118:179:223:244:277:287	4:5:6:7:8:9:10	D006966	hyperprolactinemia|hyperprolactinemia|hyperprolactinemia|hyperprolactinemia|hyperprolactinemia|hyperprolactinemia	Disease	5:33:80:93:114:297	6:34:81:94:115:298	0:1:3:4:5:10	1:NR:2	L2R	CROSS	8-9	46-47	D004298	dopamine	Chemical	8	9	0	D015175	prolactinomas	Disease	46	47	2	1:NR:2	L2R	CROSS	8-9	58-60	D004298	dopamine	Chemical	8	9	0	D011628	delayed puberty	Disease	58	60	2	1:NR:2	L2R	CROSS	8-9	136-138	D004298	dopamine	Chemical	8	9	0	D001523	Mental Disorders	Disease	136	138	6	1:NR:2	L2R	CROSS	8-9	142-144	D004298	dopamine	Chemical	8	9	0	D001714	bipolar disorder	Disease	142	144	6	1:NR:2	L2R	CROSS	8-9	145-146	D004298	dopamine	Chemical	8	9	0	D011605	psychoses	Disease	145	146	6	1:NR:2	R2L	CROSS	95-96	46-47	C047047	cabergoline|cabergoline|cabergoline|cabergoline|cabergoline|Cabergoline|Cabergoline	Chemical	95:117:178:222:243:276:286	96:118:179:223:244:277:287	4:5:6:7:8:9:10	D015175	prolactinomas	Disease	46	47	2	1:NR:2	R2L	CROSS	95-96	58-60	C047047	cabergoline|cabergoline|cabergoline|cabergoline|cabergoline|Cabergoline|Cabergoline	Chemical	95:117:178:222:243:276:286	96:118:179:223:244:277:287	4:5:6:7:8:9:10	D011628	delayed puberty	Disease	58	60	2	1:NR:2	L2R	NON-CROSS	117-118	136-138	C047047	cabergoline|cabergoline|cabergoline|cabergoline|cabergoline|Cabergoline|Cabergoline	Chemical	95:117:178:222:243:276:286	96:118:179:223:244:277:287	4:5:6:7:8:9:10	D001523	Mental Disorders	Disease	136	138	6	1:NR:2	L2R	NON-CROSS	117-118	142-144	C047047	cabergoline|cabergoline|cabergoline|cabergoline|cabergoline|Cabergoline|Cabergoline	Chemical	95:117:178:222:243:276:286	96:118:179:223:244:277:287	4:5:6:7:8:9:10	D001714	bipolar disorder	Disease	142	144	6	1:NR:2	L2R	NON-CROSS	117-118	145-146	C047047	cabergoline|cabergoline|cabergoline|cabergoline|cabergoline|Cabergoline|Cabergoline	Chemical	95:117:178:222:243:276:286	96:118:179:223:244:277:287	4:5:6:7:8:9:10	D011605	psychoses	Disease	145	146	6
11467664	Cholestatic jaundice associated with the use of metformin .|We report a patient who developed cholestatic jaundice shortly after initiation of treatment with metformin hydrochloride .|Ultrasound of the liver and abdominal CT were normal .|An ERCP showed normal biliary anatomy .|A percutaneous liver biopsy was obtained showing marked cholestasis , with portal edema , ductular proliferation , and acute inflammation .|Metformin hydrochloride was discontinued , and the patient 's jaundice resolved slowly over a period of several months .|Given the onset of his jaundice 2 wk after the initiation of metformin , we believe that this case represents an example of metformin - associated hepatotoxicity , the first such case reported .	1:CID:2	R2L	NON-CROSS	7-8	0-2	D008687	metformin|metformin hydrochloride|Metformin hydrochloride|metformin|metformin	Chemical	7:23:64:95:106	8:25:66:96:107	0:1:5:6:6	D041781	Cholestatic jaundice|cholestatic jaundice	Disease	0:15	2:17	0:1	1:CID:2	L2R	CROSS	51-52	64-66	D008687	metformin|metformin hydrochloride|Metformin hydrochloride|metformin|metformin	Chemical	7:23:64:95:106	8:25:66:96:107	0:1:5:6:6	D002779	cholestasis	Disease	51	52	4	1:NR:2	L2R	CROSS	55-56	64-66	D008687	metformin|metformin hydrochloride|Metformin hydrochloride|metformin|metformin	Chemical	7:23:64:95:106	8:25:66:96:107	0:1:5:6:6	D004487	edema	Disease	55	56	4	1:NR:2	L2R	CROSS	62-63	64-66	D008687	metformin|metformin hydrochloride|Metformin hydrochloride|metformin|metformin	Chemical	7:23:64:95:106	8:25:66:96:107	0:1:5:6:6	D007249	inflammation	Disease	62	63	4	1:NR:2	L2R	NON-CROSS	88-89	95-96	D008687	metformin|metformin hydrochloride|Metformin hydrochloride|metformin|metformin	Chemical	7:23:64:95:106	8:25:66:96:107	0:1:5:6:6	D007565	jaundice|jaundice	Disease	73:88	74:89	5:6	1:NR:2	L2R	NON-CROSS	106-107	109-110	D008687	metformin|metformin hydrochloride|Metformin hydrochloride|metformin|metformin	Chemical	7:23:64:95:106	8:25:66:96:107	0:1:5:6:6	D056486	hepatotoxicity	Disease	109	110	6
11077455	Electro - oculography , electroretinography , visual evoked potentials , and multifocal electroretinography in patients with vigabatrin - attributed visual field constriction .|PURPOSE : Symptomatic visual field constriction thought to be associated with vigabatrin has been reported .|The current study investigated the visual fields and visual electrophysiology of eight patients with known vigabatrin - attributed visual field loss , three of whom were reported previously .|Six of the patients were no longer receiving vigabatrin .|METHODS : The central and peripheral fields were examined with the Humphrey Visual Field Analyzer .|Full visual electrophysiology , including flash electroretinography ( ERG ) , pattern electroretinography , multifocal ERG using the VERIS system , electro - oculography , and flash and pattern visual evoked potentials , was undertaken .|RESULTS : Seven patients showed marked visual field constriction with some sparing of the temporal visual field .|The eighth exhibited concentric constriction .|Most electrophysiological responses were usually just within normal limits ; two patients had subnormal Arden electro - oculography indices ; and one patient showed an abnormally delayed photopic b wave .|However , five patients showed delayed 30 - Hz flicker b waves , and seven patients showed delayed oscillatory potentials .|Multifocal ERG showed abnormalities that sometimes correlated with the visual field appearance and confirmed that the deficit occurs at the retinal level .|CONCLUSION : Marked visual field constriction appears to be associated with vigabatrin therapy .|The field defects and some electrophysiological abnormalities persist when vigabatrin therapy is withdrawn .	1:CID:2	L2R	NON-CROSS	16-17	19-22	D020888	vigabatrin|vigabatrin|vigabatrin|vigabatrin|vigabatrin|vigabatrin	Chemical	16:34:54:76:240:252	17:35:55:77:241:253	0:1:2:3:11:12	D014786	visual field constriction|visual field constriction|visual field loss|visual field constriction|visual field constriction	Disease	19:26:57:136:232	22:29:60:139:235	0:1:2:6:11
11063349	Conversion to rapamycin immunosuppression in renal transplant recipients : report of an initial experience .|BACKGROUND : The aim of this study is to evaluate the effects of RAPA conversion in patients undergoing cyclosporine ( CsA ) or tacrolimus ( Tac ) toxicity .|METHODS : Twenty renal transplant recipients were switched to fixed dose rapamycin ( RAPA ) ( 5 mg / day ) 0 to 204 months posttransplant .|Drug monitoring was not initially used to adjust doses .|The indications for switch were chronic CsA or Tac nephrotoxicity ( 12 ) , acute CsA or Tac toxicity ( 3 ) , severe facial dysmorphism ( 2 ) , posttransplant lymphoproliferative disorder ( PTLD ) in remission ( 2 ) , and hepatotoxicity in 1 .|Follow - up is 7 to 24 months .|RESULTS : In the 12 patients switched because of chronic nephrotoxicity there was a significant decrease in serum creatinine [ 233 + / - 34 to 210 + / - 56 micromol / liter ( P < 0 . 05 ) at 6 months ] .|Facial dysmorphism improved in two patients .|No relapse of PTLD was observed .|Five patients developed pneumonia ( two Pneumocystis carinii pneumonia , one infectious mononucleosis with polyclonal PTLD lung infiltrate ) and two had bronchiolitis obliterans .|There were no deaths .|RAPA was discontinued in four patients , because of pneumonia in two , PTLD in one , and oral aphtous ulcers in one .|RAPA levels were high ( > 15 ng / ml ) in 7 of 13 ( 54 % ) patients .|CONCLUSIONS : RAPA conversion provides adequate immunosuppression to enable CsA withdrawal .|However , when converting patients to RAPA drug levels should be monitored to avoid over - immunosuppression and adequate antiviral and Pneumocystis carinii pneumonia prophylaxis should be given .	1:NR:2	L2R	NON-CROSS	42-43	55-56	D020123	rapamycin|RAPA|rapamycin|RAPA|RAPA|RAPA|RAPA|RAPA	Chemical	2:28:55:57:227:251:274:290	3:29:56:58:228:252:275:291	0:1:2:2:11:12:13:14	D064420	toxicity|toxicity	Disease	42:99	43:100	1:4	1:NR:2	L2R	CROSS	57-58	90-91	D020123	rapamycin|RAPA|rapamycin|RAPA|RAPA|RAPA|RAPA|RAPA	Chemical	2:28:55:57:227:251:274:290	3:29:56:58:228:252:275:291	0:1:2:2:11:12:13:14	D007674	nephrotoxicity|nephrotoxicity	Disease	90:147	91:148	4:6	1:NR:2	L2R	NON-CROSS	240-241	251-252	D020123	rapamycin|RAPA|rapamycin|RAPA|RAPA|RAPA|RAPA|RAPA	Chemical	2:28:55:57:227:251:274:290	3:29:56:58:228:252:275:291	0:1:2:2:11:12:13:14	D008232	posttransplant lymphoproliferative disorder|PTLD|PTLD|PTLD|PTLD	Disease	111:115:193:212:240	114:116:194:213:241	4:4:8:9:11	1:NR:2	L2R	CROSS	57-58	124-125	D020123	rapamycin|RAPA|rapamycin|RAPA|RAPA|RAPA|RAPA|RAPA	Chemical	2:28:55:57:227:251:274:290	3:29:56:58:228:252:275:291	0:1:2:2:11:12:13:14	D056486	hepatotoxicity	Disease	124	125	4	1:NR:2	L2R	NON-CROSS	227-228	236-237	D020123	rapamycin|RAPA|rapamycin|RAPA|RAPA|RAPA|RAPA|RAPA	Chemical	2:28:55:57:227:251:274:290	3:29:56:58:228:252:275:291	0:1:2:2:11:12:13:14	D011014	pneumonia|pneumonia	Disease	200:236	201:237	9:11	1:NR:2	L2R	NON-CROSS	290-291	305-308	D020123	rapamycin|RAPA|rapamycin|RAPA|RAPA|RAPA|RAPA|RAPA	Chemical	2:28:55:57:227:251:274:290	3:29:56:58:228:252:275:291	0:1:2:2:11:12:13:14	D011020	Pneumocystis carinii pneumonia|Pneumocystis carinii pneumonia	Disease	203:305	206:308	9:14	1:NR:2	L2R	CROSS	208-210	227-228	D020123	rapamycin|RAPA|rapamycin|RAPA|RAPA|RAPA|RAPA|RAPA	Chemical	2:28:55:57:227:251:274:290	3:29:56:58:228:252:275:291	0:1:2:2:11:12:13:14	D007244	infectious mononucleosis	Disease	208	210	9	1:NR:2	L2R	CROSS	219-221	227-228	D020123	rapamycin|RAPA|rapamycin|RAPA|RAPA|RAPA|RAPA|RAPA	Chemical	2:28:55:57:227:251:274:290	3:29:56:58:228:252:275:291	0:1:2:2:11:12:13:14	D001989	bronchiolitis obliterans	Disease	219	221	9	1:NR:2	L2R	NON-CROSS	246-248	251-252	D020123	rapamycin|RAPA|rapamycin|RAPA|RAPA|RAPA|RAPA|RAPA	Chemical	2:28:55:57:227:251:274:290	3:29:56:58:228:252:275:291	0:1:2:2:11:12:13:14	D013281	aphtous ulcers	Disease	246	248	11	1:NR:2	L2R	NON-CROSS	96-97	99-100	D016572	cyclosporine|CsA|CsA|CsA|CsA	Chemical	33:35:87:96:281	34:36:88:97:282	1:1:4:4:13	D064420	toxicity|toxicity	Disease	42:99	43:100	1:4	1:CID:2	L2R	NON-CROSS	87-88	90-91	D016572	cyclosporine|CsA|CsA|CsA|CsA	Chemical	33:35:87:96:281	34:36:88:97:282	1:1:4:4:13	D007674	nephrotoxicity|nephrotoxicity	Disease	90:147	91:148	4:6	1:NR:2	L2R	NON-CROSS	96-97	111-114	D016572	cyclosporine|CsA|CsA|CsA|CsA	Chemical	33:35:87:96:281	34:36:88:97:282	1:1:4:4:13	D008232	posttransplant lymphoproliferative disorder|PTLD|PTLD|PTLD|PTLD	Disease	111:115:193:212:240	114:116:194:213:241	4:4:8:9:11	1:NR:2	L2R	NON-CROSS	96-97	124-125	D016572	cyclosporine|CsA|CsA|CsA|CsA	Chemical	33:35:87:96:281	34:36:88:97:282	1:1:4:4:13	D056486	hepatotoxicity	Disease	124	125	4	1:NR:2	L2R	CROSS	236-237	281-282	D016572	cyclosporine|CsA|CsA|CsA|CsA	Chemical	33:35:87:96:281	34:36:88:97:282	1:1:4:4:13	D011014	pneumonia|pneumonia	Disease	200:236	201:237	9:11	1:NR:2	L2R	CROSS	281-282	305-308	D016572	cyclosporine|CsA|CsA|CsA|CsA	Chemical	33:35:87:96:281	34:36:88:97:282	1:1:4:4:13	D011020	Pneumocystis carinii pneumonia|Pneumocystis carinii pneumonia	Disease	203:305	206:308	9:14	1:NR:2	L2R	CROSS	208-210	281-282	D016572	cyclosporine|CsA|CsA|CsA|CsA	Chemical	33:35:87:96:281	34:36:88:97:282	1:1:4:4:13	D007244	infectious mononucleosis	Disease	208	210	9	1:NR:2	L2R	CROSS	219-221	281-282	D016572	cyclosporine|CsA|CsA|CsA|CsA	Chemical	33:35:87:96:281	34:36:88:97:282	1:1:4:4:13	D001989	bronchiolitis obliterans	Disease	219	221	9	1:NR:2	L2R	CROSS	246-248	281-282	D016572	cyclosporine|CsA|CsA|CsA|CsA	Chemical	33:35:87:96:281	34:36:88:97:282	1:1:4:4:13	D013281	aphtous ulcers	Disease	246	248	11	1:NR:2	L2R	NON-CROSS	98-99	99-100	D016559	tacrolimus|Tac|Tac|Tac	Chemical	38:40:89:98	39:41:90:99	1:1:4:4	D064420	toxicity|toxicity	Disease	42:99	43:100	1:4	1:CID:2	L2R	NON-CROSS	89-90	90-91	D016559	tacrolimus|Tac|Tac|Tac	Chemical	38:40:89:98	39:41:90:99	1:1:4:4	D007674	nephrotoxicity|nephrotoxicity	Disease	90:147	91:148	4:6	1:NR:2	L2R	NON-CROSS	98-99	111-114	D016559	tacrolimus|Tac|Tac|Tac	Chemical	38:40:89:98	39:41:90:99	1:1:4:4	D008232	posttransplant lymphoproliferative disorder|PTLD|PTLD|PTLD|PTLD	Disease	111:115:193:212:240	114:116:194:213:241	4:4:8:9:11	1:NR:2	L2R	NON-CROSS	98-99	124-125	D016559	tacrolimus|Tac|Tac|Tac	Chemical	38:40:89:98	39:41:90:99	1:1:4:4	D056486	hepatotoxicity	Disease	124	125	4	1:NR:2	L2R	CROSS	98-99	200-201	D016559	tacrolimus|Tac|Tac|Tac	Chemical	38:40:89:98	39:41:90:99	1:1:4:4	D011014	pneumonia|pneumonia	Disease	200:236	201:237	9:11	1:NR:2	L2R	CROSS	98-99	203-206	D016559	tacrolimus|Tac|Tac|Tac	Chemical	38:40:89:98	39:41:90:99	1:1:4:4	D011020	Pneumocystis carinii pneumonia|Pneumocystis carinii pneumonia	Disease	203:305	206:308	9:14	1:NR:2	L2R	CROSS	98-99	208-210	D016559	tacrolimus|Tac|Tac|Tac	Chemical	38:40:89:98	39:41:90:99	1:1:4:4	D007244	infectious mononucleosis	Disease	208	210	9	1:NR:2	L2R	CROSS	98-99	219-221	D016559	tacrolimus|Tac|Tac|Tac	Chemical	38:40:89:98	39:41:90:99	1:1:4:4	D001989	bronchiolitis obliterans	Disease	219	221	9	1:NR:2	L2R	CROSS	98-99	246-248	D016559	tacrolimus|Tac|Tac|Tac	Chemical	38:40:89:98	39:41:90:99	1:1:4:4	D013281	aphtous ulcers	Disease	246	248	11	1:NR:2	R2L	CROSS	155-156	99-100	D003404	creatinine	Chemical	155	156	6	D064420	toxicity|toxicity	Disease	42:99	43:100	1:4	1:NR:2	R2L	NON-CROSS	155-156	147-148	D003404	creatinine	Chemical	155	156	6	D007674	nephrotoxicity|nephrotoxicity	Disease	90:147	91:148	4:6	1:NR:2	R2L	CROSS	193-194	155-156	D003404	creatinine	Chemical	155	156	6	D008232	posttransplant lymphoproliferative disorder|PTLD|PTLD|PTLD|PTLD	Disease	111:115:193:212:240	114:116:194:213:241	4:4:8:9:11	1:NR:2	R2L	CROSS	155-156	124-125	D003404	creatinine	Chemical	155	156	6	D056486	hepatotoxicity	Disease	124	125	4	1:NR:2	L2R	CROSS	155-156	200-201	D003404	creatinine	Chemical	155	156	6	D011014	pneumonia|pneumonia	Disease	200:236	201:237	9:11	1:NR:2	L2R	CROSS	155-156	203-206	D003404	creatinine	Chemical	155	156	6	D011020	Pneumocystis carinii pneumonia|Pneumocystis carinii pneumonia	Disease	203:305	206:308	9:14	1:NR:2	L2R	CROSS	155-156	208-210	D003404	creatinine	Chemical	155	156	6	D007244	infectious mononucleosis	Disease	208	210	9	1:NR:2	L2R	CROSS	155-156	219-221	D003404	creatinine	Chemical	155	156	6	D001989	bronchiolitis obliterans	Disease	219	221	9	1:NR:2	L2R	CROSS	155-156	246-248	D003404	creatinine	Chemical	155	156	6	D013281	aphtous ulcers	Disease	246	248	11
10091616	Worsening of levodopa - induced dyskinesias by motor and mental tasks .|Ten patients who had Parkinson 's disease with disabling dyskinesia were included in this study to evaluate the role of mental ( mental calculation ) and motor ( flexion / extension of right fingers , flexion / extension of left fingers , flexion / extension of the neck , speaking aloud ) tasks on the worsening of peak - dose dyskinesia following administration of an effective single dose of apomorphine .|Compared with the score at rest ( 1 . 3 + / - 0 . 3 ) , a significant aggravation of the dyskinesia score was observed during speaking aloud ( 5 . 2 + / - 1 . 1 , p < 0 . 05 ) , movements of right ( 4 . 5 + / - 1 . 0 , p < 0 . 05 ) and left ( 3 . 7 + / - 0 . 8 , p < 0 . 05 ) fingers , movements of the neck ( 5 . 1 + / - 1 . 0 , p < 0 . 05 ) , and mental calculation ( 3 . 1 + / - 1 . 0 , p < 0 . 05 ) .|These results suggest that activation tasks such as " speaking aloud " could be used for objective assessment of dyskinesia severity .	1:CID:2	L2R	NON-CROSS	2-3	5-6	D007980	levodopa	Chemical	2	3	0	D004409	dyskinesias|dyskinesia|dyskinesia|dyskinesia|dyskinesia	Disease	5:21:72:106:234	6:22:73:107:235	0:1:1:2:3	1:NR:2	L2R	CROSS	2-3	16-19	D007980	levodopa	Chemical	2	3	0	D010300	Parkinson 's disease	Disease	16	19	1	1:CID:2	R2L	NON-CROSS	81-82	72-73	D001058	apomorphine	Chemical	81	82	1	D004409	dyskinesias|dyskinesia|dyskinesia|dyskinesia|dyskinesia	Disease	5:21:72:106:234	6:22:73:107:235	0:1:1:2:3	1:NR:2	R2L	NON-CROSS	81-82	16-19	D001058	apomorphine	Chemical	81	82	1	D010300	Parkinson 's disease	Disease	16	19	1
9952311	Structural and functional impairment of mitochondria in adriamycin - induced cardiomyopathy in mice : suppression of cytochrome c oxidase II gene expression .|The use of adriamycin ( ADR ) in cancer chemotherapy has been limited due to its cumulative cardiovascular toxicity .|Earlier observations that ADR interacts with mitochondrial cytochrome c oxidase ( COX ) and suppresses its enzyme activity led us to investigate ADR 's action on the cardiovascular functions and heart mitochondrial morphology in Balb - c mice i . p .|treated with ADR for several weeks .|At various times during treatment , the animals were assessed for cardiovascular functions by electrocardiography and for heart tissue damage by electron microscopy .|In parallel , total RNA was extracted from samples of dissected heart and analyzed by Northern blot hybridization to determine the steady - state level of three RNA transcripts encoded by the COXII , COXIII , and COXIV genes .|Similarly , samples obtained from the liver of the same animals were analyzed for comparative studies .|Our results indicated that 1 ) treatment of mice with ADR caused cardiovascular arrhythmias characterized by bradycardia , extension of ventricular depolarization time ( tQRS ) , and failure of QRS at high concentrations ( 10 - 14 mg / kg body weight cumulative dose ) ; 2 ) the heart mitochondria underwent swelling , fusion , dissolution , and / or disruption of mitochondrial cristae after several weeks of treatment .|Such abnormalities were not observed in the mitochondria of liver tissue ; and 3 ) among the three genes of COX enzyme examined , only COXII gene expression was suppressed by ADR treatment , mainly after 8 weeks in both heart and liver .|Knowing that heart mitochondria represent almost 40 % of heart muscle by weight , we conclude that the deteriorating effects of ADR on cardiovascular function involve mitochondrial structural and functional impairment .	1:CID:2	R2L	NON-CROSS	7-8	0-6	D004317	adriamycin|adriamycin|ADR|ADR|ADR|ADR|ADR|ADR|ADR	Chemical	7:26:28:46:65:87:183:276:310	8:27:29:47:66:88:184:277:311	0:1:1:2:2:3:7:8:9	D028361	Structural and functional impairment of mitochondria|mitochondrial structural and functional impairment	Disease	0:315	6:320	0:9	1:NR:2	L2R	NON-CROSS	7-8	10-11	D004317	adriamycin|adriamycin|ADR|ADR|ADR|ADR|ADR|ADR|ADR	Chemical	7:26:28:46:65:87:183:276:310	8:27:29:47:66:88:184:277:311	0:1:1:2:2:3:7:8:9	D009202	cardiomyopathy	Disease	10	11	0	1:NR:2	L2R	NON-CROSS	28-29	31-32	D004317	adriamycin|adriamycin|ADR|ADR|ADR|ADR|ADR|ADR|ADR	Chemical	7:26:28:46:65:87:183:276:310	8:27:29:47:66:88:184:277:311	0:1:1:2:2:3:7:8:9	D009369	cancer	Disease	31	32	1	1:NR:2	L2R	NON-CROSS	40-42	46-47	D004317	adriamycin|adriamycin|ADR|ADR|ADR|ADR|ADR|ADR|ADR	Chemical	7:26:28:46:65:87:183:276:310	8:27:29:47:66:88:184:277:311	0:1:1:2:2:3:7:8:9	D002318	cardiovascular toxicity	Disease	40	42	1	1:NR:2	L2R	NON-CROSS	183-184	185-187	D004317	adriamycin|adriamycin|ADR|ADR|ADR|ADR|ADR|ADR|ADR	Chemical	7:26:28:46:65:87:183:276:310	8:27:29:47:66:88:184:277:311	0:1:1:2:2:3:7:8:9	D001145	cardiovascular arrhythmias	Disease	185	187	7	1:CID:2	L2R	NON-CROSS	183-184	189-190	D004317	adriamycin|adriamycin|ADR|ADR|ADR|ADR|ADR|ADR|ADR	Chemical	7:26:28:46:65:87:183:276:310	8:27:29:47:66:88:184:277:311	0:1:1:2:2:3:7:8:9	D001919	bradycardia	Disease	189	190	7	1:NR:2	L2R	NON-CROSS	183-184	226-227	D004317	adriamycin|adriamycin|ADR|ADR|ADR|ADR|ADR|ADR|ADR	Chemical	7:26:28:46:65:87:183:276:310	8:27:29:47:66:88:184:277:311	0:1:1:2:2:3:7:8:9	D004487	swelling	Disease	226	227	7
9915601	Enhanced bradycardia induced by beta - adrenoceptor antagonists in rats pretreated with isoniazid .|High doses of isoniazid increase hypotension induced by vasodilators and change the accompanying reflex tachycardia to bradycardia , an interaction attributed to decreased synthesis of brain gamma - aminobutyric acid ( GABA ) .|In the present study , the possible enhancement by isoniazid of bradycardia induced by beta - adrenoceptor antagonists was determined in rats anaesthetised with chloralose - urethane .|Isoniazid significantly increased bradycardia after propranolol , pindolol , labetalol and atenolol , as well as after clonidine , but not after hexamethonium or carbachol .|Enhancement was not observed in rats pretreated with methylatropine or previously vagotomised .|These results are compatible with interference by isoniazid with GABAergic inhibition of cardiac parasympathetic tone .|Such interference could be exerted centrally , possibly at the nucleus ambiguus , or peripherally at the sinus node .	1:CID:2	R2L	NON-CROSS	59-60	57-58	D007538	isoniazid|isoniazid|isoniazid|Isoniazid|isoniazid	Chemical	12:17:57:76:122	13:18:58:77:123	0:1:2:3:5	D001919	bradycardia|bradycardia|bradycardia|bradycardia	Disease	1:30:59:79	2:31:60:80	0:1:2:3	1:NR:2	R2L	NON-CROSS	40-44	30-31	D005680	gamma - aminobutyric acid|GABA	Chemical	40:45	44:46	1:1	D001919	bradycardia|bradycardia|bradycardia|bradycardia	Disease	1:30:59:79	2:31:60:80	0:1:2:3	1:NR:2	R2L	NON-CROSS	79-80	72-73	D002698	chloralose	Chemical	72	73	2	D001919	bradycardia|bradycardia|bradycardia|bradycardia	Disease	1:30:59:79	2:31:60:80	0:1:2:3	1:NR:2	R2L	NON-CROSS	79-80	74-75	D014520	urethane	Chemical	74	75	2	D001919	bradycardia|bradycardia|bradycardia|bradycardia	Disease	1:30:59:79	2:31:60:80	0:1:2:3	1:NR:2	R2L	NON-CROSS	81-82	79-80	D011433	propranolol	Chemical	81	82	3	D001919	bradycardia|bradycardia|bradycardia|bradycardia	Disease	1:30:59:79	2:31:60:80	0:1:2:3	1:NR:2	R2L	NON-CROSS	83-84	79-80	D010869	pindolol	Chemical	83	84	3	D001919	bradycardia|bradycardia|bradycardia|bradycardia	Disease	1:30:59:79	2:31:60:80	0:1:2:3	1:NR:2	R2L	NON-CROSS	85-86	79-80	D007741	labetalol	Chemical	85	86	3	D001919	bradycardia|bradycardia|bradycardia|bradycardia	Disease	1:30:59:79	2:31:60:80	0:1:2:3	1:NR:2	R2L	NON-CROSS	87-88	79-80	D001262	atenolol	Chemical	87	88	3	D001919	bradycardia|bradycardia|bradycardia|bradycardia	Disease	1:30:59:79	2:31:60:80	0:1:2:3	1:NR:2	R2L	NON-CROSS	93-94	79-80	D003000	clonidine	Chemical	93	94	3	D001919	bradycardia|bradycardia|bradycardia|bradycardia	Disease	1:30:59:79	2:31:60:80	0:1:2:3	1:NR:2	R2L	NON-CROSS	98-99	79-80	D018738	hexamethonium	Chemical	98	99	3	D001919	bradycardia|bradycardia|bradycardia|bradycardia	Disease	1:30:59:79	2:31:60:80	0:1:2:3	1:NR:2	R2L	NON-CROSS	100-101	79-80	D002217	carbachol	Chemical	100	101	3	D001919	bradycardia|bradycardia|bradycardia|bradycardia	Disease	1:30:59:79	2:31:60:80	0:1:2:3	1:NR:2	R2L	CROSS	110-111	79-80	C006649	methylatropine	Chemical	110	111	4	D001919	bradycardia|bradycardia|bradycardia|bradycardia	Disease	1:30:59:79	2:31:60:80	0:1:2:3	1:CID:2	L2R	NON-CROSS	17-18	19-20	D007538	isoniazid|isoniazid|isoniazid|Isoniazid|isoniazid	Chemical	12:17:57:76:122	13:18:58:77:123	0:1:2:3:5	D007022	hypotension	Disease	19	20	1	1:NR:2	L2R	NON-CROSS	17-18	28-29	D007538	isoniazid|isoniazid|isoniazid|Isoniazid|isoniazid	Chemical	12:17:57:76:122	13:18:58:77:123	0:1:2:3:5	D013610	tachycardia	Disease	28	29	1	1:NR:2	R2L	NON-CROSS	40-44	19-20	D005680	gamma - aminobutyric acid|GABA	Chemical	40:45	44:46	1:1	D007022	hypotension	Disease	19	20	1	1:NR:2	R2L	CROSS	72-73	19-20	D002698	chloralose	Chemical	72	73	2	D007022	hypotension	Disease	19	20	1	1:NR:2	R2L	CROSS	74-75	19-20	D014520	urethane	Chemical	74	75	2	D007022	hypotension	Disease	19	20	1	1:NR:2	R2L	CROSS	81-82	19-20	D011433	propranolol	Chemical	81	82	3	D007022	hypotension	Disease	19	20	1	1:NR:2	R2L	CROSS	83-84	19-20	D010869	pindolol	Chemical	83	84	3	D007022	hypotension	Disease	19	20	1	1:NR:2	R2L	CROSS	85-86	19-20	D007741	labetalol	Chemical	85	86	3	D007022	hypotension	Disease	19	20	1	1:NR:2	R2L	CROSS	87-88	19-20	D001262	atenolol	Chemical	87	88	3	D007022	hypotension	Disease	19	20	1	1:NR:2	R2L	CROSS	93-94	19-20	D003000	clonidine	Chemical	93	94	3	D007022	hypotension	Disease	19	20	1	1:NR:2	R2L	CROSS	98-99	19-20	D018738	hexamethonium	Chemical	98	99	3	D007022	hypotension	Disease	19	20	1	1:NR:2	R2L	CROSS	100-101	19-20	D002217	carbachol	Chemical	100	101	3	D007022	hypotension	Disease	19	20	1	1:NR:2	R2L	CROSS	110-111	19-20	C006649	methylatropine	Chemical	110	111	4	D007022	hypotension	Disease	19	20	1	1:NR:2	R2L	NON-CROSS	40-44	28-29	D005680	gamma - aminobutyric acid|GABA	Chemical	40:45	44:46	1:1	D013610	tachycardia	Disease	28	29	1	1:NR:2	R2L	CROSS	72-73	28-29	D002698	chloralose	Chemical	72	73	2	D013610	tachycardia	Disease	28	29	1	1:NR:2	R2L	CROSS	74-75	28-29	D014520	urethane	Chemical	74	75	2	D013610	tachycardia	Disease	28	29	1	1:NR:2	R2L	CROSS	81-82	28-29	D011433	propranolol	Chemical	81	82	3	D013610	tachycardia	Disease	28	29	1	1:NR:2	R2L	CROSS	83-84	28-29	D010869	pindolol	Chemical	83	84	3	D013610	tachycardia	Disease	28	29	1	1:NR:2	R2L	CROSS	85-86	28-29	D007741	labetalol	Chemical	85	86	3	D013610	tachycardia	Disease	28	29	1	1:NR:2	R2L	CROSS	87-88	28-29	D001262	atenolol	Chemical	87	88	3	D013610	tachycardia	Disease	28	29	1	1:NR:2	R2L	CROSS	93-94	28-29	D003000	clonidine	Chemical	93	94	3	D013610	tachycardia	Disease	28	29	1	1:NR:2	R2L	CROSS	98-99	28-29	D018738	hexamethonium	Chemical	98	99	3	D013610	tachycardia	Disease	28	29	1	1:NR:2	R2L	CROSS	100-101	28-29	D002217	carbachol	Chemical	100	101	3	D013610	tachycardia	Disease	28	29	1	1:NR:2	R2L	CROSS	110-111	28-29	C006649	methylatropine	Chemical	110	111	4	D013610	tachycardia	Disease	28	29	1
9758264	Epileptogenic activity of folic acid after drug induces SLE ( folic acid and epilepsy )|OBJECTIVE : To study the effect of folic acid - containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy - related side effects .|STUDY DESIGN : First a randomised trial , later periconception care including in total 12225 females .|RESULTS : Of 60 epileptic women with periconceptional folic acid ( 0 . 8 mg ) - containing multivitamin supplementation , no one developed epilepsy - related side effects during the periconception period .|One epileptic woman delivered a newborn with cleft lip and palate .|Another patient exhibited with a cluster of seizures after the periconception period using another multivitamin .|This 22 - year - old epileptic woman was treated continuously by carbamazepine and a folic acid ( 1 mg ) - containing multivitamin from the 20th week of gestation .|She developed status epilepticus and later symptoms of systemic lupus erythematodes .|Her pregnancy ended with stillbirth .|CONCLUSIONS : The epileptic pregnant patient 's autoimmune disease ( probably drug - induced lupus ) could damage the blood - brain barrier , therefore the therapeutic dose ( > or = 1 mg ) of folic acid triggered a cluster of seizures .|Physiological dose ( < 1 mg ) of folic acid both in healthy and 60 epileptic women , all without any autoimmune disease , did not increase the risk for epileptic seizures .	1:CID:2	L2R	NON-CROSS	8-9	10-12	D005492	folic acid|folic acid|folic acid|folic acid|folic acid|folic acid|folic acid	Chemical	3:10:22:77:146:216:232	5:12:24:79:148:218:234	0:0:1:3:6:9:10	D008180	SLE|systemic lupus erythematodes|lupus	Disease	8:170:194	9:173:195	0:7:9	1:NR:2	L2R	NON-CROSS	10-12	13-14	D005492	folic acid|folic acid|folic acid|folic acid|folic acid|folic acid|folic acid	Chemical	3:10:22:77:146:216:232	5:12:24:79:148:218:234	0:0:1:3:6:9:10	D004827	epilepsy|epileptic|epilepsy|epileptic|epilepsy|epileptic|epileptic|epileptic|epileptic|epileptic seizures	Disease	13:29:46:73:93:104:137:183:239:254	14:30:47:74:94:105:138:184:240:256	0:1:1:3:3:4:6:9:10:10	1:NR:2	L2R	NON-CROSS	22-24	43-45	D005492	folic acid|folic acid|folic acid|folic acid|folic acid|folic acid|folic acid	Chemical	3:10:22:77:146:216:232	5:12:24:79:148:218:234	0:0:1:3:6:9:10	D000014	birth defects	Disease	43	45	1	1:NR:2	L2R	CROSS	77-79	110-114	D005492	folic acid|folic acid|folic acid|folic acid|folic acid|folic acid|folic acid	Chemical	3:10:22:77:146:216:232	5:12:24:79:148:218:234	0:0:1:3:6:9:10	D002971	cleft lip and palate	Disease	110	114	4	1:NR:2	L2R	CROSS	77-79	110-114	D005492	folic acid|folic acid|folic acid|folic acid|folic acid|folic acid|folic acid	Chemical	3:10:22:77:146:216:232	5:12:24:79:148:218:234	0:0:1:3:6:9:10	D002972	cleft lip and palate	Disease	110	114	4	1:CID:2	L2R	NON-CROSS	216-218	222-223	D005492	folic acid|folic acid|folic acid|folic acid|folic acid|folic acid|folic acid	Chemical	3:10:22:77:146:216:232	5:12:24:79:148:218:234	0:0:1:3:6:9:10	D012640	seizures|seizures	Disease	122:222	123:223	5:9	1:NR:2	L2R	CROSS	146-148	164-166	D005492	folic acid|folic acid|folic acid|folic acid|folic acid|folic acid|folic acid	Chemical	3:10:22:77:146:216:232	5:12:24:79:148:218:234	0:0:1:3:6:9:10	D013226	status epilepticus	Disease	164	166	7	1:NR:2	L2R	CROSS	146-148	178-179	D005492	folic acid|folic acid|folic acid|folic acid|folic acid|folic acid|folic acid	Chemical	3:10:22:77:146:216:232	5:12:24:79:148:218:234	0:0:1:3:6:9:10	D050497	stillbirth	Disease	178	179	8	1:NR:2	L2R	NON-CROSS	232-234	245-247	D005492	folic acid|folic acid|folic acid|folic acid|folic acid|folic acid|folic acid	Chemical	3:10:22:77:146:216:232	5:12:24:79:148:218:234	0:0:1:3:6:9:10	D001327	autoimmune disease|autoimmune disease	Disease	187:245	189:247	9:10	1:NR:2	R2L	CROSS	170-173	143-144	D002220	carbamazepine	Chemical	143	144	6	D008180	SLE|systemic lupus erythematodes|lupus	Disease	8:170:194	9:173:195	0:7:9	1:NR:2	R2L	NON-CROSS	143-144	137-138	D002220	carbamazepine	Chemical	143	144	6	D004827	epilepsy|epileptic|epilepsy|epileptic|epilepsy|epileptic|epileptic|epileptic|epileptic|epileptic seizures	Disease	13:29:46:73:93:104:137:183:239:254	14:30:47:74:94:105:138:184:240:256	0:1:1:3:3:4:6:9:10:10	1:NR:2	R2L	CROSS	143-144	43-45	D002220	carbamazepine	Chemical	143	144	6	D000014	birth defects	Disease	43	45	1	1:NR:2	R2L	CROSS	143-144	110-114	D002220	carbamazepine	Chemical	143	144	6	D002971	cleft lip and palate	Disease	110	114	4	1:NR:2	R2L	CROSS	143-144	110-114	D002220	carbamazepine	Chemical	143	144	6	D002972	cleft lip and palate	Disease	110	114	4	1:NR:2	R2L	CROSS	143-144	122-123	D002220	carbamazepine	Chemical	143	144	6	D012640	seizures|seizures	Disease	122:222	123:223	5:9	1:NR:2	L2R	CROSS	143-144	164-166	D002220	carbamazepine	Chemical	143	144	6	D013226	status epilepticus	Disease	164	166	7	1:NR:2	L2R	CROSS	143-144	178-179	D002220	carbamazepine	Chemical	143	144	6	D050497	stillbirth	Disease	178	179	8	1:NR:2	L2R	CROSS	143-144	187-189	D002220	carbamazepine	Chemical	143	144	6	D001327	autoimmune disease|autoimmune disease	Disease	187:245	189:247	9:10
9669632	Effects of cisapride on symptoms and postcibal small - bowel motor function in patients with irritable bowel syndrome .|BACKGROUND : Irritable bowel syndrome is a common cause of abdominal pain and discomfort and may be related to disordered gastrointestinal motility .|Our aim was to assess the effects of long - term treatment with a prokinetic agent , cisapride , on postprandial jejunal motility and symptoms in the irritable bowel syndrome ( IBS ) .|METHODS : Thirty - eight patients with IBS ( constipation - predominant , n = 17 ; diarrhoea - predominant , n = 21 ) underwent 24 - h ambulatory jejunal manometry before and after 12 week 's treatment [ cisapride , 5 mg three times daily ( n = 19 ) or placebo ( n = 19 ) ] .|RESULTS : In diarrhoea - predominant patients significant differences in contraction characteristics were observed between the cisapride and placebo groups .|In cisapride - treated diarrhoea - predominant patients the mean contraction amplitude was higher ( 29 . 3 + / - 3 . 2 versus 24 . 9 + / - 2 . 6 mm Hg , cisapride versus placebo ( P < 0 . 001 ) ; pretreatment , 25 . 7 + / - 6 . 0 mm Hg ) , the mean contraction duration longer ( 3 . 4 + / - 0 . 2 versus 3 . 0 + / - 0 . 2 sec , cisapride versus placebo ( P < 0 . 001 ) ; pretreatment , 3 . 1 + / - 0 . 5 sec ) , and the mean contraction frequency lower ( 2 . 0 + / - 0 . 2 versus 2 . 5 + / - 0 . 4 cont . / min , cisapride versus placebo ( P < 0 . 001 ) ; pretreatment , 2 . 5 + / - 1 . 1 cont . / min ] than patients treated with placebo .|No significant differences in jejunal motility were found in the constipation - predominant IBS group .|Symptoms were assessed by using a visual analogue scale before and after treatment .|Symptom scores relating to the severity of constipation were lower in cisapride - treated constipation - predominant IBS patients [ score , 54 + / - 5 versus 67 + / - 14 mm , cisapride versus placebo ( P < 0 . 05 ) ; pretreatment , 62 + / - 19 mm ] .|Diarrhoea - predominant IBS patients had a higher pain score after cisapride therapy [ score , 55 + / - 15 versus 34 + / - 12 mm , cisapride versus placebo ( P < 0 . 05 ) ; pretreatment , 67 + / - 19 mm ] .|CONCLUSION : Cisapride affects jejunal contraction characteristics and some symptoms in IBS .	1:NR:2	L2R	NON-CROSS	378-379	384-385	D020117	cisapride|cisapride|cisapride|cisapride|cisapride|cisapride|cisapride|cisapride|cisapride|cisapride|cisapride|cisapride|Cisapride	Chemical	2:59:116:153:159:195:248:304:378:402:434:452:475	3:60:117:154:160:196:249:305:379:403:435:453:476	0:2:3:4:5:5:5:5:8:8:9:9:10	D043183	irritable bowel syndrome|Irritable bowel syndrome|irritable bowel syndrome|IBS|IBS|IBS|IBS|IBS|IBS	Disease	15:21:69:73:83:350:384:426:484	18:24:72:74:84:351:385:427:485	0:1:2:2:3:6:8:9:10	1:CID:2	L2R	CROSS	2-3	29-31	D020117	cisapride|cisapride|cisapride|cisapride|cisapride|cisapride|cisapride|cisapride|cisapride|cisapride|cisapride|cisapride|Cisapride	Chemical	2:59:116:153:159:195:248:304:378:402:434:452:475	3:60:117:154:160:196:249:305:379:403:435:453:476	0:2:3:4:5:5:5:5:8:8:9:9:10	D015746	abdominal pain	Disease	29	31	1	1:NR:2	L2R	CROSS	38-41	59-60	D020117	cisapride|cisapride|cisapride|cisapride|cisapride|cisapride|cisapride|cisapride|cisapride|cisapride|cisapride|cisapride|Cisapride	Chemical	2:59:116:153:159:195:248:304:378:402:434:452:475	3:60:117:154:160:196:249:305:379:403:435:453:476	0:2:3:4:5:5:5:5:8:8:9:9:10	D005767	disordered gastrointestinal motility	Disease	38	41	1	1:NR:2	L2R	NON-CROSS	378-379	381-382	D020117	cisapride|cisapride|cisapride|cisapride|cisapride|cisapride|cisapride|cisapride|cisapride|cisapride|cisapride|cisapride|Cisapride	Chemical	2:59:116:153:159:195:248:304:378:402:434:452:475	3:60:117:154:160:196:249:305:379:403:435:453:476	0:2:3:4:5:5:5:5:8:8:9:9:10	D003248	constipation|constipation|constipation|constipation	Disease	85:347:374:381	86:348:375:382	3:6:8:8	1:NR:2	L2R	NON-CROSS	159-160	162-163	D020117	cisapride|cisapride|cisapride|cisapride|cisapride|cisapride|cisapride|cisapride|cisapride|cisapride|cisapride|cisapride|Cisapride	Chemical	2:59:116:153:159:195:248:304:378:402:434:452:475	3:60:117:154:160:196:249:305:379:403:435:453:476	0:2:3:4:5:5:5:5:8:8:9:9:10	D003967	diarrhoea|diarrhoea|diarrhoea|Diarrhoea	Disease	93:140:162:423	94:141:163:424	3:4:5:9	1:NR:2	L2R	NON-CROSS	431-432	434-435	D020117	cisapride|cisapride|cisapride|cisapride|cisapride|cisapride|cisapride|cisapride|cisapride|cisapride|cisapride|cisapride|Cisapride	Chemical	2:59:116:153:159:195:248:304:378:402:434:452:475	3:60:117:154:160:196:249:305:379:403:435:453:476	0:2:3:4:5:5:5:5:8:8:9:9:10	D010146	pain	Disease	431	432	9
9326871	Clarithromycin - induced ventricular tachycardia .|Clarithromycin is a relatively new macrolide antibiotic that offers twice - daily dosing .|It differs from erythromycin only in the methylation of the hydroxyl group at position 6 .|Although the side - effect profile of erythromycin is established , including gastroenteritis and interactions with other drugs subject to hepatic mixed - function oxidase metabolism , experience with the newer macrolides is still being recorded .|Cardiotoxicity has been demonstrated after both intravenous and oral administration of erythromycin but has never been reported with the newer macrolides .|We report a case of ventricular dysrhythmias that occurred after six therapeutic doses of clarithromycin .|The dysrhythmias resolved after discontinuation of the drug .	1:CID:2	L2R	NON-CROSS	3-5	6-7	D017291	Clarithromycin|Clarithromycin|clarithromycin	Chemical	0:6:109	1:7:110	0:1:5	D017180	ventricular tachycardia	Disease	3	5	0	1:NR:2	L2R	CROSS	6-7	48-49	D017291	Clarithromycin|Clarithromycin|clarithromycin	Chemical	0:6:109	1:7:110	0:1:5	D005759	gastroenteritis	Disease	48	49	3	1:NR:2	L2R	CROSS	73-74	109-110	D017291	Clarithromycin|Clarithromycin|clarithromycin	Chemical	0:6:109	1:7:110	0:1:5	D066126	Cardiotoxicity	Disease	73	74	4	1:NR:2	L2R	NON-CROSS	109-110	112-113	D017291	Clarithromycin|Clarithromycin|clarithromycin	Chemical	0:6:109	1:7:110	0:1:5	D001145	ventricular dysrhythmias|dysrhythmias	Disease	100:112	102:113	5:6	1:NR:2	R2L	CROSS	11-12	3-5	D018942	macrolide|macrolides|macrolides	Chemical	11:67:93	12:68:94	1:3:4	D017180	ventricular tachycardia	Disease	3	5	0	1:NR:2	R2L	CROSS	23-24	3-5	D004917	erythromycin|erythromycin|erythromycin	Chemical	23:43:84	24:44:85	2:3:4	D017180	ventricular tachycardia	Disease	3	5	0	1:NR:2	L2R	NON-CROSS	48-49	67-68	D018942	macrolide|macrolides|macrolides	Chemical	11:67:93	12:68:94	1:3:4	D005759	gastroenteritis	Disease	48	49	3	1:NR:2	L2R	NON-CROSS	67-68	73-74	D018942	macrolide|macrolides|macrolides	Chemical	11:67:93	12:68:94	1:3:4	D066126	Cardiotoxicity	Disease	73	74	4	1:NR:2	L2R	CROSS	93-94	100-102	D018942	macrolide|macrolides|macrolides	Chemical	11:67:93	12:68:94	1:3:4	D001145	ventricular dysrhythmias|dysrhythmias	Disease	100:112	102:113	5:6	1:CID:2	L2R	NON-CROSS	43-44	48-49	D004917	erythromycin|erythromycin|erythromycin	Chemical	23:43:84	24:44:85	2:3:4	D005759	gastroenteritis	Disease	48	49	3	1:NR:2	L2R	NON-CROSS	73-74	84-85	D004917	erythromycin|erythromycin|erythromycin	Chemical	23:43:84	24:44:85	2:3:4	D066126	Cardiotoxicity	Disease	73	74	4	1:NR:2	L2R	CROSS	84-85	100-102	D004917	erythromycin|erythromycin|erythromycin	Chemical	23:43:84	24:44:85	2:3:4	D001145	ventricular dysrhythmias|dysrhythmias	Disease	100:112	102:113	5:6
9226773	Persistent nephrogenic diabetes insipidus following lithium therapy .|We report the case of a patient who developed severe hypernatraemic dehydration following a head injury .|Ten years previously he had been diagnosed to have lithium - induced nephrogenic diabetes insipidus , and lithium therapy had been discontinued .|He remained thirsty and polyuric despite cessation of lithium and investigations on admission showed him to have normal osmoregulated thirst and vasopressin secretion , with clear evidence of nephrogenic diabetes insipidus .|Lithium induced nephrogenic diabetes insipidus is considered to be reversible on cessation of therapy but polyuria persisted in this patient for ten years after lithium was stopped .|We discuss the possible renal mechanisms and the implications for management of patients with lithium - induced nephrogenic diabetes insipidus .	1:CID:2	R2L	NON-CROSS	5-6	1-4	D008094	lithium|lithium|lithium|lithium|Lithium|lithium|lithium	Chemical	5:34:42:56:80:104:122	6:35:43:57:81:105:123	0:2:2:3:4:4:5	D018500	nephrogenic diabetes insipidus|nephrogenic diabetes insipidus|nephrogenic diabetes insipidus|nephrogenic diabetes insipidus|nephrogenic diabetes insipidus	Disease	1:37:76:82:125	4:40:79:85:128	0:2:3:4:5	1:NR:2	R2L	NON-CROSS	76-79	69-70	D014667	vasopressin	Chemical	69	70	3	D018500	nephrogenic diabetes insipidus|nephrogenic diabetes insipidus|nephrogenic diabetes insipidus|nephrogenic diabetes insipidus|nephrogenic diabetes insipidus	Disease	1:37:76:82:125	4:40:79:85:128	0:2:3:4:5	1:NR:2	L2R	CROSS	5-6	19-20	D008094	lithium|lithium|lithium|lithium|Lithium|lithium|lithium	Chemical	5:34:42:56:80:104:122	6:35:43:57:81:105:123	0:2:2:3:4:4:5	D003681	dehydration	Disease	19	20	1	1:NR:2	L2R	CROSS	22-24	34-35	D008094	lithium|lithium|lithium|lithium|Lithium|lithium|lithium	Chemical	5:34:42:56:80:104:122	6:35:43:57:81:105:123	0:2:2:3:4:4:5	D006259	head injury	Disease	22	24	1	1:CID:2	L2R	NON-CROSS	52-53	56-57	D008094	lithium|lithium|lithium|lithium|Lithium|lithium|lithium	Chemical	5:34:42:56:80:104:122	6:35:43:57:81:105:123	0:2:2:3:4:4:5	D011141	polyuric|polyuria	Disease	52:95	53:96	3:4	1:NR:2	R2L	CROSS	69-70	19-20	D014667	vasopressin	Chemical	69	70	3	D003681	dehydration	Disease	19	20	1	1:NR:2	R2L	CROSS	69-70	22-24	D014667	vasopressin	Chemical	69	70	3	D006259	head injury	Disease	22	24	1	1:NR:2	R2L	NON-CROSS	69-70	52-53	D014667	vasopressin	Chemical	69	70	3	D011141	polyuric|polyuria	Disease	52:95	53:96	3:4
8600333	Late cardiotoxicity after treatment for a malignant bone tumor .|Cardiac function was assessed in long - term survivors of malignant bone tumors who were treated according to Rosen 's T5 or T10 protocol , both including doxorubicin .|Thirty - one patients , age 10 - 45 years ( median age 17 . 8 years ) were evaluated 2 . 3 - 14 . 1 years ( median 8 . 9 years ) following completion of treatment .|Cumulative doses of doxorubicin were 225 - 550 mg / m2 ( median dose 360 ) .|The evaluation consisted of a history , physical examination , electrocardiogram ( ECG ) , signal averaged ECG , 24 - hour ambulatory ECG , echocardiography and radionuclide angiography .|Eighteen of 31 ( 58 % ) patients showed cardiac toxicity , defined as having one or more of the following abnormalities : late potentials , complex ventricular arrhythmias , left ventricular dilation , decreased shortening fraction , or decreased ejection fraction .|The incidence of cardiac abnormalities increased with length of follow - up ( P < or = . 05 ) .|No correlation could be demonstrated between cumulative dose of doxorubicin and cardiac status , except for heart rate variability .|When adjusted to body surface area , the left ventricular posterior wall thickness ( LVPW index ) was decreased in all patients .|The incidence of doxorubicin - induced cardiotoxicity is high and increases with follow - up , irrespective of cumulative dose .|Life - long cardiac follow - up in these patients is warranted .|The results of our study suggest that heart rate variability and LVPW index could be sensitive indicators for cardiotoxicity .	1:NR:2	R2L	CROSS	28-34	1-2	C053519	Rosen 's T5 or T10 protocol	Chemical	28	34	1	D066126	cardiotoxicity|cardiac toxicity|cardiotoxicity|cardiotoxicity	Disease	1:135:239:285	2:137:240:286	0:5:9:11	1:NR:2	R2L	NON-CROSS	239-240	236-237	D004317	doxorubicin|doxorubicin|doxorubicin|doxorubicin	Chemical	37:82:199:236	38:83:200:237	1:3:7:9	D066126	cardiotoxicity|cardiac toxicity|cardiotoxicity|cardiotoxicity	Disease	1:135:239:285	2:137:240:286	0:5:9:11	1:NR:2	R2L	NON-CROSS	28-34	21-23	C053519	Rosen 's T5 or T10 protocol	Chemical	28	34	1	D001859	bone tumor|bone tumors	Disease	7:21	9:23	0:1	1:NR:2	R2L	NON-CROSS	37-38	21-23	D004317	doxorubicin|doxorubicin|doxorubicin|doxorubicin	Chemical	37:82:199:236	38:83:200:237	1:3:7:9	D001859	bone tumor|bone tumors	Disease	7:21	9:23	0:1	1:NR:2	L2R	CROSS	28-34	153-155	C053519	Rosen 's T5 or T10 protocol	Chemical	28	34	1	D001145	ventricular arrhythmias	Disease	153	155	5	1:NR:2	L2R	CROSS	28-34	157-159	C053519	Rosen 's T5 or T10 protocol	Chemical	28	34	1	D002311	ventricular dilation	Disease	157	159	5	1:NR:2	L2R	CROSS	28-34	172-174	C053519	Rosen 's T5 or T10 protocol	Chemical	28	34	1	D006331	cardiac abnormalities	Disease	172	174	6	1:NR:2	L2R	CROSS	153-155	199-200	D004317	doxorubicin|doxorubicin|doxorubicin|doxorubicin	Chemical	37:82:199:236	38:83:200:237	1:3:7:9	D001145	ventricular arrhythmias	Disease	153	155	5	1:NR:2	L2R	CROSS	157-159	199-200	D004317	doxorubicin|doxorubicin|doxorubicin|doxorubicin	Chemical	37:82:199:236	38:83:200:237	1:3:7:9	D002311	ventricular dilation	Disease	157	159	5	1:CID:2	L2R	CROSS	172-174	199-200	D004317	doxorubicin|doxorubicin|doxorubicin|doxorubicin	Chemical	37:82:199:236	38:83:200:237	1:3:7:9	D006331	cardiac abnormalities	Disease	172	174	6
8514073	Venous complications of midazolam versus diazepam .|Although some studies have suggested fewer venous complications are associated with midazolam than with diazepam for endoscopic procedures , this variable has not been well documented .|We prospectively evaluated the incidence of venous complications after intravenous injection of diazepam or midazolam in 122 consecutive patients undergoing colonoscopy and esophagogastroduodenoscopy .|Overall , venous complications were more frequent with diazepam ( 22 of 62 patients ) than with midazolam ( 4 of 60 patients ) ( p < 0 . 001 ) .|A palpable venous cord was present in 23 % ( 14 of 62 ) of patients in the diazepam group , compared with 2 % ( 1 of 60 patients ) in the midazolam group ( p < 0 . 002 ) .|Pain at the injection site occurred in 35 % ( 22 of 62 ) of patients in the diazepam group compared with 7 % ( 4 of 60 patients ) in the midazolam group ( p < 0 . 001 ) .|Swelling and warmth at the injection site were not significantly different between the two groups .|Smoking , nonsteroidal anti - inflammatory drug use , intravenous catheter site , dwell time of the needle , alcohol use , and pain during the injection had no effect on the incidence of venous complications .	1:CID:2	R2L	NON-CROSS	3-4	0-2	D008874	midazolam|midazolam|midazolam|midazolam|midazolam|midazolam	Chemical	3:18:48:75:123:165	4:19:49:76:124:166	0:1:2:3:4:5	D014652	Venous complications|venous complications|venous complications|venous complications|venous complications	Disease	0:13:40:60:225	2:15:42:62:227	0:1:2:3:7	1:CID:2	R2L	NON-CROSS	5-6	0-2	D003975	diazepam|diazepam|diazepam|diazepam|diazepam|diazepam	Chemical	5:21:46:66:108:151	6:22:47:67:109:152	0:1:2:3:4:5	D014652	Venous complications|venous complications|venous complications|venous complications|venous complications	Disease	0:13:40:60:225	2:15:42:62:227	0:1:2:3:7	1:NR:2	R2L	NON-CROSS	225-227	210-211	D000431	alcohol	Chemical	210	211	7	D014652	Venous complications|venous complications|venous complications|venous complications|venous complications	Disease	0:13:40:60:225	2:15:42:62:227	0:1:2:3:7	1:NR:2	L2R	NON-CROSS	123-124	133-134	D008874	midazolam|midazolam|midazolam|midazolam|midazolam|midazolam	Chemical	3:18:48:75:123:165	4:19:49:76:124:166	0:1:2:3:4:5	D010146	Pain|pain	Disease	133:214	134:215	5:7	1:NR:2	L2R	CROSS	165-166	175-176	D008874	midazolam|midazolam|midazolam|midazolam|midazolam|midazolam	Chemical	3:18:48:75:123:165	4:19:49:76:124:166	0:1:2:3:4:5	D004487	Swelling	Disease	175	176	6	1:NR:2	L2R	NON-CROSS	133-134	151-152	D003975	diazepam|diazepam|diazepam|diazepam|diazepam|diazepam	Chemical	5:21:46:66:108:151	6:22:47:67:109:152	0:1:2:3:4:5	D010146	Pain|pain	Disease	133:214	134:215	5:7	1:NR:2	L2R	CROSS	151-152	175-176	D003975	diazepam|diazepam|diazepam|diazepam|diazepam|diazepam	Chemical	5:21:46:66:108:151	6:22:47:67:109:152	0:1:2:3:4:5	D004487	Swelling	Disease	175	176	6	1:NR:2	R2L	NON-CROSS	214-215	210-211	D000431	alcohol	Chemical	210	211	7	D010146	Pain|pain	Disease	133:214	134:215	5:7	1:NR:2	R2L	CROSS	210-211	175-176	D000431	alcohol	Chemical	210	211	7	D004487	Swelling	Disease	175	176	6
8492347	Tetany and rhabdomyolysis due to surreptitious furosemide - - importance of magnesium supplementation .|Diuretics may induce hypokalemia , hypocalcemia and hypomagnesemia .|While severe hypokalemia may cause muscle weakness , severe hypomagnesemia is associated with muscle spasms and tetany which can not be corrected by potassium and calcium supplementation alone ( 1 , 2 ) .|Surreptitious diuretic ingestion has been described , mainly in women who are concerned that they are obese or edematous .|Symptomatic hypokalemia has been reported in such patients ( 3 - 7 ) and in one case hypocalcemia was observed ( 8 ) , but the effects of magnesium depletion were not noted in these patients .	1:CID:2	R2L	NON-CROSS	6-7	0-1	D005665	furosemide	Chemical	6	7	0	D013746	Tetany|tetany	Disease	0:39	1:40	0:2	1:NR:2	R2L	NON-CROSS	11-12	0-1	D008274	magnesium|magnesium	Chemical	11:105	12:106	0:4	D013746	Tetany|tetany	Disease	0:39	1:40	0:2	1:NR:2	R2L	NON-CROSS	46-47	39-40	D011188	potassium	Chemical	46	47	2	D013746	Tetany|tetany	Disease	0:39	1:40	0:2	1:NR:2	R2L	NON-CROSS	48-49	39-40	D002118	calcium	Chemical	48	49	2	D013746	Tetany|tetany	Disease	0:39	1:40	0:2	1:CID:2	R2L	NON-CROSS	6-7	2-3	D005665	furosemide	Chemical	6	7	0	D012206	rhabdomyolysis	Disease	2	3	0	1:NR:2	R2L	NON-CROSS	11-12	2-3	D008274	magnesium|magnesium	Chemical	11:105	12:106	0:4	D012206	rhabdomyolysis	Disease	2	3	0	1:NR:2	R2L	CROSS	46-47	2-3	D011188	potassium	Chemical	46	47	2	D012206	rhabdomyolysis	Disease	2	3	0	1:NR:2	R2L	CROSS	48-49	2-3	D002118	calcium	Chemical	48	49	2	D012206	rhabdomyolysis	Disease	2	3	0	1:NR:2	L2R	CROSS	6-7	17-18	D005665	furosemide	Chemical	6	7	0	D007008	hypokalemia|hypokalemia|hypokalemia	Disease	17:25:78	18:26:79	1:2:4	1:NR:2	L2R	CROSS	6-7	19-20	D005665	furosemide	Chemical	6	7	0	D006996	hypocalcemia|hypocalcemia	Disease	19:94	20:95	1:4	1:NR:2	L2R	CROSS	6-7	21-22	D005665	furosemide	Chemical	6	7	0	C537153	hypomagnesemia|hypomagnesemia	Disease	21:32	22:33	1:2	1:NR:2	L2R	CROSS	6-7	28-30	D005665	furosemide	Chemical	6	7	0	D018908	muscle weakness	Disease	28	30	2	1:NR:2	L2R	CROSS	6-7	36-38	D005665	furosemide	Chemical	6	7	0	D013035	muscle spasms	Disease	36	38	2	1:NR:2	L2R	CROSS	6-7	73-74	D005665	furosemide	Chemical	6	7	0	D009765	obese	Disease	73	74	3	1:NR:2	L2R	CROSS	6-7	75-76	D005665	furosemide	Chemical	6	7	0	D004487	edematous	Disease	75	76	3	1:NR:2	L2R	NON-CROSS	11-12	17-18	D008274	magnesium|magnesium	Chemical	11:105	12:106	0:4	D007008	hypokalemia|hypokalemia|hypokalemia	Disease	17:25:78	18:26:79	1:2:4	1:NR:2	L2R	NON-CROSS	11-12	19-20	D008274	magnesium|magnesium	Chemical	11:105	12:106	0:4	D006996	hypocalcemia|hypocalcemia	Disease	19:94	20:95	1:4	1:NR:2	L2R	CROSS	11-12	21-22	D008274	magnesium|magnesium	Chemical	11:105	12:106	0:4	C537153	hypomagnesemia|hypomagnesemia	Disease	21:32	22:33	1:2	1:NR:2	L2R	CROSS	11-12	28-30	D008274	magnesium|magnesium	Chemical	11:105	12:106	0:4	D018908	muscle weakness	Disease	28	30	2	1:NR:2	L2R	CROSS	11-12	36-38	D008274	magnesium|magnesium	Chemical	11:105	12:106	0:4	D013035	muscle spasms	Disease	36	38	2	1:NR:2	L2R	CROSS	73-74	105-106	D008274	magnesium|magnesium	Chemical	11:105	12:106	0:4	D009765	obese	Disease	73	74	3	1:NR:2	L2R	CROSS	75-76	105-106	D008274	magnesium|magnesium	Chemical	11:105	12:106	0:4	D004487	edematous	Disease	75	76	3	1:NR:2	R2L	NON-CROSS	46-47	25-26	D011188	potassium	Chemical	46	47	2	D007008	hypokalemia|hypokalemia|hypokalemia	Disease	17:25:78	18:26:79	1:2:4	1:NR:2	R2L	NON-CROSS	48-49	25-26	D002118	calcium	Chemical	48	49	2	D007008	hypokalemia|hypokalemia|hypokalemia	Disease	17:25:78	18:26:79	1:2:4	1:NR:2	R2L	CROSS	46-47	19-20	D011188	potassium	Chemical	46	47	2	D006996	hypocalcemia|hypocalcemia	Disease	19:94	20:95	1:4	1:NR:2	R2L	CROSS	48-49	19-20	D002118	calcium	Chemical	48	49	2	D006996	hypocalcemia|hypocalcemia	Disease	19:94	20:95	1:4	1:NR:2	R2L	NON-CROSS	46-47	32-33	D011188	potassium	Chemical	46	47	2	C537153	hypomagnesemia|hypomagnesemia	Disease	21:32	22:33	1:2	1:NR:2	R2L	NON-CROSS	48-49	32-33	D002118	calcium	Chemical	48	49	2	C537153	hypomagnesemia|hypomagnesemia	Disease	21:32	22:33	1:2	1:NR:2	R2L	NON-CROSS	46-47	28-30	D011188	potassium	Chemical	46	47	2	D018908	muscle weakness	Disease	28	30	2	1:NR:2	R2L	NON-CROSS	48-49	28-30	D002118	calcium	Chemical	48	49	2	D018908	muscle weakness	Disease	28	30	2	1:NR:2	R2L	NON-CROSS	46-47	36-38	D011188	potassium	Chemical	46	47	2	D013035	muscle spasms	Disease	36	38	2	1:NR:2	R2L	NON-CROSS	48-49	36-38	D002118	calcium	Chemical	48	49	2	D013035	muscle spasms	Disease	36	38	2	1:NR:2	L2R	CROSS	46-47	73-74	D011188	potassium	Chemical	46	47	2	D009765	obese	Disease	73	74	3	1:NR:2	L2R	CROSS	46-47	75-76	D011188	potassium	Chemical	46	47	2	D004487	edematous	Disease	75	76	3	1:NR:2	L2R	CROSS	48-49	73-74	D002118	calcium	Chemical	48	49	2	D009765	obese	Disease	73	74	3	1:NR:2	L2R	CROSS	48-49	75-76	D002118	calcium	Chemical	48	49	2	D004487	edematous	Disease	75	76	3
8410199	Loss of glutamate decarboxylase mRNA - containing neurons in the rat dentate gyrus following pilocarpine - induced seizures .|In situ hybridization methods were used to determine if glutamic acid decarboxylase ( GAD ) mRNA - containing neurons within the hilus of the dentate gyrus are vulnerable to seizure - induced damage in a model of chronic seizures .|Sprague - Dawley rats were injected intraperitoneally with pilocarpine , and the hippocampal formation was studied histologically at 1 , 2 , 4 , and 8 week intervals after pilocarpine - induced seizures .|In situ hybridization histochemistry , using a digoxigenin - labeled GAD cRNA probe , demonstrated a substantial decrease in the number of GAD mRNA - containing neurons in the hilus of the dentate gyrus in the pilocarpine - treated rats as compared to controls at all time intervals .|Additional neuronanatomical studies , including cresyl violet staining , neuronal degeneration methods , and histochemical localization of glial fibrillary acidic protein , suggested that the decrease in the number of GAD mRNA - containing neurons was related to neuronal loss rather than to a decrease in GAD mRNA levels .|The loss of GAD mRNA - containing neurons in the hilus contrasted with the relative preservation of labeled putative basket cells along the inner margin of the granule cell layer .|Quantitative analyses of labeled neurons in three regions of the dentate gyrus in the 1 and 2 week groups showed statistically significant decreases in the mean number of GAD mRNA - containing neurons in the hilus of both groups of experimental animals .|No significant differences were found in the molecular layer or the granule cell layer , which included labeled neurons along the lower margin of the granule cell layer .|The results indicate that , in this model , a subpopulation of GAD mRNA - containing neurons within the dentate gyrus is selectively vulnerable to seizure - induced damage .|Such differential vulnerability appears to be another indication of the heterogeneity of GABA neurons .	1:NR:2	L2R	NON-CROSS	17-18	28-30	D018698	glutamate|glutamic acid	Chemical	2:28	3:30	0:1	D012640	seizures|seizure|seizures|seizures|seizure	Disease	17:48:57:91:320	18:49:58:92:321	0:1:1:2:8	1:NR:2	L2R	CROSS	28-30	151-153	D018698	glutamate|glutamic acid	Chemical	2:28	3:30	0:1	D009410	neuronal degeneration|neuronal loss	Disease	151:180	153:182	4:4	1:CID:2	L2R	NON-CROSS	14-15	17-18	D010862	pilocarpine|pilocarpine|pilocarpine|pilocarpine	Chemical	14:67:88:129	15:68:89:130	0:2:2:3	D012640	seizures|seizure|seizures|seizures|seizure	Disease	17:48:57:91:320	18:49:58:92:321	0:1:1:2:8	1:CID:2	L2R	CROSS	129-130	151-153	D010862	pilocarpine|pilocarpine|pilocarpine|pilocarpine	Chemical	14:67:88:129	15:68:89:130	0:2:2:3	D009410	neuronal degeneration|neuronal loss	Disease	151:180	153:182	4:4	1:NR:2	R2L	CROSS	100-101	91-92	D004076	digoxigenin	Chemical	100	101	3	D012640	seizures|seizure|seizures|seizures|seizure	Disease	17:48:57:91:320	18:49:58:92:321	0:1:1:2:8	1:NR:2	R2L	CROSS	147-149	91-92	C028911	cresyl violet	Chemical	147	149	4	D012640	seizures|seizure|seizures|seizures|seizure	Disease	17:48:57:91:320	18:49:58:92:321	0:1:1:2:8	1:NR:2	R2L	CROSS	337-338	320-321	D005680	GABA	Chemical	337	338	9	D012640	seizures|seizure|seizures|seizures|seizure	Disease	17:48:57:91:320	18:49:58:92:321	0:1:1:2:8	1:NR:2	L2R	CROSS	100-101	151-153	D004076	digoxigenin	Chemical	100	101	3	D009410	neuronal degeneration|neuronal loss	Disease	151:180	153:182	4:4	1:NR:2	L2R	NON-CROSS	147-149	151-153	C028911	cresyl violet	Chemical	147	149	4	D009410	neuronal degeneration|neuronal loss	Disease	151:180	153:182	4:4	1:NR:2	R2L	CROSS	337-338	180-182	D005680	GABA	Chemical	337	338	9	D009410	neuronal degeneration|neuronal loss	Disease	151:180	153:182	4:4
7791169	Protective effect of misoprostol on indomethacin induced renal dysfunction in elderly patients .|OBJECTIVE : To evaluate the possible protective effects of misoprostol on renal function in hospitalized elderly patients treated with indomethacin .|METHODS : Forty - five hospitalized elderly patients ( > 65 years old ) who required therapy with nonsteroidal antiinflammatory drugs ( NSAID ) were randomly assigned to receive either indomethacin , 150 mg / day ( Group A ) , or indomethacin 150 mg / day plus misoprostol at 0 . 6 mg / day ( Group B ) .|Laboratory variables of renal function [ serum creatinine , blood urea nitrogen ( BUN ) and electrolytes ] were evaluated before initiation of therapy and every 2 days , until termination of the study ( a period of at least 6 days ) .|Response to treatment was estimated by the visual analog scale for severity of pain .|RESULTS : Forty - two patients completed the study , 22 in Group A and 20 in Group B .|BUN and creatinine increased by > 50 % of baseline levels in 54 and 45 % of Group A patients , respectively , compared to only 20 and 10 % of Group B patients ( p < 0 . 05 ) .|Potassium ( K ) increment of 0 . 6 mEq / l or more was observed in 50 % of Group A , but in only 15 % of Group B patients ( p < 0 . 05 ) .|The mean increments in BUN , creatinine , and K were reduced by 63 , 80 , and 42 % , respectively , in Group B patients compared to Group A .|Response to treatment did not differ significantly between the 2 groups .|CONCLUSION : Hospitalized elderly patients are at risk for developing indomethacin related renal dysfunction .|Addition of misoprostol can minimize this renal impairment without affecting pain control .	1:NR:2	L2R	NON-CROSS	3-4	7-9	D016595	misoprostol|misoprostol|misoprostol|misoprostol	Chemical	3:22:82:317	4:23:83:318	0:1:2:11	D007674	renal dysfunction|renal dysfunction|renal impairment	Disease	7:312:321	9:314:323	0:10:11	1:NR:2	L2R	NON-CROSS	317-318	325-326	D016595	misoprostol|misoprostol|misoprostol|misoprostol	Chemical	3:22:82:317	4:23:83:318	0:1:2:11	D010146	pain|pain	Disease	152:325	153:326	4:11	1:CID:2	L2R	NON-CROSS	5-6	7-9	D007213	indomethacin|indomethacin|indomethacin|indomethacin|indomethacin	Chemical	5:32:64:76:310	6:33:65:77:311	0:1:2:2:10	D007674	renal dysfunction|renal dysfunction|renal impairment	Disease	7:312:321	9:314:323	0:10:11	1:NR:2	L2R	CROSS	310-311	325-326	D007213	indomethacin|indomethacin|indomethacin|indomethacin|indomethacin	Chemical	5:32:64:76:310	6:33:65:77:311	0:1:2:2:10	D010146	pain|pain	Disease	152:325	153:326	4:11	1:NR:2	R2L	CROSS	312-314	262-263	D003404	creatinine|creatinine|creatinine	Chemical	102:176:262	103:177:263	3:6:8	D007674	renal dysfunction|renal dysfunction|renal impairment	Disease	7:312:321	9:314:323	0:10:11	1:NR:2	R2L	CROSS	312-314	260-261	D001806	blood urea nitrogen|BUN|BUN|BUN	Chemical	104:108:174:260	107:109:175:261	3:3:6:8	D007674	renal dysfunction|renal dysfunction|renal impairment	Disease	7:312:321	9:314:323	0:10:11	1:NR:2	R2L	CROSS	312-314	265-266	D011188	Potassium|K|K	Chemical	216:218:265	217:219:266	7:7:8	D007674	renal dysfunction|renal dysfunction|renal impairment	Disease	7:312:321	9:314:323	0:10:11	1:NR:2	L2R	CROSS	152-153	176-177	D003404	creatinine|creatinine|creatinine	Chemical	102:176:262	103:177:263	3:6:8	D010146	pain|pain	Disease	152:325	153:326	4:11	1:NR:2	L2R	CROSS	152-153	174-175	D001806	blood urea nitrogen|BUN|BUN|BUN	Chemical	104:108:174:260	107:109:175:261	3:3:6:8	D010146	pain|pain	Disease	152:325	153:326	4:11	1:NR:2	R2L	CROSS	325-326	265-266	D011188	Potassium|K|K	Chemical	216:218:265	217:219:266	7:7:8	D010146	pain|pain	Disease	152:325	153:326	4:11
6728084	Nephrotoxic effects of aminoglycoside treatment on renal protein reabsorption and accumulation .|To quantify the effects of gentamicin , kanamycin and netilmicin on renal protein reabsorption and accumulation , these drugs were administered to rats intraperitoneally ( 30 mg / kg / day ) for 7 , 14 or 21 days .|Scanning electron microscopy of the glomerular endothelia , urinary measurements of sodium , potassium , endogenous lysozyme , N - acetyl - beta - D - glucosaminidase ( NAG ) as well as clearance and accumulation experiments after i . v .|administration of egg - white lysozyme and measurements of inulin clearance ( GFR ) were done in each treatment group .|Gentamicin administration decreased diameter , density and shape of endothelial fenestrae .|Kanamycin and netilmicin appeared to have no effect at the dose used .|All three aminoglycosides decreased GFR and increased urinary excretion of sodium and potassium .|While gentamicin and kanamycin decreased the percentage reabsorption and accumulation of lysozyme after i . v .|administration of egg - white lysozyme netilmicin had no effect .|Daily excretion of total protein , endogenous lysozyme and NAG increased only after treatment with kanamycin and gentamicin .|Thus , aminoglycosides may act as nephrotoxicants at glomerular and / or tubular level inducing impairment of renal reabsorption and accumulation of proteins .	1:NR:2	R2L	NON-CROSS	3-4	0-1	D000617	aminoglycoside|aminoglycosides|aminoglycosides	Chemical	3:142:203	4:143:204	0:6:10	D007674	Nephrotoxic|impairment of renal reabsorption	Disease	0:216	1:220	0:10	1:CID:2	R2L	CROSS	17-18	0-1	D005839	gentamicin|Gentamicin|gentamicin|gentamicin	Chemical	17:115:155:199	18:116:156:200	1:4:7:9	D007674	Nephrotoxic|impairment of renal reabsorption	Disease	0:216	1:220	0:10	1:CID:2	R2L	CROSS	19-20	0-1	D007612	kanamycin|Kanamycin|kanamycin|kanamycin	Chemical	19:127:157:197	20:128:158:198	1:5:7:9	D007674	Nephrotoxic|impairment of renal reabsorption	Disease	0:216	1:220	0:10	1:NR:2	R2L	CROSS	21-22	0-1	D009428	netilmicin|netilmicin|netilmicin	Chemical	21:129:177	22:130:178	1:5:8	D007674	Nephrotoxic|impairment of renal reabsorption	Disease	0:216	1:220	0:10	1:NR:2	R2L	CROSS	63-64	0-1	D012964	sodium|sodium	Chemical	63:150	64:151	2:6	D007674	Nephrotoxic|impairment of renal reabsorption	Disease	0:216	1:220	0:10	1:NR:2	R2L	CROSS	216-220	152-153	D011188	potassium|potassium	Chemical	65:152	66:153	2:6	D007674	Nephrotoxic|impairment of renal reabsorption	Disease	0:216	1:220	0:10
6111982	Pharmacology of GYKI - 41 099 ( chlorpropanol , Tobanum ) a new potent beta - adrenergic antagonist .|The compound GYKI - 41 099 , as a beta - adrenergic antagonist , is 3 - 8 times more potent than propranolol in vitro and in vivo .|Its antiarrhythmic effectiveness surpasses that of propranolol and pindolol inhibiting the ouabain arrhythmia in dogs and cats .|GYKI - 41 900 has a negligible cardiodepressant activity ; it is not cardioselective .|The compound shows a rapid and long lasting effect .|There was a prolonged elimination of the radioactivity after the injection of 14C - 41 099 to rats and dogs .|The half life of the unlabeled substance in humans was more than 10 hours .	1:NR:2	L2R	CROSS	21-25	60-61	C025725	GYKI - 41 099|chlorpropanol|Tobanum|GYKI - 41 099	Chemical	2:7:9:21	6:8:10:25	0:0:0:1	D001145	arrhythmia	Disease	60	61	2	1:NR:2	L2R	NON-CROSS	54-55	60-61	D011433	propranolol|propranolol	Chemical	41:54	42:55	1:2	D001145	arrhythmia	Disease	60	61	2	1:NR:2	L2R	NON-CROSS	56-57	60-61	D010869	pindolol	Chemical	56	57	2	D001145	arrhythmia	Disease	60	61	2	1:CID:2	L2R	NON-CROSS	59-60	60-61	D010042	ouabain	Chemical	59	60	2	D001145	arrhythmia	Disease	60	61	2
3123611	Chorea associated with oral contraception .|Three patients developed chorea while receiving oral contraceptives .|Two were young patients whose chorea developed long after treatment had been started and disappeared soon after it had been discontinued .|The third patient had acute amphetamine - induced chorea after prolonged oral contraception .|Prolonged administration of female sex hormones is a possible cause of chorea in women who have not previously had chorea or rheumatic fever .	1:CID:2	R2L	NON-CROSS	3-5	0-1	D003276	oral contraception|oral contraceptives|oral contraception	Chemical	3:12:48	5:14:50	0:1:3	D002819	Chorea|chorea|chorea|chorea|chorea|chorea	Disease	0:9:20:45:62:70	1:10:21:46:63:71	0:1:2:3:4:4	1:CID:2	R2L	NON-CROSS	45-46	42-43	D000661	amphetamine	Chemical	42	43	3	D002819	Chorea|chorea|chorea|chorea|chorea|chorea	Disease	0:9:20:45:62:70	1:10:21:46:63:71	0:1:2:3:4:4	1:NR:2	L2R	CROSS	48-50	72-74	D003276	oral contraception|oral contraceptives|oral contraception	Chemical	3:12:48	5:14:50	0:1:3	D012213	rheumatic fever	Disease	72	74	4	1:NR:2	L2R	CROSS	42-43	72-74	D000661	amphetamine	Chemical	42	43	3	D012213	rheumatic fever	Disease	72	74	4
761833	Reversal of ammonia coma in rats by L - dopa : a peripheral effect .|Ammonia coma was produced in rats within 10 to 15 minutes of an intraperitonealinjection of 1 . 7 mmol NH4CL .|This coma was prevented with 1 . 68 mmol L - dopa given by gastric intubation 15 minutes before the ammonium salt injection .|The effect of L - dopa was correlated with a decrease in blood and brain ammonia , an increase in brain dopamine , and an increase in renal excretion of ammonia and urea .|Intraventricular infusion of dopamine sufficient to raise the brain dopamine to the same extent did not prevent the ammonia coma nor affect the blood and brain ammonia concentrations .|Bilateral nephrectomy eliminated the beneficial effect of L - dopa on blood and brain ammonia and the ammonia coma was not prevented .|Thus , the reduction in blood and brain ammonia and the prevention of ammonia coma after L - dopa , can be accounted for by the peripheral effect of dopamine on renal function rather than its central action .|These results provide a reasonable explanation for the beneficial effects observed in some encephalopathic patients receiving L - dopa .	1:NR:2	L2R	NON-CROSS	2-3	3-4	D000641	ammonia|Ammonia|ammonia|ammonia|ammonia|ammonia|ammonia|ammonia|ammonia|ammonia	Chemical	2:15:75:90:112:120:137:140:154:159	3:16:76:91:113:121:138:141:155:160	0:1:3:3:4:4:5:5:6:6	D003128	coma|coma|coma|coma|coma|coma	Disease	3:16:37:113:141:160	4:17:38:114:142:161	0:1:2:4:5:6	1:NR:2	L2R	CROSS	159-160	198-199	D000641	ammonia|Ammonia|ammonia|ammonia|ammonia|ammonia|ammonia|ammonia|ammonia|ammonia	Chemical	2:15:75:90:112:120:137:140:154:159	3:16:76:91:113:121:138:141:155:160	0:1:3:3:4:4:5:5:6:6	D001927	encephalopathic	Disease	198	199	7	1:NR:2	R2L	NON-CROSS	162-165	160-161	D007980	L - dopa|L - dopa|L - dopa|L - dopa|L - dopa|L - dopa	Chemical	7:45:63:130:162:201	10:48:66:133:165:204	0:2:3:5:6:7	D003128	coma|coma|coma|coma|coma|coma	Disease	3:16:37:113:141:160	4:17:38:114:142:161	0:1:2:4:5:6	1:CID:2	R2L	NON-CROSS	37-38	34-35	D000643	NH4CL	Chemical	34	35	1	D003128	coma|coma|coma|coma|coma|coma	Disease	3:16:37:113:141:160	4:17:38:114:142:161	0:1:2:4:5:6	1:NR:2	R2L	NON-CROSS	56-58	37-38	D064751	ammonium salt	Chemical	56	58	2	D003128	coma|coma|coma|coma|coma|coma	Disease	3:16:37:113:141:160	4:17:38:114:142:161	0:1:2:4:5:6	1:NR:2	R2L	NON-CROSS	113-114	103-104	D004298	dopamine|dopamine|dopamine|dopamine	Chemical	81:97:103:175	82:98:104:176	3:4:4:6	D003128	coma|coma|coma|coma|coma|coma	Disease	3:16:37:113:141:160	4:17:38:114:142:161	0:1:2:4:5:6	1:NR:2	R2L	CROSS	113-114	92-93	D014508	urea	Chemical	92	93	3	D003128	coma|coma|coma|coma|coma|coma	Disease	3:16:37:113:141:160	4:17:38:114:142:161	0:1:2:4:5:6	1:NR:2	L2R	NON-CROSS	198-199	201-204	D007980	L - dopa|L - dopa|L - dopa|L - dopa|L - dopa|L - dopa	Chemical	7:45:63:130:162:201	10:48:66:133:165:204	0:2:3:5:6:7	D001927	encephalopathic	Disease	198	199	7	1:NR:2	L2R	CROSS	34-35	198-199	D000643	NH4CL	Chemical	34	35	1	D001927	encephalopathic	Disease	198	199	7	1:NR:2	L2R	CROSS	56-58	198-199	D064751	ammonium salt	Chemical	56	58	2	D001927	encephalopathic	Disease	198	199	7	1:NR:2	L2R	CROSS	175-176	198-199	D004298	dopamine|dopamine|dopamine|dopamine	Chemical	81:97:103:175	82:98:104:176	3:4:4:6	D001927	encephalopathic	Disease	198	199	7	1:NR:2	L2R	CROSS	92-93	198-199	D014508	urea	Chemical	92	93	3	D001927	encephalopathic	Disease	198	199	7
18589141	Heparin - induced thrombocytopenia after liver transplantation .|BACKGROUND : Unfractionated heparin sodium ( UFH ) or low - molecular weight heparin ( LMWH ) is used in anticoagulant protocols at several institutions to prevent thrombosis after liver transplantation .|Heparin - induced thrombocytopenia ( HIT ) is an adverse immune - mediated reaction to heparin , resulting in platelet count decreases of more than 50 % .|The frequencies of HIT after liver transplantation and platelet factor 4 / heparin - reactive antibody ( HIT antibody ) positivity in liver transplantation patients , however , are unknown .|PATIENTS AND METHODS : The 32 men and 20 women underwent living donor liver transplantation .|We started LMWH ( 25 IU / kg / h ) on postoperative day ( POD ) 1 , switching to UFH ( 5000 U / d ) on POD 2 or 3 .|The dose of UFH was changed according to the activated clotting time level .|HIT antibody levels were measured the day before surgery and on POD 7 and 14 .|Platelet count was measured daily for 3 weeks .|RESULTS : The average platelet counts preoperatively , and on POD 7 , 14 , and 21 were 65 , 88 , 149 , and 169 x 10 ( 9 ) / L , respectively .|Two patients developed hepatic artery thrombosis on POD 11 and 19 , respectively , although they were HIT antibody - negative and their platelet counts were stable .|In 2 other patients , the platelet count decreased suddenly from 107 x 10 ( 9 ) / L on POD 4 to 65 x 10 ( 9 ) / L on POD 6 and from 76 x 10 ( 9 ) / L on POD 7 to 33 x 10 ( 9 ) / L on POD 9 , respectively .|The heparin - induced platelet aggregation test was negative in these patients .|The percentage of HIT antibody - positive patients was 0 . 5 % preoperatively , 5 . 6 % on POD 7 , and 5 . 6 % on POD 14 .|None of the subjects / patients developed UFH - related HIT .|CONCLUSIONS : In our series , the occurrence of HIT after liver transplantation was uncommon .	1:CID:2	L2R	NON-CROSS	0-1	3-4	D006493	Heparin|Unfractionated heparin sodium|UFH|Heparin|heparin|heparin|UFH|UFH|heparin|UFH	Chemical	0:10:14:40:55:80:136:152:315:366	1:13:15:41:56:81:137:153:316:367	0:1:1:2:2:3:5:6:12:14	D013921	thrombocytopenia|thrombocytopenia|HIT|HIT|HIT|HIT|HIT|HIT|HIT|HIT	Disease	3:43:45:71:85:163:241:330:369:380	4:44:46:72:86:164:242:331:370:381	0:2:2:3:3:7:10:13:14:15	1:NR:2	L2R	NON-CROSS	35-36	40-41	D006493	Heparin|Unfractionated heparin sodium|UFH|Heparin|heparin|heparin|UFH|UFH|heparin|UFH	Chemical	0:10:14:40:55:80:136:152:315:366	1:13:15:41:56:81:137:153:316:367	0:1:1:2:2:3:5:6:12:14	D013927	thrombosis|thrombosis	Disease	35:229	36:230	1:10	1:NR:2	L2R	NON-CROSS	315-316	318-320	D006493	Heparin|Unfractionated heparin sodium|UFH|Heparin|heparin|heparin|UFH|UFH|heparin|UFH	Chemical	0:10:14:40:55:80:136:152:315:366	1:13:15:41:56:81:137:153:316:367	0:1:1:2:2:3:5:6:12:14	D001791	platelet aggregation	Disease	318	320	12	1:NR:2	R2L	CROSS	17-22	3-4	D006495	low - molecular weight heparin	Chemical	17	22	1	D013921	thrombocytopenia|thrombocytopenia|HIT|HIT|HIT|HIT|HIT|HIT|HIT|HIT	Disease	3:43:45:71:85:163:241:330:369:380	4:44:46:72:86:164:242:331:370:381	0:2:2:3:3:7:10:13:14:15	1:NR:2	L2R	NON-CROSS	17-22	35-36	D006495	low - molecular weight heparin	Chemical	17	22	1	D013927	thrombosis|thrombosis	Disease	35:229	36:230	1:10	1:NR:2	L2R	CROSS	17-22	318-320	D006495	low - molecular weight heparin	Chemical	17	22	1	D001791	platelet aggregation	Disease	318	320	12
16418614	PTU - associated vasculitis in a girl with Turner Syndrome and Graves ' disease .|Palpable purpura is a concerning clinical finding in pediatric patients and can have many causes , including infectious and autoimmune processes .|A rare cause , drug - induced vasculitis , may result from the production of antineutrophil cytoplasmic antibodies ( ANCAs ) in response to a medication .|We report a girl with Turner syndrome and Graves ' disease who presented with palpable purpuric lesions .|The diagnosis of propylthiouracil ( PTU ) - associated vasculitis was made by observation of consistent clinical features , the detection of elevated ANA and ANCA in the blood , and the observed clinical resolution of symptoms following withdrawal of PTU .|Subsequent treatment of persistent hyperthyroidism with radioablation did not result in an exacerbation of the vasculitis , a complication described in prior case reports .	1:CID:2	L2R	NON-CROSS	0-1	3-4	D011441	PTU|propylthiouracil|PTU|PTU	Chemical	0:85:87:122	1:86:88:123	0:4:4:4	D014657	vasculitis|vasculitis|vasculitis|vasculitis	Disease	3:44:91:139	4:45:92:140	0:2:4:5	1:NR:2	L2R	NON-CROSS	0-1	8-10	D011441	PTU|propylthiouracil|PTU|PTU	Chemical	0:85:87:122	1:86:88:123	0:4:4:4	D014424	Turner Syndrome|Turner syndrome	Disease	8:69	10:71	0:3	1:NR:2	L2R	NON-CROSS	0-1	11-14	D011441	PTU|propylthiouracil|PTU|PTU	Chemical	0:85:87:122	1:86:88:123	0:4:4:4	D006111	Graves ' disease|Graves ' disease	Disease	11:72	14:75	0:3	1:NR:2	L2R	CROSS	79-81	85-86	D011441	PTU|propylthiouracil|PTU|PTU	Chemical	0:85:87:122	1:86:88:123	0:4:4:4	D011693	purpura|purpuric lesions	Disease	16:79	17:81	1:3	1:NR:2	L2R	CROSS	122-123	128-129	D011441	PTU|propylthiouracil|PTU|PTU	Chemical	0:85:87:122	1:86:88:123	0:4:4:4	D006980	hyperthyroidism	Disease	128	129	5
15893386	Succinylcholine - induced masseter muscle rigidity during bronchoscopic removal of a tracheal foreign body .|Masseter muscle rigidity during general anesthesia is considered an early warning sign of a possible episode of malignant hyperthermia .|The decision whether to continue or discontinue the procedure depends on the urgency of the surgery and severity of masseter muscle rigidity .|Here , we describe a case of severe masseter muscle rigidity ( jaw of steel ) after succinylcholine ( Sch ) administration during general anesthetic management for rigid bronchoscopic removal of a tracheal foreign body .|Anesthesia was continued uneventfully with propofol infusion while all facilities were available to detect and treat malignant hyperthermia .	1:CID:2	L2R	NON-CROSS	0-1	3-6	D013390	Succinylcholine|succinylcholine|Sch	Chemical	0:75:77	1:76:78	0:3:3	D014313	masseter muscle rigidity|Masseter muscle rigidity|masseter muscle rigidity|masseter muscle rigidity|jaw of steel	Disease	3:15:54:66:70	6:18:57:69:73	0:1:2:3:3	1:NR:2	L2R	CROSS	0-1	32-34	D013390	Succinylcholine|succinylcholine|Sch	Chemical	0:75:77	1:76:78	0:3:3	D008305	malignant hyperthermia|malignant hyperthermia	Disease	32:110	34:112	1:4	1:NR:2	R2L	CROSS	99-100	70-73	D015742	propofol	Chemical	99	100	4	D014313	masseter muscle rigidity|Masseter muscle rigidity|masseter muscle rigidity|masseter muscle rigidity|jaw of steel	Disease	3:15:54:66:70	6:18:57:69:73	0:1:2:3:3	1:NR:2	R2L	NON-CROSS	110-112	99-100	D015742	propofol	Chemical	99	100	4	D008305	malignant hyperthermia|malignant hyperthermia	Disease	32:110	34:112	1:4
15814210	Minor neurological dysfunction , cognitive development , and somatic development at the age of 3 to 7 years after dexamethasone treatment in very - low birth - weight infants .|The objective of this study was to assess minor neurological dysfunction , cognitive development , and somatic development after dexamethasone therapy in very - low - birthweight infants .|Thirty - three children after dexamethasone treatment were matched to 33 children without dexamethasone treatment .|Data were assessed at the age of 3 - 7 years .|Dexamethasone was started between the 7th and the 28th day of life over 7 days with a total dose of 2 . 35 mg / kg / day .|Exclusion criteria were asphyxia , malformations , major surgical interventions , small for gestational age , intraventricular haemorrhage grades III and IV , periventricular leukomalacia , and severe psychomotor retardation .|Each child was examined by a neuropediatrician for minor neurological dysfunctions and tested by a psychologist for cognitive development with a Kaufman Assessment Battery for Children and a Draw - a - Man Test .|There were no differences in demographic data , growth , and socio - economic status between the two groups .|Fine motor skills and gross motor function were significantly better in the control group ( p < 0 . 01 ) .|In the Draw - a - Man Test , the control group showed better results ( p < 0 . 001 ) .|There were no differences in development of speech , social development , and the Kaufman Assessment Battery for Children .|After dexamethasone treatment , children showed a higher rate of minor neurological dysfunctions .|Neurological development was affected even without neurological diagnosis .|Further long - term follow - up studies will be necessary to fully evaluate the impact of dexamethasone on neurological and cognitive development .	1:CID:2	R2L	NON-CROSS	49-50	39-41	D003907	dexamethasone|dexamethasone|dexamethasone|dexamethasone|Dexamethasone|dexamethasone|dexamethasone	Chemical	19:49:64:72:87:268:307	20:50:65:73:88:269:308	0:1:2:2:4:11:13	D009422	neurological dysfunction|neurological dysfunction|neurological dysfunctions|neurological dysfunctions	Disease	1:39:156:278	3:41:158:280	0:1:6:11	1:NR:2	L2R	CROSS	87-88	119-120	D003907	dexamethasone|dexamethasone|dexamethasone|dexamethasone|Dexamethasone|dexamethasone|dexamethasone	Chemical	19:49:64:72:87:268:307	20:50:65:73:88:269:308	0:1:2:2:4:11:13	D001237	asphyxia	Disease	119	120	5	1:NR:2	L2R	CROSS	87-88	121-122	D003907	dexamethasone|dexamethasone|dexamethasone|dexamethasone|Dexamethasone|dexamethasone|dexamethasone	Chemical	19:49:64:72:87:268:307	20:50:65:73:88:269:308	0:1:2:2:4:11:13	D000014	malformations	Disease	121	122	5	1:NR:2	L2R	CROSS	87-88	133-134	D003907	dexamethasone|dexamethasone|dexamethasone|dexamethasone|Dexamethasone|dexamethasone|dexamethasone	Chemical	19:49:64:72:87:268:307	20:50:65:73:88:269:308	0:1:2:2:4:11:13	D006470	haemorrhage	Disease	133	134	5	1:NR:2	L2R	CROSS	87-88	139-141	D003907	dexamethasone|dexamethasone|dexamethasone|dexamethasone|Dexamethasone|dexamethasone|dexamethasone	Chemical	19:49:64:72:87:268:307	20:50:65:73:88:269:308	0:1:2:2:4:11:13	D007969	periventricular leukomalacia	Disease	139	141	5	1:NR:2	L2R	CROSS	87-88	144-146	D003907	dexamethasone|dexamethasone|dexamethasone|dexamethasone|Dexamethasone|dexamethasone|dexamethasone	Chemical	19:49:64:72:87:268:307	20:50:65:73:88:269:308	0:1:2:2:4:11:13	D011596	psychomotor retardation	Disease	144	146	5
11912119	Force overflow and levodopa - induced dyskinesias in Parkinson 's disease .|We assessed force coordination of the hand in Parkinson 's disease and its relationship to motor complications of levodopa therapy , particularly to levodopa - induced dyskinesias ( LID ) .|We studied two groups of Parkinson 's disease patients with ( Parkinson 's disease + LID , n = 23 ) and without levodopa - induced dyskinesias ( Parkinson 's disease - LID , n = 10 ) , and age - matched healthy controls .|The motor score of the Unified Parkinson 's Disease Rating Scale , a dyskinesia score and force in a grip - lift paradigm were assessed ON and OFF levodopa .|A pathological increase of forces was seen in ON - state in Parkinson 's disease + LID only .|In Parkinson 's disease + LID , the force involved in pressing down the object before lifting was significantly increased by levodopa ( by 61 % , P < 0 . 05 ) .|An overshooting of peak grip force by 51 % ( P < 0 . 05 ) and of static grip force by 45 % ( P < 0 . 01 ) was observed in the ON - compared with the OFF - drug condition .|In contrast , no excessive force was found in Parkinson 's disease - LID .|Peak grip force in ON - state was 140 % ( P < 0 . 05 ) higher in Parkinson 's disease + LID than in Parkinson 's disease - LID , while static grip force was increased by 138 % ( P < 0 . 01 ) between groups .|Severity of peak - dose dyskinesias was strongly correlated with grip force in ON - state ( r = 0 . 79 with peak force , P < 0 . 01 ) .|No correlation was observed between forces and the motor score as well as with the daily dose of dopaminergic medication .|Force excess was only observed in patients with LID and motor fluctuations .|A close relationship was seen between the overshooting of forces and dyskinesias in the ON - drug condition .|We postulate that both LID and grip force excess share common pathophysiological mechanisms related to motor fluctuations .	1:CID:2	L2R	NON-CROSS	3-4	6-7	D007980	levodopa|levodopa|levodopa|levodopa|levodopa|levodopa	Chemical	3:30:35:66:117:159	4:31:36:67:118:160	0:1:1:2:3:5	D004409	dyskinesias|dyskinesias|LID|LID|dyskinesias|LID|dyskinesia|LID|LID|LID|LID|LID|dyskinesias|LID|dyskinesias|LID	Disease	6:38:40:58:69:75:102:135:143:230:255:262:288:345:361:373	7:39:41:59:70:76:103:136:144:231:256:263:289:346:362:374	0:1:1:2:2:2:3:4:5:7:8:8:9:11:12:13	1:NR:2	L2R	NON-CROSS	3-4	8-11	D007980	levodopa|levodopa|levodopa|levodopa|levodopa|levodopa	Chemical	3:30:35:66:117:159	4:31:36:67:118:160	0:1:1:2:3:5	D010300	Parkinson 's disease|Parkinson 's disease|Parkinson 's disease|Parkinson 's disease|Parkinson 's disease|Parkinson 's Disease|Parkinson 's disease|Parkinson 's disease|Parkinson 's disease|Parkinson 's disease|Parkinson 's disease	Disease	8:20:48:54:71:95:131:139:226:251:258	11:23:51:57:74:98:134:142:229:254:261	0:1:2:2:2:3:4:5:7:8:8
9105126	Postinfarction ventricular septal defect associated with long - term steroid therapy .|Two cases of postinfarction ventricular septal rupture in patients on long - term steroid therapy are presented and the favourable outcome in both cases described .|A possible association between steroid therapy and subsequent postinfarction septal rupture is discussed .	1:CID:2	R2L	NON-CROSS	47-49	42-43	D013256	steroid|steroid|steroid	Chemical	9:25:42	10:26:43	0:1:2	D018658	ventricular septal defect|ventricular septal rupture|septal rupture	Disease	1:16:47	4:19:49	0:1:2
8599504	Angioedema associated with droperidol administration .|Angioedema , also known as angioneurotic edema or Quincke 's disease , is a well - demarcated , localized edema involving the subcutaneous tissues that may cause upper - airway obstruction .|We report the case of a previously healthy 19 - year - old man with no known drug allergies in whom angioedema with significant tongue swelling and protrusion developed within 10 minutes of the administration of a single IV dose of droperidol .	1:CID:2	R2L	NON-CROSS	3-4	0-1	D004329	droperidol|droperidol	Chemical	3:79	4:80	0:2	D000799	Angioedema|Angioedema|angioneurotic edema|Quincke 's disease|angioedema	Disease	0:6:11:14:59	1:7:13:17:60	0:1:1:1:2	1:NR:2	L2R	NON-CROSS	62-64	79-80	D004329	droperidol|droperidol	Chemical	3:79	4:80	0:2	D004487	edema|tongue swelling	Disease	25:62	26:64	1:2	1:NR:2	L2R	CROSS	3-4	33-37	D004329	droperidol|droperidol	Chemical	3:79	4:80	0:2	D000402	upper - airway obstruction	Disease	33	37	1	1:NR:2	L2R	NON-CROSS	55-57	79-80	D004329	droperidol|droperidol	Chemical	3:79	4:80	0:2	D004342	drug allergies	Disease	55	57	2	1:NR:2	L2R	NON-CROSS	62-64	79-80	D004329	droperidol|droperidol	Chemical	3:79	4:80	0:2	D014060	tongue swelling	Disease	62	64	2
8546130	Clarithromycin - associated visual hallucinations in a patient with chronic renal failure on continuous ambulatory peritoneal dialysis .|Visual hallucinations are a rare event in chronic renal failure and not related to uremia per se .|Unreported in the literature is visual hallucinations occurring in association with the new macrolide antibiotic , clarithromycin .|We describe such a case in a patient with end - stage renal disease ( ESRD ) maintained on continuous ambulatory peritoneal dialysis ( CAPD ) .|The combination of a relatively high dose of clarithromycin in face of chronic renal failure in a functionally anephric patient , with underlying aluminum intoxication , may have facilitated the appearance of this neurotoxic side effect .|It is important to understand the pharmacokinetics of medications in face of chronic renal failure , the possibility of drug interactions , and how these factors should help guide medication therapy in the ESRD patient .	1:CID:2	L2R	NON-CROSS	0-1	3-5	D017291	Clarithromycin|clarithromycin|clarithromycin	Chemical	0:52:89	1:53:90	0:2:4	D006212	visual hallucinations|Visual hallucinations|visual hallucinations	Disease	3:18:41	5:20:43	0:1:2	1:NR:2	L2R	NON-CROSS	89-90	93-96	D017291	Clarithromycin|clarithromycin|clarithromycin	Chemical	0:52:89	1:53:90	0:2:4	D007676	chronic renal failure|chronic renal failure|end - stage renal disease|ESRD|chronic renal failure|chronic renal failure|ESRD	Disease	9:25:63:69:93:130:151	12:28:68:70:96:133:152	0:1:3:3:4:5:5	1:NR:2	L2R	CROSS	32-33	52-53	D017291	Clarithromycin|clarithromycin|clarithromycin	Chemical	0:52:89	1:53:90	0:2:4	D014511	uremia	Disease	32	33	1	1:NR:2	L2R	NON-CROSS	89-90	114-115	D017291	Clarithromycin|clarithromycin|clarithromycin	Chemical	0:52:89	1:53:90	0:2:4	D020258	neurotoxic	Disease	114	115	4	1:NR:2	R2L	NON-CROSS	49-50	41-43	D018942	macrolide	Chemical	49	50	2	D006212	visual hallucinations|Visual hallucinations|visual hallucinations	Disease	3:18:41	5:20:43	0:1:2	1:NR:2	R2L	CROSS	104-105	41-43	D000535	aluminum	Chemical	104	105	4	D006212	visual hallucinations|Visual hallucinations|visual hallucinations	Disease	3:18:41	5:20:43	0:1:2	1:NR:2	R2L	CROSS	63-68	49-50	D018942	macrolide	Chemical	49	50	2	D007676	chronic renal failure|chronic renal failure|end - stage renal disease|ESRD|chronic renal failure|chronic renal failure|ESRD	Disease	9:25:63:69:93:130:151	12:28:68:70:96:133:152	0:1:3:3:4:5:5	1:NR:2	R2L	NON-CROSS	104-105	93-96	D000535	aluminum	Chemical	104	105	4	D007676	chronic renal failure|chronic renal failure|end - stage renal disease|ESRD|chronic renal failure|chronic renal failure|ESRD	Disease	9:25:63:69:93:130:151	12:28:68:70:96:133:152	0:1:3:3:4:5:5	1:NR:2	R2L	CROSS	49-50	32-33	D018942	macrolide	Chemical	49	50	2	D014511	uremia	Disease	32	33	1	1:NR:2	R2L	CROSS	104-105	32-33	D000535	aluminum	Chemical	104	105	4	D014511	uremia	Disease	32	33	1	1:NR:2	L2R	CROSS	49-50	114-115	D018942	macrolide	Chemical	49	50	2	D020258	neurotoxic	Disease	114	115	4	1:NR:2	L2R	NON-CROSS	104-105	114-115	D000535	aluminum	Chemical	104	105	4	D020258	neurotoxic	Disease	114	115	4
7724492	Acute renal toxicity of doxorubicin ( adriamycin ) - loaded cyanoacrylate nanoparticles .|Acute doxorubicin - loaded nanoparticle ( DXNP ) renal toxicity was explored in both normal rats and rats with experimental glomerulonephritis .|In normal rats , 2 / 6 rats given free doxorubicin ( DX ) ( 5 mg / kg ) died within one week , whereas all control animals and all rats having received free NP or DXNP survived .|A 3 times higher proteinuria appeared in animals treated with DXNP than in those treated with DX .|Free NP did not provoke any proteinuria .|Two hr post - injection , DXNP was 2 . 7 times more concentrated in kidneys than free DX ( p < 0 . 025 ) .|In rats with immune experimental glomerulonephritis , 5 / 6 rats given DX died within 7 days , in contrast to animals treated by DXNP , NP , or untreated , which all survived .|Proteinuria appeared in all series , but was 2 - 5 times more intense ( p > 0 . 001 ) and prolonged after doxorubicin treatment ( 400 - 700 mg / day ) , without significant difference between DXNP and DX .|Rats treated by unloaded NP behaved as controls .|These results demonstrate that , in these experimental conditions , DXNP killed less animals than free DX , despite of an enhanced renal toxicity of the former .|Both effects ( better survival and nephrosis ) are most probably related to an enhanced capture of DXNP by cells of the mononuclear phagocyte system , including mesangial cells .	1:NR:2	R2L	NON-CROSS	4-5	1-3	D004317	doxorubicin|adriamycin|doxorubicin|doxorubicin|DX|DX|DX|DX|doxorubicin|DX|DX	Chemical	4:6:14:45:47:91:119:140:187:204:231	5:7:15:46:48:92:120:141:188:205:232	0:0:1:2:2:3:5:6:7:7:9	D007674	renal toxicity|renal toxicity|renal toxicity	Disease	1:21:237	3:23:239	0:1:9	1:NR:2	R2L	NON-CROSS	10-11	1-3	D003487	cyanoacrylate	Chemical	10	11	0	D007674	renal toxicity|renal toxicity|renal toxicity	Disease	1:21:237	3:23:239	0:1:9	1:NR:2	L2R	NON-CROSS	133-134	140-141	D004317	doxorubicin|adriamycin|doxorubicin|doxorubicin|DX|DX|DX|DX|doxorubicin|DX|DX	Chemical	4:6:14:45:47:91:119:140:187:204:231	5:7:15:46:48:92:120:141:188:205:232	0:0:1:2:2:3:5:6:7:7:9	D005921	glomerulonephritis|glomerulonephritis	Disease	33:133	34:134	1:6	1:CID:2	L2R	NON-CROSS	91-92	99-100	D004317	doxorubicin|adriamycin|doxorubicin|doxorubicin|DX|DX|DX|DX|doxorubicin|DX|DX	Chemical	4:6:14:45:47:91:119:140:187:204:231	5:7:15:46:48:92:120:141:188:205:232	0:0:1:2:2:3:5:6:7:7:9	D011507	proteinuria|proteinuria|Proteinuria	Disease	79:99:163	80:100:164	3:4:7	1:NR:2	L2R	CROSS	231-232	249-250	D004317	doxorubicin|adriamycin|doxorubicin|doxorubicin|DX|DX|DX|DX|doxorubicin|DX|DX	Chemical	4:6:14:45:47:91:119:140:187:204:231	5:7:15:46:48:92:120:141:188:205:232	0:0:1:2:2:3:5:6:7:7:9	D009401	nephrosis	Disease	249	250	10	1:NR:2	L2R	CROSS	10-11	33-34	D003487	cyanoacrylate	Chemical	10	11	0	D005921	glomerulonephritis|glomerulonephritis	Disease	33:133	34:134	1:6	1:NR:2	L2R	CROSS	10-11	79-80	D003487	cyanoacrylate	Chemical	10	11	0	D011507	proteinuria|proteinuria|Proteinuria	Disease	79:99:163	80:100:164	3:4:7	1:NR:2	L2R	CROSS	10-11	249-250	D003487	cyanoacrylate	Chemical	10	11	0	D009401	nephrosis	Disease	249	250	10
7619765	Etoposide - related myocardial infarction .|The occurrence of a myocardial infarction is reported after chemotherapy containing etoposide , in a man with no risk factors for coronary heart disease .|Possible causal mechanisms are discussed .	1:CID:2	L2R	NON-CROSS	0-1	3-5	D005047	Etoposide|etoposide	Chemical	0:17	1:18	0:1	D009203	myocardial infarction|myocardial infarction	Disease	3:10	5:12	0:1	1:NR:2	L2R	NON-CROSS	17-18	27-30	D005047	Etoposide|etoposide	Chemical	0:17	1:18	0:1	D003327	coronary heart disease	Disease	27	30	1
7416947	Subjective assessment of sexual dysfunction of patients on long - term administration of digoxin .|Various data suggest that male patients who have received digoxin on a longterm basis have increased levels of serum estrogen and decreased levels of plasma testosterone and luteinizing hormone ( LH ) .|This study was undertaken to investigate the links between the long - term administration of digoxin therapy and sexual behavior , and the effect of digoxin on plasma levels of estradiol , testosterone , and LH .|The patients of the study and control group ( without digoxin ) were of similar cardiac functional capacity and age ( 25 - 40 years ) and were randomly selected from the rheumatic heart disease patients .|A subjective assessment of sexual behavior in the study and control groups was carried out , using parameters such as sexual desire , sexual excitement , and frequency of sexual relations .|Personal interviews and a questionnaire were also used for the evaluation of sexual behavior .|The findings support the reports concerning digoxin effect on plasma estradiol , testosterone , and LH .|The differences in the means were significant .|Tests used to evaluate the changes in sexual behavior showed a significant decrease in sexual desire , sexual excitement phase ( erection ) , and frequency of sexual relations in the study group .	1:CID:2	R2L	NON-CROSS	13-14	3-5	D004077	digoxin|digoxin|digoxin|digoxin|digoxin|digoxin	Chemical	13:24:63:73:95:175	14:25:64:74:96:176	0:1:2:2:3:6	D020018	sexual dysfunction|decrease in sexual desire	Disease	3:206	5:210	0:8	1:NR:2	R2L	CROSS	34-35	3-5	D004967	estrogen	Chemical	34	35	1	D020018	sexual dysfunction|decrease in sexual desire	Disease	3:206	5:210	0:8	1:NR:2	R2L	CROSS	206-210	181-182	D013739	testosterone|testosterone|testosterone	Chemical	40:80:181	41:81:182	1:2:6	D020018	sexual dysfunction|decrease in sexual desire	Disease	3:206	5:210	0:8	1:NR:2	R2L	CROSS	206-210	179-180	D004958	estradiol|estradiol	Chemical	78:179	79:180	2:6	D020018	sexual dysfunction|decrease in sexual desire	Disease	3:206	5:210	0:8	1:NR:2	L2R	NON-CROSS	95-96	117-120	D004077	digoxin|digoxin|digoxin|digoxin|digoxin|digoxin	Chemical	13:24:63:73:95:175	14:25:64:74:96:176	0:1:2:2:3:6	D012214	rheumatic heart disease	Disease	117	120	3	1:NR:2	L2R	CROSS	34-35	117-120	D004967	estrogen	Chemical	34	35	1	D012214	rheumatic heart disease	Disease	117	120	3	1:NR:2	L2R	CROSS	80-81	117-120	D013739	testosterone|testosterone|testosterone	Chemical	40:80:181	41:81:182	1:2:6	D012214	rheumatic heart disease	Disease	117	120	3	1:NR:2	L2R	CROSS	78-79	117-120	D004958	estradiol|estradiol	Chemical	78:179	79:180	2:6	D012214	rheumatic heart disease	Disease	117	120	3
7263204	Fatal aplastic anemia due to indomethacin - - lymphocyte transformation tests in vitro .|Although indomethacin has been implicated as a possible cause of aplastic anemia on the basis of a few clinical observations , its role has not been definitely established .|A case of fatal aplastic anemia is described in which no drugs other than allopurinol and indomethacin were given .|Indomethacin was first given four weeks prior to the onset of symptoms .|A positive lymphocyte transformation test with indomethacin in vitro further substantiates the potential role of this drug in causing aplastic anemia in a susceptible patient .|Fortunately , this seems to be a very rare complication .	1:CID:2	R2L	NON-CROSS	5-6	1-3	D007213	indomethacin|indomethacin|indomethacin|Indomethacin|indomethacin	Chemical	5:15:59:63:82	6:16:60:64:83	0:1:2:3:4	D000741	aplastic anemia|aplastic anemia|aplastic anemia|aplastic anemia	Disease	1:24:47:95	3:26:49:97	0:1:2:4	1:NR:2	R2L	NON-CROSS	57-58	47-49	D000493	allopurinol	Chemical	57	58	2	D000741	aplastic anemia|aplastic anemia|aplastic anemia|aplastic anemia	Disease	1:24:47:95	3:26:49:97	0:1:2:4
7066357	Plasma and urinary lipids and lipoproteins during the development of nephrotic syndrome induced in the rat by puromycin aminonucleoside .|This study was undertaken to ascertain whether the alterations of plasma lipoproteins found in nephrotic syndrome induced by puromycin aminonucleoside were due to nephrotic syndrome per se , or , at least in part , to the aminonucleoside .|The purpose of the present study was to investigate the changes in plasma and urinary lipoproteins during the administration of puromycin aminonucleoside ( 20 mg / kg for 7 days ) and the subsequent development of nephrotic syndrome .|Since massive albuminuria occurred after 6 days of treatment , the time - course study was divided into two stages : pre - nephrotic stage ( day 1 - 5 ) and nephrotic stage ( day 6 - 11 ) .|In pre - nephrotic stage the plasma level of fatty acids , triacylglycerol and VLDL decreased while that of phospholipid , cholesteryl esters and HDL remained constant .|Plasma apolipoprotein A - I tended to increase ( 40 % increase at day 5 ) .|At the beginning of nephrotic stage ( day 6 ) the concentration of plasma albumin dropped to a very low level , while that of apolipoprotein A - I increased abruptly ( 4 - fold increase ) and continued to rise , although less steeply , in the following days .|The plasma concentration of HDL followed the same pattern .|Plasma VLDL and LDL increased at a later stage ( day 9 ) .|Plasma apolipoprotein A - I was found not only in HDL ( 1 . 063 - 1 . 210 g / ml ) but also in the LDL density class ( 1 . 025 - 1 . 050 g / ml ) .|In the pre - nephrotic stage lipoproteinuria was negligible , while in the early nephrotic stage the urinary loss of plasma lipoproteins consisted mainly of HDL .|These observations indicate that puromycin aminonucleoside alters plasma lipoproteins by lowering VLDL and increasing HDL .|It is likely that the early and striking increase of plasma HDL found in nephrotic rats is related to a direct effect of the drug on HDL metabolism .	1:CID:2	R2L	NON-CROSS	38-40	34-36	D011692	puromycin aminonucleoside|puromycin aminonucleoside|aminonucleoside|puromycin aminonucleoside|puromycin aminonucleoside	Chemical	17:38:57:79:333	19:40:58:81:335	0:1:1:2:11	D009404	nephrotic syndrome|nephrotic syndrome|nephrotic syndrome|nephrotic syndrome|nephrotic|nephrotic|nephrotic|nephrotic|nephrotic|nephrotic|nephrotic	Disease	10:34:43:95:121:130:142:188:306:316:359	12:36:45:97:122:131:143:189:307:317:360	0:1:1:2:3:3:4:6:10:10:12	1:NR:2	R2L	NON-CROSS	148-150	142-143	D005227	fatty acids	Chemical	148	150	4	D009404	nephrotic syndrome|nephrotic syndrome|nephrotic syndrome|nephrotic syndrome|nephrotic|nephrotic|nephrotic|nephrotic|nephrotic|nephrotic|nephrotic	Disease	10:34:43:95:121:130:142:188:306:316:359	12:36:45:97:122:131:143:189:307:317:360	0:1:1:2:3:3:4:6:10:10:12	1:NR:2	R2L	NON-CROSS	151-152	142-143	D014280	triacylglycerol	Chemical	151	152	4	D009404	nephrotic syndrome|nephrotic syndrome|nephrotic syndrome|nephrotic syndrome|nephrotic|nephrotic|nephrotic|nephrotic|nephrotic|nephrotic|nephrotic	Disease	10:34:43:95:121:130:142:188:306:316:359	12:36:45:97:122:131:143:189:307:317:360	0:1:1:2:3:3:4:6:10:10:12	1:NR:2	R2L	NON-CROSS	160-162	142-143	D002788	cholesteryl esters	Chemical	160	162	4	D009404	nephrotic syndrome|nephrotic syndrome|nephrotic syndrome|nephrotic syndrome|nephrotic|nephrotic|nephrotic|nephrotic|nephrotic|nephrotic|nephrotic	Disease	10:34:43:95:121:130:142:188:306:316:359	12:36:45:97:122:131:143:189:307:317:360	0:1:1:2:3:3:4:6:10:10:12	1:NR:2	L2R	CROSS	79-81	100-101	D011692	puromycin aminonucleoside|puromycin aminonucleoside|aminonucleoside|puromycin aminonucleoside|puromycin aminonucleoside	Chemical	17:38:57:79:333	19:40:58:81:335	0:1:1:2:11	D000419	albuminuria	Disease	100	101	3	1:NR:2	R2L	CROSS	148-150	100-101	D005227	fatty acids	Chemical	148	150	4	D000419	albuminuria	Disease	100	101	3	1:NR:2	R2L	CROSS	151-152	100-101	D014280	triacylglycerol	Chemical	151	152	4	D000419	albuminuria	Disease	100	101	3	1:NR:2	R2L	CROSS	160-162	100-101	D002788	cholesteryl esters	Chemical	160	162	4	D000419	albuminuria	Disease	100	101	3
7007443	Circulating lysosomal enzymes and acute hepatic necrosis .|The activities of the lysosomal enzymes acid and neutral protease , N - acetylglucosaminidase , and acid phosphatase were measured in the serum of patients with fulminant hepatic failure .|Acid protease ( cathepsin D ) activity was increased about tenfold in patients who died and nearly fourfold in those who survived fulminant hepatic failure after paracetamol overdose , whereas activities were increased equally in patients with fulminant hepatic failure due to viral hepatitis whether or not they survived .|A correlation was found between serum acid protease activity and prothrombin time , and the increase in cathepsin D activity was sustained over several days compared with aspartate aminotransferase , which showed a sharp early peak and then a fall .|Circulating lysosomal proteases can damage other organs , and measurement of their activity may therefore be of added value in assessing prognosis in this condition .	1:CID:2	R2L	NON-CROSS	64-65	60-63	D000082	paracetamol	Chemical	64	65	2	D017114	acute hepatic necrosis|fulminant hepatic failure|fulminant hepatic failure|fulminant hepatic failure	Disease	4:34:60:75	7:37:63:78	0:1:2:2	1:NR:2	R2L	CROSS	115-116	75-78	D001224	aspartate	Chemical	115	116	3	D017114	acute hepatic necrosis|fulminant hepatic failure|fulminant hepatic failure|fulminant hepatic failure	Disease	4:34:60:75	7:37:63:78	0:1:2:2	1:NR:2	L2R	NON-CROSS	64-65	65-66	D000082	paracetamol	Chemical	64	65	2	D062787	overdose	Disease	65	66	2	1:NR:2	L2R	NON-CROSS	64-65	80-82	D000082	paracetamol	Chemical	64	65	2	D006525	viral hepatitis	Disease	80	82	2	1:NR:2	R2L	CROSS	115-116	65-66	D001224	aspartate	Chemical	115	116	3	D062787	overdose	Disease	65	66	2	1:NR:2	R2L	CROSS	115-116	80-82	D001224	aspartate	Chemical	115	116	3	D006525	viral hepatitis	Disease	80	82	2
3762968	Transketolase abnormality in tolazamide - induced Wernicke 's encephalopathy .|We studied a thiamine - dependent enzyme , transketolase , from fibroblasts of a diabetic patient who developed Wernicke 's encephalopathy when treated with tolazamide , in order to delineate if this patient also had transketolase abnormality [ high Km for thiamine pyrophosphate ( TPP ) ] , as previously reported in postalcoholic Wernicke - Korsakoff syndrome .|In addition to this patient , we also studied this enzyme from three diabetic kindreds without any history of Wernicke 's encephalopathy and from four normal controls .|We found that the above - mentioned patient and one of the diabetic kindreds with no history of Wernicke 's encephalopathy had abnormal transketolase as determined by its Km for TPP .|These data suggest a similarity between postalcoholic Wernicke - Korsakoff syndrome and the patient with tolazamide - induced Wernicke 's encephalopathy from the standpoint of transketolase abnormality .	1:CID:2	L2R	NON-CROSS	3-4	6-9	D014042	tolazamide|tolazamide|tolazamide	Chemical	3:34:143	4:35:144	0:1:4	D014899	Wernicke 's encephalopathy|Wernicke 's encephalopathy|Wernicke 's encephalopathy|Wernicke 's encephalopathy|Wernicke 's encephalopathy	Disease	6:28:87:114:146	9:31:90:117:149	0:1:2:3:4	1:NR:2	L2R	NON-CROSS	24-25	34-35	D014042	tolazamide|tolazamide|tolazamide	Chemical	3:34:143	4:35:144	0:1:4	D003920	diabetic|diabetic|diabetic	Disease	24:81:108	25:82:109	1:2:3	1:NR:2	L2R	NON-CROSS	135-139	143-144	D014042	tolazamide|tolazamide|tolazamide	Chemical	3:34:143	4:35:144	0:1:4	D020915	Wernicke - Korsakoff syndrome|Wernicke - Korsakoff syndrome	Disease	63:135	67:139	1:4	1:NR:2	R2L	NON-CROSS	13-14	6-9	D013831	thiamine	Chemical	13	14	1	D014899	Wernicke 's encephalopathy|Wernicke 's encephalopathy|Wernicke 's encephalopathy|Wernicke 's encephalopathy|Wernicke 's encephalopathy	Disease	6:28:87:114:146	9:31:90:117:149	0:1:2:3:4	1:NR:2	R2L	NON-CROSS	126-127	114-117	D013835	thiamine pyrophosphate|TPP|TPP	Chemical	51:54:126	53:55:127	1:1:3	D014899	Wernicke 's encephalopathy|Wernicke 's encephalopathy|Wernicke 's encephalopathy|Wernicke 's encephalopathy|Wernicke 's encephalopathy	Disease	6:28:87:114:146	9:31:90:117:149	0:1:2:3:4	1:NR:2	L2R	NON-CROSS	13-14	24-25	D013831	thiamine	Chemical	13	14	1	D003920	diabetic|diabetic|diabetic	Disease	24:81:108	25:82:109	1:2:3	1:NR:2	L2R	NON-CROSS	13-14	63-67	D013831	thiamine	Chemical	13	14	1	D020915	Wernicke - Korsakoff syndrome|Wernicke - Korsakoff syndrome	Disease	63:135	67:139	1:4	1:NR:2	R2L	NON-CROSS	126-127	108-109	D013835	thiamine pyrophosphate|TPP|TPP	Chemical	51:54:126	53:55:127	1:1:3	D003920	diabetic|diabetic|diabetic	Disease	24:81:108	25:82:109	1:2:3	1:NR:2	L2R	NON-CROSS	54-55	63-67	D013835	thiamine pyrophosphate|TPP|TPP	Chemical	51:54:126	53:55:127	1:1:3	D020915	Wernicke - Korsakoff syndrome|Wernicke - Korsakoff syndrome	Disease	63:135	67:139	1:4
3413271	Mechanisms of myocardial ischemia induced by epinephrine : comparison with exercise - induced ischemia .|The role of epinephrine in eliciting myocardial ischemia was examined in patients with coronary artery disease .|Objective signs of ischemia and factors increasing myocardial oxygen consumption were compared during epinephrine infusion and supine bicycle exercise .|Both epinephrine and exercise produced myocardial ischemia as evidenced by ST segment depression and angina .|However , the mechanisms of myocardial ischemia induced by epinephrine were significantly different from those of exercise .|Exercise - induced myocardial ischemia was marked predominantly by increased heart rate and rate - pressure product with a minor contribution of end - diastolic volume , while epinephrine - induced ischemia was characterized by a marked increase in contractility and a less pronounced increase in heart rate and rate - pressure product .|These findings indicate that ischemia produced by epinephrine , as may occur during states of emotional distress , has a mechanism distinct from that due to physical exertion .	1:CID:2	R2L	NON-CROSS	6-7	2-4	D004837	epinephrine|epinephrine|epinephrine|epinephrine|epinephrine|epinephrine|epinephrine	Chemical	6:18:45:53:77:114:147	7:19:46:54:78:115:148	0:1:2:3:4:5:6	D017202	myocardial ischemia|myocardial ischemia|myocardial ischemia|myocardial ischemia|myocardial ischemia	Disease	2:21:57:73:89	4:23:59:75:91	0:1:3:4:5	1:NR:2	R2L	CROSS	57-59	40-41	D010100	oxygen	Chemical	40	41	2	D017202	myocardial ischemia|myocardial ischemia|myocardial ischemia|myocardial ischemia|myocardial ischemia	Disease	2:21:57:73:89	4:23:59:75:91	0:1:3:4:5	1:NR:2	L2R	NON-CROSS	114-115	117-118	D004837	epinephrine|epinephrine|epinephrine|epinephrine|epinephrine|epinephrine|epinephrine	Chemical	6:18:45:53:77:114:147	7:19:46:54:78:115:148	0:1:2:3:4:5:6	D007511	ischemia|ischemia|ischemia|ischemia	Disease	13:35:117:144	14:36:118:145	0:2:5:6	1:NR:2	L2R	NON-CROSS	18-19	28-31	D004837	epinephrine|epinephrine|epinephrine|epinephrine|epinephrine|epinephrine|epinephrine	Chemical	6:18:45:53:77:114:147	7:19:46:54:78:115:148	0:1:2:3:4:5:6	D003324	coronary artery disease	Disease	28	31	1	1:NR:2	L2R	NON-CROSS	53-54	64-65	D004837	epinephrine|epinephrine|epinephrine|epinephrine|epinephrine|epinephrine|epinephrine	Chemical	6:18:45:53:77:114:147	7:19:46:54:78:115:148	0:1:2:3:4:5:6	D003866	depression	Disease	64	65	3	1:NR:2	L2R	NON-CROSS	66-67	77-78	D004837	epinephrine|epinephrine|epinephrine|epinephrine|epinephrine|epinephrine|epinephrine	Chemical	6:18:45:53:77:114:147	7:19:46:54:78:115:148	0:1:2:3:4:5:6	D000787	angina	Disease	66	67	3	1:NR:2	R2L	NON-CROSS	40-41	35-36	D010100	oxygen	Chemical	40	41	2	D007511	ischemia|ischemia|ischemia|ischemia	Disease	13:35:117:144	14:36:118:145	0:2:5:6	1:NR:2	R2L	CROSS	40-41	28-31	D010100	oxygen	Chemical	40	41	2	D003324	coronary artery disease	Disease	28	31	1	1:NR:2	L2R	CROSS	40-41	64-65	D010100	oxygen	Chemical	40	41	2	D003866	depression	Disease	64	65	3	1:NR:2	L2R	CROSS	40-41	66-67	D010100	oxygen	Chemical	40	41	2	D000787	angina	Disease	66	67	3
3088349	Transient contralateral rotation following unilateral substantia nigra lesion reflects susceptibility of the nigrostriatal system to exhaustion by amphetamine .|Following unilateral 6 - OHDA induced SN lesion , a transient period of contralateral rotation has been reported to precede the predominant ipsilateral circling .|In order to clarify the nature of this initial contralateral rotation we examined the effect of the duration of recovery period after the lesion , on amphetamine - induced rotational behavior .|Three days post lesion , most rats circled predominantly contralaterally to the lesion .|Such contralateral rotation may result from either degeneration - induced breakdown of the DA pool , or lesion - induced increase of DA turnover in the spared neurons .|A substantial degree of contralateral preference was still evident when amphetamine was administered for the first time 24 days after lesioning , indicating involvement of spared cells in the contralateral rotation .|However , regardless of the duration of recovery ( and irrespective of either lesion volume , amphetamine dose , or post - lesion motor exercise ) , amphetamine - induced rotation tended to become gradually more ipsilateral as the observation session progressed , and all rats circled ipsilaterally to the lesion in response to further amphetamine injections .|These findings suggest that amphetamine has an irreversible effect on the post - lesion DA pool contributing to contralateral rotation .	1:CID:2	R2L	NON-CROSS	181-182	178-179	D000661	amphetamine|amphetamine|amphetamine|amphetamine|amphetamine|amphetamine|amphetamine	Chemical	17:70:129:167:178:206:213	18:71:130:168:179:207:214	0:2:5:6:6:6:7	D009069	contralateral rotation|contralateral rotation|ipsilateral circling|contralateral rotation|rotational behavior|contralateral rotation|contralateral rotation|rotation|contralateral rotation	Disease	1:32:41:53:73:91:148:181:227	3:34:43:55:75:93:150:182:229	0:1:1:2:2:4:5:6:7	1:NR:2	R2L	NON-CROSS	32-34	21-24	D016627	6 - OHDA	Chemical	21	24	1	D009069	contralateral rotation|contralateral rotation|ipsilateral circling|contralateral rotation|rotational behavior|contralateral rotation|contralateral rotation|rotation|contralateral rotation	Disease	1:32:41:53:73:91:148:181:227	3:34:43:55:75:93:150:182:229	0:1:1:2:2:4:5:6:7
3001299	Thyroid function and urine - concentrating ability during lithium treatment .|It has been suggested that adenylate cyclase inhibition may be important in the development of both nephrogenic diabetes insipidus and hypothyroidism during lithium treatment .|We measured serum thyroxine and urine - concentrating ability ( Umax ) in response to desmopressin ( DDAVP ) in 85 patients receiving lithium .|Hypothyroidism developed in eight patients while they were taking lithium .|Impaired Umax was found in both euthyroid and hypothyroid patients while some hypothyroid patients concentrated their urine well .|It is concluded that the dominant mechanisms by which lithium exerts these two effects are different .	1:NR:2	L2R	NON-CROSS	27-30	33-34	D008094	lithium|lithium|lithium|lithium|lithium	Chemical	8:33:59:70:100	9:34:60:71:101	0:1:2:3:5	D018500	nephrogenic diabetes insipidus	Disease	27	30	1	1:CID:2	L2R	NON-CROSS	31-32	33-34	D008094	lithium|lithium|lithium|lithium|lithium	Chemical	8:33:59:70:100	9:34:60:71:101	0:1:2:3:5	D007037	hypothyroidism|Hypothyroidism|hypothyroid|hypothyroid	Disease	31:61:80:84	32:62:81:85	1:3:4:4	1:NR:2	R2L	CROSS	39-40	27-30	D013974	thyroxine	Chemical	39	40	2	D018500	nephrogenic diabetes insipidus	Disease	27	30	1	1:NR:2	R2L	CROSS	39-40	31-32	D013974	thyroxine	Chemical	39	40	2	D007037	hypothyroidism|Hypothyroidism|hypothyroid|hypothyroid	Disease	31:61:80:84	32:62:81:85	1:3:4:4
2004015	Sensitivity of erythroid progenitor colonies to erythropoietin in azidothymidine treated immunodeficient mice .|The anaemia induced by 3 ' - azido - 3 ' dideoxythymidine ( AZT ) is poorly understood .|We have used a murine model of AIDS , infection of female C57BL / 6 mice with LP - BM5 murine leukaemia ( MuLV ) virus , to determine if AZT - induced anaemia is due , in part , to decreased responsiveness of erythropoietic precursors ( BFU - e ) to erythropoietin ( EPO ) .|Mice in the early stage of LP - BM5 MuLV disease were given AZT in their drinking water at 1 . 0 and 2 . 5 mg / ml .|AZT produced anaemia in both groups , in a dose - dependent fashion .|Despite the anaemia , the number of splenic and bone marrow BFU - e in AZT treated mice increased up to five - fold over levels observed in infected untreated animals after 15 d of treatment .|Colony formation by splenic and bone marrow BFUe was stimulated at lower concentrations of EPO in mice receiving AZT for 15 d than for infected , untreated mice .|By day 30 , sensitivity of both splenic and bone marrow BFU - e of treated animals returned to that observed from cells of infected untreated animals .|The mean plasma levels of EPO observed in AZT treated mice were appropriate for the degree of anaemia observed when compared with phenylhydrazine ( PHZ ) treated mice .|The numbers of BFU - e and the percentage of bone marrow erythroblasts observed were comparable in AZT and PHZ treated mice with similar degrees of anaemia .|However , reticulocytosis was inappropriate for the degree of anaemia observed in AZT treated infected mice .|AZT - induced peripheral anaemia in the face of increased numbers of BFU - e and increased levels of plasma EPO suggest a lesion in terminal differentiation .	1:NR:2	L2R	NON-CROSS	8-9	10-11	D015215	azidothymidine|3 ' - azido - 3 ' dideoxythymidine|AZT|AZT|AZT|AZT|AZT|AZT|AZT|AZT|AZT|AZT	Chemical	8:17:26:62:102:119:148:188:235:273:296:301	9:25:27:63:103:120:149:189:236:274:297:302	0:1:1:2:3:4:5:6:8:9:10:11	C565469	immunodeficient	Disease	10	11	0	1:CID:2	L2R	NON-CROSS	119-120	121-122	D015215	azidothymidine|3 ' - azido - 3 ' dideoxythymidine|AZT|AZT|AZT|AZT|AZT|AZT|AZT|AZT|AZT|AZT	Chemical	8:17:26:62:102:119:148:188:235:273:296:301	9:25:27:63:103:120:149:189:236:274:297:302	0:1:1:2:3:4:5:6:8:9:10:11	D000740	anaemia|anaemia|anaemia|anaemia|anaemia|anaemia|anaemia|anaemia	Disease	14:65:121:135:244:282:293:305	15:66:122:136:245:283:294:306	1:2:4:5:8:9:10:11	1:NR:2	L2R	NON-CROSS	26-27	39-40	D015215	azidothymidine|3 ' - azido - 3 ' dideoxythymidine|AZT|AZT|AZT|AZT|AZT|AZT|AZT|AZT|AZT|AZT	Chemical	8:17:26:62:102:119:148:188:235:273:296:301	9:25:27:63:103:120:149:189:236:274:297:302	0:1:1:2:3:4:5:6:8:9:10:11	D000163	AIDS	Disease	39	40	2	1:NR:2	L2R	NON-CROSS	26-27	41-42	D015215	azidothymidine|3 ' - azido - 3 ' dideoxythymidine|AZT|AZT|AZT|AZT|AZT|AZT|AZT|AZT|AZT|AZT	Chemical	8:17:26:62:102:119:148:188:235:273:296:301	9:25:27:63:103:120:149:189:236:274:297:302	0:1:1:2:3:4:5:6:8:9:10:11	D007239	infection	Disease	41	42	2	1:NR:2	L2R	NON-CROSS	53-54	62-63	D015215	azidothymidine|3 ' - azido - 3 ' dideoxythymidine|AZT|AZT|AZT|AZT|AZT|AZT|AZT|AZT|AZT|AZT	Chemical	8:17:26:62:102:119:148:188:235:273:296:301	9:25:27:63:103:120:149:189:236:274:297:302	0:1:1:2:3:4:5:6:8:9:10:11	D007938	leukaemia	Disease	53	54	2	1:NR:2	L2R	NON-CROSS	286-287	296-297	D015215	azidothymidine|3 ' - azido - 3 ' dideoxythymidine|AZT|AZT|AZT|AZT|AZT|AZT|AZT|AZT|AZT|AZT	Chemical	8:17:26:62:102:119:148:188:235:273:296:301	9:25:27:63:103:120:149:189:236:274:297:302	0:1:1:2:3:4:5:6:8:9:10:11	D045262	reticulocytosis	Disease	286	287	10	1:NR:2	R2L	CROSS	249-250	10-11	C030299	phenylhydrazine|PHZ|PHZ	Chemical	249:251:275	250:252:276	8:8:9	C565469	immunodeficient	Disease	10	11	0	1:NR:2	R2L	NON-CROSS	249-250	244-245	C030299	phenylhydrazine|PHZ|PHZ	Chemical	249:251:275	250:252:276	8:8:9	D000740	anaemia|anaemia|anaemia|anaemia|anaemia|anaemia|anaemia|anaemia	Disease	14:65:121:135:244:282:293:305	15:66:122:136:245:283:294:306	1:2:4:5:8:9:10:11	1:NR:2	R2L	CROSS	249-250	39-40	C030299	phenylhydrazine|PHZ|PHZ	Chemical	249:251:275	250:252:276	8:8:9	D000163	AIDS	Disease	39	40	2	1:NR:2	R2L	CROSS	249-250	41-42	C030299	phenylhydrazine|PHZ|PHZ	Chemical	249:251:275	250:252:276	8:8:9	D007239	infection	Disease	41	42	2	1:NR:2	R2L	CROSS	249-250	53-54	C030299	phenylhydrazine|PHZ|PHZ	Chemical	249:251:275	250:252:276	8:8:9	D007938	leukaemia	Disease	53	54	2	1:NR:2	L2R	CROSS	275-276	286-287	C030299	phenylhydrazine|PHZ|PHZ	Chemical	249:251:275	250:252:276	8:8:9	D045262	reticulocytosis	Disease	286	287	10
1732442	Detection of abnormal cardiac adrenergic neuron activity in adriamycin - induced cardiomyopathy with iodine - 125 - metaiodobenzylguanidine .|Radiolabeled metaiodobenzylguanidine ( MIBG ) , an analog of norepinephrine ( NE ) , serves as an index of adrenergic neuron integrity and function .|Using a rat model of adriamycin - induced cardiomyopathy , we tested the hypothesis that abnormal cardiac adrenergic neuron activity may appear and be exacerbated dose - dependently in adriamycin cardiomyopathy .|The degree of vacuolar degeneration of myocardial cells was analyzed in relation to the duration of adriamycin treatment ( 2 mg / kg , once a week ) .|There were no abnormalities or only isolated degeneration in the 1 - or 2 - wk treatment groups , isolated or scattered degeneration in half of the 3 - wk group , frequent scattered degeneration in the 4 - wk group , scattered or focal degeneration in the 5 - wk group , and extensive degeneration in the 8 - wk group .|Myocardial accumulation of [ 125I ] MIBG 4 hr after intravenous injection did not differ between the controls and the groups treated 3 wk or less .|However , the 4 - wk group had a slightly lower accumulation in the right ventricular wall ( 82 % of the control ) and significantly lower accumulation in the left ventricular wall ( about 66 % of the control : p less than 0 . 05 ) .|In the 5 - wk group , MIBG accumulation in the right and left ventricular wall was 35 % and 27 % of that in controls , respectively ( p less than 0 . 001 ) .|In the 8 - wk group , MIBG accumulation in the right and left ventricular wall was 18 % and 14 % of that in controls , respectively ( p less than 0 . 001 ) .|Thus , MIBG accumulation in the myocardium decreased in an adriamycin dose - dependent manner .|The appearance of impaired cardiac adrenergic neuron activity in the presence of slight myocardial impairment ( scattered or focal vacuolar degeneration ) indicates that MIBG scintigraphy may be a useful method for detection of adriamycin - induced cardiomyopathy .	1:CID:2	L2R	NON-CROSS	73-74	74-75	D004317	adriamycin|adriamycin|adriamycin|adriamycin|adriamycin|adriamycin	Chemical	8:49:73:92:328:368	9:50:74:93:329:369	0:2:2:3:9:10	D009202	cardiomyopathy|cardiomyopathy|cardiomyopathy|myocardial impairment|cardiomyopathy	Disease	11:52:74:347:371	12:53:75:349:372	0:2:2:10:10	1:NR:2	L2R	NON-CROSS	73-74	79-84	D004317	adriamycin|adriamycin|adriamycin|adriamycin|adriamycin|adriamycin	Chemical	8:49:73:92:328:368	9:50:74:93:329:369	0:2:2:3:9:10	C536522	vacuolar degeneration of myocardial cells|vacuolar degeneration	Disease	79:353	84:355	3:10	1:NR:2	R2L	NON-CROSS	13-18	11-12	D019797	iodine - 125 - metaiodobenzylguanidine|Radiolabeled metaiodobenzylguanidine|MIBG|MIBG|MIBG|MIBG|MIBG|MIBG	Chemical	13:19:22:174:251:288:320:358	18:21:23:175:252:289:321:359	0:1:1:5:7:8:9:10	D009202	cardiomyopathy|cardiomyopathy|cardiomyopathy|myocardial impairment|cardiomyopathy	Disease	11:52:74:347:371	12:53:75:349:372	0:2:2:10:10	1:NR:2	R2L	CROSS	28-29	11-12	D009638	norepinephrine|NE	Chemical	28:30	29:31	1:1	D009202	cardiomyopathy|cardiomyopathy|cardiomyopathy|myocardial impairment|cardiomyopathy	Disease	11:52:74:347:371	12:53:75:349:372	0:2:2:10:10	1:NR:2	L2R	NON-CROSS	353-355	358-359	D019797	iodine - 125 - metaiodobenzylguanidine|Radiolabeled metaiodobenzylguanidine|MIBG|MIBG|MIBG|MIBG|MIBG|MIBG	Chemical	13:19:22:174:251:288:320:358	18:21:23:175:252:289:321:359	0:1:1:5:7:8:9:10	C536522	vacuolar degeneration of myocardial cells|vacuolar degeneration	Disease	79:353	84:355	3:10	1:NR:2	L2R	CROSS	30-31	79-84	D009638	norepinephrine|NE	Chemical	28:30	29:31	1:1	C536522	vacuolar degeneration of myocardial cells|vacuolar degeneration	Disease	79:353	84:355	3:10
1423339	Amnestic syndrome associated with propranolol toxicity : a case report .|An elderly woman developed an Alzheimer - like subacute dementia as a result of propranolol toxicity .|Analysis of the manifestations showed that severe impairment of memory accounted for virtually all of the abnormalities .|There is evidence that cerebral reactions to drug toxicity can exhibit patterns that suggest highly selective involvement of functional subdivisions of the brain .	1:CID:2	R2L	NON-CROSS	4-5	0-2	D011433	propranolol|propranolol	Chemical	4:25	5:26	0:1	D000647	Amnestic syndrome	Disease	0	2	0	1:NR:2	L2R	NON-CROSS	4-5	5-6	D011433	propranolol|propranolol	Chemical	4:25	5:26	0:1	D064420	toxicity|toxicity|toxicity	Disease	5:26:54	6:27:55	0:1:3	1:NR:2	L2R	NON-CROSS	16-17	25-26	D011433	propranolol|propranolol	Chemical	4:25	5:26	0:1	D000544	Alzheimer	Disease	16	17	1	1:NR:2	L2R	NON-CROSS	20-21	25-26	D011433	propranolol|propranolol	Chemical	4:25	5:26	0:1	D003704	dementia	Disease	20	21	1
921394	Biphasic response of the SA node of the dog heart in vivo to selective administration of ketamine .|Effect of ketamine on the SA node of the dog heart was studied in vivo using a selective perfusion technique of the SA node artery .|Injections of ketamine in doses from 100 microgram to 3 mg into the artery produced a depression of the SA nodal activity by a direct action .|This depression was followed by the sudden appearance of a stimulatory phase .|Bilateral vagotomy and sympathectomy or prior administration of a ganglion blocker failed to inhibit the occurrence of the ketamine - induced tachycardia , while it was completely abolished in the reserpinized dogs or by a prior injection of a beta - blocking agent into the SA node artery .|This may indicate that an activation of the peripheral adrenergic mechanism plays an important role in the induction of the excitatory effect of ketamine injected in the SA node artery .	1:NR:2	L2R	NON-CROSS	46-47	60-61	D007649	ketamine|ketamine|ketamine|ketamine|ketamine	Chemical	16:20:46:102:156	17:21:47:103:157	0:1:2:4:5	D003866	depression|depression	Disease	60:72	61:73	2:3	1:CID:2	L2R	NON-CROSS	102-103	105-106	D007649	ketamine|ketamine|ketamine|ketamine|ketamine	Chemical	16:20:46:102:156	17:21:47:103:157	0:1:2:4:5	D013610	tachycardia	Disease	105	106	4
871943	The use of serum cholinesterase in succinylcholine apnoea .|Fifteen patients demonstrating unexpected prolonged apnoea lasting several hours after succinylcholine have been treated by a new preparation of human serum cholinesterase .|Adequate spontaneous respiration was re - established in an average period of ten minutes after the injection .|In 12 patients biochemical genetic examinations confirmed the presence of an atypical serum cholinesterase .|In three patients none of the usual variants were found .|It is therefore supposed that other unknown variants of serum cholinesterase exist which can not hydrolyze succinylcholine .|The use of serum cholinesterase in succinylcholine apnoea provided considerable relief to both patient and anaesthetist .	1:CID:2	L2R	NON-CROSS	6-7	7-8	D013390	succinylcholine|succinylcholine|succinylcholine|succinylcholine	Chemical	6:19:92:100	7:20:93:101	0:1:5:6	D001049	apnoea|apnoea|apnoea	Disease	7:14:101	8:15:102	0:1:6
1355091	Orthostatic hypotension occurs following alpha 2 - adrenoceptor blockade in chronic prazosin - pretreated conscious spontaneously hypertensive rats .|1 . Studies were performed to evaluate whether chronic prazosin treatment alters the alpha 2 - adrenoceptor function for orthostatic control of arterial blood pressure in conscious spontaneously hypertensive rats ( SHR ) .|2 .|Conscious SHR ( male 300 - 350 g ) were subjected to 90 degrees head - up tilts for 60 s following acute administration of prazosin ( 0 . 1 mg kg - 1 i . p . ) or rauwolscine ( 3 mg kg - 1 i . v . ) .|Orthostatic hypotension was determined by the average decrease ( % ) in mean arterial pressure ( MAP femoral ) over the 60 - s tilt period .|The basal MAP of conscious SHR was reduced to a similar extent by prazosin ( - 23 % ( - ) - 26 % MAP ) and rauwolscine ( - 16 % ( - ) - 33 % MAP ) .|However , the head - up tilt induced orthostatic hypotension in the SHR treated with prazosin ( - 16 % MAP , n = 6 ) , but not in the SHR treated with rauwolscine ( less than + 2 % MAP , n = 6 ) .|3 .|Conscious SHR were treated for 4 days with prazosin at 2 mg kg - 1 day - 1 i . p .|for chronic alpha 1 - adrenoceptor blockade .|MAP in conscious SHR after chronic prazosin treatment was 14 % lower than in the untreated SHR ( n = 8 ) .|Head - up tilts in these rats did not produce orthostatic hypotension when performed either prior to or after acute dosing of prazosin ( 0 . 1 mg kg - 1 i . p . ) .|Conversely , administration of rauwolscine ( 3 mg kg - 1 i . v . ) in chronic prazosin treated SHR decreased the basal MAP by 12 - 31 % ( n = 4 ) , and subsequent tilts induced further drops of MAP by 19 - 23 % in these rats .|4 .|The pressor responses and bradycardia to the alpha 1 - agonist cirazoline ( 0 . 6 and 2 micrograms kg - 1 i . v . ) , the alpha 2 - agonist Abbott - 53693 ( 1 and 3 micrograms kg - 1 i . v . ) , and noradrenaline ( 0 . 1 and 1 . 0 micrograms kg - 1 i . v . ) were determined in conscious SHR with and without chronic prazosin pretreatment .|Both the pressor and bradycardia effects of cirazoline were abolished in chronic prazosin treated SHR ( n = 4 ) as compared to the untreated SHR ( n = 4 ) .|On the other hand , the pressor effects of Abbott - 53693 were similar in both groups of SHR , but the accompanying bradycardia was greater in SHR with chronic prazosin treatment than without such treatment .|Furthermore , the bradycardia that accompanied the noradrenaline - induced pressor effect in SHR was similar with and without chronic prazosin treatment despite a 47 - 71 % reduction of the pressor effect in chronic alpha 1 - receptor blocked SHR . ( ABSTRACT TRUNCATED AT 400 WORDS )	1:CID:2	R2L	NON-CROSS	191-192	184-186	D011224	prazosin|prazosin|prazosin|prazosin|prazosin|prazosin|prazosin|prazosin|prazosin|prazosin|prazosin|prazosin|prazosin	Chemical	11:28:80:148:191:234:262:301:334:449:464:514:541	12:29:81:149:192:235:263:302:335:450:465:515:542	0:1:3:5:6:8:10:11:12:14:15:16:17	D007024	Orthostatic hypotension|Orthostatic hypotension|orthostatic hypotension|orthostatic hypotension	Disease	0:108:184:289	2:110:186:291	0:4:6:11	1:NR:2	R2L	NON-CROSS	108-110	95-96	D015016	rauwolscine|rauwolscine|rauwolscine|rauwolscine	Chemical	95:162:210:320	96:163:211:321	3:5:6:12	D007024	Orthostatic hypotension|Orthostatic hypotension|orthostatic hypotension|orthostatic hypotension	Disease	0:108:184:289	2:110:186:291	0:4:6:11	1:NR:2	R2L	CROSS	382-383	289-291	C014282	cirazoline|cirazoline	Chemical	382:459	383:460	14:15	D007024	Orthostatic hypotension|Orthostatic hypotension|orthostatic hypotension|orthostatic hypotension	Disease	0:108:184:289	2:110:186:291	0:4:6:11	1:NR:2	R2L	CROSS	404-407	289-291	C056299	Abbott - 53693|Abbott - 53693	Chemical	404:493	407:496	14:16	D007024	Orthostatic hypotension|Orthostatic hypotension|orthostatic hypotension|orthostatic hypotension	Disease	0:108:184:289	2:110:186:291	0:4:6:11	1:NR:2	R2L	CROSS	422-423	289-291	D009638	noradrenaline|noradrenaline	Chemical	422:528	423:529	14:17	D007024	Orthostatic hypotension|Orthostatic hypotension|orthostatic hypotension|orthostatic hypotension	Disease	0:108:184:289	2:110:186:291	0:4:6:11	1:NR:2	L2R	NON-CROSS	11-12	16-17	D011224	prazosin|prazosin|prazosin|prazosin|prazosin|prazosin|prazosin|prazosin|prazosin|prazosin|prazosin|prazosin|prazosin	Chemical	11:28:80:148:191:234:262:301:334:449:464:514:541	12:29:81:149:192:235:263:302:335:450:465:515:542	0:1:3:5:6:8:10:11:12:14:15:16:17	D006973	hypertensive|hypertensive	Disease	16:47	17:48	0:1	1:NR:2	L2R	NON-CROSS	449-450	456-457	D011224	prazosin|prazosin|prazosin|prazosin|prazosin|prazosin|prazosin|prazosin|prazosin|prazosin|prazosin|prazosin|prazosin	Chemical	11:28:80:148:191:234:262:301:334:449:464:514:541	12:29:81:149:192:235:263:302:335:450:465:515:542	0:1:3:5:6:8:10:11:12:14:15:16:17	D001919	bradycardia|bradycardia|bradycardia|bradycardia	Disease	375:456:507:524	376:457:508:525	14:15:16:17	1:NR:2	R2L	CROSS	95-96	47-48	D015016	rauwolscine|rauwolscine|rauwolscine|rauwolscine	Chemical	95:162:210:320	96:163:211:321	3:5:6:12	D006973	hypertensive|hypertensive	Disease	16:47	17:48	0:1	1:CID:2	R2L	CROSS	382-383	47-48	C014282	cirazoline|cirazoline	Chemical	382:459	383:460	14:15	D006973	hypertensive|hypertensive	Disease	16:47	17:48	0:1	1:CID:2	R2L	CROSS	404-407	47-48	C056299	Abbott - 53693|Abbott - 53693	Chemical	404:493	407:496	14:16	D006973	hypertensive|hypertensive	Disease	16:47	17:48	0:1	1:CID:2	R2L	CROSS	422-423	47-48	D009638	noradrenaline|noradrenaline	Chemical	422:528	423:529	14:17	D006973	hypertensive|hypertensive	Disease	16:47	17:48	0:1	1:NR:2	L2R	CROSS	320-321	375-376	D015016	rauwolscine|rauwolscine|rauwolscine|rauwolscine	Chemical	95:162:210:320	96:163:211:321	3:5:6:12	D001919	bradycardia|bradycardia|bradycardia|bradycardia	Disease	375:456:507:524	376:457:508:525	14:15:16:17	1:CID:2	R2L	NON-CROSS	459-460	456-457	C014282	cirazoline|cirazoline	Chemical	382:459	383:460	14:15	D001919	bradycardia|bradycardia|bradycardia|bradycardia	Disease	375:456:507:524	376:457:508:525	14:15:16:17	1:CID:2	R2L	NON-CROSS	507-508	493-496	C056299	Abbott - 53693|Abbott - 53693	Chemical	404:493	407:496	14:16	D001919	bradycardia|bradycardia|bradycardia|bradycardia	Disease	375:456:507:524	376:457:508:525	14:15:16:17	1:CID:2	R2L	NON-CROSS	528-529	524-525	D009638	noradrenaline|noradrenaline	Chemical	422:528	423:529	14:17	D001919	bradycardia|bradycardia|bradycardia|bradycardia	Disease	375:456:507:524	376:457:508:525	14:15:16:17
8638876	Coexistence of cerebral venous sinus and internal carotid artery thrombosis associated with exogenous sex hormones .|A case report .|A forty - six year - old premenopausal woman developed headache , nausea and vomiting , left hemiparesis and seizure two days after parenteral use of progesterone and estradiol .|Diabetes mellitus ( DM ) was found during admission .|Computed tomography showed a hemorrhagic infarct in the right frontal lobe and increased density in the superior sagittal sinus ( SSS ) .|Left carotid angiography found occlusion of the left internal carotid artery ( ICA ) .|Right carotid angiograms failed to show the SSS and inferior sagittal sinus , suggestive of venous sinus thrombosis .|Coexistence of the cerebral artery and the venous sinus occlusion has been described infrequently .|In this case , the authors postulate that the use of estradiol and progesterone and the underlying DM increased vascular thrombogenicity , which provided a common denominator for thrombosis of both the ICA and the venous sinus .	1:CID:2	R2L	NON-CROSS	160-169	145-146	D011374	progesterone|progesterone	Chemical	46:145	47:146	2:8	D012851	cerebral venous sinus and internal carotid artery thrombosis|venous sinus thrombosis|thrombosis of both the ICA and the venous sinus	Disease	2:113:160	10:116:169	0:6:8	1:CID:2	R2L	NON-CROSS	160-169	143-144	D004958	estradiol|estradiol	Chemical	48:143	49:144	2:8	D012851	cerebral venous sinus and internal carotid artery thrombosis|venous sinus thrombosis|thrombosis of both the ICA and the venous sinus	Disease	2:113:160	10:116:169	0:6:8	1:CID:2	R2L	NON-CROSS	160-169	145-146	D011374	progesterone|progesterone	Chemical	46:145	47:146	2:8	D002341	cerebral venous sinus and internal carotid artery thrombosis|thrombosis of both the ICA and the venous sinus	Disease	2:160	10:169	0:8	1:CID:2	R2L	NON-CROSS	160-169	143-144	D004958	estradiol|estradiol	Chemical	48:143	49:144	2:8	D002341	cerebral venous sinus and internal carotid artery thrombosis|thrombosis of both the ICA and the venous sinus	Disease	2:160	10:169	0:8	1:NR:2	R2L	NON-CROSS	46-47	30-31	D011374	progesterone|progesterone	Chemical	46:145	47:146	2:8	D006261	headache	Disease	30	31	2	1:NR:2	R2L	NON-CROSS	48-49	30-31	D004958	estradiol|estradiol	Chemical	48:143	49:144	2:8	D006261	headache	Disease	30	31	2	1:NR:2	R2L	NON-CROSS	46-47	32-33	D011374	progesterone|progesterone	Chemical	46:145	47:146	2:8	D009325	nausea	Disease	32	33	2	1:NR:2	R2L	NON-CROSS	48-49	32-33	D004958	estradiol|estradiol	Chemical	48:143	49:144	2:8	D009325	nausea	Disease	32	33	2	1:NR:2	R2L	NON-CROSS	46-47	34-35	D011374	progesterone|progesterone	Chemical	46:145	47:146	2:8	D014839	vomiting	Disease	34	35	2	1:NR:2	R2L	NON-CROSS	48-49	34-35	D004958	estradiol|estradiol	Chemical	48:143	49:144	2:8	D014839	vomiting	Disease	34	35	2	1:NR:2	R2L	NON-CROSS	46-47	37-38	D011374	progesterone|progesterone	Chemical	46:145	47:146	2:8	D010291	hemiparesis	Disease	37	38	2	1:NR:2	R2L	NON-CROSS	48-49	37-38	D004958	estradiol|estradiol	Chemical	48:143	49:144	2:8	D010291	hemiparesis	Disease	37	38	2	1:NR:2	R2L	NON-CROSS	46-47	39-40	D011374	progesterone|progesterone	Chemical	46:145	47:146	2:8	D012640	seizure	Disease	39	40	2	1:NR:2	R2L	NON-CROSS	48-49	39-40	D004958	estradiol|estradiol	Chemical	48:143	49:144	2:8	D012640	seizure	Disease	39	40	2	1:NR:2	L2R	NON-CROSS	46-47	50-52	D011374	progesterone|progesterone	Chemical	46:145	47:146	2:8	D003920	Diabetes mellitus|DM|DM	Disease	50:53:149	52:54:150	3:3:8	1:CID:2	L2R	CROSS	46-47	64-66	D011374	progesterone|progesterone	Chemical	46:145	47:146	2:8	D002543	hemorrhagic infarct	Disease	64	66	4	1:CID:2	L2R	CROSS	46-47	64-66	D011374	progesterone|progesterone	Chemical	46:145	47:146	2:8	D002544	hemorrhagic infarct|cerebral artery and the venous sinus occlusion	Disease	64:120	66:127	4:7	1:NR:2	L2R	CROSS	46-47	87-94	D011374	progesterone|progesterone	Chemical	46:145	47:146	2:8	D001157	occlusion of the left internal carotid artery	Disease	87	94	5	1:NR:2	L2R	NON-CROSS	48-49	50-52	D004958	estradiol|estradiol	Chemical	48:143	49:144	2:8	D003920	Diabetes mellitus|DM|DM	Disease	50:53:149	52:54:150	3:3:8	1:CID:2	L2R	CROSS	48-49	64-66	D004958	estradiol|estradiol	Chemical	48:143	49:144	2:8	D002543	hemorrhagic infarct	Disease	64	66	4	1:CID:2	L2R	CROSS	48-49	64-66	D004958	estradiol|estradiol	Chemical	48:143	49:144	2:8	D002544	hemorrhagic infarct|cerebral artery and the venous sinus occlusion	Disease	64:120	66:127	4:7	1:NR:2	L2R	CROSS	48-49	87-94	D004958	estradiol|estradiol	Chemical	48:143	49:144	2:8	D001157	occlusion of the left internal carotid artery	Disease	87	94	5
1628552	Chloroquine related complete heart block with blindness : case report .|A 27 - year old African woman with history of regular chloroquine ingestion presented with progressive deterioration of vision , easy fatiguability , dyspnoea , dizziness progressing to syncopal attacks .|Ophthalmological assessment revealed features of chloroquine retinopathy , cardiac assessment revealed features of heart failure and a complete heart block with right bundle branch block pattern .|The heart block was treated by pacemaker insertion and the heart failure resolved spontaneously following chloroquine discontinuation .|She however remains blind .	1:NR:2	L2R	NON-CROSS	0-1	3-5	D002738	Chloroquine|chloroquine|chloroquine|chloroquine	Chemical	0:22:47:84	1:23:48:85	0:1:2:3	D006327	heart block|heart block|heart block	Disease	3:60:70	5:62:72	0:2:3	1:CID:2	L2R	NON-CROSS	0-1	6-7	D002738	Chloroquine|chloroquine|chloroquine|chloroquine	Chemical	0:22:47:84	1:23:48:85	0:1:2:3	D001766	blindness|blind	Disease	6:90	7:91	0:4	1:NR:2	L2R	NON-CROSS	22-23	27-30	D002738	Chloroquine|chloroquine|chloroquine|chloroquine	Chemical	0:22:47:84	1:23:48:85	0:1:2:3	D015354	deterioration of vision	Disease	27	30	1	1:CID:2	L2R	NON-CROSS	22-23	32-33	D002738	Chloroquine|chloroquine|chloroquine|chloroquine	Chemical	0:22:47:84	1:23:48:85	0:1:2:3	D005221	fatiguability	Disease	32	33	1	1:CID:2	L2R	NON-CROSS	22-23	34-35	D002738	Chloroquine|chloroquine|chloroquine|chloroquine	Chemical	0:22:47:84	1:23:48:85	0:1:2:3	D004417	dyspnoea	Disease	34	35	1	1:CID:2	L2R	NON-CROSS	36-37	47-48	D002738	Chloroquine|chloroquine|chloroquine|chloroquine	Chemical	0:22:47:84	1:23:48:85	0:1:2:3	D004244	dizziness	Disease	36	37	1	1:CID:2	L2R	NON-CROSS	39-41	47-48	D002738	Chloroquine|chloroquine|chloroquine|chloroquine	Chemical	0:22:47:84	1:23:48:85	0:1:2:3	D013575	syncopal attacks	Disease	39	41	1	1:CID:2	L2R	NON-CROSS	47-48	48-49	D002738	Chloroquine|chloroquine|chloroquine|chloroquine	Chemical	0:22:47:84	1:23:48:85	0:1:2:3	D012164	retinopathy	Disease	48	49	2	1:CID:2	L2R	NON-CROSS	79-81	84-85	D002738	Chloroquine|chloroquine|chloroquine|chloroquine	Chemical	0:22:47:84	1:23:48:85	0:1:2:3	D006333	heart failure|heart failure	Disease	55:79	57:81	2:3	1:CID:2	L2R	NON-CROSS	47-48	63-67	D002738	Chloroquine|chloroquine|chloroquine|chloroquine	Chemical	0:22:47:84	1:23:48:85	0:1:2:3	D002037	right bundle branch block	Disease	63	67	2
11524350	Systemic toxicity and resuscitation in bupivacaine - , levobupivacaine - , or ropivacaine - infused rats .|We compared the systemic toxicity of bupivacaine , levobupivacaine , and ropivacaine in anesthetized rats .|We also compared the ability to resuscitate rats after lethal doses of these local anesthetics .|Bupivacaine , levobupivacaine , or ropivacaine was infused at a rate of 2 mg .|kg ( - 1 ) .|min ( - 1 ) while electrocardiogram , electroencephalogram , and arterial pressure were continuously monitored .|When asystole was recorded , drug infusion was stopped and a resuscitation sequence was begun .|Epinephrine 0 . 01 mg / kg was administered at 1 - min intervals while external cardiac compressions were applied .|Resuscitation was considered successful when a systolic arterial pressure > or = 100 mm Hg was achieved within 5 min .|The cumulative doses of levobupivacaine and ropivacaine that produced seizures were similar and were larger than those of bupivacaine .|The cumulative doses of levobupivacaine that produced dysrhythmias and asystole were smaller than the corresponding doses of ropivacaine , but they were larger than those of bupivacaine .|The number of successful resuscitations did not differ among groups .|However , a smaller dose of epinephrine was required in the Ropivacaine group than in the other groups .|We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine - induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine .	1:NR:2	R2L	NON-CROSS	23-24	21-22	D002045	bupivacaine|bupivacaine|Bupivacaine|bupivacaine|bupivacaine|bupivacaine|bupivacaine	Chemical	5:23:49:163:191:238:263	6:24:50:164:192:239:264	0:1:3:9:10:13:13	D064420	toxicity|toxicity|toxicity	Disease	1:21:228	2:22:229	0:1:13	1:NR:2	R2L	NON-CROSS	230-231	228-229	C476513	levobupivacaine|levobupivacaine|levobupivacaine|levobupivacaine|levobupivacaine|levobupivacaine|levobupivacaine	Chemical	8:25:51:149:169:230:265	9:26:52:150:170:231:266	0:1:3:9:10:13:13	D064420	toxicity|toxicity|toxicity	Disease	1:21:228	2:22:229	0:1:13	1:NR:2	R2L	NON-CROSS	28-29	21-22	C037663	ropivacaine|ropivacaine|ropivacaine|ropivacaine|ropivacaine|Ropivacaine|ropivacaine|ropivacaine	Chemical	12:28:54:151:182:215:236:247	13:29:55:152:183:216:237:248	0:1:3:9:10:12:13:13	D064420	toxicity|toxicity|toxicity	Disease	1:21:228	2:22:229	0:1:13	1:NR:2	R2L	CROSS	228-229	210-211	D004837	Epinephrine|epinephrine	Chemical	103:210	104:211	7:12	D064420	toxicity|toxicity|toxicity	Disease	1:21:228	2:22:229	0:1:13	1:NR:2	L2R	NON-CROSS	163-164	174-175	D002045	bupivacaine|bupivacaine|Bupivacaine|bupivacaine|bupivacaine|bupivacaine|bupivacaine	Chemical	5:23:49:163:191:238:263	6:24:50:164:192:239:264	0:1:3:9:10:13:13	D006323	asystole|asystole|cardiac arrest	Disease	88:174:250	89:175:252	6:10:13	1:NR:2	L2R	NON-CROSS	154-155	163-164	D002045	bupivacaine|bupivacaine|Bupivacaine|bupivacaine|bupivacaine|bupivacaine|bupivacaine	Chemical	5:23:49:163:191:238:263	6:24:50:164:192:239:264	0:1:3:9:10:13:13	D012640	seizures	Disease	154	155	9	1:NR:2	L2R	NON-CROSS	163-164	172-173	D002045	bupivacaine|bupivacaine|Bupivacaine|bupivacaine|bupivacaine|bupivacaine|bupivacaine	Chemical	5:23:49:163:191:238:263	6:24:50:164:192:239:264	0:1:3:9:10:13:13	D001145	dysrhythmias	Disease	172	173	10	1:CID:2	L2R	NON-CROSS	169-170	174-175	C476513	levobupivacaine|levobupivacaine|levobupivacaine|levobupivacaine|levobupivacaine|levobupivacaine|levobupivacaine	Chemical	8:25:51:149:169:230:265	9:26:52:150:170:231:266	0:1:3:9:10:13:13	D006323	asystole|asystole|cardiac arrest	Disease	88:174:250	89:175:252	6:10:13	1:CID:2	L2R	NON-CROSS	149-150	154-155	C476513	levobupivacaine|levobupivacaine|levobupivacaine|levobupivacaine|levobupivacaine|levobupivacaine|levobupivacaine	Chemical	8:25:51:149:169:230:265	9:26:52:150:170:231:266	0:1:3:9:10:13:13	D012640	seizures	Disease	154	155	9	1:CID:2	L2R	NON-CROSS	169-170	172-173	C476513	levobupivacaine|levobupivacaine|levobupivacaine|levobupivacaine|levobupivacaine|levobupivacaine|levobupivacaine	Chemical	8:25:51:149:169:230:265	9:26:52:150:170:231:266	0:1:3:9:10:13:13	D001145	dysrhythmias	Disease	172	173	10	1:CID:2	L2R	NON-CROSS	247-248	250-252	C037663	ropivacaine|ropivacaine|ropivacaine|ropivacaine|ropivacaine|Ropivacaine|ropivacaine|ropivacaine	Chemical	12:28:54:151:182:215:236:247	13:29:55:152:183:216:237:248	0:1:3:9:10:12:13:13	D006323	asystole|asystole|cardiac arrest	Disease	88:174:250	89:175:252	6:10:13	1:CID:2	L2R	NON-CROSS	151-152	154-155	C037663	ropivacaine|ropivacaine|ropivacaine|ropivacaine|ropivacaine|Ropivacaine|ropivacaine|ropivacaine	Chemical	12:28:54:151:182:215:236:247	13:29:55:152:183:216:237:248	0:1:3:9:10:12:13:13	D012640	seizures	Disease	154	155	9	1:CID:2	L2R	NON-CROSS	172-173	182-183	C037663	ropivacaine|ropivacaine|ropivacaine|ropivacaine|ropivacaine|Ropivacaine|ropivacaine|ropivacaine	Chemical	12:28:54:151:182:215:236:247	13:29:55:152:183:216:237:248	0:1:3:9:10:12:13:13	D001145	dysrhythmias	Disease	172	173	10	1:NR:2	R2L	CROSS	103-104	88-89	D004837	Epinephrine|epinephrine	Chemical	103:210	104:211	7:12	D006323	asystole|asystole|cardiac arrest	Disease	88:174:250	89:175:252	6:10:13	1:NR:2	L2R	CROSS	103-104	154-155	D004837	Epinephrine|epinephrine	Chemical	103:210	104:211	7:12	D012640	seizures	Disease	154	155	9	1:NR:2	L2R	CROSS	172-173	210-211	D004837	Epinephrine|epinephrine	Chemical	103:210	104:211	7:12	D001145	dysrhythmias	Disease	172	173	10
10027919	22 - oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure .|BACKGROUND : Calcitriol therapy suppresses serum levels of parathyroid hormone ( PTH ) in patients with renal failure but has several drawbacks , including hypercalcemia and / or marked suppression of bone turnover , which may lead to adynamic bone disease .|A new vitamin D analogue , 22 - oxacalcitriol ( OCT ) , has been shown to have promising characteristics .|This study was undertaken to determine the effects of OCT on serum PTH levels and bone turnover in states of normal or impaired renal function .|METHODS : Sixty dogs were either nephrectomized ( Nx , N = 38 ) or sham - operated ( Sham , N = 22 ) .|The animals received supplemental phosphate to enhance PTH secretion .|Fourteen weeks after the start of phosphate supplementation , half of the Nx and Sham dogs received doses of OCT ( three times per week ) ; the other half were given vehicle for 60 weeks .|Thereafter , the treatment modalities for a subset of animals were crossed over for an additional eight months .|Biochemical and hormonal indices of calcium and bone metabolism were measured throughout the study , and bone biopsies were done at baseline , 60 weeks after OCT or vehicle treatment , and at the end of the crossover period .|RESULTS : In Nx dogs , OCT significantly decreased serum PTH levels soon after the induction of renal insufficiency .|In long - standing secondary hyperparathyroidism , OCT ( 0 . 03 microg / kg ) stabilized serum PTH levels during the first months .|Serum PTH levels rose thereafter , but the rise was less pronounced compared with baseline than the rise seen in Nx control .|These effects were accompanied by episodes of hypercalcemia and hyperphosphatemia .|In animals with normal renal function , OCT induced a transient decrease in serum PTH levels at a dose of 0 . 1 microg / kg , which was not sustained with lowering of the doses .|In Nx dogs , OCT reversed abnormal bone formation , such as woven osteoid and fibrosis , but did not significantly alter the level of bone turnover .|In addition , OCT improved mineralization lag time , ( that is , the rate at which osteoid mineralizes ) in both Nx and Sham dogs .|CONCLUSIONS : These results indicate that even though OCT does not completely prevent the occurrence of hypercalcemia in experimental dogs with renal insufficiency , it may be of use in the management of secondary hyperparathyroidism because it does not induce low bone turnover and , therefore , does not increase the risk of adynamic bone disease .	1:NR:2	L2R	NON-CROSS	0-3	4-6	C051883	22 - oxacalcitriol|22 - oxacalcitriol|OCT|OCT|OCT|OCT|OCT|OCT|OCT|OCT|OCT|OCT	Chemical	0:65:69:89:161:224:244:265:324:358:385:417	3:68:70:90:162:225:245:266:325:359:386:418	0:2:2:3:6:8:9:10:13:14:15:16	D006962	secondary hyperparathyroidism|secondary hyperparathyroidism|secondary hyperparathyroidism	Disease	4:262:442	6:264:444	0:10:16	1:NR:2	L2R	NON-CROSS	0-3	8-11	C051883	22 - oxacalcitriol|22 - oxacalcitriol|OCT|OCT|OCT|OCT|OCT|OCT|OCT|OCT|OCT|OCT	Chemical	0:65:69:89:161:224:244:265:324:358:385:417	3:68:70:90:162:225:245:266:325:359:386:418	0:2:2:3:6:8:9:10:13:14:15:16	D001851	low bone turnover|suppression of bone turnover|adynamic bone disease|low bone turnover|adynamic bone disease	Disease	8:46:55:449:462	11:50:58:452:465	0:1:1:16:16	1:NR:2	L2R	NON-CROSS	255-257	265-266	C051883	22 - oxacalcitriol|22 - oxacalcitriol|OCT|OCT|OCT|OCT|OCT|OCT|OCT|OCT|OCT|OCT	Chemical	0:65:69:89:161:224:244:265:324:358:385:417	3:68:70:90:162:225:245:266:325:359:386:418	0:2:2:3:6:8:9:10:13:14:15:16	D051437	renal failure|renal failure|renal insufficiency|renal insufficiency	Disease	14:33:255:430	16:35:257:432	0:1:9:16	1:CID:2	L2R	NON-CROSS	417-418	425-426	C051883	22 - oxacalcitriol|22 - oxacalcitriol|OCT|OCT|OCT|OCT|OCT|OCT|OCT|OCT|OCT|OCT	Chemical	0:65:69:89:161:224:244:265:324:358:385:417	3:68:70:90:162:225:245:266:325:359:386:418	0:2:2:3:6:8:9:10:13:14:15:16	D006934	hypercalcemia|hypercalcemia|hypercalcemia	Disease	41:313:425	42:314:426	1:12:16	1:NR:2	L2R	NON-CROSS	89-90	102-105	C051883	22 - oxacalcitriol|22 - oxacalcitriol|OCT|OCT|OCT|OCT|OCT|OCT|OCT|OCT|OCT|OCT	Chemical	0:65:69:89:161:224:244:265:324:358:385:417	3:68:70:90:162:225:245:266:325:359:386:418	0:2:2:3:6:8:9:10:13:14:15:16	D007674	impaired renal function	Disease	102	105	3	1:CID:2	L2R	CROSS	315-316	324-325	C051883	22 - oxacalcitriol|22 - oxacalcitriol|OCT|OCT|OCT|OCT|OCT|OCT|OCT|OCT|OCT|OCT	Chemical	0:65:69:89:161:224:244:265:324:358:385:417	3:68:70:90:162:225:245:266:325:359:386:418	0:2:2:3:6:8:9:10:13:14:15:16	D054559	hyperphosphatemia	Disease	315	316	12	1:NR:2	L2R	NON-CROSS	358-359	369-370	C051883	22 - oxacalcitriol|22 - oxacalcitriol|OCT|OCT|OCT|OCT|OCT|OCT|OCT|OCT|OCT|OCT	Chemical	0:65:69:89:161:224:244:265:324:358:385:417	3:68:70:90:162:225:245:266:325:359:386:418	0:2:2:3:6:8:9:10:13:14:15:16	D005355	fibrosis	Disease	369	370	14	1:NR:2	R2L	CROSS	19-20	4-6	D002117	Calcitriol	Chemical	19	20	1	D006962	secondary hyperparathyroidism|secondary hyperparathyroidism|secondary hyperparathyroidism	Disease	4:262:442	6:264:444	0:10:16	1:NR:2	R2L	CROSS	61-63	4-6	D014807	vitamin D	Chemical	61	63	2	D006962	secondary hyperparathyroidism|secondary hyperparathyroidism|secondary hyperparathyroidism	Disease	4:262:442	6:264:444	0:10:16	1:NR:2	R2L	CROSS	262-264	148-149	D010710	phosphate|phosphate	Chemical	136:148	137:149	5:6	D006962	secondary hyperparathyroidism|secondary hyperparathyroidism|secondary hyperparathyroidism	Disease	4:262:442	6:264:444	0:10:16	1:NR:2	R2L	CROSS	262-264	203-204	D002118	calcium	Chemical	203	204	8	D006962	secondary hyperparathyroidism|secondary hyperparathyroidism|secondary hyperparathyroidism	Disease	4:262:442	6:264:444	0:10:16	1:CID:2	R2L	NON-CROSS	19-20	8-11	D002117	Calcitriol	Chemical	19	20	1	D001851	low bone turnover|suppression of bone turnover|adynamic bone disease|low bone turnover|adynamic bone disease	Disease	8:46:55:449:462	11:50:58:452:465	0:1:1:16:16	1:NR:2	R2L	CROSS	61-63	55-58	D014807	vitamin D	Chemical	61	63	2	D001851	low bone turnover|suppression of bone turnover|adynamic bone disease|low bone turnover|adynamic bone disease	Disease	8:46:55:449:462	11:50:58:452:465	0:1:1:16:16	1:NR:2	R2L	CROSS	136-137	55-58	D010710	phosphate|phosphate	Chemical	136:148	137:149	5:6	D001851	low bone turnover|suppression of bone turnover|adynamic bone disease|low bone turnover|adynamic bone disease	Disease	8:46:55:449:462	11:50:58:452:465	0:1:1:16:16	1:NR:2	R2L	CROSS	203-204	55-58	D002118	calcium	Chemical	203	204	8	D001851	low bone turnover|suppression of bone turnover|adynamic bone disease|low bone turnover|adynamic bone disease	Disease	8:46:55:449:462	11:50:58:452:465	0:1:1:16:16	1:NR:2	R2L	NON-CROSS	19-20	14-16	D002117	Calcitriol	Chemical	19	20	1	D051437	renal failure|renal failure|renal insufficiency|renal insufficiency	Disease	14:33:255:430	16:35:257:432	0:1:9:16	1:NR:2	R2L	CROSS	61-63	33-35	D014807	vitamin D	Chemical	61	63	2	D051437	renal failure|renal failure|renal insufficiency|renal insufficiency	Disease	14:33:255:430	16:35:257:432	0:1:9:16	1:NR:2	R2L	CROSS	136-137	33-35	D010710	phosphate|phosphate	Chemical	136:148	137:149	5:6	D051437	renal failure|renal failure|renal insufficiency|renal insufficiency	Disease	14:33:255:430	16:35:257:432	0:1:9:16	1:NR:2	R2L	CROSS	255-257	203-204	D002118	calcium	Chemical	203	204	8	D051437	renal failure|renal failure|renal insufficiency|renal insufficiency	Disease	14:33:255:430	16:35:257:432	0:1:9:16	1:CID:2	L2R	NON-CROSS	19-20	41-42	D002117	Calcitriol	Chemical	19	20	1	D006934	hypercalcemia|hypercalcemia|hypercalcemia	Disease	41:313:425	42:314:426	1:12:16	1:NR:2	L2R	CROSS	19-20	102-105	D002117	Calcitriol	Chemical	19	20	1	D007674	impaired renal function	Disease	102	105	3	1:NR:2	L2R	CROSS	19-20	315-316	D002117	Calcitriol	Chemical	19	20	1	D054559	hyperphosphatemia	Disease	315	316	12	1:NR:2	L2R	CROSS	19-20	369-370	D002117	Calcitriol	Chemical	19	20	1	D005355	fibrosis	Disease	369	370	14	1:NR:2	R2L	CROSS	61-63	41-42	D014807	vitamin D	Chemical	61	63	2	D006934	hypercalcemia|hypercalcemia|hypercalcemia	Disease	41:313:425	42:314:426	1:12:16	1:NR:2	R2L	CROSS	136-137	41-42	D010710	phosphate|phosphate	Chemical	136:148	137:149	5:6	D006934	hypercalcemia|hypercalcemia|hypercalcemia	Disease	41:313:425	42:314:426	1:12:16	1:NR:2	R2L	CROSS	313-314	203-204	D002118	calcium	Chemical	203	204	8	D006934	hypercalcemia|hypercalcemia|hypercalcemia	Disease	41:313:425	42:314:426	1:12:16	1:NR:2	L2R	CROSS	61-63	102-105	D014807	vitamin D	Chemical	61	63	2	D007674	impaired renal function	Disease	102	105	3	1:NR:2	L2R	CROSS	61-63	315-316	D014807	vitamin D	Chemical	61	63	2	D054559	hyperphosphatemia	Disease	315	316	12	1:NR:2	L2R	CROSS	61-63	369-370	D014807	vitamin D	Chemical	61	63	2	D005355	fibrosis	Disease	369	370	14	1:NR:2	R2L	CROSS	136-137	102-105	D010710	phosphate|phosphate	Chemical	136:148	137:149	5:6	D007674	impaired renal function	Disease	102	105	3	1:NR:2	R2L	CROSS	203-204	102-105	D002118	calcium	Chemical	203	204	8	D007674	impaired renal function	Disease	102	105	3	1:NR:2	L2R	CROSS	148-149	315-316	D010710	phosphate|phosphate	Chemical	136:148	137:149	5:6	D054559	hyperphosphatemia	Disease	315	316	12	1:NR:2	L2R	CROSS	148-149	369-370	D010710	phosphate|phosphate	Chemical	136:148	137:149	5:6	D005355	fibrosis	Disease	369	370	14	1:NR:2	L2R	CROSS	203-204	315-316	D002118	calcium	Chemical	203	204	8	D054559	hyperphosphatemia	Disease	315	316	12	1:NR:2	L2R	CROSS	203-204	369-370	D002118	calcium	Chemical	203	204	8	D005355	fibrosis	Disease	369	370	14
8643966	Chemotherapy of advanced inoperable non - small cell lung cancer with paclitaxel : a phase II trial .|Paclitaxel ( Taxol ; Bristol - Myers Squibb Company , Princeton , NJ ) has demonstrated significant antineoplastic activity against different tumor types , notably ovarian and breast carcinoma .|Two phase II trials of 24 - hour paclitaxel infusions in chemotherapy - naive patients with stage IIIB or IV non - small cell lung cancer ( NSCLC ) reported response rates of 21 % and 24 % .|Leukopenia was dose limiting : as many as 62 . 5 % of patients experienced grade 4 leukopenia .|We investigated the efficacy and toxicity of a 3 - hour paclitaxel infusion in a phase II trial in patients with inoperable stage IIIB or IV NSCLC .|The 58 patients treated ( 41 men and 17 women ) had a median age of 59 years ( age range , 25 to 75 ) and a performance status of 0 through 2 .|Most patients ( 72 . 4 % ) had stage IV NSCLC .|Paclitaxel 225 mg / m2 was infused over 3 hours every 3 weeks with standard prophylactic premedication .|Of 50 patients evaluable for response , 12 ( 24 % ) had partial remission , 26 ( 52 % ) had no change , and 12 had disease progression ( 24 % ) .|Hematologic toxicities were mild : only one patient ( 2 % ) developed grade 3 or 4 neutropenia , while 29 % had grade 1 or 2 .|Grade 1 or 2 polyneuropathy affected 56 % of patients while only one ( 2 % ) experienced severe polyneuropathy .|Similarly , grade 1 or 2 myalgia / arthralgia was observed in 63 . 2 % of patients , but only 14 . 3 % experienced grade 3 or 4 .|Nausea and vomiting were infrequent , with 14 % of patients experiencing grade 1 or 2 and only 2 % experiencing grade 3 or 4 .|Paclitaxel is thus an active single agent in this patient population , with a 3 - hour infusion proving comparably effective to a 24 - hour infusion and superior in terms of the incidence of hematologic and nonhematologic toxicity .|Further phase II studies with paclitaxel combined with other drugs active against NSCLC are indicated , and phase III studies comparing paclitaxel with standard chemotherapy remain to be completed .	1:NR:2	R2L	NON-CROSS	11-12	4-10	D017239	paclitaxel|Paclitaxel|Taxol|paclitaxel|paclitaxel|Paclitaxel|Paclitaxel|paclitaxel|paclitaxel	Chemical	11:18:20:56:117:182:341:386:402	12:19:21:57:118:183:342:387:403	0:1:1:2:4:7:13:14:14	D002289	non - small cell lung cancer|non - small cell lung cancer|NSCLC|NSCLC|NSCLC|NSCLC	Disease	4:68:75:132:180:393	10:74:76:133:181:394	0:2:2:4:6:14	1:NR:2	L2R	NON-CROSS	39-40	56-57	D017239	paclitaxel|Paclitaxel|Taxol|paclitaxel|paclitaxel|Paclitaxel|Paclitaxel|paclitaxel|paclitaxel	Chemical	11:18:20:56:117:182:341:386:402	12:19:21:57:118:183:342:387:403	0:1:1:2:4:7:13:14:14	D009369	tumor	Disease	39	40	1	1:NR:2	L2R	NON-CROSS	43-47	56-57	D017239	paclitaxel|Paclitaxel|Taxol|paclitaxel|paclitaxel|Paclitaxel|Paclitaxel|paclitaxel|paclitaxel	Chemical	11:18:20:56:117:182:341:386:402	12:19:21:57:118:183:342:387:403	0:1:1:2:4:7:13:14:14	D010051	ovarian and breast carcinoma	Disease	43	47	1	1:NR:2	L2R	NON-CROSS	43-47	56-57	D017239	paclitaxel|Paclitaxel|Taxol|paclitaxel|paclitaxel|Paclitaxel|Paclitaxel|paclitaxel|paclitaxel	Chemical	11:18:20:56:117:182:341:386:402	12:19:21:57:118:183:342:387:403	0:1:1:2:4:7:13:14:14	D001943	ovarian and breast carcinoma	Disease	43	47	1	1:NR:2	L2R	CROSS	104-105	117-118	D017239	paclitaxel|Paclitaxel|Taxol|paclitaxel|paclitaxel|Paclitaxel|Paclitaxel|paclitaxel|paclitaxel	Chemical	11:18:20:56:117:182:341:386:402	12:19:21:57:118:183:342:387:403	0:1:1:2:4:7:13:14:14	D007970	Leukopenia|leukopenia	Disease	87:104	88:105	3:3	1:NR:2	L2R	NON-CROSS	111-112	117-118	D017239	paclitaxel|Paclitaxel|Taxol|paclitaxel|paclitaxel|Paclitaxel|Paclitaxel|paclitaxel|paclitaxel	Chemical	11:18:20:56:117:182:341:386:402	12:19:21:57:118:183:342:387:403	0:1:1:2:4:7:13:14:14	D064420	toxicity|toxicities|toxicity	Disease	111:236:379	112:237:380	4:9:13	1:CID:2	L2R	CROSS	182-183	252-253	D017239	paclitaxel|Paclitaxel|Taxol|paclitaxel|paclitaxel|Paclitaxel|Paclitaxel|paclitaxel|paclitaxel	Chemical	11:18:20:56:117:182:341:386:402	12:19:21:57:118:183:342:387:403	0:1:1:2:4:7:13:14:14	D009503	neutropenia	Disease	252	253	9	1:CID:2	L2R	CROSS	282-283	341-342	D017239	paclitaxel|Paclitaxel|Taxol|paclitaxel|paclitaxel|Paclitaxel|Paclitaxel|paclitaxel|paclitaxel	Chemical	11:18:20:56:117:182:341:386:402	12:19:21:57:118:183:342:387:403	0:1:1:2:4:7:13:14:14	D011115	polyneuropathy|polyneuropathy	Disease	267:282	268:283	10:10	1:CID:2	L2R	CROSS	290-291	341-342	D017239	paclitaxel|Paclitaxel|Taxol|paclitaxel|paclitaxel|Paclitaxel|Paclitaxel|paclitaxel|paclitaxel	Chemical	11:18:20:56:117:182:341:386:402	12:19:21:57:118:183:342:387:403	0:1:1:2:4:7:13:14:14	D063806	myalgia	Disease	290	291	11	1:CID:2	L2R	CROSS	292-293	341-342	D017239	paclitaxel|Paclitaxel|Taxol|paclitaxel|paclitaxel|Paclitaxel|Paclitaxel|paclitaxel|paclitaxel	Chemical	11:18:20:56:117:182:341:386:402	12:19:21:57:118:183:342:387:403	0:1:1:2:4:7:13:14:14	D018771	arthralgia	Disease	292	293	11	1:CID:2	L2R	CROSS	315-316	341-342	D017239	paclitaxel|Paclitaxel|Taxol|paclitaxel|paclitaxel|Paclitaxel|Paclitaxel|paclitaxel|paclitaxel	Chemical	11:18:20:56:117:182:341:386:402	12:19:21:57:118:183:342:387:403	0:1:1:2:4:7:13:14:14	D009325	Nausea	Disease	315	316	12	1:CID:2	L2R	CROSS	317-318	341-342	D017239	paclitaxel|Paclitaxel|Taxol|paclitaxel|paclitaxel|Paclitaxel|Paclitaxel|paclitaxel|paclitaxel	Chemical	11:18:20:56:117:182:341:386:402	12:19:21:57:118:183:342:387:403	0:1:1:2:4:7:13:14:14	D014839	vomiting	Disease	317	318	12
6695415	Cerebral hemorrhage associated with phenylpropanolamine in combination with caffeine .|Phenylpropanolamine ( PPA ) is a drug that has been associated with serious side effects including stroke .|It is often combined with caffeine in diet preparations and " look - alike " pills .|In order to determine if PPA / caffeine can lead to stroke in normotensive and / or hypertensive rats , we administered the combination in six times the allowed human dose calculated on a per weight basis for the rats two times per day for five days .|Subarachnoid and cerebral hemorrhage was noted in 18 % of the hypertensive rats .|A single PPA / caffeine administration ( same dose ) lead to acute hypertension in both the normotensive and hypertensive animals .|These results suggest that PPA / caffeine can lead to cerebral hemorrhage in previously hypertensive animals when administered in greater than the allowed dosage .|An acute elevation in blood pressure may be a contributing factor .	1:CID:2	R2L	NON-CROSS	4-5	0-2	D010665	phenylpropanolamine|Phenylpropanolamine|PPA|PPA|PPA|PPA	Chemical	4:10:12:50:109:133	5:11:13:51:110:134	0:1:1:3:5:6	D002543	Cerebral hemorrhage|Subarachnoid and cerebral hemorrhage|cerebral hemorrhage	Disease	0:93:139	2:97:141	0:4:6	1:CID:2	R2L	NON-CROSS	139-141	135-136	D002110	caffeine|caffeine|caffeine|caffeine|caffeine	Chemical	8:33:52:111:135	9:34:53:112:136	0:2:3:5:6	D002543	Cerebral hemorrhage|Subarachnoid and cerebral hemorrhage|cerebral hemorrhage	Disease	0:93:139	2:97:141	0:4:6	1:CID:2	L2R	NON-CROSS	50-51	56-57	D010665	phenylpropanolamine|Phenylpropanolamine|PPA|PPA|PPA|PPA	Chemical	4:10:12:50:109:133	5:11:13:51:110:134	0:1:1:3:5:6	D020521	stroke|stroke	Disease	26:56	27:57	1:3	1:CID:2	L2R	NON-CROSS	104-105	109-110	D010665	phenylpropanolamine|Phenylpropanolamine|PPA|PPA|PPA|PPA	Chemical	4:10:12:50:109:133	5:11:13:51:110:134	0:1:1:3:5:6	D006973	hypertensive|hypertensive|hypertension|hypertensive|hypertensive	Disease	62:104:120:126:143	63:105:121:127:144	3:4:5:5:6	1:CID:2	L2R	CROSS	93-97	109-110	D010665	phenylpropanolamine|Phenylpropanolamine|PPA|PPA|PPA|PPA	Chemical	4:10:12:50:109:133	5:11:13:51:110:134	0:1:1:3:5:6	D013345	Subarachnoid and cerebral hemorrhage	Disease	93	97	4	1:NR:2	L2R	NON-CROSS	52-53	56-57	D002110	caffeine|caffeine|caffeine|caffeine|caffeine	Chemical	8:33:52:111:135	9:34:53:112:136	0:2:3:5:6	D020521	stroke|stroke	Disease	26:56	27:57	1:3	1:CID:2	L2R	NON-CROSS	104-105	111-112	D002110	caffeine|caffeine|caffeine|caffeine|caffeine	Chemical	8:33:52:111:135	9:34:53:112:136	0:2:3:5:6	D006973	hypertensive|hypertensive|hypertension|hypertensive|hypertensive	Disease	62:104:120:126:143	63:105:121:127:144	3:4:5:5:6	1:CID:2	L2R	CROSS	93-97	111-112	D002110	caffeine|caffeine|caffeine|caffeine|caffeine	Chemical	8:33:52:111:135	9:34:53:112:136	0:2:3:5:6	D013345	Subarachnoid and cerebral hemorrhage	Disease	93	97	4
6637851	Long - term efficacy and toxicity of high - dose amiodarone therapy for ventricular tachycardia or ventricular fibrillation .|Amiodarone was administered to 154 patients who had sustained , symptomatic ventricular tachycardia ( VT ) ( n = 118 ) or a cardiac arrest ( n = 36 ) and who were refractory to conventional antiarrhythmic drugs .|The loading dose was 800 mg / day for 6 weeks and the maintenance dose was 600 mg / day .|Sixty - nine percent of patients continued treatment with amiodarone and had no recurrence of symptomatic VT or ventricular fibrillation ( VF ) over a follow - up of 6 to 52 months ( mean + / - standard deviation 14 . 2 + / - 8 . 2 ) .|Six percent of the patients had a nonfatal recurrence of VT and were successfully managed by continuing amiodarone at a higher dose or by the addition of a conventional antiarrhythmic drug .|One or more adverse drug reactions occurred in 51 % of patients .|Adverse effects forced a reduction in the dose of amiodarone in 41 % and discontinuation of amiodarone in 10 % of patients .|The most common symptomatic adverse reactions were tremor or ataxia ( 35 % ) , nausea and anorexia ( 8 % ) , visual halos or blurring ( 6 % ) , thyroid function abnormalities ( 6 % ) and pulmonary interstitial infiltrates ( 5 % ) .|Although large - dose amiodarone is highly effective in the long - term treatment of VT or VF refractory to conventional antiarrhythmic drugs , it causes significant toxicity in approximately 50 % of patients .|However , when the dose is adjusted based on clinical response or the development of adverse effects , 75 % of patients with VT or VF can be successfully managed with amiodarone .	1:NR:2	R2L	NON-CROSS	10-11	5-6	D000638	amiodarone|Amiodarone|amiodarone|amiodarone|amiodarone|amiodarone|amiodarone|amiodarone	Chemical	10:19:88:147:184:191:250:312	11:20:89:148:185:192:251:313	0:1:3:4:6:6:8:9	D064420	toxicity|toxicity	Disease	5:273	6:274	0:8	1:NR:2	L2R	NON-CROSS	10-11	13-15	D000638	amiodarone|Amiodarone|amiodarone|amiodarone|amiodarone|amiodarone|amiodarone|amiodarone	Chemical	10:19:88:147:184:191:250:312	11:20:89:148:185:192:251:313	0:1:3:4:6:6:8:9	D017180	ventricular tachycardia|ventricular tachycardia|VT|VT|VT|VT|VT	Disease	13:30:33:95:140:261:304	15:32:34:96:141:262:305	0:1:1:3:4:8:9	1:NR:2	L2R	NON-CROSS	16-18	19-20	D000638	amiodarone|Amiodarone|amiodarone|amiodarone|amiodarone|amiodarone|amiodarone|amiodarone	Chemical	10:19:88:147:184:191:250:312	11:20:89:148:185:192:251:313	0:1:3:4:6:6:8:9	D014693	ventricular fibrillation|ventricular fibrillation|VF|VF|VF	Disease	16:97:100:263:306	18:99:101:264:307	0:3:3:8:9	1:NR:2	L2R	NON-CROSS	19-20	42-44	D000638	amiodarone|Amiodarone|amiodarone|amiodarone|amiodarone|amiodarone|amiodarone|amiodarone	Chemical	10:19:88:147:184:191:250:312	11:20:89:148:185:192:251:313	0:1:3:4:6:6:8:9	D006323	cardiac arrest	Disease	42	44	1	1:NR:2	L2R	CROSS	191-192	205-206	D000638	amiodarone|Amiodarone|amiodarone|amiodarone|amiodarone|amiodarone|amiodarone|amiodarone	Chemical	10:19:88:147:184:191:250:312	11:20:89:148:185:192:251:313	0:1:3:4:6:6:8:9	D014202	tremor	Disease	205	206	7	1:CID:2	L2R	CROSS	191-192	207-208	D000638	amiodarone|Amiodarone|amiodarone|amiodarone|amiodarone|amiodarone|amiodarone|amiodarone	Chemical	10:19:88:147:184:191:250:312	11:20:89:148:185:192:251:313	0:1:3:4:6:6:8:9	D001259	ataxia	Disease	207	208	7	1:CID:2	L2R	CROSS	191-192	213-214	D000638	amiodarone|Amiodarone|amiodarone|amiodarone|amiodarone|amiodarone|amiodarone|amiodarone	Chemical	10:19:88:147:184:191:250:312	11:20:89:148:185:192:251:313	0:1:3:4:6:6:8:9	D009325	nausea	Disease	213	214	7	1:CID:2	L2R	CROSS	191-192	215-216	D000638	amiodarone|Amiodarone|amiodarone|amiodarone|amiodarone|amiodarone|amiodarone|amiodarone	Chemical	10:19:88:147:184:191:250:312	11:20:89:148:185:192:251:313	0:1:3:4:6:6:8:9	D000855	anorexia	Disease	215	216	7	1:CID:2	L2R	CROSS	221-225	250-251	D000638	amiodarone|Amiodarone|amiodarone|amiodarone|amiodarone|amiodarone|amiodarone|amiodarone	Chemical	10:19:88:147:184:191:250:312	11:20:89:148:185:192:251:313	0:1:3:4:6:6:8:9	D014786	visual halos or blurring	Disease	221	225	7	1:CID:2	L2R	CROSS	230-233	250-251	D000638	amiodarone|Amiodarone|amiodarone|amiodarone|amiodarone|amiodarone|amiodarone|amiodarone	Chemical	10:19:88:147:184:191:250:312	11:20:89:148:185:192:251:313	0:1:3:4:6:6:8:9	D013959	thyroid function abnormalities	Disease	230	233	7
8800187	Effect of calcium chloride and 4 - aminopyridine therapy on desipramine toxicity in rats .|BACKGROUND : Hypotension is a major contributor to mortality in tricyclic antidepressant overdose .|Recent data suggest that tricyclic antidepressants inhibit calcium influx in some tissues .|This study addressed the potential role of calcium channel blockade in tricyclic antidepressant - induced hypotension .|METHODS : Two interventions were studied that have been shown previously to improve blood pressure with calcium channel blocker overdose .|CaCl2 and 4 - aminopyridine .|Anesthetized rats received the tricyclic antidepressant desipramine IP to produce hypotension , QRS prolongation , and bradycardia .|Fifteen min later , animals received CaCl2 , NaHCO3 , or saline .|In a second experiment , rats received tricyclic antidepressant desipramine IP followed in 15 min by 4 - aminopyridine or saline .|RESULTS : NaHCO3 briefly ( 5 min ) reversed hypotension and QRS prolongation .|CaCl2 and 4 - aminopyridine failed to improve blood pressure .|The incidence of ventricular arrhythmias ( p = 0 . 004 ) and seizures ( p = 0 . 03 ) in the CaCl2 group was higher than the other groups .|CONCLUSION : The administration of CaCl2 or 4 - aminopyridine did not reverse tricyclic antidepressant - induced hypotension in rats .|CaCl2 therapy may possibly worsen both cardiovascular and central nervous system toxicity .|These findings do not support a role for calcium channel inhibition in the pathogenesis of tricyclic antidepressant - induced hypotension .	1:NR:2	L2R	NON-CROSS	2-4	11-12	D002122	calcium chloride|CaCl2|CaCl2|CaCl2|CaCl2|CaCl2|CaCl2	Chemical	2:80:110:153:187:201:217	4:81:111:154:188:202:218	0:5:7:10:11:12:13	D064420	toxicity	Disease	11	12	0	1:NR:2	L2R	NON-CROSS	213-214	217-218	D002122	calcium chloride|CaCl2|CaCl2|CaCl2|CaCl2|CaCl2|CaCl2	Chemical	2:80:110:153:187:201:217	4:81:111:154:188:202:218	0:5:7:10:11:12:13	D007022	Hypotension|hypotension|hypotension|hypotension|hypotension|hypotension	Disease	17:57:96:148:213:249	18:58:97:149:214:250	1:3:6:9:12:14	1:NR:2	L2R	CROSS	78-79	80-81	D002122	calcium chloride|CaCl2|CaCl2|CaCl2|CaCl2|CaCl2|CaCl2	Chemical	2:80:110:153:187:201:217	4:81:111:154:188:202:218	0:5:7:10:11:12:13	D062787	overdose|overdose	Disease	27:78	28:79	1:4	1:NR:2	L2R	CROSS	102-103	110-111	D002122	calcium chloride|CaCl2|CaCl2|CaCl2|CaCl2|CaCl2|CaCl2	Chemical	2:80:110:153:187:201:217	4:81:111:154:188:202:218	0:5:7:10:11:12:13	D001919	bradycardia	Disease	102	103	6	1:CID:2	L2R	NON-CROSS	153-154	167-169	D002122	calcium chloride|CaCl2|CaCl2|CaCl2|CaCl2|CaCl2|CaCl2	Chemical	2:80:110:153:187:201:217	4:81:111:154:188:202:218	0:5:7:10:11:12:13	D001145	ventricular arrhythmias	Disease	167	169	11	1:NR:2	L2R	NON-CROSS	177-178	187-188	D002122	calcium chloride|CaCl2|CaCl2|CaCl2|CaCl2|CaCl2|CaCl2	Chemical	2:80:110:153:187:201:217	4:81:111:154:188:202:218	0:5:7:10:11:12:13	D012640	seizures	Disease	177	178	11	1:NR:2	L2R	NON-CROSS	217-218	223-229	D002122	calcium chloride|CaCl2|CaCl2|CaCl2|CaCl2|CaCl2|CaCl2	Chemical	2:80:110:153:187:201:217	4:81:111:154:188:202:218	0:5:7:10:11:12:13	D002318	cardiovascular and central nervous system toxicity	Disease	223	229	13	1:NR:2	L2R	NON-CROSS	217-218	223-229	D002122	calcium chloride|CaCl2|CaCl2|CaCl2|CaCl2|CaCl2|CaCl2	Chemical	2:80:110:153:187:201:217	4:81:111:154:188:202:218	0:5:7:10:11:12:13	D002493	cardiovascular and central nervous system toxicity	Disease	223	229	13	1:NR:2	L2R	NON-CROSS	5-8	11-12	D015761	4 - aminopyridine|4 - aminopyridine|4 - aminopyridine|4 - aminopyridine|4 - aminopyridine	Chemical	5:82:133:155:203	8:85:136:158:206	0:5:8:10:12	D064420	toxicity	Disease	11	12	0	1:NR:2	L2R	NON-CROSS	203-206	213-214	D015761	4 - aminopyridine|4 - aminopyridine|4 - aminopyridine|4 - aminopyridine|4 - aminopyridine	Chemical	5:82:133:155:203	8:85:136:158:206	0:5:8:10:12	D007022	Hypotension|hypotension|hypotension|hypotension|hypotension|hypotension	Disease	17:57:96:148:213:249	18:58:97:149:214:250	1:3:6:9:12:14	1:NR:2	L2R	CROSS	78-79	82-85	D015761	4 - aminopyridine|4 - aminopyridine|4 - aminopyridine|4 - aminopyridine|4 - aminopyridine	Chemical	5:82:133:155:203	8:85:136:158:206	0:5:8:10:12	D062787	overdose|overdose	Disease	27:78	28:79	1:4	1:NR:2	L2R	CROSS	82-85	102-103	D015761	4 - aminopyridine|4 - aminopyridine|4 - aminopyridine|4 - aminopyridine|4 - aminopyridine	Chemical	5:82:133:155:203	8:85:136:158:206	0:5:8:10:12	D001919	bradycardia	Disease	102	103	6	1:NR:2	L2R	CROSS	155-158	167-169	D015761	4 - aminopyridine|4 - aminopyridine|4 - aminopyridine|4 - aminopyridine|4 - aminopyridine	Chemical	5:82:133:155:203	8:85:136:158:206	0:5:8:10:12	D001145	ventricular arrhythmias	Disease	167	169	11	1:NR:2	L2R	CROSS	155-158	177-178	D015761	4 - aminopyridine|4 - aminopyridine|4 - aminopyridine|4 - aminopyridine|4 - aminopyridine	Chemical	5:82:133:155:203	8:85:136:158:206	0:5:8:10:12	D012640	seizures	Disease	177	178	11	1:NR:2	L2R	CROSS	203-206	223-229	D015761	4 - aminopyridine|4 - aminopyridine|4 - aminopyridine|4 - aminopyridine|4 - aminopyridine	Chemical	5:82:133:155:203	8:85:136:158:206	0:5:8:10:12	D002318	cardiovascular and central nervous system toxicity	Disease	223	229	13	1:NR:2	L2R	CROSS	203-206	223-229	D015761	4 - aminopyridine|4 - aminopyridine|4 - aminopyridine|4 - aminopyridine|4 - aminopyridine	Chemical	5:82:133:155:203	8:85:136:158:206	0:5:8:10:12	D002493	cardiovascular and central nervous system toxicity	Disease	223	229	13	1:NR:2	L2R	NON-CROSS	10-11	11-12	D003891	desipramine|desipramine|desipramine	Chemical	10:92:126	11:93:127	0:6:8	D064420	toxicity	Disease	11	12	0	1:CID:2	L2R	NON-CROSS	92-93	96-97	D003891	desipramine|desipramine|desipramine	Chemical	10:92:126	11:93:127	0:6:8	D007022	Hypotension|hypotension|hypotension|hypotension|hypotension|hypotension	Disease	17:57:96:148:213:249	18:58:97:149:214:250	1:3:6:9:12:14	1:NR:2	L2R	CROSS	78-79	92-93	D003891	desipramine|desipramine|desipramine	Chemical	10:92:126	11:93:127	0:6:8	D062787	overdose|overdose	Disease	27:78	28:79	1:4	1:CID:2	L2R	NON-CROSS	92-93	102-103	D003891	desipramine|desipramine|desipramine	Chemical	10:92:126	11:93:127	0:6:8	D001919	bradycardia	Disease	102	103	6	1:CID:2	L2R	CROSS	126-127	167-169	D003891	desipramine|desipramine|desipramine	Chemical	10:92:126	11:93:127	0:6:8	D001145	ventricular arrhythmias	Disease	167	169	11	1:NR:2	L2R	CROSS	126-127	177-178	D003891	desipramine|desipramine|desipramine	Chemical	10:92:126	11:93:127	0:6:8	D012640	seizures	Disease	177	178	11	1:NR:2	L2R	CROSS	126-127	223-229	D003891	desipramine|desipramine|desipramine	Chemical	10:92:126	11:93:127	0:6:8	D002318	cardiovascular and central nervous system toxicity	Disease	223	229	13	1:NR:2	L2R	CROSS	126-127	223-229	D003891	desipramine|desipramine|desipramine	Chemical	10:92:126	11:93:127	0:6:8	D002493	cardiovascular and central nervous system toxicity	Disease	223	229	13	1:NR:2	R2L	CROSS	36-37	11-12	D002118	calcium|calcium|calcium|calcium	Chemical	36:49:75:238	37:50:76:239	2:3:4:14	D064420	toxicity	Disease	11	12	0	1:NR:2	R2L	CROSS	112-113	11-12	D017693	NaHCO3|NaHCO3	Chemical	112:141	113:142	7:9	D064420	toxicity	Disease	11	12	0	1:NR:2	R2L	NON-CROSS	57-58	49-50	D002118	calcium|calcium|calcium|calcium	Chemical	36:49:75:238	37:50:76:239	2:3:4:14	D007022	Hypotension|hypotension|hypotension|hypotension|hypotension|hypotension	Disease	17:57:96:148:213:249	18:58:97:149:214:250	1:3:6:9:12:14	1:NR:2	R2L	NON-CROSS	148-149	141-142	D017693	NaHCO3|NaHCO3	Chemical	112:141	113:142	7:9	D007022	Hypotension|hypotension|hypotension|hypotension|hypotension|hypotension	Disease	17:57:96:148:213:249	18:58:97:149:214:250	1:3:6:9:12:14	1:NR:2	R2L	NON-CROSS	78-79	75-76	D002118	calcium|calcium|calcium|calcium	Chemical	36:49:75:238	37:50:76:239	2:3:4:14	D062787	overdose|overdose	Disease	27:78	28:79	1:4	1:NR:2	R2L	CROSS	112-113	78-79	D017693	NaHCO3|NaHCO3	Chemical	112:141	113:142	7:9	D062787	overdose|overdose	Disease	27:78	28:79	1:4	1:NR:2	L2R	CROSS	75-76	102-103	D002118	calcium|calcium|calcium|calcium	Chemical	36:49:75:238	37:50:76:239	2:3:4:14	D001919	bradycardia	Disease	102	103	6	1:NR:2	L2R	CROSS	167-169	238-239	D002118	calcium|calcium|calcium|calcium	Chemical	36:49:75:238	37:50:76:239	2:3:4:14	D001145	ventricular arrhythmias	Disease	167	169	11	1:NR:2	L2R	CROSS	177-178	238-239	D002118	calcium|calcium|calcium|calcium	Chemical	36:49:75:238	37:50:76:239	2:3:4:14	D012640	seizures	Disease	177	178	11	1:NR:2	L2R	CROSS	223-229	238-239	D002118	calcium|calcium|calcium|calcium	Chemical	36:49:75:238	37:50:76:239	2:3:4:14	D002318	cardiovascular and central nervous system toxicity	Disease	223	229	13	1:NR:2	L2R	CROSS	223-229	238-239	D002118	calcium|calcium|calcium|calcium	Chemical	36:49:75:238	37:50:76:239	2:3:4:14	D002493	cardiovascular and central nervous system toxicity	Disease	223	229	13	1:NR:2	R2L	CROSS	112-113	102-103	D017693	NaHCO3|NaHCO3	Chemical	112:141	113:142	7:9	D001919	bradycardia	Disease	102	103	6	1:NR:2	L2R	CROSS	141-142	167-169	D017693	NaHCO3|NaHCO3	Chemical	112:141	113:142	7:9	D001145	ventricular arrhythmias	Disease	167	169	11	1:NR:2	L2R	CROSS	141-142	177-178	D017693	NaHCO3|NaHCO3	Chemical	112:141	113:142	7:9	D012640	seizures	Disease	177	178	11	1:NR:2	L2R	CROSS	141-142	223-229	D017693	NaHCO3|NaHCO3	Chemical	112:141	113:142	7:9	D002318	cardiovascular and central nervous system toxicity	Disease	223	229	13	1:NR:2	L2R	CROSS	141-142	223-229	D017693	NaHCO3|NaHCO3	Chemical	112:141	113:142	7:9	D002493	cardiovascular and central nervous system toxicity	Disease	223	229	13
7707116	Phase I trial of 13 - cis - retinoic acid in children with neuroblastoma following bone marrow transplantation .|PURPOSE : Treatment of neuroblastoma cell lines with 13 - cis - retinoic acid ( cis - RA ) can cause sustained inhibition of proliferation .|Since cis - RA has demonstrated clinical responses in neuroblastoma patients , it may be effective in preventing relapse after cytotoxic therapy .|This phase I trial was designed to determine the maximal - tolerated dosage ( MTD ) , toxicities , and pharmacokinetics of cis - RA administered on an intermittent schedule in children with neuroblastoma following bone marrow transplantation ( BMT ) .|PATIENTS AND METHODS : Fifty - one assessable patients , 2 to 12 years of age , were treated with oral cis - RA administered in two equally divided doses daily for 2 weeks , followed by a 2 - week rest period , for up to 12 courses .|The dose was escalated from 100 to 200 mg / m2 / d until dose - limiting toxicity ( DLT ) was observed .|A single intrapatient dose escalation was permitted .|RESULTS : The MTD of cis - RA was 160 mg / m2 / d .|Dose - limiting toxicities in six of nine patients at 200 mg / m2 / d included hypercalcemia ( n = 3 ) , rash ( n = 2 ) , and anemia / thrombocytopenia / emesis / rash ( n = 1 ) .|All toxicities resolved after cis - RA was discontinued .|Three complete responses were observed in marrow metastases .|Serum levels of 7 . 4 + / - 3 . 0 mumol / L ( peak ) and 4 . 0 + / - 2 . 8 mumol / L ( trough ) at the MTD were maintained during 14 days of therapy .|The DLT correlated with serum levels > or = 10 mumol / L .|CONCLUSION : The MTD of cis - RA given on this intermittent schedule was 160 mg / m2 / d .|Serum levels known to be effective against neuroblastoma in vitro were achieved at this dose .|The DLT included hypercalcemia , and may be predicted by serum cis - RA levels .|Monitoring of serum calcium and cis - RA levels is indicated in future trials .	1:NR:2	L2R	NON-CROSS	4-10	13-14	D015474	13 - cis - retinoic acid|13 - cis - retinoic acid|cis - RA|cis - RA|cis - RA|cis - RA|cis - RA|cis - RA|cis - RA|cis - RA|cis - RA	Chemical	4:27:34:46:90:131:197:257:336:379:389	10:33:37:49:93:134:200:260:339:382:392	0:1:1:2:3:4:7:9:13:15:16	D009447	neuroblastoma|neuroblastoma|neuroblastoma|neuroblastoma|neuroblastoma	Disease	13:23:54:101:359	14:24:55:102:360	0:1:2:3:14	1:NR:2	L2R	NON-CROSS	254-255	257-260	D015474	13 - cis - retinoic acid|13 - cis - retinoic acid|cis - RA|cis - RA|cis - RA|cis - RA|cis - RA|cis - RA|cis - RA|cis - RA|cis - RA	Chemical	4:27:34:46:90:131:197:257:336:379:389	10:33:37:49:93:134:200:260:339:382:392	0:1:1:2:3:4:7:9:13:15:16	D064420	toxicities|toxicity|toxicities|toxicities	Disease	85:177:211:254	86:178:212:255	3:5:8:9	1:CID:2	L2R	NON-CROSS	371-372	379-382	D015474	13 - cis - retinoic acid|13 - cis - retinoic acid|cis - RA|cis - RA|cis - RA|cis - RA|cis - RA|cis - RA|cis - RA|cis - RA|cis - RA	Chemical	4:27:34:46:90:131:197:257:336:379:389	10:33:37:49:93:134:200:260:339:382:392	0:1:1:2:3:4:7:9:13:15:16	D006934	hypercalcemia|hypercalcemia	Disease	225:371	226:372	8:15	1:CID:2	L2R	CROSS	246-247	257-260	D015474	13 - cis - retinoic acid|13 - cis - retinoic acid|cis - RA|cis - RA|cis - RA|cis - RA|cis - RA|cis - RA|cis - RA|cis - RA|cis - RA	Chemical	4:27:34:46:90:131:197:257:336:379:389	10:33:37:49:93:134:200:260:339:382:392	0:1:1:2:3:4:7:9:13:15:16	D005076	rash|rash	Disease	232:246	233:247	8:8	1:CID:2	L2R	CROSS	240-241	257-260	D015474	13 - cis - retinoic acid|13 - cis - retinoic acid|cis - RA|cis - RA|cis - RA|cis - RA|cis - RA|cis - RA|cis - RA|cis - RA|cis - RA	Chemical	4:27:34:46:90:131:197:257:336:379:389	10:33:37:49:93:134:200:260:339:382:392	0:1:1:2:3:4:7:9:13:15:16	D000740	anemia	Disease	240	241	8	1:CID:2	L2R	CROSS	242-243	257-260	D015474	13 - cis - retinoic acid|13 - cis - retinoic acid|cis - RA|cis - RA|cis - RA|cis - RA|cis - RA|cis - RA|cis - RA|cis - RA|cis - RA	Chemical	4:27:34:46:90:131:197:257:336:379:389	10:33:37:49:93:134:200:260:339:382:392	0:1:1:2:3:4:7:9:13:15:16	D013921	thrombocytopenia	Disease	242	243	8	1:CID:2	L2R	CROSS	244-245	257-260	D015474	13 - cis - retinoic acid|13 - cis - retinoic acid|cis - RA|cis - RA|cis - RA|cis - RA|cis - RA|cis - RA|cis - RA|cis - RA|cis - RA	Chemical	4:27:34:46:90:131:197:257:336:379:389	10:33:37:49:93:134:200:260:339:382:392	0:1:1:2:3:4:7:9:13:15:16	D014839	emesis	Disease	244	245	8	1:NR:2	L2R	CROSS	257-260	270-271	D015474	13 - cis - retinoic acid|13 - cis - retinoic acid|cis - RA|cis - RA|cis - RA|cis - RA|cis - RA|cis - RA|cis - RA|cis - RA|cis - RA	Chemical	4:27:34:46:90:131:197:257:336:379:389	10:33:37:49:93:134:200:260:339:382:392	0:1:1:2:3:4:7:9:13:15:16	D009362	metastases	Disease	270	271	10	1:NR:2	R2L	CROSS	387-388	359-360	D002118	calcium	Chemical	387	388	16	D009447	neuroblastoma|neuroblastoma|neuroblastoma|neuroblastoma|neuroblastoma	Disease	13:23:54:101:359	14:24:55:102:360	0:1:2:3:14	1:NR:2	R2L	CROSS	387-388	254-255	D002118	calcium	Chemical	387	388	16	D064420	toxicities|toxicity|toxicities|toxicities	Disease	85:177:211:254	86:178:212:255	3:5:8:9	1:NR:2	R2L	CROSS	387-388	371-372	D002118	calcium	Chemical	387	388	16	D006934	hypercalcemia|hypercalcemia	Disease	225:371	226:372	8:15	1:NR:2	R2L	CROSS	387-388	246-247	D002118	calcium	Chemical	387	388	16	D005076	rash|rash	Disease	232:246	233:247	8:8	1:NR:2	R2L	CROSS	387-388	240-241	D002118	calcium	Chemical	387	388	16	D000740	anemia	Disease	240	241	8	1:NR:2	R2L	CROSS	387-388	242-243	D002118	calcium	Chemical	387	388	16	D013921	thrombocytopenia	Disease	242	243	8	1:NR:2	R2L	CROSS	387-388	244-245	D002118	calcium	Chemical	387	388	16	D014839	emesis	Disease	244	245	8	1:NR:2	R2L	CROSS	387-388	270-271	D002118	calcium	Chemical	387	388	16	D009362	metastases	Disease	270	271	10
6892185	Effect of calcium chloride on gross behavioural changes produced by carbachol and eserine in cats .|The effect of calcium chloride injected into the cerebral ventricles of group - housed unanaesthetized cats upon vocalization ( rage , hissing and snarling ) , fighting ( attack with paws and claws , defense with paws and claws and biting ) , mydriasis , tremor and clonic - tonic convulsions produced by carbachol and eserine injected similarly was investigated .|Calcium chloride depressed or almost completely abolished the vocalization and fighting due to carbachol and eserine .|On the other hand , mydriasis , tremor and clonic - tonic convulsions evoked by carbachol and eserine were not significantly changed by calcium chloride .|It is apparent that calcium chloride can " dissociate " vocalization and fighting from autonomic and motor phenomena such as mydriasis , tremor and clonic - tonic convulsions caused by carbachol and eserine .|Calcium chloride inhibited the vocalization and fighting produced by carbachol and eserine most probably by a nonspecific stabilizing action on central muscarinic cholinoceptive sites .|These results further support the view that calcium ions in excess have an atropine - like action also in the central nervous system .	1:NR:2	L2R	NON-CROSS	140-141	154-156	D002122	calcium chloride|calcium chloride|Calcium chloride|calcium chloride|calcium chloride|Calcium chloride	Chemical	2:19:77:117:124:154	4:21:79:119:126:156	0:1:2:3:4:5	D015878	mydriasis|mydriasis|mydriasis	Disease	59:99:140	60:100:141	1:3:4	1:NR:2	L2R	NON-CROSS	142-143	154-156	D002122	calcium chloride|calcium chloride|Calcium chloride|calcium chloride|calcium chloride|Calcium chloride	Chemical	2:19:77:117:124:154	4:21:79:119:126:156	0:1:2:3:4:5	D014202	tremor|tremor|tremor	Disease	61:101:142	62:102:143	1:3:4	1:NR:2	L2R	NON-CROSS	144-148	154-156	D002122	calcium chloride|calcium chloride|Calcium chloride|calcium chloride|calcium chloride|Calcium chloride	Chemical	2:19:77:117:124:154	4:21:79:119:126:156	0:1:2:3:4:5	D004830	clonic - tonic convulsions|clonic - tonic convulsions|clonic - tonic convulsions	Disease	63:103:144	67:107:148	1:3:4	1:CID:2	L2R	NON-CROSS	90-91	99-100	D002217	carbachol|carbachol|carbachol|carbachol|carbachol|carbachol	Chemical	10:69:90:109:150:163	11:70:91:110:151:164	0:1:2:3:4:5	D015878	mydriasis|mydriasis|mydriasis	Disease	59:99:140	60:100:141	1:3:4	1:CID:2	L2R	NON-CROSS	61-62	69-70	D002217	carbachol|carbachol|carbachol|carbachol|carbachol|carbachol	Chemical	10:69:90:109:150:163	11:70:91:110:151:164	0:1:2:3:4:5	D014202	tremor|tremor|tremor	Disease	61:101:142	62:102:143	1:3:4	1:CID:2	L2R	NON-CROSS	144-148	150-151	D002217	carbachol|carbachol|carbachol|carbachol|carbachol|carbachol	Chemical	10:69:90:109:150:163	11:70:91:110:151:164	0:1:2:3:4:5	D004830	clonic - tonic convulsions|clonic - tonic convulsions|clonic - tonic convulsions	Disease	63:103:144	67:107:148	1:3:4	1:CID:2	L2R	NON-CROSS	92-93	99-100	D010830	eserine|eserine|eserine|eserine|eserine|eserine	Chemical	12:71:92:111:152:165	13:72:93:112:153:166	0:1:2:3:4:5	D015878	mydriasis|mydriasis|mydriasis	Disease	59:99:140	60:100:141	1:3:4	1:CID:2	L2R	NON-CROSS	92-93	101-102	D010830	eserine|eserine|eserine|eserine|eserine|eserine	Chemical	12:71:92:111:152:165	13:72:93:112:153:166	0:1:2:3:4:5	D014202	tremor|tremor|tremor	Disease	61:101:142	62:102:143	1:3:4	1:CID:2	L2R	NON-CROSS	144-148	152-153	D010830	eserine|eserine|eserine|eserine|eserine|eserine	Chemical	12:71:92:111:152:165	13:72:93:112:153:166	0:1:2:3:4:5	D004830	clonic - tonic convulsions|clonic - tonic convulsions|clonic - tonic convulsions	Disease	63:103:144	67:107:148	1:3:4	1:NR:2	R2L	CROSS	186-187	140-141	D002118	calcium	Chemical	186	187	6	D015878	mydriasis|mydriasis|mydriasis	Disease	59:99:140	60:100:141	1:3:4	1:NR:2	R2L	CROSS	192-193	140-141	D001285	atropine	Chemical	192	193	6	D015878	mydriasis|mydriasis|mydriasis	Disease	59:99:140	60:100:141	1:3:4	1:NR:2	R2L	CROSS	186-187	142-143	D002118	calcium	Chemical	186	187	6	D014202	tremor|tremor|tremor	Disease	61:101:142	62:102:143	1:3:4	1:NR:2	R2L	CROSS	192-193	142-143	D001285	atropine	Chemical	192	193	6	D014202	tremor|tremor|tremor	Disease	61:101:142	62:102:143	1:3:4	1:NR:2	R2L	CROSS	186-187	144-148	D002118	calcium	Chemical	186	187	6	D004830	clonic - tonic convulsions|clonic - tonic convulsions|clonic - tonic convulsions	Disease	63:103:144	67:107:148	1:3:4	1:NR:2	R2L	CROSS	192-193	144-148	D001285	atropine	Chemical	192	193	6	D004830	clonic - tonic convulsions|clonic - tonic convulsions|clonic - tonic convulsions	Disease	63:103:144	67:107:148	1:3:4
6216862	Multiple side effects of penicillamine therapy in one patient with rheumatoid arthritis .|Skin rashes , proteinuria , systemic lupus erythematosus , polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis .|A patient who had developed all 5 is now described .|The skin lesion resembled elastosis perforans serpiginosa , which has been reported as a rare side effect in patients with Wilson 's disease but not in patients with rheumatoid arthritis treated with penicillamine .	1:NR:2	L2R	NON-CROSS	80-82	84-85	D010396	penicillamine|penicillamine|penicillamine	Chemical	4:33:84	5:34:85	0:1:3	D001172	rheumatoid arthritis|rheumatoid arthritis|rheumatoid arthritis	Disease	10:38:80	12:40:82	0:1:3	1:CID:2	L2R	NON-CROSS	4-5	13-15	D010396	penicillamine|penicillamine|penicillamine	Chemical	4:33:84	5:34:85	0:1:3	D005076	Skin rashes	Disease	13	15	1	1:CID:2	L2R	NON-CROSS	4-5	16-17	D010396	penicillamine|penicillamine|penicillamine	Chemical	4:33:84	5:34:85	0:1:3	D011507	proteinuria	Disease	16	17	1	1:CID:2	L2R	NON-CROSS	18-21	33-34	D010396	penicillamine|penicillamine|penicillamine	Chemical	4:33:84	5:34:85	0:1:3	D008180	systemic lupus erythematosus	Disease	18	21	1	1:CID:2	L2R	NON-CROSS	22-23	33-34	D010396	penicillamine|penicillamine|penicillamine	Chemical	4:33:84	5:34:85	0:1:3	D017285	polymyositis	Disease	22	23	1	1:CID:2	L2R	NON-CROSS	24-26	33-34	D010396	penicillamine|penicillamine|penicillamine	Chemical	4:33:84	5:34:85	0:1:3	D009157	myasthenia gravis	Disease	24	26	1	1:NR:2	L2R	NON-CROSS	33-34	53-55	D010396	penicillamine|penicillamine|penicillamine	Chemical	4:33:84	5:34:85	0:1:3	D012871	skin lesion	Disease	53	55	3	1:NR:2	L2R	NON-CROSS	33-34	56-59	D010396	penicillamine|penicillamine|penicillamine	Chemical	4:33:84	5:34:85	0:1:3	C536202	elastosis perforans serpiginosa	Disease	56	59	3	1:NR:2	L2R	NON-CROSS	72-75	84-85	D010396	penicillamine|penicillamine|penicillamine	Chemical	4:33:84	5:34:85	0:1:3	D006527	Wilson 's disease	Disease	72	75	3
2004	Electrocardiographic changes and cardiac arrhythmias in patients receiving psychotropic drugs .|Eight patients had cardiac manifestations that were life - threatening in five while taking psychotropic drugs , either phenothiazines or tricyclic antidepressants .|Although most patients were receiving several drugs , Mellaril ( thioridazine ) appeared to be responsible for five cases of ventricular tachycardia , one of which was fatal in a 35 year old woman .|Supraventricular tachycardia developed in one patient receiving Thorazine ( chlorpromazine ) .|Aventyl ( nortriptyline ) and Elavil ( amitriptyline ) each produced left bundle branch block in a 73 year old woman .|Electrocardiographic T and U wave abnormalities were present in most patients .|The ventricular arrhythmias responded to intravenous administration of lidocaine and to direct current electric shock ; ventricular pacing was required in some instances and intravenous administration of propranolol combined with ventricular pacing in one .|The tachyarrhythmias generally subsided within 48 hours after administration of the drugs was stopped .|Five of the eight patients were 50 years of age or younger ; only one clearly had antecedent heart disease .|Major cardiac arrhythmias are a potential hazard in patients without heart disease who are receiving customary therapeutic doses of psychotropic drugs .|A prospective clinical trial is suggested to quantify the risk of cardiac complications to patients receiving phenothiazines or tricyclic antidepressant drugs .	1:NR:2	R2L	CROSS	29-30	3-5	D010640	phenothiazines|phenothiazines	Chemical	29:224	30:225	1:10	D001145	cardiac arrhythmias|ventricular arrhythmias|cardiac arrhythmias	Disease	3:116:187	5:118:189	0:6:9	1:NR:2	R2L	CROSS	42-43	3-5	D013881	Mellaril|thioridazine	Chemical	42:44	43:45	2:2	D001145	cardiac arrhythmias|ventricular arrhythmias|cardiac arrhythmias	Disease	3:116:187	5:118:189	0:6:9	1:NR:2	R2L	CROSS	116-118	78-79	D002746	Thorazine|chlorpromazine	Chemical	76:78	77:79	3:3	D001145	cardiac arrhythmias|ventricular arrhythmias|cardiac arrhythmias	Disease	3:116:187	5:118:189	0:6:9	1:NR:2	R2L	CROSS	116-118	83-84	D009661	Aventyl|nortriptyline	Chemical	81:83	82:84	4:4	D001145	cardiac arrhythmias|ventricular arrhythmias|cardiac arrhythmias	Disease	3:116:187	5:118:189	0:6:9	1:NR:2	R2L	CROSS	116-118	88-89	D000639	Elavil|amitriptyline	Chemical	86:88	87:89	4:4	D001145	cardiac arrhythmias|ventricular arrhythmias|cardiac arrhythmias	Disease	3:116:187	5:118:189	0:6:9	1:NR:2	R2L	NON-CROSS	123-124	116-118	D008012	lidocaine	Chemical	123	124	6	D001145	cardiac arrhythmias|ventricular arrhythmias|cardiac arrhythmias	Disease	3:116:187	5:118:189	0:6:9	1:NR:2	R2L	NON-CROSS	142-143	116-118	D011433	propranolol	Chemical	142	143	6	D001145	cardiac arrhythmias|ventricular arrhythmias|cardiac arrhythmias	Disease	3:116:187	5:118:189	0:6:9	1:NR:2	L2R	CROSS	29-30	54-56	D010640	phenothiazines|phenothiazines	Chemical	29:224	30:225	1:10	D017180	ventricular tachycardia	Disease	54	56	2	1:NR:2	L2R	CROSS	29-30	69-71	D010640	phenothiazines|phenothiazines	Chemical	29:224	30:225	1:10	D013617	Supraventricular tachycardia	Disease	69	71	3	1:NR:2	L2R	CROSS	29-30	92-96	D010640	phenothiazines|phenothiazines	Chemical	29:224	30:225	1:10	D002037	left bundle branch block	Disease	92	96	4	1:NR:2	L2R	CROSS	151-152	224-225	D010640	phenothiazines|phenothiazines	Chemical	29:224	30:225	1:10	D013610	tachyarrhythmias	Disease	151	152	7	1:NR:2	L2R	CROSS	196-198	224-225	D010640	phenothiazines|phenothiazines	Chemical	29:224	30:225	1:10	D006331	heart disease|heart disease	Disease	183:196	185:198	8:9	1:NR:2	L2R	NON-CROSS	219-221	224-225	D010640	phenothiazines|phenothiazines	Chemical	29:224	30:225	1:10	D005117	cardiac complications	Disease	219	221	10	1:CID:2	L2R	NON-CROSS	44-45	54-56	D013881	Mellaril|thioridazine	Chemical	42:44	43:45	2:2	D017180	ventricular tachycardia	Disease	54	56	2	1:CID:2	L2R	CROSS	44-45	69-71	D013881	Mellaril|thioridazine	Chemical	42:44	43:45	2:2	D013617	Supraventricular tachycardia	Disease	69	71	3	1:NR:2	L2R	CROSS	44-45	92-96	D013881	Mellaril|thioridazine	Chemical	42:44	43:45	2:2	D002037	left bundle branch block	Disease	92	96	4	1:NR:2	L2R	CROSS	44-45	151-152	D013881	Mellaril|thioridazine	Chemical	42:44	43:45	2:2	D013610	tachyarrhythmias	Disease	151	152	7	1:NR:2	L2R	CROSS	44-45	183-185	D013881	Mellaril|thioridazine	Chemical	42:44	43:45	2:2	D006331	heart disease|heart disease	Disease	183:196	185:198	8:9	1:NR:2	L2R	CROSS	44-45	219-221	D013881	Mellaril|thioridazine	Chemical	42:44	43:45	2:2	D005117	cardiac complications	Disease	219	221	10	1:NR:2	R2L	CROSS	76-77	54-56	D002746	Thorazine|chlorpromazine	Chemical	76:78	77:79	3:3	D017180	ventricular tachycardia	Disease	54	56	2	1:NR:2	R2L	CROSS	81-82	54-56	D009661	Aventyl|nortriptyline	Chemical	81:83	82:84	4:4	D017180	ventricular tachycardia	Disease	54	56	2	1:NR:2	R2L	CROSS	86-87	54-56	D000639	Elavil|amitriptyline	Chemical	86:88	87:89	4:4	D017180	ventricular tachycardia	Disease	54	56	2	1:NR:2	R2L	CROSS	123-124	54-56	D008012	lidocaine	Chemical	123	124	6	D017180	ventricular tachycardia	Disease	54	56	2	1:NR:2	R2L	CROSS	142-143	54-56	D011433	propranolol	Chemical	142	143	6	D017180	ventricular tachycardia	Disease	54	56	2	1:NR:2	R2L	NON-CROSS	76-77	69-71	D002746	Thorazine|chlorpromazine	Chemical	76:78	77:79	3:3	D013617	Supraventricular tachycardia	Disease	69	71	3	1:NR:2	R2L	CROSS	81-82	69-71	D009661	Aventyl|nortriptyline	Chemical	81:83	82:84	4:4	D013617	Supraventricular tachycardia	Disease	69	71	3	1:NR:2	R2L	CROSS	86-87	69-71	D000639	Elavil|amitriptyline	Chemical	86:88	87:89	4:4	D013617	Supraventricular tachycardia	Disease	69	71	3	1:NR:2	R2L	CROSS	123-124	69-71	D008012	lidocaine	Chemical	123	124	6	D013617	Supraventricular tachycardia	Disease	69	71	3	1:NR:2	R2L	CROSS	142-143	69-71	D011433	propranolol	Chemical	142	143	6	D013617	Supraventricular tachycardia	Disease	69	71	3	1:NR:2	L2R	CROSS	78-79	92-96	D002746	Thorazine|chlorpromazine	Chemical	76:78	77:79	3:3	D002037	left bundle branch block	Disease	92	96	4	1:NR:2	L2R	CROSS	78-79	151-152	D002746	Thorazine|chlorpromazine	Chemical	76:78	77:79	3:3	D013610	tachyarrhythmias	Disease	151	152	7	1:NR:2	L2R	CROSS	78-79	183-185	D002746	Thorazine|chlorpromazine	Chemical	76:78	77:79	3:3	D006331	heart disease|heart disease	Disease	183:196	185:198	8:9	1:NR:2	L2R	CROSS	78-79	219-221	D002746	Thorazine|chlorpromazine	Chemical	76:78	77:79	3:3	D005117	cardiac complications	Disease	219	221	10	1:CID:2	L2R	NON-CROSS	83-84	92-96	D009661	Aventyl|nortriptyline	Chemical	81:83	82:84	4:4	D002037	left bundle branch block	Disease	92	96	4	1:NR:2	L2R	CROSS	83-84	151-152	D009661	Aventyl|nortriptyline	Chemical	81:83	82:84	4:4	D013610	tachyarrhythmias	Disease	151	152	7	1:NR:2	L2R	CROSS	83-84	183-185	D009661	Aventyl|nortriptyline	Chemical	81:83	82:84	4:4	D006331	heart disease|heart disease	Disease	183:196	185:198	8:9	1:NR:2	L2R	CROSS	83-84	219-221	D009661	Aventyl|nortriptyline	Chemical	81:83	82:84	4:4	D005117	cardiac complications	Disease	219	221	10	1:CID:2	L2R	NON-CROSS	88-89	92-96	D000639	Elavil|amitriptyline	Chemical	86:88	87:89	4:4	D002037	left bundle branch block	Disease	92	96	4	1:NR:2	L2R	CROSS	88-89	151-152	D000639	Elavil|amitriptyline	Chemical	86:88	87:89	4:4	D013610	tachyarrhythmias	Disease	151	152	7	1:NR:2	L2R	CROSS	88-89	183-185	D000639	Elavil|amitriptyline	Chemical	86:88	87:89	4:4	D006331	heart disease|heart disease	Disease	183:196	185:198	8:9	1:NR:2	L2R	CROSS	88-89	219-221	D000639	Elavil|amitriptyline	Chemical	86:88	87:89	4:4	D005117	cardiac complications	Disease	219	221	10	1:NR:2	R2L	CROSS	123-124	92-96	D008012	lidocaine	Chemical	123	124	6	D002037	left bundle branch block	Disease	92	96	4	1:NR:2	R2L	CROSS	142-143	92-96	D011433	propranolol	Chemical	142	143	6	D002037	left bundle branch block	Disease	92	96	4	1:NR:2	L2R	CROSS	123-124	151-152	D008012	lidocaine	Chemical	123	124	6	D013610	tachyarrhythmias	Disease	151	152	7	1:NR:2	L2R	CROSS	123-124	183-185	D008012	lidocaine	Chemical	123	124	6	D006331	heart disease|heart disease	Disease	183:196	185:198	8:9	1:NR:2	L2R	CROSS	123-124	219-221	D008012	lidocaine	Chemical	123	124	6	D005117	cardiac complications	Disease	219	221	10	1:NR:2	L2R	CROSS	142-143	151-152	D011433	propranolol	Chemical	142	143	6	D013610	tachyarrhythmias	Disease	151	152	7	1:NR:2	L2R	CROSS	142-143	183-185	D011433	propranolol	Chemical	142	143	6	D006331	heart disease|heart disease	Disease	183:196	185:198	8:9	1:NR:2	L2R	CROSS	142-143	219-221	D011433	propranolol	Chemical	142	143	6	D005117	cardiac complications	Disease	219	221	10
6118280	Serotonergic drugs , benzodiazepines and baclofen block muscimol - induced myoclonic jerks in a strain of mice .|In male Swiss mice , muscimol produced myoclonic jerks .|A 3 mg / kg ( i . p . ) dose induced this response in all of the mice tested and the peak response of 73 jerks per min was observed between 27 and 45 min .|Increasing the brain serotonin levels by the administration of 5 - hydroxytryptophan ( 80 - 160 mg / kg ) in combination with a peripheral decarboxylase inhibitor resulted in an inhibition of the muscimol effect .|However , in a similar experiment l - dopa ( 80 - 160 mg / kg ) was without effect .|In doses of 3 - 10 mg / kg , the serotonin receptor agonist MK - 212 caused a dose - dependent blockade of the response of muscimol .|Of the benzodiazepines , clonazepam ( 0 . 1 - 0 . 3 mg / kg ) was found to be several fold more potent than diazepam ( 0 . 3 - 3 mg / kg ) in blocking the myoclonic jerks .|While ( - ) - baclofen ( 1 - 3 mg / kg ) proved to be an effective antagonist of muscimol , its ( + ) - isomer ( 5 - 20 mg / kg ) lacked this property .|Considering the fact that 5 - HTP and the benzodiazepines have been found to be beneficial in the management of clinical myoclonus , the muscimol - induced myoclonus seems to be a satisfactory animal model that may prove useful for the development of new drug treatments for this condition .|Our present study indicated the possible value of MK - 212 and ( - ) - baclofen in the management of clinical myoclonus .	1:NR:2	L2R	NON-CROSS	3-4	10-12	D001569	benzodiazepines|benzodiazepines|benzodiazepines	Chemical	3:154:245	4:155:246	0:6:8	D009207	myoclonic jerks|myoclonic jerks|myoclonic jerks|myoclonus|myoclonus|myoclonus	Disease	10:25:192:257:263:308	12:27:194:258:264:309	0:1:6:8:8:9	1:NR:2	L2R	NON-CROSS	5-6	10-12	D001418	baclofen|baclofen|baclofen	Chemical	5:200:302	6:201:303	0:7:9	D009207	myoclonic jerks|myoclonic jerks|myoclonic jerks|myoclonus|myoclonus|myoclonus	Disease	10:25:192:257:263:308	12:27:194:258:264:309	0:1:6:8:8:9	1:CID:2	L2R	NON-CROSS	23-24	25-27	D009118	muscimol|muscimol|muscimol|muscimol|muscimol|muscimol	Chemical	7:23:99:150:216:260	8:24:100:151:217:261	0:1:3:5:7:8	D009207	myoclonic jerks|myoclonic jerks|myoclonic jerks|myoclonus|myoclonus|myoclonus	Disease	10:25:192:257:263:308	12:27:194:258:264:309	0:1:6:8:8:9	1:NR:2	R2L	CROSS	69-70	25-27	D012701	serotonin|serotonin	Chemical	69:134	70:135	3:5	D009207	myoclonic jerks|myoclonic jerks|myoclonic jerks|myoclonus|myoclonus|myoclonus	Disease	10:25:192:257:263:308	12:27:194:258:264:309	0:1:6:8:8:9	1:NR:2	R2L	NON-CROSS	257-258	240-243	D006916	5 - hydroxytryptophan|5 - HTP	Chemical	75:240	78:243	3:8	D009207	myoclonic jerks|myoclonic jerks|myoclonic jerks|myoclonus|myoclonus|myoclonus	Disease	10:25:192:257:263:308	12:27:194:258:264:309	0:1:6:8:8:9	1:NR:2	R2L	CROSS	108-111	25-27	D007980	l - dopa	Chemical	108	111	4	D009207	myoclonic jerks|myoclonic jerks|myoclonic jerks|myoclonus|myoclonus|myoclonus	Disease	10:25:192:257:263:308	12:27:194:258:264:309	0:1:6:8:8:9	1:NR:2	R2L	NON-CROSS	308-309	294-297	C014896	MK - 212|MK - 212	Chemical	137:294	140:297	5:9	D009207	myoclonic jerks|myoclonic jerks|myoclonic jerks|myoclonus|myoclonus|myoclonus	Disease	10:25:192:257:263:308	12:27:194:258:264:309	0:1:6:8:8:9	1:NR:2	R2L	NON-CROSS	192-194	156-157	D002998	clonazepam	Chemical	156	157	6	D009207	myoclonic jerks|myoclonic jerks|myoclonic jerks|myoclonus|myoclonus|myoclonus	Disease	10:25:192:257:263:308	12:27:194:258:264:309	0:1:6:8:8:9	1:NR:2	R2L	NON-CROSS	192-194	178-179	D003975	diazepam	Chemical	178	179	6	D009207	myoclonic jerks|myoclonic jerks|myoclonic jerks|myoclonus|myoclonus|myoclonus	Disease	10:25:192:257:263:308	12:27:194:258:264:309	0:1:6:8:8:9
3703509	Hyperglycemic acidotic coma and death in Kearns - Sayre syndrome .|This paper presents the clinical and metabolic findings in two young boys with long - standing Kearns - Sayre syndrome .|Following short exposure to oral prednisone , both boys developed lethargy , increasing somnolence , polydipsia , polyphagia , and polyuria .|Both presented in the emergency room with profound coma , hypotension , severe hyperglycemia , and acidosis .|Nonketotic lactic acidosis was present in one and ketosis without a known serum lactate level was present in the other .|Respiratory failure rapidly ensued and both patients expired in spite of efforts at resuscitation .|We believe these two cases represent a newly described and catastrophic metabolic - endocrine failure in the Kearns - Sayre syndrome .	1:CID:2	R2L	CROSS	67-68	37-38	D011241	prednisone	Chemical	37	38	2	D006943	Hyperglycemic acidotic coma|hyperglycemia	Disease	0:67	3:68	0:3	1:NR:2	R2L	CROSS	85-86	67-68	D019344	lactate	Chemical	85	86	4	D006943	Hyperglycemic acidotic coma|hyperglycemia	Disease	0:67	3:68	0:3	1:CID:2	R2L	CROSS	37-38	0-3	D011241	prednisone	Chemical	37	38	2	D000140	Hyperglycemic acidotic coma|lactic acidosis	Disease	0:73	3:75	0:4	1:NR:2	R2L	NON-CROSS	85-86	73-75	D019344	lactate	Chemical	85	86	4	D000140	Hyperglycemic acidotic coma|lactic acidosis	Disease	0:73	3:75	0:4	1:CID:2	R2L	CROSS	62-63	37-38	D011241	prednisone	Chemical	37	38	2	D003128	Hyperglycemic acidotic coma|coma	Disease	0:62	3:63	0:3	1:NR:2	R2L	CROSS	85-86	62-63	D019344	lactate	Chemical	85	86	4	D003128	Hyperglycemic acidotic coma|coma	Disease	0:62	3:63	0:3	1:NR:2	R2L	CROSS	37-38	27-31	D011241	prednisone	Chemical	37	38	2	D007625	Kearns - Sayre syndrome|Kearns - Sayre syndrome|Kearns - Sayre syndrome	Disease	6:27:125	10:31:129	0:1:6	1:NR:2	R2L	CROSS	125-129	85-86	D019344	lactate	Chemical	85	86	4	D007625	Kearns - Sayre syndrome|Kearns - Sayre syndrome|Kearns - Sayre syndrome	Disease	6:27:125	10:31:129	0:1:6	1:NR:2	L2R	NON-CROSS	37-38	42-43	D011241	prednisone	Chemical	37	38	2	D053609	lethargy	Disease	42	43	2	1:NR:2	L2R	NON-CROSS	37-38	45-46	D011241	prednisone	Chemical	37	38	2	D006970	somnolence	Disease	45	46	2	1:NR:2	L2R	NON-CROSS	37-38	47-48	D011241	prednisone	Chemical	37	38	2	D059606	polydipsia	Disease	47	48	2	1:NR:2	L2R	NON-CROSS	37-38	49-50	D011241	prednisone	Chemical	37	38	2	D006963	polyphagia	Disease	49	50	2	1:NR:2	L2R	NON-CROSS	37-38	52-53	D011241	prednisone	Chemical	37	38	2	D011141	polyuria	Disease	52	53	2	1:CID:2	L2R	CROSS	37-38	64-65	D011241	prednisone	Chemical	37	38	2	D007022	hypotension	Disease	64	65	3	1:NR:2	L2R	CROSS	37-38	70-71	D011241	prednisone	Chemical	37	38	2	D000138	acidosis	Disease	70	71	3	1:CID:2	L2R	CROSS	37-38	80-81	D011241	prednisone	Chemical	37	38	2	D007662	ketosis	Disease	80	81	4	1:NR:2	L2R	CROSS	37-38	93-95	D011241	prednisone	Chemical	37	38	2	D012131	Respiratory failure	Disease	93	95	5	1:NR:2	R2L	CROSS	85-86	42-43	D019344	lactate	Chemical	85	86	4	D053609	lethargy	Disease	42	43	2	1:NR:2	R2L	CROSS	85-86	45-46	D019344	lactate	Chemical	85	86	4	D006970	somnolence	Disease	45	46	2	1:NR:2	R2L	CROSS	85-86	47-48	D019344	lactate	Chemical	85	86	4	D059606	polydipsia	Disease	47	48	2	1:NR:2	R2L	CROSS	85-86	49-50	D019344	lactate	Chemical	85	86	4	D006963	polyphagia	Disease	49	50	2	1:NR:2	R2L	CROSS	85-86	52-53	D019344	lactate	Chemical	85	86	4	D011141	polyuria	Disease	52	53	2	1:NR:2	R2L	CROSS	85-86	64-65	D019344	lactate	Chemical	85	86	4	D007022	hypotension	Disease	64	65	3	1:NR:2	R2L	CROSS	85-86	70-71	D019344	lactate	Chemical	85	86	4	D000138	acidosis	Disease	70	71	3	1:NR:2	R2L	NON-CROSS	85-86	80-81	D019344	lactate	Chemical	85	86	4	D007662	ketosis	Disease	80	81	4	1:NR:2	L2R	CROSS	85-86	93-95	D019344	lactate	Chemical	85	86	4	D012131	Respiratory failure	Disease	93	95	5
20683499	Effects of active constituents of Crocus sativus L . , crocin on streptozocin - induced model of sporadic Alzheimer 's disease in male rats .|BACKGROUND : The involvement of water - soluble carotenoids , crocins , as the main and active components of Crocus sativus L . extract in learning and memory processes has been proposed .|In the present study , the effect of crocins on sporadic Alzheimer 's disease induced by intracerebroventricular ( icv ) streptozocin ( STZ ) in male rats was investigated .|METHODS : Male adult Wistar rats ( n = 90 and 260 - 290 g ) were divided into 1 , control ; 2 and 3 , crocins ( 15 and 30 mg / kg ) ; 4 , STZ ; 5 and 6 , STZ + crocins ( 15 and 30 mg / kg ) groups .|In Alzheimer 's disease groups , rats were injected with STZ - icv bilaterally ( 3 mg / kg ) in first day and 3 days later , a similar STZ - icv application was repeated .|In STZ + crocin animal groups , crocin was applied in doses of 15 and 30 mg / kg , i . p . , one day pre - surgery and continued for three weeks .|Prescription of crocin in each dose was repeated once for two days .|However , the learning and memory performance was assessed using passive avoidance paradigm , and for spatial cognition evaluation , Y - maze task was used .|RESULTS : It was found out that crocin ( 30 mg / kg ) - treated STZ - injected rats show higher correct choices and lower errors in Y - maze than vehicle - treated STZ - injected rats .|In addition , crocin in the mentioned dose could significantly attenuated learning and memory impairment in treated STZ - injected group in passive avoidance test .|CONCLUSION : Therefore , these results demonstrate the effectiveness of crocin ( 30 mg / kg ) in antagonizing the cognitive deficits caused by STZ - icv in rats and its potential in the treatment of neurodegenerative diseases such as Alzheimer 's disease .	1:NR:2	L2R	NON-CROSS	66-67	69-72	C029036	crocin|crocins|crocins|crocins|crocins|crocin|crocin|crocin|crocin|crocin|crocin	Chemical	10:35:66:115:135:186:190:221:266:302:335	11:36:67:116:136:187:191:222:267:303:336	0:1:2:3:3:5:5:6:8:9:10	D000544	Alzheimer 's disease|Alzheimer 's disease|Alzheimer 's disease|Alzheimer 's disease	Disease	18:69:147:365	21:72:150:368	0:2:4:10	1:NR:2	L2R	NON-CROSS	302-303	310-314	C029036	crocin|crocins|crocins|crocins|crocins|crocin|crocin|crocin|crocin|crocin|crocin	Chemical	10:35:66:115:135:186:190:221:266:302:335	11:36:67:116:136:187:191:222:267:303:336	0:1:2:3:3:5:5:6:8:9:10	D007859	learning and memory impairment	Disease	310	314	9	1:NR:2	L2R	NON-CROSS	302-303	310-314	C029036	crocin|crocins|crocins|crocins|crocins|crocin|crocin|crocin|crocin|crocin|crocin	Chemical	10:35:66:115:135:186:190:221:266:302:335	11:36:67:116:136:187:191:222:267:303:336	0:1:2:3:3:5:5:6:8:9:10	D008569	learning and memory impairment	Disease	310	314	9	1:NR:2	L2R	NON-CROSS	335-336	345-347	C029036	crocin|crocins|crocins|crocins|crocins|crocin|crocin|crocin|crocin|crocin|crocin	Chemical	10:35:66:115:135:186:190:221:266:302:335	11:36:67:116:136:187:191:222:267:303:336	0:1:2:3:3:5:5:6:8:9:10	D003072	cognitive deficits	Disease	345	347	10	1:NR:2	L2R	NON-CROSS	335-336	361-363	C029036	crocin|crocins|crocins|crocins|crocins|crocin|crocin|crocin|crocin|crocin|crocin	Chemical	10:35:66:115:135:186:190:221:266:302:335	11:36:67:116:136:187:191:222:267:303:336	0:1:2:3:3:5:5:6:8:9:10	D019636	neurodegenerative diseases	Disease	361	363	10	1:CID:2	L2R	NON-CROSS	12-13	18-21	D013311	streptozocin|streptozocin|STZ|STZ|STZ|STZ|STZ|STZ|STZ|STZ|STZ|STZ	Chemical	12:78:80:127:133:156:176:184:275:294:316:349	13:79:81:128:134:157:177:185:276:295:317:350	0:2:2:3:3:4:4:5:8:8:9:10	D000544	Alzheimer 's disease|Alzheimer 's disease|Alzheimer 's disease|Alzheimer 's disease	Disease	18:69:147:365	21:72:150:368	0:2:4:10	1:NR:2	L2R	NON-CROSS	310-314	316-317	D013311	streptozocin|streptozocin|STZ|STZ|STZ|STZ|STZ|STZ|STZ|STZ|STZ|STZ	Chemical	12:78:80:127:133:156:176:184:275:294:316:349	13:79:81:128:134:157:177:185:276:295:317:350	0:2:2:3:3:4:4:5:8:8:9:10	D007859	learning and memory impairment	Disease	310	314	9	1:NR:2	L2R	NON-CROSS	310-314	316-317	D013311	streptozocin|streptozocin|STZ|STZ|STZ|STZ|STZ|STZ|STZ|STZ|STZ|STZ	Chemical	12:78:80:127:133:156:176:184:275:294:316:349	13:79:81:128:134:157:177:185:276:295:317:350	0:2:2:3:3:4:4:5:8:8:9:10	D008569	learning and memory impairment	Disease	310	314	9	1:CID:2	L2R	NON-CROSS	345-347	349-350	D013311	streptozocin|streptozocin|STZ|STZ|STZ|STZ|STZ|STZ|STZ|STZ|STZ|STZ	Chemical	12:78:80:127:133:156:176:184:275:294:316:349	13:79:81:128:134:157:177:185:276:295:317:350	0:2:2:3:3:4:4:5:8:8:9:10	D003072	cognitive deficits	Disease	345	347	10	1:NR:2	L2R	NON-CROSS	349-350	361-363	D013311	streptozocin|streptozocin|STZ|STZ|STZ|STZ|STZ|STZ|STZ|STZ|STZ|STZ	Chemical	12:78:80:127:133:156:176:184:275:294:316:349	13:79:81:128:134:157:177:185:276:295:317:350	0:2:2:3:3:4:4:5:8:8:9:10	D019636	neurodegenerative diseases	Disease	361	363	10	1:NR:2	R2L	CROSS	33-34	18-21	D002338	carotenoids	Chemical	33	34	1	D000544	Alzheimer 's disease|Alzheimer 's disease|Alzheimer 's disease|Alzheimer 's disease	Disease	18:69:147:365	21:72:150:368	0:2:4:10	1:NR:2	L2R	CROSS	33-34	310-314	D002338	carotenoids	Chemical	33	34	1	D007859	learning and memory impairment	Disease	310	314	9	1:NR:2	L2R	CROSS	33-34	310-314	D002338	carotenoids	Chemical	33	34	1	D008569	learning and memory impairment	Disease	310	314	9	1:NR:2	L2R	CROSS	33-34	345-347	D002338	carotenoids	Chemical	33	34	1	D003072	cognitive deficits	Disease	345	347	10	1:NR:2	L2R	CROSS	33-34	361-363	D002338	carotenoids	Chemical	33	34	1	D019636	neurodegenerative diseases	Disease	361	363	10
20466178	Rosaceiform dermatitis associated with topical tacrolimus treatment .|We describe herein 3 patients who developed rosacea - like dermatitis eruptions while using 0 . 03 % or 0 . 1 % tacrolimus ointment for facial dermatitis .|Skin biopsy specimens showed telangiectasia and noncaseating epithelioid granulomatous tissue formation in the papillary to mid dermis .|Continuous topical use of immunomodulators such as tacrolimus or pimecrolimus should be regarded as a potential cause of rosaceiform dermatitis , although many cases have not been reported .	1:NR:2	R2L	NON-CROSS	5-6	1-2	D016559	tacrolimus|tacrolimus|tacrolimus	Chemical	5:31:62	6:32:63	0:1:3	D003872	dermatitis|dermatitis|dermatitis	Disease	1:18:74	2:19:75	0:1:3	1:CID:2	R2L	NON-CROSS	74-75	64-65	C117268	pimecrolimus	Chemical	64	65	3	D003872	dermatitis|dermatitis|dermatitis	Disease	1:18:74	2:19:75	0:1:3	1:NR:2	L2R	NON-CROSS	5-6	15-16	D016559	tacrolimus|tacrolimus|tacrolimus	Chemical	5:31:62	6:32:63	0:1:3	D012393	rosacea	Disease	15	16	1	1:NR:2	L2R	NON-CROSS	19-20	31-32	D016559	tacrolimus|tacrolimus|tacrolimus	Chemical	5:31:62	6:32:63	0:1:3	D003875	eruptions	Disease	19	20	1	1:NR:2	L2R	NON-CROSS	31-32	34-36	D016559	tacrolimus|tacrolimus|tacrolimus	Chemical	5:31:62	6:32:63	0:1:3	D005148	facial dermatitis	Disease	34	36	1	1:NR:2	L2R	CROSS	31-32	41-42	D016559	tacrolimus|tacrolimus|tacrolimus	Chemical	5:31:62	6:32:63	0:1:3	D013684	telangiectasia	Disease	41	42	2	1:NR:2	R2L	CROSS	64-65	15-16	C117268	pimecrolimus	Chemical	64	65	3	D012393	rosacea	Disease	15	16	1	1:CID:2	R2L	CROSS	64-65	19-20	C117268	pimecrolimus	Chemical	64	65	3	D003875	eruptions	Disease	19	20	1	1:NR:2	R2L	CROSS	64-65	34-36	C117268	pimecrolimus	Chemical	64	65	3	D005148	facial dermatitis	Disease	34	36	1	1:CID:2	R2L	CROSS	64-65	41-42	C117268	pimecrolimus	Chemical	64	65	3	D013684	telangiectasia	Disease	41	42	2
19944736	A novel animal model to evaluate the ability of a drug delivery system to promote the passage through the BBB .|The purpose of this investigation was to explore the potentiality of a novel animal model to be used for the in vivo evaluation of the ability of a drug delivery system to promote the passage through the blood - brain barrier ( BBB ) and / or to improve the brain localization of a bioactive compound .|A Tween 80 - coated poly - L - lactid acid nanoparticles was used as a model of colloidal drug delivery system , able to trespass the BBB .|Tacrine , administered in LiCl pre - treated rats , induces electrocorticographic seizures and delayed hippocampal damage .|The toxic effects of tacrine - loaded poly - L - lactid acid nanoparticles ( 5mg / kg ) , a saline solution of tacrine ( 5mg / kg ) and an empty colloidal nanoparticle suspension were compared following i . p .|administration in LiCl - pre - treated Wistar rats .|All the animals treated with tacrine - loaded nanoparticles showed an earlier outcome of CNS adverse symptoms , i . e . epileptic onset , with respect to those animals treated with the free compound ( 10 min vs . 22 min respectively ) .|In addition , tacrine - loaded nanoparticles administration induced damage of neuronal cells in CA1 field of the hippocampus in all treated animals , while the saline solution of tacrine only in 60 % of animals .|Empty nanoparticles provided similar results to control ( saline - treated ) group of animals .|In conclusion , the evaluation of time - to - onset of symptoms and the severity of neurodegenerative processes induced by the tacrine - lithium model of epilepsy in the rat , could be used to evaluate preliminarily the capability of a drug delivery system to trespass ( or not ) the BBB in vivo .	1:CID:2	L2R	NON-CROSS	119-120	129-130	D013619	Tacrine|tacrine|tacrine|tacrine|tacrine|tacrine|tacrine	Chemical	107:129:149:183:226:252:298	108:130:150:184:227:253:299	3:4:4:6:7:7:9	D012640	seizures	Disease	119	120	3	1:CID:2	L2R	NON-CROSS	226-227	232-236	D013619	Tacrine|tacrine|tacrine|tacrine|tacrine|tacrine|tacrine	Chemical	107:129:149:183:226:252:298	108:130:150:184:227:253:299	3:4:4:6:7:7:9	D001930	hippocampal damage|damage of neuronal cells	Disease	122:232	124:236	3:7	1:NR:2	L2R	NON-CROSS	298-299	303-304	D013619	Tacrine|tacrine|tacrine|tacrine|tacrine|tacrine|tacrine	Chemical	107:129:149:183:226:252:298	108:130:150:184:227:253:299	3:4:4:6:7:7:9	D004827	epileptic|epilepsy	Disease	200:303	201:304	6:9	1:CID:2	L2R	NON-CROSS	111-112	119-120	D018021	LiCl|LiCl	Chemical	111:170	112:171	3:5	D012640	seizures	Disease	119	120	3	1:CID:2	L2R	NON-CROSS	111-112	122-124	D018021	LiCl|LiCl	Chemical	111:170	112:171	3:5	D001930	hippocampal damage|damage of neuronal cells	Disease	122:232	124:236	3:7	1:NR:2	L2R	CROSS	170-171	200-201	D018021	LiCl|LiCl	Chemical	111:170	112:171	3:5	D004827	epileptic|epilepsy	Disease	200:303	201:304	6:9	1:NR:2	R2L	CROSS	300-301	119-120	D008094	lithium	Chemical	300	301	9	D012640	seizures	Disease	119	120	3	1:NR:2	R2L	CROSS	300-301	232-236	D008094	lithium	Chemical	300	301	9	D001930	hippocampal damage|damage of neuronal cells	Disease	122:232	124:236	3:7	1:NR:2	R2L	NON-CROSS	303-304	300-301	D008094	lithium	Chemical	300	301	9	D004827	epileptic|epilepsy	Disease	200:303	201:304	6:9
19721134	The antiarrhythmic effect and possible ionic mechanisms of pilocarpine on animal models .|This study was designed to evaluate the effects of pilocarpine and explore the underlying ionic mechanism , using both aconitine - induced rat and ouabain - induced guinea pig arrhythmia models .|Confocal microscopy was used to measure intracellular free - calcium concentrations ( [ Ca ( 2 + ) ] ( i ) ) in isolated myocytes .|The current data showed that pilocarpine significantly delayed onset of arrhythmias , decreased the time course of ventricular tachycardia and fibrillation , reduced arrhythmia score , and increased the survival time of arrhythmic rats and guinea pigs .|[ Ca ( 2 + ) ] ( i ) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine .|Moreover , M ( 3 ) - muscarinic acetylcholine receptor ( mAChR ) antagonist 4 - DAMP ( 4 - diphenylacetoxy - N - methylpiperidine - methiodide ) partially abolished the beneficial effects of pilocarpine .|These data suggest that pilocarpine produced antiarrhythmic actions on arrhythmic rat and guinea pig models induced by aconitine or ouabain via stimulating the cardiac M ( 3 ) - mAChR .|The mechanism may be related to the improvement of Ca ( 2 + ) handling .	1:NR:2	L2R	NON-CROSS	77-78	82-83	D010862	pilocarpine|pilocarpine|pilocarpine|pilocarpine|pilocarpine|pilocarpine	Chemical	8:22:77:133:169:175	9:23:78:134:170:176	0:1:3:4:5:6	D001145	arrhythmia|arrhythmias|arrhythmia|arrhythmic|arrhythmic	Disease	42:82:95:104:180	43:83:96:105:181	1:3:3:3:6	1:NR:2	L2R	NON-CROSS	77-78	89-93	D010862	pilocarpine|pilocarpine|pilocarpine|pilocarpine|pilocarpine|pilocarpine	Chemical	8:22:77:133:169:175	9:23:78:134:170:176	0:1:3:4:5:6	D017180	ventricular tachycardia and fibrillation	Disease	89	93	3	1:NR:2	L2R	NON-CROSS	77-78	89-93	D010862	pilocarpine|pilocarpine|pilocarpine|pilocarpine|pilocarpine|pilocarpine	Chemical	8:22:77:133:169:175	9:23:78:134:170:176	0:1:3:4:5:6	D014693	ventricular tachycardia and fibrillation	Disease	89	93	3	1:CID:2	L2R	NON-CROSS	180-181	188-189	D000157	aconitine|aconitine|aconitine	Chemical	32:123:188	33:124:189	1:4:6	D001145	arrhythmia|arrhythmias|arrhythmia|arrhythmic|arrhythmic	Disease	42:82:95:104:180	43:83:96:105:181	1:3:3:3:6	1:NR:2	L2R	CROSS	89-93	123-124	D000157	aconitine|aconitine|aconitine	Chemical	32:123:188	33:124:189	1:4:6	D017180	ventricular tachycardia and fibrillation	Disease	89	93	3	1:NR:2	L2R	CROSS	89-93	123-124	D000157	aconitine|aconitine|aconitine	Chemical	32:123:188	33:124:189	1:4:6	D014693	ventricular tachycardia and fibrillation	Disease	89	93	3	1:CID:2	L2R	NON-CROSS	37-38	42-43	D010042	ouabain|ouabain|ouabain	Chemical	37:125:190	38:126:191	1:4:6	D001145	arrhythmia|arrhythmias|arrhythmia|arrhythmic|arrhythmic	Disease	42:82:95:104:180	43:83:96:105:181	1:3:3:3:6	1:NR:2	L2R	CROSS	89-93	125-126	D010042	ouabain|ouabain|ouabain	Chemical	37:125:190	38:126:191	1:4:6	D017180	ventricular tachycardia and fibrillation	Disease	89	93	3	1:NR:2	L2R	CROSS	89-93	125-126	D010042	ouabain|ouabain|ouabain	Chemical	37:125:190	38:126:191	1:4:6	D014693	ventricular tachycardia and fibrillation	Disease	89	93	3	1:NR:2	R2L	CROSS	111-112	104-105	D002118	calcium|Ca|Ca|Ca	Chemical	54:58:111:211	55:59:112:212	2:2:4:7	D001145	arrhythmia|arrhythmias|arrhythmia|arrhythmic|arrhythmic	Disease	42:82:95:104:180	43:83:96:105:181	1:3:3:3:6	1:NR:2	R2L	CROSS	180-181	143-144	D000109	acetylcholine	Chemical	143	144	5	D001145	arrhythmia|arrhythmias|arrhythmia|arrhythmic|arrhythmic	Disease	42:82:95:104:180	43:83:96:105:181	1:3:3:3:6	1:NR:2	R2L	CROSS	180-181	153-162	C042375	4 - DAMP|4 - diphenylacetoxy - N - methylpiperidine - methiodide	Chemical	149:153	152:162	5:5	D001145	arrhythmia|arrhythmias|arrhythmia|arrhythmic|arrhythmic	Disease	42:82:95:104:180	43:83:96:105:181	1:3:3:3:6	1:NR:2	L2R	CROSS	89-93	111-112	D002118	calcium|Ca|Ca|Ca	Chemical	54:58:111:211	55:59:112:212	2:2:4:7	D017180	ventricular tachycardia and fibrillation	Disease	89	93	3	1:NR:2	L2R	CROSS	89-93	111-112	D002118	calcium|Ca|Ca|Ca	Chemical	54:58:111:211	55:59:112:212	2:2:4:7	D014693	ventricular tachycardia and fibrillation	Disease	89	93	3	1:NR:2	R2L	CROSS	143-144	89-93	D000109	acetylcholine	Chemical	143	144	5	D017180	ventricular tachycardia and fibrillation	Disease	89	93	3	1:NR:2	R2L	CROSS	149-152	89-93	C042375	4 - DAMP|4 - diphenylacetoxy - N - methylpiperidine - methiodide	Chemical	149:153	152:162	5:5	D017180	ventricular tachycardia and fibrillation	Disease	89	93	3	1:NR:2	R2L	CROSS	143-144	89-93	D000109	acetylcholine	Chemical	143	144	5	D014693	ventricular tachycardia and fibrillation	Disease	89	93	3	1:NR:2	R2L	CROSS	149-152	89-93	C042375	4 - DAMP|4 - diphenylacetoxy - N - methylpiperidine - methiodide	Chemical	149:153	152:162	5:5	D014693	ventricular tachycardia and fibrillation	Disease	89	93	3
17786501	Disulfiram - induced transient optic and peripheral neuropathy : a case report .|AIM : To report a case of optic and peripheral neuropathy after chronic use of disulfiram for alcohol dependence management .|MATERIALS AND METHODS : A case report .|RESULTS : A 57 - year - old male presented with gradual loss of vision in both eyes with intermittent headaches for 2 months .|He also complained of paraesthesia with numbness in both feet .|His vision was 6 / 15 and 2 / 60 in the right and left eyes , respectively .|Fundoscopy revealed bilaterally swollen optic nerve heads .|Visual field testing confirmed bilateral central - caecal scotomata .|He had been taking disulfiram for alcohol dependence for the preceding 3 years .|Disulfiram discontinuation lead to an immediate symptomatic improvement .|CONCLUSION : Physicians initiating long - term disulfiram therapy should be aware of these adverse effects .|They should recommend annual ophthalmic reviews with visual field testing .|Patients should be reassured with respect to the reversibility of these adverse effects .	1:CID:2	L2R	NON-CROSS	0-1	4-8	D004221	Disulfiram|disulfiram|disulfiram|Disulfiram|disulfiram	Chemical	0:28:119:129:145	1:29:120:130:146	0:1:8:9:10	D009901	optic and peripheral neuropathy|optic and peripheral neuropathy	Disease	4:20	8:24	0:1	1:NR:2	L2R	NON-CROSS	0-1	4-8	D004221	Disulfiram|disulfiram|disulfiram|Disulfiram|disulfiram	Chemical	0:28:119:129:145	1:29:120:130:146	0:1:8:9:10	D010523	optic and peripheral neuropathy|optic and peripheral neuropathy	Disease	4:20	8:24	0:1	1:NR:2	L2R	NON-CROSS	28-29	30-32	D004221	Disulfiram|disulfiram|disulfiram|Disulfiram|disulfiram	Chemical	0:28:119:129:145	1:29:120:130:146	0:1:8:9:10	D000437	alcohol dependence|alcohol dependence	Disease	30:121	32:123	1:8	1:NR:2	L2R	CROSS	28-29	54-57	D004221	Disulfiram|disulfiram|disulfiram|Disulfiram|disulfiram	Chemical	0:28:119:129:145	1:29:120:130:146	0:1:8:9:10	D014786	loss of vision	Disease	54	57	3	1:NR:2	L2R	CROSS	28-29	62-63	D004221	Disulfiram|disulfiram|disulfiram|Disulfiram|disulfiram	Chemical	0:28:119:129:145	1:29:120:130:146	0:1:8:9:10	D006261	headaches	Disease	62	63	3	1:CID:2	L2R	CROSS	28-29	71-72	D004221	Disulfiram|disulfiram|disulfiram|Disulfiram|disulfiram	Chemical	0:28:119:129:145	1:29:120:130:146	0:1:8:9:10	D010292	paraesthesia	Disease	71	72	4	1:NR:2	L2R	CROSS	28-29	73-74	D004221	Disulfiram|disulfiram|disulfiram|Disulfiram|disulfiram	Chemical	0:28:119:129:145	1:29:120:130:146	0:1:8:9:10	D006987	numbness	Disease	73	74	4	1:CID:2	L2R	CROSS	113-114	119-120	D004221	Disulfiram|disulfiram|disulfiram|Disulfiram|disulfiram	Chemical	0:28:119:129:145	1:29:120:130:146	0:1:8:9:10	D012607	scotomata	Disease	113	114	7
16960342	Sustained clinical improvement of a patient with decompensated hepatitis B virus - related cirrhosis after treatment with lamivudine monotherapy .|Hepatitis B virus ( HBV ) infection , which causes liver cirrhosis and hepatocellular carcinoma , remains a major health problem in Asian countries .|Recent development of vaccine for prevention is reported to be successful in reducing the size of chronically infected carriers , although the standard medical therapies have not been established up to now .|In this report , we encountered a patient with decompensated HBV - related cirrhosis who exhibited the dramatic improvements after antiviral therapy .|The patient was a 50 - year - old woman .|Previous conventional medical treatments were not effective for this patient , thus this patient had been referred to our hospital .|However , the administration of lamivudine , a reverse transcriptase inhibitor , for 23 months dramatically improved her liver severity .|During this period , no drug resistant mutant HBV emerged , and the serum HBV - DNA level was continuously suppressed .|These virological responses were also maintained even after the antiviral therapy was discontinued .|Moreover , both hepatitis B surface antigen and e antigen were observed to have disappeared in this patient .|The administration of lamivudine to patients with HBV - related cirrhosis , like our present case , should be considered as an initial medical therapeutic option , especially in countries where liver transplantation is not reliably available .	1:NR:2	R2L	NON-CROSS	20-27	17-18	D019259	lamivudine|lamivudine|lamivudine	Chemical	17:138:212	18:139:213	0:6:10	D006509	hepatitis B|Hepatitis B virus ( HBV ) infection	Disease	8:20	10:27	0:1	1:CID:2	R2L	CROSS	193-200	20-27	D006514	hepatitis B surface antigen and e antigen	Chemical	193	200	9	D006509	hepatitis B|Hepatitis B virus ( HBV ) infection	Disease	8:20	10:27	0:1	1:CID:2	R2L	CROSS	193-200	20-27	D006513	hepatitis B surface antigen and e antigen	Chemical	193	200	9	D006509	hepatitis B|Hepatitis B virus ( HBV ) infection	Disease	8:20	10:27	0:1	1:NR:2	R2L	NON-CROSS	17-18	13-14	D019259	lamivudine|lamivudine|lamivudine	Chemical	17:138:212	18:139:213	0:6:10	D005355	cirrhosis|cirrhosis|cirrhosis	Disease	13:91:219	14:92:220	0:3:10	1:NR:2	R2L	CROSS	219-220	193-200	D006514	hepatitis B surface antigen and e antigen	Chemical	193	200	9	D005355	cirrhosis|cirrhosis|cirrhosis	Disease	13:91:219	14:92:220	0:3:10	1:NR:2	R2L	CROSS	219-220	193-200	D006513	hepatitis B surface antigen and e antigen	Chemical	193	200	9	D005355	cirrhosis|cirrhosis|cirrhosis	Disease	13:91:219	14:92:220	0:3:10	1:NR:2	L2R	CROSS	17-18	30-32	D019259	lamivudine|lamivudine|lamivudine	Chemical	17:138:212	18:139:213	0:6:10	D008103	liver cirrhosis	Disease	30	32	1	1:NR:2	L2R	CROSS	17-18	33-35	D019259	lamivudine|lamivudine|lamivudine	Chemical	17:138:212	18:139:213	0:6:10	D006528	hepatocellular carcinoma	Disease	33	35	1	1:NR:2	R2L	CROSS	193-200	30-32	D006514	hepatitis B surface antigen and e antigen	Chemical	193	200	9	D008103	liver cirrhosis	Disease	30	32	1	1:NR:2	R2L	CROSS	193-200	30-32	D006513	hepatitis B surface antigen and e antigen	Chemical	193	200	9	D008103	liver cirrhosis	Disease	30	32	1	1:NR:2	R2L	CROSS	193-200	33-35	D006514	hepatitis B surface antigen and e antigen	Chemical	193	200	9	D006528	hepatocellular carcinoma	Disease	33	35	1	1:NR:2	R2L	CROSS	193-200	33-35	D006513	hepatitis B surface antigen and e antigen	Chemical	193	200	9	D006528	hepatocellular carcinoma	Disease	33	35	1
11226639	Dual effects of melatonin on barbiturate - induced narcosis in rats .|Melatonin affects the circadian sleep / wake cycle , but it is not clear whether it may influence drug - induced narcosis .|Sodium thiopenthal was administered intraperitoneally into male rats pre - treated with melatonin ( 0 . 05 , 0 . 5 , 5 and 50 mg / kg ) .|Melatonin pre - treatment affected in a dual manner barbiturate narcosis , however , no dose - effect correlation was found .|In particular , low doses reduced the latency to and prolonged the duration of barbiturate narcosis .|In contrast , the highest dose of melatonin ( 50 mg / kg ) caused a paradoxical increase in the latency and produced a sustained reduction of the duration of narcosis , and a reduction in mortality rate .|Melatonin 0 . 5 and 5 mg / kg influenced the duration but not the latency of ketamine - or diazepam - induced narcosis .|Thus , the dual action of melatonin on pharmacological narcosis seems to be specific for the barbiturate mechanism of action .	1:CID:2	L2R	NON-CROSS	174-175	177-178	D008550	melatonin|Melatonin|melatonin|Melatonin|melatonin|Melatonin|melatonin	Chemical	3:12:47:65:111:143:174	4:13:48:66:112:144:175	0:1:2:3:5:6:7	D053608	narcosis|narcosis|narcosis|narcosis|narcosis|narcosis|narcosis	Disease	8:33:75:102:134:166:177	9:34:76:103:135:167:178	0:1:3:4:5:6:7	1:NR:2	L2R	NON-CROSS	74-75	75-76	C032232	barbiturate|barbiturate|barbiturate|barbiturate	Chemical	5:74:101:184	6:75:102:185	0:3:4:7	D053608	narcosis|narcosis|narcosis|narcosis|narcosis|narcosis|narcosis	Disease	8:33:75:102:134:166:177	9:34:76:103:135:167:178	0:1:3:4:5:6:7	1:CID:2	R2L	CROSS	35-37	33-34	D013874	Sodium thiopenthal	Chemical	35	37	2	D053608	narcosis|narcosis|narcosis|narcosis|narcosis|narcosis|narcosis	Disease	8:33:75:102:134:166:177	9:34:76:103:135:167:178	0:1:3:4:5:6:7	1:CID:2	R2L	NON-CROSS	166-167	160-161	D007649	ketamine	Chemical	160	161	6	D053608	narcosis|narcosis|narcosis|narcosis|narcosis|narcosis|narcosis	Disease	8:33:75:102:134:166:177	9:34:76:103:135:167:178	0:1:3:4:5:6:7	1:CID:2	R2L	NON-CROSS	166-167	163-164	D003975	diazepam	Chemical	163	164	6	D053608	narcosis|narcosis|narcosis|narcosis|narcosis|narcosis|narcosis	Disease	8:33:75:102:134:166:177	9:34:76:103:135:167:178	0:1:3:4:5:6:7
9228650	Effects of NIK - 247 on cholinesterase and scopolamine - induced amnesia .|The effects of NIK - 247 on cholinesterase , scopolamine - induced amnesia and spontaneous movement were examined and compared with those of the well - known cholinesterase inhibitors tacrine and E - 2020 .|NIK - 247 , tacrine and E - 2020 all strongly inhibited acetylcholinesterase ( AChE ) in human red blood cells ( IC50s = 1 . 0 x 10 ( - 6 ) , 2 . 9 x 10 ( - 7 ) and 3 . 7 x 10 ( - 8 ) M , respectively ) .|In addition , NIK - 247 and tacrine , but not E - 2020 , strongly inhibited butyrylcholinestrase ( BuChE ) in human serum .|All three drugs produced mixed inhibition of AChE activity .|Moreover , the inhibitory effect of NIK - 247 on AChE was reversible .|All compounds at 0 . 1 - 1 mg / kg p . o .|significantly improved the amnesia induced by scopolamine ( 0 . 5 mg / kg s . c . ) in rats performing a passive avoidance task .|The three compounds at 1 and 3 mg / kg p . o .|did not significantly decrease spontaneous movement by rats .|These findings suggest that NIK - 247 at a low dose ( 0 . 1 - 1 mg / kg p . o . ) improves scopolamine - induced amnesia but does not affect spontaneous movement .|The findings suggest that NIK - 247 may be a useful drug for the treatment of Alzheimer 's disease .	1:CID:2	L2R	NON-CROSS	11-12	16-19	C049860	NIK - 247|NIK - 247|NIK - 247|NIK - 247|NIK - 247|NIK - 247|NIK - 247	Chemical	2:16:48:109:147:224:261	5:19:51:112:150:227:264	0:1:2:3:5:10:11	D000647	amnesia|amnesia|amnesia|amnesia	Disease	11:25:173:249	12:26:174:250	0:1:7:10	1:NR:2	L2R	NON-CROSS	261-264	273-276	C049860	NIK - 247|NIK - 247|NIK - 247|NIK - 247|NIK - 247|NIK - 247|NIK - 247	Chemical	2:16:48:109:147:224:261	5:19:51:112:150:227:264	0:1:2:3:5:10:11	D000544	Alzheimer 's disease	Disease	273	276	11	1:CID:2	L2R	NON-CROSS	8-9	11-12	D012601	scopolamine|scopolamine|scopolamine|scopolamine	Chemical	8:22:176:246	9:23:177:247	0:1:7:10	D000647	amnesia|amnesia|amnesia|amnesia	Disease	11:25:173:249	12:26:174:250	0:1:7:10	1:NR:2	L2R	CROSS	246-247	273-276	D012601	scopolamine|scopolamine|scopolamine|scopolamine	Chemical	8:22:176:246	9:23:177:247	0:1:7:10	D000544	Alzheimer 's disease	Disease	273	276	11	1:CID:2	R2L	NON-CROSS	42-43	25-26	D013619	tacrine|tacrine|tacrine	Chemical	42:52:113	43:53:114	1:2:3	D000647	amnesia|amnesia|amnesia|amnesia	Disease	11:25:173:249	12:26:174:250	0:1:7:10	1:CID:2	R2L	NON-CROSS	44-47	25-26	C076946	E - 2020|E - 2020|E - 2020	Chemical	44:54:117	47:57:120	1:2:3	D000647	amnesia|amnesia|amnesia|amnesia	Disease	11:25:173:249	12:26:174:250	0:1:7:10	1:NR:2	L2R	CROSS	113-114	273-276	D013619	tacrine|tacrine|tacrine	Chemical	42:52:113	43:53:114	1:2:3	D000544	Alzheimer 's disease	Disease	273	276	11	1:NR:2	L2R	CROSS	117-120	273-276	C076946	E - 2020|E - 2020|E - 2020	Chemical	44:54:117	47:57:120	1:2:3	D000544	Alzheimer 's disease	Disease	273	276	11
8766220	Nightmares and hallucinations after long - term intake of tramadol combined with antidepressants .|Tramadol is a weak opioid with effects on adrenergic and serotonergic neurotransmission that is used to treat cancer pain and chronic non malignant pain .|This drug was initiated in association with paroxetine and dosulepine hydrochloride in a tetraparetic patient with chronic pain .|Fifty - six days after initiation of the treatment the patient presented hallucinations that only stopped after the withdrawal of psycho - active drugs and tramadol .|The case report questions the long term use of pain killers combined with psycho - active drugs in chronic non malignant pain , especially if pain is under control .	1:CID:2	R2L	NON-CROSS	9-10	2-3	D014147	tramadol|Tramadol|tramadol	Chemical	9:14:83	10:15:84	0:1:3	D006212	hallucinations|hallucinations	Disease	2:70	3:71	0:3	1:CID:2	R2L	CROSS	70-71	46-47	D017374	paroxetine	Chemical	46	47	2	D006212	hallucinations|hallucinations	Disease	2:70	3:71	0:3	1:CID:2	R2L	CROSS	70-71	48-50	D004308	dosulepine hydrochloride	Chemical	48	50	2	D006212	hallucinations|hallucinations	Disease	2:70	3:71	0:3	1:NR:2	L2R	NON-CROSS	14-15	31-32	D014147	tramadol|Tramadol|tramadol	Chemical	9:14:83	10:15:84	0:1:3	D009369	cancer	Disease	31	32	1	1:NR:2	L2R	NON-CROSS	83-84	94-95	D014147	tramadol|Tramadol|tramadol	Chemical	9:14:83	10:15:84	0:1:3	D010146	pain|pain|pain|pain|pain	Disease	32:37:94:106:110	33:38:95:107:111	1:1:4:4:4	1:NR:2	L2R	CROSS	55-57	83-84	D014147	tramadol|Tramadol|tramadol	Chemical	9:14:83	10:15:84	0:1:3	D059350	chronic pain	Disease	55	57	2	1:NR:2	R2L	CROSS	46-47	31-32	D017374	paroxetine	Chemical	46	47	2	D009369	cancer	Disease	31	32	1	1:NR:2	R2L	CROSS	48-50	31-32	D004308	dosulepine hydrochloride	Chemical	48	50	2	D009369	cancer	Disease	31	32	1	1:NR:2	R2L	CROSS	46-47	37-38	D017374	paroxetine	Chemical	46	47	2	D010146	pain|pain|pain|pain|pain	Disease	32:37:94:106:110	33:38:95:107:111	1:1:4:4:4	1:NR:2	R2L	CROSS	48-50	37-38	D004308	dosulepine hydrochloride	Chemical	48	50	2	D010146	pain|pain|pain|pain|pain	Disease	32:37:94:106:110	33:38:95:107:111	1:1:4:4:4	1:NR:2	L2R	NON-CROSS	46-47	55-57	D017374	paroxetine	Chemical	46	47	2	D059350	chronic pain	Disease	55	57	2	1:NR:2	L2R	NON-CROSS	48-50	55-57	D004308	dosulepine hydrochloride	Chemical	48	50	2	D059350	chronic pain	Disease	55	57	2
8441146	Apparent cure of rheumatoid arthritis by bone marrow transplantation .|We describe the induction of sustained remissions and possible cure of severe erosive rheumatoid arthritis ( RA ) by bone marrow transplantation ( BMT ) in 2 patients .|BMT was used to treat severe aplastic anemia which was caused by gold in one case and D - penicillamine in the other .|In the 8 and 6 years since the transplants ( representing 8 and 4 years since cessation of all immunosuppressive therapy , respectively ) , the RA in each case has been completely quiescent .|Although short term remission of severe RA following BMT has been reported , these are the first cases for which prolonged followup has been available .|This experience raises the question of the role of BMT itself as a therapeutic option for patients with uncontrolled destructive synovitis .	1:NR:2	R2L	CROSS	51-52	26-27	D006046	gold	Chemical	51	52	2	D001172	rheumatoid arthritis|rheumatoid arthritis|RA|RA|RA	Disease	3:23:26:89:104	5:25:27:90:105	0:1:1:3:4	1:NR:2	R2L	CROSS	56-59	26-27	D010396	D - penicillamine	Chemical	56	59	2	D001172	rheumatoid arthritis|rheumatoid arthritis|RA|RA|RA	Disease	3:23:26:89:104	5:25:27:90:105	0:1:1:3:4	1:CID:2	R2L	NON-CROSS	51-52	45-47	D006046	gold	Chemical	51	52	2	D000741	aplastic anemia	Disease	45	47	2	1:CID:2	R2L	NON-CROSS	56-59	45-47	D010396	D - penicillamine	Chemical	56	59	2	D000741	aplastic anemia	Disease	45	47	2	1:NR:2	L2R	CROSS	51-52	144-145	D006046	gold	Chemical	51	52	2	D013585	synovitis	Disease	144	145	5	1:NR:2	L2R	CROSS	56-59	144-145	D010396	D - penicillamine	Chemical	56	59	2	D013585	synovitis	Disease	144	145	5
3653576	Urinary enzymes and protein patterns as indicators of injury to different regions of the kidney .|Acute experimental models of renal damage to the proximal tubular , glomerular , and papillary regions of the rat were produced by administration of hexachloro - 1 : 3 - butadiene ( HCBD ) , puromycin aminonucleoside ( PAN ) , and 2 - bromoethylamine ( BEA ) , respectively .|Several routine indicators of nephrotoxicity , the enzymes alkaline phosphatase and N - acetyl - beta - glucosaminidase , and the molecular weight of protein excretion were determined on urine samples .|Tubular damage produced by HCBD or BEA was discriminated both quantitatively and qualitatively from glomerular damage produced by PAN .|The latter was characterized by a pronounced increase in protein excretion , especially proteins with molecular weight greater than 40 , 000 Da .|In contrast , protein excretion in tubular damage was raised only slightly and characterized by excretion of proteins of a wide range of molecular weights .|Proximal tubular damage caused by HCBD and papillary damage caused by BEA were distinguished both by conventional urinalysis ( volume and specific gravity ) and by measurement of the two urinary enzymes .|Alkaline phosphatase and glucose were markedly and transiently elevated in proximal tubular damage and N - acetyl - beta - glucosaminidase showed a sustained elevation in papillary damage .|It is concluded that both selective urinary enzymes and the molecular weight pattern of urinary proteins can be used to provide diagnostic information about the possible site of renal damage .	1:NR:2	R2L	NON-CROSS	113-115	103-104	C001335	hexachloro - 1 : 3 - butadiene|HCBD|HCBD|HCBD	Chemical	40:48:103:174	47:49:104:175	1:1:3:6	D007674	injury to different regions of the kidney|nephrotoxicity|glomerular damage|renal damage	Disease	8:71:113:259	15:72:115:261	0:2:3:8	1:NR:2	R2L	NON-CROSS	117-118	113-115	D011692	puromycin aminonucleoside|PAN|PAN	Chemical	51:54:117	53:55:118	1:1:3	D007674	injury to different regions of the kidney|nephrotoxicity|glomerular damage|renal damage	Disease	8:71:113:259	15:72:115:261	0:2:3:8	1:NR:2	R2L	NON-CROSS	113-115	105-106	C004504	2 - bromoethylamine|BEA|BEA|BEA	Chemical	58:62:105:180	61:63:106:181	1:1:3:6	D007674	injury to different regions of the kidney|nephrotoxicity|glomerular damage|renal damage	Disease	8:71:113:259	15:72:115:261	0:2:3:8	1:NR:2	R2L	CROSS	259-261	205-206	D005947	glucose	Chemical	205	206	7	D007674	injury to different regions of the kidney|nephrotoxicity|glomerular damage|renal damage	Disease	8:71:113:259	15:72:115:261	0:2:3:8	1:CID:2	R2L	NON-CROSS	40-47	16-22	C001335	hexachloro - 1 : 3 - butadiene|HCBD|HCBD|HCBD	Chemical	40:48:103:174	47:49:104:175	1:1:3:6	D058186	Acute experimental models of renal damage	Disease	16	22	1	1:CID:2	R2L	NON-CROSS	51-53	16-22	D011692	puromycin aminonucleoside|PAN|PAN	Chemical	51:54:117	53:55:118	1:1:3	D058186	Acute experimental models of renal damage	Disease	16	22	1	1:CID:2	R2L	NON-CROSS	58-61	16-22	C004504	2 - bromoethylamine|BEA|BEA|BEA	Chemical	58:62:105:180	61:63:106:181	1:1:3:6	D058186	Acute experimental models of renal damage	Disease	16	22	1	1:NR:2	R2L	CROSS	205-206	16-22	D005947	glucose	Chemical	205	206	7	D058186	Acute experimental models of renal damage	Disease	16	22	1	1:NR:2	L2R	CROSS	91-93	103-104	C001335	hexachloro - 1 : 3 - butadiene|HCBD|HCBD|HCBD	Chemical	40:48:103:174	47:49:104:175	1:1:3:6	D011507	protein excretion|protein excretion|protein excretion|excretion of proteins	Disease	91:128:146:158	93:130:148:161	2:4:5:5	1:CID:2	L2R	CROSS	117-118	128-130	D011692	puromycin aminonucleoside|PAN|PAN	Chemical	51:54:117	53:55:118	1:1:3	D011507	protein excretion|protein excretion|protein excretion|excretion of proteins	Disease	91:128:146:158	93:130:148:161	2:4:5:5	1:NR:2	L2R	CROSS	91-93	105-106	C004504	2 - bromoethylamine|BEA|BEA|BEA	Chemical	58:62:105:180	61:63:106:181	1:1:3:6	D011507	protein excretion|protein excretion|protein excretion|excretion of proteins	Disease	91:128:146:158	93:130:148:161	2:4:5:5	1:NR:2	R2L	CROSS	205-206	158-161	D005947	glucose	Chemical	205	206	7	D011507	protein excretion|protein excretion|protein excretion|excretion of proteins	Disease	91:128:146:158	93:130:148:161	2:4:5:5
2750819	Neuromuscular blockade with magnesium sulfate and nifedipine .|A patient who received tocolysis with nifedipine developed neuromuscular blockade after 500 mg of magnesium sulfate was administered .|This reaction demonstrates that nifedipine can seriously potentiate the toxicity of magnesium .|Caution should be exercised when these two tocolytics are combined .	1:CID:2	R2L	NON-CROSS	3-5	0-2	D008278	magnesium sulfate|magnesium sulfate	Chemical	3:22	5:24	0:1	D020879	Neuromuscular blockade|neuromuscular blockade	Disease	0:16	2:18	0:1	1:CID:2	R2L	NON-CROSS	16-18	14-15	D009543	nifedipine|nifedipine|nifedipine	Chemical	6:14:31	7:15:32	0:1:2	D020879	Neuromuscular blockade|neuromuscular blockade	Disease	0:16	2:18	0:1	1:NR:2	R2L	CROSS	38-39	16-18	D008274	magnesium	Chemical	38	39	2	D020879	Neuromuscular blockade|neuromuscular blockade	Disease	0:16	2:18	0:1	1:NR:2	L2R	CROSS	22-24	36-37	D008278	magnesium sulfate|magnesium sulfate	Chemical	3:22	5:24	0:1	D064420	toxicity	Disease	36	37	2	1:NR:2	L2R	NON-CROSS	31-32	36-37	D009543	nifedipine|nifedipine|nifedipine	Chemical	6:14:31	7:15:32	0:1:2	D064420	toxicity	Disease	36	37	2	1:NR:2	R2L	NON-CROSS	38-39	36-37	D008274	magnesium	Chemical	38	39	2	D064420	toxicity	Disease	36	37	2
1899352	Ifosfamide continuous infusion without mesna .|A phase I trial of a 14 - day cycle .|Twenty patients received 27 courses of ifosfamide administered as a 24 - hour continuous infusion for 14 days without Mesna .|The goal of the study was to deliver a dose rate and total cumulative dose of ifosfamide that would be comparable to standard bolus or short - term infusions administered with Mesna .|Dose escalations proceeded from 200 to 300 , 400 , 450 , 500 , and 550 mg / m2 / d .|Four patients developed transient microscopic hematuria at 400 , 450 , and 500 mg / m2 / d .|There were no instances of macroscopic hematuria .|At 550 mg / m2 / d , three patients experienced nonurologic toxicity ; confusion ( 1 ) , nausea ( 1 ) , and Grade 2 leukopenia ( 1 ) .|The recommended dose of 500 mg / m2 / d delivers a total dose of 7 g / m2 per cycle , which is comparable to that delivered in clinical practice for bolus or short - term infusion .|Because few patients received multiple courses over time , the cumulative effects are indeterminate in the present trial .|The frequency and predictability of hematuria are not precise , and at least daily monitoring by urine Hematest is essential , adding Mesna to the infusate in patients with persistent hematuria .|The protracted infusion schedule for ifosfamide permits convenient outpatient administration without Mesna and reduces the drug cost of clinical usage of this agent by up to 890 per cycle .|Clinical activity was demonstrated in a single patient , but a comparative trial of standard bolus schedules with the protracted infusion schedule will be necessary to determine if the clinical effectiveness of the drug is maintained .	1:CID:2	L2R	CROSS	240-241	247-248	D007069	Ifosfamide|ifosfamide|ifosfamide|ifosfamide	Chemical	0:23:54:247	1:24:55:248	0:2:3:11	D006417	hematuria|hematuria|hematuria|hematuria	Disease	98:118:215:240	99:119:216:241	5:6:10:10	1:NR:2	L2R	CROSS	54-55	132-133	D007069	Ifosfamide|ifosfamide|ifosfamide|ifosfamide	Chemical	0:23:54:247	1:24:55:248	0:2:3:11	D064420	toxicity	Disease	132	133	7	1:CID:2	L2R	CROSS	54-55	134-135	D007069	Ifosfamide|ifosfamide|ifosfamide|ifosfamide	Chemical	0:23:54:247	1:24:55:248	0:2:3:11	D003221	confusion	Disease	134	135	7	1:CID:2	L2R	CROSS	54-55	139-140	D007069	Ifosfamide|ifosfamide|ifosfamide|ifosfamide	Chemical	0:23:54:247	1:24:55:248	0:2:3:11	D009325	nausea	Disease	139	140	7	1:CID:2	L2R	CROSS	54-55	147-148	D007069	Ifosfamide|ifosfamide|ifosfamide|ifosfamide	Chemical	0:23:54:247	1:24:55:248	0:2:3:11	D007970	leukopenia	Disease	147	148	7	1:NR:2	L2R	NON-CROSS	232-233	240-241	D015080	mesna|Mesna|Mesna|Mesna|Mesna	Chemical	4:36:69:232:253	5:37:70:233:254	0:2:3:10:11	D006417	hematuria|hematuria|hematuria|hematuria	Disease	98:118:215:240	99:119:216:241	5:6:10:10	1:NR:2	L2R	CROSS	69-70	132-133	D015080	mesna|Mesna|Mesna|Mesna|Mesna	Chemical	4:36:69:232:253	5:37:70:233:254	0:2:3:10:11	D064420	toxicity	Disease	132	133	7	1:NR:2	L2R	CROSS	69-70	134-135	D015080	mesna|Mesna|Mesna|Mesna|Mesna	Chemical	4:36:69:232:253	5:37:70:233:254	0:2:3:10:11	D003221	confusion	Disease	134	135	7	1:NR:2	L2R	CROSS	69-70	139-140	D015080	mesna|Mesna|Mesna|Mesna|Mesna	Chemical	4:36:69:232:253	5:37:70:233:254	0:2:3:10:11	D009325	nausea	Disease	139	140	7	1:NR:2	L2R	CROSS	69-70	147-148	D015080	mesna|Mesna|Mesna|Mesna|Mesna	Chemical	4:36:69:232:253	5:37:70:233:254	0:2:3:10:11	D007970	leukopenia	Disease	147	148	7
18161408	Myocardial infarction in pregnancy associated with clomiphene citrate for ovulation induction : a case report .|BACKGROUND : Clomiphene citrate ( CC ) is commonly prescribed for ovulation induction .|It is considered safe , with minimal side effects .|Thromboembolism is a rare but life - threatening complication that has been reported after ovulation induction with CC .|Spontaneous coronary thrombosis or thromboembolism with subsequent clot lysis has been suggested as one of the most common causes of myocardial infarction ( MI ) during pregnancy , with a subsequently normal coronary angiogram .|CASE : A 33 - year - old woman with a 5 - week gestation had recently received CC for ovulation induction and presented with chest pain .|An electrocardiogram showed a lateral and anterior wall myocardial infarction .|Cardiac enzymes showed a peak rise in troponin I to 9 . 10 ng / mL .|An initial exercise stress test was normal .|At the time of admission , the patient was at high risk of radiation injury to the fetus , so a coronary angiogram was postponed until the second trimester .|It showed normal coronary vessels .|CONCLUSION : This appears to be the first reported case documenting a possible association between CC and myocardial infarction .|Thrombosis might be a rare but hazardous complication of CC .|Given this life - threatening complication , appropriate prophylactic measures should be used in high - risk woman undergoing ovarian stimulation .	1:CID:2	R2L	NON-CROSS	211-213	209-210	D002996	clomiphene citrate|Clomiphene citrate|CC|CC|CC|CC|CC	Chemical	6:18:21:57:112:209:223	8:20:22:58:113:210:224	0:1:1:3:5:11:12	D009203	Myocardial infarction|myocardial infarction|MI|myocardial infarction|myocardial infarction	Disease	0:79:82:130:211	2:81:83:132:213	0:4:4:6:11	1:CID:2	L2R	NON-CROSS	57-58	63-64	D002996	clomiphene citrate|Clomiphene citrate|CC|CC|CC|CC|CC	Chemical	6:18:21:57:112:209:223	8:20:22:58:113:210:224	0:1:1:3:5:11:12	D013923	Thromboembolism|thromboembolism	Disease	40:63	41:64	3:4	1:NR:2	L2R	CROSS	57-58	60-62	D002996	clomiphene citrate|Clomiphene citrate|CC|CC|CC|CC|CC	Chemical	6:18:21:57:112:209:223	8:20:22:58:113:210:224	0:1:1:3:5:11:12	D003328	coronary thrombosis	Disease	60	62	4	1:NR:2	L2R	NON-CROSS	112-113	119-121	D002996	clomiphene citrate|Clomiphene citrate|CC|CC|CC|CC|CC	Chemical	6:18:21:57:112:209:223	8:20:22:58:113:210:224	0:1:1:3:5:11:12	D002637	chest pain	Disease	119	121	5	1:NR:2	L2R	CROSS	171-173	209-210	D002996	clomiphene citrate|Clomiphene citrate|CC|CC|CC|CC|CC	Chemical	6:18:21:57:112:209:223	8:20:22:58:113:210:224	0:1:1:3:5:11:12	D011832	radiation injury	Disease	171	173	9	1:NR:2	L2R	NON-CROSS	209-210	214-215	D002996	clomiphene citrate|Clomiphene citrate|CC|CC|CC|CC|CC	Chemical	6:18:21:57:112:209:223	8:20:22:58:113:210:224	0:1:1:3:5:11:12	D013927	Thrombosis	Disease	214	215	12
17574447	Hepatonecrosis and cholangitis related to long - term phenobarbital therapy : an autopsy report of two patients .|Phenobarbital ( PB ) has a reputation for safety , and it is commonly believed that PB - related increases in serum aminotransferase levels do not indicate or predict the development of significant chronic liver disease .|Here we report of two adult patients with a long history of epilepsy treated with PB who died suddenly : one as consequence of cardiac arrest , the other of acute bronchopneumonia .|At autopsy , analysis of liver parenchyma revealed rich portal inflammatory infiltrate , which consisted of mixed eosinophil and monocyte cells , associated with several foci of necrosis surrounded by a hard ring of non - specific granulomatous tissue .|Inflammatory reactions of internal and external hepatic biliary ducts were also seen .|Our findings illustrate that PB may be associated with chronic liver damage , which may lead to more serious and deleterious consequences .|For this reason , each clinician should recognize this entity in the differential diagnosis of PB - related asymptomatic chronic hepatic enzyme dysfunction .	1:CID:2	R2L	NON-CROSS	8-9	2-3	D010634	phenobarbital|Phenobarbital|PB|PB|PB|PB|PB	Chemical	8:18:20:34:70:145:179	9:19:21:35:71:146:180	0:1:1:1:2:5:6	D002761	cholangitis	Disease	2	3	0	1:CID:2	L2R	NON-CROSS	145-146	151-153	D010634	phenobarbital|Phenobarbital|PB|PB|PB|PB|PB	Chemical	8:18:20:34:70:145:179	9:19:21:35:71:146:180	0:1:1:1:2:5:6	D008107	liver disease|liver damage	Disease	52:151	54:153	1:5	1:NR:2	L2R	NON-CROSS	67-68	70-71	D010634	phenobarbital|Phenobarbital|PB|PB|PB|PB|PB	Chemical	8:18:20:34:70:145:179	9:19:21:35:71:146:180	0:1:1:1:2:5:6	D004827	epilepsy	Disease	67	68	2	1:NR:2	L2R	NON-CROSS	70-71	79-81	D010634	phenobarbital|Phenobarbital|PB|PB|PB|PB|PB	Chemical	8:18:20:34:70:145:179	9:19:21:35:71:146:180	0:1:1:1:2:5:6	D006323	cardiac arrest	Disease	79	81	2	1:NR:2	L2R	NON-CROSS	70-71	86-87	D010634	phenobarbital|Phenobarbital|PB|PB|PB|PB|PB	Chemical	8:18:20:34:70:145:179	9:19:21:35:71:146:180	0:1:1:1:2:5:6	D001996	bronchopneumonia	Disease	86	87	2	1:NR:2	L2R	CROSS	115-116	145-146	D010634	phenobarbital|Phenobarbital|PB|PB|PB|PB|PB	Chemical	8:18:20:34:70:145:179	9:19:21:35:71:146:180	0:1:1:1:2:5:6	D009336	necrosis	Disease	115	116	3	1:NR:2	L2R	NON-CROSS	179-180	183-187	D010634	phenobarbital|Phenobarbital|PB|PB|PB|PB|PB	Chemical	8:18:20:34:70:145:179	9:19:21:35:71:146:180	0:1:1:1:2:5:6	D056487	chronic hepatic enzyme dysfunction	Disease	183	187	6
16710500	Ethambutol - associated optic neuropathy .|INTRODUCTION : Ethambutol is used in the treatment of tuberculosis , which is still prevalent in Southeast Asia , and can be associated with permanent visual loss .|We report 3 cases which presented with bitemporal hemianopia .|CLINICAL PICTURE : Three patients with ethambutol - associated toxic optic neuropathy are described .|All 3 patients had loss of central visual acuity , colour vision ( Ishihara ) and visual field .|The visual field loss had a bitemporal flavour , suggesting involvement of the optic chiasm .|TREATMENT : Despite stopping ethambutol on diagnosis , visual function continued to deteriorate for a few months .|Subsequent improvement was mild in 2 cases .|In the third case , visual acuity and colour vision normalised but the optic discs were pale .|OUTCOME : All 3 patients had some permanent loss of visual function .|CONCLUSIONS : Ethambutol usage is associated with permanent visual loss and should be avoided if possible or used with caution and proper ophthalmological follow - up .|The author postulates that in cases of ethambutol associated chiasmopathy , ethambutol may initially affect the optic nerves and subsequently progress to involve the optic chiasm .	1:CID:2	L2R	NON-CROSS	0-1	3-5	D004977	Ethambutol|Ethambutol|ethambutol|ethambutol|Ethambutol|ethambutol|ethambutol	Chemical	0:8:50:98:153:185:189	1:9:51:99:154:186:190	0:1:3:6:10:11:11	D009901	optic neuropathy|optic neuropathy	Disease	3:54	5:56	0:3	1:NR:2	L2R	NON-CROSS	8-9	15-16	D004977	Ethambutol|Ethambutol|ethambutol|ethambutol|Ethambutol|ethambutol|ethambutol	Chemical	0:8:50:98:153:185:189	1:9:51:99:154:186:190	0:1:3:6:10:11:11	D014376	tuberculosis	Disease	15	16	1	1:CID:2	L2R	NON-CROSS	153-154	159-161	D004977	Ethambutol|Ethambutol|ethambutol|ethambutol|Ethambutol|ethambutol|ethambutol	Chemical	0:8:50:98:153:185:189	1:9:51:99:154:186:190	0:1:3:6:10:11:11	D014786	visual loss|loss of central visual acuity , colour vision ( Ishihara ) and visual field|visual field loss|loss of visual function|visual loss	Disease	31:63:79:146:159	33:77:82:150:161	1:4:5:9:10	1:NR:2	L2R	CROSS	41-43	50-51	D004977	Ethambutol|Ethambutol|ethambutol|ethambutol|Ethambutol|ethambutol|ethambutol	Chemical	0:8:50:98:153:185:189	1:9:51:99:154:186:190	0:1:3:6:10:11:11	D006423	bitemporal hemianopia	Disease	41	43	2
11694026	Tolerability of nimesulide and paracetamol in patients with NSAID - induced urticaria / angioedema .|Previous studies evaluated the tolerance of nimesulide and paracetamol in subjects with cutaneous , respiratory and anaphylactoid reactions induced by nonsteroidal anti - inflammatory drugs ( NSAIDs ) .|In this study we investigated tolerability and reliability of nimesulide and paracetamol in a very large number of patients with an exclusive well - documented history of NSAID - induced urticaria / angioedema .|Furthermore , we evaluated whether some factors have the potential to increase the risk of reaction to paracetamol and nimesulide .|A single - placebo - controlled oral challenge procedure with nimesulide or paracetamol was applied to 829 patients with a history of NSAID - induced urticaria / angioedema .|A total of 75 / 829 ( 9 . 4 % ) patients experienced reactions to nimesulide or paracetamol .|Of the 715 patients tested with nimesulide 62 ( 8 . 6 % ) showed a positive test , while of 114 subjects submitted to the challenge with paracetamol , 13 ( 9 . 6 % ) did not tolerate this drug .|Furthermore , 18 . 28 % of patients with a history of chronic urticaria and 11 . 8 % of subjects with an history of NSAID - induced urticaria / angioedema or angioedema alone ( with or without chronic urticaria ) resulted to be intolerant to alternative drugs .|Taken together , our results confirm the good tolerability of nimesulide and paracetamol in patients who experienced urticaria / angioedema caused by NSAIDs .|However , the risk of reaction to these alternative study drugs is statistically increased by a history of chronic urticaria and , above all , by a history of NSAID - induced angioedema .	1:NR:2	L2R	NON-CROSS	250-251	257-258	C012655	nimesulide|nimesulide|nimesulide|nimesulide|nimesulide|nimesulide|nimesulide|nimesulide	Chemical	2:21:53:97:109:144:154:250	3:22:54:98:110:145:155:251	0:1:2:3:4:5:6:8	D014581	urticaria|urticaria|urticaria|urticaria|urticaria|urticaria|urticaria|urticaria	Disease	11:74:124:204:219:230:257:283	12:75:125:205:220:231:258:284	0:2:4:7:7:7:8:9	1:CID:2	L2R	NON-CROSS	13-14	21-22	C012655	nimesulide|nimesulide|nimesulide|nimesulide|nimesulide|nimesulide|nimesulide|nimesulide	Chemical	2:21:53:97:109:144:154:250	3:22:54:98:110:145:155:251	0:1:2:3:4:5:6:8	D000799	angioedema|angioedema|angioedema|angioedema|angioedema|angioedema|angioedema	Disease	13:76:126:221:223:259:296	14:77:127:222:224:260:297	0:2:4:7:7:8:9	1:NR:2	L2R	NON-CROSS	252-253	257-258	D000082	paracetamol|paracetamol|paracetamol|paracetamol|paracetamol|paracetamol|paracetamol|paracetamol	Chemical	4:23:55:95:111:146:176:252	5:24:56:96:112:147:177:253	0:1:2:3:4:5:6:8	D014581	urticaria|urticaria|urticaria|urticaria|urticaria|urticaria|urticaria|urticaria	Disease	11:74:124:204:219:230:257:283	12:75:125:205:220:231:258:284	0:2:4:7:7:7:8:9	1:CID:2	L2R	NON-CROSS	252-253	259-260	D000082	paracetamol|paracetamol|paracetamol|paracetamol|paracetamol|paracetamol|paracetamol|paracetamol	Chemical	4:23:55:95:111:146:176:252	5:24:56:96:112:147:177:253	0:1:2:3:4:5:6:8	D000799	angioedema|angioedema|angioedema|angioedema|angioedema|angioedema|angioedema	Disease	13:76:126:221:223:259:296	14:77:127:222:224:260:297	0:2:4:7:7:8:9	1:NR:2	L2R	NON-CROSS	8-9	11-12	D000894	NSAID|nonsteroidal anti - inflammatory drugs|NSAIDs|NSAID|NSAID|NSAID|NSAIDs|NSAID	Chemical	8:35:41:71:121:216:262:293	9:40:42:72:122:217:263:294	0:1:1:2:4:7:8:9	D014581	urticaria|urticaria|urticaria|urticaria|urticaria|urticaria|urticaria|urticaria	Disease	11:74:124:204:219:230:257:283	12:75:125:205:220:231:258:284	0:2:4:7:7:7:8:9	1:CID:2	L2R	NON-CROSS	259-260	262-263	D000894	NSAID|nonsteroidal anti - inflammatory drugs|NSAIDs|NSAID|NSAID|NSAID|NSAIDs|NSAID	Chemical	8:35:41:71:121:216:262:293	9:40:42:72:122:217:263:294	0:1:1:2:4:7:8:9	D000799	angioedema|angioedema|angioedema|angioedema|angioedema|angioedema|angioedema	Disease	13:76:126:221:223:259:296	14:77:127:222:224:260:297	0:2:4:7:7:8:9
11282081	Effects of verapamil on atrial fibrillation and its electrophysiological determinants in dogs .|BACKGROUND : Atrial tachycardia - induced remodeling promotes the occurrence and maintenance of atrial fibrillation ( AF ) and decreases L - type Ca ( 2 + ) current .|There is also a clinical suggestion that acute L - type Ca ( 2 ) channel blockade can promote AF , consistent with an AF promoting effect of Ca ( 2 + ) channel inhibition .|METHODS : To evaluate the potential mechanisms of AF promotion by Ca ( 2 + ) channel blockers , we administered verapamil to morphine - chloralose anesthetized dogs .|Diltiazem was used as a comparison drug and autonomic blockade with atropine and nadolol was applied in some experiments .|Epicardial mapping with 240 epicardial electrodes was used to evaluate activation during AF .|RESULTS : Verapamil caused AF promotion in six dogs , increasing mean duration of AF induced by burst pacing , from 8 + / - 4 s ( mean + / - S . E . ) to 95 + / - 39 s ( P < 0 . 01 vs . control ) at a loading dose of 0 . 1 mg / kg and 228 + / - 101 s ( P < 0 . 0005 vs . control ) at a dose of 0 . 2 mg / kg .|Underlying electrophysiological mechanisms were studied in detail in five additional dogs under control conditions and in the presence of the higher dose of verapamil .|In these experiments , verapamil shortened mean effective refractory period ( ERP ) from 122 + / - 5 to 114 + / - 4 ms ( P < 0 . 02 ) at a cycle length of 300 ms , decreased ERP heterogeneity ( from 15 + / - 1 to 10 + / - 1 % , P < 0 . 05 ) , heterogeneously accelerated atrial conduction and decreased the cycle length of AF ( 94 + / - 4 to 84 + / - 3 ms , P < 0 . 005 ) .|Diltiazem did not affect ERP , AF cycle length or AF duration , but produced conduction acceleration similar to that caused by verapamil ( n = 5 ) .|In the presence of autonomic blockade , verapamil failed to promote AF and increased , rather than decreasing , refractoriness .|Neither verapamil nor diltiazem affected atrial conduction in the presence of autonomic blockade .|Epicardial mapping suggested that verapamil promoted AF by increasing the number of simultaneous wavefronts reflected by separate zones of reactivation in each cycle .|CONCLUSIONS : Verapamil promotes AF in normal dogs by promoting multiple circuit reentry , an effect dependent on intact autonomic tone and not shared by diltiazem .	1:CID:2	L2R	NON-CROSS	2-3	4-6	D014700	verapamil|verapamil|Verapamil|verapamil|verapamil|verapamil|verapamil|verapamil|verapamil|Verapamil	Chemical	2:100:144:258:264:380:394:409:426:448	3:101:145:259:265:381:395:410:427:449	0:3:6:7:8:9:10:11:12:13	D001281	atrial fibrillation|atrial fibrillation|AF|AF|AF|AF|AF|AF|AF|AF|AF|AF|AF|AF|AF	Disease	4:26:29:62:67:87:140:146:156:336:364:368:398:428:450	6:28:30:63:68:88:141:147:157:337:365:369:399:429:451	0:1:1:2:2:3:5:6:6:8:9:9:10:12:13	1:NR:2	L2R	CROSS	2-3	15-17	D014700	verapamil|verapamil|Verapamil|verapamil|verapamil|verapamil|verapamil|verapamil|verapamil|Verapamil	Chemical	2:100:144:258:264:380:394:409:426:448	3:101:145:259:265:381:395:410:427:449	0:3:6:7:8:9:10:11:12:13	D013617	Atrial tachycardia	Disease	15	17	1	1:NR:2	R2L	NON-CROSS	90-91	87-88	D002118	Ca|Ca|Ca|Ca	Chemical	36:54:71:90	37:55:72:91	1:2:2:3	D001281	atrial fibrillation|atrial fibrillation|AF|AF|AF|AF|AF|AF|AF|AF|AF|AF|AF|AF|AF	Disease	4:26:29:62:67:87:140:146:156:336:364:368:398:428:450	6:28:30:63:68:88:141:147:157:337:365:369:399:429:451	0:1:1:2:2:3:5:6:6:8:9:9:10:12:13	1:NR:2	R2L	NON-CROSS	102-103	87-88	D009020	morphine	Chemical	102	103	3	D001281	atrial fibrillation|atrial fibrillation|AF|AF|AF|AF|AF|AF|AF|AF|AF|AF|AF|AF|AF	Disease	4:26:29:62:67:87:140:146:156:336:364:368:398:428:450	6:28:30:63:68:88:141:147:157:337:365:369:399:429:451	0:1:1:2:2:3:5:6:6:8:9:9:10:12:13	1:NR:2	R2L	NON-CROSS	104-105	87-88	D002698	chloralose	Chemical	104	105	3	D001281	atrial fibrillation|atrial fibrillation|AF|AF|AF|AF|AF|AF|AF|AF|AF|AF|AF|AF|AF	Disease	4:26:29:62:67:87:140:146:156:336:364:368:398:428:450	6:28:30:63:68:88:141:147:157:337:365:369:399:429:451	0:1:1:2:2:3:5:6:6:8:9:9:10:12:13	1:NR:2	R2L	NON-CROSS	364-365	358-359	D004110	Diltiazem|Diltiazem|diltiazem|diltiazem	Chemical	108:358:411:471	109:359:412:472	4:9:11:13	D001281	atrial fibrillation|atrial fibrillation|AF|AF|AF|AF|AF|AF|AF|AF|AF|AF|AF|AF|AF	Disease	4:26:29:62:67:87:140:146:156:336:364:368:398:428:450	6:28:30:63:68:88:141:147:157:337:365:369:399:429:451	0:1:1:2:2:3:5:6:6:8:9:9:10:12:13	1:NR:2	R2L	CROSS	140-141	119-120	D001285	atropine	Chemical	119	120	4	D001281	atrial fibrillation|atrial fibrillation|AF|AF|AF|AF|AF|AF|AF|AF|AF|AF|AF|AF|AF	Disease	4:26:29:62:67:87:140:146:156:336:364:368:398:428:450	6:28:30:63:68:88:141:147:157:337:365:369:399:429:451	0:1:1:2:2:3:5:6:6:8:9:9:10:12:13	1:NR:2	R2L	CROSS	140-141	121-122	D009248	nadolol	Chemical	121	122	4	D001281	atrial fibrillation|atrial fibrillation|AF|AF|AF|AF|AF|AF|AF|AF|AF|AF|AF|AF|AF	Disease	4:26:29:62:67:87:140:146:156:336:364:368:398:428:450	6:28:30:63:68:88:141:147:157:337:365:369:399:429:451	0:1:1:2:2:3:5:6:6:8:9:9:10:12:13	1:NR:2	R2L	NON-CROSS	36-37	15-17	D002118	Ca|Ca|Ca|Ca	Chemical	36:54:71:90	37:55:72:91	1:2:2:3	D013617	Atrial tachycardia	Disease	15	17	1	1:NR:2	R2L	CROSS	102-103	15-17	D009020	morphine	Chemical	102	103	3	D013617	Atrial tachycardia	Disease	15	17	1	1:NR:2	R2L	CROSS	104-105	15-17	D002698	chloralose	Chemical	104	105	3	D013617	Atrial tachycardia	Disease	15	17	1	1:NR:2	R2L	CROSS	108-109	15-17	D004110	Diltiazem|Diltiazem|diltiazem|diltiazem	Chemical	108:358:411:471	109:359:412:472	4:9:11:13	D013617	Atrial tachycardia	Disease	15	17	1	1:NR:2	R2L	CROSS	119-120	15-17	D001285	atropine	Chemical	119	120	4	D013617	Atrial tachycardia	Disease	15	17	1	1:NR:2	R2L	CROSS	121-122	15-17	D009248	nadolol	Chemical	121	122	4	D013617	Atrial tachycardia	Disease	15	17	1
10074612	Hypotension , bradycardia , and asystole after high - dose intravenous methylprednisolone in a monitored patient .|We report a case of hypotension , bradycardia , and asystole after intravenous administration of high - dose methylprednisolone in a 73 - year - old patient who underwent electrocardiographic ( ECG ) monitoring throughout the episode .|There was a history of ischemic cardiac disease 9 years earlier .|The patient was admitted with a pulmonary - renal syndrome with hemoptysis , rapidly progressive renal failure , and hypoxemia that required mechanical ventilation in the intensive care unit .|After receiving advanced cardiopulmonary resuscitation , the patient recovered cardiac rhythm .|The ECG showed a junctional rhythm without ventricular arrhythmia .|This study reviews the current proposed mechanisms of sudden death after a high dose of intravenous methylprednisolone ( IVMP ) .|These mechanisms are not well understood because , in most cases , the patients were not monitored at the moment of the event .|Rapid infusion and underlying cardiac disease were important risk factors in the case reported here , and the authors discount ventricular arrhythmia as the main mechanism .	1:CID:2	R2L	NON-CROSS	11-12	0-1	D008775	methylprednisolone|methylprednisolone|methylprednisolone|IVMP	Chemical	11:35:135:137	12:36:136:138	0:1:6:6	D007022	Hypotension|hypotension	Disease	0:22	1:23	0:1	1:CID:2	R2L	NON-CROSS	11-12	2-3	D008775	methylprednisolone|methylprednisolone|methylprednisolone|IVMP	Chemical	11:35:135:137	12:36:136:138	0:1:6:6	D001919	bradycardia|bradycardia	Disease	2:24	3:25	0:1	1:CID:2	R2L	NON-CROSS	11-12	5-6	D008775	methylprednisolone|methylprednisolone|methylprednisolone|IVMP	Chemical	11:35:135:137	12:36:136:138	0:1:6:6	D006323	asystole|asystole	Disease	5:27	6:28	0:1	1:NR:2	L2R	CROSS	35-36	60-61	D008775	methylprednisolone|methylprednisolone|methylprednisolone|IVMP	Chemical	11:35:135:137	12:36:136:138	0:1:6:6	D007511	ischemic	Disease	60	61	2	1:NR:2	L2R	CROSS	35-36	61-63	D008775	methylprednisolone|methylprednisolone|methylprednisolone|IVMP	Chemical	11:35:135:137	12:36:136:138	0:1:6:6	D006331	cardiac disease|cardiac disease	Disease	61:168	63:170	2:8	1:NR:2	L2R	CROSS	35-36	73-77	D008775	methylprednisolone|methylprednisolone|methylprednisolone|IVMP	Chemical	11:35:135:137	12:36:136:138	0:1:6:6	C538458	pulmonary - renal syndrome	Disease	73	77	3	1:NR:2	L2R	CROSS	35-36	78-79	D008775	methylprednisolone|methylprednisolone|methylprednisolone|IVMP	Chemical	11:35:135:137	12:36:136:138	0:1:6:6	D006469	hemoptysis	Disease	78	79	3	1:NR:2	L2R	CROSS	35-36	82-84	D008775	methylprednisolone|methylprednisolone|methylprednisolone|IVMP	Chemical	11:35:135:137	12:36:136:138	0:1:6:6	D051437	renal failure	Disease	82	84	3	1:NR:2	L2R	CROSS	86-87	135-136	D008775	methylprednisolone|methylprednisolone|methylprednisolone|IVMP	Chemical	11:35:135:137	12:36:136:138	0:1:6:6	D000860	hypoxemia	Disease	86	87	3	1:NR:2	L2R	CROSS	116-118	135-136	D008775	methylprednisolone|methylprednisolone|methylprednisolone|IVMP	Chemical	11:35:135:137	12:36:136:138	0:1:6:6	D001145	ventricular arrhythmia|ventricular arrhythmia	Disease	116:184	118:186	5:8	1:NR:2	L2R	NON-CROSS	127-129	135-136	D008775	methylprednisolone|methylprednisolone|methylprednisolone|IVMP	Chemical	11:35:135:137	12:36:136:138	0:1:6:6	D003645	sudden death	Disease	127	129	6
9209318	Lifetime treatment of mice with azidothymidine ( AZT ) produces myelodysplasia .|AZT has induced a macrocytic anemia in AIDS patients on long term AZT therapy .|It is generally assumed that DNA elongation is stopped by the insertion of AZT into the chain in place of thymidine thus preventing the phosphate hydroxyl linkages and therefore suppresses hemopoietic progenitor cell proliferation in an early stage of differentiation .|CBA / Ca male mice started on AZT 0 . 75 mg / ml H2O at 84 days of age and kept on it for 687 days when dosage reduced to 0 . 5 mg / ml H2O for a group , another group removed from AZT to see recovery , and third group remained on 0 . 75 mg .|At 687 days mice that had been on 0 . 75 mg had average platelet counts of 2 . 5 x 10 ( 6 ) .|Histological examination on 9 of 10 mice with such thrombocytopenia showed changes compatible with myelodysplastic syndrome ( MDS ) .|A variety of histological patterns was observed .|There were two cases of hypocellular myelodysplasia , two cases of hypersegmented myelodysplastic granulocytosis , two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei , one case of megakaryocytic myelosis associated with a hyperplastic marrow , dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis , hemosiderosis and a hypocellular marrow .|Above mentioned AZT incorporation may have induced an ineffective hemopoiesis in the primitive hemopoietic progenitor cells , which is known to be seen commonly in the myelodysplastic syndrome .	1:CID:2	L2R	NON-CROSS	10-11	12-13	D015215	azidothymidine|AZT|AZT|AZT|AZT|AZT|AZT|AZT	Chemical	5:7:12:24:40:75:114:242	6:8:13:25:41:76:115:243	0:0:1:1:2:3:3:8	D009190	myelodysplasia|myelodysplastic syndrome|MDS|myelodysplasia|myelodysplastic|dysmyelopoiesis|myelodysplasia|myelodysplastic syndrome	Disease	10:169:172:189:195:221:230:266	11:171:173:190:196:222:231:268	0:5:5:7:7:7:7:8	1:CID:2	L2R	NON-CROSS	12-13	16-18	D015215	azidothymidine|AZT|AZT|AZT|AZT|AZT|AZT|AZT	Chemical	5:7:12:24:40:75:114:242	6:8:13:25:41:76:115:243	0:0:1:1:2:3:3:8	D000748	macrocytic anemia	Disease	16	18	1	1:NR:2	L2R	NON-CROSS	19-20	24-25	D015215	azidothymidine|AZT|AZT|AZT|AZT|AZT|AZT|AZT	Chemical	5:7:12:24:40:75:114:242	6:8:13:25:41:76:115:243	0:0:1:1:2:3:3:8	D000163	AIDS	Disease	19	20	1	1:CID:2	L2R	CROSS	114-115	164-165	D015215	azidothymidine|AZT|AZT|AZT|AZT|AZT|AZT|AZT	Chemical	5:7:12:24:40:75:114:242	6:8:13:25:41:76:115:243	0:0:1:1:2:3:3:8	D013921	thrombocytopenia	Disease	164	165	5	1:NR:2	L2R	CROSS	237-239	242-243	D015215	azidothymidine|AZT|AZT|AZT|AZT|AZT|AZT|AZT	Chemical	5:7:12:24:40:75:114:242	6:8:13:25:41:76:115:243	0:0:1:1:2:3:3:8	D001855	hyperplastic marrow|hypocellular marrow|hypocellular marrow	Disease	218:224:237	220:226:239	7:7:7	1:NR:2	L2R	CROSS	234-235	242-243	D015215	azidothymidine|AZT|AZT|AZT|AZT|AZT|AZT|AZT	Chemical	5:7:12:24:40:75:114:242	6:8:13:25:41:76:115:243	0:0:1:1:2:3:3:8	D006486	hemosiderosis	Disease	234	235	7	1:NR:2	R2L	CROSS	47-48	10-11	D013936	thymidine	Chemical	47	48	2	D009190	myelodysplasia|myelodysplastic syndrome|MDS|myelodysplasia|myelodysplastic|dysmyelopoiesis|myelodysplasia|myelodysplastic syndrome	Disease	10:169:172:189:195:221:230:266	11:171:173:190:196:222:231:268	0:5:5:7:7:7:7:8	1:NR:2	R2L	CROSS	51-52	10-11	D010710	phosphate	Chemical	51	52	2	D009190	myelodysplasia|myelodysplastic syndrome|MDS|myelodysplasia|myelodysplastic|dysmyelopoiesis|myelodysplasia|myelodysplastic syndrome	Disease	10:169:172:189:195:221:230:266	11:171:173:190:196:222:231:268	0:5:5:7:7:7:7:8	1:NR:2	R2L	CROSS	47-48	16-18	D013936	thymidine	Chemical	47	48	2	D000748	macrocytic anemia	Disease	16	18	1	1:NR:2	R2L	CROSS	51-52	16-18	D010710	phosphate	Chemical	51	52	2	D000748	macrocytic anemia	Disease	16	18	1	1:NR:2	R2L	CROSS	47-48	19-20	D013936	thymidine	Chemical	47	48	2	D000163	AIDS	Disease	19	20	1	1:NR:2	R2L	CROSS	51-52	19-20	D010710	phosphate	Chemical	51	52	2	D000163	AIDS	Disease	19	20	1	1:NR:2	L2R	CROSS	47-48	164-165	D013936	thymidine	Chemical	47	48	2	D013921	thrombocytopenia	Disease	164	165	5	1:NR:2	L2R	CROSS	47-48	218-220	D013936	thymidine	Chemical	47	48	2	D001855	hyperplastic marrow|hypocellular marrow|hypocellular marrow	Disease	218:224:237	220:226:239	7:7:7	1:NR:2	L2R	CROSS	47-48	234-235	D013936	thymidine	Chemical	47	48	2	D006486	hemosiderosis	Disease	234	235	7	1:NR:2	L2R	CROSS	51-52	164-165	D010710	phosphate	Chemical	51	52	2	D013921	thrombocytopenia	Disease	164	165	5	1:NR:2	L2R	CROSS	51-52	218-220	D010710	phosphate	Chemical	51	52	2	D001855	hyperplastic marrow|hypocellular marrow|hypocellular marrow	Disease	218:224:237	220:226:239	7:7:7	1:NR:2	L2R	CROSS	51-52	234-235	D010710	phosphate	Chemical	51	52	2	D006486	hemosiderosis	Disease	234	235	7
8742498	Influence of diet free of NAD - precursors on acetaminophen hepatotoxicity in mice .|Recently , we demonstrated the hepatoprotective effects of nicotinic acid amide , a selective inhibitor of poly ( ADP - ribose ) polymerase ( PARP ; EC 2 . 4 . 2 . 30 ) on mice suffering from acetaminophen ( AAP ) - hepatitis , suggesting that the AAP - induced liver injury involves a step which depends on adenoribosylation .|The present study investigates the effects of a diet free of precursors of NAD , the substrate on which PARP acts , in female NMRI mice with AAP hepatitis and evaluates the influence of simultaneous ethanol consumption in these animals .|Liver injuries were quantified as serum activities of glutamate - oxaloacetate transaminase ( GOT ) and glutamate - pyruvate transaminase ( GPT ) .|While AAP caused a 117 - fold elevation of serum transaminase activities in mice kept on a standard laboratory diet , which was significantly exacerbated by ethanol and inhibited by nicotinic acid amide ( NAA ) , adverse effects were noted in animals fed a diet free of precursors of NAD .|In these animals , only minor increases of serum transaminase activities were measured in the presence of AAP , and unlike the exacerbation caused by ethanol in mice on a standard diet , the liver damage was inhibited by 50 % by ethanol .|A further 64 % reduction of hepatitis was observed , when NAA was given to ethanol / AAP - mice .|Our results provide evidence that the AAP - induced hepatitis and its exacerbation by ethanol can either be reduced by end - product inhibition of PARP by NAA or by dietary depletion of the enzyme 's substrate NAD .|We see the main application of NAA as for the combinational use in pharmaceutical preparations of acetaminophen in order to avoid hepatic damage in patients treated with this widely used analgesic .	1:NR:2	L2R	NON-CROSS	5-6	10-11	D009243	NAD|NAD|NAD|NAD	Chemical	5:89:191:295	6:90:192:296	0:2:4:7	D056486	hepatotoxicity|hepatitis|liver injury|hepatitis|Liver injuries|liver damage|hepatitis|hepatitis|hepatic damage	Disease	10:58:66:104:117:227:243:267:318	11:59:68:105:119:229:244:268:320	0:1:1:2:3:5:6:7:8	1:CID:2	L2R	NON-CROSS	9-10	10-11	D000082	acetaminophen|acetaminophen|AAP|AAP|AAP|AAP|AAP|AAP|AAP|acetaminophen	Chemical	9:53:55:63:103:142:210:254:264:313	10:54:56:64:104:143:211:255:265:314	0:1:1:1:2:4:5:6:7:8	D056486	hepatotoxicity|hepatitis|liver injury|hepatitis|Liver injuries|liver damage|hepatitis|hepatitis|hepatic damage	Disease	10:58:66:104:117:227:243:267:318	11:59:68:105:119:229:244:268:320	0:1:1:2:3:5:6:7:8	1:NR:2	R2L	NON-CROSS	248-249	243-244	D009536	nicotinic acid amide|nicotinic acid amide|NAA|NAA|NAA|NAA	Chemical	22:171:175:248:285:303	25:174:176:249:286:304	1:4:4:6:7:8	D056486	hepatotoxicity|hepatitis|liver injury|hepatitis|Liver injuries|liver damage|hepatitis|hepatitis|hepatic damage	Disease	10:58:66:104:117:227:243:267:318	11:59:68:105:119:229:244:268:320	0:1:1:2:3:5:6:7:8	1:NR:2	R2L	NON-CROSS	30-36	10-11	D011064	poly ( ADP - ribose )	Chemical	30	36	1	D056486	hepatotoxicity|hepatitis|liver injury|hepatitis|Liver injuries|liver damage|hepatitis|hepatitis|hepatic damage	Disease	10:58:66:104:117:227:243:267:318	11:59:68:105:119:229:244:268:320	0:1:1:2:3:5:6:7:8	1:CID:2	R2L	NON-CROSS	272-273	267-268	D000431	ethanol|ethanol|ethanol|ethanol|ethanol|ethanol	Chemical	111:167:218:235:252:272	112:168:219:236:253:273	2:4:5:5:6:7	D056486	hepatotoxicity|hepatitis|liver injury|hepatitis|Liver injuries|liver damage|hepatitis|hepatitis|hepatic damage	Disease	10:58:66:104:117:227:243:267:318	11:59:68:105:119:229:244:268:320	0:1:1:2:3:5:6:7:8	1:NR:2	R2L	NON-CROSS	125-126	117-119	D018698	glutamate|glutamate	Chemical	125:133	126:134	3:3	D056486	hepatotoxicity|hepatitis|liver injury|hepatitis|Liver injuries|liver damage|hepatitis|hepatitis|hepatic damage	Disease	10:58:66:104:117:227:243:267:318	11:59:68:105:119:229:244:268:320	0:1:1:2:3:5:6:7:8	1:NR:2	R2L	NON-CROSS	127-128	117-119	D062907	oxaloacetate	Chemical	127	128	3	D056486	hepatotoxicity|hepatitis|liver injury|hepatitis|Liver injuries|liver damage|hepatitis|hepatitis|hepatic damage	Disease	10:58:66:104:117:227:243:267:318	11:59:68:105:119:229:244:268:320	0:1:1:2:3:5:6:7:8	1:NR:2	R2L	NON-CROSS	135-136	117-119	D019289	pyruvate	Chemical	135	136	3	D056486	hepatotoxicity|hepatitis|liver injury|hepatitis|Liver injuries|liver damage|hepatitis|hepatitis|hepatic damage	Disease	10:58:66:104:117:227:243:267:318	11:59:68:105:119:229:244:268:320	0:1:1:2:3:5:6:7:8
2435991	Antiarrhythmic plasma concentrations of cibenzoline on canine ventricular arrhythmias .|Using two - stage coronary ligation - , digitalis - , and adrenaline - induced canine ventricular arrhythmias , antiarrhythmic effects of cibenzoline were examined and the minimum effective plasma concentration for each arrhythmia model was determined .|Cibenzoline suppressed all the arrhythmias , and the minimum effective plasma concentrations for arrhythmias induced by 24 - h coronary ligation , 48 - h coronary ligation , digitalis , and adrenaline were 1 . 9 + / - 0 . 9 ( by 8 mg / kg i . v . ) , 1 . 6 + / - 0 . 5 ( by 8 mg / kg i . v . ) , 0 . 6 + / - 0 . 2 ( by 2 mg / kg i . v . ) , and 3 . 5 + / - 1 . 3 ( by 5 mg / kg i . v . ) micrograms / ml , respectively ( mean + / - SDM , n = 6 - 7 ) .|The concentration for adrenaline - induced arrhythmia was significantly higher than those for the other types of arrhythmias .|This pharmacological profile is similar to those of mexiletine and tocainide , and all three drugs have central nervous system ( CNS ) stimulant action .|Because cibenzoline had only weak hypotensive and sinus node depressive effects and was found to be orally active when given to coronary ligation arrhythmia dogs , its clinical usefulness is expected .	1:NR:2	L2R	NON-CROSS	4-5	7-9	C032151	cibenzoline|cibenzoline|Cibenzoline|cibenzoline	Chemical	4:32:48:230	5:33:49:231	0:1:2:5	D001145	ventricular arrhythmias|ventricular arrhythmias|arrhythmia|arrhythmias|arrhythmias|arrhythmia|arrhythmias|arrhythmia	Disease	7:26:43:52:61:190:201:252	9:28:44:53:62:191:202:253	0:1:1:2:2:3:3:5	1:NR:2	L2R	NON-CROSS	230-231	234-235	C032151	cibenzoline|cibenzoline|Cibenzoline|cibenzoline	Chemical	4:32:48:230	5:33:49:231	0:1:2:5	D007022	hypotensive	Disease	234	235	5	1:NR:2	L2R	NON-CROSS	230-231	238-239	C032151	cibenzoline|cibenzoline|Cibenzoline|cibenzoline	Chemical	4:32:48:230	5:33:49:231	0:1:2:5	D003866	depressive	Disease	238	239	5	1:CID:2	R2L	NON-CROSS	26-28	18-19	D004071	digitalis|digitalis	Chemical	18:76	19:77	1:2	D001145	ventricular arrhythmias|ventricular arrhythmias|arrhythmia|arrhythmias|arrhythmias|arrhythmia|arrhythmias|arrhythmia	Disease	7:26:43:52:61:190:201:252	9:28:44:53:62:191:202:253	0:1:1:2:2:3:3:5	1:CID:2	R2L	NON-CROSS	190-191	187-188	D004837	adrenaline|adrenaline|adrenaline	Chemical	22:79:187	23:80:188	1:2:3	D001145	ventricular arrhythmias|ventricular arrhythmias|arrhythmia|arrhythmias|arrhythmias|arrhythmia|arrhythmias|arrhythmia	Disease	7:26:43:52:61:190:201:252	9:28:44:53:62:191:202:253	0:1:1:2:2:3:3:5	1:NR:2	R2L	CROSS	211-212	201-202	D008801	mexiletine	Chemical	211	212	4	D001145	ventricular arrhythmias|ventricular arrhythmias|arrhythmia|arrhythmias|arrhythmias|arrhythmia|arrhythmias|arrhythmia	Disease	7:26:43:52:61:190:201:252	9:28:44:53:62:191:202:253	0:1:1:2:2:3:3:5	1:NR:2	R2L	CROSS	213-214	201-202	D016677	tocainide	Chemical	213	214	4	D001145	ventricular arrhythmias|ventricular arrhythmias|arrhythmia|arrhythmias|arrhythmias|arrhythmia|arrhythmias|arrhythmia	Disease	7:26:43:52:61:190:201:252	9:28:44:53:62:191:202:253	0:1:1:2:2:3:3:5	1:NR:2	L2R	CROSS	76-77	234-235	D004071	digitalis|digitalis	Chemical	18:76	19:77	1:2	D007022	hypotensive	Disease	234	235	5	1:NR:2	L2R	CROSS	76-77	238-239	D004071	digitalis|digitalis	Chemical	18:76	19:77	1:2	D003866	depressive	Disease	238	239	5	1:NR:2	L2R	CROSS	187-188	234-235	D004837	adrenaline|adrenaline|adrenaline	Chemical	22:79:187	23:80:188	1:2:3	D007022	hypotensive	Disease	234	235	5	1:NR:2	L2R	CROSS	187-188	238-239	D004837	adrenaline|adrenaline|adrenaline	Chemical	22:79:187	23:80:188	1:2:3	D003866	depressive	Disease	238	239	5	1:NR:2	L2R	CROSS	211-212	234-235	D008801	mexiletine	Chemical	211	212	4	D007022	hypotensive	Disease	234	235	5	1:NR:2	L2R	CROSS	211-212	238-239	D008801	mexiletine	Chemical	211	212	4	D003866	depressive	Disease	238	239	5	1:NR:2	L2R	CROSS	213-214	234-235	D016677	tocainide	Chemical	213	214	4	D007022	hypotensive	Disease	234	235	5	1:NR:2	L2R	CROSS	213-214	238-239	D016677	tocainide	Chemical	213	214	4	D003866	depressive	Disease	238	239	5
950631	Immunopathology of penicillamine - induced glomerular disease .|Four patients with rheumatoid arthritis developed heavy proteinuria after five to 12 months of treatment with D - penicillamine .|Light microscopy of renal biopsy samples showed minimal glomerular capillary wall thickening and mesangial matrix increase , or no departure from normal .|Electron microscopy , however , revealed subepithelial electron - dense deposits , fusion of epithelial cell foot processes , and evidence of mesangial cell hyperactivity .|Immunofluorescence microscopy demonstrated granular capillary wall deposits of IgG and C3 .|The findings were similar to those in early membranous glomerulonephritis , differences being observed however in the results of staining for the early - acting complement components C1q and C4 .|It is tentatively concluded that complement was activated by the classical pathway .	1:CID:2	L2R	NON-CROSS	2-3	5-7	D010396	penicillamine|D - penicillamine	Chemical	2:24	3:27	0:1	D007674	glomerular disease	Disease	5	7	0	1:NR:2	L2R	NON-CROSS	2-3	11-13	D010396	penicillamine|D - penicillamine	Chemical	2:24	3:27	0:1	D001172	rheumatoid arthritis	Disease	11	13	1	1:CID:2	L2R	NON-CROSS	15-16	24-27	D010396	penicillamine|D - penicillamine	Chemical	2:24	3:27	0:1	D011507	proteinuria	Disease	15	16	1	1:NR:2	L2R	CROSS	24-27	97-99	D010396	penicillamine|D - penicillamine	Chemical	2:24	3:27	0:1	D015433	membranous glomerulonephritis	Disease	97	99	5
663266	Ventricular fibrillation from diatrizoate with and without chelating agents .|The toxicity of Renografin 76 % was compared with that of Hypaque 76 % by selective injection of each into the right coronary artery of dogs .|Renografin contains the chelating agents sodium citrate and disodium edetate , while Hypaque contains calcium disodium edetate and no sodium citrate .|Ventricular fibrillation occurred significantly more often with Renografin , suggesting that chelating agents contribute to toxicity in coronary angiography .	1:NR:2	R2L	NON-CROSS	3-4	0-2	D003973	diatrizoate|Hypaque	Chemical	3:49	4:50	0:2	D014693	Ventricular fibrillation|Ventricular fibrillation	Disease	0:59	2:61	0:3	1:CID:2	R2L	CROSS	13-16	0-2	C027278	Renografin 76 %|Hypaque 76 %	Chemical	13:21	16:24	1:1	D014693	Ventricular fibrillation|Ventricular fibrillation	Disease	0:59	2:61	0:3	1:NR:2	R2L	NON-CROSS	66-67	59-61	D003974	Renografin|Renografin	Chemical	37:66	38:67	2:3	D014693	Ventricular fibrillation|Ventricular fibrillation	Disease	0:59	2:61	0:3	1:CID:2	R2L	CROSS	59-61	56-58	C102006	sodium citrate|sodium citrate	Chemical	42:56	44:58	2:2	D014693	Ventricular fibrillation|Ventricular fibrillation	Disease	0:59	2:61	0:3	1:CID:2	R2L	CROSS	59-61	51-54	D004492	disodium edetate|calcium disodium edetate	Chemical	45:51	47:54	2:2	D014693	Ventricular fibrillation|Ventricular fibrillation	Disease	0:59	2:61	0:3	1:NR:2	L2R	CROSS	3-4	11-12	D003973	diatrizoate|Hypaque	Chemical	3:49	4:50	0:2	D064420	toxicity|toxicity	Disease	11:74	12:75	1:3	1:NR:2	R2L	NON-CROSS	13-16	11-12	C027278	Renografin 76 %|Hypaque 76 %	Chemical	13:21	16:24	1:1	D064420	toxicity|toxicity	Disease	11:74	12:75	1:3	1:NR:2	R2L	NON-CROSS	74-75	66-67	D003974	Renografin|Renografin	Chemical	37:66	38:67	2:3	D064420	toxicity|toxicity	Disease	11:74	12:75	1:3	1:NR:2	R2L	CROSS	74-75	56-58	C102006	sodium citrate|sodium citrate	Chemical	42:56	44:58	2:2	D064420	toxicity|toxicity	Disease	11:74	12:75	1:3	1:NR:2	R2L	CROSS	74-75	51-54	D004492	disodium edetate|calcium disodium edetate	Chemical	45:51	47:54	2:2	D064420	toxicity|toxicity	Disease	11:74	12:75	1:3
19319147	Rapid reversal of anticoagulation reduces hemorrhage volume in a mouse model of warfarin - associated intracerebral hemorrhage .|Warfarin - associated intracerebral hemorrhage ( W - ICH ) is a severe type of stroke .|There is no consensus on the optimal treatment for W - ICH .|Using a mouse model , we tested whether the rapid reversal of anticoagulation using human prothrombin complex concentrate ( PCC ) can reduce hemorrhagic blood volume .|Male CD - 1 mice were treated with warfarin ( 2 mg / kg over 24 h ) , resulting in a mean ( + / - s . d . ) International Normalized Ratio of 3 . 5 + / - 0 . 9 .|First , we showed that an intravenous administration of human PCC rapidly reversed anticoagulation in mice .|Second , a stereotactic injection of collagenase was administered to induce hemorrhage in the right striatum .|Forty - five minutes later , the animals were randomly treated with PCC ( 100 U / kg ) or saline i . v .|( n = 12 per group ) .|Twenty - four hours after hemorrhage induction , hemorrhagic blood volume was quantified using a photometric hemoglobin assay .|The mean hemorrhagic blood volume was reduced in PCC - treated animals ( 6 . 5 + / - 3 . 1 microL ) compared with saline controls ( 15 . 3 + / - 11 . 2 microL , P = 0 . 015 ) .|In the saline group , 45 % of the mice developed large hematomas ( i . e . , > 15 microL ) .|In contrast , such extensive lesions were never found in the PCC group .|We provide experimental data suggesting PCC to be an effective acute treatment for W - ICH in terms of reducing hemorrhagic blood volume .|Future studies are needed to assess the therapeutic potential emerging from our finding for human W - ICH .	1:NR:2	R2L	NON-CROSS	12-13	5-6	D014859	warfarin|Warfarin|warfarin	Chemical	12:18:83	13:19:84	0:1:4	D006470	hemorrhage|hemorrhage|hemorrhage	Disease	5:149:193	6:150:194	0:6:9	1:NR:2	R2L	CROSS	149-150	131-132	C025667	prothrombin complex concentrate|PCC|PCC|PCC|PCC|PCC|PCC	Chemical	63:67:131:167:215:289:297	66:68:132:168:216:290:298	3:3:5:7:10:12:13	D006470	hemorrhage|hemorrhage|hemorrhage	Disease	5:149:193	6:150:194	0:6:9	1:CID:2	L2R	NON-CROSS	15-17	18-19	D014859	warfarin|Warfarin|warfarin	Chemical	12:18:83	13:19:84	0:1:4	D002543	intracerebral hemorrhage|intracerebral hemorrhage|ICH|ICH|ICH|ICH	Disease	15:21:26:46:307:333	17:23:27:47:308:334	0:1:1:2:13:14	1:NR:2	L2R	NON-CROSS	18-19	33-34	D014859	warfarin|Warfarin|warfarin	Chemical	12:18:83	13:19:84	0:1:4	D020521	stroke	Disease	33	34	1	1:NR:2	L2R	CROSS	83-84	266-267	D014859	warfarin|Warfarin|warfarin	Chemical	12:18:83	13:19:84	0:1:4	D006406	hematomas	Disease	266	267	11	1:NR:2	R2L	NON-CROSS	307-308	297-298	C025667	prothrombin complex concentrate|PCC|PCC|PCC|PCC|PCC|PCC	Chemical	63:67:131:167:215:289:297	66:68:132:168:216:290:298	3:3:5:7:10:12:13	D002543	intracerebral hemorrhage|intracerebral hemorrhage|ICH|ICH|ICH|ICH	Disease	15:21:26:46:307:333	17:23:27:47:308:334	0:1:1:2:13:14	1:NR:2	R2L	CROSS	63-66	33-34	C025667	prothrombin complex concentrate|PCC|PCC|PCC|PCC|PCC|PCC	Chemical	63:67:131:167:215:289:297	66:68:132:168:216:290:298	3:3:5:7:10:12:13	D020521	stroke	Disease	33	34	1	1:NR:2	L2R	CROSS	266-267	289-290	C025667	prothrombin complex concentrate|PCC|PCC|PCC|PCC|PCC|PCC	Chemical	63:67:131:167:215:289:297	66:68:132:168:216:290:298	3:3:5:7:10:12:13	D006406	hematomas	Disease	266	267	11
16634859	Impact of alcohol exposure after pregnancy recognition on ultrasonographic fetal growth measures .|BACKGROUND : More than 3 decades after Jones and Smith ( 1973 ) reported on the devastation caused by alcohol exposure on fetal development , the rates of heavy drinking during pregnancy remain relatively unchanged .|Early identification of fetal alcohol exposure and maternal abstinence led to better infant outcomes .|This study examined the utility of biometry for detecting alcohol - related fetal growth impairment .|METHODS : We obtained fetal ultrasound measures from routine ultrasound examinations for 167 pregnant hazardous drinkers who were enrolled in a brief alcohol intervention study .|The fetal measures for women who quit after learning of their pregnancies were compared with measures for women who continued some drinking throughout the course of their pregnancies .|Because intensity of alcohol consumption is associated with poorer fetal outcomes , separate analyses were conducted for the heavy ( average of > or = 5 drinks per drinking day ) alcohol consumers .|Fetal measures from the heavy - exposed fetuses were also compared with measures from a nondrinking group that was representative of normal , uncomplicated pregnancies from our clinics .|Analyses of covariance were used to determine whether there were differences between groups after controlling for influences of gestational age and drug abuse .|RESULTS : Nearly half of the pregnant drinkers abstained after learning of their pregnancies .|When women reportedly quit drinking early in their pregnancies , fetal growth measures were not significantly different from a non - alcohol - exposed group , regardless of prior drinking patterns .|Any alcohol consumption postpregnancy recognition among the heavy drinkers resulted in reduced cerebellar growth as well as decreased cranial to body growth in comparison with women who either quit drinking or who were nondrinkers .|Amphetamine abuse was predictive of larger cranial to body growth ratios .|CONCLUSIONS : Alterations in fetal biometric measurements were observed among the heavy drinkers only when they continued drinking after becoming aware of their pregnancies .|Although the reliance on self - reported drinking is a limitation in this study , these findings support the benefits of early abstinence and the potential for ultrasound examinations in the detection of fetal alcohol effects .	1:CID:2	L2R	NON-CROSS	73-74	77-79	D000431	alcohol|alcohol|alcohol|alcohol|alcohol|alcohol|alcohol|alcohol|alcohol|alcohol	Chemical	2:32:53:73:102:138:166:258:270:375	3:33:54:74:103:139:167:259:271:376	0:1:2:3:4:6:6:10:11:14	D006130	growth impairment|reduced cerebellar growth|decreased cranial to body growth	Disease	77:280:286	79:283:291	3:11:11	1:NR:2	L2R	CROSS	219-221	258-259	D000431	alcohol|alcohol|alcohol|alcohol|alcohol|alcohol|alcohol|alcohol|alcohol|alcohol	Chemical	2:32:53:73:102:138:166:258:270:375	3:33:54:74:103:139:167:259:271:376	0:1:2:3:4:6:6:10:11:14	D019966	drug abuse	Disease	219	221	8	1:CID:2	R2L	CROSS	304-305	286-291	D000661	Amphetamine	Chemical	304	305	12	D006130	growth impairment|reduced cerebellar growth|decreased cranial to body growth	Disease	77:280:286	79:283:291	3:11:11	1:NR:2	R2L	CROSS	304-305	219-221	D000661	Amphetamine	Chemical	304	305	12	D019966	drug abuse	Disease	219	221	8
16471092	Urinary symptoms and quality of life changes in Thai women with overactive bladder after tolterodine treatment .|OBJECTIVES : To study the urinary symptoms and quality of life changes in Thai women with overactive bladder ( OAB ) after tolterodine treatment .|MATERIAL AND METHOD : Thirty women ( aged 30 - 77 years ) diagnosed as having OAB at the Gynecology Clinic , King Chulalongkorn Memorial Hospital from January to April 2004 were included in the present study .|Tolterodine 2 mg , twice daily was given .|After 8 weeks treatment , changes in micturition diary variables and tolerability were determined .|Short form 36 ( SF36 ) questionaires ( Thai version ) were given before and after 8 weeks of treatment .|RESULTS : At 8 weeks , all micturition per day decreased from 16 .|7 + / - 5 .|3 to 6 .|7 + / - 2 . 4 times per day .|The number of nocturia episodes decreased from 5 . 4 + / - 4 . 2 to 1 . 1 + / - 1 . 0 times per night .|The most common side effect was dry month in 5 cases ( 16 . 7 % ) with 2 cases reporting a moderate degree and 1 case with severe degree .|Only one case ( 3 . 3 % ) withdrew from the present study due to a severe dry mouth .|The SF - 36 scores changed significantly in the domains of physical functioning , role function emotional , social function and mental heath .|CONCLUSION : Tolterodine was well tolerated and its effects improved the quality of life in Thai women with OAB .	1:NR:2	R2L	NON-CROSS	14-15	11-13	C099041	tolterodine|tolterodine|Tolterodine|Tolterodine	Chemical	14:39:80:268	15:40:81:269	0:1:3:14	D053201	overactive bladder|overactive bladder|OAB|OAB|OAB	Disease	11:33:36:58:284	13:35:37:59:285	0:1:1:2:14	1:NR:2	L2R	CROSS	80-81	163-164	C099041	tolterodine|tolterodine|Tolterodine|Tolterodine	Chemical	14:39:80:268	15:40:81:269	0:1:3:14	D053158	nocturia	Disease	163	164	10	1:CID:2	L2R	CROSS	239-241	268-269	C099041	tolterodine|tolterodine|Tolterodine|Tolterodine	Chemical	14:39:80:268	15:40:81:269	0:1:3:14	D014987	dry month|dry mouth	Disease	196:239	198:241	11:12
16174948	Absence of acute cerebral vasoconstriction after cocaine - associated subarachnoid hemorrhage .|INTRODUCTION : Cocaine use has been associated with neurovascular complications , including arterial vasoconstriction and vasculitis .|However , there are few studies of angiographic effects of cocaine on human cerebral arteries .|Information on these effects could be obtained from angiograms of patients with cocaine - associated subarachnoid hemorrhage ( SAH ) who underwent angiography shortly after cocaine use .|METHODS : We screened patients with SAH retrospectively and identified those with positive urine toxicology for cocaine or its metabolites .|Quantitative arterial diameter measurements from angiograms of these patients were compared to measurements from control patients with SAH who were matched for factors known to influence arterial diameter .|Qualitative comparisons of small artery changes also were made .|RESULTS : Thirteen patients with positive cocaine toxicology were compared to 26 controls .|There were no significant differences between groups in the mean diameters of the intradural internal carotid , sphenoidal segment of the middle cerebral , precommunicating segment of the anterior cerebral , or basilar arteries ( p greater than 0 . 05 for all comparisons , unpaired t - tests ) .|There also were no significant differences between groups when expressing diameters as the sum of the precommunicating segment of the anterior cerebral + sphenoidal segment of the middle cerebral + supraclinoid internal carotid artery + basilar artery divided by the diameter of the petrous internal carotid artery ( p greater than 0 . 05 , unpaired t - tests ) .|Qualitative assessments showed two arterial irregularities in the distal vasculature in each group .|CONCLUSION : No quantitative evidence for narrowing of large cerebral arteries or qualitative angiographic evidence for distal narrowing or vasculitis could be found in patients who underwent angiography after aneurysmal SAH associated with cocaine use .	1:CID:2	L2R	NON-CROSS	6-7	9-11	D003042	cocaine|Cocaine|cocaine|cocaine|cocaine|cocaine|cocaine|cocaine	Chemical	6:14:39:57:70:89:139:306	7:15:40:58:71:90:140:307	0:1:2:3:3:4:7:11	D013345	subarachnoid hemorrhage|subarachnoid hemorrhage|SAH|SAH|SAH|SAH	Disease	9:60:63:79:111:303	11:62:64:80:112:304	0:3:3:4:5:11	1:NR:2	L2R	NON-CROSS	14-15	20-22	D003042	cocaine|Cocaine|cocaine|cocaine|cocaine|cocaine|cocaine|cocaine	Chemical	6:14:39:57:70:89:139:306	7:15:40:58:71:90:140:307	0:1:2:3:3:4:7:11	D013901	neurovascular complications	Disease	20	22	1	1:NR:2	L2R	NON-CROSS	27-28	39-40	D003042	cocaine|Cocaine|cocaine|cocaine|cocaine|cocaine|cocaine|cocaine	Chemical	6:14:39:57:70:89:139:306	7:15:40:58:71:90:140:307	0:1:2:3:3:4:7:11	D014657	vasculitis|vasculitis	Disease	27:292	28:293	1:11	1:CID:2	L2R	NON-CROSS	302-303	306-307	D003042	cocaine|Cocaine|cocaine|cocaine|cocaine|cocaine|cocaine|cocaine	Chemical	6:14:39:57:70:89:139:306	7:15:40:58:71:90:140:307	0:1:2:3:3:4:7:11	D017542	aneurysmal	Disease	302	303	11
15042318	Atrial fibrillation following chemotherapy for stage IIIE diffuse large B - cell gastric lymphoma in a patient with myotonic dystrophy ( Steinert 's disease ) .|The authors describe the unusual association between diffuse B - cell gastric lymphoma and myotonic dystrophy , the most common form of adult muscular dystrophy , and sudden atrial fibrillation following one cycle of doxorubicin - based chemotherapy in the same patient .|Atrial fibrillation or other cardiac arrhythmias are unusual complications in patients treated with chemotherapy .|The cardiac toxicity intrinsically associated with the aggressive chemotherapy employed could function as a triggering factor for the arrhythmia in the predisposed myocardium of this patient .	1:CID:2	R2L	NON-CROSS	60-61	54-56	D004317	doxorubicin	Chemical	60	61	1	D001281	Atrial fibrillation|atrial fibrillation|Atrial fibrillation	Disease	0:54:69	2:56:71	0:1:2	1:NR:2	R2L	NON-CROSS	60-61	37-39	D004317	doxorubicin	Chemical	60	61	1	C535648	gastric lymphoma|gastric lymphoma	Disease	12:37	14:39	0:1	1:NR:2	R2L	NON-CROSS	60-61	40-42	D004317	doxorubicin	Chemical	60	61	1	D009223	myotonic dystrophy|Steinert 's disease|myotonic dystrophy	Disease	18:21:40	20:24:42	0:0:1	1:NR:2	R2L	NON-CROSS	60-61	49-51	D004317	doxorubicin	Chemical	60	61	1	D009136	muscular dystrophy	Disease	49	51	1	1:NR:2	L2R	CROSS	60-61	73-75	D004317	doxorubicin	Chemical	60	61	1	D001145	cardiac arrhythmias|arrhythmia	Disease	73:102	75:103	2:3	1:NR:2	L2R	CROSS	60-61	85-87	D004317	doxorubicin	Chemical	60	61	1	D066126	cardiac toxicity	Disease	85	87	3
12448656	A phase II study of thalidomide in advanced metastatic renal cell carcinoma .|OBJECTIVES : To evaluate the toxicity and activity of thalidomide in patients with advanced metastatic renal cell cancer and to measure changes of one angiogenic factor , vascular endothelial growth factor ( VEGF ) 165 , with therapy .|PATIENTS AND METHODS : 29 patients were enrolled on a study of thalidomide using an intra - patient dose escalation schedule .|Patients began thalidomide at 400 mg / d and escalated as tolerated to 1200 mg / d by day 54 .|Fifty - nine per cent of patients had had previous therapy with IL - 2 and 52 % were performance status 2 or 3 .|Systemic plasma VEGF165 levels were measured by dual monoclonal ELISA in 8 patients .|RESULTS : 24 patients were evaluable for response with one partial response of 11 months duration of a patient with hepatic and pulmonary metastases ( 4 % ) , one minor response , and 2 patients stable for over 6 months .|Somnolence and constipation were prominent toxicities and most patients could not tolerate the 1200 mg / day dose level .|Systemic plasma VEGF165 levels did not change with therapy .|CONCLUSION : These results are consistent with a low level of activity of thalidomide in renal cell carcinoma .|Administration of doses over 800 mg / day was difficult to achieve in this patient population , however lower doses were practical .|The dose - response relationship , if any , of thalidomide for renal cell carcinoma is unclear .	1:NR:2	L2R	NON-CROSS	219-220	221-224	D013792	thalidomide|thalidomide|thalidomide|thalidomide|thalidomide|thalidomide	Chemical	5:22:64:76:219:258	6:23:65:77:220:259	0:1:2:3:9:11	D002292	renal cell carcinoma|renal cell cancer|renal cell carcinoma|renal cell carcinoma	Disease	9:28:221:260	12:31:224:263	0:1:9:11	1:NR:2	L2R	NON-CROSS	18-19	22-23	D013792	thalidomide|thalidomide|thalidomide|thalidomide|thalidomide|thalidomide	Chemical	5:22:64:76:219:258	6:23:65:77:220:259	0:1:2:3:9:11	D064420	toxicity|toxicities	Disease	18:181	19:182	1:7	1:NR:2	L2R	CROSS	157-158	219-220	D013792	thalidomide|thalidomide|thalidomide|thalidomide|thalidomide|thalidomide	Chemical	5:22:64:76:219:258	6:23:65:77:220:259	0:1:2:3:9:11	D009362	metastases	Disease	157	158	6	1:CID:2	L2R	CROSS	176-177	219-220	D013792	thalidomide|thalidomide|thalidomide|thalidomide|thalidomide|thalidomide	Chemical	5:22:64:76:219:258	6:23:65:77:220:259	0:1:2:3:9:11	D006970	Somnolence	Disease	176	177	7	1:CID:2	L2R	CROSS	178-179	219-220	D013792	thalidomide|thalidomide|thalidomide|thalidomide|thalidomide|thalidomide	Chemical	5:22:64:76:219:258	6:23:65:77:220:259	0:1:2:3:9:11	D003248	constipation	Disease	178	179	7
12231232	The striatum as a target for anti - rigor effects of an antagonist of mGluR1 , but not an agonist of group II metabotropic glutamate receptors .|The aim of the present study was to find out whether the metabotropic receptor 1 ( mGluR1 ) and group II mGluRs , localized in the striatum , are involved in antiparkinsonian - like effects in rats .|Haloperidol ( 1 mg / kg ip ) induced parkinsonian - like muscle rigidity , measured as an increased resistance of a rat 's hind foot to passive flexion and extension at the ankle joint .|( RS ) - 1 - aminoindan - 1 , 5 - dicarboxylic acid ( AIDA ; 0 . 5 - 15 microg / 0 . 5 microl ) , a potent and selective mGluR1 antagonist , or ( 2R , 4R ) - 4 - aminopyrrolidine - 2 , 4 - dicarboxylate ( 2R , 4R - APDC ; 7 . 5 - 15 microg / 0 . 5 microl ) , a selective group II agonist , was injected bilaterally into the striatum of haloperidol - treated animals .|AIDA in doses of 7 . 5 - 15 microg / 0 . 5 microl diminished the haloperidol - induced muscle rigidity .|In contrast , 2R , 4R - APDC injections were ineffective .|The present results may suggest that the blockade of striatal mGluR1 , but not the stimulation of group II mGluRs , may ameliorate parkinsonian muscle rigidity .	1:NR:2	L2R	CROSS	24-25	74-75	D018698	glutamate	Chemical	24	25	0	D010300	parkinsonian|parkinsonian	Disease	74:250	75:251	2:6	1:NR:2	L2R	CROSS	24-25	77-79	D018698	glutamate	Chemical	24	25	0	D009127	muscle rigidity|muscle rigidity|muscle rigidity	Disease	77:212:251	79:214:253	2:4:6	1:NR:2	L2R	NON-CROSS	65-66	74-75	D006220	Haloperidol|haloperidol|haloperidol	Chemical	65:187:209	66:188:210	2:3:4	D010300	parkinsonian|parkinsonian	Disease	74:250	75:251	2:6	1:CID:2	L2R	NON-CROSS	209-210	212-214	D006220	Haloperidol|haloperidol|haloperidol	Chemical	65:187:209	66:188:210	2:3:4	D009127	muscle rigidity|muscle rigidity|muscle rigidity	Disease	77:212:251	79:214:253	2:4:6	1:NR:2	R2L	CROSS	101-115	74-75	C095756	( RS ) - 1 - aminoindan - 1 , 5 - dicarboxylic acid|AIDA|AIDA	Chemical	101:116:192	115:117:193	3:3:4	D010300	parkinsonian|parkinsonian	Disease	74:250	75:251	2:6	1:NR:2	R2L	CROSS	250-251	218-223	C097299	( 2R , 4R ) - 4 - aminopyrrolidine - 2 , 4 - dicarboxylate|2R , 4R - APDC|2R , 4R - APDC	Chemical	139:155:218	154:160:223	3:3:5	D010300	parkinsonian|parkinsonian	Disease	74:250	75:251	2:6	1:NR:2	R2L	NON-CROSS	212-214	192-193	C095756	( RS ) - 1 - aminoindan - 1 , 5 - dicarboxylic acid|AIDA|AIDA	Chemical	101:116:192	115:117:193	3:3:4	D009127	muscle rigidity|muscle rigidity|muscle rigidity	Disease	77:212:251	79:214:253	2:4:6	1:NR:2	R2L	CROSS	218-223	212-214	C097299	( 2R , 4R ) - 4 - aminopyrrolidine - 2 , 4 - dicarboxylate|2R , 4R - APDC|2R , 4R - APDC	Chemical	139:155:218	154:160:223	3:3:5	D009127	muscle rigidity|muscle rigidity|muscle rigidity	Disease	77:212:251	79:214:253	2:4:6
11847945	Acute cholestatic hepatitis after exposure to isoflurane .|OBJECTIVE : To report a case of acute cholestatic hepatitis following exposure to the inhalational anesthetic isoflurane .|CASE SUMMARY : A 70 - year - old healthy woman from Iraq developed acute cholestatic hepatitis 3 weeks following repair of the right rotator cuff under general anesthesia .|There was no evidence for viral , autoimmune , or metabolic causes of hepatitis .|No other medications were involved except for dipyrone for analgesia .|The alanine aminotransferase was elevated to a peak concentration of 1533 U / L and the serum bilirubin reached a peak of 17 . 0 mg / dL .|There was slow improvement over 4 months .|Accidental reexposure by the patient to dipyrone was uneventful .|DISCUSSION : The clinical and histologic picture of this case resembles halothane hepatitis , which has a significant mortality rate .|CONCLUSIONS : Isoflurane , a common anesthetic agent , can cause severe cholestatic hepatitis .	1:CID:2	R2L	NON-CROSS	6-7	1-3	D007530	isoflurane|isoflurane|Isoflurane	Chemical	6:24:152	7:25:153	0:1:9	D002779	cholestatic hepatitis|cholestatic hepatitis|cholestatic hepatitis|cholestatic hepatitis	Disease	1:16:41:162	3:18:43:164	0:1:2:9	1:NR:2	R2L	CROSS	78-79	41-43	D004177	dipyrone|dipyrone	Chemical	78:125	79:126	4:7	D002779	cholestatic hepatitis|cholestatic hepatitis|cholestatic hepatitis|cholestatic hepatitis	Disease	1:16:41:162	3:18:43:164	0:1:2:9	1:NR:2	R2L	CROSS	83-84	41-43	D000409	alanine	Chemical	83	84	5	D002779	cholestatic hepatitis|cholestatic hepatitis|cholestatic hepatitis|cholestatic hepatitis	Disease	1:16:41:162	3:18:43:164	0:1:2:9	1:NR:2	R2L	CROSS	99-100	41-43	D001663	bilirubin	Chemical	99	100	5	D002779	cholestatic hepatitis|cholestatic hepatitis|cholestatic hepatitis|cholestatic hepatitis	Disease	1:16:41:162	3:18:43:164	0:1:2:9	1:CID:2	R2L	NON-CROSS	6-7	1-3	D007530	isoflurane|isoflurane|Isoflurane	Chemical	6:24:152	7:25:153	0:1:9	D056486	cholestatic hepatitis|cholestatic hepatitis|cholestatic hepatitis|hepatitis|cholestatic hepatitis	Disease	1:16:41:69:162	3:18:43:70:164	0:1:2:3:9	1:NR:2	R2L	CROSS	78-79	69-70	D004177	dipyrone|dipyrone	Chemical	78:125	79:126	4:7	D056486	cholestatic hepatitis|cholestatic hepatitis|cholestatic hepatitis|hepatitis|cholestatic hepatitis	Disease	1:16:41:69:162	3:18:43:70:164	0:1:2:3:9	1:NR:2	R2L	CROSS	83-84	69-70	D000409	alanine	Chemical	83	84	5	D056486	cholestatic hepatitis|cholestatic hepatitis|cholestatic hepatitis|hepatitis|cholestatic hepatitis	Disease	1:16:41:69:162	3:18:43:70:164	0:1:2:3:9	1:NR:2	R2L	CROSS	99-100	69-70	D001663	bilirubin	Chemical	99	100	5	D056486	cholestatic hepatitis|cholestatic hepatitis|cholestatic hepatitis|hepatitis|cholestatic hepatitis	Disease	1:16:41:69:162	3:18:43:70:164	0:1:2:3:9	1:NR:2	L2R	CROSS	24-25	80-81	D007530	isoflurane|isoflurane|Isoflurane	Chemical	6:24:152	7:25:153	0:1:9	D000699	analgesia	Disease	80	81	4	1:NR:2	L2R	CROSS	140-142	152-153	D007530	isoflurane|isoflurane|Isoflurane	Chemical	6:24:152	7:25:153	0:1:9	C562477	halothane hepatitis	Disease	140	142	8	1:NR:2	L2R	NON-CROSS	78-79	80-81	D004177	dipyrone|dipyrone	Chemical	78:125	79:126	4:7	D000699	analgesia	Disease	80	81	4	1:NR:2	L2R	CROSS	125-126	140-142	D004177	dipyrone|dipyrone	Chemical	78:125	79:126	4:7	C562477	halothane hepatitis	Disease	140	142	8	1:NR:2	R2L	CROSS	83-84	80-81	D000409	alanine	Chemical	83	84	5	D000699	analgesia	Disease	80	81	4	1:NR:2	R2L	CROSS	99-100	80-81	D001663	bilirubin	Chemical	99	100	5	D000699	analgesia	Disease	80	81	4	1:NR:2	L2R	CROSS	83-84	140-142	D000409	alanine	Chemical	83	84	5	C562477	halothane hepatitis	Disease	140	142	8	1:NR:2	L2R	CROSS	99-100	140-142	D001663	bilirubin	Chemical	99	100	5	C562477	halothane hepatitis	Disease	140	142	8
11284996	Calcitonin gene - related peptide levels during nitric oxide - induced headache in patients with chronic tension - type headache .|It has been proposed that nitric oxide ( NO ) induced headache in primary headaches may be associated with release of calcitonin gene - related peptide ( CGRP ) .|In the present study we aimed to investigate plasma levels of CGRP during headache induced by the NO donor glyceryl trinitrate ( GTN ) in 16 patients with chronic tension - type headache and 16 healthy controls .|The subjects were randomly allocated to receive 0 . 5 microg / kg / min GTN or placebo over 20 min on two headache - free days .|Blood samples were collected at baseline , 10 , 20 and 60 min after start of infusion .|Both patients and controls developed significantly stronger immediate headache on the GTN day than on the placebo day and the headache was significantly more pronounced in patients than in controls .|There was no difference between the area under the CGRP curve ( AUCCGRP ) on GTN vs . placebo day in either patients ( P = 0 . 65 ) or controls ( P = 0 . 48 ) .|The AUCCGRP recorded on the GTN day did not differ between patients and controls ( P = 0 . 36 ) .|Both in patients and controls , CGRP levels changed significantly over time , on both the GTN and placebo days ( P < 0 . 05 ) .|The present study indicates that NO - induced immediate headache is not associated with release of CGRP .	1:CID:2	L2R	NON-CROSS	7-9	11-12	D009569	nitric oxide|nitric oxide|NO|NO|NO	Chemical	7:26:29:68:261	9:28:30:69:262	0:1:1:2:9	D006261	headache|headache|headache|headache|headache|headache|headache	Disease	11:32:64:112:143:155:265	12:33:65:113:144:156:266	0:1:2:3:5:5:9	1:NR:2	L2R	NON-CROSS	68-69	80-84	D009569	nitric oxide|nitric oxide|NO|NO|NO	Chemical	7:26:29:68:261	9:28:30:69:262	0:1:1:2:9	D018781	tension - type headache|tension - type headache	Disease	16:80	20:84	0:2	1:NR:2	L2R	NON-CROSS	29-30	34-36	D009569	nitric oxide|nitric oxide|NO|NO|NO	Chemical	7:26:29:68:261	9:28:30:69:262	0:1:1:2:9	D051270	primary headaches	Disease	34	36	1	1:CID:2	R2L	NON-CROSS	146-147	143-144	D005996	glyceryl trinitrate|GTN|GTN|GTN|GTN|GTN|GTN	Chemical	70:73:104:146:181:211:244	72:74:105:147:182:212:245	2:2:3:5:6:7:8	D006261	headache|headache|headache|headache|headache|headache|headache	Disease	11:32:64:112:143:155:265	12:33:65:113:144:156:266	0:1:2:3:5:5:9	1:NR:2	R2L	NON-CROSS	80-84	73-74	D005996	glyceryl trinitrate|GTN|GTN|GTN|GTN|GTN|GTN	Chemical	70:73:104:146:181:211:244	72:74:105:147:182:212:245	2:2:3:5:6:7:8	D018781	tension - type headache|tension - type headache	Disease	16:80	20:84	0:2	1:NR:2	R2L	CROSS	70-72	34-36	D005996	glyceryl trinitrate|GTN|GTN|GTN|GTN|GTN|GTN	Chemical	70:73:104:146:181:211:244	72:74:105:147:182:212:245	2:2:3:5:6:7:8	D051270	primary headaches	Disease	34	36	1
11078231	Myocardial ischemia due to coronary artery spasm during dobutamine stress echocardiography .|Dobutamine stress echocardiography ( DSE ) is a useful and safe provocation test for myocardial ischemia .|Until now , the test has been focused only on the organic lesion in the coronary artery , and positive DSE has indicated the presence of significant fixed coronary artery stenosis .|The aim of the present study is to examine whether myocardial ischemia due to coronary spasm is induced by dobutamine .|We performed DSE on 51 patients with coronary spastic angina but without significant fixed coronary artery stenosis .|All patients had anginal attacks at rest with ST elevation on the electrocardiogram ( variant angina ) .|Coronary spasm was induced by intracoronary injection of acetylcholine , and no fixed coronary artery stenosis was documented on angiograms in all patients .|DSE was performed with intravenous dobutamine infusion with an incremental doses of 5 , 10 , 20 , 30 , and 40 microg / kg / min every 5 minutes .|Of the 51 patients , 7 patients showed asynergy with ST elevation .|All 7 patients ( 13 . 7 % ) had chest pain during asynergy , and both chest pain and electrocardiographic changes were preceded by asynergy .|These findings indicate that dobutamine can provoke coronary spasm in some patients with coronary spastic angina .|When DSE is performed to evaluate coronary artery disease , not only fixed coronary stenosis , but also coronary spasm should be considered as a genesis of asynergy .	1:NR:2	R2L	NON-CROSS	8-9	0-2	D004280	dobutamine|Dobutamine|dobutamine|dobutamine|dobutamine	Chemical	8:12:80:147:217	9:13:81:148:218	0:1:3:7:10	D017202	Myocardial ischemia|myocardial ischemia|myocardial ischemia	Disease	0:26:71	2:28:73	0:1:3	1:NR:2	R2L	CROSS	126-127	71-73	D000109	acetylcholine	Chemical	126	127	6	D017202	Myocardial ischemia|myocardial ischemia|myocardial ischemia	Disease	0:26:71	2:28:73	0:1:3	1:CID:2	R2L	NON-CROSS	8-9	4-7	D004280	dobutamine|Dobutamine|dobutamine|dobutamine|dobutamine	Chemical	8:12:80:147:217	9:13:81:148:218	0:1:3:7:10	D003329	coronary artery spasm|coronary spasm|coronary spasm|coronary spasm	Disease	4:75:220:248	7:77:222:250	0:3:10:11	1:NR:2	R2L	CROSS	126-127	75-77	D000109	acetylcholine	Chemical	126	127	6	D003329	coronary artery spasm|coronary spasm|coronary spasm|coronary spasm	Disease	4:75:220:248	7:77:222:250	0:3:10:11	1:NR:2	L2R	CROSS	131-134	147-148	D004280	dobutamine|Dobutamine|dobutamine|dobutamine|dobutamine	Chemical	8:12:80:147:217	9:13:81:148:218	0:1:3:7:10	D023921	coronary artery stenosis|coronary artery stenosis|coronary artery stenosis|coronary stenosis	Disease	57:96:131:243	60:99:134:245	2:4:6:11	1:CID:2	L2R	NON-CROSS	80-81	89-92	D004280	dobutamine|Dobutamine|dobutamine|dobutamine|dobutamine	Chemical	8:12:80:147:217	9:13:81:148:218	0:1:3:7:10	D000788	coronary spastic angina|variant angina|coronary spastic angina	Disease	89:114:226	92:116:229	4:5:10	1:NR:2	L2R	CROSS	80-81	103-104	D004280	dobutamine|Dobutamine|dobutamine|dobutamine|dobutamine	Chemical	8:12:80:147:217	9:13:81:148:218	0:1:3:7:10	D000787	anginal	Disease	103	104	5	1:NR:2	L2R	CROSS	203-205	217-218	D004280	dobutamine|Dobutamine|dobutamine|dobutamine|dobutamine	Chemical	8:12:80:147:217	9:13:81:148:218	0:1:3:7:10	D002637	chest pain|chest pain	Disease	196:203	198:205	9:9	1:NR:2	L2R	CROSS	217-218	236-239	D004280	dobutamine|Dobutamine|dobutamine|dobutamine|dobutamine	Chemical	8:12:80:147:217	9:13:81:148:218	0:1:3:7:10	D003324	coronary artery disease	Disease	236	239	11	1:NR:2	R2L	NON-CROSS	131-134	126-127	D000109	acetylcholine	Chemical	126	127	6	D023921	coronary artery stenosis|coronary artery stenosis|coronary artery stenosis|coronary stenosis	Disease	57:96:131:243	60:99:134:245	2:4:6:11	1:NR:2	R2L	CROSS	126-127	114-116	D000109	acetylcholine	Chemical	126	127	6	D000788	coronary spastic angina|variant angina|coronary spastic angina	Disease	89:114:226	92:116:229	4:5:10	1:NR:2	R2L	CROSS	126-127	103-104	D000109	acetylcholine	Chemical	126	127	6	D000787	anginal	Disease	103	104	5	1:NR:2	L2R	CROSS	126-127	196-198	D000109	acetylcholine	Chemical	126	127	6	D002637	chest pain|chest pain	Disease	196:203	198:205	9:9	1:NR:2	L2R	CROSS	126-127	236-239	D000109	acetylcholine	Chemical	126	127	6	D003324	coronary artery disease	Disease	236	239	11
10523326	Nitric oxide synthase expression in the course of lead - induced hypertension .|We recently showed elevated reactive oxygen species ( ROS ) , reduced urinary excretion of NO metabolites ( NOx ) , and increased NO sequestration as nitrotyrosine in various tissues in rats with lead - induced hypertension .|This study was designed to discern whether the reduction in urinary NOx in lead - induced hypertension is , in part , due to depressed NO synthase ( NOS ) expression .|Male Sprague - Dawley rats were randomly assigned to a lead - treated group ( given lead acetate , 100 ppm , in drinking water and regular rat chow ) , a group given lead and vitamin E - fortified chow , or a normal control group given either regular food and water or vitamin E - fortified food for 12 weeks .|Tail blood pressure , urinary NOx excretion , plasma malondialdehyde ( MDA ) , and endothelial and inducible NOS ( eNOS and iNOS ) isotypes in the aorta and kidney were measured .|The lead - treated group exhibited a rise in blood pressure and plasma MDA concentration , a fall in urinary NOx excretion , and a paradoxical rise in vascular and renal tissue eNOS and iNOS expression .|Vitamin E supplementation ameliorated hypertension , lowered plasma MDA concentration , and raised urinary NOx excretion while significantly lowering vascular , but not renal , tissue eNOS and iNOS expression .|Vitamin E supplementation had no effect on either blood pressure , plasma MDA , or NOS expression in the control group .|The study also revealed significant inhibition of NOS enzymatic activity by lead in cell - free preparations .|In conclusion , lead - induced hypertension in this model was associated with a compensatory upregulation of renal and vascular eNOS and iNOS expression .|This is , in part , due to ROS - mediated NO inactivation , lead - associated inhibition of NOS activity , and perhaps stimulatory actions of increased shear stress associated with hypertension .	1:NR:2	L2R	NON-CROSS	67-68	76-77	D009569	Nitric oxide|NO|NO|NO|NO	Chemical	0:28:36:76:323	2:29:37:77:324	0:1:1:2:10	D006973	hypertension|hypertension|hypertension|hypertension|hypertension|hypertension	Disease	11:49:67:220:293:344	12:50:68:221:294:345	0:1:2:6:9:10	1:CID:2	L2R	NON-CROSS	8-9	11-12	D007854	lead|lead|lead|lead|lead|lead|lead|lead|lead	Chemical	8:46:64:93:117:180:280:290:326	9:47:65:94:118:181:281:291:327	0:1:2:3:3:5:8:9:10	D006973	hypertension|hypertension|hypertension|hypertension|hypertension|hypertension	Disease	11:49:67:220:293:344	12:50:68:221:294:345	0:1:2:6:9:10	1:NR:2	R2L	NON-CROSS	18-19	11-12	D010100	oxygen	Chemical	18	19	1	D006973	hypertension|hypertension|hypertension|hypertension|hypertension|hypertension	Disease	11:49:67:220:293:344	12:50:68:221:294:345	0:1:2:6:9:10	1:NR:2	R2L	NON-CROSS	49-50	39-40	C002744	nitrotyrosine	Chemical	39	40	1	D006973	hypertension|hypertension|hypertension|hypertension|hypertension|hypertension	Disease	11:49:67:220:293:344	12:50:68:221:294:345	0:1:2:6:9:10	1:NR:2	R2L	CROSS	99-101	67-68	C008261	lead acetate	Chemical	99	101	3	D006973	hypertension|hypertension|hypertension|hypertension|hypertension|hypertension	Disease	11:49:67:220:293:344	12:50:68:221:294:345	0:1:2:6:9:10	1:NR:2	R2L	NON-CROSS	220-221	216-218	D014810	vitamin E|vitamin E|Vitamin E|Vitamin E	Chemical	119:137:216:247	121:139:218:249	3:3:6:7	D006973	hypertension|hypertension|hypertension|hypertension|hypertension|hypertension	Disease	11:49:67:220:293:344	12:50:68:221:294:345	0:1:2:6:9:10	1:NR:2	R2L	NON-CROSS	224-225	220-221	D008315	malondialdehyde|MDA|MDA|MDA|MDA	Chemical	155:157:192:224:259	156:158:193:225:260	4:4:5:6:7	D006973	hypertension|hypertension|hypertension|hypertension|hypertension|hypertension	Disease	11:49:67:220:293:344	12:50:68:221:294:345	0:1:2:6:9:10
9867728	Risk for valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication .|BACKGROUND : Because uncontrolled echocardiographic surveys suggested that up to 30 % to 38 % of users of fenfluramine and dexfenfluramine had valvular disease , these drugs were withdrawn from the market .|OBJECTIVE : To determine the risk for new or worsening valvular abnormalities among users of fenfluramine or dexfenfluramine who underwent echocardiography before they began to take these medications .|DESIGN : Cohort study .|SETTING : Academic primary care practices .|PATIENTS : 46 patients who used fenfluramine or dexfenfluramine for 14 days or more and had echocardiograms obtained before therapy .|MEASUREMENTS : Follow - up echocardiography .|The primary outcome was new or worsening valvulopathy , defined as progression of either aortic or mitral regurgitation by at least one degree of severity and disease that met U . S .|Food and Drug Administration criteria ( at least mild aortic regurgitation or moderate mitral regurgitation ) .|RESULTS : Two patients ( 4 . 3 % [ 95 % CI , 0 . 6 % to 14 . 8 % ] ) receiving fenfluramine - phentermine developed valvular heart disease .|One had baseline bicuspid aortic valve and mild aortic regurgitation that progressed to moderate regurgitation .|The second patient developed new moderate aortic insufficiency .|CONCLUSION : Users of diet medications are at risk for valvular heart disease .|However , the incidence may be lower than that reported previously .	1:NR:2	R2L	NON-CROSS	8-9	2-5	D005277	fenfluramine|fenfluramine|fenfluramine|fenfluramine|fenfluramine	Chemical	8:37:67:99:197	9:38:68:100:198	0:1:2:5:9	D006349	valvular heart disease|valvular disease|valvular abnormalities|valvulopathy|valvular heart disease|valvular heart disease	Disease	2:41:62:128:201:240	5:43:64:129:204:243	0:1:2:7:9:12	1:NR:2	R2L	NON-CROSS	41-43	39-40	D020372	dexfenfluramine|dexfenfluramine|dexfenfluramine|dexfenfluramine	Chemical	10:39:69:101	11:40:70:102	0:1:2:5	D006349	valvular heart disease|valvular disease|valvular abnormalities|valvulopathy|valvular heart disease|valvular heart disease	Disease	2:41:62:128:201:240	5:43:64:129:204:243	0:1:2:7:9:12	1:NR:2	R2L	NON-CROSS	201-204	199-200	D010645	phentermine	Chemical	199	200	9	D006349	valvular heart disease|valvular disease|valvular abnormalities|valvulopathy|valvular heart disease|valvular heart disease	Disease	2:41:62:128:201:240	5:43:64:129:204:243	0:1:2:7:9:12	1:CID:2	L2R	CROSS	197-198	213-215	D005277	fenfluramine|fenfluramine|fenfluramine|fenfluramine|fenfluramine	Chemical	8:37:67:99:197	9:38:68:100:198	0:1:2:5:9	D001022	aortic or mitral regurgitation|aortic regurgitation|aortic regurgitation|aortic insufficiency	Disease	135:163:213:227	139:165:215:229	7:8:10:11	1:NR:2	L2R	CROSS	167-169	197-198	D005277	fenfluramine|fenfluramine|fenfluramine|fenfluramine|fenfluramine	Chemical	8:37:67:99:197	9:38:68:100:198	0:1:2:5:9	D008944	aortic or mitral regurgitation|mitral regurgitation	Disease	135:167	139:169	7:8	1:NR:2	L2R	CROSS	197-198	208-211	D005277	fenfluramine|fenfluramine|fenfluramine|fenfluramine|fenfluramine	Chemical	8:37:67:99:197	9:38:68:100:198	0:1:2:5:9	C562388	bicuspid aortic valve	Disease	208	211	10	1:NR:2	L2R	CROSS	101-102	135-139	D020372	dexfenfluramine|dexfenfluramine|dexfenfluramine|dexfenfluramine	Chemical	10:39:69:101	11:40:70:102	0:1:2:5	D001022	aortic or mitral regurgitation|aortic regurgitation|aortic regurgitation|aortic insufficiency	Disease	135:163:213:227	139:165:215:229	7:8:10:11	1:NR:2	L2R	CROSS	101-102	135-139	D020372	dexfenfluramine|dexfenfluramine|dexfenfluramine|dexfenfluramine	Chemical	10:39:69:101	11:40:70:102	0:1:2:5	D008944	aortic or mitral regurgitation|mitral regurgitation	Disease	135:167	139:169	7:8	1:NR:2	L2R	CROSS	101-102	208-211	D020372	dexfenfluramine|dexfenfluramine|dexfenfluramine|dexfenfluramine	Chemical	10:39:69:101	11:40:70:102	0:1:2:5	C562388	bicuspid aortic valve	Disease	208	211	10	1:CID:2	R2L	CROSS	213-215	199-200	D010645	phentermine	Chemical	199	200	9	D001022	aortic or mitral regurgitation|aortic regurgitation|aortic regurgitation|aortic insufficiency	Disease	135:163:213:227	139:165:215:229	7:8:10:11	1:NR:2	R2L	CROSS	199-200	167-169	D010645	phentermine	Chemical	199	200	9	D008944	aortic or mitral regurgitation|mitral regurgitation	Disease	135:167	139:169	7:8	1:NR:2	L2R	CROSS	199-200	208-211	D010645	phentermine	Chemical	199	200	9	C562388	bicuspid aortic valve	Disease	208	211	10
9636837	Carboplatin toxic effects on the peripheral nervous system of the rat .|BACKGROUND : The most striking of carboplatin 's advantages ( CBDCA ) over cisplatin ( CDDP ) is its markedly reduced rate of neurotoxic effects .|However , the use of CBDCA higher - intensity schedules and the association with other neurotoxic drugs in polychemotherapy may cause some concern about its safety with respect to peripheral nervous system damage .|MATERIALS AND METHODS : Two different schedules of CBDCA administration ( 10 mg / kg and 15 mg / kg i . p .|twice a week for nine times ) were evaluated in Wistar rats .|Neurotoxicity was assessed for behavioral ( tail - flick test ) , neurophysiological ( nerve conduction velocity in the tail nerve ) , morphological , morphometrical and analytical effects .|RESULTS : CBDCA administration induced dose - dependent peripheral neurotoxicity .|Pain perception and nerve conduction velocity in the tail were significantly impaired , particularly after the high - dose treatment .|The dorsal root ganglia sensory neurons and , to a lesser extent , satellite cells showed the same changes as those induced by CDDP , mainly affecting the nucleus and nucleolus of ganglionic sensory neurons .|Moreover , significant amounts of platinum were detected in the dorsal root ganglia and kidney after CBDCA treatment .|CONCLUSIONS : CBDCA is neurotoxic in our model , and the type of pathological changes it induces are so closely similar to those caused by CDDP that it is probable that neurotoxicity is induced in the two drugs by the same mechanism .|This model can be used alone or in combination with other drugs to explore the effect of CBDCA on the peripheral nervous system .	1:NR:2	L2R	NON-CROSS	228-229	230-231	D016190	Carboplatin|carboplatin|CBDCA|CBDCA|CBDCA|CBDCA|CBDCA|CBDCA|CBDCA	Chemical	0:18:22:43:80:141:223:228:286	1:19:23:44:81:142:224:229:287	0:1:1:2:3:6:9:10:11	D020258	neurotoxic|neurotoxic|Neurotoxicity|neurotoxic|neurotoxicity	Disease	35:53:109:230:257	36:54:110:231:258	1:2:5:10:10	1:CID:2	L2R	NON-CROSS	141-142	147-149	D016190	Carboplatin|carboplatin|CBDCA|CBDCA|CBDCA|CBDCA|CBDCA|CBDCA|CBDCA	Chemical	0:18:22:43:80:141:223:228:286	1:19:23:44:81:142:224:229:287	0:1:1:2:3:6:9:10:11	D010523	peripheral nervous system damage|peripheral neurotoxicity	Disease	67:147	71:149	2:6	1:NR:2	L2R	CROSS	141-142	150-151	D016190	Carboplatin|carboplatin|CBDCA|CBDCA|CBDCA|CBDCA|CBDCA|CBDCA|CBDCA	Chemical	0:18:22:43:80:141:223:228:286	1:19:23:44:81:142:224:229:287	0:1:1:2:3:6:9:10:11	D010146	Pain	Disease	150	151	7	1:NR:2	L2R	NON-CROSS	251-252	257-258	D002945	cisplatin|CDDP|CDDP|CDDP	Chemical	25:27:194:251	26:28:195:252	1:1:8:10	D020258	neurotoxic|neurotoxic|Neurotoxicity|neurotoxic|neurotoxicity	Disease	35:53:109:230:257	36:54:110:231:258	1:2:5:10:10	1:CID:2	L2R	CROSS	27-28	67-71	D002945	cisplatin|CDDP|CDDP|CDDP	Chemical	25:27:194:251	26:28:195:252	1:1:8:10	D010523	peripheral nervous system damage|peripheral neurotoxicity	Disease	67:147	71:149	2:6	1:NR:2	L2R	CROSS	150-151	194-195	D002945	cisplatin|CDDP|CDDP|CDDP	Chemical	25:27:194:251	26:28:195:252	1:1:8:10	D010146	Pain	Disease	150	151	7	1:NR:2	R2L	CROSS	230-231	212-213	D010984	platinum	Chemical	212	213	9	D020258	neurotoxic|neurotoxic|Neurotoxicity|neurotoxic|neurotoxicity	Disease	35:53:109:230:257	36:54:110:231:258	1:2:5:10:10	1:NR:2	R2L	CROSS	212-213	147-149	D010984	platinum	Chemical	212	213	9	D010523	peripheral nervous system damage|peripheral neurotoxicity	Disease	67:147	71:149	2:6	1:NR:2	R2L	CROSS	212-213	150-151	D010984	platinum	Chemical	212	213	9	D010146	Pain	Disease	150	151	7
9579567	Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case - control study .|F d ration Nationale des Centres de Lutte Contre le Cancer ( FNCLCC ) .|Since tamoxifen is widely used in breast cancer treatment and has been proposed for the prevention of breast cancer , its endometrial iatrogenic effects must be carefully examined .|We have investigated the association between endometrial cancer and tamoxifen use or other treatments in women treated for breast cancer in a case - control study .|Cases of endometrial cancer diagnosed after breast cancer ( n = 135 ) and 467 controls matched for age , year of diagnosis of breast cancer and hospital and survival time with an intact uterus were included .|Women who had received tamoxifen were significantly more likely to have endometrial cancer diagnosed than those who had not ( crude relative risk = 4 . 9 , p = 0 . 0001 ) .|Univariate and adjusted analyses showed that the risk increased with the length of treatment ( p = 0 . 0001 ) or the cumulative dose of tamoxifen received ( p = 0 . 0001 ) , irrespective of the daily dose .|Women who had undergone pelvic radiotherapy also had a higher risk ( crude relative risk = 7 . 8 , p = 0 . 0001 ) .|After adjusting for confounding factors , the risk was higher for tamoxifen users ( p = 0 . 0012 ) , treatment for more than 3 years ( all p < 0 . 03 ) and pelvic radiotherapy ( p = 0 . 012 ) .|Women who had endometrial cancer and had received tamoxifen had more advanced disease and poorer prognosis than those with endometrial cancer who had not received this treatment .|Our results suggest a causal role of tamoxifen in endometrial cancer , particularly when used as currently proposed for breast cancer prevention .|Pelvic radiotherapy may be an additional iatrogenic factor for women with breast cancer .|Endometrial cancers diagnosed in women treated with tamoxifen have poorer prognosis .|Women who receive tamoxifen for breast cancer should be offered gynaecological surveillance during and after treatment .|A long - term evaluation of the risk - benefit ratio of tamoxifen as a preventive treatment for breast cancer is clearly warranted .	1:CID:2	R2L	NON-CROSS	72-73	69-71	D013629	tamoxifen|tamoxifen|tamoxifen|tamoxifen|tamoxifen|tamoxifen|tamoxifen|tamoxifen|tamoxifen|tamoxifen	Chemical	35:72:132:189:243:286:313:350:358:384	36:73:133:190:244:287:314:351:359:385	2:3:5:6:8:9:10:12:13:14	D016889	endometrial carcinoma|endometrial cancer|endometrial cancer|endometrial cancer|endometrial cancer|endometrial cancer|endometrial cancer|Endometrial cancers	Disease	3:69:92:139:281:297:315:343	5:71:94:141:283:299:317:345	0:3:4:5:9:9:10:12	1:NR:2	R2L	NON-CROSS	360-362	358-359	D013629	tamoxifen|tamoxifen|tamoxifen|tamoxifen|tamoxifen|tamoxifen|tamoxifen|tamoxifen|tamoxifen|tamoxifen	Chemical	35:72:132:189:243:286:313:350:358:384	36:73:133:190:244:287:314:351:359:385	2:3:5:6:8:9:10:12:13:14	D001943	breast cancer|breast cancer|breast cancer|breast cancer|breast cancer|breast cancer|breast cancer|breast cancer|breast cancer|breast cancer	Disease	8:40:51:81:96:114:325:340:360:390	10:42:53:83:98:116:327:342:362:392	0:2:2:3:4:4:10:11:13:14	1:NR:2	L2R	NON-CROSS	286-287	289-291	D013629	tamoxifen|tamoxifen|tamoxifen|tamoxifen|tamoxifen|tamoxifen|tamoxifen|tamoxifen|tamoxifen|tamoxifen	Chemical	35:72:132:189:243:286:313:350:358:384	36:73:133:190:244:287:314:351:359:385	2:3:5:6:8:9:10:12:13:14	D020178	advanced disease	Disease	289	291	9
9205462	Granulosa cell tumor of the ovary associated with antecedent tamoxifen use .|BACKGROUND : Increased attention has been focused recently on the estrogenic effects of tamoxifen .|Review of the literature reveals an association between tamoxifen use and gynecologic tumors .|CASE : A 52 - year - old postmenopausal woman was treated with tamoxifen for stage II estrogen receptor - positive breast carcinoma .|Her aspartate transaminase and alanine transaminase levels increase markedly after 6 months of tamoxifen use .|After an additional 17 months of elevated serum transaminases , the patient was found to have a stage Ic granulosa cell tumor of the ovary .|CONCLUSION : Patients with tamoxifen - induced liver dysfunction may be at increased risk for granulosa cell tumors because of alterations in tamoxifen metabolism .	1:CID:2	R2L	NON-CROSS	9-10	0-6	D013629	tamoxifen|tamoxifen|tamoxifen|tamoxifen|tamoxifen|tamoxifen|tamoxifen	Chemical	9:25:35:54:78:111:129	10:26:36:55:79:112:130	0:1:2:3:4:6:6	C537296	Granulosa cell tumor of the ovary|granulosa cell tumor of the ovary	Disease	0:100	6:106	0:5	1:NR:2	R2L	CROSS	100-106	58-59	D004967	estrogen	Chemical	58	59	3	C537296	Granulosa cell tumor of the ovary|granulosa cell tumor of the ovary	Disease	0:100	6:106	0:5	1:NR:2	R2L	CROSS	100-106	66-67	D001224	aspartate	Chemical	66	67	4	C537296	Granulosa cell tumor of the ovary|granulosa cell tumor of the ovary	Disease	0:100	6:106	0:5	1:NR:2	R2L	CROSS	100-106	69-70	D000409	alanine	Chemical	69	70	4	C537296	Granulosa cell tumor of the ovary|granulosa cell tumor of the ovary	Disease	0:100	6:106	0:5	1:NR:2	L2R	NON-CROSS	35-36	39-40	D013629	tamoxifen|tamoxifen|tamoxifen|tamoxifen|tamoxifen|tamoxifen|tamoxifen	Chemical	9:25:35:54:78:111:129	10:26:36:55:79:112:130	0:1:2:3:4:6:6	D009369	tumors	Disease	39	40	2	1:NR:2	L2R	NON-CROSS	54-55	62-64	D013629	tamoxifen|tamoxifen|tamoxifen|tamoxifen|tamoxifen|tamoxifen|tamoxifen	Chemical	9:25:35:54:78:111:129	10:26:36:55:79:112:130	0:1:2:3:4:6:6	D001943	breast carcinoma	Disease	62	64	3	1:CID:2	L2R	NON-CROSS	111-112	114-116	D013629	tamoxifen|tamoxifen|tamoxifen|tamoxifen|tamoxifen|tamoxifen|tamoxifen	Chemical	9:25:35:54:78:111:129	10:26:36:55:79:112:130	0:1:2:3:4:6:6	D017093	liver dysfunction	Disease	114	116	6	1:NR:2	L2R	NON-CROSS	122-125	129-130	D013629	tamoxifen|tamoxifen|tamoxifen|tamoxifen|tamoxifen|tamoxifen|tamoxifen	Chemical	9:25:35:54:78:111:129	10:26:36:55:79:112:130	0:1:2:3:4:6:6	D006106	granulosa cell tumors	Disease	122	125	6	1:NR:2	R2L	CROSS	58-59	39-40	D004967	estrogen	Chemical	58	59	3	D009369	tumors	Disease	39	40	2	1:NR:2	R2L	CROSS	66-67	39-40	D001224	aspartate	Chemical	66	67	4	D009369	tumors	Disease	39	40	2	1:NR:2	R2L	CROSS	69-70	39-40	D000409	alanine	Chemical	69	70	4	D009369	tumors	Disease	39	40	2	1:NR:2	L2R	NON-CROSS	58-59	62-64	D004967	estrogen	Chemical	58	59	3	D001943	breast carcinoma	Disease	62	64	3	1:NR:2	L2R	CROSS	58-59	114-116	D004967	estrogen	Chemical	58	59	3	D017093	liver dysfunction	Disease	114	116	6	1:NR:2	L2R	CROSS	58-59	122-125	D004967	estrogen	Chemical	58	59	3	D006106	granulosa cell tumors	Disease	122	125	6	1:NR:2	R2L	CROSS	66-67	62-64	D001224	aspartate	Chemical	66	67	4	D001943	breast carcinoma	Disease	62	64	3	1:NR:2	R2L	CROSS	69-70	62-64	D000409	alanine	Chemical	69	70	4	D001943	breast carcinoma	Disease	62	64	3	1:NR:2	L2R	CROSS	66-67	114-116	D001224	aspartate	Chemical	66	67	4	D017093	liver dysfunction	Disease	114	116	6	1:NR:2	L2R	CROSS	66-67	122-125	D001224	aspartate	Chemical	66	67	4	D006106	granulosa cell tumors	Disease	122	125	6	1:NR:2	L2R	CROSS	69-70	114-116	D000409	alanine	Chemical	69	70	4	D017093	liver dysfunction	Disease	114	116	6	1:NR:2	L2R	CROSS	69-70	122-125	D000409	alanine	Chemical	69	70	4	D006106	granulosa cell tumors	Disease	122	125	6
9098464	A murine model of adenomyosis : the effects of hyperprolactinemia induced by fluoxetine hydrochloride , a selective serotonin reuptake inhibitor , on adenomyosis induction in Wistar albino rats .|OBJECTIVE : The aim of this study was to investigate whether fluoxetine given to castrated and noncastrated rats caused hyperprolactinemia and its effects with respect to adenomyosis .|DESIGN : Fluoxetine , a serotonin reuptake inhibitor , was given to Wistar Albino rats for 98 days to produce hyperprolactinemia .|The drug was given to two groups consisting of castrated and noncastrated rats and compared to two groups of castrated and noncastrated controls .|Prolactin levels were measured and the uteri of the rats were removed for histopathological analysis at the end of 98 days .|SETTING : Marmara University School of Medicine , Department of Histology and Embryology , Zeynep Kamil Women and Children 's Hospital .|MAIN OUTCOME MEASURES : Serum prolactin levels , uterine histopathology .|RESULTS : The prolactin levels of castrated and noncastrated groups treated with fluoxetine were statistically significantly higher when compared to their respective control groups .|Histological studies revealed 11 cases of adenomyosis , all within the noncastrated group receiving fluoxetine .|CONCLUSION : It was suggested that high serum prolactin levels cause degeneration of myometrial cells in the presence of ovarian steroids that results in a myometrial invasion by endometrial stroma .|This invasion eventually progresses to adenomyosis .	1:CID:2	R2L	NON-CROSS	59-60	55-56	D005473	fluoxetine hydrochloride|fluoxetine|Fluoxetine|fluoxetine|fluoxetine	Chemical	12:40:59:170:197	14:41:60:171:198	0:1:2:7:8	D062788	adenomyosis|adenomyosis|adenomyosis|adenomyosis|adenomyosis	Disease	4:22:55:189:235	5:23:56:190:236	0:0:1:8:10	1:NR:2	R2L	NON-CROSS	22-23	17-18	D012701	serotonin|serotonin	Chemical	17:62	18:63	0:2	D062788	adenomyosis|adenomyosis|adenomyosis|adenomyosis|adenomyosis	Disease	4:22:55:189:235	5:23:56:190:236	0:0:1:8:10	1:NR:2	R2L	CROSS	235-236	219-220	D013256	steroids	Chemical	219	220	9	D062788	adenomyosis|adenomyosis|adenomyosis|adenomyosis|adenomyosis	Disease	4:22:55:189:235	5:23:56:190:236	0:0:1:8:10	1:CID:2	R2L	NON-CROSS	12-14	9-10	D005473	fluoxetine hydrochloride|fluoxetine|Fluoxetine|fluoxetine|fluoxetine	Chemical	12:40:59:170:197	14:41:60:171:198	0:1:2:7:8	D006966	hyperprolactinemia|hyperprolactinemia|hyperprolactinemia	Disease	9:48:77	10:49:78	0:1:2	1:NR:2	R2L	NON-CROSS	17-18	9-10	D012701	serotonin|serotonin	Chemical	17:62	18:63	0:2	D006966	hyperprolactinemia|hyperprolactinemia|hyperprolactinemia	Disease	9:48:77	10:49:78	0:1:2	1:NR:2	R2L	CROSS	219-220	77-78	D013256	steroids	Chemical	219	220	9	D006966	hyperprolactinemia|hyperprolactinemia|hyperprolactinemia	Disease	9:48:77	10:49:78	0:1:2
8424298	Effects of deliberate hypotension induced by labetalol with isoflurane on neuropsychological function .|The effect of deliberate hypotension on brain function measured by neuropsychological tests was studied in 41 adult patients .|Twenty - four patients were anaesthetized for middle - ear surgery with deliberate hypotension induced by labetalol with isoflurane ( hypotensive group ) .|Seventeen patients without hypotension served as a control group .|The mean arterial pressure was 77 + / - 2 mmHg ( 10 . 3 + / - 0 . 3 kPa ) before hypotension and 50 + / - 0 mmHg ( 6 . 7 + / - 0 . 0 kPa ) during hypotension in the hypotensive group , and 86 + / - 2 mmHg ( 11 . 5 + / - 0 . 3 kPa ) during anaesthesia in the control group .|The following psychological tests were performed : four subtests of the Wechsler Adult Intelligence Scale ( similarities , digit span , vocabulary and digit symbol ) , Trail - Making tests A and B , Zung tests ( self - rating anxiety scale and self - rating depression scale ) and two - part memory test battery with immediate and delayed recall .|The tests were performed preoperatively and 2 days postoperatively .|There were no statistically significant differences between the groups in any of the tests in the changes from preoperative value to postoperative value .|The results indicate that hypotension induced by labetalol with isoflurane has no significant harmful effects on mental functions compared to normotensive anaesthesia .	1:CID:2	R2L	NON-CROSS	6-7	3-4	D007741	labetalol|labetalol|labetalol	Chemical	6:48:247	7:49:248	0:2:8	D007022	hypotension|hypotension|hypotension|hypotensive|hypotension|hypotension|hypotension|hypotensive|hypotension	Disease	3:17:45:52:59:90:111:114:244	4:18:46:53:60:91:112:115:245	0:1:2:2:3:4:4:4:8	1:CID:2	R2L	NON-CROSS	52-53	50-51	D007530	isoflurane|isoflurane|isoflurane	Chemical	8:50:249	9:51:250	0:2:8	D007022	hypotension|hypotension|hypotension|hypotensive|hypotension|hypotension|hypotension|hypotensive|hypotension	Disease	3:17:45:52:59:90:111:114:244	4:18:46:53:60:91:112:115:245	0:1:2:2:3:4:4:4:8	1:NR:2	L2R	CROSS	184-185	247-248	D007741	labetalol|labetalol|labetalol	Chemical	6:48:247	7:49:248	0:2:8	D001008	anxiety	Disease	184	185	5	1:NR:2	L2R	CROSS	190-191	247-248	D007741	labetalol|labetalol|labetalol	Chemical	6:48:247	7:49:248	0:2:8	D003866	depression	Disease	190	191	5	1:NR:2	L2R	CROSS	184-185	249-250	D007530	isoflurane|isoflurane|isoflurane	Chemical	8:50:249	9:51:250	0:2:8	D001008	anxiety	Disease	184	185	5	1:NR:2	L2R	CROSS	190-191	249-250	D007530	isoflurane|isoflurane|isoflurane	Chemical	8:50:249	9:51:250	0:2:8	D003866	depression	Disease	190	191	5
7880714	Auditory disturbance associated with interscalene brachial plexus block .|We performed an audiometric study in 20 patients who underwent surgery of the shoulder region under an interscalene brachial plexus block ( IBPB ) .|Bupivacaine 0 . 75 % with adrenaline was given followed by a 24 - hr continuous infusion of 0 . 25 % bupivacaine .|Three audiometric threshold measurements ( 0 . 25 - 18 kHz ) were made : the first before IBPB , the second 2 - 6 h after surgery and the third on the first day after operation .|In four patients hearing impairment on the side of the block was demonstrated after operation , in three measurements on the day of surgery and in one on the following day .|The frequencies at which the impairment occurred varied between patients ; in one only low frequencies ( 0 . 25 - 0 . 5 kHz ) were involved .|The maximum change in threshold was 35 dB at 6 kHz measured at the end of the continuous infusion of bupivacaine .|This patient had hearing threshold changes ( 15 - 20 dB ) at 6 - 10 kHz on the opposite side also .|IBPB may cause transient auditory dysfunction in the ipsilateral ear , possibly via an effect on sympathetic innervation .	1:CID:2	L2R	CROSS	56-57	99-101	D002045	Bupivacaine|bupivacaine|bupivacaine	Chemical	34:56:177	35:57:178	2:2:6	D034381	hearing impairment	Disease	99	101	4	1:NR:2	L2R	CROSS	177-178	206-208	D002045	Bupivacaine|bupivacaine|bupivacaine	Chemical	34:56:177	35:57:178	2:2:6	D006311	auditory dysfunction	Disease	206	208	8	1:CID:2	L2R	CROSS	40-41	99-101	D004837	adrenaline	Chemical	40	41	2	D034381	hearing impairment	Disease	99	101	4	1:NR:2	L2R	CROSS	40-41	206-208	D004837	adrenaline	Chemical	40	41	2	D006311	auditory dysfunction	Disease	206	208	8
7102237	Midazolam compared with thiopentone as an induction agent .|In patients premedicated with scopolamine + morphine ( + 5 mg nitrazepam the evening before surgery ) , the sleep - inducing effect of midazolam 0 . 15 mg / kg i . v .|was clearly slower in onset than that of thiopentone 4 . 67 mg / kg i . v .|Somewhat fewer cardiovascular and local sequelae were found in the midazolam group , but , although apnoea occurred less often in the midazolam group it lasted longer .|On the whole , the differences between midazolam and thiopentone had no apparent clinical consequences .|Midazolam is a new alternative agent for induction in combination anaesthesia .	1:CID:2	L2R	NON-CROSS	73-74	79-80	D008874	Midazolam|midazolam|midazolam|midazolam|midazolam|Midazolam	Chemical	0:33:73:85:98:107	1:34:74:86:99:108	0:1:3:3:4:5	D001049	apnoea	Disease	79	80	3	1:CID:2	L2R	CROSS	79-80	100-101	D013874	thiopentone|thiopentone|thiopentone	Chemical	3:52:100	4:53:101	0:2:4	D001049	apnoea	Disease	79	80	3	1:NR:2	L2R	CROSS	13-14	79-80	D012601	scopolamine	Chemical	13	14	1	D001049	apnoea	Disease	79	80	3	1:NR:2	L2R	CROSS	15-16	79-80	D009020	morphine	Chemical	15	16	1	D001049	apnoea	Disease	79	80	3	1:NR:2	L2R	CROSS	20-21	79-80	D009567	nitrazepam	Chemical	20	21	1	D001049	apnoea	Disease	79	80	3
6769133	Cardiotoxic and possible leukemogenic effects of adriamycin in nonhuman primates .|10 monkeys ( macaques ) received adriamycin by monthly intravenous injections at 12 mg / m2 ( 1 mg / kg ) .|8 of the 10 monkeys developed congestive heart failure at an average cumulative adriamycin dose ( 310 mg / m2 ) well below that considered the safe upper limit ( 550 mg / m2 ) in man .|Histologically , the myocardial lesions resembled those found in human anthracycline - induced cardiomyopathy .|1 of the 10 monkeys developed acute myeloblastic leukemia after receiving 324 mg / m2 of adriamycin ; the 10th monkey is alive and well 26 months after the last dose of drug .|Our results suggest that adriamycin is a more potent cardiotoxin in monkeys than in man , and that leukemia may be a consequence of prolonged treatment with this drug .	1:NR:2	R2L	NON-CROSS	6-7	0-1	D004317	adriamycin|adriamycin|adriamycin|adriamycin|adriamycin	Chemical	6:17:47:103:125	7:18:48:104:126	0:1:2:4:5	D066126	Cardiotoxic	Disease	0	1	0	1:NR:2	R2L	CROSS	82-83	0-1	D018943	anthracycline	Chemical	82	83	3	D066126	Cardiotoxic	Disease	0	1	0	1:CID:2	L2R	NON-CROSS	40-43	47-48	D004317	adriamycin|adriamycin|adriamycin|adriamycin|adriamycin	Chemical	6:17:47:103:125	7:18:48:104:126	0:1:2:4:5	D006333	congestive heart failure	Disease	40	43	2	1:NR:2	L2R	CROSS	75-77	103-104	D004317	adriamycin|adriamycin|adriamycin|adriamycin|adriamycin	Chemical	6:17:47:103:125	7:18:48:104:126	0:1:2:4:5	D001768	myocardial lesions	Disease	75	77	3	1:NR:2	L2R	CROSS	85-86	103-104	D004317	adriamycin|adriamycin|adriamycin|adriamycin|adriamycin	Chemical	6:17:47:103:125	7:18:48:104:126	0:1:2:4:5	D009202	cardiomyopathy	Disease	85	86	3	1:CID:2	L2R	NON-CROSS	93-96	103-104	D004317	adriamycin|adriamycin|adriamycin|adriamycin|adriamycin	Chemical	6:17:47:103:125	7:18:48:104:126	0:1:2:4:5	D015470	acute myeloblastic leukemia	Disease	93	96	4	1:NR:2	L2R	NON-CROSS	125-126	139-140	D004317	adriamycin|adriamycin|adriamycin|adriamycin|adriamycin	Chemical	6:17:47:103:125	7:18:48:104:126	0:1:2:4:5	D007938	leukemia	Disease	139	140	5	1:NR:2	R2L	CROSS	82-83	40-43	D018943	anthracycline	Chemical	82	83	3	D006333	congestive heart failure	Disease	40	43	2	1:NR:2	R2L	NON-CROSS	82-83	75-77	D018943	anthracycline	Chemical	82	83	3	D001768	myocardial lesions	Disease	75	77	3	1:NR:2	L2R	NON-CROSS	82-83	85-86	D018943	anthracycline	Chemical	82	83	3	D009202	cardiomyopathy	Disease	85	86	3	1:NR:2	L2R	CROSS	82-83	93-96	D018943	anthracycline	Chemical	82	83	3	D015470	acute myeloblastic leukemia	Disease	93	96	4	1:NR:2	L2R	CROSS	82-83	139-140	D018943	anthracycline	Chemical	82	83	3	D007938	leukemia	Disease	139	140	5
6292680	Doxorubicin cardiomyopathy in children with left - sided Wilms tumor .|Two children with Wilms tumor of the left kidney experienced severe anthracycline cardiomyopathy after irradiation to the tumor bed and conventional dosage of doxorubicin .|The cardiomyopathy is attributed 1 ) to the fact that radiation fields for left Wilms tumor include the lower portion of the heart and 2 ) to the interaction of doxorubicin and irradiation on cardiac muscle .|It is recommended that doxorubicin dosage be sharply restricted in children with Wilms tumor of the left kidney who receive postoperative irradiation .	1:CID:2	L2R	NON-CROSS	0-1	1-2	D004317	Doxorubicin|doxorubicin|doxorubicin|doxorubicin	Chemical	0:34:66:77	1:35:67:78	0:1:2:3	D009202	cardiomyopathy|cardiomyopathy|cardiomyopathy	Disease	1:23:37	2:24:38	0:1:2	1:NR:2	L2R	NON-CROSS	0-1	8-10	D004317	Doxorubicin|doxorubicin|doxorubicin|doxorubicin	Chemical	0:34:66:77	1:35:67:78	0:1:2:3	D009396	Wilms tumor|Wilms tumor|Wilms tumor|Wilms tumor	Disease	8:14:50:85	10:16:52:87	0:1:2:3	1:NR:2	L2R	NON-CROSS	28-29	34-35	D004317	Doxorubicin|doxorubicin|doxorubicin|doxorubicin	Chemical	0:34:66:77	1:35:67:78	0:1:2:3	D009369	tumor	Disease	28	29	1	1:NR:2	R2L	NON-CROSS	23-24	22-23	D018943	anthracycline	Chemical	22	23	1	D009202	cardiomyopathy|cardiomyopathy|cardiomyopathy	Disease	1:23:37	2:24:38	0:1:2	1:NR:2	R2L	NON-CROSS	22-23	14-16	D018943	anthracycline	Chemical	22	23	1	D009396	Wilms tumor|Wilms tumor|Wilms tumor|Wilms tumor	Disease	8:14:50:85	10:16:52:87	0:1:2:3	1:NR:2	L2R	NON-CROSS	22-23	28-29	D018943	anthracycline	Chemical	22	23	1	D009369	tumor	Disease	28	29	1
3969369	Promotional effects of testosterone and dietary fat on prostate carcinogenesis in genetically susceptible rats .|Germfree ( GF ) Lobund strain Wistar ( LW ) rats , fed vegetable diet L - 485 , have developed prostate adenocarcinomas spontaneously ( 10 % incidence ) at average age 34 months .|Conventional LW rats , implanted with testosterone at age 4 months , developed a higher incidence of prostate cancer after an average interval of 14 months : 24 % had developed gross tumors , and 40 % when it included microscopic tumors .|Preliminary results indicate that testosterone - treated LW rats that were fed the same diet , which was supplemented with corn oil up to 20 % fat , developed prostate cancer after intervals of 6 - 12 months .|Aged GF Sprague - Dawley ( SD ) rats have not developed prostate cancer spontaneously .|Conventional SD rats fed diet L - 485 and treated with testosterone developed only prostatitis .|Experimental designs should consider genetic susceptibility as a basic prerequisite for studies on experimental prostate cancer .	1:NR:2	L2R	NON-CROSS	3-4	9-10	D013739	testosterone|testosterone|testosterone|testosterone	Chemical	3:56:97:159	4:57:98:160	0:2:3:5	D063646	carcinogenesis	Disease	9	10	0	1:CID:2	L2R	NON-CROSS	56-57	67-69	D013739	testosterone|testosterone|testosterone|testosterone	Chemical	3:56:97:159	4:57:98:160	0:2:3:5	D011471	prostate adenocarcinomas|prostate cancer|prostate cancer|prostate cancer|prostate cancer	Disease	36:67:122:144:178	38:69:124:146:180	1:2:3:4:6	1:NR:2	L2R	NON-CROSS	91-92	97-98	D013739	testosterone|testosterone|testosterone|testosterone	Chemical	3:56:97:159	4:57:98:160	0:2:3:5	D009369	tumors|tumors	Disease	82:91	83:92	2:2	1:CID:2	L2R	NON-CROSS	159-160	162-163	D013739	testosterone|testosterone|testosterone|testosterone	Chemical	3:56:97:159	4:57:98:160	0:2:3:5	D011472	prostatitis	Disease	162	163	5
3108839	Mitomycin C associated hemolytic uremic syndrome .|Mitomycin C associated Hemolytic Uremic Syndrome ( HUS ) is a potentially fatal but uncommon condition that is not yet widely recognised .|It consists of microangiopathic hemolytic anemia , thrombocytopenia and progressive renal failure associated with mitomycin C treatment and affects about 10 % of patients treated with this agent .|The renal failure usually develops about 8 - 10 mth after start of mitomycin C treatment and the mortality is approximately 60 % from renal failure or pulmonary edema .|Renal lesions are similar to those seen in idiopathic HUS and include arteriolar fibrin thrombi , expanded subendothelial zones in glomerular capillary walls , ischemic wrinkling of glomerular basement membranes and mesangiolysis .|The mechanism of action is postulated as mitomycin C - induced endothelial cell damage .|We describe the clinical course and pathological findings in a 65 yr - old man with gastric adenocarcinoma who developed renal failure and thrombocytopenia while on treatment with mitomycin C and died in pulmonary edema .	1:CID:2	L2R	NON-CROSS	0-2	3-6	D016685	Mitomycin C|Mitomycin C|mitomycin C|mitomycin C|mitomycin C|mitomycin C	Chemical	0:7:44:72:129:165	2:9:46:74:131:167	0:1:2:3:5:6	D006463	hemolytic uremic syndrome|Hemolytic Uremic Syndrome|HUS|HUS	Disease	3:10:14:98	6:13:15:99	0:1:1:4	1:NR:2	L2R	NON-CROSS	34-36	44-46	D016685	Mitomycin C|Mitomycin C|mitomycin C|mitomycin C|mitomycin C|mitomycin C	Chemical	0:7:44:72:129:165	2:9:46:74:131:167	0:1:2:3:5:6	D000743	hemolytic anemia	Disease	34	36	2	1:NR:2	L2R	NON-CROSS	160-161	165-167	D016685	Mitomycin C|Mitomycin C|mitomycin C|mitomycin C|mitomycin C|mitomycin C	Chemical	0:7:44:72:129:165	2:9:46:74:131:167	0:1:2:3:5:6	D013921	thrombocytopenia|thrombocytopenia	Disease	37:160	38:161	2:6	1:CID:2	L2R	NON-CROSS	40-42	44-46	D016685	Mitomycin C|Mitomycin C|mitomycin C|mitomycin C|mitomycin C|mitomycin C	Chemical	0:7:44:72:129:165	2:9:46:74:131:167	0:1:2:3:5:6	D051437	renal failure|renal failure|renal failure|Renal lesions|renal failure	Disease	40:60:83:89:157	42:62:85:91:159	2:3:3:4:6	1:NR:2	L2R	NON-CROSS	165-167	170-172	D016685	Mitomycin C|Mitomycin C|mitomycin C|mitomycin C|mitomycin C|mitomycin C	Chemical	0:7:44:72:129:165	2:9:46:74:131:167	0:1:2:3:5:6	D011654	pulmonary edema|pulmonary edema	Disease	86:170	88:172	3:6	1:NR:2	L2R	CROSS	103-104	129-131	D016685	Mitomycin C|Mitomycin C|mitomycin C|mitomycin C|mitomycin C|mitomycin C	Chemical	0:7:44:72:129:165	2:9:46:74:131:167	0:1:2:3:5:6	D013927	thrombi	Disease	103	104	4	1:NR:2	L2R	CROSS	113-114	129-131	D016685	Mitomycin C|Mitomycin C|mitomycin C|mitomycin C|mitomycin C|mitomycin C	Chemical	0:7:44:72:129:165	2:9:46:74:131:167	0:1:2:3:5:6	D007511	ischemic	Disease	113	114	4	1:NR:2	L2R	NON-CROSS	153-155	165-167	D016685	Mitomycin C|Mitomycin C|mitomycin C|mitomycin C|mitomycin C|mitomycin C	Chemical	0:7:44:72:129:165	2:9:46:74:131:167	0:1:2:3:5:6	D013274	gastric adenocarcinoma	Disease	153	155	6
2466960	Continuous ambulatory ECG monitoring during fluorouracil therapy : a prospective study .|Although there have been anecdotal reports of cardiac toxicity associated with fluorouracil ( 5 - FU ) therapy , this phenomenon has not been studied in a systematic fashion .|We prospectively performed continuous ambulatory ECG monitoring on 25 patients undergoing 5 - FU infusion for treatment of solid tumors in order to assess the incidence of ischemic ST changes .|Patients were monitored for 23 + / - 4 hours before 5 - FU infusion , and 98 + / - 9 hours during 5 - FU infusion .|Anginal episodes were rare : only one patient had angina ( during 5 - FU infusion ) .|However , asymptomatic ST changes ( greater than or equal to 1 mm ST deviation ) were common : six of 25 patients ( 24 % ) had ST changes before 5 - FU infusion v 17 ( 68 % ) during 5 - FU infusion ( P less than . 002 ) .|The incidence of ischemic episodes per patient per hour was 0 . 05 + / - 0 . 02 prior to 5 - FU infusion v 0 . 13 + / - 0 . 03 during 5 - FU infusion ( P less than . 001 ) ; the duration of ECG changes was 0 . 6 + / - 0 . 3 minutes per patient per hour before 5 - FU v 1 . 9 + / - 0 . 5 minutes per patient per hour during 5 - FU ( P less than . 01 ) .|ECG changes were more common among patients with known coronary artery disease .|There were two cases of sudden death , both of which occurred at the end of the chemotherapy course .|We conclude that 5 - FU infusion is associated with a significant increase in silent ST segment deviation suggestive of ischemia , particularly among patients with coronary artery disease .|The mechanism and clinical significance of these ECG changes remain to be determined .	1:NR:2	L2R	NON-CROSS	19-21	23-24	D005472	fluorouracil|fluorouracil|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU	Chemical	5:23:25:53:84:97:114:151:162:195:210:243:262:309	6:24:28:56:87:100:117:154:165:198:213:246:265:312	0:1:1:2:3:3:4:5:5:6:6:6:6:9	D066126	cardiac toxicity	Disease	19	21	1	1:NR:2	L2R	NON-CROSS	53-56	61-62	D005472	fluorouracil|fluorouracil|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU	Chemical	5:23:25:53:84:97:114:151:162:195:210:243:262:309	6:24:28:56:87:100:117:154:165:198:213:246:265:312	0:1:1:2:3:3:4:5:5:6:6:6:6:9	D009369	tumors	Disease	61	62	2	1:CID:2	L2R	NON-CROSS	162-165	177-178	D005472	fluorouracil|fluorouracil|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU	Chemical	5:23:25:53:84:97:114:151:162:195:210:243:262:309	6:24:28:56:87:100:117:154:165:198:213:246:265:312	0:1:1:2:3:3:4:5:5:6:6:6:6:9	D007511	ischemic|ischemic|ischemia	Disease	69:177:326	70:178:327	2:6:9	1:CID:2	L2R	NON-CROSS	97-100	102-103	D005472	fluorouracil|fluorouracil|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU	Chemical	5:23:25:53:84:97:114:151:162:195:210:243:262:309	6:24:28:56:87:100:117:154:165:198:213:246:265:312	0:1:1:2:3:3:4:5:5:6:6:6:6:9	D000787	Anginal|angina	Disease	102:111	103:112	4:4	1:NR:2	L2R	NON-CROSS	262-265	282-285	D005472	fluorouracil|fluorouracil|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU	Chemical	5:23:25:53:84:97:114:151:162:195:210:243:262:309	6:24:28:56:87:100:117:154:165:198:213:246:265:312	0:1:1:2:3:3:4:5:5:6:6:6:6:9	D003324	coronary artery disease|coronary artery disease	Disease	282:332	285:335	7:9	1:NR:2	L2R	CROSS	291-293	309-312	D005472	fluorouracil|fluorouracil|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU	Chemical	5:23:25:53:84:97:114:151:162:195:210:243:262:309	6:24:28:56:87:100:117:154:165:198:213:246:265:312	0:1:1:2:3:3:4:5:5:6:6:6:6:9	D003645	sudden death	Disease	291	293	8
2320800	Lethal anuria complicating high dose ifosfamide chemotherapy in a breast cancer patient with an impaired renal function .|A sixty - year - old woman with advanced breast cancer , previously treated with cisplatin , developed an irreversible lethal renal failure with anuria , the day after 5 g / m2 bolus ifosfamide .|Postrenal failure was excluded by echography .|A prerenal component could have contributed to renal failure because of a transient hypotension , due to an increasing ascitis , occurring just before anuria .|However , correction of the hemodynamic parameters did not improve renal function .|Ifosfamide is a known nephrotoxic drug with demonstrated tubulopathies .|We strongly suspect that this lethal anuria was mainly due to ifosfamide , occurring in a patient having received previous cisplatin chemotherapy and with poor kidney perfusion due to transient hypotension .|We recommend careful use of ifosfamide in patients pretreated with nephrotoxic chemotherapy and inadequate renal perfusion .	1:CID:2	R2L	NON-CROSS	5-6	1-2	D007069	ifosfamide|ifosfamide|Ifosfamide|ifosfamide|ifosfamide	Chemical	5:52:100:121:147	6:53:101:122:148	0:1:5:6:7	D001002	anuria|anuria|anuria|anuria	Disease	1:42:85:116	2:43:86:117	0:1:3:6	1:NR:2	R2L	NON-CROSS	42-43	33-34	D002945	cisplatin|cisplatin	Chemical	33:130	34:131	1:6	D001002	anuria|anuria|anuria|anuria	Disease	1:42:85:116	2:43:86:117	0:1:3:6	1:NR:2	L2R	NON-CROSS	5-6	9-11	D007069	ifosfamide|ifosfamide|Ifosfamide|ifosfamide|ifosfamide	Chemical	5:52:100:121:147	6:53:101:122:148	0:1:5:6:7	D001943	breast cancer|breast cancer	Disease	9:27	11:29	0:1	1:CID:2	L2R	NON-CROSS	52-53	54-56	D007069	ifosfamide|ifosfamide|Ifosfamide|ifosfamide|ifosfamide	Chemical	5:52:100:121:147	6:53:101:122:148	0:1:5:6:7	D007674	impaired renal function|Postrenal failure|nephrotoxic|tubulopathies|nephrotoxic	Disease	14:54:104:108:152	17:56:105:109:153	0:2:5:5:7	1:NR:2	L2R	NON-CROSS	39-41	52-53	D007069	ifosfamide|ifosfamide|Ifosfamide|ifosfamide|ifosfamide	Chemical	5:52:100:121:147	6:53:101:122:148	0:1:5:6:7	D051437	renal failure|renal failure	Disease	39:68	41:70	1:3	1:NR:2	L2R	NON-CROSS	140-141	147-148	D007069	ifosfamide|ifosfamide|Ifosfamide|ifosfamide|ifosfamide	Chemical	5:52:100:121:147	6:53:101:122:148	0:1:5:6:7	D007022	hypotension|hypotension	Disease	74:140	75:141	3:6	1:NR:2	R2L	NON-CROSS	33-34	27-29	D002945	cisplatin|cisplatin	Chemical	33:130	34:131	1:6	D001943	breast cancer|breast cancer	Disease	9:27	11:29	0:1	1:NR:2	R2L	CROSS	33-34	14-17	D002945	cisplatin|cisplatin	Chemical	33:130	34:131	1:6	D007674	impaired renal function|Postrenal failure|nephrotoxic|tubulopathies|nephrotoxic	Disease	14:54:104:108:152	17:56:105:109:153	0:2:5:5:7	1:NR:2	L2R	NON-CROSS	33-34	39-41	D002945	cisplatin|cisplatin	Chemical	33:130	34:131	1:6	D051437	renal failure|renal failure	Disease	39:68	41:70	1:3	1:NR:2	L2R	NON-CROSS	130-131	140-141	D002945	cisplatin|cisplatin	Chemical	33:130	34:131	1:6	D007022	hypotension|hypotension	Disease	74:140	75:141	3:6
2220369	Central vein thrombosis and topical dipivalyl epinephrine .|A report is given on an 83 - year - old female who acquired central vein thrombosis in her seeing eye one day after having started topical medication with dipivalyl epinephrine for advanced glaucoma discovered in the other eye .|From present knowledge about the effects of adrenergic eye drops on ocular blood circulation , it is difficult to suggest an association between the two events , which may be coincidental only .	1:CID:2	R2L	NON-CROSS	5-7	1-3	C015173	dipivalyl epinephrine|dipivalyl epinephrine	Chemical	5:37	7:39	0:1	D020246	vein thrombosis|vein thrombosis	Disease	1:23	3:25	0:1	1:NR:2	L2R	NON-CROSS	37-39	41-42	C015173	dipivalyl epinephrine|dipivalyl epinephrine	Chemical	5:37	7:39	0:1	D005901	glaucoma	Disease	41	42	1
326460	Amelioration of bendrofluazide - induced hypokalemia by timolol .|The beta adrenergic blocking drug , timolol , tended to correct the hypokalemia of short - term bendrofluazide treatment in 6 healthy male subjects and although the effect was small it was significant .|Timolol also reduced the rise in plasma aldosterone and urine potassium excretion following bendrofluazide and increased the urine sodium / potassium ratio .|There was no evidence of a shift of potassium from the intracellular to the extracellular space .	1:CID:2	L2R	NON-CROSS	2-3	5-6	D001539	bendrofluazide|bendrofluazide|bendrofluazide	Chemical	2:26:56	3:27:57	0:1:2	D007008	hypokalemia|hypokalemia	Disease	5:21	6:22	0:1	1:NR:2	R2L	NON-CROSS	7-8	5-6	D013999	timolol|timolol|Timolol	Chemical	7:15:43	8:16:44	0:1:2	D007008	hypokalemia|hypokalemia	Disease	5:21	6:22	0:1	1:NR:2	R2L	CROSS	50-51	21-22	D000450	aldosterone	Chemical	50	51	2	D007008	hypokalemia|hypokalemia	Disease	5:21	6:22	0:1	1:NR:2	R2L	CROSS	53-54	21-22	D011188	potassium|potassium|potassium	Chemical	53:63:74	54:64:75	2:2:3	D007008	hypokalemia|hypokalemia	Disease	5:21	6:22	0:1	1:NR:2	R2L	CROSS	61-62	21-22	D012964	sodium	Chemical	61	62	2	D007008	hypokalemia|hypokalemia	Disease	5:21	6:22	0:1
20331935	A cross - sectional evaluation of the effect of risperidone and selective serotonin reuptake inhibitors on bone mineral density in boys .|OBJECTIVE : The aim of the present study was to investigate the effect of risperidone - induced hyperprolactinemia on trabecular bone mineral density ( BMD ) in children and adolescents .|METHOD : Medically healthy 7 - to 17 - year - old males chronically treated , in a naturalistic setting , with risperidone were recruited for this cross - sectional study through child psychiatry outpatient clinics between November 2005 and June 2007 .|Anthropometric measurements and laboratory testing were conducted .|The clinical diagnoses were based on chart review , and developmental and treatment history was obtained from the medical record .|Volumetric BMD of the ultradistal radius was measured using peripheral quantitative computed tomography , and areal BMD of the lumbar spine was estimated using dual - energy x - ray absorptiometry .|RESULTS : Hyperprolactinemia was present in 49 % of 83 boys ( n = 41 ) treated with risperidone for a mean of 2 . 9 years .|Serum testosterone concentration increased with pubertal status but was not affected by hyperprolactinemia .|As expected , bone mineral content and BMD increased with sexual maturity .|After adjusting for the stage of sexual development and height and BMI z scores , serum prolactin was negatively associated with trabecular volumetric BMD at the ultradistal radius ( P < . 03 ) .|Controlling for relevant covariates , we also found treatment with selective serotonin reuptake inhibitors ( SSRIs ) to be associated with lower trabecular BMD at the radius ( P = . 03 ) and BMD z score at the lumbar spine ( P < . 05 ) .|These findings became more marked when the analysis was restricted to non - Hispanic white patients .|Of 13 documented fractures , 3 occurred after risperidone and SSRIs were started , and none occurred in patients with hyperprolactinemia .|CONCLUSIONS : This is the first study to link risperidone - induced hyperprolactinemia and SSRI treatment to lower BMD in children and adolescents .|Future research should evaluate the longitudinal course of this adverse event to determine its temporal stability and whether a higher fracture rate ensues .	1:CID:2	L2R	NON-CROSS	36-37	39-40	D018967	risperidone|risperidone|risperidone|risperidone|risperidone|risperidone	Chemical	9:36:75:175:320:343	10:37:76:176:321:344	0:1:2:6:12:13	D006966	hyperprolactinemia|Hyperprolactinemia|hyperprolactinemia|hyperprolactinemia|hyperprolactinemia	Disease	39:159:197:332:346	40:160:198:333:347	1:6:7:12:13	1:NR:2	L2R	NON-CROSS	315-316	320-321	D018967	risperidone|risperidone|risperidone|risperidone|risperidone|risperidone	Chemical	9:36:75:175:320:343	10:37:76:176:321:344	0:1:2:6:12:13	D050723	fractures	Disease	315	316	12	1:NR:2	L2R	CROSS	12-13	39-40	D012701	serotonin|serotonin	Chemical	12:258	13:259	0:10	D006966	hyperprolactinemia|Hyperprolactinemia|hyperprolactinemia|hyperprolactinemia|hyperprolactinemia	Disease	39:159:197:332:346	40:160:198:333:347	1:6:7:12:13	1:NR:2	L2R	CROSS	258-259	315-316	D012701	serotonin|serotonin	Chemical	12:258	13:259	0:10	D050723	fractures	Disease	315	316	12	1:NR:2	R2L	NON-CROSS	197-198	186-187	D013739	testosterone	Chemical	186	187	7	D006966	hyperprolactinemia|Hyperprolactinemia|hyperprolactinemia|hyperprolactinemia|hyperprolactinemia	Disease	39:159:197:332:346	40:160:198:333:347	1:6:7:12:13	1:NR:2	L2R	CROSS	186-187	315-316	D013739	testosterone	Chemical	186	187	7	D050723	fractures	Disease	315	316	12
19707748	Seizures associated with levofloxacin : case presentation and literature review .|PURPOSE : We present a case of a patient who developed seizures shortly after initiating treatment with levofloxacin and to discuss the potential drug - drug interactions related to the inhibition of cytochrome P450 ( CYP ) 1A2 in this case , as well as in other cases , of levofloxacin - induced seizures .|METHODS : Several biomedical databases were searched including MEDLINE , Cochrane and Ovid .|The main search terms utilized were case report and levofloxacin .|The search was limited to studies published in English .|RESULTS : Six cases of levofloxacin - induced seizures have been reported in the literature .|Drug - drug interactions related to the inhibition of CYP1A2 by levofloxacin are likely involved in the clinical outcome of these cases .|CONCLUSIONS : Clinicians are exhorted to pay close attention when initiating levofloxacin therapy in patients taking medications with epileptogenic properties that are CYP1A2 substrates .	1:CID:2	R2L	NON-CROSS	3-4	0-1	D064704	levofloxacin|levofloxacin|levofloxacin|levofloxacin|levofloxacin|levofloxacin|levofloxacin	Chemical	3:28:61:89:106:128:151	4:29:62:90:107:129:152	0:1:1:3:5:6:7	D012640	Seizures|seizures|seizures|seizures	Disease	0:22:64:109	1:23:65:110	0:1:1:5
19692487	Mice lacking mPGES - 1 are resistant to lithium - induced polyuria .|Cyclooxygenase - 2 activity is required for the development of lithium - induced polyuria .|However , the involvement of a specific , terminal prostaglandin ( PG ) isomerase has not been evaluated .|The present study was undertaken to assess lithium - induced polyuria in mice deficient in microsomal prostaglandin E synthase - 1 ( mPGES - 1 ) .|A 2 - wk administration of LiCl ( 4 mmol . kg ( - 1 ) . day ( - 1 ) ip ) in mPGES - 1 + / + mice led to a marked polyuria with hyposmotic urine .|This was associated with elevated renal mPGES - 1 protein expression and increased urine PGE ( 2 ) excretion .|In contrast , mPGES - 1 - / - mice were largely resistant to lithium - induced polyuria and a urine concentrating defect , accompanied by nearly complete blockade of high urine PGE ( 2 ) and cAMP output .|Immunoblotting , immunohistochemistry , and quantitative ( q ) RT - PCR consistently detected a significant decrease in aquaporin - 2 ( AQP2 ) protein expression in both the renal cortex and medulla of lithium - treated + / + mice .|This decrease was significantly attenuated in the - / - mice .|qRT - PCR detected similar patterns of changes in AQP2 mRNA in the medulla but not in the cortex .|Similarly , the total protein abundance of the Na - K - 2Cl cotransporter ( NKCC2 ) in the medulla but not in the cortex of the + / + mice was significantly reduced by lithium treatment .|In contrast , the dowregulation of renal medullary NKCC2 expression was significantly attenuated in the - / - mice .|We conclude that mPGES - 1 - derived PGE ( 2 ) mediates lithium - induced polyuria likely via inhibition of AQP2 and NKCC2 expression .	1:NR:2	L2R	NON-CROSS	8-9	11-12	D008094	lithium|lithium|lithium|lithium|lithium|lithium|lithium	Chemical	8:23:54:149:209:284:320	9:24:55:150:210:285:321	0:1:3:6:7:10:12	D011141	polyuria|polyuria|polyuria|polyuria|polyuria|polyuria	Disease	11:26:57:110:152:323	12:27:58:111:153:324	0:1:3:4:6:12	1:NR:2	R2L	CROSS	37-38	26-27	D011453	prostaglandin|PG	Chemical	37:39	38:40	2:2	D011141	polyuria|polyuria|polyuria|polyuria|polyuria|polyuria	Disease	11:26:57:110:152:323	12:27:58:111:153:324	0:1:3:4:6:12	1:NR:2	R2L	NON-CROSS	63-65	57-58	D011458	prostaglandin E	Chemical	63	65	3	D011141	polyuria|polyuria|polyuria|polyuria|polyuria|polyuria	Disease	11:26:57:110:152:323	12:27:58:111:153:324	0:1:3:4:6:12	1:CID:2	R2L	NON-CROSS	80-81	57-58	D018021	LiCl	Chemical	80	81	4	D011141	polyuria|polyuria|polyuria|polyuria|polyuria|polyuria	Disease	11:26:57:110:152:323	12:27:58:111:153:324	0:1:3:4:6:12	1:NR:2	R2L	NON-CROSS	323-324	315-319	D015232	PGE ( 2 )|PGE ( 2 )|PGE ( 2 )	Chemical	129:167:315	133:171:319	5:6:12	D011141	polyuria|polyuria|polyuria|polyuria|polyuria|polyuria	Disease	11:26:57:110:152:323	12:27:58:111:153:324	0:1:3:4:6:12	1:NR:2	R2L	CROSS	323-324	257-258	D012964	Na	Chemical	257	258	10	D011141	polyuria|polyuria|polyuria|polyuria|polyuria|polyuria	Disease	11:26:57:110:152:323	12:27:58:111:153:324	0:1:3:4:6:12	1:NR:2	R2L	CROSS	323-324	259-260	D011188	K	Chemical	259	260	10	D011141	polyuria|polyuria|polyuria|polyuria|polyuria|polyuria	Disease	11:26:57:110:152:323	12:27:58:111:153:324	0:1:3:4:6:12	1:NR:2	R2L	CROSS	323-324	261-262	D002713	Cl	Chemical	261	262	10	D011141	polyuria|polyuria|polyuria|polyuria|polyuria|polyuria	Disease	11:26:57:110:152:323	12:27:58:111:153:324	0:1:3:4:6:12
19289093	Identification of a simple and sensitive microplate method for the detection of oversulfated chondroitin sulfate in heparin products .|Heparin is a commonly implemented anticoagulant used to treat critically ill patients .|Recently , a number of commercial lots of heparin products were found to be contaminated with an oversulfated chondroitin sulfate ( OSCS ) derivative that could elicit a hypotensive response in pigs following a single high - dose infusion .|Using both contaminated heparin products and the synthetically produced derivative , we showed that the OSCS produces dose - dependent hypotension in pigs .|The no observed effect level ( NOEL ) for this contaminant appears to be approximately 1mg / kg , corresponding to a contamination level of approximately 3 % .|We also demonstrated that OSCS can be identified in heparin products using a simple , inexpensive , commercially available heparin enzyme immunoassay ( EIA ) kit that has a limit of detection of approximately 0 . 1 % , well below the NOEL .|This kit may provide a useful method to test heparin products for contamination with oversulfated GAG derivatives .	1:CID:2	L2R	NON-CROSS	50-52	60-61	D002809	chondroitin sulfate|chondroitin sulfate	Chemical	13:50	15:52	0:2	D007022	hypotensive|hypotension	Disease	60:92	61:93	2:3	1:NR:2	L2R	NON-CROSS	60-61	75-76	D006493	heparin|Heparin|heparin|heparin|heparin|heparin|heparin	Chemical	16:19:40:75:134:144:178	17:20:41:76:135:145:179	0:1:2:3:5:5:6	D007022	hypotensive|hypotension	Disease	60:92	61:93	2:3
18627295	Doxorubicin cardiomyopathy - induced inflammation and apoptosis are attenuated by gene deletion of the kinin B1 receptor .|Clinical use of the anthracycline doxorubicin ( DOX ) is limited by its cardiotoxic effects , which are attributed to the induction of apoptosis .|To elucidate the possible role of the kinin B1 receptor ( B1R ) during the development of DOX cardiomyopathy , we studied B1R knockout mice ( B1R ( - / - ) ) by investigating cardiac inflammation and apoptosis after induction of DOX - induced cardiomyopathy .|DOX control mice showed cardiac dysfunction measured by pressure - volume loops in vivo .|This was associated with a reduced activation state of AKT , as well as an increased bax / bcl2 ratio in Western blots , indicating cardiac apoptosis .|Furthermore , mRNA levels of the proinflammatory cytokine interleukin 6 were increased in the cardiac tissue .|In DOX B1R ( - / - ) mice , cardiac dysfunction was improved compared to DOX control mice , which was associated with normalization of the bax / bcl - 2 ratio and interleukin 6 , as well as AKT activation state .|These findings suggest that B1R is detrimental in DOX cardiomyopathy in that it mediates the inflammatory response and apoptosis .|These insights might have useful implications for future studies utilizing B1R antagonists for treatment of human DOX cardiomyopathy .	1:CID:2	L2R	NON-CROSS	0-1	1-2	D004317	Doxorubicin|doxorubicin|DOX|DOX|DOX|DOX|DOX|DOX|DOX|DOX	Chemical	0:23:25:60:85:90:151:166:202:230	1:24:26:61:86:91:152:167:203:231	0:1:1:2:2:3:6:6:7:8	D009202	cardiomyopathy|cardiomyopathy|cardiomyopathy|cardiomyopathy|cardiomyopathy	Disease	1:61:88:203:231	2:62:89:204:232	0:2:2:7:8	1:NR:2	L2R	NON-CROSS	0-1	4-5	D004317	Doxorubicin|doxorubicin|DOX|DOX|DOX|DOX|DOX|DOX|DOX|DOX	Chemical	0:23:25:60:85:90:151:166:202:230	1:24:26:61:86:91:152:167:203:231	0:1:1:2:2:3:6:6:7:8	D007249	inflammation|inflammation	Disease	4:79	5:80	0:2	1:NR:2	L2R	NON-CROSS	25-26	31-32	D004317	Doxorubicin|doxorubicin|DOX|DOX|DOX|DOX|DOX|DOX|DOX|DOX	Chemical	0:23:25:60:85:90:151:166:202:230	1:24:26:61:86:91:152:167:203:231	0:1:1:2:2:3:6:6:7:8	D066126	cardiotoxic	Disease	31	32	1	1:NR:2	L2R	NON-CROSS	90-91	94-96	D004317	Doxorubicin|doxorubicin|DOX|DOX|DOX|DOX|DOX|DOX|DOX|DOX	Chemical	0:23:25:60:85:90:151:166:202:230	1:24:26:61:86:91:152:167:203:231	0:1:1:2:2:3:6:6:7:8	D006331	cardiac dysfunction|cardiac apoptosis|cardiac dysfunction	Disease	94:130:160	96:132:162	3:4:6	1:NR:2	R2L	CROSS	22-23	1-2	D018943	anthracycline	Chemical	22	23	1	D009202	cardiomyopathy|cardiomyopathy|cardiomyopathy|cardiomyopathy|cardiomyopathy	Disease	1:61:88:203:231	2:62:89:204:232	0:2:2:7:8	1:NR:2	R2L	CROSS	22-23	4-5	D018943	anthracycline	Chemical	22	23	1	D007249	inflammation|inflammation	Disease	4:79	5:80	0:2	1:NR:2	L2R	NON-CROSS	22-23	31-32	D018943	anthracycline	Chemical	22	23	1	D066126	cardiotoxic	Disease	31	32	1	1:NR:2	L2R	CROSS	22-23	94-96	D018943	anthracycline	Chemical	22	23	1	D006331	cardiac dysfunction|cardiac apoptosis|cardiac dysfunction	Disease	94:130:160	96:132:162	3:4:6
18405372	Hepatotoxicity associated with sulfasalazine in inflammatory arthritis : A case series from a local surveillance of serious adverse events .|BACKGROUND : Spontaneous reporting systems for adverse drug reactions ( ADRs ) are handicapped by under - reporting and limited detail on individual cases .|We report an investigation from a local surveillance for serious adverse drug reactions associated with disease modifying anti - rheumatic drugs that was triggered by the occurrence of liver failure in two of our patients .|METHODS : Serious ADR reports have been solicited from local clinicians by regular postcards over the past seven years .|Patients ' , who had hepatotoxicity on sulfasalazine and met a definition of a serious ADR , were identified .|Two clinicians reviewed structured case reports and assessed causality by consensus and by using a causality assessment instrument .|The likely frequency of hepatotoxicity with sulfasalazine was estimated by making a series of conservative assumptions .|RESULTS : Ten cases were identified : eight occurred during surveillance .|Eight patients were hospitalised , two in hepatic failure - one died after a liver transplant .|All but one event occurred within 6 weeks of treatment .|Seven patients had a skin rash , three eosinophilia and one interstitial nephritis .|Five patients were of Black British of African or Caribbean descent .|Liver enzymes showed a hepatocellular pattern in four cases and a mixed pattern in six .|Drug - related hepatotoxicity was judged probable or highly probable in 8 patients .|The likely frequency of serious hepatotoxicity with sulfasalazine was estimated at 0 . 4 % of treated patients .|CONCLUSION : Serious hepatotoxicity associated with sulfasalazine appears to be under - appreciated and intensive monitoring and vigilance in the first 6 weeks of treatment is especially important .	1:CID:2	R2L	NON-CROSS	108-109	106-107	D012460	sulfasalazine|sulfasalazine|sulfasalazine|sulfasalazine|sulfasalazine	Chemical	3:108:146:260:278	4:109:147:261:279	0:4:6:14:15	D056486	Hepatotoxicity|hepatotoxicity|hepatotoxicity|hepatotoxicity|hepatotoxicity|hepatotoxicity	Disease	0:106:144:242:258:275	1:107:145:243:259:276	0:4:6:13:14:15	1:NR:2	L2R	NON-CROSS	3-4	6-7	D012460	sulfasalazine|sulfasalazine|sulfasalazine|sulfasalazine|sulfasalazine	Chemical	3:108:146:260:278	4:109:147:261:279	0:4:6:14:15	D001168	arthritis	Disease	6	7	0	1:NR:2	L2R	CROSS	146-147	176-178	D012460	sulfasalazine|sulfasalazine|sulfasalazine|sulfasalazine|sulfasalazine	Chemical	3:108:146:260:278	4:109:147:261:279	0:4:6:14:15	D017093	liver failure|hepatic failure	Disease	73:176	75:178	2:8	1:NR:2	L2R	CROSS	146-147	201-203	D012460	sulfasalazine|sulfasalazine|sulfasalazine|sulfasalazine|sulfasalazine	Chemical	3:108:146:260:278	4:109:147:261:279	0:4:6:14:15	D005076	skin rash	Disease	201	203	10	1:NR:2	L2R	CROSS	205-206	260-261	D012460	sulfasalazine|sulfasalazine|sulfasalazine|sulfasalazine|sulfasalazine	Chemical	3:108:146:260:278	4:109:147:261:279	0:4:6:14:15	D004802	eosinophilia	Disease	205	206	10	1:NR:2	L2R	CROSS	208-210	260-261	D012460	sulfasalazine|sulfasalazine|sulfasalazine|sulfasalazine|sulfasalazine	Chemical	3:108:146:260:278	4:109:147:261:279	0:4:6:14:15	D009395	interstitial nephritis	Disease	208	210	10
18356633	An evaluation of amikacin nephrotoxicity in the hematology / oncology population .|Amikacin is an aminoglycoside commonly used to provide empirical double gram - negative treatment for febrile neutropenia and other suspected infections .|Strategies of extended - interval and conventional dosing have been utilized extensively in the general medical population ; however , data are lacking to support a dosing strategy in the hematology / oncology population .|To evaluate amikacin - associated nephrotoxicity in an adult hematology / oncology population , a prospective , randomized , open - label trial was conducted at a university - affiliated medical center .|Forty patients with a diagnosis consistent with a hematologic / oncologic disorder that required treatment with an aminoglycoside were randomized to either conventional or extended - interval amikacin .|The occurrence of nephrotoxicity by means of an increase in serum creatinine and evaluation of efficacy via amikacin serum concentrations with respective pathogens were assessed .|The occurrence of nephrotoxicity was similar between the conventional and extended - interval groups , at 10 % and 5 % , respectively ( P = 1 . 00 ) .|Six patients in the conventional group had a positive culture , compared with none in the extended - interval group ( P = 0 . 002 ) .|The occurrence of nephrotoxicity was similar between the two dosing regimens , but the distribution of risk factors was variable between the two groups .|Efficacy could not be assessed .	1:CID:2	L2R	NON-CROSS	3-4	4-5	D000583	amikacin|Amikacin|amikacin|amikacin|amikacin	Chemical	3:12:71:129:148	4:13:72:130:149	0:1:3:4:5	D007674	nephrotoxicity|nephrotoxicity|nephrotoxicity|nephrotoxicity|nephrotoxicity	Disease	4:74:134:160:219	5:75:135:161:220	0:3:5:6:8	1:NR:2	L2R	NON-CROSS	12-13	27-29	D000583	amikacin|Amikacin|amikacin|amikacin|amikacin	Chemical	3:12:71:129:148	4:13:72:130:149	0:1:3:4:5	D009503	febrile neutropenia	Disease	27	29	1	1:NR:2	L2R	NON-CROSS	12-13	32-33	D000583	amikacin|Amikacin|amikacin|amikacin|amikacin	Chemical	3:12:71:129:148	4:13:72:130:149	0:1:3:4:5	D007239	infections	Disease	32	33	1	1:NR:2	L2R	NON-CROSS	110-114	129-130	D000583	amikacin|Amikacin|amikacin|amikacin|amikacin	Chemical	3:12:71:129:148	4:13:72:130:149	0:1:3:4:5	D006402	hematologic / oncologic disorder	Disease	110	114	4	1:NR:2	L2R	NON-CROSS	110-114	129-130	D000583	amikacin|Amikacin|amikacin|amikacin|amikacin	Chemical	3:12:71:129:148	4:13:72:130:149	0:1:3:4:5	D009369	hematologic / oncologic disorder	Disease	110	114	4	1:NR:2	R2L	CROSS	15-16	4-5	D000617	aminoglycoside|aminoglycoside	Chemical	15:119	16:120	1:4	D007674	nephrotoxicity|nephrotoxicity|nephrotoxicity|nephrotoxicity|nephrotoxicity	Disease	4:74:134:160:219	5:75:135:161:220	0:3:5:6:8	1:NR:2	R2L	NON-CROSS	142-143	134-135	D003404	creatinine	Chemical	142	143	5	D007674	nephrotoxicity|nephrotoxicity|nephrotoxicity|nephrotoxicity|nephrotoxicity	Disease	4:74:134:160:219	5:75:135:161:220	0:3:5:6:8	1:NR:2	L2R	NON-CROSS	15-16	27-29	D000617	aminoglycoside|aminoglycoside	Chemical	15:119	16:120	1:4	D009503	febrile neutropenia	Disease	27	29	1	1:NR:2	L2R	NON-CROSS	15-16	32-33	D000617	aminoglycoside|aminoglycoside	Chemical	15:119	16:120	1:4	D007239	infections	Disease	32	33	1	1:NR:2	L2R	NON-CROSS	110-114	119-120	D000617	aminoglycoside|aminoglycoside	Chemical	15:119	16:120	1:4	D006402	hematologic / oncologic disorder	Disease	110	114	4	1:NR:2	L2R	NON-CROSS	110-114	119-120	D000617	aminoglycoside|aminoglycoside	Chemical	15:119	16:120	1:4	D009369	hematologic / oncologic disorder	Disease	110	114	4	1:NR:2	R2L	CROSS	142-143	27-29	D003404	creatinine	Chemical	142	143	5	D009503	febrile neutropenia	Disease	27	29	1	1:NR:2	R2L	CROSS	142-143	32-33	D003404	creatinine	Chemical	142	143	5	D007239	infections	Disease	32	33	1	1:NR:2	R2L	CROSS	142-143	110-114	D003404	creatinine	Chemical	142	143	5	D006402	hematologic / oncologic disorder	Disease	110	114	4	1:NR:2	R2L	CROSS	142-143	110-114	D003404	creatinine	Chemical	142	143	5	D009369	hematologic / oncologic disorder	Disease	110	114	4
16574713	Memory function and serotonin transporter promoter gene polymorphism in ecstasy ( MDMA ) users .|Although 3 , 4 - methylenedioxymethamphetamine ( MDMA or ecstasy ) has been shown to damage brain serotonin ( 5 - HT ) neurons in animals and possibly humans , little is known about the long - term consequences of MDMA - induced 5 - HT neurotoxic lesions on functions in which 5 - HT is involved , such as cognitive function .|Because 5 - HT transporters play a key element in the regulation of synaptic 5 - HT transmission it may be important to control for the potential covariance effect of a polymorphism in the 5 - HT transporter promoter gene region ( 5 - HTTLPR ) when studying the effects of MDMA as well as cognitive functioning .|The aim of the study was to investigate the effects of moderate and heavy MDMA use on cognitive function , as well as the effects of long - term abstention from MDMA , in subjects genotyped for 5 - HTTLPR .|A second aim of the study was to determine whether these effects differ for females and males .|Fifteen moderate MDMA users ( < 55 lifetime tablets ) , 22 heavy MDMA + users ( > 55 lifetime tablets ) , 16 ex - MDMA + users ( last tablet > 1 year ago ) and 13 controls were compared on a battery of neuropsychological tests .|DNA from peripheral nuclear blood cells was genotyped for 5 - HTTLPR using standard polymerase chain reaction methods . A significant group effect was observed only on memory function tasks ( p = 0 . 04 ) but not on reaction times ( p = 0 . 61 ) or attention / executive functioning ( p = 0 . 59 ) .|Heavy and ex - MDMA + users performed significantly poorer on memory tasks than controls .|In contrast , no evidence of memory impairment was observed in moderate MDMA users .|No significant effect of 5 - HTTLPR or gender was observed .|While the use of MDMA in quantities that may be considered " moderate " is not associated with impaired memory functioning , heavy use of MDMA use may lead to long lasting memory impairments .|No effect of 5 - HTTLPR or gender on memory function or MDMA use was observed .	1:NR:2	L2R	NON-CROSS	58-61	61-63	D012701	serotonin|serotonin|5 - HT|5 - HT|5 - HT|5 - HT|5 - HT|5 - HT	Chemical	3:32:34:58:67:79:92:112	4:33:37:61:70:82:95:115	0:1:1:1:1:2:2:2	D020258	neurotoxic lesions	Disease	61	63	1	1:NR:2	L2R	CROSS	112-115	328-330	D012701	serotonin|serotonin|5 - HT|5 - HT|5 - HT|5 - HT|5 - HT|5 - HT	Chemical	3:32:34:58:67:79:92:112	4:33:37:61:70:82:95:115	0:1:1:1:1:2:2:2	D008569	memory impairment|impaired memory functioning|memory impairments	Disease	328:367:381	330:370:383	8:10:10	1:NR:2	L2R	NON-CROSS	55-56	61-63	D018817	ecstasy|MDMA|3 , 4 - methylenedioxymethamphetamine|MDMA|ecstasy|MDMA|MDMA|MDMA|MDMA|MDMA|MDMA|MDMA|MDMA|MDMA|MDMA|MDMA|MDMA	Chemical	9:11:16:22:24:55:129:150:167:197:208:221:310:334:353:374:396	10:12:21:23:25:56:130:151:168:198:209:222:311:335:354:375:397	0:0:1:1:1:1:2:3:3:5:5:5:7:8:10:10:11	D020258	neurotoxic lesions	Disease	61	63	1	1:CID:2	L2R	NON-CROSS	367-370	374-375	D018817	ecstasy|MDMA|3 , 4 - methylenedioxymethamphetamine|MDMA|ecstasy|MDMA|MDMA|MDMA|MDMA|MDMA|MDMA|MDMA|MDMA|MDMA|MDMA|MDMA|MDMA	Chemical	9:11:16:22:24:55:129:150:167:197:208:221:310:334:353:374:396	10:12:21:23:25:56:130:151:168:198:209:222:311:335:354:375:397	0:0:1:1:1:1:2:3:3:5:5:5:7:8:10:10:11	D008569	memory impairment|impaired memory functioning|memory impairments	Disease	328:367:381	330:370:383	8:10:10
15638391	Aging process of epithelial cells of the rat prostate lateral lobe in experimental hyperprolactinemia induced by haloperidol .|The aim of the study was to examine the influence of hyperprolactinemia , induced by haloperidol ( HAL ) on age related morphology and function changes of epithelial cells in rat prostate lateral lobe .|The study was performed on sexually mature male rats .|Serum concentrations of prolactin ( PRL ) and testosterone ( T ) were measured .|Tissue sections were evaluated with light and electron microscopy .|Immunohistochemical reactions for Anti - Proliferating Cell Nuclear Antigen ( PCNA ) were performed .|In rats of the experimental group , the mean concentration of : PRL was more than twice higher , whereas T concentration was almost twice lower than that in the control group .|Light microscopy visualized the following : hypertrophy and epithelium hyperplasia of the glandular ducts , associated with increased PCNA expression .|Electron microscopy revealed changes in columnar epithelial cells , concerning organelles , engaged in protein synthesis and secretion .	1:CID:2	R2L	NON-CROSS	16-17	13-14	D006220	haloperidol|haloperidol|HAL	Chemical	16:33:35	17:34:36	0:1:1	D006966	hyperprolactinemia|hyperprolactinemia	Disease	13:29	14:30	0:1	1:NR:2	R2L	CROSS	68-69	29-30	D011388	PRL|PRL	Chemical	68:115	69:116	3:6	D006966	hyperprolactinemia|hyperprolactinemia	Disease	13:29	14:30	0:1	1:NR:2	R2L	CROSS	71-72	29-30	D013739	testosterone|T|T	Chemical	71:73:123	72:74:124	3:3:6	D006966	hyperprolactinemia|hyperprolactinemia	Disease	13:29	14:30	0:1	1:NR:2	L2R	CROSS	35-36	142-143	D006220	haloperidol|haloperidol|HAL	Chemical	16:33:35	17:34:36	0:1:1	D006984	hypertrophy	Disease	142	143	7	1:NR:2	L2R	CROSS	35-36	145-146	D006220	haloperidol|haloperidol|HAL	Chemical	16:33:35	17:34:36	0:1:1	D006965	hyperplasia	Disease	145	146	7	1:NR:2	L2R	CROSS	115-116	142-143	D011388	PRL|PRL	Chemical	68:115	69:116	3:6	D006984	hypertrophy	Disease	142	143	7	1:NR:2	L2R	CROSS	115-116	145-146	D011388	PRL|PRL	Chemical	68:115	69:116	3:6	D006965	hyperplasia	Disease	145	146	7	1:NR:2	L2R	CROSS	123-124	142-143	D013739	testosterone|T|T	Chemical	71:73:123	72:74:124	3:3:6	D006984	hypertrophy	Disease	142	143	7	1:NR:2	L2R	CROSS	123-124	145-146	D013739	testosterone|T|T	Chemical	71:73:123	72:74:124	3:3:6	D006965	hyperplasia	Disease	145	146	7
15531665	Does supplemental vitamin C increase cardiovascular disease risk in women with diabetes ?|BACKGROUND : Vitamin C acts as a potent antioxidant ; however , it can also be a prooxidant and glycate protein under certain circumstances in vitro .|These observations led us to hypothesize that a high intake of vitamin C in diabetic persons might promote atherosclerosis .|OBJECTIVE : The objective was to examine the relation between vitamin C intake and mortality from cardiovascular disease .|DESIGN : We studied the relation between vitamin C intake and mortality from total cardiovascular disease ( n = 281 ) , coronary artery disease ( n = 175 ) , and stroke ( n = 57 ) in 1923 postmenopausal women who reported being diabetic at baseline .|Diet was assessed with a food - frequency questionnaire at baseline , and subjects initially free of coronary artery disease were prospectively followed for 15 y .|RESULTS : After adjustment for cardiovascular disease risk factors , type of diabetes medication used , duration of diabetes , and intakes of folate , vitamin E , and beta - carotene , the adjusted relative risks of total cardiovascular disease mortality were 1 . 0 , 0 . 97 , 1 . 11 , 1 . 47 , and 1 . 84 ( P for trend < 0 . 01 ) across quintiles of total vitamin C intake from food and supplements .|Adjusted relative risks of coronary artery disease were 1 . 0 , 0 . 81 , 0 . 99 , 1 . 26 , and 1 . 91 ( P for trend = 0 . 01 ) and of stroke were 1 . 0 , 0 . 52 , 1 . 23 , 2 . 22 , and 2 . 57 ( P for trend < 0 . 01 ) .|When dietary and supplemental vitamin C were analyzed separately , only supplemental vitamin C showed a positive association with mortality endpoints .|Vitamin C intake was unrelated to mortality from cardiovascular disease in the nondiabetic subjects at baseline .|CONCLUSION : A high vitamin C intake from supplements is associated with an increased risk of cardiovascular disease mortality in postmenopausal women with diabetes .	1:CID:2	L2R	NON-CROSS	2-4	5-7	D001205	vitamin C|Vitamin C|vitamin C|vitamin C|vitamin C|vitamin C|vitamin C|vitamin C|Vitamin C|vitamin C	Chemical	2:15:51:70:86:231:314:322:332:353	4:17:53:72:88:233:316:324:334:355	0:1:2:3:4:6:8:8:9:10	D002318	cardiovascular disease|cardiovascular disease|cardiovascular disease|cardiovascular disease|cardiovascular disease|cardiovascular disease|cardiovascular disease	Disease	5:76:93:160:194:340:365	7:78:95:162:196:342:367	0:3:4:6:6:9:10	1:NR:2	L2R	NON-CROSS	51-53	54-55	D001205	vitamin C|Vitamin C|vitamin C|vitamin C|vitamin C|vitamin C|vitamin C|vitamin C|Vitamin C|vitamin C	Chemical	2:15:51:70:86:231:314:322:332:353	4:17:53:72:88:233:316:324:334:355	0:1:2:3:4:6:8:8:9:10	D003920	diabetes|diabetic|diabetic|diabetes|diabetes|diabetes	Disease	11:54:124:167:173:372	12:55:125:168:174:373	0:2:4:6:6:10	1:NR:2	L2R	NON-CROSS	51-53	58-59	D001205	vitamin C|Vitamin C|vitamin C|vitamin C|vitamin C|vitamin C|vitamin C|vitamin C|Vitamin C|vitamin C	Chemical	2:15:51:70:86:231:314:322:332:353	4:17:53:72:88:233:316:324:334:355	0:1:2:3:4:6:8:8:9:10	D050197	atherosclerosis	Disease	58	59	2	1:NR:2	L2R	NON-CROSS	231-233	243-246	D001205	vitamin C|Vitamin C|vitamin C|vitamin C|vitamin C|vitamin C|vitamin C|vitamin C|Vitamin C|vitamin C	Chemical	2:15:51:70:86:231:314:322:332:353	4:17:53:72:88:233:316:324:334:355	0:1:2:3:4:6:8:8:9:10	D003324	coronary artery disease|coronary artery disease|coronary artery disease	Disease	101:145:243	104:148:246	4:5:7	1:NR:2	L2R	NON-CROSS	86-88	111-112	D001205	vitamin C|Vitamin C|vitamin C|vitamin C|vitamin C|vitamin C|vitamin C|vitamin C|Vitamin C|vitamin C	Chemical	2:15:51:70:86:231:314:322:332:353	4:17:53:72:88:233:316:324:334:355	0:1:2:3:4:6:8:8:9:10	D020521	stroke|stroke	Disease	111:278	112:279	4:7	1:NR:2	R2L	NON-CROSS	194-196	178-179	D005492	folate	Chemical	178	179	6	D002318	cardiovascular disease|cardiovascular disease|cardiovascular disease|cardiovascular disease|cardiovascular disease|cardiovascular disease|cardiovascular disease	Disease	5:76:93:160:194:340:365	7:78:95:162:196:342:367	0:3:4:6:6:9:10	1:NR:2	R2L	NON-CROSS	194-196	180-182	D014810	vitamin E	Chemical	180	182	6	D002318	cardiovascular disease|cardiovascular disease|cardiovascular disease|cardiovascular disease|cardiovascular disease|cardiovascular disease|cardiovascular disease	Disease	5:76:93:160:194:340:365	7:78:95:162:196:342:367	0:3:4:6:6:9:10	1:NR:2	R2L	NON-CROSS	194-196	184-187	D019207	beta - carotene	Chemical	184	187	6	D002318	cardiovascular disease|cardiovascular disease|cardiovascular disease|cardiovascular disease|cardiovascular disease|cardiovascular disease|cardiovascular disease	Disease	5:76:93:160:194:340:365	7:78:95:162:196:342:367	0:3:4:6:6:9:10	1:NR:2	R2L	NON-CROSS	178-179	173-174	D005492	folate	Chemical	178	179	6	D003920	diabetes|diabetic|diabetic|diabetes|diabetes|diabetes	Disease	11:54:124:167:173:372	12:55:125:168:174:373	0:2:4:6:6:10	1:NR:2	R2L	NON-CROSS	180-182	173-174	D014810	vitamin E	Chemical	180	182	6	D003920	diabetes|diabetic|diabetic|diabetes|diabetes|diabetes	Disease	11:54:124:167:173:372	12:55:125:168:174:373	0:2:4:6:6:10	1:NR:2	R2L	NON-CROSS	184-187	173-174	D019207	beta - carotene	Chemical	184	187	6	D003920	diabetes|diabetic|diabetic|diabetes|diabetes|diabetes	Disease	11:54:124:167:173:372	12:55:125:168:174:373	0:2:4:6:6:10	1:NR:2	R2L	CROSS	178-179	58-59	D005492	folate	Chemical	178	179	6	D050197	atherosclerosis	Disease	58	59	2	1:NR:2	R2L	CROSS	180-182	58-59	D014810	vitamin E	Chemical	180	182	6	D050197	atherosclerosis	Disease	58	59	2	1:NR:2	R2L	CROSS	184-187	58-59	D019207	beta - carotene	Chemical	184	187	6	D050197	atherosclerosis	Disease	58	59	2	1:NR:2	R2L	CROSS	178-179	145-148	D005492	folate	Chemical	178	179	6	D003324	coronary artery disease|coronary artery disease|coronary artery disease	Disease	101:145:243	104:148:246	4:5:7	1:NR:2	R2L	CROSS	180-182	145-148	D014810	vitamin E	Chemical	180	182	6	D003324	coronary artery disease|coronary artery disease|coronary artery disease	Disease	101:145:243	104:148:246	4:5:7	1:NR:2	R2L	CROSS	184-187	145-148	D019207	beta - carotene	Chemical	184	187	6	D003324	coronary artery disease|coronary artery disease|coronary artery disease	Disease	101:145:243	104:148:246	4:5:7	1:NR:2	R2L	CROSS	178-179	111-112	D005492	folate	Chemical	178	179	6	D020521	stroke|stroke	Disease	111:278	112:279	4:7	1:NR:2	R2L	CROSS	180-182	111-112	D014810	vitamin E	Chemical	180	182	6	D020521	stroke|stroke	Disease	111:278	112:279	4:7	1:NR:2	R2L	CROSS	184-187	111-112	D019207	beta - carotene	Chemical	184	187	6	D020521	stroke|stroke	Disease	111:278	112:279	4:7
12851669	Absolute and attributable risk of venous thromboembolism in women on combined cyproterone acetate and ethinylestradiol .|OBJECTIVE : To achieve absolute risk estimates of venous thromboembolism ( VTE ) among women on cyproterone acetate plus ethinylestradiol ( CPA / EE ) , and among women on combined oral contraceptives ( COCs ) .|METHODS : From the Danish National Register of Patients ( NRP ) , 1996 to 1998 , the records of 1 . 1 million Danish women , ages 15 to 44 years , were searched for evidence of VTE .|COC use was ascertained through mailed questionnaires .|Sales statistics of COCs and CPA / EE were provided through Danish Drug Statistics .|RESULTS : During the time frame of the study , 330 women were found to have had VTE while on COCs .|Of these women , 67 were on levonorgestrel - containing COCs .|Eleven were on CPA / EE .|The corresponding absolute risk of VTE was 3 . 4 ( range , 3 . 1 - 3 . 8 ) per 10 000 women years among the women on COCs , 4 . 2 ( range , 3 . 2 - 5 . 2 ) per 10 000 women years among women on levonorgestrel - containing COCs , and 3 . 1 ( range , 1 . 3 - 4 . 9 ) per 10 000 women years among the women on CPA / EE .|CONCLUSION : Our results suggest the absolute risk of VTE among Danish women on COCs is similar to that among women taking CPA / EE .	1:NR:2	R2L	NON-CROSS	11-13	5-7	D017373	cyproterone acetate|cyproterone acetate|CPA|CPA|CPA|CPA|CPA	Chemical	11:32:37:106:153:240:266	13:34:38:107:154:241:267	0:1:1:4:7:8:9	D054556	venous thromboembolism|venous thromboembolism|VTE|VTE|VTE|VTE|VTE	Disease	5:24:27:91:133:162:253	7:26:28:92:134:163:254	0:1:1:2:5:8:9	1:NR:2	R2L	NON-CROSS	162-163	155-156	D004997	ethinylestradiol|ethinylestradiol|EE|EE|EE|EE|EE	Chemical	14:35:39:108:155:242:268	15:36:40:109:156:243:269	0:1:1:4:7:8:9	D054556	venous thromboembolism|venous thromboembolism|VTE|VTE|VTE|VTE|VTE	Disease	5:24:27:91:133:162:253	7:26:28:92:134:163:254	0:1:1:2:5:8:9	1:CID:2	R2L	NON-CROSS	93-94	91-92	D003277	combined oral contraceptives|COCs|COC|COCs|COCs|COCs|COCs|COCs|COCs	Chemical	46:50:93:104:136:148:187:214:258	49:51:94:105:137:149:188:215:259	1:1:3:4:5:6:8:8:9	D054556	venous thromboembolism|venous thromboembolism|VTE|VTE|VTE|VTE|VTE	Disease	5:24:27:91:133:162:253	7:26:28:92:134:163:254	0:1:1:2:5:8:9	1:NR:2	R2L	NON-CROSS	145-146	133-134	D016912	levonorgestrel|levonorgestrel	Chemical	145:211	146:212	6:8	D054556	venous thromboembolism|venous thromboembolism|VTE|VTE|VTE|VTE|VTE	Disease	5:24:27:91:133:162:253	7:26:28:92:134:163:254	0:1:1:2:5:8:9
12842176	Effect of lindane on hepatic and brain cytochrome P450s and influence of P450 modulation in lindane induced neurotoxicity .|Oral administration of lindane ( 2 . 5 , 5 , 10 and 15 mg / kg , body weight ) for 5 days was found to produce a dose - dependent increase in the activity of P450 dependent 7 - ethoxyresorufin - O - deethylase ( EROD ) , 7 - pentoxyresorufin - O - dealkylase ( PROD ) and N - nitrosodimethylamine demethylase ( NDMA - d ) in rat brain and liver .|A significant increase in the hepatic and brain P450 monooxygenases was also observed when the duration of exposure of low dose ( 2 . 5 mg / kg ) of lindane was increased from 5 days to 15 or 21 days .|As observed with different doses , the magnitude of induction in the activity of P450 monooxygenases was several fold higher in liver microsomes when compared with the brain .|Western blotting studies have indicated that the increase in the P450 enzymes could be due to the increase in the expression of P450 1A1 / 1A2 , 2B1 / 2B2 and 2E1 isoenzymes .|In vitro studies using organic inhibitors specific for individual P450 isoenzymes and antibody inhibition experiments have further demonstrated that the increase in the activity of PROD , EROD and NDMA - d are due to the increase in the levels of P450 2B1 / 2B2 , 1A1 / 1A2 and 2E1 isoenzymes , respectively .|Induction studies have further shown that while pretreatment of 3 - methylcholanthrene ( MC ) , an inducer of P4501A1 / 1A2 , did not produce any significant effect in the incidence of lindane induced convulsions , pretreatment with phenobarbital ( PB ) , an inducer of P450 2B1 / 2B2 or ethanol , an inducer of P450 2E1 catalysed reactions , significantly increased the incidence of lindane induced convulsions .|Similarly , when the P450 - mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity .	1:NR:2	L2R	NON-CROSS	15-16	17-18	D001556	lindane|lindane|lindane|lindane|lindane|lindane|lindane|lindane|lindane	Chemical	2:15:22:125:288:322:335:350:353	3:16:23:126:289:323:336:351:354	0:0:1:2:6:6:7:7:7	D020258	neurotoxicity	Disease	17	18	0	1:CID:2	L2R	NON-CROSS	288-289	290-291	D001556	lindane|lindane|lindane|lindane|lindane|lindane|lindane|lindane|lindane	Chemical	2:15:22:125:288:322:335:350:353	3:16:23:126:289:323:336:351:354	0:0:1:2:6:6:7:7:7	D012640	convulsions|convulsions|convulsions	Disease	290:324:343	291:325:344	6:6:7	1:NR:2	L2R	NON-CROSS	353-354	372-373	D001556	lindane|lindane|lindane|lindane|lindane|lindane|lindane|lindane|lindane	Chemical	2:15:22:125:288:322:335:350:353	3:16:23:126:289:323:336:351:354	0:0:1:2:6:6:7:7:7	D064420	toxicity	Disease	372	373	7	1:NR:2	R2L	CROSS	80-83	17-18	D004128	N - nitrosodimethylamine|NDMA|NDMA	Chemical	80:85:229	83:86:230	1:1:5	D020258	neurotoxicity	Disease	17	18	0	1:NR:2	R2L	CROSS	264-267	17-18	D008748	3 - methylcholanthrene|MC	Chemical	264:268	267:269	6:6	D020258	neurotoxicity	Disease	17	18	0	1:NR:2	R2L	CROSS	294-295	17-18	D010634	phenobarbital	Chemical	294	295	6	D020258	neurotoxicity	Disease	17	18	0	1:NR:2	R2L	CROSS	307-308	17-18	D000431	ethanol|ethanol	Chemical	307:363	308:364	6:7	D020258	neurotoxicity	Disease	17	18	0	1:NR:2	R2L	CROSS	339-341	17-18	C018021	cobalt chloride	Chemical	339	341	7	D020258	neurotoxicity	Disease	17	18	0	1:NR:2	L2R	CROSS	229-230	290-291	D004128	N - nitrosodimethylamine|NDMA|NDMA	Chemical	80:85:229	83:86:230	1:1:5	D012640	convulsions|convulsions|convulsions	Disease	290:324:343	291:325:344	6:6:7	1:NR:2	L2R	CROSS	229-230	372-373	D004128	N - nitrosodimethylamine|NDMA|NDMA	Chemical	80:85:229	83:86:230	1:1:5	D064420	toxicity	Disease	372	373	7	1:NR:2	L2R	NON-CROSS	268-269	290-291	D008748	3 - methylcholanthrene|MC	Chemical	264:268	267:269	6:6	D012640	convulsions|convulsions|convulsions	Disease	290:324:343	291:325:344	6:6:7	1:NR:2	L2R	CROSS	268-269	372-373	D008748	3 - methylcholanthrene|MC	Chemical	264:268	267:269	6:6	D064420	toxicity	Disease	372	373	7	1:NR:2	R2L	NON-CROSS	294-295	290-291	D010634	phenobarbital	Chemical	294	295	6	D012640	convulsions|convulsions|convulsions	Disease	290:324:343	291:325:344	6:6:7	1:NR:2	R2L	NON-CROSS	307-308	290-291	D000431	ethanol|ethanol	Chemical	307:363	308:364	6:7	D012640	convulsions|convulsions|convulsions	Disease	290:324:343	291:325:344	6:6:7	1:NR:2	R2L	NON-CROSS	343-344	339-341	C018021	cobalt chloride	Chemical	339	341	7	D012640	convulsions|convulsions|convulsions	Disease	290:324:343	291:325:344	6:6:7	1:NR:2	L2R	CROSS	294-295	372-373	D010634	phenobarbital	Chemical	294	295	6	D064420	toxicity	Disease	372	373	7	1:NR:2	L2R	NON-CROSS	363-364	372-373	D000431	ethanol|ethanol	Chemical	307:363	308:364	6:7	D064420	toxicity	Disease	372	373	7	1:NR:2	L2R	NON-CROSS	339-341	372-373	C018021	cobalt chloride	Chemical	339	341	7	D064420	toxicity	Disease	372	373	7
12745515	Seizure associated with sleep deprivation and sustained - release bupropion .|This case report describes a generalized seizure associated with sustained - release bupropion use and sleep deprivation .|The subject , a 31 - year - old female smoker , was participating in a clinical trial evaluating an investigational medication for smoking cessation that used sustained - release bupropion as an active control .|After 5 weeks of bupropion use , the subject experienced a generalized tonic clonic seizure after staying up nearly all night packing and moving to a new residence .|The patient had no other risk factors for seizures .|We suggest that sleep deprivation may add to the risk of bupropion - associated seizures .	1:CID:2	R2L	NON-CROSS	118-119	115-116	D016642	bupropion|bupropion|bupropion|bupropion|bupropion	Chemical	9:23:59:69:115	10:24:60:70:116	0:1:2:3:5	D012640	Seizure|seizure|seizure|seizures|seizures	Disease	0:17:79:102:118	1:18:80:103:119	0:1:3:4:5	1:NR:2	R2L	NON-CROSS	26-28	23-24	D016642	bupropion|bupropion|bupropion|bupropion|bupropion	Chemical	9:23:59:69:115	10:24:60:70:116	0:1:2:3:5	D012892	sleep deprivation|sleep deprivation|sleep deprivation	Disease	3:26:107	5:28:109	0:1:5
12571256	Nephrotoxic effects in high - risk patients undergoing angiography .|BACKGROUND : The use of iodinated contrast medium can result in nephropathy .|Whether iso - osmolar contrast medium is less nephrotoxic than low - osmolar contrast medium in high - risk patients is uncertain .|METHODS : We conducted a randomized , double - blind , prospective , multicenter study comparing the nephrotoxic effects of an iso - osmolar , dimeric , nonionic contrast medium , iodixanol , with those of a low - osmolar , nonionic , monomeric contrast medium , iohexol .|The study involved 129 patients with diabetes with serum creatinine concentrations of 1 . 5 to 3 . 5 mg per deciliter who underwent coronary or aortofemoral angiography .|The primary end point was the peak increase from base line in the creatinine concentration during the three days after angiography .|Other end points were an increase in the creatinine concentration of 0 . 5 mg per deciliter or more , an increase of 1 . 0 mg per deciliter or more , and a change in the creatinine concentration from day 0 to day 7 .|RESULTS : The creatinine concentration increased significantly less in patients who received iodixanol .|From day 0 to day 3 , the mean peak increase in creatinine was 0 . 13 mg per deciliter in the iodixanol group and 0 . 55 mg per deciliter in the iohexol group ( P = 0 . 001 ; the increase with iodixanol minus the increase with iohexol , - 0 . 42 mg per deciliter [ 95 percent confidence interval , - 0 . 73 to - 0 . 22 ] ) .|Two of the 64 patients in the iodixanol group ( 3 percent ) had an increase in the creatinine concentration of 0 . 5 mg per deciliter or more , as compared with 17 of the 65 patients in the iohexol group ( 26 percent ) ( P = 0 . 002 ; odds ratio for such an increase in the iodixanol group , 0 . 09 [ 95 percent confidence interval , 0 . 02 to 0 . 41 ] ) .|No patient receiving iodixanol had an increase of 1 . 0 mg per deciliter or more , but 10 patients in the iohexol group ( 15 percent ) did .|The mean change in the creatinine concentration from day 0 to day 7 was 0 . 07 mg per deciliter in the iodixanol group and 0 . 24 mg per deciliter in the iohexol group ( P = 0 . 003 ; value in the iodixanol group minus the value in the iohexol group , - 0 . 17 mg per deciliter [ 95 percent confidence interval , - 0 . 34 to - 0 . 07 ] ) .|CONCLUSIONS : Nephropathy induced by contrast medium may be less likely to develop in high - risk patients when iodixanol is used rather than a low - osmolar , nonionic contrast medium .	1:NR:2	R2L	NON-CROSS	77-78	63-64	C044834	iodixanol|iodixanol|iodixanol|iodixanol|iodixanol|iodixanol|iodixanol|iodixanol|iodixanol|iodixanol	Chemical	77:204:228:251:290:344:369:418:441:495	78:205:229:252:291:345:370:419:442:496	3:7:8:8:9:9:10:11:11:12	D007674	Nephrotoxic|nephropathy|nephrotoxic|nephrotoxic|Nephropathy	Disease	0:21:31:63:478	1:22:32:64:479	0:1:2:3:12	1:CID:2	R2L	NON-CROSS	93-94	63-64	D007472	iohexol|iohexol|iohexol|iohexol|iohexol|iohexol|iohexol	Chemical	93:239:256:323:388:429:448	94:240:257:324:389:430:449	3:8:8:9:10:11:11	D007674	Nephrotoxic|nephropathy|nephrotoxic|nephrotoxic|Nephropathy	Disease	0:21:31:63:478	1:22:32:64:479	0:1:2:3:12	1:NR:2	R2L	CROSS	104-105	63-64	D003404	creatinine|creatinine|creatinine|creatinine|creatinine|creatinine|creatinine|creatinine	Chemical	104:137:154:183:195:218:301:401	105:138:155:184:196:219:302:402	4:5:6:6:7:8:9:11	D007674	Nephrotoxic|nephropathy|nephrotoxic|nephrotoxic|Nephropathy	Disease	0:21:31:63:478	1:22:32:64:479	0:1:2:3:12	1:NR:2	L2R	CROSS	77-78	101-102	C044834	iodixanol|iodixanol|iodixanol|iodixanol|iodixanol|iodixanol|iodixanol|iodixanol|iodixanol|iodixanol	Chemical	77:204:228:251:290:344:369:418:441:495	78:205:229:252:291:345:370:419:442:496	3:7:8:8:9:9:10:11:11:12	D003920	diabetes	Disease	101	102	4	1:NR:2	L2R	CROSS	93-94	101-102	D007472	iohexol|iohexol|iohexol|iohexol|iohexol|iohexol|iohexol	Chemical	93:239:256:323:388:429:448	94:240:257:324:389:430:449	3:8:8:9:10:11:11	D003920	diabetes	Disease	101	102	4	1:NR:2	R2L	NON-CROSS	104-105	101-102	D003404	creatinine|creatinine|creatinine|creatinine|creatinine|creatinine|creatinine|creatinine	Chemical	104:137:154:183:195:218:301:401	105:138:155:184:196:219:302:402	4:5:6:6:7:8:9:11	D003920	diabetes	Disease	101	102	4
9514561	Experimental cranial pain elicited by capsaicin : a PET study .|Using a positron emission tomography ( PET ) study it was shown recently that in migraine without aura certain areas in the brain stem were activated during the headache state , but not in the headache free interval .|It was suggested that this brain stem activation is inherent to the migraine attack itself and represents the so called ' migraine generator ' .|To test this hypothesis we performed an experimental pain study in seven healthy volunteers , using the same positioning in the PET scanner as in the migraine patients .|A small amount of capsaicin was administered subcutaneously in the right forehead to evoke a burning painful sensation in the first division of the trigeminal nerve .|Increases of regional cerebral blood flow ( rCBF ) were found bilaterally in the insula , in the anterior cingulate cortex , the cavernous sinus and the cerebellum .|Using the same stereotactic space limits as in the above mentioned migraine study no brain stem activation was found in the acute pain state compared to the pain free state .|The increase of activation in the region of the cavernous sinus however , suggests that this structure is more likely to be involved in trigeminal transmitted pain as such , rather than in a specific type of headache as was suggested for cluster headache .	1:CID:2	R2L	NON-CROSS	5-6	2-3	D002211	capsaicin|capsaicin	Chemical	5:108	6:109	0:4	D010146	pain|pain|painful|pain|pain|pain	Disease	2:83:120:182:187:217	3:84:121:183:188:218	0:3:4:6:6:7	1:NR:2	L2R	CROSS	101-102	108-109	D002211	capsaicin|capsaicin	Chemical	5:108	6:109	0:4	D008881	migraine|migraine|migraine|migraine|migraine	Disease	26:62:71:101:171	27:63:72:102:172	1:2:2:3:6	1:NR:2	L2R	CROSS	5-6	39-40	D002211	capsaicin|capsaicin	Chemical	5:108	6:109	0:4	D006261	headache|headache|headache	Disease	39:46:228	40:47:229	1:1:7	1:NR:2	L2R	CROSS	108-109	233-235	D002211	capsaicin|capsaicin	Chemical	5:108	6:109	0:4	D003027	cluster headache	Disease	233	235	7
9165568	Neuroleptic malignant syndrome with risperidone .|Neuroleptic malignant syndrome is thought to be a result of dopamine D2 receptor blockade in the striatum of the basal ganglia .|Risperidone , a benzisoxazole derivative antipsychotic , has high serotonin 5 - HT2 receptor blockade and dose - related D2 receptor blockade .|The high ratio is believed to impart the low frequency of extrapyramidal symptoms with risperidone at low dosages .|With this low frequency of extrapyramidal symptoms , it was thought the frequency of neuroleptic malignant syndrome might also be lowered .|A 73 - year - old woman developed neuroleptic malignant syndrome after monotherapy with risperidone .|The syndrome reversed after discontinuing risperidone and starting treatment with dantrolene and bromocriptine .|It appears that the protection from extrapyramidal side effects observed with risperidone does not ensure protection from neuroleptic malignant syndrome .	1:CID:2	R2L	NON-CROSS	4-5	0-3	D018967	risperidone|Risperidone|risperidone|risperidone|risperidone|risperidone	Chemical	4:28:65:106:113:133	5:29:66:107:114:134	0:2:3:5:6:7	D009459	Neuroleptic malignant syndrome|Neuroleptic malignant syndrome|neuroleptic malignant syndrome|neuroleptic malignant syndrome|neuroleptic malignant syndrome	Disease	0:6:84:100:139	3:9:87:103:142	0:1:4:5:7	1:NR:2	R2L	NON-CROSS	16-17	6-9	D004298	dopamine	Chemical	16	17	1	D009459	Neuroleptic malignant syndrome|Neuroleptic malignant syndrome|neuroleptic malignant syndrome|neuroleptic malignant syndrome|neuroleptic malignant syndrome	Disease	0:6:84:100:139	3:9:87:103:142	0:1:4:5:7	1:NR:2	R2L	CROSS	31-32	6-9	C441200	benzisoxazole	Chemical	31	32	2	D009459	Neuroleptic malignant syndrome|Neuroleptic malignant syndrome|neuroleptic malignant syndrome|neuroleptic malignant syndrome|neuroleptic malignant syndrome	Disease	0:6:84:100:139	3:9:87:103:142	0:1:4:5:7	1:NR:2	R2L	CROSS	37-38	6-9	D012701	serotonin	Chemical	37	38	2	D009459	Neuroleptic malignant syndrome|Neuroleptic malignant syndrome|neuroleptic malignant syndrome|neuroleptic malignant syndrome|neuroleptic malignant syndrome	Disease	0:6:84:100:139	3:9:87:103:142	0:1:4:5:7	1:NR:2	R2L	CROSS	118-119	100-103	D003620	dantrolene	Chemical	118	119	6	D009459	Neuroleptic malignant syndrome|Neuroleptic malignant syndrome|neuroleptic malignant syndrome|neuroleptic malignant syndrome|neuroleptic malignant syndrome	Disease	0:6:84:100:139	3:9:87:103:142	0:1:4:5:7	1:NR:2	R2L	CROSS	120-121	100-103	D001971	bromocriptine	Chemical	120	121	6	D009459	Neuroleptic malignant syndrome|Neuroleptic malignant syndrome|neuroleptic malignant syndrome|neuroleptic malignant syndrome|neuroleptic malignant syndrome	Disease	0:6:84:100:139	3:9:87:103:142	0:1:4:5:7	1:NR:2	L2R	NON-CROSS	62-64	65-66	D018967	risperidone|Risperidone|risperidone|risperidone|risperidone|risperidone	Chemical	4:28:65:106:113:133	5:29:66:107:114:134	0:2:3:5:6:7	D001480	extrapyramidal symptoms|extrapyramidal symptoms	Disease	62:75	64:77	3:4	1:NR:2	L2R	CROSS	16-17	62-64	D004298	dopamine	Chemical	16	17	1	D001480	extrapyramidal symptoms|extrapyramidal symptoms	Disease	62:75	64:77	3:4	1:NR:2	L2R	CROSS	31-32	62-64	C441200	benzisoxazole	Chemical	31	32	2	D001480	extrapyramidal symptoms|extrapyramidal symptoms	Disease	62:75	64:77	3:4	1:NR:2	L2R	CROSS	37-38	62-64	D012701	serotonin	Chemical	37	38	2	D001480	extrapyramidal symptoms|extrapyramidal symptoms	Disease	62:75	64:77	3:4	1:NR:2	R2L	CROSS	118-119	75-77	D003620	dantrolene	Chemical	118	119	6	D001480	extrapyramidal symptoms|extrapyramidal symptoms	Disease	62:75	64:77	3:4	1:NR:2	R2L	CROSS	120-121	75-77	D001971	bromocriptine	Chemical	120	121	6	D001480	extrapyramidal symptoms|extrapyramidal symptoms	Disease	62:75	64:77	3:4
9154656	Hepatic and extrahepatic angiotensinogen gene expression in rats with acute nephrotic syndrome .|Plasma concentration and urine excretion of the renin - angiotensin system proteins are altered in rats with nephrotic syndrome ( NS ) .|In this work the messenger ribonucleic acid ( mRNA ) levels of angiotensinogen ( Ao ) were analyzed with the slot - blot hybridization technique in liver and other extrahepatic tissues : kidney , heart , brain , and adrenal gland from control , nephrotic , and pair - fed ( PF ) rats .|NS was induced by a single injection of puromycin amino - nucleoside ( PAN ) .|Although a great urinary excretion and half - normal plasma levels of Ao were observed on day 6 after PAN injection , when NS was clearly established , hepatic Ao mRNA levels did not change .|Furthermore , the Ao mRNA levels did not change in any of the extrahepatic tissues studied on day 6 , nor did its hepatic levels at days 1 , 3 , 5 , or 7 after PAN injection .|These data suggest that the hepatic and extrahepatic Ao mRNA levels are unaltered during the development of the acute NS induced by PAN .	1:NR:2	R2L	NON-CROSS	30-32	22-23	D000809	angiotensin	Chemical	22	23	1	D009404	nephrotic syndrome|nephrotic syndrome|NS|nephrotic|NS|NS|NS	Disease	10:30:33:80:91:130:201	12:32:34:81:92:131:202	0:1:1:2:3:4:6	1:CID:2	R2L	NON-CROSS	204-205	201-202	D011692	puromycin amino - nucleoside|PAN|PAN|PAN|PAN	Chemical	99:104:126:179:204	103:105:127:180:205	3:3:4:5:6	D009404	nephrotic syndrome|nephrotic syndrome|NS|nephrotic|NS|NS|NS	Disease	10:30:33:80:91:130:201	12:32:34:81:92:131:202	0:1:1:2:3:4:6
8911359	Cyclophosphamide associated bladder cancer - - a highly aggressive disease : analysis of 12 cases .|PURPOSE : We gained knowledge of the etiology , treatment and prevention of cyclophosphamide associated urothelial cancer .|MATERIALS AND METHODS : The medical records of 6 men and 6 women ( mean age 55 years ) with cyclophosphamide associated bladder cancer were reviewed .|RESULTS : All tumors were grade 3 or 4 transitional cell carcinoma .|Of the 5 patients initially treated with endoscopic resection alone only 1 is alive without disease .|Of the 6 patients who underwent early cystectomy 4 were alive at 24 to 111 months .|The remaining patient with extensive cancer underwent partial cystectomy for palliation and died 3 months later .|CONCLUSIONS : Cyclophosphamide associated bladder tumor is an aggressive disease .|However , long - term survival is possible when radical cystectomy is performed for bladder tumors with any sign of invasion and for recurrent high grade disease , even when noninvasive .	1:CID:2	L2R	NON-CROSS	0-1	2-4	D003520	Cyclophosphamide|cyclophosphamide|cyclophosphamide|Cyclophosphamide	Chemical	0:29:54:127	1:30:55:128	0:1:2:7	D001749	bladder cancer|bladder cancer|bladder tumor|bladder tumors	Disease	2:56:129:150	4:58:131:152	0:2:7:8	1:NR:2	L2R	NON-CROSS	29-30	31-33	D003520	Cyclophosphamide|cyclophosphamide|cyclophosphamide|Cyclophosphamide	Chemical	0:29:54:127	1:30:55:128	0:1:2:7	D014523	urothelial cancer	Disease	31	33	1	1:NR:2	L2R	CROSS	54-55	64-65	D003520	Cyclophosphamide|cyclophosphamide|cyclophosphamide|Cyclophosphamide	Chemical	0:29:54:127	1:30:55:128	0:1:2:7	D009369	tumors|cancer	Disease	64:113	65:114	3:6	1:NR:2	L2R	CROSS	54-55	72-73	D003520	Cyclophosphamide|cyclophosphamide|cyclophosphamide|Cyclophosphamide	Chemical	0:29:54:127	1:30:55:128	0:1:2:7	D002277	carcinoma	Disease	72	73	3
8686832	Leg and back pain after spinal anaesthesia involving hyperbaric 5 % lignocaine .|Fifty - four patients , aged 27 - 90 years , who were given lignocaine 5 % in 6 . 8 % glucose solution for spinal anaesthesia were studied .|Thirteen of these patients experienced pain in the legs and / or back after recovery from anaesthesia .|The patients affected were younger ( p < 0 . 05 ) and the site of the dural puncture was higher ( p < 0 . 01 ) than those individuals without pain .|Five of the 13 patients ( 38 % ) with pain and seven of the 41 patients ( 17 % ) without pain admitted to a high alcohol intake , which might be a contributing factor .|Leg and / or back pain is associated with the intrathecal use of hyperbaric 5 % lignocaine .	1:CID:2	R2L	NON-CROSS	11-12	0-4	D008012	lignocaine|lignocaine|lignocaine	Chemical	11:27:148	12:28:149	0:1:5	D001416	Leg and back pain|pain in the legs and / or back|Leg and / or back pain	Disease	0:48:132	4:56:138	0:2:5	1:NR:2	R2L	CROSS	48-56	35-36	D005947	glucose	Chemical	35	36	1	D001416	Leg and back pain|pain in the legs and / or back|Leg and / or back pain	Disease	0:48:132	4:56:138	0:2:5	1:NR:2	R2L	CROSS	132-138	122-123	D000431	alcohol	Chemical	122	123	4	D001416	Leg and back pain|pain in the legs and / or back|Leg and / or back pain	Disease	0:48:132	4:56:138	0:2:5	1:NR:2	L2R	CROSS	117-118	148-149	D008012	lignocaine|lignocaine|lignocaine	Chemical	11:27:148	12:28:149	0:1:5	D010146	pain|pain|pain	Disease	93:105:117	94:106:118	3:4:4	1:NR:2	L2R	CROSS	35-36	93-94	D005947	glucose	Chemical	35	36	1	D010146	pain|pain|pain	Disease	93:105:117	94:106:118	3:4:4	1:NR:2	R2L	NON-CROSS	122-123	117-118	D000431	alcohol	Chemical	122	123	4	D010146	pain|pain|pain	Disease	93:105:117	94:106:118	3:4:4
8607407	Acute blood pressure elevations with caffeine in men with borderline systemic hypertension .|Whether the vasoconstrictive actions of caffeine are enhanced in hypertensive persons has not been demonstrated .|Thus , caffeine ( 3 . 3 mg / kg ) versus placebo was tested in 48 healthy men ( aged 20 to 35 years ) selected after screening on 2 separate occasions .|Borderline hypertensive men ( n = 24 ) were selected with screening systolic blood pressure ( BP ) of 140 to 160 mm Hg and / or diastolic BP 90 to 99 mm Hg .|Low - risk controls ( n = 24 ) reported no parental history of hypertension and had screening BP < 130 / 85 mm Hg .|Participants were then tested on 2 occasions after 12 - hour abstinence from caffeine in each of 2 protocols ; this required a total of 4 laboratory visits .|Caffeine - induced changes in diastolic BP were 2 to 3 times larger in borderline subjects than in controls ( + 8 . 4 vs + 3 . 8 mm Hg , p < 0 . 0001 ) , and were attributable to larger changes in impedance - derived measures of systemic vascular resistance ( + 135 vs + 45 dynes . s . cm - 5 , p < 0 . 004 ) .|These findings were consistent and reached significance in both protocols .|The percentage of borderline subjects in whom diastolic BP changes exceeded the median control response was 96 % .|Consequently , whereas all participants exhibited normotensive levels during the resting predrug baseline , 33 % of borderline subjects achieved hypertensive BP levels after caffeine ingestion .|Thus , in borderline hypertensive men , exaggerated responses to caffeine were : selective for diastolic BP , consistent with greater vasoconstriction , replicated in 2 protocols , and representative of nearly all borderline hypertensives .|We suspect that the potential for caffeine to stabilize high resistance states in susceptible persons suggests that its use may facilitate their disease progression , as well as hinder accurate diagnosis and treatment .	1:CID:2	L2R	NON-CROSS	18-19	22-23	D002110	caffeine|caffeine|caffeine|caffeine|Caffeine|caffeine|caffeine|caffeine	Chemical	5:18:31:137:153:282:295:327	6:19:32:138:154:283:296:328	0:1:2:5:6:9:10:11	D006973	hypertension|hypertensive|hypertensive|hypertension|hypertensive|hypertensive|hypertensives	Disease	11:22:64:112:278:289:319	12:23:65:113:279:290:320	0:1:3:4:9:10:10
8111719	Hallucinations and ifosfamide - induced neurotoxicity .|BACKGROUND : Hallucinations as a symptom of central neurotoxicity are a known but poorly described side effect of ifosfamide .|Most cases of ifosfamide - induced hallucinations have been reported with other mental status changes .|METHODS : The authors interviewed six persons with ifosfamide - induced hallucinations in the presence of a clear sensorium .|All patients were receiving high - dose ifosfamide as part of their bone marrow transplant procedure .|RESULTS : Hallucinations occurred only when the patient 's eyes were closed and , in all but one case , were reported as disturbing or frightening .|Underreporting of these hallucinations by patients is likely .|CONCLUSIONS : Hallucinations may be the sole or first manifestation of neurotoxicity .|The incidence may be dose and infusion - time related .|The clinician should be alerted for possible ifosfamide - induced hallucinations , which may occur without other signs of neurotoxicity .|" Eyes - closed " hallucinatory experiences appear to be an unusual feature of this presentation .|Patients anxious about this experience respond well to support and education about this occurrence .|Optimal pharmacologic management of disturbed patients is unclear .|If agitation becomes marked , high - potency neuroleptics ( i . e . , haloperidol ) may be effective .	1:CID:2	R2L	NON-CROSS	2-3	0-1	D007069	ifosfamide|ifosfamide|ifosfamide|ifosfamide|ifosfamide|ifosfamide	Chemical	2:25:30:51:70:147	3:26:31:52:71:148	0:1:2:3:4:9	D006212	Hallucinations|Hallucinations|hallucinations|hallucinations|Hallucinations|hallucinations|Hallucinations|hallucinations|hallucinatory	Disease	0:9:33:54:82:110:118:150:166	1:10:34:55:83:111:119:151:167	0:1:2:3:5:6:7:9:10	1:NR:2	R2L	CROSS	217-218	166-167	D006220	haloperidol	Chemical	217	218	13	D006212	Hallucinations|Hallucinations|hallucinations|hallucinations|Hallucinations|hallucinations|Hallucinations|hallucinations|hallucinatory	Disease	0:9:33:54:82:110:118:150:166	1:10:34:55:83:111:119:151:167	0:1:2:3:5:6:7:9:10	1:NR:2	L2R	NON-CROSS	2-3	5-6	D007069	ifosfamide|ifosfamide|ifosfamide|ifosfamide|ifosfamide|ifosfamide	Chemical	2:25:30:51:70:147	3:26:31:52:71:148	0:1:2:3:4:9	D020258	neurotoxicity|neurotoxicity|neurotoxicity|neurotoxicity	Disease	5:15:127:159	6:16:128:160	0:1:7:9	1:NR:2	L2R	CROSS	147-148	203-204	D007069	ifosfamide|ifosfamide|ifosfamide|ifosfamide|ifosfamide|ifosfamide	Chemical	2:25:30:51:70:147	3:26:31:52:71:148	0:1:2:3:4:9	D011595	agitation	Disease	203	204	13	1:NR:2	R2L	CROSS	217-218	159-160	D006220	haloperidol	Chemical	217	218	13	D020258	neurotoxicity|neurotoxicity|neurotoxicity|neurotoxicity	Disease	5:15:127:159	6:16:128:160	0:1:7:9	1:NR:2	R2L	NON-CROSS	217-218	203-204	D006220	haloperidol	Chemical	217	218	13	D011595	agitation	Disease	203	204	13
7059267	Chlorpropamide - induced optic neuropathy .|A 65 - year - old woman with adult - onset diabetes treated with chlorpropamide ( Diabenese ) had a toxic optic neuropathy that resolved with discontinuation of chlorpropamide therapy .|Visual loss occurs in diabetics for a variety of reasons , and accurate diagnosis is necessary to institute appropriate therapy .|The possibility of a drug - induced optic neuropathy should be considered in the differential diagnosis of visual loss in diabetics .	1:CID:2	L2R	NON-CROSS	0-1	3-5	D002747	Chlorpropamide|chlorpropamide|Diabenese|chlorpropamide	Chemical	0:20:22:34	1:21:23:35	0:1:1:1	D009901	optic neuropathy|toxic optic neuropathy|optic neuropathy	Disease	3:26:65	5:29:67	0:1:3	1:NR:2	L2R	NON-CROSS	14-18	22-23	D002747	Chlorpropamide|chlorpropamide|Diabenese|chlorpropamide	Chemical	0:20:22:34	1:21:23:35	0:1:1:1	D003924	adult - onset diabetes	Disease	14	18	1	1:NR:2	L2R	CROSS	34-35	37-39	D002747	Chlorpropamide|chlorpropamide|Diabenese|chlorpropamide	Chemical	0:20:22:34	1:21:23:35	0:1:1:1	D014786	Visual loss|visual loss	Disease	37:75	39:77	2:3	1:NR:2	L2R	CROSS	34-35	41-42	D002747	Chlorpropamide|chlorpropamide|Diabenese|chlorpropamide	Chemical	0:20:22:34	1:21:23:35	0:1:1:1	D003920	diabetics|diabetics	Disease	41:78	42:79	2:3
6381653	Levodopa - induced dyskinesia and thalamotomy .|Levodopa - induced dyskinesia of the limbs in thirteen cases of Parkinsonism , which was choreic , ballistic or dystonic in type , was alleviated almost completely by stereotaxic surgery using a microelectrode technique for the ventralis oralis anterior and posterior nuclei of the thalamus , but much less by the ventralis intermedius nucleus .|Control of levodopa - induced dyskinesias by thalamic lesions in the course of routine treatment of Parkinsonism is discussed .	1:CID:2	L2R	NON-CROSS	0-1	3-4	D007980	Levodopa|Levodopa|levodopa	Chemical	0:7:64	1:8:65	0:1:2	D004409	dyskinesia|dyskinesia|dyskinesias	Disease	3:10:67	4:11:68	0:1:2	1:NR:2	L2R	NON-CROSS	7-8	18-19	D007980	Levodopa|Levodopa|levodopa	Chemical	0:7:64	1:8:65	0:1:2	D010302	Parkinsonism|Parkinsonism	Disease	18:78	19:79	1:2	1:NR:2	L2R	NON-CROSS	7-8	26-27	D007980	Levodopa|Levodopa|levodopa	Chemical	0:7:64	1:8:65	0:1:2	D020821	dystonic	Disease	26	27	1	1:NR:2	L2R	NON-CROSS	64-65	69-71	D007980	Levodopa|Levodopa|levodopa	Chemical	0:7:64	1:8:65	0:1:2	D013786	thalamic lesions	Disease	69	71	2
3950060	Factors associated with nephrotoxicity and clinical outcome in patients receiving amikacin .|Data from 60 patients treated with amikacin were analyzed for factors associated with nephrotoxicity .|In 42 of these patients , data were examined for factors associated with clinical outcome .|Variables evaluated included patient weight , age , sex , serum creatinine level , creatinine clearance , duration of therapy , total dose , mean daily dose , organism minimum inhibitory concentration ( MIC ) , mean peak levels , mean trough levels , mean area under the serum concentration - time curve ( AUC ) , total AUC , mean AUC greater than MIC , total AUC greater than MIC , mean Schumacher 's intensity factor ( IF ) , total IF , In ( mean maximum concentration [ Cmax ] / MIC ) .|Model - dependent pharmacokinetic parameters were calculated by computer based on a one - compartment model .|When the parameters were examined individually , duration of therapy and total AUC correlated significantly ( P less than . 05 ) with nephrotoxicity .|In contrast , a stepwise discriminant function analysis identified only duration of therapy ( P less than . 001 ) as an important factor .|Based on this model and on Bayes ' theorem , the predictive accuracy of identifying " nephrotoxic " patients increased from 0 . 17 to 0 . 39 .|When examined individually , mean IF , MIC , total dose , mean daily dose , and ln ( mean Cmax / MIC ) correlated significantly ( P less than . 05 ) with cure .|In contrast , a simultaneous multivariable analysis identified IF , MIC , and total dose according to one model and ln ( mean Cmax / MIC ) according to a second statistical model of parameters selected to have the greatest prospective value .|Based on Bayes ' theorem and the first model , the predictive accuracy of identifying patients not cured increased from 0 . 19 to 0 . 83 .|For the second model , the predictive accuracy increased from 0 . 19 to 0 . 50 . ( ABSTRACT TRUNCATED AT 250 WORDS )	1:CID:2	R2L	NON-CROSS	10-11	3-4	D000583	amikacin|amikacin	Chemical	10:18	11:19	0:1	D007674	nephrotoxicity|nephrotoxicity|nephrotoxicity|nephrotoxic	Disease	3:25:179:222	4:26:180:223	0:1:5:7	1:NR:2	R2L	CROSS	54-55	25-26	D003404	creatinine|creatinine	Chemical	54:57	55:58	3:3	D007674	nephrotoxicity|nephrotoxicity|nephrotoxicity|nephrotoxic	Disease	3:25:179:222	4:26:180:223	0:1:5:7
3311455	Cardiac transplantation : improved quality of survival with a modified immunosuppressive protocol .|The effects on renal function on two different immunosuppressive protocols were evaluated retrospectively in two subsequent groups of heart transplant recipients .|In group I , cyclosporine was given before the procedure at a loading dose of 17 . 5 mg / kg and then continued after the procedure to keep a whole blood level about 1000 ng / ml .|In group II , cyclosporine was started only after the procedure at a lower dosage and was complemented by azathioprine , which was used for the first postoperative week .|Group II showed a better perioperative renal function as determined by serum blood urea nitrogen and serum creatinine levels .|Group II also showed a significant decrease of chronic nephrotoxicity secondary to long - term therapy with cyclosporine .|Despite this improvement in late renal function , group II still shows a slow rise in serum creatinine .|We think that even these lower dosages of cyclosporine can cause chronic nephrotoxicity and that further modification of the immunosuppressive regimen is required to completely abolish this toxic side effect .	1:CID:2	L2R	NON-CROSS	170-171	174-175	D016572	cyclosporine|cyclosporine|cyclosporine|cyclosporine	Chemical	39:78:141:170	40:79:142:171	2:3:5:7	D007674	nephrotoxicity|nephrotoxicity	Disease	133:174	134:175	5:7	1:NR:2	L2R	CROSS	93-94	133-134	D001379	azathioprine	Chemical	93	94	3	D007674	nephrotoxicity|nephrotoxicity	Disease	133:174	134:175	5:7	1:NR:2	L2R	CROSS	117-119	133-134	D001806	urea nitrogen	Chemical	117	119	4	D007674	nephrotoxicity|nephrotoxicity	Disease	133:174	134:175	5:7	1:NR:2	L2R	CROSS	121-122	133-134	D003404	creatinine|creatinine	Chemical	121:160	122:161	4:6	D007674	nephrotoxicity|nephrotoxicity	Disease	133:174	134:175	5:7
2051906	Reversible cholestasis with bile duct injury following azathioprine therapy .|A case report .|A 67 - year - old patient , with primary polymyositis and without previous evidence of liver disease , developed clinical and biochemical features of severe cholestasis 3 months after initiation of azathioprine therapy .|Liver biopsy showed cholestasis with both cytological and architectural alterations of interlobular bile ducts .|Azathioprine withdrawal resulted after 7 weeks in the resolution of clinical and biochemical abnormalities .|It is believed that this is the first reported case of reversible azathioprine - induced cholestasis associated with histological evidence of bile duct injury .	1:CID:2	R2L	NON-CROSS	7-8	3-6	D001379	azathioprine|azathioprine|Azathioprine|azathioprine	Chemical	7:46:64:91	8:47:65:92	0:2:4:5	D002779	cholestasis|bile duct injury|cholestasis|cholestasis|cholestasis|bile duct injury	Disease	1:3:40:52:94:100	2:6:41:53:95:103	0:0:2:3:5:5	1:NR:2	L2R	NON-CROSS	7-8	24-25	D001379	azathioprine|azathioprine|Azathioprine|azathioprine	Chemical	7:46:64:91	8:47:65:92	0:2:4:5	D017285	polymyositis	Disease	24	25	2	1:NR:2	L2R	NON-CROSS	30-32	46-47	D001379	azathioprine|azathioprine|Azathioprine|azathioprine	Chemical	7:46:64:91	8:47:65:92	0:2:4:5	D008107	liver disease	Disease	30	32	2
2021202	Renal function and hemodynamics during prolonged isoflurane - induced hypotension in humans .|The effect of isoflurane - induced hypotension on glomerular function and renal blood flow was investigated in 20 human subjects .|Glomerular filtration rate ( GFR ) and effective renal plasma flow ( ERPF ) were measured by inulin and para - aminohippurate ( PAH ) clearance , respectively .|Anesthesia was maintained with fentanyl , nitrous oxide , oxygen , and isoflurane .|Hypotension was induced for 236 . 9 + / - 15 . 1 min by increasing the isoflurane inspired concentration to maintain a mean arterial pressure of 59 . 8 + / - 0 . 4 mmHg .|GFR and ERPF decreased with the induction of anesthesia but not significantly more during hypotension .|Postoperatively , ERPF returned to preoperative values , whereas GFR was higher than preoperative values .|Renal vascular resistance increased during anesthesia but decreased when hypotension was induced , allowing the maintenance of renal blood flow .|We conclude that renal compensatory mechanisms are preserved during isoflurane - induced hypotension and that renal function and hemodynamics quickly return to normal when normotension is resumed .	1:CID:2	L2R	NON-CROSS	75-76	77-78	D007530	isoflurane|isoflurane|isoflurane|isoflurane|isoflurane	Chemical	6:16:75:94:177	7:17:76:95:178	0:1:3:4:8	D007022	hypotension|hypotension|Hypotension|hypotension|hypotension|hypotension	Disease	9:19:77:129:156:180	10:20:78:130:157:181	0:1:4:5:7:8	1:NR:2	R2L	CROSS	77-78	57-58	D010130	para - aminohippurate|PAH	Chemical	53:57	56:58	2:2	D007022	hypotension|hypotension|Hypotension|hypotension|hypotension|hypotension	Disease	9:19:77:129:156:180	10:20:78:130:157:181	0:1:4:5:7:8	1:NR:2	R2L	CROSS	77-78	67-68	D005283	fentanyl	Chemical	67	68	3	D007022	hypotension|hypotension|Hypotension|hypotension|hypotension|hypotension	Disease	9:19:77:129:156:180	10:20:78:130:157:181	0:1:4:5:7:8	1:NR:2	R2L	CROSS	77-78	69-71	D009609	nitrous oxide	Chemical	69	71	3	D007022	hypotension|hypotension|Hypotension|hypotension|hypotension|hypotension	Disease	9:19:77:129:156:180	10:20:78:130:157:181	0:1:4:5:7:8	1:NR:2	R2L	CROSS	77-78	72-73	D010100	oxygen	Chemical	72	73	3	D007022	hypotension|hypotension|Hypotension|hypotension|hypotension|hypotension	Disease	9:19:77:129:156:180	10:20:78:130:157:181	0:1:4:5:7:8
1848636	Debrisoquine phenotype and the pharmacokinetics and beta - 2 receptor pharmacodynamics of metoprolol and its enantiomers .|The metabolism of the cardioselective beta - blocker metoprolol is under genetic control of the debrisoquine / sparteine type .|The two metabolic phenotypes , extensive ( EM ) and poor metabolizers ( PM ) , show different stereoselective metabolism , resulting in apparently higher beta - 1 adrenoceptor antagonistic potency of racemic metoprolol in EMs .|We investigated if the latter also applies to the beta - 2 adrenoceptor antagonism by metoprolol .|The drug effect studied was the antagonism by metoprolol of terbutaline - induced hypokalemia .|By using pharmacokinetic pharmacodynamic modeling the pharmacodynamics of racemic metoprolol and the active S - isomer , were quantitated in EMs and PMs in terms of IC50 values , representing metoprolol plasma concentrations resulting in half - maximum receptor occupancy .|Six EMs received 0 . 5 mg of terbutaline s . c .|on two different occasions : 1 ) 1 hr after administration of a placebo and 2 ) 1 hr after 150 mg of metoprolol p . o .|Five PMs were studied according to the same protocol , except for a higher terbutaline dose ( 0 . 75 mg ) on day 2 .|Blood samples for the analysis of plasma potassium , terbutaline , metoprolol ( racemic , R - and S - isomer ) , and alpha - hydroxymetoprolol concentrations were taken at regular time intervals , during 8 hr after metoprolol .|In PMs , metoprolol increased the terbutaline area under the plasma concentration vs . time curve ( + 67 % ) .|Higher metoprolol / alpha - hydroxymetoprolol ratios in PMs were predictive for higher R - / S - isomer ratios of unchanged drug .|There was a difference in metoprolol potency with higher racemic metoprolol IC50 values in PMs ( 72 + / - 7 ng . ml - 1 ) than EMs ( 42 + / - 8 ng . ml - 1 , P less than . 001 ) . ( ABSTRACT TRUNCATED AT 250 WORDS )	1:NR:2	L2R	CROSS	32-33	104-105	D003647	Debrisoquine|debrisoquine	Chemical	0:32	1:33	0:1	D007008	hypokalemia	Disease	104	105	4	1:NR:2	L2R	NON-CROSS	99-100	104-105	D008790	metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol	Chemical	12:25:70:89:99:115:136:183:225:253:258:278:306:311	13:26:71:90:100:116:137:184:226:254:259:279:307:312	0:1:2:3:4:5:5:7:9:9:10:11:12:12	D007008	hypokalemia	Disease	104	105	4	1:NR:2	L2R	CROSS	34-35	104-105	D013034	sparteine	Chemical	34	35	1	D007008	hypokalemia	Disease	104	105	4	1:CID:2	L2R	NON-CROSS	101-102	104-105	D013726	terbutaline|terbutaline|terbutaline|terbutaline|terbutaline	Chemical	101:155:202:223:261	102:156:203:224:262	4:6:8:9:10	D007008	hypokalemia	Disease	104	105	4	1:NR:2	R2L	CROSS	221-222	104-105	D011188	potassium	Chemical	221	222	9	D007008	hypokalemia	Disease	104	105	4	1:NR:2	R2L	CROSS	238-241	104-105	C029504	alpha - hydroxymetoprolol|alpha - hydroxymetoprolol	Chemical	238:280	241:283	9:11	D007008	hypokalemia	Disease	104	105	4
1445986	Cefotetan - induced immune hemolytic anemia .|Immune hemolytic anemia due to a drug - adsorption mechanism has been described primarily in patients receiving penicillins and first - generation cephalosporins .|We describe a patient who developed anemia while receiving intravenous cefotetan .|Cefotetan - dependent antibodies were detected in the patient 's serum and in an eluate prepared from his red blood cells .|The eluate also reacted weakly with red blood cells in the absence of cefotetan , suggesting the concomitant formation of warm - reactive autoantibodies .|These observations , in conjunction with clinical and laboratory evidence of extravascular hemolysis , are consistent with drug - induced hemolytic anemia , possibly involving both drug - adsorption and autoantibody formation mechanisms .|This case emphasizes the need for increased awareness of hemolytic reactions to all cephalosporins .	1:CID:2	L2R	NON-CROSS	0-1	4-6	D015313	Cefotetan|cefotetan|Cefotetan|cefotetan	Chemical	0:41:43:78	1:42:44:79	0:2:3:4	D000743	hemolytic anemia|hemolytic anemia|hemolytic anemia	Disease	4:8:110	6:10:112	0:1:5	1:NR:2	L2R	NON-CROSS	37-38	41-42	D015313	Cefotetan|cefotetan|Cefotetan|cefotetan	Chemical	0:41:43:78	1:42:44:79	0:2:3:4	D000740	anemia	Disease	37	38	2	1:NR:2	L2R	CROSS	78-79	102-103	D015313	Cefotetan|cefotetan|Cefotetan|cefotetan	Chemical	0:41:43:78	1:42:44:79	0:2:3:4	D006461	hemolysis	Disease	102	103	5	1:NR:2	R2L	NON-CROSS	24-25	8-10	D010406	penicillins	Chemical	24	25	1	D000743	hemolytic anemia|hemolytic anemia|hemolytic anemia	Disease	4:8:110	6:10:112	0:1:5	1:NR:2	R2L	NON-CROSS	29-30	8-10	D002511	cephalosporins|cephalosporins	Chemical	29:137	30:138	1:6	D000743	hemolytic anemia|hemolytic anemia|hemolytic anemia	Disease	4:8:110	6:10:112	0:1:5	1:NR:2	L2R	CROSS	24-25	37-38	D010406	penicillins	Chemical	24	25	1	D000740	anemia	Disease	37	38	2	1:NR:2	L2R	CROSS	24-25	102-103	D010406	penicillins	Chemical	24	25	1	D006461	hemolysis	Disease	102	103	5	1:NR:2	L2R	CROSS	29-30	37-38	D002511	cephalosporins|cephalosporins	Chemical	29:137	30:138	1:6	D000740	anemia	Disease	37	38	2	1:NR:2	L2R	CROSS	102-103	137-138	D002511	cephalosporins|cephalosporins	Chemical	29:137	30:138	1:6	D006461	hemolysis	Disease	102	103	5
982002	Acute renal failure subsequent to the administration of rifampicin .|A follow - up study of cases reported earlier .|A clinical presentation is made of a 2 - 3 year follow - up of six cases of acute renal failure that have been reported earlier .|The patients had developed transient renal failure after the intermittent administration of rifampicin .|The stage of olig - anuria lasted for 1 - 3 weeks , and five of the patients were treated by hemodialysis .|Two of the patients died due to unrelated causes during the follow - up period .|The four patients re - examined were clinically cured .|Pathologic findings by light microscopy and immunofluorescence at biopsy were scarce .|Nothing abnormal was seen by electron microscopy in two of the cases studied .|Renal function was normal .|In three cases the excretion at 131I - hippuran renography was slightly slowed .|Although in the acute stage the renal lesions histologically appeared toxic , evidence suggestive of an immunological mechanism can not be excluded .	1:CID:2	R2L	NON-CROSS	8-9	0-3	D012293	rifampicin|rifampicin	Chemical	8:59	9:60	0:3	D058186	Acute renal failure|acute renal failure	Disease	0:38	3:41	0:2	1:NR:2	L2R	NON-CROSS	52-54	59-60	D012293	rifampicin|rifampicin	Chemical	8:59	9:60	0:3	D051437	renal failure	Disease	52	54	3	1:NR:2	L2R	CROSS	59-60	66-67	D012293	rifampicin|rifampicin	Chemical	8:59	9:60	0:3	D001002	anuria	Disease	66	67	4	1:NR:2	L2R	CROSS	59-60	161-163	D012293	rifampicin|rifampicin	Chemical	8:59	9:60	0:3	D007674	renal lesions	Disease	161	163	11
343678	Type B hepatitis after needle - stick exposure : prevention with hepatitis B immune globulin .|Final report of the Veterans Administration Cooperative Study .|Hepatitis B immune globulin ( HBIG ) and immune serum globulin ( ISG ) were examined in a randomized , double - blind trial to assess their relative efficacies in preventing type B hepatitis after needle - stick exposure to hepatitis B surface antigen ( HBsAG ) - positive donors .|Clinical hepatitis developed in 1 . 4 % of HBIG and in 5 . 9 % of ISG recipients ( P = 0 . 016 ) , and seroconversion ( anti - HBs ) occurred in 5 . 6 % and 20 . 7 % of them respectively ( P less than 0 . 001 ) .|Mild and transient side - effects were noted in 3 . 0 % of ISG and in 3 . 2 % of HBIG recipients .|Available donor sera were examined for DNA polymerase ( DNAP ) and e antigen and antibody ( HBeAg ; anti - HBE ) .|Both DNAP and HBeAg showed a highly statistically significant correlation with the infectivity of HBsAg - positive donors .|Hepatitis B immune globulin remained significantly superior to ISG in preventing type B hepatitis even when the analysis was confined to these two high - risk subgroups .|The efficacy of ISG in preventing type B hepatitis can not be ascertained because a true placebo group was not included .	1:NR:2	R2L	NON-CROSS	201-203	196-197	D006514	hepatitis B surface antigen|HBsAG|HBsAg	Chemical	65:70:196	69:71:197	2:2:6	D006509	Type B hepatitis|hepatitis B|Hepatitis B|type B hepatitis|Hepatitis B|type B hepatitis|type B hepatitis	Disease	0:11:25:56:201:212:235	3:13:27:59:203:215:238	0:0:2:2:7:7:8	1:CID:2	R2L	CROSS	201-203	185-186	D006513	HBeAg|HBeAg	Chemical	175:185	176:186	5:6	D006509	Type B hepatitis|hepatitis B|Hepatitis B|type B hepatitis|Hepatitis B|type B hepatitis|type B hepatitis	Disease	0:11:25:56:201:212:235	3:13:27:59:203:215:238	0:0:2:2:7:7:8	1:NR:2	L2R	CROSS	70-71	77-78	D006514	hepatitis B surface antigen|HBsAG|HBsAg	Chemical	65:70:196	69:71:197	2:2:6	D056486	hepatitis	Disease	77	78	3	1:NR:2	R2L	CROSS	175-176	77-78	D006513	HBeAg|HBeAg	Chemical	175:185	176:186	5:6	D056486	hepatitis	Disease	77	78	3
8888541	Serotonin syndrome from venlafaxine - tranylcypromine interaction .|Excessive stimulation of serotonin 5HT1A receptors causes a syndrome of serotonin excess that consists of shivering , muscle rigidity , salivation , confusion , agitation and hyperthermia .|The most common cause of this syndrome is an interaction between a monoamine oxidase inhibitor ( MAOI ) and a specific serotonin reuptake inhibitor .|Venlafaxine is a new antidepressant agent that inhibits the reuptake of serotonin and norepinephrine .|We report a venlafaxine - MAOI interaction that resulted in the serotonin syndrome in a 23 - y - old male who was taking tranylcypromine for depression .|He had been well until the morning of presentation when he took 1 / 2 tab of venlafaxine .|Within 2 h he became confused with jerking movements of his extremities , tremors and rigidity .|He was brought directly to a hospital where he was found to be agitated and confused with shivering , myoclonic jerks , rigidity , salivation and diaphoresis .|His pupils were 7 mm and sluggishly reactive to light .|Vital signs were : blood pressure 120 / 67 mm Hg , heart rate 127 / min , respiratory rate 28 / min , and temperature 97 F .|After 180 mg of diazepam i . v .|he remained tremulous with muscle rigidity and clenched jaws .|He was intubated for airway protection and because of hypoventilation , and was paralyzed to control muscle rigidity .|His subsequent course was remarkable for non - immune thrombocytopenia which resolved .|The patient 's maximal temperature was 101 . 2 F and his CPK remained < 500 units / L with no other evidence of rhabdomyolysis .|His mental status normalized and he was transferred to a psychiatry ward .|This patient survived without sequelae due to the aggressive sedation and neuromuscular paralysis .	1:CID:2	R2L	NON-CROSS	3-4	0-2	C047426	venlafaxine|Venlafaxine|venlafaxine|venlafaxine	Chemical	3:61:79:121	4:62:80:122	0:3:4:5	D020230	Serotonin syndrome|serotonin syndrome	Disease	0:87	2:89	0:4	1:CID:2	R2L	NON-CROSS	5-6	0-2	D014191	tranylcypromine|tranylcypromine	Chemical	5:100	6:101	0:4	D020230	Serotonin syndrome|serotonin syndrome	Disease	0:87	2:89	0:4	1:NR:2	R2L	CROSS	11-12	0-2	D012701	serotonin|serotonin|serotonin|serotonin	Chemical	11:18:57:72	12:19:58:73	1:1:2:3	D020230	Serotonin syndrome|serotonin syndrome	Disease	0:87	2:89	0:4	1:NR:2	R2L	CROSS	87-89	74-75	D009638	norepinephrine	Chemical	74	75	3	D020230	Serotonin syndrome|serotonin syndrome	Disease	0:87	2:89	0:4	1:NR:2	R2L	CROSS	212-213	87-89	D003975	diazepam	Chemical	212	213	10	D020230	Serotonin syndrome|serotonin syndrome	Disease	0:87	2:89	0:4	1:CID:2	L2R	CROSS	121-122	138-139	C047426	venlafaxine|Venlafaxine|venlafaxine|venlafaxine	Chemical	3:61:79:121	4:62:80:122	0:3:4:5	D009127	muscle rigidity|rigidity|rigidity|muscle rigidity|muscle rigidity	Disease	25:138:162:221:243	27:139:163:223:245	1:6:7:11:12	1:CID:2	L2R	CROSS	3-4	28-29	C047426	venlafaxine|Venlafaxine|venlafaxine|venlafaxine	Chemical	3:61:79:121	4:62:80:122	0:3:4:5	D012798	salivation|salivation	Disease	28:164	29:165	1:7	1:CID:2	L2R	CROSS	3-4	30-31	C047426	venlafaxine|Venlafaxine|venlafaxine|venlafaxine	Chemical	3:61:79:121	4:62:80:122	0:3:4:5	D003221	confusion	Disease	30	31	1	1:NR:2	L2R	CROSS	3-4	32-33	C047426	venlafaxine|Venlafaxine|venlafaxine|venlafaxine	Chemical	3:61:79:121	4:62:80:122	0:3:4:5	D011595	agitation	Disease	32	33	1	1:CID:2	L2R	CROSS	34-35	61-62	C047426	venlafaxine|Venlafaxine|venlafaxine|venlafaxine	Chemical	3:61:79:121	4:62:80:122	0:3:4:5	D005334	hyperthermia	Disease	34	35	1	1:NR:2	L2R	NON-CROSS	102-103	121-122	C047426	venlafaxine|Venlafaxine|venlafaxine|venlafaxine	Chemical	3:61:79:121	4:62:80:122	0:3:4:5	D003866	depression	Disease	102	103	4	1:CID:2	L2R	CROSS	121-122	136-137	C047426	venlafaxine|Venlafaxine|venlafaxine|venlafaxine	Chemical	3:61:79:121	4:62:80:122	0:3:4:5	D014202	tremors	Disease	136	137	6	1:CID:2	L2R	CROSS	121-122	159-161	C047426	venlafaxine|Venlafaxine|venlafaxine|venlafaxine	Chemical	3:61:79:121	4:62:80:122	0:3:4:5	D009207	myoclonic jerks	Disease	159	161	7	1:NR:2	L2R	CROSS	121-122	236-237	C047426	venlafaxine|Venlafaxine|venlafaxine|venlafaxine	Chemical	3:61:79:121	4:62:80:122	0:3:4:5	D007040	hypoventilation	Disease	236	237	12	1:NR:2	L2R	CROSS	121-122	240-241	C047426	venlafaxine|Venlafaxine|venlafaxine|venlafaxine	Chemical	3:61:79:121	4:62:80:122	0:3:4:5	D010243	paralyzed|paralysis	Disease	240:310	241:311	12:16	1:CID:2	L2R	CROSS	121-122	255-256	C047426	venlafaxine|Venlafaxine|venlafaxine|venlafaxine	Chemical	3:61:79:121	4:62:80:122	0:3:4:5	D013921	thrombocytopenia	Disease	255	256	13	1:NR:2	L2R	CROSS	121-122	283-284	C047426	venlafaxine|Venlafaxine|venlafaxine|venlafaxine	Chemical	3:61:79:121	4:62:80:122	0:3:4:5	D012206	rhabdomyolysis	Disease	283	284	14	1:CID:2	L2R	CROSS	5-6	25-27	D014191	tranylcypromine|tranylcypromine	Chemical	5:100	6:101	0:4	D009127	muscle rigidity|rigidity|rigidity|muscle rigidity|muscle rigidity	Disease	25:138:162:221:243	27:139:163:223:245	1:6:7:11:12	1:CID:2	L2R	CROSS	5-6	28-29	D014191	tranylcypromine|tranylcypromine	Chemical	5:100	6:101	0:4	D012798	salivation|salivation	Disease	28:164	29:165	1:7	1:CID:2	L2R	CROSS	5-6	30-31	D014191	tranylcypromine|tranylcypromine	Chemical	5:100	6:101	0:4	D003221	confusion	Disease	30	31	1	1:NR:2	L2R	CROSS	5-6	32-33	D014191	tranylcypromine|tranylcypromine	Chemical	5:100	6:101	0:4	D011595	agitation	Disease	32	33	1	1:CID:2	L2R	CROSS	5-6	34-35	D014191	tranylcypromine|tranylcypromine	Chemical	5:100	6:101	0:4	D005334	hyperthermia	Disease	34	35	1	1:NR:2	L2R	NON-CROSS	100-101	102-103	D014191	tranylcypromine|tranylcypromine	Chemical	5:100	6:101	0:4	D003866	depression	Disease	102	103	4	1:CID:2	L2R	CROSS	100-101	136-137	D014191	tranylcypromine|tranylcypromine	Chemical	5:100	6:101	0:4	D014202	tremors	Disease	136	137	6	1:CID:2	L2R	CROSS	100-101	159-161	D014191	tranylcypromine|tranylcypromine	Chemical	5:100	6:101	0:4	D009207	myoclonic jerks	Disease	159	161	7	1:NR:2	L2R	CROSS	100-101	236-237	D014191	tranylcypromine|tranylcypromine	Chemical	5:100	6:101	0:4	D007040	hypoventilation	Disease	236	237	12	1:NR:2	L2R	CROSS	100-101	240-241	D014191	tranylcypromine|tranylcypromine	Chemical	5:100	6:101	0:4	D010243	paralyzed|paralysis	Disease	240:310	241:311	12:16	1:CID:2	L2R	CROSS	100-101	255-256	D014191	tranylcypromine|tranylcypromine	Chemical	5:100	6:101	0:4	D013921	thrombocytopenia	Disease	255	256	13	1:NR:2	L2R	CROSS	100-101	283-284	D014191	tranylcypromine|tranylcypromine	Chemical	5:100	6:101	0:4	D012206	rhabdomyolysis	Disease	283	284	14	1:NR:2	L2R	NON-CROSS	18-19	25-27	D012701	serotonin|serotonin|serotonin|serotonin	Chemical	11:18:57:72	12:19:58:73	1:1:2:3	D009127	muscle rigidity|rigidity|rigidity|muscle rigidity|muscle rigidity	Disease	25:138:162:221:243	27:139:163:223:245	1:6:7:11:12	1:NR:2	L2R	NON-CROSS	18-19	28-29	D012701	serotonin|serotonin|serotonin|serotonin	Chemical	11:18:57:72	12:19:58:73	1:1:2:3	D012798	salivation|salivation	Disease	28:164	29:165	1:7	1:NR:2	L2R	NON-CROSS	18-19	30-31	D012701	serotonin|serotonin|serotonin|serotonin	Chemical	11:18:57:72	12:19:58:73	1:1:2:3	D003221	confusion	Disease	30	31	1	1:NR:2	L2R	NON-CROSS	18-19	32-33	D012701	serotonin|serotonin|serotonin|serotonin	Chemical	11:18:57:72	12:19:58:73	1:1:2:3	D011595	agitation	Disease	32	33	1	1:NR:2	L2R	NON-CROSS	18-19	34-35	D012701	serotonin|serotonin|serotonin|serotonin	Chemical	11:18:57:72	12:19:58:73	1:1:2:3	D005334	hyperthermia	Disease	34	35	1	1:NR:2	L2R	CROSS	72-73	102-103	D012701	serotonin|serotonin|serotonin|serotonin	Chemical	11:18:57:72	12:19:58:73	1:1:2:3	D003866	depression	Disease	102	103	4	1:NR:2	L2R	CROSS	72-73	136-137	D012701	serotonin|serotonin|serotonin|serotonin	Chemical	11:18:57:72	12:19:58:73	1:1:2:3	D014202	tremors	Disease	136	137	6	1:NR:2	L2R	CROSS	72-73	159-161	D012701	serotonin|serotonin|serotonin|serotonin	Chemical	11:18:57:72	12:19:58:73	1:1:2:3	D009207	myoclonic jerks	Disease	159	161	7	1:NR:2	L2R	CROSS	72-73	236-237	D012701	serotonin|serotonin|serotonin|serotonin	Chemical	11:18:57:72	12:19:58:73	1:1:2:3	D007040	hypoventilation	Disease	236	237	12	1:NR:2	L2R	CROSS	72-73	240-241	D012701	serotonin|serotonin|serotonin|serotonin	Chemical	11:18:57:72	12:19:58:73	1:1:2:3	D010243	paralyzed|paralysis	Disease	240:310	241:311	12:16	1:NR:2	L2R	CROSS	72-73	255-256	D012701	serotonin|serotonin|serotonin|serotonin	Chemical	11:18:57:72	12:19:58:73	1:1:2:3	D013921	thrombocytopenia	Disease	255	256	13	1:NR:2	L2R	CROSS	72-73	283-284	D012701	serotonin|serotonin|serotonin|serotonin	Chemical	11:18:57:72	12:19:58:73	1:1:2:3	D012206	rhabdomyolysis	Disease	283	284	14	1:NR:2	R2L	CROSS	74-75	25-27	D009638	norepinephrine	Chemical	74	75	3	D009127	muscle rigidity|rigidity|rigidity|muscle rigidity|muscle rigidity	Disease	25:138:162:221:243	27:139:163:223:245	1:6:7:11:12	1:NR:2	R2L	CROSS	221-223	212-213	D003975	diazepam	Chemical	212	213	10	D009127	muscle rigidity|rigidity|rigidity|muscle rigidity|muscle rigidity	Disease	25:138:162:221:243	27:139:163:223:245	1:6:7:11:12	1:NR:2	R2L	CROSS	74-75	28-29	D009638	norepinephrine	Chemical	74	75	3	D012798	salivation|salivation	Disease	28:164	29:165	1:7	1:NR:2	R2L	CROSS	212-213	164-165	D003975	diazepam	Chemical	212	213	10	D012798	salivation|salivation	Disease	28:164	29:165	1:7	1:NR:2	R2L	CROSS	74-75	30-31	D009638	norepinephrine	Chemical	74	75	3	D003221	confusion	Disease	30	31	1	1:NR:2	R2L	CROSS	212-213	30-31	D003975	diazepam	Chemical	212	213	10	D003221	confusion	Disease	30	31	1	1:NR:2	R2L	CROSS	74-75	32-33	D009638	norepinephrine	Chemical	74	75	3	D011595	agitation	Disease	32	33	1	1:NR:2	R2L	CROSS	212-213	32-33	D003975	diazepam	Chemical	212	213	10	D011595	agitation	Disease	32	33	1	1:NR:2	R2L	CROSS	74-75	34-35	D009638	norepinephrine	Chemical	74	75	3	D005334	hyperthermia	Disease	34	35	1	1:NR:2	R2L	CROSS	212-213	34-35	D003975	diazepam	Chemical	212	213	10	D005334	hyperthermia	Disease	34	35	1	1:NR:2	L2R	CROSS	74-75	102-103	D009638	norepinephrine	Chemical	74	75	3	D003866	depression	Disease	102	103	4	1:NR:2	L2R	CROSS	74-75	136-137	D009638	norepinephrine	Chemical	74	75	3	D014202	tremors	Disease	136	137	6	1:NR:2	L2R	CROSS	74-75	159-161	D009638	norepinephrine	Chemical	74	75	3	D009207	myoclonic jerks	Disease	159	161	7	1:NR:2	L2R	CROSS	74-75	236-237	D009638	norepinephrine	Chemical	74	75	3	D007040	hypoventilation	Disease	236	237	12	1:NR:2	L2R	CROSS	74-75	240-241	D009638	norepinephrine	Chemical	74	75	3	D010243	paralyzed|paralysis	Disease	240:310	241:311	12:16	1:NR:2	L2R	CROSS	74-75	255-256	D009638	norepinephrine	Chemical	74	75	3	D013921	thrombocytopenia	Disease	255	256	13	1:NR:2	L2R	CROSS	74-75	283-284	D009638	norepinephrine	Chemical	74	75	3	D012206	rhabdomyolysis	Disease	283	284	14	1:NR:2	R2L	CROSS	212-213	102-103	D003975	diazepam	Chemical	212	213	10	D003866	depression	Disease	102	103	4	1:NR:2	R2L	CROSS	212-213	136-137	D003975	diazepam	Chemical	212	213	10	D014202	tremors	Disease	136	137	6	1:NR:2	R2L	CROSS	212-213	159-161	D003975	diazepam	Chemical	212	213	10	D009207	myoclonic jerks	Disease	159	161	7	1:NR:2	L2R	CROSS	212-213	236-237	D003975	diazepam	Chemical	212	213	10	D007040	hypoventilation	Disease	236	237	12	1:NR:2	L2R	CROSS	212-213	240-241	D003975	diazepam	Chemical	212	213	10	D010243	paralyzed|paralysis	Disease	240:310	241:311	12:16	1:NR:2	L2R	CROSS	212-213	255-256	D003975	diazepam	Chemical	212	213	10	D013921	thrombocytopenia	Disease	255	256	13	1:NR:2	L2R	CROSS	212-213	283-284	D003975	diazepam	Chemical	212	213	10	D012206	rhabdomyolysis	Disease	283	284	14
8106150	Effect of nondopaminergic drugs on L - dopa - induced dyskinesias in MPTP - treated monkeys .|A group of four monkeys was rendered parkinsonian with the toxin MPTP .|They were then treated chronically with L - DOPA / benserazide 50 / 12 . 5 mg / kg given orally daily for 2 months .|This dose produced a striking antiparkinsonian effect , but all animals manifested dyskinesia .|A series of agents acting primarily on neurotransmitters other than dopamine were then tested in combination with L - DOPA to see if the dyskinetic movements would be modified .|Several drugs , including clonidine , physostigmine , methysergide , 5 - MDOT , propranolol , and MK - 801 , markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology .|However , yohimbine and meperidine reduced predominantly the dyskinetic movements .|Baclofen was also useful in one monkey against a more dystonic form of dyskinesia .|Atropine converted the dystonic movements into chorea .	1:NR:2	L2R	NON-CROSS	5-8	10-11	D007980	L - dopa|L - DOPA	Chemical	5:87	8:90	0:4	D004409	dyskinesias|dyskinesia|dyskinetic|dyskinetic|dyskinetic|dyskinesia	Disease	10:68:94:124:145:161	11:69:95:125:146:162	0:3:4:5:6:7	1:NR:2	L2R	CROSS	5-8	24-25	D007980	L - dopa|L - DOPA	Chemical	5:87	8:90	0:4	D020734	parkinsonian|parkinsonian	Disease	24:134	25:135	1:5	1:NR:2	L2R	CROSS	87-90	158-159	D007980	L - dopa|L - DOPA	Chemical	5:87	8:90	0:4	D020821	dystonic|dystonic	Disease	158:166	159:167	7:8	1:NR:2	L2R	CROSS	87-90	169-170	D007980	L - dopa|L - DOPA	Chemical	5:87	8:90	0:4	D002819	chorea	Disease	169	170	8	1:NR:2	R2L	NON-CROSS	12-13	10-11	D015632	MPTP|MPTP	Chemical	12:28	13:29	0:1	D004409	dyskinesias|dyskinesia|dyskinetic|dyskinetic|dyskinetic|dyskinesia	Disease	10:68:94:124:145:161	11:69:95:125:146:162	0:3:4:5:6:7	1:CID:2	R2L	CROSS	36-41	10-11	C005177	L - DOPA / benserazide	Chemical	36	41	2	D004409	dyskinesias|dyskinesia|dyskinetic|dyskinetic|dyskinetic|dyskinesia	Disease	10:68:94:124:145:161	11:69:95:125:146:162	0:3:4:5:6:7	1:NR:2	R2L	NON-CROSS	80-81	68-69	D004298	dopamine	Chemical	80	81	4	D004409	dyskinesias|dyskinesia|dyskinetic|dyskinetic|dyskinetic|dyskinesia	Disease	10:68:94:124:145:161	11:69:95:125:146:162	0:3:4:5:6:7	1:NR:2	R2L	NON-CROSS	104-105	94-95	D003000	clonidine	Chemical	104	105	5	D004409	dyskinesias|dyskinesia|dyskinetic|dyskinetic|dyskinetic|dyskinesia	Disease	10:68:94:124:145:161	11:69:95:125:146:162	0:3:4:5:6:7	1:NR:2	R2L	NON-CROSS	106-107	94-95	D010830	physostigmine	Chemical	106	107	5	D004409	dyskinesias|dyskinesia|dyskinetic|dyskinetic|dyskinetic|dyskinesia	Disease	10:68:94:124:145:161	11:69:95:125:146:162	0:3:4:5:6:7	1:NR:2	R2L	NON-CROSS	108-109	94-95	D008784	methysergide	Chemical	108	109	5	D004409	dyskinesias|dyskinesia|dyskinetic|dyskinetic|dyskinetic|dyskinesia	Disease	10:68:94:124:145:161	11:69:95:125:146:162	0:3:4:5:6:7	1:NR:2	R2L	NON-CROSS	124-125	114-115	D011433	propranolol	Chemical	114	115	5	D004409	dyskinesias|dyskinesia|dyskinetic|dyskinetic|dyskinetic|dyskinesia	Disease	10:68:94:124:145:161	11:69:95:125:146:162	0:3:4:5:6:7	1:NR:2	R2L	NON-CROSS	124-125	117-120	D016291	MK - 801	Chemical	117	120	5	D004409	dyskinesias|dyskinesia|dyskinetic|dyskinetic|dyskinetic|dyskinesia	Disease	10:68:94:124:145:161	11:69:95:125:146:162	0:3:4:5:6:7	1:NR:2	R2L	NON-CROSS	145-146	139-140	D015016	yohimbine	Chemical	139	140	6	D004409	dyskinesias|dyskinesia|dyskinetic|dyskinetic|dyskinetic|dyskinesia	Disease	10:68:94:124:145:161	11:69:95:125:146:162	0:3:4:5:6:7	1:NR:2	R2L	NON-CROSS	145-146	141-142	D008614	meperidine	Chemical	141	142	6	D004409	dyskinesias|dyskinesia|dyskinetic|dyskinetic|dyskinetic|dyskinesia	Disease	10:68:94:124:145:161	11:69:95:125:146:162	0:3:4:5:6:7	1:NR:2	R2L	NON-CROSS	148-149	145-146	D001418	Baclofen	Chemical	148	149	7	D004409	dyskinesias|dyskinesia|dyskinetic|dyskinetic|dyskinetic|dyskinesia	Disease	10:68:94:124:145:161	11:69:95:125:146:162	0:3:4:5:6:7	1:NR:2	R2L	CROSS	163-164	161-162	D001285	Atropine	Chemical	163	164	8	D004409	dyskinesias|dyskinesia|dyskinetic|dyskinetic|dyskinetic|dyskinesia	Disease	10:68:94:124:145:161	11:69:95:125:146:162	0:3:4:5:6:7	1:CID:2	L2R	NON-CROSS	24-25	28-29	D015632	MPTP|MPTP	Chemical	12:28	13:29	0:1	D020734	parkinsonian|parkinsonian	Disease	24:134	25:135	1:5	1:NR:2	L2R	CROSS	28-29	158-159	D015632	MPTP|MPTP	Chemical	12:28	13:29	0:1	D020821	dystonic|dystonic	Disease	158:166	159:167	7:8	1:NR:2	L2R	CROSS	28-29	169-170	D015632	MPTP|MPTP	Chemical	12:28	13:29	0:1	D002819	chorea	Disease	169	170	8	1:NR:2	R2L	CROSS	36-41	24-25	C005177	L - DOPA / benserazide	Chemical	36	41	2	D020734	parkinsonian|parkinsonian	Disease	24:134	25:135	1:5	1:NR:2	R2L	CROSS	134-135	80-81	D004298	dopamine	Chemical	80	81	4	D020734	parkinsonian|parkinsonian	Disease	24:134	25:135	1:5	1:NR:2	R2L	NON-CROSS	134-135	104-105	D003000	clonidine	Chemical	104	105	5	D020734	parkinsonian|parkinsonian	Disease	24:134	25:135	1:5	1:NR:2	R2L	NON-CROSS	134-135	106-107	D010830	physostigmine	Chemical	106	107	5	D020734	parkinsonian|parkinsonian	Disease	24:134	25:135	1:5	1:NR:2	R2L	NON-CROSS	134-135	108-109	D008784	methysergide	Chemical	108	109	5	D020734	parkinsonian|parkinsonian	Disease	24:134	25:135	1:5	1:NR:2	R2L	NON-CROSS	134-135	114-115	D011433	propranolol	Chemical	114	115	5	D020734	parkinsonian|parkinsonian	Disease	24:134	25:135	1:5	1:NR:2	R2L	NON-CROSS	134-135	117-120	D016291	MK - 801	Chemical	117	120	5	D020734	parkinsonian|parkinsonian	Disease	24:134	25:135	1:5	1:NR:2	R2L	CROSS	139-140	134-135	D015016	yohimbine	Chemical	139	140	6	D020734	parkinsonian|parkinsonian	Disease	24:134	25:135	1:5	1:NR:2	R2L	CROSS	141-142	134-135	D008614	meperidine	Chemical	141	142	6	D020734	parkinsonian|parkinsonian	Disease	24:134	25:135	1:5	1:NR:2	R2L	CROSS	148-149	134-135	D001418	Baclofen	Chemical	148	149	7	D020734	parkinsonian|parkinsonian	Disease	24:134	25:135	1:5	1:NR:2	R2L	CROSS	163-164	134-135	D001285	Atropine	Chemical	163	164	8	D020734	parkinsonian|parkinsonian	Disease	24:134	25:135	1:5	1:NR:2	L2R	CROSS	36-41	158-159	C005177	L - DOPA / benserazide	Chemical	36	41	2	D020821	dystonic|dystonic	Disease	158:166	159:167	7:8	1:NR:2	L2R	CROSS	36-41	169-170	C005177	L - DOPA / benserazide	Chemical	36	41	2	D002819	chorea	Disease	169	170	8	1:NR:2	L2R	CROSS	80-81	158-159	D004298	dopamine	Chemical	80	81	4	D020821	dystonic|dystonic	Disease	158:166	159:167	7:8	1:NR:2	L2R	CROSS	80-81	169-170	D004298	dopamine	Chemical	80	81	4	D002819	chorea	Disease	169	170	8	1:NR:2	L2R	CROSS	104-105	158-159	D003000	clonidine	Chemical	104	105	5	D020821	dystonic|dystonic	Disease	158:166	159:167	7:8	1:NR:2	L2R	CROSS	104-105	169-170	D003000	clonidine	Chemical	104	105	5	D002819	chorea	Disease	169	170	8	1:NR:2	L2R	CROSS	106-107	158-159	D010830	physostigmine	Chemical	106	107	5	D020821	dystonic|dystonic	Disease	158:166	159:167	7:8	1:NR:2	L2R	CROSS	106-107	169-170	D010830	physostigmine	Chemical	106	107	5	D002819	chorea	Disease	169	170	8	1:NR:2	L2R	CROSS	108-109	158-159	D008784	methysergide	Chemical	108	109	5	D020821	dystonic|dystonic	Disease	158:166	159:167	7:8	1:NR:2	L2R	CROSS	108-109	169-170	D008784	methysergide	Chemical	108	109	5	D002819	chorea	Disease	169	170	8	1:NR:2	L2R	CROSS	114-115	158-159	D011433	propranolol	Chemical	114	115	5	D020821	dystonic|dystonic	Disease	158:166	159:167	7:8	1:NR:2	L2R	CROSS	114-115	169-170	D011433	propranolol	Chemical	114	115	5	D002819	chorea	Disease	169	170	8	1:NR:2	L2R	CROSS	117-120	158-159	D016291	MK - 801	Chemical	117	120	5	D020821	dystonic|dystonic	Disease	158:166	159:167	7:8	1:NR:2	L2R	CROSS	117-120	169-170	D016291	MK - 801	Chemical	117	120	5	D002819	chorea	Disease	169	170	8	1:NR:2	L2R	CROSS	139-140	158-159	D015016	yohimbine	Chemical	139	140	6	D020821	dystonic|dystonic	Disease	158:166	159:167	7:8	1:NR:2	L2R	CROSS	139-140	169-170	D015016	yohimbine	Chemical	139	140	6	D002819	chorea	Disease	169	170	8	1:NR:2	L2R	CROSS	141-142	158-159	D008614	meperidine	Chemical	141	142	6	D020821	dystonic|dystonic	Disease	158:166	159:167	7:8	1:NR:2	L2R	CROSS	141-142	169-170	D008614	meperidine	Chemical	141	142	6	D002819	chorea	Disease	169	170	8	1:NR:2	L2R	NON-CROSS	148-149	158-159	D001418	Baclofen	Chemical	148	149	7	D020821	dystonic|dystonic	Disease	158:166	159:167	7:8	1:NR:2	L2R	CROSS	148-149	169-170	D001418	Baclofen	Chemical	148	149	7	D002819	chorea	Disease	169	170	8	1:NR:2	R2L	NON-CROSS	166-167	163-164	D001285	Atropine	Chemical	163	164	8	D020821	dystonic|dystonic	Disease	158:166	159:167	7:8	1:NR:2	L2R	NON-CROSS	163-164	169-170	D001285	Atropine	Chemical	163	164	8	D002819	chorea	Disease	169	170	8
21418164	CCNU ( lomustine ) toxicity in dogs : a retrospective study ( 2002 - 07 ) .|OBJECTIVE : To describe the incidence of haematological , renal , hepatic and gastrointestinal toxicities in tumour - bearing dogs receiving 1 - ( 2 - chloroethyl ) - 3 - cyclohexyl - 1 - nitrosourea ( CCNU ) .|DESIGN : The medical records of 206 dogs that were treated with CCNU at the Melbourne Veterinary Specialist Centre between February 2002 and December 2007 were retrospectively evaluated .|RESULTS : Of the 206 dogs treated with CCNU , 185 met the inclusion criteria for at least one class of toxicity .|CCNU was used most commonly in the treatment of lymphoma , mast cell tumour , brain tumour , histiocytic tumours and epitheliotropic lymphoma .|Throughout treatment , 56 . 9 % of dogs experienced neutropenia , 34 . 2 % experienced anaemia and 14 . 2 % experienced thrombocytopenia .|Gastrointestinal toxicosis was detected in 37 . 8 % of dogs , the most common sign of which was vomiting ( 24 . 3 % ) .|Potential renal toxicity and elevated alanine transaminase ( ALT ) concentration were reported in 12 . 2 % and 48 . 8 % of dogs , respectively .|The incidence of hepatic failure was 1 . 2 % .|CONCLUSIONS : CCNU - associated toxicity in dogs is common , but is usually not life threatening .	1:NR:2	L2R	NON-CROSS	2-3	4-5	D008130	CCNU|lomustine|1 - ( 2 - chloroethyl ) - 3 - cyclohexyl - 1 - nitrosourea|CCNU|CCNU|CCNU|CCNU|CCNU	Chemical	0:2:38:54:69:94:109:227	1:3:53:55:70:95:110:228	0:0:1:1:2:3:4:9	D064420	toxicity|toxicity|toxicity|toxicity	Disease	4:107:188:230	5:108:189:231	0:3:7:9	1:NR:2	L2R	NON-CROSS	24-32	54-55	D008130	CCNU|lomustine|1 - ( 2 - chloroethyl ) - 3 - cyclohexyl - 1 - nitrosourea|CCNU|CCNU|CCNU|CCNU|CCNU	Chemical	0:2:38:54:69:94:109:227	1:3:53:55:70:95:110:228	0:0:1:1:2:3:4:9	D006402	haematological , renal , hepatic and gastrointestinal toxicities	Disease	24	32	1	1:CID:2	L2R	NON-CROSS	24-32	54-55	D008130	CCNU|lomustine|1 - ( 2 - chloroethyl ) - 3 - cyclohexyl - 1 - nitrosourea|CCNU|CCNU|CCNU|CCNU|CCNU	Chemical	0:2:38:54:69:94:109:227	1:3:53:55:70:95:110:228	0:0:1:1:2:3:4:9	D007674	haematological , renal , hepatic and gastrointestinal toxicities	Disease	24	32	1	1:NR:2	L2R	NON-CROSS	24-32	54-55	D008130	CCNU|lomustine|1 - ( 2 - chloroethyl ) - 3 - cyclohexyl - 1 - nitrosourea|CCNU|CCNU|CCNU|CCNU|CCNU	Chemical	0:2:38:54:69:94:109:227	1:3:53:55:70:95:110:228	0:0:1:1:2:3:4:9	D056486	haematological , renal , hepatic and gastrointestinal toxicities	Disease	24	32	1	1:CID:2	L2R	NON-CROSS	24-32	54-55	D008130	CCNU|lomustine|1 - ( 2 - chloroethyl ) - 3 - cyclohexyl - 1 - nitrosourea|CCNU|CCNU|CCNU|CCNU|CCNU	Chemical	0:2:38:54:69:94:109:227	1:3:53:55:70:95:110:228	0:0:1:1:2:3:4:9	D005767	haematological , renal , hepatic and gastrointestinal toxicities|Gastrointestinal toxicosis	Disease	24:159	32:161	1:6	1:NR:2	L2R	NON-CROSS	109-110	118-119	D008130	CCNU|lomustine|1 - ( 2 - chloroethyl ) - 3 - cyclohexyl - 1 - nitrosourea|CCNU|CCNU|CCNU|CCNU|CCNU	Chemical	0:2:38:54:69:94:109:227	1:3:53:55:70:95:110:228	0:0:1:1:2:3:4:9	D008223	lymphoma|epitheliotropic lymphoma	Disease	118:130	119:132	4:4	1:NR:2	L2R	NON-CROSS	109-110	120-123	D008130	CCNU|lomustine|1 - ( 2 - chloroethyl ) - 3 - cyclohexyl - 1 - nitrosourea|CCNU|CCNU|CCNU|CCNU|CCNU	Chemical	0:2:38:54:69:94:109:227	1:3:53:55:70:95:110:228	0:0:1:1:2:3:4:9	D034801	mast cell tumour	Disease	120	123	4	1:NR:2	L2R	NON-CROSS	109-110	124-126	D008130	CCNU|lomustine|1 - ( 2 - chloroethyl ) - 3 - cyclohexyl - 1 - nitrosourea|CCNU|CCNU|CCNU|CCNU|CCNU	Chemical	0:2:38:54:69:94:109:227	1:3:53:55:70:95:110:228	0:0:1:1:2:3:4:9	D001932	brain tumour	Disease	124	126	4	1:NR:2	L2R	NON-CROSS	109-110	127-129	D008130	CCNU|lomustine|1 - ( 2 - chloroethyl ) - 3 - cyclohexyl - 1 - nitrosourea|CCNU|CCNU|CCNU|CCNU|CCNU	Chemical	0:2:38:54:69:94:109:227	1:3:53:55:70:95:110:228	0:0:1:1:2:3:4:9	D015620	histiocytic tumours	Disease	127	129	4	1:CID:2	L2R	CROSS	109-110	143-144	D008130	CCNU|lomustine|1 - ( 2 - chloroethyl ) - 3 - cyclohexyl - 1 - nitrosourea|CCNU|CCNU|CCNU|CCNU|CCNU	Chemical	0:2:38:54:69:94:109:227	1:3:53:55:70:95:110:228	0:0:1:1:2:3:4:9	D009503	neutropenia	Disease	143	144	5	1:CID:2	L2R	CROSS	109-110	150-151	D008130	CCNU|lomustine|1 - ( 2 - chloroethyl ) - 3 - cyclohexyl - 1 - nitrosourea|CCNU|CCNU|CCNU|CCNU|CCNU	Chemical	0:2:38:54:69:94:109:227	1:3:53:55:70:95:110:228	0:0:1:1:2:3:4:9	D000740	anaemia	Disease	150	151	5	1:CID:2	L2R	CROSS	109-110	157-158	D008130	CCNU|lomustine|1 - ( 2 - chloroethyl ) - 3 - cyclohexyl - 1 - nitrosourea|CCNU|CCNU|CCNU|CCNU|CCNU	Chemical	0:2:38:54:69:94:109:227	1:3:53:55:70:95:110:228	0:0:1:1:2:3:4:9	D013921	thrombocytopenia	Disease	157	158	5	1:CID:2	L2R	CROSS	178-179	227-228	D008130	CCNU|lomustine|1 - ( 2 - chloroethyl ) - 3 - cyclohexyl - 1 - nitrosourea|CCNU|CCNU|CCNU|CCNU|CCNU	Chemical	0:2:38:54:69:94:109:227	1:3:53:55:70:95:110:228	0:0:1:1:2:3:4:9	D014839	vomiting	Disease	178	179	6	1:CID:2	L2R	CROSS	217-219	227-228	D008130	CCNU|lomustine|1 - ( 2 - chloroethyl ) - 3 - cyclohexyl - 1 - nitrosourea|CCNU|CCNU|CCNU|CCNU|CCNU	Chemical	0:2:38:54:69:94:109:227	1:3:53:55:70:95:110:228	0:0:1:1:2:3:4:9	D017093	hepatic failure	Disease	217	219	8	1:NR:2	R2L	NON-CROSS	191-192	188-189	D000409	alanine	Chemical	191	192	7	D064420	toxicity|toxicity|toxicity|toxicity	Disease	4:107:188:230	5:108:189:231	0:3:7:9	1:NR:2	R2L	CROSS	191-192	24-32	D000409	alanine	Chemical	191	192	7	D006402	haematological , renal , hepatic and gastrointestinal toxicities	Disease	24	32	1	1:NR:2	R2L	CROSS	191-192	24-32	D000409	alanine	Chemical	191	192	7	D007674	haematological , renal , hepatic and gastrointestinal toxicities	Disease	24	32	1	1:NR:2	R2L	CROSS	191-192	24-32	D000409	alanine	Chemical	191	192	7	D056486	haematological , renal , hepatic and gastrointestinal toxicities	Disease	24	32	1	1:NR:2	R2L	CROSS	191-192	159-161	D000409	alanine	Chemical	191	192	7	D005767	haematological , renal , hepatic and gastrointestinal toxicities|Gastrointestinal toxicosis	Disease	24:159	32:161	1:6	1:NR:2	R2L	CROSS	191-192	130-132	D000409	alanine	Chemical	191	192	7	D008223	lymphoma|epitheliotropic lymphoma	Disease	118:130	119:132	4:4	1:NR:2	R2L	CROSS	191-192	120-123	D000409	alanine	Chemical	191	192	7	D034801	mast cell tumour	Disease	120	123	4	1:NR:2	R2L	CROSS	191-192	124-126	D000409	alanine	Chemical	191	192	7	D001932	brain tumour	Disease	124	126	4	1:NR:2	R2L	CROSS	191-192	127-129	D000409	alanine	Chemical	191	192	7	D015620	histiocytic tumours	Disease	127	129	4	1:NR:2	R2L	CROSS	191-192	143-144	D000409	alanine	Chemical	191	192	7	D009503	neutropenia	Disease	143	144	5	1:NR:2	R2L	CROSS	191-192	150-151	D000409	alanine	Chemical	191	192	7	D000740	anaemia	Disease	150	151	5	1:NR:2	R2L	CROSS	191-192	157-158	D000409	alanine	Chemical	191	192	7	D013921	thrombocytopenia	Disease	157	158	5	1:NR:2	R2L	CROSS	191-192	178-179	D000409	alanine	Chemical	191	192	7	D014839	vomiting	Disease	178	179	6	1:NR:2	L2R	CROSS	191-192	217-219	D000409	alanine	Chemical	191	192	7	D017093	hepatic failure	Disease	217	219	8
9121607	Neuroactive steroids protect against pilocarpine - and kainic acid - induced limbic seizures and status epilepticus in mice .|Several structurally related metabolites of progesterone ( 3 alpha - hydroxy pregnane - 20 - ones ) and deoxycorticosterone ( 3 alpha - hydroxy pregnane - 21 - diol - 20 - ones ) and their 3 beta - epimers were evaluated for protective activity against pilocarpine - , kainic acid - and N - methyl - D - aspartate ( NMDA ) - induced seizures in mice .|Steroids with the 3 - hydroxy group in the alpha - position and 5 - H in the alpha - or beta - configurations were highly effective in protecting against pilocarpine ( 416 mg / kg , s . c . ) - induced limbic motor seizures and status epilepticus ( ED50 values , 7 . 0 - 18 . 7 mg / kg , i . p . ) .|The corresponding epimers with the 3 - hydroxy group in the beta - position were also effective but less potent ( ED50 values , 33 . 8 - 63 . 5 , i . p . ) .|Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures , steroids with the 5 alpha , 3 alpha - configuration had comparable or higher protective index values ( TD50 for motor impairment divided by ED50 for seizure protection ) than clonazepam , indicating that some neuroactive steroids may have lower relative toxicity .|Steroids with the 5 alpha , 3 alpha - or 5 beta , 3 alpha - configurations also produced a dose - dependent delay in the onset of limbic seizures induced by kainic acid ( 32 mg / kg , s . c . ) , but did not completely protect against the seizures .|However , when a second dose of the steroid was administered 1 hr after the first dose , complete protection from the kainic acid - induced limbic seizures and status epilepticus was obtained .|The steroids also caused a dose - dependent delay in NMDA ( 257 mg / kg , s . c . ) - induced lethality , but did not completely protect against NMDA seizures or lethality .|We conclude that neuroactive steroids are highly effective in protecting against pilocarpine - and kainic acid - induced seizures and status epilepticus in mice , and may be of utility in the treatment of some forms of status epilepticus in humans .	1:NR:2	L2R	NON-CROSS	213-214	215-216	D013256	steroids|Steroids|steroids|steroids|steroids|Steroids|steroid|steroids|steroids	Chemical	1:88:200:215:251:258:321:348:388	2:89:201:216:252:259:322:349:389	0:2:4:4:4:5:6:7:8	D012640	seizures|seizures|seizures|seizures|seizure|seizures|seizures|seizures|seizures|seizures	Disease	12:84:134:213:241:287:311:340:380:402	13:85:135:214:242:288:312:341:381:403	0:1:2:4:4:5:5:6:7:8	1:NR:2	L2R	NON-CROSS	342-344	348-349	D013256	steroids|Steroids|steroids|steroids|steroids|Steroids|steroid|steroids|steroids	Chemical	1:88:200:215:251:258:321:348:388	2:89:201:216:252:259:322:349:389	0:2:4:4:4:5:6:7:8	D013226	status epilepticus|status epilepticus|status epilepticus|status epilepticus|status epilepticus	Disease	14:136:342:404:421	16:138:344:406:423	0:2:6:8:8	1:NR:2	L2R	NON-CROSS	256-257	258-259	D013256	steroids|Steroids|steroids|steroids|steroids|Steroids|steroid|steroids|steroids	Chemical	1:88:200:215:251:258:321:348:388	2:89:201:216:252:259:322:349:389	0:2:4:4:4:5:6:7:8	D064420	toxicity	Disease	256	257	4	1:CID:2	L2R	NON-CROSS	212-213	213-214	D010862	pilocarpine|pilocarpine|pilocarpine|pilocarpine|pilocarpine	Chemical	4:65:118:212:395	5:66:119:213:396	0:1:2:4:8	D012640	seizures|seizures|seizures|seizures|seizure|seizures|seizures|seizures|seizures|seizures	Disease	12:84:134:213:241:287:311:340:380:402	13:85:135:214:242:288:312:341:381:403	0:1:2:4:4:5:5:6:7:8	1:CID:2	L2R	NON-CROSS	395-396	404-406	D010862	pilocarpine|pilocarpine|pilocarpine|pilocarpine|pilocarpine	Chemical	4:65:118:212:395	5:66:119:213:396	0:1:2:4:8	D013226	status epilepticus|status epilepticus|status epilepticus|status epilepticus|status epilepticus	Disease	14:136:342:404:421	16:138:344:406:423	0:2:6:8:8	1:NR:2	L2R	NON-CROSS	212-213	256-257	D010862	pilocarpine|pilocarpine|pilocarpine|pilocarpine|pilocarpine	Chemical	4:65:118:212:395	5:66:119:213:396	0:1:2:4:8	D064420	toxicity	Disease	256	257	4	1:CID:2	L2R	NON-CROSS	398-400	402-403	D007608	kainic acid|kainic acid|kainic acid|kainic acid|kainic acid	Chemical	7:68:290:335:398	9:70:292:337:400	0:1:5:6:8	D012640	seizures|seizures|seizures|seizures|seizure|seizures|seizures|seizures|seizures|seizures	Disease	12:84:134:213:241:287:311:340:380:402	13:85:135:214:242:288:312:341:381:403	0:1:2:4:4:5:5:6:7:8	1:CID:2	L2R	NON-CROSS	398-400	404-406	D007608	kainic acid|kainic acid|kainic acid|kainic acid|kainic acid	Chemical	7:68:290:335:398	9:70:292:337:400	0:1:5:6:8	D013226	status epilepticus|status epilepticus|status epilepticus|status epilepticus|status epilepticus	Disease	14:136:342:404:421	16:138:344:406:423	0:2:6:8:8	1:NR:2	L2R	CROSS	256-257	290-292	D007608	kainic acid|kainic acid|kainic acid|kainic acid|kainic acid	Chemical	7:68:290:335:398	9:70:292:337:400	0:1:5:6:8	D064420	toxicity	Disease	256	257	4	1:NR:2	R2L	NON-CROSS	24-25	12-13	D011374	progesterone|3 alpha - hydroxy pregnane - 20 - ones	Chemical	24:26	25:35	1:1	D012640	seizures|seizures|seizures|seizures|seizure|seizures|seizures|seizures|seizures|seizures	Disease	12:84:134:213:241:287:311:340:380:402	13:85:135:214:242:288:312:341:381:403	0:1:2:4:4:5:5:6:7:8	1:NR:2	R2L	NON-CROSS	37-38	12-13	D003900	deoxycorticosterone|3 alpha - hydroxy pregnane - 21 - diol - 20 - ones	Chemical	37:39	38:52	1:1	D012640	seizures|seizures|seizures|seizures|seizure|seizures|seizures|seizures|seizures|seizures	Disease	12:84:134:213:241:287:311:340:380:402	13:85:135:214:242:288:312:341:381:403	0:1:2:4:4:5:5:6:7:8	1:NR:2	R2L	NON-CROSS	380-381	379-380	D016202	N - methyl - D - aspartate|NMDA|NMDA|NMDA	Chemical	72:80:357:379	79:81:358:380	1:1:7:7	D012640	seizures|seizures|seizures|seizures|seizure|seizures|seizures|seizures|seizures|seizures	Disease	12:84:134:213:241:287:311:340:380:402	13:85:135:214:242:288:312:341:381:403	0:1:2:4:4:5:5:6:7:8	1:NR:2	R2L	NON-CROSS	213-214	207-208	D001569	benzodiazepine	Chemical	207	208	4	D012640	seizures|seizures|seizures|seizures|seizure|seizures|seizures|seizures|seizures|seizures	Disease	12:84:134:213:241:287:311:340:380:402	13:85:135:214:242:288:312:341:381:403	0:1:2:4:4:5:5:6:7:8	1:NR:2	R2L	NON-CROSS	245-246	241-242	D002998	clonazepam|clonazepam	Chemical	208:245	209:246	4:4	D012640	seizures|seizures|seizures|seizures|seizure|seizures|seizures|seizures|seizures|seizures	Disease	12:84:134:213:241:287:311:340:380:402	13:85:135:214:242:288:312:341:381:403	0:1:2:4:4:5:5:6:7:8	1:NR:2	R2L	CROSS	24-25	14-16	D011374	progesterone|3 alpha - hydroxy pregnane - 20 - ones	Chemical	24:26	25:35	1:1	D013226	status epilepticus|status epilepticus|status epilepticus|status epilepticus|status epilepticus	Disease	14:136:342:404:421	16:138:344:406:423	0:2:6:8:8	1:NR:2	R2L	CROSS	37-38	14-16	D003900	deoxycorticosterone|3 alpha - hydroxy pregnane - 21 - diol - 20 - ones	Chemical	37:39	38:52	1:1	D013226	status epilepticus|status epilepticus|status epilepticus|status epilepticus|status epilepticus	Disease	14:136:342:404:421	16:138:344:406:423	0:2:6:8:8	1:NR:2	R2L	CROSS	357-358	342-344	D016202	N - methyl - D - aspartate|NMDA|NMDA|NMDA	Chemical	72:80:357:379	79:81:358:380	1:1:7:7	D013226	status epilepticus|status epilepticus|status epilepticus|status epilepticus|status epilepticus	Disease	14:136:342:404:421	16:138:344:406:423	0:2:6:8:8	1:NR:2	R2L	CROSS	207-208	136-138	D001569	benzodiazepine	Chemical	207	208	4	D013226	status epilepticus|status epilepticus|status epilepticus|status epilepticus|status epilepticus	Disease	14:136:342:404:421	16:138:344:406:423	0:2:6:8:8	1:NR:2	R2L	CROSS	208-209	136-138	D002998	clonazepam|clonazepam	Chemical	208:245	209:246	4:4	D013226	status epilepticus|status epilepticus|status epilepticus|status epilepticus|status epilepticus	Disease	14:136:342:404:421	16:138:344:406:423	0:2:6:8:8	1:NR:2	L2R	CROSS	26-35	256-257	D011374	progesterone|3 alpha - hydroxy pregnane - 20 - ones	Chemical	24:26	25:35	1:1	D064420	toxicity	Disease	256	257	4	1:NR:2	L2R	CROSS	39-52	256-257	D003900	deoxycorticosterone|3 alpha - hydroxy pregnane - 21 - diol - 20 - ones	Chemical	37:39	38:52	1:1	D064420	toxicity	Disease	256	257	4	1:NR:2	L2R	CROSS	256-257	357-358	D016202	N - methyl - D - aspartate|NMDA|NMDA|NMDA	Chemical	72:80:357:379	79:81:358:380	1:1:7:7	D064420	toxicity	Disease	256	257	4	1:NR:2	L2R	NON-CROSS	207-208	256-257	D001569	benzodiazepine	Chemical	207	208	4	D064420	toxicity	Disease	256	257	4	1:NR:2	L2R	NON-CROSS	245-246	256-257	D002998	clonazepam|clonazepam	Chemical	208:245	209:246	4:4	D064420	toxicity	Disease	256	257	4
7905523	The safety and efficacy of combination N - butyl - deoxynojirimycin ( SC - 48334 ) and zidovudine in patients with HIV - 1 infection and 200 - 500 CD4 cells / mm3 .|We conducted a double - blind , randomized phase II study to evaluate the safety and activity of combination therapy with N - butyl - deoxynojirimycin ( SC - 48334 ) ( an alpha - glucosidase I inhibitor ) and zidovudine versus zidovudine alone .|Patients with 200 to 500 CD4 cells / mm3 who tolerated < or = 12 weeks of prior zidovudine therapy received SC - 48334 ( 1000 mg every 8 h ) and zidovudine ( 100 mg every 8 h ) or zidovudine and placebo .|Sixty patients received combination therapy and 58 , zidovudine and placebo .|Twenty - three patients ( 38 % ) and 15 ( 26 % ) , in the combination and zidovudine groups , respectively , discontinued therapy ( p = 0 . 15 ) .|The mean SC - 48334 steady - state trough level ( 4 . 04 + / - 0 . 99 micrograms / ml ) was below the in vitro inhibitory concentration for human immunodeficiency virus ( HIV ) .|The mean increase in CD4 cells at week 4 was 73 . 8 cells / mm3 and 52 . 4 cells / mm3 for the combination and zidovudine groups , respectively ( p > 0 . 36 ) .|For patients with prior zidovudine therapy , the mean change in CD4 cells in the combination and zidovudine groups was 63 . 7 cells / mm3 and 4 . 9 cells / mm3 at week 8 and 6 . 8 cells / mm3 and - 45 . 1 cells / mm3 at week 16 , respectively .|The number of patients with suppression of HIV p24 antigenemia in the combination and zidovudine groups was six ( 40 % ) and two ( 11 % ) at week 4 ( p = 0 . 10 ) and five ( 45 % ) and two ( 14 % ) at week 24 ( p = 0 . 08 ) , respectively .|Diarrhea , flatulence , abdominal pain , and weight loss were common for combination recipients . ( ABSTRACT TRUNCATED AT 250 WORDS )	1:NR:2	L2R	NON-CROSS	12-15	21-25	C059896	N - butyl - deoxynojirimycin|SC - 48334|N - butyl - deoxynojirimycin|SC - 48334|SC - 48334|SC - 48334	Chemical	6:12:55:61:100:172	11:15:60:64:103:175	0:0:1:1:2:5	D015658	HIV - 1 infection	Disease	21	25	0	1:NR:2	L2R	NON-CROSS	172-175	203-204	C059896	N - butyl - deoxynojirimycin|SC - 48334|N - butyl - deoxynojirimycin|SC - 48334|SC - 48334|SC - 48334	Chemical	6:12:55:61:100:172	11:15:60:64:103:175	0:0:1:1:2:5	D007153	immunodeficiency	Disease	203	204	5	1:CID:2	L2R	CROSS	172-175	368-369	C059896	N - butyl - deoxynojirimycin|SC - 48334|N - butyl - deoxynojirimycin|SC - 48334|SC - 48334|SC - 48334	Chemical	6:12:55:61:100:172	11:15:60:64:103:175	0:0:1:1:2:5	D003967	Diarrhea	Disease	368	369	9	1:CID:2	L2R	CROSS	172-175	370-371	C059896	N - butyl - deoxynojirimycin|SC - 48334|N - butyl - deoxynojirimycin|SC - 48334|SC - 48334|SC - 48334	Chemical	6:12:55:61:100:172	11:15:60:64:103:175	0:0:1:1:2:5	D005414	flatulence	Disease	370	371	9	1:CID:2	L2R	CROSS	172-175	372-374	C059896	N - butyl - deoxynojirimycin|SC - 48334|N - butyl - deoxynojirimycin|SC - 48334|SC - 48334|SC - 48334	Chemical	6:12:55:61:100:172	11:15:60:64:103:175	0:0:1:1:2:5	D015746	abdominal pain	Disease	372	374	9	1:CID:2	L2R	CROSS	172-175	376-378	C059896	N - butyl - deoxynojirimycin|SC - 48334|N - butyl - deoxynojirimycin|SC - 48334|SC - 48334|SC - 48334	Chemical	6:12:55:61:100:172	11:15:60:64:103:175	0:0:1:1:2:5	D015431	weight loss	Disease	376	378	9	1:NR:2	L2R	NON-CROSS	17-18	21-25	D015215	zidovudine|zidovudine|zidovudine|zidovudine|zidovudine|zidovudine|zidovudine|zidovudine|zidovudine|zidovudine|zidovudine|zidovudine	Chemical	17:74:76:97:111:120:132:155:236:252:265:319	18:75:77:98:112:121:133:156:237:253:266:320	0:1:1:2:2:2:3:4:6:7:7:8	D015658	HIV - 1 infection	Disease	21	25	0	1:NR:2	L2R	CROSS	203-204	236-237	D015215	zidovudine|zidovudine|zidovudine|zidovudine|zidovudine|zidovudine|zidovudine|zidovudine|zidovudine|zidovudine|zidovudine|zidovudine	Chemical	17:74:76:97:111:120:132:155:236:252:265:319	18:75:77:98:112:121:133:156:237:253:266:320	0:1:1:2:2:2:3:4:6:7:7:8	D007153	immunodeficiency	Disease	203	204	5	1:CID:2	L2R	CROSS	319-320	368-369	D015215	zidovudine|zidovudine|zidovudine|zidovudine|zidovudine|zidovudine|zidovudine|zidovudine|zidovudine|zidovudine|zidovudine|zidovudine	Chemical	17:74:76:97:111:120:132:155:236:252:265:319	18:75:77:98:112:121:133:156:237:253:266:320	0:1:1:2:2:2:3:4:6:7:7:8	D003967	Diarrhea	Disease	368	369	9	1:CID:2	L2R	CROSS	319-320	370-371	D015215	zidovudine|zidovudine|zidovudine|zidovudine|zidovudine|zidovudine|zidovudine|zidovudine|zidovudine|zidovudine|zidovudine|zidovudine	Chemical	17:74:76:97:111:120:132:155:236:252:265:319	18:75:77:98:112:121:133:156:237:253:266:320	0:1:1:2:2:2:3:4:6:7:7:8	D005414	flatulence	Disease	370	371	9	1:CID:2	L2R	CROSS	319-320	372-374	D015215	zidovudine|zidovudine|zidovudine|zidovudine|zidovudine|zidovudine|zidovudine|zidovudine|zidovudine|zidovudine|zidovudine|zidovudine	Chemical	17:74:76:97:111:120:132:155:236:252:265:319	18:75:77:98:112:121:133:156:237:253:266:320	0:1:1:2:2:2:3:4:6:7:7:8	D015746	abdominal pain	Disease	372	374	9	1:CID:2	L2R	CROSS	319-320	376-378	D015215	zidovudine|zidovudine|zidovudine|zidovudine|zidovudine|zidovudine|zidovudine|zidovudine|zidovudine|zidovudine|zidovudine|zidovudine	Chemical	17:74:76:97:111:120:132:155:236:252:265:319	18:75:77:98:112:121:133:156:237:253:266:320	0:1:1:2:2:2:3:4:6:7:7:8	D015431	weight loss	Disease	376	378	9
3431591	Recent preclinical and clinical studies with the thymidylate synthase inhibitor N10 - propargyl - 5 , 8 - dideazafolic acid ( CB 3717 ) .|CB 3717 , N10 - propargyl - 5 , 8 - dideazafolic acid , is a tight - binding inhibitor of thymidylate synthase ( TS ) whose cytotoxicity is mediated solely through the inhibition of this enzyme .|Recent preclinical studies have focused on the intracellular formation of CB 3717 polyglutamates .|Following a 12 - hour exposure of L1210 cells to 50 microM [ 3H ] CB 3717 , 30 % of the extractable radioactivity could be accounted for as CB 3717 tetra - and pentaglutamate , as determined by high - pressure liquid chromatography ( HPLC ) analyses .|As inhibitors of isolated L1210 TS , CB 3717 di - , tri - , tetra - and pentaglutamate are 26 - , 87 - , 119 - and 114 - fold more potent than CB 3717 , respectively , and their formation may , therefore , be an important determinant of CB 3717 cytotoxicity .|In early clinical studies with CB 3717 , activity has been seen in breast cancer , ovarian cancer , hepatoma , and mesothelioma .|Toxicities included hepatotoxicity , malaise , and dose - limiting nephrotoxicity .|This latter effect is thought to be due to drug precipitation within the renal tubule as a result of the poor solubility of CB 3717 under acidic conditions .|In an attempt to overcome this problem , a clinical trial of CB 3717 administered with alkaline diuresis is under way .|Preliminary results at 400 and 500 mg / m2 suggest that a reduction in nephrotoxicity may have been achieved with only 1 instance of renal toxicity in 10 patients .|Hepatotoxicity and malaise are again the most frequent side effects .|Evidence of antitumor activity has been seen in 3 patients .|Pharmacokinetic investigations have shown that alkaline diuresis does not alter CB 3717 plasma levels or urinary excretion and that satisfactory urinary alkalinization can be readily achieved .	1:NR:2	L2R	NON-CROSS	178-180	180-181	C031662	N10 - propargyl - 5 , 8 - dideazafolic acid|CB 3717|CB 3717|N10 - propargyl - 5 , 8 - dideazafolic acid|CB 3717|CB 3717|CB 3717|CB 3717|CB 3717|CB 3717|CB 3717|CB 3717|CB 3717	Chemical	10:21:25:28:73:92:106:161:178:187:241:259:331	20:23:27:38:75:94:108:163:180:189:243:261:333	0:0:1:1:2:3:3:4:4:5:7:8:12	D064420	cytotoxicity|cytotoxicity|Toxicities	Disease	52:180:206	53:181:207	1:4:6	1:NR:2	L2R	NON-CROSS	187-189	195-197	C031662	N10 - propargyl - 5 , 8 - dideazafolic acid|CB 3717|CB 3717|N10 - propargyl - 5 , 8 - dideazafolic acid|CB 3717|CB 3717|CB 3717|CB 3717|CB 3717|CB 3717|CB 3717|CB 3717|CB 3717	Chemical	10:21:25:28:73:92:106:161:178:187:241:259:331	20:23:27:38:75:94:108:163:180:189:243:261:333	0:0:1:1:2:3:3:4:4:5:7:8:12	D001943	breast cancer	Disease	195	197	5	1:NR:2	L2R	NON-CROSS	187-189	198-200	C031662	N10 - propargyl - 5 , 8 - dideazafolic acid|CB 3717|CB 3717|N10 - propargyl - 5 , 8 - dideazafolic acid|CB 3717|CB 3717|CB 3717|CB 3717|CB 3717|CB 3717|CB 3717|CB 3717|CB 3717	Chemical	10:21:25:28:73:92:106:161:178:187:241:259:331	20:23:27:38:75:94:108:163:180:189:243:261:333	0:0:1:1:2:3:3:4:4:5:7:8:12	D010051	ovarian cancer	Disease	198	200	5	1:NR:2	L2R	NON-CROSS	187-189	201-202	C031662	N10 - propargyl - 5 , 8 - dideazafolic acid|CB 3717|CB 3717|N10 - propargyl - 5 , 8 - dideazafolic acid|CB 3717|CB 3717|CB 3717|CB 3717|CB 3717|CB 3717|CB 3717|CB 3717|CB 3717	Chemical	10:21:25:28:73:92:106:161:178:187:241:259:331	20:23:27:38:75:94:108:163:180:189:243:261:333	0:0:1:1:2:3:3:4:4:5:7:8:12	D006528	hepatoma	Disease	201	202	5	1:NR:2	L2R	NON-CROSS	187-189	204-205	C031662	N10 - propargyl - 5 , 8 - dideazafolic acid|CB 3717|CB 3717|N10 - propargyl - 5 , 8 - dideazafolic acid|CB 3717|CB 3717|CB 3717|CB 3717|CB 3717|CB 3717|CB 3717|CB 3717|CB 3717	Chemical	10:21:25:28:73:92:106:161:178:187:241:259:331	20:23:27:38:75:94:108:163:180:189:243:261:333	0:0:1:1:2:3:3:4:4:5:7:8:12	D008654	mesothelioma	Disease	204	205	5	1:CID:2	L2R	CROSS	187-189	208-209	C031662	N10 - propargyl - 5 , 8 - dideazafolic acid|CB 3717|CB 3717|N10 - propargyl - 5 , 8 - dideazafolic acid|CB 3717|CB 3717|CB 3717|CB 3717|CB 3717|CB 3717|CB 3717|CB 3717|CB 3717	Chemical	10:21:25:28:73:92:106:161:178:187:241:259:331	20:23:27:38:75:94:108:163:180:189:243:261:333	0:0:1:1:2:3:3:4:4:5:7:8:12	D056486	hepatotoxicity|Hepatotoxicity	Disease	208:299	209:300	6:10	1:CID:2	L2R	CROSS	187-189	210-211	C031662	N10 - propargyl - 5 , 8 - dideazafolic acid|CB 3717|CB 3717|N10 - propargyl - 5 , 8 - dideazafolic acid|CB 3717|CB 3717|CB 3717|CB 3717|CB 3717|CB 3717|CB 3717|CB 3717|CB 3717	Chemical	10:21:25:28:73:92:106:161:178:187:241:259:331	20:23:27:38:75:94:108:163:180:189:243:261:333	0:0:1:1:2:3:3:4:4:5:7:8:12	D005221	malaise|malaise	Disease	210:301	211:302	6:10	1:CID:2	L2R	CROSS	259-261	283-284	C031662	N10 - propargyl - 5 , 8 - dideazafolic acid|CB 3717|CB 3717|N10 - propargyl - 5 , 8 - dideazafolic acid|CB 3717|CB 3717|CB 3717|CB 3717|CB 3717|CB 3717|CB 3717|CB 3717|CB 3717	Chemical	10:21:25:28:73:92:106:161:178:187:241:259:331	20:23:27:38:75:94:108:163:180:189:243:261:333	0:0:1:1:2:3:3:4:4:5:7:8:12	D007674	nephrotoxicity|nephrotoxicity|renal toxicity	Disease	216:283:293	217:284:295	6:9:9
33969	Ethopropazine and benztropine in neuroleptic - induced parkinsonism .|In a 12 - week controlled study ethopropazine was compared to benztropine in the treatment of parkinsonism induced by fluphenazine enanthate in 60 schizophrenic outpatients .|Ethopropazine and benztropine were found to be equally effective in controlling parkinsonian symptoms and were as efficacious as procyclidine , their previous antiparkinsonian drug .|However , benztropine treated patients had a significant increase in tardive dyskinesia compared to their condition during procyclindine treatment , and significantly more anxiety and depression than ethopropazine treated patients .|This suggests that benztropine is not the anticholinergic drug of choice in the treatment of neuroleptic - induced parkinsonian symptoms , because of its more toxic central and peripheral atropinic effect .	1:NR:2	L2R	NON-CROSS	0-1	7-8	C084820	Ethopropazine|ethopropazine|Ethopropazine|ethopropazine	Chemical	0:16:35:87	1:17:36:88	0:1:2:3	D010302	parkinsonism|parkinsonism|parkinsonian symptoms|parkinsonian symptoms	Disease	7:25:46:109	8:26:48:111	0:1:2:4	1:NR:2	L2R	NON-CROSS	32-33	35-36	C084820	Ethopropazine|ethopropazine|Ethopropazine|ethopropazine	Chemical	0:16:35:87	1:17:36:88	0:1:2:3	D012559	schizophrenic	Disease	32	33	1	1:NR:2	L2R	NON-CROSS	70-72	87-88	C084820	Ethopropazine|ethopropazine|Ethopropazine|ethopropazine	Chemical	0:16:35:87	1:17:36:88	0:1:2:3	D004409	tardive dyskinesia	Disease	70	72	3	1:NR:2	L2R	NON-CROSS	83-84	87-88	C084820	Ethopropazine|ethopropazine|Ethopropazine|ethopropazine	Chemical	0:16:35:87	1:17:36:88	0:1:2:3	D001008	anxiety	Disease	83	84	3	1:NR:2	L2R	NON-CROSS	85-86	87-88	C084820	Ethopropazine|ethopropazine|Ethopropazine|ethopropazine	Chemical	0:16:35:87	1:17:36:88	0:1:2:3	D003866	depression	Disease	85	86	3	1:NR:2	L2R	NON-CROSS	2-3	7-8	D001590	benztropine|benztropine|benztropine|benztropine|benztropine	Chemical	2:20:37:62:94	3:21:38:63:95	0:1:2:3:4	D010302	parkinsonism|parkinsonism|parkinsonian symptoms|parkinsonian symptoms	Disease	7:25:46:109	8:26:48:111	0:1:2:4	1:NR:2	L2R	NON-CROSS	32-33	37-38	D001590	benztropine|benztropine|benztropine|benztropine|benztropine	Chemical	2:20:37:62:94	3:21:38:63:95	0:1:2:3:4	D012559	schizophrenic	Disease	32	33	1	1:CID:2	L2R	NON-CROSS	62-63	70-72	D001590	benztropine|benztropine|benztropine|benztropine|benztropine	Chemical	2:20:37:62:94	3:21:38:63:95	0:1:2:3:4	D004409	tardive dyskinesia	Disease	70	72	3	1:CID:2	L2R	NON-CROSS	83-84	94-95	D001590	benztropine|benztropine|benztropine|benztropine|benztropine	Chemical	2:20:37:62:94	3:21:38:63:95	0:1:2:3:4	D001008	anxiety	Disease	83	84	3	1:CID:2	L2R	NON-CROSS	85-86	94-95	D001590	benztropine|benztropine|benztropine|benztropine|benztropine	Chemical	2:20:37:62:94	3:21:38:63:95	0:1:2:3:4	D003866	depression	Disease	85	86	3	1:CID:2	R2L	NON-CROSS	28-30	25-26	C017610	fluphenazine enanthate	Chemical	28	30	1	D010302	parkinsonism|parkinsonism|parkinsonian symptoms|parkinsonian symptoms	Disease	7:25:46:109	8:26:48:111	0:1:2:4	1:NR:2	R2L	NON-CROSS	53-54	46-48	D011352	procyclidine|procyclindine	Chemical	53:77	54:78	2:3	D010302	parkinsonism|parkinsonism|parkinsonian symptoms|parkinsonian symptoms	Disease	7:25:46:109	8:26:48:111	0:1:2:4	1:NR:2	L2R	NON-CROSS	28-30	32-33	C017610	fluphenazine enanthate	Chemical	28	30	1	D012559	schizophrenic	Disease	32	33	1	1:NR:2	L2R	CROSS	28-30	70-72	C017610	fluphenazine enanthate	Chemical	28	30	1	D004409	tardive dyskinesia	Disease	70	72	3	1:NR:2	L2R	CROSS	28-30	83-84	C017610	fluphenazine enanthate	Chemical	28	30	1	D001008	anxiety	Disease	83	84	3	1:NR:2	L2R	CROSS	28-30	85-86	C017610	fluphenazine enanthate	Chemical	28	30	1	D003866	depression	Disease	85	86	3	1:NR:2	R2L	CROSS	53-54	32-33	D011352	procyclidine|procyclindine	Chemical	53:77	54:78	2:3	D012559	schizophrenic	Disease	32	33	1	1:NR:2	L2R	NON-CROSS	70-72	77-78	D011352	procyclidine|procyclindine	Chemical	53:77	54:78	2:3	D004409	tardive dyskinesia	Disease	70	72	3	1:NR:2	L2R	NON-CROSS	77-78	83-84	D011352	procyclidine|procyclindine	Chemical	53:77	54:78	2:3	D001008	anxiety	Disease	83	84	3	1:NR:2	L2R	NON-CROSS	77-78	85-86	D011352	procyclidine|procyclindine	Chemical	53:77	54:78	2:3	D003866	depression	Disease	85	86	3
16844102	Effect of alpha - tocopherol and deferoxamine on methamphetamine - induced neurotoxicity .|Methamphetamine ( MA ) - induced dopaminergic neurotoxicity is believed to be associated with the increased formation of free radicals .|This study examined the effect of alpha - tocopherol ( alpha - TC ) , a scavenger of reactive oxygen species , and deferoxamine ( DFO ) , an iron chelator , on the MA - induced neurotoxicity .|Male rats were treated with MA ( 10 mg / kg , every 2 h for four injections ) .|The rat received either alpha - TC ( 20 mg / kg ) intraperitoneally for 3 days and 30 min prior to MA administration or DFO ( 50 mg / kg ) subcutaneously 30 min before MA administration .|The concentrations of dopamine ( DA ) , serotonin and their metabolites decreased significantly after MA administration , which was inhibited by the alpha - TC and DFO pretreatment .|alpha - TC and DFO attenuated the MA - induced hyperthermia as well as the alterations in the locomotor activity .|The level of lipid peroxidation was higher and the reduced glutathione concentration was lower in the MA - treated rats .|These changes were significantly attenuated by alpha - TC and DFO .|This suggests that alpha - TC and DFO ameliorate the MA - induced neuronal damage by decreasing the level of oxidative stress .	1:NR:2	L2R	NON-CROSS	2-5	11-12	D024502	alpha - tocopherol|alpha - tocopherol|alpha - TC|alpha - TC|alpha - TC|alpha - TC|alpha - TC|alpha - TC	Chemical	2:40:44:97:155:162:210:219	5:43:47:100:158:165:213:222	0:2:2:4:5:6:8:9	D020258	neurotoxicity|neurotoxicity|neurotoxicity	Disease	11:20:71	12:21:72	0:1:2	1:NR:2	L2R	NON-CROSS	162-165	172-173	D024502	alpha - tocopherol|alpha - tocopherol|alpha - TC|alpha - TC|alpha - TC|alpha - TC|alpha - TC|alpha - TC	Chemical	2:40:44:97:155:162:210:219	5:43:47:100:158:165:213:222	0:2:2:4:5:6:8:9	D005334	hyperthermia	Disease	172	173	6	1:NR:2	L2R	NON-CROSS	219-222	229-231	D024502	alpha - tocopherol|alpha - tocopherol|alpha - TC|alpha - TC|alpha - TC|alpha - TC|alpha - TC|alpha - TC	Chemical	2:40:44:97:155:162:210:219	5:43:47:100:158:165:213:222	0:2:2:4:5:6:8:9	D009422	neuronal damage	Disease	229	231	9	1:NR:2	L2R	NON-CROSS	6-7	11-12	D003676	deferoxamine|deferoxamine|DFO|DFO|DFO|DFO|DFO|DFO	Chemical	6:57:59:118:159:166:214:223	7:58:60:119:160:167:215:224	0:2:2:4:5:6:8:9	D020258	neurotoxicity|neurotoxicity|neurotoxicity	Disease	11:20:71	12:21:72	0:1:2	1:NR:2	L2R	NON-CROSS	166-167	172-173	D003676	deferoxamine|deferoxamine|DFO|DFO|DFO|DFO|DFO|DFO	Chemical	6:57:59:118:159:166:214:223	7:58:60:119:160:167:215:224	0:2:2:4:5:6:8:9	D005334	hyperthermia	Disease	172	173	6	1:NR:2	L2R	NON-CROSS	223-224	229-231	D003676	deferoxamine|deferoxamine|DFO|DFO|DFO|DFO|DFO|DFO	Chemical	6:57:59:118:159:166:214:223	7:58:60:119:160:167:215:224	0:2:2:4:5:6:8:9	D009422	neuronal damage	Disease	229	231	9	1:NR:2	L2R	NON-CROSS	11-12	13-14	D008694	methamphetamine|Methamphetamine|MA|MA|MA|MA|MA|MA|MA|MA|MA	Chemical	8:13:15:68:78:115:129:147:169:199:226	9:14:16:69:79:116:130:148:170:200:227	0:1:1:2:3:4:4:5:6:7:9	D020258	neurotoxicity|neurotoxicity|neurotoxicity	Disease	11:20:71	12:21:72	0:1:2	1:CID:2	L2R	NON-CROSS	169-170	172-173	D008694	methamphetamine|Methamphetamine|MA|MA|MA|MA|MA|MA|MA|MA|MA	Chemical	8:13:15:68:78:115:129:147:169:199:226	9:14:16:69:79:116:130:148:170:200:227	0:1:1:2:3:4:4:5:6:7:9	D005334	hyperthermia	Disease	172	173	6	1:CID:2	L2R	NON-CROSS	226-227	229-231	D008694	methamphetamine|Methamphetamine|MA|MA|MA|MA|MA|MA|MA|MA|MA	Chemical	8:13:15:68:78:115:129:147:169:199:226	9:14:16:69:79:116:130:148:170:200:227	0:1:1:2:3:4:4:5:6:7:9	D009422	neuronal damage	Disease	229	231	9	1:NR:2	R2L	NON-CROSS	71-72	53-54	D010100	oxygen	Chemical	53	54	2	D020258	neurotoxicity|neurotoxicity|neurotoxicity	Disease	11:20:71	12:21:72	0:1:2	1:NR:2	R2L	NON-CROSS	71-72	63-64	D007501	iron	Chemical	63	64	2	D020258	neurotoxicity|neurotoxicity|neurotoxicity	Disease	11:20:71	12:21:72	0:1:2	1:NR:2	R2L	CROSS	135-136	71-72	D004298	dopamine|DA	Chemical	135:137	136:138	5:5	D020258	neurotoxicity|neurotoxicity|neurotoxicity	Disease	11:20:71	12:21:72	0:1:2	1:NR:2	R2L	CROSS	140-141	71-72	D012701	serotonin	Chemical	140	141	5	D020258	neurotoxicity|neurotoxicity|neurotoxicity	Disease	11:20:71	12:21:72	0:1:2	1:NR:2	R2L	CROSS	193-194	71-72	D005978	glutathione	Chemical	193	194	7	D020258	neurotoxicity|neurotoxicity|neurotoxicity	Disease	11:20:71	12:21:72	0:1:2	1:NR:2	L2R	CROSS	53-54	172-173	D010100	oxygen	Chemical	53	54	2	D005334	hyperthermia	Disease	172	173	6	1:NR:2	L2R	CROSS	53-54	229-231	D010100	oxygen	Chemical	53	54	2	D009422	neuronal damage	Disease	229	231	9	1:NR:2	L2R	CROSS	63-64	172-173	D007501	iron	Chemical	63	64	2	D005334	hyperthermia	Disease	172	173	6	1:NR:2	L2R	CROSS	63-64	229-231	D007501	iron	Chemical	63	64	2	D009422	neuronal damage	Disease	229	231	9	1:NR:2	L2R	CROSS	137-138	172-173	D004298	dopamine|DA	Chemical	135:137	136:138	5:5	D005334	hyperthermia	Disease	172	173	6	1:NR:2	L2R	CROSS	137-138	229-231	D004298	dopamine|DA	Chemical	135:137	136:138	5:5	D009422	neuronal damage	Disease	229	231	9	1:NR:2	L2R	CROSS	140-141	172-173	D012701	serotonin	Chemical	140	141	5	D005334	hyperthermia	Disease	172	173	6	1:NR:2	L2R	CROSS	140-141	229-231	D012701	serotonin	Chemical	140	141	5	D009422	neuronal damage	Disease	229	231	9	1:NR:2	R2L	CROSS	193-194	172-173	D005978	glutathione	Chemical	193	194	7	D005334	hyperthermia	Disease	172	173	6	1:NR:2	L2R	CROSS	193-194	229-231	D005978	glutathione	Chemical	193	194	7	D009422	neuronal damage	Disease	229	231	9
14633084	Use of dexamethasone with mesna for the prevention of ifosfamide - induced hemorrhagic cystitis .|AIM : Hemorrhagic cystitis ( HC ) is a limiting side - effect of chemotherapy with ifosfamide ( IFS ) .|In the study presented here , we investigated the use of dexamethasone in combination with mesna for the prevention of IFS - induced HC .|METHODS : Male Wistar rats ( 150 - 200 g ; 6 rats per group ) were treated with saline or mesna 5 min ( i . p . ) before and 2 and 6 h after ( v . o . ) administration of IFS .|One , two or three doses of mesna were replaced with dexamethasone alone or with dexamethasone plus mesna .|Cystitis was evaluated 24 h after its induction by the changes in bladder wet weight and by macroscopic and microscopic analysis .|RESULTS : The replacement of the last dose or the last two doses of mesna with dexamethasone reduced the increase in bladder wet weight induced by IFS by 84 . 79 % and 89 . 13 % , respectively .|In addition , it almost abolished the macroscopic and microscopic alterations induced by IFS .|Moreover , the addition of dexamethasone to the last two doses of mesna was more efficient than three doses of mesna alone when evaluated microscopically .|CONCLUSION : Dexamethasone in combination with mesna was efficient in blocking IFS - induced HC .|However , the replacement of last two doses of mesna with saline or all of the mesna doses with dexamethasone did not prevent HC .	1:NR:2	L2R	NON-CROSS	265-266	269-270	D003907	dexamethasone|dexamethasone|dexamethasone|dexamethasone|dexamethasone|dexamethasone|Dexamethasone|dexamethasone	Chemical	2:47:119:123:165:209:232:265	3:48:120:124:166:210:233:266	0:2:4:4:6:8:9:10	D006470	hemorrhagic cystitis|Hemorrhagic cystitis|HC|HC|HC|HC	Disease	12:17:20:59:244:269	14:19:21:60:245:270	0:1:1:2:9:10	1:NR:2	L2R	NON-CROSS	123-124	127-128	D003907	dexamethasone|dexamethasone|dexamethasone|dexamethasone|dexamethasone|dexamethasone|Dexamethasone|dexamethasone	Chemical	2:47:119:123:165:209:232:265	3:48:120:124:166:210:233:266	0:2:4:4:6:8:9:10	D003556	hemorrhagic cystitis|Hemorrhagic cystitis|HC|HC|Cystitis|HC|HC	Disease	12:17:20:59:127:244:269	14:19:21:60:128:245:270	0:1:1:2:5:9:10	1:NR:2	L2R	NON-CROSS	262-263	269-270	D015080	mesna|mesna|mesna|mesna|mesna|mesna|mesna|mesna|mesna|mesna|mesna	Chemical	4:51:82:115:125:163:216:224:236:255:262	5:52:83:116:126:164:217:225:237:256:263	0:2:3:4:4:6:8:8:9:10:10	D006470	hemorrhagic cystitis|Hemorrhagic cystitis|HC|HC|HC|HC	Disease	12:17:20:59:244:269	14:19:21:60:245:270	0:1:1:2:9:10	1:NR:2	L2R	NON-CROSS	125-126	127-128	D015080	mesna|mesna|mesna|mesna|mesna|mesna|mesna|mesna|mesna|mesna|mesna	Chemical	4:51:82:115:125:163:216:224:236:255:262	5:52:83:116:126:164:217:225:237:256:263	0:2:3:4:4:6:8:8:9:10:10	D003556	hemorrhagic cystitis|Hemorrhagic cystitis|HC|HC|Cystitis|HC|HC	Disease	12:17:20:59:127:244:269	14:19:21:60:128:245:270	0:1:1:2:5:9:10	1:CID:2	L2R	NON-CROSS	9-10	12-14	D007069	ifosfamide|ifosfamide|IFS|IFS|IFS|IFS|IFS|IFS	Chemical	9:31:33:56:106:175:202:241	10:32:34:57:107:176:203:242	0:1:1:2:3:6:7:9	D006470	hemorrhagic cystitis|Hemorrhagic cystitis|HC|HC|HC|HC	Disease	12:17:20:59:244:269	14:19:21:60:245:270	0:1:1:2:9:10	1:CID:2	L2R	NON-CROSS	9-10	12-14	D007069	ifosfamide|ifosfamide|IFS|IFS|IFS|IFS|IFS|IFS	Chemical	9:31:33:56:106:175:202:241	10:32:34:57:107:176:203:242	0:1:1:2:3:6:7:9	D003556	hemorrhagic cystitis|Hemorrhagic cystitis|HC|HC|Cystitis|HC|HC	Disease	12:17:20:59:127:244:269	14:19:21:60:128:245:270	0:1:1:2:5:9:10
11999899	Behavioral effects of MK - 801 on reserpine - treated mice .|The effects of dizocilpine ( MK - 801 ) , a noncompetitive N - methyl - D - aspartate ( NMDA ) receptor antagonist , were studied on dopamine - related behaviors induced by reserpine treatments .|This study focuses on behavioral syndromes that may used as models for Parkinson 's disease , or tardive dyskinesia , and its response after glutamatergic blockage .|Reserpine ( 1 mg / kg ) , administered once every other day for 4 days , produced increases in orofacial dyskinesia , tongue protrusion and vacuous chewing in mice , which are signs indicative of tardive dyskinesia .|Reserpine also produced tremor and catalepsy , which are signs suggestive of Parkinson 's disease .|MK - 801 ( 0 . 1 mg / kg ) , administered 30 min before the observation test , prevented the vacuous chewing movements , tongue protrusions and catalepsy induced by reserpine .|However , MK - 801 injection produced a significant increase of tremor in reserpine - treated mice .|Reserpine ( 1 mg / kg ) , administered 90 min before the test and followed by apomophine injection ( 0 . 1 mg / kg ) 5 min before the test , did not produce oral dyskinesia in mice .|On the other hand , reserpine induced increases in tremor and catalepsy compared to control mice .|MK - 801 ( 0 . 1 mg / kg ) administration attenuated the catalepsy and tremor induced by reserpine .|Pretreatment with reserpine ( 1 mg / kg ) 24 h before the observation test produced increases in vacuous chewing movements and tongue protrusion , as well as increases in tremor and catalepsy , whereas MK - 801 ( 0 . 1 mg / kg ) injection 90 min before the test reversed the effects of reserpine .|These results show that reserpine produces different and abnormal movements , which are related to dose and schedule employed and can be considered as parkinsonian - like and tardive dsykinesia signs .|The glutamatergic blockage produced by NMDA can restore these signs , such as vacuous chewing movements , tongue protrusions , catalepsy and tremor according to the employed model .	1:NR:2	L2R	CROSS	127-130	131-134	D016291	MK - 801|dizocilpine|MK - 801|MK - 801|MK - 801|MK - 801|MK - 801	Chemical	3:15:17:131:167:241:297	6:16:20:134:170:244:300	0:1:1:5:6:9:10	D010300	Parkinson 's disease|Parkinson 's disease|parkinsonian	Disease	61:127:344	64:130:345	2:4:11	1:NR:2	L2R	CROSS	112-114	131-134	D016291	MK - 801|dizocilpine|MK - 801|MK - 801|MK - 801|MK - 801|MK - 801	Chemical	3:15:17:131:167:241:297	6:16:20:134:170:244:300	0:1:1:5:6:9:10	D004409	tardive dyskinesia|tardive dyskinesia|abnormal movements|tardive dsykinesia	Disease	66:112:328:348	68:114:330:350	2:3:11:11	1:NR:2	L2R	CROSS	219-221	241-244	D016291	MK - 801|dizocilpine|MK - 801|MK - 801|MK - 801|MK - 801|MK - 801	Chemical	3:15:17:131:167:241:297	6:16:20:134:170:244:300	0:1:1:5:6:9:10	D009069	orofacial dyskinesia|oral dyskinesia	Disease	96:219	98:221	3:7	1:NR:2	L2R	NON-CROSS	292-293	297-300	D016291	MK - 801|dizocilpine|MK - 801|MK - 801|MK - 801|MK - 801|MK - 801	Chemical	3:15:17:131:167:241:297	6:16:20:134:170:244:300	0:1:1:5:6:9:10	D014202	tremor|tremor|tremor|tremor|tremor|tremor	Disease	118:176:233:257:292:374	119:177:234:258:293:375	4:6:8:9:10:12	1:NR:2	L2R	NON-CROSS	294-295	297-300	D016291	MK - 801|dizocilpine|MK - 801|MK - 801|MK - 801|MK - 801|MK - 801	Chemical	3:15:17:131:167:241:297	6:16:20:134:170:244:300	0:1:1:5:6:9:10	D002375	catalepsy|catalepsy|catalepsy|catalepsy|catalepsy|catalepsy	Disease	120:160:235:255:294:372	121:161:236:256:295:373	4:5:8:9:10:12	1:NR:2	L2R	NON-CROSS	115-116	127-130	D012110	reserpine|reserpine|Reserpine|Reserpine|reserpine|reserpine|Reserpine|reserpine|reserpine|reserpine|reserpine|reserpine	Chemical	7:46:76:115:163:178:183:229:260:264:318:324	8:47:77:116:164:179:184:230:261:265:319:325	0:1:3:4:5:6:7:8:9:10:10:11	D010300	Parkinson 's disease|Parkinson 's disease|parkinsonian	Disease	61:127:344	64:130:345	2:4:11	1:CID:2	L2R	NON-CROSS	112-114	115-116	D012110	reserpine|reserpine|Reserpine|Reserpine|reserpine|reserpine|Reserpine|reserpine|reserpine|reserpine|reserpine|reserpine	Chemical	7:46:76:115:163:178:183:229:260:264:318:324	8:47:77:116:164:179:184:230:261:265:319:325	0:1:3:4:5:6:7:8:9:10:10:11	D004409	tardive dyskinesia|tardive dyskinesia|abnormal movements|tardive dsykinesia	Disease	66:112:328:348	68:114:330:350	2:3:11:11	1:NR:2	L2R	NON-CROSS	219-221	229-230	D012110	reserpine|reserpine|Reserpine|Reserpine|reserpine|reserpine|Reserpine|reserpine|reserpine|reserpine|reserpine|reserpine	Chemical	7:46:76:115:163:178:183:229:260:264:318:324	8:47:77:116:164:179:184:230:261:265:319:325	0:1:3:4:5:6:7:8:9:10:10:11	D009069	orofacial dyskinesia|oral dyskinesia	Disease	96:219	98:221	3:7	1:CID:2	L2R	NON-CROSS	176-177	178-179	D012110	reserpine|reserpine|Reserpine|Reserpine|reserpine|reserpine|Reserpine|reserpine|reserpine|reserpine|reserpine|reserpine	Chemical	7:46:76:115:163:178:183:229:260:264:318:324	8:47:77:116:164:179:184:230:261:265:319:325	0:1:3:4:5:6:7:8:9:10:10:11	D014202	tremor|tremor|tremor|tremor|tremor|tremor	Disease	118:176:233:257:292:374	119:177:234:258:293:375	4:6:8:9:10:12	1:CID:2	L2R	NON-CROSS	160-161	163-164	D012110	reserpine|reserpine|Reserpine|Reserpine|reserpine|reserpine|Reserpine|reserpine|reserpine|reserpine|reserpine|reserpine	Chemical	7:46:76:115:163:178:183:229:260:264:318:324	8:47:77:116:164:179:184:230:261:265:319:325	0:1:3:4:5:6:7:8:9:10:10:11	D002375	catalepsy|catalepsy|catalepsy|catalepsy|catalepsy|catalepsy	Disease	120:160:235:255:294:372	121:161:236:256:295:373	4:5:8:9:10:12	1:NR:2	L2R	CROSS	344-345	357-358	D016202	N - methyl - D - aspartate|NMDA|NMDA	Chemical	24:32:357	31:33:358	1:1:12	D010300	Parkinson 's disease|Parkinson 's disease|parkinsonian	Disease	61:127:344	64:130:345	2:4:11	1:NR:2	L2R	CROSS	348-350	357-358	D016202	N - methyl - D - aspartate|NMDA|NMDA	Chemical	24:32:357	31:33:358	1:1:12	D004409	tardive dyskinesia|tardive dyskinesia|abnormal movements|tardive dsykinesia	Disease	66:112:328:348	68:114:330:350	2:3:11:11	1:NR:2	L2R	CROSS	32-33	96-98	D016202	N - methyl - D - aspartate|NMDA|NMDA	Chemical	24:32:357	31:33:358	1:1:12	D009069	orofacial dyskinesia|oral dyskinesia	Disease	96:219	98:221	3:7	1:NR:2	L2R	NON-CROSS	357-358	374-375	D016202	N - methyl - D - aspartate|NMDA|NMDA	Chemical	24:32:357	31:33:358	1:1:12	D014202	tremor|tremor|tremor|tremor|tremor|tremor	Disease	118:176:233:257:292:374	119:177:234:258:293:375	4:6:8:9:10:12	1:NR:2	L2R	NON-CROSS	357-358	372-373	D016202	N - methyl - D - aspartate|NMDA|NMDA	Chemical	24:32:357	31:33:358	1:1:12	D002375	catalepsy|catalepsy|catalepsy|catalepsy|catalepsy|catalepsy	Disease	120:160:235:255:294:372	121:161:236:256:295:373	4:5:8:9:10:12	1:NR:2	L2R	CROSS	40-41	61-64	D004298	dopamine	Chemical	40	41	1	D010300	Parkinson 's disease|Parkinson 's disease|parkinsonian	Disease	61:127:344	64:130:345	2:4:11	1:NR:2	L2R	CROSS	40-41	66-68	D004298	dopamine	Chemical	40	41	1	D004409	tardive dyskinesia|tardive dyskinesia|abnormal movements|tardive dsykinesia	Disease	66:112:328:348	68:114:330:350	2:3:11:11	1:NR:2	L2R	CROSS	40-41	96-98	D004298	dopamine	Chemical	40	41	1	D009069	orofacial dyskinesia|oral dyskinesia	Disease	96:219	98:221	3:7	1:NR:2	L2R	CROSS	40-41	118-119	D004298	dopamine	Chemical	40	41	1	D014202	tremor|tremor|tremor|tremor|tremor|tremor	Disease	118:176:233:257:292:374	119:177:234:258:293:375	4:6:8:9:10:12	1:NR:2	L2R	CROSS	40-41	120-121	D004298	dopamine	Chemical	40	41	1	D002375	catalepsy|catalepsy|catalepsy|catalepsy|catalepsy|catalepsy	Disease	120:160:235:255:294:372	121:161:236:256:295:373	4:5:8:9:10:12	1:NR:2	R2L	CROSS	200-201	127-130	D001058	apomophine	Chemical	200	201	7	D010300	Parkinson 's disease|Parkinson 's disease|parkinsonian	Disease	61:127:344	64:130:345	2:4:11	1:NR:2	R2L	CROSS	200-201	112-114	D001058	apomophine	Chemical	200	201	7	D004409	tardive dyskinesia|tardive dyskinesia|abnormal movements|tardive dsykinesia	Disease	66:112:328:348	68:114:330:350	2:3:11:11	1:NR:2	R2L	NON-CROSS	219-221	200-201	D001058	apomophine	Chemical	200	201	7	D009069	orofacial dyskinesia|oral dyskinesia	Disease	96:219	98:221	3:7	1:NR:2	R2L	CROSS	200-201	176-177	D001058	apomophine	Chemical	200	201	7	D014202	tremor|tremor|tremor|tremor|tremor|tremor	Disease	118:176:233:257:292:374	119:177:234:258:293:375	4:6:8:9:10:12	1:NR:2	R2L	CROSS	235-236	200-201	D001058	apomophine	Chemical	200	201	7	D002375	catalepsy|catalepsy|catalepsy|catalepsy|catalepsy|catalepsy	Disease	120:160:235:255:294:372	121:161:236:256:295:373	4:5:8:9:10:12
9431903	Effect of glyceryl trinitrate on the sphincter of Oddi spasm evoked by prostigmine - morphine administration .|OBJECTIVE : In this study the effect of glyceryl trinitrate on the prostigmine - morphine - induced sphincter of Oddi spasm was evaluated in nine female patients with sphincter of Oddi dyskinesia .|METHOD : Sphincter of Oddi spasm was induced by prostigmine - morphine administration ( 0 . 5 mg prostigmine intramuscularly and 10 mg morphine subcutaneously ) and visualized by quantitative hepatobiliary scintigraphy .|The entire procedure was repeated during glyceryl trinitrate infusion ( Nitrolingual 1 microg / kg / min for 120 min ) .|RESULTS : Prostigmine - morphine provocation caused significant increases in the time to peak activity ( Tmax ) over the hepatic hilum ( HH : 34 . 33 + / - 5 . 05 vs . 22 . 77 + / - 3 . 26 ) and the common bile duct ( CBD : 60 . 44 + / - 5 . 99 vs . 40 . 0 + / - 2 . 88 ) and in the half - time of excretion ( T1 / 2 ) over the liver parenchyma ( LP : 120 . 04 + / - 16 . 01 vs . 27 . 37 + / - 2 . 19 ) , HH ( 117 . 61 + / - 14 . 71 vs . 31 . 85 + / - 3 . 99 ) and CBD ( 158 . 11 + / - 9 . 18 vs . 40 . 1 + / - 6 . 24 ) , indicating a complete spasm at the level of the sphincter of Oddi .|Glyceryl trinitrate infusion completely normalized the prostigmine - morphine - induced alterations in these quantitative parameters ( TmaX over the LP : 11 . 33 + / - 1 . 13 ; over the HH : 18 . 88 + / - 1 . 48 ; and over the CBD : 36 . 22 + / - 1 . 92 ; and T1 / 2 over the LP : 28 . 21 + / - 1 . 83 ; over the HH : 33 . 42 + / - 3 . 10 ; and over the CBD : 41 . 66 + / - 6 . 33 ) , suggesting an effective sphincter - relaxing effect of glyceryl trinitrate .|CONCLUSION : These results provide the first evidence of the effectiveness of glyceryl trinitrate on the morphine - induced sphincter of Oddi spasm in humans .|Since glyceryl trinitrate is able to overcome even the drastic effect of morphine , it might be of relevance in the treatment of sphincter of Oddi dyskinesia .	1:NR:2	L2R	NON-CROSS	2-4	6-10	D005996	glyceryl trinitrate|glyceryl trinitrate|glyceryl trinitrate|Nitrolingual|Glyceryl trinitrate|glyceryl trinitrate|glyceryl trinitrate|glyceryl trinitrate	Chemical	2:25:89:93:283:400:415:430	4:27:91:94:285:402:417:432	0:1:3:3:5:5:6:7	D046628	sphincter of Oddi spasm|sphincter of Oddi spasm|sphincter of Oddi dyskinesia|Sphincter of Oddi spasm|sphincter of Oddi spasm|sphincter of Oddi dyskinesia	Disease	6:34:45:52:422:452	10:38:49:56:426:456	0:1:1:2:6:7	1:NR:2	L2R	NON-CROSS	2-4	6-10	D005996	glyceryl trinitrate|glyceryl trinitrate|glyceryl trinitrate|Nitrolingual|Glyceryl trinitrate|glyceryl trinitrate|glyceryl trinitrate|glyceryl trinitrate	Chemical	2:25:89:93:283:400:415:430	4:27:91:94:285:402:417:432	0:1:3:3:5:5:6:7	D013035	sphincter of Oddi spasm|sphincter of Oddi spasm|Sphincter of Oddi spasm|spasm|sphincter of Oddi spasm	Disease	6:34:52:273:422	10:38:56:274:426	0:1:2:4:6	1:CID:2	R2L	NON-CROSS	12-13	6-10	D009388	prostigmine|prostigmine|prostigmine|prostigmine|Prostigmine|prostigmine	Chemical	12:29:59:68:107:289	13:30:60:69:108:290	0:1:2:2:4:5	D046628	sphincter of Oddi spasm|sphincter of Oddi spasm|sphincter of Oddi dyskinesia|Sphincter of Oddi spasm|sphincter of Oddi spasm|sphincter of Oddi dyskinesia	Disease	6:34:45:52:422:452	10:38:49:56:426:456	0:1:1:2:6:7	1:CID:2	R2L	NON-CROSS	422-426	419-420	D009020	morphine|morphine|morphine|morphine|morphine|morphine|morphine|morphine	Chemical	14:31:61:73:109:291:419:441	15:32:62:74:110:292:420:442	0:1:2:2:4:5:6:7	D046628	sphincter of Oddi spasm|sphincter of Oddi spasm|sphincter of Oddi dyskinesia|Sphincter of Oddi spasm|sphincter of Oddi spasm|sphincter of Oddi dyskinesia	Disease	6:34:45:52:422:452	10:38:49:56:426:456	0:1:1:2:6:7	1:CID:2	R2L	NON-CROSS	12-13	6-10	D009388	prostigmine|prostigmine|prostigmine|prostigmine|Prostigmine|prostigmine	Chemical	12:29:59:68:107:289	13:30:60:69:108:290	0:1:2:2:4:5	D013035	sphincter of Oddi spasm|sphincter of Oddi spasm|Sphincter of Oddi spasm|spasm|sphincter of Oddi spasm	Disease	6:34:52:273:422	10:38:56:274:426	0:1:2:4:6	1:CID:2	R2L	NON-CROSS	422-426	419-420	D009020	morphine|morphine|morphine|morphine|morphine|morphine|morphine|morphine	Chemical	14:31:61:73:109:291:419:441	15:32:62:74:110:292:420:442	0:1:2:2:4:5:6:7	D013035	sphincter of Oddi spasm|sphincter of Oddi spasm|Sphincter of Oddi spasm|spasm|sphincter of Oddi spasm	Disease	6:34:52:273:422	10:38:56:274:426	0:1:2:4:6
8665051	Effects of acute steroid administration on ventilatory and peripheral muscles in rats .|Occasional case reports have shown that acute myopathy may occur in patients treated with massive doses of corticosteroids .|The mechanism of this myopathy is poorly understood .|Therefore , 60 male rats were randomly assigned to receive daily injection of saline ( C ) , methylprednisolone ( M ) , or triamcinolone ( T ) 80 mg / kg / d for 5 d .|Nutritional intake , measured daily in 15 animals , showed a significant reduction of food intake in the steroid - treated groups ( - 50 and - 79 % in M and T , respectively ) .|This was associated with a similar loss in body weight .|In the 45 remaining animals , diaphragm contractility and histopathologic features of several muscles were studied .|Weights of respiratory and peripheral muscles were similarly decreased after steroid treatment .|Maximal twitches of the diaphragm were lower in the C group ( 653 + / - 174 g / cm ( 2 ) ) than in the M group ( 837 + / - 171 g / cm ( 2 ) ; p < 0 . 05 ) and the T group ( 765 + / - 145 g / cm ( 2 ) , NS ) .|Half - relaxation time was prolonged in both steroid groups , and time to peak tension was longer with M , whereas tetanic tensions were similar .|Steroid treatment also induced a leftward shift of the force - frequency curve at 25 and 50 Hz when compared with saline treatment ( p < 0 . 05 ) .|ATPase staining of the diaphragm , scalenus medius , and gastrocnemius showed type IIb fiber atrophy in the steroid groups and also diaphragmatic type IIa atrophy with T , whereas histologic examinations revealed a normal muscular pattern with absence of necrosis .|Finally , a pair - fed ( PF ) study , performed in 18 rats ( C , T , and PF ) , showed that muscle atrophy was considerably less pronounced in PF animals than in T - treated animals .|We conclude that ( 1 ) short - term treatment with massive doses of steroids induced severe respiratory and limb muscle wasting ; ( 2 ) both types of steroids induced predominantly type IIb atrophy , resulting in the expected alterations in diaphragm contractile properties ; ( 3 ) neither steroid caused muscle necrosis ; ( 4 ) type IIb atrophy was not caused by acute nutritional deprivation alone .	1:NR:2	L2R	CROSS	3-4	20-21	D013256	steroid|steroid|steroid|steroid|Steroid|steroid|steroids|steroids|steroid	Chemical	3:97:154:233:252:301:381:396:417	4:98:155:234:253:302:382:397:418	0:4:7:9:10:11:13:13:13	D009135	myopathy|myopathy	Disease	20:36	21:37	1:2	1:NR:2	L2R	NON-CROSS	91-95	97-98	D013256	steroid|steroid|steroid|steroid|Steroid|steroid|steroids|steroids|steroid	Chemical	3:97:154:233:252:301:381:396:417	4:98:155:234:253:302:382:397:418	0:4:7:9:10:11:13:13:13	D000855	reduction of food intake	Disease	91	95	4	1:NR:2	L2R	CROSS	97-98	122-126	D013256	steroid|steroid|steroid|steroid|Steroid|steroid|steroids|steroids|steroid	Chemical	3:97:154:233:252:301:381:396:417	4:98:155:234:253:302:382:397:418	0:4:7:9:10:11:13:13:13	D015431	loss in body weight	Disease	122	126	5	1:NR:2	L2R	NON-CROSS	247-248	252-253	D013256	steroid|steroid|steroid|steroid|Steroid|steroid|steroids|steroids|steroid	Chemical	3:97:154:233:252:301:381:396:417	4:98:155:234:253:302:382:397:418	0:4:7:9:10:11:13:13:13	D013746	tetanic	Disease	247	248	9	1:NR:2	L2R	NON-CROSS	298-299	301-302	D013256	steroid|steroid|steroid|steroid|Steroid|steroid|steroids|steroids|steroid	Chemical	3:97:154:233:252:301:381:396:417	4:98:155:234:253:302:382:397:418	0:4:7:9:10:11:13:13:13	D009133	atrophy|atrophy|muscle atrophy|atrophy	Disease	298:308:351:427	299:309:353:428	11:11:12:13	1:NR:2	L2R	NON-CROSS	417-418	420-421	D013256	steroid|steroid|steroid|steroid|Steroid|steroid|steroids|steroids|steroid	Chemical	3:97:154:233:252:301:381:396:417	4:98:155:234:253:302:382:397:418	0:4:7:9:10:11:13:13:13	D009336	necrosis|necrosis	Disease	323:420	324:421	11:13	1:NR:2	L2R	NON-CROSS	396-397	401-402	D013256	steroid|steroid|steroid|steroid|Steroid|steroid|steroids|steroids|steroid	Chemical	3:97:154:233:252:301:381:396:417	4:98:155:234:253:302:382:397:418	0:4:7:9:10:11:13:13:13	D001284	atrophy	Disease	401	402	13	1:NR:2	R2L	NON-CROSS	36-37	30-31	D000305	corticosteroids	Chemical	30	31	1	D009135	myopathy|myopathy	Disease	20:36	21:37	1:2	1:NR:2	R2L	CROSS	59-60	36-37	D008775	methylprednisolone|M|M|M|M	Chemical	59:61:109:184:244	60:62:110:185:245	3:3:4:8:9	D009135	myopathy|myopathy	Disease	20:36	21:37	1:2	1:NR:2	R2L	CROSS	65-66	36-37	D014221	triamcinolone|T|T|T|T|T|T	Chemical	65:67:111:207:310:343:362	66:68:112:208:311:344:363	3:3:4:8:11:12:12	D009135	myopathy|myopathy	Disease	20:36	21:37	1:2	1:NR:2	L2R	CROSS	30-31	91-95	D000305	corticosteroids	Chemical	30	31	1	D000855	reduction of food intake	Disease	91	95	4	1:NR:2	L2R	CROSS	30-31	122-126	D000305	corticosteroids	Chemical	30	31	1	D015431	loss in body weight	Disease	122	126	5	1:NR:2	L2R	CROSS	30-31	247-248	D000305	corticosteroids	Chemical	30	31	1	D013746	tetanic	Disease	247	248	9	1:NR:2	L2R	CROSS	30-31	298-299	D000305	corticosteroids	Chemical	30	31	1	D009133	atrophy|atrophy|muscle atrophy|atrophy	Disease	298:308:351:427	299:309:353:428	11:11:12:13	1:NR:2	L2R	CROSS	30-31	323-324	D000305	corticosteroids	Chemical	30	31	1	D009336	necrosis|necrosis	Disease	323:420	324:421	11:13	1:NR:2	L2R	CROSS	30-31	401-402	D000305	corticosteroids	Chemical	30	31	1	D001284	atrophy	Disease	401	402	13	1:CID:2	L2R	NON-CROSS	91-95	109-110	D008775	methylprednisolone|M|M|M|M	Chemical	59:61:109:184:244	60:62:110:185:245	3:3:4:8:9	D000855	reduction of food intake	Disease	91	95	4	1:CID:2	L2R	CROSS	109-110	122-126	D008775	methylprednisolone|M|M|M|M	Chemical	59:61:109:184:244	60:62:110:185:245	3:3:4:8:9	D015431	loss in body weight	Disease	122	126	5	1:NR:2	L2R	NON-CROSS	244-245	247-248	D008775	methylprednisolone|M|M|M|M	Chemical	59:61:109:184:244	60:62:110:185:245	3:3:4:8:9	D013746	tetanic	Disease	247	248	9	1:CID:2	L2R	CROSS	244-245	298-299	D008775	methylprednisolone|M|M|M|M	Chemical	59:61:109:184:244	60:62:110:185:245	3:3:4:8:9	D009133	atrophy|atrophy|muscle atrophy|atrophy	Disease	298:308:351:427	299:309:353:428	11:11:12:13	1:NR:2	L2R	CROSS	244-245	323-324	D008775	methylprednisolone|M|M|M|M	Chemical	59:61:109:184:244	60:62:110:185:245	3:3:4:8:9	D009336	necrosis|necrosis	Disease	323:420	324:421	11:13	1:NR:2	L2R	CROSS	244-245	401-402	D008775	methylprednisolone|M|M|M|M	Chemical	59:61:109:184:244	60:62:110:185:245	3:3:4:8:9	D001284	atrophy	Disease	401	402	13	1:CID:2	L2R	NON-CROSS	91-95	111-112	D014221	triamcinolone|T|T|T|T|T|T	Chemical	65:67:111:207:310:343:362	66:68:112:208:311:344:363	3:3:4:8:11:12:12	D000855	reduction of food intake	Disease	91	95	4	1:CID:2	L2R	CROSS	111-112	122-126	D014221	triamcinolone|T|T|T|T|T|T	Chemical	65:67:111:207:310:343:362	66:68:112:208:311:344:363	3:3:4:8:11:12:12	D015431	loss in body weight	Disease	122	126	5	1:NR:2	L2R	CROSS	207-208	247-248	D014221	triamcinolone|T|T|T|T|T|T	Chemical	65:67:111:207:310:343:362	66:68:112:208:311:344:363	3:3:4:8:11:12:12	D013746	tetanic	Disease	247	248	9	1:CID:2	L2R	NON-CROSS	308-309	310-311	D014221	triamcinolone|T|T|T|T|T|T	Chemical	65:67:111:207:310:343:362	66:68:112:208:311:344:363	3:3:4:8:11:12:12	D009133	atrophy|atrophy|muscle atrophy|atrophy	Disease	298:308:351:427	299:309:353:428	11:11:12:13	1:NR:2	L2R	NON-CROSS	310-311	323-324	D014221	triamcinolone|T|T|T|T|T|T	Chemical	65:67:111:207:310:343:362	66:68:112:208:311:344:363	3:3:4:8:11:12:12	D009336	necrosis|necrosis	Disease	323:420	324:421	11:13	1:NR:2	L2R	CROSS	362-363	401-402	D014221	triamcinolone|T|T|T|T|T|T	Chemical	65:67:111:207:310:343:362	66:68:112:208:311:344:363	3:3:4:8:11:12:12	D001284	atrophy	Disease	401	402	13
7785794	Refractory cardiogenic shock and complete heart block after verapamil SR and metoprolol treatment .|A case report .|A seventy - eight - year - old woman presented with complete heart block and refractory hypotension two days after a therapeutic dose of sustained - release verapamil with concomitant use of metoprolol .|The patient continued to remain hypotensive with complete heart block , even with multiple uses of intravenous atropine as well as high doses of pressor agents such as dopamine and dobutamine .|However , shortly after the use of intravenous calcium chloride , the refractory hypotension and complete heart block resolved .	1:NR:2	R2L	NON-CROSS	8-9	1-3	D014700	verapamil|verapamil	Chemical	8:45	9:46	0:2	D012770	cardiogenic shock	Disease	1	3	0	1:NR:2	R2L	NON-CROSS	11-12	1-3	D008790	metoprolol|metoprolol	Chemical	11:50	12:51	0:2	D012770	cardiogenic shock	Disease	1	3	0	1:NR:2	R2L	CROSS	69-70	1-3	D001285	atropine	Chemical	69	70	3	D012770	cardiogenic shock	Disease	1	3	0	1:NR:2	R2L	CROSS	80-81	1-3	D004298	dopamine	Chemical	80	81	3	D012770	cardiogenic shock	Disease	1	3	0	1:NR:2	R2L	CROSS	82-83	1-3	D004280	dobutamine	Chemical	82	83	3	D012770	cardiogenic shock	Disease	1	3	0	1:NR:2	R2L	CROSS	92-94	1-3	D002122	calcium chloride	Chemical	92	94	4	D012770	cardiogenic shock	Disease	1	3	0	1:CID:2	R2L	NON-CROSS	8-9	5-7	D014700	verapamil|verapamil	Chemical	8:45	9:46	0:2	D006327	heart block|heart block|heart block|heart block	Disease	5:30:60:100	7:32:62:102	0:2:3:4	1:CID:2	R2L	NON-CROSS	11-12	5-7	D008790	metoprolol|metoprolol	Chemical	11:50	12:51	0:2	D006327	heart block|heart block|heart block|heart block	Disease	5:30:60:100	7:32:62:102	0:2:3:4	1:NR:2	R2L	NON-CROSS	69-70	60-62	D001285	atropine	Chemical	69	70	3	D006327	heart block|heart block|heart block|heart block	Disease	5:30:60:100	7:32:62:102	0:2:3:4	1:NR:2	R2L	NON-CROSS	80-81	60-62	D004298	dopamine	Chemical	80	81	3	D006327	heart block|heart block|heart block|heart block	Disease	5:30:60:100	7:32:62:102	0:2:3:4	1:NR:2	R2L	NON-CROSS	100-102	82-83	D004280	dobutamine	Chemical	82	83	3	D006327	heart block|heart block|heart block|heart block	Disease	5:30:60:100	7:32:62:102	0:2:3:4	1:NR:2	R2L	NON-CROSS	100-102	92-94	D002122	calcium chloride	Chemical	92	94	4	D006327	heart block|heart block|heart block|heart block	Disease	5:30:60:100	7:32:62:102	0:2:3:4	1:CID:2	L2R	NON-CROSS	34-35	45-46	D014700	verapamil|verapamil	Chemical	8:45	9:46	0:2	D007022	hypotension|hypotensive|hypotension	Disease	34:57:97	35:58:98	2:3:4	1:CID:2	L2R	NON-CROSS	50-51	57-58	D008790	metoprolol|metoprolol	Chemical	11:50	12:51	0:2	D007022	hypotension|hypotensive|hypotension	Disease	34:57:97	35:58:98	2:3:4	1:NR:2	R2L	NON-CROSS	69-70	57-58	D001285	atropine	Chemical	69	70	3	D007022	hypotension|hypotensive|hypotension	Disease	34:57:97	35:58:98	2:3:4	1:NR:2	R2L	NON-CROSS	97-98	80-81	D004298	dopamine	Chemical	80	81	3	D007022	hypotension|hypotensive|hypotension	Disease	34:57:97	35:58:98	2:3:4	1:NR:2	R2L	NON-CROSS	97-98	82-83	D004280	dobutamine	Chemical	82	83	3	D007022	hypotension|hypotensive|hypotension	Disease	34:57:97	35:58:98	2:3:4	1:NR:2	R2L	NON-CROSS	97-98	92-94	D002122	calcium chloride	Chemical	92	94	4	D007022	hypotension|hypotensive|hypotension	Disease	34:57:97	35:58:98	2:3:4
8958188	A phase I clinical study of the antipurine antifolate lometrexol ( DDATHF ) given with oral folic acid .|Lometrexol is an antifolate which inhibits glycinamide ribonucleotide formyltransferase ( GARFT ) , an enzyme essential for de novo purine synthesis .|Extensive experimental and limited clinical data have shown that lometrexol has activity against tumours which are refractory to other drugs , notably methotrexate .|However , the initial clinical development of lometrexol was curtailed because of severe and cumulative antiproliferative toxicities .|Preclinical murine studies demonstrated that the toxicity of lometrexol can be prevented by low dose folic acid administration , i . e . for 7 days prior to and 7 days following a single bolus dose .|This observation prompted a Phase I clinical study of lometrexol given with folic acid supplementation which has confirmed that the toxicity of lometrexol can be markedly reduced by folic acid supplementation .|Thrombocytopenia and mucositis were the major toxicities .|There was no clear relationship between clinical toxicity and the extent of plasma folate elevation .|Associated studies demonstrated that lometrexol plasma pharmacokinetics were not altered by folic acid administration indicating that supplementation is unlikely to reduce toxicity by enhancing lometrexol plasma clearance .|The work described in this report has identified for the first time a clinically acceptable schedule for the administration of a GARFT inhibitor .|This information will facilitate the future evaluation of this class of compounds in cancer therapy .	1:NR:2	L2R	CROSS	7-8	54-55	D000983	antipurine	Chemical	7	8	0	D009369	tumours|cancer	Disease	54:241	55:242	2:10	1:NR:2	L2R	CROSS	7-8	81-82	D000983	antipurine	Chemical	7	8	0	D064420	toxicities|toxicity|toxicity|toxicities|toxicity|toxicity	Disease	81:89:140:158:167:197	82:90:141:159:168:198	3:4:5:6:7:8	1:NR:2	L2R	CROSS	7-8	152-153	D000983	antipurine	Chemical	7	8	0	D013921	Thrombocytopenia	Disease	152	153	6	1:NR:2	L2R	CROSS	7-8	154-155	D000983	antipurine	Chemical	7	8	0	D052016	mucositis	Disease	154	155	6	1:NR:2	L2R	NON-CROSS	50-51	54-55	C045894	lometrexol|DDATHF|Lometrexol|lometrexol|lometrexol|lometrexol|lometrexol|lometrexol|lometrexol|lometrexol	Chemical	9:11:19:50:72:91:129:142:180:200	10:12:20:51:73:92:130:143:181:201	0:0:1:2:3:4:5:5:8:8	D009369	tumours|cancer	Disease	54:241	55:242	2:10	1:NR:2	L2R	NON-CROSS	89-90	91-92	C045894	lometrexol|DDATHF|Lometrexol|lometrexol|lometrexol|lometrexol|lometrexol|lometrexol|lometrexol|lometrexol	Chemical	9:11:19:50:72:91:129:142:180:200	10:12:20:51:73:92:130:143:181:201	0:0:1:2:3:4:5:5:8:8	D064420	toxicities|toxicity|toxicity|toxicities|toxicity|toxicity	Disease	81:89:140:158:167:197	82:90:141:159:168:198	3:4:5:6:7:8	1:CID:2	L2R	CROSS	142-143	152-153	C045894	lometrexol|DDATHF|Lometrexol|lometrexol|lometrexol|lometrexol|lometrexol|lometrexol|lometrexol|lometrexol	Chemical	9:11:19:50:72:91:129:142:180:200	10:12:20:51:73:92:130:143:181:201	0:0:1:2:3:4:5:5:8:8	D013921	Thrombocytopenia	Disease	152	153	6	1:CID:2	L2R	CROSS	142-143	154-155	C045894	lometrexol|DDATHF|Lometrexol|lometrexol|lometrexol|lometrexol|lometrexol|lometrexol|lometrexol|lometrexol	Chemical	9:11:19:50:72:91:129:142:180:200	10:12:20:51:73:92:130:143:181:201	0:0:1:2:3:4:5:5:8:8	D052016	mucositis	Disease	154	155	6	1:NR:2	L2R	CROSS	16-18	54-55	D005492	folic acid|folic acid|folic acid|folic acid|folate|folic acid	Chemical	16:98:132:148:173:187	18:100:134:150:174:189	0:4:5:5:7:8	D009369	tumours|cancer	Disease	54:241	55:242	2:10	1:NR:2	L2R	NON-CROSS	167-168	173-174	D005492	folic acid|folic acid|folic acid|folic acid|folate|folic acid	Chemical	16:98:132:148:173:187	18:100:134:150:174:189	0:4:5:5:7:8	D064420	toxicities|toxicity|toxicity|toxicities|toxicity|toxicity	Disease	81:89:140:158:167:197	82:90:141:159:168:198	3:4:5:6:7:8	1:NR:2	L2R	CROSS	148-150	152-153	D005492	folic acid|folic acid|folic acid|folic acid|folate|folic acid	Chemical	16:98:132:148:173:187	18:100:134:150:174:189	0:4:5:5:7:8	D013921	Thrombocytopenia	Disease	152	153	6	1:NR:2	L2R	CROSS	148-150	154-155	D005492	folic acid|folic acid|folic acid|folic acid|folate|folic acid	Chemical	16:98:132:148:173:187	18:100:134:150:174:189	0:4:5:5:7:8	D052016	mucositis	Disease	154	155	6	1:NR:2	L2R	CROSS	25-27	54-55	C402896	glycinamide ribonucleotide	Chemical	25	27	1	D009369	tumours|cancer	Disease	54:241	55:242	2:10	1:NR:2	L2R	CROSS	25-27	81-82	C402896	glycinamide ribonucleotide	Chemical	25	27	1	D064420	toxicities|toxicity|toxicity|toxicities|toxicity|toxicity	Disease	81:89:140:158:167:197	82:90:141:159:168:198	3:4:5:6:7:8	1:NR:2	L2R	CROSS	25-27	152-153	C402896	glycinamide ribonucleotide	Chemical	25	27	1	D013921	Thrombocytopenia	Disease	152	153	6	1:NR:2	L2R	CROSS	25-27	154-155	C402896	glycinamide ribonucleotide	Chemical	25	27	1	D052016	mucositis	Disease	154	155	6	1:NR:2	L2R	CROSS	38-39	54-55	D011687	purine	Chemical	38	39	1	D009369	tumours|cancer	Disease	54:241	55:242	2:10	1:NR:2	L2R	CROSS	38-39	81-82	D011687	purine	Chemical	38	39	1	D064420	toxicities|toxicity|toxicity|toxicities|toxicity|toxicity	Disease	81:89:140:158:167:197	82:90:141:159:168:198	3:4:5:6:7:8	1:NR:2	L2R	CROSS	38-39	152-153	D011687	purine	Chemical	38	39	1	D013921	Thrombocytopenia	Disease	152	153	6	1:NR:2	L2R	CROSS	38-39	154-155	D011687	purine	Chemical	38	39	1	D052016	mucositis	Disease	154	155	6	1:NR:2	R2L	NON-CROSS	63-64	54-55	D008727	methotrexate	Chemical	63	64	2	D009369	tumours|cancer	Disease	54:241	55:242	2:10	1:NR:2	L2R	CROSS	63-64	81-82	D008727	methotrexate	Chemical	63	64	2	D064420	toxicities|toxicity|toxicity|toxicities|toxicity|toxicity	Disease	81:89:140:158:167:197	82:90:141:159:168:198	3:4:5:6:7:8	1:NR:2	L2R	CROSS	63-64	152-153	D008727	methotrexate	Chemical	63	64	2	D013921	Thrombocytopenia	Disease	152	153	6	1:NR:2	L2R	CROSS	63-64	154-155	D008727	methotrexate	Chemical	63	64	2	D052016	mucositis	Disease	154	155	6
2557556	Involvement of the mu - opiate receptor in peripheral analgesia .|The intradermal injection of mu ( morphine , Tyr - D - Ala - Gly - NMe - Phe - Gly - ol and morphiceptin ) , kappa ( trans - 3 , 4 - dichloro - N - methyl - N [ 2 - ( 1 - pyrrolidinyl ) cyclohexyl ] benzeneactemide ) and delta ( [ D - Pen2 . 5 ] - enkephalin and [ D - Ser2 ] - [ Leu ] enkephalin - Thr ) selective opioid - agonists , by themselves , did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat .|Intradermal injection of mu , but not delta or kappa opioid - agonists , however , produced dose - dependent inhibition of prostaglandin E2 - induced hyperalgesia .|The analgesic effect of the mu - agonist morphine was dose - dependently antagonized by naloxone and prevented by co - injection of pertussis toxin .|Morphine did not , however , alter the hyperalgesia induced by 8 - bromo cyclic adenosine monophosphate .|We conclude that the analgesic action of opioids on the peripheral terminals of primary afferents is via a binding site with characteristics of the mu - opioid receptor and that this action is mediated by inhibition of the cyclic adenosine monophosphate second messenger system .	1:NR:2	R2L	CROSS	17-18	9-10	D009020	morphine|morphine|Morphine	Chemical	17:150:168	18:151:169	1:3:4	D000699	analgesia	Disease	9	10	0	1:NR:2	R2L	CROSS	19-34	9-10	D020875	Tyr - D - Ala - Gly - NMe - Phe - Gly - ol	Chemical	19	34	1	D000699	analgesia	Disease	9	10	0	1:NR:2	R2L	CROSS	35-36	9-10	C028889	morphiceptin	Chemical	35	36	1	D000699	analgesia	Disease	9	10	0	1:NR:2	R2L	CROSS	40-64	9-10	D019900	trans - 3 , 4 - dichloro - N - methyl - N [ 2 - ( 1 - pyrrolidinyl ) cyclohexyl ] benzeneactemide	Chemical	40	64	1	D000699	analgesia	Disease	9	10	0	1:NR:2	R2L	CROSS	68-77	9-10	D020881	[ D - Pen2 . 5 ] - enkephalin	Chemical	68	77	1	D000699	analgesia	Disease	9	10	0	1:NR:2	R2L	CROSS	78-90	9-10	C034318	[ D - Ser2 ] - [ Leu ] enkephalin - Thr	Chemical	78	90	1	D000699	analgesia	Disease	9	10	0	1:NR:2	R2L	CROSS	136-138	9-10	D015232	prostaglandin E2	Chemical	136	138	2	D000699	analgesia	Disease	9	10	0	1:NR:2	R2L	CROSS	157-158	9-10	D009270	naloxone	Chemical	157	158	3	D000699	analgesia	Disease	9	10	0	1:NR:2	R2L	CROSS	179-185	9-10	D015124	8 - bromo cyclic adenosine monophosphate	Chemical	179	185	4	D000699	analgesia	Disease	9	10	0	1:NR:2	R2L	CROSS	224-227	9-10	D000242	cyclic adenosine monophosphate	Chemical	224	227	5	D000699	analgesia	Disease	9	10	0	1:NR:2	L2R	NON-CROSS	168-169	176-177	D009020	morphine|morphine|Morphine	Chemical	17:150:168	18:151:169	1:3:4	D006930	hyperalgesia|hyperalgesia	Disease	140:176	141:177	2:4	1:NR:2	L2R	CROSS	19-34	140-141	D020875	Tyr - D - Ala - Gly - NMe - Phe - Gly - ol	Chemical	19	34	1	D006930	hyperalgesia|hyperalgesia	Disease	140:176	141:177	2:4	1:NR:2	L2R	CROSS	35-36	140-141	C028889	morphiceptin	Chemical	35	36	1	D006930	hyperalgesia|hyperalgesia	Disease	140:176	141:177	2:4	1:NR:2	L2R	CROSS	40-64	140-141	D019900	trans - 3 , 4 - dichloro - N - methyl - N [ 2 - ( 1 - pyrrolidinyl ) cyclohexyl ] benzeneactemide	Chemical	40	64	1	D006930	hyperalgesia|hyperalgesia	Disease	140:176	141:177	2:4	1:NR:2	L2R	CROSS	68-77	140-141	D020881	[ D - Pen2 . 5 ] - enkephalin	Chemical	68	77	1	D006930	hyperalgesia|hyperalgesia	Disease	140:176	141:177	2:4	1:NR:2	L2R	CROSS	78-90	140-141	C034318	[ D - Ser2 ] - [ Leu ] enkephalin - Thr	Chemical	78	90	1	D006930	hyperalgesia|hyperalgesia	Disease	140:176	141:177	2:4	1:CID:2	L2R	NON-CROSS	136-138	140-141	D015232	prostaglandin E2	Chemical	136	138	2	D006930	hyperalgesia|hyperalgesia	Disease	140:176	141:177	2:4	1:NR:2	R2L	CROSS	157-158	140-141	D009270	naloxone	Chemical	157	158	3	D006930	hyperalgesia|hyperalgesia	Disease	140:176	141:177	2:4	1:CID:2	R2L	NON-CROSS	179-185	176-177	D015124	8 - bromo cyclic adenosine monophosphate	Chemical	179	185	4	D006930	hyperalgesia|hyperalgesia	Disease	140:176	141:177	2:4	1:NR:2	R2L	CROSS	224-227	176-177	D000242	cyclic adenosine monophosphate	Chemical	224	227	5	D006930	hyperalgesia|hyperalgesia	Disease	140:176	141:177	2:4
15580403	Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C .|BACKGROUND : Hemolytic anemia is one of the major adverse events of the combination therapy of interferon and ribavirin .|Because of ribavirin - related hemolytic anemia , dose reduction is a common event in this therapy .|In this clinical retrospective cohort study we have examined the suitable timing of ribavirin reduction in patients with hemolysis during combination therapy .|METHODS : Thirty - seven of 160 patients who had HCV - genotype 1b , had high virus load , and received 24 - week combination therapy developed anemia with hemoglobin level < 10 g / dl or anemia - related signs during therapy .|After that , these 37 patients were reduced one tablet of ribavirin ( 200 mg ) per day .|After reduction of ribavirin , 27 of 37 patients could continue combination therapy for a total of 24 weeks ( group A ) .|However , 10 of 37 patients with reduction of ribavirin could not continue combination therapy because their < 8 . 5 g / dl hemoglobin values decreased to or anemia - related severe side effects occurred ( group B ) .|We assessed the final efficacy and safety after reduction of ribavirin in groups A and B .|RESULTS : A sustained virological response ( SVR ) was 29 . 6 % ( 8 / 27 ) in group A and 10 % ( 1 / 10 ) in group B , respectively .|A 34 . 4 % ( 12 / 27 ) of SVR + biological response in group A was higher than 10 % ( 1 / 10 ) in group B ( P = 0 . 051 ) , with slight significance .|With respect to hemoglobin level at the time of ribavirin reduction , a rate of continuation of therapy in patients with > or = 10 g / dl hemoglobin was higher than that in patients with < 10 g / dl ( P = 0 . 036 ) .|CONCLUSIONS : Reduction of ribavirin at hemoglobin level > or = 10 g / dl is suitable in terms of efficacy and side effects .	1:NR:2	L2R	NON-CROSS	3-4	8-9	D012254	ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin	Chemical	3:15:39:43:72:138:149:179:221:316:360	4:16:40:44:73:139:150:180:222:317:361	0:0:1:2:3:5:6:7:8:11:12	D006461	hemolysis|hemolysis	Disease	8:77	9:78	0:3	1:NR:2	L2R	NON-CROSS	15-16	17-20	D012254	ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin	Chemical	3:15:39:43:72:138:149:179:221:316:360	4:16:40:44:73:139:150:180:222:317:361	0:0:1:2:3:5:6:7:8:11:12	D019698	chronic hepatitis C	Disease	17	20	0	1:CID:2	L2R	NON-CROSS	43-44	46-48	D012254	ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin	Chemical	3:15:39:43:72:138:149:179:221:316:360	4:16:40:44:73:139:150:180:222:317:361	0:0:1:2:3:5:6:7:8:11:12	D000743	Hemolytic anemia|hemolytic anemia	Disease	23:46	25:48	1:2	1:NR:2	L2R	NON-CROSS	120-121	138-139	D012254	ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin	Chemical	3:15:39:43:72:138:149:179:221:316:360	4:16:40:44:73:139:150:180:222:317:361	0:0:1:2:3:5:6:7:8:11:12	D000740	anemia|anemia|anemia	Disease	110:120:199	111:121:200	4:4:7	1:NR:2	R2L	NON-CROSS	13-14	8-9	D007372	interferon|interferon	Chemical	13:37	14:38	0:1	D006461	hemolysis|hemolysis	Disease	8:77	9:78	0:3	1:NR:2	L2R	NON-CROSS	13-14	17-20	D007372	interferon|interferon	Chemical	13:37	14:38	0:1	D019698	chronic hepatitis C	Disease	17	20	0	1:CID:2	L2R	NON-CROSS	37-38	46-48	D007372	interferon|interferon	Chemical	13:37	14:38	0:1	D000743	Hemolytic anemia|hemolytic anemia	Disease	23:46	25:48	1:2	1:NR:2	L2R	CROSS	37-38	110-111	D007372	interferon|interferon	Chemical	13:37	14:38	0:1	D000740	anemia|anemia|anemia	Disease	110:120:199	111:121:200	4:4:7
15075188	Increased expression and apical targeting of renal ENaC subunits in puromycin aminonucleoside - induced nephrotic syndrome in rats .|Nephrotic syndrome is often accompanied by sodium retention and generalized edema .|However , the molecular basis for the decreased renal sodium excretion remains undefined .|We hypothesized that epithelial Na channel ( ENaC ) subunit dysregulation may be responsible for the increased sodium retention .|An experimental group of rats was treated with puromycin aminonucleoside ( PAN ; 180 mg / kg iv ) , whereas the control group received only vehicle .|After 7 days , PAN treatment induced significant proteinuria , hypoalbuminemia , decreased urinary sodium excretion , and extensive ascites .|The protein abundance of alpha - ENaC and beta - ENaC was increased in the inner stripe of the outer medulla ( ISOM ) and in the inner medulla ( IM ) but was not altered in the cortex .|gamma - ENaC abundance was increased in the cortex , ISOM , and IM .|Immunoperoxidase brightfield - and laser - scanning confocal fluorescence microscopy demonstrated increased targeting of alpha - ENaC , beta - ENaC , and gamma - ENaC subunits to the apical plasma membrane in the distal convoluted tubule ( DCT2 ) , connecting tubule , and cortical and medullary collecting duct segments .|Immunoelectron microscopy further revealed an increased labeling of alpha - ENaC in the apical plasma membrane of cortical collecting duct principal cells of PAN - treated rats , indicating enhanced apical targeting of alpha - ENaC subunits .|In contrast , the protein abundances of Na ( + ) / H ( + ) exchanger type 3 ( NHE3 ) , Na ( + ) - K ( + ) - 2Cl ( - ) cotransporter ( BSC - 1 ) , and thiazide - sensitive Na ( + ) - Cl ( - ) cotransporter ( TSC ) were decreased .|Moreover , the abundance of the alpha ( 1 ) - subunit of the Na - K - ATPase was decreased in the cortex and ISOM , but it remained unchanged in the IM .|In conclusion , the increased or sustained expression of ENaC subunits combined with increased apical targeting in the DCT2 , connecting tubule , and collecting duct are likely to play a role in the sodium retention associated with PAN - induced nephrotic syndrome .|The decreased abundance of NHE3 , BSC - 1 , TSC , and Na - K - ATPase may play a compensatory role to promote sodium excretion .	1:CID:2	L2R	NON-CROSS	10-12	14-16	D011692	puromycin aminonucleoside|puromycin aminonucleoside|PAN|PAN|PAN|PAN	Chemical	10:73:76:97:244:396	12:75:77:98:245:397	0:4:4:5:9:12	D009404	nephrotic syndrome|Nephrotic syndrome|nephrotic syndrome	Disease	14:19:399	16:21:401	0:1:12	1:NR:2	L2R	CROSS	10-12	29-30	D011692	puromycin aminonucleoside|puromycin aminonucleoside|PAN|PAN|PAN|PAN	Chemical	10:73:76:97:244:396	12:75:77:98:245:397	0:4:4:5:9:12	D004487	edema	Disease	29	30	1	1:CID:2	L2R	NON-CROSS	97-98	101-102	D011692	puromycin aminonucleoside|puromycin aminonucleoside|PAN|PAN|PAN|PAN	Chemical	10:73:76:97:244:396	12:75:77:98:245:397	0:4:4:5:9:12	D011507	proteinuria	Disease	101	102	5	1:CID:2	L2R	NON-CROSS	97-98	103-104	D011692	puromycin aminonucleoside|puromycin aminonucleoside|PAN|PAN|PAN|PAN	Chemical	10:73:76:97:244:396	12:75:77:98:245:397	0:4:4:5:9:12	D034141	hypoalbuminemia	Disease	103	104	5	1:CID:2	L2R	NON-CROSS	97-98	112-113	D011692	puromycin aminonucleoside|puromycin aminonucleoside|PAN|PAN|PAN|PAN	Chemical	10:73:76:97:244:396	12:75:77:98:245:397	0:4:4:5:9:12	D001201	ascites	Disease	112	113	5	1:NR:2	R2L	NON-CROSS	25-26	19-21	D012964	sodium|sodium|Na|sodium|sodium|Na|Na|Na|Na|sodium|Na|sodium	Chemical	25:40:49:62:107:266:282:307:337:392:415:427	26:41:50:63:108:267:283:308:338:393:416:428	1:2:3:3:5:10:10:10:11:12:13:13	D009404	nephrotic syndrome|Nephrotic syndrome|nephrotic syndrome	Disease	14:19:399	16:21:401	0:1:12	1:NR:2	R2L	CROSS	399-401	271-272	D006859	H	Chemical	271	272	10	D009404	nephrotic syndrome|Nephrotic syndrome|nephrotic syndrome	Disease	14:19:399	16:21:401	0:1:12	1:NR:2	R2L	CROSS	417-418	399-401	D011188	K|K|K	Chemical	287:339:417	288:340:418	10:11:13	D009404	nephrotic syndrome|Nephrotic syndrome|nephrotic syndrome	Disease	14:19:399	16:21:401	0:1:12	1:NR:2	R2L	CROSS	399-401	312-313	D002713	Cl|Cl	Chemical	292:312	293:313	10:10	D009404	nephrotic syndrome|Nephrotic syndrome|nephrotic syndrome	Disease	14:19:399	16:21:401	0:1:12	1:NR:2	R2L	CROSS	399-401	304-305	D049971	thiazide	Chemical	304	305	10	D009404	nephrotic syndrome|Nephrotic syndrome|nephrotic syndrome	Disease	14:19:399	16:21:401	0:1:12	1:NR:2	L2R	NON-CROSS	25-26	29-30	D012964	sodium|sodium|Na|sodium|sodium|Na|Na|Na|Na|sodium|Na|sodium	Chemical	25:40:49:62:107:266:282:307:337:392:415:427	26:41:50:63:108:267:283:308:338:393:416:428	1:2:3:3:5:10:10:10:11:12:13:13	D004487	edema	Disease	29	30	1	1:NR:2	L2R	NON-CROSS	101-102	107-108	D012964	sodium|sodium|Na|sodium|sodium|Na|Na|Na|Na|sodium|Na|sodium	Chemical	25:40:49:62:107:266:282:307:337:392:415:427	26:41:50:63:108:267:283:308:338:393:416:428	1:2:3:3:5:10:10:10:11:12:13:13	D011507	proteinuria	Disease	101	102	5	1:NR:2	L2R	NON-CROSS	103-104	107-108	D012964	sodium|sodium|Na|sodium|sodium|Na|Na|Na|Na|sodium|Na|sodium	Chemical	25:40:49:62:107:266:282:307:337:392:415:427	26:41:50:63:108:267:283:308:338:393:416:428	1:2:3:3:5:10:10:10:11:12:13:13	D034141	hypoalbuminemia	Disease	103	104	5	1:NR:2	L2R	NON-CROSS	107-108	112-113	D012964	sodium|sodium|Na|sodium|sodium|Na|Na|Na|Na|sodium|Na|sodium	Chemical	25:40:49:62:107:266:282:307:337:392:415:427	26:41:50:63:108:267:283:308:338:393:416:428	1:2:3:3:5:10:10:10:11:12:13:13	D001201	ascites	Disease	112	113	5	1:NR:2	R2L	CROSS	271-272	29-30	D006859	H	Chemical	271	272	10	D004487	edema	Disease	29	30	1	1:NR:2	R2L	CROSS	287-288	29-30	D011188	K|K|K	Chemical	287:339:417	288:340:418	10:11:13	D004487	edema	Disease	29	30	1	1:NR:2	R2L	CROSS	292-293	29-30	D002713	Cl|Cl	Chemical	292:312	293:313	10:10	D004487	edema	Disease	29	30	1	1:NR:2	R2L	CROSS	304-305	29-30	D049971	thiazide	Chemical	304	305	10	D004487	edema	Disease	29	30	1	1:NR:2	R2L	CROSS	271-272	101-102	D006859	H	Chemical	271	272	10	D011507	proteinuria	Disease	101	102	5	1:NR:2	R2L	CROSS	287-288	101-102	D011188	K|K|K	Chemical	287:339:417	288:340:418	10:11:13	D011507	proteinuria	Disease	101	102	5	1:NR:2	R2L	CROSS	292-293	101-102	D002713	Cl|Cl	Chemical	292:312	293:313	10:10	D011507	proteinuria	Disease	101	102	5	1:NR:2	R2L	CROSS	304-305	101-102	D049971	thiazide	Chemical	304	305	10	D011507	proteinuria	Disease	101	102	5	1:NR:2	R2L	CROSS	271-272	103-104	D006859	H	Chemical	271	272	10	D034141	hypoalbuminemia	Disease	103	104	5	1:NR:2	R2L	CROSS	287-288	103-104	D011188	K|K|K	Chemical	287:339:417	288:340:418	10:11:13	D034141	hypoalbuminemia	Disease	103	104	5	1:NR:2	R2L	CROSS	292-293	103-104	D002713	Cl|Cl	Chemical	292:312	293:313	10:10	D034141	hypoalbuminemia	Disease	103	104	5	1:NR:2	R2L	CROSS	304-305	103-104	D049971	thiazide	Chemical	304	305	10	D034141	hypoalbuminemia	Disease	103	104	5	1:NR:2	R2L	CROSS	271-272	112-113	D006859	H	Chemical	271	272	10	D001201	ascites	Disease	112	113	5	1:NR:2	R2L	CROSS	287-288	112-113	D011188	K|K|K	Chemical	287:339:417	288:340:418	10:11:13	D001201	ascites	Disease	112	113	5	1:NR:2	R2L	CROSS	292-293	112-113	D002713	Cl|Cl	Chemical	292:312	293:313	10:10	D001201	ascites	Disease	112	113	5	1:NR:2	R2L	CROSS	304-305	112-113	D049971	thiazide	Chemical	304	305	10	D001201	ascites	Disease	112	113	5
14745746	Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition ? A pilot study .|This pilot study examines whether hormone therapy for breast cancer affects cognition .|Patients participating in a randomised trial of anastrozole , tamoxifen alone or combined ( ATAC ) ( n = 94 ) and a group of women without breast cancer ( n = 35 ) completed a battery of neuropsychological measures .|Compared with the control group , the patients were impaired on a processing speed task ( p = 0 . 032 ) and on a measure of immediate verbal memory ( p = 0 . 026 ) after controlling for the use of hormone replacement therapy in both groups .|Patient group performance was not significantly related to length of treatment or measures of psychological morbidity .|The results showed specific impairments in processing speed and verbal memory in women receiving hormonal therapy for the treatment of breast cancer .|Verbal memory may be especially sensitive to changes in oestrogen levels , a finding commonly reported in studies of hormone replacement therapy in healthy women .|In view of the increased use of hormone therapies in an adjuvant and preventative setting their impact on cognitive functioning should be investigated more thoroughly .	1:NR:2	R2L	NON-CROSS	42-43	30-32	C090450	anastrozole	Chemical	42	43	2	D001943	breast cancer|breast cancer|breast cancer|breast cancer	Disease	7:30:62:163	9:32:64:165	0:1:2:5	1:NR:2	R2L	NON-CROSS	44-45	30-32	D013629	tamoxifen	Chemical	44	45	2	D001943	breast cancer|breast cancer|breast cancer|breast cancer	Disease	7:30:62:163	9:32:64:165	0:1:2:5	1:NR:2	R2L	CROSS	175-176	163-165	D004967	oestrogen	Chemical	175	176	6	D001943	breast cancer|breast cancer|breast cancer|breast cancer	Disease	7:30:62:163	9:32:64:165	0:1:2:5	1:CID:2	R2L	CROSS	42-43	11-17	C090450	anastrozole	Chemical	42	43	2	D008569	detrimental effect on memory and cognition	Disease	11	17	0	1:CID:2	R2L	CROSS	44-45	11-17	D013629	tamoxifen	Chemical	44	45	2	D008569	detrimental effect on memory and cognition	Disease	11	17	0	1:NR:2	R2L	CROSS	175-176	11-17	D004967	oestrogen	Chemical	175	176	6	D008569	detrimental effect on memory and cognition	Disease	11	17	0	1:CID:2	R2L	CROSS	42-43	11-17	C090450	anastrozole	Chemical	42	43	2	D003072	detrimental effect on memory and cognition	Disease	11	17	0	1:CID:2	R2L	CROSS	44-45	11-17	D013629	tamoxifen	Chemical	44	45	2	D003072	detrimental effect on memory and cognition	Disease	11	17	0	1:NR:2	R2L	CROSS	175-176	11-17	D004967	oestrogen	Chemical	175	176	6	D003072	detrimental effect on memory and cognition	Disease	11	17	0
11208990	Association of nitric oxide production and apoptosis in a model of experimental nephropathy .|BACKGROUND : In recent studies increased amounts of nitric oxide ( NO ) and apoptosis have been implicated in various pathological conditions in the kidney .|We have studied the role of NO and its association with apoptosis in an experimental model of nephrotic syndrome induced by a single injection of adriamycin ( ADR ) .|METHODS : The alteration in the NO pathway was assessed by measuring nitrite levels in serum / urine and by evaluating the changes in vascular reactivity of the isolated perfused rat kidney ( IPRK ) system .|Rats were stratified into control groups and ADR - induced nephropathy groups .|These two groups were then divided into : group 1 , animals receiving saline ; and group 2 , animals receiving aminoguanidine ( AG ) which is a specific inhibitor of inducible - NO synthase .|On day 21 , rats were sacrificed after obtaining material for biochemical analysis .|RESULTS : Histopathological examination of the kidneys of rats treated with ADR revealed focal areas of mesangial proliferation and mild tubulointerstitial inflammation .|They also had significantly higher levels of proteinuria compared with control and treatment groups ( P < 0 . 05 ) .|Urine nitrite levels were significantly increased in the ADR - nephropathy group ( P < 0 . 05 ) .|In the IPRK phenylephrine and acetylcholine related responses were significantly impaired in the ADR - nephropathy group .|Apoptosis was not detected in controls .|However , in the ADR - nephropathy group , numerous apoptotic cells were identified in the tubulointerstitial areas .|Double staining revealed numerous interstitial apoptotic cells to stain for ED1 , a marker for monocytes / macrophages .|Treatment with AG prevented the impairment of renal vascular bed responses and reduced both urine nitrite levels and apoptosis to control levels .|CONCLUSION : We suggest that interactions between NO and apoptosis are important in the pathogenesis of the ADR - induced nephrosis .	1:NR:2	L2R	NON-CROSS	2-4	12-13	D009569	nitric oxide|nitric oxide|NO|NO|NO|NO|NO	Chemical	2:22:25:46:76:153:328	4:24:26:47:77:154:329	0:1:1:2:3:5:15	D007674	nephropathy|nephropathy|nephropathy|nephropathy|nephropathy	Disease	12:117:225:250:266	13:118:226:251:267	0:4:9:10:12	1:NR:2	L2R	NON-CROSS	46-47	57-59	D009569	nitric oxide|nitric oxide|NO|NO|NO|NO|NO	Chemical	2:22:25:46:76:153:328	4:24:26:47:77:154:329	0:1:1:2:3:5:15	D009404	nephrotic syndrome	Disease	57	59	2	1:NR:2	L2R	CROSS	153-154	186-188	D009569	nitric oxide|nitric oxide|NO|NO|NO|NO|NO	Chemical	2:22:25:46:76:153:328	4:24:26:47:77:154:329	0:1:1:2:3:5:15	C537346	mesangial proliferation	Disease	186	188	7	1:NR:2	L2R	CROSS	153-154	190-192	D009569	nitric oxide|nitric oxide|NO|NO|NO|NO|NO	Chemical	2:22:25:46:76:153:328	4:24:26:47:77:154:329	0:1:1:2:3:5:15	D009395	tubulointerstitial inflammation	Disease	190	192	7	1:NR:2	L2R	CROSS	153-154	200-201	D009569	nitric oxide|nitric oxide|NO|NO|NO|NO|NO	Chemical	2:22:25:46:76:153:328	4:24:26:47:77:154:329	0:1:1:2:3:5:15	D011507	proteinuria	Disease	200	201	8	1:NR:2	L2R	NON-CROSS	328-329	341-342	D009569	nitric oxide|nitric oxide|NO|NO|NO|NO|NO	Chemical	2:22:25:46:76:153:328	4:24:26:47:77:154:329	0:1:1:2:3:5:15	D009401	nephrosis	Disease	341	342	15	1:NR:2	R2L	NON-CROSS	225-226	223-224	D004317	adriamycin|ADR|ADR|ADR|ADR|ADR|ADR|ADR	Chemical	65:67:114:181:223:248:264:338	66:68:115:182:224:249:265:339	2:2:4:7:9:10:12:15	D007674	nephropathy|nephropathy|nephropathy|nephropathy|nephropathy	Disease	12:117:225:250:266	13:118:226:251:267	0:4:9:10:12	1:NR:2	R2L	NON-CROSS	225-226	216-217	D009573	nitrite|nitrite|nitrite	Chemical	82:216:313	83:217:314	3:9:14	D007674	nephropathy|nephropathy|nephropathy|nephropathy|nephropathy	Disease	12:117:225:250:266	13:118:226:251:267	0:4:9:10:12	1:NR:2	R2L	CROSS	141-142	117-118	C004479	aminoguanidine|AG|AG	Chemical	141:143:300	142:144:301	5:5:14	D007674	nephropathy|nephropathy|nephropathy|nephropathy|nephropathy	Disease	12:117:225:250:266	13:118:226:251:267	0:4:9:10:12	1:NR:2	R2L	NON-CROSS	250-251	238-239	D010656	phenylephrine	Chemical	238	239	10	D007674	nephropathy|nephropathy|nephropathy|nephropathy|nephropathy	Disease	12:117:225:250:266	13:118:226:251:267	0:4:9:10:12	1:NR:2	R2L	NON-CROSS	250-251	240-241	D000109	acetylcholine	Chemical	240	241	10	D007674	nephropathy|nephropathy|nephropathy|nephropathy|nephropathy	Disease	12:117:225:250:266	13:118:226:251:267	0:4:9:10:12	1:CID:2	R2L	NON-CROSS	65-66	57-59	D004317	adriamycin|ADR|ADR|ADR|ADR|ADR|ADR|ADR	Chemical	65:67:114:181:223:248:264:338	66:68:115:182:224:249:265:339	2:2:4:7:9:10:12:15	D009404	nephrotic syndrome	Disease	57	59	2	1:NR:2	R2L	CROSS	82-83	57-59	D009573	nitrite|nitrite|nitrite	Chemical	82:216:313	83:217:314	3:9:14	D009404	nephrotic syndrome	Disease	57	59	2	1:NR:2	R2L	CROSS	141-142	57-59	C004479	aminoguanidine|AG|AG	Chemical	141:143:300	142:144:301	5:5:14	D009404	nephrotic syndrome	Disease	57	59	2	1:NR:2	R2L	CROSS	238-239	57-59	D010656	phenylephrine	Chemical	238	239	10	D009404	nephrotic syndrome	Disease	57	59	2	1:NR:2	R2L	CROSS	240-241	57-59	D000109	acetylcholine	Chemical	240	241	10	D009404	nephrotic syndrome	Disease	57	59	2	1:NR:2	L2R	NON-CROSS	181-182	186-188	D004317	adriamycin|ADR|ADR|ADR|ADR|ADR|ADR|ADR	Chemical	65:67:114:181:223:248:264:338	66:68:115:182:224:249:265:339	2:2:4:7:9:10:12:15	C537346	mesangial proliferation	Disease	186	188	7	1:NR:2	L2R	NON-CROSS	181-182	190-192	D004317	adriamycin|ADR|ADR|ADR|ADR|ADR|ADR|ADR	Chemical	65:67:114:181:223:248:264:338	66:68:115:182:224:249:265:339	2:2:4:7:9:10:12:15	D009395	tubulointerstitial inflammation	Disease	190	192	7	1:CID:2	L2R	CROSS	181-182	200-201	D004317	adriamycin|ADR|ADR|ADR|ADR|ADR|ADR|ADR	Chemical	65:67:114:181:223:248:264:338	66:68:115:182:224:249:265:339	2:2:4:7:9:10:12:15	D011507	proteinuria	Disease	200	201	8	1:NR:2	L2R	NON-CROSS	338-339	341-342	D004317	adriamycin|ADR|ADR|ADR|ADR|ADR|ADR|ADR	Chemical	65:67:114:181:223:248:264:338	66:68:115:182:224:249:265:339	2:2:4:7:9:10:12:15	D009401	nephrosis	Disease	341	342	15	1:NR:2	L2R	CROSS	186-188	216-217	D009573	nitrite|nitrite|nitrite	Chemical	82:216:313	83:217:314	3:9:14	C537346	mesangial proliferation	Disease	186	188	7	1:NR:2	L2R	CROSS	190-192	216-217	D009573	nitrite|nitrite|nitrite	Chemical	82:216:313	83:217:314	3:9:14	D009395	tubulointerstitial inflammation	Disease	190	192	7	1:NR:2	L2R	CROSS	200-201	216-217	D009573	nitrite|nitrite|nitrite	Chemical	82:216:313	83:217:314	3:9:14	D011507	proteinuria	Disease	200	201	8	1:NR:2	L2R	CROSS	313-314	341-342	D009573	nitrite|nitrite|nitrite	Chemical	82:216:313	83:217:314	3:9:14	D009401	nephrosis	Disease	341	342	15	1:NR:2	L2R	CROSS	143-144	186-188	C004479	aminoguanidine|AG|AG	Chemical	141:143:300	142:144:301	5:5:14	C537346	mesangial proliferation	Disease	186	188	7	1:NR:2	L2R	CROSS	143-144	190-192	C004479	aminoguanidine|AG|AG	Chemical	141:143:300	142:144:301	5:5:14	D009395	tubulointerstitial inflammation	Disease	190	192	7	1:NR:2	L2R	CROSS	143-144	200-201	C004479	aminoguanidine|AG|AG	Chemical	141:143:300	142:144:301	5:5:14	D011507	proteinuria	Disease	200	201	8	1:NR:2	L2R	CROSS	300-301	341-342	C004479	aminoguanidine|AG|AG	Chemical	141:143:300	142:144:301	5:5:14	D009401	nephrosis	Disease	341	342	15	1:NR:2	R2L	CROSS	238-239	186-188	D010656	phenylephrine	Chemical	238	239	10	C537346	mesangial proliferation	Disease	186	188	7	1:NR:2	R2L	CROSS	240-241	186-188	D000109	acetylcholine	Chemical	240	241	10	C537346	mesangial proliferation	Disease	186	188	7	1:NR:2	R2L	CROSS	238-239	190-192	D010656	phenylephrine	Chemical	238	239	10	D009395	tubulointerstitial inflammation	Disease	190	192	7	1:NR:2	R2L	CROSS	240-241	190-192	D000109	acetylcholine	Chemical	240	241	10	D009395	tubulointerstitial inflammation	Disease	190	192	7	1:NR:2	R2L	CROSS	238-239	200-201	D010656	phenylephrine	Chemical	238	239	10	D011507	proteinuria	Disease	200	201	8	1:NR:2	R2L	CROSS	240-241	200-201	D000109	acetylcholine	Chemical	240	241	10	D011507	proteinuria	Disease	200	201	8	1:NR:2	L2R	CROSS	238-239	341-342	D010656	phenylephrine	Chemical	238	239	10	D009401	nephrosis	Disease	341	342	15	1:NR:2	L2R	CROSS	240-241	341-342	D000109	acetylcholine	Chemical	240	241	10	D009401	nephrosis	Disease	341	342	15
9201797	The attenuating effect of carteolol hydrochloride , a beta - adrenoceptor antagonist , on neuroleptic - induced catalepsy in rats .|It is known that beta - adrenoceptor antagonists are effective in the treatment of akathisia , one of the extrapyramidal side effects that occur during neuroleptic treatment .|Neuroleptic - induced catalepsy , a model of neuroleptic - induced extrapyramidal side effects , was considered suitable as a model for predicting neuroleptic - induced akathisia in humans , although neuroleptic - induced catalepsy was not considered a specific test for neuroleptic - induced akathisia .|Therefore , the effects of carteolol , a beta - adrenoceptor antagonist , on haloperidol - induced catalepsy in rats were behaviorally studied and compared with those of propranolol and biperiden , a muscarinic receptor antagonist .|Carteolol , as well as propranolol and biperiden , inhibited the haloperidol - induced catalepsy .|The inhibitory effect of carteolol was almost comparable to that of propranolol , but was weaker than that of biperiden .|Carteolol did not evoke postsynaptic dopamine receptor - stimulating behavioral signs such as stereotypy and hyperlocomotion in rats .|Carteolol did not antagonize the inhibitory effects of haloperidol on apomorphine - induced stereotypy and locomotor activity in rats .|In addition , carteolol did not evoke 5 - HT1A receptor - stimulating behavioral signs such as flat body posture and forepaw treading and did not inhibit 5 - hydroxytryptophan - induced head twitch in rats .|Finally , carteolol did not inhibit physostigmine - induced lethality in rats .|These results strongly suggest that carteolol improves haloperidol - induced catalepsy via its beta - adrenoceptor antagonistic activity and is expected to be effective in the treatment of akathisia without attenuating neuroleptic - induced antipsychotic effects due to its postsynaptic dopamine receptor antagonistic activity .	1:NR:2	L2R	NON-CROSS	264-265	269-270	D002354	carteolol hydrochloride|carteolol|Carteolol|carteolol|Carteolol|Carteolol|carteolol|carteolol|carteolol	Chemical	4:101:133:153:170:189:212:248:264	6:102:134:154:171:190:213:249:265	0:3:4:5:6:7:8:9:10	D002375	catalepsy|catalepsy|catalepsy|catalepsy|catalepsy|catalepsy	Disease	17:52:83:113:147:269	18:53:84:114:148:270	0:2:2:3:4:10	1:NR:2	L2R	NON-CROSS	94-95	101-102	D002354	carteolol hydrochloride|carteolol|Carteolol|carteolol|Carteolol|Carteolol|carteolol|carteolol|carteolol	Chemical	4:101:133:153:170:189:212:248:264	6:102:134:154:171:190:213:249:265	0:3:4:5:6:7:8:9:10	D017109	akathisia|akathisia|akathisia|akathisia	Disease	35:75:94:287	36:76:95:288	1:2:2:10	1:NR:2	L2R	NON-CROSS	185-186	189-190	D002354	carteolol hydrochloride|carteolol|Carteolol|carteolol|Carteolol|Carteolol|carteolol|carteolol|carteolol	Chemical	4:101:133:153:170:189:212:248:264	6:102:134:154:171:190:213:249:265	0:3:4:5:6:7:8:9:10	D009069	hyperlocomotion	Disease	185	186	6	1:CID:2	R2L	NON-CROSS	113-114	110-111	D006220	haloperidol|haloperidol|haloperidol|haloperidol	Chemical	110:144:197:266	111:145:198:267	3:4:7:10	D002375	catalepsy|catalepsy|catalepsy|catalepsy|catalepsy|catalepsy	Disease	17:52:83:113:147:269	18:53:84:114:148:270	0:2:2:3:4:10	1:NR:2	R2L	NON-CROSS	147-148	138-139	D011433	propranolol|propranolol|propranolol	Chemical	124:138:160	125:139:161	3:4:5	D002375	catalepsy|catalepsy|catalepsy|catalepsy|catalepsy|catalepsy	Disease	17:52:83:113:147:269	18:53:84:114:148:270	0:2:2:3:4:10	1:NR:2	R2L	NON-CROSS	147-148	140-141	D001712	biperiden|biperiden|biperiden	Chemical	126:140:168	127:141:169	3:4:5	D002375	catalepsy|catalepsy|catalepsy|catalepsy|catalepsy|catalepsy	Disease	17:52:83:113:147:269	18:53:84:114:148:270	0:2:2:3:4:10	1:NR:2	R2L	NON-CROSS	175-176	147-148	D004298	dopamine|dopamine	Chemical	175:299	176:300	6:10	D002375	catalepsy|catalepsy|catalepsy|catalepsy|catalepsy|catalepsy	Disease	17:52:83:113:147:269	18:53:84:114:148:270	0:2:2:3:4:10	1:NR:2	R2L	CROSS	199-200	147-148	D001058	apomorphine	Chemical	199	200	7	D002375	catalepsy|catalepsy|catalepsy|catalepsy|catalepsy|catalepsy	Disease	17:52:83:113:147:269	18:53:84:114:148:270	0:2:2:3:4:10	1:NR:2	R2L	CROSS	269-270	236-239	D006916	5 - hydroxytryptophan	Chemical	236	239	8	D002375	catalepsy|catalepsy|catalepsy|catalepsy|catalepsy|catalepsy	Disease	17:52:83:113:147:269	18:53:84:114:148:270	0:2:2:3:4:10	1:NR:2	R2L	CROSS	269-270	252-253	D010830	physostigmine	Chemical	252	253	9	D002375	catalepsy|catalepsy|catalepsy|catalepsy|catalepsy|catalepsy	Disease	17:52:83:113:147:269	18:53:84:114:148:270	0:2:2:3:4:10	1:NR:2	R2L	NON-CROSS	110-111	94-95	D006220	haloperidol|haloperidol|haloperidol|haloperidol	Chemical	110:144:197:266	111:145:198:267	3:4:7:10	D017109	akathisia|akathisia|akathisia|akathisia	Disease	35:75:94:287	36:76:95:288	1:2:2:10	1:NR:2	R2L	CROSS	124-125	94-95	D011433	propranolol|propranolol|propranolol	Chemical	124:138:160	125:139:161	3:4:5	D017109	akathisia|akathisia|akathisia|akathisia	Disease	35:75:94:287	36:76:95:288	1:2:2:10	1:NR:2	R2L	CROSS	126-127	94-95	D001712	biperiden|biperiden|biperiden	Chemical	126:140:168	127:141:169	3:4:5	D017109	akathisia|akathisia|akathisia|akathisia	Disease	35:75:94:287	36:76:95:288	1:2:2:10	1:NR:2	R2L	NON-CROSS	299-300	287-288	D004298	dopamine|dopamine	Chemical	175:299	176:300	6:10	D017109	akathisia|akathisia|akathisia|akathisia	Disease	35:75:94:287	36:76:95:288	1:2:2:10	1:NR:2	R2L	CROSS	287-288	199-200	D001058	apomorphine	Chemical	199	200	7	D017109	akathisia|akathisia|akathisia|akathisia	Disease	35:75:94:287	36:76:95:288	1:2:2:10	1:NR:2	R2L	CROSS	287-288	236-239	D006916	5 - hydroxytryptophan	Chemical	236	239	8	D017109	akathisia|akathisia|akathisia|akathisia	Disease	35:75:94:287	36:76:95:288	1:2:2:10	1:NR:2	R2L	CROSS	287-288	252-253	D010830	physostigmine	Chemical	252	253	9	D017109	akathisia|akathisia|akathisia|akathisia	Disease	35:75:94:287	36:76:95:288	1:2:2:10	1:NR:2	L2R	CROSS	185-186	197-198	D006220	haloperidol|haloperidol|haloperidol|haloperidol	Chemical	110:144:197:266	111:145:198:267	3:4:7:10	D009069	hyperlocomotion	Disease	185	186	6	1:NR:2	L2R	CROSS	160-161	185-186	D011433	propranolol|propranolol|propranolol	Chemical	124:138:160	125:139:161	3:4:5	D009069	hyperlocomotion	Disease	185	186	6	1:NR:2	L2R	CROSS	168-169	185-186	D001712	biperiden|biperiden|biperiden	Chemical	126:140:168	127:141:169	3:4:5	D009069	hyperlocomotion	Disease	185	186	6	1:NR:2	L2R	NON-CROSS	175-176	185-186	D004298	dopamine|dopamine	Chemical	175:299	176:300	6:10	D009069	hyperlocomotion	Disease	185	186	6	1:NR:2	R2L	CROSS	199-200	185-186	D001058	apomorphine	Chemical	199	200	7	D009069	hyperlocomotion	Disease	185	186	6	1:NR:2	R2L	CROSS	236-239	185-186	D006916	5 - hydroxytryptophan	Chemical	236	239	8	D009069	hyperlocomotion	Disease	185	186	6	1:NR:2	R2L	CROSS	252-253	185-186	D010830	physostigmine	Chemical	252	253	9	D009069	hyperlocomotion	Disease	185	186	6
8267029	Penicillamine - induced rapidly progressive glomerulonephritis in a patient with rheumatoid arthritis .|A 67 - year - old woman with rheumatoid arthritis presented rapidly progressive glomerulonephritis ( RPGN ) after 5 months of D - penicillamine ( 250 mg / day ) treatment .|Light microscopy study showed severe glomerulonephritis with crescent formation in 60 % of the glomeruli and infiltration of inflammatory cells in the wall of an arteriole .|Immunofluorescence revealed scanty granular IgG , IgA and C3 deposits along the capillary walls and mesangium .|The patient was treated with steroid pulse , plasmapheresis , cyclophosphamide and antiplatelet agents .|A complete recovery of renal function was achieved in a few weeks .|This new case of RPGN in the course of D - penicillamine treatment emphasizes the need for frequent monitoring of renal function and evaluation of urinary sediment and proteinuria in these patients .|The prompt discontinuation of D - penicillamine and vigorous treatment measures could allow for a good prognosis as in this case .	1:CID:2	L2R	NON-CROSS	0-1	5-6	D010396	Penicillamine|D - penicillamine|D - penicillamine|D - penicillamine	Chemical	0:34:126:154	1:37:129:157	0:1:6:7	D005921	glomerulonephritis|glomerulonephritis|RPGN|glomerulonephritis|RPGN	Disease	5:26:28:50:121	6:27:29:51:122	0:1:1:2:6	1:NR:2	L2R	NON-CROSS	0-1	10-12	D010396	Penicillamine|D - penicillamine|D - penicillamine|D - penicillamine	Chemical	0:34:126:154	1:37:129:157	0:1:6:7	D001172	rheumatoid arthritis|rheumatoid arthritis	Disease	10:21	12:23	0:1	1:NR:2	L2R	NON-CROSS	145-146	154-157	D010396	Penicillamine|D - penicillamine|D - penicillamine|D - penicillamine	Chemical	0:34:126:154	1:37:129:157	0:1:6:7	D011507	proteinuria	Disease	145	146	6	1:NR:2	R2L	CROSS	121-122	94-95	D013256	steroid	Chemical	94	95	4	D005921	glomerulonephritis|glomerulonephritis|RPGN|glomerulonephritis|RPGN	Disease	5:26:28:50:121	6:27:29:51:122	0:1:1:2:6	1:NR:2	R2L	CROSS	121-122	99-100	D003520	cyclophosphamide	Chemical	99	100	4	D005921	glomerulonephritis|glomerulonephritis|RPGN|glomerulonephritis|RPGN	Disease	5:26:28:50:121	6:27:29:51:122	0:1:1:2:6	1:NR:2	R2L	CROSS	121-122	101-103	D010975	antiplatelet agents	Chemical	101	103	4	D005921	glomerulonephritis|glomerulonephritis|RPGN|glomerulonephritis|RPGN	Disease	5:26:28:50:121	6:27:29:51:122	0:1:1:2:6	1:NR:2	R2L	CROSS	94-95	21-23	D013256	steroid	Chemical	94	95	4	D001172	rheumatoid arthritis|rheumatoid arthritis	Disease	10:21	12:23	0:1	1:NR:2	R2L	CROSS	99-100	21-23	D003520	cyclophosphamide	Chemical	99	100	4	D001172	rheumatoid arthritis|rheumatoid arthritis	Disease	10:21	12:23	0:1	1:NR:2	R2L	CROSS	101-103	21-23	D010975	antiplatelet agents	Chemical	101	103	4	D001172	rheumatoid arthritis|rheumatoid arthritis	Disease	10:21	12:23	0:1	1:NR:2	L2R	CROSS	94-95	145-146	D013256	steroid	Chemical	94	95	4	D011507	proteinuria	Disease	145	146	6	1:NR:2	L2R	CROSS	99-100	145-146	D003520	cyclophosphamide	Chemical	99	100	4	D011507	proteinuria	Disease	145	146	6	1:NR:2	L2R	CROSS	101-103	145-146	D010975	antiplatelet agents	Chemical	101	103	4	D011507	proteinuria	Disease	145	146	6
2528969	Nature , time course and dose dependence of zidovudine - related side effects : results from the Multicenter Canadian Azidothymidine Trial .|To characterize the nature , time course and dose dependency of zidovudine - related side effects , we undertook a multicenter , prospective , dose - range finding study .|Our study group consisted of 74 HIV - positive homosexual men belonging to groups II B , III and IV C2 from the Centers for Disease Control ( CDC ) classification of HIV disease .|Following a 3 - week observation period , volunteers were treated with zidovudine 600 mg / day for 18 weeks , 900 mg / day for 9 weeks and 1200 mg / day for 9 weeks , followed by a washout period of 6 weeks after which they were re - started on 1200 mg / day or the highest tolerated dose at 8 - hourly intervals .|Subjects were randomly assigned to 4 - hourly or 8 - hourly regimens within CDC groups while taking 600 and 1200 mg / day .|Clinical and laboratory evaluations were performed at 3 - week intervals .|Symptomatic adverse effects were present in 96 % of subjects , most commonly nausea ( 64 % ) , fatigue ( 55 % ) and headache ( 49 % ) .|These were generally self - limited , reappearing briefly at each dose increment .|A decrease in hemoglobin occurred shortly after initiation of therapy .|This was not dose dependent and reversed rapidly upon discontinuation of treatment .|A red blood cell count decrease , a mean cell volume increase and a granulocyte count decrease developed early in a dose - independent fashion , reverting at least partially during the washout phase .|The decrease in reticulocyte count was dose related between 600 and 900 mg / day with no further change when the dose was escalated to 1200 mg / day .|Bone marrow changes occurred rapidly as demonstrated by megaloblastosis in 95 % of 65 specimens at week 18 . ( ABSTRACT TRUNCATED AT 250 WORDS )	1:NR:2	L2R	CROSS	84-86	99-100	D015215	zidovudine|Azidothymidine|zidovudine|zidovudine	Chemical	8:19:33:99	9:20:34:100	0:0:1:3	D015658	HIV disease	Disease	84	86	2	1:CID:2	L2R	CROSS	99-100	205-206	D015215	zidovudine|Azidothymidine|zidovudine|zidovudine	Chemical	8:19:33:99	9:20:34:100	0:0:1:3	D009325	nausea	Disease	205	206	6	1:CID:2	L2R	CROSS	99-100	211-212	D015215	zidovudine|Azidothymidine|zidovudine|zidovudine	Chemical	8:19:33:99	9:20:34:100	0:0:1:3	D005221	fatigue	Disease	211	212	6	1:CID:2	L2R	CROSS	99-100	217-218	D015215	zidovudine|Azidothymidine|zidovudine|zidovudine	Chemical	8:19:33:99	9:20:34:100	0:0:1:3	D006261	headache	Disease	217	218	6
384871	Bilateral optic neuropathy due to combined ethambutol and isoniazid treatment .|The case of a 40 - year - old patient who underwent an unsuccessful cadaver kidney transplantation and was treated with ethambutol and isoniazid is reported .|A bilateral retrobulbar neuropathy with an unusual central bitemporal hemianopic scotoma was found .|Ethambutol was stopped and only small improvement of the visual acuity followed .|Isoniazid was discontinued later , followed by a dramatic improvement in the visual acuity .|The hazards of optic nerve toxicity due to ethambutol are known .|We emphasize the potential danger in the use of ethambutol and isoniazid .	1:CID:2	R2L	NON-CROSS	6-7	0-3	D004977	ethambutol|ethambutol|Ethambutol|ethambutol|ethambutol	Chemical	6:32:52:88:101	7:33:53:89:102	0:1:3:5:6	D009901	Bilateral optic neuropathy|bilateral retrobulbar neuropathy	Disease	0:39	3:42	0:2	1:CID:2	R2L	NON-CROSS	39-42	34-35	D007538	isoniazid|isoniazid|Isoniazid|isoniazid	Chemical	8:34:65:103	9:35:66:104	0:1:4:6	D009901	Bilateral optic neuropathy|bilateral retrobulbar neuropathy	Disease	0:39	3:42	0:2	1:CID:2	L2R	CROSS	48-49	52-53	D004977	ethambutol|ethambutol|Ethambutol|ethambutol|ethambutol	Chemical	6:32:52:88:101	7:33:53:89:102	0:1:3:5:6	D012607	scotoma	Disease	48	49	2	1:NR:2	L2R	NON-CROSS	85-86	88-89	D004977	ethambutol|ethambutol|Ethambutol|ethambutol|ethambutol	Chemical	6:32:52:88:101	7:33:53:89:102	0:1:3:5:6	D064420	toxicity	Disease	85	86	5	1:CID:2	L2R	CROSS	34-35	48-49	D007538	isoniazid|isoniazid|Isoniazid|isoniazid	Chemical	8:34:65:103	9:35:66:104	0:1:4:6	D012607	scotoma	Disease	48	49	2	1:NR:2	L2R	CROSS	85-86	103-104	D007538	isoniazid|isoniazid|Isoniazid|isoniazid	Chemical	8:34:65:103	9:35:66:104	0:1:4:6	D064420	toxicity	Disease	85	86	5
133615	Progestational agents and blood coagulation .|VII .|Thromboembolic and other complications of oral contraceptive therapy in relationship to pretreatment levels of blood coagulation factors : summary report of a ten - year study .|During a ten - year period , 348 women were studied for a total of 5 , 877 patient months in four separate studies relating oral contraceptives to changes in hematologic parameters .|Significant increases in certain factors of the blood coagulation and fibrinolysin systems ( factors I , II , VII , VIII , IX , and X and plasminogen ) were observed in the treated groups .|Severe complications developed in four patients .|All four had an abnormal blood coagulation profile , suggesting " hypercoagulability " before initiation of therapy .|Some of these findings represented the most extreme abnormalities seen in the entire group of patients ; some increased further during therapy .|One of these patients developed a myocardial infarction before receiving any medication , shortly after the base - line values were obtained .|One patient developed retinopathy 19 months after she began therapy , and another developed thrombophlebitis after 27 months of therapy .|The fourth patient developed thrombophlebitis 14 days after initiation of contraceptive therapy .|All four patients were of the A or AB blood group .|Previous studies suggested the possiblility of increased propensity for thromboembolic episodes in patients possessing the A antigen .|It appears from these data that hematologic work - ups may be useful in women who are about to start long - term oral contraceptive therapy .	1:CID:2	R2L	NON-CROSS	22-24	13-15	D003276	oral contraceptive|oral contraceptives|oral contraceptive	Chemical	13:60:262	15:62:264	2:3:13	D001778	blood coagulation|blood coagulation|blood coagulation|blood coagulation	Disease	3:22:75:116	5:24:77:118	0:2:4:6	1:NR:2	R2L	NON-CROSS	13-15	8-9	D003276	oral contraceptive|oral contraceptives|oral contraceptive	Chemical	13:60:262	15:62:264	2:3:13	D013923	Thromboembolic|thromboembolic episodes	Disease	8:230	9:232	2:12	1:NR:2	L2R	CROSS	60-62	122-123	D003276	oral contraceptive|oral contraceptives|oral contraceptive	Chemical	13:60:262	15:62:264	2:3:13	D019851	hypercoagulability	Disease	122	123	6	1:CID:2	L2R	CROSS	60-62	158-160	D003276	oral contraceptive|oral contraceptives|oral contraceptive	Chemical	13:60:262	15:62:264	2:3:13	D009203	myocardial infarction	Disease	158	160	8	1:CID:2	L2R	CROSS	178-179	262-264	D003276	oral contraceptive|oral contraceptives|oral contraceptive	Chemical	13:60:262	15:62:264	2:3:13	D012164	retinopathy	Disease	178	179	9	1:CID:2	L2R	CROSS	200-201	262-264	D003276	oral contraceptive|oral contraceptives|oral contraceptive	Chemical	13:60:262	15:62:264	2:3:13	D013924	thrombophlebitis|thrombophlebitis	Disease	189:200	190:201	9:10
17263743	Cardiac arrest in a child with cerebral palsy undergoing sevoflurane induction of anesthesia after preoperative clonidine .|Clonidine is a frequently administered alpha2 - adrenergic agonist which can decrease heart rate and blood pressure .|We present a case of a 5 - year - old child with cerebral palsy and seizure disorder , receiving clonidine for restlessness , who presented for placement of a baclofen pump .|Without the knowledge of the medical personnel , the patient 's mother administered three doses of clonidine during the evening before and morning of surgery to reduce anxiety .|During induction of anesthesia , the patient developed bradycardia and hypotension requiring cardiac resuscitation .|There are no previous reports of clonidine - associated cardiac arrest in a child undergoing induction of anesthesia .	1:NR:2	R2L	NON-CROSS	9-10	0-2	C009250	sevoflurane	Chemical	9	10	0	D006323	Cardiac arrest|cardiac arrest	Disease	0:121	2:123	0:5	1:CID:2	R2L	NON-CROSS	121-123	118-119	D003000	clonidine|Clonidine|clonidine|clonidine|clonidine	Chemical	15:17:55:84:118	16:18:56:85:119	0:1:2:3:5	D006323	Cardiac arrest|cardiac arrest	Disease	0:121	2:123	0:5	1:NR:2	R2L	CROSS	121-123	65-66	D001418	baclofen	Chemical	65	66	2	D006323	Cardiac arrest|cardiac arrest	Disease	0:121	2:123	0:5	1:NR:2	R2L	NON-CROSS	9-10	6-8	C009250	sevoflurane	Chemical	9	10	0	D002547	cerebral palsy|cerebral palsy	Disease	6:48	8:50	0:2	1:NR:2	R2L	NON-CROSS	55-56	48-50	D003000	clonidine|Clonidine|clonidine|clonidine|clonidine	Chemical	15:17:55:84:118	16:18:56:85:119	0:1:2:3:5	D002547	cerebral palsy|cerebral palsy	Disease	6:48	8:50	0:2	1:NR:2	R2L	NON-CROSS	65-66	48-50	D001418	baclofen	Chemical	65	66	2	D002547	cerebral palsy|cerebral palsy	Disease	6:48	8:50	0:2	1:NR:2	L2R	CROSS	9-10	51-53	C009250	sevoflurane	Chemical	9	10	0	D004827	seizure disorder	Disease	51	53	2	1:NR:2	L2R	CROSS	9-10	57-58	C009250	sevoflurane	Chemical	9	10	0	D011595	restlessness	Disease	57	58	2	1:NR:2	L2R	CROSS	9-10	95-96	C009250	sevoflurane	Chemical	9	10	0	D001008	anxiety	Disease	95	96	3	1:NR:2	L2R	CROSS	9-10	105-106	C009250	sevoflurane	Chemical	9	10	0	D001919	bradycardia	Disease	105	106	4	1:NR:2	L2R	CROSS	9-10	107-108	C009250	sevoflurane	Chemical	9	10	0	D007022	hypotension	Disease	107	108	4	1:NR:2	L2R	NON-CROSS	51-53	55-56	D003000	clonidine|Clonidine|clonidine|clonidine|clonidine	Chemical	15:17:55:84:118	16:18:56:85:119	0:1:2:3:5	D004827	seizure disorder	Disease	51	53	2	1:NR:2	L2R	NON-CROSS	55-56	57-58	D003000	clonidine|Clonidine|clonidine|clonidine|clonidine	Chemical	15:17:55:84:118	16:18:56:85:119	0:1:2:3:5	D011595	restlessness	Disease	57	58	2	1:NR:2	L2R	NON-CROSS	84-85	95-96	D003000	clonidine|Clonidine|clonidine|clonidine|clonidine	Chemical	15:17:55:84:118	16:18:56:85:119	0:1:2:3:5	D001008	anxiety	Disease	95	96	3	1:CID:2	L2R	CROSS	105-106	118-119	D003000	clonidine|Clonidine|clonidine|clonidine|clonidine	Chemical	15:17:55:84:118	16:18:56:85:119	0:1:2:3:5	D001919	bradycardia	Disease	105	106	4	1:CID:2	L2R	CROSS	107-108	118-119	D003000	clonidine|Clonidine|clonidine|clonidine|clonidine	Chemical	15:17:55:84:118	16:18:56:85:119	0:1:2:3:5	D007022	hypotension	Disease	107	108	4	1:NR:2	R2L	NON-CROSS	65-66	51-53	D001418	baclofen	Chemical	65	66	2	D004827	seizure disorder	Disease	51	53	2	1:NR:2	R2L	NON-CROSS	65-66	57-58	D001418	baclofen	Chemical	65	66	2	D011595	restlessness	Disease	57	58	2	1:NR:2	L2R	CROSS	65-66	95-96	D001418	baclofen	Chemical	65	66	2	D001008	anxiety	Disease	95	96	3	1:NR:2	L2R	CROSS	65-66	105-106	D001418	baclofen	Chemical	65	66	2	D001919	bradycardia	Disease	105	106	4	1:NR:2	L2R	CROSS	65-66	107-108	D001418	baclofen	Chemical	65	66	2	D007022	hypotension	Disease	107	108	4
17241657	Effects of UMB24 and ( + / - ) - SM 21 , putative sigma2 - preferring antagonists , on behavioral toxic and stimulant effects of cocaine in mice .|Earlier studies have demonstrated that antagonism of sigma1 receptors attenuates the convulsive , lethal , locomotor stimulatory and rewarding actions of cocaine in mice .|In contrast , the contribution of sigma2 receptors is unclear because experimental tools to selectively target this subtype are unavailable .|To begin addressing this need , we characterized UMB24 ( 1 - ( 2 - phenethyl ) - 4 - ( 2 - pyridyl ) - piperazine ) and ( + / - ) - SM 21 ( 3alpha - tropanyl - 2 - ( 4 - chorophenoxy ) butyrate ) in receptor binding and behavioral studies .|Receptor binding studies confirmed that UMB24 and ( + / - ) - SM 21 display preferential affinity for sigma2 over sigma1 receptors .|In behavioral studies , pretreatment of Swiss Webster mice with UMB24 or ( + / - ) - SM 21 significantly attenuated cocaine - induced convulsions and locomotor activity , but not lethality .|When administered alone , ( + / - ) - SM 21 produced no significant effects compared to control injections of saline , but UMB24 had locomotor depressant actions .|Together , the data suggest that sigma2 receptor antagonists have the potential to attenuate some of the behavioral effects of cocaine , and further development of more selective , high affinity ligands are warranted .	1:NR:2	L2R	NON-CROSS	168-169	183-184	C519696	UMB24|UMB24|1 - ( 2 - phenethyl ) - 4 - ( 2 - pyridyl ) - piperazine|UMB24|UMB24|UMB24	Chemical	2:84:86:139:168:216	3:85:103:140:169:217	0:3:3:4:5:6	D012640	convulsive|convulsions	Disease	41:183	42:184	1:5	1:NR:2	L2R	NON-CROSS	176-178	183-184	C107044	SM 21|SM 21|3alpha - tropanyl - 2 - ( 4 - chorophenoxy ) butyrate|SM 21|SM 21|SM 21	Chemical	10:111:114:147:176:202	12:113:126:149:178:204	0:3:3:4:5:6	D012640	convulsive|convulsions	Disease	41:183	42:184	1:5	1:CID:2	L2R	NON-CROSS	180-181	183-184	D003042	cocaine|cocaine|cocaine|cocaine	Chemical	26:51:180:242	27:52:181:243	0:1:5:7	D012640	convulsive|convulsions	Disease	41:183	42:184	1:5
14982270	Methimazole - induced cholestatic jaundice .|Methimazole is a widely used and generally well - tolerated antithyroid agent .|A 43 - year - old woman had severe jaundice and itching 1 month after receiving methimazole ( 10 mg tid ) and propranolol ( 20 mg tid ) for treatment of hyperthyroidism .|The patient continued treatment for another 4 days after the appearance of jaundice until she finished both medications .|When seen at the emergency department 2 weeks later , she still had severe icterus , pruritus , and hyperbilirubinemia , formed mainly of the conjugated fraction .|Methimazole - induced cholestasis was diagnosed , and propranolol therapy was resumed .|Over the following 9 days , the symptoms improved and plasma bilirubin levels were normal after 12 weeks without methimazole .|In rare cases within the first few weeks of therapy , this drug can cause severe and reversible cholestatic jaundice .|Physicians and patients should be aware of this adverse effect so that , upon occurrence , they can discontinue methimazole therapy and avoid unnecessary invasive procedures .	1:CID:2	L2R	NON-CROSS	3-5	6-7	D008713	Methimazole|Methimazole|methimazole|Methimazole|methimazole|methimazole	Chemical	0:6:35:100:132:174	1:7:36:101:133:175	0:1:2:5:6:8	D041781	cholestatic jaundice|cholestatic jaundice	Disease	3:152	5:154	0:7	1:NR:2	L2R	NON-CROSS	28-29	35-36	D008713	Methimazole|Methimazole|methimazole|Methimazole|methimazole|methimazole	Chemical	0:6:35:100:132:174	1:7:36:101:133:175	0:1:2:5:6:8	D007565	jaundice|jaundice|icterus	Disease	28:65:86	29:66:87	2:3:4	1:CID:2	L2R	NON-CROSS	30-31	35-36	D008713	Methimazole|Methimazole|methimazole|Methimazole|methimazole|methimazole	Chemical	0:6:35:100:132:174	1:7:36:101:133:175	0:1:2:5:6:8	D011537	itching|pruritus	Disease	30:88	31:89	2:4	1:NR:2	L2R	NON-CROSS	35-36	51-52	D008713	Methimazole|Methimazole|methimazole|Methimazole|methimazole|methimazole	Chemical	0:6:35:100:132:174	1:7:36:101:133:175	0:1:2:5:6:8	D006980	hyperthyroidism	Disease	51	52	2	1:CID:2	L2R	CROSS	91-92	100-101	D008713	Methimazole|Methimazole|methimazole|Methimazole|methimazole|methimazole	Chemical	0:6:35:100:132:174	1:7:36:101:133:175	0:1:2:5:6:8	D006932	hyperbilirubinemia	Disease	91	92	4	1:NR:2	L2R	NON-CROSS	100-101	103-104	D008713	Methimazole|Methimazole|methimazole|Methimazole|methimazole|methimazole	Chemical	0:6:35:100:132:174	1:7:36:101:133:175	0:1:2:5:6:8	D002779	cholestasis	Disease	103	104	5	1:NR:2	R2L	CROSS	42-43	3-5	D011433	propranolol|propranolol	Chemical	42:108	43:109	2:5	D041781	cholestatic jaundice|cholestatic jaundice	Disease	3:152	5:154	0:7	1:NR:2	R2L	CROSS	152-154	124-125	D001663	bilirubin	Chemical	124	125	6	D041781	cholestatic jaundice|cholestatic jaundice	Disease	3:152	5:154	0:7	1:NR:2	R2L	NON-CROSS	42-43	28-29	D011433	propranolol|propranolol	Chemical	42:108	43:109	2:5	D007565	jaundice|jaundice|icterus	Disease	28:65:86	29:66:87	2:3:4	1:NR:2	R2L	CROSS	124-125	86-87	D001663	bilirubin	Chemical	124	125	6	D007565	jaundice|jaundice|icterus	Disease	28:65:86	29:66:87	2:3:4	1:NR:2	R2L	NON-CROSS	42-43	30-31	D011433	propranolol|propranolol	Chemical	42:108	43:109	2:5	D011537	itching|pruritus	Disease	30:88	31:89	2:4	1:NR:2	R2L	CROSS	124-125	88-89	D001663	bilirubin	Chemical	124	125	6	D011537	itching|pruritus	Disease	30:88	31:89	2:4	1:NR:2	L2R	NON-CROSS	42-43	51-52	D011433	propranolol|propranolol	Chemical	42:108	43:109	2:5	D006980	hyperthyroidism	Disease	51	52	2	1:NR:2	L2R	CROSS	91-92	108-109	D011433	propranolol|propranolol	Chemical	42:108	43:109	2:5	D006932	hyperbilirubinemia	Disease	91	92	4	1:NR:2	L2R	NON-CROSS	103-104	108-109	D011433	propranolol|propranolol	Chemical	42:108	43:109	2:5	D002779	cholestasis	Disease	103	104	5	1:NR:2	R2L	CROSS	124-125	51-52	D001663	bilirubin	Chemical	124	125	6	D006980	hyperthyroidism	Disease	51	52	2	1:NR:2	R2L	CROSS	124-125	91-92	D001663	bilirubin	Chemical	124	125	6	D006932	hyperbilirubinemia	Disease	91	92	4	1:NR:2	R2L	CROSS	124-125	103-104	D001663	bilirubin	Chemical	124	125	6	D002779	cholestasis	Disease	103	104	5
12911170	Ciprofloxacin - induced acute interstitial nephritis and autoimmune hemolytic anemia .|Ciprofloxacin has been associated with several side effects including interstitial nephritis and hemolytic anemia .|The combination of both side effects is extremely rare .|In this report , we describe a case of ciprofloxacin - induced interstitial nephritis and autoimmune hemolytic anemia .|Hemolytic anemia improved after stopping the drug and initiation of steroid therapy .|Unfortunately , acute interstitial nephritis was irreversible and the patient developed end - stage renal disease .	1:CID:2	L2R	NON-CROSS	45-46	48-50	D002939	Ciprofloxacin|Ciprofloxacin|ciprofloxacin	Chemical	0:11:45	1:12:46	0:1:3	D009395	interstitial nephritis|interstitial nephritis|interstitial nephritis|interstitial nephritis	Disease	4:20:48:71	6:22:50:73	0:1:3:5	1:NR:2	L2R	NON-CROSS	7-10	11-12	D002939	Ciprofloxacin|Ciprofloxacin|ciprofloxacin	Chemical	0:11:45	1:12:46	0:1:3	D000744	autoimmune hemolytic anemia|autoimmune hemolytic anemia	Disease	7:51	10:54	0:3	1:CID:2	L2R	NON-CROSS	45-46	55-57	D002939	Ciprofloxacin|Ciprofloxacin|ciprofloxacin	Chemical	0:11:45	1:12:46	0:1:3	D000743	hemolytic anemia|Hemolytic anemia	Disease	23:55	25:57	1:4	1:CID:2	L2R	CROSS	45-46	79-84	D002939	Ciprofloxacin|Ciprofloxacin|ciprofloxacin	Chemical	0:11:45	1:12:46	0:1:3	D007676	end - stage renal disease	Disease	79	84	5	1:NR:2	R2L	CROSS	71-73	65-66	D013256	steroid	Chemical	65	66	4	D009395	interstitial nephritis|interstitial nephritis|interstitial nephritis|interstitial nephritis	Disease	4:20:48:71	6:22:50:73	0:1:3:5	1:NR:2	R2L	CROSS	65-66	51-54	D013256	steroid	Chemical	65	66	4	D000744	autoimmune hemolytic anemia|autoimmune hemolytic anemia	Disease	7:51	10:54	0:3	1:NR:2	R2L	NON-CROSS	65-66	55-57	D013256	steroid	Chemical	65	66	4	D000743	hemolytic anemia|Hemolytic anemia	Disease	23:55	25:57	1:4	1:NR:2	L2R	CROSS	65-66	79-84	D013256	steroid	Chemical	65	66	4	D007676	end - stage renal disease	Disease	79	84	5
11195262	Contribution of sodium valproate to the syndrome of inappropriate secretion of antidiuretic hormone .|We report the case of a 62 - year - old man who was administered sodium valproate ( VPA ) and who subsequently developed the syndrome of inappropriate secretion of antidiuretic hormone ( SIADH ) .|He had been taking VPA for treatment of idiopathic generalized tonic - clonic convulsions since he was 56 years old .|After substituting VPA with zonisamide , the serum sodium level returned to normal .|We consider this episode of SIADH to be the result of a combination of factors including a weakness of the central nervous system and the long - term administration of VPA .	1:CID:2	L2R	NON-CROSS	2-4	6-13	D014635	sodium valproate|sodium valproate|VPA|VPA|VPA|VPA	Chemical	2:29:32:54:73:115	4:31:33:55:74:116	0:1:1:2:3:4	D007177	syndrome of inappropriate secretion of antidiuretic hormone|syndrome of inappropriate secretion of antidiuretic hormone|SIADH|SIADH	Disease	6:39:47:90	13:46:48:91	0:1:1:4	1:NR:2	L2R	NON-CROSS	54-55	60-64	D014635	sodium valproate|sodium valproate|VPA|VPA|VPA|VPA	Chemical	2:29:32:54:73:115	4:31:33:55:74:116	0:1:1:2:3:4	D004830	tonic - clonic convulsions	Disease	60	64	2	1:NR:2	L2R	NON-CROSS	102-108	115-116	D014635	sodium valproate|sodium valproate|VPA|VPA|VPA|VPA	Chemical	2:29:32:54:73:115	4:31:33:55:74:116	0:1:1:2:3:4	D002493	weakness of the central nervous system	Disease	102	108	4	1:NR:2	R2L	CROSS	90-91	75-76	C022189	zonisamide	Chemical	75	76	3	D007177	syndrome of inappropriate secretion of antidiuretic hormone|syndrome of inappropriate secretion of antidiuretic hormone|SIADH|SIADH	Disease	6:39:47:90	13:46:48:91	0:1:1:4	1:NR:2	R2L	CROSS	90-91	79-80	D012964	sodium	Chemical	79	80	3	D007177	syndrome of inappropriate secretion of antidiuretic hormone|syndrome of inappropriate secretion of antidiuretic hormone|SIADH|SIADH	Disease	6:39:47:90	13:46:48:91	0:1:1:4	1:NR:2	R2L	CROSS	75-76	60-64	C022189	zonisamide	Chemical	75	76	3	D004830	tonic - clonic convulsions	Disease	60	64	2	1:NR:2	R2L	CROSS	79-80	60-64	D012964	sodium	Chemical	79	80	3	D004830	tonic - clonic convulsions	Disease	60	64	2	1:NR:2	L2R	CROSS	75-76	102-108	C022189	zonisamide	Chemical	75	76	3	D002493	weakness of the central nervous system	Disease	102	108	4	1:NR:2	L2R	CROSS	79-80	102-108	D012964	sodium	Chemical	79	80	3	D002493	weakness of the central nervous system	Disease	102	108	4
10728962	Vasopressin in the treatment of milrinone - induced hypotension in severe heart failure .|The use of phosphodiesterase inhibitors such as milrinone in the treatment of severe heart failure is frequently restricted because they cause vasodilation and hypotension .|In patients with decompensated heart failure with hypotension after treatment with milrinone , low doses of vasopressin restored blood pressure without inhibiting the inotropic effect of milrinone .	1:CID:2	L2R	NON-CROSS	0-1	8-9	D014667	Vasopressin|vasopressin	Chemical	0:55	1:56	0:2	D007022	hypotension|hypotension|hypotension	Disease	8:37:46	9:38:47	0:1:2	1:NR:2	L2R	NON-CROSS	0-1	11-13	D014667	Vasopressin|vasopressin	Chemical	0:55	1:56	0:2	D006333	heart failure|heart failure|heart failure	Disease	11:27:43	13:29:45	0:1:2	1:CID:2	L2R	NON-CROSS	5-6	8-9	D020105	milrinone|milrinone|milrinone|milrinone	Chemical	5:21:50:65	6:22:51:66	0:1:2:2	D007022	hypotension|hypotension|hypotension	Disease	8:37:46	9:38:47	0:1:2	1:NR:2	L2R	NON-CROSS	5-6	11-13	D020105	milrinone|milrinone|milrinone|milrinone	Chemical	5:21:50:65	6:22:51:66	0:1:2:2	D006333	heart failure|heart failure|heart failure	Disease	11:27:43	13:29:45	0:1:2
7647582	Halogenated anesthetics form liver adducts and antigens that cross - react with halothane - induced antibodies .|Two halogenated anesthetics , enflurane and isoflurane , have been associated with an allergic - type hepatic injury both alone and following previous exposure to halothane .|Halothane hepatitis appears to involve an aberrant immune response .|An antibody response to a protein - bound biotransformation product ( trifluoroacetyl adduct ) has been detected on halothane hepatitis patients .|This study was performed to determine cross - reactivity between enflurane and isoflurane with the hypersensitivity induced by halothane .|The subcellular and lobular production of hepatic neoantigens recognized by halothane - induced antibodies following enflurane and isoflurane , and the biochemical nature of these neoantigens was investigated in two animal models .|Enflurane administration resulted in neoantigens detected in both the microsomal and cytosolic fraction of liver homogenates and in the centrilobular region of the liver .|In the same liver , biochemical analysis detected fluorinated liver adducts that were up to 20 - fold greater in guinea pigs than in rats .|This supports and extends previous evidence for a mechanism by which enflurane and / or isoflurane could produce a hypersensitivity condition similar to that of halothane hepatitis either alone or subsequent to halothane administration .|The guinea pig would appear to be a useful model for further investigations of the immunological response to these antigens .	1:CID:2	L2R	NON-CROSS	44-45	45-46	D006221	halothane|halothane|Halothane|halothane|halothane|halothane|halothane|halothane	Chemical	12:42:44:72:94:106:205:212	13:43:45:73:95:107:206:213	0:1:2:3:4:5:8:8	D056486	hepatic injury|hepatitis|hepatitis|hepatitis	Disease	33:45:73:206	35:46:74:207	1:2:3:8	1:NR:2	L2R	NON-CROSS	91-92	94-95	D006221	halothane|halothane|Halothane|halothane|halothane|halothane|halothane|halothane	Chemical	12:42:44:72:94:106:205:212	13:43:45:73:95:107:206:213	0:1:2:3:4:5:8:8	D004342	hypersensitivity|hypersensitivity	Disease	91:199	92:200	4:8	1:CID:2	L2R	NON-CROSS	21-22	33-35	D004737	enflurane|enflurane|enflurane|Enflurane|enflurane	Chemical	21:86:111:129:191	22:87:112:130:192	1:4:5:6:8	D056486	hepatic injury|hepatitis|hepatitis|hepatitis	Disease	33:45:73:206	35:46:74:207	1:2:3:8	1:NR:2	L2R	NON-CROSS	86-87	91-92	D004737	enflurane|enflurane|enflurane|Enflurane|enflurane	Chemical	21:86:111:129:191	22:87:112:130:192	1:4:5:6:8	D004342	hypersensitivity|hypersensitivity	Disease	91:199	92:200	4:8	1:CID:2	L2R	NON-CROSS	23-24	33-35	D007530	isoflurane|isoflurane|isoflurane|isoflurane	Chemical	23:88:113:195	24:89:114:196	1:4:5:8	D056486	hepatic injury|hepatitis|hepatitis|hepatitis	Disease	33:45:73:206	35:46:74:207	1:2:3:8	1:NR:2	L2R	NON-CROSS	88-89	91-92	D007530	isoflurane|isoflurane|isoflurane|isoflurane	Chemical	23:88:113:195	24:89:114:196	1:4:5:8	D004342	hypersensitivity|hypersensitivity	Disease	91:199	92:200	4:8	1:NR:2	R2L	NON-CROSS	73-74	65-66	D014269	trifluoroacetyl	Chemical	65	66	3	D056486	hepatic injury|hepatitis|hepatitis|hepatitis	Disease	33:45:73:206	35:46:74:207	1:2:3:8	1:NR:2	L2R	CROSS	65-66	91-92	D014269	trifluoroacetyl	Chemical	65	66	3	D004342	hypersensitivity|hypersensitivity	Disease	91:199	92:200	4:8
4090988	Induction by paracetamol of bladder and liver tumours in the rat .|Effects on hepatocyte fine structure .|Groups of male and female inbred Leeds strain rats were fed diets containing either 0 . 5 % or 1 . 0 % paracetamol by weight for up to 18 months .|At the 1 . 0 % dosage level , 20 % of rats of both sexes developed neoplastic nodules of the liver , a statistically significant incidence .|These rats also showed gross enlargement of their livers and an increase in foci of cellular alteration , the latter also being observed in the low dosage male rats .|Papillomas of the transitional epithelium of the bladder developed in all paracetamol - treated groups , and three rats bore bladder carcinomas .|However , significant yields of bladder tumours were only obtained from low dosage females and high dosage males .|Additionally , 20 to 25 % of paracetamol - treated rats developed hyperplasia of the bladder epithelium , which was not coincident with the presence of bladder calculi .|A low yield of tumours at various other sites also arose following paracetamol feeding .|An electron microscope study of the livers of paracetamol - treated rats revealed ultrastructural changes in the hepatocytes that resemble those that result from exposure to a variety of known hepatocarcinogens .	1:CID:2	L2R	NON-CROSS	2-3	4-8	D000082	paracetamol|paracetamol|paracetamol|paracetamol|paracetamol|paracetamol	Chemical	2:41:119:157:191:202	3:42:120:158:192:203	0:2:5:7:8:9	D001749	bladder and liver tumours|bladder carcinomas|bladder tumours	Disease	4:128:136	8:130:138	0:5:6	1:CID:2	L2R	NON-CROSS	2-3	4-8	D000082	paracetamol|paracetamol|paracetamol|paracetamol|paracetamol|paracetamol	Chemical	2:41:119:157:191:202	3:42:120:158:192:203	0:2:5:7:8:9	D008113	bladder and liver tumours|hepatocarcinogens	Disease	4:224	8:225	0:9	1:NR:2	L2R	NON-CROSS	108-109	119-120	D000082	paracetamol|paracetamol|paracetamol|paracetamol|paracetamol|paracetamol	Chemical	2:41:119:157:191:202	3:42:120:158:192:203	0:2:5:7:8:9	D010212	Papillomas	Disease	108	109	5	1:CID:2	L2R	NON-CROSS	157-158	162-163	D000082	paracetamol|paracetamol|paracetamol|paracetamol|paracetamol|paracetamol	Chemical	2:41:119:157:191:202	3:42:120:158:192:203	0:2:5:7:8:9	D006965	hyperplasia	Disease	162	163	7	1:NR:2	L2R	NON-CROSS	176-178	191-192	D000082	paracetamol|paracetamol|paracetamol|paracetamol|paracetamol|paracetamol	Chemical	2:41:119:157:191:202	3:42:120:158:192:203	0:2:5:7:8:9	D001744	bladder calculi	Disease	176	178	7	1:NR:2	L2R	NON-CROSS	183-184	191-192	D000082	paracetamol|paracetamol|paracetamol|paracetamol|paracetamol|paracetamol	Chemical	2:41:119:157:191:202	3:42:120:158:192:203	0:2:5:7:8:9	D009369	tumours	Disease	183	184	8
4038130	Rat extraocular muscle regeneration .|Repair of local anesthetic - induced damage .|Local anesthetics that are commonly used in ophthalmic surgery ( 0 . 75 % bupivacaine hydrochloride , 2 . 0 % mepivacaine hydrochloride , and 2 . 0 % lidocaine hydrochloride plus 1 : 100 , 000 epinephrine ) were injected into the retrobulbar area of rat eyes .|Controls were injected with physiological saline .|All three anesthetics produced massive degeneration of the extraocular muscles .|Muscle degeneration is followed by regeneration of the damaged muscle fibers .|In addition to muscle damage , severe damage was also seen in harderian glands , especially after exposure to mepivacaine and lidocaine plus epinephrine .|With these findings in rats , it is hypothesized that the temporary diplopia sometimes seen in patients after ophthalmic surgery might be due to anesthetic - induced damage to the extraocular muscles .	1:CID:2	L2R	CROSS	27-29	80-82	D002045	bupivacaine hydrochloride	Chemical	27	29	2	D009135	Muscle degeneration|muscle damage	Disease	80:95	82:97	5:6	1:NR:2	L2R	CROSS	27-29	129-130	D002045	bupivacaine hydrochloride	Chemical	27	29	2	D004172	diplopia	Disease	129	130	7	1:CID:2	L2R	NON-CROSS	95-97	111-112	D008619	mepivacaine hydrochloride|mepivacaine	Chemical	34:111	36:112	2:6	D009135	Muscle degeneration|muscle damage	Disease	80:95	82:97	5:6	1:NR:2	L2R	CROSS	111-112	129-130	D008619	mepivacaine hydrochloride|mepivacaine	Chemical	34:111	36:112	2:6	D004172	diplopia	Disease	129	130	7	1:CID:2	L2R	NON-CROSS	95-97	113-114	D008012	lidocaine hydrochloride|lidocaine	Chemical	42:113	44:114	2:6	D009135	Muscle degeneration|muscle damage	Disease	80:95	82:97	5:6	1:NR:2	L2R	CROSS	113-114	129-130	D008012	lidocaine hydrochloride|lidocaine	Chemical	42:113	44:114	2:6	D004172	diplopia	Disease	129	130	7	1:NR:2	L2R	NON-CROSS	95-97	115-116	D004837	epinephrine|epinephrine	Chemical	50:115	51:116	2:6	D009135	Muscle degeneration|muscle damage	Disease	80:95	82:97	5:6	1:NR:2	L2R	CROSS	115-116	129-130	D004837	epinephrine|epinephrine	Chemical	50:115	51:116	2:6	D004172	diplopia	Disease	129	130	7
2907585	Reversal of neuroleptic - induced catalepsy by novel aryl - piperazine anxiolytic drugs .|The novel anxiolytic drug , buspirone , reverses catalepsy induced by haloperidol .|A series of aryl - piperazine analogues of buspirone and other 5 - hydroxytryptaminergic agonists were tested for their ability to reverse haloperidol induced catalepsy .|Those drugs with strong affinity for 5 - hydroxytryptamine1a receptors were able to reverse catalepsy .|Drugs with affinity for other 5 - HT receptors or weak affinity were ineffective .|However , inhibition of postsynaptic 5 - HT receptors neither inhibited nor potentiated reversal of catalepsy and leaves open the question as to the site or mechanism for this effect .	1:NR:2	R2L	NON-CROSS	22-23	19-20	D002065	buspirone|buspirone	Chemical	19:35	20:36	1:2	D002375	catalepsy|catalepsy|catalepsy|catalepsy|catalepsy	Disease	5:22:51:67:99	6:23:52:68:100	0:1:2:3:5	1:CID:2	R2L	NON-CROSS	51-52	49-50	D006220	haloperidol|haloperidol	Chemical	25:49	26:50	1:2	D002375	catalepsy|catalepsy|catalepsy|catalepsy|catalepsy	Disease	5:22:51:67:99	6:23:52:68:100	0:1:2:3:5	1:NR:2	R2L	NON-CROSS	51-52	38-42	D058825	5 - hydroxytryptaminergic agonists	Chemical	38	42	2	D002375	catalepsy|catalepsy|catalepsy|catalepsy|catalepsy	Disease	5:22:51:67:99	6:23:52:68:100	0:1:2:3:5	1:NR:2	R2L	NON-CROSS	74-77	67-68	D012701	5 - hydroxytryptamine|5 - HT|5 - HT	Chemical	59:74:89	62:77:92	3:4:5	D002375	catalepsy|catalepsy|catalepsy|catalepsy|catalepsy	Disease	5:22:51:67:99	6:23:52:68:100	0:1:2:3:5
2894433	Diazepam facilitates reflex bradycardia in conscious rats .|The effects of diazepam on cardiovascular function were assessed in conscious rats .|Intravenous administration of diazepam ( 1 - 30 mg kg - 1 ) produced a dose - dependent decrease in both the mean arterial pressure and the heart rate .|Also , reflex bradycardia was produced in rats by intravenous infusion of adrenaline ( 1 . 25 - 2 . 5 micrograms kg - 1 ) .|Intravenous pretreatment of the rats with diazepam , although causing no change in the adrenaline - induced pressor effect , did enhance the adrenaline - induced reflex bradycardia .|However , the diazepam enhancement of adrenaline - induced reflex bradycardia was antagonized by pretreatment of rats with an intravenous dose of picrotoxin ( an agent blocks chloride channels by binding to sites associated with the benzodiazepine - GABA - chloride channel macromolecular complex ) .|The data indicate that diazepam acts through the benzodiazepine - GABA - chloride channel macromolecular complex within the central nervous system to facilitate reflex bradycardia mediated through baroreceptor reflexes in response to an acute increase in arterial pressure .	1:CID:2	L2R	NON-CROSS	0-1	3-4	D003975	Diazepam|diazepam|diazepam|diazepam|diazepam|diazepam	Chemical	0:11:24:84:110:157	1:12:25:85:111:158	0:1:2:4:5:6	D001919	bradycardia|bradycardia|bradycardia|bradycardia|bradycardia	Disease	3:54:105:117:177	4:55:106:118:178	0:3:4:5:6	1:CID:2	R2L	NON-CROSS	105-106	101-102	D004837	adrenaline|adrenaline|adrenaline|adrenaline	Chemical	63:92:101:113	64:93:102:114	3:4:4:5	D001919	bradycardia|bradycardia|bradycardia|bradycardia|bradycardia	Disease	3:54:105:117:177	4:55:106:118:178	0:3:4:5:6	1:NR:2	R2L	NON-CROSS	129-130	117-118	D010852	picrotoxin	Chemical	129	130	5	D001919	bradycardia|bradycardia|bradycardia|bradycardia|bradycardia	Disease	3:54:105:117:177	4:55:106:118:178	0:3:4:5:6	1:NR:2	R2L	NON-CROSS	177-178	165-166	D002712	chloride|chloride|chloride	Chemical	134:147:165	135:148:166	5:5:6	D001919	bradycardia|bradycardia|bradycardia|bradycardia|bradycardia	Disease	3:54:105:117:177	4:55:106:118:178	0:3:4:5:6	1:NR:2	R2L	NON-CROSS	177-178	161-162	D001569	benzodiazepine|benzodiazepine	Chemical	143:161	144:162	5:6	D001919	bradycardia|bradycardia|bradycardia|bradycardia|bradycardia	Disease	3:54:105:117:177	4:55:106:118:178	0:3:4:5:6	1:NR:2	R2L	NON-CROSS	177-178	163-164	D005680	GABA|GABA	Chemical	145:163	146:164	5:6	D001919	bradycardia|bradycardia|bradycardia|bradycardia|bradycardia	Disease	3:54:105:117:177	4:55:106:118:178	0:3:4:5:6
2790457	Chronic carbamazepine inhibits the development of local anesthetic seizures kindled by cocaine and lidocaine .|The effects of carbamazepine ( CBZ ) treatment on local anesthetic - kindled seizures and lethality were evaluated in different stages of the kindling process and under different methods of CBZ administration .|Chronic oral CBZ inhibited the development of both lidocaine - and cocaine - induced seizures , but had little effect on the fully developed local anesthetic seizures .|Chronic CBZ also decreased the incidence of seizure - related mortality in the cocaine - injected rats .|Acute CBZ over a range of doses ( 15 - 50 mg / kg ) had no effect on completed lidocaine - kindled or acute cocaine - induced seizures .|Repeated i . p .|injection of CBZ ( 15 mg / kg ) also was without effect on the development of lidocaine - or cocaine - kindled seizures .|The differential effects of CBZ depending upon stage of seizure development suggest that distinct mechanisms underlie the development versus maintenance of local anesthetic - kindled seizures .|The effectiveness of chronic but not repeated , intermittent injections of CBZ suggests that different biochemical consequences result from the different treatment regimens .|The possible utility of chronic CBZ in preventing the development of toxic side effects in human cocaine users is suggested by these data , but remains to be directly evaluated .	1:NR:2	L2R	NON-CROSS	74-75	77-78	D002220	carbamazepine|carbamazepine|CBZ|CBZ|CBZ|CBZ|CBZ|CBZ|CBZ|CBZ|CBZ	Chemical	1:18:20:45:50:77:95:131:158:192:210	2:19:21:46:51:78:96:132:159:193:211	0:1:1:1:2:3:4:6:7:8:9	D012640	seizures|seizures|seizures|seizures|seizure|seizures|seizures|seizure|seizures	Disease	8:28:62:74:83:122:152:163:179	9:29:63:75:84:123:153:164:180	0:1:2:2:3:4:6:7:7	1:CID:2	R2L	NON-CROSS	11-12	8-9	D003042	cocaine|cocaine|cocaine|cocaine|cocaine|cocaine	Chemical	11:59:89:119:149:221	12:60:90:120:150:222	0:2:3:4:6:9	D012640	seizures|seizures|seizures|seizures|seizure|seizures|seizures|seizure|seizures	Disease	8:28:62:74:83:122:152:163:179	9:29:63:75:84:123:153:164:180	0:1:2:2:3:4:6:7:7	1:CID:2	R2L	NON-CROSS	13-14	8-9	D008012	lidocaine|lidocaine|lidocaine|lidocaine	Chemical	13:56:114:146	14:57:115:147	0:2:4:6	D012640	seizures|seizures|seizures|seizures|seizure|seizures|seizures|seizure|seizures	Disease	8:28:62:74:83:122:152:163:179	9:29:63:75:84:123:153:164:180	0:1:2:2:3:4:6:7:7
2334179	D - penicillamine in the treatment of localized scleroderma .|Localized scleroderma has no recognized internal organ involvement but may be disfiguring and disabling when the cutaneous lesions are extensive or affect children .|There is no accepted or proven treatment for localized scleroderma .|Case reports of 11 patients with severe , extensive localized scleroderma who were treated with D - penicillamine are summarized in this article .|This drug was judged to have a favorable effect on the disease course in 7 ( 64 % ) of 11 patients .|Improvement began within 3 to 6 months and consisted of cessation of active cutaneous lesions in all 7 patients , skin softening in 5 , and more normal growth of the affected limb in 2 of 3 children .|Joint stiffness and contractures also improved .|The dose of D - penicillamine associated with a favorable response was as low as 2 to 5 mg / kg per day given over a period ranging from 15 to 53 months .|D - Penicillamine caused nephrotic syndrome in 1 patient and milder reversible proteinuria in 3 other patients ; none developed renal insufficiency .|These data suggest that D - penicillamine may be effective in severe cases of localized scleroderma .	1:NR:2	L2R	NON-CROSS	0-3	7-9	D010396	D - penicillamine|D - penicillamine|D - penicillamine|D - Penicillamine|D - penicillamine	Chemical	0:60:141:172:199	3:63:144:175:202	0:3:7:8:9	D012594	localized scleroderma|Localized scleroderma|localized scleroderma|localized scleroderma|localized scleroderma	Disease	7:10:42:54:209	9:12:44:56:211	0:1:2:3:9	1:NR:2	L2R	CROSS	134-135	141-144	D010396	D - penicillamine|D - penicillamine|D - penicillamine|D - Penicillamine|D - penicillamine	Chemical	0:60:141:172:199	3:63:144:175:202	0:3:7:8:9	D003286	contractures	Disease	134	135	6	1:CID:2	L2R	NON-CROSS	172-175	176-178	D010396	D - penicillamine|D - penicillamine|D - penicillamine|D - Penicillamine|D - penicillamine	Chemical	0:60:141:172:199	3:63:144:175:202	0:3:7:8:9	D009404	nephrotic syndrome	Disease	176	178	8	1:CID:2	L2R	NON-CROSS	172-175	184-185	D010396	D - penicillamine|D - penicillamine|D - penicillamine|D - Penicillamine|D - penicillamine	Chemical	0:60:141:172:199	3:63:144:175:202	0:3:7:8:9	D011507	proteinuria	Disease	184	185	8	1:NR:2	L2R	NON-CROSS	192-194	199-202	D010396	D - penicillamine|D - penicillamine|D - penicillamine|D - Penicillamine|D - penicillamine	Chemical	0:60:141:172:199	3:63:144:175:202	0:3:7:8:9	D051437	renal insufficiency	Disease	192	194	8
1969772	Preservation of renal blood flow during hypotension induced with fenoldopam in dogs .|The introduction of drugs that could induce hypotension with different pharmacological actions would be advantageous because side effects unique to a specific drug could be minimized by selecting appropriate therapy .|Specific dopamine - 1 , ( DA1 ) and dopamine - 2 ( DA2 ) receptor agonists are now under clinical investigation .|Fenoldopam mesylate is a specific DA1 receptor agonist that lowers blood pressure by vasodilatation .|The hypothesis that fenoldopam could be used to induce hypotension and preserve blood flow to the kidney was tested .|Systemic aortic blood pressure and renal blood flow were measured continuously with a carotid arterial catheter and an electromagnetic flow probe respectively , in order to compare the cardiovascular and renal vascular effects of fenoldopam and sodium nitroprusside in ten dogs under halothane general anaesthesia .|Mean arterial pressure was decreased 30 + / - 8 per cent from control with infusion of fenoldopam ( 3 . 4 + / - 2 . 0 micrograms . kg - 1 . min - 1 ) and 34 + / - 4 per cent with infusion of sodium nitroprusside ( 5 . 9 micrograms . kg - 1 . min - 1 ) ( NS ) .|Renal blood flow ( RBF ) increased during fenoldopam - induced hypotension 11 + / - 7 per cent and decreased 21 + / - 8 per cent during sodium nitroprusside - induced hypotension ( P less than 0 . 01 ) .|Sodium nitroprusside is a non - selective arteriolar and venous vasodilator that can produce redistribution of blood flow away from the kidney during induced hypotension .|Fenoldopam is a selective dopamine - 1 ( DA1 ) receptor agonist that causes vasodilatation to the kidney and other organs with DA1 receptors and preserves blood flow to the kidney during induced hypotension .	1:CID:2	R2L	NON-CROSS	9-10	6-7	D018818	fenoldopam|Fenoldopam mesylate|fenoldopam|fenoldopam|fenoldopam|fenoldopam	Chemical	9:67:85:136:165:225	10:69:86:137:166:226	0:3:4:5:6:7	D007022	hypotension|hypotension|hypotension|hypotension|hypotension|hypotension|hypotension	Disease	6:20:91:228:250:284:319	7:21:92:229:251:285:320	0:1:4:7:7:8:9	1:NR:2	R2L	NON-CROSS	290-291	284-285	D004298	dopamine|DA|dopamine|DA|dopamine	Chemical	45:50:53:57:290	46:51:54:58:291	2:2:2:2:9	D007022	hypotension|hypotension|hypotension|hypotension|hypotension|hypotension|hypotension	Disease	6:20:91:228:250:284:319	7:21:92:229:251:285:320	0:1:4:7:7:8:9	1:NR:2	R2L	NON-CROSS	250-251	246-247	D012964	sodium|sodium|sodium	Chemical	138:197:246	139:198:247	5:6:7	D007022	hypotension|hypotension|hypotension|hypotension|hypotension|hypotension|hypotension	Disease	6:20:91:228:250:284:319	7:21:92:229:251:285:320	0:1:4:7:7:8:9	1:CID:2	R2L	NON-CROSS	250-251	247-248	D009599	nitroprusside|nitroprusside|nitroprusside|nitroprusside	Chemical	139:198:247:261	140:199:248:262	5:6:7:8	D007022	hypotension|hypotension|hypotension|hypotension|hypotension|hypotension|hypotension	Disease	6:20:91:228:250:284:319	7:21:92:229:251:285:320	0:1:4:7:7:8:9	1:CID:2	R2L	CROSS	144-145	91-92	D006221	halothane	Chemical	144	145	5	D007022	hypotension|hypotension|hypotension|hypotension|hypotension|hypotension|hypotension	Disease	6:20:91:228:250:284:319	7:21:92:229:251:285:320	0:1:4:7:7:8:9
1700207	Antiarrhythmic effects of optical isomers of cibenzoline on canine ventricular arrhythmias .|Antiarrhythmic effects of ( + ) - cibenzoline and ( - ) - cibenzoline were examined using two canine ventricular arrhythmia models .|Digitalis arrhythmia , which is suppressed by Na channel blockers , was induced by intermittent intravenous ( i . v . ) injection of ouabain in pentobarbital - anesthetized dogs .|Adrenaline arrhythmia , which is suppressed by Ca channel blockers , was induced by adrenaline infusion in halothane - anesthetized dogs .|Ten and 5 mg / kg i . v .|( + ) - cibenzoline suppressed digitalis - and adrenaline - induced arrhythmias , respectively .|The minimum effective plasma concentrations of ( + ) - cibenzoline for digitalis - and adrenaline - induced arrhythmias were 1 . 4 + / - 0 . 4 and 2 . 0 + / - 0 . 6 micrograms / ml , respectively ( mean + / - SD , n = 6 ) .|A lower dose of 1 mg / kg i . v .|of ( - ) - cibenzoline suppressed the digitalis - induced arrhythmia , whereas 5 mg / kg i . v .|was needed to suppress adrenaline - induced arrhythmias .|The minimum effective plasma concentrations of ( - ) - cibenzoline for digitalis - and adrenaline - induced arrhythmia were 0 . 06 + / - 0 . 04 and 0 . 7 + / - 0 . 1 micrograms / ml , respectively ( mean + / - SD , n = 6 ) .|The stronger antiarrhythmic effect of ( - ) - cibenzoline indicates that ( - ) - isomer may have an effect nearly 5 - 20 times stronger in suppressing Na channels , but effects of both drugs on Ca channels may be almost equipotent .	1:NR:2	L2R	NON-CROSS	6-7	9-11	C032151	cibenzoline|cibenzoline|cibenzoline|cibenzoline|cibenzoline|cibenzoline|cibenzoline|cibenzoline	Chemical	6:19:25:102:124:187:223:278	7:20:26:103:125:188:224:279	0:1:1:5:6:8:10:11	D001145	ventricular arrhythmias|ventricular arrhythmia|arrhythmia|Adrenaline arrhythmia|arrhythmias|arrhythmias|arrhythmia|arrhythmias|arrhythmia	Disease	9:31:36:66:110:132:193:211:231	11:33:37:68:111:133:194:212:232	0:1:2:3:5:6:8:9:10	1:NR:2	R2L	NON-CROSS	36-37	35-36	D004070	Digitalis|digitalis|digitalis|digitalis|digitalis	Chemical	35:104:126:190:225	36:105:127:191:226	2:5:6:8:10	D001145	ventricular arrhythmias|ventricular arrhythmia|arrhythmia|Adrenaline arrhythmia|arrhythmias|arrhythmias|arrhythmia|arrhythmias|arrhythmia	Disease	9:31:36:66:110:132:193:211:231	11:33:37:68:111:133:194:212:232	0:1:2:3:5:6:8:9:10	1:NR:2	R2L	NON-CROSS	42-43	36-37	D012964	Na|Na	Chemical	42:298	43:299	2:11	D001145	ventricular arrhythmias|ventricular arrhythmia|arrhythmia|Adrenaline arrhythmia|arrhythmias|arrhythmias|arrhythmia|arrhythmias|arrhythmia	Disease	9:31:36:66:110:132:193:211:231	11:33:37:68:111:133:194:212:232	0:1:2:3:5:6:8:9:10	1:CID:2	R2L	NON-CROSS	66-68	59-60	D010042	ouabain	Chemical	59	60	2	D001145	ventricular arrhythmias|ventricular arrhythmia|arrhythmia|Adrenaline arrhythmia|arrhythmias|arrhythmias|arrhythmia|arrhythmias|arrhythmia	Disease	9:31:36:66:110:132:193:211:231	11:33:37:68:111:133:194:212:232	0:1:2:3:5:6:8:9:10	1:NR:2	R2L	NON-CROSS	66-68	61-62	D010424	pentobarbital	Chemical	61	62	2	D001145	ventricular arrhythmias|ventricular arrhythmia|arrhythmia|Adrenaline arrhythmia|arrhythmias|arrhythmias|arrhythmia|arrhythmias|arrhythmia	Disease	9:31:36:66:110:132:193:211:231	11:33:37:68:111:133:194:212:232	0:1:2:3:5:6:8:9:10	1:NR:2	R2L	NON-CROSS	73-74	66-68	D002118	Ca|Ca	Chemical	73:307	74:308	3:11	D001145	ventricular arrhythmias|ventricular arrhythmia|arrhythmia|Adrenaline arrhythmia|arrhythmias|arrhythmias|arrhythmia|arrhythmias|arrhythmia	Disease	9:31:36:66:110:132:193:211:231	11:33:37:68:111:133:194:212:232	0:1:2:3:5:6:8:9:10	1:CID:2	R2L	NON-CROSS	110-111	107-108	D004837	adrenaline|adrenaline|adrenaline|adrenaline|adrenaline	Chemical	80:107:129:208:228	81:108:130:209:229	3:5:6:9:10	D001145	ventricular arrhythmias|ventricular arrhythmia|arrhythmia|Adrenaline arrhythmia|arrhythmias|arrhythmias|arrhythmia|arrhythmias|arrhythmia	Disease	9:31:36:66:110:132:193:211:231	11:33:37:68:111:133:194:212:232	0:1:2:3:5:6:8:9:10	1:NR:2	R2L	NON-CROSS	83-84	66-68	D006221	halothane	Chemical	83	84	3	D001145	ventricular arrhythmias|ventricular arrhythmia|arrhythmia|Adrenaline arrhythmia|arrhythmias|arrhythmias|arrhythmia|arrhythmias|arrhythmia	Disease	9:31:36:66:110:132:193:211:231	11:33:37:68:111:133:194:212:232	0:1:2:3:5:6:8:9:10
19761039	Effect of Hibiscus rosa sinensis on reserpine - induced neurobehavioral and biochemical alterations in rats .|Effect of methanolic extract of Hibiscus rosa sinensis ( 100 - 300 mg / kg ) was studied on reserpine - induced orofacial dyskinesia and neurochemical alterations .|The rats were treated with intraperitoneal reserpine ( 1 mg / kg , ip ) for 3 days every other day .|On day 5 , vacuous chewing movements and tongue protrusions were counted for 5 min .|Reserpine treated rats significantly developed vacuous chewing movements and tongue protrusions however , coadministration of Hibiscus rosa sinensis roots extract ( 100 , 200 and 300 mg / kg , per orally ) attenuated the effects .|Biochemical analysis of brain revealed that the reserpine treatment significantly increased lipid peroxidation and decreased levels of superoxide dismutase ( SOD ) , catalase ( CAT ) and glutathione reductase ( GSH ) , an index of oxidative stress process .|Coadministration of extract significantly reduced the lipid peroxidation and reversed the decrease in brain SOD , CAT and GSH levels .|The results of the present study suggested that Hibiscus rosa sinensis had a protective role against reserpine - induced orofacial dyskinesia and oxidative stress .	1:NR:2	L2R	NON-CROSS	189-192	201-202	D010936	Hibiscus rosa sinensis|Hibiscus rosa sinensis|Hibiscus rosa sinensis|Hibiscus rosa sinensis	Chemical	2:21:97:189	5:24:100:192	0:1:4:7	D004409	dyskinesia|dyskinesia	Disease	39:201	40:202	1:7	1:CID:2	L2R	NON-CROSS	35-36	39-40	D012110	reserpine|reserpine|reserpine|Reserpine|reserpine|reserpine	Chemical	6:35:50:82:126:197	7:36:51:83:127:198	0:1:2:4:5:7	D004409	dyskinesia|dyskinesia	Disease	39:201	40:202	1:7	1:NR:2	R2L	CROSS	201-202	136-137	D013481	superoxide	Chemical	136	137	5	D004409	dyskinesia|dyskinesia	Disease	39:201	40:202	1:7	1:NR:2	R2L	CROSS	201-202	147-148	D005978	glutathione	Chemical	147	148	5	D004409	dyskinesia|dyskinesia	Disease	39:201	40:202	1:7
11704023	Comparison of aqueous and gellan ophthalmic timolol with placebo on the 24 - hour heart rate response in patients on treatment for glaucoma .|PURPOSE : Topical beta - blocker treatment is routine therapy in the management of patients with glaucoma .|Therapy results in systemic absorption , however , the degree of reduction of resting and peak heart rate has not been quantified .|DESIGN : This trial evaluated the effect of placebo , 0 . 5 % aqueous timolol ( timolol solution ) and a 0 . 5 % timolol suspension that forms a gel on application to the conjunctiva ( timolol gellan ) on the 24 - hour heart rate in patients currently being treated for glaucoma to quantify the reduction in mean heart rate .|METHODS : Forty - three Caucasian patients with primary open - angle glaucoma or ocular hypertension with a mean ( + / - SD ) age of 63 ( + / - 8 ) years were randomized and crossed over in a double - masked manner to 14 days of treatment with placebo ( morning and evening in both eyes ) , timolol solution ( morning and evening in both eyes ) , or timolol gellan ( morning in both eyes with placebo in the evening ) .|On the 13th day of each period , heart rate was recorded continuously during a typical , ambulant 24 - hour period .|RESULTS : Both timolol solution and timolol gellan reduced the mean 24 - hour heart rate compared with placebo ( P < or = . 001 ) , and this reduction was most pronounced during the daytime ( - 7 . 5 % change in mean heart rate , - 5 . 7 beats / min ) .|Timolol gellan showed a numerically but not significantly smaller reduction in 24 - hour heart rate , compared with timolol solution .|During the night , the mean 12 - hour heart rate on placebo and timolol gellan were both significantly less than on timolol solution ; the difference between solution and gellan treatments was statistically significant ( P = . 01 ) .|CONCLUSIONS : Both timolol solution and timolol gellan decrease the mean 24 - hour heart rate compared with placebo .|This response was most pronounced during the active daytime period .|These data quantify the modest bradycardia associated with ophthalmic beta - blocker therapy in a typical patient population on therapy for glaucoma .|Although exercise performance was not assessed in this trial , reductions of this magnitude should not have substantial clinical consequences .	1:NR:2	L2R	NON-CROSS	6-7	22-23	D013999	timolol|timolol|timolol|timolol|timolol|timolol|timolol|timolol|timolol|Timolol|timolol|timolol|timolol|timolol|timolol	Chemical	6:80:82:91:103:191:203:243:246:298:317:334:342:365:368	7:81:83:92:104:192:204:244:247:299:318:335:343:366:369	0:3:3:3:3:4:4:6:6:7:7:8:8:9:9	D005901	glaucoma|glaucoma|glaucoma|glaucoma	Disease	22:40:119:414	23:41:120:415	0:1:3:11	1:NR:2	L2R	NON-CROSS	103-104	138-142	D013999	timolol|timolol|timolol|timolol|timolol|timolol|timolol|timolol|timolol|Timolol|timolol|timolol|timolol|timolol|timolol	Chemical	6:80:82:91:103:191:203:243:246:298:317:334:342:365:368	7:81:83:92:104:192:204:244:247:299:318:335:343:366:369	0:3:3:3:3:4:4:6:6:7:7:8:8:9:9	D005902	open - angle glaucoma	Disease	138	142	4	1:NR:2	L2R	NON-CROSS	103-104	143-145	D013999	timolol|timolol|timolol|timolol|timolol|timolol|timolol|timolol|timolol|Timolol|timolol|timolol|timolol|timolol|timolol	Chemical	6:80:82:91:103:191:203:243:246:298:317:334:342:365:368	7:81:83:92:104:192:204:244:247:299:318:335:343:366:369	0:3:3:3:3:4:4:6:6:7:7:8:8:9:9	D009798	ocular hypertension	Disease	143	145	4	1:CID:2	L2R	CROSS	368-369	398-399	D013999	timolol|timolol|timolol|timolol|timolol|timolol|timolol|timolol|timolol|Timolol|timolol|timolol|timolol|timolol|timolol	Chemical	6:80:82:91:103:191:203:243:246:298:317:334:342:365:368	7:81:83:92:104:192:204:244:247:299:318:335:343:366:369	0:3:3:3:3:4:4:6:6:7:7:8:8:9:9	D001919	bradycardia	Disease	398	399	11
19300240	5 flourouracil - induced apical ballooning syndrome : a case report .|The apical ballooning syndrome ( ABS ) is a recently described stress - mediated acute cardiac syndrome characterized by transient wall - motion abnormalities involving the apex and midventricle with hyperkinesis of the basal left ventricular ( LV ) segments without obstructive epicardial coronary disease .|Cardiotoxicity is not an uncommon adverse effect of chemotherapeutic agents .|However , there are no reports of ABS secondary to chemotherapeutic agents .|We describe the case of a woman who developed the syndrome after chemotherapy for metastatic cancer .|A 79 - year - old woman presented with typical ischemic chest pain , elevated cardiac enzymes with significant ST - segment abnormalities on her electrocardiogram .|She underwent recent chemotherapy with fluorouracil for metastatic colorectal cancer .|Echocardiography revealed a wall - motion abnormality involving the apical and periapical segments which appeared akinetic .|Coronary angiography revealed no obstructive coronary lesions .|The patient was stabilized with medical therapy .|Four weeks later she remained completely asymptomatic .|Echocardiogram revealed a normal ejection fraction and a resolution of the apical akinesis .|Pathogenetic mechanisms of cardiac complications in cancer patients undergoing chemotherapy include coronary vasospasm , endothelial damage and consequent thrombus formation .|In our patient , both supraphysiologic levels of plasma catecholamines and stress related neuropeptides caused by cancer diagnosis as well as chemotherapy may have contributed the development of ABS .	1:CID:2	L2R	NON-CROSS	0-2	4-7	D005472	5 flourouracil|fluorouracil	Chemical	0:131	2:132	0:6	D054549	apical ballooning syndrome|apical ballooning syndrome|ABS|ABS|ABS	Disease	4:13:17:76:241	7:16:18:77:242	0:1:1:3:13	1:NR:2	L2R	CROSS	0-2	26-29	D005472	5 flourouracil|fluorouracil	Chemical	0:131	2:132	0:6	D006331	acute cardiac syndrome	Disease	26	29	1	1:NR:2	L2R	CROSS	0-2	42-43	D005472	5 flourouracil|fluorouracil	Chemical	0:131	2:132	0:6	D006948	hyperkinesis	Disease	42	43	1	1:NR:2	L2R	CROSS	0-2	54-57	D005472	5 flourouracil|fluorouracil	Chemical	0:131	2:132	0:6	D003327	epicardial coronary disease	Disease	54	57	1	1:NR:2	L2R	CROSS	0-2	58-59	D005472	5 flourouracil|fluorouracil	Chemical	0:131	2:132	0:6	D066126	Cardiotoxicity	Disease	58	59	2	1:NR:2	L2R	CROSS	97-98	131-132	D005472	5 flourouracil|fluorouracil	Chemical	0:131	2:132	0:6	D009369	cancer|cancer|cancer	Disease	97:198:229	98:199:230	4:12:13	1:NR:2	L2R	CROSS	109-110	131-132	D005472	5 flourouracil|fluorouracil	Chemical	0:131	2:132	0:6	D007511	ischemic	Disease	109	110	5	1:CID:2	L2R	CROSS	110-112	131-132	D005472	5 flourouracil|fluorouracil	Chemical	0:131	2:132	0:6	D002637	chest pain	Disease	110	112	5	1:NR:2	L2R	NON-CROSS	131-132	134-136	D005472	5 flourouracil|fluorouracil	Chemical	0:131	2:132	0:6	D015179	colorectal cancer	Disease	134	136	6	1:NR:2	L2R	CROSS	131-132	152-153	D005472	5 flourouracil|fluorouracil	Chemical	0:131	2:132	0:6	D018476	akinetic|akinesis	Disease	152:190	153:191	7:11	1:NR:2	L2R	CROSS	131-132	195-197	D005472	5 flourouracil|fluorouracil	Chemical	0:131	2:132	0:6	D005117	cardiac complications	Disease	195	197	12	1:NR:2	L2R	CROSS	131-132	203-205	D005472	5 flourouracil|fluorouracil	Chemical	0:131	2:132	0:6	D003329	coronary vasospasm	Disease	203	205	12	1:NR:2	L2R	CROSS	131-132	210-211	D005472	5 flourouracil|fluorouracil	Chemical	0:131	2:132	0:6	D013927	thrombus	Disease	210	211	12	1:NR:2	R2L	NON-CROSS	241-242	222-223	D002395	catecholamines	Chemical	222	223	13	D054549	apical ballooning syndrome|apical ballooning syndrome|ABS|ABS|ABS	Disease	4:13:17:76:241	7:16:18:77:242	0:1:1:3:13	1:NR:2	R2L	CROSS	222-223	26-29	D002395	catecholamines	Chemical	222	223	13	D006331	acute cardiac syndrome	Disease	26	29	1	1:NR:2	R2L	CROSS	222-223	42-43	D002395	catecholamines	Chemical	222	223	13	D006948	hyperkinesis	Disease	42	43	1	1:NR:2	R2L	CROSS	222-223	54-57	D002395	catecholamines	Chemical	222	223	13	D003327	epicardial coronary disease	Disease	54	57	1	1:NR:2	R2L	CROSS	222-223	58-59	D002395	catecholamines	Chemical	222	223	13	D066126	Cardiotoxicity	Disease	58	59	2	1:NR:2	R2L	NON-CROSS	229-230	222-223	D002395	catecholamines	Chemical	222	223	13	D009369	cancer|cancer|cancer	Disease	97:198:229	98:199:230	4:12:13	1:NR:2	R2L	CROSS	222-223	109-110	D002395	catecholamines	Chemical	222	223	13	D007511	ischemic	Disease	109	110	5	1:NR:2	R2L	CROSS	222-223	110-112	D002395	catecholamines	Chemical	222	223	13	D002637	chest pain	Disease	110	112	5	1:NR:2	R2L	CROSS	222-223	134-136	D002395	catecholamines	Chemical	222	223	13	D015179	colorectal cancer	Disease	134	136	6	1:NR:2	R2L	CROSS	222-223	190-191	D002395	catecholamines	Chemical	222	223	13	D018476	akinetic|akinesis	Disease	152:190	153:191	7:11	1:NR:2	R2L	CROSS	222-223	195-197	D002395	catecholamines	Chemical	222	223	13	D005117	cardiac complications	Disease	195	197	12	1:NR:2	R2L	CROSS	222-223	203-205	D002395	catecholamines	Chemical	222	223	13	D003329	coronary vasospasm	Disease	203	205	12	1:NR:2	R2L	CROSS	222-223	210-211	D002395	catecholamines	Chemical	222	223	13	D013927	thrombus	Disease	210	211	12
18006530	Reduction of pain during induction with target - controlled propofol and remifentanil .|BACKGROUND : Pain on injection of propofol is unpleasant .|We hypothesized that propofol infusion pain might be prevented by infusing remifentanil before starting the propofol infusion in a clinical setting where target - controlled infusions ( TCI ) of both drugs were used .|A prospective , randomized , double - blind , placebo - controlled trial was performed to determine the effect - site concentration ( Ce ) of remifentanil to prevent the pain without producing complications .|METHODS : A total of 128 patients undergoing general surgery were randomly allocated to receive normal saline ( control ) or remifentanil to a target Ce of 2 ng ml ( - 1 ) ( R2 ) , 4 ng ml ( - 1 ) ( R4 ) , or 6 ng ml ( - 1 ) ( R6 ) administered via TCI .|After the target Ce was achieved , the infusion of propofol was started .|Remifentanil - related complications were assessed during the remifentanil infusion , and pain caused by propofol was evaluated using a four - point scale during the propofol infusion .|RESULTS : The incidence of pain was significantly lower in Groups R4 and R6 than in the control and R2 groups ( 12 / 32 and 6 / 31 vs 26 / 31 and 25 / 32 , respectively , P < 0 . 001 ) .|Pain was less severe in Groups R4 and R6 than in the control and R2 groups ( P < 0 . 001 ) .|However , both incidence and severity of pain were not different between Groups R4 and R6 .|No significant complications were observed during the study .|CONCLUSIONS : During induction of anaesthesia with TCI of propofol and remifentanil , a significant reduction in propofol infusion pain was achieved without significant complications by prior administration of remifentanil at a target Ce of 4 ng ml ( - 1 ) .	1:CID:2	R2L	NON-CROSS	28-29	26-27	D015742	propofol|propofol|propofol|propofol|propofol|propofol|propofol|propofol|propofol	Chemical	9:19:26:38:167:186:197:306:314	10:20:27:39:168:187:198:307:315	0:1:2:2:5:6:6:11:11	D010146	pain|Pain|pain|pain|pain|pain|Pain|pain|pain	Disease	2:15:28:88:183:205:247:278:316	3:16:29:89:184:206:248:279:317	0:1:2:3:6:7:8:9:11	1:NR:2	R2L	NON-CROSS	15-16	11-12	C071741	remifentanil|remifentanil|remifentanil|remifentanil|Remifentanil|remifentanil|remifentanil|remifentanil	Chemical	11:34:84:114:171:179:308:326	12:35:85:115:172:180:309:327	0:2:3:4:6:6:11:11	D010146	pain|Pain|pain|pain|pain|pain|Pain|pain|pain	Disease	2:15:28:88:183:205:247:278:316	3:16:29:89:184:206:248:279:317	0:1:2:3:6:7:8:9:11
17702969	Prenatal exposure to fluoxetine induces fetal pulmonary hypertension in the rat .|RATIONALE : Fluoxetine is a selective serotonin reuptake inhibitor antidepressant widely used by pregnant women .|Epidemiological data suggest that fluoxetine exposure prenatally increases the prevalence of persistent pulmonary hypertension syndrome of the newborn .|The mechanism responsible for this effect is unclear and paradoxical , considering the current evidence of a pulmonary hypertension protective fluoxetine effect in adult rodents .|OBJECTIVES : To evaluate the fluoxetine effect on fetal rat pulmonary vascular smooth muscle mechanical properties and cell proliferation rate .|METHODS : Pregnant rats were treated with fluoxetine ( 10 mg / kg ) from Day 11 through Day 21 of gestation .|MEASUREMENTS AND MAIN RESULTS : Fetuses were delivered by cesarean section .|As compared with controls , fluoxetine exposure resulted in fetal pulmonary hypertension as evidenced by an increase in the weight ratio of the right ventricle to the left ventricle plus septum ( P = 0 . 02 ) and by an increase in pulmonary arterial medial thickness ( P < 0 . 01 ) .|Postnatal mortality was increased among experimental animals , and arterial oxygen saturation was 96 + / - 1 % in 1 - day - old control animals and significantly lower ( P < 0 . 01 ) in fluoxetine - exposed pups ( 79 + / - 2 % ) .|In vitro , fluoxetine induced pulmonary arterial muscle contraction in fetal , but not adult , animals ( P < 0 . 01 ) and reduced serotonin - induced contraction at both ages ( P < 0 . 01 ) .|After in utero exposure to a low fluoxetine concentration the pulmonary arterial smooth muscle cell proliferation rate was significantly increased in fetal , but not adult , cells ( P < 0 . 01 ) .|CONCLUSIONS : In contrast to the adult , fluoxetine exposure in utero induces pulmonary hypertension in the fetal rat as a result of a developmentally regulated increase in pulmonary vascular smooth muscle proliferation .	1:CID:2	L2R	NON-CROSS	3-4	5-8	D005473	fluoxetine|Fluoxetine|fluoxetine|fluoxetine|fluoxetine|fluoxetine|fluoxetine|fluoxetine|fluoxetine|fluoxetine|fluoxetine	Chemical	3:14:32:67:78:101:134:222:238:283:320	4:15:33:68:79:102:135:223:239:284:321	0:1:2:3:4:5:7:8:9:10:11	D005315	fetal pulmonary hypertension|fetal pulmonary hypertension	Disease	5:138	8:141	0:7	1:CID:2	L2R	NON-CROSS	3-4	5-8	D005473	fluoxetine|Fluoxetine|fluoxetine|fluoxetine|fluoxetine|fluoxetine|fluoxetine|fluoxetine|fluoxetine|fluoxetine|fluoxetine	Chemical	3:14:32:67:78:101:134:222:238:283:320	4:15:33:68:79:102:135:223:239:284:321	0:1:2:3:4:5:7:8:9:10:11	D006976	fetal pulmonary hypertension|pulmonary hypertension syndrome|pulmonary hypertension|fetal pulmonary hypertension|pulmonary hypertension	Disease	5:40:64:138:325	8:43:66:141:327	0:2:3:7:11	1:NR:2	R2L	CROSS	18-19	5-8	D012701	serotonin|serotonin	Chemical	18:261	19:262	1:9	D005315	fetal pulmonary hypertension|fetal pulmonary hypertension	Disease	5:138	8:141	0:7	1:NR:2	R2L	CROSS	194-195	138-141	D010100	oxygen	Chemical	194	195	8	D005315	fetal pulmonary hypertension|fetal pulmonary hypertension	Disease	5:138	8:141	0:7	1:NR:2	R2L	CROSS	18-19	5-8	D012701	serotonin|serotonin	Chemical	18:261	19:262	1:9	D006976	fetal pulmonary hypertension|pulmonary hypertension syndrome|pulmonary hypertension|fetal pulmonary hypertension|pulmonary hypertension	Disease	5:40:64:138:325	8:43:66:141:327	0:2:3:7:11	1:NR:2	R2L	CROSS	194-195	138-141	D010100	oxygen	Chemical	194	195	8	D006976	fetal pulmonary hypertension|pulmonary hypertension syndrome|pulmonary hypertension|fetal pulmonary hypertension|pulmonary hypertension	Disease	5:40:64:138:325	8:43:66:141:327	0:2:3:7:11
17344330	Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen .|BACKGROUND : Methadone is prescribed to heroin addicts to decrease illicit opioid use .|Prolongation of the QT interval in the ECG of patients with torsade de pointes ( TdP ) has been reported in methadone users .|As heroin addicts sometimes faint while using illicit drugs , doctors might attribute too many episodes of syncope to illicit drug use and thereby underestimate the incidence of TdP in this special population , and the high mortality in this population may , in part , be caused by the proarrhythmic effect of methadone .|METHODS : In this cross - sectional study interview , ECGs and blood samples were collected in a population of adult heroin addicts treated with methadone or buprenorphine on a daily basis .|Of the patients at the Drug Addiction Service in the municipal of Copenhagen , 450 ( approximately 52 % ) were included .|The QT interval was estimated from 12 lead ECGs .|All participants were interviewed about any experience of syncope .|The association between opioid dose and QT , and methadone dose and reporting of syncope was assessed using multivariate linear regression and logistic regression , respectively .|RESULTS : Methadone dose was associated with longer QT interval of 0 . 140 ms / mg ( p = 0 . 002 ) .|No association between buprenorphine and QTc was found .|Among the subjects treated with methadone , 28 % men and 32 % women had prolonged QTc interval .|None of the subjects treated with buprenorphine had QTc interval > 0 . 440 s ( ( 1 / 2 ) ) .|A 50 mg higher methadone dose was associated with a 1 . 2 ( 95 % CI 1 . 1 to 1 . 4 ) times higher odds for syncope .|CONCLUSIONS : Methadone is associated with QT prolongation and higher reporting of syncope in a population of heroin addicts .	1:CID:2	R2L	NON-CROSS	323-324	319-320	D008691	methadone|Methadone|methadone|methadone|methadone|methadone|Methadone|methadone|methadone|Methadone	Chemical	8:20:53:109:136:196:216:253:294:323	9:21:54:110:137:197:217:254:295:324	0:1:2:3:4:8:9:11:13:14	D013575	Syncope|syncope|syncope|syncope|syncope|syncope	Disease	0:73:185:201:319:333	1:74:186:202:320:334	0:3:7:8:13:14	1:NR:2	R2L	NON-CROSS	338-339	333-334	D003932	heroin|heroin|heroin|heroin|heroin	Chemical	10:24:57:132:338	11:25:58:133:339	0:1:3:4:14	D013575	Syncope|syncope|syncope|syncope|syncope|syncope	Disease	0:73:185:201:319:333	1:74:186:202:320:334	0:3:7:8:13:14	1:NR:2	R2L	CROSS	242-243	201-202	D002047	buprenorphine|buprenorphine|buprenorphine	Chemical	138:242:273	139:243:274	4:10:12	D013575	Syncope|syncope|syncope|syncope|syncope|syncope	Disease	0:73:185:201:319:333	1:74:186:202:320:334	0:3:7:8:13:14	1:CID:2	R2L	NON-CROSS	327-329	323-324	D008691	methadone|Methadone|methadone|methadone|methadone|methadone|Methadone|methadone|methadone|Methadone	Chemical	8:20:53:109:136:196:216:253:294:323	9:21:54:110:137:197:217:254:295:324	0:1:2:3:4:8:9:11:13:14	D008133	QT prolongation|prolonged QTc interval|QT prolongation	Disease	2:263:327	4:266:329	0:11:14	1:NR:2	R2L	NON-CROSS	10-11	2-4	D003932	heroin|heroin|heroin|heroin|heroin	Chemical	10:24:57:132:338	11:25:58:133:339	0:1:3:4:14	D008133	QT prolongation|prolonged QTc interval|QT prolongation	Disease	2:263:327	4:266:329	0:11:14	1:NR:2	R2L	CROSS	273-274	263-266	D002047	buprenorphine|buprenorphine|buprenorphine	Chemical	138:242:273	139:243:274	4:10:12	D008133	QT prolongation|prolonged QTc interval|QT prolongation	Disease	2:263:327	4:266:329	0:11:14	1:NR:2	L2R	NON-CROSS	47-48	53-54	D008691	methadone|Methadone|methadone|methadone|methadone|methadone|Methadone|methadone|methadone|Methadone	Chemical	8:20:53:109:136:196:216:253:294:323	9:21:54:110:137:197:217:254:295:324	0:1:2:3:4:8:9:11:13:14	D016171	torsade de pointes|TdP|TdP	Disease	43:47:84	46:48:85	2:2:3	1:NR:2	L2R	NON-CROSS	47-48	57-58	D003932	heroin|heroin|heroin|heroin|heroin	Chemical	10:24:57:132:338	11:25:58:133:339	0:1:3:4:14	D016171	torsade de pointes|TdP|TdP	Disease	43:47:84	46:48:85	2:2:3	1:NR:2	R2L	CROSS	138-139	84-85	D002047	buprenorphine|buprenorphine|buprenorphine	Chemical	138:242:273	139:243:274	4:10:12	D016171	torsade de pointes|TdP|TdP	Disease	43:47:84	46:48:85	2:2:3
16826348	Peripheral neuropathy caused by high - dose cytosine arabinoside treatment in a patient with acute myeloid leukemia .|The central nervous system toxicity of high - dose cytosine arabinoside is well recognized , but the toxicity of cytosine arabinoside in the peripheral nervous system has been infrequently reported .|A 49 - year - old Japanese man was diagnosed with acute myeloid leukemia .|After he achieved complete remission , he received high - dose cytosine arabinoside treatment ( 2 g / m2 twice a day for 5 days ; total , 20 g / m2 ) as consolidation therapy .|The first course of high - dose cytosine arabinoside resulted in no unusual symptoms , but on day 21 of the second course of treatment , the patient complained of numbness in his right foot .|Electromyogram and nerve - conduction studies showed peripheral neuropathy in both peroneal nerves .|This neuropathy was gradually resolving ; however , after the patient received allogeneic bone marrow transplantation , the symptoms worsened , with the development of graft - versus - host disease , and the symptoms subsequently responded to methylprednisolone .|Although the mechanisms of peripheral neuropathy are still unclear , high - dose cytosine arabinoside is a therapy that is potentially toxic to the peripheral nervous system , and auto / alloimmunity may play an important role in these mechanisms .	1:CID:2	R2L	NON-CROSS	7-9	0-2	D003561	cytosine arabinoside|cytosine arabinoside|cytosine arabinoside|cytosine arabinoside|cytosine arabinoside|cytosine arabinoside	Chemical	7:27:37:75:108:204	9:29:39:77:110:206	0:1:1:3:4:7	D010523	Peripheral neuropathy|peripheral neuropathy|peripheral neuropathy	Disease	0:144:195	2:146:197	0:5:7	1:NR:2	R2L	CROSS	195-197	189-190	D008775	methylprednisolone	Chemical	189	190	6	D010523	Peripheral neuropathy|peripheral neuropathy|peripheral neuropathy	Disease	0:144:195	2:146:197	0:5:7	1:NR:2	L2R	NON-CROSS	7-9	14-17	D003561	cytosine arabinoside|cytosine arabinoside|cytosine arabinoside|cytosine arabinoside|cytosine arabinoside|cytosine arabinoside	Chemical	7:27:37:75:108:204	9:29:39:77:110:206	0:1:1:3:4:7	D015470	acute myeloid leukemia|acute myeloid leukemia	Disease	14:60	17:63	0:2	1:NR:2	L2R	NON-CROSS	35-36	37-39	D003561	cytosine arabinoside|cytosine arabinoside|cytosine arabinoside|cytosine arabinoside|cytosine arabinoside|cytosine arabinoside	Chemical	7:27:37:75:108:204	9:29:39:77:110:206	0:1:1:3:4:7	D064420	toxicity|toxicity	Disease	22:35	23:36	1:1	1:NR:2	L2R	NON-CROSS	108-110	131-132	D003561	cytosine arabinoside|cytosine arabinoside|cytosine arabinoside|cytosine arabinoside|cytosine arabinoside|cytosine arabinoside	Chemical	7:27:37:75:108:204	9:29:39:77:110:206	0:1:1:3:4:7	D006987	numbness	Disease	131	132	4	1:NR:2	L2R	CROSS	108-110	152-153	D003561	cytosine arabinoside|cytosine arabinoside|cytosine arabinoside|cytosine arabinoside|cytosine arabinoside|cytosine arabinoside	Chemical	7:27:37:75:108:204	9:29:39:77:110:206	0:1:1:3:4:7	D009422	neuropathy	Disease	152	153	6	1:NR:2	L2R	CROSS	176-182	204-206	D003561	cytosine arabinoside|cytosine arabinoside|cytosine arabinoside|cytosine arabinoside|cytosine arabinoside|cytosine arabinoside	Chemical	7:27:37:75:108:204	9:29:39:77:110:206	0:1:1:3:4:7	D006086	graft - versus - host disease	Disease	176	182	6	1:NR:2	R2L	CROSS	189-190	60-63	D008775	methylprednisolone	Chemical	189	190	6	D015470	acute myeloid leukemia|acute myeloid leukemia	Disease	14:60	17:63	0:2	1:NR:2	R2L	CROSS	189-190	35-36	D008775	methylprednisolone	Chemical	189	190	6	D064420	toxicity|toxicity	Disease	22:35	23:36	1:1	1:NR:2	R2L	CROSS	189-190	131-132	D008775	methylprednisolone	Chemical	189	190	6	D006987	numbness	Disease	131	132	4	1:NR:2	R2L	NON-CROSS	189-190	152-153	D008775	methylprednisolone	Chemical	189	190	6	D009422	neuropathy	Disease	152	153	6	1:NR:2	R2L	NON-CROSS	189-190	176-182	D008775	methylprednisolone	Chemical	189	190	6	D006086	graft - versus - host disease	Disease	176	182	6
16820346	Atorvastatin prevented and reversed dexamethasone - induced hypertension in the rat .|To assess the antioxidant effects of atorvastatin ( atorva ) on dexamethasone ( dex ) - induced hypertension , 60 male Sprague - Dawley rats were treated with atorva 30 mg / kg / day or tap water for 15 days .|Dex increased systolic blood pressure ( SBP ) from 109 + / - 1 . 8 to 135 + / - 0 . 6 mmHg and plasma superoxide ( 5711 + / - 284 . 9 saline , 7931 + / - 392 . 8 U / ml dex , P < 0 . 001 ) .|In this prevention study , SBP in the atorva + dex group was increased from 115 + / - 0 . 4 to 124 + / - 1 . 5 mmHg , but this was significantly lower than in the dex - only group ( P ' < 0 . 05 ) .|Atorva reversed dex - induced hypertension ( 129 + / - 0 . 6 mmHg , vs . 135 + / - 0 . 6 mmHg P ' < 0 . 05 ) and decreased plasma superoxide ( 7931 + / - 392 . 8 dex , 1187 + / - 441 . 2 atorva + dex , P < 0 . 0001 ) .|Plasma nitrate / nitrite ( NOx ) was decreased in dex - treated rats compared to saline - treated rats ( 11 . 2 + / - 1 . 08 microm , 15 . 3 + / - 1 . 17 microm , respectively , P < 0 . 05 ) .|Atorva affected neither plasma NOx nor thymus weight .|Thus , atorvastatin prevented and reversed dexamethasone - induced hypertension in the rat .	1:NR:2	L2R	NON-CROSS	164-165	169-170	C065179	Atorvastatin|atorvastatin|atorva|atorva|atorva|Atorva|atorva|Atorva|atorvastatin	Chemical	0:18:20:40:119:164:218:281:292	1:19:21:41:120:165:219:282:293	0:1:1:1:3:4:4:6:7	D006973	hypertension|hypertension|hypertension|hypertension	Disease	7:29:169:299	8:30:170:300	0:1:4:7	1:CID:2	L2R	NON-CROSS	4-5	7-8	D003907	dexamethasone|dexamethasone|dex|Dex|dex|dex|dex|dex|dex|dex|dex|dexamethasone	Chemical	4:23:25:54:102:121:151:166:209:220:239:296	5:24:26:55:103:122:152:167:210:221:240:297	0:1:1:2:2:3:3:4:4:4:5:7	D006973	hypertension|hypertension|hypertension|hypertension	Disease	7:29:169:299	8:30:170:300	0:1:4:7	1:NR:2	R2L	NON-CROSS	200-201	169-170	D013481	superoxide|superoxide	Chemical	81:200	82:201	2:4	D006973	hypertension|hypertension|hypertension|hypertension	Disease	7:29:169:299	8:30:170:300	0:1:4:7	1:NR:2	R2L	CROSS	230-231	169-170	D009566	nitrate	Chemical	230	231	5	D006973	hypertension|hypertension|hypertension|hypertension	Disease	7:29:169:299	8:30:170:300	0:1:4:7	1:NR:2	R2L	CROSS	232-233	169-170	D009573	nitrite	Chemical	232	233	5	D006973	hypertension|hypertension|hypertension|hypertension	Disease	7:29:169:299	8:30:170:300	0:1:4:7
15974569	Two prodrugs of potent and selective GluR5 kainate receptor antagonists actives in three animal models of pain .|Amino acids 5 and 7 , two potent and selective competitive GluR5 KA receptor antagonists , exhibited high GluR5 receptor affinity over other glutamate receptors .|Their ester prodrugs 6 and 8 were orally active in three models of pain : reversal of formalin - induced paw licking , carrageenan - induced thermal hyperalgesia , and capsaicin - induced mechanical hyperalgesia .	1:NR:2	L2R	NON-CROSS	7-8	16-17	D007608	kainate|KA	Chemical	7:30	8:31	0:1	D010146	pain|pain	Disease	16:57	17:58	0:2	1:NR:2	L2R	CROSS	30-31	70-72	D007608	kainate|KA	Chemical	7:30	8:31	0:1	D006930	thermal hyperalgesia|mechanical hyperalgesia	Disease	70:77	72:79	2:2	1:NR:2	R2L	CROSS	57-58	41-42	D018698	glutamate	Chemical	41	42	1	D010146	pain|pain	Disease	16:57	17:58	0:2	1:NR:2	R2L	NON-CROSS	61-62	57-58	D005557	formalin	Chemical	61	62	2	D010146	pain|pain	Disease	16:57	17:58	0:2	1:NR:2	R2L	NON-CROSS	67-68	57-58	D002351	carrageenan	Chemical	67	68	2	D010146	pain|pain	Disease	16:57	17:58	0:2	1:NR:2	R2L	NON-CROSS	74-75	57-58	D002211	capsaicin	Chemical	74	75	2	D010146	pain|pain	Disease	16:57	17:58	0:2	1:NR:2	L2R	CROSS	41-42	70-72	D018698	glutamate	Chemical	41	42	1	D006930	thermal hyperalgesia|mechanical hyperalgesia	Disease	70:77	72:79	2:2	1:NR:2	L2R	NON-CROSS	61-62	70-72	D005557	formalin	Chemical	61	62	2	D006930	thermal hyperalgesia|mechanical hyperalgesia	Disease	70:77	72:79	2:2	1:CID:2	L2R	NON-CROSS	67-68	70-72	D002351	carrageenan	Chemical	67	68	2	D006930	thermal hyperalgesia|mechanical hyperalgesia	Disease	70:77	72:79	2:2	1:CID:2	R2L	NON-CROSS	74-75	70-72	D002211	capsaicin	Chemical	74	75	2	D006930	thermal hyperalgesia|mechanical hyperalgesia	Disease	70:77	72:79	2:2
11583940	Sirolimus and mycophenolate mofetil for calcineurin - free immunosuppression in renal transplant recipients .|Calcineurin inhibitors , such as cyclosporine and tacrolimus , have been available for almost 20 years .|Although these drugs are highly effective and represent the mainstay of transplant immunosuppression , they are associated with acute and chronic nephrotoxicity .|Acute nephrotoxicity , which occurs in the early period after transplantation , leads to a higher rate of dialysis , and chronic nephrotoxicity may eventually result in graft loss .|Acute and chronic nephrotoxicity is becoming more common as the use of marginal kidneys for transplantation increases .|Two recently available immunosuppressive agents , mycophenolate mofetil and sirolimus ( rapamycin ) , have no nephrotoxicity .|The use of these drugs in combination with other agents has led to the development of new paradigms of immunosuppressive therapy .|This paper reviews the results of clinical trials that have investigated these new approaches to immunosuppression in renal transplant recipients .	1:NR:2	L2R	NON-CROSS	113-114	118-119	D020123	Sirolimus|sirolimus|rapamycin	Chemical	0:111:113	1:112:114	0:5:5	D007674	nephrotoxicity|nephrotoxicity|nephrotoxicity|nephrotoxicity|nephrotoxicity	Disease	52:55:76:87:118	53:56:77:88:119	2:3:3:4:5	1:NR:2	L2R	NON-CROSS	108-110	118-119	C063008	mycophenolate mofetil|mycophenolate mofetil	Chemical	2:108	4:110	0:5	D007674	nephrotoxicity|nephrotoxicity|nephrotoxicity|nephrotoxicity|nephrotoxicity	Disease	52:55:76:87:118	53:56:77:88:119	2:3:3:4:5	1:CID:2	L2R	CROSS	19-20	52-53	D016572	cyclosporine	Chemical	19	20	1	D007674	nephrotoxicity|nephrotoxicity|nephrotoxicity|nephrotoxicity|nephrotoxicity	Disease	52:55:76:87:118	53:56:77:88:119	2:3:3:4:5	1:CID:2	L2R	CROSS	21-22	52-53	D016559	tacrolimus	Chemical	21	22	1	D007674	nephrotoxicity|nephrotoxicity|nephrotoxicity|nephrotoxicity|nephrotoxicity	Disease	52:55:76:87:118	53:56:77:88:119	2:3:3:4:5
11245434	Erythropoietin restores the anemia - induced reduction in cyclophosphamide cytotoxicity in rat tumors .|The aim of this study was to examine the impact of anemia prevention by recombinant human erythropoietin ( rHuEPO ) treatment on the cytotoxicity of cyclophosphamide in solid experimental tumors .|Anemia was induced using a single dose of carboplatin ( 50 mg / kg i . v . ) resulting in a long - lasting reduction ( 30 % ) of the hemoglobin concentration .|In a second group , the development of anemia was prevented by rHuEPO ( 1000 IU / kg ) administered s . c .|three times / week starting 7 days before carboplatin application .|Four days after carboplatin treatment , tumors ( DS - sarcoma of the rat ) were implanted s . c .|onto the hind food dorsum .|Neither carboplatin nor rHuEPO treatment influenced tumor growth rate per se .|When tumors were treated with a single dose of cyclophosphamide ( 60 mg / kg i . p . ) 5 days after implantation , a growth delay with a subsequent regrowth of the tumors was observed .|In the anemia group , the growth delay was significantly shorter compared with nonanemic controls ( 13 . 3 days versus 8 . 6 days ) .|In the group where anemia was prevented by rHuEPO treatment , growth delay was comparable with that of nonanemic controls ( 13 . 3 days ) .|These results suggest that chemotherapy - induced anemia reduces cytotoxicity of cyclophosphamide in tumors , whereas correction of anemia by rHuEPO treatment ( epoetin alpha ) increases the sensitivity , probably as a result of an improved oxygen supply to tumor tissue .	1:NR:2	R2L	NON-CROSS	257-258	253-254	D003520	cyclophosphamide|cyclophosphamide|cyclophosphamide|cyclophosphamide	Chemical	8:39:163:257	9:40:164:258	0:1:8:11	D000740	anemia|anemia|Anemia|anemia|anemia|anemia|anemia|anemia	Disease	3:25:45:88:194:223:253:264	4:26:46:89:195:224:254:265	0:1:2:3:9:10:11:11	1:CID:2	R2L	NON-CROSS	53-54	45-46	D016190	carboplatin|carboplatin|carboplatin|carboplatin	Chemical	53:112:118:143	54:113:119:144	2:4:5:7	D000740	anemia|anemia|Anemia|anemia|anemia|anemia|anemia|anemia	Disease	3:25:45:88:194:223:253:264	4:26:46:89:195:224:254:265	0:1:2:3:9:10:11:11	1:NR:2	R2L	NON-CROSS	283-284	264-265	D010100	oxygen	Chemical	283	284	11	D000740	anemia|anemia|Anemia|anemia|anemia|anemia|anemia|anemia	Disease	3:25:45:88:194:223:253:264	4:26:46:89:195:224:254:265	0:1:2:3:9:10:11:11	1:NR:2	L2R	NON-CROSS	8-9	9-10	D003520	cyclophosphamide|cyclophosphamide|cyclophosphamide|cyclophosphamide	Chemical	8:39:163:257	9:40:164:258	0:1:8:11	D064420	cytotoxicity|cytotoxicity|cytotoxicity	Disease	9:37:255	10:38:256	0:1:11	1:NR:2	L2R	NON-CROSS	257-258	259-260	D003520	cyclophosphamide|cyclophosphamide|cyclophosphamide|cyclophosphamide	Chemical	8:39:163:257	9:40:164:258	0:1:8:11	D009369	tumors|tumors|tumors|tumor|tumors|tumors|tumors|tumor	Disease	12:43:121:148:155:188:259:286	13:44:122:149:156:189:260:287	0:1:5:7:8:8:11:11	1:NR:2	L2R	CROSS	125-126	163-164	D003520	cyclophosphamide|cyclophosphamide|cyclophosphamide|cyclophosphamide	Chemical	8:39:163:257	9:40:164:258	0:1:8:11	D012509	sarcoma	Disease	125	126	5	1:NR:2	R2L	CROSS	53-54	37-38	D016190	carboplatin|carboplatin|carboplatin|carboplatin	Chemical	53:112:118:143	54:113:119:144	2:4:5:7	D064420	cytotoxicity|cytotoxicity|cytotoxicity	Disease	9:37:255	10:38:256	0:1:11	1:NR:2	R2L	NON-CROSS	283-284	255-256	D010100	oxygen	Chemical	283	284	11	D064420	cytotoxicity|cytotoxicity|cytotoxicity	Disease	9:37:255	10:38:256	0:1:11	1:NR:2	R2L	NON-CROSS	121-122	118-119	D016190	carboplatin|carboplatin|carboplatin|carboplatin	Chemical	53:112:118:143	54:113:119:144	2:4:5:7	D009369	tumors|tumors|tumors|tumor|tumors|tumors|tumors|tumor	Disease	12:43:121:148:155:188:259:286	13:44:122:149:156:189:260:287	0:1:5:7:8:8:11:11	1:NR:2	R2L	NON-CROSS	286-287	283-284	D010100	oxygen	Chemical	283	284	11	D009369	tumors|tumors|tumors|tumor|tumors|tumors|tumors|tumor	Disease	12:43:121:148:155:188:259:286	13:44:122:149:156:189:260:287	0:1:5:7:8:8:11:11	1:NR:2	L2R	NON-CROSS	118-119	125-126	D016190	carboplatin|carboplatin|carboplatin|carboplatin	Chemical	53:112:118:143	54:113:119:144	2:4:5:7	D012509	sarcoma	Disease	125	126	5	1:NR:2	R2L	CROSS	283-284	125-126	D010100	oxygen	Chemical	283	284	11	D012509	sarcoma	Disease	125	126	5
11243580	The role of nitrergic system in lidocaine - induced convulsion in the mouse .|The effects of N - nitro - L - arginine - methyl ester ( L - NAME ) a nitric oxide ( NO ) synthase inhibitor and L - arginine , a NO precursor , were investigated on lidocaine - induced convulsions .|In the first experiment , four groups of mice received physiological saline ( 0 . 9 % ) , L - arginine ( 300 mg / kg , i . p . ) , L - NAME ( 100 mg / kg , i . p . ) and diazepam ( 2 mg / kg ) , respectively .|Thirty minutes after these injections , all mice received lidocaine ( 50 mg / kg , i . p . ) .|In the second experiment , four groups of mice received similar treatment in the first experiment , and 30 min after these injections , all mice received a higher dose of lidocaine ( 80 mg / kg ) .|L - NAME ( 100 mg / kg , i . p . ) and diazepam ( 2 mg / kg ) significantly decreased the incidence of lidocaine ( 50 mg / kg ) - induced convulsions .|In contrast , the L - arginine treatment increased the incidence of lidocaine ( 80 mg / kg , i . p . ) - induced convulsions significantly .|These results may suggest that NO is a proconvulsant mediator in lidocaine - induced convulsions .	1:CID:2	L2R	NON-CROSS	6-7	9-10	D008012	lidocaine|lidocaine|lidocaine|lidocaine|lidocaine|lidocaine|lidocaine	Chemical	6:52:125:169:204:227:255	7:53:126:170:205:228:256	0:1:3:4:5:6:7	D012640	convulsion|convulsions|convulsions|convulsions|convulsions	Disease	9:55:213:241:258	10:56:214:242:259	0:1:5:6:7	1:NR:2	R2L	NON-CROSS	17-27	9-10	D019331	N - nitro - L - arginine - methyl ester|L - NAME|L - NAME|L - NAME	Chemical	17:28:91:177	27:31:94:180	1:1:2:5	D012640	convulsion|convulsions|convulsions|convulsions|convulsions	Disease	9:55:213:241:258	10:56:214:242:259	0:1:5:6:7	1:NR:2	R2L	NON-CROSS	249-250	241-242	D009569	nitric oxide|NO|NO|NO	Chemical	33:36:46:249	35:37:47:250	1:1:1:7	D012640	convulsion|convulsions|convulsions|convulsions|convulsions	Disease	9:55:213:241:258	10:56:214:242:259	0:1:5:6:7	1:NR:2	R2L	NON-CROSS	219-222	213-214	D001120	L - arginine|L - arginine|L - arginine	Chemical	41:76:219	44:79:222	1:2:6	D012640	convulsion|convulsions|convulsions|convulsions|convulsions	Disease	9:55:213:241:258	10:56:214:242:259	0:1:5:6:7	1:NR:2	R2L	NON-CROSS	213-214	192-193	D003975	diazepam|diazepam	Chemical	106:192	107:193	2:5	D012640	convulsion|convulsions|convulsions|convulsions|convulsions	Disease	9:55:213:241:258	10:56:214:242:259	0:1:5:6:7
11079278	Effect of intravenous metoprolol or intravenous metoprolol plus glucagon on dobutamine - induced myocardial ischemia .|STUDY OBJECTIVE : To determine the effect of metoprolol on dobutamine stress testing with technetium - 99m sestamibi single - photon emission computed tomography imaging and ST - segment monitoring , and to assess the impact of intravenous glucagon on metoprolol 's effects .|DESIGN : Randomized , double - blind , placebo - controlled trial .|SETTING : Community hospital .|PATIENTS : Twenty - two patients with known reversible perfusion defects .|INTERVENTION : Patients underwent dobutamine stress tests per standard protocol .|Before dobutamine was begun , no therapy was given during the first visit , and patients were randomized on subsequent visits to receive metoprolol or metoprolol plus glucagon 1 mg .|Metoprolol was dosed to achieve a resting predobutamine heart rate below 65 beats / minute or a total intravenous dose of 20 mg .|MEASUREMENTS AND MAIN RESULTS : Metoprolol reduced maximum heart rate 31 % , summed stress scores 29 % , and summed difference scores 43 % versus control .|Metoprolol plus glucagon also reduced the maximum heart rate 29 % versus control .|Summed stress and summed difference scores were not significantly reduced , although they were 18 % and 30 % lower , respectively , than control .|No significant differences were found in any parameter between metoprolol and metoprolol - glucagon .|CONCLUSION : During dobutamine stress testing , metoprolol attenuates or eliminates evidence of myocardial ischemia .|Glucagon 1 mg , although somewhat effective , does not correct this effect to the extent that it can be administered clinically .	1:NR:2	L2R	NON-CROSS	246-247	252-254	D008790	metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|Metoprolol|Metoprolol|Metoprolol|metoprolol|metoprolol|metoprolol	Chemical	3:6:24:56:124:126:132:161:184:233:235:246	4:7:25:57:125:127:133:162:185:234:236:247	0:0:1:1:6:6:7:8:9:11:11:12	D017202	myocardial ischemia|myocardial ischemia	Disease	13:252	15:254	0:12	1:CID:2	L2R	NON-CROSS	10-11	13-15	D004280	dobutamine|dobutamine|dobutamine|dobutamine|dobutamine	Chemical	10:26:94:102:242	11:27:95:103:243	0:1:5:6:12	D017202	myocardial ischemia|myocardial ischemia	Disease	13:252	15:254	0:12	1:NR:2	R2L	CROSS	30-34	13-15	D017256	technetium - 99m sestamibi	Chemical	30	34	1	D017202	myocardial ischemia|myocardial ischemia	Disease	13:252	15:254	0:12
10910842	Prednisolone - induced muscle dysfunction is caused more by atrophy than by altered acetylcholine receptor expression .|Large doses of glucocorticoids can alter muscle physiology and susceptibility to neuromuscular blocking drugs by mechanisms not clearly understood .|We investigated the effects of moderate and large doses of prednisolone on muscle function and pharmacology , and their relationship to changes in muscle size and acetylcholine receptor ( AChR ) expression .|With institutional approval , 35 Sprague - Dawley rats were randomly allocated to receive daily subcutaneous doses of 10 mg / kg prednisolone ( P10 group ) , 100 mg / kg prednisolone ( P100 group ) , or an equal volume of saline ( S group ) for 7 days .|A fourth group of rats was pair fed ( food restricted ) with the P100 rats for 7 days ( FR group ) .|On Day 8 , the nerve - evoked peak twitch tensions , tetanic tensions , and fatigability , and the dose - response curves of d - tubocurarine in the tibialis cranialis muscle were measured in vivo and related to muscle mass or expression of AChRs .|Rate of body weight gain was depressed in the P100 , FR , and P10 groups compared with the S group .|Tibialis muscle mass was smaller in the P100 group than in the P10 or S groups .|The evoked peak twitch and tetanic tensions were less in the P100 group than in the P10 or S groups , however , tension per milligram of muscle mass was greater in the P100 group than in the S group .|The 50 % effective dose of d - tubocurarine ( microg / kg ) in the tibialis muscle was smaller in the P10 ( 33 . 6 + / - 5 . 4 ) than in the S ( 61 . 9 + / - 5 . 0 ) or the P100 ( 71 . 3 + / - 9 . 6 ) groups .|AChR expression was less in the P10 group than in the S group .|The evoked tensions correlated with muscle mass ( r ( 2 ) = 0 . 32 , P < 0 . 001 ) , however , not with expression of AChR .|The 50 % effective dose of d - tubocurarine did not correlate with muscle mass or AChR expression .|Our results suggest that the neuromuscular dysfunction after prednisolone is dose - dependent , and derives primarily from muscle atrophy and derives less so from changes in AChR expression .|IMPLICATIONS : The mechanisms by which chronic glucocorticoid therapy alters neuromuscular physiology and pharmacology are unclear .|We suggest that the observed effects are dose - dependent and derive primarily from muscle atrophy and derive less from changes in acetylcholine receptor expression .	1:CID:2	L2R	NON-CROSS	0-1	3-5	D011239	Prednisolone|prednisolone|prednisolone|prednisolone|prednisolone	Chemical	0:47:92:102:411	1:48:93:103:412	0:2:3:3:13	D018908	muscle dysfunction	Disease	3	5	0	1:NR:2	L2R	NON-CROSS	0-1	9-10	D011239	Prednisolone|prednisolone|prednisolone|prednisolone|prednisolone	Chemical	0:47:92:102:411	1:48:93:103:412	0:2:3:3:13	D001284	atrophy	Disease	9	10	0	1:NR:2	L2R	CROSS	102-103	158-159	D011239	Prednisolone|prednisolone|prednisolone|prednisolone|prednisolone	Chemical	0:47:92:102:411	1:48:93:103:412	0:2:3:3:13	D013746	tetanic|tetanic	Disease	158:237	159:238	5:8	1:NR:2	L2R	NON-CROSS	408-410	411-412	D011239	Prednisolone|prednisolone|prednisolone|prednisolone|prednisolone	Chemical	0:47:92:102:411	1:48:93:103:412	0:2:3:3:13	D009468	neuromuscular dysfunction	Disease	408	410	13	1:CID:2	L2R	NON-CROSS	411-412	421-423	D011239	Prednisolone|prednisolone|prednisolone|prednisolone|prednisolone	Chemical	0:47:92:102:411	1:48:93:103:412	0:2:3:3:13	D009133	muscle atrophy|muscle atrophy	Disease	421:464	423:466	13:15	1:NR:2	R2L	NON-CROSS	13-14	3-5	D000109	acetylcholine|acetylcholine|acetylcholine	Chemical	13:63:472	14:64:473	0:2:15	D018908	muscle dysfunction	Disease	3	5	0	1:NR:2	R2L	CROSS	171-174	3-5	D014403	d - tubocurarine|d - tubocurarine|d - tubocurarine	Chemical	171:279:390	174:282:393	5:9:12	D018908	muscle dysfunction	Disease	3	5	0	1:NR:2	R2L	NON-CROSS	13-14	9-10	D000109	acetylcholine|acetylcholine|acetylcholine	Chemical	13:63:472	14:64:473	0:2:15	D001284	atrophy	Disease	9	10	0	1:NR:2	R2L	CROSS	171-174	9-10	D014403	d - tubocurarine|d - tubocurarine|d - tubocurarine	Chemical	171:279:390	174:282:393	5:9:12	D001284	atrophy	Disease	9	10	0	1:NR:2	L2R	CROSS	63-64	158-159	D000109	acetylcholine|acetylcholine|acetylcholine	Chemical	13:63:472	14:64:473	0:2:15	D013746	tetanic|tetanic	Disease	158:237	159:238	5:8	1:NR:2	L2R	CROSS	408-410	472-473	D000109	acetylcholine|acetylcholine|acetylcholine	Chemical	13:63:472	14:64:473	0:2:15	D009468	neuromuscular dysfunction	Disease	408	410	13	1:NR:2	L2R	NON-CROSS	464-466	472-473	D000109	acetylcholine|acetylcholine|acetylcholine	Chemical	13:63:472	14:64:473	0:2:15	D009133	muscle atrophy|muscle atrophy	Disease	421:464	423:466	13:15	1:NR:2	R2L	NON-CROSS	171-174	158-159	D014403	d - tubocurarine|d - tubocurarine|d - tubocurarine	Chemical	171:279:390	174:282:393	5:9:12	D013746	tetanic|tetanic	Disease	158:237	159:238	5:8	1:NR:2	L2R	CROSS	390-393	408-410	D014403	d - tubocurarine|d - tubocurarine|d - tubocurarine	Chemical	171:279:390	174:282:393	5:9:12	D009468	neuromuscular dysfunction	Disease	408	410	13	1:NR:2	L2R	CROSS	390-393	421-423	D014403	d - tubocurarine|d - tubocurarine|d - tubocurarine	Chemical	171:279:390	174:282:393	5:9:12	D009133	muscle atrophy|muscle atrophy	Disease	421:464	423:466	13:15
10533019	Rapid reversal of life - threatening diltiazem - induced tetany with calcium chloride .|We describe a patient who developed tetany with sudden respiratory arrest after the infusion of intravenous diltiazem .|The administration of calcium chloride rapidly resolved the patient 's tetany with prompt recovery of respiratory function , averting the need for more aggressive airway management and ventilatory support .|The emergency physician should be aware that life - threatening tetany may accompany the administration of intravenous diltiazem and that calcium chloride may be a rapid and effective remedy .	1:CID:2	L2R	NON-CROSS	6-7	9-10	D004110	diltiazem|diltiazem|diltiazem	Chemical	6:30:79	7:31:80	0:1:3	D013746	tetany|tetany|tetany|tetany	Disease	9:20:42:72	10:21:43:73	0:1:2:3	1:NR:2	L2R	NON-CROSS	23-25	30-31	D004110	diltiazem|diltiazem|diltiazem	Chemical	6:30:79	7:31:80	0:1:3	D012131	respiratory arrest	Disease	23	25	1	1:NR:2	R2L	NON-CROSS	11-13	9-10	D002122	calcium chloride|calcium chloride|calcium chloride	Chemical	11:35:82	13:37:84	0:2:3	D013746	tetany|tetany|tetany|tetany	Disease	9:20:42:72	10:21:43:73	0:1:2:3	1:NR:2	L2R	CROSS	11-13	23-25	D002122	calcium chloride|calcium chloride|calcium chloride	Chemical	11:35:82	13:37:84	0:2:3	D012131	respiratory arrest	Disease	23	25	1
10414674	Effects of nonsteroidal anti - inflammatory drugs on hemostasis in patients with aneurysmal subarachnoid hemorrhage .|Platelet function is impaired by nonsteroidal anti - inflammatory drugs ( NSAIDs ) with prominent anti - inflammatory properties .|Their safety in patients undergoing intracranial surgery is under debate .|Patients with aneurysmal subarachnoid hemorrhage ( SAH ) were randomized to receive either ketoprofen , 100 mg , three times a day ( ketoprofen group , n = 9 ) or a weak NSAID , acetaminophen , 1 g , three times a day ( acetaminophen group , n = 9 ) starting immediately after the diagnosis of aneurysmal SAH .|Treatment was continued for 3 days postoperatively .|Test blood samples were taken before treatment and surgery as well as on the first , third , and fifth postoperative mornings .|Maximal platelet aggregation induced by 6 microM of adenosine diphosphate decreased after administration of ketoprofen .|Aggregation was lower ( P < . 05 ) in the ketoprofen group than in the acetaminophen group just before surgery and on the third postoperative day .|In contrast , maximal platelet aggregation increased in the acetaminophen group on the third postoperative day as compared with the pretreatment platelet aggregation results ( P < . 05 ) .|One patient in the ketoprofen group developed a postoperative intracranial hematoma .|Coagulation ( prothrombin time [ PT ] , activated partial thromboplastin time [ APPT ] , fibrinogen concentration , and antithrombin III [ AT III ] ) was comparable between the two groups .|Ketoprofen but not acetaminophen impaired platelet function in patients with SAH .|If ketoprofen is used before surgery on cerebral artery aneurysms , it may pose an additional risk factor for hemorrhage .	1:NR:2	R2L	NON-CROSS	273-274	270-271	D007660	ketoprofen|ketoprofen|ketoprofen|ketoprofen|ketoprofen|Ketoprofen|ketoprofen	Chemical	60:70:153:166:218:260:273	61:71:154:167:219:261:274	3:3:6:7:9:11:12	D013345	aneurysmal subarachnoid hemorrhage|aneurysmal subarachnoid hemorrhage|SAH|SAH|SAH	Disease	12:49:53:106:270	15:52:54:107:271	0:3:3:3:11	1:NR:2	R2L	NON-CROSS	270-271	263-264	D000082	acetaminophen|acetaminophen|acetaminophen|acetaminophen|acetaminophen	Chemical	82:92:171:192:263	83:93:172:193:264	3:3:7:8:11	D013345	aneurysmal subarachnoid hemorrhage|aneurysmal subarachnoid hemorrhage|SAH|SAH|SAH	Disease	12:49:53:106:270	15:52:54:107:271	0:3:3:3:11	1:NR:2	R2L	CROSS	147-149	106-107	D000244	adenosine diphosphate	Chemical	147	149	6	D013345	aneurysmal subarachnoid hemorrhage|aneurysmal subarachnoid hemorrhage|SAH|SAH|SAH	Disease	12:49:53:106:270	15:52:54:107:271	0:3:3:3:11	1:NR:2	L2R	NON-CROSS	70-71	105-106	D007660	ketoprofen|ketoprofen|ketoprofen|ketoprofen|ketoprofen|Ketoprofen|ketoprofen	Chemical	60:70:153:166:218:260:273	61:71:154:167:219:261:274	3:3:6:7:9:11:12	D017542	aneurysmal	Disease	105	106	3	1:CID:2	L2R	NON-CROSS	140-142	153-154	D007660	ketoprofen|ketoprofen|ketoprofen|ketoprofen|ketoprofen|Ketoprofen|ketoprofen	Chemical	60:70:153:166:218:260:273	61:71:154:167:219:261:274	3:3:6:7:9:11:12	D001791	platelet aggregation|platelet aggregation|platelet aggregation	Disease	140:187:204	142:189:206	6:8:8	1:CID:2	L2R	NON-CROSS	218-219	224-225	D007660	ketoprofen|ketoprofen|ketoprofen|ketoprofen|ketoprofen|Ketoprofen|ketoprofen	Chemical	60:70:153:166:218:260:273	61:71:154:167:219:261:274	3:3:6:7:9:11:12	D006406	hematoma	Disease	224	225	9	1:NR:2	L2R	NON-CROSS	273-274	280-282	D007660	ketoprofen|ketoprofen|ketoprofen|ketoprofen|ketoprofen|Ketoprofen|ketoprofen	Chemical	60:70:153:166:218:260:273	61:71:154:167:219:261:274	3:3:6:7:9:11:12	D002532	artery aneurysms	Disease	280	282	12	1:NR:2	L2R	NON-CROSS	273-274	291-292	D007660	ketoprofen|ketoprofen|ketoprofen|ketoprofen|ketoprofen|Ketoprofen|ketoprofen	Chemical	60:70:153:166:218:260:273	61:71:154:167:219:261:274	3:3:6:7:9:11:12	D006470	hemorrhage	Disease	291	292	12	1:NR:2	L2R	NON-CROSS	92-93	105-106	D000082	acetaminophen|acetaminophen|acetaminophen|acetaminophen|acetaminophen	Chemical	82:92:171:192:263	83:93:172:193:264	3:3:7:8:11	D017542	aneurysmal	Disease	105	106	3	1:NR:2	L2R	NON-CROSS	187-189	192-193	D000082	acetaminophen|acetaminophen|acetaminophen|acetaminophen|acetaminophen	Chemical	82:92:171:192:263	83:93:172:193:264	3:3:7:8:11	D001791	platelet aggregation|platelet aggregation|platelet aggregation	Disease	140:187:204	142:189:206	6:8:8	1:NR:2	L2R	CROSS	192-193	224-225	D000082	acetaminophen|acetaminophen|acetaminophen|acetaminophen|acetaminophen	Chemical	82:92:171:192:263	83:93:172:193:264	3:3:7:8:11	D006406	hematoma	Disease	224	225	9	1:NR:2	L2R	CROSS	263-264	280-282	D000082	acetaminophen|acetaminophen|acetaminophen|acetaminophen|acetaminophen	Chemical	82:92:171:192:263	83:93:172:193:264	3:3:7:8:11	D002532	artery aneurysms	Disease	280	282	12	1:NR:2	L2R	CROSS	263-264	291-292	D000082	acetaminophen|acetaminophen|acetaminophen|acetaminophen|acetaminophen	Chemical	82:92:171:192:263	83:93:172:193:264	3:3:7:8:11	D006470	hemorrhage	Disease	291	292	12	1:NR:2	R2L	CROSS	147-149	105-106	D000244	adenosine diphosphate	Chemical	147	149	6	D017542	aneurysmal	Disease	105	106	3	1:NR:2	R2L	NON-CROSS	147-149	140-142	D000244	adenosine diphosphate	Chemical	147	149	6	D001791	platelet aggregation|platelet aggregation|platelet aggregation	Disease	140:187:204	142:189:206	6:8:8	1:NR:2	L2R	CROSS	147-149	224-225	D000244	adenosine diphosphate	Chemical	147	149	6	D006406	hematoma	Disease	224	225	9	1:NR:2	L2R	CROSS	147-149	280-282	D000244	adenosine diphosphate	Chemical	147	149	6	D002532	artery aneurysms	Disease	280	282	12	1:NR:2	L2R	CROSS	147-149	291-292	D000244	adenosine diphosphate	Chemical	147	149	6	D006470	hemorrhage	Disease	291	292	12
9523850	Value of methylprednisolone in prevention of the arthralgia - myalgia syndrome associated with the total dose infusion of iron dextran : a double blind randomized trial .|The safety and efficacy of total dose infusion ( TDI ) of iron dextran has been well documented .|In 40 % of treated patients , an arthralgia - myalgia syndrome develops .|The purpose of this randomized , double - blind , prospective study was to investigate whether intravenous ( i . v . ) administration of methylprednisolone ( MP ) prevents this complication .|Sixty - five patients , 34 women and 31 men , ages 36 to 80 years , received either normal saline before and after TDI ( group 1 ) , 125 mg i . v .|MP before and saline after TDI ( group 2 ) , or 125 mg i . v .|MP before and after TDI ( group 3 ) .|Patients were observed for 72 hours and reactions were recorded and graded according to severity .|Fifty - eight percent of group 1 patients , 33 % of group 2 , and 26 % of group 3 had reactions to TDI .|The severity of reactions ( minimal , mild , and moderate , respectively ) was as follows : group 1 - - 6 , 6 , and 2 ; group 2 - - 1 , 5 , and 0 ; group 3 - - 5 , 1 , and 0 .|Data were analyzed by the two - sided Fisher 's exact test using 95 % confidence intervals with the approximation of Woolf .|These data demonstrate that administration of MP before and after TDI reduces the frequency and severity of the arthralgia - myalgia syndrome .|We conclude that 125 mg i . v .|MP should be given routinely before and after TDI of iron dextran .	1:NR:2	L2R	NON-CROSS	2-3	7-8	D008775	methylprednisolone|methylprednisolone|MP|MP|MP|MP|MP	Chemical	2:85:87:129:147:279:305	3:86:88:130:148:280:306	0:3:3:5:6:11:13	D018771	arthralgia|arthralgia|arthralgia	Disease	7:54:291	8:55:292	0:2:11	1:NR:2	L2R	NON-CROSS	2-3	9-10	D008775	methylprednisolone|methylprednisolone|MP|MP|MP|MP|MP	Chemical	2:85:87:129:147:279:305	3:86:88:130:148:280:306	0:3:3:5:6:11:13	D063806	myalgia|myalgia|myalgia	Disease	9:56:293	10:57:294	0:2:11	1:CID:2	R2L	NON-CROSS	18-20	7-8	D007505	iron dextran|iron dextran|iron dextran	Chemical	18:39:315	20:41:317	0:1:13	D018771	arthralgia|arthralgia|arthralgia	Disease	7:54:291	8:55:292	0:2:11	1:NR:2	R2L	NON-CROSS	18-20	9-10	D007505	iron dextran|iron dextran|iron dextran	Chemical	18:39:315	20:41:317	0:1:13	D063806	myalgia|myalgia|myalgia	Disease	9:56:293	10:57:294	0:2:11
8384253	Long - term effects of vincristine on the peripheral nervous system .|Forty patients with Non - Hodgkin 's Lymphoma treated with vincristine between 1984 and 1990 ( cumulative dose 12 mg in 18 - 24 weeks ) were investigated in order to evaluate the long term effects of vincristine on the peripheral nervous system .|The patients were interviewed with emphasis on neuropathic symptoms .|Physical and quantitative sensory examination with determination of vibratory perception and thermal discrimination thresholds were performed , four to 77 months ( median 34 months ) after vincristine treatment .|Twenty - seven patients reported neuropathic symptoms .|In 13 of these 27 patients symptoms were still present at the time of examination .|In these patients sensory signs and symptoms predominated .|In the other 14 patients symptoms had been present in the past .|Symptoms persisted maximally 40 months since cessation of therapy .|There was no age difference between patients with and without complaints at the time of examination .|Normal reflexes were found in two third of patients .|Neuropathic complaints were not very troublesome on the long term .|It is concluded that with the above mentioned vincristine dose schedule signs and symptoms of vincristine neuropathy are reversible for a great deal and prognosis is fairly good .	1:NR:2	L2R	NON-CROSS	15-20	22-23	D014750	vincristine|vincristine|vincristine|vincristine|vincristine|vincristine	Chemical	5:22:49:93:198:205	6:23:50:94:199:206	0:1:1:3:12:12	D008228	Non - Hodgkin 's Lymphoma	Disease	15	20	1	1:CID:2	L2R	CROSS	93-94	101-103	D014750	vincristine|vincristine|vincristine|vincristine|vincristine|vincristine	Chemical	5:22:49:93:198:205	6:23:50:94:199:206	0:1:1:3:12:12	D012678	neuropathic symptoms|neuropathic symptoms	Disease	63:101	65:103	2:4	1:NR:2	L2R	NON-CROSS	205-206	206-207	D014750	vincristine|vincristine|vincristine|vincristine|vincristine|vincristine	Chemical	5:22:49:93:198:205	6:23:50:94:199:206	0:1:1:3:12:12	D009422	neuropathy	Disease	206	207	12
8268147	A case of polymyositis in a patient with primary biliary cirrhosis treated with D - penicillamine .|Although D - penicillamine has been used for many rheumatologic diseases , toxicity limits its usefulness in many patients .|Polymyositis / dermatomyositis can develop as one of the autoimmune complications of D - penicillamine treatment , but its exact pathogenesis remains unclear .|We report a patient with primary biliary cirrhosis , who developed polymyositis while receiving D - penicillamine therapy .|We described the special clinical course of the patient .|Patients receiving D - penicillamine therapy should be followed carefully for the development of autoimmune complications like polymyositis / dermatomyositis .	1:CID:2	R2L	NON-CROSS	75-78	72-73	D010396	D - penicillamine|D - penicillamine|D - penicillamine|D - penicillamine|D - penicillamine	Chemical	13:18:49:75:92	16:21:52:78:95	0:1:2:3:5	D017285	polymyositis|Polymyositis|polymyositis|polymyositis	Disease	3:37:72:107	4:38:73:108	0:2:3:5	1:NR:2	R2L	NON-CROSS	13-16	8-11	D010396	D - penicillamine|D - penicillamine|D - penicillamine|D - penicillamine|D - penicillamine	Chemical	13:18:49:75:92	16:21:52:78:95	0:1:2:3:5	D008105	primary biliary cirrhosis|primary biliary cirrhosis	Disease	8:66	11:69	0:3	1:NR:2	L2R	NON-CROSS	18-21	26-28	D010396	D - penicillamine|D - penicillamine|D - penicillamine|D - penicillamine|D - penicillamine	Chemical	13:18:49:75:92	16:21:52:78:95	0:1:2:3:5	D012216	rheumatologic diseases	Disease	26	28	1	1:NR:2	L2R	NON-CROSS	18-21	29-30	D010396	D - penicillamine|D - penicillamine|D - penicillamine|D - penicillamine|D - penicillamine	Chemical	13:18:49:75:92	16:21:52:78:95	0:1:2:3:5	D064420	toxicity	Disease	29	30	1	1:NR:2	L2R	NON-CROSS	39-40	49-52	D010396	D - penicillamine|D - penicillamine|D - penicillamine|D - penicillamine|D - penicillamine	Chemical	13:18:49:75:92	16:21:52:78:95	0:1:2:3:5	D003882	dermatomyositis|dermatomyositis	Disease	39:109	40:110	2:5
8251368	Photodistributed nifedipine - induced facial telangiectasia .|Five months after starting nifedipine ( Adalat ) , two patients developed photodistributed facial telangiectasia , which became more noticeable with time .|Neither patient complained of photosensitivity or flushing .|Both patients reported a significant cosmetic improvement after discontinuing the drug .|One commenced the closely related drug amlodipine 3 years later , with recurrence of telangiectasia .|The photodistribution of the telangiectasia suggests a significant drug / light interaction .	1:CID:2	L2R	NON-CROSS	1-2	5-6	D009543	nifedipine|nifedipine|Adalat	Chemical	1:11:13	2:12:14	0:1:1	D013684	telangiectasia|telangiectasia|telangiectasia|telangiectasia	Disease	5:21:64:70	6:22:65:71	0:1:4:5	1:NR:2	L2R	CROSS	13-14	36-37	D009543	nifedipine|nifedipine|Adalat	Chemical	1:11:13	2:12:14	0:1:1	D005483	flushing	Disease	36	37	2	1:CID:2	R2L	NON-CROSS	64-65	56-57	D017311	amlodipine	Chemical	56	57	4	D013684	telangiectasia|telangiectasia|telangiectasia|telangiectasia	Disease	5:21:64:70	6:22:65:71	0:1:4:5	1:NR:2	R2L	CROSS	56-57	36-37	D017311	amlodipine	Chemical	56	57	4	D005483	flushing	Disease	36	37	2
7542793	Nephrotoxicity of cyclosporin A and FK506 : inhibition of calcineurin phosphatase .|Cyclosporin A ( CsA ; 50 mg / kg ) and Fujimycine ( FK506 ; 5 mg / kg ) , but not the related macrolide immunosuppressant rapamycin ( 5 mg / kg ) , caused a reduction of glomerular filtration rate , degenerative changes of proximal tubular epithelium , and hypertrophy of the juxtaglomerular apparatus in male Wistar rats when given for 10 days .|The molecular mechanisms of CsA and FK506 toxicity were investigated .|Cyclophilin A and FK506 - binding protein , the main intracytoplasmic receptors for CsA and FK506 , respectively , were each detected in renal tissue extract .|In the kidney , high levels of immunoreactive and enzymatically active calcineurin were found which were inhibited by the immunosuppressants CsA and FK506 , but not by rapamycin .|Finally , specific immunophilin - drug - calcineurin complexes formed only in the presence of CsA and FK506 , but not rapamycin .|These results suggest that the nephrotoxic effects of CsA and FK506 is likely mediated through binding to renal immunophilin and inhibiting calcineurin phosphatase .	1:CID:2	R2L	NON-CROSS	2-4	0-1	D016572	cyclosporin A|Cyclosporin A|CsA|CsA|CsA|CsA|CsA|CsA	Chemical	2:12:15:82:102:136:160:176	4:14:16:83:103:137:161:177	0:1:1:2:3:4:5:6	D007674	Nephrotoxicity|nephrotoxic	Disease	0:173	1:174	0:6	1:CID:2	R2L	NON-CROSS	5-6	0-1	D016559	FK506|Fujimycine|FK506|FK506|FK506|FK506|FK506|FK506|FK506	Chemical	5:23:25:84:92:104:138:162:178	6:24:26:85:93:105:139:163:179	0:1:1:2:3:3:4:5:6	D007674	Nephrotoxicity|nephrotoxic	Disease	0:173	1:174	0:6	1:NR:2	R2L	CROSS	37-38	0-1	D018942	macrolide	Chemical	37	38	1	D007674	Nephrotoxicity|nephrotoxic	Disease	0:173	1:174	0:6	1:NR:2	R2L	CROSS	173-174	166-167	D020123	rapamycin|rapamycin|rapamycin	Chemical	39:143:166	40:144:167	1:4:5	D007674	Nephrotoxicity|nephrotoxic	Disease	0:173	1:174	0:6	1:NR:2	L2R	NON-CROSS	63-64	82-83	D016572	cyclosporin A|Cyclosporin A|CsA|CsA|CsA|CsA|CsA|CsA	Chemical	2:12:15:82:102:136:160:176	4:14:16:83:103:137:161:177	0:1:1:2:3:4:5:6	D006984	hypertrophy	Disease	63	64	1	1:NR:2	L2R	NON-CROSS	82-83	85-86	D016572	cyclosporin A|Cyclosporin A|CsA|CsA|CsA|CsA|CsA|CsA	Chemical	2:12:15:82:102:136:160:176	4:14:16:83:103:137:161:177	0:1:1:2:3:4:5:6	D064420	toxicity	Disease	85	86	2	1:NR:2	L2R	NON-CROSS	63-64	84-85	D016559	FK506|Fujimycine|FK506|FK506|FK506|FK506|FK506|FK506|FK506	Chemical	5:23:25:84:92:104:138:162:178	6:24:26:85:93:105:139:163:179	0:1:1:2:3:3:4:5:6	D006984	hypertrophy	Disease	63	64	1	1:NR:2	L2R	NON-CROSS	84-85	85-86	D016559	FK506|Fujimycine|FK506|FK506|FK506|FK506|FK506|FK506|FK506	Chemical	5:23:25:84:92:104:138:162:178	6:24:26:85:93:105:139:163:179	0:1:1:2:3:3:4:5:6	D064420	toxicity	Disease	85	86	2	1:NR:2	L2R	NON-CROSS	37-38	63-64	D018942	macrolide	Chemical	37	38	1	D006984	hypertrophy	Disease	63	64	1	1:NR:2	L2R	CROSS	37-38	85-86	D018942	macrolide	Chemical	37	38	1	D064420	toxicity	Disease	85	86	2	1:NR:2	L2R	NON-CROSS	39-40	63-64	D020123	rapamycin|rapamycin|rapamycin	Chemical	39:143:166	40:144:167	1:4:5	D006984	hypertrophy	Disease	63	64	1	1:NR:2	L2R	CROSS	39-40	85-86	D020123	rapamycin|rapamycin|rapamycin	Chemical	39:143:166	40:144:167	1:4:5	D064420	toxicity	Disease	85	86	2
7337133	Massive cerebral edema associated with fulminant hepatic failure in acetaminophen overdose : possible role of cranial decompression .|Cerebral edema may complicate the course of fulminant hepatic failure .|Response to conventional therapy has been disappointing .|We present a patient with fatal acetaminophen - induced fulminant hepatic failure , with signs and symptoms of cerebral edema , unresponsive to conventional medical therapy .|Cranial decompression was carried out .|A justification of the need for further evaluation of cranial decompression in such patients is presented .	1:CID:2	R2L	NON-CROSS	9-10	1-3	D000082	acetaminophen|acetaminophen	Chemical	9:43	10:44	0:3	D001929	cerebral edema|Cerebral edema|cerebral edema	Disease	1:18:55	3:20:57	0:1:3	1:CID:2	R2L	NON-CROSS	9-10	6-8	D000082	acetaminophen|acetaminophen	Chemical	9:43	10:44	0:3	D017093	hepatic failure|fulminant hepatic failure|fulminant hepatic failure	Disease	6:25:46	8:28:49	0:1:3	1:NR:2	L2R	NON-CROSS	9-10	10-11	D000082	acetaminophen|acetaminophen	Chemical	9:43	10:44	0:3	D062787	overdose	Disease	10	11	0
4069770	Gentamicin nephropathy in a neonate .|The clinical and autopsy findings in a premature baby who died of acute renal failure after therapy with gentamicin ( 5 mg / kg / day ) and penicillin are presented .|The serum gentamicin concentration had reached toxic levels when anuria developed .|Numerous periodic acid Schiff ( PAS ) positive , diastase resistant cytoplasmic inclusion bodies which appeared as myelin figures in cytosegresomes under the electron microscope were identified in the proximal convoluted tubules .|The pathological changes induced by gentamicin in the human neonatal kidneys have not been previously reported .	1:NR:2	L2R	NON-CROSS	0-1	1-2	D005839	Gentamicin|gentamicin|gentamicin|gentamicin	Chemical	0:24:40:88	1:25:41:89	0:1:2:4	D007674	nephropathy	Disease	1	2	0	1:CID:2	L2R	NON-CROSS	18-21	24-25	D005839	Gentamicin|gentamicin|gentamicin|gentamicin	Chemical	0:24:40:88	1:25:41:89	0:1:2:4	D058186	acute renal failure	Disease	18	21	1	1:NR:2	L2R	NON-CROSS	40-41	47-48	D005839	Gentamicin|gentamicin|gentamicin|gentamicin	Chemical	0:24:40:88	1:25:41:89	0:1:2:4	D001002	anuria	Disease	47	48	2	1:NR:2	R2L	CROSS	34-35	1-2	D010406	penicillin	Chemical	34	35	1	D007674	nephropathy	Disease	1	2	0	1:NR:2	R2L	CROSS	51-53	1-2	D010504	periodic acid	Chemical	51	53	3	D007674	nephropathy	Disease	1	2	0	1:NR:2	R2L	NON-CROSS	34-35	18-21	D010406	penicillin	Chemical	34	35	1	D058186	acute renal failure	Disease	18	21	1	1:NR:2	R2L	CROSS	51-53	18-21	D010504	periodic acid	Chemical	51	53	3	D058186	acute renal failure	Disease	18	21	1	1:NR:2	L2R	CROSS	34-35	47-48	D010406	penicillin	Chemical	34	35	1	D001002	anuria	Disease	47	48	2	1:NR:2	R2L	CROSS	51-53	47-48	D010504	periodic acid	Chemical	51	53	3	D001002	anuria	Disease	47	48	2
3780814	Anti - carcinogenic action of phenobarbital given simultaneously with diethylnitrosamine in the rat .|The present work has been planned in order to elucidate the effect of phenobarbital ( PB : 15 mg per rat of ingested dose ) on carcinogenesis when it is administered simultaneously with diethylnitrosamine ( DEN : 10 mg / kg / day ) .|Wistar rats ( 180 g ) were treated by DEN alone or by DEN + PB during 2 , 4 and 6 weeks according to our schedule for hepatocarcinogenesis .|After the end of the treatment , the number and the size of induced PAS positive preneoplastic foci was significantly reduced when PB was given simultaneously with DEN for 4 and 6 weeks .|The mitotic inhibition and the production of micronuclei normally observed after partial hepatectomy in DEN treated rats were also significantly decreased in DEN + PB treated rats .|When the treatment last only 2 weeks , the presence of PB did not change significantly the last parameters .|In DEN + PB treated rats , the survival was prolonged and the tumor incidence decreased as compared with the results obtained by DEN alone .|It is concluded that PB , which promotes carcinogenesis when administered after the DEN treatment , reduces the carcinogen effect when given simultaneously with DEN .|This ' anti - carcinogen ' effect acts on the initiation as well as on the promotion of the precancerous lesions .|Biochemical investigations are in progress to obtain more information about this ' paradoxical ' PB effect .	1:NR:2	R2L	NON-CROSS	5-6	2-3	D010634	phenobarbital|phenobarbital|PB|PB|PB|PB|PB|PB|PB|PB	Chemical	5:27:29:74:111:147:162:174:201:259	6:28:30:75:112:148:163:175:202:260	0:1:1:2:3:4:5:6:7:9	D063646	carcinogenic|carcinogenesis|hepatocarcinogenesis|carcinogenesis	Disease	2:40:87:205	3:41:88:206	0:1:2:7	1:NR:2	R2L	NON-CROSS	210-211	205-206	D004052	diethylnitrosamine|diethylnitrosamine|DEN|DEN|DEN|DEN|DEN|DEN|DEN|DEN|DEN|DEN	Chemical	9:47:49:68:72:116:137:145:172:194:210:221	10:48:50:69:73:117:138:146:173:195:211:222	0:1:1:2:2:3:4:4:6:6:7:7	D063646	carcinogenic|carcinogenesis|hepatocarcinogenesis|carcinogenesis	Disease	2:40:87:205	3:41:88:206	0:1:2:7	1:NR:2	L2R	NON-CROSS	105-107	111-112	D010634	phenobarbital|phenobarbital|PB|PB|PB|PB|PB|PB|PB|PB	Chemical	5:27:29:74:111:147:162:174:201:259	6:28:30:75:112:148:163:175:202:260	0:1:1:2:3:4:5:6:7:9	D011230	preneoplastic foci|precancerous lesions	Disease	105:242	107:244	3:8	1:NR:2	L2R	NON-CROSS	174-175	184-185	D010634	phenobarbital|phenobarbital|PB|PB|PB|PB|PB|PB|PB|PB	Chemical	5:27:29:74:111:147:162:174:201:259	6:28:30:75:112:148:163:175:202:260	0:1:1:2:3:4:5:6:7:9	D009369	tumor	Disease	184	185	6	1:CID:2	L2R	NON-CROSS	105-107	116-117	D004052	diethylnitrosamine|diethylnitrosamine|DEN|DEN|DEN|DEN|DEN|DEN|DEN|DEN|DEN|DEN	Chemical	9:47:49:68:72:116:137:145:172:194:210:221	10:48:50:69:73:117:138:146:173:195:211:222	0:1:1:2:2:3:4:4:6:6:7:7	D011230	preneoplastic foci|precancerous lesions	Disease	105:242	107:244	3:8	1:NR:2	L2R	NON-CROSS	184-185	194-195	D004052	diethylnitrosamine|diethylnitrosamine|DEN|DEN|DEN|DEN|DEN|DEN|DEN|DEN|DEN|DEN	Chemical	9:47:49:68:72:116:137:145:172:194:210:221	10:48:50:69:73:117:138:146:173:195:211:222	0:1:1:2:2:3:4:4:6:6:7:7	D009369	tumor	Disease	184	185	6
3780697	Post - operative rigidity after fentanyl administration .|A case of thoraco - abdominal rigidity leading to respiratory failure is described in the post - operative period in an elderly patient who received a moderate dose of fentanyl .|This was successfully reversed by naloxone .|The mechanisms possibly implicated in this accident are discussed .	1:CID:2	R2L	NON-CROSS	5-6	3-4	D005283	fentanyl|fentanyl	Chemical	5:37	6:38	0:1	D009127	rigidity|rigidity	Disease	3:14	4:15	0:1	1:NR:2	R2L	CROSS	44-45	14-15	D009270	naloxone	Chemical	44	45	2	D009127	rigidity|rigidity	Disease	3:14	4:15	0:1	1:NR:2	L2R	NON-CROSS	5-6	17-19	D005283	fentanyl|fentanyl	Chemical	5:37	6:38	0:1	D012131	respiratory failure	Disease	17	19	1	1:NR:2	R2L	CROSS	44-45	17-19	D009270	naloxone	Chemical	44	45	2	D012131	respiratory failure	Disease	17	19	1
3686155	Postpartum psychosis induced by bromocriptine .|Two multigravida patients with no prior psychiatric history were seen with postpartum psychosis , having received bromocriptine for inhibition of lactation .|Bromocriptine given in high doses has been associated with psychosis in patients receiving the drug for Parkinson 's disease .|These cases demonstrate that bromocriptine may cause psychosis even when given in low doses .	1:CID:2	R2L	NON-CROSS	4-5	1-2	D001971	bromocriptine|bromocriptine|Bromocriptine|bromocriptine	Chemical	4:22:28:52	5:23:29:53	0:1:2:3	D011605	psychosis|psychosis|psychosis|psychosis	Disease	1:18:37:55	2:19:38:56	0:1:2:3	1:NR:2	L2R	NON-CROSS	4-5	12-13	D001971	bromocriptine|bromocriptine|Bromocriptine|bromocriptine	Chemical	4:22:28:52	5:23:29:53	0:1:2:3	D001523	psychiatric	Disease	12	13	1	1:NR:2	L2R	NON-CROSS	22-23	24-27	D001971	bromocriptine|bromocriptine|Bromocriptine|bromocriptine	Chemical	4:22:28:52	5:23:29:53	0:1:2:3	D007775	inhibition of lactation	Disease	24	27	1	1:NR:2	L2R	NON-CROSS	44-47	52-53	D001971	bromocriptine|bromocriptine|Bromocriptine|bromocriptine	Chemical	4:22:28:52	5:23:29:53	0:1:2:3	D010300	Parkinson 's disease	Disease	44	47	2
3137399	A prospective study on the dose dependency of cardiotoxicity induced by mitomycin C .|Since 1975 mitomycin C ( MMC ) has been suggested to be cardiotoxic , especially when combined with or given following doxorubicin .|Data on dose dependency or incidence concerning this side effect were not known .|We have initiated a prospective study to obtain some more data on these subjects .|Forty - four MMC - treated patients were studied , 37 of them could be evaluated .|All patients were studied by repeated physical examinations , chest X - rays , electro - and echocardiography and radionuclide left ventricular ejection fraction ( EF ) determinations .|The results were evaluated per cumulative dose level .|One of the patients developed cardiac failure after 30 mg m - 2 MMC and only 150 mg m - 2 doxorubicin .|The cardiac failure was predicted by a drop in EF determined during a cold pressor test .|None of the other patients developed clinical cardiotoxicity , nor did the studied parameters change .|The literature on this subject was also reviewed .|Based on the combined data from the present study and the literature , we suggest that MMC - related cardiotoxicity is dose dependent , occurring at cumulative dose levels of 30 mg m - 2 or more , mainly in patients also ( previously or simultaneously ) treated with doxorubicin .|The incidence is likely to be less than 10 % even for this risk group .	1:NR:2	R2L	NON-CROSS	11-13	8-9	D016685	mitomycin C|mitomycin C|MMC|MMC|MMC|MMC	Chemical	11:16:19:69:134:202	13:18:20:70:135:203	0:1:1:4:7:11	D066126	cardiotoxicity|cardiotoxic|cardiotoxicity|cardiotoxicity	Disease	8:26:168:205	9:27:169:206	0:1:9:11	1:NR:2	R2L	NON-CROSS	35-36	26-27	D004317	doxorubicin|doxorubicin|doxorubicin	Chemical	35:142:235	36:143:236	1:7:11	D066126	cardiotoxicity|cardiotoxic|cardiotoxicity|cardiotoxicity	Disease	8:26:168:205	9:27:169:206	0:1:9:11	1:CID:2	L2R	NON-CROSS	126-128	134-135	D016685	mitomycin C|mitomycin C|MMC|MMC|MMC|MMC	Chemical	11:16:19:69:134:202	13:18:20:70:135:203	0:1:1:4:7:11	D006333	cardiac failure|cardiac failure	Disease	126:145	128:147	7:8	1:CID:2	L2R	NON-CROSS	142-143	145-147	D004317	doxorubicin|doxorubicin|doxorubicin	Chemical	35:142:235	36:143:236	1:7:11	D006333	cardiac failure|cardiac failure	Disease	126:145	128:147	7:8
2709684	Phlorizin - induced glycosuria does not prevent gentamicin nephrotoxicity in rats .|Because rats with streptozotocin - induced diabetes mellitus ( DM ) have a high solute diuresis ( glycosuria of 10 to 12 g / day ) , we have suggested that this may in part be responsible for their resistance to gentamicin - induced acute renal failure ( ARF ) .|The protection from gentamicin nephrotoxicity was studied in non - diabetic rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with phlorizin ( P ) .|DM rats with mild glycosuria ( similar in degree to that of the P treated animals ) were also studied .|Unanesthetized adult female , Sprague - Dawley rats were divided in four groups and studied for 15 days .|Group 1 ( P alone ) received P , 360 mg / day , for 15 days ; Group II ( P + gentamicin ) ; Group III ( gentamicin alone ) and Group IV ( mild DM + gentamicin ) .|Nephrotoxic doses ( 40 mg / kg body wt / day ) of gentamicin were injected during the last nine days of study to the animals of groups II to IV .|In Group I , P induced a moderate and stable glycosuria ( 3 . 9 + / - 0 . 1 g / day , SE ) , and no functional or morphologic evidence of renal dysfunction ( baseline CCr 2 . 1 + / - 0 . 1 ml / min , undetectable lysozymuria ) or damage ( tubular necrosis score [ maximum 4 ] , zero ) .|In Group II , P did not prevent gentamicin - ARF ( maximal decrease in CCr at day 9 . 89 % , P less than 0 . 001 ; peak lysozymuria , 1863 + / - 321 micrograms / day ; and tubular necrosis score , 3 . 9 + / - 0 . 1 ) .|These values were not different from those of Group III : maximal decrease in CCr 73 % ( P less than 0 . 001 ) ; lysozymuria , 2147 + / - 701 micrograms / day ; tubular necrosis score , 3 . 8 + / - 0 . 1 . ( ABSTRACT TRUNCATED AT 250 WORDS )	1:NR:2	L2R	NON-CROSS	0-1	3-4	D010695	Phlorizin|phlorizin|P|P|P|P|P|P|P|P|P	Chemical	0:87:89:105:135:139:153:210:280:299:352	1:88:90:106:136:140:154:211:281:300:353	0:2:2:3:5:5:5:7:8:8:9	D006029	glycosuria|glycosuria|glycosuria|glycosuria	Disease	3:29:96:216	4:30:97:217	0:1:3:7	1:NR:2	L2R	NON-CROSS	0-1	8-9	D010695	Phlorizin|phlorizin|P|P|P|P|P|P|P|P|P	Chemical	0:87:89:105:135:139:153:210:280:299:352	1:88:90:106:136:140:154:211:281:300:353	0:2:2:3:5:5:5:7:8:8:9	D007674	nephrotoxicity|nephrotoxicity|Nephrotoxic|renal dysfunction	Disease	8:67:174:241	9:68:175:243	0:2:6:7	1:NR:2	L2R	NON-CROSS	89-90	92-93	D010695	Phlorizin|phlorizin|P|P|P|P|P|P|P|P|P	Chemical	0:87:89:105:135:139:153:210:280:299:352	1:88:90:106:136:140:154:211:281:300:353	0:2:2:3:5:5:5:7:8:8:9	D003920	diabetes mellitus|DM|diabetic|DM|DM	Disease	18:21:73:92:169	20:22:74:93:170	1:1:2:3:5	1:NR:2	L2R	NON-CROSS	280-281	286-287	D010695	Phlorizin|phlorizin|P|P|P|P|P|P|P|P|P	Chemical	0:87:89:105:135:139:153:210:280:299:352	1:88:90:106:136:140:154:211:281:300:353	0:2:2:3:5:5:5:7:8:8:9	D058186	acute renal failure|ARF|ARF	Disease	56:60:286	59:61:287	1:1:8	1:NR:2	L2R	NON-CROSS	265-267	280-281	D010695	Phlorizin|phlorizin|P|P|P|P|P|P|P|P|P	Chemical	0:87:89:105:135:139:153:210:280:299:352	1:88:90:106:136:140:154:211:281:300:353	0:2:2:3:5:5:5:7:8:8:9	D009956	tubular necrosis|tubular necrosis|tubular necrosis	Disease	265:319:371	267:321:373	7:8:9	1:NR:2	R2L	NON-CROSS	7-8	3-4	D005839	gentamicin|gentamicin|gentamicin|gentamicin|gentamicin|gentamicin|gentamicin|gentamicin	Chemical	7:53:66:155:161:171:187:284	8:54:67:156:162:172:188:285	0:1:2:5:5:5:6:8	D006029	glycosuria|glycosuria|glycosuria|glycosuria	Disease	3:29:96:216	4:30:97:217	0:1:3:7	1:NR:2	R2L	NON-CROSS	15-16	3-4	D013311	streptozotocin	Chemical	15	16	1	D006029	glycosuria|glycosuria|glycosuria|glycosuria	Disease	3:29:96:216	4:30:97:217	0:1:3:7	1:NR:2	R2L	CROSS	96-97	84-85	D005947	glucose	Chemical	84	85	2	D006029	glycosuria|glycosuria|glycosuria|glycosuria	Disease	3:29:96:216	4:30:97:217	0:1:3:7	1:NR:2	L2R	NON-CROSS	7-8	8-9	D005839	gentamicin|gentamicin|gentamicin|gentamicin|gentamicin|gentamicin|gentamicin|gentamicin	Chemical	7:53:66:155:161:171:187:284	8:54:67:156:162:172:188:285	0:1:2:5:5:5:6:8	D007674	nephrotoxicity|nephrotoxicity|Nephrotoxic|renal dysfunction	Disease	8:67:174:241	9:68:175:243	0:2:6:7	1:NR:2	L2R	NON-CROSS	169-170	171-172	D005839	gentamicin|gentamicin|gentamicin|gentamicin|gentamicin|gentamicin|gentamicin|gentamicin	Chemical	7:53:66:155:161:171:187:284	8:54:67:156:162:172:188:285	0:1:2:5:5:5:6:8	D003920	diabetes mellitus|DM|diabetic|DM|DM	Disease	18:21:73:92:169	20:22:74:93:170	1:1:2:3:5	1:CID:2	L2R	NON-CROSS	284-285	286-287	D005839	gentamicin|gentamicin|gentamicin|gentamicin|gentamicin|gentamicin|gentamicin|gentamicin	Chemical	7:53:66:155:161:171:187:284	8:54:67:156:162:172:188:285	0:1:2:5:5:5:6:8	D058186	acute renal failure|ARF|ARF	Disease	56:60:286	59:61:287	1:1:8	1:NR:2	L2R	NON-CROSS	265-267	284-285	D005839	gentamicin|gentamicin|gentamicin|gentamicin|gentamicin|gentamicin|gentamicin|gentamicin	Chemical	7:53:66:155:161:171:187:284	8:54:67:156:162:172:188:285	0:1:2:5:5:5:6:8	D009956	tubular necrosis|tubular necrosis|tubular necrosis	Disease	265:319:371	267:321:373	7:8:9	1:NR:2	R2L	CROSS	15-16	8-9	D013311	streptozotocin	Chemical	15	16	1	D007674	nephrotoxicity|nephrotoxicity|Nephrotoxic|renal dysfunction	Disease	8:67:174:241	9:68:175:243	0:2:6:7	1:NR:2	R2L	NON-CROSS	84-85	67-68	D005947	glucose	Chemical	84	85	2	D007674	nephrotoxicity|nephrotoxicity|Nephrotoxic|renal dysfunction	Disease	8:67:174:241	9:68:175:243	0:2:6:7	1:CID:2	L2R	NON-CROSS	15-16	18-20	D013311	streptozotocin	Chemical	15	16	1	D003920	diabetes mellitus|DM|diabetic|DM|DM	Disease	18:21:73:92:169	20:22:74:93:170	1:1:2:3:5	1:NR:2	L2R	NON-CROSS	15-16	56-59	D013311	streptozotocin	Chemical	15	16	1	D058186	acute renal failure|ARF|ARF	Disease	56:60:286	59:61:287	1:1:8	1:NR:2	L2R	CROSS	15-16	265-267	D013311	streptozotocin	Chemical	15	16	1	D009956	tubular necrosis|tubular necrosis|tubular necrosis	Disease	265:319:371	267:321:373	7:8:9	1:NR:2	R2L	NON-CROSS	92-93	84-85	D005947	glucose	Chemical	84	85	2	D003920	diabetes mellitus|DM|diabetic|DM|DM	Disease	18:21:73:92:169	20:22:74:93:170	1:1:2:3:5	1:NR:2	R2L	CROSS	84-85	60-61	D005947	glucose	Chemical	84	85	2	D058186	acute renal failure|ARF|ARF	Disease	56:60:286	59:61:287	1:1:8	1:NR:2	L2R	CROSS	84-85	265-267	D005947	glucose	Chemical	84	85	2	D009956	tubular necrosis|tubular necrosis|tubular necrosis	Disease	265:319:371	267:321:373	7:8:9
458486	Tiapride in levodopa - induced involuntary movements .|Tiapride , a substituted benzamide derivative closely related to metoclopramide , reduced levodopa - induced peak dose involuntary movements in 16 patients with idiopathic Parkinson 's disease .|However , an unacceptable increase in disability from Parkinsonism with aggravation of end - of - dose akinesia led to its cessation in 14 patients .|Tiapride had no effect on levodopa - induced early morning of " off - period " segmental dystonia .|These results fail to support the notion that levodopa - induced dyskinesias are caused by overstimulation of a separate group of dopamine receptors .	1:NR:2	L2R	NON-CROSS	5-7	8-9	D063325	Tiapride|Tiapride|Tiapride	Chemical	0:8:62	1:9:63	0:1:3	D004409	involuntary movements|involuntary movements|akinesia|dyskinesias	Disease	5:25:53:92	7:27:54:93	0:1:2:4	1:NR:2	L2R	NON-CROSS	44-45	62-63	D063325	Tiapride|Tiapride|Tiapride	Chemical	0:8:62	1:9:63	0:1:3	D010300	idiopathic Parkinson 's disease|Parkinsonism	Disease	31:44	35:45	1:2	1:NR:2	L2R	NON-CROSS	62-63	79-80	D063325	Tiapride|Tiapride|Tiapride	Chemical	0:8:62	1:9:63	0:1:3	D004421	dystonia	Disease	79	80	3	1:CID:2	L2R	NON-CROSS	2-3	5-7	D007980	levodopa|levodopa|levodopa|levodopa	Chemical	2:20:67:89	3:21:68:90	0:1:3:4	D004409	involuntary movements|involuntary movements|akinesia|dyskinesias	Disease	5:25:53:92	7:27:54:93	0:1:2:4	1:NR:2	L2R	NON-CROSS	20-21	31-35	D007980	levodopa|levodopa|levodopa|levodopa	Chemical	2:20:67:89	3:21:68:90	0:1:3:4	D010300	idiopathic Parkinson 's disease|Parkinsonism	Disease	31:44	35:45	1:2	1:NR:2	L2R	NON-CROSS	79-80	89-90	D007980	levodopa|levodopa|levodopa|levodopa	Chemical	2:20:67:89	3:21:68:90	0:1:3:4	D004421	dystonia	Disease	79	80	3	1:NR:2	R2L	NON-CROSS	12-13	5-7	C037689	benzamide	Chemical	12	13	1	D004409	involuntary movements|involuntary movements|akinesia|dyskinesias	Disease	5:25:53:92	7:27:54:93	0:1:2:4	1:NR:2	R2L	NON-CROSS	25-27	17-18	D008787	metoclopramide	Chemical	17	18	1	D004409	involuntary movements|involuntary movements|akinesia|dyskinesias	Disease	5:25:53:92	7:27:54:93	0:1:2:4	1:NR:2	R2L	NON-CROSS	102-103	92-93	D004298	dopamine	Chemical	102	103	4	D004409	involuntary movements|involuntary movements|akinesia|dyskinesias	Disease	5:25:53:92	7:27:54:93	0:1:2:4	1:NR:2	L2R	NON-CROSS	12-13	31-35	C037689	benzamide	Chemical	12	13	1	D010300	idiopathic Parkinson 's disease|Parkinsonism	Disease	31:44	35:45	1:2	1:NR:2	L2R	CROSS	12-13	79-80	C037689	benzamide	Chemical	12	13	1	D004421	dystonia	Disease	79	80	3	1:NR:2	L2R	NON-CROSS	17-18	31-35	D008787	metoclopramide	Chemical	17	18	1	D010300	idiopathic Parkinson 's disease|Parkinsonism	Disease	31:44	35:45	1:2	1:NR:2	L2R	CROSS	17-18	79-80	D008787	metoclopramide	Chemical	17	18	1	D004421	dystonia	Disease	79	80	3	1:NR:2	R2L	CROSS	102-103	44-45	D004298	dopamine	Chemical	102	103	4	D010300	idiopathic Parkinson 's disease|Parkinsonism	Disease	31:44	35:45	1:2	1:NR:2	R2L	CROSS	102-103	79-80	D004298	dopamine	Chemical	102	103	4	D004421	dystonia	Disease	79	80	3
21294084	Effects of the hippocampal deep brain stimulation on cortical epileptic discharges in penicillin - induced epilepsy model in rats .|AIM : Experimental and clinical studies have revealed that hippocampal DBS can control epileptic activity , but the mechanism of action is obscure and optimal stimulation parameters are not clearly defined .|The aim was to evaluate the effects of high frequency hippocampal stimulation on cortical epileptic activity in penicillin - induced epilepsy model .|MATERIAL AND METHODS : Twenty - five Sprague - Dawley rats were implanted DBS electrodes .|In group - 1 ( n = 10 ) hippocampal DBS was off and in the group - 2 ( n = 10 ) hippocampal DBS was on ( 185 Hz , 0 . 5V , 1V , 2V , and 5V for 60 sec ) following penicillin G injection intracortically .|In the control group hippocampal DBS was on following 8 l saline injection intracortically .|EEG recordings were obtained before and 15 minutes following penicillin - G injection , and at 10th minutes following each stimulus for analysis in terms of frequency , amplitude , and power spectrum .|RESULTS : High frequency hippocampal DBS suppressed the acute penicillin - induced cortical epileptic activity independent from stimulus intensity .|In the control group , hippocampal stimulation alone lead only to diffuse slowing of cerebral bioelectrical activity at 5V stimulation .|CONCLUSION : Our results revealed that continuous high frequency stimulation of the hippocampus suppressed acute cortical epileptic activity effectively without causing secondary epileptic discharges .|These results are important in terms of defining the optimal parameters of hippocampal DBS in patients with epilepsy .	1:NR:2	R2L	NON-CROSS	12-13	9-10	D010406	penicillin|penicillin|penicillin	Chemical	12:69:201	13:70:202	0:2:7	D004827	epileptic|epilepsy|epileptic|epileptic|epilepsy|epileptic|epileptic|epileptic|epilepsy	Disease	9:15:33:66:72:205:249:255:275	10:16:34:67:73:206:250:256:276	0:0:1:2:2:7:9:9:10	1:CID:2	R2L	CROSS	205-206	167-170	D010400	penicillin G|penicillin - G	Chemical	138:167	140:170	4:6	D004827	epileptic|epilepsy|epileptic|epileptic|epilepsy|epileptic|epileptic|epileptic|epilepsy	Disease	9:15:33:66:72:205:249:255:275	10:16:34:67:73:206:250:256:276	0:0:1:2:2:7:9:9:10
20727411	Neural correlates of S - ketamine induced psychosis during overt continuous verbal fluency .|The glutamatergic N - methyl - D - aspartate ( NMDA ) receptor has been implicated in the pathophysiology of schizophrenia .|Administered to healthy volunteers , a subanesthetic dose of the non - competitive NMDA receptor antagonist ketamine leads to psychopathological symptoms similar to those observed in schizophrenia .|In patients with schizophrenia , ketamine exacerbates the core symptoms of illness , supporting the hypothesis of a glutamatergic dysfunction .|In a counterbalanced , placebo - controlled , double - blind study design , healthy subjects were administered a continuous subanesthetic S - ketamine infusion while differences in BOLD responses measured with fMRI were detected .|During the scanning period , subjects performed continuous overt verbal fluency tasks ( phonological , lexical and semantic ) .|Ketamine - induced psychopathological symptoms were assessed with the Positive and Negative Syndrome Scale ( PANSS ) .|Ketamine elicited psychosis like psychopathology .|Post - hoc t - tests revealed significant differences between placebo and ketamine for the amounts of words generated during lexical and semantic verbal fluency , while the phonological domain remained unaffected .|Ketamine led to enhanced cortical activations in supramarginal and frontal brain regions for phonological and lexical verbal fluency , but not for semantic verbal fluency .|Ketamine induces activation changes in healthy subjects similar to those observed in patients with schizophrenia , particularly in frontal and temporal brain regions .|Our results provide further support for the hypothesis of an NMDA receptor dysfunction in the pathophysiology of schizophrenia .	1:NR:2	R2L	CROSS	16-23	7-8	D016202	N - methyl - D - aspartate|NMDA|NMDA|NMDA	Chemical	16:24:49:258	23:25:50:259	1:1:2:11	D011605	psychosis|psychosis	Disease	7:161	8:162	0:7	1:CID:2	R2L	NON-CROSS	161-162	159-160	D007649	ketamine|ketamine|Ketamine|Ketamine|ketamine|Ketamine|Ketamine	Chemical	52:69:141:159:177:198:224	53:70:142:160:178:199:225	2:3:6:7:8:9:10	D011605	psychosis|psychosis	Disease	7:161	8:162	0:7	1:NR:2	L2R	NON-CROSS	258-259	265-266	D016202	N - methyl - D - aspartate|NMDA|NMDA|NMDA	Chemical	16:24:49:258	23:25:50:259	1:1:2:11	D012559	schizophrenia|schizophrenia|schizophrenia|schizophrenia|schizophrenia	Disease	34:62:67:238:265	35:63:68:239:266	1:2:3:10:11	1:NR:2	L2R	CROSS	49-50	82-84	D016202	N - methyl - D - aspartate|NMDA|NMDA|NMDA	Chemical	16:24:49:258	23:25:50:259	1:1:2:11	D018754	glutamatergic dysfunction	Disease	82	84	3	1:NR:2	R2L	NON-CROSS	69-70	67-68	D007649	ketamine|ketamine|Ketamine|Ketamine|ketamine|Ketamine|Ketamine	Chemical	52:69:141:159:177:198:224	53:70:142:160:178:199:225	2:3:6:7:8:9:10	D012559	schizophrenia|schizophrenia|schizophrenia|schizophrenia|schizophrenia	Disease	34:62:67:238:265	35:63:68:239:266	1:2:3:10:11	1:NR:2	L2R	NON-CROSS	69-70	82-84	D007649	ketamine|ketamine|Ketamine|Ketamine|ketamine|Ketamine|Ketamine	Chemical	52:69:141:159:177:198:224	53:70:142:160:178:199:225	2:3:6:7:8:9:10	D018754	glutamatergic dysfunction	Disease	82	84	3
20533999	Dopamine is not essential for the development of methamphetamine - induced neurotoxicity .|It is widely believed that dopamine ( DA ) mediates methamphetamine ( METH ) - induced toxicity to brain dopaminergic neurons , because drugs that interfere with DA neurotransmission decrease toxicity , whereas drugs that increase DA neurotransmission enhance toxicity .|However , temperature effects of drugs that have been used to manipulate brain DA neurotransmission confound interpretation of the data .|Here we show that the recently reported ability of L - dihydroxyphenylalanine to reverse the protective effect of alpha - methyl - para - tyrosine on METH - induced DA neurotoxicity is also confounded by drug effects on body temperature .|Further , we show that mice genetically engineered to be deficient in brain DA develop METH neurotoxicity , as long as the thermic effects of METH are preserved .|In addition , we demonstrate that mice genetically engineered to have unilateral brain DA deficits develop METH - induced dopaminergic deficits that are of comparable magnitude on both sides of the brain .|Taken together , these findings demonstrate that DA is not essential for the development of METH - induced dopaminergic neurotoxicity and suggest that mechanisms independent of DA warrant more intense investigation .	1:NR:2	L2R	NON-CROSS	104-105	105-106	D004298	Dopamine|dopamine|DA|DA|DA|DA|DA|DA|DA|DA|DA	Chemical	0:18:20:40:49:67:104:129:158:185:204	1:19:21:41:50:68:105:130:159:186:205	0:1:1:1:1:2:3:4:5:6:6	D020258	neurotoxicity|neurotoxicity|neurotoxicity|neurotoxicity	Disease	11:105:132:197	12:106:133:198	0:3:4:6	1:NR:2	L2R	NON-CROSS	40-41	43-44	D004298	Dopamine|dopamine|DA|DA|DA|DA|DA|DA|DA|DA|DA	Chemical	0:18:20:40:49:67:104:129:158:185:204	1:19:21:41:50:68:105:130:159:186:205	0:1:1:1:1:2:3:4:5:6:6	D064420	toxicity|toxicity|toxicity	Disease	29:43:52	30:44:53	1:1:1	1:NR:2	L2R	NON-CROSS	158-159	164-166	D004298	Dopamine|dopamine|DA|DA|DA|DA|DA|DA|DA|DA|DA	Chemical	0:18:20:40:49:67:104:129:158:185:204	1:19:21:41:50:68:105:130:159:186:205	0:1:1:1:1:2:3:4:5:6:6	D009461	dopaminergic deficits	Disease	164	166	5	1:CID:2	L2R	NON-CROSS	131-132	132-133	D008694	methamphetamine|methamphetamine|METH|METH|METH|METH|METH|METH	Chemical	8:23:25:101:131:141:161:193	9:24:26:102:132:142:162:194	0:1:1:3:4:4:5:6	D020258	neurotoxicity|neurotoxicity|neurotoxicity|neurotoxicity	Disease	11:105:132:197	12:106:133:198	0:3:4:6	1:NR:2	L2R	NON-CROSS	25-26	29-30	D008694	methamphetamine|methamphetamine|METH|METH|METH|METH|METH|METH	Chemical	8:23:25:101:131:141:161:193	9:24:26:102:132:142:162:194	0:1:1:3:4:4:5:6	D064420	toxicity|toxicity|toxicity	Disease	29:43:52	30:44:53	1:1:1	1:NR:2	L2R	NON-CROSS	161-162	164-166	D008694	methamphetamine|methamphetamine|METH|METH|METH|METH|METH|METH	Chemical	8:23:25:101:131:141:161:193	9:24:26:102:132:142:162:194	0:1:1:3:4:4:5:6	D009461	dopaminergic deficits	Disease	164	166	5	1:NR:2	R2L	NON-CROSS	105-106	84-87	D007980	L - dihydroxyphenylalanine	Chemical	84	87	3	D020258	neurotoxicity|neurotoxicity|neurotoxicity|neurotoxicity	Disease	11:105:132:197	12:106:133:198	0:3:4:6	1:NR:2	R2L	NON-CROSS	105-106	93-100	D019805	alpha - methyl - para - tyrosine	Chemical	93	100	3	D020258	neurotoxicity|neurotoxicity|neurotoxicity|neurotoxicity	Disease	11:105:132:197	12:106:133:198	0:3:4:6	1:NR:2	R2L	CROSS	84-87	52-53	D007980	L - dihydroxyphenylalanine	Chemical	84	87	3	D064420	toxicity|toxicity|toxicity	Disease	29:43:52	30:44:53	1:1:1	1:NR:2	R2L	CROSS	93-100	52-53	D019805	alpha - methyl - para - tyrosine	Chemical	93	100	3	D064420	toxicity|toxicity|toxicity	Disease	29:43:52	30:44:53	1:1:1	1:NR:2	L2R	CROSS	84-87	164-166	D007980	L - dihydroxyphenylalanine	Chemical	84	87	3	D009461	dopaminergic deficits	Disease	164	166	5	1:NR:2	L2R	CROSS	93-100	164-166	D019805	alpha - methyl - para - tyrosine	Chemical	93	100	3	D009461	dopaminergic deficits	Disease	164	166	5
20304337	Brainstem dysgenesis in an infant prenatally exposed to cocaine .|Many authors described the effects on the fetus of maternal cocaine abuse during pregnancy .|Vasoconstriction appears to be the common mechanism of action leading to a wide range of fetal anomalies .|We report on an infant with multiple cranial - nerve involvement attributable to brainstem dysgenesis , born to a cocaine - addicted mother .	1:NR:2	L2R	CROSS	8-9	20-22	D003042	cocaine	Chemical	8	9	0	D019970	cocaine abuse|cocaine - addicted	Disease	20:62	22:65	1:3	1:NR:2	L2R	CROSS	8-9	40-42	D003042	cocaine	Chemical	8	9	0	D005315	fetal anomalies	Disease	40	42	2	1:CID:2	L2R	CROSS	8-9	49-54	D003042	cocaine	Chemical	8	9	0	D003389	multiple cranial - nerve involvement	Disease	49	54	3
20103708	The protective role of Nrf2 in streptozotocin - induced diabetic nephropathy .|OBJECTIVE : Diabetic nephropathy is one of the major causes of renal failure , which is accompanied by the production of reactive oxygen species ( ROS ) .|Nrf2 is the primary transcription factor that controls the antioxidant response essential for maintaining cellular redox homeostasis .|Here , we report our findings demonstrating a protective role of Nrf2 against diabetic nephropathy .|RESEARCH DESIGN AND METHODS : We explore the protective role of Nrf2 against diabetic nephropathy using human kidney biopsy tissues from diabetic nephropathy patients , a streptozotocin - induced diabetic nephropathy model in Nrf2 ( - / - ) mice , and cultured human mesangial cells .|RESULTS : The glomeruli of human diabetic nephropathy patients were under oxidative stress and had elevated Nrf2 levels .|In the animal study , Nrf2 was demonstrated to be crucial in ameliorating streptozotocin - induced renal damage .|This is evident by Nrf2 ( - / - ) mice having higher ROS production and suffering from greater oxidative DNA damage and renal injury compared with Nrf2 ( + / + ) mice .|Mechanistic studies in both in vivo and in vitro systems showed that the Nrf2 - mediated protection against diabetic nephropathy is , at least , partially through inhibition of transforming growth factor - beta1 ( TGF - beta1 ) and reduction of extracellular matrix production .|In human renal mesangial cells , high glucose induced ROS production and activated expression of Nrf2 and its downstream genes .|Furthermore , activation or overexpression of Nrf2 inhibited the promoter activity of TGF - beta1 in a dose - dependent manner , whereas knockdown of Nrf2 by siRNA enhanced TGF - beta1 transcription and fibronectin production .|CONCLUSIONS : This work clearly indicates a protective role of Nrf2 in diabetic nephropathy , suggesting that dietary or therapeutic activation of Nrf2 could be used as a strategy to prevent or slow down the progression of diabetic nephropathy .	1:CID:2	L2R	NON-CROSS	6-7	9-11	D013311	streptozotocin|streptozotocin|streptozotocin	Chemical	6:100:153	7:101:154	0:4:6	D003928	diabetic nephropathy|Diabetic nephropathy|diabetic nephropathy|diabetic nephropathy|diabetic nephropathy|diabetic nephropathy|diabetic nephropathy|diabetic nephropathy|diabetic nephropathy|diabetic nephropathy	Disease	9:14:71:87:95:103:127:212:310:335	11:16:73:89:97:105:129:214:312:337	0:1:3:4:4:4:5:8:11:11	1:NR:2	L2R	CROSS	6-7	23-25	D013311	streptozotocin|streptozotocin|streptozotocin	Chemical	6:100:153	7:101:154	0:4:6	D051437	renal failure	Disease	23	25	1	1:NR:2	L2R	NON-CROSS	153-154	156-158	D013311	streptozotocin|streptozotocin|streptozotocin	Chemical	6:100:153	7:101:154	0:4:6	D058186	renal damage|renal injury	Disease	156:182	158:184	6:7	1:NR:2	R2L	NON-CROSS	34-35	14-16	D010100	oxygen	Chemical	34	35	1	D003928	diabetic nephropathy|Diabetic nephropathy|diabetic nephropathy|diabetic nephropathy|diabetic nephropathy|diabetic nephropathy|diabetic nephropathy|diabetic nephropathy|diabetic nephropathy|diabetic nephropathy	Disease	9:14:71:87:95:103:127:212:310:335	11:16:73:89:97:105:129:214:312:337	0:1:3:4:4:4:5:8:11:11	1:NR:2	R2L	CROSS	247-248	212-214	D005947	glucose	Chemical	247	248	9	D003928	diabetic nephropathy|Diabetic nephropathy|diabetic nephropathy|diabetic nephropathy|diabetic nephropathy|diabetic nephropathy|diabetic nephropathy|diabetic nephropathy|diabetic nephropathy|diabetic nephropathy	Disease	9:14:71:87:95:103:127:212:310:335	11:16:73:89:97:105:129:214:312:337	0:1:3:4:4:4:5:8:11:11	1:NR:2	R2L	NON-CROSS	34-35	23-25	D010100	oxygen	Chemical	34	35	1	D051437	renal failure	Disease	23	25	1	1:NR:2	R2L	CROSS	247-248	23-25	D005947	glucose	Chemical	247	248	9	D051437	renal failure	Disease	23	25	1	1:NR:2	L2R	CROSS	34-35	156-158	D010100	oxygen	Chemical	34	35	1	D058186	renal damage|renal injury	Disease	156:182	158:184	6:7	1:NR:2	R2L	CROSS	247-248	182-184	D005947	glucose	Chemical	247	248	9	D058186	renal damage|renal injury	Disease	156:182	158:184	6:7
19996135	High - dose tranexamic Acid is associated with nonischemic clinical seizures in cardiac surgical patients .|BACKGROUND : In 2 separate centers , we observed a notable increase in the incidence of postoperative convulsive seizures from 1 . 3 % to 3 . 8 % in patients having undergone major cardiac surgical procedures .|These events were temporally coincident with the initial use of high - dose tranexamic acid ( TXA ) therapy after withdrawal of aprotinin from general clinical usage .|The purpose of this review was to perform a retrospective analysis to examine whether there was a relation between TXA usage and seizures after cardiac surgery .|METHODS : An in - depth chart review was undertaken in all 24 patients who developed perioperative seizures .|Electroencephalographic activity was recorded in 11 of these patients , and all patients had a formal neurological evaluation and brain imaging studies .|RESULTS : Twenty - one of the 24 patients did not have evidence of new cerebral ischemic injury , but seizures were likely due to ischemic brain injury in 3 patients .|All patients with seizures did not have permanent neurological abnormalities .|All 24 patients with seizures received high doses of TXA intraoperatively ranging from 61 to 259 mg / kg , had a mean age of 69 . 9 years , and 21 of 24 had undergone open chamber rather than coronary bypass procedures .|All but one patient were managed using cardiopulmonary bypass .|No evidence of brain ischemic , metabolic , or hyperthermia - induced causes for their seizures was apparent .|CONCLUSION : Our results suggest that use of high - dose TXA in older patients in conjunction with cardiopulmonary bypass and open - chamber cardiac surgery is associated with clinical seizures in susceptible patients .	1:CID:2	L2R	NON-CROSS	101-102	104-105	D014148	tranexamic Acid|tranexamic acid|TXA|TXA|TXA|TXA	Chemical	3:67:70:101:203:278	5:69:71:102:204:279	0:2:2:3:8:11	D012640	seizures|convulsive|seizures|seizures|seizures|seizures|seizures|seizures|seizures|seizures	Disease	10:33:34:104:126:171:186:198:263:297	11:34:35:105:127:172:187:199:264:298	0:1:1:3:4:6:7:8:10:11	1:NR:2	L2R	CROSS	176-179	203-204	D014148	tranexamic Acid|tranexamic acid|TXA|TXA|TXA|TXA	Chemical	3:67:70:101:203:278	5:69:71:102:204:279	0:2:2:3:8:11	D001930	cerebral ischemic injury|ischemic brain injury	Disease	166:176	169:179	6:6	1:NR:2	L2R	CROSS	191-193	203-204	D014148	tranexamic Acid|tranexamic acid|TXA|TXA|TXA|TXA	Chemical	3:67:70:101:203:278	5:69:71:102:204:279	0:2:2:3:8:11	D009422	neurological abnormalities	Disease	191	193	7	1:NR:2	L2R	CROSS	251-253	278-279	D014148	tranexamic Acid|tranexamic acid|TXA|TXA|TXA|TXA	Chemical	3:67:70:101:203:278	5:69:71:102:204:279	0:2:2:3:8:11	D002546	brain ischemic	Disease	251	253	10	1:NR:2	L2R	CROSS	257-258	278-279	D014148	tranexamic Acid|tranexamic acid|TXA|TXA|TXA|TXA	Chemical	3:67:70:101:203:278	5:69:71:102:204:279	0:2:2:3:8:11	D005334	hyperthermia	Disease	257	258	10
19674115	Recurrent dysosmia induced by pyrazinamide .|Pyrazinamide can have adverse effects such as hepatic toxicity , hyperuricemia or digestive disorders .|In rare cases , alterations in taste and smell function have been reported for pyrazinamide when combined with other drugs .|We report a case of reversible olfactory disorder related to pyrazinamide in a woman , with a positive rechallenge .|The patient presented every day a sensation of smelling something burning 15 min after drug intake .|Dysosmia disappeared completely after pyrazinamide withdrawal and recurred after its rechallenge .|The case was reported to the Tunisian Centre of Pharmacovigilance .	1:CID:2	R2L	NON-CROSS	4-5	1-2	D011718	pyrazinamide|Pyrazinamide|pyrazinamide|pyrazinamide|pyrazinamide	Chemical	4:6:35:52:83	5:7:36:53:84	0:1:2:3:5	D000857	dysosmia|olfactory disorder|Dysosmia	Disease	1:48:79	2:50:80	0:3:5	1:NR:2	L2R	NON-CROSS	6-7	13-15	D011718	pyrazinamide|Pyrazinamide|pyrazinamide|pyrazinamide|pyrazinamide	Chemical	4:6:35:52:83	5:7:36:53:84	0:1:2:3:5	D056486	hepatic toxicity	Disease	13	15	1	1:NR:2	L2R	NON-CROSS	6-7	16-17	D011718	pyrazinamide|Pyrazinamide|pyrazinamide|pyrazinamide|pyrazinamide	Chemical	4:6:35:52:83	5:7:36:53:84	0:1:2:3:5	D033461	hyperuricemia	Disease	16	17	1
19139001	Longitudinal assessment of air conduction audiograms in a phase III clinical trial of difluoromethylornithine and sulindac for prevention of sporadic colorectal adenomas .|A phase III clinical trial assessed the recurrence of adenomatous polyps after treatment for 36 months with difluoromethylornithine ( DFMO ) plus sulindac or matched placebos .|Temporary hearing loss is a known toxicity of treatment with DFMO , thus a comprehensive approach was developed to analyze serial air conduction audiograms .|The generalized estimating equation method estimated the mean difference between treatment arms with regard to change in air conduction pure tone thresholds while accounting for within - subject correlation due to repeated measurements at frequencies .|Based on 290 subjects , there was an average difference of 0 . 50 dB between subjects treated with DFMO plus sulindac compared with those treated with placebo ( 95 % confidence interval , - 0 . 64 to 1 . 63 dB ; P = 0 . 39 ) , adjusted for baseline values , age , and frequencies .|In the normal speech range of 500 to 3 , 000 Hz , an estimated difference of 0 . 99 dB ( - 0 . 17 to 2 . 14 dB ; P = 0 . 09 ) was detected .|Dose intensity did not add information to models .|There were 14 of 151 ( 9 . 3 % ) in the DFMO plus sulindac group and 4 of 139 ( 2 . 9 % ) in the placebo group who experienced at least 15 dB hearing reduction from baseline in 2 or more consecutive frequencies across the entire range tested ( P = 0 . 02 ) .|Follow - up air conduction done at least 6 months after end of treatment showed an adjusted mean difference in hearing thresholds of 1 . 08 dB ( - 0 . 81 to 2 . 96 dB ; P = 0 . 26 ) between treatment arms .|There was no significant difference in the proportion of subjects in the DFMO plus sulindac group who experienced clinically significant hearing loss compared with the placebo group .|The estimated attributable risk of ototoxicity from exposure to the drug is 8 . 4 % ( 95 % confidence interval , - 2 . 0 % to 18 . 8 % ; P = 0 . 12 ) .|There is a < 2 dB difference in mean threshold for patients treated with DFMO plus sulindac compared with those treated with placebo .	1:NR:2	L2R	NON-CROSS	13-14	20-22	D000518	difluoromethylornithine|difluoromethylornithine|DFMO|DFMO|DFMO|DFMO|DFMO|DFMO	Chemical	13:40:42:60:130:235:342:412	14:41:43:61:131:236:343:413	0:1:1:2:4:7:9:11	D015179	colorectal adenomas	Disease	20	22	0	1:NR:2	L2R	NON-CROSS	32-34	40-41	D000518	difluoromethylornithine|difluoromethylornithine|DFMO|DFMO|DFMO|DFMO|DFMO|DFMO	Chemical	13:40:42:60:130:235:342:412	14:41:43:61:131:236:343:413	0:1:1:2:4:7:9:11	D018256	adenomatous polyps	Disease	32	34	1	1:NR:2	L2R	NON-CROSS	342-343	350-352	D000518	difluoromethylornithine|difluoromethylornithine|DFMO|DFMO|DFMO|DFMO|DFMO|DFMO	Chemical	13:40:42:60:130:235:342:412	14:41:43:61:131:236:343:413	0:1:1:2:4:7:9:11	D034381	hearing loss|hearing loss	Disease	51:350	53:352	2:9	1:NR:2	L2R	NON-CROSS	56-57	60-61	D000518	difluoromethylornithine|difluoromethylornithine|DFMO|DFMO|DFMO|DFMO|DFMO|DFMO	Chemical	13:40:42:60:130:235:342:412	14:41:43:61:131:236:343:413	0:1:1:2:4:7:9:11	D064420	toxicity	Disease	56	57	2	1:NR:2	L2R	CROSS	342-343	363-364	D000518	difluoromethylornithine|difluoromethylornithine|DFMO|DFMO|DFMO|DFMO|DFMO|DFMO	Chemical	13:40:42:60:130:235:342:412	14:41:43:61:131:236:343:413	0:1:1:2:4:7:9:11	D006311	ototoxicity	Disease	363	364	10	1:NR:2	L2R	NON-CROSS	15-16	20-22	D013467	sulindac|sulindac|sulindac|sulindac|sulindac|sulindac	Chemical	15:45:132:237:344:414	16:46:133:238:345:415	0:1:4:7:9:11	D015179	colorectal adenomas	Disease	20	22	0	1:NR:2	L2R	NON-CROSS	32-34	45-46	D013467	sulindac|sulindac|sulindac|sulindac|sulindac|sulindac	Chemical	15:45:132:237:344:414	16:46:133:238:345:415	0:1:4:7:9:11	D018256	adenomatous polyps	Disease	32	34	1	1:CID:2	L2R	NON-CROSS	45-46	51-53	D013467	sulindac|sulindac|sulindac|sulindac|sulindac|sulindac	Chemical	15:45:132:237:344:414	16:46:133:238:345:415	0:1:4:7:9:11	D034381	hearing loss|hearing loss	Disease	51:350	53:352	2:9	1:NR:2	L2R	CROSS	45-46	56-57	D013467	sulindac|sulindac|sulindac|sulindac|sulindac|sulindac	Chemical	15:45:132:237:344:414	16:46:133:238:345:415	0:1:4:7:9:11	D064420	toxicity	Disease	56	57	2	1:NR:2	L2R	CROSS	344-345	363-364	D013467	sulindac|sulindac|sulindac|sulindac|sulindac|sulindac	Chemical	15:45:132:237:344:414	16:46:133:238:345:415	0:1:4:7:9:11	D006311	ototoxicity	Disease	363	364	10
18239197	Increased mental slowing associated with the APOE epsilon4 allele after trihexyphenidyl oral anticholinergic challenge in healthy elderly .|OBJECTIVES : The objectives of this study were to examine the relationship between APOE epsilon4 and subjective effects of trihexyphenidyl on measures reflecting sedation and confusion and to investigate the relationship between trihexyphenidyl - induced subjective effects and objective memory performance .|METHODS : This study comprised 24 cognitively intact , health elderly adults ( 12 APOE epsilon4 carriers ) at an outpatient geriatric psychiatry research clinic .|This was a randomized , double blind , placebo - controlled , three - way , crossover experimental design .|All participants received 1 . 0 mg or 2 . 0 mg trihexyphenidyl or placebo administered in counterbalanced sequences over a period of three consecutive weeks .|Bond and Lader 's visual analog scales and alternate versions of the Buschke Selective Reminding Test were administered in a repeated measures design at baseline , 1 , 2 . 5 , and 5 hours postdrug administration .|RESULTS : A 2 . 0 - mg oral dose of trihexyphenidyl resulted in increased subjective ratings of mental slowness in carriers of the APOE epsilon4 allele only .|Drug effects as determined by difference scores between 2 . 0 mg trihexyphenidyl and placebo on ratings of mental slowness significantly correlated with total and delayed recall on the Buschke Selective Reminding Test in carriers of the APOE epsilon4 allele only .|However , no significant effects were found with other visual analog scales reflecting subjective sedation and clear - headedness .|CONCLUSION : The epsilon4 allele in healthy elderly was associated with increased subjective mental slowing after trihexyphenidyl anticholinergic challenge .	1:CID:2	R2L	NON-CROSS	278-279	275-277	D014282	trihexyphenidyl|trihexyphenidyl|trihexyphenidyl|trihexyphenidyl|trihexyphenidyl|trihexyphenidyl|trihexyphenidyl	Chemical	10:37:50:118:182:212:278	11:38:51:119:183:213:279	0:1:1:4:6:7:9	D003072	mental slowing|mental slowness|mental slowness|mental slowing	Disease	1:189:218:275	3:191:220:277	0:6:7:9	1:NR:2	L2R	NON-CROSS	37-38	43-44	D014282	trihexyphenidyl|trihexyphenidyl|trihexyphenidyl|trihexyphenidyl|trihexyphenidyl|trihexyphenidyl|trihexyphenidyl	Chemical	10:37:50:118:182:212:278	11:38:51:119:183:213:279	0:1:1:4:6:7:9	D003221	confusion	Disease	43	44	1
17194457	Behavioral effects of pubertal anabolic androgenic steroid exposure in male rats with low serotonin .|The goal of this study was to assess the interactive effects of chronic anabolic androgenic steroid ( AAS ) exposure and brain serotonin ( 5 - hydroxytryptamine , 5 - HT ) depletion on behavior of pubertal male rats .|Serotonin was depleted beginning on postnatal day 26 with parachlorophenylalanine ( PCPA 100 mg / kg , every other day ) ; controls received saline .|At puberty ( P40 ) , half the PCPA - treated rats and half the saline - treated rats began treatment with testosterone ( T , 5 mg / kg , 5 days / week ) .|Behavioral measures included locomotion , irritability , copulation , partner preference , and aggression .|Animals were tested for aggression in their home cage , both with and without physical provocation ( mild tail pinch ) .|Brain levels of 5 - HT and its metabolite , 5 - hydroxyindoleacetic acid ( 5 - HIAA ) , were determined using HPLC .|PCPA significantly and substantially depleted 5 - HT and 5 - HIAA in all brain regions examined .|Chronic T treatment significantly decreased 5 - HT and 5 - HIAA in certain brain areas , but to a much lesser extent than PCPA .|Chronic exposure to PCPA alone significantly decreased locomotor activity and increased irritability but had no effect on sexual behavior , partner preference , or aggression .|T alone had no effect on locomotion , irritability , or sexual behavior but increased partner preference and aggression .|The most striking effect of combining T + PCPA was a significant increase in attack frequency as well as a significant decrease in the latency to attack , particularly following physical provocation .|Based on these data , it can be speculated that pubertal AAS users with low central 5 - HT may be especially prone to exhibit aggressive behavior .	1:NR:2	L2R	CROSS	30-31	123-124	D013256	steroid|steroid	Chemical	6:30	7:31	0:1	D001523	irritability|aggression|aggression|irritability|aggression|irritability|aggression|aggressive behavior	Disease	123:131:137:235:248:258:268:328	124:132:138:236:249:259:269:330	4:4:5:9:9:10:10:12	1:NR:2	L2R	NON-CROSS	319-322	328-330	D012701	serotonin|serotonin|5 - hydroxytryptamine|5 - HT|Serotonin|5 - HT|5 - HT|5 - HT|5 - HT	Chemical	13:37:39:43:55:158:185:203:319	14:38:42:46:56:161:188:206:322	0:1:1:1:2:6:7:8:12	D001523	irritability|aggression|aggression|irritability|aggression|irritability|aggression|aggressive behavior	Disease	123:131:137:235:248:258:268:328	124:132:138:236:249:259:269:330	4:4:5:9:9:10:10:12	1:CID:2	L2R	NON-CROSS	248-249	250-251	D013739	testosterone|T|T|T|T	Chemical	103:105:199:250:276	104:106:200:251:277	3:3:8:10:11	D001523	irritability|aggression|aggression|irritability|aggression|irritability|aggression|aggressive behavior	Disease	123:131:137:235:248:258:268:328	124:132:138:236:249:259:269:330	4:4:5:9:9:10:10:12	1:NR:2	R2L	CROSS	235-236	207-210	D006897	5 - hydroxyindoleacetic acid|5 - HIAA|5 - HIAA|5 - HIAA	Chemical	165:170:189:207	169:173:192:210	6:6:7:8	D001523	irritability|aggression|aggression|irritability|aggression|irritability|aggression|aggressive behavior	Disease	123:131:137:235:248:258:268:328	124:132:138:236:249:259:269:330	4:4:5:9:9:10:10:12
16132524	Intracavitary chemotherapy ( paclitaxel / carboplatin liquid crystalline cubic phases ) for recurrent glioblastoma - - clinical observations .|Human malignant brain tumors have a poor prognosis in spite of surgery and radiation therapy .|Cubic phases consist of curved biocontinuous lipid bilayers , separating two congruent networks of water channels .|Used as a host for cytotoxic drugs , the gel - like matrix can easily be applied to the walls of a surgical resection cavity .|For human glioblastoma recurrences , the feasibility , safety , and short - term effects of a surgical intracavitary application of paclitaxel and carboplatin encapsulated by liquid crystalline cubic phases are examined in a pilot study .|A total of 12 patients with a recurrence of a glioblastoma multiforme underwent re - resection and received an intracavitary application of paclitaxel and carboplatin cubic phases in different dosages .|Six of the patients received more than 15 mg paclitaxel and suffered from moderate to severe brain edema , while the remaining patients received only a total of 15 mg paclitaxel .|In the latter group , brain edema was markedly reduced and dealt medically .|Intracavitary chemotherapy in recurrent glioblastoma using cubic phases is feasible and safe , yet the clinical benefit remains to be examined in a clinical phase II study .	1:NR:2	L2R	NON-CROSS	3-4	13-14	D017239	paclitaxel|paclitaxel|paclitaxel|paclitaxel|paclitaxel	Chemical	3:99:137:155:176	4:100:138:156:177	0:4:5:6:6	D005909	glioblastoma|glioblastoma|glioblastoma|glioblastoma	Disease	13:80:125:196	14:81:126:197	0:4:5:8	1:NR:2	L2R	CROSS	3-4	21-23	D017239	paclitaxel|paclitaxel|paclitaxel|paclitaxel|paclitaxel	Chemical	3:99:137:155:176	4:100:138:156:177	0:4:5:6:6	D001932	brain tumors	Disease	21	23	1	1:CID:2	L2R	NON-CROSS	155-156	162-164	D017239	paclitaxel|paclitaxel|paclitaxel|paclitaxel|paclitaxel	Chemical	3:99:137:155:176	4:100:138:156:177	0:4:5:6:6	D001929	brain edema|brain edema	Disease	162:183	164:185	6:7	1:NR:2	L2R	NON-CROSS	5-6	13-14	D016190	carboplatin|carboplatin|carboplatin	Chemical	5:101:139	6:102:140	0:4:5	D005909	glioblastoma|glioblastoma|glioblastoma|glioblastoma	Disease	13:80:125:196	14:81:126:197	0:4:5:8	1:NR:2	L2R	CROSS	5-6	21-23	D016190	carboplatin|carboplatin|carboplatin	Chemical	5:101:139	6:102:140	0:4:5	D001932	brain tumors	Disease	21	23	1	1:NR:2	L2R	CROSS	139-140	162-164	D016190	carboplatin|carboplatin|carboplatin	Chemical	5:101:139	6:102:140	0:4:5	D001929	brain edema|brain edema	Disease	162:183	164:185	6:7
12907924	Methylphenidate - induced obsessive - compulsive symptoms in an elderly man .|An 82 - year - old man with treatment - resistant depression and early Alzheimer 's disease was started on methylphenidate .|Significant obsessive - compulsive behavior ensued but diminished over several weeks when methylphenidate was replaced by fluvoxamine .|The patient had no prior psychiatric history , but he had a sister with obsessive - compulsive disorder .|It appears that methylphenidate precipitated the patient 's pathological behavior .	1:CID:2	L2R	NON-CROSS	0-1	3-7	D008774	Methylphenidate|methylphenidate|methylphenidate|methylphenidate	Chemical	0:32:46:74	1:33:47:75	0:1:2:4	D009771	obsessive - compulsive symptoms|obsessive - compulsive behavior|obsessive - compulsive disorder	Disease	3:35:66	7:39:70	0:2:3	1:NR:2	L2R	NON-CROSS	20-24	32-33	D008774	Methylphenidate|methylphenidate|methylphenidate|methylphenidate	Chemical	0:32:46:74	1:33:47:75	0:1:2:4	D061218	treatment - resistant depression	Disease	20	24	1	1:NR:2	L2R	NON-CROSS	26-29	32-33	D008774	Methylphenidate|methylphenidate|methylphenidate|methylphenidate	Chemical	0:32:46:74	1:33:47:75	0:1:2:4	D000544	Alzheimer 's disease	Disease	26	29	1	1:NR:2	L2R	CROSS	46-47	57-58	D008774	Methylphenidate|methylphenidate|methylphenidate|methylphenidate	Chemical	0:32:46:74	1:33:47:75	0:1:2:4	D001523	psychiatric	Disease	57	58	3	1:NR:2	R2L	NON-CROSS	50-51	35-39	D016666	fluvoxamine	Chemical	50	51	2	D009771	obsessive - compulsive symptoms|obsessive - compulsive behavior|obsessive - compulsive disorder	Disease	3:35:66	7:39:70	0:2:3	1:NR:2	R2L	CROSS	50-51	20-24	D016666	fluvoxamine	Chemical	50	51	2	D061218	treatment - resistant depression	Disease	20	24	1	1:NR:2	R2L	CROSS	50-51	26-29	D016666	fluvoxamine	Chemical	50	51	2	D000544	Alzheimer 's disease	Disease	26	29	1	1:NR:2	L2R	CROSS	50-51	57-58	D016666	fluvoxamine	Chemical	50	51	2	D001523	psychiatric	Disease	57	58	3
12139551	Cardiac arrest after intravenous metoclopramide - a case of five repeated injections of metoclopramide causing five episodes of cardiac arrest .|We describe a patient where intravenous injection of metoclopramide was immediately followed by asystole repeatedly .|The patient received metoclopramide 10 mg i . v .|five times during 48 h .|After interviewing the attending nurses and reviewing the written documentation , it is clear that every administration of metoclopramide was immediately ( within s ) followed by asystole .|The asystole lasted 15 - 30 s on four occasions , on one occasion it lasted 2 min .|The patient received atropine 0 . 5 - 1 mg and chest compressions , before sinus rhythm again took over .|We interpret this as episodes of cardiac arrest caused by metoclopramide .|The rapid injection via the central venous route and the concomitant tapering of dopamine infusion might have contributed in precipitating the adverse drug reaction .	1:CID:2	R2L	NON-CROSS	4-5	0-2	D008787	metoclopramide|metoclopramide|metoclopramide|metoclopramide|metoclopramide|metoclopramide	Chemical	4:13:29:40:71:132	5:14:30:41:72:133	0:0:1:2:4:7	D006323	Cardiac arrest|cardiac arrest|asystole|asystole|asystole|cardiac arrest	Disease	0:18:34:80:83:128	2:20:35:81:84:130	0:0:1:4:5:7	1:NR:2	R2L	CROSS	104-105	83-84	D001285	atropine	Chemical	104	105	6	D006323	Cardiac arrest|cardiac arrest|asystole|asystole|asystole|cardiac arrest	Disease	0:18:34:80:83:128	2:20:35:81:84:130	0:0:1:4:5:7	1:NR:2	R2L	CROSS	147-148	128-130	D004298	dopamine	Chemical	147	148	8	D006323	Cardiac arrest|cardiac arrest|asystole|asystole|asystole|cardiac arrest	Disease	0:18:34:80:83:128	2:20:35:81:84:130	0:0:1:4:5:7
10411803	Severe immune hemolytic anemia associated with prophylactic use of cefotetan in obstetric and gynecologic procedures .|Second - and third - generation cephalosporins , especially cefotetan , are increasingly associated with severe , sometimes fatal immune hemolytic anemia .|We noticed that 10 of our 35 cases of cefotetan - induced hemolytic anemias were in patients who had received cefotetan prophylactically for obstetric and gynecologic procedures .|Eight of these cases of severe immune hemolytic anemia are described .	1:CID:2	R2L	NON-CROSS	51-53	48-49	D015313	cefotetan|cefotetan|cefotetan|cefotetan	Chemical	9:25:48:59	10:26:49:60	0:1:2:2	D000743	hemolytic anemia|hemolytic anemia|hemolytic anemias|hemolytic anemia	Disease	2:36:51:74	4:38:53:76	0:1:2:3	1:NR:2	R2L	NON-CROSS	36-38	22-23	D002511	cephalosporins	Chemical	22	23	1	D000743	hemolytic anemia|hemolytic anemia|hemolytic anemias|hemolytic anemia	Disease	2:36:51:74	4:38:53:76	0:1:2:3
10225068	Cauda equina syndrome after spinal anaesthesia with hyperbaric 5 % lignocaine : a review of six cases of cauda equina syndrome reported to the Swedish Pharmaceutical Insurance 1993 - 1997 .|Six cases of cauda equina syndrome with varying severity were reported to the Swedish Pharmaceutical Insurance during the period 1993 - 1997 .|All were associated with spinal anaesthesia using hyperbaric 5 % lignocaine .|Five cases had single - shot spinal anaesthesia and one had a repeat spinal anaesthetic due to inadequate block .|The dose of hyperbaric 5 % lignocaine administered ranged from 60 to 120 mg .|Three of the cases were most likely caused by direct neurotoxicity of hyperbaric 5 % lignocaine .|In the other 3 cases , direct neurotoxicity was also probable , but unfortunately radiological investigations were not done to definitely exclude a compressive aetiology .|All cases sustained permanent neurological deficits .|We recommend that hyperbaric lignocaine should be administered in concentrations not greater than 2 % and at a total dose preferably not exceeding 60 mg .	1:CID:2	R2L	NON-CROSS	10-11	0-3	D008012	lignocaine|lignocaine|lignocaine|lignocaine|lignocaine	Chemical	10:64:92:116:155	11:65:93:117:156	0:2:4:5:8	D011128	Cauda equina syndrome|cauda equina syndrome|cauda equina syndrome	Disease	0:18:34	3:21:37	0:0:1	1:NR:2	L2R	NON-CROSS	111-112	116-117	D008012	lignocaine|lignocaine|lignocaine|lignocaine|lignocaine	Chemical	10:64:92:116:155	11:65:93:117:156	0:2:4:5:8	D020258	neurotoxicity|neurotoxicity	Disease	111:125	112:126	5:6	1:NR:2	L2R	CROSS	148-150	155-156	D008012	lignocaine|lignocaine|lignocaine|lignocaine|lignocaine	Chemical	10:64:92:116:155	11:65:93:117:156	0:2:4:5:8	D009461	neurological deficits	Disease	148	150	7
9549528	Cortical motor overactivation in parkinsonian patients with L - dopa - induced peak - dose dyskinesia .|We have studied the regional cerebral blood flow ( rCBF ) changes induced by the execution of a finger - to - thumb opposition motor task in the supplementary and primary motor cortex of two groups of parkinsonian patients on L - dopa medication , the first one without L - dopa induced dyskinesia ( n = 23 ) and the other with moderate peak - dose dyskinesia ( n = 15 ) , and of a group of 14 normal subjects .|Single photon emission tomography with i . v .|133Xe was used to measure the rCBF changes .|The dyskinetic parkinsonian patients exhibited a pattern of response which was markedly different from those of the normal subjects and non - dyskinetic parkinsonian patients , with a significant overactivation in the supplementary motor area and the ipsi - and contralateral primary motor areas .|These results are compatible with the hypothesis that an hyperkinetic abnormal involuntary movement , like L - dopa - induced peak dose dyskinesia , is due to a disinhibition of the primary and associated motor cortex secondary to an excessive outflow of the pallidothalamocortical motor loop .	1:NR:2	R2L	NON-CROSS	7-10	4-5	D007980	L - dopa|L - dopa|L - dopa|L - dopa	Chemical	7:57:66:178	10:60:69:181	0:1:1:5	D020734	parkinsonian|parkinsonian|parkinsonian|parkinsonian	Disease	4:54:120:141	5:55:121:142	0:1:4:4	1:CID:2	L2R	NON-CROSS	66-69	70-71	D007980	L - dopa|L - dopa|L - dopa|L - dopa	Chemical	7:57:66:178	10:60:69:181	0:1:1:5	D004409	dyskinesia|dyskinesia|dyskinesia|dyskinetic|dyskinetic|abnormal involuntary movement|dyskinesia	Disease	15:70:84:119:140:173:185	16:71:85:120:141:176:186	0:1:1:4:4:5:5	1:NR:2	L2R	NON-CROSS	172-173	178-181	D007980	L - dopa|L - dopa|L - dopa|L - dopa	Chemical	7:57:66:178	10:60:69:181	0:1:1:5	D006948	hyperkinetic	Disease	172	173	5
7843916	Dexamethasone - induced ocular hypertension in perfusion - cultured human eyes .|PURPOSE : Glucocorticoid administration can lead to the development of ocular hypertension and corticosteroid glaucoma in a subset of the population through a decrease in the aqueous humor outflow facility .|The purpose of this study was to determine whether glucocorticoid treatment can directly affect the outflow facility of isolated , perfusion - cultured human eyes .|METHODS : The anterior segments of human donor eyes from regional eye banks were placed in a constant flow , variable pressure perfusion culture system .|Paired eyes were perfused in serum - free media with or without 10 ( - 7 ) M dexamethasone for 12 days .|Intraocular pressure was monitored daily .|After incubation , the eyes were morphologically characterized by light microscopy , transmission and scanning electron microscopy , and scanning laser confocal microscopy .|RESULTS : A significant increase in intraocular pressure developed in 13 of the 44 pairs of eyes perfused with dexamethasone with an average pressure rise of 17 . 5 + / - 3 . 8 mm Hg after 12 days of dexamethasone exposure .|The contralateral control eyes , which did not receive dexamethasone , maintained a stable intraocular pressure during the same period .|The outflow pathway of the untreated eyes appeared morphologically normal .|In contrast , the dexamethasone - treated hypertensive eyes had thickened trabecular beams , decreased intertrabecular spaces , thickened juxtacanalicular tissue , activated trabecular meshwork cells , and increased amounts of amorphogranular extracellular material , especially in the juxtacanalicular tissue and beneath the endothelial lining of the canal of Schlemm .|The dexamethasone - treated nonresponder eyes appeared to be morphologically similar to the untreated eyes , although several subtle dexamethasone - induced morphologic changes were evident .|CONCLUSION : Dexamethasone treatment of isolated , perfusion - cultured human eyes led to the generation of ocular hypertension in approximately 30 % of the dexamethasone - treated eyes .|Steroid treatment resulted in morphologic changes in the trabecular meshwork similar to those reported for corticosteroid glaucoma and open angle glaucoma .|This system may provide an acute model in which to study the pathogenic mechanisms involved in steroid glaucoma and primary open angle glaucoma .	1:CID:2	L2R	NON-CROSS	0-1	3-5	D003907	Dexamethasone|dexamethasone|dexamethasone|dexamethasone|dexamethasone|dexamethasone|dexamethasone|dexamethasone|Dexamethasone|dexamethasone	Chemical	0:113:167:189:201:228:276:294:304:327	1:114:168:190:202:229:277:295:305:328	0:4:7:7:8:10:11:11:12:12	D009798	ocular hypertension|ocular hypertension|hypertensive eyes|ocular hypertension	Disease	3:22:231:319	5:24:233:321	0:1:10:12	1:NR:2	L2R	CROSS	327-328	347-349	D003907	Dexamethasone|dexamethasone|dexamethasone|dexamethasone|dexamethasone|dexamethasone|dexamethasone|dexamethasone|Dexamethasone|dexamethasone	Chemical	0:113:167:189:201:228:276:294:304:327	1:114:168:190:202:229:277:295:305:328	0:4:7:7:8:10:11:11:12:12	D005901	corticosteroid glaucoma|corticosteroid glaucoma|steroid glaucoma	Disease	25:347:370	27:349:372	1:13:14	1:NR:2	L2R	CROSS	327-328	350-353	D003907	Dexamethasone|dexamethasone|dexamethasone|dexamethasone|dexamethasone|dexamethasone|dexamethasone|dexamethasone|Dexamethasone|dexamethasone	Chemical	0:113:167:189:201:228:276:294:304:327	1:114:168:190:202:229:277:295:305:328	0:4:7:7:8:10:11:11:12:12	D005902	open angle glaucoma|primary open angle glaucoma	Disease	350:373	353:377	13:14	1:NR:2	R2L	CROSS	332-333	319-321	D013256	Steroid	Chemical	332	333	13	D009798	ocular hypertension|ocular hypertension|hypertensive eyes|ocular hypertension	Disease	3:22:231:319	5:24:233:321	0:1:10:12	1:NR:2	R2L	NON-CROSS	347-349	332-333	D013256	Steroid	Chemical	332	333	13	D005901	corticosteroid glaucoma|corticosteroid glaucoma|steroid glaucoma	Disease	25:347:370	27:349:372	1:13:14	1:NR:2	L2R	NON-CROSS	332-333	350-353	D013256	Steroid	Chemical	332	333	13	D005902	open angle glaucoma|primary open angle glaucoma	Disease	350:373	353:377	13:14
7803371	Cognitive deterioration from long - term abuse of dextromethorphan : a case report .|Dextromethorphan ( DM ) , the dextrorotatory isomer of 3 - hydroxy - N - methylmorphinan , is the main ingredient in a number of widely available , over - the - counter antitussives .|Initial studies ( Bornstein 1968 ) showed that it possessed no respiratory suppressant effects and no addiction liability .|Subsequently , however , several articles reporting abuse of this drug have appeared in the literature .|The drug is known to cause a variety of acute toxic effects , ranging from nausea , restlessness , insomnia , ataxia , slurred speech and nystagmus to mood changes , perceptual alterations , inattention , disorientation and aggressive behavior ( Rammer et al 1988 ; Katona and Watson 1986 ; Isbell and Fraser 1953 ; Devlin et al 1985 ; McCarthy 1971 ; Dodds and Revai 1967 ; Degkwitz 1964 ; Hildebrand et al 1989 ) .|There have also been two reported fatalities from DM overdoses ( Fleming 1986 ) .|However , there are no reports describing the effects of chronic abuse .|This report describes a case of cognitive deterioration resulting from prolonged use of DM .	1:CID:2	R2L	NON-CROSS	204-205	197-199	D003915	dextromethorphan|Dextromethorphan|DM|DM|DM	Chemical	8:14:16:171:204	9:15:17:172:205	0:1:1:5:7	D003072	Cognitive deterioration|cognitive deterioration	Disease	0:197	2:199	0:7	1:NR:2	R2L	CROSS	23-30	0-2	D007981	3 - hydroxy - N - methylmorphinan	Chemical	23	30	1	D003072	Cognitive deterioration|cognitive deterioration	Disease	0:197	2:199	0:7	1:NR:2	L2R	CROSS	100-101	171-172	D003915	dextromethorphan|Dextromethorphan|DM|DM|DM	Chemical	8:14:16:171:204	9:15:17:172:205	0:1:1:5:7	D009325	nausea	Disease	100	101	4	1:NR:2	L2R	CROSS	102-103	171-172	D003915	dextromethorphan|Dextromethorphan|DM|DM|DM	Chemical	8:14:16:171:204	9:15:17:172:205	0:1:1:5:7	D011595	restlessness	Disease	102	103	4	1:NR:2	L2R	CROSS	104-105	171-172	D003915	dextromethorphan|Dextromethorphan|DM|DM|DM	Chemical	8:14:16:171:204	9:15:17:172:205	0:1:1:5:7	D007319	insomnia	Disease	104	105	4	1:NR:2	L2R	CROSS	106-107	171-172	D003915	dextromethorphan|Dextromethorphan|DM|DM|DM	Chemical	8:14:16:171:204	9:15:17:172:205	0:1:1:5:7	D001259	ataxia	Disease	106	107	4	1:NR:2	L2R	CROSS	111-112	171-172	D003915	dextromethorphan|Dextromethorphan|DM|DM|DM	Chemical	8:14:16:171:204	9:15:17:172:205	0:1:1:5:7	C564088	nystagmus	Disease	111	112	4	1:NR:2	L2R	CROSS	123-125	171-172	D003915	dextromethorphan|Dextromethorphan|DM|DM|DM	Chemical	8:14:16:171:204	9:15:17:172:205	0:1:1:5:7	D001523	aggressive behavior	Disease	123	125	4	1:NR:2	L2R	CROSS	23-30	100-101	D007981	3 - hydroxy - N - methylmorphinan	Chemical	23	30	1	D009325	nausea	Disease	100	101	4	1:NR:2	L2R	CROSS	23-30	102-103	D007981	3 - hydroxy - N - methylmorphinan	Chemical	23	30	1	D011595	restlessness	Disease	102	103	4	1:NR:2	L2R	CROSS	23-30	104-105	D007981	3 - hydroxy - N - methylmorphinan	Chemical	23	30	1	D007319	insomnia	Disease	104	105	4	1:NR:2	L2R	CROSS	23-30	106-107	D007981	3 - hydroxy - N - methylmorphinan	Chemical	23	30	1	D001259	ataxia	Disease	106	107	4	1:NR:2	L2R	CROSS	23-30	111-112	D007981	3 - hydroxy - N - methylmorphinan	Chemical	23	30	1	C564088	nystagmus	Disease	111	112	4	1:NR:2	L2R	CROSS	23-30	123-125	D007981	3 - hydroxy - N - methylmorphinan	Chemical	23	30	1	D001523	aggressive behavior	Disease	123	125	4
7437994	Long - term lithium treatment and the kidney .|Interim report on fifty patients .|This is a report on the first part of our study of the effects of long - term lithium treatment on the kidney .|Creatinine clearance , maximum urinary osmolality and 24 hour urine volume have been tested in 50 affectively ill patients who have been on long - term lithium for more than one year .|These findings have been compared with norms and with values of the same tests from screening prior to lithium , available for most of our patients .|No evidence was found for any reduction of glomerular filtration during lithium treatment .|Low clearance values found in several patients could be accounted for by their age and their pre - lithium values .|Urinary concentration defect appeared frequent but the extent of the impairment is difficult to assess because of the uncertainty about the norms applicable to this group of patients .|The concentration defect appeared reversible , at least in part .|Polyuria above 3 litres / 24 hours was found in 10 % of patients .|An attempt is made to draw practical conclusions from the preliminary findings .	1:CID:2	L2R	CROSS	131-132	174-175	D008094	lithium|lithium|lithium|lithium|lithium|lithium	Chemical	3:33:65:90:110:131	4:34:66:91:111:132	0:2:3:4:5:6	D011141	Polyuria	Disease	174	175	9	1:NR:2	L2R	CROSS	39-40	174-175	D003404	Creatinine	Chemical	39	40	3	D011141	Polyuria	Disease	174	175	9
6496797	Complete heart block following a single dose of trazodone .|Forty minutes after receiving a single starting dose of trazodone , a patient developed complete heart block .|The case illustrates that , despite the results of earlier studies , trazodone 's effect on cardiac conduction may be severe in individuals at risk for conduction delay .	1:CID:2	R2L	NON-CROSS	8-9	1-3	D014196	trazodone|trazodone|trazodone	Chemical	8:19:40	9:20:41	0:1:2	D006327	heart block|heart block	Disease	1:25	3:27	0:1
3411101	Quinidine phenylethylbarbiturate - induced fulminant hepatitis in a pregnant woman .|A case report .|We report the case of a 19 - year - old Laotian patient affected by fulminant hepatitis during the third trimester of her pregnancy after a 1 - month administration of quinidine phenylethylbarbiturate .|After delivery , the patient underwent orthotopic liver transplantation .|The patient was in good condition 16 months after liver transplantation .|Quinidine itself or phenylethylbarbiturate may be responsible for fulminant hepatitis in this patient .	1:CID:2	L2R	NON-CROSS	0-2	5-6	C033457	Quinidine phenylethylbarbiturate|quinidine phenylethylbarbiturate|phenylethylbarbiturate	Chemical	0:46:74	2:48:75	0:2:5	D056486	hepatitis|hepatitis|hepatitis	Disease	5:31:80	6:32:81	0:2:5	1:NR:2	R2L	NON-CROSS	80-81	71-72	D011802	Quinidine	Chemical	71	72	5	D056486	hepatitis|hepatitis|hepatitis	Disease	5:31:80	6:32:81	0:2:5
2598570	The epidemiology of the acute flank pain syndrome from suprofen .|Suprofen , a new nonsteroidal anti - inflammatory drug , was marketed in early 1986 as an analgesic agent .|Until physicians began reporting an unusual acute flank pain syndrome to the spontaneous reporting system , 700 , 000 persons used the drug in the United States .|Through August 1986 , a total of 163 cases of this syndrome were reported .|To elucidate the epidemiology of the syndrome , a case - control study was performed , comparing 62 of the case patients who had been reported to the spontaneous reporting system to 185 suprofen - exposed control subjects who did not have the syndrome .|Case patients were more likely to be men ( odds ratio , 3 . 8 ; 95 % confidence interval , 1 . 2 - 12 . 1 ) , suffer from hay fever and asthma ( odds ratio , 3 . 4 ; 95 % confidence interval , 1 . 0 - 11 . 9 ) ; to participate in regular exercise ( odds ratio , 5 . 9 ; 95 % confidence interval , 1 . 1 - 30 . 7 ) , especially in the use of Nautilus equipment ( p = 0 . 02 ) ; and to use alcohol ( odds ratio , 4 . 4 ; 95 % confidence interval , 1 . 1 - 17 . 5 ) .|Possible risk factors included young age , concurrent use of other analgesic agents ( especially ibuprofen ) , preexisting renal disease , a history of kidney stones , a history of gout , a recent increase in activity , a recent increase in sun exposure , and residence in the Sunbelt .|These were findings that were suggestive but did not reach conventional statistical significance .|These findings are consistent with the postulated mechanism for this unusual syndrome : acute diffuse crystallization of uric acid in renal tubules .	1:CID:2	R2L	NON-CROSS	9-10	5-7	D013496	suprofen|Suprofen|suprofen	Chemical	9:11:107	10:12:108	0:1:4	D021501	flank pain|flank pain	Disease	5:38	7:40	0:2	1:NR:2	R2L	CROSS	222-223	38-40	D000431	alcohol	Chemical	222	223	5	D021501	flank pain|flank pain	Disease	5:38	7:40	0:2	1:NR:2	R2L	CROSS	260-261	38-40	D007052	ibuprofen	Chemical	260	261	6	D021501	flank pain|flank pain	Disease	5:38	7:40	0:2	1:NR:2	R2L	CROSS	328-330	38-40	D014527	uric acid	Chemical	328	330	8	D021501	flank pain|flank pain	Disease	5:38	7:40	0:2	1:NR:2	L2R	CROSS	107-108	151-153	D013496	suprofen|Suprofen|suprofen	Chemical	9:11:107	10:12:108	0:1:4	D006255	hay fever	Disease	151	153	5	1:NR:2	L2R	CROSS	107-108	154-155	D013496	suprofen|Suprofen|suprofen	Chemical	9:11:107	10:12:108	0:1:4	D001249	asthma	Disease	154	155	5	1:NR:2	L2R	CROSS	107-108	264-266	D013496	suprofen|Suprofen|suprofen	Chemical	9:11:107	10:12:108	0:1:4	D007674	renal disease	Disease	264	266	6	1:NR:2	L2R	CROSS	107-108	270-272	D013496	suprofen|Suprofen|suprofen	Chemical	9:11:107	10:12:108	0:1:4	D007669	kidney stones	Disease	270	272	6	1:NR:2	L2R	CROSS	107-108	276-277	D013496	suprofen|Suprofen|suprofen	Chemical	9:11:107	10:12:108	0:1:4	D006073	gout	Disease	276	277	6	1:NR:2	R2L	NON-CROSS	222-223	151-153	D000431	alcohol	Chemical	222	223	5	D006255	hay fever	Disease	151	153	5	1:NR:2	R2L	CROSS	260-261	151-153	D007052	ibuprofen	Chemical	260	261	6	D006255	hay fever	Disease	151	153	5	1:NR:2	R2L	CROSS	328-330	151-153	D014527	uric acid	Chemical	328	330	8	D006255	hay fever	Disease	151	153	5	1:NR:2	R2L	NON-CROSS	222-223	154-155	D000431	alcohol	Chemical	222	223	5	D001249	asthma	Disease	154	155	5	1:NR:2	R2L	CROSS	260-261	154-155	D007052	ibuprofen	Chemical	260	261	6	D001249	asthma	Disease	154	155	5	1:NR:2	R2L	CROSS	328-330	154-155	D014527	uric acid	Chemical	328	330	8	D001249	asthma	Disease	154	155	5	1:NR:2	L2R	CROSS	222-223	264-266	D000431	alcohol	Chemical	222	223	5	D007674	renal disease	Disease	264	266	6	1:NR:2	L2R	CROSS	222-223	270-272	D000431	alcohol	Chemical	222	223	5	D007669	kidney stones	Disease	270	272	6	1:NR:2	L2R	CROSS	222-223	276-277	D000431	alcohol	Chemical	222	223	5	D006073	gout	Disease	276	277	6	1:NR:2	L2R	NON-CROSS	260-261	264-266	D007052	ibuprofen	Chemical	260	261	6	D007674	renal disease	Disease	264	266	6	1:NR:2	L2R	NON-CROSS	260-261	270-272	D007052	ibuprofen	Chemical	260	261	6	D007669	kidney stones	Disease	270	272	6	1:NR:2	L2R	NON-CROSS	260-261	276-277	D007052	ibuprofen	Chemical	260	261	6	D006073	gout	Disease	276	277	6	1:NR:2	R2L	CROSS	328-330	264-266	D014527	uric acid	Chemical	328	330	8	D007674	renal disease	Disease	264	266	6	1:NR:2	R2L	CROSS	328-330	270-272	D014527	uric acid	Chemical	328	330	8	D007669	kidney stones	Disease	270	272	6	1:NR:2	R2L	CROSS	328-330	276-277	D014527	uric acid	Chemical	328	330	8	D006073	gout	Disease	276	277	6
1415380	Hemolytic - uremic syndrome associated with ingestion of quinine .|Hemolytic - uremic syndrome following quinine ingestion is a newly described phenomenon , with just two previous descriptions of 4 cases in the literature .|We describe a 5th case .|The reaction may be mediated by the presence of antibodies reactive against platelets in the presence of quinine .|Treatment has included use of plasma exchange , prednisone , aspirin , and dipyridamole .|The patients have all regained some degree of renal function .|However , it is unclear whether pharmacological treatment or spontaneous resolution is responsible for the improvement .|Quinine - associated hemolytic - uremic syndrome probably occurs more often than is recognized .|It is important to recognize this reaction when it occurs and to avoid further quinine exposure , since the reaction seems to be recurrent .	1:CID:2	R2L	NON-CROSS	15-16	10-14	D011803	quinine|quinine|quinine|Quinine|quinine	Chemical	8:15:58:103:132	9:16:59:104:133	0:1:3:7:8	D006463	Hemolytic - uremic syndrome|Hemolytic - uremic syndrome|hemolytic - uremic syndrome	Disease	0:10:106	4:14:110	0:1:7	1:NR:2	R2L	CROSS	106-110	68-69	D011241	prednisone	Chemical	68	69	4	D006463	Hemolytic - uremic syndrome|Hemolytic - uremic syndrome|hemolytic - uremic syndrome	Disease	0:10:106	4:14:110	0:1:7	1:NR:2	R2L	CROSS	106-110	70-71	D001241	aspirin	Chemical	70	71	4	D006463	Hemolytic - uremic syndrome|Hemolytic - uremic syndrome|hemolytic - uremic syndrome	Disease	0:10:106	4:14:110	0:1:7	1:NR:2	R2L	CROSS	106-110	73-74	D004176	dipyridamole	Chemical	73	74	4	D006463	Hemolytic - uremic syndrome|Hemolytic - uremic syndrome|hemolytic - uremic syndrome	Disease	0:10:106	4:14:110	0:1:7
1255900	Pyeloureteral filling defects associated with systemic anticoagulation : a case report .|The etiology of pyeloureteritis cystica has long been attributed to chronic infection and inflammation .|A case is presented that is unique in that the acute onset and the rapid resolution of pyeloureteral filling defects in this patient were documented by radiography .|There is no evidence of antecedent or concurrent infection in this patient .|The disease occurred subsequent to the initiation of heparin therapy for suspected pelvic thrombophlebitis and cleared rapidly subsequent to its discontinuation .|The rate of resolution of the radiographic findings may be helpful in distinguishing between true pyeloureteritis cystica and submucosal hemorrhage .	1:CID:2	R2L	CROSS	105-107	76-77	D006493	heparin	Chemical	76	77	4	D011702	pyeloureteritis cystica|pyeloureteritis cystica	Disease	15:105	17:107	1:5	1:NR:2	R2L	CROSS	76-77	63-64	D006493	heparin	Chemical	76	77	4	D007239	infection|infection	Disease	23:63	24:64	1:3	1:NR:2	R2L	CROSS	76-77	25-26	D006493	heparin	Chemical	76	77	4	D007249	inflammation	Disease	25	26	1	1:NR:2	L2R	NON-CROSS	76-77	81-82	D006493	heparin	Chemical	76	77	4	D013924	thrombophlebitis	Disease	81	82	4	1:NR:2	L2R	CROSS	76-77	108-110	D006493	heparin	Chemical	76	77	4	D006470	submucosal hemorrhage	Disease	108	110	5
85485	Changes in peroxisomes in preneoplastic liver and hepatoma of mice induced by alpha - benzene hexachloride .|Peroxisomes in hepatomas and hyperplastic preneoplastic liver lesions induced in mice by 500 ppm alpha - benzene hexachloride were examined histochemically and electron microscopically .|Although most of the hepatomas were well - differentiated tumors and contained a considerable number of peroxisomes , the tumor cells did not respond to ethyl - alpha - p - chlorophenoxyisobutyrate with proliferation of peroxisomes .|At the 16th week of carcinogen feeding , hyperplastic nodules appeared and advanced to further stages .|A majority of the nodules showed a considerable number of peroxisomes and the inductive proliferation of peroxisomes .|Within the nodules , foci of proliferation of the cells that showed no inducibility of proliferation of peroxisomes appeared .|These cells proliferated further , replacing the most part of the nodules , and with this process hepatomas appeared to have been formed .|No abnormal matrical inclusions of peroxisomes were formed in the cells of hyperplastic nodules by ethyl - alpha - p - chlorophenoxyisobutyrate unlike in the case of rats .	1:CID:2	R2L	NON-CROSS	19-20	12-16	D001556	alpha - benzene hexachloride|alpha - benzene hexachloride	Chemical	12:31	16:35	0:1	D006528	hepatoma|hepatomas|hepatomas|hepatomas	Disease	7:19:46:151	8:20:47:152	0:1:2:6	1:NR:2	R2L	NON-CROSS	67-74	46-47	C012282	ethyl - alpha - p - chlorophenoxyisobutyrate|ethyl - alpha - p - chlorophenoxyisobutyrate	Chemical	67:173	74:180	2:7	D006528	hepatoma|hepatomas|hepatomas|hepatomas	Disease	7:19:46:151	8:20:47:152	0:1:2:6	1:NR:2	L2R	NON-CROSS	23-25	31-35	D001556	alpha - benzene hexachloride|alpha - benzene hexachloride	Chemical	12:31	16:35	0:1	D017093	liver lesions	Disease	23	25	1	1:NR:2	L2R	CROSS	31-35	51-52	D001556	alpha - benzene hexachloride|alpha - benzene hexachloride	Chemical	12:31	16:35	0:1	D009369	tumors|tumor	Disease	51:61	52:62	2:2	1:NR:2	R2L	CROSS	67-74	23-25	C012282	ethyl - alpha - p - chlorophenoxyisobutyrate|ethyl - alpha - p - chlorophenoxyisobutyrate	Chemical	67:173	74:180	2:7	D017093	liver lesions	Disease	23	25	1	1:NR:2	R2L	NON-CROSS	67-74	61-62	C012282	ethyl - alpha - p - chlorophenoxyisobutyrate|ethyl - alpha - p - chlorophenoxyisobutyrate	Chemical	67:173	74:180	2:7	D009369	tumors|tumor	Disease	51:61	52:62	2:2
48362	Quinidine hepatitis .|Long - term administration of quinidine was associated with persistent elevation of serum concentrations of SGOT , lactic acid dehydrogenase , and alkaline phosphatase .|Liver biopsy showed active hepatitis .|Discontinuance of quinidine therapy led to normalization of liver function tests .|A challenge dose of quinidine caused clinical symptoms and abrupt elevation of SGOT , alkaline phosphatase , and lactic acid dehydrogenase values .|We concluded that this patient had quinidine hepatotoxicity and believe that this is the first case reported with liver biopsy documentation .|This report also suggests that , even after long - term administration , the hepatic toxicity is reversible .	1:CID:2	L2R	NON-CROSS	0-1	1-2	D011802	Quinidine|quinidine|quinidine|quinidine|quinidine	Chemical	0:8:36:50:75	1:9:37:51:76	0:1:3:4:5	D056486	hepatitis|hepatitis|hepatotoxicity|hepatic toxicity	Disease	1:32:76:105	2:33:77:107	0:2:5:6	1:NR:2	R2L	CROSS	76-77	64-66	D019344	lactic acid|lactic acid	Chemical	20:64	22:66	1:4	D056486	hepatitis|hepatitis|hepatotoxicity|hepatic toxicity	Disease	1:32:76:105	2:33:77:107	0:2:5:6
9067481	Cholesteryl hemisuccinate treatment protects rodents from the toxic effects of acetaminophen , adriamycin , carbon tetrachloride , chloroform and galactosamine .|In addition to its use as a stabilizer / rigidifier of membranes , cholesteryl hemisuccinate , tris salt ( CS ) administration has also been shown to protect rats from the hepatotoxic effects of carbon tetrachloride ( CCl4 ) .|To further our understanding of the mechanism of CS cytoprotection , we examined in rats and mice the protective abilities of CS and the non - hydrolyzable ether form of CS , gamma - cholesteryloxybutyric acid , tris salt ( CSE ) against acetaminophen - , adriamycin - , carbon tetrachloride - , chloroform - and galactosamine - induced toxicity .|The results of these studies demonstrated that CS - mediated protection is not selective for a particular species , organ system or toxic chemical .|A 24 - h pretreatment of both rats and mice with a single dose of CS ( 100mg / kg , i . p . ) , resulted in significant protection against the hepatotoxic effects of CCl4 , CHCl3 , acetaminophen and galactosamine and against the lethal ( and presumably cardiotoxic ) effect of adriamycin administration .|Maximal CS - mediated protection was observed in experimental animals pretreated 24 h prior to the toxic insult .|These data suggest that CS intervenes in a critical cellular event that is an important common pathway to toxic cell death .|The mechanism of CS protection does not appear to be dependent on the inhibition of chemical bioactivation to a toxic reactive intermediate ( in light of the protection observed against galactosamine hepatotoxicity ) .|However , based on the data presented , we can not exclude the possibility that CS administration inhibits chemical bioactivation .|Our findings do suggest that CS - mediated protection is dependent on the action of the intact anionic CS molecule ( non - hydrolyzable CSE was as protective as CS ) , whose mechanism has yet to be defined .	1:NR:2	L2R	NON-CROSS	34-36	52-53	C013440	Cholesteryl hemisuccinate|cholesteryl hemisuccinate	Chemical	0:34	2:36	0:1	D056486	hepatotoxic|hepatotoxic|hepatotoxicity	Disease	52:180:276	53:181:277	1:4:7	1:NR:2	L2R	CROSS	34-36	120-121	C013440	Cholesteryl hemisuccinate|cholesteryl hemisuccinate	Chemical	0:34	2:36	0:1	D064420	toxicity	Disease	120	121	2	1:NR:2	L2R	CROSS	34-36	197-198	C013440	Cholesteryl hemisuccinate|cholesteryl hemisuccinate	Chemical	0:34	2:36	0:1	D066126	cardiotoxic	Disease	197	198	4	1:CID:2	L2R	NON-CROSS	180-181	187-188	D000082	acetaminophen|acetaminophen|acetaminophen	Chemical	10:104:187	11:105:188	0:2:4	D056486	hepatotoxic|hepatotoxic|hepatotoxicity	Disease	52:180:276	53:181:277	1:4:7	1:NR:2	L2R	NON-CROSS	104-105	120-121	D000082	acetaminophen|acetaminophen|acetaminophen	Chemical	10:104:187	11:105:188	0:2:4	D064420	toxicity	Disease	120	121	2	1:NR:2	L2R	NON-CROSS	187-188	197-198	D000082	acetaminophen|acetaminophen|acetaminophen	Chemical	10:104:187	11:105:188	0:2:4	D066126	cardiotoxic	Disease	197	198	4	1:NR:2	L2R	NON-CROSS	180-181	201-202	D004317	adriamycin|adriamycin|adriamycin	Chemical	12:107:201	13:108:202	0:2:4	D056486	hepatotoxic|hepatotoxic|hepatotoxicity	Disease	52:180:276	53:181:277	1:4:7	1:NR:2	L2R	NON-CROSS	107-108	120-121	D004317	adriamycin|adriamycin|adriamycin	Chemical	12:107:201	13:108:202	0:2:4	D064420	toxicity	Disease	120	121	2	1:CID:2	L2R	NON-CROSS	197-198	201-202	D004317	adriamycin|adriamycin|adriamycin	Chemical	12:107:201	13:108:202	0:2:4	D066126	cardiotoxic	Disease	197	198	4	1:CID:2	L2R	NON-CROSS	180-181	183-184	D002251	carbon tetrachloride|carbon tetrachloride|CCl4|carbon tetrachloride|CCl4	Chemical	14:55:58:110:183	16:57:59:112:184	0:1:1:2:4	D056486	hepatotoxic|hepatotoxic|hepatotoxicity	Disease	52:180:276	53:181:277	1:4:7	1:NR:2	L2R	NON-CROSS	110-112	120-121	D002251	carbon tetrachloride|carbon tetrachloride|CCl4|carbon tetrachloride|CCl4	Chemical	14:55:58:110:183	16:57:59:112:184	0:1:1:2:4	D064420	toxicity	Disease	120	121	2	1:NR:2	L2R	NON-CROSS	183-184	197-198	D002251	carbon tetrachloride|carbon tetrachloride|CCl4|carbon tetrachloride|CCl4	Chemical	14:55:58:110:183	16:57:59:112:184	0:1:1:2:4	D066126	cardiotoxic	Disease	197	198	4	1:CID:2	L2R	NON-CROSS	180-181	185-186	D002725	chloroform|chloroform|CHCl3	Chemical	17:114:185	18:115:186	0:2:4	D056486	hepatotoxic|hepatotoxic|hepatotoxicity	Disease	52:180:276	53:181:277	1:4:7	1:NR:2	L2R	NON-CROSS	114-115	120-121	D002725	chloroform|chloroform|CHCl3	Chemical	17:114:185	18:115:186	0:2:4	D064420	toxicity	Disease	120	121	2	1:NR:2	L2R	NON-CROSS	185-186	197-198	D002725	chloroform|chloroform|CHCl3	Chemical	17:114:185	18:115:186	0:2:4	D066126	cardiotoxic	Disease	197	198	4	1:CID:2	L2R	NON-CROSS	275-276	276-277	D005688	galactosamine|galactosamine|galactosamine|galactosamine	Chemical	19:117:189:275	20:118:190:276	0:2:4:7	D056486	hepatotoxic|hepatotoxic|hepatotoxicity	Disease	52:180:276	53:181:277	1:4:7	1:NR:2	L2R	NON-CROSS	117-118	120-121	D005688	galactosamine|galactosamine|galactosamine|galactosamine	Chemical	19:117:189:275	20:118:190:276	0:2:4:7	D064420	toxicity	Disease	120	121	2	1:NR:2	L2R	NON-CROSS	189-190	197-198	D005688	galactosamine|galactosamine|galactosamine|galactosamine	Chemical	19:117:189:275	20:118:190:276	0:2:4:7	D066126	cardiotoxic	Disease	197	198	4	1:NR:2	R2L	CROSS	93-97	52-53	C103872	gamma - cholesteryloxybutyric acid	Chemical	93	97	2	D056486	hepatotoxic|hepatotoxic|hepatotoxicity	Disease	52:180:276	53:181:277	1:4:7	1:NR:2	L2R	NON-CROSS	93-97	120-121	C103872	gamma - cholesteryloxybutyric acid	Chemical	93	97	2	D064420	toxicity	Disease	120	121	2	1:NR:2	L2R	CROSS	93-97	197-198	C103872	gamma - cholesteryloxybutyric acid	Chemical	93	97	2	D066126	cardiotoxic	Disease	197	198	4
19274460	DSMM XI study : dose definition for intravenous cyclophosphamide in combination with bortezomib / dexamethasone for remission induction in patients with newly diagnosed myeloma .|A clinical trial was initiated to evaluate the recommended dose of cyclophosphamide in combination with bortezomib and dexamethasone as induction treatment before stem cell transplantation for younger patients with newly diagnosed multiple myeloma ( MM ) .|Thirty patients were treated with three 21 - day cycles of bortezomib 1 . 3 mg / m ( 2 ) on days 1 , 4 , 8 , and 11 plus dexamethasone 40 mg on the day of bortezomib injection and the day after plus cyclophosphamide at 900 , 1 , 200 , or 1 , 500 mg / m ( 2 ) on day 1 .|The maximum tolerated dose of cyclophosphamide was defined as 900 mg / m ( 2 ) .|At this dose level , 92 % of patients achieved at least a partial response .|The overall response rate [ complete response ( CR ) plus partial response ( PR ) ] across all dose levels was 77 % , with a 10 % CR rate .|No patient experienced progressive disease .|The most frequent adverse events were hematological and gastrointestinal toxicities as well as neuropathy .|The results suggest that bortezomib in combination with cyclophosphamide at 900 mg / m ( 2 ) and dexamethasone is an effective induction treatment for patients with newly diagnosed MM that warrants further investigation .	1:NR:2	L2R	NON-CROSS	23-24	36-37	D003520	cyclophosphamide|cyclophosphamide|cyclophosphamide|cyclophosphamide|cyclophosphamide	Chemical	8:36:108:135:224	9:37:109:136:225	0:1:2:3:8	D009101	myeloma|multiple myeloma|MM|MM	Disease	23:56:59:245	24:58:60:246	0:1:1:8	1:CID:2	L2R	CROSS	207-211	224-225	D003520	cyclophosphamide|cyclophosphamide|cyclophosphamide|cyclophosphamide|cyclophosphamide	Chemical	8:36:108:135:224	9:37:109:136:225	0:1:2:3:8	D006402	hematological and gastrointestinal toxicities	Disease	207	211	7	1:CID:2	L2R	CROSS	207-211	224-225	D003520	cyclophosphamide|cyclophosphamide|cyclophosphamide|cyclophosphamide|cyclophosphamide	Chemical	8:36:108:135:224	9:37:109:136:225	0:1:2:3:8	D005767	hematological and gastrointestinal toxicities	Disease	207	211	7	1:CID:2	L2R	CROSS	214-215	224-225	D003520	cyclophosphamide|cyclophosphamide|cyclophosphamide|cyclophosphamide|cyclophosphamide	Chemical	8:36:108:135:224	9:37:109:136:225	0:1:2:3:8	D009422	neuropathy	Disease	214	215	7	1:NR:2	L2R	NON-CROSS	12-13	23-24	C400082	bortezomib|bortezomib|bortezomib|bortezomib|bortezomib	Chemical	12:40:73:101:220	13:41:74:102:221	0:1:2:2:8	D009101	myeloma|multiple myeloma|MM|MM	Disease	23:56:59:245	24:58:60:246	0:1:1:8	1:CID:2	L2R	CROSS	207-211	220-221	C400082	bortezomib|bortezomib|bortezomib|bortezomib|bortezomib	Chemical	12:40:73:101:220	13:41:74:102:221	0:1:2:2:8	D006402	hematological and gastrointestinal toxicities	Disease	207	211	7	1:CID:2	L2R	CROSS	207-211	220-221	C400082	bortezomib|bortezomib|bortezomib|bortezomib|bortezomib	Chemical	12:40:73:101:220	13:41:74:102:221	0:1:2:2:8	D005767	hematological and gastrointestinal toxicities	Disease	207	211	7	1:CID:2	L2R	CROSS	214-215	220-221	C400082	bortezomib|bortezomib|bortezomib|bortezomib|bortezomib	Chemical	12:40:73:101:220	13:41:74:102:221	0:1:2:2:8	D009422	neuropathy	Disease	214	215	7	1:NR:2	L2R	NON-CROSS	14-15	23-24	D003907	dexamethasone|dexamethasone|dexamethasone|dexamethasone	Chemical	14:42:94:234	15:43:95:235	0:1:2:8	D009101	myeloma|multiple myeloma|MM|MM	Disease	23:56:59:245	24:58:60:246	0:1:1:8	1:CID:2	L2R	CROSS	207-211	234-235	D003907	dexamethasone|dexamethasone|dexamethasone|dexamethasone	Chemical	14:42:94:234	15:43:95:235	0:1:2:8	D006402	hematological and gastrointestinal toxicities	Disease	207	211	7	1:CID:2	L2R	CROSS	207-211	234-235	D003907	dexamethasone|dexamethasone|dexamethasone|dexamethasone	Chemical	14:42:94:234	15:43:95:235	0:1:2:8	D005767	hematological and gastrointestinal toxicities	Disease	207	211	7	1:CID:2	L2R	CROSS	214-215	234-235	D003907	dexamethasone|dexamethasone|dexamethasone|dexamethasone	Chemical	14:42:94:234	15:43:95:235	0:1:2:8	D009422	neuropathy	Disease	214	215	7
18201582	Results of a comparative , phase III , 12 - week , multicenter , prospective , randomized , double - blind assessment of the efficacy and tolerability of a fixed - dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stage II hypertension .|OBJECTIVE : The aim of this study was to evaluate the efficacy and tolerability of a new fixed - dose combination ( FDC ) of telmisartan 40 mg + amlodipine 5 mg ( T + A ) compared with amlodipine 5 - mg monotherapy ( A ) in adult Indian patients with stage II hypertension .|METHODS : This comparative , Phase III , 12 - week , multicenter , prospective , randomized , double - blind study was conducted in Indian patients aged 18 to 65 years with established stage II hypertension .|Patients were treated with oral FDC of T + A or A QD before breakfast for 12 weeks ; blood pressure ( BP ) and heart rate were measured in the sitting position .|Primary efficacy end points were reduction in clinical systolic BP ( SBP ) / diastolic BP ( DBP ) from baseline to study end and number of responders ( ie , patients who achieved target SBP / DBP < 130 / < 80 mm Hg ) at end of study .|Tolerability was assessed by treatment - emergent adverse events , identified using physical examination , laboratory analysis , and electrocardiography .|RESULTS : A total of 210 patients were enrolled in the study ; 203 patients ( 143 men , 60 women ) completed the study while 7 were lost to follow - up ( 4 patients in the T + A group and 3 in the A group ) and considered with - drawn .|At study end , statistically significant percentage reductions from baseline within groups and between groups were observed in SBP ( T + A [ - 27 . 4 % ] ; A [ - 16 . 6 % ] ) and DBP ( T + A [ - 20 . 1 % ] ; A [ - 13 . 3 % ] ) ( all , P < 0 . 05 ) .|Response rates were 87 . 3 % ( 89 / 102 ) in the T + A group and 69 . 3 % ( 70 / 101 ) in the A group ( P < 0 . 05 ) .|The prevalences of adverse events were not significantly different between the 2 treatment groups ( T + A , 16 . 0 % [ 17 / 106 ] ; A , 15 . 4 % [ 16 / 104 ] ) .|Peripheral edema was reported in 8 . 5 % patients ( 9 / 106 ) in the T + A group compared with 13 . 5 % ( 14 / 104 ) in the A group , and cough was reported in 3 . 8 % patients ( 4 / 106 ) in the T + A group and 1 . 0 % ( 1 / 104 ) patients in the A group ; these differences did not reach statistical significance .|The incidences of headache , dizziness , and diarrhea were similar between the 2 groups .|CONCLUSIONS : Among these Indian patients with stage II hypertension , the FDC of T + A was found to be significantly more effective , with regard to BP reductions , than A , and both treatments were well tolerated .	1:NR:2	L2R	NON-CROSS	34-35	46-47	C084178	telmisartan|telmisartan	Chemical	34:73	35:74	0:1	D006973	hypertension|hypertension|hypertension|hypertension	Disease	46:102:140:565	47:103:141:566	0:1:2:12	1:CID:2	L2R	CROSS	73-74	459-460	C084178	telmisartan|telmisartan	Chemical	34:73	35:74	0:1	D004487	edema	Disease	459	460	10	1:CID:2	L2R	CROSS	73-74	496-497	C084178	telmisartan|telmisartan	Chemical	34:73	35:74	0:1	D003371	cough	Disease	496	497	10	1:CID:2	L2R	CROSS	73-74	543-544	C084178	telmisartan|telmisartan	Chemical	34:73	35:74	0:1	D006261	headache	Disease	543	544	11	1:CID:2	L2R	CROSS	73-74	545-546	C084178	telmisartan|telmisartan	Chemical	34:73	35:74	0:1	D004244	dizziness	Disease	545	546	11	1:CID:2	L2R	CROSS	73-74	548-549	C084178	telmisartan|telmisartan	Chemical	34:73	35:74	0:1	D003967	diarrhea	Disease	548	549	11	1:NR:2	L2R	NON-CROSS	38-39	46-47	D017311	amlodipine|amlodipine|amlodipine|amlodipine	Chemical	36:38:77:87	37:39:78:88	0:0:1:1	D006973	hypertension|hypertension|hypertension|hypertension	Disease	46:102:140:565	47:103:141:566	0:1:2:12	1:CID:2	L2R	CROSS	87-88	459-460	D017311	amlodipine|amlodipine|amlodipine|amlodipine	Chemical	36:38:77:87	37:39:78:88	0:0:1:1	D004487	edema	Disease	459	460	10	1:CID:2	L2R	CROSS	87-88	496-497	D017311	amlodipine|amlodipine|amlodipine|amlodipine	Chemical	36:38:77:87	37:39:78:88	0:0:1:1	D003371	cough	Disease	496	497	10	1:CID:2	L2R	CROSS	87-88	543-544	D017311	amlodipine|amlodipine|amlodipine|amlodipine	Chemical	36:38:77:87	37:39:78:88	0:0:1:1	D006261	headache	Disease	543	544	11	1:CID:2	L2R	CROSS	87-88	545-546	D017311	amlodipine|amlodipine|amlodipine|amlodipine	Chemical	36:38:77:87	37:39:78:88	0:0:1:1	D004244	dizziness	Disease	545	546	11	1:CID:2	L2R	CROSS	87-88	548-549	D017311	amlodipine|amlodipine|amlodipine|amlodipine	Chemical	36:38:77:87	37:39:78:88	0:0:1:1	D003967	diarrhea	Disease	548	549	11
11337188	Cutaneous leucocytoclastic vasculitis associated with oxacillin .|A 67 - year - old man who was treated with oxacillin for one week because of Staphylococcus aureus bacteremia , developed renal failure and diffuse , symmetric , palpable purpuric lesions on his feet .|Necrotic blisters were noted on his fingers .|Skin biopsies showed findings diagnostic of leucocytoclastic vasculitis .|Oxacillin was discontinued and patient was treated with corticosteroids .|The rash disappeared after three weeks and renal function returned to normal .|Leucocytoclastic vasculitis presents as palpable purpura of the lower extremities often accompanied by abdominal pain , arthralgia , and renal involvement .|Etiologic factors or associated disorders include infections , medications , collagen vascular disease and neoplasia .|However , in half of the cases no etiologic factor is identified .|Usually it is a self - limited disorder , but corticosteroid therapy may be needed in life - threatening cases since early treatment with corticosteroids in severe cases can prevent complications .|Oxacillin should be included among the drugs that can cause leucocytoclastic vasculitis .	1:CID:2	R2L	NON-CROSS	60-61	57-59	D010068	oxacillin|oxacillin|Oxacillin|Oxacillin	Chemical	5:18:60:166	6:19:61:167	0:1:4:10	D018366	Cutaneous leucocytoclastic vasculitis|leucocytoclastic vasculitis|Leucocytoclastic vasculitis|leucocytoclastic vasculitis	Disease	0:57:83:176	3:59:85:178	0:3:6:10	1:CID:2	R2L	CROSS	68-69	57-59	D000305	corticosteroids|corticosteroid|corticosteroids	Chemical	68:144:158	69:145:159	4:9:9	D018366	Cutaneous leucocytoclastic vasculitis|leucocytoclastic vasculitis|Leucocytoclastic vasculitis|leucocytoclastic vasculitis	Disease	0:57:83:176	3:59:85:178	0:3:6:10	1:NR:2	L2R	NON-CROSS	18-19	24-27	D010068	oxacillin|oxacillin|Oxacillin|Oxacillin	Chemical	5:18:60:166	6:19:61:167	0:1:4:10	D013203	Staphylococcus aureus bacteremia	Disease	24	27	1	1:NR:2	L2R	NON-CROSS	18-19	24-27	D010068	oxacillin|oxacillin|Oxacillin|Oxacillin	Chemical	5:18:60:166	6:19:61:167	0:1:4:10	D016470	Staphylococcus aureus bacteremia	Disease	24	27	1	1:CID:2	L2R	NON-CROSS	18-19	29-31	D010068	oxacillin|oxacillin|Oxacillin|Oxacillin	Chemical	5:18:60:166	6:19:61:167	0:1:4:10	D051437	renal failure	Disease	29	31	1	1:NR:2	L2R	NON-CROSS	18-19	37-39	D010068	oxacillin|oxacillin|Oxacillin|Oxacillin	Chemical	5:18:60:166	6:19:61:167	0:1:4:10	D011693	purpuric lesions|purpura	Disease	37:88	39:89	1:6	1:NR:2	L2R	CROSS	43-45	60-61	D010068	oxacillin|oxacillin|Oxacillin|Oxacillin	Chemical	5:18:60:166	6:19:61:167	0:1:4:10	D009336	Necrotic blisters	Disease	43	45	2	1:NR:2	L2R	CROSS	43-45	60-61	D010068	oxacillin|oxacillin|Oxacillin|Oxacillin	Chemical	5:18:60:166	6:19:61:167	0:1:4:10	D001768	Necrotic blisters	Disease	43	45	2	1:NR:2	L2R	CROSS	60-61	71-72	D010068	oxacillin|oxacillin|Oxacillin|Oxacillin	Chemical	5:18:60:166	6:19:61:167	0:1:4:10	D005076	rash	Disease	71	72	5	1:NR:2	L2R	CROSS	60-61	96-98	D010068	oxacillin|oxacillin|Oxacillin|Oxacillin	Chemical	5:18:60:166	6:19:61:167	0:1:4:10	D015746	abdominal pain	Disease	96	98	6	1:NR:2	L2R	CROSS	60-61	99-100	D010068	oxacillin|oxacillin|Oxacillin|Oxacillin	Chemical	5:18:60:166	6:19:61:167	0:1:4:10	D018771	arthralgia	Disease	99	100	6	1:NR:2	L2R	CROSS	60-61	102-104	D010068	oxacillin|oxacillin|Oxacillin|Oxacillin	Chemical	5:18:60:166	6:19:61:167	0:1:4:10	D007674	renal involvement	Disease	102	104	6	1:NR:2	L2R	CROSS	60-61	111-112	D010068	oxacillin|oxacillin|Oxacillin|Oxacillin	Chemical	5:18:60:166	6:19:61:167	0:1:4:10	D007239	infections	Disease	111	112	7	1:NR:2	L2R	CROSS	115-118	166-167	D010068	oxacillin|oxacillin|Oxacillin|Oxacillin	Chemical	5:18:60:166	6:19:61:167	0:1:4:10	D003095	collagen vascular disease	Disease	115	118	7	1:NR:2	L2R	CROSS	119-120	166-167	D010068	oxacillin|oxacillin|Oxacillin|Oxacillin	Chemical	5:18:60:166	6:19:61:167	0:1:4:10	D009369	neoplasia	Disease	119	120	7	1:NR:2	R2L	CROSS	68-69	24-27	D000305	corticosteroids|corticosteroid|corticosteroids	Chemical	68:144:158	69:145:159	4:9:9	D013203	Staphylococcus aureus bacteremia	Disease	24	27	1	1:NR:2	R2L	CROSS	68-69	24-27	D000305	corticosteroids|corticosteroid|corticosteroids	Chemical	68:144:158	69:145:159	4:9:9	D016470	Staphylococcus aureus bacteremia	Disease	24	27	1	1:CID:2	R2L	CROSS	68-69	29-31	D000305	corticosteroids|corticosteroid|corticosteroids	Chemical	68:144:158	69:145:159	4:9:9	D051437	renal failure	Disease	29	31	1	1:NR:2	R2L	CROSS	88-89	68-69	D000305	corticosteroids|corticosteroid|corticosteroids	Chemical	68:144:158	69:145:159	4:9:9	D011693	purpuric lesions|purpura	Disease	37:88	39:89	1:6	1:NR:2	R2L	CROSS	68-69	43-45	D000305	corticosteroids|corticosteroid|corticosteroids	Chemical	68:144:158	69:145:159	4:9:9	D009336	Necrotic blisters	Disease	43	45	2	1:NR:2	R2L	CROSS	68-69	43-45	D000305	corticosteroids|corticosteroid|corticosteroids	Chemical	68:144:158	69:145:159	4:9:9	D001768	Necrotic blisters	Disease	43	45	2	1:NR:2	L2R	CROSS	68-69	71-72	D000305	corticosteroids|corticosteroid|corticosteroids	Chemical	68:144:158	69:145:159	4:9:9	D005076	rash	Disease	71	72	5	1:NR:2	L2R	CROSS	68-69	96-98	D000305	corticosteroids|corticosteroid|corticosteroids	Chemical	68:144:158	69:145:159	4:9:9	D015746	abdominal pain	Disease	96	98	6	1:NR:2	L2R	CROSS	68-69	99-100	D000305	corticosteroids|corticosteroid|corticosteroids	Chemical	68:144:158	69:145:159	4:9:9	D018771	arthralgia	Disease	99	100	6	1:NR:2	L2R	CROSS	68-69	102-104	D000305	corticosteroids|corticosteroid|corticosteroids	Chemical	68:144:158	69:145:159	4:9:9	D007674	renal involvement	Disease	102	104	6	1:NR:2	L2R	CROSS	111-112	144-145	D000305	corticosteroids|corticosteroid|corticosteroids	Chemical	68:144:158	69:145:159	4:9:9	D007239	infections	Disease	111	112	7	1:NR:2	L2R	CROSS	115-118	144-145	D000305	corticosteroids|corticosteroid|corticosteroids	Chemical	68:144:158	69:145:159	4:9:9	D003095	collagen vascular disease	Disease	115	118	7	1:NR:2	L2R	CROSS	119-120	144-145	D000305	corticosteroids|corticosteroid|corticosteroids	Chemical	68:144:158	69:145:159	4:9:9	D009369	neoplasia	Disease	119	120	7
6308526	Naloxazone pretreatment modifies cardiorespiratory , temperature , and behavioral effects of morphine .|Behavioral and cardiorespiratory responses to a lethal dose of morphine were evaluated in rats pretreated with saline or naloxazone , an antagonist of high - affinity mu 1 opioid receptors .|Pretreatment with naloxazone significantly blocked morphine analgesia , catalepsy and hypothermia at a dose which completely eliminated high - affinity binding in brain membranes .|Moreover , naloxazone significantly attenuated the morphine - induced hypotension and respiratory depression , whereas morphine - induced bradycardia was less affected .|Results indicate that subpopulations of mu receptors may mediate selective behavioral and cardiorespiratory responses to morphine .	1:NR:2	L2R	NON-CROSS	46-47	50-51	C024224	Naloxazone|naloxazone|naloxazone|naloxazone	Chemical	0:31:46:71	1:32:47:72	0:1:2:3	D000699	analgesia	Disease	50	51	2	1:NR:2	L2R	NON-CROSS	46-47	52-53	C024224	Naloxazone|naloxazone|naloxazone|naloxazone	Chemical	0:31:46:71	1:32:47:72	0:1:2:3	D002375	catalepsy	Disease	52	53	2	1:NR:2	L2R	NON-CROSS	46-47	54-55	C024224	Naloxazone|naloxazone|naloxazone|naloxazone	Chemical	0:31:46:71	1:32:47:72	0:1:2:3	D007035	hypothermia	Disease	54	55	2	1:NR:2	L2R	NON-CROSS	71-72	78-79	C024224	Naloxazone|naloxazone|naloxazone|naloxazone	Chemical	0:31:46:71	1:32:47:72	0:1:2:3	D007022	hypotension	Disease	78	79	3	1:NR:2	L2R	NON-CROSS	71-72	80-82	C024224	Naloxazone|naloxazone|naloxazone|naloxazone	Chemical	0:31:46:71	1:32:47:72	0:1:2:3	D012131	respiratory depression	Disease	80	82	3	1:NR:2	L2R	NON-CROSS	71-72	87-88	C024224	Naloxazone|naloxazone|naloxazone|naloxazone	Chemical	0:31:46:71	1:32:47:72	0:1:2:3	D001919	bradycardia	Disease	87	88	3	1:NR:2	L2R	NON-CROSS	49-50	50-51	D009020	morphine|morphine|morphine|morphine|morphine|morphine	Chemical	11:22:49:75:84:107	12:23:50:76:85:108	0:1:2:3:3:4	D000699	analgesia	Disease	50	51	2	1:CID:2	L2R	NON-CROSS	49-50	52-53	D009020	morphine|morphine|morphine|morphine|morphine|morphine	Chemical	11:22:49:75:84:107	12:23:50:76:85:108	0:1:2:3:3:4	D002375	catalepsy	Disease	52	53	2	1:CID:2	L2R	NON-CROSS	49-50	54-55	D009020	morphine|morphine|morphine|morphine|morphine|morphine	Chemical	11:22:49:75:84:107	12:23:50:76:85:108	0:1:2:3:3:4	D007035	hypothermia	Disease	54	55	2	1:CID:2	L2R	NON-CROSS	75-76	78-79	D009020	morphine|morphine|morphine|morphine|morphine|morphine	Chemical	11:22:49:75:84:107	12:23:50:76:85:108	0:1:2:3:3:4	D007022	hypotension	Disease	78	79	3	1:NR:2	L2R	NON-CROSS	80-82	84-85	D009020	morphine|morphine|morphine|morphine|morphine|morphine	Chemical	11:22:49:75:84:107	12:23:50:76:85:108	0:1:2:3:3:4	D012131	respiratory depression	Disease	80	82	3	1:CID:2	L2R	NON-CROSS	84-85	87-88	D009020	morphine|morphine|morphine|morphine|morphine|morphine	Chemical	11:22:49:75:84:107	12:23:50:76:85:108	0:1:2:3:3:4	D001919	bradycardia	Disease	87	88	3
15897593	Dexrazoxane protects against myelosuppression from the DNA cleavage - enhancing drugs etoposide and daunorubicin but not doxorubicin .|PURPOSE : The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage - enhancing drugs that are widely used in clinical oncology ; however , myelosuppression and cardiac toxicity limit their use .|Dexrazoxane ( ICRF - 187 ) is recommended for protection against anthracycline - induced cardiotoxicity .|EXPERIMENTAL DESIGN : Because of their widespread use , the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated : Sensitivity of human and murine blood progenitor cells to etoposide , daunorubicin , and doxorubicin + / - dexrazoxane was determined in granulocyte - macrophage colony forming assays .|Likewise , in vivo , B6D2F1 mice were treated with etoposide , daunorubicin , and doxorubicin , with or without dexrazoxane over a wide range of doses : posttreatment , a full hematologic evaluation was done .|RESULTS : Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay ; however , dexrazoxane neither reduced myelosuppression , weight loss , nor the in vitro cytotoxicity from doxorubicin .|CONCLUSION : Although our findings support the observation that dexrazoxane reduces neither hematologic activity nor antitumor activity from doxorubicin clinically , the potent antagonism of daunorubicin activity raises concern ; a possible interference with anticancer efficacy certainly would call for renewed attention .|Our data also suggest that significant etoposide dose escalation is perhaps possible by the use of dexrazoxane .|Clinical trials in patients with brain metastases combining dexrazoxane and high doses of etoposide is ongoing with the aim of improving efficacy without aggravating hematologic toxicity .|If successful , this represents an exciting mechanism for pharmacologic regulation of side effects from cytotoxic chemotherapy .	1:NR:2	L2R	NON-CROSS	168-169	170-171	D064730	Dexrazoxane|Dexrazoxane|ICRF - 187|dexrazoxane|dexrazoxane|dexrazoxane|dexrazoxane|dexrazoxane|dexrazoxane|dexrazoxane|dexrazoxane	Chemical	0:54:56:85:115:146:168:192:217:267:277	1:55:59:86:116:147:169:193:218:268:278	0:2:2:3:3:4:5:5:6:7:8	D001855	myelosuppression|myelosuppression|myelosuppression|myelosuppression	Disease	3:46:170:195	4:47:171:196	0:1:5:5	1:NR:2	L2R	NON-CROSS	48-50	54-55	D064730	Dexrazoxane|Dexrazoxane|ICRF - 187|dexrazoxane|dexrazoxane|dexrazoxane|dexrazoxane|dexrazoxane|dexrazoxane|dexrazoxane|dexrazoxane	Chemical	0:54:56:85:115:146:168:192:217:267:277	1:55:59:86:116:147:169:193:218:268:278	0:2:2:3:3:4:5:5:6:7:8	D066126	cardiac toxicity|cardiotoxicity	Disease	48:68	50:69	1:2	1:NR:2	L2R	NON-CROSS	80-82	85-86	D064730	Dexrazoxane|Dexrazoxane|ICRF - 187|dexrazoxane|dexrazoxane|dexrazoxane|dexrazoxane|dexrazoxane|dexrazoxane|dexrazoxane|dexrazoxane	Chemical	0:54:56:85:115:146:168:192:217:267:277	1:55:59:86:116:147:169:193:218:268:278	0:2:2:3:3:4:5:5:6:7:8	D006402	hematologic toxicity|hematologic toxicity	Disease	80:293	82:295	3:8	1:NR:2	L2R	NON-CROSS	168-169	172-174	D064730	Dexrazoxane|Dexrazoxane|ICRF - 187|dexrazoxane|dexrazoxane|dexrazoxane|dexrazoxane|dexrazoxane|dexrazoxane|dexrazoxane|dexrazoxane	Chemical	0:54:56:85:115:146:168:192:217:267:277	1:55:59:86:116:147:169:193:218:268:278	0:2:2:3:3:4:5:5:6:7:8	D015431	weight loss|weight loss	Disease	172:197	174:199	5:5	1:NR:2	L2R	NON-CROSS	192-193	204-205	D064730	Dexrazoxane|Dexrazoxane|ICRF - 187|dexrazoxane|dexrazoxane|dexrazoxane|dexrazoxane|dexrazoxane|dexrazoxane|dexrazoxane|dexrazoxane	Chemical	0:54:56:85:115:146:168:192:217:267:277	1:55:59:86:116:147:169:193:218:268:278	0:2:2:3:3:4:5:5:6:7:8	D064420	cytotoxicity	Disease	204	205	5	1:NR:2	L2R	NON-CROSS	275-276	277-278	D064730	Dexrazoxane|Dexrazoxane|ICRF - 187|dexrazoxane|dexrazoxane|dexrazoxane|dexrazoxane|dexrazoxane|dexrazoxane|dexrazoxane|dexrazoxane	Chemical	0:54:56:85:115:146:168:192:217:267:277	1:55:59:86:116:147:169:193:218:268:278	0:2:2:3:3:4:5:5:6:7:8	D009362	metastases	Disease	275	276	8	1:NR:2	R2L	NON-CROSS	177-178	170-171	D005047	etoposide|etoposide|etoposide|etoposide|etoposide|etoposide|etoposide	Chemical	11:28:106:136:177:257:282	12:29:107:137:178:258:283	0:1:3:4:5:7:8	D001855	myelosuppression|myelosuppression|myelosuppression|myelosuppression	Disease	3:46:170:195	4:47:171:196	0:1:5:5	1:NR:2	R2L	NON-CROSS	175-176	170-171	D003630	daunorubicin|daunorubicin|daunorubicin|daunorubicin|daunorubicin|daunorubicin	Chemical	13:22:108:138:175:233	14:23:109:139:176:234	0:1:3:4:5:6	D001855	myelosuppression|myelosuppression|myelosuppression|myelosuppression	Disease	3:46:170:195	4:47:171:196	0:1:5:5	1:NR:2	R2L	NON-CROSS	206-207	195-196	D004317	doxorubicin|doxorubicin|doxorubicin|doxorubicin|doxorubicin|doxorubicin	Chemical	16:24:111:141:206:226	17:25:112:142:207:227	0:1:3:4:5:6	D001855	myelosuppression|myelosuppression|myelosuppression|myelosuppression	Disease	3:46:170:195	4:47:171:196	0:1:5:5	1:NR:2	R2L	NON-CROSS	21-22	3-4	D018943	anthracyclines|anthracycline	Chemical	21:65	22:66	1:2	D001855	myelosuppression|myelosuppression|myelosuppression|myelosuppression	Disease	3:46:170:195	4:47:171:196	0:1:5:5	1:NR:2	R2L	NON-CROSS	46-47	27-28	D011034	epipodophyllotoxin	Chemical	27	28	1	D001855	myelosuppression|myelosuppression|myelosuppression|myelosuppression	Disease	3:46:170:195	4:47:171:196	0:1:5:5	1:NR:2	L2R	NON-CROSS	28-29	48-50	D005047	etoposide|etoposide|etoposide|etoposide|etoposide|etoposide|etoposide	Chemical	11:28:106:136:177:257:282	12:29:107:137:178:258:283	0:1:3:4:5:7:8	D066126	cardiac toxicity|cardiotoxicity	Disease	48:68	50:69	1:2	1:CID:2	L2R	NON-CROSS	282-283	293-295	D005047	etoposide|etoposide|etoposide|etoposide|etoposide|etoposide|etoposide	Chemical	11:28:106:136:177:257:282	12:29:107:137:178:258:283	0:1:3:4:5:7:8	D006402	hematologic toxicity|hematologic toxicity	Disease	80:293	82:295	3:8	1:CID:2	L2R	NON-CROSS	172-174	177-178	D005047	etoposide|etoposide|etoposide|etoposide|etoposide|etoposide|etoposide	Chemical	11:28:106:136:177:257:282	12:29:107:137:178:258:283	0:1:3:4:5:7:8	D015431	weight loss|weight loss	Disease	172:197	174:199	5:5	1:NR:2	L2R	NON-CROSS	177-178	204-205	D005047	etoposide|etoposide|etoposide|etoposide|etoposide|etoposide|etoposide	Chemical	11:28:106:136:177:257:282	12:29:107:137:178:258:283	0:1:3:4:5:7:8	D064420	cytotoxicity	Disease	204	205	5	1:NR:2	L2R	NON-CROSS	275-276	282-283	D005047	etoposide|etoposide|etoposide|etoposide|etoposide|etoposide|etoposide	Chemical	11:28:106:136:177:257:282	12:29:107:137:178:258:283	0:1:3:4:5:7:8	D009362	metastases	Disease	275	276	8	1:NR:2	L2R	NON-CROSS	22-23	48-50	D003630	daunorubicin|daunorubicin|daunorubicin|daunorubicin|daunorubicin|daunorubicin	Chemical	13:22:108:138:175:233	14:23:109:139:176:234	0:1:3:4:5:6	D066126	cardiac toxicity|cardiotoxicity	Disease	48:68	50:69	1:2	1:CID:2	L2R	NON-CROSS	80-82	108-109	D003630	daunorubicin|daunorubicin|daunorubicin|daunorubicin|daunorubicin|daunorubicin	Chemical	13:22:108:138:175:233	14:23:109:139:176:234	0:1:3:4:5:6	D006402	hematologic toxicity|hematologic toxicity	Disease	80:293	82:295	3:8	1:CID:2	L2R	NON-CROSS	172-174	175-176	D003630	daunorubicin|daunorubicin|daunorubicin|daunorubicin|daunorubicin|daunorubicin	Chemical	13:22:108:138:175:233	14:23:109:139:176:234	0:1:3:4:5:6	D015431	weight loss|weight loss	Disease	172:197	174:199	5:5	1:NR:2	L2R	NON-CROSS	175-176	204-205	D003630	daunorubicin|daunorubicin|daunorubicin|daunorubicin|daunorubicin|daunorubicin	Chemical	13:22:108:138:175:233	14:23:109:139:176:234	0:1:3:4:5:6	D064420	cytotoxicity	Disease	204	205	5	1:NR:2	L2R	CROSS	233-234	275-276	D003630	daunorubicin|daunorubicin|daunorubicin|daunorubicin|daunorubicin|daunorubicin	Chemical	13:22:108:138:175:233	14:23:109:139:176:234	0:1:3:4:5:6	D009362	metastases	Disease	275	276	8	1:NR:2	L2R	NON-CROSS	24-25	48-50	D004317	doxorubicin|doxorubicin|doxorubicin|doxorubicin|doxorubicin|doxorubicin	Chemical	16:24:111:141:206:226	17:25:112:142:207:227	0:1:3:4:5:6	D066126	cardiac toxicity|cardiotoxicity	Disease	48:68	50:69	1:2	1:CID:2	L2R	NON-CROSS	80-82	111-112	D004317	doxorubicin|doxorubicin|doxorubicin|doxorubicin|doxorubicin|doxorubicin	Chemical	16:24:111:141:206:226	17:25:112:142:207:227	0:1:3:4:5:6	D006402	hematologic toxicity|hematologic toxicity	Disease	80:293	82:295	3:8	1:CID:2	L2R	NON-CROSS	197-199	206-207	D004317	doxorubicin|doxorubicin|doxorubicin|doxorubicin|doxorubicin|doxorubicin	Chemical	16:24:111:141:206:226	17:25:112:142:207:227	0:1:3:4:5:6	D015431	weight loss|weight loss	Disease	172:197	174:199	5:5	1:NR:2	L2R	NON-CROSS	204-205	206-207	D004317	doxorubicin|doxorubicin|doxorubicin|doxorubicin|doxorubicin|doxorubicin	Chemical	16:24:111:141:206:226	17:25:112:142:207:227	0:1:3:4:5:6	D064420	cytotoxicity	Disease	204	205	5	1:NR:2	L2R	CROSS	226-227	275-276	D004317	doxorubicin|doxorubicin|doxorubicin|doxorubicin|doxorubicin|doxorubicin	Chemical	16:24:111:141:206:226	17:25:112:142:207:227	0:1:3:4:5:6	D009362	metastases	Disease	275	276	8	1:NR:2	L2R	NON-CROSS	65-66	68-69	D018943	anthracyclines|anthracycline	Chemical	21:65	22:66	1:2	D066126	cardiac toxicity|cardiotoxicity	Disease	48:68	50:69	1:2	1:NR:2	L2R	CROSS	65-66	80-82	D018943	anthracyclines|anthracycline	Chemical	21:65	22:66	1:2	D006402	hematologic toxicity|hematologic toxicity	Disease	80:293	82:295	3:8	1:NR:2	L2R	CROSS	65-66	172-174	D018943	anthracyclines|anthracycline	Chemical	21:65	22:66	1:2	D015431	weight loss|weight loss	Disease	172:197	174:199	5:5	1:NR:2	L2R	CROSS	65-66	204-205	D018943	anthracyclines|anthracycline	Chemical	21:65	22:66	1:2	D064420	cytotoxicity	Disease	204	205	5	1:NR:2	L2R	CROSS	65-66	275-276	D018943	anthracyclines|anthracycline	Chemical	21:65	22:66	1:2	D009362	metastases	Disease	275	276	8	1:NR:2	L2R	NON-CROSS	27-28	48-50	D011034	epipodophyllotoxin	Chemical	27	28	1	D066126	cardiac toxicity|cardiotoxicity	Disease	48:68	50:69	1:2	1:NR:2	L2R	CROSS	27-28	80-82	D011034	epipodophyllotoxin	Chemical	27	28	1	D006402	hematologic toxicity|hematologic toxicity	Disease	80:293	82:295	3:8	1:NR:2	L2R	CROSS	27-28	172-174	D011034	epipodophyllotoxin	Chemical	27	28	1	D015431	weight loss|weight loss	Disease	172:197	174:199	5:5	1:NR:2	L2R	CROSS	27-28	204-205	D011034	epipodophyllotoxin	Chemical	27	28	1	D064420	cytotoxicity	Disease	204	205	5	1:NR:2	L2R	CROSS	27-28	275-276	D011034	epipodophyllotoxin	Chemical	27	28	1	D009362	metastases	Disease	275	276	8
6817363	Effects of the novel compound aniracetam ( Ro 13 - 5057 ) upon impaired learning and memory in rodents .|The effect of aniracetam ( Ro 13 - 5057 , 1 - anisoyl - 2 - pyrrolidinone ) was studied on various forms of experimentally impaired cognitive functions ( learning and memory ) in rodents and produced the following effects : ( 1 ) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session ; ( 2 ) partial ( rats ) or complete ( mice ) prevention of the scopolamine - induced short - term amnesia for a passive avoidance task ; ( 3 ) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition ; ( 4 ) prevention of the long - term retention - or retrieval - deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition ; ( 5 ) reversal , when administered as late as 1 h before the retention test , of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously ; ( 6 ) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing ( 24 h after acquisition ) .|These improvements or normalizations of impaired cognitive functions were seen at oral aniracetam doses of 10 - 100 mg / kg .|Generally , the dose - response curves were bell - shaped .|The mechanisms underlying the activity of aniracetam and its ' therapeutic window ' are unknown .|Piracetam , another pyrrolidinone derivative was used for comparison .|It was active only in six of nine tests and had about one - tenth the potency of aniracetam .|The results indicate that aniracetam improves cognitive functions which are impaired by different procedure and in different phases of the learning and memory process .	1:NR:2	L2R	NON-CROSS	7-11	13-17	C036466	aniracetam|Ro 13 - 5057|aniracetam|Ro 13 - 5057|1 - anisoyl - 2 - pyrrolidinone|aniracetam|aniracetam|aniracetam|aniracetam	Chemical	5:7:23:25:30:257:285:323:329	6:11:24:29:37:258:286:324:330	0:0:1:1:1:2:4:6:7	D007859	impaired learning and memory	Disease	13	17	0	1:NR:2	L2R	NON-CROSS	7-11	13-17	C036466	aniracetam|Ro 13 - 5057|aniracetam|Ro 13 - 5057|1 - anisoyl - 2 - pyrrolidinone|aniracetam|aniracetam|aniracetam|aniracetam	Chemical	5:7:23:25:30:257:285:323:329	6:11:24:29:37:258:286:324:330	0:0:1:1:1:2:4:6:7	D008569	impaired learning and memory	Disease	13	17	0	1:NR:2	L2R	NON-CROSS	250-253	257-258	C036466	aniracetam|Ro 13 - 5057|aniracetam|Ro 13 - 5057|1 - anisoyl - 2 - pyrrolidinone|aniracetam|aniracetam|aniracetam|aniracetam	Chemical	5:7:23:25:30:257:285:323:329	6:11:24:29:37:258:286:324:330	0:0:1:1:1:2:4:6:7	D003072	impaired cognitive functions|impaired cognitive functions	Disease	45:250	48:253	1:2	1:NR:2	L2R	NON-CROSS	232-233	257-258	C036466	aniracetam|Ro 13 - 5057|aniracetam|Ro 13 - 5057|1 - anisoyl - 2 - pyrrolidinone|aniracetam|aniracetam|aniracetam|aniracetam	Chemical	5:7:23:25:30:257:285:323:329	6:11:24:29:37:258:286:324:330	0:0:1:1:1:2:4:6:7	D006935	hypercapnia|hypercapnia	Disease	81:232	82:233	1:1	1:NR:2	L2R	NON-CROSS	30-37	109-110	C036466	aniracetam|Ro 13 - 5057|aniracetam|Ro 13 - 5057|1 - anisoyl - 2 - pyrrolidinone|aniracetam|aniracetam|aniracetam|aniracetam	Chemical	5:7:23:25:30:257:285:323:329	6:11:24:29:37:258:286:324:330	0:0:1:1:1:2:4:6:7	D000647	amnesia|amnesia	Disease	109:122	110:123	1:1	1:NR:2	R2L	CROSS	103-104	13-17	D012601	scopolamine	Chemical	103	104	1	D007859	impaired learning and memory	Disease	13	17	0	1:NR:2	R2L	CROSS	165-166	13-17	D002701	chloramphenicol	Chemical	165	166	1	D007859	impaired learning and memory	Disease	13	17	0	1:NR:2	R2L	CROSS	167-168	13-17	D003513	cycloheximide|cycloheximide	Chemical	167:204	168:205	1:1	D007859	impaired learning and memory	Disease	13	17	0	1:NR:2	R2L	CROSS	295-296	13-17	D010889	Piracetam	Chemical	295	296	5	D007859	impaired learning and memory	Disease	13	17	0	1:NR:2	R2L	CROSS	298-299	13-17	D011760	pyrrolidinone	Chemical	298	299	5	D007859	impaired learning and memory	Disease	13	17	0	1:NR:2	R2L	CROSS	103-104	13-17	D012601	scopolamine	Chemical	103	104	1	D008569	impaired learning and memory	Disease	13	17	0	1:CID:2	R2L	CROSS	165-166	13-17	D002701	chloramphenicol	Chemical	165	166	1	D008569	impaired learning and memory	Disease	13	17	0	1:CID:2	R2L	CROSS	167-168	13-17	D003513	cycloheximide|cycloheximide	Chemical	167:204	168:205	1:1	D008569	impaired learning and memory	Disease	13	17	0	1:NR:2	R2L	CROSS	295-296	13-17	D010889	Piracetam	Chemical	295	296	5	D008569	impaired learning and memory	Disease	13	17	0	1:NR:2	R2L	CROSS	298-299	13-17	D011760	pyrrolidinone	Chemical	298	299	5	D008569	impaired learning and memory	Disease	13	17	0	1:NR:2	R2L	NON-CROSS	103-104	45-48	D012601	scopolamine	Chemical	103	104	1	D003072	impaired cognitive functions|impaired cognitive functions	Disease	45:250	48:253	1:2	1:NR:2	R2L	NON-CROSS	250-253	165-166	D002701	chloramphenicol	Chemical	165	166	1	D003072	impaired cognitive functions|impaired cognitive functions	Disease	45:250	48:253	1:2	1:NR:2	R2L	NON-CROSS	250-253	204-205	D003513	cycloheximide|cycloheximide	Chemical	167:204	168:205	1:1	D003072	impaired cognitive functions|impaired cognitive functions	Disease	45:250	48:253	1:2	1:NR:2	R2L	CROSS	295-296	250-253	D010889	Piracetam	Chemical	295	296	5	D003072	impaired cognitive functions|impaired cognitive functions	Disease	45:250	48:253	1:2	1:NR:2	R2L	CROSS	298-299	250-253	D011760	pyrrolidinone	Chemical	298	299	5	D003072	impaired cognitive functions|impaired cognitive functions	Disease	45:250	48:253	1:2	1:NR:2	R2L	NON-CROSS	103-104	81-82	D012601	scopolamine	Chemical	103	104	1	D006935	hypercapnia|hypercapnia	Disease	81:232	82:233	1:1	1:NR:2	R2L	NON-CROSS	232-233	165-166	D002701	chloramphenicol	Chemical	165	166	1	D006935	hypercapnia|hypercapnia	Disease	81:232	82:233	1:1	1:NR:2	R2L	NON-CROSS	232-233	204-205	D003513	cycloheximide|cycloheximide	Chemical	167:204	168:205	1:1	D006935	hypercapnia|hypercapnia	Disease	81:232	82:233	1:1	1:NR:2	R2L	CROSS	295-296	232-233	D010889	Piracetam	Chemical	295	296	5	D006935	hypercapnia|hypercapnia	Disease	81:232	82:233	1:1	1:NR:2	R2L	CROSS	298-299	232-233	D011760	pyrrolidinone	Chemical	298	299	5	D006935	hypercapnia|hypercapnia	Disease	81:232	82:233	1:1	1:CID:2	L2R	NON-CROSS	103-104	109-110	D012601	scopolamine	Chemical	103	104	1	D000647	amnesia|amnesia	Disease	109:122	110:123	1:1	1:NR:2	R2L	NON-CROSS	165-166	122-123	D002701	chloramphenicol	Chemical	165	166	1	D000647	amnesia|amnesia	Disease	109:122	110:123	1:1	1:NR:2	R2L	NON-CROSS	167-168	122-123	D003513	cycloheximide|cycloheximide	Chemical	167:204	168:205	1:1	D000647	amnesia|amnesia	Disease	109:122	110:123	1:1	1:NR:2	R2L	CROSS	295-296	122-123	D010889	Piracetam	Chemical	295	296	5	D000647	amnesia|amnesia	Disease	109:122	110:123	1:1	1:NR:2	R2L	CROSS	298-299	122-123	D011760	pyrrolidinone	Chemical	298	299	5	D000647	amnesia|amnesia	Disease	109:122	110:123	1:1
11900788	Nicotine potentiation of morphine - induced catalepsy in mice .|In the present study , effects of nicotine on catalepsy induced by morphine in mice have been investigated .|Morphine but not nicotine induced a dose - dependent catalepsy .|The response of morphine was potentiated by nicotine .|Intraperitoneal administration of atropine , naloxone , mecamylamine , and hexamethonium to mice reduced catalepsy induced by a combination of morphine with nicotine .|Intracerebroventricular injection of atropine , hexamethonium , and naloxone also decreased catalepsy induced by morphine plus nicotine .|Intraperitoneal administration of atropine , but not intraperitoneal or intracerebroventricular injection of hexamethonium , decreased the effect of a single dose of morphine .|It was concluded that morphine catalepsy can be elicited by opioid and cholinergic receptors , and the potentiation of morphine induced by nicotine may also be mediated through cholinergic receptor mechanisms .	1:CID:2	L2R	NON-CROSS	17-18	19-20	D009538	Nicotine|nicotine|nicotine|nicotine|nicotine|nicotine|nicotine	Chemical	0:17:32:47:71:89:137	1:18:33:48:72:90:138	0:1:2:3:4:5:7	D002375	catalepsy|catalepsy|catalepsy|catalepsy|catalepsy|catalepsy	Disease	6:19:38:63:84:120	7:20:39:64:85:121	0:1:2:4:5:7	1:CID:2	L2R	NON-CROSS	119-120	120-121	D009020	morphine|morphine|Morphine|morphine|morphine|morphine|morphine|morphine|morphine	Chemical	3:22:29:43:69:87:113:119:134	4:23:30:44:70:88:114:120:135	0:1:2:3:4:5:6:7:7	D002375	catalepsy|catalepsy|catalepsy|catalepsy|catalepsy|catalepsy	Disease	6:19:38:63:84:120	7:20:39:64:85:121	0:1:2:4:5:7	1:NR:2	R2L	NON-CROSS	84-85	76-77	D001285	atropine|atropine|atropine	Chemical	52:76:94	53:77:95	4:5:6	D002375	catalepsy|catalepsy|catalepsy|catalepsy|catalepsy|catalepsy	Disease	6:19:38:63:84:120	7:20:39:64:85:121	0:1:2:4:5:7	1:NR:2	R2L	NON-CROSS	84-85	81-82	D009270	naloxone|naloxone	Chemical	54:81	55:82	4:5	D002375	catalepsy|catalepsy|catalepsy|catalepsy|catalepsy|catalepsy	Disease	6:19:38:63:84:120	7:20:39:64:85:121	0:1:2:4:5:7	1:NR:2	R2L	NON-CROSS	63-64	56-57	D008464	mecamylamine	Chemical	56	57	4	D002375	catalepsy|catalepsy|catalepsy|catalepsy|catalepsy|catalepsy	Disease	6:19:38:63:84:120	7:20:39:64:85:121	0:1:2:4:5:7	1:NR:2	R2L	NON-CROSS	63-64	59-60	D018738	hexamethonium|hexamethonium|hexamethonium	Chemical	59:78:103	60:79:104	4:5:6	D002375	catalepsy|catalepsy|catalepsy|catalepsy|catalepsy|catalepsy	Disease	6:19:38:63:84:120	7:20:39:64:85:121	0:1:2:4:5:7
11230490	Reduced cardiotoxicity and preserved antitumor efficacy of liposome - encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized , multicenter trial of metastatic breast cancer .|PURPOSE : To determine whether Myocet ( liposome - encapsulated doxorubicin ; The Liposome Company , Elan Corporation , Princeton , NJ ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first - line treatment of metastatic breast cancer ( MBC ) .|PATIENTS AND METHODS : Two hundred ninety - seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg / m ( 2 ) of Myocet ( M ) or conventional doxorubicin ( A ) , in combination with 600 mg / m ( 2 ) of cyclophosphamide ( C ) , every 3 weeks until disease progression or unacceptable toxicity .|Cardiotoxicity was defined by reductions in left - ventricular ejection fraction , assessed by serial multigated radionuclide angiography scans , or congestive heart failure ( CHF ) .|Antitumor efficacy was assessed by objective tumor response rates ( World Health Organization criteria ) , time to progression , and survival .|RESULTS : Six percent of MC patients versus 21 % ( including five cases of CHF ) of AC patients developed cardiotoxicity ( P = . 0002 ) .|Median cumulative doxorubicin dose at onset was more than 2 , 220 mg / m ( 2 ) for MC versus 480 mg / m ( 2 ) for AC ( P = . 0001 , hazard ratio , 5 . 04 ) .|MC patients also experienced less grade 4 neutropenia .|Antitumor efficacy of MC versus AC was comparable : objective response rates , 43 % versus 43 % ; median time to progression , 5 . 1 % versus 5 . 5 months ; median time to treatment failure , 4 . 6 versus 4 . 4 months ; and median survival , 19 versus 16 months .|CONCLUSION : Myocet improves the therapeutic index of doxorubicin by significantly reducing cardiotoxicity and grade 4 neutropenia and provides comparable antitumor efficacy , when used in combination with cyclophosphamide as first - line therapy for MBC .	1:NR:2	R2L	NON-CROSS	60-61	59-60	D004317	doxorubicin|doxorubicin|Myocet|doxorubicin|doxorubicin|Myocet|doxorubicin|doxorubicin|Myocet|doxorubicin	Chemical	10:16:35:40:59:111:117:230:341:347	11:17:36:41:60:112:118:231:342:348	0:0:1:1:1:2:2:6:9:9	D066126	cardiotoxicity|cardiotoxicity|Cardiotoxicity|cardiotoxicity|cardiotoxicity	Disease	1:60:148:220:351	2:61:149:221:352	0:1:3:5:9	1:NR:2	R2L	NON-CROSS	60-61	56-57	D003520	cyclophosphamide|cyclophosphamide|cyclophosphamide|cyclophosphamide|cyclophosphamide	Chemical	12:18:56:133:367	13:19:57:134:368	0:0:1:2:9	D066126	cardiotoxicity|cardiotoxicity|Cardiotoxicity|cardiotoxicity|cardiotoxicity	Disease	1:60:148:220:351	2:61:149:221:352	0:1:3:5:9	1:NR:2	L2R	NON-CROSS	27-29	35-36	D004317	doxorubicin|doxorubicin|Myocet|doxorubicin|doxorubicin|Myocet|doxorubicin|doxorubicin|Myocet|doxorubicin	Chemical	10:16:35:40:59:111:117:230:341:347	11:17:36:41:60:112:118:231:342:348	0:0:1:1:1:2:2:6:9:9	D001943	breast cancer|breast cancer|MBC|MBC|MBC	Disease	27:73:76:90:374	29:75:77:91:375	0:1:1:2:9	1:NR:2	L2R	NON-CROSS	117-118	146-147	D004317	doxorubicin|doxorubicin|Myocet|doxorubicin|doxorubicin|Myocet|doxorubicin|doxorubicin|Myocet|doxorubicin	Chemical	10:16:35:40:59:111:117:230:341:347	11:17:36:41:60:112:118:231:342:348	0:0:1:1:1:2:2:6:9:9	D064420	toxicity	Disease	146	147	2	1:CID:2	L2R	CROSS	214-215	230-231	D004317	doxorubicin|doxorubicin|Myocet|doxorubicin|doxorubicin|Myocet|doxorubicin|doxorubicin|Myocet|doxorubicin	Chemical	10:16:35:40:59:111:117:230:341:347	11:17:36:41:60:112:118:231:342:348	0:0:1:1:1:2:2:6:9:9	D006333	congestive heart failure|CHF|CHF	Disease	169:173:214	172:174:215	3:3:5	1:NR:2	L2R	CROSS	182-183	230-231	D004317	doxorubicin|doxorubicin|Myocet|doxorubicin|doxorubicin|Myocet|doxorubicin|doxorubicin|Myocet|doxorubicin	Chemical	10:16:35:40:59:111:117:230:341:347	11:17:36:41:60:112:118:231:342:348	0:0:1:1:1:2:2:6:9:9	D009369	tumor	Disease	182	183	4	1:CID:2	L2R	NON-CROSS	347-348	355-356	D004317	doxorubicin|doxorubicin|Myocet|doxorubicin|doxorubicin|Myocet|doxorubicin|doxorubicin|Myocet|doxorubicin	Chemical	10:16:35:40:59:111:117:230:341:347	11:17:36:41:60:112:118:231:342:348	0:0:1:1:1:2:2:6:9:9	D009503	neutropenia|neutropenia	Disease	279:355	280:356	7:9	1:NR:2	L2R	NON-CROSS	367-368	374-375	D003520	cyclophosphamide|cyclophosphamide|cyclophosphamide|cyclophosphamide|cyclophosphamide	Chemical	12:18:56:133:367	13:19:57:134:368	0:0:1:2:9	D001943	breast cancer|breast cancer|MBC|MBC|MBC	Disease	27:73:76:90:374	29:75:77:91:375	0:1:1:2:9	1:NR:2	L2R	NON-CROSS	133-134	146-147	D003520	cyclophosphamide|cyclophosphamide|cyclophosphamide|cyclophosphamide|cyclophosphamide	Chemical	12:18:56:133:367	13:19:57:134:368	0:0:1:2:9	D064420	toxicity	Disease	146	147	2	1:CID:2	L2R	CROSS	133-134	169-172	D003520	cyclophosphamide|cyclophosphamide|cyclophosphamide|cyclophosphamide|cyclophosphamide	Chemical	12:18:56:133:367	13:19:57:134:368	0:0:1:2:9	D006333	congestive heart failure|CHF|CHF	Disease	169:173:214	172:174:215	3:3:5	1:NR:2	L2R	CROSS	133-134	182-183	D003520	cyclophosphamide|cyclophosphamide|cyclophosphamide|cyclophosphamide|cyclophosphamide	Chemical	12:18:56:133:367	13:19:57:134:368	0:0:1:2:9	D009369	tumor	Disease	182	183	4	1:CID:2	L2R	NON-CROSS	355-356	367-368	D003520	cyclophosphamide|cyclophosphamide|cyclophosphamide|cyclophosphamide|cyclophosphamide	Chemical	12:18:56:133:367	13:19:57:134:368	0:0:1:2:9	D009503	neutropenia|neutropenia	Disease	279:355	280:356	7:9
2594614	Protective effect of a specific platelet - activating factor antagonist , BN 52021 , on bupivacaine - induced cardiovascular impairments in rats .|Administration of the local anaesthetic bupivacaine ( 1 . 5 or 2 mg / kg , i . v . ) to rats elicited a marked decrease of mean arterial blood pressure ( MBP ) and heart rate ( HR ) leading to death ( in 67 % or 90 % of animals respectively ) .|Intravenous injection of the specific platelet - activating factor ( PAF ) antagonist BN 52021 ( 10 mg / kg ) , 30 min before bupivacaine administration ( 2 mg / kg i . v . ) suppressed both the decrease of MBP and HR .|In contrast , doses of 1 mg / kg BN 52021 given 30 min before or 10 mg / kg administered 5 min before i . v .|injection of bupivacaine were ineffective .|When BN 52021 ( 20 mg / kg i . v . ) was injected immediately after bupivacaine ( 2 mg / kg ) , a partial reversion of the decrease of MBP and HR was observed , whereas the dose of 10 mg / kg was ineffective .|A partial recovery of bupivacaine - induced ECG alterations was observed after pretreatment of the rats with BN 52021 .|Since the administration of BN 52021 , at all doses studied , did not alter MBP and HR at the doses used , the bulk of these results clearly demonstrate a protective action of BN 52021 , a specific antagonist of PAF , against bupivacaine - induced cardiovascular toxicity .|Thus , consistent with its direct effect on heart , PAF appears to be implicated in bupivacaine - induced cardiovascular alterations .	1:NR:2	L2R	NON-CROSS	11-13	18-20	C045856	BN 52021|BN 52021|BN 52021|BN 52021|BN 52021|BN 52021|BN 52021	Chemical	11:92:134:160:225:232:262	13:94:136:162:227:234:264	0:2:3:5:6:7:7	D002318	cardiovascular impairments|cardiovascular toxicity	Disease	18:275	20:277	0:7	1:NR:2	L2R	NON-CROSS	119-124	134-136	C045856	BN 52021|BN 52021|BN 52021|BN 52021|BN 52021|BN 52021|BN 52021	Chemical	11:92:134:160:225:232:262	13:94:136:162:227:234:264	0:2:3:5:6:7:7	D007022	decrease of mean arterial blood pressure ( MBP ) and heart rate ( HR )|decrease of MBP and HR|decrease of MBP and HR	Disease	49:119:189	64:124:194	1:2:5	1:NR:2	L2R	NON-CROSS	119-124	134-136	C045856	BN 52021|BN 52021|BN 52021|BN 52021|BN 52021|BN 52021|BN 52021	Chemical	11:92:134:160:225:232:262	13:94:136:162:227:234:264	0:2:3:5:6:7:7	D001919	decrease of mean arterial blood pressure ( MBP ) and heart rate ( HR )|decrease of MBP and HR|decrease of MBP and HR	Disease	49:119:189	64:124:194	1:2:5	1:NR:2	L2R	CROSS	262-264	297-299	C045856	BN 52021|BN 52021|BN 52021|BN 52021|BN 52021|BN 52021|BN 52021	Chemical	11:92:134:160:225:232:262	13:94:136:162:227:234:264	0:2:3:5:6:7:7	D018376	cardiovascular alterations	Disease	297	299	8	1:NR:2	L2R	NON-CROSS	15-16	18-20	D002045	bupivacaine|bupivacaine|bupivacaine|bupivacaine|bupivacaine|bupivacaine|bupivacaine|bupivacaine	Chemical	15:28:104:155:176:212:272:294	16:29:105:156:177:213:273:295	0:1:2:4:5:6:7:8	D002318	cardiovascular impairments|cardiovascular toxicity	Disease	18:275	20:277	0:7	1:CID:2	L2R	NON-CROSS	176-177	189-194	D002045	bupivacaine|bupivacaine|bupivacaine|bupivacaine|bupivacaine|bupivacaine|bupivacaine|bupivacaine	Chemical	15:28:104:155:176:212:272:294	16:29:105:156:177:213:273:295	0:1:2:4:5:6:7:8	D007022	decrease of mean arterial blood pressure ( MBP ) and heart rate ( HR )|decrease of MBP and HR|decrease of MBP and HR	Disease	49:119:189	64:124:194	1:2:5	1:CID:2	L2R	NON-CROSS	176-177	189-194	D002045	bupivacaine|bupivacaine|bupivacaine|bupivacaine|bupivacaine|bupivacaine|bupivacaine|bupivacaine	Chemical	15:28:104:155:176:212:272:294	16:29:105:156:177:213:273:295	0:1:2:4:5:6:7:8	D001919	decrease of mean arterial blood pressure ( MBP ) and heart rate ( HR )|decrease of MBP and HR|decrease of MBP and HR	Disease	49:119:189	64:124:194	1:2:5	1:NR:2	L2R	NON-CROSS	294-295	297-299	D002045	bupivacaine|bupivacaine|bupivacaine|bupivacaine|bupivacaine|bupivacaine|bupivacaine|bupivacaine	Chemical	15:28:104:155:176:212:272:294	16:29:105:156:177:213:273:295	0:1:2:4:5:6:7:8	D018376	cardiovascular alterations	Disease	297	299	8
2257294	Benzylacyclouridine reverses azidothymidine - induced marrow suppression without impairment of anti - human immunodeficiency virus activity .|Increased extracellular concentrations of uridine ( Urd ) have been reported to reduce , in vitro , azidothymidine ( AZT ) - induced inhibition of human granulocyte - macrophage progenitor cells without impairment of its antihuman immunodeficiency virus ( HIV ) activity .|Because of the clinical toxicities associated with chronic Urd administration , the ability of benzylacyclouridine ( BAU ) to effect , in vivo , AZT - induced anemia and leukopenia was assessed .|This agent inhibits Urd catabolism and , in vivo , increases the plasma concentration of Urd in a dose - dependent manner , without Urd - related toxicity .|In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water ( 1 . 5 mg / mL ) , the continued administration of AZT plus daily BAU ( 300 mg / kg , orally ) partially reversed AZT - induced anemia and leukopenia ( P less than . 05 ) , increased peripheral reticulocytes ( to 4 . 9 % , P less than . 01 ) , increased cellularity in the marrow , and improved megaloblastosis .|When coadministered with AZT from the onset of drug administration , BAU reduced AZT - induced marrow toxicity .|In vitro , at a concentration of 100 mumol / L , BAU possesses minimal anti - HIV activity and has no effect on the ability of AZT to reverse the HIV - induced cytopathic effect in MT4 cells .|The clinical and biochemical implications of these findings are discussed .	1:NR:2	L2R	NON-CROSS	0-1	5-7	C034753	Benzylacyclouridine|benzylacyclouridine|BAU|BAU|BAU|BAU	Chemical	0:74:76:155:218:238	1:75:77:156:219:239	0:2:2:4:5:6	D001855	marrow suppression|marrow toxicity	Disease	5:223	7:225	0:5	1:NR:2	L2R	NON-CROSS	0-1	13-14	C034753	Benzylacyclouridine|benzylacyclouridine|BAU|BAU|BAU|BAU	Chemical	0:74:76:155:218:238	1:75:77:156:219:239	0:2:2:4:5:6	D007153	immunodeficiency|immunodeficiency	Disease	13:53	14:54	0:1	1:NR:2	L2R	NON-CROSS	64-65	74-75	C034753	Benzylacyclouridine|benzylacyclouridine|BAU|BAU|BAU|BAU	Chemical	0:74:76:155:218:238	1:75:77:156:219:239	0:2:2:4:5:6	D064420	toxicities|toxicity	Disease	64:120	65:121	2:3	1:NR:2	L2R	NON-CROSS	76-77	87-88	C034753	Benzylacyclouridine|benzylacyclouridine|BAU|BAU|BAU|BAU	Chemical	0:74:76:155:218:238	1:75:77:156:219:239	0:2:2:4:5:6	D000740	anemia|anemic|anemia	Disease	87:125:169	88:126:170	2:4:4	1:NR:2	L2R	NON-CROSS	76-77	89-90	C034753	Benzylacyclouridine|benzylacyclouridine|BAU|BAU|BAU|BAU	Chemical	0:74:76:155:218:238	1:75:77:156:219:239	0:2:2:4:5:6	D007970	leukopenia|leukopenic|leukopenia	Disease	89:127:171	90:128:172	2:4:4	1:CID:2	L2R	NON-CROSS	2-3	5-7	D015215	azidothymidine|azidothymidine|AZT|AZT|AZT|AZT|AZT|AZT|AZT|AZT	Chemical	2:34:36:84:132:152:166:210:220:253	3:35:37:85:133:153:167:211:221:254	0:1:1:2:4:4:4:5:5:6	D001855	marrow suppression|marrow toxicity	Disease	5:223	7:225	0:5	1:NR:2	L2R	NON-CROSS	2-3	13-14	D015215	azidothymidine|azidothymidine|AZT|AZT|AZT|AZT|AZT|AZT|AZT|AZT	Chemical	2:34:36:84:132:152:166:210:220:253	3:35:37:85:133:153:167:211:221:254	0:1:1:2:4:4:4:5:5:6	D007153	immunodeficiency|immunodeficiency	Disease	13:53	14:54	0:1	1:NR:2	L2R	NON-CROSS	120-121	132-133	D015215	azidothymidine|azidothymidine|AZT|AZT|AZT|AZT|AZT|AZT|AZT|AZT	Chemical	2:34:36:84:132:152:166:210:220:253	3:35:37:85:133:153:167:211:221:254	0:1:1:2:4:4:4:5:5:6	D064420	toxicities|toxicity	Disease	64:120	65:121	2:3	1:CID:2	L2R	NON-CROSS	84-85	87-88	D015215	azidothymidine|azidothymidine|AZT|AZT|AZT|AZT|AZT|AZT|AZT|AZT	Chemical	2:34:36:84:132:152:166:210:220:253	3:35:37:85:133:153:167:211:221:254	0:1:1:2:4:4:4:5:5:6	D000740	anemia|anemic|anemia	Disease	87:125:169	88:126:170	2:4:4	1:CID:2	L2R	NON-CROSS	84-85	89-90	D015215	azidothymidine|azidothymidine|AZT|AZT|AZT|AZT|AZT|AZT|AZT|AZT	Chemical	2:34:36:84:132:152:166:210:220:253	3:35:37:85:133:153:167:211:221:254	0:1:1:2:4:4:4:5:5:6	D007970	leukopenia|leukopenic|leukopenia	Disease	89:127:171	90:128:172	2:4:4	1:NR:2	R2L	CROSS	21-22	5-7	D014529	uridine|Urd|Urd|Urd|Urd|Urd	Chemical	21:23:68:96:108:117	22:24:69:97:109:118	1:1:2:3:3:3	D001855	marrow suppression|marrow toxicity	Disease	5:223	7:225	0:5	1:NR:2	R2L	NON-CROSS	21-22	13-14	D014529	uridine|Urd|Urd|Urd|Urd|Urd	Chemical	21:23:68:96:108:117	22:24:69:97:109:118	1:1:2:3:3:3	D007153	immunodeficiency|immunodeficiency	Disease	13:53	14:54	0:1	1:NR:2	L2R	NON-CROSS	117-118	120-121	D014529	uridine|Urd|Urd|Urd|Urd|Urd	Chemical	21:23:68:96:108:117	22:24:69:97:109:118	1:1:2:3:3:3	D064420	toxicities|toxicity	Disease	64:120	65:121	2:3	1:NR:2	L2R	NON-CROSS	117-118	125-126	D014529	uridine|Urd|Urd|Urd|Urd|Urd	Chemical	21:23:68:96:108:117	22:24:69:97:109:118	1:1:2:3:3:3	D000740	anemia|anemic|anemia	Disease	87:125:169	88:126:170	2:4:4	1:NR:2	L2R	NON-CROSS	89-90	96-97	D014529	uridine|Urd|Urd|Urd|Urd|Urd	Chemical	21:23:68:96:108:117	22:24:69:97:109:118	1:1:2:3:3:3	D007970	leukopenia|leukopenic|leukopenia	Disease	89:127:171	90:128:172	2:4:4
10840460	Cyclophosphamide - induced cystitis in freely - moving conscious rats : behavioral approach to a new model of visceral pain .|PURPOSE : To develop a model of visceral pain in rats using a behavioral approach .|Cyclophosphamide ( CP ) , an antitumoral agent known to produce toxic effects on the bladder wall through its main toxic metabolite acrolein , was used to induce cystitis .|MATERIALS AND METHODS : CP was administered at doses of 50 , 100 and 200 mg . / kg .|i . p .|to male rats , and their behavior observed and scored .|The effects of morphine ( 0 . 5 to 4 mg . / kg .|i . v . ) on CP - induced behavioral modifications were tested administered alone and after naloxone ( 1 mg . / kg .|s . c . ) .|In addition , 90 minutes after CP injection , that is , at the time of administration of morphine , the bladder was removed in some rats for histological examination .|Finally , to show that the bladder is essential for the CP - induced behavioral modifications , female rats also received CP at doses of 200 mg . / kg .|i . p .|and of 20 mg .|by the intravesical route , and acrolein at doses of 0 . 5 mg .|by the intravesical route and of 5 mg . / kg .|i . v .|RESULTS : CP dose - relatedly induced marked behavioral modifications in male rats : breathing rate decrease , closing of the eyes and occurrence of specific postures .|Morphine dose - dependently reversed these behavioral disorders .|A dose of 0 . 5 mg . / kg .|produced a reduction of almost 50 % of the behavioral score induced by CP 200 mg . / kg .|This effect was completely prevented by pretreatment with naloxone .|At the time of administration of morphine , histological modifications of the bladder wall , such as chorionic and muscle layer edema , were observed .|In female rats , CP 200 mg . / kg .|i . p .|produced the same marked behavioral modifications as those observed in male rats .|Administered at the dose of 20 mg .|intravesically , CP did not produce any behavioral effects , whereas acrolein at 0 . 5 mg .|intravesically induced behavioral modifications identical to those under CP 200 mg . / kg .|i . p . , with the same maximal levels .|Conversely , acrolein 5 mg . / kg .|i . v .|did not produce any behavioral effects at all .|CONCLUSIONS : Overall , these results indicate that this experimental model of CP - induced cystitis may be an interesting new behavioral model of inflammatory visceral pain , allowing a better understanding of these painful syndromes and thus a better therapeutic approach to them .	1:CID:2	L2R	NON-CROSS	0-1	3-4	D003520	Cyclophosphamide|Cyclophosphamide|CP|CP|CP|CP|CP|CP|CP|CP|CP|CP|CP|CP	Chemical	0:37:39:71:123:154:190:200:252:311:358:392:416:468	1:38:40:72:124:155:191:201:253:312:359:393:417:469	0:2:2:3:7:9:10:10:16:19:22:26:27:32	D003556	cystitis|cystitis|cystitis	Disease	3:65:471	4:66:472	0:2:32	1:NR:2	L2R	NON-CROSS	28-30	37-38	D003520	Cyclophosphamide|Cyclophosphamide|CP|CP|CP|CP|CP|CP|CP|CP|CP|CP|CP|CP	Chemical	0:37:39:71:123:154:190:200:252:311:358:392:416:468	1:38:40:72:124:155:191:201:253:312:359:393:417:469	0:2:2:3:7:9:10:10:16:19:22:26:27:32	D059265	visceral pain|visceral pain|visceral pain	Disease	18:28:481	20:30:483	0:1:32	1:NR:2	L2R	CROSS	284-286	311-312	D003520	Cyclophosphamide|Cyclophosphamide|CP|CP|CP|CP|CP|CP|CP|CP|CP|CP|CP|CP	Chemical	0:37:39:71:123:154:190:200:252:311:358:392:416:468	1:38:40:72:124:155:191:201:253:312:359:393:417:469	0:2:2:3:7:9:10:10:16:19:22:26:27:32	D001523	behavioral disorders	Disease	284	286	17	1:NR:2	L2R	CROSS	349-350	358-359	D003520	Cyclophosphamide|Cyclophosphamide|CP|CP|CP|CP|CP|CP|CP|CP|CP|CP|CP|CP	Chemical	0:37:39:71:123:154:190:200:252:311:358:392:416:468	1:38:40:72:124:155:191:201:253:312:359:393:417:469	0:2:2:3:7:9:10:10:16:19:22:26:27:32	D004487	edema	Disease	349	350	21	1:CID:2	L2R	NON-CROSS	468-469	490-492	D003520	Cyclophosphamide|Cyclophosphamide|CP|CP|CP|CP|CP|CP|CP|CP|CP|CP|CP|CP	Chemical	0:37:39:71:123:154:190:200:252:311:358:392:416:468	1:38:40:72:124:155:191:201:253:312:359:393:417:469	0:2:2:3:7:9:10:10:16:19:22:26:27:32	D010146	painful syndromes	Disease	490	492	32	1:NR:2	R2L	NON-CROSS	65-66	59-60	D000171	acrolein|acrolein|acrolein|acrolein	Chemical	59:225:401:436	60:226:402:437	2:13:26:29	D003556	cystitis|cystitis|cystitis	Disease	3:65:471	4:66:472	0:2:32	1:NR:2	R2L	CROSS	105-106	65-66	D009020	morphine|morphine|Morphine|morphine	Chemical	105:166:278:334	106:167:279:335	6:9:17:21	D003556	cystitis|cystitis|cystitis	Disease	3:65:471	4:66:472	0:2:32	1:NR:2	R2L	CROSS	134-135	65-66	D009270	naloxone|naloxone	Chemical	134:326	135:327	7:20	D003556	cystitis|cystitis|cystitis	Disease	3:65:471	4:66:472	0:2:32	1:NR:2	R2L	CROSS	59-60	28-30	D000171	acrolein|acrolein|acrolein|acrolein	Chemical	59:225:401:436	60:226:402:437	2:13:26:29	D059265	visceral pain|visceral pain|visceral pain	Disease	18:28:481	20:30:483	0:1:32	1:NR:2	R2L	CROSS	105-106	28-30	D009020	morphine|morphine|Morphine|morphine	Chemical	105:166:278:334	106:167:279:335	6:9:17:21	D059265	visceral pain|visceral pain|visceral pain	Disease	18:28:481	20:30:483	0:1:32	1:NR:2	R2L	CROSS	134-135	28-30	D009270	naloxone|naloxone	Chemical	134:326	135:327	7:20	D059265	visceral pain|visceral pain|visceral pain	Disease	18:28:481	20:30:483	0:1:32	1:NR:2	L2R	CROSS	225-226	284-286	D000171	acrolein|acrolein|acrolein|acrolein	Chemical	59:225:401:436	60:226:402:437	2:13:26:29	D001523	behavioral disorders	Disease	284	286	17	1:NR:2	L2R	CROSS	349-350	401-402	D000171	acrolein|acrolein|acrolein|acrolein	Chemical	59:225:401:436	60:226:402:437	2:13:26:29	D004487	edema	Disease	349	350	21	1:CID:2	L2R	CROSS	436-437	490-492	D000171	acrolein|acrolein|acrolein|acrolein	Chemical	59:225:401:436	60:226:402:437	2:13:26:29	D010146	painful syndromes	Disease	490	492	32	1:NR:2	L2R	NON-CROSS	278-279	284-286	D009020	morphine|morphine|Morphine|morphine	Chemical	105:166:278:334	106:167:279:335	6:9:17:21	D001523	behavioral disorders	Disease	284	286	17	1:NR:2	L2R	NON-CROSS	334-335	349-350	D009020	morphine|morphine|Morphine|morphine	Chemical	105:166:278:334	106:167:279:335	6:9:17:21	D004487	edema	Disease	349	350	21	1:NR:2	L2R	CROSS	334-335	490-492	D009020	morphine|morphine|Morphine|morphine	Chemical	105:166:278:334	106:167:279:335	6:9:17:21	D010146	painful syndromes	Disease	490	492	32	1:NR:2	L2R	CROSS	284-286	326-327	D009270	naloxone|naloxone	Chemical	134:326	135:327	7:20	D001523	behavioral disorders	Disease	284	286	17	1:NR:2	L2R	CROSS	326-327	349-350	D009270	naloxone|naloxone	Chemical	134:326	135:327	7:20	D004487	edema	Disease	349	350	21	1:NR:2	L2R	CROSS	326-327	490-492	D009270	naloxone|naloxone	Chemical	134:326	135:327	7:20	D010146	painful syndromes	Disease	490	492	32
8278214	Hyperalgesia and myoclonus in terminal cancer patients treated with continuous intravenous morphine .|Eight cancer patients in the terminal stages of the disease treated with high doses of intravenous morphine developed hyperalgesia .|All cases were retrospectively sampled from three different hospitals in Copenhagen .|Five patients developed universal hyperalgesia and hyperesthesia which in 2 cases were accompanied by myoclonus .|In 3 patients a pre - existing neuralgia increased to excruciating intensity and in 2 of these cases myoclonus occurred simultaneously .|Although only few clinical descriptions of the relationship between hyperalgesia / myoclonus and high doses of morphine are available , experimental support from animal studies indicates that morphine , or its metabolites , plays a causative role for the observed behavioural syndrome .|The possible mechanisms are discussed and treatment proposals given suggesting the use of more efficacious opioids with less excitatory potency in these situations .	1:CID:2	R2L	NON-CROSS	31-32	29-30	D009020	morphine|morphine|morphine|morphine	Chemical	11:29:99:110	12:30:100:111	0:1:5:5	D006930	Hyperalgesia|hyperalgesia|hyperalgesia|hyperalgesia	Disease	0:31:49:92	1:32:50:93	0:1:3:5	1:CID:2	R2L	NON-CROSS	99-100	94-95	D009020	morphine|morphine|morphine|morphine	Chemical	11:29:99:110	12:30:100:111	0:1:5:5	D009207	myoclonus|myoclonus|myoclonus|myoclonus	Disease	2:59:79:94	3:60:80:95	0:3:4:5	1:NR:2	R2L	NON-CROSS	14-15	11-12	D009020	morphine|morphine|morphine|morphine	Chemical	11:29:99:110	12:30:100:111	0:1:5:5	D009369	cancer|cancer	Disease	5:14	6:15	0:1	1:CID:2	L2R	CROSS	29-30	51-52	D009020	morphine|morphine|morphine|morphine	Chemical	11:29:99:110	12:30:100:111	0:1:5:5	D006941	hyperesthesia	Disease	51	52	3	1:CID:2	L2R	CROSS	68-69	99-100	D009020	morphine|morphine|morphine|morphine	Chemical	11:29:99:110	12:30:100:111	0:1:5:5	D009437	neuralgia	Disease	68	69	4
3934126	A prospective study of adverse reactions associated with vancomycin therapy .|A prospective evaluation of the efficacy and safety of vancomycin was conducted in 54 consecutive patients over a 16 - month period .|Vancomycin was curative in 95 % of 43 patients with proven infection .|Drugs were ceased in six patients because of adverse reactions ; in three of these vancomycin was considered the likely cause .|Reactions included thrombophlebitis ( 20 of 54 patients ) , rash ( 4 of 54 ) , nephrotoxicity ( 4 of 50 ) , proteinuria ( 1 of 50 ) and ototoxicity ( 1 of 11 patients tested by audiometry ) .|Thrombophlebitis occurred only with infusion through peripheral cannulae ; nephrotoxicity and ototoxicity were confined to patients receiving an aminoglycoside plus vancomycin .|We conclude that vancomycin , administered appropriately , constitutes safe , effective therapy for infections caused by susceptible bacteria .	1:NR:2	L2R	NON-CROSS	34-35	45-46	D014640	vancomycin|vancomycin|Vancomycin|vancomycin|vancomycin|vancomycin	Chemical	8:20:34:62:131:136	9:21:35:63:132:137	0:1:2:3:5:6	D007239	infection|infections	Disease	45:147	46:148	2:6	1:CID:2	L2R	NON-CROSS	62-63	71-72	D014640	vancomycin|vancomycin|Vancomycin|vancomycin|vancomycin|vancomycin	Chemical	8:20:34:62:131:136	9:21:35:63:132:137	0:1:2:3:5:6	D013924	thrombophlebitis|Thrombophlebitis	Disease	71:111	72:112	4:5	1:CID:2	L2R	CROSS	62-63	79-80	D014640	vancomycin|vancomycin|Vancomycin|vancomycin|vancomycin|vancomycin	Chemical	8:20:34:62:131:136	9:21:35:63:132:137	0:1:2:3:5:6	D005076	rash	Disease	79	80	4	1:NR:2	L2R	NON-CROSS	120-121	131-132	D014640	vancomycin|vancomycin|Vancomycin|vancomycin|vancomycin|vancomycin	Chemical	8:20:34:62:131:136	9:21:35:63:132:137	0:1:2:3:5:6	D007674	nephrotoxicity|nephrotoxicity	Disease	86:120	87:121	4:5	1:CID:2	L2R	CROSS	62-63	93-94	D014640	vancomycin|vancomycin|Vancomycin|vancomycin|vancomycin|vancomycin	Chemical	8:20:34:62:131:136	9:21:35:63:132:137	0:1:2:3:5:6	D011507	proteinuria	Disease	93	94	4	1:CID:2	L2R	NON-CROSS	122-123	131-132	D014640	vancomycin|vancomycin|Vancomycin|vancomycin|vancomycin|vancomycin	Chemical	8:20:34:62:131:136	9:21:35:63:132:137	0:1:2:3:5:6	D006311	ototoxicity|ototoxicity	Disease	100:122	101:123	4:5	1:NR:2	R2L	CROSS	147-148	129-130	D000617	aminoglycoside	Chemical	129	130	5	D007239	infection|infections	Disease	45:147	46:148	2:6	1:NR:2	R2L	NON-CROSS	129-130	111-112	D000617	aminoglycoside	Chemical	129	130	5	D013924	thrombophlebitis|Thrombophlebitis	Disease	71:111	72:112	4:5	1:NR:2	R2L	CROSS	129-130	79-80	D000617	aminoglycoside	Chemical	129	130	5	D005076	rash	Disease	79	80	4	1:NR:2	R2L	NON-CROSS	129-130	120-121	D000617	aminoglycoside	Chemical	129	130	5	D007674	nephrotoxicity|nephrotoxicity	Disease	86:120	87:121	4:5	1:NR:2	R2L	CROSS	129-130	93-94	D000617	aminoglycoside	Chemical	129	130	5	D011507	proteinuria	Disease	93	94	4	1:NR:2	R2L	NON-CROSS	129-130	122-123	D000617	aminoglycoside	Chemical	129	130	5	D006311	ototoxicity|ototoxicity	Disease	100:122	101:123	4:5
1687392	Blockade of both D - 1 and D - 2 dopamine receptors may induce catalepsy in mice .|1 . The catalepsy induced by dopamine antagonists has been tested and the possible dopamine subtypes involved in catalepsy was determined .|2 .|Dopamine antagonist fluphenazine , D - 1 antagonist SCH 23390 or D - 2 antagonist sulpiride induced catalepsy .|The effect of fluphenazine and sulpiride was dose - dependent .|Combination of SCH 23390 with sulpiride did not induce catalepsy potentiation .|3 .|D - 1 agonist SKF 38393 or D - 2 agonist quinpirole decreased the catalepsy induced by fluphenazine , SCH 23390 or sulpiride .|4 .|Combination of SKF 38393 with quinpirole did not cause potentiated inhibitory effect on catalepsy induced by dopamine antagonists .|5 .|The data may indicate that although D - 2 receptor blockade is involved in catalepsy , the D - 1 receptor may plan a role .	1:NR:2	L2R	NON-CROSS	21-22	24-25	D004298	dopamine|dopamine|dopamine|Dopamine|dopamine	Chemical	10:24:32:42:128	11:25:33:43:129	0:1:1:3:9	D002375	catalepsy|catalepsy|catalepsy|catalepsy|catalepsy|catalepsy|catalepsy|catalepsy	Disease	14:21:36:59:81:100:125:147	15:22:37:60:82:101:126:148	0:1:1:3:5:7:9:11	1:CID:2	R2L	NON-CROSS	103-104	100-101	D005476	fluphenazine|fluphenazine|fluphenazine	Chemical	44:64:103	45:65:104	3:4:7	D002375	catalepsy|catalepsy|catalepsy|catalepsy|catalepsy|catalepsy|catalepsy|catalepsy	Disease	14:21:36:59:81:100:125:147	15:22:37:60:82:101:126:148	0:1:1:3:5:7:9:11	1:CID:2	R2L	NON-CROSS	105-107	100-101	C534628	SCH 23390|SCH 23390|SCH 23390	Chemical	50:74:105	52:76:107	3:5:7	D002375	catalepsy|catalepsy|catalepsy|catalepsy|catalepsy|catalepsy|catalepsy|catalepsy	Disease	14:21:36:59:81:100:125:147	15:22:37:60:82:101:126:148	0:1:1:3:5:7:9:11	1:CID:2	R2L	NON-CROSS	59-60	57-58	D013469	sulpiride|sulpiride|sulpiride|sulpiride	Chemical	57:66:77:108	58:67:78:109	3:4:5:7	D002375	catalepsy|catalepsy|catalepsy|catalepsy|catalepsy|catalepsy|catalepsy|catalepsy	Disease	14:21:36:59:81:100:125:147	15:22:37:60:82:101:126:148	0:1:1:3:5:7:9:11	1:NR:2	R2L	NON-CROSS	90-92	81-82	D015647	SKF 38393|SKF 38393	Chemical	90:114	92:116	7:9	D002375	catalepsy|catalepsy|catalepsy|catalepsy|catalepsy|catalepsy|catalepsy|catalepsy	Disease	14:21:36:59:81:100:125:147	15:22:37:60:82:101:126:148	0:1:1:3:5:7:9:11	1:NR:2	R2L	NON-CROSS	100-101	97-98	D019257	quinpirole|quinpirole	Chemical	97:117	98:118	7:9	D002375	catalepsy|catalepsy|catalepsy|catalepsy|catalepsy|catalepsy|catalepsy|catalepsy	Disease	14:21:36:59:81:100:125:147	15:22:37:60:82:101:126:148	0:1:1:3:5:7:9:11
19719056	Dextran - etodolac conjugates : synthesis , in vitro and in vivo evaluation .|Etodolac ( E ) , is a non - narcotic analgesic and antiinflammatory drug .|A biodegradable polymer dextran has been utilized as a carrier for synthesis of etodolac - dextran conjugates ( ED ) to improve its aqueous solubility and reduce gastrointestinal side effects .|An activated moiety , i . e .|N - acylimidazole derivative of etodolac ( EAI ) , was condensed with the polysaccharide polymer dextran of different molecular weights ( 40000 , 60000 , 110000 and 200000 ) .|IR spectral data confirmed formation of ester bonding in the conjugates .|Etodolac contents were evaluated by UV - spectrophotometric analysis .|The molecular weights were determined by measuring viscosity using the Mark - Howink - Sakurada equation .|In vitro hydrolysis of ED was done in aqueous buffers ( pH 1 . 2 , 7 . 4 , 9 ) and in 80 % ( v / v ) human plasma ( pH 7 . 4 ) .|At pH 9 , a higher rate of etodolac release from ED was observed as compared to aqueous buffer of pH 7 . 4 and 80 % human plasma ( pH 7 . 4 ) , following first - order kinetics .|In vivo investigations were performed in animals .|Acute analgesic and antiinflammatory activities were ascertained using acetic acid induced writhing model ( mice ) and carrageenan - induced rat paw edema model , respectively .|In comparison to control , E and ED1 - ED4 showed highly significant analgesic and antiinflammatory activities ( p < 0 . 001 ) .|Biological evaluation suggested that conjugates ( ED1 - ED4 ) retained comparable analgesic and antiinflammatory activities with remarkably reduced ulcerogenicity as compared to their parent drug - - etodolac .	1:NR:2	L2R	CROSS	84-85	239-240	D003911	Dextran|dextran|dextran|dextran	Chemical	0:32:44:84	1:33:45:85	0:2:2:4	D010146	writhing	Disease	239	240	11	1:NR:2	L2R	CROSS	84-85	250-251	D003911	Dextran|dextran|dextran|dextran	Chemical	0:32:44:84	1:33:45:85	0:2:2:4	D004487	edema	Disease	250	251	11	1:NR:2	L2R	CROSS	239-240	260-261	D017308	etodolac|Etodolac|E|etodolac|etodolac|Etodolac|etodolac|E|etodolac	Chemical	2:14:16:42:73:111:186:260:308	3:15:17:43:74:112:187:261:309	0:1:1:2:4:6:9:12:13	D010146	writhing	Disease	239	240	11	1:NR:2	L2R	CROSS	250-251	260-261	D017308	etodolac|Etodolac|E|etodolac|etodolac|Etodolac|etodolac|E|etodolac	Chemical	2:14:16:42:73:111:186:260:308	3:15:17:43:74:112:187:261:309	0:1:1:2:4:6:9:12:13	D004487	edema	Disease	250	251	11	1:NR:2	L2R	NON-CROSS	236-238	239-240	D019342	acetic acid	Chemical	236	238	11	D010146	writhing	Disease	239	240	11	1:NR:2	L2R	NON-CROSS	236-238	250-251	D019342	acetic acid	Chemical	236	238	11	D004487	edema	Disease	250	251	11	1:CID:2	R2L	NON-CROSS	245-246	239-240	D002351	carrageenan	Chemical	245	246	11	D010146	writhing	Disease	239	240	11	1:CID:2	L2R	NON-CROSS	245-246	250-251	D002351	carrageenan	Chemical	245	246	11	D004487	edema	Disease	250	251	11
15266362	Hypersensitivity myocarditis complicating hypertrophic cardiomyopathy heart .|The present report describes a case of eosinophilic myocarditis complicating hypertrophic cardiomyopathy .|The 47 - year - old female patient , known to have hypertrophic cardiomyopathy , was admitted with biventricular failure and managed aggressively with dobutamine infusion and other drugs while being assessed for heart transplantation .|On transthoracic echocardiogram , she had moderate left ventricular dysfunction with regional variability and moderate mitral regurgitation .|The recipient 's heart showed the features of apical hypertrophic cardiomyopathy and myocarditis with abundant eosinophils .|Myocarditis is rare and eosinophilic myocarditis is rarer .|It is likely that the hypersensitivity ( eosinophilic ) myocarditis was related to dobutamine infusion therapy .|Eosinophilic myocarditis has been reported with an incidence of 2 . 4 % to 7 . 2 % in explanted hearts and may be related to multidrug therapy .	1:CID:2	R2L	NON-CROSS	113-114	105-106	D004280	dobutamine|dobutamine	Chemical	44:113	45:114	2:6	D004342	Hypersensitivity|hypersensitivity	Disease	0:105	1:106	0:6	1:CID:2	R2L	NON-CROSS	113-114	109-110	D004280	dobutamine|dobutamine	Chemical	44:113	45:114	2:6	D009205	myocarditis|eosinophilic myocarditis|myocarditis|Myocarditis|eosinophilic myocarditis|myocarditis|Eosinophilic myocarditis	Disease	1:14:86:91:95:109:117	2:16:87:92:97:110:119	0:1:4:5:5:6:7	1:NR:2	R2L	NON-CROSS	44-45	32-34	D004280	dobutamine|dobutamine	Chemical	44:113	45:114	2:6	D002312	hypertrophic cardiomyopathy|hypertrophic cardiomyopathy|hypertrophic cardiomyopathy|hypertrophic cardiomyopathy	Disease	3:17:32:83	5:19:34:85	0:1:2:4	1:CID:2	R2L	NON-CROSS	117-119	113-114	D004280	dobutamine|dobutamine	Chemical	44:113	45:114	2:6	D004802	eosinophilic myocarditis|eosinophilic myocarditis|eosinophilic|Eosinophilic myocarditis	Disease	14:95:107:117	16:97:108:119	1:5:6:7	1:NR:2	R2L	NON-CROSS	44-45	38-40	D004280	dobutamine|dobutamine	Chemical	44:113	45:114	2:6	D018754	biventricular failure	Disease	38	40	2	1:NR:2	L2R	CROSS	44-45	63-66	D004280	dobutamine|dobutamine	Chemical	44:113	45:114	2:6	D018487	left ventricular dysfunction	Disease	63	66	3	1:NR:2	L2R	CROSS	44-45	71-73	D004280	dobutamine|dobutamine	Chemical	44:113	45:114	2:6	D008944	mitral regurgitation	Disease	71	73	3
14648024	All - trans - retinoic acid - induced erythema nodosum in patients with acute promyelocytic leukemia .|Erythema nodosum associated with all - trans - retinoic acid ( ATRA ) for acute promyelocytic leukemia ( APL ) is very rare .|We describe four patients with classic APL who developed erythema nodosum during ATRA therapy .|Fever and subsequent multiple painful erythematous nodules over extremities developed on D11 , D16 , D17 , and D19 , respectively , after ATRA therapy .|The skin biopsy taken from each patient was consistent with erythema nodosum .|All patients received short course of steroids .|Fever subsided rapidly and the skin lesions regressed completely .|All patients achieved complete remission without withdrawal of ATRA .|ATRA seemed to be the most possible etiology of erythema nodosum in our patients .|Short - term use of steroid is very effective in ATRA - induced erythema nodosum .	1:CID:2	L2R	NON-CROSS	50-52	53-54	D014212	All - trans - retinoic acid|all - trans - retinoic acid|ATRA|ATRA|ATRA|ATRA|ATRA|ATRA	Chemical	0:21:28:53:79:121:123:148	6:27:29:54:80:122:124:149	0:1:1:2:3:7:8:9	D004893	erythema nodosum|Erythema nodosum|erythema nodosum|erythematous nodules|erythema nodosum|erythema nodosum|erythema nodosum	Disease	8:17:50:61:92:132:151	10:19:52:63:94:134:153	0:1:2:3:4:8:9	1:NR:2	L2R	NON-CROSS	28-29	31-34	D014212	All - trans - retinoic acid|all - trans - retinoic acid|ATRA|ATRA|ATRA|ATRA|ATRA|ATRA	Chemical	0:21:28:53:79:121:123:148	6:27:29:54:80:122:124:149	0:1:1:2:3:7:8:9	D015473	acute promyelocytic leukemia|acute promyelocytic leukemia|APL|APL	Disease	13:31:35:47	16:34:36:48	0:1:1:2	1:CID:2	L2R	NON-CROSS	53-54	56-57	D014212	All - trans - retinoic acid|all - trans - retinoic acid|ATRA|ATRA|ATRA|ATRA|ATRA|ATRA	Chemical	0:21:28:53:79:121:123:148	6:27:29:54:80:122:124:149	0:1:1:2:3:7:8:9	D005334	Fever|Fever	Disease	56:103	57:104	3:6	1:NR:2	L2R	NON-CROSS	53-54	60-61	D014212	All - trans - retinoic acid|all - trans - retinoic acid|ATRA|ATRA|ATRA|ATRA|ATRA|ATRA	Chemical	0:21:28:53:79:121:123:148	6:27:29:54:80:122:124:149	0:1:1:2:3:7:8:9	D010146	painful	Disease	60	61	3	1:NR:2	R2L	NON-CROSS	101-102	92-94	D013256	steroids|steroid	Chemical	101:143	102:144	5:9	D004893	erythema nodosum|Erythema nodosum|erythema nodosum|erythematous nodules|erythema nodosum|erythema nodosum|erythema nodosum	Disease	8:17:50:61:92:132:151	10:19:52:63:94:134:153	0:1:2:3:4:8:9	1:NR:2	R2L	CROSS	101-102	47-48	D013256	steroids|steroid	Chemical	101:143	102:144	5:9	D015473	acute promyelocytic leukemia|acute promyelocytic leukemia|APL|APL	Disease	13:31:35:47	16:34:36:48	0:1:1:2	1:NR:2	R2L	CROSS	103-104	101-102	D013256	steroids|steroid	Chemical	101:143	102:144	5:9	D005334	Fever|Fever	Disease	56:103	57:104	3:6	1:NR:2	R2L	CROSS	101-102	60-61	D013256	steroids|steroid	Chemical	101:143	102:144	5:9	D010146	painful	Disease	60	61	3
11827497	Delayed - onset heparin - induced thrombocytopenia .|BACKGROUND : Heparin - induced thrombocytopenia presents 5 to 12 days after heparin exposure , with or without arterial or venous thromboemboli .|Delayed recognition and treatment of heparin - induced thrombocytopenia contribute to poor patient outcomes .|OBJECTIVE : To describe and increase awareness of a clinical scenario in which the onset or manifestations of heparin - induced thrombocytopenia are delayed .|DESIGN : Retrospective case series .|SETTING : Three large urban hospitals ( with active cardiovascular surgery programs ) .|PATIENTS : 14 patients seen over a 3 - year period in whom heparin - induced thrombocytopenia became apparent on delayed presentation with thromboembolic complications .|MEASUREMENTS : Platelet counts , onset of objectively determined thromboembolism , results of heparin - induced platelet factor 4 antibody tests , and outcomes .|RESULTS : Patients went home after hospitalizations that had included heparin exposure - - in most cases , with no thrombocytopenia recognized - - only to return to the hospital ( median , day 14 ) with thromboembolic complications .|Thromboemboli were venous ( 12 patients , 7 with pulmonary emboli ) or arterial ( 4 patients ) or both .|Platelet counts were mildly decreased in all but 2 patients on second presentation .|On readmission , 11 patients received therapeutic heparin , which worsened the patients ' clinical condition and , in all 11 cases , decreased the platelet count ( mean at readmission , 143 x 10 ( 9 ) cells / L ; mean nadir after heparin re - exposure , 39 x 10 ( 9 ) cells / L ) .|Results of serologic tests for heparin - induced antibodies were positive in all patients .|Subsequent treatments included alternative anticoagulants ( 11 patients ) , thrombolytic drugs ( 3 patients ) , inferior vena cava filters ( 3 patients ) and , eventually , warfarin ( 11 patients ) .|Three patients died .|CONCLUSIONS : Delayed - onset heparin - induced thrombocytopenia is increasingly being recognized .|To avoid disastrous outcomes , physicians must consider heparin - induced thrombocytopenia whenever a recently hospitalized patient returns with thromboembolism ; therapy with alternative anticoagulants , not heparin , should be initiated .	1:CID:2	L2R	NON-CROSS	3-4	6-7	D006493	heparin|Heparin|heparin|heparin|heparin|heparin|heparin|heparin|heparin|heparin|heparin|heparin|heparin|heparin	Chemical	3:10:20:36:64:104:130:152:224:262:283:337:354:373	4:11:21:37:65:105:131:153:225:263:284:338:355:374	0:1:1:2:3:6:7:8:11:11:12:15:16:16	D013921	thrombocytopenia|thrombocytopenia|thrombocytopenia|thrombocytopenia|thrombocytopenia|thrombocytopenia|thrombocytopenia|thrombocytopenia	Disease	6:13:39:67:107:162:340:357	7:14:40:68:108:163:341:358	0:1:2:3:6:8:15:16	1:CID:2	L2R	NON-CROSS	20-21	26-30	D006493	heparin|Heparin|heparin|heparin|heparin|heparin|heparin|heparin|heparin|heparin|heparin|heparin|heparin|heparin	Chemical	3:10:20:36:64:104:130:152:224:262:283:337:354:373	4:11:21:37:65:105:131:153:225:263:284:338:355:374	0:1:1:2:3:6:7:8:11:11:12:15:16:16	D001157	arterial or venous thromboemboli	Disease	26	30	1	1:CID:2	L2R	NON-CROSS	20-21	26-30	D006493	heparin|Heparin|heparin|heparin|heparin|heparin|heparin|heparin|heparin|heparin|heparin|heparin|heparin|heparin	Chemical	3:10:20:36:64:104:130:152:224:262:283:337:354:373	4:11:21:37:65:105:131:153:225:263:284:338:355:374	0:1:1:2:3:6:7:8:11:11:12:15:16:16	D054556	arterial or venous thromboemboli	Disease	26	30	1	1:NR:2	L2R	NON-CROSS	126-127	130-131	D006493	heparin|Heparin|heparin|heparin|heparin|heparin|heparin|heparin|heparin|heparin|heparin|heparin|heparin|heparin	Chemical	3:10:20:36:64:104:130:152:224:262:283:337:354:373	4:11:21:37:65:105:131:153:225:263:284:338:355:374	0:1:1:2:3:6:7:8:11:11:12:15:16:16	D013923	thromboembolic|thromboembolism|thromboembolic|Thromboemboli|thromboembolism	Disease	114:126:179:182:365	115:127:180:183:366	6:7:8:9:16	1:CID:2	L2R	CROSS	191-193	224-225	D006493	heparin|Heparin|heparin|heparin|heparin|heparin|heparin|heparin|heparin|heparin|heparin|heparin|heparin|heparin	Chemical	3:10:20:36:64:104:130:152:224:262:283:337:354:373	4:11:21:37:65:105:131:153:225:263:284:338:355:374	0:1:1:2:3:6:7:8:11:11:12:15:16:16	D011655	pulmonary emboli	Disease	191	193	9	1:NR:2	R2L	CROSS	340-341	322-323	D014859	warfarin	Chemical	322	323	13	D013921	thrombocytopenia|thrombocytopenia|thrombocytopenia|thrombocytopenia|thrombocytopenia|thrombocytopenia|thrombocytopenia|thrombocytopenia	Disease	6:13:39:67:107:162:340:357	7:14:40:68:108:163:341:358	0:1:2:3:6:8:15:16	1:NR:2	R2L	CROSS	322-323	26-30	D014859	warfarin	Chemical	322	323	13	D001157	arterial or venous thromboemboli	Disease	26	30	1	1:NR:2	R2L	CROSS	322-323	26-30	D014859	warfarin	Chemical	322	323	13	D054556	arterial or venous thromboemboli	Disease	26	30	1	1:NR:2	R2L	CROSS	365-366	322-323	D014859	warfarin	Chemical	322	323	13	D013923	thromboembolic|thromboembolism|thromboembolic|Thromboemboli|thromboembolism	Disease	114:126:179:182:365	115:127:180:183:366	6:7:8:9:16	1:NR:2	R2L	CROSS	322-323	191-193	D014859	warfarin	Chemical	322	323	13	D011655	pulmonary emboli	Disease	191	193	9
8841157	Valsartan , a new angiotensin II antagonist for the treatment of essential hypertension : a comparative study of the efficacy and safety against amlodipine .|OBJECTIVE : To compare the antihypertensive efficacy of a new angiotensin II antagonist , valsartan , with a reference therapy , amlodipine .|METHODS : One hundred sixty - eight adult outpatients with mild to moderate hypertension were randomly allocated in double - blind fashion and equal number to receive 80 mg valsartan or 5 mg amlodipine for 12 weeks .|After 8 weeks of therapy , in patients whose blood pressure remained uncontrolled , 5 mg amlodipine was added to the initial therapy .|Patients were assessed at 4 , 8 , and 12 weeks .|The primary efficacy variable was change from baseline in mean sitting diastolic blood pressure at 8 weeks .|Secondary variables included change in sitting systolic blood pressure and responder rates .|RESULTS : Both valsartan and amlodipine were effective at lowering blood pressure at 4 , 8 , and 12 weeks .|Similar decreases were observed in both groups , with no statistically significant differences between the groups for any variable analyzed .|For the primary variable the difference was 0 . 5 mm Hg in favor of valsartan ( p = 0 . 68 ; 95 % confidence interval , - 2 . 7 to 1 . 7 ) .|Responder rates at 8 weeks were 66 . 7 % for valsartan and 60 . 2 % for amlodipine ( p = 0 . 39 ) .|Both treatments were well tolerated .|The incidence of drug - related dependent edema was somewhat higher in the amlodipine group , particularly at a dose of 10 mg per day ( 2 . 4 % for 80 mg valsartan ; 3 . 6 % for 5 mg amlodipine ; 0 % for valsartan plus 5 mg amlodipine ; 14 . 3 % for 10 mg amlodipine ) .|CONCLUSIONS : The data show that valsartan is at least as effective as amlodipine in the treatment of mild to moderate hypertension .|The results also show valsartan to be well tolerated and suggest that it is not associated with side effects characteristic of this comparator class , dihydropyridine calcium antagonists .	1:NR:2	L2R	NON-CROSS	350-351	356-357	C081489	Valsartan|valsartan|valsartan|valsartan|valsartan|valsartan|valsartan|valsartan|valsartan|valsartan	Chemical	0:39:77:156:210:244:299:313:335:356	1:40:78:157:211:245:300:314:336:357	0:1:2:7:9:10:12:12:13:14	D006973	hypertension|hypertension|hypertension	Disease	12:61:350	13:62:351	0:2:13	1:CID:2	L2R	NON-CROSS	273-274	299-300	C081489	Valsartan|valsartan|valsartan|valsartan|valsartan|valsartan|valsartan|valsartan|valsartan|valsartan	Chemical	0:39:77:156:210:244:299:313:335:356	1:40:78:157:211:245:300:314:336:357	0:1:2:7:9:10:12:12:13:14	D004487	edema	Disease	273	274	12	1:NR:2	L2R	NON-CROSS	4-6	12-13	D000804	angiotensin II|angiotensin II	Chemical	4:35	6:37	0:1	D006973	hypertension|hypertension|hypertension	Disease	12:61:350	13:62:351	0:2:13	1:NR:2	L2R	CROSS	35-37	273-274	D000804	angiotensin II|angiotensin II	Chemical	4:35	6:37	0:1	D004487	edema	Disease	273	274	12	1:NR:2	R2L	NON-CROSS	350-351	342-343	D017311	amlodipine|amlodipine|amlodipine|amlodipine|amlodipine|amlodipine|amlodipine|amlodipine|amlodipine|amlodipine|amlodipine	Chemical	23:46:81:102:158:251:279:308:317:326:342	24:47:82:103:159:252:280:309:318:327:343	0:1:2:3:7:10:12:12:12:12:13	D006973	hypertension|hypertension|hypertension	Disease	12:61:350	13:62:351	0:2:13	1:NR:2	R2L	CROSS	377-378	350-351	C038806	dihydropyridine	Chemical	377	378	14	D006973	hypertension|hypertension|hypertension	Disease	12:61:350	13:62:351	0:2:13	1:NR:2	R2L	CROSS	378-379	350-351	D002118	calcium	Chemical	378	379	14	D006973	hypertension|hypertension|hypertension	Disease	12:61:350	13:62:351	0:2:13	1:CID:2	L2R	NON-CROSS	273-274	279-280	D017311	amlodipine|amlodipine|amlodipine|amlodipine|amlodipine|amlodipine|amlodipine|amlodipine|amlodipine|amlodipine|amlodipine	Chemical	23:46:81:102:158:251:279:308:317:326:342	24:47:82:103:159:252:280:309:318:327:343	0:1:2:3:7:10:12:12:12:12:13	D004487	edema	Disease	273	274	12	1:NR:2	R2L	CROSS	377-378	273-274	C038806	dihydropyridine	Chemical	377	378	14	D004487	edema	Disease	273	274	12	1:NR:2	R2L	CROSS	378-379	273-274	D002118	calcium	Chemical	378	379	14	D004487	edema	Disease	273	274	12
8045270	KF17837 : a novel selective adenosine A2A receptor antagonist with anticataleptic activity .|KF17837 is a novel selective adenosine A2A receptor antagonist .|Oral administration of KF17837 ( 2 . 5 , 10 . 0 and 30 . 0 mg / kg ) significantly ameliorated the cataleptic responses induced by intracerebroventricular administration of an adenosine A2A receptor agonist , CGS 21680 ( 10 micrograms ) , in a dose - dependent manner .|KF17837 also reduced the catalepsy induced by haloperidol ( 1 mg / kg i . p . ) and by reserpine ( 5 mg / kg i . p . ) .|These anticataleptic effects were exhibited dose dependently at doses from 0 . 625 and 2 . 5 mg / kg p . o . , respectively .|Moreover , KF17837 ( 0 . 625 mg / kg p . o . ) potentiated the anticataleptic effects of a subthreshold dose of L - 3 , 4 - dihydroxyphenylalanine ( L - DOPA ; 25 mg / kg i . p . ) plus benserazide ( 6 . 25 mg / kg i . p . ) .|These results suggested that KF17837 is a centrally active adenosine A2A receptor antagonist and that the dopaminergic function of the nigrostriatal pathway is potentiated by adenosine A2A receptor antagonists .|Furthermore , KF17837 may be a useful drug in the treatment of parkinsonism .	1:NR:2	L2R	NON-CROSS	73-74	77-78	C081198	KF17837|KF17837|KF17837|KF17837|KF17837|KF17837|KF17837	Chemical	0:13:26:73:134:196:224	1:14:27:74:135:197:225	0:1:2:3:5:6:7	D002375	cataleptic|catalepsy	Disease	46:77	47:78	2:3	1:NR:2	L2R	NON-CROSS	224-225	234-235	C081198	KF17837|KF17837|KF17837|KF17837|KF17837|KF17837|KF17837	Chemical	0:13:26:73:134:196:224	1:14:27:74:135:197:225	0:1:2:3:5:6:7	D010302	parkinsonism	Disease	234	235	7	1:NR:2	L2R	NON-CROSS	46-47	54-55	D000241	adenosine|adenosine|adenosine|adenosine|adenosine	Chemical	5:18:54:201:217	6:19:55:202:218	0:1:2:6:6	D002375	cataleptic|catalepsy	Disease	46:77	47:78	2:3	1:NR:2	L2R	CROSS	217-218	234-235	D000241	adenosine|adenosine|adenosine|adenosine|adenosine	Chemical	5:18:54:201:217	6:19:55:202:218	0:1:2:6:6	D010302	parkinsonism	Disease	234	235	7	1:CID:2	R2L	NON-CROSS	59-61	46-47	C061282	CGS 21680	Chemical	59	61	2	D002375	cataleptic|catalepsy	Disease	46:77	47:78	2:3	1:CID:2	R2L	NON-CROSS	80-81	77-78	D006220	haloperidol	Chemical	80	81	3	D002375	cataleptic|catalepsy	Disease	46:77	47:78	2:3	1:CID:2	R2L	NON-CROSS	93-94	77-78	D012110	reserpine	Chemical	93	94	3	D002375	cataleptic|catalepsy	Disease	46:77	47:78	2:3	1:NR:2	R2L	CROSS	156-163	77-78	D007980	L - 3 , 4 - dihydroxyphenylalanine|L - DOPA	Chemical	156:164	163:167	5:5	D002375	cataleptic|catalepsy	Disease	46:77	47:78	2:3	1:NR:2	R2L	CROSS	178-179	77-78	D001545	benserazide	Chemical	178	179	5	D002375	cataleptic|catalepsy	Disease	46:77	47:78	2:3	1:NR:2	L2R	CROSS	59-61	234-235	C061282	CGS 21680	Chemical	59	61	2	D010302	parkinsonism	Disease	234	235	7	1:NR:2	L2R	CROSS	80-81	234-235	D006220	haloperidol	Chemical	80	81	3	D010302	parkinsonism	Disease	234	235	7	1:NR:2	L2R	CROSS	93-94	234-235	D012110	reserpine	Chemical	93	94	3	D010302	parkinsonism	Disease	234	235	7	1:NR:2	L2R	CROSS	164-167	234-235	D007980	L - 3 , 4 - dihydroxyphenylalanine|L - DOPA	Chemical	156:164	163:167	5:5	D010302	parkinsonism	Disease	234	235	7	1:NR:2	L2R	CROSS	178-179	234-235	D001545	benserazide	Chemical	178	179	5	D010302	parkinsonism	Disease	234	235	7
2576810	Some central effects of repeated treatment with fluvoxamine .|We investigated the effect of repeated treatment with fluvoxamine , a selective serotonin uptake inhibitor , on behavioral effects of dopaminomimetics and methoxamine and on the animal behavior in the " behavioral despair " test .|A repeated treatment with fluvoxamine ( twice daily for 14 days ) potentiated in mice and in rats ( weaker ) the amphetamine - induced hyperactivity .|The hyperactivity induced by nomifensine in mice remained unaffected by fluvoxamine .|The stimulation of locomotor activity by intracerebroventricularly administered methoxamine was not affected by repeated treatment with fluvoxamine .|Given three times fluvoxamine had no effect on the immobilization time in the " behavioral despair " test in rats .|The results indicate that fluvoxamine given repeatedly acts differently than citalopram , another selective serotonin uptake inhibitor , and differs also from other antidepressant drugs .	1:CID:2	L2R	NON-CROSS	73-74	82-83	D016666	fluvoxamine|fluvoxamine|fluvoxamine|fluvoxamine|fluvoxamine|fluvoxamine|fluvoxamine	Chemical	7:17:49:82:100:105:127	8:18:50:83:101:106:128	0:1:2:3:4:5:6	D006948	hyperactivity|hyperactivity	Disease	70:73	71:74	2:3	1:NR:2	L2R	CROSS	21-22	70-71	D012701	serotonin|serotonin	Chemical	21:137	22:138	1:6	D006948	hyperactivity|hyperactivity	Disease	70:73	71:74	2:3	1:CID:2	L2R	CROSS	73-74	92-93	D008729	methoxamine|methoxamine	Chemical	31:92	32:93	1:4	D006948	hyperactivity|hyperactivity	Disease	70:73	71:74	2:3	1:CID:2	L2R	NON-CROSS	67-68	70-71	D000661	amphetamine	Chemical	67	68	2	D006948	hyperactivity|hyperactivity	Disease	70:73	71:74	2:3	1:CID:2	R2L	NON-CROSS	76-77	73-74	D009627	nomifensine	Chemical	76	77	3	D006948	hyperactivity|hyperactivity	Disease	70:73	71:74	2:3	1:NR:2	R2L	CROSS	133-134	73-74	D015283	citalopram	Chemical	133	134	6	D006948	hyperactivity|hyperactivity	Disease	70:73	71:74	2:3
20635749	Severe congestive heart failure patient on amiodarone presenting with myxedemic coma : a case report .|This is a case report of myxedema coma secondary to amiodarone - induced hypothyroidism in a patient with severe congestive heart failure ( CHF ) .|To our knowledge and after reviewing the literature there is one case report of myxedema coma during long term amiodarone therapy .|Myxedema coma is a life threatening condition that carries a mortality reaching as high as 20 % with treatment .|The condition is treated with intravenous thyroxine ( T4 ) or intravenous tri - iodo - thyronine ( T3 ) .|Patients with CHF on amiodarone may suffer serious morbidity and mortality from hypothyroidism , and thus may deserve closer follow up for thyroid stimulating hormone ( TSH ) levels .|This case report carries an important clinical application given the frequent usage of amiodarone among CHF patients .|The myriad clinical presentation of myxedema coma and its serious morbidity and mortality stresses the need to suspect this clinical syndrome among CHF patients presenting with hypotension , weakness or other unexplained symptoms .	1:NR:2	R2L	NON-CROSS	109-110	107-108	D000638	amiodarone|amiodarone|amiodarone|amiodarone|amiodarone	Chemical	6:26:61:109:148	7:27:62:110:149	0:1:2:5:6	D006333	congestive heart failure|congestive heart failure|CHF|CHF|CHF|CHF	Disease	1:35:39:107:150:175	4:38:40:108:151:176	0:1:1:5:6:7	1:NR:2	R2L	CROSS	107-108	92-93	D013974	thyroxine|T4	Chemical	90:92	91:93	4:4	D006333	congestive heart failure|congestive heart failure|CHF|CHF|CHF|CHF	Disease	1:35:39:107:150:175	4:38:40:108:151:176	0:1:1:5:6:7	1:NR:2	R2L	CROSS	107-108	102-103	D014284	tri - iodo - thyronine|T3	Chemical	96:102	101:103	4:4	D006333	congestive heart failure|congestive heart failure|CHF|CHF|CHF|CHF	Disease	1:35:39:107:150:175	4:38:40:108:151:176	0:1:1:5:6:7	1:CID:2	L2R	NON-CROSS	6-7	9-11	D000638	amiodarone|amiodarone|amiodarone|amiodarone|amiodarone	Chemical	6:26:61:109:148	7:27:62:110:149	0:1:2:5:6	D009230	myxedemic coma|myxedema coma|myxedema coma|Myxedema coma|myxedema coma	Disease	9:22:56:64:158	11:24:58:66:160	0:1:2:3:7	1:CID:2	L2R	NON-CROSS	6-7	9-11	D000638	amiodarone|amiodarone|amiodarone|amiodarone|amiodarone	Chemical	6:26:61:109:148	7:27:62:110:149	0:1:2:5:6	D003128	myxedemic coma|myxedema coma|myxedema coma|Myxedema coma|myxedema coma	Disease	9:22:56:64:158	11:24:58:66:160	0:1:2:3:7	1:CID:2	L2R	NON-CROSS	26-27	29-30	D000638	amiodarone|amiodarone|amiodarone|amiodarone|amiodarone	Chemical	6:26:61:109:148	7:27:62:110:149	0:1:2:5:6	D007037	hypothyroidism|hypothyroidism	Disease	29:117	30:118	1:5	1:NR:2	L2R	CROSS	148-149	179-180	D000638	amiodarone|amiodarone|amiodarone|amiodarone|amiodarone	Chemical	6:26:61:109:148	7:27:62:110:149	0:1:2:5:6	D007022	hypotension	Disease	179	180	7	1:NR:2	L2R	CROSS	148-149	181-182	D000638	amiodarone|amiodarone|amiodarone|amiodarone|amiodarone	Chemical	6:26:61:109:148	7:27:62:110:149	0:1:2:5:6	D018908	weakness	Disease	181	182	7	1:NR:2	R2L	CROSS	90-91	64-66	D013974	thyroxine|T4	Chemical	90:92	91:93	4:4	D009230	myxedemic coma|myxedema coma|myxedema coma|Myxedema coma|myxedema coma	Disease	9:22:56:64:158	11:24:58:66:160	0:1:2:3:7	1:NR:2	R2L	CROSS	96-101	64-66	D014284	tri - iodo - thyronine|T3	Chemical	96:102	101:103	4:4	D009230	myxedemic coma|myxedema coma|myxedema coma|Myxedema coma|myxedema coma	Disease	9:22:56:64:158	11:24:58:66:160	0:1:2:3:7	1:NR:2	R2L	CROSS	90-91	64-66	D013974	thyroxine|T4	Chemical	90:92	91:93	4:4	D003128	myxedemic coma|myxedema coma|myxedema coma|Myxedema coma|myxedema coma	Disease	9:22:56:64:158	11:24:58:66:160	0:1:2:3:7	1:NR:2	R2L	CROSS	96-101	64-66	D014284	tri - iodo - thyronine|T3	Chemical	96:102	101:103	4:4	D003128	myxedemic coma|myxedema coma|myxedema coma|Myxedema coma|myxedema coma	Disease	9:22:56:64:158	11:24:58:66:160	0:1:2:3:7	1:NR:2	R2L	CROSS	117-118	92-93	D013974	thyroxine|T4	Chemical	90:92	91:93	4:4	D007037	hypothyroidism|hypothyroidism	Disease	29:117	30:118	1:5	1:NR:2	R2L	CROSS	117-118	102-103	D014284	tri - iodo - thyronine|T3	Chemical	96:102	101:103	4:4	D007037	hypothyroidism|hypothyroidism	Disease	29:117	30:118	1:5	1:NR:2	L2R	CROSS	92-93	179-180	D013974	thyroxine|T4	Chemical	90:92	91:93	4:4	D007022	hypotension	Disease	179	180	7	1:NR:2	L2R	CROSS	92-93	181-182	D013974	thyroxine|T4	Chemical	90:92	91:93	4:4	D018908	weakness	Disease	181	182	7	1:NR:2	L2R	CROSS	102-103	179-180	D014284	tri - iodo - thyronine|T3	Chemical	96:102	101:103	4:4	D007022	hypotension	Disease	179	180	7	1:NR:2	L2R	CROSS	102-103	181-182	D014284	tri - iodo - thyronine|T3	Chemical	96:102	101:103	4:4	D018908	weakness	Disease	181	182	7
20394767	Fear - potentiated startle , but not light - enhanced startle , is enhanced by anxiogenic drugs .|RATIONALE AND OBJECTIVES : The light - enhanced startle paradigm ( LES ) is suggested to model anxiety , because of the non - specific cue and the long - term effect .|In contrast , the fear - potentiated startle ( FPS ) is suggested to model conditioned fear .|However , the pharmacological profiles of these two paradigms are very similar .|The present study investigated the effects of putative anxiogenic drugs on LES and FPS and aimed at determining the sensitivity of LES for anxiogenic drugs and to potentially showing a pharmacological differentiation between these two paradigms .|METHODS : Male Wistar rats received each dose of the alpha ( 2 ) - adrenoceptor antagonist yohimbine ( 0 . 25 - 1 . 0mg / kg ) , the 5 - HT ( 2C ) receptor agonist m - chlorophenylpiperazine ( mCPP , 0 . 5 - 2 . 0mg / kg ) or the GABA ( A ) inverse receptor agonist pentylenetetrazole ( PTZ , 3 - 30mg / kg ) and were subsequently tested in either LES or FPS .|RESULTS : None of the drugs enhanced LES , whereas mCPP increased percentage FPS and yohimbine increased absolute FPS values .|Furthermore , yohimbine increased baseline startle amplitude in the LES , while mCPP suppressed baseline startle in both the LES and FPS and PTZ suppressed baseline startle in the FPS .|CONCLUSIONS : In contrast to findings in the FPS paradigm , none of the drugs were able to exacerbate the LES response .|Thus , a clear pharmacological differentiation was found between LES and FPS .	1:CID:2	R2L	NON-CROSS	229-230	226-227	D015016	yohimbine|yohimbine|yohimbine	Chemical	136:218:226	137:219:227	5:6:7	D012021	startle|startle|startle|startle|startle|startle|startle	Disease	3:10:26:58:229:239:250	4:11:27:59:230:240:251	0:0:1:2:7:7:7	1:NR:2	R2L	CROSS	229-230	150-153	D012701	5 - HT	Chemical	150	153	5	D012021	startle|startle|startle|startle|startle|startle|startle	Disease	3:10:26:58:229:239:250	4:11:27:59:230:240:251	0:0:1:2:7:7:7	1:CID:2	R2L	NON-CROSS	239-240	236-237	C015068	m - chlorophenylpiperazine|mCPP|mCPP|mCPP	Chemical	158:162:213:236	161:163:214:237	5:5:6:7	D012021	startle|startle|startle|startle|startle|startle|startle	Disease	3:10:26:58:229:239:250	4:11:27:59:230:240:251	0:0:1:2:7:7:7	1:NR:2	R2L	CROSS	229-230	176-177	D005680	GABA	Chemical	176	177	5	D012021	startle|startle|startle|startle|startle|startle|startle	Disease	3:10:26:58:229:239:250	4:11:27:59:230:240:251	0:0:1:2:7:7:7	1:CID:2	R2L	NON-CROSS	250-251	247-248	D010433	pentylenetetrazole|PTZ|PTZ	Chemical	183:185:247	184:186:248	5:5:7	D012021	startle|startle|startle|startle|startle|startle|startle	Disease	3:10:26:58:229:239:250	4:11:27:59:230:240:251	0:0:1:2:7:7:7	1:NR:2	R2L	CROSS	136-137	35-36	D015016	yohimbine|yohimbine|yohimbine	Chemical	136:218:226	137:219:227	5:6:7	D001008	anxiety	Disease	35	36	1	1:NR:2	R2L	CROSS	150-153	35-36	D012701	5 - HT	Chemical	150	153	5	D001008	anxiety	Disease	35	36	1	1:NR:2	R2L	CROSS	158-161	35-36	C015068	m - chlorophenylpiperazine|mCPP|mCPP|mCPP	Chemical	158:162:213:236	161:163:214:237	5:5:6:7	D001008	anxiety	Disease	35	36	1	1:NR:2	R2L	CROSS	176-177	35-36	D005680	GABA	Chemical	176	177	5	D001008	anxiety	Disease	35	36	1	1:NR:2	R2L	CROSS	183-184	35-36	D010433	pentylenetetrazole|PTZ|PTZ	Chemical	183:185:247	184:186:248	5:5:7	D001008	anxiety	Disease	35	36	1
19203554	Proteinase 3 - antineutrophil cytoplasmic antibody - ( PR3 - ANCA ) positive necrotizing glomerulonephritis after restarting sulphasalazine treatment .|A 59 - year - old woman with ulcerative colitis developed red eyes , pleural effusion , eosinophilia and urinary abnormalities after restarting of sulphasalazine treatment .|Light microscopy of a kidney biopsy revealed segmental necrotizing glomerulonephritis without deposition of immunoglobulin or complement .|Proteinase 3 - antineutrophil cytoplasmic antibody ( PR3 - ANCA ) titer was elevated at 183 ELISA units ( EU ) in sera ( normal range less than 10 EU ) , myeloperoxidase - ANCA was negative .|PR3 - ANCA titer was 250 and 1 , 070 EU in pleural effusions on right and left side , respectively .|Although cessation of sulphasalazine treatment resulted in improvements in fever , red eyes , chest pain , titer of C - reactive protein and volume of the pleural effusions , we initiated steroid therapy , because PR3 - ANCA titer rose to 320 EU , eosinophil count increased to 1 , 100 cells / microl , and the pleural effusion remained .|One month after steroid therapy , the pleural effusion disappeared , and PR3 - ANCA titer normalized 3 months later .|This case suggests that sulphasalazine can induce PR3 - ANCA - positive necrotizing glomerulonephritis .	1:NR:2	R2L	NON-CROSS	17-18	14-15	D012460	sulphasalazine|sulphasalazine|sulphasalazine|sulphasalazine	Chemical	17:44:127:211	18:45:128:212	0:1:5:7	D005921	glomerulonephritis|glomerulonephritis	Disease	14:220	15:221	0:7	1:NR:2	R2L	CROSS	220-221	189-190	D013256	steroid|steroid	Chemical	156:189	157:190	5:6	D005921	glomerulonephritis|glomerulonephritis	Disease	14:220	15:221	0:7	1:NR:2	L2R	NON-CROSS	17-18	28-30	D012460	sulphasalazine|sulphasalazine|sulphasalazine|sulphasalazine	Chemical	17:44:127:211	18:45:128:212	0:1:5:7	D003093	ulcerative colitis	Disease	28	30	1	1:NR:2	L2R	NON-CROSS	127-128	135-137	D012460	sulphasalazine|sulphasalazine|sulphasalazine|sulphasalazine	Chemical	17:44:127:211	18:45:128:212	0:1:5:7	D005128	red eyes|red eyes	Disease	31:135	33:137	1:5	1:CID:2	L2R	NON-CROSS	34-36	44-45	D012460	sulphasalazine|sulphasalazine|sulphasalazine|sulphasalazine	Chemical	17:44:127:211	18:45:128:212	0:1:5:7	D010996	pleural effusion|pleural effusions|pleural effusions|pleural effusion|pleural effusion	Disease	34:114:151:182:193	36:116:153:184:195	1:4:5:5:6	1:NR:2	L2R	NON-CROSS	37-38	44-45	D012460	sulphasalazine|sulphasalazine|sulphasalazine|sulphasalazine	Chemical	17:44:127:211	18:45:128:212	0:1:5:7	D004802	eosinophilia	Disease	37	38	1	1:NR:2	L2R	NON-CROSS	39-41	44-45	D012460	sulphasalazine|sulphasalazine|sulphasalazine|sulphasalazine	Chemical	17:44:127:211	18:45:128:212	0:1:5:7	D001745	urinary abnormalities	Disease	39	41	1	1:CID:2	L2R	CROSS	44-45	54-57	D012460	sulphasalazine|sulphasalazine|sulphasalazine|sulphasalazine	Chemical	17:44:127:211	18:45:128:212	0:1:5:7	D005923	segmental necrotizing glomerulonephritis	Disease	54	57	2	1:CID:2	L2R	NON-CROSS	127-128	133-134	D012460	sulphasalazine|sulphasalazine|sulphasalazine|sulphasalazine	Chemical	17:44:127:211	18:45:128:212	0:1:5:7	D005334	fever	Disease	133	134	5	1:NR:2	L2R	NON-CROSS	127-128	138-140	D012460	sulphasalazine|sulphasalazine|sulphasalazine|sulphasalazine	Chemical	17:44:127:211	18:45:128:212	0:1:5:7	D002637	chest pain	Disease	138	140	5	1:NR:2	R2L	CROSS	156-157	28-30	D013256	steroid|steroid	Chemical	156:189	157:190	5:6	D003093	ulcerative colitis	Disease	28	30	1	1:NR:2	R2L	NON-CROSS	156-157	135-137	D013256	steroid|steroid	Chemical	156:189	157:190	5:6	D005128	red eyes|red eyes	Disease	31:135	33:137	1:5	1:NR:2	R2L	NON-CROSS	156-157	151-153	D013256	steroid|steroid	Chemical	156:189	157:190	5:6	D010996	pleural effusion|pleural effusions|pleural effusions|pleural effusion|pleural effusion	Disease	34:114:151:182:193	36:116:153:184:195	1:4:5:5:6	1:NR:2	R2L	CROSS	156-157	37-38	D013256	steroid|steroid	Chemical	156:189	157:190	5:6	D004802	eosinophilia	Disease	37	38	1	1:NR:2	R2L	CROSS	156-157	39-41	D013256	steroid|steroid	Chemical	156:189	157:190	5:6	D001745	urinary abnormalities	Disease	39	41	1	1:NR:2	R2L	CROSS	156-157	54-57	D013256	steroid|steroid	Chemical	156:189	157:190	5:6	D005923	segmental necrotizing glomerulonephritis	Disease	54	57	2	1:NR:2	R2L	NON-CROSS	156-157	133-134	D013256	steroid|steroid	Chemical	156:189	157:190	5:6	D005334	fever	Disease	133	134	5	1:NR:2	R2L	NON-CROSS	156-157	138-140	D013256	steroid|steroid	Chemical	156:189	157:190	5:6	D002637	chest pain	Disease	138	140	5
17049862	Is phenytoin administration safe in a hypothermic child ?|A male neonate with a Chiari malformation and a leaking myelomeningocoele underwent ventriculoperitoneal shunt insertion followed by repair of myelomeningocoele .|During anaesthesia and surgery , he inadvertently became moderately hypothermic .|Intravenous phenytoin was administered during the later part of the surgery for seizure prophylaxis .|Following phenytoin administration , the patient developed acute severe bradycardia , refractory to atropine and adrenaline .|The cardiac depressant actions of phenytoin and hypothermia can be additive .|Administration of phenytoin in the presence of hypothermia may lead to an adverse cardiac event in children .|As phenytoin is a commonly used drug , clinicians need to be aware of this interaction .	1:NR:2	L2R	NON-CROSS	78-79	80-81	D010672	phenytoin|phenytoin|phenytoin|phenytoin|phenytoin|phenytoin	Chemical	1:42:57:78:87:104	2:43:58:79:88:105	0:3:4:5:6:7	D007035	hypothermic|hypothermic|hypothermia|hypothermia	Disease	6:39:80:92	7:40:81:93	0:2:5:6	1:NR:2	L2R	CROSS	1-2	14-16	D010672	phenytoin|phenytoin|phenytoin|phenytoin|phenytoin|phenytoin	Chemical	1:42:57:78:87:104	2:43:58:79:88:105	0:3:4:5:6:7	D001139	Chiari malformation	Disease	14	16	1	1:NR:2	L2R	NON-CROSS	53-54	57-58	D010672	phenytoin|phenytoin|phenytoin|phenytoin|phenytoin|phenytoin	Chemical	1:42:57:78:87:104	2:43:58:79:88:105	0:3:4:5:6:7	D012640	seizure	Disease	53	54	3	1:CID:2	L2R	NON-CROSS	57-58	65-66	D010672	phenytoin|phenytoin|phenytoin|phenytoin|phenytoin|phenytoin	Chemical	1:42:57:78:87:104	2:43:58:79:88:105	0:3:4:5:6:7	D001919	bradycardia	Disease	65	66	4	1:NR:2	R2L	CROSS	80-81	69-70	D001285	atropine	Chemical	69	70	4	D007035	hypothermic|hypothermic|hypothermia|hypothermia	Disease	6:39:80:92	7:40:81:93	0:2:5:6	1:NR:2	R2L	CROSS	80-81	71-72	D004837	adrenaline	Chemical	71	72	4	D007035	hypothermic|hypothermic|hypothermia|hypothermia	Disease	6:39:80:92	7:40:81:93	0:2:5:6	1:NR:2	R2L	CROSS	69-70	14-16	D001285	atropine	Chemical	69	70	4	D001139	Chiari malformation	Disease	14	16	1	1:NR:2	R2L	CROSS	71-72	14-16	D004837	adrenaline	Chemical	71	72	4	D001139	Chiari malformation	Disease	14	16	1	1:NR:2	R2L	CROSS	69-70	53-54	D001285	atropine	Chemical	69	70	4	D012640	seizure	Disease	53	54	3	1:NR:2	R2L	CROSS	71-72	53-54	D004837	adrenaline	Chemical	71	72	4	D012640	seizure	Disease	53	54	3	1:NR:2	R2L	NON-CROSS	69-70	65-66	D001285	atropine	Chemical	69	70	4	D001919	bradycardia	Disease	65	66	4	1:NR:2	R2L	NON-CROSS	71-72	65-66	D004837	adrenaline	Chemical	71	72	4	D001919	bradycardia	Disease	65	66	4
16225977	Amisulpride related tic - like symptoms in an adolescent schizophrenic .|Tic disorders can be effectively treated by atypical antipsychotics such as risperidone , olanzapine and ziprasidone .|However , there are two case reports that show tic - like symptoms , including motor and phonic variants , occurring during treatment with quetiapine or clozapine .|We present a 15 - year - old girl schizophrenic who developed frequent involuntary eye - blinking movements after 5 months of amisulpride treatment ( 1000 mg per day ) .|The tic - like symptoms resolved completely after we reduced the dose of amisulpride down to 800 mg per day .|However , her psychosis recurred after the dose reduction .|We then placed her on an additional 100 mg per day of quetiapine .|She has been in complete remission under the combined medications for more than one year and maintains a fair role function .|No more tic - like symptoms or other side effects have been reported .|Together with previously reported cases , our patient suggests that tic - like symptoms might occur in certain vulnerable individuals during treatment with atypical antipsychotics such as quetiapine , clozapine , or amisulpride .	1:CID:2	L2R	NON-CROSS	0-1	2-6	C012052	Amisulpride|amisulpride|amisulpride|amisulpride	Chemical	0:78:100:200	1:79:101:201	0:3:4:9	D013981	tic - like symptoms|Tic disorders|tic - like symptoms|tic - like symptoms|tic - like symptoms|tic - like symptoms	Disease	2:11:37:88:156:178	6:13:41:92:160:182	0:1:2:4:8:9	1:NR:2	L2R	NON-CROSS	0-1	9-10	C012052	Amisulpride|amisulpride|amisulpride|amisulpride	Chemical	0:78:100:200	1:79:101:201	0:3:4:9	D012559	schizophrenic|schizophrenic	Disease	9:65	10:66	0:3	1:NR:2	L2R	NON-CROSS	69-74	78-79	C012052	Amisulpride|amisulpride|amisulpride|amisulpride	Chemical	0:78:100:200	1:79:101:201	0:3:4:9	D020820	involuntary eye - blinking movements	Disease	69	74	3	1:NR:2	L2R	CROSS	100-101	111-112	C012052	Amisulpride|amisulpride|amisulpride|amisulpride	Chemical	0:78:100:200	1:79:101:201	0:3:4:9	D011605	psychosis	Disease	111	112	5	1:NR:2	R2L	NON-CROSS	22-23	11-13	D018967	risperidone	Chemical	22	23	1	D013981	tic - like symptoms|Tic disorders|tic - like symptoms|tic - like symptoms|tic - like symptoms|tic - like symptoms	Disease	2:11:37:88:156:178	6:13:41:92:160:182	0:1:2:4:8:9	1:NR:2	R2L	NON-CROSS	24-25	11-13	C076029	olanzapine	Chemical	24	25	1	D013981	tic - like symptoms|Tic disorders|tic - like symptoms|tic - like symptoms|tic - like symptoms|tic - like symptoms	Disease	2:11:37:88:156:178	6:13:41:92:160:182	0:1:2:4:8:9	1:NR:2	R2L	NON-CROSS	37-41	26-27	C092292	ziprasidone	Chemical	26	27	1	D013981	tic - like symptoms|Tic disorders|tic - like symptoms|tic - like symptoms|tic - like symptoms|tic - like symptoms	Disease	2:11:37:88:156:178	6:13:41:92:160:182	0:1:2:4:8:9	1:NR:2	R2L	NON-CROSS	52-53	37-41	C069541	quetiapine|quetiapine|quetiapine	Chemical	52:130:195	53:131:196	2:6:9	D013981	tic - like symptoms|Tic disorders|tic - like symptoms|tic - like symptoms|tic - like symptoms|tic - like symptoms	Disease	2:11:37:88:156:178	6:13:41:92:160:182	0:1:2:4:8:9	1:NR:2	R2L	NON-CROSS	54-55	37-41	D003024	clozapine|clozapine	Chemical	54:197	55:198	2:9	D013981	tic - like symptoms|Tic disorders|tic - like symptoms|tic - like symptoms|tic - like symptoms|tic - like symptoms	Disease	2:11:37:88:156:178	6:13:41:92:160:182	0:1:2:4:8:9	1:NR:2	R2L	CROSS	22-23	9-10	D018967	risperidone	Chemical	22	23	1	D012559	schizophrenic|schizophrenic	Disease	9:65	10:66	0:3	1:NR:2	R2L	CROSS	24-25	9-10	C076029	olanzapine	Chemical	24	25	1	D012559	schizophrenic|schizophrenic	Disease	9:65	10:66	0:3	1:NR:2	R2L	CROSS	26-27	9-10	C092292	ziprasidone	Chemical	26	27	1	D012559	schizophrenic|schizophrenic	Disease	9:65	10:66	0:3	1:NR:2	R2L	CROSS	65-66	52-53	C069541	quetiapine|quetiapine|quetiapine	Chemical	52:130:195	53:131:196	2:6:9	D012559	schizophrenic|schizophrenic	Disease	9:65	10:66	0:3	1:NR:2	R2L	CROSS	65-66	54-55	D003024	clozapine|clozapine	Chemical	54:197	55:198	2:9	D012559	schizophrenic|schizophrenic	Disease	9:65	10:66	0:3	1:NR:2	L2R	CROSS	22-23	69-74	D018967	risperidone	Chemical	22	23	1	D020820	involuntary eye - blinking movements	Disease	69	74	3	1:NR:2	L2R	CROSS	22-23	111-112	D018967	risperidone	Chemical	22	23	1	D011605	psychosis	Disease	111	112	5	1:NR:2	L2R	CROSS	24-25	69-74	C076029	olanzapine	Chemical	24	25	1	D020820	involuntary eye - blinking movements	Disease	69	74	3	1:NR:2	L2R	CROSS	24-25	111-112	C076029	olanzapine	Chemical	24	25	1	D011605	psychosis	Disease	111	112	5	1:NR:2	L2R	CROSS	26-27	69-74	C092292	ziprasidone	Chemical	26	27	1	D020820	involuntary eye - blinking movements	Disease	69	74	3	1:NR:2	L2R	CROSS	26-27	111-112	C092292	ziprasidone	Chemical	26	27	1	D011605	psychosis	Disease	111	112	5	1:NR:2	L2R	CROSS	52-53	69-74	C069541	quetiapine|quetiapine|quetiapine	Chemical	52:130:195	53:131:196	2:6:9	D020820	involuntary eye - blinking movements	Disease	69	74	3	1:NR:2	L2R	CROSS	111-112	130-131	C069541	quetiapine|quetiapine|quetiapine	Chemical	52:130:195	53:131:196	2:6:9	D011605	psychosis	Disease	111	112	5	1:NR:2	L2R	CROSS	54-55	69-74	D003024	clozapine|clozapine	Chemical	54:197	55:198	2:9	D020820	involuntary eye - blinking movements	Disease	69	74	3	1:NR:2	L2R	CROSS	54-55	111-112	D003024	clozapine|clozapine	Chemical	54:197	55:198	2:9	D011605	psychosis	Disease	111	112	5
12852481	Comparison of developmental toxicology of aspirin ( acetylsalicylic acid ) in rats using selected dosing paradigms .|BACKGROUND : Analysis of the literature for nonsteroidal anti - inflammatory drugs ( NSAIDs ) suggests that a low incidence of developmental anomalies occurs in rats given NSAIDs on specific days during organogenesis .|Aspirin ( acetylsalicylic acid [ ASA ] ) , an irreversible cyclooxygenase 1 and 2 inhibitor , induces developmental anomalies when administered to Wistar rats on gestational day ( GD ) 9 , 10 , or 11 ( Kimmel CA , Wilson JG , Schumacher HJ .|Teratology 4 : 15 - 24 , 1971 ) .|There are no published ASA studies using the multiple dosing paradigm of GDs 6 to 17 .|Objectives of the current study were to compare results between Sprague - Dawley ( SD ) and Wistar strains when ASA is administered on GD 9 , 10 , or 11 ; to compare the malformation patterns following single and multiple dosings during organogenesis in SD rats ; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with ASA when a multiple dosing paradigm is used .|METHODS : ASA was administered as a single dose on GD 9 ( 0 , 250 , 500 , or 625 mg / kg ) , 10 ( 0 , 500 , 625 , or 750 mg / kg ) , or 11 ( 0 , 500 , 750 , or 1000 mg / kg ) and from GD 6 to GD 17 ( 0 , 50 , 125 , or 250 mg / kg a day ) in the multiple dose study to SD rats .|Animals were killed on GD 21 , and fetuses were examined viscerally .|RESULTS : The literature evaluation suggested that NSAIDs induce ventricular septal defects ( VSDs ) and midline defects ( MDs ) in rats and diaphragmatic hernia ( DH ) , MDs , and VSDs in rabbits ( Cook JC et al . , 2003 ) ; hence , the present study focused on these malformations , even though ASA induces several other low - incidence malformations .|In single dose studies , DH , MD , and VSD were induced on GDs 9 and 10 .|VSD also was noted following treatment on GD 11 .|In contrast , DH and MD were noted in the multiple dose study design only in the high - dose group , and VSD was noted across all dose groups .|CONCLUSIONS : High concordance in major developmental anomalies between Wistar and SD rats were noted with the exception of VSD in the SD rats and hydrocephalus in the Wistar rats .|Variations and malformations were similar when ASA was administered as a single dose or during the period of organogenesis ( GDs 6 to 17 ) .|It was also evident that , by titrating the dose to achieve a maximum tolerated dose , malformations that normally occur at low incidence , as reported from previous single dose studies , could also be induced with ASA given at multiple doses .	1:CID:2	L2R	NON-CROSS	188-189	190-191	D001241	aspirin|acetylsalicylic acid|Aspirin|acetylsalicylic acid|ASA|ASA|ASA|ASA|ASA|ASA|ASA|ASA	Chemical	5:7:51:53:56:112:145:190:201:357:463:521	6:9:52:55:57:113:146:191:202:358:464:522	0:0:2:2:2:4:5:5:6:8:13:14	D000014	developmental anomalies|developmental anomalies|malformations|malformations|malformations|developmental anomalies|malformations|malformations	Disease	38:69:188:353:364:432:459:500	40:71:189:354:365:434:460:501	1:2:5:8:8:12:13:14	1:NR:2	L2R	NON-CROSS	180-182	190-191	D001241	aspirin|acetylsalicylic acid|Aspirin|acetylsalicylic acid|ASA|ASA|ASA|ASA|ASA|ASA|ASA|ASA	Chemical	5:7:51:53:56:112:145:190:201:357:463:521	6:9:52:55:57:113:146:191:202:358:464:522	0:0:2:2:2:4:5:5:6:8:13:14	D005767	gastrointestinal toxicity	Disease	180	182	5	1:CID:2	L2R	NON-CROSS	445-446	463-464	D001241	aspirin|acetylsalicylic acid|Aspirin|acetylsalicylic acid|ASA|ASA|ASA|ASA|ASA|ASA|ASA|ASA	Chemical	5:7:51:53:56:112:145:190:201:357:463:521	6:9:52:55:57:113:146:191:202:358:464:522	0:0:2:2:2:4:5:5:6:8:13:14	D006345	ventricular septal defects|VSDs|VSDs|VSD|VSD|VSD|VSD	Disease	308:312:332:376:385:418:445	311:313:333:377:386:419:446	8:8:8:9:10:11:12	1:NR:2	L2R	NON-CROSS	357-358	373-374	D001241	aspirin|acetylsalicylic acid|Aspirin|acetylsalicylic acid|ASA|ASA|ASA|ASA|ASA|ASA|ASA|ASA	Chemical	5:7:51:53:56:112:145:190:201:357:463:521	6:9:52:55:57:113:146:191:202:358:464:522	0:0:2:2:2:4:5:5:6:8:13:14	D009436	midline defects|MDs|MDs|MD|MD	Disease	315:318:329:373:400	317:319:330:374:401	8:8:8:9:11	1:CID:2	L2R	NON-CROSS	357-358	371-372	D001241	aspirin|acetylsalicylic acid|Aspirin|acetylsalicylic acid|ASA|ASA|ASA|ASA|ASA|ASA|ASA|ASA	Chemical	5:7:51:53:56:112:145:190:201:357:463:521	6:9:52:55:57:113:146:191:202:358:464:522	0:0:2:2:2:4:5:5:6:8:13:14	D065630	diaphragmatic hernia|DH|DH|DH	Disease	323:326:371:398	325:327:372:399	8:8:9:11	1:NR:2	L2R	CROSS	451-452	463-464	D001241	aspirin|acetylsalicylic acid|Aspirin|acetylsalicylic acid|ASA|ASA|ASA|ASA|ASA|ASA|ASA|ASA	Chemical	5:7:51:53:56:112:145:190:201:357:463:521	6:9:52:55:57:113:146:191:202:358:464:522	0:0:2:2:2:4:5:5:6:8:13:14	D006849	hydrocephalus	Disease	451	452	12
11858397	Torsade de pointes induced by metoclopramide in an elderly woman with preexisting complete left bundle branch block .|There is a growing list of drugs implicated in acquired long QT syndrome and torsade de pointes .|However , the torsadogenic potential of metoclopramide , a commonly used antiemetic and prokinetic drug , has not been reported in the literature , despite its chemical similarity to procainamide .|We report on a 92 - year - old woman with preexisting complete left bundle branch block who developed torsade de pointes after intravenous and oral administration of metoclopramide .|This patient also developed torsade de pointes when cisapride and erythromycin were given simultaneously .|These two episodes were suppressed successfully after discontinuing the offending drugs and administering class IB drugs .|This is the first documentation that metoclopramide provokes torsade de pointes clinically .|Metoclopramide should be used cautiously in patients with a risk of torsade de pointes .	1:CID:2	R2L	NON-CROSS	142-143	137-140	D008787	metoclopramide|metoclopramide|metoclopramide|metoclopramide|Metoclopramide	Chemical	5:42:95:135:142	6:43:96:136:143	0:2:3:6:7	D016171	Torsade de pointes|torsade de pointes|torsade de pointes|torsade de pointes|torsade de pointes|torsade de pointes	Disease	0:32:86:101:137:153	3:35:89:104:140:156	0:1:3:4:6:7	1:NR:2	R2L	CROSS	86-89	65-66	D011342	procainamide	Chemical	65	66	2	D016171	Torsade de pointes|torsade de pointes|torsade de pointes|torsade de pointes|torsade de pointes|torsade de pointes	Disease	0:32:86:101:137:153	3:35:89:104:140:156	0:1:3:4:6:7	1:CID:2	R2L	NON-CROSS	105-106	101-104	D020117	cisapride	Chemical	105	106	4	D016171	Torsade de pointes|torsade de pointes|torsade de pointes|torsade de pointes|torsade de pointes|torsade de pointes	Disease	0:32:86:101:137:153	3:35:89:104:140:156	0:1:3:4:6:7	1:CID:2	R2L	NON-CROSS	107-108	101-104	D004917	erythromycin	Chemical	107	108	4	D016171	Torsade de pointes|torsade de pointes|torsade de pointes|torsade de pointes|torsade de pointes|torsade de pointes	Disease	0:32:86:101:137:153	3:35:89:104:140:156	0:1:3:4:6:7	1:NR:2	L2R	NON-CROSS	5-6	13-17	D008787	metoclopramide|metoclopramide|metoclopramide|metoclopramide|Metoclopramide	Chemical	5:42:95:135:142	6:43:96:136:143	0:2:3:6:7	D002037	left bundle branch block|left bundle branch block	Disease	13:80	17:84	0:3	1:NR:2	L2R	CROSS	28-31	42-43	D008787	metoclopramide|metoclopramide|metoclopramide|metoclopramide|Metoclopramide	Chemical	5:42:95:135:142	6:43:96:136:143	0:2:3:6:7	D008133	long QT syndrome	Disease	28	31	1	1:NR:2	R2L	CROSS	80-84	65-66	D011342	procainamide	Chemical	65	66	2	D002037	left bundle branch block|left bundle branch block	Disease	13:80	17:84	0:3	1:NR:2	R2L	CROSS	105-106	80-84	D020117	cisapride	Chemical	105	106	4	D002037	left bundle branch block|left bundle branch block	Disease	13:80	17:84	0:3	1:NR:2	R2L	CROSS	107-108	80-84	D004917	erythromycin	Chemical	107	108	4	D002037	left bundle branch block|left bundle branch block	Disease	13:80	17:84	0:3	1:NR:2	R2L	CROSS	65-66	28-31	D011342	procainamide	Chemical	65	66	2	D008133	long QT syndrome	Disease	28	31	1	1:NR:2	R2L	CROSS	105-106	28-31	D020117	cisapride	Chemical	105	106	4	D008133	long QT syndrome	Disease	28	31	1	1:NR:2	R2L	CROSS	107-108	28-31	D004917	erythromycin	Chemical	107	108	4	D008133	long QT syndrome	Disease	28	31	1
11009181	Apomorphine : an underutilized therapy for Parkinson 's disease .|Apomorphine was the first dopaminergic drug ever used to treat symptoms of Parkinson 's disease .|While powerful antiparkinsonian effects had been observed as early as 1951 , the potential of treating fluctuating Parkinson 's disease by subcutaneous administration of apomorphine has only recently become the subject of systematic study .|A number of small scale clinical trials have unequivocally shown that intermittent subcutaneous apomorphine injections produce antiparkinsonian benefit close if not identical to that seen with levodopa and that apomorphine rescue injections can reliably revert off - periods even in patients with complex on - off motor swings .|Continuous subcutaneous apomorphine infusions can reduce daily off - time by more than 50 % in this group of patients , which appears to be a stronger effect than that generally seen with add - on therapy with oral dopamine agonists or COMT inhibitors .|Extended follow - up studies of up to 8 years have demonstrated long - term persistence of apomorphine efficacy .|In addition , there is convincing clinical evidence that monotherapy with continuous subcutaneous apomorphine infusions is associated with marked reductions of preexisting levodopa - induced dyskinesias .|The main side effects of subcutaneous apomorphine treatment are related to cutaneous tolerability problems , whereas sedation and psychiatric complications play a lesser role .|Given the marked degree of efficacy of subcutaneous apomorphine treatment in fluctuating Parkinson 's disease , this approach seems to deserve more widespread clinical use .	1:NR:2	L2R	NON-CROSS	6-9	10-11	D001058	Apomorphine|Apomorphine|apomorphine|apomorphine|apomorphine|apomorphine|apomorphine|apomorphine|apomorphine|apomorphine	Chemical	0:10:50:74:90:112:172:188:208:235	1:11:51:75:91:113:173:189:209:236	0:1:2:3:3:4:5:6:7:8	D010300	Parkinson 's disease|Parkinson 's disease|Parkinson 's disease|Parkinson 's disease	Disease	6:22:43:239	9:25:46:242	0:1:2:8	1:NR:2	L2R	NON-CROSS	200-201	208-209	D001058	Apomorphine|Apomorphine|apomorphine|apomorphine|apomorphine|apomorphine|apomorphine|apomorphine|apomorphine|apomorphine	Chemical	0:10:50:74:90:112:172:188:208:235	1:11:51:75:91:113:173:189:209:236	0:1:2:3:3:4:5:6:7:8	D004409	dyskinesias	Disease	200	201	6	1:NR:2	L2R	NON-CROSS	208-209	220-221	D001058	Apomorphine|Apomorphine|apomorphine|apomorphine|apomorphine|apomorphine|apomorphine|apomorphine|apomorphine|apomorphine	Chemical	0:10:50:74:90:112:172:188:208:235	1:11:51:75:91:113:173:189:209:236	0:1:2:3:3:4:5:6:7:8	D001523	psychiatric	Disease	220	221	7	1:NR:2	R2L	CROSS	87-88	43-46	D007980	levodopa|levodopa	Chemical	87:197	88:198	3:6	D010300	Parkinson 's disease|Parkinson 's disease|Parkinson 's disease|Parkinson 's disease	Disease	6:22:43:239	9:25:46:242	0:1:2:8	1:NR:2	R2L	CROSS	239-242	149-150	D004298	dopamine	Chemical	149	150	4	D010300	Parkinson 's disease|Parkinson 's disease|Parkinson 's disease|Parkinson 's disease	Disease	6:22:43:239	9:25:46:242	0:1:2:8	1:CID:2	L2R	NON-CROSS	197-198	200-201	D007980	levodopa|levodopa	Chemical	87:197	88:198	3:6	D004409	dyskinesias	Disease	200	201	6	1:NR:2	L2R	CROSS	197-198	220-221	D007980	levodopa|levodopa	Chemical	87:197	88:198	3:6	D001523	psychiatric	Disease	220	221	7	1:NR:2	L2R	CROSS	149-150	200-201	D004298	dopamine	Chemical	149	150	4	D004409	dyskinesias	Disease	200	201	6	1:NR:2	L2R	CROSS	149-150	220-221	D004298	dopamine	Chemical	149	150	4	D001523	psychiatric	Disease	220	221	7
8988571	Fatal excited delirium following cocaine use : epidemiologic findings provide new evidence for mechanisms of cocaine toxicity .|We describe an outbreak of deaths from cocaine - induced excited delirium ( EDDs ) in Dade County , Florida between 1979 and 1990 .|From a registry of all cocaine - related deaths in Dade County , Florida , from 1969 - 1990 , 58 EDDs were compared with 125 victims of accidental cocaine overdose without excited delirium .|Compared with controls , EDDs were more frequently black , male , and younger .|They were less likely to have a low body mass index , and more likely to have died in police custody , to have received medical treatment immediately before death , to have survived for a longer period , to have developed hyperthermia , and to have died in summer months .|EDDs had concentrations of cocaine and benzoylecgonine in autopsy blood that were similar to those for controls .|The epidemiologic findings are most consistent with the hypothesis that chronic cocaine use disrupts dopaminergic function and , when coupled with recent cocaine use , may precipitate agitation , delirium , aberrant thermoregulation , rhabdomyolysis , and sudden death .	1:CID:2	R2L	NON-CROSS	4-5	2-3	D003042	cocaine|cocaine|cocaine|cocaine|cocaine|cocaine|cocaine|cocaine	Chemical	4:15:25:48:72:149:174:185	5:16:26:49:73:150:175:186	0:0:1:2:2:5:6:6	D003693	delirium|delirium|EDDs|EDDs|delirium|EDDs|EDDs|delirium	Disease	2:29:31:64:76:82:145:192	3:30:32:65:77:83:146:193	0:1:1:2:2:3:5:6	1:NR:2	R2L	NON-CROSS	151-152	145-146	C005618	benzoylecgonine	Chemical	151	152	5	D003693	delirium|delirium|EDDs|EDDs|delirium|EDDs|EDDs|delirium	Disease	2:29:31:64:76:82:145:192	3:30:32:65:77:83:146:193	0:1:1:2:2:3:5:6	1:NR:2	L2R	NON-CROSS	15-16	16-17	D003042	cocaine|cocaine|cocaine|cocaine|cocaine|cocaine|cocaine|cocaine	Chemical	4:15:25:48:72:149:174:185	5:16:26:49:73:150:175:186	0:0:1:2:2:5:6:6	D064420	toxicity	Disease	16	17	0	1:NR:2	L2R	NON-CROSS	72-73	73-74	D003042	cocaine|cocaine|cocaine|cocaine|cocaine|cocaine|cocaine|cocaine	Chemical	4:15:25:48:72:149:174:185	5:16:26:49:73:150:175:186	0:0:1:2:2:5:6:6	D062787	overdose	Disease	73	74	2	1:NR:2	L2R	CROSS	135-136	149-150	D003042	cocaine|cocaine|cocaine|cocaine|cocaine|cocaine|cocaine|cocaine	Chemical	4:15:25:48:72:149:174:185	5:16:26:49:73:150:175:186	0:0:1:2:2:5:6:6	D005334	hyperthermia	Disease	135	136	4	1:NR:2	L2R	NON-CROSS	185-186	190-191	D003042	cocaine|cocaine|cocaine|cocaine|cocaine|cocaine|cocaine|cocaine	Chemical	4:15:25:48:72:149:174:185	5:16:26:49:73:150:175:186	0:0:1:2:2:5:6:6	D011595	agitation	Disease	190	191	6	1:CID:2	L2R	NON-CROSS	185-186	197-198	D003042	cocaine|cocaine|cocaine|cocaine|cocaine|cocaine|cocaine|cocaine	Chemical	4:15:25:48:72:149:174:185	5:16:26:49:73:150:175:186	0:0:1:2:2:5:6:6	D012206	rhabdomyolysis	Disease	197	198	6	1:CID:2	L2R	NON-CROSS	185-186	200-202	D003042	cocaine|cocaine|cocaine|cocaine|cocaine|cocaine|cocaine|cocaine	Chemical	4:15:25:48:72:149:174:185	5:16:26:49:73:150:175:186	0:0:1:2:2:5:6:6	D003645	sudden death	Disease	200	202	6	1:NR:2	R2L	CROSS	151-152	16-17	C005618	benzoylecgonine	Chemical	151	152	5	D064420	toxicity	Disease	16	17	0	1:NR:2	R2L	CROSS	151-152	73-74	C005618	benzoylecgonine	Chemical	151	152	5	D062787	overdose	Disease	73	74	2	1:NR:2	R2L	CROSS	151-152	135-136	C005618	benzoylecgonine	Chemical	151	152	5	D005334	hyperthermia	Disease	135	136	4	1:NR:2	L2R	CROSS	151-152	190-191	C005618	benzoylecgonine	Chemical	151	152	5	D011595	agitation	Disease	190	191	6	1:NR:2	L2R	CROSS	151-152	197-198	C005618	benzoylecgonine	Chemical	151	152	5	D012206	rhabdomyolysis	Disease	197	198	6	1:NR:2	L2R	CROSS	151-152	200-202	C005618	benzoylecgonine	Chemical	151	152	5	D003645	sudden death	Disease	200	202	6
6615052	Heparin - induced thrombocytopenia , thrombosis , and hemorrhage .|Sixty - two patients with a heparin - induced thrombocytopenia are reported .|Clinical manifestations of this disorder include hemorrhage or , more frequently , thromboembolic events in patients receiving heparin .|Laboratory testing has revealed a falling platelet count , increased resistance to heparin , and aggregation of platelets by the patient 's plasma when heparin is added .|Immunologic testing has demonstrated the presence of a heparin - dependent platelet membrane antibody .|The 20 deaths , 52 hemorrhagic and thromboembolic complications , and 21 surgical procedures to manage the complications confirm the seriousness of the disorder .|Specific risk factors have not been identified ; therefore , all patients receiving heparin should be monitored .|If the platelet count falls to less than 100 , 000 / mm3 , while the patient is receiving heparin , platelet aggregation testing , using the patient 's plasma , is indicated .|Management consists of cessation of heparin , platelet anti - aggregating agents , and alternate forms of anticoagulation when indicated .	1:CID:2	L2R	NON-CROSS	0-1	3-4	D006493	Heparin|heparin|heparin|heparin|heparin|heparin|heparin|heparin|heparin	Chemical	0:16:40:54:66:78:123:147:167	1:17:41:55:67:79:124:148:168	0:1:2:3:3:4:6:7:8	D013921	thrombocytopenia|thrombocytopenia	Disease	3:19	4:20	0:1	1:NR:2	L2R	NON-CROSS	0-1	5-6	D006493	Heparin|heparin|heparin|heparin|heparin|heparin|heparin|heparin|heparin	Chemical	0:16:40:54:66:78:123:147:167	1:17:41:55:67:79:124:148:168	0:1:2:3:3:4:6:7:8	D013927	thrombosis	Disease	5	6	0	1:CID:2	L2R	NON-CROSS	0-1	8-9	D006493	Heparin|heparin|heparin|heparin|heparin|heparin|heparin|heparin|heparin	Chemical	0:16:40:54:66:78:123:147:167	1:17:41:55:67:79:124:148:168	0:1:2:3:3:4:6:7:8	D006470	hemorrhage|hemorrhage|hemorrhagic and thromboembolic complications	Disease	8:29:90	9:30:94	0:2:5	1:CID:2	L2R	NON-CROSS	35-36	40-41	D006493	Heparin|heparin|heparin|heparin|heparin|heparin|heparin|heparin|heparin	Chemical	0:16:40:54:66:78:123:147:167	1:17:41:55:67:79:124:148:168	0:1:2:3:3:4:6:7:8	D013923	thromboembolic|hemorrhagic and thromboembolic complications	Disease	35:90	36:94	2:5	1:NR:2	L2R	NON-CROSS	147-148	149-151	D006493	Heparin|heparin|heparin|heparin|heparin|heparin|heparin|heparin|heparin	Chemical	0:16:40:54:66:78:123:147:167	1:17:41:55:67:79:124:148:168	0:1:2:3:3:4:6:7:8	D001791	a falling platelet count|platelet aggregation	Disease	46:149	50:151	3:7
3952818	Cardiac toxicity of 5 - fluorouracil .|Report of a case of spontaneous angina .|We report a case of a patient with colon carcinoma and liver metastasis who presented chest pain after 5 - fluorouracil ( 5 - FU ) administration .|Clinical electrocardiographic evolution was similar to that observed in Prinzmetal 's angina , and chest pain promptly resolved with nifedipine .|These data suggest that coronary spasm may be the cause of cardiotoxicity due to 5 - FU , and that calcium antagonists may probably be used in the prevention or treatment of 5 - FU cardiotoxicity .	1:NR:2	R2L	NON-CROSS	99-100	96-99	D005472	5 - fluorouracil|5 - fluorouracil|5 - FU|5 - FU|5 - FU	Chemical	3:33:37:78:96	6:36:40:81:99	0:2:2:4:4	D066126	Cardiac toxicity|cardiotoxicity|cardiotoxicity	Disease	0:75:99	2:76:100	0:4:4	1:NR:2	R2L	CROSS	75-76	62-63	D009543	nifedipine	Chemical	62	63	3	D066126	Cardiac toxicity|cardiotoxicity|cardiotoxicity	Disease	0:75:99	2:76:100	0:4:4	1:NR:2	R2L	NON-CROSS	84-85	75-76	D002118	calcium	Chemical	84	85	4	D066126	Cardiac toxicity|cardiotoxicity|cardiotoxicity	Disease	0:75:99	2:76:100	0:4:4	1:NR:2	L2R	CROSS	3-6	13-14	D005472	5 - fluorouracil|5 - fluorouracil|5 - FU|5 - FU|5 - FU	Chemical	3:33:37:78:96	6:36:40:81:99	0:2:2:4:4	D000787	angina	Disease	13	14	1	1:NR:2	L2R	NON-CROSS	23-25	33-36	D005472	5 - fluorouracil|5 - fluorouracil|5 - FU|5 - FU|5 - FU	Chemical	3:33:37:78:96	6:36:40:81:99	0:2:2:4:4	D003110	colon carcinoma	Disease	23	25	2	1:NR:2	L2R	NON-CROSS	27-28	33-36	D005472	5 - fluorouracil|5 - fluorouracil|5 - FU|5 - FU|5 - FU	Chemical	3:33:37:78:96	6:36:40:81:99	0:2:2:4:4	D009362	metastasis	Disease	27	28	2	1:CID:2	L2R	NON-CROSS	30-32	33-36	D005472	5 - fluorouracil|5 - fluorouracil|5 - FU|5 - FU|5 - FU	Chemical	3:33:37:78:96	6:36:40:81:99	0:2:2:4:4	D002637	chest pain|chest pain	Disease	30:57	32:59	2:3	1:CID:2	L2R	CROSS	37-40	52-55	D005472	5 - fluorouracil|5 - fluorouracil|5 - FU|5 - FU|5 - FU	Chemical	3:33:37:78:96	6:36:40:81:99	0:2:2:4:4	D000788	Prinzmetal 's angina	Disease	52	55	3	1:NR:2	L2R	NON-CROSS	68-70	78-81	D005472	5 - fluorouracil|5 - fluorouracil|5 - FU|5 - FU|5 - FU	Chemical	3:33:37:78:96	6:36:40:81:99	0:2:2:4:4	D003329	coronary spasm	Disease	68	70	4	1:NR:2	R2L	CROSS	62-63	13-14	D009543	nifedipine	Chemical	62	63	3	D000787	angina	Disease	13	14	1	1:NR:2	R2L	CROSS	84-85	13-14	D002118	calcium	Chemical	84	85	4	D000787	angina	Disease	13	14	1	1:NR:2	R2L	CROSS	62-63	23-25	D009543	nifedipine	Chemical	62	63	3	D003110	colon carcinoma	Disease	23	25	2	1:NR:2	R2L	CROSS	84-85	23-25	D002118	calcium	Chemical	84	85	4	D003110	colon carcinoma	Disease	23	25	2	1:NR:2	R2L	CROSS	62-63	27-28	D009543	nifedipine	Chemical	62	63	3	D009362	metastasis	Disease	27	28	2	1:NR:2	R2L	CROSS	84-85	27-28	D002118	calcium	Chemical	84	85	4	D009362	metastasis	Disease	27	28	2	1:NR:2	R2L	NON-CROSS	62-63	57-59	D009543	nifedipine	Chemical	62	63	3	D002637	chest pain|chest pain	Disease	30:57	32:59	2:3	1:NR:2	R2L	CROSS	84-85	57-59	D002118	calcium	Chemical	84	85	4	D002637	chest pain|chest pain	Disease	30:57	32:59	2:3	1:NR:2	R2L	NON-CROSS	62-63	52-55	D009543	nifedipine	Chemical	62	63	3	D000788	Prinzmetal 's angina	Disease	52	55	3	1:NR:2	R2L	CROSS	84-85	52-55	D002118	calcium	Chemical	84	85	4	D000788	Prinzmetal 's angina	Disease	52	55	3	1:NR:2	L2R	CROSS	62-63	68-70	D009543	nifedipine	Chemical	62	63	3	D003329	coronary spasm	Disease	68	70	4	1:NR:2	R2L	NON-CROSS	84-85	68-70	D002118	calcium	Chemical	84	85	4	D003329	coronary spasm	Disease	68	70	4
3084782	Toxicity due to remission inducing drugs in rheumatoid arthritis .|Association with HLA - B35 and Cw4 antigens .|Twenty - five patients with rheumatoid arthritis ( RA ) who developed toxicity while taking remission inducing drugs and 30 without toxicity were studied for possible associations with class I and II HLA antigens .|A strong association has been found between nephritis and dermatitis due to Tiopronin ( a D - Penicillamine like compound ) and class I antigens B35 - Cw4 , and between dermatitis due to gold thiosulphate and B35 .|Compared to healthy controls a lower DR5 frequency was observed in patients with RA except for the Tiopronin related nephritis group .	1:NR:2	R2L	CROSS	66-67	40-41	D008625	Tiopronin|Tiopronin	Chemical	66:110	67:111	3:4	D064420	Toxicity|toxicity|toxicity	Disease	0:31:40	1:32:41	0:2:2	1:NR:2	R2L	CROSS	69-72	40-41	D010396	D - Penicillamine	Chemical	69	72	3	D064420	Toxicity|toxicity|toxicity	Disease	0:31:40	1:32:41	0:2:2	1:NR:2	R2L	CROSS	88-89	40-41	D006046	gold	Chemical	88	89	3	D064420	Toxicity|toxicity|toxicity	Disease	0:31:40	1:32:41	0:2:2	1:NR:2	R2L	NON-CROSS	110-111	106-107	D008625	Tiopronin|Tiopronin	Chemical	66:110	67:111	3:4	D001172	rheumatoid arthritis|rheumatoid arthritis|RA|RA	Disease	7:24:27:106	9:26:28:107	0:2:2:4	1:NR:2	R2L	CROSS	106-107	69-72	D010396	D - Penicillamine	Chemical	69	72	3	D001172	rheumatoid arthritis|rheumatoid arthritis|RA|RA	Disease	7:24:27:106	9:26:28:107	0:2:2:4	1:NR:2	R2L	CROSS	106-107	88-89	D006046	gold	Chemical	88	89	3	D001172	rheumatoid arthritis|rheumatoid arthritis|RA|RA	Disease	7:24:27:106	9:26:28:107	0:2:2:4	1:CID:2	R2L	NON-CROSS	112-113	110-111	D008625	Tiopronin|Tiopronin	Chemical	66:110	67:111	3:4	D009393	nephritis|nephritis	Disease	61:112	62:113	3:4	1:NR:2	R2L	NON-CROSS	69-72	61-62	D010396	D - Penicillamine	Chemical	69	72	3	D009393	nephritis|nephritis	Disease	61:112	62:113	3:4	1:NR:2	R2L	NON-CROSS	112-113	88-89	D006046	gold	Chemical	88	89	3	D009393	nephritis|nephritis	Disease	61:112	62:113	3:4	1:CID:2	R2L	NON-CROSS	66-67	63-64	D008625	Tiopronin|Tiopronin	Chemical	66:110	67:111	3:4	D003872	dermatitis|dermatitis	Disease	63:85	64:86	3:3	1:NR:2	R2L	NON-CROSS	69-72	63-64	D010396	D - Penicillamine	Chemical	69	72	3	D003872	dermatitis|dermatitis	Disease	63:85	64:86	3:3	1:CID:2	R2L	NON-CROSS	88-89	85-86	D006046	gold	Chemical	88	89	3	D003872	dermatitis|dermatitis	Disease	63:85	64:86	3:3
430165	Transient hemiparesis : a rare manifestation of diphenylhydantoin toxicity .|Report of two cases .|Among the common side effects of diphenylhydantoin ( DPH ) overdose , the most frequently encountered neurological signs are those of cerebellar dysfunction .|Very rarely , the toxic neurological manifestations of this drug are of cerebral origin .|Two patients are presented who suffered progressive hemiparesis due to DPH overdose .|Both had brain surgery before DPH treatment .|It is assumed that patients with some cerebral damage are liable to manifest DPH toxicity as focal neurological signs .	1:CID:2	R2L	NON-CROSS	64-65	61-62	D010672	diphenylhydantoin|diphenylhydantoin|DPH|DPH|DPH|DPH	Chemical	7:21:23:64:72:88	8:22:24:65:73:89	0:2:2:4:5:6	D010291	hemiparesis|hemiparesis	Disease	1:61	2:62	0:4	1:NR:2	L2R	NON-CROSS	7-8	8-9	D010672	diphenylhydantoin|diphenylhydantoin|DPH|DPH|DPH|DPH	Chemical	7:21:23:64:72:88	8:22:24:65:73:89	0:2:2:4:5:6	D064420	toxicity|toxicity	Disease	8:89	9:90	0:6	1:CID:2	L2R	NON-CROSS	64-65	65-66	D010672	diphenylhydantoin|diphenylhydantoin|DPH|DPH|DPH|DPH	Chemical	7:21:23:64:72:88	8:22:24:65:73:89	0:2:2:4:5:6	D062787	overdose|overdose	Disease	25:65	26:66	2:4	1:CID:2	L2R	NON-CROSS	23-24	36-38	D010672	diphenylhydantoin|diphenylhydantoin|DPH|DPH|DPH|DPH	Chemical	7:21:23:64:72:88	8:22:24:65:73:89	0:2:2:4:5:6	D002526	cerebellar dysfunction	Disease	36	38	2	1:NR:2	L2R	NON-CROSS	82-84	88-89	D010672	diphenylhydantoin|diphenylhydantoin|DPH|DPH|DPH|DPH	Chemical	7:21:23:64:72:88	8:22:24:65:73:89	0:2:2:4:5:6	D001927	cerebral damage	Disease	82	84	6
16600756	Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder .|PURPOSE : NGF and PGs in the bladder can be affected by pathological changes in the bladder and these changes can be detected in urine .|We investigated changes in urinary NGF and PGs in women with OAB .|MATERIALS AND METHODS : The study groups included 65 women with OAB and 20 without bladder symptoms who served as controls .|Evaluation included patient history , urinalysis , a voiding diary and urodynamic studies .|Urine samples were collected .|NGF , PGE2 , PGF2alpha and PGI2 were measured using enzyme - linked immunosorbent assay and compared between the groups .|In addition , correlations between urinary NGF and PG , and urodynamic parameters in patients with OAB were examined .|RESULTS : Urinary NGF , PGE2 and PGF2alpha were significantly increased in patients with OAB compared with controls ( p < 0 . 05 ) .|However , urinary PGI2 was not different between controls and patients with OAB .|In patients with OAB urinary PGE2 positively correlated with volume at first desire to void and maximum cystometric capacity ( p < 0 . 05 ) .|Urinary NGF , PGF2alpha and PGI2 did not correlate with urodynamic parameters in patients with OAB .|CONCLUSIONS : NGF and PGs have important roles in the development of OAB symptoms in female patients .|Urinary levels of these factors may be used as markers to evaluate OAB symptoms .	1:NR:2	L2R	NON-CROSS	48-49	52-53	D011453	prostaglandins|PGs|PGs|PG|PGs	Chemical	4:19:48:124:224	5:20:49:125:225	0:1:2:7:12	D053201	overactive bladder|OAB|OAB|OAB|OAB|OAB|OAB|OAB|OAB|OAB	Disease	12:52:65:132:150:174:179:218:232:250	14:53:66:133:151:175:180:219:233:251	0:2:3:7:8:9:10:11:12:13	1:CID:2	R2L	NON-CROSS	181-182	179-180	D015232	PGE2|PGE2|PGE2	Chemical	97:141:181	98:142:182	6:8:10	D053201	overactive bladder|OAB|OAB|OAB|OAB|OAB|OAB|OAB|OAB|OAB	Disease	12:52:65:132:150:174:179:218:232:250	14:53:66:133:151:175:180:219:233:251	0:2:3:7:8:9:10:11:12:13	1:CID:2	R2L	NON-CROSS	150-151	143-144	D015237	PGF2alpha|PGF2alpha|PGF2alpha	Chemical	99:143:206	100:144:207	6:8:11	D053201	overactive bladder|OAB|OAB|OAB|OAB|OAB|OAB|OAB|OAB|OAB	Disease	12:52:65:132:150:174:179:218:232:250	14:53:66:133:151:175:180:219:233:251	0:2:3:7:8:9:10:11:12:13	1:NR:2	R2L	NON-CROSS	174-175	165-166	D011464	PGI2|PGI2|PGI2	Chemical	101:165:208	102:166:209	6:9:11	D053201	overactive bladder|OAB|OAB|OAB|OAB|OAB|OAB|OAB|OAB|OAB	Disease	12:52:65:132:150:174:179:218:232:250	14:53:66:133:151:175:180:219:233:251	0:2:3:7:8:9:10:11:12:13
15686794	Acute low back pain during intravenous administration of amiodarone : a report of two cases .|Amiodarone represents an effective antiarrhythmic drug for cardioversion of recent - onset atrial fibrillation ( AF ) and maintenance of sinus rhythm .|We briefly describe two patients suffering from recent - onset atrial fibrillation , who experienced an acute devastating low back pain a few minutes after initiation of intravenous amiodarone loading .|Notably , this side effect has not been ever reported in the medical literature .|Clinicians should be aware of this reaction since prompt termination of parenteral administration leads to complete resolution .	1:CID:2	R2L	NON-CROSS	8-9	1-4	D000638	amiodarone|Amiodarone|amiodarone	Chemical	8:16:67	9:17:68	0:1:2	D017116	low back pain|low back pain	Disease	1:57	4:60	0:2	1:NR:2	L2R	NON-CROSS	16-17	28-30	D000638	amiodarone|Amiodarone|amiodarone	Chemical	8:16:67	9:17:68	0:1:2	D001281	atrial fibrillation|AF|atrial fibrillation	Disease	28:31:49	30:32:51	1:1:2
12760988	Postoperative myalgia after succinylcholine : no evidence for an inflammatory origin .|A common side effect associated with succinylcholine is postoperative myalgia .|The pathogenesis of this myalgia is still unclear ; inflammation has been suggested but without convincing evidence .|We designed the present study to investigate whether an inflammatory reaction contributes to this myalgia .|The incidence and severity of succinylcholine - associated myalgia was determined in 64 patients pretreated with saline or dexamethasone before succinylcholine ( n = 32 for each ) .|Incidence and severity of myalgia did not differ significantly between the two groups : 15 patients in the dexamethasone group complained of myalgia compared with 18 patients in the saline group , and severe myalgia was reported by five patients and three patients , respectively ( not significant ) .|At 48 h after surgery , 12 patients in both groups still suffered from myalgia ( not significant ) .|In addition , interleukin - 6 ( IL - 6 ) as an early marker of inflammation was assessed in a subgroup of 10 patients pretreated with saline .|We found an increase of IL - 6 for only three patients , but only one patient reported myalgia ; no relationship between myalgia and the increase of IL - 6 was found .|In conclusion , there is no evidence for an inflammatory origin of succinylcholine - associated myalgia .|IMPLICATIONS : Administration of dexamethasone before succinylcholine was not effective in decreasing the incidence or the severity of succinylcholine - induced postoperative myalgia .|Furthermore , there was no significant relationship between postoperative myalgia and time course of interleukin - 6 concentrations , a marker of inflammation .|Pretreatment with dexamethasone is not justified to prevent postoperative myalgia after succinylcholine .	1:CID:2	R2L	NON-CROSS	3-4	0-2	D013390	succinylcholine|succinylcholine|succinylcholine|succinylcholine|succinylcholine|succinylcholine|succinylcholine|succinylcholine	Chemical	3:18:62:77:231:242:254:295	4:19:63:78:232:243:255:296	0:1:4:4:9:10:10:12	D010149	Postoperative myalgia|postoperative myalgia|postoperative myalgia|postoperative myalgia|postoperative myalgia	Disease	0:20:257:268:292	2:22:259:270:294	0:1:10:11:12	1:NR:2	R2L	NON-CROSS	292-294	286-287	D003907	dexamethasone|dexamethasone|dexamethasone|dexamethasone	Chemical	75:104:240:286	76:105:241:287	4:5:10:12	D010149	Postoperative myalgia|postoperative myalgia|postoperative myalgia|postoperative myalgia|postoperative myalgia	Disease	0:20:257:268:292	2:22:259:270:294	0:1:10:11:12	1:CID:2	L2R	NON-CROSS	62-63	65-66	D013390	succinylcholine|succinylcholine|succinylcholine|succinylcholine|succinylcholine|succinylcholine|succinylcholine|succinylcholine	Chemical	3:18:62:77:231:242:254:295	4:19:63:78:232:243:255:296	0:1:4:4:9:10:10:12	D063806	myalgia|myalgia|myalgia|myalgia|myalgia|myalgia|myalgia|myalgia|myalgia|myalgia	Disease	27:55:65:90:108:120:150:203:208:234	28:56:66:91:109:121:151:204:209:235	2:3:4:5:5:5:6:8:8:9	1:NR:2	L2R	CROSS	282-283	295-296	D013390	succinylcholine|succinylcholine|succinylcholine|succinylcholine|succinylcholine|succinylcholine|succinylcholine|succinylcholine	Chemical	3:18:62:77:231:242:254:295	4:19:63:78:232:243:255:296	0:1:4:4:9:10:10:12	D007249	inflammation|inflammation|inflammation	Disease	32:172:282	33:173:283	2:7:11	1:NR:2	R2L	NON-CROSS	108-109	104-105	D003907	dexamethasone|dexamethasone|dexamethasone|dexamethasone	Chemical	75:104:240:286	76:105:241:287	4:5:10:12	D063806	myalgia|myalgia|myalgia|myalgia|myalgia|myalgia|myalgia|myalgia|myalgia|myalgia	Disease	27:55:65:90:108:120:150:203:208:234	28:56:66:91:109:121:151:204:209:235	2:3:4:5:5:5:6:8:8:9	1:NR:2	R2L	CROSS	286-287	282-283	D003907	dexamethasone|dexamethasone|dexamethasone|dexamethasone	Chemical	75:104:240:286	76:105:241:287	4:5:10:12	D007249	inflammation|inflammation|inflammation	Disease	32:172:282	33:173:283	2:7:11
12691807	Levodopa - induced oromandibular dystonia in progressive supranuclear palsy .|Levodopa - induced dyskinesias have been reported in Parkinson 's disease and multiple system atrophy .|Cranial dystonias are rare in patients with progressive supranuclear palsy ( PSP ) .|In this report we describe an unusual case of reversible levodopa - induced Oromandibular dystonia ( OMD ) in a PSP patient to highlight the importance of recognizing this drug related complication in the management of PSP , and discuss the possible underlying pathophysiology .	1:CID:2	L2R	NON-CROSS	0-1	4-5	D007980	Levodopa|Levodopa|levodopa	Chemical	0:10:50	1:11:51	0:1:3	D004421	dystonia|dystonias	Disease	4:27	5:28	0:2	1:NR:2	L2R	NON-CROSS	6-9	10-11	D007980	Levodopa|Levodopa|levodopa	Chemical	0:10:50	1:11:51	0:1:3	D013494	progressive supranuclear palsy|progressive supranuclear palsy|PSP|PSP|PSP	Disease	6:33:37:60:76	9:36:38:61:77	0:2:2:3:3	1:NR:2	L2R	NON-CROSS	10-11	13-14	D007980	Levodopa|Levodopa|levodopa	Chemical	0:10:50	1:11:51	0:1:3	D004409	dyskinesias	Disease	13	14	1	1:NR:2	L2R	NON-CROSS	10-11	18-21	D007980	Levodopa|Levodopa|levodopa	Chemical	0:10:50	1:11:51	0:1:3	D010300	Parkinson 's disease	Disease	18	21	1	1:NR:2	L2R	NON-CROSS	10-11	22-25	D007980	Levodopa|Levodopa|levodopa	Chemical	0:10:50	1:11:51	0:1:3	D019578	multiple system atrophy	Disease	22	25	1	1:NR:2	L2R	NON-CROSS	50-51	53-55	D007980	Levodopa|Levodopa|levodopa	Chemical	0:10:50	1:11:51	0:1:3	D008538	Oromandibular dystonia|OMD	Disease	53:56	55:57	3:3
12600698	Protective effect of edaravone against streptomycin - induced vestibulotoxicity in the guinea pig .|This study investigated alleviation of streptomycin - induced vestibulotoxicity by edaravone in guinea pigs .|Edaravone , a free radical scavenger , has potent free radical quenching action and is used in clinical practice to treat cerebral infarction .|Streptomycin was administered to the inner ear by osmotic pump for 24 h , and edaravone ( n = 8 ) or saline ( n = 6 ) was intraperitoneally injected once a day for 7 days .|We observed horizontal vestibulo - ocular reflex as a marker of postoperative vestibular function .|Animals injected with saline showed statistically smaller gains than those injected with edaravone .|These results suggest that edaravone suppresses streptomycin - induced vestibulotoxicity .	1:NR:2	L2R	NON-CROSS	22-23	24-25	C005435	edaravone|edaravone|Edaravone|edaravone|edaravone|edaravone	Chemical	3:24:29:68:118:124	4:25:30:69:119:125	0:1:2:3:5:6	D015837	vestibulotoxicity|vestibulotoxicity|vestibulotoxicity	Disease	8:22:129	9:23:130	0:1:6	1:NR:2	L2R	NON-CROSS	50-52	68-69	C005435	edaravone|edaravone|Edaravone|edaravone|edaravone|edaravone	Chemical	3:24:29:68:118:124	4:25:30:69:119:125	0:1:2:3:5:6	D002544	cerebral infarction	Disease	50	52	2	1:CID:2	L2R	NON-CROSS	5-6	8-9	D013307	streptomycin|streptomycin|Streptomycin|streptomycin	Chemical	5:19:53:126	6:20:54:127	0:1:3:6	D015837	vestibulotoxicity|vestibulotoxicity|vestibulotoxicity	Disease	8:22:129	9:23:130	0:1:6	1:NR:2	L2R	CROSS	50-52	53-54	D013307	streptomycin|streptomycin|Streptomycin|streptomycin	Chemical	5:19:53:126	6:20:54:127	0:1:3:6	D002544	cerebral infarction	Disease	50	52	2
12091028	Ketamine in war / tropical surgery ( a final tribute to the racemic mixture ) .|A technique of continuous intravenous anaesthesia with ketamine was used successfully during the Somalia civil war in 1994 and in north Uganda in 1999 for 64 operations in 62 patients , aged from 6 weeks to 70 years , undergoing limb and abdominal surgery including caesarian sections and interventions in neonates .|Operations lasting up to 2h could be performed in the absence of sophisticated equipment such as pulse oximeters or ventilators in patients on spontaneous ventilation breathing air / oxygen only .|After premedication with diazepam , glycopyrrolate and local anaesthesia , and induction with standard doses of ketamine , a maintenance dose of 10 - 20 microg / kg / min of ketamine proved safe and effective .|Emphasis was placed on bedside clinical monitoring , relying heavily on the heart rate .|Diazepam , unless contraindicated or risky , remains the only necessary complementary drug to ketamine as it buffers its cardiovascular response and decreases the duration and intensity of operative and postoperative hallucinations .|Local anaesthetic blocks were useful in decreasing the requirement for postoperative analgesia .|An antisialogue was usually unnecessary in operations lasting up to 2 h , glycopyrrolate being the best choice for its lowest psychotropic and chronotropic effects , especially in a hot climate .|Experience in war / tropical settings suggests this technique could be useful in civilian contexts such as outdoor life - saving emergency surgery or in mass casualties where , e . g .|amputation and rapid extrication were required .	1:CID:2	L2R	NON-CROSS	165-166	182-183	D007649	Ketamine|ketamine|ketamine|ketamine|ketamine	Chemical	0:23:115:130:165	1:24:116:131:166	0:1:3:3:5	D006212	hallucinations	Disease	182	183	5	1:NR:2	L2R	CROSS	165-166	195-196	D007649	Ketamine|ketamine|ketamine|ketamine|ketamine	Chemical	0:23:115:130:165	1:24:116:131:166	0:1:3:3:5	D000699	analgesia	Disease	195	196	6	1:NR:2	L2R	CROSS	96-97	182-183	D010100	oxygen	Chemical	96	97	2	D006212	hallucinations	Disease	182	183	5	1:NR:2	L2R	CROSS	96-97	195-196	D010100	oxygen	Chemical	96	97	2	D000699	analgesia	Disease	195	196	6	1:NR:2	L2R	NON-CROSS	151-152	182-183	D003975	diazepam|Diazepam	Chemical	102:151	103:152	3:5	D006212	hallucinations	Disease	182	183	5	1:NR:2	L2R	CROSS	151-152	195-196	D003975	diazepam|Diazepam	Chemical	102:151	103:152	3:5	D000699	analgesia	Disease	195	196	6	1:NR:2	L2R	CROSS	182-183	210-211	D006024	glycopyrrolate|glycopyrrolate	Chemical	104:210	105:211	3:7	D006212	hallucinations	Disease	182	183	5	1:NR:2	L2R	CROSS	195-196	210-211	D006024	glycopyrrolate|glycopyrrolate	Chemical	104:210	105:211	3:7	D000699	analgesia	Disease	195	196	6
11860495	Steroid structure and pharmacological properties determine the anti - amnesic effects of pregnenolone sulphate in the passive avoidance task in rats .|Pregnenolone sulphate ( PREGS ) has generated interest as one of the most potent memory - enhancing neurosteroids to be examined in rodent learning studies , with particular importance in the ageing process .|The mechanism by which this endogenous steroid enhances memory formation is hypothesized to involve actions on glutamatergic and GABAergic systems .|This hypothesis stems from findings that PREGS is a potent positive modulator of N - methyl - d - aspartate receptors ( NMDARs ) and a negative modulator of gamma - aminobutyric acid ( A ) receptors ( GABA ( A ) Rs ) .|Moreover , PREGS is able to reverse the amnesic - like effects of NMDAR and GABA ( A ) R ligands .|To investigate this hypothesis , the present study in rats examined the memory - altering abilities of structural analogs of PREGS , which differ in their modulation of NMDAR and / or GABA ( A ) R function .|The analogs tested were : 11 - ketopregnenolone sulphate ( an agent that is inactive at GABA ( A ) Rs and NMDARs ) , epipregnanolone ( [ 3beta - hydroxy - 5beta - pregnan - 20 - one ] sulphate , an inhibitor of both GABA ( A ) Rs and NMDARs ) , and a newly synthesized ( - ) PREGS enantiomer ( which is identical to PREGS in effects on GABA ( A ) Rs and NMDARs ) .|The memory - enhancing effects of PREGS and its analogs were tested in the passive avoidance task using the model of scopolamine - induced amnesia .|Both PREGS and its ( - ) enantiomer blocked the effects of scopolamine .|The results show that , unlike PREGS , 11 - ketopregnenolone sulphate and epipregnanolone sulphate failed to block the effect of scopolamine , suggesting that altering the modulation of NMDA receptors diminishes the memory - enhancing effects of PREGS .|Moreover , enantioselectivity was demonstrated by the ability of natural PREGS to be an order of magnitude more effective than its synthetic enantiomer in reversing scopolamine - induced amnesia .|These results identify a novel neuropharmacological site for the modulation of memory processes by neuroactive steroids .	1:NR:2	L2R	NON-CROSS	0-1	9-10	D013256	Steroid|steroid|steroids	Chemical	0:62:390	1:63:391	0:2:11	D000647	amnesic|amnesic|amnesia|amnesia	Disease	9:130:289:373	10:131:290:374	0:4:7:10	1:NR:2	R2L	NON-CROSS	12-14	9-10	C018370	pregnenolone sulphate|Pregnenolone sulphate|PREGS|PREGS|PREGS|PREGS|epipregnanolone ( [ 3beta - hydroxy - 5beta - pregnan - 20 - one ] sulphate|PREGS|PREGS|PREGS|PREGS|PREGS|epipregnanolone sulphate|PREGS|PREGS	Chemical	12:22:25:83:124:164:208:245:252:271:292:311:318:343:355	14:24:26:84:125:165:224:246:253:272:293:312:320:344:356	0:1:1:3:4:5:6:6:6:7:8:9:9:9:10	D000647	amnesic|amnesic|amnesia|amnesia	Disease	9:130:289:373	10:131:290:374	0:4:7:10	1:NR:2	R2L	CROSS	373-374	334-335	D016202	N - methyl - d - aspartate|NMDA	Chemical	90:334	97:335	3:9	D000647	amnesic|amnesic|amnesia|amnesia	Disease	9:130:289:373	10:131:290:374	0:4:7:10	1:NR:2	R2L	NON-CROSS	137-138	130-131	D005680	gamma - aminobutyric acid|GABA|GABA|GABA|GABA|GABA|GABA	Chemical	106:115:137:176:199:229:256	110:116:138:177:200:230:257	3:3:4:5:6:6:6	D000647	amnesic|amnesic|amnesia|amnesia	Disease	9:130:289:373	10:131:290:374	0:4:7:10	1:CID:2	R2L	NON-CROSS	289-290	286-287	D012601	scopolamine|scopolamine|scopolamine|scopolamine	Chemical	286:303:326:370	287:304:327:371	7:8:9:10	D000647	amnesic|amnesic|amnesia|amnesia	Disease	9:130:289:373	10:131:290:374	0:4:7:10
11752998	Preliminary efficacy assessment of intrathecal injection of an American formulation of adenosine in humans .|BACKGROUND : Preclinical studies of intrathecal adenosine suggest it may be effective in the treatment of acute and chronic pain in humans , and preliminary studies in volunteers and patients with a Swedish formulation of adenosine suggests it may be effective in hypersensitivity states but not with acute noxious stimulation .|The purpose of this study was to screen for efficacy of a different formulation of adenosine marketed in the US , using both acute noxious stimulation and capsaicin - evoked mechanical hypersensitivity .|METHODS : Following Food and Drug Administration and institutional review board approval and written informed consent , 65 volunteers were studied in two trials : an open - label , dose - escalating trial with intrathecal adenosine doses of 0 . 25 - 2 . 0 mg and a double - blind , placebo - controlled trial of adenosine , 2 mg .|Cerebrospinal fluid was obtained for pharmacokinetic analysis , and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal capsaicin injection were determined .|RESULTS : Adenosine produced no effect on pain report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal capsaicin injection for at least 24 h .|In contrast , residence time of adenosine in cerebrospinal fluid was short ( < 4 h ) .|CONCLUSIONS : These results show selective inhibition by intrathecal adenosine of hypersensitivity , presumed to reflect central sensitization in humans after peripheral capsaicin injection .|The long - lasting effect is consistent with that observed in preliminary reports of patients with chronic neuropathic pain and is not due to prolonged residence of adenosine in cerebrospinal fluid .	1:NR:2	L2R	NON-CROSS	21-22	31-35	D000241	adenosine|adenosine|adenosine|adenosine|adenosine|adenosine|Adenosine|adenosine|adenosine|adenosine	Chemical	11:21:50:81:135:157:195:231:252:295	12:22:51:82:136:158:196:232:253:296	0:1:1:2:3:3:5:6:7:8	D059787	acute and chronic pain	Disease	31	35	1	1:NR:2	L2R	NON-CROSS	21-22	31-35	D000241	adenosine|adenosine|adenosine|adenosine|adenosine|adenosine|Adenosine|adenosine|adenosine|adenosine	Chemical	11:21:50:81:135:157:195:231:252:295	12:22:51:82:136:158:196:232:253:296	0:1:1:2:3:3:5:6:7:8	D059350	acute and chronic pain	Disease	31	35	1	1:NR:2	L2R	NON-CROSS	252-253	254-255	D000241	adenosine|adenosine|adenosine|adenosine|adenosine|adenosine|Adenosine|adenosine|adenosine|adenosine	Chemical	11:21:50:81:135:157:195:231:252:295	12:22:51:82:136:158:196:232:253:296	0:1:1:2:3:3:5:6:7:8	D004342	hypersensitivity|hypersensitivity|hypersensitivity	Disease	57:97:254	58:98:255	1:2:7	1:NR:2	L2R	NON-CROSS	195-196	200-201	D000241	adenosine|adenosine|adenosine|adenosine|adenosine|adenosine|Adenosine|adenosine|adenosine|adenosine	Chemical	11:21:50:81:135:157:195:231:252:295	12:22:51:82:136:158:196:232:253:296	0:1:1:2:3:3:5:6:7:8	D010146	pain|pain	Disease	171:200	172:201	4:5	1:NR:2	L2R	NON-CROSS	185-186	195-196	D000241	adenosine|adenosine|adenosine|adenosine|adenosine|adenosine|Adenosine|adenosine|adenosine|adenosine	Chemical	11:21:50:81:135:157:195:231:252:295	12:22:51:82:136:158:196:232:253:296	0:1:1:2:3:3:5:6:7:8	D006930	mechanical hyperalgesia|allodynia|mechanical hyperalgesia|allodynia	Disease	182:185:211:214	184:186:213:215	4:4:5:5	1:NR:2	L2R	NON-CROSS	285-287	295-296	D000241	adenosine|adenosine|adenosine|adenosine|adenosine|adenosine|Adenosine|adenosine|adenosine|adenosine	Chemical	11:21:50:81:135:157:195:231:252:295	12:22:51:82:136:158:196:232:253:296	0:1:1:2:3:3:5:6:7:8	D009437	neuropathic pain	Disease	285	287	8	1:NR:2	R2L	CROSS	93-94	31-35	D002211	capsaicin|capsaicin|capsaicin|capsaicin	Chemical	93:188:217:265	94:189:218:266	2:4:5:7	D059787	acute and chronic pain	Disease	31	35	1	1:NR:2	R2L	CROSS	93-94	31-35	D002211	capsaicin|capsaicin|capsaicin|capsaicin	Chemical	93:188:217:265	94:189:218:266	2:4:5:7	D059350	acute and chronic pain	Disease	31	35	1	1:NR:2	R2L	NON-CROSS	97-98	93-94	D002211	capsaicin|capsaicin|capsaicin|capsaicin	Chemical	93:188:217:265	94:189:218:266	2:4:5:7	D004342	hypersensitivity|hypersensitivity|hypersensitivity	Disease	57:97:254	58:98:255	1:2:7	1:NR:2	L2R	NON-CROSS	188-189	200-201	D002211	capsaicin|capsaicin|capsaicin|capsaicin	Chemical	93:188:217:265	94:189:218:266	2:4:5:7	D010146	pain|pain	Disease	171:200	172:201	4:5	1:CID:2	L2R	NON-CROSS	185-186	188-189	D002211	capsaicin|capsaicin|capsaicin|capsaicin	Chemical	93:188:217:265	94:189:218:266	2:4:5:7	D006930	mechanical hyperalgesia|allodynia|mechanical hyperalgesia|allodynia	Disease	182:185:211:214	184:186:213:215	4:4:5:5	1:NR:2	L2R	CROSS	265-266	285-287	D002211	capsaicin|capsaicin|capsaicin|capsaicin	Chemical	93:188:217:265	94:189:218:266	2:4:5:7	D009437	neuropathic pain	Disease	285	287	8
10354657	Effect of lithium maintenance therapy on thyroid and parathyroid function .|OBJECTIVES : To assess changes induced by lithium maintenance therapy on the incidence of thyroid , parathyroid and ion alterations .|These were evaluated with respect to the duration of lithium therapy , age , sex , and family history ( whether or not the patient had a first - degree relative with thyroid disease ) .|DESIGN : Prospective study .|SETTING : Affective Disorders Clinic at St .|Mary 's Hospital , Montreal .|PATIENTS : One hundred and one patients ( 28 men and 73 women ) with bipolar disorder receiving lithium maintenance therapy ranging from 1 year 's to 32 years ' duration .|The control group consisted of 82 patients with no psychiatric or endocrinological diagnoses from the hospital 's out - patient clinics .|OUTCOME MEASURES : Laboratory analyses of calcium , magnesium and thyroid - stimulating hormone levels performed before beginning lithium therapy and at biannual follow - up .|RESULTS : Hypothyroidism developed in 40 patients , excluding 8 patients who were hypothyroid at baseline .|All patients having first - degree relatives affected by thyroid illness had accelerated onset of hypothyroidism ( 3 . 7 years after onset of lithium therapy ) compared with patients without a family history ( 8 . 6 years after onset of lithium therapy ) .|Women over 60 years of age were more often affected by hypothyroidism than women under 60 years of age ( 34 . 6 % versus 31 . 9 % ) .|Magnesium levels in patients on lithium treatment were unchanged from baseline levels .|After lithium treatment , calcium levels were higher than either baseline levels or control levels .|Thus , lithium treatment counteracted the decrease in plasma calcium levels associated with aging .|CONCLUSIONS : Familial thyroid illness is a risk factor for hypothyroidism and hypercalcemia during lithium therapy .	1:NR:2	L2R	NON-CROSS	309-311	320-321	D008094	lithium|lithium|lithium|lithium|lithium|lithium|lithium|lithium|lithium|lithium|lithium	Chemical	2:18:41:105:159:209:227:267:276:293:320	3:19:42:106:160:210:228:268:277:294:321	0:1:2:6:8:10:10:12:13:14:15	D013959	thyroid disease|thyroid illness|thyroid illness	Disease	64:194:309	66:196:311	2:10:15	1:NR:2	L2R	NON-CROSS	102-104	105-106	D008094	lithium|lithium|lithium|lithium|lithium|lithium|lithium|lithium|lithium|lithium|lithium	Chemical	2:18:41:105:159:209:227:267:276:293:320	3:19:42:106:160:210:228:268:277:294:321	0:1:2:6:8:10:10:12:13:14:15	D001714	bipolar disorder	Disease	102	104	6	1:NR:2	L2R	CROSS	105-106	128-129	D008094	lithium|lithium|lithium|lithium|lithium|lithium|lithium|lithium|lithium|lithium|lithium	Chemical	2:18:41:105:159:209:227:267:276:293:320	3:19:42:106:160:210:228:268:277:294:321	0:1:2:6:8:10:10:12:13:14:15	D001523	psychiatric	Disease	128	129	7	1:CID:2	L2R	NON-CROSS	316-317	320-321	D008094	lithium|lithium|lithium|lithium|lithium|lithium|lithium|lithium|lithium|lithium|lithium	Chemical	2:18:41:105:159:209:227:267:276:293:320	3:19:42:106:160:210:228:268:277:294:321	0:1:2:6:8:10:10:12:13:14:15	D007037	Hypothyroidism|hypothyroid|hypothyroidism|hypothyroidism|hypothyroidism	Disease	170:181:200:242:316	171:182:201:243:317	9:9:10:11:15	1:NR:2	L2R	NON-CROSS	318-319	320-321	D008094	lithium|lithium|lithium|lithium|lithium|lithium|lithium|lithium|lithium|lithium|lithium	Chemical	2:18:41:105:159:209:227:267:276:293:320	3:19:42:106:160:210:228:268:277:294:321	0:1:2:6:8:10:10:12:13:14:15	D006934	hypercalcemia	Disease	318	319	15	1:NR:2	R2L	CROSS	309-311	300-301	D002118	calcium|calcium|calcium	Chemical	147:279:300	148:280:301	8:13:14	D013959	thyroid disease|thyroid illness|thyroid illness	Disease	64:194:309	66:196:311	2:10:15	1:NR:2	R2L	CROSS	194-196	149-150	D008274	magnesium|Magnesium	Chemical	149:262	150:263	8:12	D013959	thyroid disease|thyroid illness|thyroid illness	Disease	64:194:309	66:196:311	2:10:15	1:NR:2	R2L	CROSS	147-148	102-104	D002118	calcium|calcium|calcium	Chemical	147:279:300	148:280:301	8:13:14	D001714	bipolar disorder	Disease	102	104	6	1:NR:2	R2L	CROSS	149-150	102-104	D008274	magnesium|Magnesium	Chemical	149:262	150:263	8:12	D001714	bipolar disorder	Disease	102	104	6	1:NR:2	R2L	CROSS	147-148	128-129	D002118	calcium|calcium|calcium	Chemical	147:279:300	148:280:301	8:13:14	D001523	psychiatric	Disease	128	129	7	1:NR:2	R2L	CROSS	149-150	128-129	D008274	magnesium|Magnesium	Chemical	149:262	150:263	8:12	D001523	psychiatric	Disease	128	129	7	1:NR:2	L2R	CROSS	300-301	316-317	D002118	calcium|calcium|calcium	Chemical	147:279:300	148:280:301	8:13:14	D007037	Hypothyroidism|hypothyroid|hypothyroidism|hypothyroidism|hypothyroidism	Disease	170:181:200:242:316	171:182:201:243:317	9:9:10:11:15	1:NR:2	L2R	CROSS	300-301	318-319	D002118	calcium|calcium|calcium	Chemical	147:279:300	148:280:301	8:13:14	D006934	hypercalcemia	Disease	318	319	15	1:NR:2	L2R	CROSS	242-243	262-263	D008274	magnesium|Magnesium	Chemical	149:262	150:263	8:12	D007037	Hypothyroidism|hypothyroid|hypothyroidism|hypothyroidism|hypothyroidism	Disease	170:181:200:242:316	171:182:201:243:317	9:9:10:11:15	1:NR:2	L2R	CROSS	262-263	318-319	D008274	magnesium|Magnesium	Chemical	149:262	150:263	8:12	D006934	hypercalcemia	Disease	318	319	15
10328196	Systemic toxicity following administration of sirolimus ( formerly rapamycin ) for psoriasis : association of capillary leak syndrome with apoptosis of lesional lymphocytes .|BACKGROUND : Sirolimus ( formerly rapamycin ) is an immunosuppressive agent that interferes with T - cell activation .|After 2 individuals with psoriasis developed a capillary leak syndrome following treatment with oral sirolimus lesional skin cells and activated peripheral blood cells were analyzed for induction of apoptosis .|OBSERVATIONS : A keratome skin specimen from 1 patient with sirolimus - induced capillary leak syndrome had a 2 . 3 - fold increase in percentage of apoptotic cells ( to 48 % ) compared with an unaffected sirolimus - treated patient with psoriasis ( 21 % ) .|Activated peripheral blood T cells from patients with psoriasis tended to exhibit greater spontaneous or dexamethasone - induced apoptosis than did normal T cells , particularly in the presence of sirolimus .|CONCLUSIONS : Severe adverse effects of sirolimus include fever , anemia , and capillary leak syndrome .|These symptoms may be the result of drug - induced apoptosis of lesional leukocytes , especially activated T lymphocytes , and possibly release of inflammatory mediators .|Because patients with severe psoriasis may develop capillary leak from various systemic therapies , clinical monitoring is advisable for patients with inflammatory diseases who are treated with immune modulators .	1:NR:2	R2L	NON-CROSS	5-6	1-2	D020123	sirolimus|rapamycin|Sirolimus|rapamycin|sirolimus|sirolimus|sirolimus|sirolimus|sirolimus	Chemical	5:8:26:29:57:83:111:152:160	6:9:27:30:58:84:112:153:161	0:0:1:1:2:3:3:4:5	D064420	toxicity	Disease	1	2	0	1:NR:2	R2L	CROSS	137-138	1-2	D003907	dexamethasone	Chemical	137	138	4	D064420	toxicity	Disease	1	2	0	1:NR:2	L2R	NON-CROSS	8-9	11-12	D020123	sirolimus|rapamycin|Sirolimus|rapamycin|sirolimus|sirolimus|sirolimus|sirolimus|sirolimus	Chemical	5:8:26:29:57:83:111:152:160	6:9:27:30:58:84:112:153:161	0:0:1:1:2:3:3:4:5	D011565	psoriasis|psoriasis|psoriasis|psoriasis|psoriasis	Disease	11:47:116:130:202	12:48:117:131:203	0:2:3:4:7	1:CID:2	L2R	NON-CROSS	83-84	86-89	D020123	sirolimus|rapamycin|Sirolimus|rapamycin|sirolimus|sirolimus|sirolimus|sirolimus|sirolimus	Chemical	5:8:26:29:57:83:111:152:160	6:9:27:30:58:84:112:153:161	0:0:1:1:2:3:3:4:5	D019559	capillary leak syndrome|capillary leak syndrome|capillary leak syndrome|capillary leak syndrome|capillary leak	Disease	15:50:86:167:205	18:53:89:170:207	0:2:3:5:7	1:NR:2	L2R	NON-CROSS	160-161	162-163	D020123	sirolimus|rapamycin|Sirolimus|rapamycin|sirolimus|sirolimus|sirolimus|sirolimus|sirolimus	Chemical	5:8:26:29:57:83:111:152:160	6:9:27:30:58:84:112:153:161	0:0:1:1:2:3:3:4:5	D005334	fever	Disease	162	163	5	1:NR:2	L2R	NON-CROSS	160-161	164-165	D020123	sirolimus|rapamycin|Sirolimus|rapamycin|sirolimus|sirolimus|sirolimus|sirolimus|sirolimus	Chemical	5:8:26:29:57:83:111:152:160	6:9:27:30:58:84:112:153:161	0:0:1:1:2:3:3:4:5	D000740	anemia	Disease	164	165	5	1:NR:2	L2R	CROSS	160-161	219-221	D020123	sirolimus|rapamycin|Sirolimus|rapamycin|sirolimus|sirolimus|sirolimus|sirolimus|sirolimus	Chemical	5:8:26:29:57:83:111:152:160	6:9:27:30:58:84:112:153:161	0:0:1:1:2:3:3:4:5	D007249	inflammatory diseases	Disease	219	221	7	1:NR:2	R2L	NON-CROSS	137-138	130-131	D003907	dexamethasone	Chemical	137	138	4	D011565	psoriasis|psoriasis|psoriasis|psoriasis|psoriasis	Disease	11:47:116:130:202	12:48:117:131:203	0:2:3:4:7	1:NR:2	R2L	CROSS	167-170	137-138	D003907	dexamethasone	Chemical	137	138	4	D019559	capillary leak syndrome|capillary leak syndrome|capillary leak syndrome|capillary leak syndrome|capillary leak	Disease	15:50:86:167:205	18:53:89:170:207	0:2:3:5:7	1:NR:2	L2R	CROSS	137-138	162-163	D003907	dexamethasone	Chemical	137	138	4	D005334	fever	Disease	162	163	5	1:NR:2	L2R	CROSS	137-138	164-165	D003907	dexamethasone	Chemical	137	138	4	D000740	anemia	Disease	164	165	5	1:NR:2	L2R	CROSS	137-138	219-221	D003907	dexamethasone	Chemical	137	138	4	D007249	inflammatory diseases	Disease	219	221	7
9630698	Contribution of the glycine site of NMDA receptors in rostral and intermediate - caudal parts of the striatum to the regulation of muscle tone in rats .|The aim of the present study was to assess the contribution of the glycine site of NMDA receptors in the striatum to the regulation of muscle tone .|Muscle tone was examined using a combined mechanoand electromyographic method , which measured simultaneously the muscle resistance ( MMG ) of the rat 's hind foot to passive extension and flexion in the ankle joint and the electromyographic activity ( EMG ) of the antagonistic muscles of that joint : gastrocnemius and tibialis anterior .|Muscle rigidity was induced by haloperidol ( 2 . 5 mg / kg i . p . ) .|5 , 7 - dichlorokynurenic acid ( 5 , 7 - DCKA ) , a selective glycine site antagonist , injected in doses of 2 . 5 and 4 . 5 microg / 0 . 5 microl bilaterally , into the rostral region of the striatum , decreased both the haloperidol - induced muscle rigidity ( MMG ) and the enhanced electromyographic activity ( EMG ) .|5 , 7 - DCKA injected bilaterally in a dose of 4 . 5 microg / 0 . 5 microl into the intermediate - caudal region of the striatum of rats not pretreated with haloperidol had no effect on the muscle tone .|The present results suggest that blockade of the glycine site of NMDA receptors in the rostral part of the striatum may be mainly responsible for the antiparkinsonian action of this drug .	1:NR:2	L2R	NON-CROSS	110-112	145-146	D005998	glycine|glycine|glycine|glycine	Chemical	3:40:145:247	4:41:146:248	0:1:4:6	D009127	Muscle rigidity|muscle rigidity	Disease	110:182	112:184	3:4	1:NR:2	L2R	CROSS	43-44	110-112	D016202	NMDA|NMDA|NMDA	Chemical	6:43:250	7:44:251	0:1:6	D009127	Muscle rigidity|muscle rigidity	Disease	110:182	112:184	3:4	1:CID:2	R2L	NON-CROSS	182-184	179-180	D006220	haloperidol|haloperidol|haloperidol	Chemical	115:179:230	116:180:231	3:4:5	D009127	Muscle rigidity|muscle rigidity	Disease	110:182	112:184	3:4	1:NR:2	R2L	NON-CROSS	196-201	182-184	C066192	5 , 7 - dichlorokynurenic acid|5 , 7 - DCKA|5 , 7 - DCKA	Chemical	129:136:196	135:141:201	4:4:5	D009127	Muscle rigidity|muscle rigidity	Disease	110:182	112:184	3:4
8480959	Efficacy and tolerability of lovastatin in 3390 women with moderate hypercholesterolemia .|OBJECTIVE : To evaluate the efficacy and safety of lovastatin in women with moderate hypercholesterolemia .|DESIGN : The Expanded Clinical Evaluation of Lovastatin ( EXCEL ) Study , a multicenter , double - blind , diet - and placebo - controlled trial , in which participants were randomly assigned to receive placebo or lovastatin at doses of 20 or 40 mg once daily , or 20 or 40 mg twice daily for 48 weeks .|SETTING : Ambulatory patients recruited by 362 participating centers throughout the United States .|PATIENTS : Women ( n = 3390 ) from the total cohort of 8245 volunteers .|MEASUREMENTS : Plasma total , low - density lipoprotein ( LDL ) , and high - density lipoprotein ( HDL ) cholesterol , and triglycerides ; and laboratory and clinical evidence of adverse events monitored periodically throughout the study .|RESULTS : Among women , lovastatin ( 20 to 80 mg / d ) produced sustained ( 12 - to 48 - week ) , dose - related changes ( P < 0 . 001 ) : decreases in LDL cholesterol ( 24 % to 40 % ) and triglycerides ( 9 % to 18 % ) , and increases in HDL cholesterol ( 6 . 7 % to 8 . 6 % ) .|Depending on the dose , from 82 % to 95 % of lovastatin - treated women achieved the National Cholesterol Education Program goal of LDL cholesterol levels less than 4 . 14 mmol / L ( 160 mg / dL ) , and 40 % to 87 % achieved the goal of 3 . 36 mmol / L ( 130 mg / dL ) .|Successive transaminase elevations greater than three times the upper limit of normal occurred in 0 . 1 % of women and were dose dependent above the 20 - mg dose .|Myopathy , defined as muscle symptoms with creatine kinase elevations greater than 10 times the upper limit of normal , was rare and associated with the highest recommended daily dose of lovastatin ( 80 mg ) .|Estrogen - replacement therapy appeared to have no effect on either the efficacy or safety profile of lovastatin .|CONCLUSION : Lovastatin is highly effective and generally well tolerated as therapy for primary hypercholesterolemia in women .	1:NR:2	L2R	NON-CROSS	21-22	26-27	D008148	lovastatin|lovastatin|Lovastatin|lovastatin|lovastatin|lovastatin|lovastatin|lovastatin|Lovastatin	Chemical	4:21:35:66:163:245:360:383:387	5:22:36:67:164:246:361:384:388	0:1:2:2:6:7:9:10:11	D006937	hypercholesterolemia|hypercholesterolemia|hypercholesterolemia	Disease	10:26:399	11:27:400	0:1:11	1:CID:2	L2R	NON-CROSS	329-330	360-361	D008148	lovastatin|lovastatin|Lovastatin|lovastatin|lovastatin|lovastatin|lovastatin|lovastatin|Lovastatin	Chemical	4:21:35:66:163:245:360:383:387	5:22:36:67:164:246:361:384:388	0:1:2:2:6:7:9:10:11	D009135	Myopathy	Disease	329	330	9	1:NR:2	R2L	CROSS	139-140	26-27	D002784	cholesterol|cholesterol|cholesterol|Cholesterol|cholesterol	Chemical	139:198:220:252:258	140:199:221:253:259	5:6:6:7:7	D006937	hypercholesterolemia|hypercholesterolemia|hypercholesterolemia	Disease	10:26:399	11:27:400	0:1:11	1:NR:2	R2L	CROSS	142-143	26-27	D014280	triglycerides|triglycerides	Chemical	142:207	143:208	5:6	D006937	hypercholesterolemia|hypercholesterolemia|hypercholesterolemia	Disease	10:26:399	11:27:400	0:1:11	1:NR:2	R2L	CROSS	399-400	336-337	D003401	creatine	Chemical	336	337	9	D006937	hypercholesterolemia|hypercholesterolemia|hypercholesterolemia	Disease	10:26:399	11:27:400	0:1:11	1:NR:2	L2R	CROSS	258-259	329-330	D002784	cholesterol|cholesterol|cholesterol|Cholesterol|cholesterol	Chemical	139:198:220:252:258	140:199:221:253:259	5:6:6:7:7	D009135	Myopathy	Disease	329	330	9	1:NR:2	L2R	CROSS	207-208	329-330	D014280	triglycerides|triglycerides	Chemical	142:207	143:208	5:6	D009135	Myopathy	Disease	329	330	9	1:NR:2	R2L	NON-CROSS	336-337	329-330	D003401	creatine	Chemical	336	337	9	D009135	Myopathy	Disease	329	330	9
7197363	REM sleep deprivation changes behavioral response to catecholaminergic and serotonergic receptor activation in rats .|The effects of REM sleep deprivation ( REMD ) on apomorphine - induced aggressiveness and quipazine - induced head twitches in rats were determined .|Forty - eight hr of REMD increased apomorphine - induced aggressiveness , and reduced ( immediately after completing of REMD ) or increased ( 96 hr after completing of REMD ) quipazine - induced head twitches .|Results are discussed in terms of similarity to pharmacological effects of other antidepressive treatments .	1:NR:2	R2L	NON-CROSS	47-48	45-46	D001058	apomorphine|apomorphine	Chemical	25:47	26:48	1:2	D012892	REM sleep deprivation|REM sleep deprivation|REMD|REMD|REMD|REMD	Disease	0:18:22:45:59:69	3:21:23:46:60:70	0:1:1:2:2:2	1:NR:2	R2L	NON-CROSS	71-72	69-70	D011814	quipazine|quipazine	Chemical	30:71	31:72	1:2	D012892	REM sleep deprivation|REM sleep deprivation|REMD|REMD|REMD|REMD	Disease	0:18:22:45:59:69	3:21:23:46:60:70	0:1:1:2:2:2	1:CID:2	L2R	NON-CROSS	25-26	28-29	D001058	apomorphine|apomorphine	Chemical	25:47	26:48	1:2	D001523	aggressiveness|aggressiveness	Disease	28:50	29:51	1:2	1:NR:2	L2R	NON-CROSS	25-26	33-35	D001058	apomorphine|apomorphine	Chemical	25:47	26:48	1:2	D009069	head twitches|head twitches	Disease	33:74	35:76	1:2	1:NR:2	R2L	NON-CROSS	30-31	28-29	D011814	quipazine|quipazine	Chemical	30:71	31:72	1:2	D001523	aggressiveness|aggressiveness	Disease	28:50	29:51	1:2	1:CID:2	L2R	NON-CROSS	30-31	33-35	D011814	quipazine|quipazine	Chemical	30:71	31:72	1:2	D009069	head twitches|head twitches	Disease	33:74	35:76	1:2
7161250	Extrapyramidal side effects and oral haloperidol : an analysis of explanatory patient and treatment characteristics .|The incidence of extrapyramidal side effects ( EPS ) was evaluated in 98 patients treated with haloperidol .|The incidence of parkinsonism was higher at higher doses of haloperidol and in younger patients .|Prophylactic antiparkinsonian medication was effective in younger but not in older patients .|However , these medications were more effective in both young and old patients when given after parkinsonism developed .|Akathisia was controlled by the benzodiazepine lorazepam in 14 out of 16 patients , while prophylactic antiparkinsonians were ineffective .|The present study points to patient characteristics that may be of significance in the development of EPS due to haloperidol .	1:CID:2	L2R	NON-CROSS	32-33	37-38	D006220	haloperidol|haloperidol|haloperidol|haloperidol	Chemical	5:32:44:121	6:33:45:122	0:1:2:6	D010302	parkinsonism|parkinsonism	Disease	37:79	38:80	2:4	1:NR:2	L2R	CROSS	44-45	82-83	D006220	haloperidol|haloperidol|haloperidol|haloperidol	Chemical	5:32:44:121	6:33:45:122	0:1:2:6	D017109	Akathisia	Disease	82	83	5	1:NR:2	R2L	CROSS	87-88	79-80	D001569	benzodiazepine	Chemical	87	88	5	D010302	parkinsonism|parkinsonism	Disease	37:79	38:80	2:4	1:NR:2	R2L	CROSS	88-89	79-80	D008140	lorazepam	Chemical	88	89	5	D010302	parkinsonism|parkinsonism	Disease	37:79	38:80	2:4	1:NR:2	R2L	NON-CROSS	87-88	82-83	D001569	benzodiazepine	Chemical	87	88	5	D017109	Akathisia	Disease	82	83	5	1:NR:2	R2L	NON-CROSS	88-89	82-83	D008140	lorazepam	Chemical	88	89	5	D017109	Akathisia	Disease	82	83	5
7053705	Hepatic veno - occlusive disease caused by 6 - thioguanine .|Clinically reversible veno - occlusive disease of the liver developed in a 23 - year - old man with acute lymphocytic leukemia after 10 months of maintenance therapy with 6 - thioguanine .|Serial liver biopsies showed the development and resolution of intense sinusoidal engorgement .|Although this disease was clinically reversible , some subintimal fibrosis about the terminal hepatic veins persisted .|This case presented a unique opportunity to observe the histologic features of clinically reversible hepatic veno - occlusive disease over time , and may be the first case of veno - occlusive related solely to 6 - thioguanine .	1:CID:2	R2L	NON-CROSS	7-10	0-5	D013866	6 - thioguanine|6 - thioguanine|6 - thioguanine	Chemical	7:40:109	10:43:112	0:1:4	D006504	Hepatic veno - occlusive disease|veno - occlusive disease of the liver|hepatic veno - occlusive disease	Disease	0:13:88	5:20:93	0:1:4	1:NR:2	L2R	NON-CROSS	30-33	40-43	D013866	6 - thioguanine|6 - thioguanine|6 - thioguanine	Chemical	7:40:109	10:43:112	0:1:4	D054198	acute lymphocytic leukemia	Disease	30	33	1	1:NR:2	L2R	CROSS	40-43	66-67	D013866	6 - thioguanine|6 - thioguanine|6 - thioguanine	Chemical	7:40:109	10:43:112	0:1:4	D005355	fibrosis	Disease	66	67	3
6402369	Treatment of ifosfamide - induced urothelial toxicity by oral administration of sodium 2 - mercaptoethane sulphonate ( MESNA ) to patients with inoperable lung cancer .|The protective effect of oral administration of the thiol compound sodium 2 - mercaptoethane sulphonate ( MESNA ) against urothelial toxicity induced by ifosfamide ( IF ) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF ( 2250 mg / m2 on days 2 - 5 ) as part of a polychemotherapy regimen repeated in a 4 - week cycle .|MESNA was given orally on the days of treatment with IF in 3 doses of 840 mg / m2 , each administered at 0 hr ( = injection of IF ) , 4 hr and 8 hr p . i .|Out of a total of 88 courses of this treatment we observed 10 episodes of asymptomatic microscopic haematuria and no episodes of gross haematuria .|In this group of 45 patients under protection with MESNA there were 5 complete remissions and 9 partial remissions ( total 31 % ) .|A further group of 25 patients under polychemotherapy with IF were treated by conventional prophylactic measures ( raised fluid intake and forced diuresis ) .|In this group there were 1 complete and 5 partial remissions ( total 24 % ) , but nearly all patients developed either gross haematuria and / or symptoms of bladder irritation ( cystitis and pollakisuria ) .|There were no appreciable differences between the MESNA series and the conventional prophylaxis series with respect to either haematological or systemic toxicity of the cytostatic treatment .|Our results support the view that MESNA , given orally in conjunction with combined cytostatic regimens which include IF , simplifies the treatment and provides optimum protection for the urinary epithelium .|Protection with oral MESNA is particularly suitable for outpatients .	1:CID:2	L2R	NON-CROSS	2-3	5-7	D007069	ifosfamide|ifosfamide|IF|IF|IF|IF|IF|IF	Chemical	2:49:51:68:104:123:194:293	3:50:52:69:105:124:195:294	0:1:1:1:2:2:5:8	D001745	urothelial toxicity|urothelial toxicity|bladder irritation	Disease	5:45:240	7:47:242	0:1:6	1:NR:2	L2R	NON-CROSS	63-65	68-69	D007069	ifosfamide|ifosfamide|IF|IF|IF|IF|IF|IF	Chemical	2:49:51:68:104:123:194:293	3:50:52:69:105:124:195:294	0:1:1:1:2:2:5:8	D008175	lung cancer|lung cancer	Disease	23:63	25:65	0:1	1:NR:2	L2R	CROSS	123-124	152-153	D007069	ifosfamide|ifosfamide|IF|IF|IF|IF|IF|IF	Chemical	2:49:51:68:104:123:194:293	3:50:52:69:105:124:195:294	0:1:1:1:2:2:5:8	D006417	haematuria|haematuria|haematuria	Disease	152:158:234	153:159:235	3:3:6	1:NR:2	L2R	CROSS	194-195	243-244	D007069	ifosfamide|ifosfamide|IF|IF|IF|IF|IF|IF	Chemical	2:49:51:68:104:123:194:293	3:50:52:69:105:124:195:294	0:1:1:1:2:2:5:8	D003556	cystitis	Disease	243	244	6	1:NR:2	L2R	CROSS	245-246	293-294	D007069	ifosfamide|ifosfamide|IF|IF|IF|IF|IF|IF	Chemical	2:49:51:68:104:123:194:293	3:50:52:69:105:124:195:294	0:1:1:1:2:2:5:8	D014555	pollakisuria	Disease	245	246	6	1:NR:2	L2R	CROSS	269-270	293-294	D007069	ifosfamide|ifosfamide|IF|IF|IF|IF|IF|IF	Chemical	2:49:51:68:104:123:194:293	3:50:52:69:105:124:195:294	0:1:1:1:2:2:5:8	D064420	toxicity	Disease	269	270	7	1:NR:2	R2L	NON-CROSS	45-47	42-43	D015080	sodium 2 - mercaptoethane sulphonate|MESNA|sodium 2 - mercaptoethane sulphonate|MESNA|MESNA|MESNA|MESNA|MESNA|MESNA	Chemical	11:17:36:42:94:169:255:281:310	16:18:41:43:95:170:256:282:311	0:0:1:1:2:4:7:8:9	D001745	urothelial toxicity|urothelial toxicity|bladder irritation	Disease	5:45:240	7:47:242	0:1:6	1:NR:2	R2L	NON-CROSS	45-47	34-35	D013438	thiol	Chemical	34	35	1	D001745	urothelial toxicity|urothelial toxicity|bladder irritation	Disease	5:45:240	7:47:242	0:1:6	1:NR:2	L2R	NON-CROSS	17-18	23-25	D015080	sodium 2 - mercaptoethane sulphonate|MESNA|sodium 2 - mercaptoethane sulphonate|MESNA|MESNA|MESNA|MESNA|MESNA|MESNA	Chemical	11:17:36:42:94:169:255:281:310	16:18:41:43:95:170:256:282:311	0:0:1:1:2:4:7:8:9	D008175	lung cancer|lung cancer	Disease	23:63	25:65	0:1	1:NR:2	L2R	CROSS	158-159	169-170	D015080	sodium 2 - mercaptoethane sulphonate|MESNA|sodium 2 - mercaptoethane sulphonate|MESNA|MESNA|MESNA|MESNA|MESNA|MESNA	Chemical	11:17:36:42:94:169:255:281:310	16:18:41:43:95:170:256:282:311	0:0:1:1:2:4:7:8:9	D006417	haematuria|haematuria|haematuria	Disease	152:158:234	153:159:235	3:3:6	1:NR:2	L2R	CROSS	243-244	255-256	D015080	sodium 2 - mercaptoethane sulphonate|MESNA|sodium 2 - mercaptoethane sulphonate|MESNA|MESNA|MESNA|MESNA|MESNA|MESNA	Chemical	11:17:36:42:94:169:255:281:310	16:18:41:43:95:170:256:282:311	0:0:1:1:2:4:7:8:9	D003556	cystitis	Disease	243	244	6	1:NR:2	L2R	CROSS	245-246	255-256	D015080	sodium 2 - mercaptoethane sulphonate|MESNA|sodium 2 - mercaptoethane sulphonate|MESNA|MESNA|MESNA|MESNA|MESNA|MESNA	Chemical	11:17:36:42:94:169:255:281:310	16:18:41:43:95:170:256:282:311	0:0:1:1:2:4:7:8:9	D014555	pollakisuria	Disease	245	246	6	1:NR:2	L2R	NON-CROSS	269-270	281-282	D015080	sodium 2 - mercaptoethane sulphonate|MESNA|sodium 2 - mercaptoethane sulphonate|MESNA|MESNA|MESNA|MESNA|MESNA|MESNA	Chemical	11:17:36:42:94:169:255:281:310	16:18:41:43:95:170:256:282:311	0:0:1:1:2:4:7:8:9	D064420	toxicity	Disease	269	270	7	1:NR:2	R2L	NON-CROSS	34-35	23-25	D013438	thiol	Chemical	34	35	1	D008175	lung cancer|lung cancer	Disease	23:63	25:65	0:1	1:NR:2	L2R	CROSS	34-35	152-153	D013438	thiol	Chemical	34	35	1	D006417	haematuria|haematuria|haematuria	Disease	152:158:234	153:159:235	3:3:6	1:NR:2	L2R	CROSS	34-35	243-244	D013438	thiol	Chemical	34	35	1	D003556	cystitis	Disease	243	244	6	1:NR:2	L2R	CROSS	34-35	245-246	D013438	thiol	Chemical	34	35	1	D014555	pollakisuria	Disease	245	246	6	1:NR:2	L2R	CROSS	34-35	269-270	D013438	thiol	Chemical	34	35	1	D064420	toxicity	Disease	269	270	7
3973521	Time course alterations of QTC interval due to hypaque 76 .|Sequential measurement of QT interval during left ventricular angiography was made 30 seconds and one , three , five and ten minutes after injection of hypaque 76 .|The subjects were ten patients found to have normal left ventricles and coronary arteries .|Significant QTC prolongation occurred in 30 seconds to one minute in association with marked hypotension and elevation of cardiac output .	1:CID:2	L2R	CROSS	36-38	55-57	C027278	hypaque 76|hypaque 76	Chemical	8:36	10:38	0:1	D008133	QTC prolongation	Disease	55	57	3	1:CID:2	L2R	CROSS	36-38	68-69	C027278	hypaque 76|hypaque 76	Chemical	8:36	10:38	0:1	D007022	hypotension	Disease	68	69	3
3461217	Production of autochthonous prostate cancer in Lobund - Wistar rats by treatments with N - nitroso - N - methylurea and testosterone .|More than 50 % of Lobund - Wistar ( L - W ) strain rats developed large , palpable prostate adenocarcinomas ( PAs ) following treatments with N - nitroso - N - methylurea ( CAS : 684 - 93 - 5 ) and testosterone propionate [ ( TP ) CAS : 57 - 85 - 2 ] , and most of the tumor - bearing rats manifested metastatic lesions .|The incubation periods averaged 10 . 6 months .|Within the same timeframe , no L - W rat developed a similar palpable PA when treated only with TP .|In L - W rats , TP acted as a tumor enhancement agent , with primary emphasis on the development of prostate cancer .	1:CID:2	R2L	NON-CROSS	50-57	45-46	D008770	N - nitroso - N - methylurea|N - nitroso - N - methylurea	Chemical	13:50	20:57	0:1	D011471	prostate cancer|prostate adenocarcinomas|PAs|PA|prostate cancer	Disease	3:42:45:117:145	5:44:46:118:147	0:1:1:3:4	1:NR:2	R2L	NON-CROSS	21-22	3-5	D013739	testosterone	Chemical	21	22	0	D011471	prostate cancer|prostate adenocarcinomas|PAs|PA|prostate cancer	Disease	3:42:45:117:145	5:44:46:118:147	0:1:1:3:4	1:CID:2	R2L	NON-CROSS	122-123	117-118	D043343	testosterone propionate|TP|TP|TP	Chemical	67:71:122:130	69:72:123:131	1:1:3:4	D011471	prostate cancer|prostate adenocarcinomas|PAs|PA|prostate cancer	Disease	3:42:45:117:145	5:44:46:118:147	0:1:1:3:4	1:NR:2	L2R	NON-CROSS	50-57	86-87	D008770	N - nitroso - N - methylurea|N - nitroso - N - methylurea	Chemical	13:50	20:57	0:1	D009369	tumor|tumor	Disease	86:134	87:135	1:4	1:NR:2	L2R	CROSS	21-22	86-87	D013739	testosterone	Chemical	21	22	0	D009369	tumor|tumor	Disease	86:134	87:135	1:4	1:NR:2	L2R	NON-CROSS	130-131	134-135	D043343	testosterone propionate|TP|TP|TP	Chemical	67:71:122:130	69:72:123:131	1:1:3:4	D009369	tumor|tumor	Disease	86:134	87:135	1:4
2840807	A dystonia - like syndrome after neuropeptide ( MSH / ACTH ) stimulation of the rat locus ceruleus .|The movement disorder investigated in these studies has some features in common with human idiopathic dystonia , and information obtained in these studies may be of potential clinical benefit .|The present experimental results indicated that peptidergic stimulation of the LC resulted in a NE - mediated inhibition of cerebellar Purkinje cells located at terminals of the ceruleo - cerebellar pathway .|However , it is not certain as to the following : ( a ) what receptors were stimulated by the ACTH N - terminal fragments at the LC that resulted in this disorder ; ( b ) whether NE , released onto Purkinje cell synapses located at terminals of the ceruleo - cerebellar pathway , did indeed cause the long - term depression at Purkinje cell synapses ( previously described by others ) that resulted in the long duration of the movement disorder ; ( c ) whether the inhibition of inhibitory Purkinje cells resulted in disinhibition or increased excitability of the unilateral cerebellar fastigial or interpositus nuclei , the output targets of the Purkinje cell axons , that may have been an important contributing factor to this disorder .|These questions are currently being investigated .	1:CID:2	R2L	NON-CROSS	8-9	1-2	D009074	MSH	Chemical	8	9	0	D004421	dystonia|dystonia	Disease	1:34	2:35	0:1	1:CID:2	R2L	NON-CROSS	10-11	1-2	D000324	ACTH|ACTH	Chemical	10:101	11:102	0:3	D004421	dystonia|dystonia	Disease	1:34	2:35	0:1	1:NR:2	L2R	CROSS	8-9	20-22	D009074	MSH	Chemical	8	9	0	D009069	movement disorder|movement disorder	Disease	20:162	22:164	1:3	1:NR:2	L2R	CROSS	8-9	143-144	D009074	MSH	Chemical	8	9	0	D003866	depression	Disease	143	144	3	1:NR:2	L2R	NON-CROSS	10-11	20-22	D000324	ACTH|ACTH	Chemical	10:101	11:102	0:3	D009069	movement disorder|movement disorder	Disease	20:162	22:164	1:3	1:NR:2	L2R	NON-CROSS	101-102	143-144	D000324	ACTH|ACTH	Chemical	10:101	11:102	0:3	D003866	depression	Disease	143	144	3
2569282	Dexmedetomidine , acting through central alpha - 2 adrenoceptors , prevents opiate - induced muscle rigidity in the rat .|The highly - selective alpha - 2 adrenergic agonist dexmedetomidine ( D - MED ) is capable of inducing muscle flaccidity and anesthesia in rats and dogs .|Intense generalized muscle rigidity is an undesirable side effect of potent opiate agonists .|Although the neurochemistry of opiate - induced rigidity has yet to be fully elucidated , recent work suggests a role for a central adrenergic mechanism .|In the present study , the authors determined if treatment with D - MED prevents the muscle rigidity caused by high - dose alfentanil anesthesia in the rat .|Animals ( n = 42 ) were treated intraperitoneally with one of the following six regimens : 1 ) L - MED ( the inactive L - isomer of medetomidine ) , 30 micrograms / kg ; 2 ) D - MED , 10 micrograms / kg ; 3 ) D - MED , 30 micrograms / kg ; 4 ) D - MED [ 30 micrograms / kg ] and the central - acting alpha - 2 antagonist , idazoxan [ 10 mg / kg ] ; 5 ) D - MED [ 30 micrograms / kg ] and the peripheral - acting alpha - 2 antagonist DG - 5128 [ 10 mg / kg ] , or ; 6 ) saline .|Baseline electromyographic activity was recorded from the gastrocnemius muscle before and after drug treatment .|Each rat was then injected with alfentanil ( ALF , 0 . 5 mg / kg sc ) .|ALF injection resulted in a marked increase in hindlimb EMG activity in the L - MED treatment group which was indistinguishable from that seen in animals treated with saline .|In contrast , D - MED prevented alfentanil - induced muscle rigidity in a dose - dependent fashion .|The small EMG values obtained in the high - dose D - MED group were comparable with those recorded in earlier studies from control animals not given any opiate .|The high - dose D - MED animals were flaccid , akinetic , and lacked a startle response during the entire experimental period . ( ABSTRACT TRUNCATED AT 250 WORDS )	1:NR:2	L2R	NON-CROSS	99-102	104-106	D020927	Dexmedetomidine|dexmedetomidine|D - MED|D - MED|D - MED|D - MED|D - MED|D - MED|D - MED|D - MED|D - MED	Chemical	0:29:31:99:156:167:178:207:308:334:358	1:30:34:102:159:170:181:210:311:337:361	0:1:1:4:5:5:5:5:9:10:11	D009127	muscle rigidity|muscle rigidity|rigidity|muscle rigidity|muscle rigidity	Disease	14:50:69:104:315	16:52:70:106:317	0:2:3:4:9	1:NR:2	L2R	NON-CROSS	31-34	39-41	D020927	Dexmedetomidine|dexmedetomidine|D - MED|D - MED|D - MED|D - MED|D - MED|D - MED|D - MED|D - MED|D - MED	Chemical	0:29:31:99:156:167:178:207:308:334:358	1:30:34:102:159:170:181:210:311:337:361	0:1:1:4:5:5:5:5:9:10:11	D009123	muscle flaccidity	Disease	39	41	1	1:NR:2	L2R	NON-CROSS	358-361	365-366	D020927	Dexmedetomidine|dexmedetomidine|D - MED|D - MED|D - MED|D - MED|D - MED|D - MED|D - MED|D - MED|D - MED	Chemical	0:29:31:99:156:167:178:207:308:334:358	1:30:34:102:159:170:181:210:311:337:361	0:1:1:4:5:5:5:5:9:10:11	D018476	akinetic	Disease	365	366	11	1:NR:2	L2R	NON-CROSS	358-361	370-371	D020927	Dexmedetomidine|dexmedetomidine|D - MED|D - MED|D - MED|D - MED|D - MED|D - MED|D - MED|D - MED|D - MED	Chemical	0:29:31:99:156:167:178:207:308:334:358	1:30:34:102:159:170:181:210:311:337:361	0:1:1:4:5:5:5:5:9:10:11	D012021	startle	Disease	370	371	11	1:CID:2	R2L	NON-CROSS	315-317	312-313	D015760	alfentanil|alfentanil|ALF|ALF|alfentanil	Chemical	111:262:264:275:312	112:263:265:276:313	4:7:7:8:9	D009127	muscle rigidity|muscle rigidity|rigidity|muscle rigidity|muscle rigidity	Disease	14:50:69:104:315	16:52:70:106:317	0:2:3:4:9	1:NR:2	R2L	CROSS	146-147	104-106	D020926	medetomidine	Chemical	146	147	5	D009127	muscle rigidity|muscle rigidity|rigidity|muscle rigidity|muscle rigidity	Disease	14:50:69:104:315	16:52:70:106:317	0:2:3:4:9	1:NR:2	R2L	CROSS	197-198	104-106	D019329	idazoxan	Chemical	197	198	5	D009127	muscle rigidity|muscle rigidity|rigidity|muscle rigidity|muscle rigidity	Disease	14:50:69:104:315	16:52:70:106:317	0:2:3:4:9	1:NR:2	R2L	CROSS	315-317	225-228	C032368	DG - 5128	Chemical	225	228	5	D009127	muscle rigidity|muscle rigidity|rigidity|muscle rigidity|muscle rigidity	Disease	14:50:69:104:315	16:52:70:106:317	0:2:3:4:9	1:NR:2	R2L	CROSS	111-112	39-41	D015760	alfentanil|alfentanil|ALF|ALF|alfentanil	Chemical	111:262:264:275:312	112:263:265:276:313	4:7:7:8:9	D009123	muscle flaccidity	Disease	39	41	1	1:NR:2	R2L	CROSS	146-147	39-41	D020926	medetomidine	Chemical	146	147	5	D009123	muscle flaccidity	Disease	39	41	1	1:NR:2	R2L	CROSS	197-198	39-41	D019329	idazoxan	Chemical	197	198	5	D009123	muscle flaccidity	Disease	39	41	1	1:NR:2	R2L	CROSS	225-228	39-41	C032368	DG - 5128	Chemical	225	228	5	D009123	muscle flaccidity	Disease	39	41	1	1:NR:2	L2R	CROSS	312-313	365-366	D015760	alfentanil|alfentanil|ALF|ALF|alfentanil	Chemical	111:262:264:275:312	112:263:265:276:313	4:7:7:8:9	D018476	akinetic	Disease	365	366	11	1:NR:2	L2R	CROSS	312-313	370-371	D015760	alfentanil|alfentanil|ALF|ALF|alfentanil	Chemical	111:262:264:275:312	112:263:265:276:313	4:7:7:8:9	D012021	startle	Disease	370	371	11	1:NR:2	L2R	CROSS	146-147	365-366	D020926	medetomidine	Chemical	146	147	5	D018476	akinetic	Disease	365	366	11	1:NR:2	L2R	CROSS	146-147	370-371	D020926	medetomidine	Chemical	146	147	5	D012021	startle	Disease	370	371	11	1:NR:2	L2R	CROSS	197-198	365-366	D019329	idazoxan	Chemical	197	198	5	D018476	akinetic	Disease	365	366	11	1:NR:2	L2R	CROSS	197-198	370-371	D019329	idazoxan	Chemical	197	198	5	D012021	startle	Disease	370	371	11	1:NR:2	L2R	CROSS	225-228	365-366	C032368	DG - 5128	Chemical	225	228	5	D018476	akinetic	Disease	365	366	11	1:NR:2	L2R	CROSS	225-228	370-371	C032368	DG - 5128	Chemical	225	228	5	D012021	startle	Disease	370	371	11
2343592	Seizure activity with imipenem therapy : incidence and risk factors .|Two elderly patients with a history of either cerebral vascular accident ( CVA ) or head trauma and no evidence of renal disease developed seizures while receiving maximum doses of imipenem / cilastatin .|Neither patient had reported previous seizures or seizure - like activity nor was receiving anticonvulsant agents .|All seizures were controlled with therapeutic doses of phenytoin .|Both patients had received maximum doses of other beta - lactam antibiotics without evidence of seizure activity .	1:NR:2	R2L	NON-CROSS	3-4	0-1	D015378	imipenem	Chemical	3	4	0	D012640	Seizure|seizures|seizures|seizure|seizures|seizure	Disease	0:35:50:52:63:87	1:36:51:53:64:88	0:1:2:2:3:4	1:CID:2	R2L	NON-CROSS	41-44	35-36	C044650	imipenem / cilastatin	Chemical	41	44	1	D012640	Seizure|seizures|seizures|seizure|seizures|seizure	Disease	0:35:50:52:63:87	1:36:51:53:64:88	0:1:2:2:3:4	1:NR:2	R2L	NON-CROSS	70-71	63-64	D010672	phenytoin	Chemical	70	71	3	D012640	Seizure|seizures|seizures|seizure|seizures|seizure	Disease	0:35:50:52:63:87	1:36:51:53:64:88	0:1:2:2:3:4	1:NR:2	R2L	NON-CROSS	87-88	80-83	D047090	beta - lactam	Chemical	80	83	4	D012640	Seizure|seizures|seizures|seizure|seizures|seizure	Disease	0:35:50:52:63:87	1:36:51:53:64:88	0:1:2:2:3:4	1:NR:2	L2R	CROSS	3-4	19-22	D015378	imipenem	Chemical	3	4	0	D020521	cerebral vascular accident|CVA	Disease	19:23	22:24	1:1	1:NR:2	L2R	CROSS	3-4	26-28	D015378	imipenem	Chemical	3	4	0	D006259	head trauma	Disease	26	28	1	1:NR:2	L2R	CROSS	3-4	32-34	D015378	imipenem	Chemical	3	4	0	D007674	renal disease	Disease	32	34	1	1:NR:2	R2L	NON-CROSS	41-44	23-24	C044650	imipenem / cilastatin	Chemical	41	44	1	D020521	cerebral vascular accident|CVA	Disease	19:23	22:24	1:1	1:NR:2	R2L	CROSS	70-71	23-24	D010672	phenytoin	Chemical	70	71	3	D020521	cerebral vascular accident|CVA	Disease	19:23	22:24	1:1	1:NR:2	R2L	CROSS	80-83	23-24	D047090	beta - lactam	Chemical	80	83	4	D020521	cerebral vascular accident|CVA	Disease	19:23	22:24	1:1	1:NR:2	R2L	NON-CROSS	41-44	26-28	C044650	imipenem / cilastatin	Chemical	41	44	1	D006259	head trauma	Disease	26	28	1	1:NR:2	R2L	CROSS	70-71	26-28	D010672	phenytoin	Chemical	70	71	3	D006259	head trauma	Disease	26	28	1	1:NR:2	R2L	CROSS	80-83	26-28	D047090	beta - lactam	Chemical	80	83	4	D006259	head trauma	Disease	26	28	1	1:NR:2	R2L	NON-CROSS	41-44	32-34	C044650	imipenem / cilastatin	Chemical	41	44	1	D007674	renal disease	Disease	32	34	1	1:NR:2	R2L	CROSS	70-71	32-34	D010672	phenytoin	Chemical	70	71	3	D007674	renal disease	Disease	32	34	1	1:NR:2	R2L	CROSS	80-83	32-34	D047090	beta - lactam	Chemical	80	83	4	D007674	renal disease	Disease	32	34	1
2055425	The ability of insulin treatment to reverse or prevent the changes in urinary bladder function caused by streptozotocin - induced diabetes mellitus .|1 . The effects of insulin treatment on in vivo and in vitro urinary bladder function in streptozotocin - diabetic rats were investigated .|2 .|Diabetes of 2 months duration resulted in decreases in body weight and increases in fluid consumption , urine volume , frequency of micturition , and average volume per micturition ; effects which were prevented by insulin treatment .|3 .|Insulin treatment also prevented the increases in contractile responses of bladder body strips from diabetic rats to nerve stimulation , ATP , and bethanechol .|4 .|Diabetes of 4 months duration also resulted in decreases in body weight , and increases in fluid consumption , urine volume , frequency of micturition , and average volume per micturition , effects which were reversed by insulin treatment for the final 2 months of the study .|5 .|Insulin treatment reversed the increases in contractile responses of bladder body strips from diabetic rats to nerve stimulation , ATP , and bethanechol .|6 .|The data indicate that the effects of streptozotocin - induced diabetes on urinary bladder function are both prevented and reversed by insulin treatment .	1:CID:2	L2R	NON-CROSS	40-41	42-43	D013311	streptozotocin|streptozotocin|streptozotocin	Chemical	17:40:199	18:41:200	0:1:11	D003920	diabetes mellitus|diabetic|Diabetes|diabetic|Diabetes|diabetic|diabetes	Disease	20:42:49:103:116:179:202	22:43:50:104:117:180:203	0:1:3:5:7:9:11	1:NR:2	R2L	NON-CROSS	109-110	103-104	D000255	ATP|ATP	Chemical	109:185	110:186	5:9	D003920	diabetes mellitus|diabetic|Diabetes|diabetic|Diabetes|diabetic|diabetes	Disease	20:42:49:103:116:179:202	22:43:50:104:117:180:203	0:1:3:5:7:9:11	1:NR:2	R2L	NON-CROSS	116-117	112-113	D018723	bethanechol|bethanechol	Chemical	112:188	113:189	5:9	D003920	diabetes mellitus|diabetic|Diabetes|diabetic|Diabetes|diabetic|diabetes	Disease	20:42:49:103:116:179:202	22:43:50:104:117:180:203	0:1:3:5:7:9:11
1711760	Delayed institution of hypertension during focal cerebral ischemia : effect on brain edema .|The effect of induced hypertension instituted after a 2 - h delay following middle cerebral artery occlusion ( MCAO ) on brain edema formation and histochemical injury was studied .|Under isoflurane anesthesia , the MCA of 14 spontaneously hypertensive rats was occluded .|In the control group ( n = 7 ) , the mean arterial pressure ( MAP ) was not manipulated .|In the hypertensive group ( n = 7 ) , the MAP was elevated by 25 - 30 mm Hg beginning 2 h after MCAO .|Four hours after MCAO , the rats were killed and the brains harvested .|The brains were sectioned along coronal planes spanning the distribution of ischemia produced by MCAO .|Specific gravity ( SG ) was determined in the subcortex and in two sites in the cortex ( core and periphery of the ischemic territory ) .|The extent of neuronal injury was determined by 2 , 3 , 5 - triphenyltetrazolium staining .|In the ischemic core , there was no difference in SG in the subcortex and cortex in the two groups .|In the periphery of the ischemic territory , SG in the cortex was greater ( less edema accumulation ) in the hypertensive group ( 1 . 041 + / - 0 . 001 vs 1 . 039 + / - 0 . 001 , P less than 0 . 05 ) .|The area of histochemical injury ( as a percent of the cross - sectional area of the hemisphere ) was less in the hypertensive group ( 33 + / - 3 % vs 21 + / - 2 % , P less than 0 . 05 ) .|The data indicate that phenylephrine - induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core , that it improves edema in the periphery of the ischemic territory , and that it reduces the area of histochemical neuronal dysfunction .	1:NR:2	R2L	NON-CROSS	53-54	45-46	D007530	isoflurane	Chemical	45	46	2	D006973	hypertension|hypertension|hypertensive|hypertensive|hypertensive|hypertensive|hypertension	Disease	3:18:53:81:221:275:307	4:19:54:82:222:276:308	0:1:2:4:10:11:12	1:NR:2	R2L	CROSS	221-222	170-177	C009591	2 , 3 , 5 - triphenyltetrazolium	Chemical	170	177	8	D006973	hypertension|hypertension|hypertensive|hypertensive|hypertensive|hypertensive|hypertension	Disease	3:18:53:81:221:275:307	4:19:54:82:222:276:308	0:1:2:4:10:11:12	1:CID:2	R2L	NON-CROSS	307-308	304-305	D010656	phenylephrine	Chemical	304	305	12	D006973	hypertension|hypertension|hypertensive|hypertensive|hypertensive|hypertensive|hypertension	Disease	3:18:53:81:221:275:307	4:19:54:82:222:276:308	0:1:2:4:10:11:12	1:NR:2	R2L	CROSS	45-46	6-8	D007530	isoflurane	Chemical	45	46	2	D002545	cerebral ischemia	Disease	6	8	0	1:NR:2	R2L	CROSS	170-177	6-8	C009591	2 , 3 , 5 - triphenyltetrazolium	Chemical	170	177	8	D002545	cerebral ischemia	Disease	6	8	0	1:NR:2	R2L	CROSS	304-305	6-8	D010656	phenylephrine	Chemical	304	305	12	D002545	cerebral ischemia	Disease	6	8	0	1:NR:2	R2L	CROSS	45-46	35-37	D007530	isoflurane	Chemical	45	46	2	D001929	brain edema|brain edema	Disease	11:35	13:37	0:1	1:NR:2	R2L	CROSS	170-177	35-37	C009591	2 , 3 , 5 - triphenyltetrazolium	Chemical	170	177	8	D001929	brain edema|brain edema	Disease	11:35	13:37	0:1	1:NR:2	R2L	CROSS	304-305	35-37	D010656	phenylephrine	Chemical	304	305	12	D001929	brain edema|brain edema	Disease	11:35	13:37	0:1	1:NR:2	R2L	CROSS	45-46	32-33	D007530	isoflurane	Chemical	45	46	2	D020244	middle cerebral artery occlusion|MCAO|MCAO|MCAO|MCAO|MCAO	Disease	27:32:103:108:133:312	31:33:104:109:134:313	1:1:4:5:6:12	1:NR:2	R2L	CROSS	170-177	133-134	C009591	2 , 3 , 5 - triphenyltetrazolium	Chemical	170	177	8	D020244	middle cerebral artery occlusion|MCAO|MCAO|MCAO|MCAO|MCAO	Disease	27:32:103:108:133:312	31:33:104:109:134:313	1:1:4:5:6:12	1:NR:2	R2L	NON-CROSS	312-313	304-305	D010656	phenylephrine	Chemical	304	305	12	D020244	middle cerebral artery occlusion|MCAO|MCAO|MCAO|MCAO|MCAO	Disease	27:32:103:108:133:312	31:33:104:109:134:313	1:1:4:5:6:12	1:NR:2	L2R	CROSS	45-46	130-131	D007530	isoflurane	Chemical	45	46	2	D007511	ischemia|ischemic|ischemic|ischemic|ischemic|ischemic	Disease	130:158:181:205:319:331	131:159:182:206:320:332	6:7:9:10:12:12	1:NR:2	L2R	CROSS	45-46	165-167	D007530	isoflurane	Chemical	45	46	2	D009410	neuronal injury|neuronal dysfunction	Disease	165:342	167:344	8:12	1:NR:2	L2R	CROSS	45-46	216-217	D007530	isoflurane	Chemical	45	46	2	D004487	edema|edema|edema	Disease	216:316:325	217:317:326	10:12:12	1:NR:2	R2L	CROSS	181-182	170-177	C009591	2 , 3 , 5 - triphenyltetrazolium	Chemical	170	177	8	D007511	ischemia|ischemic|ischemic|ischemic|ischemic|ischemic	Disease	130:158:181:205:319:331	131:159:182:206:320:332	6:7:9:10:12:12	1:NR:2	R2L	NON-CROSS	319-320	304-305	D010656	phenylephrine	Chemical	304	305	12	D007511	ischemia|ischemic|ischemic|ischemic|ischemic|ischemic	Disease	130:158:181:205:319:331	131:159:182:206:320:332	6:7:9:10:12:12	1:NR:2	R2L	NON-CROSS	170-177	165-167	C009591	2 , 3 , 5 - triphenyltetrazolium	Chemical	170	177	8	D009410	neuronal injury|neuronal dysfunction	Disease	165:342	167:344	8:12	1:NR:2	R2L	NON-CROSS	342-344	304-305	D010656	phenylephrine	Chemical	304	305	12	D009410	neuronal injury|neuronal dysfunction	Disease	165:342	167:344	8:12	1:NR:2	L2R	CROSS	170-177	216-217	C009591	2 , 3 , 5 - triphenyltetrazolium	Chemical	170	177	8	D004487	edema|edema|edema	Disease	216:316:325	217:317:326	10:12:12	1:NR:2	R2L	NON-CROSS	316-317	304-305	D010656	phenylephrine	Chemical	304	305	12	D004487	edema|edema|edema	Disease	216:316:325	217:317:326	10:12:12
1595783	Amiodarone pulmonary toxicity .|Amiodarone is an effective antiarrhythmic agent whose utility is limited by many side - effects , the most problematic being pneumonitis .|The pulmonary toxicity of amiodarone is thought to result from direct injury related to the intracellular accumulation of phospholipid and T cell - mediated hypersensitivity pneumonitis .|The clinical and radiographic features of amiodarone - induced pulmonary toxicity are characteristic but nonspecific .|The diagnosis depends on exclusion of other entities , such as heart failure , infection , and malignancy .|While withdrawal of amiodarone leads to clinical improvement in majority of cases , this is not always possible or advisable .|Dose reduction or concomitant steroid therapy may have a role in selected patients .	1:NR:2	L2R	NON-CROSS	0-1	1-3	D000638	Amiodarone|Amiodarone|amiodarone|amiodarone|amiodarone	Chemical	0:4:30:59:91	1:5:31:60:92	0:1:2:3:5	D008171	pulmonary toxicity|pulmonary toxicity|pulmonary toxicity	Disease	1:27:62	3:29:64	0:2:3	1:CID:2	L2R	NON-CROSS	24-25	30-31	D000638	Amiodarone|Amiodarone|amiodarone|amiodarone|amiodarone	Chemical	0:4:30:59:91	1:5:31:60:92	0:1:2:3:5	D011014	pneumonitis	Disease	24	25	1	1:CID:2	L2R	NON-CROSS	50-52	59-60	D000638	Amiodarone|Amiodarone|amiodarone|amiodarone|amiodarone	Chemical	0:4:30:59:91	1:5:31:60:92	0:1:2:3:5	D004342	hypersensitivity pneumonitis	Disease	50	52	2	1:NR:2	L2R	NON-CROSS	50-52	59-60	D000638	Amiodarone|Amiodarone|amiodarone|amiodarone|amiodarone	Chemical	0:4:30:59:91	1:5:31:60:92	0:1:2:3:5	D000542	hypersensitivity pneumonitis	Disease	50	52	2	1:NR:2	L2R	CROSS	80-82	91-92	D000638	Amiodarone|Amiodarone|amiodarone|amiodarone|amiodarone	Chemical	0:4:30:59:91	1:5:31:60:92	0:1:2:3:5	D006333	heart failure	Disease	80	82	4	1:NR:2	L2R	CROSS	83-84	91-92	D000638	Amiodarone|Amiodarone|amiodarone|amiodarone|amiodarone	Chemical	0:4:30:59:91	1:5:31:60:92	0:1:2:3:5	D007239	infection	Disease	83	84	4	1:NR:2	L2R	CROSS	86-87	91-92	D000638	Amiodarone|Amiodarone|amiodarone|amiodarone|amiodarone	Chemical	0:4:30:59:91	1:5:31:60:92	0:1:2:3:5	D009369	malignancy	Disease	86	87	4	1:NR:2	R2L	CROSS	113-114	62-64	D013256	steroid	Chemical	113	114	6	D008171	pulmonary toxicity|pulmonary toxicity|pulmonary toxicity	Disease	1:27:62	3:29:64	0:2:3	1:NR:2	R2L	CROSS	113-114	24-25	D013256	steroid	Chemical	113	114	6	D011014	pneumonitis	Disease	24	25	1	1:NR:2	R2L	CROSS	113-114	50-52	D013256	steroid	Chemical	113	114	6	D004342	hypersensitivity pneumonitis	Disease	50	52	2	1:NR:2	R2L	CROSS	113-114	50-52	D013256	steroid	Chemical	113	114	6	D000542	hypersensitivity pneumonitis	Disease	50	52	2	1:NR:2	R2L	CROSS	113-114	80-82	D013256	steroid	Chemical	113	114	6	D006333	heart failure	Disease	80	82	4	1:NR:2	R2L	CROSS	113-114	83-84	D013256	steroid	Chemical	113	114	6	D007239	infection	Disease	83	84	4	1:NR:2	R2L	CROSS	113-114	86-87	D013256	steroid	Chemical	113	114	6	D009369	malignancy	Disease	86	87	4
804391	Light chain proteinuria and cellular mediated immunity in rifampin treated patients with tuberculosis .|Light chain proteinuria was found in 9 of 17 tuberculosis patients treated with rifampin .|Concomitant assay of cellular mediated immunity in these patients using skin test antigen and a lymphokine in vitro test provided results that were different .|Response to Varidase skin test antigen was negative for all eight tuberculosis patients tested , but there occurred a hyper - responsiveness of the lymphocytes of these eight patients to phytomitogen ( PHA - P ) . as well as of those of seven other tuberculous patients .|This last finding may be related to time of testing and / or endogenous serum binding of rifampin which could have inhibited mitogen activity for the lymphocyte .	1:CID:2	R2L	NON-CROSS	8-9	2-3	D012293	rifampin|rifampin|rifampin	Chemical	8:27:119	9:28:120	0:1:4	D011507	proteinuria|proteinuria	Disease	2:16	3:17	0:1	1:NR:2	L2R	NON-CROSS	8-9	12-13	D012293	rifampin|rifampin|rifampin	Chemical	8:27:119	9:28:120	0:1:4	D014376	tuberculosis|tuberculosis|tuberculosis|tuberculous	Disease	12:23:65:99	13:24:66:100	0:1:3:3
28952	Initial potassium loss and hypokalaemia during chlorthalidone administration in patients with essential hypertension : the influence of dietary sodium restriction .|To investigate the initial potassium loss and development of hypokalaemia during the administration of an oral diuretic , metabolic balance studies were performed in ten patients with essential hypertension who had shown hypokalaemia under prior oral diuretic treatment .|Chlorthalidone ( 50 mg daily ) was given for 14 days .|Six patients received a normal - sodium diet and four a low - sodium ( 17 mmol / day ) diet .|All patients had a normal initial total body potassium ( 40K ) .|The electrolyte balances , weight , bromide space , plasma renin activity , and aldosterone secretion rate were measured .|In both groups a potassium deficit developed , with proportionally larger losses from the extracellular than from the intracellular compartment .|In the normal - sodium group the highest mean potassium deficit was 176 mmol on day 9 , after which some potassium was regained ; in the low - sodium group the highest deficit was 276 mmol on day 13 .|The normal - sodium group showed an immediate but temporary rise of the renin and aldosterone levels ; in the low - sodium group renin and aldosterone increased more slowly but remained elevated .|It is concluded that dietary sodium restriction increases diuretic - induced potassium loss , presumably by an increased activity of the renin - angiotensin - aldosterone system , while sodium delivery to the distal renal tubules remains sufficiently high to allow increased potassium secretion .	1:NR:2	L2R	NON-CROSS	1-2	4-5	D011188	potassium|potassium|potassium|potassium|potassium|potassium|potassium|potassium	Chemical	1:25:102:131:157:169:234:265	2:26:103:132:158:170:235:266	0:1:4:6:7:7:9:9	D007008	hypokalaemia|hypokalaemia|hypokalaemia	Disease	4:30:53	5:31:54	0:1:1	1:NR:2	L2R	NON-CROSS	1-2	12-13	D011188	potassium|potassium|potassium|potassium|potassium|potassium|potassium|potassium	Chemical	1:25:102:131:157:169:234:265	2:26:103:132:158:170:235:266	0:1:4:6:7:7:9:9	D006973	hypertension|hypertension	Disease	12:49	13:50	0:1	1:CID:2	R2L	NON-CROSS	6-7	4-5	D002752	chlorthalidone|Chlorthalidone	Chemical	6:60	7:61	0:2	D007008	hypokalaemia|hypokalaemia|hypokalaemia	Disease	4:30:53	5:31:54	0:1:1	1:NR:2	R2L	NON-CROSS	30-31	18-19	D012964	sodium|sodium|sodium|sodium|sodium|sodium|sodium|sodium|sodium	Chemical	18:78:85:152:177:192:211:228:252	19:79:86:153:178:193:212:229:253	0:3:3:7:7:8:8:9:9	D007008	hypokalaemia|hypokalaemia|hypokalaemia	Disease	4:30:53	5:31:54	0:1:1	1:NR:2	R2L	CROSS	121-122	53-54	D000450	aldosterone|aldosterone|aldosterone|aldosterone	Chemical	121:204:215:248	122:205:216:249	5:8:8:9	D007008	hypokalaemia|hypokalaemia|hypokalaemia	Disease	4:30:53	5:31:54	0:1:1	1:NR:2	R2L	CROSS	246-247	53-54	D000809	angiotensin	Chemical	246	247	9	D007008	hypokalaemia|hypokalaemia|hypokalaemia	Disease	4:30:53	5:31:54	0:1:1	1:NR:2	L2R	NON-CROSS	6-7	12-13	D002752	chlorthalidone|Chlorthalidone	Chemical	6:60	7:61	0:2	D006973	hypertension|hypertension	Disease	12:49	13:50	0:1	1:NR:2	R2L	NON-CROSS	18-19	12-13	D012964	sodium|sodium|sodium|sodium|sodium|sodium|sodium|sodium|sodium	Chemical	18:78:85:152:177:192:211:228:252	19:79:86:153:178:193:212:229:253	0:3:3:7:7:8:8:9:9	D006973	hypertension|hypertension	Disease	12:49	13:50	0:1	1:NR:2	R2L	CROSS	121-122	49-50	D000450	aldosterone|aldosterone|aldosterone|aldosterone	Chemical	121:204:215:248	122:205:216:249	5:8:8:9	D006973	hypertension|hypertension	Disease	12:49	13:50	0:1	1:NR:2	R2L	CROSS	246-247	49-50	D000809	angiotensin	Chemical	246	247	9	D006973	hypertension|hypertension	Disease	12:49	13:50	0:1
19893084	Dynamic response of blood vessel in acute renal failure .|In this study we postulated that during acute renal failure induced by gentamicin the transient or dynamic response of blood vessels could be affected , and that antioxidants can prevent the changes in dynamic responses of blood vessels .|The new approach to ex vivo blood vessel experiments in which not only the end points of vessels response within the time interval is considered , but also dynamics of this response , was used in this paper .|Our results confirm the alteration in dynamic response of blood vessels during the change of pressure in gentamicin - treated animals .|The beneficial effects of vitamin C administration to gentamicin - treated animals are also confirmed through : lower level of blood urea and creatinine and higher level of potassium .|The pressure dynamic responses of isolated blood vessels show a faster pressure change in gentamicin - treated animals ( 8 . 07 + / - 1 . 7 s vs . 5 . 64 + / - 0 . 18 s ) .|Vitamin C administration induced slowdown of pressure change back to the control values .|The pressure dynamic properties , quantitatively defined by comparative pressure dynamic and total pressure dynamic , confirm the alteration in dynamic response of blood vessels during the change of pressure in gentamicin - treated animals and beneficial effects of vitamin C administration .	1:CID:2	R2L	NON-CROSS	22-23	17-20	D005839	gentamicin|gentamicin|gentamicin|gentamicin|gentamicin	Chemical	22:105:118:154:228	23:106:119:155:229	1:3:4:5:7	D058186	acute renal failure|acute renal failure	Disease	6:17	9:20	0:1	1:NR:2	R2L	CROSS	114-116	17-20	D001205	vitamin C|Vitamin C|vitamin C	Chemical	114:183:236	116:185:238	4:6:7	D058186	acute renal failure|acute renal failure	Disease	6:17	9:20	0:1	1:NR:2	R2L	CROSS	131-132	17-20	D014508	urea	Chemical	131	132	4	D058186	acute renal failure|acute renal failure	Disease	6:17	9:20	0:1	1:NR:2	R2L	CROSS	133-134	17-20	D003404	creatinine	Chemical	133	134	4	D058186	acute renal failure|acute renal failure	Disease	6:17	9:20	0:1	1:NR:2	R2L	CROSS	138-139	17-20	D011188	potassium	Chemical	138	139	4	D058186	acute renal failure|acute renal failure	Disease	6:17	9:20	0:1
18513945	The hemodynamics of oxytocin and other vasoactive agents during neuraxial anesthesia for cesarean delivery : findings in six cases .|Oxytocin is a commonly used uterotonic that can cause significant and even fatal hypotension , particularly when given as a bolus .|The resulting hypotension can be produced by a decrease in systemic vascular resistance or cardiac output through a decrease in venous return .|Parturients with normal volume status , heart valves and pulmonary vasculature most often respond to this hypotension with a compensatory increase in heart rate and stroke volume .|Oxytocin - induced hypotension at cesarean delivery may be incorrectly attributed to blood loss .|Pulse power analysis ( also called " pulse contour analysis " ) of an arterial pressure wave form allows continuous evaluation of systemic vascular resistance and cardiac output in real time , thereby elucidating the causative factors behind changes in blood pressure .|Pulse power analysis was conducted in six cases of cesarean delivery performed under neuraxial anesthesia .|Hypotension in response to oxytocin was associated with a decrease in systemic vascular resistance and a compensatory increase in stroke volume , heart rate and cardiac output .|Pulse power analysis may be helpful in determining the etiology of and treating hypotension during cesarean delivery under neuraxial anesthesia .	1:CID:2	L2R	NON-CROSS	93-94	96-97	D010121	oxytocin|Oxytocin|Oxytocin|oxytocin	Chemical	3:20:93:171	4:21:94:172	0:1:4:7	D007022	hypotension|hypotension|hypotension|hypotension|Hypotension|hypotension	Disease	33:44:81:96:167:208	34:45:82:97:168:209	1:2:3:4:7:8	1:NR:2	L2R	NON-CROSS	90-91	93-94	D010121	oxytocin|Oxytocin|Oxytocin|oxytocin	Chemical	3:20:93:171	4:21:94:172	0:1:4:7	D020521	stroke|stroke	Disease	90:186	91:187	3:7	1:NR:2	L2R	NON-CROSS	93-94	105-107	D010121	oxytocin|Oxytocin|Oxytocin|oxytocin	Chemical	3:20:93:171	4:21:94:172	0:1:4:7	D006473	blood loss	Disease	105	107	4
18483878	Exaggerated expression of inflammatory mediators in vasoactive intestinal polypeptide knockout ( VIP - / - ) mice with cyclophosphamide ( CYP ) - induced cystitis .|Vasoactive intestinal polypeptide ( VIP ) is an immunomodulatory neuropeptide distributed in micturition pathways .|VIP ( - / - ) mice exhibit altered bladder function and neurochemical properties in micturition pathways after cyclophosphamide ( CYP ) - induced cystitis .|Given VIP 's role as an anti - inflammatory mediator , we hypothesized that VIP ( - / - ) mice would exhibit enhanced inflammatory mediator expression after cystitis .|A mouse inflammatory cytokine and receptor RT2 profiler array was used to determine regulated transcripts in the urinary bladder of wild type ( WT ) and VIP ( - / - ) mice with or without CYP - induced cystitis ( 150 mg / kg ; i . p . ; 48 h ) .|Four binary comparisons were made : WT control versus CYP treatment ( 48 h ) , VIP ( - / - ) control versus CYP treatment ( 48 h ) , WT control versus VIP ( - / - ) control , and WT with CYP treatment ( 48 h ) versus VIP ( - / - ) with CYP treatment ( 48 h ) .|The genes presented represent ( 1 ) greater than 1 . 5 - fold change in either direction and ( 2 ) the p value is less than 0 . 05 for the comparison being made .|Several regulated genes were validated using enzyme - linked immunoassays including IL - 1beta and CXCL1 .|CYP treatment significantly ( p < or = 0 . 001 ) increased expression of CXCL1 and IL - 1beta in the urinary bladder of WT and VIP ( - / - ) mice , but expression in VIP ( - / - ) mice with CYP treatment was significantly ( p < or = 0 . 001 ) greater ( 4 . 2 - to 13 - fold increase ) than that observed in WT urinary bladder ( 3 . 6 - to 5 - fold increase ) .|The data suggest that in VIP ( - / - ) mice with bladder inflammation , inflammatory mediators are increased above that observed in WT with CYP .|This shift in balance may contribute to increased bladder dysfunction in VIP ( - / - ) mice with bladder inflammation and altered neurochemical expression in micturition pathways .	1:CID:2	L2R	NON-CROSS	133-134	136-137	D003520	cyclophosphamide|CYP|cyclophosphamide|CYP|CYP|CYP|CYP|CYP|CYP|CYP|CYP|CYP	Chemical	18:20:59:61:133:161:176:197:211:272:318:388	19:21:60:62:134:162:177:198:212:273:319:389	0:0:2:2:4:5:5:5:5:8:8:9	D003556	cystitis|cystitis|cystitis|cystitis	Disease	24:65:95:136	25:66:96:137	0:2:3:4	1:NR:2	L2R	NON-CROSS	388-389	398-400	D003520	cyclophosphamide|CYP|cyclophosphamide|CYP|CYP|CYP|CYP|CYP|CYP|CYP|CYP|CYP	Chemical	18:20:59:61:133:161:176:197:211:272:318:388	19:21:60:62:134:162:177:198:212:273:319:389	0:0:2:2:4:5:5:5:5:8:8:9	D001745	bladder inflammation|bladder dysfunction|bladder inflammation	Disease	375:398:409	377:400:411	9:10:10
17923537	Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants .|OBJECTIVE : To report the incidence and management of elevated intraocular pressure ( IOP ) in patients with uveitis treated with the fluocinolone acetonide ( FA ) intravitreal implant .|DESIGN : Pooled data from 3 multicenter , double - masked , randomized , controlled , phase 2b / 3 clinical trials evaluating the safety and efficacy of the 0 . 59 - mg or 2 . 1 - mg FA intravitreal implant or standard therapy were analyzed .|RESULTS : During the 3 - year follow - up , 71 . 0 % of implanted eyes had an IOP increase of 10 mm Hg or more than baseline and 55 . 1 % , 24 . 7 % , and 6 . 2 % of eyes reached an IOP of 30 mm Hg or more , 40 mm Hg or more , and 50 mm Hg or more , respectively .|Topical IOP - lowering medication was administered in 74 . 8 % of implanted eyes , and IOP - lowering surgeries , most of which were trabeculectomies ( 76 . 2 % ) , were performed on 36 . 6 % of implanted eyes .|Intraocular pressure - lowering surgeries were considered a success ( postoperative IOP of 6 - 21 mm Hg with or without additional IOP - lowering medication ) in 85 . 1 % of eyes at 1 year .|The rate of hypotony ( IOP < / = 5 mm Hg ) following IOP - lowering surgery ( 42 . 5 % ) was not different from that of implanted eyes not subjected to surgery ( 35 . 4 % ) ( P = . 09 ) .|CONCLUSION : Elevated IOP is a significant complication with the FA intravitreal implant but may be controlled with medication and surgery .	1:NR:2	R2L	NON-CROSS	8-10	5-6	D005446	fluocinolone acetonide|fluocinolone acetonide|FA|FA	Chemical	8:34:37:82	10:36:38:83	0:1:1:2	D014605	uveitis|uveitis	Disease	5:30	6:31	0:1	1:CID:2	L2R	NON-CROSS	21-24	34-36	D005446	fluocinolone acetonide|fluocinolone acetonide|FA|FA	Chemical	8:34:37:82	10:36:38:83	0:1:1:2	D009798	elevated intraocular pressure	Disease	21	24	1	1:NR:2	L2R	CROSS	82-83	250-251	D005446	fluocinolone acetonide|fluocinolone acetonide|FA|FA	Chemical	8:34:37:82	10:36:38:83	0:1:1:2	D015814	hypotony	Disease	250	251	6
15096016	Pallidal stimulation : an alternative to pallidotomy ?|A resurgence of interest in the surgical treatment of Parkinson 's disease ( PD ) came with the rediscovery of posteroventral pallidotomy by Laitinen in 1985 .|Laitinen 's procedure improved most symptoms in drug - resistant PD , which engendered wide interest in the neurosurgical community .|Another lesioning procedure , ventrolateral thalamotomy , has become a powerful alternative to stimulate the nucleus ventralis intermedius , producing high long - term success rates and low morbidity rates .|Pallidal stimulation has not met with the same success .|According to the literature pallidotomy improves the " on " symptoms of PD , such as dyskinesias , as well as the " off " symptoms , such as rigidity , bradykinesia , and on - off fluctuations .|Pallidal stimulation improves bradykinesia and rigidity to a minor extent ; however , its strength seems to be in improving levodopa - induced dyskinesias .|Stimulation often produces an improvement in the hyper - or dyskinetic upper limbs , but increases the " freezing " phenomenon in the lower limbs at the same time .|Considering the small increase in the patient 's independence , the high costs of bilateral implants , and the difficulty most patients experience in handling the devices , the question arises as to whether bilateral pallidal stimulation is a real alternative to pallidotomy .	1:NR:2	R2L	CROSS	156-157	109-110	D007980	levodopa	Chemical	156	157	6	D010300	Parkinson 's disease|PD|PD|PD	Disease	17:21:45:109	20:22:46:110	1:1:2:5	1:CID:2	R2L	NON-CROSS	159-160	156-157	D007980	levodopa	Chemical	156	157	6	D004409	dyskinesias|dyskinesias|hyper - or dyskinetic	Disease	113:159:168	114:160:172	5:6:7	1:NR:2	R2L	NON-CROSS	156-157	141-142	D007980	levodopa	Chemical	156	157	6	D009127	rigidity|rigidity	Disease	126:141	127:142	5:6	1:NR:2	R2L	NON-CROSS	156-157	139-140	D007980	levodopa	Chemical	156	157	6	D018476	bradykinesia|bradykinesia	Disease	128:139	129:140	5:6	1:NR:2	L2R	CROSS	156-157	168-172	D007980	levodopa	Chemical	156	157	6	D006948	hyper - or dyskinetic	Disease	168	172	7
12734532	Case report : Dexatrim ( Phenylpropanolamine ) as a cause of myocardial infarction .|Phenylpropanolamine ( PPA ) is a sympathetic amine used in over - the - counter cold remedies and weight - control preparations worldwide .|Its use has been associated with hypertensive episodes and hemorrhagic strokes in younger women .|Several reports have linked the abuse of PPA with myocardial injury , especially when overdose is involved .|We report here the first case of Dexatrim ( PPA ) - induced myocardial injury in a young woman who was using it at recommended doses for weight control .|In addition , we review the 7 other cases of PPA related myocardial injury that have been reported so far .|Physicians and patients should be alert to the potential cardiac risk associated with the use of PPA , even at doses generally considered to be safe .	1:CID:2	L2R	NON-CROSS	11-13	14-15	D010665	Dexatrim|Phenylpropanolamine|Phenylpropanolamine|PPA|PPA|Dexatrim|PPA|PPA|PPA	Chemical	3:5:14:16:60:78:80:111:138	4:6:15:17:61:79:81:112:139	0:0:1:1:3:4:4:5:6	D009203	myocardial infarction	Disease	11	13	0	1:NR:2	L2R	CROSS	44-45	60-61	D010665	Dexatrim|Phenylpropanolamine|Phenylpropanolamine|PPA|PPA|Dexatrim|PPA|PPA|PPA	Chemical	3:5:14:16:60:78:80:111:138	4:6:15:17:61:79:81:112:139	0:0:1:1:3:4:4:5:6	D006973	hypertensive	Disease	44	45	2	1:NR:2	L2R	CROSS	47-49	60-61	D010665	Dexatrim|Phenylpropanolamine|Phenylpropanolamine|PPA|PPA|Dexatrim|PPA|PPA|PPA	Chemical	3:5:14:16:60:78:80:111:138	4:6:15:17:61:79:81:112:139	0:0:1:1:3:4:4:5:6	D006470	hemorrhagic strokes	Disease	47	49	2	1:NR:2	L2R	CROSS	47-49	60-61	D010665	Dexatrim|Phenylpropanolamine|Phenylpropanolamine|PPA|PPA|Dexatrim|PPA|PPA|PPA	Chemical	3:5:14:16:60:78:80:111:138	4:6:15:17:61:79:81:112:139	0:0:1:1:3:4:4:5:6	D020521	hemorrhagic strokes	Disease	47	49	2	1:NR:2	L2R	NON-CROSS	60-61	62-64	D010665	Dexatrim|Phenylpropanolamine|Phenylpropanolamine|PPA|PPA|Dexatrim|PPA|PPA|PPA	Chemical	3:5:14:16:60:78:80:111:138	4:6:15:17:61:79:81:112:139	0:0:1:1:3:4:4:5:6	D009202	myocardial injury|myocardial injury|myocardial injury	Disease	62:84:113	64:86:115	3:4:5	1:NR:2	L2R	NON-CROSS	60-61	67-68	D010665	Dexatrim|Phenylpropanolamine|Phenylpropanolamine|PPA|PPA|Dexatrim|PPA|PPA|PPA	Chemical	3:5:14:16:60:78:80:111:138	4:6:15:17:61:79:81:112:139	0:0:1:1:3:4:4:5:6	D062787	overdose	Disease	67	68	3	1:NR:2	R2L	CROSS	21-22	11-13	D000588	amine	Chemical	21	22	1	D009203	myocardial infarction	Disease	11	13	0	1:NR:2	L2R	CROSS	21-22	44-45	D000588	amine	Chemical	21	22	1	D006973	hypertensive	Disease	44	45	2	1:NR:2	L2R	CROSS	21-22	47-49	D000588	amine	Chemical	21	22	1	D006470	hemorrhagic strokes	Disease	47	49	2	1:NR:2	L2R	CROSS	21-22	47-49	D000588	amine	Chemical	21	22	1	D020521	hemorrhagic strokes	Disease	47	49	2	1:NR:2	L2R	CROSS	21-22	62-64	D000588	amine	Chemical	21	22	1	D009202	myocardial injury|myocardial injury|myocardial injury	Disease	62:84:113	64:86:115	3:4:5	1:NR:2	L2R	CROSS	21-22	67-68	D000588	amine	Chemical	21	22	1	D062787	overdose	Disease	67	68	3
12013711	Risperidone - associated , benign transient visual disturbances in schizophrenic patients with a past history of LSD abuse .|Two schizophrenic patients , who had a prior history of LSD abuse and who had previously developed EPS with classic antipsychotics , were successfully treated with risperidone .|They both reported short episodes of transient visual disturbances , which appeared immediately after starting treatment with risperidone .|This imagery resembled visual disturbances previously experienced as " flashbacks " related to prior LSD consumption .|Risperidone administration was continued and the visual disturbances gradually wore off .|During a six - month follow - up period , there was no recurrence of visual disturbances .|This phenomenon may be interpreted as a benign , short - term and self - limiting side effect which does not contraindicate the use of risperidone or interfere with treatment .|Conclusions based on two case reports should be taken with appropriate caution .	1:CID:2	L2R	NON-CROSS	64-65	69-71	D018967	Risperidone|risperidone|risperidone|Risperidone|risperidone	Chemical	0:45:64:83:138	1:46:65:84:139	0:1:2:4:6	D010468	visual disturbances|visual disturbances|visual disturbances|visual disturbances|visual disturbances	Disease	6:54:69:89:110	8:56:71:91:112	0:2:3:4:5	1:NR:2	L2R	NON-CROSS	0-1	9-10	D018967	Risperidone|risperidone|risperidone|Risperidone|risperidone	Chemical	0:45:64:83:138	1:46:65:84:139	0:1:2:4:6	D012559	schizophrenic|schizophrenic	Disease	9:20	10:21	0:1	1:NR:2	L2R	NON-CROSS	36-37	45-46	D018967	Risperidone|risperidone|risperidone|Risperidone|risperidone	Chemical	0:45:64:83:138	1:46:65:84:139	0:1:2:4:6	D001480	EPS	Disease	36	37	1	1:NR:2	R2L	NON-CROSS	16-17	6-8	D008238	LSD|LSD|LSD	Chemical	16:29:80	17:30:81	0:1:3	D010468	visual disturbances|visual disturbances|visual disturbances|visual disturbances|visual disturbances	Disease	6:54:69:89:110	8:56:71:91:112	0:2:3:4:5	1:NR:2	R2L	NON-CROSS	20-21	16-17	D008238	LSD|LSD|LSD	Chemical	16:29:80	17:30:81	0:1:3	D012559	schizophrenic|schizophrenic	Disease	9:20	10:21	0:1	1:NR:2	L2R	NON-CROSS	29-30	36-37	D008238	LSD|LSD|LSD	Chemical	16:29:80	17:30:81	0:1:3	D001480	EPS	Disease	36	37	1
11861791	Activation of poly ( ADP - ribose ) polymerase contributes to development of doxorubicin - induced heart failure .|Activation of the nuclear enzyme poly ( ADP - ribose ) polymerase ( PARP ) by oxidant - mediated DNA damage is an important pathway of cell dysfunction and tissue injury in conditions associated with oxidative stress .|Increased oxidative stress is a major factor implicated in the cardiotoxicity of doxorubicin ( DOX ) , a widely used antitumor anthracycline antibiotic .|Thus , we hypothesized that the activation of PARP may contribute to the DOX - induced cardiotoxicity .|Using a dual approach of PARP - 1 suppression , by genetic deletion or pharmacological inhibition with the phenanthridinone PARP inhibitor PJ34 , we now demonstrate the role of PARP in the development of cardiac dysfunction induced by DOX .|PARP - 1 + / + and PARP - 1 - / - mice received a single injection of DOX ( 25 mg / kg i . p ) .|Five days after DOX administration , left ventricular performance was significantly depressed in PARP - 1 + / + mice , but only to a smaller extent in PARP - 1 - / - ones .|Similar experiments were conducted in BALB / c mice treated with PJ34 or vehicle .|Treatment with a PJ34 significantly improved cardiac dysfunction and increased the survival of the animals .|In addition PJ34 significantly reduced the DOX - induced increase in the serum lactate dehydrogenase and creatine kinase activities but not metalloproteinase activation in the heart .|Thus , PARP activation contributes to the cardiotoxicity of DOX .|PARP inhibitors may exert protective effects against the development of severe cardiac complications associated with the DOX treatment .	1:NR:2	L2R	NON-CROSS	16-18	24-30	D011064	poly ( ADP - ribose )|poly ( ADP - ribose )	Chemical	2:24	8:30	0:1	D006333	heart failure	Disease	16	18	0	1:NR:2	L2R	CROSS	24-30	67-68	D011064	poly ( ADP - ribose )|poly ( ADP - ribose )	Chemical	2:24	8:30	0:1	D066126	cardiotoxicity|cardiotoxicity|cardiotoxicity	Disease	67:97:270	68:98:271	2:3:10	1:NR:2	L2R	CROSS	24-30	133-135	D011064	poly ( ADP - ribose )|poly ( ADP - ribose )	Chemical	2:24	8:30	0:1	D006331	cardiac dysfunction|cardiac dysfunction	Disease	133:226	135:228	4:8	1:NR:2	L2R	CROSS	24-30	285-287	D011064	poly ( ADP - ribose )|poly ( ADP - ribose )	Chemical	2:24	8:30	0:1	D005117	cardiac complications	Disease	285	287	11	1:CID:2	L2R	NON-CROSS	13-14	16-18	D004317	doxorubicin|doxorubicin|DOX|DOX|DOX|DOX|DOX|DOX|DOX|DOX	Chemical	13:69:71:94:137:158:172:242:272:290	14:70:72:95:138:159:173:243:273:291	0:2:2:3:4:5:6:9:10:11	D006333	heart failure	Disease	16	18	0	1:NR:2	L2R	NON-CROSS	67-68	69-70	D004317	doxorubicin|doxorubicin|DOX|DOX|DOX|DOX|DOX|DOX|DOX|DOX	Chemical	13:69:71:94:137:158:172:242:272:290	14:70:72:95:138:159:173:243:273:291	0:2:2:3:4:5:6:9:10:11	D066126	cardiotoxicity|cardiotoxicity|cardiotoxicity	Disease	67:97:270	68:98:271	2:3:10	1:NR:2	L2R	NON-CROSS	133-135	137-138	D004317	doxorubicin|doxorubicin|DOX|DOX|DOX|DOX|DOX|DOX|DOX|DOX	Chemical	13:69:71:94:137:158:172:242:272:290	14:70:72:95:138:159:173:243:273:291	0:2:2:3:4:5:6:9:10:11	D006331	cardiac dysfunction|cardiac dysfunction	Disease	133:226	135:228	4:8	1:NR:2	L2R	NON-CROSS	285-287	290-291	D004317	doxorubicin|doxorubicin|DOX|DOX|DOX|DOX|DOX|DOX|DOX|DOX	Chemical	13:69:71:94:137:158:172:242:272:290	14:70:72:95:138:159:173:243:273:291	0:2:2:3:4:5:6:9:10:11	D005117	cardiac complications	Disease	285	287	11	1:NR:2	R2L	CROSS	78-79	16-18	D018943	anthracycline	Chemical	78	79	2	D006333	heart failure	Disease	16	18	0	1:NR:2	R2L	CROSS	120-121	16-18	C434926	PJ34|PJ34|PJ34|PJ34	Chemical	120:216:223:238	121:217:224:239	4:7:8:9	D006333	heart failure	Disease	16	18	0	1:NR:2	R2L	CROSS	249-250	16-18	D019344	lactate	Chemical	249	250	9	D006333	heart failure	Disease	16	18	0	1:NR:2	R2L	CROSS	252-253	16-18	D003401	creatine	Chemical	252	253	9	D006333	heart failure	Disease	16	18	0	1:NR:2	R2L	NON-CROSS	78-79	67-68	D018943	anthracycline	Chemical	78	79	2	D066126	cardiotoxicity|cardiotoxicity|cardiotoxicity	Disease	67:97:270	68:98:271	2:3:10	1:NR:2	R2L	CROSS	120-121	97-98	C434926	PJ34|PJ34|PJ34|PJ34	Chemical	120:216:223:238	121:217:224:239	4:7:8:9	D066126	cardiotoxicity|cardiotoxicity|cardiotoxicity	Disease	67:97:270	68:98:271	2:3:10	1:NR:2	R2L	CROSS	270-271	249-250	D019344	lactate	Chemical	249	250	9	D066126	cardiotoxicity|cardiotoxicity|cardiotoxicity	Disease	67:97:270	68:98:271	2:3:10	1:NR:2	R2L	CROSS	270-271	252-253	D003401	creatine	Chemical	252	253	9	D066126	cardiotoxicity|cardiotoxicity|cardiotoxicity	Disease	67:97:270	68:98:271	2:3:10	1:NR:2	L2R	CROSS	78-79	133-135	D018943	anthracycline	Chemical	78	79	2	D006331	cardiac dysfunction|cardiac dysfunction	Disease	133:226	135:228	4:8	1:NR:2	L2R	CROSS	78-79	285-287	D018943	anthracycline	Chemical	78	79	2	D005117	cardiac complications	Disease	285	287	11	1:NR:2	L2R	NON-CROSS	223-224	226-228	C434926	PJ34|PJ34|PJ34|PJ34	Chemical	120:216:223:238	121:217:224:239	4:7:8:9	D006331	cardiac dysfunction|cardiac dysfunction	Disease	133:226	135:228	4:8	1:NR:2	L2R	CROSS	238-239	285-287	C434926	PJ34|PJ34|PJ34|PJ34	Chemical	120:216:223:238	121:217:224:239	4:7:8:9	D005117	cardiac complications	Disease	285	287	11	1:NR:2	R2L	CROSS	249-250	226-228	D019344	lactate	Chemical	249	250	9	D006331	cardiac dysfunction|cardiac dysfunction	Disease	133:226	135:228	4:8	1:NR:2	R2L	CROSS	252-253	226-228	D003401	creatine	Chemical	252	253	9	D006331	cardiac dysfunction|cardiac dysfunction	Disease	133:226	135:228	4:8	1:NR:2	L2R	CROSS	249-250	285-287	D019344	lactate	Chemical	249	250	9	D005117	cardiac complications	Disease	285	287	11	1:NR:2	L2R	CROSS	252-253	285-287	D003401	creatine	Chemical	252	253	9	D005117	cardiac complications	Disease	285	287	11
11302406	Fluconazole - induced torsade de pointes .|OBJECTIVE : To present a case of fluconazole - associated torsade de pointes ( TDP ) and discuss fluconazole 's role in causing TDP .|CASE SUMMARY : A 68 - year - old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP , including coronary artery disease , cardiomyopathy , congestive heart failure , and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP .|The TDP resolved when fluconazole was discontinued ; however , the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia ( NSVT ) until six days after drug cessation DISCUSSION : Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP .|The possible mechanism is depression of rapidly activating delayed rectifier potassium currents .|In our patient , there was no other etiology identified that could explain QT prolongation or TDP The complete disappearance of NSVT and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests fluconazole as the etiology .|CONCLUSIONS : Clinicians should be aware that fluconazole , even at low doses , may cause prolongation of the QT interval , leading to TDP .|Serial electrocardiographic monitoring may be considered when fluconazole is administered in patients who are at risk for ventricular arrhythmias .	1:CID:2	L2R	NON-CROSS	92-93	94-95	D015725	Fluconazole|fluconazole|fluconazole|fluconazole|fluconazole|fluconazole|fluconazole|fluconazole|fluconazole|fluconazole	Chemical	0:14:25:58:92:100:143:202:214:240	1:15:26:59:93:101:144:203:215:241	0:1:1:2:2:3:3:5:6:7	D016171	torsade de pointes|torsade de pointes|TDP|TDP|TDP|TDP|TDP|TDP|TDP|TDP|TDP	Disease	3:17:21:30:52:67:94:97:148:179:231	6:20:22:31:53:68:95:98:149:180:232	0:1:1:1:2:2:2:3:3:5:6	1:NR:2	L2R	NON-CROSS	58-59	70-73	D015725	Fluconazole|fluconazole|fluconazole|fluconazole|fluconazole|fluconazole|fluconazole|fluconazole|fluconazole|fluconazole	Chemical	0:14:25:58:92:100:143:202:214:240	1:15:26:59:93:101:144:203:215:241	0:1:1:2:2:3:3:5:6:7	D003324	coronary artery disease	Disease	70	73	2	1:NR:2	L2R	NON-CROSS	58-59	74-75	D015725	Fluconazole|fluconazole|fluconazole|fluconazole|fluconazole|fluconazole|fluconazole|fluconazole|fluconazole|fluconazole	Chemical	0:14:25:58:92:100:143:202:214:240	1:15:26:59:93:101:144:203:215:241	0:1:1:2:2:3:3:5:6:7	D009202	cardiomyopathy	Disease	74	75	2	1:NR:2	L2R	NON-CROSS	76-79	92-93	D015725	Fluconazole|fluconazole|fluconazole|fluconazole|fluconazole|fluconazole|fluconazole|fluconazole|fluconazole|fluconazole	Chemical	0:14:25:58:92:100:143:202:214:240	1:15:26:59:93:101:144:203:215:241	0:1:1:2:2:3:3:5:6:7	D006333	congestive heart failure	Disease	76	79	2	1:NR:2	L2R	NON-CROSS	100-101	111-114	D015725	Fluconazole|fluconazole|fluconazole|fluconazole|fluconazole|fluconazole|fluconazole|fluconazole|fluconazole|fluconazole	Chemical	0:14:25:58:92:100:143:202:214:240	1:15:26:59:93:101:144:203:215:241	0:1:1:2:2:3:3:5:6:7	D018879	premature ventricular contractions|premature ventricular contractions	Disease	111:186	114:189	3:5	1:NR:2	L2R	NON-CROSS	100-101	116-118	D015725	Fluconazole|fluconazole|fluconazole|fluconazole|fluconazole|fluconazole|fluconazole|fluconazole|fluconazole|fluconazole	Chemical	0:14:25:58:92:100:143:202:214:240	1:15:26:59:93:101:144:203:215:241	0:1:1:2:2:3:3:5:6:7	D017180	ventricular tachycardia|NSVT|NSVT	Disease	116:119:184	118:120:185	3:3:5	1:NR:2	L2R	CROSS	143-144	154-155	D015725	Fluconazole|fluconazole|fluconazole|fluconazole|fluconazole|fluconazole|fluconazole|fluconazole|fluconazole|fluconazole	Chemical	0:14:25:58:92:100:143:202:214:240	1:15:26:59:93:101:144:203:215:241	0:1:1:2:2:3:3:5:6:7	D003866	depression	Disease	154	155	4	1:NR:2	L2R	NON-CROSS	214-215	223-228	D015725	Fluconazole|fluconazole|fluconazole|fluconazole|fluconazole|fluconazole|fluconazole|fluconazole|fluconazole|fluconazole	Chemical	0:14:25:58:92:100:143:202:214:240	1:15:26:59:93:101:144:203:215:241	0:1:1:2:2:3:3:5:6:7	D008133	QT prolongation|prolongation of the QT interval	Disease	176:223	178:228	5:6	1:NR:2	L2R	NON-CROSS	240-241	250-252	D015725	Fluconazole|fluconazole|fluconazole|fluconazole|fluconazole|fluconazole|fluconazole|fluconazole|fluconazole|fluconazole	Chemical	0:14:25:58:92:100:143:202:214:240	1:15:26:59:93:101:144:203:215:241	0:1:1:2:2:3:3:5:6:7	D001145	ventricular arrhythmias	Disease	250	252	7	1:NR:2	R2L	CROSS	160-161	148-149	D011188	potassium	Chemical	160	161	4	D016171	torsade de pointes|torsade de pointes|TDP|TDP|TDP|TDP|TDP|TDP|TDP|TDP|TDP	Disease	3:17:21:30:52:67:94:97:148:179:231	6:20:22:31:53:68:95:98:149:180:232	0:1:1:1:2:2:2:3:3:5:6	1:NR:2	R2L	CROSS	160-161	70-73	D011188	potassium	Chemical	160	161	4	D003324	coronary artery disease	Disease	70	73	2	1:NR:2	R2L	CROSS	160-161	74-75	D011188	potassium	Chemical	160	161	4	D009202	cardiomyopathy	Disease	74	75	2	1:NR:2	R2L	CROSS	160-161	76-79	D011188	potassium	Chemical	160	161	4	D006333	congestive heart failure	Disease	76	79	2	1:NR:2	R2L	CROSS	186-189	160-161	D011188	potassium	Chemical	160	161	4	D018879	premature ventricular contractions|premature ventricular contractions	Disease	111:186	114:189	3:5	1:NR:2	R2L	CROSS	184-185	160-161	D011188	potassium	Chemical	160	161	4	D017180	ventricular tachycardia|NSVT|NSVT	Disease	116:119:184	118:120:185	3:3:5	1:NR:2	R2L	NON-CROSS	160-161	154-155	D011188	potassium	Chemical	160	161	4	D003866	depression	Disease	154	155	4	1:NR:2	L2R	CROSS	160-161	176-178	D011188	potassium	Chemical	160	161	4	D008133	QT prolongation|prolongation of the QT interval	Disease	176:223	178:228	5:6	1:NR:2	L2R	CROSS	160-161	250-252	D011188	potassium	Chemical	160	161	4	D001145	ventricular arrhythmias	Disease	250	252	7
11058428	High - dose methylprednisolone may do more harm for spinal cord injury .|Because of the National Acute Spinal Cord Injury Studies ( NASCIS ) , high - dose methylprednisolone became the standard of care for the acute spinal cord injury .|In the NASCIS , there was no mention regarding the possibility of acute corticosteroid myopathy that high - dose methylprednisolone may cause .|The dosage of methylprednisolone recommended by the NASCIS 3 is the highest dose of steroids ever being used during a 2 - day period for any clinical condition .|We hypothesize that it may cause some damage to the muscle of spinal cord injury patients .|Further , steroid myopathy recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the steroid myopathy , instead of any protection that methylprednisolone offers to the spinal cord injury .|To our knowledge , this is the first discussion considering the possibility that the methylprednisolone recommended by NASCIS may cause acute corticosteroid myopathy .	1:NR:2	L2R	NON-CROSS	145-146	149-152	D008775	methylprednisolone|methylprednisolone|methylprednisolone|methylprednisolone|methylprednisolone|methylprednisolone	Chemical	3:29:61:68:145:167	4:30:62:69:146:168	0:1:2:3:5:6	D013119	spinal cord injury|Spinal Cord Injury|spinal cord injury|spinal cord injury|spinal cord injury	Disease	9:18:38:106:149	12:21:41:109:152	0:1:1:4:5	1:CID:2	L2R	NON-CROSS	56-57	61-62	D008775	methylprednisolone|methylprednisolone|methylprednisolone|methylprednisolone|methylprednisolone|methylprednisolone	Chemical	3:29:61:68:145:167	4:30:62:69:146:168	0:1:2:3:5:6	D009135	myopathy|damage to the muscle|myopathy|myopathy|myopathy	Disease	56:101:114:138:175	57:105:115:139:176	2:4:5:5:6	1:NR:2	R2L	CROSS	55-56	38-41	D000305	corticosteroid|corticosteroid	Chemical	55:174	56:175	2:6	D013119	spinal cord injury|Spinal Cord Injury|spinal cord injury|spinal cord injury|spinal cord injury	Disease	9:18:38:106:149	12:21:41:109:152	0:1:1:4:5	1:NR:2	R2L	NON-CROSS	113-114	106-109	D013256	steroids|steroid|steroid	Chemical	79:113:137	80:114:138	3:5:5	D013119	spinal cord injury|Spinal Cord Injury|spinal cord injury|spinal cord injury|spinal cord injury	Disease	9:18:38:106:149	12:21:41:109:152	0:1:1:4:5	1:NR:2	L2R	NON-CROSS	55-56	56-57	D000305	corticosteroid|corticosteroid	Chemical	55:174	56:175	2:6	D009135	myopathy|damage to the muscle|myopathy|myopathy|myopathy	Disease	56:101:114:138:175	57:105:115:139:176	2:4:5:5:6	1:NR:2	R2L	NON-CROSS	114-115	113-114	D013256	steroids|steroid|steroid	Chemical	79:113:137	80:114:138	3:5:5	D009135	myopathy|damage to the muscle|myopathy|myopathy|myopathy	Disease	56:101:114:138:175	57:105:115:139:176	2:4:5:5:6
11022397	Probing peripheral and central cholinergic system responses .|OBJECTIVE : The pharmacological response to drugs that act on the cholinergic system of the iris has been used to predict deficits in central cholinergic functioning due to diseases such as Alzheimer 's disease , yet correlations between central and peripheral responses have not been properly studied .|This study assessed the effect of normal aging on ( 1 ) the tropicamide - induced increase in pupil diameter , and ( 2 ) the reversal of this effect with pilocarpine .|Scopolamine was used as a positive control to detect age - dependent changes in central cholinergic functioning in the elderly .|DESIGN : Randomized double - blind controlled trial .|PARTICIPANTS : Ten healthy elderly ( mean age 70 ) and 9 young ( mean age 33 ) volunteers .|INTERVENTIONS : Pupil diameter was monitored using a computerized infrared pupillometer over 4 hours .|The study involved 4 sessions .|In 1 session , tropicamide ( 20 microL , 0 . 01 % ) was administered to one eye and placebo to the other .|In another session , tropicamide ( 20 microL , 0 . 01 % ) was administered to both eyes , followed 23 minutes later by the application of pilocarpine ( 20 microL , 0 . 1 % ) to one eye and placebo to the other .|All eye drops were given in a randomized order .|In 2 separate sessions , a single dose of scopolamine ( 0 . 5 mg , intravenously ) or placebo was administered , and the effects on word recall were measured using the Buschke Selective Reminding Test over 2 hours .|OUTCOME MEASURES : Pupil size at time points after administration of tropicamide and pilocarpine ; scopolamine - induced impairment in word recall .|RESULTS : There was no significant difference between elderly and young volunteers in pupillary response to tropicamide at any time point ( p > 0 . 05 ) .|The elderly group had a significantly greater pilocarpine - induced net decrease in pupil size 85 , 125 , 165 and 215 minutes after administration , compared with the young group ( p < 0 . 05 ) .|Compared with the young group , the elderly group had greater scopolamine - induced impairment in word recall 60 , 90 and 120 minutes after administration ( p < 0 . 05 ) .|CONCLUSION : There is an age - related pupillary response to pilocarpine that is not found with tropicamide .|Thus , pilocarpine may be useful to assess variations in central cholinergic function in elderly patients .	1:NR:2	R2L	CROSS	69-70	39-42	D014331	tropicamide|tropicamide|tropicamide|tropicamide|tropicamide|tropicamide	Chemical	69:164:189:294:322:425	70:165:190:295:323:426	2:8:9:12:13:16	D000544	Alzheimer 's disease	Disease	39	42	1	1:NR:2	R2L	CROSS	87-88	39-42	D010862	pilocarpine|pilocarpine|pilocarpine|pilocarpine|pilocarpine|pilocarpine	Chemical	87:213:296:342:419:429	88:214:297:343:420:430	2:9:12:14:16:17	D000544	Alzheimer 's disease	Disease	39	42	1	1:NR:2	R2L	CROSS	89-90	39-42	D012601	Scopolamine|scopolamine|scopolamine|scopolamine	Chemical	89:251:298:385	90:252:299:386	3:11:12:15	D000544	Alzheimer 's disease	Disease	39	42	1	1:NR:2	L2R	NON-CROSS	294-295	301-305	D014331	tropicamide|tropicamide|tropicamide|tropicamide|tropicamide|tropicamide	Chemical	69:164:189:294:322:425	70:165:190:295:323:426	2:8:9:12:13:16	D008569	impairment in word recall|impairment in word recall	Disease	301:388	305:392	12:15	1:NR:2	L2R	NON-CROSS	296-297	301-305	D010862	pilocarpine|pilocarpine|pilocarpine|pilocarpine|pilocarpine|pilocarpine	Chemical	87:213:296:342:419:429	88:214:297:343:420:430	2:9:12:14:16:17	D008569	impairment in word recall|impairment in word recall	Disease	301:388	305:392	12:15	1:CID:2	L2R	NON-CROSS	298-299	301-305	D012601	Scopolamine|scopolamine|scopolamine|scopolamine	Chemical	89:251:298:385	90:252:299:386	3:11:12:15	D008569	impairment in word recall|impairment in word recall	Disease	301:388	305:392	12:15
10692744	Acetazolamide - induced Gerstmann syndrome .|Acute confusion induced by acetazolamide is a well known adverse drug reaction in patients with renal impairment .|We report a case of acetazolamide - induced Gerstmann syndrome in a patient with normal renal function , to highlight predisposing factors that are frequently overlooked .	1:CID:2	L2R	NON-CROSS	0-1	3-5	D000086	Acetazolamide|acetazolamide|acetazolamide	Chemical	0:10:29	1:11:30	0:1:2	D005862	Gerstmann syndrome|Gerstmann syndrome	Disease	3:32	5:34	0:2	1:NR:2	L2R	NON-CROSS	7-8	10-11	D000086	Acetazolamide|acetazolamide|acetazolamide	Chemical	0:10:29	1:11:30	0:1:2	D003221	confusion	Disease	7	8	1	1:NR:2	L2R	NON-CROSS	21-23	29-30	D000086	Acetazolamide|acetazolamide|acetazolamide	Chemical	0:10:29	1:11:30	0:1:2	D007674	renal impairment	Disease	21	23	1
10565806	Hypomania - like syndrome induced by olanzapine .|We report a female patient with a diagnosis of a not otherwise specified psychotic disorder ( DSM - IV ) who developed hypomania shortly after the introduction of olanzapine treatment .	1:CID:2	R2L	NON-CROSS	6-7	0-1	C076029	olanzapine|olanzapine	Chemical	6:36	7:37	0:1	D001714	Hypomania|hypomania	Disease	0:30	1:31	0:1	1:NR:2	L2R	NON-CROSS	21-23	36-37	C076029	olanzapine|olanzapine	Chemical	6:36	7:37	0:1	D011618	psychotic disorder	Disease	21	23	1
9061311	Neutrophil superoxide and hydrogen peroxide production in patients with acute liver failure .|Defects in superoxide and hydrogen peroxide production may be implicated in the high incidence of bacterial infections in patients with acute liver failure ( ALF ) .|In the present study , oxygen radical production in patients with ALF due to paracetamol overdose was compared with that of healthy volunteers .|Neutrophils from 14 ALF patients were stimulated via the complement receptors using zymosan opsonized with ALF or control serum .|Superoxide and hydrogen peroxide production by ALF neutrophils stimulated with zymosan opsonized with ALF serum was significantly reduced compared with the control subjects ( P < 0 . 01 ) .|This defect persisted when zymosan opsonized by control serum was used ( P < 0 . 05 ) .|Superoxide and hydrogen peroxide production in neutrophils stimulated with formyl - methionyl - leucyl - phenylalanine ( fMLP ) from a further 18 ALF patients was unaffected compared with control neutrophils .|Serum C3 complement levels were significantly reduced in ALF patients compared with control subjects ( P < 0 . 0005 ) .|These results demonstrate a neutrophil defect in ALF due to paracetamol overdose , that is complement dependent but independent of serum complement , possibly connected to the complement receptor .	1:NR:2	L2R	NON-CROSS	79-80	84-85	D013481	superoxide|superoxide|Superoxide|Superoxide	Chemical	1:15:84:134	2:16:85:135	0:1:4:6	D017114	acute liver failure|acute liver failure|ALF|ALF|ALF|ALF|ALF|ALF|ALF|ALF|ALF	Disease	9:33:37:51:67:79:90:97:157:174:195	12:36:38:52:68:80:91:98:158:175:196	0:1:1:2:3:3:4:4:6:7:8	1:NR:2	L2R	NON-CROSS	15-16	28-30	D013481	superoxide|superoxide|Superoxide|Superoxide	Chemical	1:15:84:134	2:16:85:135	0:1:4:6	D001424	bacterial infections	Disease	28	30	1	1:NR:2	L2R	CROSS	55-56	84-85	D013481	superoxide|superoxide|Superoxide|Superoxide	Chemical	1:15:84:134	2:16:85:135	0:1:4:6	D062787	overdose|overdose	Disease	55:199	56:200	2:8	1:NR:2	L2R	NON-CROSS	86-88	90-91	D006861	hydrogen peroxide|hydrogen peroxide|hydrogen peroxide|hydrogen peroxide	Chemical	3:17:86:136	5:19:88:138	0:1:4:6	D017114	acute liver failure|acute liver failure|ALF|ALF|ALF|ALF|ALF|ALF|ALF|ALF|ALF	Disease	9:33:37:51:67:79:90:97:157:174:195	12:36:38:52:68:80:91:98:158:175:196	0:1:1:2:3:3:4:4:6:7:8	1:NR:2	L2R	NON-CROSS	17-19	28-30	D006861	hydrogen peroxide|hydrogen peroxide|hydrogen peroxide|hydrogen peroxide	Chemical	3:17:86:136	5:19:88:138	0:1:4:6	D001424	bacterial infections	Disease	28	30	1	1:NR:2	L2R	CROSS	55-56	86-88	D006861	hydrogen peroxide|hydrogen peroxide|hydrogen peroxide|hydrogen peroxide	Chemical	3:17:86:136	5:19:88:138	0:1:4:6	D062787	overdose|overdose	Disease	55:199	56:200	2:8	1:NR:2	R2L	NON-CROSS	51-52	45-46	D010100	oxygen	Chemical	45	46	2	D017114	acute liver failure|acute liver failure|ALF|ALF|ALF|ALF|ALF|ALF|ALF|ALF|ALF	Disease	9:33:37:51:67:79:90:97:157:174:195	12:36:38:52:68:80:91:98:158:175:196	0:1:1:2:3:3:4:4:6:7:8	1:CID:2	R2L	NON-CROSS	54-55	51-52	D000082	paracetamol|paracetamol	Chemical	54:198	55:199	2:8	D017114	acute liver failure|acute liver failure|ALF|ALF|ALF|ALF|ALF|ALF|ALF|ALF|ALF	Disease	9:33:37:51:67:79:90:97:157:174:195	12:36:38:52:68:80:91:98:158:175:196	0:1:1:2:3:3:4:4:6:7:8	1:NR:2	R2L	NON-CROSS	157-158	151-152	D009240	formyl - methionyl - leucyl - phenylalanine|fMLP	Chemical	143:151	150:152	6:6	D017114	acute liver failure|acute liver failure|ALF|ALF|ALF|ALF|ALF|ALF|ALF|ALF|ALF	Disease	9:33:37:51:67:79:90:97:157:174:195	12:36:38:52:68:80:91:98:158:175:196	0:1:1:2:3:3:4:4:6:7:8	1:NR:2	R2L	CROSS	45-46	28-30	D010100	oxygen	Chemical	45	46	2	D001424	bacterial infections	Disease	28	30	1	1:NR:2	R2L	CROSS	54-55	28-30	D000082	paracetamol|paracetamol	Chemical	54:198	55:199	2:8	D001424	bacterial infections	Disease	28	30	1	1:NR:2	R2L	CROSS	143-150	28-30	D009240	formyl - methionyl - leucyl - phenylalanine|fMLP	Chemical	143:151	150:152	6:6	D001424	bacterial infections	Disease	28	30	1	1:NR:2	L2R	NON-CROSS	45-46	55-56	D010100	oxygen	Chemical	45	46	2	D062787	overdose|overdose	Disease	55:199	56:200	2:8	1:NR:2	L2R	NON-CROSS	54-55	55-56	D000082	paracetamol|paracetamol	Chemical	54:198	55:199	2:8	D062787	overdose|overdose	Disease	55:199	56:200	2:8	1:NR:2	R2L	CROSS	199-200	151-152	D009240	formyl - methionyl - leucyl - phenylalanine|fMLP	Chemical	143:151	150:152	6:6	D062787	overdose|overdose	Disease	55:199	56:200	2:8
8617710	Absence of effect of sertraline on time - based sensitization of cognitive impairment with haloperidol .|This double - blind , randomized , placebo - controlled study evaluated the effects of haloperidol alone and haloperidol plus sertraline on cognitive and psychomotor function in 24 healthy male subjects .|METHOD : All subjects received placebo on Day 1 and haloperidol 2 mg on Days 2 and 25 .|From Days 9 to 25 , subjects were randomly assigned to either sertraline ( 12 subjects ) or placebo ( 12 subjects ) ; the sertraline dose was titrated from 50 to 200 mg / day from Days 9 to 16 , and remained at 200 mg / day for the final 10 days of the drug administration period .|Cognitive function testing was performed before dosing and over a 24 - hour period after dosing on Days 1 , 2 , and 25 .|RESULTS : Impairment of cognitive function was observed 6 to 8 hours after administration of haloperidol on Day 2 but was not evident 23 hours after dosing .|When single - dose haloperidol was given again 25 days later , greater impairment with earlier onset was noted in several tests in both treatment groups , suggesting enhancement of this effect .|There was no indication that sertraline exacerbated the impairment produced by haloperidol since an equivalent effect also occurred in the placebo group .|Three subjects ( 2 on sertraline and 1 on placebo ) withdrew from the study because of side effects .|Ten subjects in each group reported side effects related to treatment .|The side effect profiles of sertraline and of placebo were similar .|CONCLUSION : Haloperidol produced a clear profile of cognitive impairment that was not worsened by concomitant sertraline administration .	1:NR:2	L2R	NON-CROSS	4-5	11-13	D020280	sertraline|sertraline|sertraline|sertraline|sertraline|sertraline|sertraline|sertraline	Chemical	4:36:79:92:218:241:273:296	5:37:80:93:219:242:274:297	0:1:3:3:7:8:10:11	D003072	cognitive impairment|Impairment of cognitive function|cognitive impairment	Disease	11:154:288	13:158:290	0:5:11	1:CID:2	R2L	NON-CROSS	14-15	11-13	D006220	haloperidol|haloperidol|haloperidol|haloperidol|haloperidol|haloperidol|haloperidol|Haloperidol	Chemical	14:31:34:58:167:184:224:282	15:32:35:59:168:185:225:283	0:1:1:2:5:6:7:11	D003072	cognitive impairment|Impairment of cognitive function|cognitive impairment	Disease	11:154:288	13:158:290	0:5:11
8494478	Ciprofloxacin - induced nephrotoxicity in patients with cancer .|Nephrotoxicity associated with ciprofloxacin is uncommon .|Five patients with cancer who developed acute renal failure that followed treatment with ciprofloxacin are described and an additional 15 cases reported in the literature are reviewed .|Other than elevation of serum creatinine levels , characteristic clinical manifestations and abnormal laboratory findings are not frequently present .|Allergic interstitial nephritis is believed to be the underlying pathological - process .|Definitive diagnosis requires performance of renal biopsy , although this is not always feasible .|An improvement in renal function that followed the discontinuation of the offending antibiotic supports the presumptive diagnosis of ciprofloxacin - induced acute renal failure .	1:NR:2	L2R	NON-CROSS	0-1	3-4	D002939	Ciprofloxacin|ciprofloxacin|ciprofloxacin|ciprofloxacin	Chemical	0:12:29:110	1:13:30:111	0:1:2:6	D007674	nephrotoxicity|Nephrotoxicity	Disease	3:9	4:10	0:1	1:NR:2	L2R	NON-CROSS	7-8	12-13	D002939	Ciprofloxacin|ciprofloxacin|ciprofloxacin|ciprofloxacin	Chemical	0:12:29:110	1:13:30:111	0:1:2:6	D009369	cancer|cancer	Disease	7:19	8:20	0:2	1:CID:2	L2R	NON-CROSS	110-111	113-116	D002939	Ciprofloxacin|ciprofloxacin|ciprofloxacin|ciprofloxacin	Chemical	0:12:29:110	1:13:30:111	0:1:2:6	D058186	acute renal failure|acute renal failure	Disease	22:113	25:116	2:6	1:NR:2	L2R	CROSS	29-30	65-67	D002939	Ciprofloxacin|ciprofloxacin|ciprofloxacin|ciprofloxacin	Chemical	0:12:29:110	1:13:30:111	0:1:2:6	D009395	interstitial nephritis	Disease	65	67	4	1:NR:2	R2L	CROSS	49-50	9-10	D003404	creatinine	Chemical	49	50	3	D007674	nephrotoxicity|Nephrotoxicity	Disease	3:9	4:10	0:1	1:NR:2	R2L	CROSS	49-50	19-20	D003404	creatinine	Chemical	49	50	3	D009369	cancer|cancer	Disease	7:19	8:20	0:2	1:NR:2	R2L	CROSS	49-50	22-25	D003404	creatinine	Chemical	49	50	3	D058186	acute renal failure|acute renal failure	Disease	22:113	25:116	2:6	1:NR:2	L2R	CROSS	49-50	65-67	D003404	creatinine	Chemical	49	50	3	D009395	interstitial nephritis	Disease	65	67	4
8475949	Case report : pentamidine and polymorphic ventricular tachycardia revisited .|Pentamidine isethionate has been associated with ventricular tachyarrhythmias , including torsade de pointes .|This article reports two cases of this complication and reviews all reported cases to date .|Pentamidine - induced torsade de pointes may be related to serum magnesium levels and hypomagnesemia may synergistically induce torsade .|Torsade de pointes occurred after an average of 10 days of treatment with pentamidine .|In these patients , no other acute side effects of pentamidine were observed .|Torsade de pointes can be treated when recognized early , possibly without discontinuation of pentamidine .|When QTc interval prolongation is observed , early magnesium supplementation is advocated .	1:NR:2	L2R	NON-CROSS	3-4	6-8	D010419	pentamidine|Pentamidine isethionate|Pentamidine|pentamidine|pentamidine|pentamidine	Chemical	3:10:40:73:85:103	4:12:41:74:86:104	0:1:3:4:5:6	D017180	ventricular tachycardia|ventricular tachyarrhythmias	Disease	6:16	8:18	0:1	1:CID:2	L2R	NON-CROSS	40-41	43-46	D010419	pentamidine|Pentamidine isethionate|Pentamidine|pentamidine|pentamidine|pentamidine	Chemical	3:10:40:73:85:103	4:12:41:74:86:104	0:1:3:4:5:6	D016171	torsade de pointes|torsade de pointes|Torsade de pointes|Torsade de pointes	Disease	20:43:60:89	23:46:63:92	1:3:4:6	1:NR:2	L2R	NON-CROSS	40-41	54-55	D010419	pentamidine|Pentamidine isethionate|Pentamidine|pentamidine|pentamidine|pentamidine	Chemical	3:10:40:73:85:103	4:12:41:74:86:104	0:1:3:4:5:6	C537153	hypomagnesemia	Disease	54	55	3	1:NR:2	L2R	CROSS	103-104	106-109	D010419	pentamidine|Pentamidine isethionate|Pentamidine|pentamidine|pentamidine|pentamidine	Chemical	3:10:40:73:85:103	4:12:41:74:86:104	0:1:3:4:5:6	D008133	QTc interval prolongation	Disease	106	109	7	1:NR:2	R2L	CROSS	51-52	16-18	D008274	magnesium|magnesium	Chemical	51:113	52:114	3:7	D017180	ventricular tachycardia|ventricular tachyarrhythmias	Disease	6:16	8:18	0:1	1:NR:2	R2L	NON-CROSS	51-52	43-46	D008274	magnesium|magnesium	Chemical	51:113	52:114	3:7	D016171	torsade de pointes|torsade de pointes|Torsade de pointes|Torsade de pointes	Disease	20:43:60:89	23:46:63:92	1:3:4:6	1:NR:2	L2R	NON-CROSS	51-52	54-55	D008274	magnesium|magnesium	Chemical	51:113	52:114	3:7	C537153	hypomagnesemia	Disease	54	55	3	1:NR:2	L2R	NON-CROSS	106-109	113-114	D008274	magnesium|magnesium	Chemical	51:113	52:114	3:7	D008133	QTc interval prolongation	Disease	106	109	7
7710775	Time dependence of plasma malondialdehyde , oxypurines , and nucleosides during incomplete cerebral ischemia in the rat .|Incomplete cerebral ischemia ( 30 min ) was induced in the rat by bilaterally clamping the common carotid arteries .|Peripheral venous blood samples were withdrawn from the femoral vein four times ( once every 5 min ) before ischemia ( 0 time ) and 5 , 15 , and 30 min after ischemia .|Plasma extracts were analyzed by a highly sensitive high - performance liquid chromatographic method for the direct determination of malondialdehyde , oxypurines , and nucleosides .|During ischemia , a time - dependent increase of plasma oxypurines and nucleosides was observed .|Plasma malondialdehyde , which was present in minimal amount at zero time ( 0 . 058 mumol / liter plasma ; SD 0 . 015 ) , increased after 5 min of ischemia , resulting in a fivefold increase after 30 min of carotid occlusion ( 0 . 298 mumol / liter plasma ; SD 0 . 078 ) .|Increased plasma malondialdehyde was also recorded in two other groups of animals subjected to the same experimental model , one receiving 20 mg / kg b . w .|of the cyclooxygenase inhibitor acetylsalicylate intravenously immediately before ischemia , the other receiving 650 micrograms / kg b . w .|of the hypotensive drug nitroprusside at a flow rate of 103 microliters / min intravenously during ischemia , although in this latter group malondialdehyde was significantly higher .|The present data indicate that the determination of malondialdehyde , oxypurines , and nucleosides in peripheral blood , may be used to monitor the metabolic alterations of tissues occurring during ischemic phenomena . ( ABSTRACT TRUNCATED AT 250 WORDS )	1:CID:2	L2R	NON-CROSS	4-5	12-14	D008315	malondialdehyde|malondialdehyde|malondialdehyde|malondialdehyde|malondialdehyde|malondialdehyde	Chemical	4:92:116:177:248:261	5:93:117:178:249:262	0:3:5:6:8:9	D002545	cerebral ischemia|cerebral ischemia	Disease	12:19	14:21	0:1	1:NR:2	L2R	NON-CROSS	241-242	248-249	D008315	malondialdehyde|malondialdehyde|malondialdehyde|malondialdehyde|malondialdehyde|malondialdehyde	Chemical	4:92:116:177:248:261	5:93:117:178:249:262	0:3:5:6:8:9	D007511	ischemia|ischemia|ischemia|ischemia|ischemia|ischemia|ischemic	Disease	57:71:100:147:212:241:283	58:72:101:148:213:242:284	2:2:4:5:7:8:9	1:NR:2	L2R	NON-CROSS	227-228	248-249	D008315	malondialdehyde|malondialdehyde|malondialdehyde|malondialdehyde|malondialdehyde|malondialdehyde	Chemical	4:92:116:177:248:261	5:93:117:178:249:262	0:3:5:6:8:9	D007022	hypotensive	Disease	227	228	8	1:NR:2	L2R	NON-CROSS	9-10	12-14	D009705	nucleosides|nucleosides|nucleosides|nucleosides	Chemical	9:97:111:266	10:98:112:267	0:3:4:9	D002545	cerebral ischemia|cerebral ischemia	Disease	12:19	14:21	0:1	1:NR:2	L2R	NON-CROSS	97-98	100-101	D009705	nucleosides|nucleosides|nucleosides|nucleosides	Chemical	9:97:111:266	10:98:112:267	0:3:4:9	D007511	ischemia|ischemia|ischemia|ischemia|ischemia|ischemia|ischemic	Disease	57:71:100:147:212:241:283	58:72:101:148:213:242:284	2:2:4:5:7:8:9	1:NR:2	L2R	CROSS	227-228	266-267	D009705	nucleosides|nucleosides|nucleosides|nucleosides	Chemical	9:97:111:266	10:98:112:267	0:3:4:9	D007022	hypotensive	Disease	227	228	8	1:NR:2	R2L	CROSS	208-209	19-21	D001241	acetylsalicylate	Chemical	208	209	7	D002545	cerebral ischemia|cerebral ischemia	Disease	12:19	14:21	0:1	1:NR:2	R2L	CROSS	229-230	19-21	D009599	nitroprusside	Chemical	229	230	8	D002545	cerebral ischemia|cerebral ischemia	Disease	12:19	14:21	0:1	1:NR:2	R2L	NON-CROSS	212-213	208-209	D001241	acetylsalicylate	Chemical	208	209	7	D007511	ischemia|ischemia|ischemia|ischemia|ischemia|ischemia|ischemic	Disease	57:71:100:147:212:241:283	58:72:101:148:213:242:284	2:2:4:5:7:8:9	1:NR:2	R2L	NON-CROSS	241-242	229-230	D009599	nitroprusside	Chemical	229	230	8	D007511	ischemia|ischemia|ischemia|ischemia|ischemia|ischemia|ischemic	Disease	57:71:100:147:212:241:283	58:72:101:148:213:242:284	2:2:4:5:7:8:9	1:NR:2	L2R	CROSS	208-209	227-228	D001241	acetylsalicylate	Chemical	208	209	7	D007022	hypotensive	Disease	227	228	8	1:NR:2	R2L	NON-CROSS	229-230	227-228	D009599	nitroprusside	Chemical	229	230	8	D007022	hypotensive	Disease	227	228	8
7650771	Cholinergic toxicity resulting from ocular instillation of echothiophate iodide eye drops .|A patient developed a severe cholinergic syndrome from the use of echothiophate iodide ophthalmic drops , presented with profound muscle weakness and was initially given the diagnosis of myasthenia gravis .|Red blood cell and serum cholinesterase levels were severely depressed and symptoms resolved spontaneously following discontinuation of the eye drops .	1:NR:2	R2L	NON-CROSS	7-9	1-2	D004456	echothiophate iodide|echothiophate iodide	Chemical	7:23	9:25	0:1	D064420	toxicity	Disease	1	2	0	1:CID:2	L2R	NON-CROSS	23-25	31-33	D004456	echothiophate iodide|echothiophate iodide	Chemical	7:23	9:25	0:1	D018908	muscle weakness	Disease	31	33	1	1:NR:2	L2R	NON-CROSS	23-25	40-42	D004456	echothiophate iodide|echothiophate iodide	Chemical	7:23	9:25	0:1	D009157	myasthenia gravis	Disease	40	42	1
7565311	Acute renal failure in high dose carboplatin chemotherapy .|Carboplatin has been reported to cause acute renal failure when administered in high doses to adult patients .|We report a 4 1 / 2 - year - old girl who was treated with high - dose carboplatin for metastatic parameningeal embryonal rhabdomyosarcoma .|Acute renal failure developed followed by a slow partial recovery of renal function .|Possible contributing factors are discussed .	1:CID:2	R2L	NON-CROSS	6-7	0-3	D016190	carboplatin|Carboplatin|carboplatin	Chemical	6:9:46	7:10:47	0:1:2	D058186	Acute renal failure|acute renal failure|Acute renal failure	Disease	0:15:53	3:18:56	0:1:3	1:NR:2	L2R	NON-CROSS	46-47	50-52	D016190	carboplatin|Carboplatin|carboplatin	Chemical	6:9:46	7:10:47	0:1:2	D018233	embryonal rhabdomyosarcoma	Disease	50	52	2
7421734	Endometrial carcinoma after Hodgkin disease in childhood .|A 34 - year - old patient developed metastic endometrial carcinoma after Hodgkin disease in childhood .|She had ovarian failure after abdominal irradiation and chemotherapy for Hodgkin disease , and received exogenous estrogens , a treatment implicated in the development of endometrial cancer in menopausal women .|Young women on replacement estrogens for ovarian failure after cancer therapy may also have increased risk of endometrial carcinoma and should be examined periodically .	1:CID:2	R2L	NON-CROSS	60-61	50-52	D004967	estrogens|estrogens	Chemical	41:60	42:61	2:3	D016889	Endometrial carcinoma|endometrial carcinoma|endometrial cancer|endometrial carcinoma	Disease	0:17:50:73	2:19:52:75	0:1:2:3	1:NR:2	R2L	NON-CROSS	41-42	35-37	D004967	estrogens|estrogens	Chemical	41:60	42:61	2:3	D006689	Hodgkin disease|Hodgkin disease|Hodgkin disease	Disease	3:20:35	5:22:37	0:1:2	1:NR:2	R2L	NON-CROSS	62-64	60-61	D004967	estrogens|estrogens	Chemical	41:60	42:61	2:3	D010049	ovarian failure|ovarian failure	Disease	27:62	29:64	2:3	1:NR:2	L2R	NON-CROSS	60-61	65-66	D004967	estrogens|estrogens	Chemical	41:60	42:61	2:3	D009369	cancer	Disease	65	66	3
6732043	Induction of the obstructive sleep apnea syndrome in a woman by exogenous androgen administration .|We documented airway occlusion during sleep and an abnormally high supraglottic resistance while awake in a 54 - yr - old woman who had developed physical changes and the syndrome of obstructive sleep apnea while being administered exogenous androgens .|When the androgens were withdrawn , the patient 's physical changes , symptoms , sleep study , and supraglottic resistance all returned to normal .|A rechallenge with androgen produced symptoms of obstructive sleep apnea that abated upon withdrawal of the hormone .|Previous reports have favored a role of androgens in the pathogenesis of sleep apnea .|Our report provides direct evidence for this role .|Structural and functional measurements indicate that androgens exert a permissive or necessary action on the structural configuration of the oropharynx that predisposes to obstruction during sleep .|Development of the obstructive sleep apnea syndrome must be considered a possible side effect of androgen therapy .	1:CID:2	R2L	NON-CROSS	87-90	83-84	D000728	androgen|androgens|androgens|androgen|androgens|androgens|androgen	Chemical	12:53:57:83:105:128:164	13:54:58:84:106:129:165	0:1:2:3:4:6:7	D020181	obstructive sleep apnea syndrome|syndrome of obstructive sleep apnea|obstructive sleep apnea|obstructive sleep apnea syndrome	Disease	3:44:87:152	7:49:90:156	0:1:3:7	1:NR:2	L2R	NON-CROSS	105-106	110-112	D000728	androgen|androgens|androgens|androgen|androgens|androgens|androgen	Chemical	12:53:57:83:105:128:164	13:54:58:84:106:129:165	0:1:2:3:4:6:7	D012891	sleep apnea	Disease	110	112	4
6454943	Effect of captopril on pre - existing and aminonucleoside - induced proteinuria in spontaneously hypertensive rats .|Proteinuria is a side effect of captopril treatment in hypertensive patients .|The possibility of reproducing the same renal abnormality with captopril was examined in SHR .|Oral administration of captopril at 100 mg / kg for 14 days failed to aggravate proteinuria pre - existing in SHR .|Also , captopril treatment failed to potentiate or facilitate development of massive proteinuria invoked by puromycin aminonucleoside in SHR .|Captopril had little or no demonstrable effects on serum electrolyte concentrations , excretion of urine , sodium and potassium , endogenous creatinine clearance , body weight , and food and water consumption .|However , ketone bodies were consistently present in urine and several lethalities occurred during multiple dosing of captopril in SHR .	1:NR:2	L2R	NON-CROSS	17-18	23-24	D002216	captopril|captopril|captopril|captopril|captopril|Captopril|captopril	Chemical	2:23:38:47:68:86:136	3:24:39:48:69:87:137	0:1:2:3:4:5:6	D011507	proteinuria|Proteinuria|proteinuria|proteinuria	Disease	11:17:59:78	12:18:60:79	0:1:3:4	1:NR:2	L2R	NON-CROSS	23-24	26-27	D002216	captopril|captopril|captopril|captopril|captopril|Captopril|captopril	Chemical	2:23:38:47:68:86:136	3:24:39:48:69:87:137	0:1:2:3:4:5:6	D006973	hypertensive|hypertensive	Disease	14:26	15:27	0:1	1:NR:2	L2R	NON-CROSS	35-37	38-39	D002216	captopril|captopril|captopril|captopril|captopril|Captopril|captopril	Chemical	2:23:38:47:68:86:136	3:24:39:48:69:87:137	0:1:2:3:4:5:6	D007674	renal abnormality	Disease	35	37	2	1:CID:2	L2R	NON-CROSS	8-9	11-12	D011692	aminonucleoside|puromycin aminonucleoside	Chemical	8:81	9:83	0:4	D011507	proteinuria|Proteinuria|proteinuria|proteinuria	Disease	11:17:59:78	12:18:60:79	0:1:3:4	1:NR:2	L2R	NON-CROSS	8-9	14-15	D011692	aminonucleoside|puromycin aminonucleoside	Chemical	8:81	9:83	0:4	D006973	hypertensive|hypertensive	Disease	14:26	15:27	0:1	1:NR:2	L2R	CROSS	8-9	35-37	D011692	aminonucleoside|puromycin aminonucleoside	Chemical	8:81	9:83	0:4	D007674	renal abnormality	Disease	35	37	2	1:NR:2	R2L	CROSS	102-103	78-79	D012964	sodium	Chemical	102	103	5	D011507	proteinuria|Proteinuria|proteinuria|proteinuria	Disease	11:17:59:78	12:18:60:79	0:1:3:4	1:NR:2	R2L	CROSS	104-105	78-79	D011188	potassium	Chemical	104	105	5	D011507	proteinuria|Proteinuria|proteinuria|proteinuria	Disease	11:17:59:78	12:18:60:79	0:1:3:4	1:NR:2	R2L	CROSS	107-108	78-79	D003404	creatinine	Chemical	107	108	5	D011507	proteinuria|Proteinuria|proteinuria|proteinuria	Disease	11:17:59:78	12:18:60:79	0:1:3:4	1:NR:2	R2L	CROSS	121-122	78-79	D007659	ketone	Chemical	121	122	6	D011507	proteinuria|Proteinuria|proteinuria|proteinuria	Disease	11:17:59:78	12:18:60:79	0:1:3:4	1:NR:2	R2L	CROSS	102-103	26-27	D012964	sodium	Chemical	102	103	5	D006973	hypertensive|hypertensive	Disease	14:26	15:27	0:1	1:NR:2	R2L	CROSS	104-105	26-27	D011188	potassium	Chemical	104	105	5	D006973	hypertensive|hypertensive	Disease	14:26	15:27	0:1	1:NR:2	R2L	CROSS	107-108	26-27	D003404	creatinine	Chemical	107	108	5	D006973	hypertensive|hypertensive	Disease	14:26	15:27	0:1	1:NR:2	R2L	CROSS	121-122	26-27	D007659	ketone	Chemical	121	122	6	D006973	hypertensive|hypertensive	Disease	14:26	15:27	0:1	1:NR:2	R2L	CROSS	102-103	35-37	D012964	sodium	Chemical	102	103	5	D007674	renal abnormality	Disease	35	37	2	1:NR:2	R2L	CROSS	104-105	35-37	D011188	potassium	Chemical	104	105	5	D007674	renal abnormality	Disease	35	37	2	1:NR:2	R2L	CROSS	107-108	35-37	D003404	creatinine	Chemical	107	108	5	D007674	renal abnormality	Disease	35	37	2	1:NR:2	R2L	CROSS	121-122	35-37	D007659	ketone	Chemical	121	122	6	D007674	renal abnormality	Disease	35	37	2
6153967	Epileptogenic properties of enflurane and their clinical interpretation .|Three cases of EEG changes induced by single exposure to enflurane anesthesia are reported .|In one patient , enflurane administered during a donor nephrectomy resulted in unexpected partial motor seizures .|Until the cause of the seizures was correctly identified , the patient was inappropriately treated with anticonvulsants .|Two other patients suffered from partial , complex and generalized seizures uncontrolled by medication .|Epileptic foci delineated and activated by enflurane were surgically ablated and the patients are now seizure - free .|Previous exposures to enflurane have to be disclosed to avoid mistakes in clinical interpretation of the EEG .|On the other hand , enflurane may prove to be a safe fast acting activator of epileptic foci during corticography or depth electrode intraoperative recordings .	1:CID:2	L2R	NON-CROSS	89-90	96-97	D004737	enflurane|enflurane|enflurane|enflurane|enflurane|enflurane	Chemical	3:19:28:80:96:116	4:20:29:81:97:117	0:1:2:5:6:7	D012640	seizures|seizures|seizures|seizure	Disease	39:46:69:89	40:47:70:90	2:3:4:5	1:NR:2	L2R	NON-CROSS	74-75	80-81	D004737	enflurane|enflurane|enflurane|enflurane|enflurane|enflurane	Chemical	3:19:28:80:96:116	4:20:29:81:97:117	0:1:2:5:6:7	D004827	Epileptic|epileptic	Disease	74:127	75:128	5:7
3183120	Reversible cerebral lesions associated with tiazofurin usage : MR demonstration .|Tiazofurin is an experimental chemotherapeutic agent currently undergoing clinical evaluation .|We report our results with magnetic resonance ( MR ) in demonstrating reversible cerebral abnormalities concurrent with the use of this drug .|The abnormalities on MR were correlated with findings on CT as well as with cerebral angiography .|The utility of MR in the evaluation of patients receiving this new agent is illustrated .	1:CID:2	R2L	NON-CROSS	5-6	1-3	C033706	tiazofurin|Tiazofurin	Chemical	5:11	6:12	0:1	D001927	cerebral lesions|cerebral abnormalities	Disease	1:35	3:37	0:2
3120485	Antagonism of diazepam - induced sedative effects by Ro15 - 1788 in patients after surgery under lumbar epidural block .|A double - blind placebo - controlled investigation of efficacy and safety .|The aim of this study was to assess the efficacy of Ro15 - 1788 and a placebo in reversing diazepam - induced effects after surgery under epidural block , and to evaluate the local tolerance and general safety of Ro15 - 1788 .|Fifty - seven patients were sedated with diazepam for surgery under epidural anaesthesia .|Antagonism of diazepam - induced effects by Ro15 - 1788 was investigated postoperatively in a double - blind placebo - controlled trial .|The patient 's subjective assessment of mood rating , an objective test of performance , a test for amnesia , and vital signs were recorded for up to 300 min after administration of the trial drug .|No significant differences between the two groups were observed for mood rating , amnesia , or vital signs .|The Ro15 - 1788 group showed a significant improvement in the performance test up to 120 min after administration of the drug .|There was no evidence of reaction at the injection site .	1:CID:2	L2R	CROSS	92-93	131-132	D003975	diazepam|diazepam|diazepam|diazepam	Chemical	2:52:83:92	3:53:84:93	0:2:3:4	D000647	amnesia|amnesia	Disease	131:163	132:164	5:6	1:NR:2	L2R	CROSS	163-164	170-173	D005442	Ro15 - 1788|Ro15 - 1788|Ro15 - 1788|Ro15 - 1788|Ro15 - 1788	Chemical	8:44:72:97:170	11:47:75:100:173	0:2:2:4:7	D000647	amnesia|amnesia	Disease	131:163	132:164	5:6
2886572	Enhanced stimulus - induced neurotransmitter overflow in epinephrine - induced hypertensive rats is not mediated by prejunctional beta - adrenoceptor activation .|The present study examines the effect of 6 - day epinephrine treatment ( 100 micrograms / kg per h , s . c . ) on stimulus - induced ( 1 Hz ) endogenous neurotransmitter overflow from the isolated perfused kidney of vehicle - and epinephrine - treated rats .|Renal catecholamine stores and stimulus - induced overflow in the vehicle - treated group consisted of norepinephrine only .|However , epinephrine treatment resulted in the incorporation of epinephrine into renal catecholamine stores such that approximately 40 % of the catecholamine present was epinephrine while the norepinephrine content was reduced by a similar degree .|Total tissue catecholamine content of the kidney on a molar basis was unchanged .|Stimulus - induced fractional overflow of neurotransmitter from the epinephrine - treated kidneys was approximately twice normal and consisted of both norepinephrine and epinephrine in proportions similar to those found in the kidney .|This difference in fractional overflow between groups was not affected by neuronal and extraneuronal uptake blockade .|Propranolol had no effect on stimulus - induced overflow in either group .|Phentolamine increased stimulus - induced overflow in both groups although the increment in overflow was greater in the epinephrine - treated group .|In conclusion , chronic epinephrine treatment results in enhanced fractional neurotransmitter overflow .|However , neither alterations in prejunctional beta - adrenoceptor influences nor alterations in neuronal and extraneuronal uptake mechanisms appear to be responsible for this alteration .|Furthermore , data obtained with phentolamine alone do not suggest alpha - adrenoceptor desensitization as the cause of the enhanced neurotransmitter overflow after epinephrine treatment .	1:CID:2	L2R	NON-CROSS	7-8	10-11	D004837	epinephrine|epinephrine|epinephrine|epinephrine|epinephrine|epinephrine|epinephrine|epinephrine|epinephrine|epinephrine|epinephrine	Chemical	7:32:67:93:100:115:150:164:223:232:290	8:33:68:94:101:116:151:165:224:233:291	0:1:1:3:3:3:5:5:8:9:11	D006973	hypertensive	Disease	10	11	0	1:NR:2	R2L	CROSS	73-74	10-11	D002395	catecholamine|catecholamine|catecholamine|catecholamine	Chemical	73:103:112:129	74:104:113:130	2:3:3:4	D006973	hypertensive	Disease	10	11	0	1:NR:2	R2L	CROSS	88-89	10-11	D009638	norepinephrine|norepinephrine|norepinephrine	Chemical	88:118:162	89:119:163	2:3:5	D006973	hypertensive	Disease	10	11	0	1:NR:2	R2L	CROSS	192-193	10-11	D011433	Propranolol	Chemical	192	193	7	D006973	hypertensive	Disease	10	11	0	1:NR:2	R2L	CROSS	205-206	10-11	D010646	Phentolamine|phentolamine	Chemical	205:272	206:273	8:11	D006973	hypertensive	Disease	10	11	0
1079693	Ocular manifestations of juvenile rheumatoid arthritis .|We followed 210 cases of juvenile rheumatoid arthritis closely for eleven years .|Thirty - six of the 210 patients ( 17 . 2 % ) developed iridocyclitis .|Iridocyclitis was seen most frequently in young female patients ( 0 to 4 years ) with the monoarticular or pauciatricular form of the arthritis .|However , 30 % of the patients developed uveitis after 16 years of age .|Although 61 % of patients had a noncontributory ocular history on entry , 42 % had active uveitis on entry .|Our approach was effective in detecting uveitis in new cases and exacerbations of uveitis in established cases .|Forty - four percent of patients with uveitis had one or more identifiable signs or symptoms , such as red eye , ocular pain , decreased visual acuity , or photophobia , in order of decreasing frequency .|Even after early detection and prompt treatment , 41 % of cases of uveitis did not respond to more than six months of intensive topical treatment with corticosteroids and mydriatics .|Despite this , there was a dramatic decrease in the 50 % incidence of blinding complications of uveitis cited in earlier studies .|Cataract and band keratopathy occurred in only 22 and 13 % of our group , respectively .|We used chloroquine or hydroxychloroquine in 173 of 210 cases and found only one case of chorioretinopathy attributable to these drugs .|Systemically administered corticosteroids were used in 75 of 210 cases ; a significant number of posterior subcapsular cataracts was found .|Typical keratoconjunctivitis sicca developed in three of the uveitis cases .|This association with uveitis and JRA was not noted previously .|Surgical treatment of cataracts , band keratopathy , and glaucoma achieved uniformly discouraging results .	1:NR:2	R2L	CROSS	180-181	12-15	D000305	corticosteroids|corticosteroids	Chemical	180:248	181:249	8:12	D001171	juvenile rheumatoid arthritis|juvenile rheumatoid arthritis	Disease	3:12	6:15	0:1	1:NR:2	R2L	CROSS	226-227	12-15	D002738	chloroquine	Chemical	226	227	11	D001171	juvenile rheumatoid arthritis|juvenile rheumatoid arthritis	Disease	3:12	6:15	0:1	1:NR:2	R2L	CROSS	228-229	12-15	D006886	hydroxychloroquine	Chemical	228	229	11	D001171	juvenile rheumatoid arthritis|juvenile rheumatoid arthritis	Disease	3:12	6:15	0:1	1:NR:2	R2L	CROSS	180-181	36-37	D000305	corticosteroids|corticosteroids	Chemical	180:248	181:249	8:12	D015863	iridocyclitis|Iridocyclitis	Disease	34:36	35:37	2:3	1:NR:2	R2L	CROSS	226-227	36-37	D002738	chloroquine	Chemical	226	227	11	D015863	iridocyclitis|Iridocyclitis	Disease	34:36	35:37	2:3	1:NR:2	R2L	CROSS	228-229	36-37	D006886	hydroxychloroquine	Chemical	228	229	11	D015863	iridocyclitis|Iridocyclitis	Disease	34:36	35:37	2:3	1:NR:2	R2L	CROSS	180-181	59-60	D000305	corticosteroids|corticosteroids	Chemical	180:248	181:249	8:12	D001168	arthritis	Disease	59	60	3	1:NR:2	R2L	CROSS	226-227	59-60	D002738	chloroquine	Chemical	226	227	11	D001168	arthritis	Disease	59	60	3	1:NR:2	R2L	CROSS	228-229	59-60	D006886	hydroxychloroquine	Chemical	228	229	11	D001168	arthritis	Disease	59	60	3	1:NR:2	R2L	NON-CROSS	180-181	166-167	D000305	corticosteroids|corticosteroids	Chemical	180:248	181:249	8:12	D014605	uveitis|uveitis|uveitis|uveitis|uveitis|uveitis|uveitis|uveitis|uveitis	Disease	69:93:103:110:122:166:201:275:281	70:94:104:111:123:167:202:276:282	4:5:6:6:7:8:9:13:14	1:NR:2	R2L	CROSS	226-227	201-202	D002738	chloroquine	Chemical	226	227	11	D014605	uveitis|uveitis|uveitis|uveitis|uveitis|uveitis|uveitis|uveitis|uveitis	Disease	69:93:103:110:122:166:201:275:281	70:94:104:111:123:167:202:276:282	4:5:6:6:7:8:9:13:14	1:NR:2	R2L	CROSS	228-229	201-202	D006886	hydroxychloroquine	Chemical	228	229	11	D014605	uveitis|uveitis|uveitis|uveitis|uveitis|uveitis|uveitis|uveitis|uveitis	Disease	69:93:103:110:122:166:201:275:281	70:94:104:111:123:167:202:276:282	4:5:6:6:7:8:9:13:14	1:NR:2	R2L	CROSS	180-181	137-139	D000305	corticosteroids|corticosteroids	Chemical	180:248	181:249	8:12	D058447	ocular pain	Disease	137	139	7	1:NR:2	R2L	CROSS	226-227	137-139	D002738	chloroquine	Chemical	226	227	11	D058447	ocular pain	Disease	137	139	7	1:NR:2	R2L	CROSS	228-229	137-139	D006886	hydroxychloroquine	Chemical	228	229	11	D058447	ocular pain	Disease	137	139	7	1:NR:2	R2L	CROSS	180-181	140-143	D000305	corticosteroids|corticosteroids	Chemical	180:248	181:249	8:12	D014786	decreased visual acuity	Disease	140	143	7	1:NR:2	R2L	CROSS	226-227	140-143	D002738	chloroquine	Chemical	226	227	11	D014786	decreased visual acuity	Disease	140	143	7	1:NR:2	R2L	CROSS	228-229	140-143	D006886	hydroxychloroquine	Chemical	228	229	11	D014786	decreased visual acuity	Disease	140	143	7	1:NR:2	R2L	CROSS	180-181	145-146	D000305	corticosteroids|corticosteroids	Chemical	180:248	181:249	8:12	D020795	photophobia	Disease	145	146	7	1:NR:2	R2L	CROSS	226-227	145-146	D002738	chloroquine	Chemical	226	227	11	D020795	photophobia	Disease	145	146	7	1:NR:2	R2L	CROSS	228-229	145-146	D006886	hydroxychloroquine	Chemical	228	229	11	D020795	photophobia	Disease	145	146	7	1:NR:2	L2R	NON-CROSS	248-249	263-264	D000305	corticosteroids|corticosteroids	Chemical	180:248	181:249	8:12	D002386	Cataract|cataracts|cataracts	Disease	207:263:292	208:264:293	10:12:15	1:NR:2	L2R	CROSS	180-181	209-211	D000305	corticosteroids|corticosteroids	Chemical	180:248	181:249	8:12	C562399	band keratopathy|band keratopathy	Disease	209:294	211:296	10:15	1:NR:2	L2R	CROSS	240-241	248-249	D000305	corticosteroids|corticosteroids	Chemical	180:248	181:249	8:12	D012164	chorioretinopathy	Disease	240	241	11	1:NR:2	L2R	CROSS	248-249	268-269	D000305	corticosteroids|corticosteroids	Chemical	180:248	181:249	8:12	D007637	keratoconjunctivitis	Disease	268	269	13	1:NR:2	L2R	CROSS	248-249	298-299	D000305	corticosteroids|corticosteroids	Chemical	180:248	181:249	8:12	D005901	glaucoma	Disease	298	299	15	1:NR:2	R2L	CROSS	226-227	207-208	D002738	chloroquine	Chemical	226	227	11	D002386	Cataract|cataracts|cataracts	Disease	207:263:292	208:264:293	10:12:15	1:NR:2	R2L	CROSS	228-229	207-208	D006886	hydroxychloroquine	Chemical	228	229	11	D002386	Cataract|cataracts|cataracts	Disease	207:263:292	208:264:293	10:12:15	1:NR:2	R2L	CROSS	226-227	209-211	D002738	chloroquine	Chemical	226	227	11	C562399	band keratopathy|band keratopathy	Disease	209:294	211:296	10:15	1:NR:2	R2L	CROSS	228-229	209-211	D006886	hydroxychloroquine	Chemical	228	229	11	C562399	band keratopathy|band keratopathy	Disease	209:294	211:296	10:15	1:NR:2	L2R	NON-CROSS	226-227	240-241	D002738	chloroquine	Chemical	226	227	11	D012164	chorioretinopathy	Disease	240	241	11	1:NR:2	L2R	CROSS	226-227	268-269	D002738	chloroquine	Chemical	226	227	11	D007637	keratoconjunctivitis	Disease	268	269	13	1:NR:2	L2R	CROSS	226-227	298-299	D002738	chloroquine	Chemical	226	227	11	D005901	glaucoma	Disease	298	299	15	1:CID:2	L2R	NON-CROSS	228-229	240-241	D006886	hydroxychloroquine	Chemical	228	229	11	D012164	chorioretinopathy	Disease	240	241	11	1:NR:2	L2R	CROSS	228-229	268-269	D006886	hydroxychloroquine	Chemical	228	229	11	D007637	keratoconjunctivitis	Disease	268	269	13	1:NR:2	L2R	CROSS	228-229	298-299	D006886	hydroxychloroquine	Chemical	228	229	11	D005901	glaucoma	Disease	298	299	15
803783	Water intoxication associated with oxytocin administration during saline - induced abortion .|Four cases of water intoxication in connection with oxytocin administration during saline - induced abortions are described .|The mechanism of water intoxication is discussed in regard to these cases .|Oxytocin administration during midtrimester - induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff , aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia , muscular irritability , or headaches .|The oxytocin should be given only in Ringers lactate or , alternately , in Ringers lactate and a 5 per cent dextrose and water solutions .|The urinary output should be monitored and the oxytocin administration discontinued and the serum electrolytes checked if the urinary output decreases .|The oxytocin should not be administered in excess of 36 hours .|If the patient has not aborted by then the oxytocin should be discontinued for 10 to 12 hours in order to perform electrolyte determinations and correct any electrolyte imbalance .	1:CID:2	R2L	NON-CROSS	4-5	0-2	D010121	oxytocin|oxytocin|Oxytocin|oxytocin|oxytocin|oxytocin|oxytocin	Chemical	4:20:43:99:132:147:167	5:21:44:100:133:148:168	0:1:3:4:5:6:7	D014869	Water intoxication|water intoxication|water intoxication|water intoxication	Disease	0:15:33:73	2:17:35:75	0:1:2:3	1:NR:2	R2L	CROSS	106-107	73-75	D019344	lactate|lactate	Chemical	106:113	107:114	4:4	D014869	Water intoxication|water intoxication|water intoxication|water intoxication	Disease	0:15:33:73	2:17:35:75	0:1:2:3	1:NR:2	R2L	CROSS	119-120	73-75	D005947	dextrose	Chemical	119	120	4	D014869	Water intoxication|water intoxication|water intoxication|water intoxication	Disease	0:15:33:73	2:17:35:75	0:1:2:3	1:NR:2	L2R	NON-CROSS	4-5	10-11	D010121	oxytocin|oxytocin|Oxytocin|oxytocin|oxytocin|oxytocin|oxytocin	Chemical	4:20:43:99:132:147:167	5:21:44:100:133:148:168	0:1:3:4:5:6:7	D000031	abortion|abortions|abortions	Disease	10:26:49	11:27:50	0:1:3	1:NR:2	L2R	NON-CROSS	90-91	99-100	D010121	oxytocin|oxytocin|Oxytocin|oxytocin|oxytocin|oxytocin|oxytocin	Chemical	4:20:43:99:132:147:167	5:21:44:100:133:148:168	0:1:3:4:5:6:7	D001247	asthenia	Disease	90	91	3	1:NR:2	L2R	NON-CROSS	93-94	99-100	D010121	oxytocin|oxytocin|Oxytocin|oxytocin|oxytocin|oxytocin|oxytocin	Chemical	4:20:43:99:132:147:167	5:21:44:100:133:148:168	0:1:3:4:5:6:7	D001523	irritability	Disease	93	94	3	1:NR:2	L2R	NON-CROSS	96-97	99-100	D010121	oxytocin|oxytocin|Oxytocin|oxytocin|oxytocin|oxytocin|oxytocin	Chemical	4:20:43:99:132:147:167	5:21:44:100:133:148:168	0:1:3:4:5:6:7	D006261	headaches	Disease	96	97	3	1:NR:2	R2L	CROSS	106-107	49-50	D019344	lactate|lactate	Chemical	106:113	107:114	4:4	D000031	abortion|abortions|abortions	Disease	10:26:49	11:27:50	0:1:3	1:NR:2	R2L	CROSS	119-120	49-50	D005947	dextrose	Chemical	119	120	4	D000031	abortion|abortions|abortions	Disease	10:26:49	11:27:50	0:1:3	1:NR:2	R2L	CROSS	106-107	90-91	D019344	lactate|lactate	Chemical	106:113	107:114	4:4	D001247	asthenia	Disease	90	91	3	1:NR:2	R2L	CROSS	119-120	90-91	D005947	dextrose	Chemical	119	120	4	D001247	asthenia	Disease	90	91	3	1:NR:2	R2L	CROSS	106-107	93-94	D019344	lactate|lactate	Chemical	106:113	107:114	4:4	D001523	irritability	Disease	93	94	3	1:NR:2	R2L	CROSS	119-120	93-94	D005947	dextrose	Chemical	119	120	4	D001523	irritability	Disease	93	94	3	1:NR:2	R2L	CROSS	106-107	96-97	D019344	lactate|lactate	Chemical	106:113	107:114	4:4	D006261	headaches	Disease	96	97	3	1:NR:2	R2L	CROSS	119-120	96-97	D005947	dextrose	Chemical	119	120	4	D006261	headaches	Disease	96	97	3
